(19) World Intellectual Property Organization International Bureau



E IDDDO DENIDIDO NI DIDIN BENDUNIBI I IL NO DENID NOVO IDNO NIDEN ADDI DIDINA NA PROPERTI (BID NIDI IDDD

(43) International Publication Date 30 August 2001 (30.08.2001)

PCT

(10) International Publication Number WO 01/62927 A2

- (51) International Patent Classification?: C12N 15/12, C07K 14/47, 16/18, A61K 38/17, A01K 67/027, G01N 33/50, 33/68, C12Q 1/68
- (21) International Application Number: PCT/US01/06059
- (22) International Filing Date: 21 February 2001 (21.02.2001)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/205,286

١,	Friority Data.		
	60/184,777	24 February 2000 (24.02.2000)	US
	60/184,797	24 February 2000 (24.02.2000)	US
	60/184,698	24 February 2000 (24.02.2000)	US
	60/184,770	24 February 2000 (24.02.2000)	US
	60/184,774	24 February 2000 (24.02.2000)	US
	60/184,693	24 February 2000 (24.02.2000)	US
	60/184,771	24 February 2000 (24.02.2000)	US
	60/184,813	24 February 2000 (24.02.2000)	US
	60/184,773	24 February 2000 (24.02.2000)	US
	60/184,776	24 February 2000 (24.02.2000)	US
	60/184,769	24 February 2000 (24.02.2000)	US
	60/184,768	24 February 2000 (24.02.2000)	US
	60/184,837	24 February 2000 (24.02.2000)	US
	60/184,697	24 February 2000 (24.02.2000)	US
	60/184,841	24 February 2000 (24.02.2000)	US
	60/184,772	24 February 2000 (24.02.2000)	US
	60/185,213	24 February 2000 (24.02.2000)	US
	60/185,216	24 February 2000 (24.02.2000)	US
	60/203,785	12 May 2000 (12.05.2000)	US
	60/204,226	15 May 2000 (15.05.2000)	US
	60/204,821	16 May 2000 (16.05.2000)	US
	60/204,908	16 May 2000 (16.05.2000)	US
	60/204,525	16 May 2000 (16.05.2000)	US
	60/205,232	16 May 2000 (16.05.2000)	US
	60/204,863	17 May 2000 (17.05.2000)	US
	60/205,221	17 May 2000 (17.05.2000)	US
	60/204,815	17 May 2000 (17.05.2000)	US
	60/205,285	17 May 2000 (17.05.2000)	US
	60/205,323	17 May 2000 (17.05.2000)	US
	60/205,287	17 May 2000 (17.05.2000)	US
	60/205,324	17 May 2000 (17.05.2000)	US
		4534 4000 45 05 4000	

(71) Applicant (for all designated States except US): INCYTE GENOMICS, INC. [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PANZER, Scott. R. [US/US]; 571 Bobolink Circle, Sunnyvale, CA 94087 (US). SPIRO, Peter, A. [US/US]; 410 Sheridan Avenue #333, Palo Alto, CA 94306 (US). BANVILLE, Steven, C. [US/US]; 365 Monroe Drive, Palo Alto, CA 94306 (US). SHAH, Purvi [IN/US]; 859 Salt Lake Drive, San Jose, CA 95133 (US). CHALUP, Michael, S. [US/US]; 183 Acalanes Drive, Apt.#6, Sunnyvale, CA 94086 (US). CHANG, Simon, C. [US/US]; 1901 Rock Street #103, Mountain View, CA 94043 (US). CHEN, Alice [US/US]; 4405 Norwalk Drive #22, San Jose, CA 95129 (US). D'SA, Steven, A. [CA/US]; 40 Newell Road, Apt.#13, East Palo Alto, CA 94303 (US). AMSHEY, Stefan [US/US]; 1605 20th Street, San Francisco, CA 94107 (US). DAHL, Christopher, R. [US/US]; 41277 Roberts Avenue #6, Fremont, CA 94538 (US). DAM, Tam, C. [US/US]; 2180 Mendota Way, San Jose, CA (US). DANIELS, Susan, E. [GB/US]; 136 Seale Avenue, Palo Alto, CA 94301 (US). DUFOUR, Gerard, E. [US/US]; 5327 Greenridge Road, Castro Valley, CA 94552-2619 (US). FLORES, Vincent [US/US]; 35000 Begonia Street, Union City, CA 94587 (US). FONG, Willy, T. [US/US]; 572 Cambridge Street, San Francisco, CA 94134 (US). GREENAWALT, Lila, B. [US/US]; 1596 Ballantree Way, San Jose, CA 95118-2106 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive, #17, Mountain View, CA 94040 (US). JONES, Anissa, L. [US/US]; 445 South 15th Street, San Jose, CA 95112 (US). LIU, Tommy, F. [US/US]; 201 Ottilia Street, Daly City, CA 94014 (US). ROSEBERRY, Ann, M. [US/US]; 725 Sapphire Street, Redwood City, CA 94061 (US). ROSEN, Bruce, H. [US/US]; 177 Hanna Way, Menlo Park, CA 94025 (US). RUSSO, Frank, D. [US/US]; 939 Rosette Court, Sunnyvale, CA 94086 (US). STOCKDREHER, Theresa, K. [US/US]; 1596 Ontario Drive #2, Sunnyvale, CA 94087 (US). DAFFO, Abel [US/US]; 1750 Stokes Street #70, San Jose, CA 95126 (US). WRIGHT, Rachel, J. [NZ/US]; 333 Anna Avenue, Mountain View, CA 94043 (US). YAP, Pierre, E. [US/US]; 201 Happy Hollow Court, Lafayette, CA 94549-6243 (US). YU, Jimmy, Y. [US/US]; 3655 Wyndham Drive, Fremont, CA 94536 (US). BRADLEY,

[Continued on next page]

(54) Title: MOLECULES FOR DIAGNOSTICS AND THERAPEUTICS

17 May 2000 (17.05.2000)

(57) Abstract: The present invention provides purified human polynucleotides for diagnostics and therapeutics (dithp). Also encompassed are the polypeptides (DITHP) encoded by dithp. The invention also provides for the use of dithp, or complements, oligonucleotides, or fragments thereof in diagnostic assays. The invention further provides for vectors and host cells containing dithp for the expression of DITHP. The invention additionally provides for the use of isolated and purified DITHP to induce antibodies and to screen libraries of compounds and the use of anti-DITHP antibodies in diagnostic assays. Also provided are microarrays containing dithp and methods of use.

US

WO 01/62927 A2



Diana, L. [US/US]; 3260 Crystal Heights Drive, Soquel, CA 95073 (US). BRATCHER, Shawn, R. [US/US]; 550 Ortega Avenue #B321, Mountain View, CA 94040 (US). CHEN, Wensheng [CN/US]; 210 Easy Street #25, Mountain View, CA 94043 (US). COHEN, Howard, J. [US/US]; 3272 Cowper Street, Palo Alto, CA 94306-3004 (US). HODGSON, David, M. [US/US]; 2795 Windwood Drive, Apartment 165, Ann Arbor, MI 48105 (US). LINCOLN, Stephen, E. [US/US]; 725 Sapphire Street, Redwood City, CA 94061 (US). JACKSON, Stuart [US/US]; 230 Monroe Drive, #17, Mountain View, CA 94040 (US).

- (74) Agents: HAMLET-COX, Diana et al.; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

10

15

20

25

30

MOLECULES FOR DIAGNOSTICS AND THERAPEUTICS

TECHNICAL FIELD

The present invention relates to human molecules and to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases associated with, as well as effects of exogenous compounds on, the expression of human molecules.

BACKGROUND OF THE INVENTION

The human genome is comprised of thousands of genes, many encoding gene products that function in the maintenance and growth of the various cells and tissues in the body. Aberrant expression or mutations in these genes and their products is the cause of, or is associated with, a variety of human diseases such as cancer and other cell proliferative disorders, autoimmune/inflammatory disorders, infections, developmental disorders, endocrine disorders, metabolic disorders, neurological disorders, gastrointestinal disorders, transport disorders, and connective tissue disorders. The identification of these genes and their products is the basis of an ever-expanding effort to find markers for early detection of diseases, and targets for their prevention and treatment. Therefore, these genes and their products are useful as diagnostics and therapeutics. These genes may encode, for example, enzyme molecules, molecules associated with growth and development, biochemical pathway molecules, extracellular information transmission molecules, receptor molecules, intracellular signaling molecules, membrane transport molecules, protein modification and maintenance molecules, nucleic acid synthesis and modification molecules, adhesion molecules, antigen recognition molecules, secreted and extracellular matrix molecules, cytoskeletal molecules, ribosomal molecules, electron transfer associated molecules, transcription factor molecules, chromatin molecules, cell membrane molecules, and organelle associated molecules.

For example, cancer represents a type of cell proliferative disorder that affects nearly every tissue in the body. A wide variety of molecules, either aberrantly expressed or mutated, can be the cause of, or involved with, various cancers because tissue growth involves complex and ordered patterns of cell proliferation, cell differentiation, and apoptosis. Cell proliferation must be regulated to maintain both the number of cells and their spatial organization. This regulation depends upon the appropriate expression of proteins which control cell cycle progression in response to extracellular signals such as growth factors and other mitogens, and intracellular cues such as DNA damage or nutrient starvation. Molecules which directly or indirectly modulate cell cycle progression fall into several categories, including growth factors and their receptors, second messenger and signal transduction proteins, oncogene products, tumor-suppressor proteins, and mitosis-promoting factors.

Aberrant expression or mutations in any of these gene products can result in cell proliferative disorders such as cancer. Oncogenes are genes generally derived from normal genes that, through abnormal expression or mutation, can effect the transformation of a normal cell to a malignant one (oncogenesis). Oncoproteins, encoded by oncogenes, can affect cell proliferation in a variety of ways and include growth factors, growth factor receptors, intracellular signal transducers, nuclear transcription factors, and cell-cycle control proteins. In contrast, tumor-suppressor genes are involved in inhibiting cell proliferation. Mutations which cause reduced function or loss of function in tumor-suppressor genes result in aberrant cell proliferation and cancer. Although many different genes and their products have been found to be associated with cell proliferative disorders such as cancer, many more may exist that are yet to be discovered.

DNA-based arrays can provide a simple way to explore the expression of a single polymorphic gene or a large number of genes. When the expression of a single gene is explored, DNA-based arrays are employed to detect the expression of specific gene variants. For example, a p53 tumor suppressor gene array is used to determine whether individuals are carrying mutations that predispose them to cancer. A cytochrome p450 gene array is useful to determine whether individuals have one of a number of specific mutations that could result in increased drug metabolism, drug resistance or drug toxicity.

DNA-based array technology is especially relevant for the rapid screening of expression of a large number of genes. There is a growing awareness that gene expression is affected in a global fashion. A genetic predisposition, disease or therapeutic treatment may affect, directly or indirectly, the expression of a large number of genes. In some cases the interactions may be expected, such as when the genes are part of the same signaling pathway. In other cases, such as when the genes participate in separate signaling pathways, the interactions may be totally unexpected. Therefore, DNA-based arrays can be used to investigate how genetic predisposition, disease, or therapeutic treatment affects the expression of a large number of genes.

25

Enzyme Molecules

The cellular processes of biogenesis and biodegradation involve a number of key enzyme classes including oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. These enzyme classes are each comprised of numerous substrate-specific enzymes having precise and well regulated functions. These enzymes function by facilitating metabolic processes such as glycolysis, the tricarboxylic cycle, and fatty acid metabolism; synthesis or degradation of amino acids, steroids, phospholipids, alcohols, etc.; regulation of cell signalling, proliferation, inflamation, apoptosis, etc., and through catalyzing critical steps in DNA replication and repair, and the process of translation. Oxidoreductases

Many pathways of biogenesis and biodegradation require oxidoreductase (dehydrogenase or reductase) activity, coupled to the reduction or oxidation of a donor or acceptor cofactor. Potential cofactors include cytochromes, oxygen, disulfide, iron-sulfur proteins, flavin adenine dinucleotide (FAD), and the nicotinamide adenine dinucleotides NAD and NADP (Newsholme, E.A. and A.R. Leech (1983) Biochemistry for the Medical Sciences, John Wiley and Sons, Chichester, U.K., pp. 779-793). Reductase activity catalyzes the transfer of electrons between substrate(s) and cofactor(s) with concurrent oxidation of the cofactor. The reverse dehydrogenase reaction catalyzes the reduction of a cofactor and consequent oxidation of the substrate. Oxidoreductase enzymes are a broad superfamily of proteins that catalyze numerous reactions in all cells of organisms ranging from bacteria to plants to humans. These reactions include metabolism of sugar, certain detoxification reactions in the liver, and the synthesis or degradation of fatty acids, amino acids, glucocorticoids, estrogens, androgens, and prostaglandins. Different family members are named according to the direction in which their reactions are typically catalyzed; thus they may be referred to as oxidoreductases, oxidases, reductases, or dehydrogenases. In addition, family members often have distinct cellular localizations, including the cytosol, the plasma membrane, mitochondrial inner or outer membrane, and peroxisomes.

Short-chain alcohol dehydrogenases (SCADs) are a family of dehydrogenases that only share 15% to 30% sequence identity, with similarity predominantly in the coenzyme binding domain and the substrate binding domain. In addition to the well-known role in detoxification of ethanol, SCADs are also involved in synthesis and degradation of fatty acids, steroids, and some prostaglandins, and are therefore implicated in a variety of disorders such as lipid storage disease, myopathy, SCAD deficiency, and certain genetic disorders. For example, retinol dehydrogenase is a SCAD-family member (Simon, A. et al. (1995) J. Biol. Chem. 270:1107-1112) that converts retinol to retinal, the precursor of retinoic acid. Retinoic acid, a regulator of differentiation and apoptosis, has been shown to down-regulate genes involved in cell proliferation and inflammation (Chai, X. et al. (1995) J. Biol. Chem. 270:3900-3904). In addition, retinol dehydrogenase has been linked to hereditary eye diseases such as autosomal recessive childhood-onset severe retinal dystrophy (Simon, A. et al. (1996) Genomics 36:424-430).

Propagation of nerve impulses, modulation of cell proliferation and differentiation, induction of the immune response, and tissue homeostasis involve neurotransmitter metabolism (Weiss, B. (1991) Neurotoxicology 12:379-386; Collins, S.M. et al. (1992) Ann. N.Y. Acad. Sci. 664:415-424; Brown, J.K. and H. Imam (1991) J. Inherit. Metab. Dis. 14:436-458). Many pathways of neurotransmitter metabolism require oxidoreductase activity, coupled to reduction or oxidation of a cofactor, such as NAD+/NADH (Newsholme, E.A. and A.R. Leech (1983) Biochemistry for the

10

15

20

25

Medical Sciences, John Wiley and Sons, Chichester, U.K. pp. 779-793). Degradation of catecholamines (epinephrine or norepinephrine) requires alcohol dehydrogenase (in the brain) or aldehyde dehydrogenase (in peripheral tissue). NAD+-dependent aldehyde dehydrogenase oxidizes 5-hydroxyindole-3-acetate (the product of 5-hydroxytryptamine (serotonin) metabolism) in the brain, blood platelets, liver and pulmonary endothelium (Newsholme, supra, p. 786). Other neurotransmitter degradation pathways that utilize NAD+/NADH-dependent oxidoreductase activity include those of L-DOPA (precursor of dopamine, a neuronal excitatory compound), glycine (an inhibitory neurotransmitter in the brain and spinal cord), histamine (liberated from mast cells during the inflammatory response), and taurine (an inhibitory neurotransmitter of the brain stem, spinal cord and retina) (Newsholme, supra, pp. 790, 792). Epigenetic or genetic defects in neurotransmitter metabolic pathways can result in a spectrum of disease states in different tissues including Parkinson disease and inherited myoclonus (McCance, K.L. and S.E. Huether (1994) Pathophysiology, Mosby-Year Book, Inc., St. Louis MO, pp. 402-404; Gundlach, A.L. (1990) FASEB J. 4:2761-2766).

Tetrahydrofolate is a derivatized glutamate molecule that acts as a carrier, providing activated one-carbon units to a wide variety of biosynthetic reactions, including synthesis of purines, pyrimidines, and the amino acid methionine. Tetrahydrofolate is generated by the activity of a holoenzyme complex called tetrahydrofolate synthase, which includes three enzyme activities: tetrahydrofolate dehydrogenase, tetrahydrofolate cyclohydrolase, and tetrahydrofolate synthetase. Thus, tetrahydrofolate dehydrogenase plays an important role in generating building blocks for nucleic and amino acids, crucial to proliferating cells.

3-Hydroxyacyl-CoA dehydrogenase (3HACD) is involved in fatty acid metabolism. It catalyzes the reduction of 3-hydroxyacyl-CoA to 3-oxoacyl-CoA, with concomitant oxidation of NAD to NADH, in the mitochondria and peroxisomes of eukaryotic cells. In peroxisomes, 3HACD and enoyl-CoA hydratase form an enzyme complex called bifunctional enzyme, defects in which are associated with peroxisomal bifunctional enzyme deficiency. This interruption in fatty acid metabolism produces accumulation of very-long chain fatty acids, disrupting development of the brain, bone, and adrenal glands. Infants born with this deficiency typically die within 6 months (Watkins, P. et al. (1989) J. Clin. Invest. 83:771-777; Online Mendelian Inheritance in Man (OMIM), #261515). The neurodegeneration that is characteristic of Alzheimer's disease involves development of extracellular plaques in certain brain regions. A major protein component of these plaques is the peptide amyloid- β (A β), which is one of several cleavage products of amyloid precursor protein (APP). 3HACD has been shown to bind the A β peptide, and is overexpressed in neurons affected in Alzheimer's disease. In addition, an antibody against 3HACD can block the toxic effects of A β in a cell culture model of Alzheimer's disease (Yan, S. et al. (1997) Nature 389:689-695; OMIM,

25 .

#602057).

10

15

20

25

30

Steroids, such as estrogen, testosterone, corticosterone, and others, are generated from a common precursor, cholesterol, and are interconverted into one another. A wide variety of enzymes act upon cholesterol, including a number of dehydrogenases. Steroid dehydrogenases, such as the hydroxysteroid dehydrogenases, are involved in hypertension, fertility, and cancer (Duax, W.L. and D. Ghosh (1997) Steroids 62:95-100). One such dehydrogenase is 3-oxo-5-\alpha-steroid dehydrogenase (OASD), a microsomal membrane protein highly expressed in prostate and other androgen-responsive tissues. OASD catalyzes the conversion of testosterone into dihydrotestosterone, which is the most potent androgen. Dihydrotestosterone is essential for the formation of the male phenotype during embryogenesis, as well as for proper androgen-mediated growth of tissues such as the prostate and male genitalia. A defect in OASD that prevents the conversion of testosterone into dihydrotestosterone leads to a rare form of male pseudohermaphroditis, characterized by defective formation of the external genitalia (Andersson, S. et al. (1991) Nature 354:159-161; Labrie, F. et al. (1992) Endocrinology 131:1571-1573; OMIM #264600). Thus, OASD plays a central role in sexual differentiation and androgen physiology.

 17β -hydroxysteroid dehydrogenase (17β HSD6) plays an important role in the regulation of the male reproductive hormone, dihydrotestosterone (DHTT). 17β HSD6 acts to reduce levels of DHTT by oxidizing a precursor of DHTT, 3α -diol, to androsterone which is readily glucuronidated and removed from tissues. 17β HSD6 is active with both androgen and estrogen substrates when expressed in embryonic kidney 293 cells. At least five other isozymes of 17β HSD have been identified that catalyze oxidation and/or reduction reactions in various tissues with preferences for different steroid substrates (Biswas, M.G. and D.W. Russell (1997) J. Biol. Chem. 272:15959-15966). For example, 17β HSD1 preferentially reduces estradiol and is abundant in the ovary and placenta. 17β HSD2 catalyzes oxidation of androgens and is present in the endometrium and placenta. 17β HSD3 is exclusively a reductive enzyme in the testis (Geissler, W.M. et al. (1994) Nat. Genet. 7:34-39). An excess of androgens such as DHTT can contribute to certain disease states such as benign prostatic hyperplasia and prostate cancer.

Oxidoreductases are components of the fatty acid metabolism pathways in mitochondria and peroxisomes. The main beta-oxidation pathway degrades both saturated and unsaturated fatty acids, while the auxiliary pathway performs additional steps required for the degradation of unsaturated fatty acids. The auxiliary beta-oxidation enzyme 2,4-dienoyl-CoA reductase catalyzes the removal of even-numbered double bonds from unsaturated fatty acids prior to their entry into the main beta-oxidation pathway. The enzyme may also remove odd-numbered double bonds from unsaturated fatty acids (Koivuranta, K.T. et al. (1994) Biochem. J. 304:787-792; Smeland, T.E. et al. (1992) Proc.

Natl. Acad. Sci. USA 89:6673-6677). 2,4-dienoyl-CoA reductase is located in both mitochondria and peroxisomes. Inherited deficiencies in mitochondrial and peroxisomal beta-oxidation enzymes are associated with severe diseases, some of which manifest themselves soon after birth and lead to death within a few years. Defects in beta-oxidation are associated with Reye's syndrome, Zellweger syndrome, neonatal adrenoleukodystrophy, infantile Refsum's disease, acyl-CoA oxidase deficiency, and bifunctional protein deficiency (Suzuki, Y. et al. (1994) Am. J. Hum. Genet. 54:36-43; Hoefler, supra; Cotran, R.S. et al. (1994) Robbins Pathologic Basis of Disease, W.B. Saunders Co., Philadelphia PA, p.866). Peroxisomal beta-oxidation is impaired in cancerous tissue. Although neoplastic human breast epithelial cells have the same number of peroxisomes as do normal cells, fatty acyl-CoA oxidase activity is lower than in control tissue (el Bouhtoury, F. et al. (1992) J. Pathol. 166:27-35). Human colon carcinomas have fewer peroxisomes than normal colon tissue and have lower fatty-acyl-CoA oxidase and bifunctional enzyme (including enoyl-CoA hydratase) activities than normal tissue (Cable, S. et al. (1992) Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 62:221-226). Another important oxidoreductase is isocitrate dehydrogenase, which catalyzes the conversion of isocitrate to a-ketoglutarate, a substrate of the citric acid cycle. Isocitrate dehydrogenase can be either NAD or NADP dependent, and is found in the cytosol, mitochondria, and peroxisomes. Activity of isocitrate dehydrogenase is regulated developmentally, and by hormones, neurotransmitters, and growth factors.

Hydroxypyruvate reductase (HPR), a peroxisomal 2-hydroxyacid dehydrogenase in the glycolate pathway, catalyzes the conversion of hydroxypyruvate to glycerate with the oxidation of both NADH and NADPH. The reverse dehydrogenase reaction reduces NAD⁺ and NADP⁺. HPR recycles nucleotides and bases back into pathways leading to the synthesis of ATP and GTP. ATP and GTP are used to produce DNA and RNA and to control various aspects of signal transduction and energy metabolism. Inhibitors of purine nucleotide biosynthesis have long been employed as antiproliferative agents to treat cancer and viral diseases. HPR also regulates biochemical synthesis of serine and cellular serine levels available for protein synthesis.

The mitochondrial electron transport (or respiratory) chain is a series of oxidoreductase-type enzyme complexes in the mitochondrial membrane that is responsible for the transport of electrons from NADH through a series of redox centers within these complexes to oxygen, and the coupling of this oxidation to the synthesis of ATP (oxidative phosphorylation). ATP then provides the primary source of energy for driving a cell's many energy-requiring reactions. The key complexes in the respiratory chain are NADH:ubiquinone oxidoreductase (complex I), succinate:ubiquinone oxidoreductase (complex III), cytochrome c oxidase (complex IV), and ATP synthase (complex V) (Alberts, B. et al. (1994) Molecular Biology of the

15

20

. 25

<u>Cell</u>, Garland Publishing, Inc., New York NY, pp. 677-678). All of these complexes are located on the inner matrix side of the mitochondrial membrane except complex II, which is on the cytosolic side. Complex II transports electrons generated in the citric acid cycle to the respiratory chain. The electrons generated by oxidation of succinate to fumarate in the citric acid cycle are transferred through electron carriers in complex II to membrane bound ubiquinone (Q). Transcriptional regulation of these nuclear-encoded genes appears to be the predominant means for controlling the biogenesis of respiratory enzymes. Defects and altered expression of enzymes in the respiratory chain are associated with a variety of disease conditions.

Other dehydrogenase activities using NAD as a cofactor are also important in mitochondrial function. 3-hydroxyisobutyrate dehydrogenase (3HBD), important in valine catabolism, catalyzes the NAD-dependent oxidation of 3-hydroxyisobutyrate to methylmalonate semialdehyde within mitochondria. Elevated levels of 3-hydroxyisobutyrate have been reported in a number of disease states, including ketoacidosis, methylmalonic acidemia, and other disorders associated with deficiencies in methylmalonate semialdehyde dehydrogenase (Rougraff, P.M. et al. (1989) J. Biol. Chem. 264:5899-5903).

Another mitochondrial dehydrogenase important in amino acid metabolism is the enzyme isovaleryl-CoA-dehydrogenase (IVD). IVD is involved in leucine metabolism and catalyzes the oxidation of isovaleryl-CoA to 3-methylcrotonyl-CoA. Human IVD is a tetrameric flavoprotein that is encoded in the nucleus and synthesized in the cytosol as a 45 kDa precursor with a mitochondrial import signal sequence. A genetic deficiency, caused by a mutation in the gene encoding IVD, results in the condition known as isovaleric acidemia. This mutation results in inefficient mitochondrial import and processing of the IVD precursor (Vockley, J. et al. (1992) J. Biol. Chem. 267:2494-2501). Transferases

Transferases are enzymes that catalyze the transfer of molecular groups. The reaction may involve an oxidation, reduction, or cleavage of covalent bonds, and is often specific to a substrate or to particular sites on a type of substrate. Transferases participate in reactions essential to such functions as synthesis and degradation of cell components, regulation of cell functions including cell signaling, cell proliferation, inflamation, apoptosis, secretion and excretion. Transferases are involved in key steps in disease processes involving these functions. Transferases are frequently classified according to the type of group transferred. For example, methyl transferases transfer one-carbon methyl groups, amino transferases transfer nitrogenous amino groups, and similarly denominated enzymes transfer aldehyde or ketone, acyl, glycosyl, alkyl or aryl, isoprenyl, saccharyl, phosphorous-containing, sulfur-containing, or selenium-containing groups, as well as small enzymatic groups such as Coenzyme A.

10

15

20

25

Acyl transferases include peroxisomal carnitine octanoyl transferase, which is involved in the fatty acid beta-oxidation pathway, and mitochondrial carnitine palmitoyl transferases, involved in fatty acid metabolism and transport. Choline O-acetyl transferase catalyzes the biosynthesis of the neurotransmitter acetylcholine.

Amino transferases play key roles in protein synthesis and degradation, and they contribute to other processes as well. For example, the amino transferase 5-aminolevulinic acid synthase catalyzes the addition of succinyl-CoA to glycine, the first step in heme biosynthesis. Other amino transferases participate in pathways important for neurological function and metabolism. For example, glutaminephenylpyruvate amino transferase, also known as glutamine transaminase K (GTK), catalyzes several reactions with a pyridoxal phosphate cofactor. GTK catalyzes the reversible conversion of Lglutamine and phenylpyruvate to 2-oxoglutaramate and L-phenylalanine. Other amino acid substrates for GTK include L-methionine, L-histidine, and L-tyrosine. GTK also catalyzes the conversion of kynurenine to kynurenic acid, a tryptophan metabolite that is an antagonist of the N-methyl-Daspartate (NMDA) receptor in the brain and may exert a neuromodulatory function. Alteration of the kynurenine metabolic pathway may be associated with several neurological disorders. GTK also plays a role in the metabolism of halogenated xenobiotics conjugated to glutathione, leading to nephrotoxicity in rats and neurotoxicity in humans. GTK is expressed in kidney, liver, and brain. Both human and rat GTKs contain a putative pyridoxal phosphate binding site (ExPASy ENZYME: EC 2.6.1.64; Perry, S.J. et al. (1993) Mol. Pharmacol. 43:660-665; Perry, S. et al. (1995) FEBS Lett. 360:277-280; and Alberati-Giani, D. et al. (1995) J. Neurochem. 64:1448-1455). A second amino transferase associated with this pathway is kynurenine/α-aminoadipate amino transferase (AadAT). AadAT catalyzes the reversible conversion of α -aminoadipate and α -ketoglutarate to α -ketoadipate and L-glutamate during lysine metabolism. AadAT also catalyzes the transamination of kynurenine to kynurenic acid. A cytosolic AadAT is expressed in rat kidney, liver, and brain (Nakatani, Y. et al. (1970) Biochim, Biophys. Acta 198:219-228; Buchli, R. et al. (1995) J. Biol. Chem. 270:29330-29335).

Glycosyl transferases include the mammalian UDP-glucouronosyl transferases, a family of membrane-bound microsomal enzymes catalyzing the transfer of glucouronic acid to lipophilic substrates in reactions that play important roles in detoxification and excretion of drugs, carcinogens, and other foreign substances. Another mammalian glycosyl transferase, mammalian UDP-galactose-ceramide galactosyl transferase, catalyzes the transfer of galactose to ceramide in the synthesis of galactocerebrosides in myelin membranes of the nervous system. The UDP-glycosyl transferases share a conserved signature domain of about 50 amino acid residues (PROSITE: PDOC00359, http://expasy.hcuge.ch/sprot/prosite.html).

Methyl transferases are involved in a variety of pharmacologically important processes. Nicotinamide N-methyl transferase catalyzes the N-methylation of nicotinamides and other pyridines, an important step in the cellular handling of drugs and other foreign compounds. Phenylethanolamine N-methyl transferase catalyzes the conversion of noradrenalin to adrenalin. 6-Omethylguanine-DNA methyl transferase reverses DNA methylation, an important step in carcinogenesis. Uroporphyrin-III C-methyl transferase, which catalyzes the transfer of two methyl groups from S-adenosyl-L-methionine to uroporphyrinogen III, is the first specific enzyme in the biosynthesis of cobalamin, a dietary enzyme whose uptake is deficient in pernicious anemia. Proteinarginine methyl transferases catalyze the posttranslational methylation of arginine residues in proteins, resulting in the mono- and dimethylation of arginine on the guanidino group. Substrates include histones, myelin basic protein, and heterogeneous nuclear ribonucleoproteins involved in mRNA processing, splicing, and transport. Protein-arginine methyl transferase interacts with proteins upregulated by mitogens, with proteins involved in chronic lymphocytic leukemia, and with interferon, suggesting an important role for methylation in cytokine receptor signaling (Lin, W.-J. et al. (1996) J. Biol. Chem. 271:15034-15044; Abramovich, C. et al. (1997) EMBO J. 16:260-266; and Scott, H.S. et al. (1998) Genomics 48:330-340).

Phosphotransferases catalyze the transfer of high-energy phosphate groups and are important in energy-requiring and -releasing reactions. The metabolic enzyme creatine kinase catalyzes the reversible phosphate transfer between creatine/creatine phosphate and ATP/ADP. Glycocyamine kinase catalyzes phosphate transfer from ATP to guanidoacetate, and arginine kinase catalyzes phosphate transfer from ATP to arginine. A cysteine-containing active site is conserved in this family (PROSITE: PDOC00103).

Prenyl transferases are heterodimers, consisting of an alpha and a beta subunit, that catalyze the transfer of an isoprenyl group. An example of a prenyl transferase is the mammalian protein farnesyl transferase. The alpha subunit of farnesyl transferase consists of 5 repeats of 34 amino acids each, with each repeat containing an invariant tryptophan (PROSITE: PDOC00703).

Saccharyl transferases are glycating enzymes involved in a variety of metabolic processes. Oligosacchryl transferase-48, for example, is a receptor for advanced glycation endproducts. Accumulation of these endproducts is observed in vascular complications of diabetes, macrovascular disease, renal insufficiency, and Alzheimer's disease (Thornalley, P.J. (1998) Cell Mol. Biol. (Noisy-Le-Grand) 44:1013-1023).

Coenzyme A (CoA) transferase catalyzes the transfer of CoA between two carboxylic acids. Succinyl CoA:3-oxoacid CoA transferase, for example, transfers CoA from succinyl-CoA to a recipient such as acetoacetate. Acetoacetate is essential to the metabolism of ketone bodies, which

10

15

20

25

15

20

30

BNSDOCID: <WO 0162927A2 | 3



accumulate in tissues affected by metabolic disorders such as diabetes (PROSITE: PDOC00980). <u>Hydrolases</u>

Hydrolysis is the breaking of a covalent bond in a substrate by introduction of a molecule of water. The reaction involves a nucleophilic attack by the water molecule's oxygen atom on a target bond in the substrate. The water molecule is split across the target bond, breaking the bond and generating two product molecules. Hydrolases participate in reactions essential to such functions as synthesis and degradation of cell components, and for regulation of cell functions including cell signaling, cell proliferation, inflamation, apoptosis, secretion and excretion. Hydrolases are involved in key steps in disease processes involving these functions. Hydrolytic enzymes, or hydrolases, may be grouped by substrate specificity into classes including phosphatases, peptidases, lysophospholipases, phosphodiesterases, glycosidases, and glyoxalases.

Phosphatases hydrolytically remove phosphate groups from proteins, an energy-providing step that regulates many cellular processes, including intracellular signaling pathways that in turn control cell growth and differentiation, cell-cell contact, the cell cycle, and oncogenesis.

Lysophospholipases (LPLs) regulate intracellular lipids by catalyzing the hydrolysis of ester bonds to remove an acyl group, a key step in lipid degradation. Small LPL isoforms, approximately 15-30 kD, function as hydrolases; larger isoforms function both as hydrolases and transacylases. A particular substrate for LPLs, lysophosphatidylcholine, causes lysis of cell membranes. LPL activity is regulated by signaling molecules important in numerous pathways, including the inflammatory response.

Peptidases, also called proteases, cleave peptide bonds that form the backbone of peptide or protein chains. Proteolytic processing is essential to cell growth, differentiation, remodeling, and homeostasis as well as inflammation and immune response. Since typical protein half-lives range from hours to a few days, peptidases are continually cleaving precursor proteins to their active form, removing signal sequences from targeted proteins, and degrading aged or defective proteins. Peptidases function in bacterial, parasitic, and viral invasion and replication within a host. Examples of peptidases include trypsin and chymotrypsin (components of the complement cascade and the blood-clotting cascade) lysosomal cathepsins, calpains, pepsin, renin, and chymosin (Beynon, R.J. and J.S. Bond (1994) Proteolytic Enzymes: A Practical Approach, Oxford University Press, New York NY, pp. 1-5).

The phosphodiesterases catalyze the hydrolysis of one of the two ester bonds in a phosphodiester compound. Phosphodiesterases are therefore crucial to a variety of cellular processes. Phosphodiesterases include DNA and RNA endo- and exo-nucleases, which are essential to cell growth and replication as well as protein synthesis. Another phosphodiesterase is acid

sphingomyelinase, which hydrolyzes the membrane phospholipid sphingomyelin to ceramide and phosphorylcholine. Phosphorylcholine is used in the synthesis of phosphatidylcholine, which is involved in numerous intracellular signaling pathways. Ceramide is an essential precursor for the generation of gangliosides, membrane lipids found in high concentration in neural tissue. Defective acid sphingomyelinase phosphodiesterase leads to a build-up of sphingomyelin molecules in lysosomes, resulting in Niemann-Pick disease.

Glycosidases catalyze the cleavage of hemiacetyl bonds of glycosides, which are compounds that contain one or more sugar. Mammalian lactase-phlorizin hydrolase, for example, is an intestinal enzyme that splits lactose. Mammalian beta-galactosidase removes the terminal galactose from gangliosides, glycoproteins, and glycosaminoglycans, and deficiency of this enzyme is associated with a gangliosidosis known as Morquio disease type B. Vertebrate lysosomal alpha-glucosidase, which hydrolyzes glycogen, maltose, and isomaltose, and vertebrate intestinal sucrase-isomaltase, which hydrolyzes sucrose, maltose, and isomaltose, are widely distributed members of this family with highly conserved sequences at their active sites.

The glyoxylase system is involved in gluconeogenesis, the production of glucose from storage compounds in the body. It consists of glyoxylase I, which catalyzes the formation of S-D-lactoylglutathione from methyglyoxal, a side product of triose-phosphate energy metabolism, and glyoxylase II, which hydrolyzes S-D-lactoylglutathione to D-lactic acid and reduced glutathione. Glyoxylases are involved in hyperglycemia, non-insulin-dependent diabetes mellitus, the detoxification of bacterial toxins, and in the control of cell proliferation and microtubule assembly. Lyases

Lyases are a class of enzymes that catalyze the cleavage of C-C, C-O, C-N, C-S, C-(halide), P-O or other bonds without hydrolysis or oxidation to form two molecules, at least one of which contains a double bond (Stryer, L. (1995) <u>Biochemistry</u> W.H. Freeman and Co. New York, NY p.620). Lyases are critical components of cellular biochemistry with roles in metabolic energy production including fatty acid metabolism, as well as other diverse enzymatic processes. Further classification of lyases reflects the type of bond cleaved as well as the nature of the cleaved group.

The group of C-C lyases include carboxyl-lyases (decarboxylases), aldehyde-lyases (aldolases), oxo-acid-lyases and others. The C-O lyase group includes hydro-lyases, lyases acting on polysaccharides and other lyases. The C-N lyase group includes ammonia-lyases, amidine-lyases, amine-lyases (deaminases) and other lyases.

Proper regulation of lyases is critical to normal physiology. For example, mutation induced deficiencies in the uroporphyrinogen decarboxylase can lead to photosensitive cutaneous lesions in the genetically-linked disorder familial porphyria cutanea tarda (Mendez, M. et al. (1998) Am. J.

5

10

15

20

25

Genet. 63:1363-1375). It has also been shown that adenosine deaminase (ADA) deficiency stems from genetic mutations in the ADA gene, resulting in the disorder severe combined immunodeficiency disease (SCID) (Hershfield, M.S. (1998) Semin. Hematol. 35:291-298).

Isomerases

Isomerases are a class of enzymes that catalyze geometric or structural changes within a molecule to form a single product. This class includes racemases and epimerases, cis-transisomerases, intramolecular oxidoreductases, intramolecular transferases (mutases) and intramolecular lyases. Isomerases are critical components of cellular biochemistry with roles in metabolic energy production including glycolysis, as well as other diverse enzymatic processes (Stryer, L. (1995) Biochemistry, W.H. Freeman and Co., New York NY, pp.483-507).

Racemases are a subset of isomerases that catalyze inversion of a molecules configuration around the asymmetric carbon atom in a substrate having a single center of asymmetry, thereby interconverting two racemers. Epimerases are another subset of isomerases that catalyze inversion of configuration around an asymmetric carbon atom in a substrate with more than one center of symmetry, thereby interconverting two epimers. Racemases and epimerases can act on amino acids and derivatives, hydroxy acids and derivatives, as well as carbohydrates and derivatives. The interconversion of UDP-galactose and UDP-glucose is catalyzed by UDP-galactose-4'-epimerase. Proper regulation and function of this epimerase is essential to the synthesis of glycoproteins and glycolipids. Elevated blood galactose levels have been correlated with UDP-galactose-4'-epimerase deficiency in screening programs of infants (Gitzelmann, R. (1972) Helv. Paediat. Acta 27:125-130).

Oxidoreductases can be isomerases as well. Oxidoreductases catalyze the reversible transfer of electrons from a substrate that becomes oxidized to a substrate that becomes reduced. This class of enzymes includes dehydrogenases, hydroxylases, oxidases, oxygenases, peroxidases, and reductases. Proper maintenance of oxidoreductase levels is physiologically important. For example, genetically-linked deficiencies in lipoamide dehydrogenase can result in lactic acidosis (Robinson, B.H. et al. (1977) Pediat. Res. 11:1198-1202).

Another subgroup of isomerases are the transferases (or mutases). Transferases transfer a chemical group from one compound (the donor) to another compound (the acceptor). The types of groups transferred by these enzymes include acyl groups, amino groups, phosphate groups (phosphotransferases or phosphomutases), and others. The transferase carnitine palmitoyltransferase is an important component of fatty acid metabolism. Genetically-linked deficiencies in this transferase can lead to myopathy (Scriver, C.R. et al. (1995) The Metabolic and Molecular Basis of Inherited Disease, McGraw-Hill, New York NY, pp.1501-1533).

Yet another subgroup of isomerases are the topoisomerases. Topoisomerases are enzymes

that affect the topological state of DNA. For example, defects in topoisomerases or their regulation can affect normal physiology. Reduced levels of topoisomerase II have been correlated with some of the DNA processing defects associated with the disorder ataxia-telangiectasia (Singh, S.P. et al. (1988) Nucleic Acids Res. 16:3919-3929).

5 Ligases

10

15

20

25

30

Ligases catalyze the formation of a bond between two substrate molecules. The process involves the hydrolysis of a pyrophosphate bond in ATP or a similar energy donor. Ligases are classified based on the nature of the type of bond they form, which can include carbon-oxygen, carbon-sulfur, carbon-nitrogen, carbon-carbon and phosphoric ester bonds.

Ligases forming carbon-oxygen bonds include the aminoacyl-transfer RNA (tRNA) synthetases which are important RNA-associated enzymes with roles in translation. Protein biosynthesis depends on each amino acid forming a linkage with the appropriate tRNA. The aminoacyl-tRNA synthetases are responsible for the activation and correct attachment of an amino acid with its cognate tRNA. The 20 aminoacyl-tRNA synthetase enzymes can be divided into two structural classes, and each class is characterized by a distinctive topology of the catalytic domain. Class I enzymes contain a catalytic domain based on the nucleotide-binding Rossman fold. Class II enzymes contain a central catalytic domain, which consists of a seven-stranded antiparallel \(\theta\)-sheet motif, as well as N- and C- terminal regulatory domains. Class II enzymes are separated into two groups based on the heterodimeric or homodimeric structure of the enzyme; the latter group is further subdivided by the structure of the N- and C-terminal regulatory domains (Hartlein, M. and S. Cusack (1995) J. Mol. Evol. 40:519-530). Autoantibodies against aminoacyl-tRNAs are generated by patients with dermatomyositis and polymyositis, and correlate strongly with complicating interstitial lung disease (ILD). These antibodies appear to be generated in response to viral infection, and coxsackie virus has been used to induce experimental viral myositis in animals.

Ligases forming carbon-sulfur bonds (Acid-thiol ligases) mediate a large number of cellular biosynthetic intermediary metabolism processes involve intermolecular transfer of carbon atom-containing substrates (carbon substrates). Examples of such reactions include the tricarboxylic acid cycle, synthesis of fatty acids and long-chain phospholipids, synthesis of alcohols and aldehydes, synthesis of intermediary metabolites, and reactions involved in the amino acid degradation pathways. Some of these reactions require input of energy, usually in the form of conversion of ATP to either ADP or AMP and pyrophosphate.

In many cases, a carbon substrate is derived from a small molecule containing at least two carbon atoms. The carbon substrate is often covalently bound to a larger molecule which acts as a carbon substrate carrier molecule within the cell. In the biosynthetic mechanisms described above,

the carrier molecule is coenzyme A. Coenzyme A (CoA) is structurally related to derivatives of the nucleotide ADP and consists of 4'-phosphopantetheine linked via a phosphodiester bond to the alpha phosphate group of adenosine 3',5'-bisphosphate. The terminal thiol group of 4'-phosphopantetheine acts as the site for carbon substrate bond formation. The predominant carbon substrates which utilize CoA as a carrier molecule during biosynthesis and intermediary metabolism in the cell are acetyl, succinyl, and propionyl moieties, collectively referred to as acyl groups. Other carbon substrates include enoyl lipid, which acts as a fatty acid oxidation intermediate, and carnitine, which acts as an acetyl-CoA flux regulator/mitochondrial acyl group transfer protein. Acyl-CoA and acetyl-CoA are synthesized in the cell by acyl-CoA synthetase and acetyl-CoA synthetase, respectively.

Activation of fatty acids is mediated by at least three forms of acyl-CoA synthetase activity: i) acetyl-CoA synthetase, which activates acetate and several other low molecular weight carboxylic acids and is found in muscle mitochondria and the cytosol of other tissues; ii) medium-chain acyl-CoA synthetase, which activates fatty acids containing between four and eleven carbon atoms (predominantly from dietary sources), and is present only in liver mitochondria; and iii) acyl CoA synthetase, which is specific for long chain fatty acids with between six and twenty carbon atoms, and is found in microsomes and the mitochondria. Proteins associated with acyl-CoA synthetase activity have been identified from many sources including bacteria, yeast, plants, mouse, and man. The activity of acyl-CoA synthetase may be modulated by phosphorylation of the enzyme by cAMP-dependent protein kinase.

Ligases forming carbon-nitrogen bonds include amide synthases such as glutamine synthetase (glutamate-ammonia ligase) that catalyzes the amination of glutamic acid to glutamine by ammonia using the energy of ATP hydrolysis. Glutamine is the primary source for the amino group in various amide transfer reactions involved in de novo pyrimidine nucleotide synthesis and in purine and pyrimidine ribonucleotide interconversions. Overexpression of glutamine synthetase has been observed in primary liver cancer (Christa, L. et al. (1994) Gastroent. 106:1312-1320).

Acid-amino-acid ligases (peptide synthases) are represented by the ubiquitin proteases which are associated with the ubiquitin conjugation system (UCS), a major pathway for the degradation of cellular proteins in eukaryotic cells and some bacteria. The UCS mediates the elimination of abnormal proteins and regulates the half-lives of important regulatory proteins that control cellular processes such as gene transcription and cell cycle progression. In the UCS pathway, proteins targeted for degradation are conjugated to a ubiquitin (Ub), a small heat stable protein. Ub is first activated by a ubiquitin-activating enzyme (E1), and then transferred to one of several Ubconjugating enzymes (E2). E2 then links the Ub molecule through its C-terminal glycine to an internal lysine (acceptor lysine) of a target protein. The ubiquitinated protein is then recognized and

30

10.

degraded by proteasome, a large, multisubunit proteolytic enzyme complex, and ubiquitin is released for reutilization by ubiquitin protease. The UCS is implicated in the degradation of mitotic cyclic kinases, oncoproteins, tumor suppressor genes such as p53, viral proteins, cell surface receptors associated with signal transduction, transcriptional regulators, and mutated or damaged proteins (Ciechanover, A. (1994) Cell 79:13-21). A murine proto-oncogene, Unp, encodes a nuclear ubiquitin protease whose overexpression leads to oncogenic transformation of NIH3T3 cells, and the human homolog of this gene is consistently elevated in small cell tumors and adenocarcinomas of the lung (Gray, D.A. (1995) Oncogene 10:2179-2183).

Cyclo-ligases and other carbon-nitrogen ligases comprise various enzymes and enzyme complexes that participate in the de novo pathways to purine and pyrimidine biosynthesis. Because these pathways are critical to the synthesis of nucleotides for replication of both RNA and DNA, many of these enzymes have been the targets of clinical agents for the treatment of cell proliferative disorders such as cancer and infectious diseases.

10

15

20

25

30

BNSDOCID: <WO 0162927A2 1 >

Purine biosynthesis occurs de novo from the amino acids glycine and glutamine, and other small molecules. Three of the key reactions in this process are catalyzed by a trifunctional enzyme composed of glycinamide-ribonucleotide synthetase (GARS), aminoimidazole ribonucleotide synthetase (AIRS), and glycinamide ribonucleotide transformylase (GART). Together these three enzymes combine ribosylamine phosphate with glycine to yield phosphoribosyl aminoimidazole, a precursor to both adenylate and guanylate nucleotides. This trifunctional protein has been implicated in the pathology of Downs syndrome (Aimi, J. et al. (1990) Nucleic Acid Res. 18:6665-6672). Adenylosuccinate synthetase catalyzes a later step in purine biosynthesis that converts inosinic acid to adenylosuccinate, a key step on the path to ATP synthesis. This enzyme is also similar to another carbon-nitrogen ligase, argininosuccinate synthetase, that catalyzes a similar reaction in the urea cycle (Powell, S.M. et al. (1992) FEBS Lett. 303:4-10).

Like the de novo biosynthesis of purines, de novo synthesis of the pyrimidine nucleotides uridylate and cytidylate also arises from a common precursor, in this instance the nucleotide orotidylate derived from orotate and phosphoribosyl pyrophosphate (PPRP). Again a trifunctional enzyme comprising three carbon-nitrogen ligases plays a key role in the process. In this case the enzymes aspartate transcarbamylase (ATCase), carbamyl phosphate synthetase II, and dihydroorotase (DHOase) are encoded by a single gene called CAD. Together these three enzymes combine the initial reactants in pyrimidine biosynthesis, glutamine, CO₂ and ATP to form dihydroorotate, the precursor to orotate and orotidylate (Iwahana, H. et al. (1996) Biochem. Biophys. Res. Commun. 219:249-255). Further steps then lead to the synthesis of uridine nucleotides from orotidylate. Cytidine nucleotides are derived from uridine-5'-triphosphate (UTP) by the amidation of UTP using

glutamine as the amino donor and the enzyme CTP synthetase. Regulatory mutations in the human CTP synthetase are believed to confer multi-drug resistance to agents widely used in cancer therapy (Yamauchi, M. et al. (1990) EMBO J. 9:2095-2099).

Ligases forming carbon-carbon bonds include the carboxylases acetyl-CoA carboxylase and pyruvate carboxylase. Acetyl-CoA carboxylase catalyzes the carboxylation of acetyl-CoA from CO₂ and H₂O using the energy of ATP hydrolysis. Acetyl-CoA carboxylase is the rate-limiting step in the biogenesis of long-chain fatty acids. Two isoforms of acetyl-CoA carboxylase, types I and types II, are expressed in human in a tissue-specific manner (Ha, J. et al. (1994) Eur. J. Biochem. 219:297-306). Pyruvate carboxylase is a nuclear-encoded mitochondrial enzyme that catalyzes the conversion of pyruvate to oxaloacetate, a key intermediate in the citric acid cycle.

Ligases forming phosphoric ester bonds include the DNA ligases involved in both DNA replication and repair, DNA ligases seal phosphodiester bonds between two adjacent nucleotides in a DNA chain using the energy from ATP hydrolysis to first activate the free 5'-phosphate of one nucleotide and then react it with the 3'-OH group of the adjacent nucleotide. This resealing reaction is used in both DNA replication to join small DNA fragments called Okazaki fragments that are transiently formed in the process of replicating new DNA, and in DNA repair. DNA repair is the process by which accidental base changes, such as those produced by oxidative damage, hydrolytic attack, or uncontrolled methylation of DNA, are corrected before replication or transcription of the DNA can occur. Bloom's syndrome is an inherited human disease in which individuals are partially deficient in DNA ligation and consequently have an increased incidence of cancer (Alberts, B. et al. (1994) The Molecular Biology of the Cell, Garland Publishing Inc., New York NY, p. 247).

Molecules Associated with Growth and Development

Human growth and development requires the spatial and temporal regulation of cell differentiation, cell proliferation, and apoptosis. These processes coordinately control reproduction, aging, embryogenesis, morphogenesis, organogenesis, and tissue repair and maintenance. At the cellular level, growth and development is governed by the cell's decision to enter into or exit from the cell division cycle and by the cell's commitment to a terminally differentiated state. These decisions are made by the cell in response to extracellular signals and other environmental cues it receives. The following discussion focuses on the molecular mechanisms of cell division, reproduction, cell differentiation and proliferation, apoptosis, and aging.

Cell Division

Cell division is the fundamental process by which all living things grow and reproduce. In unicellular organisms such as yeast and bacteria, each cell division doubles the number of organisms,

while in multicellular species many rounds of cell division are required to replace cells lost by wear or by programmed cell death, and for cell differentiation to produce a new tissue or organ. Details of the cell division cycle may vary, but the basic process consists of three principle events. The first event, interphase, involves preparations for cell division, replication of the DNA, and production of essential proteins. In the second event, mitosis, the nuclear material is divided and separates to opposite sides of the cell. The final event, cytokinesis, is division and fission of the cell cytoplasm. The sequence and timing of cell cycle transitions is under the control of the cell cycle regulation system which controls the process by positive or negative regulatory circuits at various check points.

Regulated progression of the cell cycle depends on the integration of growth control pathways with the basic cell cycle machinery. Cell cycle regulators have been identified by selecting for human and yeast cDNAs that block or activate cell cycle arrest signals in the yeast mating pheromone pathway when they are overexpressed. Known regulators include human CPR (cell cycle progression restoration) genes, such as CPR8 and CPR2, and yeast CDC (cell division control) genes, including CDC91, that block the arrest signals. The CPR genes express a variety of proteins including cyclins, tumor suppressor binding proteins, chaperones, transcription factors, translation factors, and RNA-binding proteins (Edwards, M.C. et al.(1997) Genetics 147:1063-1076).

Several cell cycle transitions, including the entry and exit of a cell from mitosis, are dependent upon the activation and inhibition of cyclin-dependent kinases (Cdks). The Cdks are composed of a kinase subunit, Cdk, and an activating subunit, cyclin, in a complex that is subject to many levels of regulation. There appears to be a single Cdk in Saccharomyces cerevisiae and Saccharomyces pombe whereas mammals have a variety of specialized Cdks. Cyclins act by binding to and activating cyclin-dependent protein kinases which then phosphorylate and activate selected proteins involved in the mitotic process. The Cdk-cyclin complex is both positively and negatively regulated by phosphorylation, and by targeted degradation involving molecules such as CDC4 and CDC53. In addition, Cdks are further regulated by binding to inhibitors and other proteins such as Suc1 that modify their specificity or accessibility to regulators (Patra, D. and W.G. Dunphy (1996) Genes Dev. 10:1503-1515; and Mathias, N. et al. (1996) Mol. Cell Biol. 16:6634-6643).

Reproduction

The male and female reproductive systems are complex and involve many aspects of growth and development. The anatomy and physiology of the male and female reproductive systems are reviewed in (Guyton, A.C. (1991) <u>Textbook of Medical Physiology</u>, W.B. Saunders Co., Philadelphia PA, pp. 899-928).

The male reproductive system includes the process of spermatogenesis, in which the sperm are formed, and male reproductive functions are regulated by various hormones and their effects on

والمنظومين والمراكب والمواري

10

15

20

25

accessory sexual organs, cellular metabolism, growth, and other bodily functions.

Spermatogenesis begins at puberty as a result of stimulation by gonadotropic hormones released from the anterior pituitary. Immature sperm (spermatogonia) undergo several mitotic cell divisions before undergoing meiosis and full maturation. The testes secrete several male sex hormones, the most abundant being testosterone, that is essential for growth and division of the immature sperm, and for the masculine characteristics of the male body. Three other male sex hormones, gonadotropinreleasing hormone (GnRH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) control sexual function.

The uterus, ovaries, fallopian tubes, vagina, and breasts comprise the female reproductive system. The ovaries and uterus are the source of ova and the location of fetal development, respectively. The fallopian tubes and vagina are accessory organs attached to the top and bottom of the uterus, respectively. Both the uterus and ovaries have additional roles in the development and loss of reproductive capability during a female's lifetime. The primary role of the breasts is lactation. Multiple endocrine signals from the ovaries, uterus, pituitary, hypothalamus, adrenal glands, and other 15 tissues coordinate reproduction and lactation. These signals vary during the monthly menstruation cycle and during the female's lifetime. Similarly, the sensitivity of reproductive organs to these endocrine signals varies during the female's lifetime.

A combination of positive and negative feedback to the ovaries, pituitary and hypothalamus glands controls physiologic changes during the monthly ovulation and endometrial cycles. The anterior pituitary secretes two major gonadotropin hormones, follicle-stimulating hormone (FSH) and luteinizing hormone (LH), regulated by negative feedback of steroids, most notably by ovarian estradiol. If fertilization does not occur, estrogen and progesterone levels decrease. This sudden reduction of the ovarian hormones leads to menstruation, the desquamation of the endometrium.

Hormones further govern all the steps of pregnancy, parturition, lactation, and menopause. During pregnancy large quantities of human chorionic gonadotropin (hCG), estrogens, progesterone, and human chorionic somatomammotropin (hCS) are formed by the placenta. hCG, a glycoprotein similar to luteinizing hormone, stimulates the corpus luteum to continue producing more progesterone and estrogens, rather than to involute as occurs if the ovum is not fertilized. hCS is similar to growth hormone and is crucial for fetal nutrition.

The female breast also matures during pregnancy. Large amounts of estrogen secreted by the placenta trigger growth and branching of the breast milk ductal system while lactation is initiated by the secretion of prolactin by the pituitary gland.

Parturition involves several hormonal changes that increase uterine contractility toward the end of pregnancy, as follows. The levels of estrogens increase more than those of progesterone. Oxytocin

25

30

is secreted by the neurohypophysis. Concomitantly, uterine sensitivity to oxytocin increases. The fetus itself secretes oxytocin, cortisol (from adrenal glands), and prostaglandins.

Menopause occurs when most of the ovarian follicles have degenerated. The ovary then produces less estradiol, reducing the negative feedback on the pituitary and hypothalamus glands. Mean levels of circulating FSH and LH increase, even as ovulatory cycles continue. Therefore, the ovary is less responsive to gonadotropins, and there is an increase in the time between menstrual cycles. Consequently, menstrual bleeding ceases and reproductive capability ends.

Cell Differentiation and Proliferation

Tissue growth involves complex and ordered patterns of cell proliferation, cell differentiation, and apoptosis. Cell proliferation must be regulated to maintain both the number of cells and their spatial organization. This regulation depends upon the appropriate expression of proteins which control cell cycle progression in response to extracellular signals, such as growth factors and other mitogens, and intracellular cues, such as DNA damage or nutrient starvation. Molecules which directly or indirectly modulate cell cycle progression fall into several categories, including growth factors and their receptors, second messenger and signal transduction proteins, oncogene products, tumor-suppressor proteins, and mitosis-promoting factors.

Growth factors were originally described as serum factors required to promote cell proliferation. Most growth factors are large, secreted polypeptides that act on cells in their local environment. Growth factors bind to and activate specific cell surface receptors and initiate intracellular signal transduction cascades. Many growth factor receptors are classified as receptor tyrosine kinases which undergo autophosphorylation upon ligand binding. Autophosphorylation enables the receptor to interact with signal transduction proteins characterized by the presence of SH2 or SH3 domains (Src homology regions 2 or 3). These proteins then modulate the activity state of small G-proteins, such as Ras, Rab, and Rho, along with GTPase activating proteins (GAPs), guanine nucleotide releasing proteins (GNRPs), and other guanine nucleotide exchange factors. Small G proteins act as molecular switches that activate other downstream events, such as mitogen-activated protein kinase (MAP kinase) cascades. MAP kinases ultimately activate transcription of mitosis-promoting genes.

In addition to growth factors, small signaling peptides and hormones also influence cell proliferation. These molecules bind primarily to another class of receptor, the trimeric G-protein coupled receptor (GPCR), found predominantly on the surface of immune, neuronal and neuroendocrine cells. Upon ligand binding, the GPCR activates a trimeric G protein which in turn triggers increased levels of intracellular second messengers such as phospholipase C, Ca2+, and cyclic AMP. Most GPCR-mediated signaling pathways indirectly promote cell proliferation by causing the secretion or

The Contract of the Contract o

10

15

20

25

breakdown of other signaling molecules that have direct mitogenic effects. These signaling cascades often involve activation of kinases and phosphatases. Some growth factors, such as some members of the transforming growth factor beta (TGF-β) family, act on some cells to stimulate cell proliferation and on other cells to inhibit it. Growth factors may also stimulate a cell at one concentration and inhibit the same cell at another concentration. Most growth factors also have a multitude of other actions besides the regulation of cell growth and division: they can control the proliferation, survival, differentiation, migration, or function of cells depending on the circumstance. For example, the tumor necrosis factor/nerve growth factor (TNF/NGF) family can activate or inhibit cell death, as well as regulate proliferation and differentiation. The cell response depends on the type of cell, its stage of differentiation and transformation status, which surface receptors are stimulated, and the types of stimuli acting on the cell (Smith, A. et al. (1994) Cell 76:959-962; and Nocentini, G. et al. (1997) Proc. Natl. Acad. Sci. USA 94:6216-6221).

Neighboring cells in a tissue compete for growth factors, and when provided with "unlimited" quantities in a perfused system will grow to even higher cell densities before reaching density-dependent inhibition of cell division. Cells often demonstrate an anchorage dependence of cell division as well. This anchorage dependence may be associated with the formation of focal contacts linking the cytoskeleton with the extracellular matrix (ECM). The expression of ECM components can be stimulated by growth factors. For example, TGF-β stimulates fibroblasts to produce a variety of ECM proteins, including fibronectin, collagen, and tenascin (Pearson, C.A. et al. (1988) EMBO J. 7:2677-2981). In fact, for some cell types specific ECM molecules, such as laminin or fibronectin, may act as growth factors. Tenascin-C and -R, expressed in developing and lesioned neural tissue, provide stimulatory/anti-adhesive or inhibitory properties, respectively, for axonal growth (Faissner, A. (1997) Cell Tissue Res. 290:331-341).

Cancers are associated with the activation of oncogenes which are derived from normal cellular genes. These oncogenes encode oncoproteins which convert normal cells into malignant cells. Some oncoproteins are mutant isoforms of the normal protein, and other oncoproteins are abnormally expressed with respect to location or amount of expression. The latter category of oncoprotein causes cancer by altering transcriptional control of cell proliferation. Five classes of oncoproteins are known to affect cell cycle controls. These classes include growth factors, growth factor receptors, intracellular signal transducers, nuclear transcription factors, and cell-cycle control proteins. Viral oncogenes are integrated into the human genome after infection of human cells by certain viruses. Examples of viral oncogenes include v-src, v-abl, and v-fps.

Many oncogenes have been identified and characterized. These include sis, erbA, erbB, her-2, mutated G_s, src, abl, ras, crk, jun, fos, myc, and mutated tumor-suppressor genes such as RB, p53,

mdm2, Cip1, p16, and cyclin D. Transformation of normal genes to oncogenes may also occur by chromosomal translocation. The Philadelphia chromosome, characteristic of chronic myeloid leukemia and a subset of acute lymphoblastic leukemias, results from a reciprocal translocation between chromosomes 9 and 22 that moves a truncated portion of the proto-oncogene c-abl to the breakpoint cluster region (bcr) on chromosome 22.

Tumor-suppressor genes are involved in regulating cell proliferation. Mutations which cause reduced or loss of function in tumor-suppressor genes result in uncontrolled cell proliferation. For example, the retinoblastoma gene product (RB), in a non-phosphorylated state, binds several early-response genes and suppresses their transcription, thus blocking cell division. Phosphorylation of RB causes it to dissociate from the genes, releasing the suppression, and allowing cell division to proceed. Apoptosis

Apoptosis is the genetically controlled process by which unneeded or defective cells undergo programmed cell death. Selective elimination of cells is as important for morphogenesis and tissue remodeling as is cell proliferation and differentiation. Lack of apoptosis may result in hyperplasia and other disorders associated with increased cell proliferation. Apoptosis is also a critical component of the immune response. Immune cells such as cytotoxic T-cells and natural killer cells prevent the spread of disease by inducing apoptosis in tumor cells and virus-infected cells. In addition, immune cells that fail to distinguish self molecules from foreign molecules must be eliminated by apoptosis to avoid an autoimmune response.

Apoptotic cells undergo distinct morphological changes. Hallmarks of apoptosis include cell shrinkage, nuclear and cytoplasmic condensation, and alterations in plasma membrane topology. Biochemically, apoptotic cells are characterized by increased intracellular calcium concentration, fragmentation of chromosomal DNA, and expression of novel cell surface components.

The molecular mechanisms of apoptosis are highly conserved, and many of the key protein regulators and effectors of apoptosis have been identified. Apoptosis generally proceeds in response to a signal which is transduced intracellularly and results in altered patterns of gene expression and protein activity. Signaling molecules such as hormones and cytokines are known both to stimulate and to inhibit apoptosis through interactions with cell surface receptors. Transcription factors also play an important role in the onset of apoptosis. A number of downstream effector molecules, particularly proteases such as the cysteine proteases called caspases, have been implicated in the degradation of cellular components and the proteolytic activation of other apoptotic effectors.

Aging and Senescence

Studies of the aging process or senescence have shown a number of characteristic cellular and molecular changes (Fauci et al. (1998) <u>Harrison's Principles of Internal Medicine</u>, McGraw-Hill, New

10

15

20

25

York NY, p.37). These characteristics include increases in chromosome structural abnormalities, DNA cross-linking, incidence of single-stranded breaks in DNA, losses in DNA methylation, and degradation of telomere regions. In addition to these DNA changes, post-translational alterations of proteins increase including, deamidation, oxidation, cross-linking, and nonenzymatic glycation. Still further molecular changes occur in the mitochondria of aging cells through deterioration of structure. These changes eventually contribute to decreased function in every organ of the body.

Biochemical Pathway Molecules

Biochemical pathways are responsible for regulating metabolism, growth and development,
protein secretion and trafficking, environmental responses, and ecological interactions including
immune response and response to parasites.

DNA replication

Deoxyribonucleic acid (DNA), the genetic material, is found in both the nucleus and mitochondria of human cells. The bulk of human DNA is nuclear, in the form of linear chromosomes, while mitochondrial DNA is circular. DNA replication begins at specific sites called origins of replication. Bidirectional synthesis occurs from the origin via two growing forks that move in opposite directions. Replication is semi-conservative, with each daughter duplex containing one old strand and its newly synthesized complementary partner. Proteins involved in DNA replication include DNA polymerases, DNA primase, telomerase, DNA helicase, topoisomerases, DNA ligases, replication factors, and DNA-binding proteins.

DNA Recombination and Repair

Cells are constantly faced with replication errors and environmental assault (such as ultraviolet irradiation) that can produce DNA damage. Damage to DNA consists of any change that modifies the structure of the molecule. Changes to DNA can be divided into two general classes, single base changes and structural distortions. Any damage to DNA can produce a mutation, and the mutation may produce a disorder, such as cancer.

Changes in DNA are recognized by repair systems within the cell. These repair systems act to correct the damage and thus prevent any deleterious affects of a mutational event. Repair systems can be divided into three general types, direct repair, excision repair, and retrieval systems. Proteins involved in DNA repair include DNA polymerase, excision repair proteins, excision and cross link repair proteins, recombination and repair proteins, RAD51 proteins, and BLN and WRN proteins that are homologs of RecQ helicase. When the repair systems are eliminated, cells become exceedingly sensitive to environmental mutagens, such as ultraviolet irradiation. Patients with disorders associated with a loss in DNA repair systems often exhibit a high sensitivity to environmental mutagens.

Examples of such disorders include xeroderma pigmentosum (XP), Bloom's syndrome (BS), and Werner's syndrome (WS) (Yamagata, K. et al. (1998) Proc. Natl. Acad. Sci. USA 95:8733-8738), ataxia telangiectasia, Cockayne's syndrome, and Fanconi's anemia.

Recombination is the process whereby new DNA sequences are generated by the movements of large pieces of DNA. In homologous recombination, which occurs during meiosis and DNA repair, parent DNA duplexes align at regions of sequence similarity, and new DNA molecules form by the breakage and joining of homologous segments. Proteins involved include RAD51 recombinase. In site-specific recombination, two specific but not necessarily homologous DNA sequences are exchanged. In the immune system this process generates a diverse collection of antibody and T cell receptor genes. Proteins involved in site-specific recombination in the immune system include recombination activating genes 1 and 2 (RAG1 and RAG2). A defect in immune system site-specific recombination causes severe combined immunodeficiency disease in mice.

RNA Metabolism

10

15

20

25

30

Ribonucleic acid (RNA) is a linear single-stranded polymer of four nucleotides, ATP, CTP, UTP, and GTP. In most organisms, RNA is transcribed as a copy of DNA, the genetic material of the organism. In retroviruses RNA rather than DNA serves as the genetic material. RNA copies of the genetic material encode proteins or serve various structural, catalytic, or regulatory roles in organisms. RNA is classified according to its cellular localization and function. Messenger RNAs (mRNAs) encode polypeptides. Ribosomal RNAs (rRNAs) are assembled, along with ribosomal proteins, into ribosomes, which are cytoplasmic particles that translate mRNA into polypeptides. Transfer RNAs (tRNAs) are cytosolic adaptor molecules that function in mRNA translation by recognizing both an mRNA codon and the amino acid that matches that codon. Heterogeneous nuclear RNAs (hnRNAs) include mRNA precursors and other nuclear RNAs of various sizes. Small nuclear RNAs (snRNAs) are a part of the nuclear spliceosome complex that removes intervening, non-coding sequences (introns) and rejoins exons in pre-mRNAs.

RNA Transcription

The transcription process synthesizes an RNA copy of DNA. Proteins involved include multisubunit RNA polymerases, transcription factors IIA, IIB, IID, IIE, IIF, IIH, and IIJ. Many transcription factors incorporate DNA-binding structural motifs which comprise either α -helices or β sheets that bind to the major groove of DNA. Four well-characterized structural motifs are helix-turnhelix, zinc finger, leucine zipper, and helix-loop-helix.

RNA Processing

Various proteins are necessary for processing of transcribed RNAs in the nucleus. Pre-mRNA processing steps include capping at the 5' end with methylguanosine, polyadenylating the 3' end, and

splicing to remove introns. The spliceosomal complex is comprised of five small nuclear ribonucleoprotein particles (snRNPs) designated U1, U2, U4, U5, and U6. Each snRNP contains a single species of snRNA and about ten proteins. The RNA components of some snRNPs recognize and base-pair with intron consensus sequences. The protein components mediate spliceosome assembly and the splicing reaction. Autoantibodies to snRNP proteins are found in the blood of patients with systemic lupus erythematosus (Stryer, L. (1995) <u>Biochemistry</u> W.H. Freeman and Company, New York NY, p. 863).

Heterogeneous nuclear ribonucleoproteins (hnRNPs) have been identified that have roles in splicing, exporting of the mature RNAs to the cytoplasm, and mRNA translation (Biamonti, G. et al. (1998) Clin. Exp. Rheumatol. 16:317-326). Some examples of hnRNPs include the yeast proteins Hrp1p, involved in cleavage and polyadenylation at the 3' end of the RNA; Cbp80p, involved in capping the 5' end of the RNA; and Npl3p, a homolog of mammalian hnRNP A1, involved in export of mRNA from the nucleus (Shen, E.C. et al. (1998) Genes Dev. 12:679-691). HnRNPs have been shown to be important targets of the autoimmune response in rheumatic diseases (Biamonti, supra).

Many snRNP proteins, hnRNP proteins, and alternative splicing factors are characterized by an RNA recognition motif (RRM). (Reviewed in Birney, E. et al. (1993) Nucleic Acids Res. 21:5803-5816.) The RRM is about 80 amino acids in length and forms four β -strands and two α -helices arranged in an α/β sandwich. The RRM contains a core RNP-1 octapeptide motif along with surrounding conserved sequences.

20 RNA Stability and Degradation

RNA helicases alter and regulate RNA conformation and secondary structure by using energy derived from ATP hydrolysis to destabilize and unwind RNA duplexes. The most well-characterized and ubiquitous family of RNA helicases is the DEAD-box family, so named for the conserved B-type ATP-binding motif which is diagnostic of proteins in this family. Over 40 DEAD-box helicases have been identified in organisms as diverse as bacteria, insects, yeast, amphibians, mammals, and plants. DEAD-box helicases function in diverse processes such as translation initiation, splicing, ribosome assembly, and RNA editing, transport, and stability. Some DEAD-box helicases play tissue- and stage-specific roles in spermatogenesis and embryogenesis. (Reviewed in Linder, P. et al. (1989) Nature 337:121-122.)

Overexpression of the DEAD-box 1 protein (DDX1) may play a role in the progression of neuroblastoma (Nb) and retinoblastoma (Rb) tumors. Other DEAD-box helicases have been implicated either directly or indirectly in ultraviolet light-induced tumors, B cell lymphoma, and myeloid malignancies. (Reviewed in Godbout, R. et al. (1998) J. Biol. Chem. 273:21161-21168.)

Ribonucleases (RNases) catalyze the hydrolysis of phosphodiester bonds in RNA chains, thus

30

cleaving the RNA. For example, RNase P is a ribonucleoprotein enzyme which cleaves the 5' end of pre-tRNAs as part of their maturation process. RNase H digests the RNA strand of an RNA/DNA hybrid. Such hybrids occur in cells invaded by retroviruses, and RNase H is an important enzyme in the retroviral replication cycle. RNase H domains are often found as a domain associated with reverse transcriptases. RNase activity in serum and cell extracts is elevated in a variety of cancers and infectious diseases (Schein, C.H. (1997) Nat. Biotechnol. 15:529-536). Regulation of RNase activity is being investigated as a means to control tumor angiogenesis, allergic reactions, viral infection and replication, and fungal infections.

Protein Translation

10

15

25

30

The eukaryotic ribosome is composed of a 60S (large) subunit and a 40S (small) subunit, which together form the 80S ribosome. In addition to the 18S, 28S, 5S, and 5.8S rRNAs, the ribosome also contains more than fifty proteins. The ribosomal proteins have a prefix which denotes the subunit to which they belong, either L (large) or S (small). Three important sites are identified on the ribosome. The aminoacyl-tRNA site (A site) is where charged tRNAs (with the exception of the initiator-tRNA) bind on arrival at the ribosome. The peptidyl-tRNA site (P site) is where new peptide bonds are formed, as well as where the initiator tRNA binds. The exit site (E site) is where deacylated tRNAs bind prior to their release from the ribosome. (Translation is reviewed in Stryer, L. (1995)

Biochemistry, W.H. Freeman and Company, New York NY, pp. 875-908; and Lodish, H. et al. (1995)

Molecular Cell Biology, Scientific American Books, New York NY, pp. 119-138.)

20 tRNA Charging

Protein biosynthesis depends on each amino acid forming a linkage with the appropriate tRNA. The aminoacyl-tRNA synthetases are responsible for the activation and correct attachment of an amino acid with its cognate tRNA. The 20 aminoacyl-tRNA synthetase enzymes can be divided into two structural classes, Class I and Class II. Autoantibodies against aminoacyl-tRNAs are generated by patients with dermatomyositis and polymyositis, and correlate strongly with complicating interstitial lung disease (ILD). These antibodies appear to be generated in response to viral infection, and coxsackie virus has been used to induce experimental viral myositis in animals.

Translation Initiation

Initiation of translation can be divided into three stages. The first stage brings an initiator transfer RNA (Met-tRNA_t) together with the 40S ribosomal subunit to form the 43S preinitiation complex. The second stage binds the 43S preinitiation complex to the mRNA, followed by migration of the complex to the correct AUG initiation codon. The third stage brings the 60S ribosomal subunit to the 40S subunit to generate an 80S ribosome at the initiation codon. Regulation of translation primarily involves the first and second stage in the initiation process (Pain, V.M. (1996) Eur. J. Biochem.

a secretary at the secretary

236:747-771).

10

Several initiation factors, many of which contain multiple subunits, are involved in bringing an initiator tRNA and 40S ribosomal subunit together. eIF2, a guanine nucleotide binding protein, recruits the initiator tRNA to the 40S ribosomal subunit. Only when eIF2 is bound to GTP does it associate with the initiator tRNA. eIF2B, a guanine nucleotide exchange protein, is responsible for converting eIF2 from the GDP-bound inactive form to the GTP-bound active form. Two other factors, eIF1A and eIF3 bind and stabilize the 40S subunit by interacting with 18S ribosomal RNA and specific ribosomal structural proteins. eIF3 is also involved in association of the 40S ribosomal subunit with mRNA. The Met-tRNA_f, eIF1A, eIF3, and 40S ribosomal subunit together make up the 43S preinitiation complex (Pain, supra).

Additional factors are required for binding of the 43S preinitiation complex to an mRNA molecule, and the process is regulated at several levels. eIF4F is a complex consisting of three proteins: eIF4E, eIF4A, and eIF4G. eIF4E recognizes and binds to the mRNA 5'-terminal m'GTP cap, eIF4A is a bidirectional RNA-dependent helicase, and eIF4G is a scaffolding polypeptide. eIF4G has three binding domains. The N-terminal third of eIF4G interacts with eIF4E, the central third interacts with eIF4A, and the C-terminal third interacts with eIF3 bound to the 43S preinitiation complex. Thus, eIF4G acts as a bridge between the 40S ribosomal subunit and the mRNA (Hentze, M.W. (1997) Science 275:500-501).

The ability of eIF4F to initiate binding of the 43S preinitiation complex is regulated by structural features of the mRNA. The mRNA molecule has an untranslated region (UTR) between the 5' cap and the AUG start codon. In some mRNAs this region forms secondary structures that impede binding of the 43S preinitiation complex. The helicase activity of eIF4A is thought to function in removing this secondary structure to facilitate binding of the 43S preinitiation complex (Pain, supra). Translation Elongation

Elongation is the process whereby additional amino acids are joined to the initiator methionine to form the complete polypeptide chain. The elongation factors EF1 α , EF1 β γ , and EF2 are involved in elongating the polypeptide chain following initiation. EF1 α is a GTP-binding protein. In EF1 α 's GTP-bound form, it brings an aminoacyl-tRNA to the ribosome's A site. The amino acid attached to the newly arrived aminoacyl-tRNA forms a peptide bond with the initiator methionine. The GTP on EF1 α is hydrolyzed to GDP, and EF1 α -GDP dissociates from the ribosome. EF1 β γ binds EF1 α -GDP and induces the dissociation of GDP from EF1 α , allowing EF1 α to bind GTP and a new cycle to begin.

As subsequent aminoacyl-tRNAs are brought to the ribosome, EF-G, another GTP-binding protein, catalyzes the translocation of tRNAs from the A site to the P site and finally to the E site of the ribosome. This allows the processivity of translation.

Translation Termination

The release factor eRF carries out termination of translation. eRF recognizes stop codons in the mRNA, leading to the release of the polypeptide chain from the ribosome.

Post-Translational Pathways

5

10

15

20

25

30

Proteins may be modified after translation by the addition of phosphate, sugar, prenyl, fatty acid, and other chemical groups. These modifications are often required for proper protein activity. Enzymes involved in post-translational modification include kinases, phosphatases, glycosyltransferases, and prenyltransferases. The conformation of proteins may also be modified after translation by the introduction and rearrangement of disulfide bonds (rearrangement catalyzed by protein disulfide isomerase), the isomerization of proline sidechains by prolyl isomerase, and by interactions with molecular chaperone proteins.

Proteins may also be cleaved by proteases. Such cleavage may result in activation, inactivation, or complete degradation of the protein. Proteases include serine proteases, cysteine proteases, aspartic proteases, and metalloproteases. Signal peptidase in the endoplasmic reticulum (ER) lumen cleaves the signal peptide from membrane or secretory proteins that are imported into the ER. Ubiquitin proteases are associated with the ubiquitin conjugation system (UCS), a major pathway for the degradation of cellular proteins in eukaryotic cells and some bacteria. The UCS mediates the elimination of abnormal proteins and regulates the half-lives of important regulatory proteins that control cellular processes such as gene transcription and cell cycle progression. In the UCS pathway, proteins targeted for degradation are conjugated to a ubiquitin, a small heat stable protein. Proteins involved in the UCS include ubiquitin-activating enzyme, ubiquitin-conjugating enzymes, ubiquitin-ligases, and ubiquitin C-terminal hydrolases. The ubiquitinated protein is then recognized and degraded by the proteasome, a large, multisubunit proteolytic enzyme complex, and ubiquitin is released for reutilization by ubiquitin protease.

Lipid Metabolism

Lipids are water-insoluble, oily or greasy substances that are soluble in nonpolar solvents such as chloroform or ether. Neutral fats (triacylglycerols) serve as major fuels and energy stores. Polar lipids, such as phospholipids, sphingolipids, glycolipids, and cholesterol, are key structural components of cell membranes.

Lipid metabolism is involved in human diseases and disorders. In the arterial disease atherosclerosis, fatty lesions form on the inside of the arterial wall. These lesions promote the loss of arterial flexibility and the formation of blood clots (Guyton, A.C. <u>Textbook of Medical Physiology</u> (1991) W.B. Saunders Company, Philadelphia PA, pp.760-763). In Tay-Sachs disease, the GM₂ ganglioside (a sphingolipid) accumulates in lysosomes of the central nervous system due to a lack of the

20 mm to 10 mm to 10

enzyme N-acetylhexosaminidase. Patients suffer nervous system degeneration leading to early death (Fauci, A.S. et al. (1998) Harrison's Principles of Internal Medicine McGraw-Hill, New York NY, p. 2171). The Niemann-Pick diseases are caused by defects in lipid metabolism. Niemann-Pick diseases types A and B are caused by accumulation of sphingomyelin (a sphingolipid) and other lipids in the central nervous system due to a defect in the enzyme sphingomyelinase, leading to neurodegeneration and lung disease. Niemann-Pick disease type C results from a defect in cholesterol transport, leading to the accumulation of sphingomyelin and cholesterol in lysosomes and a secondary reduction in sphingomyelinase activity. Neurological symptoms such as grand mal seizures, ataxia, and loss of previously learned speech, manifest 1-2 years after birth. A mutation in the NPC protein, which contains a putative cholesterol-sensing domain, was found in a mouse model of Niemann-Pick disease type C (Fauci, supra, p. 2175; Loftus, S.K. et al. (1997) Science 277:232-235). (Lipid metabolism is reviewed in Stryer, L. (1995) Biochemistry, W.H. Freeman and Company, New York NY; Lehninger, A. (1982) Principles of Biochemistry Worth Publishers, Inc., New York NY; and ExPASy "Biochemical Pathways" index of Boehringer Mannheim World Wide Web site.)

15 Fatty Acid Synthesis

20

Fatty acids are long-chain organic acids with a single carboxyl group and a long non-polar hydrocarbon tail. Long-chain fatty acids are essential components of glycolipids, phospholipids, and cholesterol, which are building blocks for biological membranes, and of triglycerides, which are biological fuel molecules. Long-chain fatty acids are also substrates for eicosanoid production, and are important in the functional modification of certain complex carbohydrates and proteins. 16-carbon and 18-carbon fatty acids are the most common.

Fatty acid synthesis occurs in the cytoplasm. In the first step, acetyl-Coenzyme A (CoA) carboxylase (ACC) synthesizes malonyl-CoA from acetyl-CoA and bicarbonate. The enzymes which catalyze the remaining reactions are covalently linked into a single polypeptide chain, referred to as the multifunctional enzyme fatty acid synthase (FAS). FAS catalyzes the synthesis of palmitate from acetyl-CoA and malonyl-CoA. FAS contains acetyl transferase, malonyl transferase, β -ketoacetyl synthase, acyl carrier protein, β -ketoacyl reductase, dehydratase, enoyl reductase, and thioesterase activities. The final product of the FAS reaction is the 16-carbon fatty acid palmitate. Further elongation, as well as unsaturation, of palmitate by accessory enzymes of the ER produces the variety of long chain fatty acids required by the individual cell. These enzymes include a NADH-cytochrome b_5 reductase, cytochrome b_5 , and a desaturase.

Phospholipid and Triacylglycerol Synthesis

Triacylglycerols, also known as triglycerides and neutral fats, are major energy stores in animals. Triacylglycerols are esters of glycerol with three fatty acid chains. Glycerol-3-phosphate is

produced from dihydroxyacetone phosphate by the enzyme glycerol phosphate dehydrogenase or from glycerol by glycerol kinase. Fatty acid-CoA's are produced from fatty acids by fatty acyl-CoA synthetases. Glyercol-3-phosphate is acylated with two fatty acyl-CoA's by the enzyme glycerol phosphate acyltransferase to give phosphatidate. Phosphatidate phosphatase converts phosphatidate to diacylglycerol, which is subsequently acylated to a triacylglyercol by the enzyme diglyceride acyltransferase. Phosphatidate phosphatase and diglyceride acyltransferase form a triacylglyerol synthetase complex bound to the ER membrane.

A major class of phospholipids are the phosphoglycerides, which are composed of a glycerol backbone, two fatty acid chains, and a phosphorylated alcohol. Phosphoglycerides are components of cell membranes. Principal phosphoglycerides are phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl inositol, and diphosphatidyl glycerol. Many enzymes involved in phosphoglyceride synthesis are associated with membranes (Meyers, R.A. (1995). Molecular Biology and Biotechnology, VCH Publishers Inc., New York NY, pp. 494-501). Phosphatidate is converted to CDP-diacylglycerol by the enzyme phosphatidate cytidylyltransferase (ExPASy ENZYME EC 2.7.7.41). Transfer of the diacylglycerol group from CDP-diacylglycerol to serine to yield phosphatidyl serine, or to inositol to yield phosphatidyl inositol, is catalyzed by the enzymes CDP-diacylglycerolserine O-phosphatidyltransferase and CDP-diacylglycerol-inositol 3-phosphatidyltransferase, respectively (ExPASy ENZYME EC 2.7.8.8; ExPASy ENZYME EC 2.7.8.11). The enzyme phosphatidyl serine decarboxylase catalyzes the conversion of phosphatidyl serine to phosphatidyl ethanolamine, using a pyruvate cofactor (Voelker, D.R. (1997) Biochim. Biophys. Acta 1348:236-244). Phosphatidyl choline is formed using diet-derived choline by the reaction of CDP-choline with 1,2diacylglycerol, catalyzed by diacylglycerol cholinephosphotransferase (ExPASy ENZYME 2.7.8.2). Sterol, Steroid, and Isoprenoid Metabolism

Cholesterol, composed of four fused hydrocarbon rings with an alcohol at one end, moderates the fluidity of membranes in which it is incorporated. In addition, cholesterol is used in the synthesis of steroid hormones such as cortisol, progesterone, estrogen, and testosterone. Bile salts derived from cholesterol facilitate the digestion of lipids. Cholesterol in the skin forms a barrier that prevents excess water evaporation from the body. Farnesyl and geranylgeranyl groups, which are derived from cholesterol biosynthesis intermediates, are post-translationally added to signal transduction proteins such as ras and protein-targeting proteins such as rab. These modifications are important for the activities of these proteins (Guyton, supra; Stryer, supra, pp. 279-280, 691-702, 934).

Mammals obtain cholesterol derived from both <u>de novo</u> biosynthesis and the diet. The liver is the major site of cholesterol biosynthesis in mammals. Two acetyl-CoA molecules initially condense to form acetoacetyl-CoA, catalyzed by a thiolase. Acetoacetyl-CoA condenses with a third acetyl-CoA to

Comment of March 1979 and the Property

10

15

20

25

form hydroxymethylglutaryl-CoA (HMG-CoA), catalyzed by HMG-CoA synthase. Conversion of HMG-CoA to cholesterol is accomplished via a series of enzymatic steps known as the mevalonate pathway. The rate-limiting step is the conversion of HMG-CoA to mevalonate by HMG-CoA reductase. The drug lovastatin, a potent inhibitor of HMG-CoA reductase, is given to patients to reduce their serum cholesterol levels. Other mevalonate pathway enzymes include mevalonate kinase, phosphomevalonate kinase, diphosphomevalonate decarboxylase, isopentenyldiphosphate isomerase, dimethylallyl transferase, geranyl transferase, farnesyl-diphosphate farnesyltransferase, squalene monooxygenase, lanosterol synthase, lathosterol oxidase, and 7-dehydrocholesterol reductase.

Cholesterol is used in the synthesis of steroid hormones such as cortisol, progesterone, aldosterone, estrogen, and testosterone. First, cholesterol is converted to pregnenolone by cholesterol monooxygenases. The other steroid hormones are synthesized from pregnenolone by a series of enzyme-catalyzed reactions including oxidations, isomerizations, hydroxylations, reductions, and demethylations. Examples of these enzymes include steroid Δ -isomerase, 3β -hydroxy- Δ^5 -steroid dehydrogenase, steroid 21-monooxygenase, steroid 19-hydroxylase, and 3β -hydroxysteroid dehydrogenase. Cholesterol is also the precursor to vitamin D.

Numerous compounds contain 5-carbon isoprene units derived from the mevalonate pathway intermediate isopentenyl pyrophosphate. Isoprenoid groups are found in vitamin K, ubiquinone, retinal, dolichol phosphate (a carrier of oligosaccharides needed for N-linked glycosylation), and farnesyl and geranylgeranyl groups that modify proteins. Enzymes involved include farnesyl transferase, polyprenyl transferases, dolichyl phosphatase, and dolichyl kinase.

Sphingolipid Metabolism

Sphingolipids are an important class of membrane lipids that contain sphingosine, a long chain amino alcohol. They are composed of one long-chain fatty acid, one polar head alcohol, and sphingosine or sphingosine derivative. The three classes of sphingolipids are sphingomyelins, cerebrosides, and gangliosides. Sphingomyelins, which contain phosphocholine or phosphoethanolamine as their head group, are abundant in the myelin sheath surrounding nerve cells. Galactocerebrosides, which contain a glucose or galactose head group, are characteristic of the brain. Other cerebrosides are found in nonneural tissues. Gangliosides, whose head groups contain multiple sugar units, are abundant in the brain, but are also found in nonneural tissues.

Sphingolipids are built on a sphingosine backbone. Sphingosine is acylated to ceramide by the enzyme sphingosine acetyltransferase. Ceramide and phosphatidyl choline are converted to sphingomyelin by the enzyme ceramide choline phosphotransferase. Cerebrosides are synthesized by the linkage of glucose or galactose to ceramide by a transferase. Sequential addition of sugar residues to ceramide by transferase enzymes yields gangliosides.

30

10

Eicosanoid Metabolism

Eicosanoids, including prostaglandins, prostacyclin, thromboxanes, and leukotrienes, are 20-carbon molecules derived from fatty acids. Eicosanoids are signaling molecules which have roles in pain, fever, and inflammation. The precursor of all eicosanoids is arachidonate, which is generated from phospholipids by phospholipase A_2 and from diacylglycerols by diacylglycerol lipase. Leukotrienes are produced from arachidonate by the action of lipoxygenases. Prostaglandin synthase, reductases, and isomerases are responsible for the synthesis of the prostaglandins. Prostaglandins have roles in inflammation, blood flow, ion transport, synaptic transmission, and sleep. Prostacyclin and the thromboxanes are derived from a precursor prostaglandin by the action of prostacyclin synthase and thromboxane synthases, respectively.

Ketone Body Metabolism

10

15

20

25

30

Pairs of acetyl-CoA molecules derived from fatty acid oxidation in the liver can condense to form acetoacetyl-CoA, which subsequently forms acetoacetate, D-3-hydroxybutyrate, and acetone. These three products are known as ketone bodies. Enzymes involved in ketone body metabolism include HMG-CoA synthetase, HMG-CoA cleavage enzyme, D-3-hydroxybutyrate dehydrogenase, acetoacetate decarboxylase, and 3-ketoacyl-CoA transferase. Ketone bodies are a normal fuel supply of the heart and renal cortex. Acetoacetate produced by the liver is transported to cells where the acetoacetate is converted back to acetyl-CoA and enters the citric acid cycle. In times of starvation, ketone bodies produced from stored triacylglyerols become an important fuel source, especially for the brain. Abnormally high levels of ketone bodies are observed in diabetics. Diabetic coma can result if ketone body levels become too great.

Lipid Mobilization

Within cells, fatty acids are transported by cytoplasmic fatty acid binding proteins (Online Mendelian Inheritance in Man (OMIM) *134650 Fatty Acid-Binding Protein 1, Liver; FABP1). Diazepam binding inhibitor (DBI), also known as endozepine and acyl CoA-binding protein, is an endogenous γ-aminobutyric acid (GABA) receptor ligand which is thought to down-regulate the effects of GABA. DBI binds medium- and long-chain acyl-CoA esters with very high affinity and may function as an intracellular carrier of acyl-CoA esters (OMIM *125950 Diazepam Binding Inhibitor; DBI; PROSITE PDOC00686 Acyl-CoA-binding protein signature).

Fat stored in liver and adipose triglycerides may be released by hydrolysis and transported in the blood. Free fatty acids are transported in the blood by albumin. Triacylglycerols and cholesterol esters in the blood are transported in lipoprotein particles. The particles consist of a core of hydrophobic lipids surrounded by a shell of polar lipids and apolipoproteins. The protein components serve in the solubilization of hydrophobic lipids and also contain cell-targeting signals. Lipoproteins

include chylomicrons, chylomicron remnants, very-low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL).

There is a strong inverse correlation between the levels of plasma HDL and risk of premature coronary heart disease.

Triacylglycerols in chylomicrons and VLDL are hydrolyzed by lipoprotein lipases that line blood vessels in muscle and other tissues that use fatty acids. Cell surface LDL receptors bind LDL particles which are then internalized by endocytosis. Absence of the LDL receptor, the cause of the disease familial hypercholesterolemia, leads to increased plasma cholesterol levels and ultimately to atherosclerosis. Plasma cholesteryl ester transfer protein mediates the transfer of cholesteryl esters from HDL to apolipoprotein B-containing lipoproteins. Cholesteryl ester transfer protein is important in the reverse cholesterol transport system and may play a role in atherosclerosis (Yamashita, S. et al. (1997) Curr. Opin. Lipidol. 8:101-110). Macrophage scavenger receptors, which bind and internalize modified lipoproteins, play a role in lipid transport and may contribute to atherosclerosis (Greaves, D.R. et al. (1998) Curr. Opin. Lipidol. 9:425-432).

Proteins involved in cholesterol uptake and biosynthesis are tightly regulated in response to cellular cholesterol levels. The sterol regulatory element binding protein (SREBP) is a sterol-responsive transcription factor. Under normal cholesterol conditions, SREBP resides in the ER membrane. When cholesterol levels are low, a regulated cleavage of SREBP occurs which releases the extracellular domain of the protein. This cleaved domain is then transported to the nucleus where it activates the transcription of the LDL receptor gene, and genes encoding enzymes of cholesterol synthesis, by binding the sterol regulatory element (SRE) upstream of the genes (Yang, J. et al. (1995) J. Biol. Chem. 270:12152-12161). Regulation of cholesterol uptake and biosynthesis also occurs via the oxysterol-binding protein (OSBP). OSBP is a high-affinity intracellular receptor for a variety of oxysterols that down-regulate cholesterol synthesis and stimulate cholesterol esterification (Lagace, T.A. et al. (1997) Biochem. J. 326:205-213).

Beta-oxidation

Mitochondrial and peroxisomal beta-oxidation enzymes degrade saturated and unsaturated fatty acids by sequential removal of two-carbon units from CoA-activated fatty acids. The main beta-oxidation pathway degrades both saturated and unsaturated fatty acids while the auxiliary pathway performs additional steps required for the degradation of unsaturated fatty acids.

The pathways of mitochondrial and peroxisomal beta-oxidation use similar enzymes, but have different substrate specificities and functions. Mitochondria oxidize short-, medium-, and long-chain fatty acids to produce energy for cells. Mitochondrial beta-oxidation is a major energy source for cardiac and skeletal muscle. In liver, it provides ketone bodies to the peripheral circulation when

10

15

glucose levels are low as in starvation, endurance exercise, and diabetes (Eaton, S. et al. (1996) Biochem. J. 320:345-357). Peroxisomes oxidize medium-, long-, and very-long-chain fatty acids, dicarboxylic fatty acids, branched fatty acids, prostaglandins, xenobiotics, and bile acid intermediates. The chief roles of peroxisomal beta-oxidation are to shorten toxic lipophilic carboxylic acids to facilitate their excretion and to shorten very-long-chain fatty acids prior to mitochondrial beta-oxidation (Mannaerts, G.P. and P.P. van Veldhoven (1993) Biochimie 75:147-158).

Enzymes involved in beta-oxidation include acyl CoA synthetase, carnitine acyltransferase, acyl CoA dehydrogenases, enoyl CoA hydratases, L-3-hydroxyacyl CoA dehydrogenase, β -ketothiolase, 2,4-dienoyl CoA reductase, and isomerase.

10 Lipid Cleavage and Degradation

Triglycerides are hydrolyzed to fatty acids and glycerol by lipases. Lysophospholipases (LPLs) are widely distributed enzymes that metabolize intracellular lipids, and occur in numerous isoforms. Small isoforms, approximately 15-30 kD, function as hydrolases; large isoforms, those exceeding 60 kD, function both as hydrolases and transacylases. A particular substrate for LPLs, lysophosphatidylcholine, causes lysis of cell membranes when it is formed or imported into a cell. LPLs are regulated by lipid factors including acylcarnitine, arachidonic acid, and phosphatidic acid. These lipid factors are signaling molecules important in numerous pathways, including the inflammatory response. (Anderson, R. et al. (1994) Toxicol. Appl. Pharmacol. 125:176-183; Selle, H. et al. (1993); Eur. J. Biochem. 212:411-416.)

The secretory phospholipase A_2 (PLA2) superfamily comprises a number of heterogeneous enzymes whose common feature is to hydrolyze the sn-2 fatty acid acyl ester bond of phosphoglycerides. Hydrolysis of the glycerophospholipids releases free fatty acids and lysophospholipids. PLA2 activity generates precursors for the biosynthesis of biologically active lipids, hydroxy fatty acids, and platelet-activating factor. PLA2 hydrolysis of the sn-2 ester bond in phospholipids generates free fatty acids, such as arachidonic acid and lysophospholipids.

Carbon and Carbohydrate Metabolism

Carbohydrates, including sugars or saccharides, starch, and cellulose, are aldehyde or ketone compounds with multiple hydroxyl groups. The importance of carbohydrate metabolism is demonstrated by the sensitive regulatory system in place for maintenance of blood glucose levels. Two pancreatic hormones, insulin and glucagon, promote increased glucose uptake and storage by cells, and increased glucose release from cells, respectively. Carbohydrates have three important roles in mammalian cells. First, carbohydrates are used as energy stores, fuels, and metabolic intermediates. Carbohydrates are broken down to form energy in glycolysis and are stored as glycogen for later use. Second, the sugars deoxyribose and ribose form part of the structural support of DNA and RNA,

15

20

25

respectively. Third, carbohydrate modifications are added to secreted and membrane proteins and lipids as they traverse the secretory pathway. Cell surface carbohydrate-containing macromolecules, including glycoproteins, glycolipids, and transmembrane proteoglycans, mediate adhesion with other cells and with components of the extracellular matrix. The extracellular matrix is comprised of diverse glycoproteins, glycosaminoglycans (GAGs), and carbohydrate-binding proteins which are secreted from the cell and assembled into an organized meshwork in close association with the cell surface. The interaction of the cell with the surrounding matrix profoundly influences cell shape, strength, flexibility, motility, and adhesion. These dynamic properties are intimately associated with signal transduction pathways controlling cell proliferation and differentiation, tissue construction, and embryonic development.

Carbohydrate metabolism is altered in several disorders including diabetes mellitus, hyperglycemia, hypoglycemia, galactosemia, galactokinase deficiency, and UDP-galactose-4-epimerase deficiency (Fauci, A.S. et al. (1998) Harrison's Principles of Internal Medicine, McGraw-Hill, New York NY, pp. 2208-2209). Altered carbohydrate metabolism is associated with cancer. Reduced GAG and proteoglycan expression is associated with human lung carcinomas (Nackaerts, K. et al. (1997) Int. J. Cancer 74:335-345). The carbohydrate determinants sialyl Lewis A and sialyl Lewis X are frequently expressed on human cancer cells (Kannagi, R. (1997) Glycoconj. J. 14:577-584). Alterations of the N-linked carbohydrate core structure of cell surface glycoproteins are linked to colon and pancreatic cancers (Schwarz, R.E. et al. (1996) Cancer Lett. 107:285-291). Reduced expression of the Sda blood group carbohydrate structure in cell surface glycolipids and glycoproteins is observed in gastrointestinal cancer (Dohi, T. et al. (1996) Int. J. Cancer 67:626-663). (Carbon and carbohydrate metabolism is reviewed in Stryer, L. (1995) Biochemistry W.H. Freeman and Company, New York NY; Lehninger, A.L. (1982) Principles of Biochemistry Worth Publishers Inc., New York NY.) Glycolysis

Enzymes of the glycolytic pathway convert the sugar glucose to pyruvate while simultaneously producing ATP. The pathway also provides building blocks for the synthesis of cellular components such as long-chain fatty acids. After glycolysis, pyrvuate is converted to acetyl-Coenzyme A, which, in aerobic organisms, enters the citric acid cycle. Glycolytic enzymes include hexokinase, phosphoglucose isomerase, phosphofructokinase, aldolase, triose phosphate isomerase, glyceraldehyde 3-phosphate dehydrogenase, phosphoglycerate kinase, phosphoglyceromutase, enolase, and pyruvate kinase. Of these, phosphofructokinase, hexokinase, and pyruvate kinase are important in regulating the rate of glycolysis.

Gluconeogenesis

10

15

Gluconeogenesis is the synthesis of glucose from noncarbohydrate precursors such as lactate and amino acids. The pathway, which functions mainly in times of starvation and intense exercise, occurs mostly in the liver and kidney. Responsible enzymes include pyruvate carboxylase, phosphoenolpyruvate carboxykinase, fructose 1,6-bisphosphatase, and glucose-6-phosphatase.

Pentose Phosphate Pathway

Pentose phosphate pathway enzymes are responsible for generating the reducing agent NADPH, while at the same time oxidizing glucose-6-phosphate to ribose-5-phosphate. Ribose-5-phosphate and its derivatives become part of important biological molecules such as ATP, Coenzyme A, NAD+, FAD, RNA, and DNA. The pentose phosphate pathway has both oxidative and non-oxidative branches. The oxidative branch steps, which are catalyzed by the enzymes glucose-6-phosphate dehydrogenase, lactonase, and 6-phosphogluconate dehydrogenase, convert glucose-6-phosphate and NADP+ to ribulose-6-phosphate and NADPH. The non-oxidative branch steps, which are catalyzed by the enzymes phosphopentose isomerase, phosphopentose epimerase, transketolase, and transaldolase, allow the interconversion of three-, four-, five-, six-, and seven-carbon sugars.

Glucouronate Metabolism

10

15

25

30

Glucuronate is a monosaccharide which, in the form of D-glucuronic acid, is found in the GAGs chondroitin and dermatan. D-glucuronic acid is also important in the detoxification and excretion of foreign organic compounds such as phenol. Enzymes involved in glucuronate metabolism include UDP-glucose dehydrogenase and glucuronate reductase.

20 Disaccharide Metabolism

Disaccharides must be hydrolyzed to monosaccharides to be digested. Lactose, a disaccharide found in milk, is hydrolyzed to galactose and glucose by the enzyme lactase. Maltose is derived from plant starch and is hydrolyzed to glucose by the enzyme maltase. Sucrose is derived from plants and is hydrolyzed to glucose and fructose by the enzyme sucrase. Trehalose, a disaccharide found mainly in insects and mushrooms, is hydrolyzed to glucose by the enzyme trehalase (OMIM *275360 Trehalase; Ruf, J. et al. (1990) J. Biol. Chem. 265:15034-15039). Lactase, maltase, sucrase, and trehalase are bound to mucosal cells lining the small intestine, where they participate in the digestion of dietary disaccharides. The enzyme lactose synthetase, composed of the catalytic subunit galactosyltransferase and the modifier subunit α -lactalbumin, converts UDP-galactose and glucose to lactose in the mammary glands.

Glycogen, Starch, and Chitin Metabolism

Glycogen is the storage form of carbohydrates in mammals. Mobilization of glycogen maintains glucose levels between meals and during muscular activity. Glycogen is stored mainly in the liver and in skeletal muscle in the form of cytoplasmic granules. These granules contain enzymes that

catalyze the synthesis and degradation of glycogen, as well as enzymes that regulate these processes. Enzymes that catalyze the degradation of glycogen include glycogen phosphorylase, a transferase, α -1,6-glucosidase, and phosphoglucomutase. Enzymes that catalyze the synthesis of glycogen include UDP-glucose pyrophosphorylase, glycogen synthesis, a branching enzyme, and nucleoside diphosphokinase. The enzymes of glycogen synthesis and degradation are tightly regulated by the hormones insulin, glucagon, and epinephrine. Starch, a plant-derived polysaccharide, is hydrolyzed to maltose, maltotriose, and α -dextrin by α -amylase, an enzyme secreted by the salivary glands and pancreas. Chitin is a polysaccharide found in insects and crustacea. A chitotriosidase is secreted by macrophages and may play a role in the degradation of chitin-containing pathogens (Boot, R.G. et al. (1995) J. Biol. Chem. 270:26252-26256).

Peptidoglycans and Glycosaminoglycans

Glycosaminoglycans (GAGs) are anionic linear unbranched polysaccharides composed of repetitive disaccharide units. These repetitive units contain a derivative of an amino sugar, either glucosamine or galactosamine. GAGs exist free or as part of proteoglycans, large molecules composed of a core protein attached to one or more GAGs. GAGs are found on the cell surface, inside cells, and in the extracellular matrix. Changes in GAG levels are associated with several autoimmune diseases including autoimmune thyroid disease, autoimmune diabetes mellitus, and systemic lupus erythematosus (Hansen, C. et al. (1996) Clin. Exp. Rheum. 14 (Suppl. 15):S59-S67). GAGs include chondroitin sulfate, keratan sulfate, heparin, heparan sulfate, dermatan sulfate, and hyaluronan.

The GAG hyaluronan (HA) is found in the extracellular matrix of many cells, especially in soft connective tissues, and is abundant in synovial fluid (Pitsillides, A.A. et al. (1993) Int. J. Exp. Pathol. 74:27-34). HA seems to play important roles in cell regulation, development, and differentiation (Laurent, T.C. and J.R. Fraser (1992) FASEB J. 6:2397-2404). Hyaluronidase is an enzyme that degrades HA to oligosaccharides. Hyaluronidases may function in cell adhesion, infection, angiogenesis, signal transduction, reproduction, cancer, and inflammation.

Proteoglycans, also known as peptidoglycans, are found in the extracellular matrix of connective tissues such as cartilage and are essential for distributing the load in weight-bearing joints. Cell-surface-attached proteoglycans anchor cells to the extracellular matrix. Both extracellular and cell-surface proteoglycans bind growth factors, facilitating their binding to cell-surface receptors and subsequent triggering of signal transduction pathways.

Amino Acid and Nitrogen Metabolism

NH₄⁺ is assimilated into amino acids by the actions of two enzymes, glutamate dehydrogenase and glutamine synthetase. The carbon skeletons of amino acids come from the intermediates of glycolysis, the pentose phosphate pathway, or the citric acid cycle. Of the twenty

10


10

15

20

25

30



amino acids used in proteins, humans can synthesize only thirteen (nonessential amino acids). The remaining nine must come from the diet (essential amino acids). Enzymes involved in nonessential amino acid biosynthesis include glutamate kinase dehydrogenase, pyrroline carboxylate reductase, asparagine synthetase, phenylalanine oxygenase, methionine adenosyltransferase, adenosylhomocysteinase, cystathionine β -synthase, cystathionine γ -lyase, phosphoglycerate dehydrogenase, phosphoserine transaminase, phosphoserine phosphatase, serine hydroxylmethyltransferase, and glycine synthase.

Metabolism of amino acids takes place almost entirely in the liver, where the amino group is removed by aminotransferases (transaminases), for example, alanine aminotransferase. The amino group is transferred to α -ketoglutarate to form glutamate. Glutamate dehydrogenase converts glutamate to NH₄⁺ and α -ketoglutarate. NH₄⁺ is converted to urea by the urea cycle which is catalyzed by the enzymes arginase, ornithine transcarbamoylase, arginosuccinate synthetase, and arginosuccinase. Carbamoyl phosphate synthetase is also involved in urea formation. Enzymes involved in the metabolism of the carbon skeleton of amino acids include serine dehydratase, asparaginase, glutaminase, propionyl CoA carboxylase, methylmalonyl CoA mutase, branched-chain α -keto dehydrogenase complex, isovaleryl CoA dehydrogenase, β -methylcrotonyl CoA carboxylase, phenylalanine hydroxylase, p-hydroxylphenylpyruvate hydroxylase, and homogentisate oxidase.

Polyamines, which include spermidine, putrescine, and spermine, bind tightly to nucleic acids and are abundant in rapidly proliferating cells. Enzymes involved in polyamine synthesis include ornithine decarboxylase.

Diseases involved in amino acid and nitrogen metabolism include hyperammonemia, carbamoyl phosphate synthetase deficiency, urea cycle enzyme deficiencies, methylmalonic aciduria, maple syrup disease, alcaptonuria, and phenylketonuria.

Energy Metabolism

Cells derive energy from metabolism of ingested compounds that may be roughly categorized as carbohydrates, fats, or proteins. Energy is also stored in polymers such as triglycerides (fats) and glycogen (carbohydrates). Metabolism proceeds along separate reaction pathways connected by key intermediates such as acetyl coenzyme A (acetyl-CoA). Metabolic pathways feature anaerobic and aerobic degradation, coupled with the energy-requiring reactions such as phosphorylation of adenosine diphosphate (ADP) to the triphosphate (ATP) or analogous phosphorylations of guanosine (GDP/GTP), uridine (UDP/UTP), or cytidine (CDP/CTP). Subsequent dephosphorylation of the triphosphate drives reactions needed for cell maintenance, growth, and proliferation.

Digestive enzymes convert carbohydrates and sugars to glucose; fructose and galactose are converted in the liver to glucose. Enzymes involved in these conversions include galactose-1-

phosphate uridyl transferase and UDP-galactose-4 epimerase. In the cytoplasm, glycolysis converts glucose to pyruvate in a series of reactions coupled to ATP synthesis.

Pyruvate is transported into the mitochondria and converted to acetyl-CoA for oxidation via the citric acid cycle, involving pyruvate dehydrogenase components, dihydrolipoyl transacetylase, and dihydrolipoyl dehydrogenase. Enzymes involved in the citric acid cycle include: citrate synthetase, aconitases, isocitrate dehydrogenase, alpha-ketoglutarate dehydrogenase complex including transsuccinylases, succinyl CoA synthetase, succinate dehydrogenase, fumarases, and malate dehydrogenase. Acetyl CoA is oxidized to CO_2 with concomitant formation of NADH, FADH₂, and GTP. In oxidative phosphorylation, the transport of electrons from NADH and FADH₂ to oxygen by dehydrogenases is coupled to the synthesis of ATP from ADP and P_i by the F_0F_1 ATPase complex in the mitochondrial inner membrane. Enzyme complexes responsible for electron transport and ATP synthesis include the F_0F_1 ATPase complex, ubiquinone(CoQ)-cytochrome c reductase, ubiquinone reductase, cytochrome b, cytochrome c_1 , FeS protein, and cytochrome c oxidase.

Triglycerides are hydrolyzed to fatty acids and glycerol by lipases. Glycerol is then phosphorylated to glycerol-3-phosphate by glycerol kinase and glycerol phosphate dehydrogenase, and degraded by the glycolysis. Fatty acids are transported into the mitochondria as fatty acylcarnitine esters and undergo oxidative degradation.

In addition to metabolic disorders such as diabetes and obesity, disorders of energy metabolism are associated with cancers (Dorward, A. et al. (1997) J. Bioenerg. Biomembr. 29:385-392), autism (Lombard, J. (1998) Med. Hypotheses 50:497-500), neurodegenerative disorders (Alexi, T. et al. (1998) Neuroreport 9:R57-64), and neuromuscular disorders (DiMauro, S. et al. (1998) Biochim. Biophys. Acta 1366:199-210). The myocardium is heavily dependent on oxidative metabolism, so metabolic dysfunction often leads to heart disease (DiMauro, S. and M. Hirano (1998) Curr. Opin. Cardiol. 13:190-197).

For a review of energy metabolism enzymes and intermediates, see Stryer, L. et al. (1995) <u>Biochemistry</u>, W.H. Freeman and Co., San Francisco CA, pp. 443-652. For a review of energy metabolism regulation, see Lodish, H. et al. (1995) <u>Molecular Cell Biology</u>, Scientific American Books, New York NY, pp. 744-770.

Cofactor Metabolism

Cofactors, including coenzymes and prosthetic groups, are small molecular weight inorganic or organic compounds that are required for the action of an enzyme. Many cofactors contain vitamins as a component. Cofactors include thiamine pyrophosphate, flavin adenine dinucleotide, flavin mononucleotide, nicotinamide adenine dinucleotide, pyridoxal phosphate, coenzyme A, tetrahydrofolate, lipoamide, and heme. The vitamins biotin and cobalamin are associated with

15

25

enzymes as well. Heme, a prosthetic group found in myoglobin and hemoglobin, consists of protoporphyrin group bound to iron. Porphyrin groups contain four substituted pyrroles covalently joined in a ring, often with a bound metal atom. Enzymes involved in porphyrin synthesis include δ -aminolevulinate synthase, δ -aminolevulinate dehydrase, porphobilinogen deaminase, and cosynthase. Deficiencies in heme formation cause porphyrias. Heme is broken down as a part of erythrocyte turnover. Enzymes involved in heme degradation include heme oxygenase and biliverdin reductase.

Iron is a required cofactor for many enzymes. Besides the heme-containing enzymes, iron is found in iron-sulfur clusters in proteins including aconitase, succinate dehydrogenase, and NADH-Q reductase. Iron is transported in the blood by the protein transferrin. Binding of transferrin to the transferrin receptor on cell surfaces allows uptake by receptor mediated endocytosis. Cytosolic iron is bound to ferritin protein.

A molybdenum-containing cofactor (molybdopterin) is found in enzymes including sulfite oxidase, xanthine dehydrogenase, and aldehyde oxidase. Molybdopterin biosynthesis is performed by two molybdenum cofactor synthesizing enzymes. Deficiencies in these enzymes cause mental retardation and lens dislocation. Other diseases caused by defects in cofactor metabolism include pernicious anemia and methylmalonic aciduria.

Secretion and Trafficking

5

10

15

20

25

30

Eukaryotic cells are bound by a lipid bilayer membrane and subdivided into functionally distinct, membrane bound compartments. The membranes maintain the essential differences between the cytosol, the extracellular environment, and the lumenal space of each intracellular organelle. As lipid membranes are highly impermeable to most polar molecules, transport of essential nutrients, metabolic waste products, cell signaling molecules, macromolecules and proteins across lipid membranes and between organelles must be mediated by a variety of transport-associated molecules. Protein Trafficking

In eukaryotes, some proteins are synthesized on ER-bound ribosomes, co-translationally imported into the ER, delivered from the ER to the Golgi complex for post-translational processing and sorting, and transported from the Golgi to specific intracellular and extracellular destinations. All cells possess a constitutive transport process which maintains homeostasis between the cell and its environment. In many differentiated cell types, the basic machinery is modified to carry out specific transport functions. For example, in endocrine glands, hormones and other secreted proteins are packaged into secretory granules for regulated exocytosis to the cell exterior. In macrophage, foreign extracellular material is engulfed (phagocytosis) and delivered to lysosomes for degradation. In fat and muscle cells, glucose transporters are stored in vesicles which fuse with the plasma membrane only in response to insulin stimulation.

A TO HER TOTAL OF DEPAR

The Secretory Pathway

Synthesis of most integral membrane proteins, secreted proteins, and proteins destined for the lumen of a particular organelle occurs on ER-bound ribosomes. These proteins are co-translationally imported into the ER. The proteins leave the ER via membrane-bound vesicles which bud off the ER at specific sites and fuse with each other (homotypic fusion) to form the ER-Golgi Intermediate Compartment (ERGIC). The ERGIC matures progressively through the *cis, medial*, and *trans* cisternal stacks of the Golgi, modifying the enzyme composition by retrograde transport of specific Golgi enzymes. In this way, proteins moving through the Golgi undergo post-translational modification, such as glycosylation. The final Golgi compartment is the Trans-Golgi Network (TGN), where both membrane and lumenal proteins are sorted for their final destination. Transport vesicles destined for intracellular compartments, such as the lysosome, bud off the TGN. What remains is a secretory vesicle which contains proteins destined for the plasma membrane, such as receptors, adhesion molecules, and ion channels, and secretory proteins, such as hormones, neurotransmitters, and digestive enzymes. Secretory vesicles eventually fuse with the plasma membrane (Glick, B.S. and V. Malhotra (1998) Cell 95:883-889).

The secretory process can be constitutive or regulated. Most cells have a constitutive pathway for secretion, whereby vesicles derived from maturation of the TGN require no specific signal to fuse with the plasma membrane. In many cells, such as endocrine cells, digestive cells, and neurons, vesicle pools derived from the TGN collect in the cytoplasm and do not fuse with the plasma membrane until they are directed to by a specific signal.

Endocytosis

10

15

Endocytosis, wherein cells internalize material from the extracellular environment, is essential for transmission of neuronal, metabolic, and proliferative signals; uptake of many essential nutrients; and defense against invading organisms. Most cells exhibit two forms of endocytosis. The first, phagocytosis, is an actin-driven process exemplified in macrophage and neutrophils. Material to be endocytosed contacts numerous cell surface receptors which stimulate the plasma membrane to extend and surround the particle, enclosing it in a membrane-bound phagosome. In the mammalian immune system, IgG-coated particles bind Fc receptors on the surface of phagocytic leukocytes. Activation of the Fc receptors initiates a signal cascade involving src-family cytosolic kinases and the monomeric GTP-binding (G) protein Rho. The resulting actin reorganization leads to phagocytosis of the particle. This process is an important component of the humoral immune response, allowing the processing and presentation of bacterial-derived peptides to antigen-specific T-lymphocytes.

The second form of endocytosis, pinocytosis, is a more generalized uptake of material from the external milieu. Like phagocytosis, pinocytosis is activated by ligand binding to cell surface receptors.

Activation of individual receptors stimulates an internal response that includes coalescence of the receptor-ligand complexes and formation of clathrin-coated pits. Invagination of the plasma membrane at clathrin-coated pits produces an endocytic vesicle within the cell cytoplasm. These vesicles undergo homotypic fusion to form an early endosomal (EE) compartment. The tubulovesicular EE serves as a sorting site for incoming material. ATP-driven proton pumps in the EE membrane lowers the pH of the EE lumen (pH 6.3-6.8). The acidic environment causes many ligands to dissociate from their receptors. The receptors, along with membrane and other integral membrane proteins, are recycled back to the plasma membrane by budding off the tubular extensions of the EE in recycling vesicles (RV). This selective removal of recycled components produces a carrier vesicle containing ligand and other material from the external environment. The carrier vesicle fuses with TGN-derived vesicles which contain hydrolytic enzymes. The acidic environment of the resulting late endosome (LE) activates the hydrolytic enzymes which degrade the ligands and other material. As digestion takes place, the LE fuses with the lysosome where digestion is completed (Mellman, I. (1996) Annu. Rev. Cell Dev. Biol. 12:575-625).

Recycling vesicles may return directly to the plasma membrane. Receptors internalized and returned directly to the plasma membrane have a turnover rate of 2-3 minutes. Some RVs undergo microtubule-directed relocation to a perinuclear site, from which they then return to the plasma membrane. Receptors following this route have a turnover rate of 5-10 minutes. Still other RVs are retained within the cell until an appropriate signal is received (Mellman, <u>supra</u>; and James, D.E. et al. (1994) Trends Cell Biol. 4:120-126).

Vesicle Formation

10

15

20

25

30

Several steps in the transit of material along the secretory and endocytic pathways require the formation of transport vesicles. Specifically, vesicles form at the transitional endoplasmic reticulum (tER), the rim of Golgi cisternae, the face of the Trans-Golgi Network (TGN), the plasma membrane (PM), and tubular extensions of the endosomes. The process begins with the budding of a vesicle out of the donor membrane. The membrane-bound vesicle contains proteins to be transported and is surrounded by a protective coat made up of protein subunits recruited from the cytosol. The initial budding and coating processes are controlled by a cytosolic ras-like GTP-binding protein, ADP-ribosylating factor (Arf), and adapter proteins (AP). Different isoforms of both Arf and AP are involved at different sites of budding. Another small G-protein, dynamin, forms a ring complex around the neck of the forming vesicle and may provide the mechanochemical force to accomplish the final step of the budding process. The coated vesicle complex is then transported through the cytosol. During the transport process, Arf-bound GTP is hydrolyzed to GDP and the coat dissociates from the transport vesicle (West, M.A. et al. (1997) J. Cell Biol. 138:1239-1254). Two different classes of coat protein

have also been identified. Clathrin coats form on the TGN and PM surfaces, whereas coatomer or COP coats form on the ER and Golgi. COP coats can further be distinguished as COPI, involved in retrograde traffic through the Golgi and from the Golgi to the ER, and COPII, involved in anterograde traffic from the ER to the Golgi (Mellman, supra). The COP coat consists of two major components, a G-protein (Arf or Sar) and coat protomer (coatomer). Coatomer is an equimolar complex of seven proteins, termed alpha-, beta-, beta-, gamma-, delta-, epsilon- and zeta-COP. (Harter, C. and F.T. Wieland (1998) Proc. Natl. Acad. Sci. USA 95:11649-11654.)

Membrane Fusion

10

20

Transport vesicles undergo homotypic or heterotypic fusion in the secretory and endocytotic pathways. Molecules required for appropriate targeting and fusion of vesicles with their target membrane include proteins incorporated in the vesicle membrane, the target membrane, and proteins recruited from the cytosol. During budding of the vesicle from the donor compartment, an integral membrane protein, VAMP (vesicle-associated membrane protein) is incorporated into the vesicle. Soon after the vesicle uncoats, a cytosolic prenylated GTP-binding protein, Rab (a member of the Ras 15 superfamily), is inserted into the vesicle membrane. GTP-bound Rab proteins are directed into nascent transport vesicles where they interact with VAMP. Following vesicle transport, GTPase activating proteins (GAPs) in the target membrane convert Rab proteins to the GDP-bound form. A cytosolic protein, guanine-nucleotide dissociation inhibitor (GDI) helps return GDP-bound Rab proteins to their membrane of origin. Several Rab isoforms have been identified and appear to associate with specific compartments within the cell. Rab proteins appear to play a role in mediating the function of a viral gene, Rev, which is essential for replication of HIV-1, the virus responsible for AIDS (Flavell, R.A. et al. (1996) Proc. Natl. Acad. Sci. USA 93:4421-4424).

Docking of the transport vesicle with the target membrane involves the formation of a complex between the vesicle SNAP receptor (v-SNARE), target membrane (t-) SNAREs, and certain other membrane and cytosolic proteins. Many of these other proteins have been identified although their exact functions in the docking complex remain uncertain (Tellam, J.T. et al. (1995) J. Biol. Chem. 270:5857-5863; and Hata, Y. and T.C. Sudhof (1995) J. Biol. Chem. 270:13022-13028). N-ethylmaleimide sensitive factor (NSF) and soluble NSF-attachment protein (α -SNAP and β -SNAP) are two such proteins that are conserved from yeast to man and function in most intracellular membrane fusion reactions. Sec1 represents a family of yeast proteins that function at many different stages in the secretory pathway including membrane fusion. Recently, mammalian homologs of Sec1, called Munc-18 proteins, have been identified (Katagiri, H. et al. (1995) J. Biol. Chem. 270:4963-4966; Hata et al. supra).

The SNARE complex involves three SNARE molecules, one in the vesicular membrane and

two in the target membrane. Synaptotagmin is an integral membrane protein in the synaptic vesicle which associates with the t-SNARE syntaxin in the docking complex. Synaptotagmin binds calcium in a complex with negatively charged phospholipids, which allows the cytosolic SNAP protein to displace synaptotagmin from syntaxin and fusion to occur. Thus, synaptotagmin is a negative regulator of fusion in the neuron (Littleton, J.T. et al. (1993) Cell 74:1125-1134). The most abundant membrane protein of synaptic vesicles appears to be the glycoprotein synaptophysin, a 38 kDa protein with four transmembrane domains.

Specificity between a vesicle and its target is derived from the v-SNARE, t-SNAREs, and associated proteins involved. Different isoforms of SNAREs and Rabs show distinct cellular and subcellular distributions. VAMP-1/synaptobrevin, membrane-anchored synaptosome-associated protein of 25 kDa (SNAP-25), syntaxin-1, Rab3A, Rab15, and Rab23 are predominantly expressed in the brain and nervous system. Different syntaxin, VAMP, and Rab proteins are associated with distinct subcellular compartments and their vesicular carriers.

Nuclear Transport

10

15

20

25

30

Transport of proteins and RNA between the nucleus and the cytoplasm occurs through nuclear pore complexes (NPCs). NPC-mediated transport occurs in both directions through the nuclear envelope. All nuclear proteins are imported from the cytoplasm, their site of synthesis. tRNA and mRNA are exported from the nucleus, their site of synthesis, to the cytoplasm, their site of function. Processing of small nuclear RNAs involves export into the cytoplasm, assembly with proteins and modifications such as hypermethylation to produce small nuclear ribonuclear proteins (snRNPs), and subsequent import of the snRNPs back into the nucleus. The assembly of ribosomes requires the initial import of ribosomal proteins from the cytoplasm, their incorporation with RNA into ribosomal subunits, and export back to the cytoplasm. (Görlich, D. and I.W. Mattaj (1996) Science 271:1513-1518.)

The transport of proteins and mRNAs across the NPC is selective, dependent on nuclear localization signals, and generally requires association with nuclear transport factors. Nuclear localization signals (NLS) consist of short stretches of amino acids enriched in basic residues. NLS are found on proteins that are targeted to the nucleus, such as the glucocorticoid receptor. The NLS is recognized by the NLS receptor, importin, which then interacts with the monomeric GTP-binding protein Ran. This NLS protein/receptor/Ran complex navigates the nuclear pore with the help of the homodimeric protein nuclear transport factor 2 (NTF2). NTF2 binds the GDP-bound form of Ran and to multiple proteins of the nuclear pore complex containing FXFG repeat motifs, such as p62. (Paschal, B. et al. (1997) J. Biol. Chem. 272:21534-21539; and Wong, D.H. et al. (1997) Mol. Cell Biol. 17:3755-3767). Some proteins are dissociated before nuclear mRNAs are transported across the

NPC while others are dissociated shortly after nuclear mRNA transport across the NPC and are reimported into the nucleus.

Disease Correlation

The etiology of numerous human diseases and disorders can be attributed to defects in the transport or secretion of proteins. For example, abnormal hormonal secretion is linked to disorders such as diabetes insipidus (vasopressin), hyper- and hypoglycemia (insulin, glucagon), Grave's disease and goiter (thyroid hormone), and Cushing's and Addison's diseases (adrenocorticotropic hormone, ACTH). Moreover, cancer cells secrete excessive amounts of hormones or other biologically active peptides. Disorders related to excessive secretion of biologically active peptides by tumor cells include fasting hypoglycemia due to increased insulin secretion from insulinoma-islet cell tumors; hypertension due to increased epinephrine and norepinephrine secreted from pheochromocytomas of the adrenal medulla and sympathetic paraganglia; and carcinoid syndrome, which is characterized by abdominal cramps, diarrhea, and valvular heart disease caused by excessive amounts of vasoactive substances such as serotonin, bradykinin, histamine, prostaglandins, and polypeptide hormones, secreted from intestinal tumors. Biologically active peptides that are ectopically synthesized in and secreted from tumor cells include ACTH and vasopressin (lung and pancreatic cancers); parathyroid hormone (lung and bladder cancers); calcitonin (lung and breast cancers); and thyroid-stimulating hormone (medullary thyroid carcinoma). Such peptides may be useful as diagnostic markers for tumorigenesis (Schwartz, M.Z. (1997) Semin. Pediatr. Surg. 3:141-146; and Said, S.I. and G.R. Faloona (1975) N. Engl. J. Med. 293:155-160).

Defective nuclear transport may play a role in cancer. The BRCA1 protein contains three potential NLSs which interact with importin alpha, and is transported into the nucleus by the importin/NPC pathway. In breast cancer cells the BRCA1 protein is aberrantly localized in the cytoplasm. The mislocation of the BRCA1 protein in breast cancer cells may be due to a defect in the NPC nuclear import pathway (Chen, C.F. et al. (1996) J. Biol. Chem. 271:32863-32868).

It has been suggested that in some breast cancers, the tumor-suppressing activity of p53 is inactivated by the sequestration of the protein in the cytoplasm, away from its site of action in the cell nucleus. Cytoplasmic wild-type p53 was also found in human cervical carcinoma cell lines. (Moll, U.M. et al. (1992) Proc. Natl. Acad. Sci. USA 89:7262-7266; and Liang, X.H. et al. (1993) Oncogene 8:2645-2652.)

Environmental Responses

Organisms respond to the environment by a number of pathways. Heat shock proteins, including hsp 70, hsp60, hsp90, and hsp 40, assist organisms in coping with heat damage to cellular proteins.

Aquaporins (AQP) are channels that transport water and, in some cases, nonionic small solutes such as urea and glycerol. Water movement is important for a number of physiological processes including renal fluid filtration, aqueous humor generation in the eye, cerebrospinal fluid production in the brain, and appropriate hydration of the lung. Aquaporins are members of the major intrinsic protein (MIP) family of membrane transporters (King, L.S. and P. Agre (1996) Annu. Rev. Physiol. 58:619-648; Ishibashi, K. et al. (1997) J. Biol. Chem. 272:20782-20786). The study of aquaporins may have relevance to understanding edema formation and fluid balance in both normal physiology and disease states (King, supra). Mutations in AQP2 cause autosomal recessive nephrogenic diabetes insipidus (OMIM *107777 Aquaporin 2; AQP2). Reduced AQP4 expression in skeletal muscle may be associated with Duchenne muscular dystrophy (Frigeri, A. et al. (1998) J. Clin. Invest. 102:695-703). Mutations in AQP0 cause autosomal dominant cataracts in the mouse (OMIM *154050 Major Intrinsic Protein of Lens Fiber; MIP).

The metallothioneins (MTs) are a group of small (61 amino acids), cysteine-rich proteins that bind heavy metals such as cadmium, zinc, mercury, lead, and copper and are thought to play a role in metal detoxification or the metabolism and homeostasis of metals. Arsenite-resistance proteins have been identified in hamsters that are resistant to toxic levels of arsenite (Rossman, T.G. et al. (1997) Mutat. Res. 386:307-314).

Humans respond to light and odors by specific protein pathways. Proteins involved in light perception include rhodopsin, transducin, and cGMP phosphodiesterase. Proteins involved in odor perception include multiple olfactory receptors. Other proteins are important in human Circadian rhythms and responses to wounds.

Immunity and Host Defense

All vertebrates have developed sophisticated and complex immune systems that provide protection from viral, bacterial, fungal and parasitic infections. Included in these systems are the processes of humoral immunity, the complement cascade and the inflammatory response (Paul, W.E. (1993) Fundamental Immunology, Raven Press, Ltd., New York NY, pp.1-20).

The cellular components of the humoral immune system include six different types of leukocytes: monocytes, lymphocytes, polymorphonuclear granulocytes (consisting of neutrophils, eosinophils, and basophils) and plasma cells. Additionally, fragments of megakaryocytes, a seventh type of white blood cell in the bone marrow, occur in large numbers in the blood as platelets.

Leukocytes are formed from two stem cell lineages in bone marrow. The myeloid stem cell line produces granulocytes and monocytes and, the lymphoid stem cell produces lymphocytes. Lymphoid cells travel to the thymus, spleen and lymph nodes, where they mature and differentiate into lymphocytes. Leukocytes are responsible for defending the body against invading pathogens.

ora in grant that carrier and

10

15

20

25

Neutrophils and monocytes attack invading bacteria, viruses, and other pathogens and destroy them by phagocytosis. Monocytes enter tissues and differentiate into macrophages which are extremely phagocytic. Lymphocytes and plasma cells are a part of the immune system which recognizes specific foreign molecules and organisms and inactivates them, as well as signals other cells to attack the invaders.

Granulocytes and monocytes are formed and stored in the bone marrow until needed.

Megakaryocytes are produced in bone marrow, where they fragment into platelets and are released into the bloodstream. The main function of platelets is to activate the blood clotting mechanism.

Lymphocytes and plasma cells are produced in various lymphogenous organs, including the lymph nodes, spleen, thymus, and tonsils.

Both neutrophils and macrophages exhibit chemotaxis towards sites of inflammation. Tissue inflammation in response to pathogen invasion results in production of chemo-attractants for leukocytes, such as endotoxins or other bacterial products, prostaglandins, and products of leukocytes or platelets.

Basophils participate in the release of the chemicals involved in the inflammatory process. The main function of basophils is secretion of these chemicals to such a degree that they have been referred to as "unicellular endocrine glands." A distinct aspect of basophilic secretion is that the contents of granules go directly into the extracellular environment, not into vacuoles as occurs with neutrophils, eosinophils and monocytes. Basophils have receptors for the Fc fragment of immunoglobulin E (IgE) that are not present on other leukocytes. Crosslinking of membrane IgE with anti-IgE or other ligands triggers degranulation.

Eosinophils are bi- or multi-nucleated white blood cells which contain eosinophilic granules. Their plasma membrane is characterized by Ig receptors, particularly IgG and IgE. Generally, eosinophils are stored in the bone marrow until recruited for use at a site of inflammation or invasion. They have specific functions in parasitic infections and allergic reactions, and are thought to detoxify some of the substances released by mast cells and basophils which cause inflammation. Additionally, they phagocytize antigen-antibody complexes and further help prevent spread of the inflammation.

Macrophages are monocytes that have left the blood stream to settle in tissue. Once monocytes have migrated into tissues, they do not re-enter the bloodstream. The mononuclear phagocyte system is comprised of precursor cells in the bone marrow, monocytes in circulation, and macrophages in tissues. The system is capable of very fast and extensive phagocytosis. A macrophage may phagocytize over 100 bacteria, digest them and extrude residues, and then survive for many more months. Macrophages are also capable of ingesting large particles, including red blood cells and malarial parasites. They increase several-fold in size and transform into macrophages

10

15

that are characteristic of the tissue they have entered, surviving in tissues for several months.

Mononuclear phagocytes are essential in defending the body against invasion by foreign pathogens, particularly intracellular microorganisms such as M. tuberculosis, listeria, leishmania and toxoplasma. Macrophages can also control the growth of tumorous cells, via both phagocytosis and secretion of hydrolytic enzymes. Another important function of macrophages is that of processing antigen and presenting them in a biochemically modified form to lymphocytes.

The immune system responds to invading microorganisms in two major ways: antibody production and cell mediated responses. Antibodies are immunoglobulin proteins produced by B-lymphocytes which bind to specific antigens and cause inactivation or promote destruction of the antigen by other cells. Cell-mediated immune responses involve T-lymphocytes (T cells) that react with foreign antigen on the surface of infected host cells. Depending on the type of T cell, the infected cell is either killed or signals are secreted which activate macrophages and other cells to destroy the infected cell (Paul, supra).

T-lymphocytes originate in the bone marrow or liver in fetuses. Precursor cells migrate via the blood to the thymus, where they are processed to mature into T-lymphocytes. This processing is crucial because of positive and negative selection of T cells that will react with foreign antigen and not with self molecules. After processing, T cells continuously circulate in the blood and secondary lymphoid tissues, such as lymph nodes, spleen, certain epithelium-associated tissues in the gastrointestinal tract, respiratory tract and skin. When T-lymphocytes are presented with the complementary antigen, they are stimulated to proliferate and release large numbers of activated T cells into the lymph system and the blood system. These activated T cells can survive and circulate for several days. At the same time, T memory cells are created, which remain in the lymphoid tissue for months or years. Upon subsequent exposure to that specific antigen, these memory cells will respond more rapidly and with a stronger response than induced by the original antigen. This creates an "immunological memory" that can provide immunity for years.

There are two major types of T cells: cytotoxic T cells destroy infected host cells, and helper T cells activate other white blood cells via chemical signals. One class of helper cell, $T_{\rm H}1$, activates macrophages to destroy ingested microorganisms, while another, $T_{\rm H}2$, stimulates the production of antibodies by B cells.

Cytotoxic T cells directly attack the infected target cell. In virus-infected cells, peptides derived from viral proteins are generated by the proteasome. These peptides are transported into the ER by the transporter associated with antigen processing (TAP) (Pamer, E. and P. Cresswell (1998) Annu. Rev. Immunol. 16:323-358). Once inside the ER, the peptides bind MHC I chains, and the peptide/MHC I complex is transported to the cell surface. Receptors on the surface of T cells bind to

10

15

20

25

antigen presented on cell surface MHC molecules. Once activated by binding to antigen, T cells secrete γ-interferon, a signal molecule that induces the expression of genes necessary for presenting viral (or other) antigens to cytotoxic T cells. Cytotoxic T cells kill the infected cell by stimulating

programmed cell death.

10

BNSDOCID: <WO__0162927A2_I_>

Helper T cells constitute up to 75% of the total T cell population. They regulate the immune functions by producing a variety of lymphokines that act on other cells in the immune system and on bone marrow. Among these lymphokines are: interleukins-2,3,4,5,6; granulocyte-monocyte colony stimulating factor, and γ -interferon.

Helper T cells are required for most B cells to respond to antigen. When an activated helper cell contacts a B cell, its centrosome and Golgi apparatus become oriented toward the B cell, aiding the directing of signal molecules, such as transmembrane-bound protein called CD40 ligand, onto the B cell surface to interact with the CD40 transmembrane protein. Secreted signals also help B cells to proliferate and mature and, in some cases, to switch the class of antibody being produced.

B-lymphocytes (B cells) produce antibodies which react with specific antigenic proteins

presented by pathogens. Once activated, B cells become filled with extensive rough endoplasmic reticulum and are known as plasma cells. As with T cells, interaction of B cells with antigen stimulates proliferation of only those B cells which produce antibody specific to that antigen. There are five classes of antibodies, known as immunoglobulins, which together comprise about 20% of total plasma protein. Each class mediates a characteristic biological response after antigen binding.

Upon activation by specific antigen B cells switch from making membrane-bound antibody to secretion of that antibody.

Antibodies, or immunoglobulins (Ig), are the founding members of the Ig superfamily and the central components of the humoral immune response. Antibodies are either expressed on the surface of B cells or secreted by B cells into the circulation. Antibodies bind and neutralize blood-borne foreign antigens. The prototypical antibody is a tetramer consisting of two identical heavy polypeptide chains (H-chains) and two identical light polypeptide chains (L-chains) interlinked by disulfide bonds. This arrangement confers the characteristic Y-shape to antibody molecules. Antibodies are classified based on their H-chain composition. The five antibody classes, IgA, IgD, IgE, IgG and IgM, are defined by the α , δ , ϵ , γ , and μ H-chain types. There are two types of L-chains, κ and λ , either of which may associate as a pair with any H-chain pair. IgG, the most common class of antibody found in the circulation, is tetrameric, while the other classes of antibodies are generally variants or multimers of this basic structure.

H-chains and L-chains each contain an N-terminal variable region and a C-terminal constant region. Both H-chains and L-chains contain repeated Ig domains. For example, a typical H-chain

contains four Ig domains, three of which occur within the constant region and one of which occurs within the variable region and contributes to the formation of the antigen recognition site. Likewise, a typical L-chain contains two Ig domains, one of which occurs within the constant region and one of which occurs within the variable region. In addition, H chains such as μ have been shown to associate with other polypeptides during differentiation of the B cell.

Antibodies can be described in terms of their two main functional domains. Antigen recognition is mediated by the Fab (antigen binding fragment) region of the antibody, while effector functions are mediated by the Fc (crystallizable fragment) region. Binding of antibody to an antigen, such as a bacterium, triggers the destruction of the antigen by phagocytic white blood cells such as macrophages and neutrophils. These cells express surface receptors that specifically bind to the antibody Fc region and allow the phagocytic cells to engulf, ingest, and degrade the antibody-bound antigen. The Fc receptors expressed by phagocytic cells are single-pass transmembrane glycoproteins of about 300 to 400 amino acids (Sears, D.W. et al. (1990) J. Immunol. 144:371-378). The extracellular portion of the Fc receptor typically contains two or three Ig domains.

Diseases which cause over- or under-abundance of any one type of leukocyte usually result in the entire immune defense system becoming involved. A well-known autoimmune disease is AIDS (Acquired Immunodeficiency Syndrome) where the number of helper T cells is depleted, leaving the patient susceptible to infection by microorganisms and parasites. Another widespread medical condition attributable to the immune system is that of allergic reactions to certain antigens. Allergic reactions include: hay fever, asthma, anaphylaxis, and urticaria (hives). Leukemias are an excess production of white blood cells, to the point where a major portion of the body's metabolic resources are directed solely at proliferation of white blood cells, leaving other tissues to starve. Leukopenia or agranulocytosis occurs when the bone marrow stops producing white blood cells. This leaves the body unprotected against foreign microorganisms, including those which normally inhabit skin, mucous membranes, and gastrointestinal tract. If all white blood cell production stops completely, infection will occur within two days and death may follow only 1 to 4 days later.

Impaired phagocytosis occurs in several diseases, including monocytic leukemia, systemic lupus, and granulomatous disease. In such a situation, macrophages can phagocytize normally, but the enveloped organism is not killed. A defect in the plasma membrane enzyme which converts oxygen to lethally reactive forms results in abscess formation in liver, lungs, spleen, lymph nodes, and beneath the skin. Eosinophilia is an excess of eosinophils commonly observed in patients with allergies (hay fever, asthma), allergic reactions to drugs, rheumatoid arthritis, and cancers (Hodgkin's disease, lung, and liver cancer) (Isselbacher, K.J. et al. (1994) Harrison's Principles of Internal Medicine, McGraw-Hill, Inc., New York NY).

10

15

20

25

Host defense is further augmented by the complement system. The complement system serves as an effector system and is involved in infectious agent recognition. It can function as an independent immune network or in conjunction with other humoral immune responses. The complement system is comprised of numerous plasma and membrane proteins that act in a cascade of reaction sequences whereby one component activates the next. The result is a rapid and amplified response to infection through either an inflammatory response or increased phagocytosis.

The complement system has more than 30 protein components which can be divided into functional groupings including modified serine proteases, membrane-binding proteins and regulators of complement activation. Activation occurs through two different pathways the classical and the alternative. Both pathways serve to destroy infectious agents through distinct triggering mechanisms that eventually merge with the involvement of the component C3.

The classical pathway requires antibody binding to infectious agent antigens. The antibodies serve to define the target and initiate the complement system cascade, culminating in the destruction of the infectious agent. In this pathway, since the antibody guides initiation of the process, the complement can be seen as an effector arm of the humoral immune system.

The alternative pathway of the complement system does not require the presence of preexisting antibodies for targeting infectious agent destruction. Rather, this pathway, through low levels of an activated component, remains constantly primed and provides surveillance in the nonimmune host to enable targeting and destruction of infectious agents. In this case foreign material triggers the cascade, thereby facilitating phagocytosis or lysis (Paul, <u>supra</u>, pp.918-919).

Another important component of host defense is the process of inflammation. Inflammatory responses are divided into four categories on the basis of pathology and include allergic inflammation, cytotoxic antibody mediated inflammation, immune complex mediated inflammation and monocyte mediated inflammation. Inflammation manifests as a combination of each of these forms with one predominating.

Allergic acute inflammation is observed in individuals wherein specific antigens stimulate IgE antibody production. Mast cells and basophils are subsequently activated by the attachment of antigen-IgE complexes, resulting in the release of cytoplasmic granule contents such as histamine. The products of activated mast cells can increase vascular permeability and constrict the smooth muscle of breathing passages, resulting in anaphylaxis or asthma. Acute inflammation is also mediated by cytotoxic antibodies and can result in the destruction of tissue through the binding of complement-fixing antibodies to cells. The responsible antibodies are of the IgG or IgM types. Resultant clinical disorders include autoimmune hemolytic anemia and thrombocytopenia as associated with systemic lupus erythematosis.

10

15

Immune complex mediated acute inflammation involves the IgG or IgM antibody types which combine with antigen to activate the complement cascade. When such immune complexes bind to neutrophils and macrophages they activate the respiratory burst to form protein- and vessel-damaging agents such as hydrogen peroxide, hydroxyl radical, hypochlorous acid, and chloramines. Clinical manifestations include rheumatoid arthritis and systemic lupus erythematosus.

In chronic inflammation or delayed-type hypersensitivity, macrophages are activated and process antigen for presentation to T cells that subsequently produce lymphokines and monokines. This type of inflammatory response is likely important for defense against intracellular parasites and certain viruses. Clinical associations include, granulomatous disease, tuberculosis, leprosy, and sarcoidosis (Paul, W.E., supra, pp.1017-1018).

Extracellular Information Transmission Molecules

Intercellular communication is essential for the growth and survival of multicellular organisms, and in particular, for the function of the endocrine, nervous, and immune systems. In addition, intercellular communication is critical for developmental processes such as tissue construction and organogenesis, in which cell proliferation, cell differentiation, and morphogenesis must be spatially and temporally regulated in a precise and coordinated manner. Cells communicate with one another through the secretion and uptake of diverse types of signaling molecules such as hormones, growth factors, neuropeptides, and cytokines.

20 Hormones

5

10

15

25

30

Hormones are signaling molecules that coordinately regulate basic physiological processes from embryogenesis throughout adulthood. These processes include metabolism, respiration, reproduction, excretion, fetal tissue differentiation and organogenesis, growth and development, homeostasis, and the stress response. Hormonal secretions and the nervous system are tightly integrated and interdependent. Hormones are secreted by endocrine glands, primarily the hypothalamus and pituitary, the thyroid and parathyroid, the pancreas, the adrenal glands, and the ovaries and testes.

The secretion of hormones into the circulation is tightly controlled. Hormones are often secreted in diurnal, pulsatile, and cyclic patterns. Hormone secretion is regulated by perturbations in blood biochemistry, by other upstream-acting hormones, by neural impulses, and by negative feedback loops. Blood hormone concentrations are constantly monitored and adjusted to maintain optimal, steady-state levels. Once secreted, hormones act only on those target cells that express specific receptors.

Most disorders of the endocrine system are caused by either hyposecretion or hypersecretion of hormones. Hyposecretion often occurs when a hormone's gland of origin is damaged or otherwise

impaired. Hypersecretion often results from the proliferation of tumors derived from hormone-secreting cells. Inappropriate hormone levels may also be caused by defects in regulatory feedback loops or in the processing of hormone precursors. Endocrine malfunction may also occur when the target cell fails to respond to the hormone.

Hormones can be classified biochemically as polypeptides, steroids, eicosanoids, or amines. Polypeptides, which include diverse hormones such as insulin and growth hormone, vary in size and ' function and are often synthesized as inactive precursors that are processed intracellularly into mature, active forms. Amines, which include epinephrine and dopamine, are amino acid derivatives that function in neuroendocrine signaling. Steroids, which include the cholesterol-derived hormones estrogen and testosterone, function in sexual development and reproduction. Eicosanoids, which include prostaglandins and prostacyclins, are fatty acid derivatives that function in a variety of processes. Most polypeptides and some amines are soluble in the circulation where they are highly susceptible to proteolytic degradation within seconds after their secretion. Steroids and lipids are insoluble and must be transported in the circulation by carrier proteins. The following discussion will 15 focus primarily on polypeptide hormones.

Hormones secreted by the hypothalamus and pituitary gland play a critical role in endocrine function by coordinately regulating hormonal secretions from other endocrine glands in response to neural signals. Hypothalamic hormones include thyrotropin-releasing hormone, gonadotropin-releasing hormone, somatostatin, growth-hormone releasing factor, corticotropin-releasing hormone, substance P, dopamine, and prolactin-releasing hormone. These hormones directly regulate the secretion of hormones from the anterior lobe of the pituitary. Hormones secreted by the anterior pituitary include adrenocorticotropic hormone (ACTH), melanocyte-stimulating hormone, somatotropic hormones such as growth hormone and prolactin, glycoprotein hormones such as thyroid-stimulating hormone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH), β -lipotropin, and β -endorphins. These hormones regulate hormonal secretions from the thyroid, pancreas, and adrenal glands, and act directly on the reproductive organs to stimulate ovulation and spermatogenesis. The posterior pituitary synthesizes and secretes antidiuretic hormone (ADH, vasopressin) and oxytocin.

Disorders of the hypothalamus and pituitary often result from lesions such as primary brain tumors, adenomas, infarction associated with pregnancy, hypophysectomy, aneurysms, vascular malformations, thrombosis, infections, immunological disorders, and complications due to head trauma. Such disorders have profound effects on the function of other endocrine glands. Disorders associated with hypopituitarism include hypogonadism, Sheehan syndrome, diabetes insipidus, Kallman's disease, Hand-Schuller-Christian disease, Letterer-Siwe disease, sarcoidosis, empty sella syndrome, and dwarfism. Disorders associated with hyperpituitarism include acromegaly, giantism, and syndrome of

inappropriate ADH secretion (SIADH), often caused by benign adenomas.

Hormones secreted by the thyroid and parathyroid primarily control metabolic rates and the regulation of serum calcium levels, respectively. Thyroid hormones include calcitonin, somatostatin, and thyroid hormone. The parathyroid secretes parathyroid hormone. Disorders associated with hypothyroidism include goiter, myxedema, acute thyroiditis associated with bacterial infection, subacute thyroiditis associated with viral infection, autoimmune thyroiditis (Hashimoto's disease), and cretinism. Disorders associated with hyperthyroidism include thyrotoxicosis and its various forms, Grave's disease, pretibial myxedema, toxic multinodular goiter, thyroid carcinoma, and Plummer's disease. Disorders associated with hyperparathyroidism include Conn disease (chronic hypercalemia) leading to bone resorption and parathyroid hyperplasia.

Hormones secreted by the pancreas regulate blood glucose levels by modulating the rates of carbohydrate, fat, and protein metabolism. Pancreatic hormones include insulin, glucagon, amylin, γ-aminobutyric acid, gastrin, somatostatin, and pancreatic polypeptide. The principal disorder associated with pancreatic dysfunction is diabetes mellitus caused by insufficient insulin activity. Diabetes mellitus is generally classified as either Type I (insulin-dependent, juvenile diabetes) or Type II (non-insulin-dependent, adult diabetes). The treatment of both forms by insulin replacement therapy is well known. Diabetes mellitus often leads to acute complications such as hypoglycemia (insulin shock), coma, diabetic ketoacidosis, lactic acidosis, and chronic complications leading to disorders of the eye, kidney, skin, bone, joint, cardiovascular system, nervous system, and to decreased resistance to infection.

The anatomy, physiology, and diseases related to hormonal function are reviewed in McCance, K.L. and S.E. Huether (1994) <u>Pathophysiology: The Biological Basis for Disease in Adults and Children</u>, Mosby-Year Book, Inc., St. Louis MO; Greenspan, F.S. and J.D. Baxter (1994) <u>Basic and Clinical Endocrinology</u>, Appleton and Lange, East Norwalk CT.

25 Growth Factors

5

10

15

20

Growth factors are secreted proteins that mediate intercellular communication. Unlike hormones, which travel great distances via the circulatory system, most growth factors are primarily local mediators that act on neighboring cells. Most growth factors contain a hydrophobic N-terminal signal peptide sequence which directs the growth factor into the secretory pathway. Most growth factors also undergo post-translational modifications within the secretory pathway. These modifications can include proteolysis, glycosylation, phosphorylation, and intramolecular disulfide bond formation. Once secreted, growth factors bind to specific receptors on the surfaces of neighboring target cells, and the bound receptors trigger intracellular signal transduction pathways. These signal transduction pathways elicit specific cellular responses in the target cells. These responses can include

يعمونهم بمؤاخران أأسار فاطراف المراجات الماسا

the modulation of gene expression and the stimulation or inhibition of cell division, cell differentiation, and cell motility.

Growth factors fall into at least two broad and overlapping classes. The broadest class includes the large polypeptide growth factors, which are wide-ranging in their effects. These factors include epidermal growth factor (EGF), fibroblast growth factor (FGF), transforming growth factor- β (TGF- β), insulin-like growth factor (IGF), nerve growth factor (NGF), and platelet-derived growth factor (PDGF), each defining a family of numerous related factors. The large polypeptide growth factors, with the exception of NGF, act as mitogens on diverse cell types to stimulate wound healing, bone synthesis and remodeling, extracellular matrix synthesis, and proliferation of epithelial, epidermal, and connective tissues. Members of the TGF- β , EGF, and FGF families also function as inductive signals in the differentiation of embryonic tissue. NGF functions specifically as a neurotrophic factor, promoting neuronal growth and differentiation.

Another class of growth factors includes the hematopoietic growth factors, which are narrow in their target specificity. These factors stimulate the proliferation and differentiation of blood cells such as B-lymphocytes, T-lymphocytes, erythrocytes, platelets, eosinophils, basophils, neutrophils, macrophages, and their stem cell precursors. These factors include the colony-stimulating factors (G-CSF, M-CSF, GM-CSF, and CSF1-3), erythropoietin, and the cytokines. The cytokines are specialized hematopoietic factors secreted by cells of the immune system and are discussed in detail below.

Growth factors play critical roles in neoplastic transformation of cells in vitro and in tumor progression in vivo. Overexpression of the large polypeptide growth factors promotes the proliferation and transformation of cells in culture. Inappropriate expression of these growth factors by tumor cells in vivo may contribute to tumor vascularization and metastasis. Inappropriate activity of hematopoietic growth factors can result in anemias, leukemias, and lymphomas. Moreover, growth factors are both structurally and functionally related to oncoproteins, the potentially cancer-causing products of proto-oncogenes. Certain FGF and PDGF family members are themselves homologous to oncoproteins, whereas receptors for some members of the EGF, NGF, and FGF families are encoded by proto-oncogenes. Growth factors also affect the transcriptional regulation of both proto-oncogenes and oncosuppressor genes (Pimentel, E. (1994) Handbook of Growth Factors, CRC Press, Ann Arbor MI; McKay, I. and I. Leigh, eds. (1993) Growth Factors: A Practical Approach, Oxford University Press, New York NY; Habenicht, A., ed. (1990) Growth Factors, Differentiation Factors, and Cytokines, Springer-Verlag, New York NY).

In addition, some of the large polypeptide growth factors play crucial roles in the induction of the primordial germ layers in the developing embryo. This induction ultimately results in the formation of the embryonic mesoderm, ectoderm, and endoderm which in turn provide the framework for the

entire adult body plan. Disruption of this inductive process would be catastrophic to embryonic development.

Small Peptide Factors - Neuropeptides and Vasomediators

Neuropeptides and vasomediators (NP/VM) comprise a family of small peptide factors, typically of 20 amino acids or less. These factors generally function in neuronal excitation and inhibition of vasoconstriction/vasodilation, muscle contraction, and hormonal secretions from the brain and other endocrine tissues. Included in this family are neuropeptides and neuropeptide hormones such as bombesin, neuropeptide Y, neurotensin, neuromedin N, melanocortins, opioids, galanin, somatostatin, tachykinins, urotensin II and related peptides involved in smooth muscle stimulation, vasopressin, vasoactive intestinal peptide, and circulatory system-borne signaling molecules such as angiotensin, complement, calcitonin, endothelins, formyl-methionyl peptides, glucagon, cholecystokinin, gastrin, and many of the peptide hormones discussed above. NP/VMs can transduce signals directly, modulate the activity or release of other neurotransmitters and hormones, and act as catalytic enzymes in signaling cascades. The effects of NP/VMs range from extremely brief to long-lasting. (Reviewed in Martin, C.R. et al. (1985) Endocrine Physiology, Oxford University Press, New York NY, pp. 57-62.)

Cytokines

10

. 15

20

25

30

Cytokines comprise a family of signaling molecules that modulate the immune system and the inflammatory response. Cytokines are usually secreted by leukocytes, or white blood cells, in response to injury or infection. Cytokines function as growth and differentiation factors that act primarily on cells of the immune system such as B- and T-lymphocytes, monocytes, macrophages, and granulocytes. Like other signaling molecules, cytokines bind to specific plasma membrane receptors and trigger intracellular signal transduction pathways which alter gene expression patterns. There is considerable potential for the use of cytokines in the treatment of inflammation and immune system disorders.

Cytokine structure and function have been extensively characterized in vitro. Most cytokines are small polypeptides of about 30 kilodaltons or less. Over 50 cytokines have been identified from human and rodent sources. Examples of cytokine subfamilies include the interferons (IFN- α , - β , and - γ), the interleukins (IL1-IL13), the tumor necrosis factors (TNF- α and - β), and the chemokines. Many cytokines have been produced using recombinant DNA techniques, and the activities of individual cytokines have been determined in vitro. These activities include regulation of leukocyte proliferation, differentiation, and motility.

The activity of an individual cytokine <u>in vitro</u> may not reflect the full scope of that cytokine's activity <u>in vivo</u>. Cytokines are not expressed individually <u>in vivo</u> but are instead expressed in combination with a multitude of other cytokines when the organism is challenged with a stimulus.

Together, these cytokines collectively modulate the immune response in a manner appropriate for that particular stimulus. Therefore, the physiological activity of a cytokine is determined by the stimulus itself and by complex interactive networks among co-expressed cytokines which may demonstrate both synergistic and antagonistic relationships.

Chemokines comprise a cytokine subfamily with over 30 members. (Reviewed in Wells, T. N.C. and M.C. Peitsch (1997) J. Leukoc. Biol. 61:545-550.) Chemokines were initially identified as chemotactic proteins that recruit monocytes and macrophages to sites of inflammation. Recent evidence indicates that chemokines may also play key roles in hematopoiesis and HIV-1 infection. Chemokines are small proteins which range from about 6-15 kilodaltons in molecular weight. Chemokines are further classified as C, CC, CXC, or CX₃C based on the number and position of critical cysteine residues. The CC chemokines, for example, each contain a conserved motif consisting of two consecutive cysteines followed by two additional cysteines which occur downstream at 24- and 16residue intervals, respectively (ExPASy PROSITE database, documents PS00472 and PDOC00434). The presence and spacing of these four cysteine residues are highly conserved, whereas the intervening residues diverge significantly. However, a conserved tyrosine located about 15 residues downstream of the cysteine doublet seems to be important for chemotactic activity. Most of the human genes encoding CC chemokines are clustered on chromosome 17, although there are a few examples of CC chemokine genes that map elsewhere. Other chemokines include lymphotactin (C chemokine); macrophage chemotactic and activating factor (MCAF/MCP-1; CC chemokine); platelet factor 4 and IL-8 (CXC chemokines); and fractalkine and neurotractin (CX₃C chemokines). (Reviewed in Luster, A.D. (1998) N. Engl. J. Med. 338:436-445.)

Receptor Molecules

The term receptor describes proteins that specifically recognize other molecules. The category is broad and includes proteins with a variety of functions. The bulk of receptors are cell surface proteins which bind extracellular ligands and produce cellular responses in the areas of growth, differentiation, endocytosis, and immune response. Other receptors facilitate the selective transport of proteins out of the endoplasmic reticulum and localize enzymes to particular locations in the cell. The term may also be applied to proteins which act as receptors for ligands with known or unknown chemical composition and which interact with other cellular components. For example, the steroid hormone receptors bind to and regulate transcription of DNA.

Regulation of cell proliferation, differentiation, and migration is important for the formation and function of tissues. Regulatory proteins such as growth factors coordinately control these cellular processes and act as mediators in cell-cell signaling pathways. Growth factors are secreted proteins

20

25

that bind to specific cell-surface receptors on target cells. The bound receptors trigger intracellular signal transduction pathways which activate various downstream effectors that regulate gene expression, cell division, cell differentiation, cell motility, and other cellular processes.

Cell surface receptors are typically integral plasma membrane proteins. These receptors recognize hormones such as catecholamines; peptide hormones; growth and differentiation factors; small peptide factors such as thyrotropin-releasing hormone; galanin, somatostatin, and tachykinins; and circulatory system-borne signaling molecules. Cell surface receptors on immune system cells recognize antigens, antibodies, and major histocompatibility complex (MHC)-bound peptides. Other cell surface receptors bind ligands to be internalized by the cell. This receptor-mediated endocytosis functions in the uptake of low density lipoproteins (LDL), transferrin, glucose- or mannose-terminal glycoproteins, galactose-terminal glycoproteins, immunoglobulins, phosphovitellogenins, fibrin, proteinase-inhibitor complexes, plasminogen activators, and thrombospondin (Lodish, H. et al. (1995) Molecular Cell Biology, Scientific American Books, New York NY, p. 723; Mikhailenko, I. et al. (1997) J. Biol. Chem. 272:6784-6791).

15 Receptor Protein Kinases

5

10

20

25

30

Many growth factor receptors, including receptors for epidermal growth factor, platelet-derived growth factor, fibroblast growth factor, as well as the growth modulator α-thrombin, contain intrinsic protein kinase activities. When growth factor binds to the receptor, it triggers the autophosphorylation of a serine, threonine, or tyrosine residue on the receptor. These phosphorylated sites are recognition sites for the binding of other cytoplasmic signaling proteins. These proteins participate in signaling pathways that eventually link the initial receptor activation at the cell surface to the activation of a specific intracellular target molecule. In the case of tyrosine residue autophosphorylation, these signaling proteins contain a common domain referred to as a Src homology (SH) domain. SH2 domains and SH3 domains are found in phospholipase C-γ, PI-3-K p85 regulatory subunit, Ras-GTPase activating protein, and pp60°-src (Lowenstein, E.J. et al. (1992) Cell 70:431-442). The cytokine family of receptors share a different common binding domain and include transmembrane receptors for growth hormone (GH), interleukins, erythropoietin, and prolactin.

Other receptors and second messenger-binding proteins have intrinsic serine/threonine protein kinase activity. These include activin/TGF- β /BMP-superfamily receptors, calcium- and diacylglycerolactivated/phospholipid-dependant protein kinase (PK-C), and RNA-dependant protein kinase (PK-R). In addition, other serine/threonine protein kinases, including nematode Twitchin, have fibronectin-like, immunoglobulin C2-like domains.

G-Protein Coupled Receptors

G-protein coupled receptors (GPCRs) are integral membrane proteins characterized by the

I for the state of the state of

presence of seven hydrophobic transmembrane domains which span the plasma membrane and form a bundle of antiparallel alpha (α) helices. These proteins range in size from under 400 to over 1000 amino acids (Strosberg, A.D. (1991) Eur. J. Biochem. 196:1-10; Coughlin, S.R. (1994) Curr. Opin. Cell Biol. 6:191-197). The amino-terminus of the GPCR is extracellular, of variable length and often glycosylated; the carboxy-terminus is cytoplasmic and generally phosphorylated. Extracellular loops of the GPCR alternate with intracellular loops and link the transmembrane domains. The most conserved domains of GPCRs are the transmembrane domains and the first two cytoplasmic loops. The transmembrane domains account for structural and functional features of the receptor. In most cases, the bundle of α helices forms a binding pocket. In addition, the extracellular N-terminal segment or one or more of the three extracellular loops may also participate in ligand binding. Ligand binding activates the receptor by inducing a conformational change in intracellular portions of the receptor. The activated receptor, in turn, interacts with an intracellular heterotrimeric guanine nucleotide binding (G) protein complex which mediates further intracellular signaling activities, generally the production of second messengers such as cyclic AMP (cAMP), phospholipase C, inositol triphosphate, or interactions 15 with ion channel proteins (Baldwin, J.M. (1994) Curr. Opin. Cell Biol. 6:180-190).

GPCRs include those for acetylcholine, adenosine, epinephrine and norepinephrine, bombesin, bradykinin, chemokines, dopamine, endothelin, γ-aminobutyric acid (GABA), follicle-stimulating hormone (FSH), glutamate, gonadotropin-releasing hormone (GnRH), hepatocyte growth factor, histamine, leukotrienes, melanocortins, neuropeptide Y, opioid peptides, opsins, prostanoids, serotonin, somatostatin, tachykinins, thrombin, thyrotropin-releasing hormone (TRH), vasoactive intestinal polypeptide family, vasopressin and oxytocin, and orphan receptors.

GPCR mutations, which may cause loss of function or constitutive activation, have been associated with numerous human diseases (Coughlin, supra). For instance, retinitis pigmentosa may arise from mutations in the rhodopsin gene. Rhodopsin is the retinal photoreceptor which is located within the discs of the eye rod cell. Parma, J. et al. (1993, Nature 365:649-651) report that somatic activating mutations in the thyrotropin receptor cause hyperfunctioning thyroid adenomas and suggest that certain GPCRs susceptible to constitutive activation may behave as protooncogenes.

Nuclear Receptors

Nuclear receptors bind small molecules such as hormones or second messengers, leading to increased receptor-binding affinity to specific chromosomal DNA elements. In addition the affinity for other nuclear proteins may also be altered. Such binding and protein-protein interactions may regulate and modulate gene expression. Examples of such receptors include the steroid hormone receptors family, the retinoic acid receptors family, and the thyroid hormone receptors family. Ligand-Gated Receptor Ion Channels

10

Ligand-gated receptor ion channels fall into two categories. The first category, extracellular ligand-gated receptor ion channels (ELGs), rapidly transduce neurotransmitter-binding events into electrical signals, such as fast synaptic neurotransmission. ELG function is regulated by post-translational modification. The second category, intracellular ligand-gated receptor ion channels (ILGs), are activated by many intracellular second messengers and do not require post-translational modification(s) to effect a channel-opening response.

ELGs depolarize excitable cells to the threshold of action potential generation. In non-excitable cells, ELGs permit a limited calcium ion-influx during the presence of agonist. ELGs include channels directly gated by neurotransmitters such as acetylcholine, L-glutamate, glycine, ATP, serotonin, GABA, and histamine. ELG genes encode proteins having strong structural and functional similarities. ILGs are encoded by distinct and unrelated gene families and include receptors for cAMP, cGMP, calcium ions, ATP, and metabolites of arachidonic acid.

Macrophage Scavenger Receptors

Macrophage scavenger receptors with broad ligand specificity may participate in the binding of low density lipoproteins (LDL) and foreign antigens. Scavenger receptors types I and II are trimeric membrane proteins with each subunit containing a small N-terminal intracellular domain, a transmembrane domain, a large extracellular domain, and a C-terminal cysteine-rich domain. The extracellular domain contains a short spacer domain, an α-helical coiled-coil domain, and a triple helical collagenous domain. These receptors have been shown to bind a spectrum of ligands, including chemically modified lipoproteins and albumin, polyribonucleotides, polysaccharides, phospholipids, and asbestos (Matsumoto, A. et al. (1990) Proc. Natl. Acad. Sci. USA 87:9133-9137; Elomaa, O. et al. (1995) Cell 80:603-609). The scavenger receptors are thought to play a key role in atherogenesis by mediating uptake of modified LDL in arterial walls, and in host defense by binding bacterial endotoxins, bacteria, and protozoa.

25 T-Cell Receptors

5

10

15

20

T cells play a dual role in the immune system as effectors and regulators, coupling antigen recognition with the transmission of signals that induce cell death in infected cells and stimulate proliferation of other immune cells. Although a population of T cells can recognize a wide range of different antigens, an individual T cell can only recognize a single antigen and only when it is presented to the T cell receptor (TCR) as a peptide complexed with a major histocompatibility molecule (MHC) on the surface of an antigen presenting cell. The TCR on most T cells consists of immunoglobulin-like integral membrane glycoproteins containing two polypeptide subunits, α and β , of similar molecular weight. Both TCR subunits have an extracellular domain containing both variable and constant regions, a transmembrane domain that traverses the membrane once, and a short intracellular domain

(Saito, H. et al. (1984) Nature 309:757-762). The genes for the TCR subunits are constructed through somatic rearrangement of different gene segments. Interaction of antigen in the proper MHC context with the TCR initiates signaling cascades that induce the proliferation, maturation, and function of cellular components of the immune system (Weiss, A. (1991) Annu. Rev. Genet. 25:487-510). Rearrangements in TCR genes and alterations in TCR expression have been noted in lymphomas, leukemias, autoimmune disorders, and immunodeficiency disorders (Aisenberg, A.C. et al. (1985) N. Engl. J. Med. 313:529-533; Weiss, supra).

Intracellular Signaling Molecules

10

Intracellular signaling is the general process by which cells respond to extracellular signals (hormones, neurotransmitters, growth and differentiation factors, etc.) through a cascade of biochemical reactions that begins with the binding of a signaling molecule to a cell membrane receptor and ends with the activation of an intracellular target molecule. Intermediate steps in the process involve the activation of various cytoplasmic proteins by phosphorylation via protein kinases, and their deactivation by protein phosphatases, and the eventual translocation of some of these activated proteins to the cell nucleus where the transcription of specific genes is triggered. The intracellular signaling process regulates all types of cell functions including cell proliferation, cell differentiation, and gene transcription, and involves a diversity of molecules including protein kinases and phosphatases, and second messenger molecules, such as cyclic nucleotides, calcium-calmodulin, inositol, and various mitogens, that regulate protein phosphorylation.

Protein Phosphorylation

Protein kinases and phosphatases play a key role in the intracellular signaling process by controlling the phosphorylation and activation of various signaling proteins. The high energy phosphate for this reaction is generally transferred from the adenosine triphosphate molecule (ATP) to a particular protein by a protein kinase and removed from that protein by a protein phosphatase. Protein kinases are roughly divided into two groups: those that phosphorylate tyrosine residues (protein tyrosine kinases, PTK) and those that phosphorylate serine or threonine residues (serine/threonine kinases, STK). A few protein kinases have dual specificity for serine/threonine and tyrosine residues. Almost all kinases contain a conserved 250-300 amino acid catalytic domain containing specific residues and sequence motifs characteristic of the kinase family (Hardie, G. and S. Hanks (1995) The Protein Kinase Facts Books, Vol I:7-20, Academic Press, San Diego CA).

STKs include the second messenger dependent protein kinases such as the cyclic-AMP dependent protein kinases (PKA), involved in mediating hormone-induced cellular responses; calcium-calmodulin (CaM) dependent protein kinases, involved in regulation of smooth muscle

contraction, glycogen breakdown, and neurotransmission; and the mitogen-activated protein kinases (MAP) which mediate signal transduction from the cell surface to the nucleus via phosphorylation cascades. Altered PKA expression is implicated in a variety of disorders and diseases including cancer, thyroid disorders, diabetes, atherosclerosis, and cardiovascular disease (Isselbacher, K.J. et al. (1994) Harrison's Principles of Internal Medicine McGraw-Hill, New York NY, pp. 416-431, 1887).

PTKs are divided into transmembrane, receptor PTKs and nontransmembrane, non-receptor PTKs. Transmembrane PTKs are receptors for most growth factors. Non-receptor PTKs lack transmembrane regions and, instead, form complexes with the intracellular regions of cell surface receptors. Receptors that function through non-receptor PTKs include those for cytokines and hormones (growth hormone and prolactin) and antigen-specific receptors on T and B lymphocytes. Many of these PTKs were first identified as the products of mutant oncogenes in cancer cells in which their activation was no longer subject to normal cellular controls. In fact, about one third of the known oncogenes encode PTKs, and it is well known that cellular transformation (oncogenesis) is often accompanied by increased tyrosine phosphorylation activity (Charbonneau, H. and N.K. Tonks (1992) Annu. Rev. Cell Biol. 8:463-493).

An additional family of protein kinases previously thought to exist only in procaryotes is the histidine protein kinase family (HPK). HPKs bear little homology with mammalian STKs or PTKs but have distinctive sequence motifs of their own (Davie, J.R. et al. (1995) J. Biol. Chem. 270:19861-19867). A histidine residue in the N-terminal half of the molecule (region I) is an autophosphorylation site. Three additional motifs located in the C-terminal half of the molecule include an invariant asparagine residue in region II and two glycine-rich loops characteristic of nucleotide binding domains in regions III and IV. Recently a branched chain alpha-ketoacid dehydrogenase kinase has been found with characteristics of HPK in rat (Davie, supra).

Protein phosphatases regulate the effects of protein kinases by removing phosphate groups from molecules previously activated by kinases. The two principal categories of protein phosphatases are the protein (serine/threonine) phosphatases (PPs) and the protein tyrosine phosphatases (PTPs). PPs dephosphorylate phosphoserine/threonine residues and are important regulators of many cAMP-mediated hormone responses (Cohen, P. (1989) Annu. Rev. Biochem. 58:453-508). PTPs reverse the effects of protein tyrosine kinases and play a significant role in cell cycle and cell signaling processes (Charbonneau, supra). As previously noted, many PTKs are encoded by oncogenes, and oncogenesis is often accompanied by increased tyrosine phosphorylation activity. It is therefore possible that PTPs may prevent or reverse cell transformation and the growth of various cancers by controlling the levels of tyrosine phosphorylation in cells. This hypothesis is supported by studies showing that overexpression of PTPs can suppress transformation in cells, and that specific

CALLEGE CONTRACTOR STATES

10

15

20

25

inhibition of PTPs can enhance cell transformation (Charbonneau, <u>supra</u>). Phospholipid and Inositol-Phosphate Signaling

Inositol phospholipids (phosphoinositides) are involved in an intracellular signaling pathway that begins with binding of a signaling molecule to a G-protein linked receptor in the plasma

membrane. This leads to the phosphorylation of phosphatidylinositol (PI) residues on the inner side of the plasma membrane to the biphosphate state (PIP₂) by inositol kinases. Simultaneously, the G-protein linked receptor binding stimulates a trimeric G-protein which in turn activates a phosphoinositide-specific phospholipase C-β. Phospholipase C-β then cleaves PIP₂ into two products, inositol triphosphate (IP₃) and diacylglycerol. These two products act as mediators for separate signaling events. IP₃ diffuses through the plasma membrane to induce calcium release from the endoplasmic reticulum (ER), while diacylglycerol remains in the membrane and helps activate protein kinase C, an STK that phosphorylates selected proteins in the target cell. The calcium response initiated by IP₃ is terminated by the dephosphorylation of IP₃ by specific inositol phosphatases. Cellular responses that are mediated by this pathway are glycogen breakdown in the liver in response to vasopressin, smooth muscle contraction in response to acetylcholine, and thrombin-induced platelet aggregation.

Cyclic Nucleotide Signaling

Cyclic nucleotides (cAMP and cGMP) function as intracellular second messengers to transduce a variety of extracellular signals including hormones, light, and neurotransmitters. In particular, cyclic-AMP dependent protein kinases (PKA) are thought to account for all of the effects of cAMP in most mammalian cells, including various hormone-induced cellular responses. Visual excitation and the phototransmission of light signals in the eye is controlled by cyclic-GMP regulated, Ca²⁺-specific channels. Because of the importance of cellular levels of cyclic nucleotides in mediating these various responses, regulating the synthesis and breakdown of cyclic nucleotides is an important matter. Thus adenylyl cyclase, which synthesizes cAMP from AMP, is activated to increase cAMP levels in muscle by binding of adrenaline to β -andrenergic receptors, while activation of guanylate cyclase and increased cGMP levels in photoreceptors leads to reopening of the Ca²⁺-specific channels and recovery of the dark state in the eye. In contrast, hydrolysis of cyclic nucleotides by cAMP and cGMP-specific phosphodiesterases (PDEs) produces the opposite of these and other effects mediated by increased cyclic nucleotide levels. PDEs appear to be particularly important in the regulation of cyclic nucleotides, considering the diversity found in this family of proteins. At least seven families of mammalian PDEs (PDE1-7) have been identified based on substrate specificity and affinity, sensitivity to cofactors, and sensitivity to inhibitory drugs (Beavo, J.A. (1995) Physiological Reviews 75:725-748). PDE inhibitors have been found to be particularly

useful in treating various clinical disorders. Rolipram, a specific inhibitor of PDE4, has been used in the treatment of depression, and similar inhibitors are undergoing evaluation as anti-inflammatory agents. Theophylline is a nonspecific PDE inhibitor used in the treatment of bronchial asthma and other respiratory diseases (Banner, K.H. and C.P. Page (1995) Eur. Respir. J. 8:996-1000).

5 G-Protein Signaling

10

15

20

25

30

Guanine nucleotide binding proteins (G-proteins) are critical mediators of signal transduction between a particular class of extracellular receptors, the G-protein coupled receptors (GPCR), and intracellular second messengers such as cAMP and Ca²⁺. G-proteins are linked to the cytosolic side of a GPCR such that activation of the GPCR by ligand binding stimulates binding of the G-protein to GTP, inducing an "active" state in the G-protein. In the active state, the G-protein acts as a signal to trigger other events in the cell such as the increase of cAMP levels or the release of Ca²⁺ into the cytosol from the ER, which, in turn, regulate phosphorylation and activation of other intracellular proteins. Recycling of the G-protein to the inactive state involves hydrolysis of the bound GTP to GDP by a GTPase activity in the G-protein. (See Alberts, B. et al. (1994) Molecular Biology of the Cell, Garland Publishing, Inc., New York NY, pp.734-759.) Two structurally distinct classes of G-proteins are recognized: heterotrimeric G-proteins, consisting of three different subunits, and monomeric, low molecular weight (LMW), G-proteins consisting of a single polypeptide chain.

The three polypeptide subunits of heterotrimeric G-proteins are the α , β , and γ subunits. The α subunit binds and hydrolyzes GTP. The β and γ subunits form a tight complex that anchors the protein to the inner side of the plasma membrane. The β subunits, also known as G- β proteins or β transducins, contain seven tandem repeats of the WD-repeat sequence motif, a motif found in many proteins with regulatory functions. Mutations and variant expression of β transducin proteins are linked with various disorders (Neer, E.J. et al. (1994) Nature 371:297-300; Margottin, F. et al. (1998) Mol. Cell 1:565-574).

LMW GTP-proteins are GTPases which regulate cell growth, cell cycle control, protein secretion, and intracellular vesicle interaction. They consist of single polypeptides which, like the α subunit of the heterotrimeric G-proteins, are able to bind and hydrolyze GTP, thus cycling between an inactive and an active state. At least sixty members of the LMW G-protein superfamily have been identified and are currently grouped into the six subfamilies of ras, rho, arf, sar1, ran, and rab. Activated ras genes were initially found in human cancers, and subsequent studies confirmed that ras function is critical in determining whether cells continue to grow or become differentiated. Other members of the LMW G-protein superfamily have roles in signal transduction that vary with the function of the activated genes and the locations of the G-proteins.

Guanine nucleotide exchange factors regulate the activities of LMW G-proteins by

COUNTY MANGETHAME

determining whether GTP or GDP is bound. GTPase-activating protein (GAP) binds to GTP-ras and induces it to hydrolyze GTP to GDP. In contrast, guanine nucleotide releasing protein (GNRP) binds to GDP-ras and induces the release of GDP and the binding of GTP.

Other regulators of G-protein signaling (RGS) also exist that act primarily by negatively regulating the G-protein pathway by an unknown mechanism (Druey, K.M. et al. (1996) Nature 379:742-746). Some 15 members of the RGS family have been identified. RGS family members are related structurally through similarities in an approximately 120 amino acid region termed the RGS domain and functionally by their ability to inhibit the interleukin (cytokine) induction of MAP kinase in cultured mammalian 293T cells (Druey, supra).

10 <u>Calcium Signaling Molecules</u>

Ca⁺² is another second messenger molecule that is even more widely used as an intracellular mediator than cAMP. Two pathways exist by which Ca⁺² can enter the cytosol in response to extracellular signals: One pathway acts primarily in nerve signal transduction where Ca⁺² enters a nerve terminal through a voltage-gated Ca⁺² channel. The second is a more ubiquitous pathway in which Ca⁺² is released from the ER into the cytosol in response to binding of an extracellular signaling molecule to a receptor. Ca²⁺ directly activates regulatory enzymes, such as protein kinase C, which trigger signal transduction pathways. Ca²⁺ also binds to specific Ca²⁺-binding proteins (CBPs) such as calmodulin (CaM) which then activate multiple target proteins in the cell including enzymes, membrane transport pumps, and ion channels. CaM interactions are involved in a multitude of cellular processes including, but not limited to, gene regulation, DNA synthesis, cell cycle progression, mitosis, cytokinesis, cytoskeletal organization, muscle contraction, signal transduction, ion homeostasis, exocytosis, and metabolic regulation (Celio, M.R. et al. (1996) Guidebook to Calcium-binding Proteins, Oxford University Press, Oxford, UK, pp. 15-20). Some CBPs can serve as a storage depot for Ca²⁺ in an inactive state. Calsequestrin is one such CBP that is expressed in isoforms specific to cardiac muscle and skeletal muscle. It is suggested that calsequestrin binds Ca²⁺ in a rapidly exchangeable state that is released during Ca²⁺ -signaling conditions (Celio, M.R. et al. (1996) Guidebook to Calcium-binding Proteins, Oxford University Press, New York NY, pp. 222-224).

Cyclins

Cell division is the fundamental process by which all living things grow and reproduce. In most organisms, the cell cycle consists of three principle steps; interphase, mitosis, and cytokinesis. Interphase, involves preparations for cell division, replication of the DNA and production of essential proteins. In mitosis, the nuclear material is divided and separates to opposite sides of the cell. Cytokinesis is the final division and fission of the cell cytoplasm to produce the daughter cells.

10

20

25

30



and a CAR State that is

The entry and exit of a cell from mitosis is regulated by the synthesis and destruction of a family of activating proteins called cyclins. Cyclins act by binding to and activating a group of cyclin-dependent protein kinases (Cdks) which then phosphorylate and activate selected proteins involved in the mitotic process. Several types of cyclins exist. (Ciechanover, A. (1994) Cell 79:13-21.) Two principle types are mitotic cyclin, or cyclin B, which controls entry of the cell into mitosis, and G1 cyclin, which controls events that drive the cell out of mitosis.

Signal Complex Scaffolding Proteins

Ceretain proteins in intracellular signaling pathways serve to link or cluster other proteins involved in the signaling cascade. A conserved protein domain called the PDZ domain has been identified in various membrane-associated signaling proteins. This domain has been implicated in receptor and ion channel clustering and in the targeting of multiprotein signaling complexes to specialized functional regions of the cytosolic face of the plasma membrane. (For a review of PDZ domain-containing proteins, see Ponting, C.P. et al. (1997) Bioessays 19:469-479.) A large proportion of PDZ domains are found in the eukaryotic MAGUK (membrane-associated guanylate kinase) protein family, members of which bind to the intracellular domains of receptors and channels. However, PDZ domains are also found in diverse membrane-localized proteins such as protein tyrosine phosphatases, serine/threonine kinases, G-protein cofactors, and synapse-associated proteins such as syntrophins and neuronal nitric oxide synthase (nNOS). Generally, about one to three PDZ domains are found in a given protein, although up to nine PDZ domains have been identified in a single protein.

Membrane Transport Molecules

The plasma membrane acts as a barrier to most molecules. Transport between the cytoplasm and the extracellular environment, and between the cytoplasm and lumenal spaces of cellular organelles requires specific transport proteins. Each transport protein carries a particular class of molecule, such as ions, sugars, or amino acids, and often is specific to a certain molecular species of the class. A variety of human inherited diseases are caused by a mutation in a transport protein. For example, cystinuria is an inherited disease that results from the inability to transport cystine, the disulfide-linked dimer of cysteine, from the urine into the blood. Accumulation of cystine in the urine leads to the formation of cystine stones in the kidneys.

Transport proteins are multi-pass transmembrane proteins, which either actively transport molecules across the membrane or passively allow them to cross. Active transport involves directional pumping of a solute across the membrane, usually against an electrochemical gradient. Active transport is tightly coupled to a source of metabolic energy, such as ATP hydrolysis or an

electrochemically favorable ion gradient. Passive transport involves the movement of a solute down its electrochemical gradient. Transport proteins can be further classified as either carrier proteins or channel proteins. Carrier proteins, which can function in active or passive transport, bind to a specific solute to be transported and undergo a conformational change which transfers the bound solute across the membrane. Channel proteins, which only function in passive transport, form hydrophilic pores across the membrane. When the pores open, specific solutes, such as inorganic ions, pass through the membrane and down the electrochemical gradient of the solute.

Carrier proteins which transport a single solute from one side of the membrane to the other are called uniporters. In contrast, coupled transporters link the transfer of one solute with simultaneous or sequential transfer of a second solute, either in the same direction (symport) or in the opposite direction (antiport). For example, intestinal and kidney epithelium contains a variety of symporter systems driven by the sodium gradient that exists across the plasma membrane. Sodium moves into the cell down its electrochemical gradient and brings the solute into the cell with it. The sodium gradient that provides the driving force for solute uptake is maintained by the ubiquitous Na⁺/K⁺ ATPase. Sodium-coupled transporters include the mammalian glucose transporter (SGLT1), iodide transporter (NIS), and multivitamin transporter (SMVT). All three transporters have twelve putative transmembrane segments, extracellular glycosylation sites, and cytoplasmically-oriented Nand C-termini. NIS plays a crucial role in the evaluation, diagnosis, and treatment of various thyroid pathologies because it is the molecular basis for radioiodide thyroid-imaging techniques and for specific targeting of radioisotopes to the thyroid gland (Levy, O. et al. (1997) Proc. Natl. Acad. Sci. USA 94:5568-5573). SMVT is expressed in the intestinal mucosa, kidney, and placenta, and is implicated in the transport of the water-soluble vitamins, e.g., biotin and pantothenate (Prasad, P.D. et al. (1998) J. Biol. Chem. 273:7501-7506).

Transporters play a major role in the regulation of pH, excretion of drugs, and the cellular K^+/Na^+ balance. Monocarboxylate anion transporters are proton-coupled symporters with a broad substrate specificity that includes L-lactate, pyruvate, and the ketone bodies acetate, acetoacetate, and beta-hydroxybutyrate. At least seven isoforms have been identified to date. The isoforms are predicted to have twelve transmembrane (TM) helical domains with a large intracellular loop between TM6 and TM7, and play a critical role in maintaining intracellular pH by removing the protons that are produced stoichiometrically with lactate during glycolysis. The best characterized H(+)-monocarboxylate transporter is that of the erythrocyte membrane, which transports L-lactate and a wide range of other aliphatic monocarboxylates. Other cells possess H(+)-linked monocarboxylate transporters with differing substrate and inhibitor selectivities. In particular, cardiac muscle and tumor cells have transporters that differ in their K_m values for certain substrates, including stereoselectivity for L- over

D-lactate, and in their sensitivity to inhibitors. There are Na(+)-monocarboxylate cotransporters on the luminal surface of intestinal and kidney epithelia, which allow the uptake of lactate, pyruvate, and ketone bodies in these tissues. In addition, there are specific and selective transporters for organic cations and organic anions in organs including the kidney, intestine and liver. Organic anion transporters are selective for hydrophobic, charged molecules with electron-attracting side groups. Organic cation transporters, such as the ammonium transporter, mediate the secretion of a variety of drugs and endogenous metabolites, and contribute to the maintenance of intercellular pH. (Poole, R.C. and A.P. Halestrap (1993) Am. J. Physiol. 264:C761-C782; Price, N.T. et al. (1998) Biochem. J. 329:321-328; and Martinelle, K. and I. Haggstrom (1993) J. Biotechnol. 30: 339-350.)

The largest and most diverse family of transport proteins known is the ATP-binding cassette (ABC) transporters. As a family, ABC transporters can transport substances that differ markedly in chemical structure and size, ranging from small molecules such as ions, sugars, amino acids, peptides, and phospholipids, to lipopeptides, large proteins, and complex hydrophobic drugs. ABC proteins consist of four modules: two nucleotide-binding domains (NBD), which hydrolyze ATP to supply the energy required for transport, and two membrane-spanning domains (MSD), each containing six putative transmembrane segments. These four modules may be encoded by a single gene, as is the case for the cystic fibrosis transmembrane regulator (CFTR), or by separate genes. When encoded by separate genes, each gene product contains a single NBD and MSD. These "half-molecules" form homo- and heterodimers, such as Tap1 and Tap2, the endoplasmic reticulum-based major histocompatibility (MHC) peptide transport system. Several genetic diseases are attributed to defects in ABC transporters, such as the following diseases and their corresponding proteins: cystic fibrosis (CFTR, an ion channel), adrenoleukodystrophy (adrenoleukodystrophy protein, ALDP), Zellweger syndrome (peroxisomal membrane protein-70, PMP70), and hyperinsulinemic hypoglycemia (sulfonylurea receptor, SUR). Overexpression of the multidrug resistance (MDR) protein, another ABC transporter, in human cancer cells makes the cells resistant to a variety of cytotoxic drugs used in chemotherapy (Taglight, D. and S. Michaelis (1998) Meth. Enzymol. 292:131-163).

Transport of fatty acids across the plasma membrane can occur by diffusion, a high capacity, low affinity process. However, under normal physiological conditions a significant fraction of fatty acid transport appears to occur via a high affinity, low capacity protein-mediated transport process. Fatty acid transport protein (FATP), an integral membrane protein with four transmembrane segments, is expressed in tissues exhibiting high levels of plasma membrane fatty acid flux, such as muscle, heart, and adipose. Expression of FATP is upregulated in 3T3-L1 cells during adipose conversion, and expression in COS7 fibroblasts elevates uptake of long-chain fatty acids (Hui, T.Y. et al. (1998) J. Biol. Chem. 273:27420-27429).

in I gen with the the Conta

10

15

20

25

Ion Channels

10

The electrical potential of a cell is generated and maintained by controlling the movement of ions across the plasma membrane. The movement of ions requires ion channels, which form an ion-selective pore within the membrane. There are two basic types of ion channels, ion transporters and gated ion channels. Ion transporters utilize the energy obtained from ATP hydrolysis to actively transport an ion against the ion's concentration gradient. Gated ion channels allow passive flow of an ion down the ion's electrochemical gradient under restricted conditions. Together, these types of ion channels generate, maintain, and utilize an electrochemical gradient that is used in 1) electrical impulse conduction down the axon of a nerve cell, 2) transport of molecules into cells against concentration gradients, 3) initiation of muscle contraction, and 4) endocrine cell secretion.

Ion transporters generate and maintain the resting electrical potential of a cell. Utilizing the energy derived from ATP hydrolysis, they transport ions against the ion's concentration gradient. These transmembrane ATPases are divided into three families. The phosphorylated (P) class ion transporters, including Na⁺-K⁺ ATPase, Ca²⁺-ATPase, and H⁺-ATPase, are activated by a phosphorylation event. P-class ion transporters are responsible for maintaining resting potential distributions such that cytosolic concentrations of Na⁺ and Ca²⁺ are low and cytosolic concentration of K⁺ is high. The vacuolar (V) class of ion transporters includes H⁺ pumps on intracellular organelles, such as lysosomes and Golgi. V-class ion transporters are responsible for generating the low pH within the lumen of these organelles that is required for function. The coupling factor (F) class consists of H⁺ pumps in the mitochondria. F-class ion transporters utilize a proton gradient to generate ATP from ADP and inorganic phosphate (P_i).

The resting potential of the cell is utilized in many processes involving carrier proteins and gated ion channels. Carrier proteins utilize the resting potential to transport molecules into and out of the cell. Amino acid and glucose transport into many cells is linked to sodium ion co-transport (symport) so that the movement of Na⁺ down an electrochemical gradient drives transport of the other molecule up a concentration gradient. Similarly, cardiac muscle links transfer of Ca²⁺ out of the cell with transport of Na⁺ into the cell (antiport).

Ion channels share common structural and mechanistic themes. The channel consists of four or five subunits or protein monomers that are arranged like a barrel in the plasma membrane. Each subunit typically consists of six potential transmembrane segments (S1, S2, S3, S4, S5, and S6). The center of the barrel forms a pore lined by α -helices or β -strands. The side chains of the amino acid residues comprising the α -helices or β -strands establish the charge (cation or anion) selectivity of the channel. The degree of selectivity, or what specific ions are allowed to pass through the channel, depends on the diameter of the narrowest part of the pore.

Gated ion channels control ion flow by regulating the opening and closing of pores. These channels are categorized according to the manner of regulating the gating function. Mechanically-gated channels open pores in response to mechanical stress, voltage-gated channels open pores in response to changes in membrane potential, and ligand-gated channels open pores in the presence of a specific ion, nucleotide, or neurotransmitter.

Voltage-gated Na⁺ and K⁺ channels are necessary for the function of electrically excitable cells, such as nerve and muscle cells. Action potentials, which lead to neurotransmitter release and muscle contraction, arise from large, transient changes in the permeability of the membrane to Na⁺ and K⁺ ions. Depolarization of the membrane beyond the threshold level opens voltage-gated Na⁺ channels. Sodium ions flow into the cell, further depolarizing the membrane and opening more voltage-gated Na⁺ channels, which propagates the depolarization down the length of the cell. Depolarization also opens voltage-gated potassium channels. Consequently, potassium ions flow outward, which leads to repolarization of the membrane. Voltage-gated channels utilize charged residues in the fourth transmembrane segment (S4) to sense voltage change. The open state lasts only about 1 millisecond, at which time the channel spontaneously converts into an inactive state that cannot be opened irrespective of the membrane potential. Inactivation is mediated by the channel's N-terminus, which acts as a plug that closes the pore. The transition from an inactive to a closed state requires a return to resting potential.

Voltage-gated Na⁺ channels are heterotrimeric complexes composed of a 260 kDa pore forming α subunit that associates with two smaller auxiliary subunits, $\beta 1$ and $\beta 2$. The $\beta 2$ subunit is an integral membrane glycoprotein that contains an extracellular Ig domain, and its association with α and $\beta 1$ subunits correlates with increased functional expression of the channel, a change in its gating properties, and an increase in whole cell capacitance due to an increase in membrane surface area. (Isom, L.L. et al. (1995) Cell 83:433-442.)

Voltage-gated Ca²⁺ channels are involved in presynaptic neurotransmitter release, and heart and skeletal muscle contraction. The voltage-gated Ca²⁺ channels from skeletal muscle (L-type) and brain (N-type) have been purified, and though their functions differ dramatically, they have similar subunit compositions. The channels are composed of three subunits. The α_1 subunit forms the membrane pore and voltage sensor, while the $\alpha_2\delta$ and β subunits modulate the voltage-dependence, gating properties, and the current amplitude of the channel. These subunits are encoded by at least six α_1 , one $\alpha_2\delta$, and four β genes. A fourth subunit, γ , has been identified in skeletal muscle. (Walker, D. et al. (1998) J. Biol. Chem. 273:2361-2367; and Jay, S.D. et al. (1990) Science 248:490-492.)

Chloride channels are necessary in endocrine secretion and in regulation of cytosolic and organelle pH. In secretory epithelial cells, Cl⁻ enters the cell across a basolateral membrane through an

The Committee of the Co

10

15

20

25

Na⁺, K⁺/Cl⁻ cotransporter, accumulating in the cell above its electrochemical equilibrium concentration. Secretion of Cl⁻ from the apical surface, in response to hormonal stimulation, leads to flow of Na⁺ and water into the secretory lumen. The cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride channel encoded by the gene for cystic fibrosis, a common fatal genetic disorder in humans. Loss of CFTR function decreases transepithelial water secretion and, as a result, the layers of mucus that coat the respiratory tree, pancreatic ducts, and intestine are dehydrated and difficult to clear. The resulting blockage of these sites leads to pancreatic insufficiency, "meconium ileus", and devastating "chronic obstructive pulmonary disease" (Al-Awqati, Q. et al. (1992) J. Exp. Biol. 172:245-266).

Many intracellular organelles contain H⁺-ATPase pumps that generate transmembrane pH and electrochemical differences by moving protons from the cytosol to the organelle lumen. If the membrane of the organelle is permeable to other ions, then the electrochemical gradient can be abrogated without affecting the pH differential. In fact, removal of the electrochemical barrier allows more H⁺ to be pumped across the membrane, increasing the pH differential. Cl⁻ is the sole counterion of H⁺ translocation in a number of organelles, including chromaffin granules, Golgi vesicles, lysosomes, and endosomes. Functions that require a low vacuolar pH include uptake of small molecules such as biogenic amines in chromaffin granules, processing of vacuolar constituents such as pro-hormones by proteolytic enzymes, and protein degradation in lysosomes (Al-Awqati, supra).

Ligand-gated channels open their pores when an extracellular or intracellular mediator binds to the channel. Neurotransmitter-gated channels are channels that open when a neurotransmitter binds to their extracellular domain. These channels exist in the postsynaptic membrane of nerve or muscle cells. There are two types of neurotransmitter-gated channels. Sodium channels open in response to excitatory neurotransmitters, such as acetylcholine, glutamate, and serotonin. This opening causes an influx of Na^+ and produces the initial localized depolarization that activates the voltage-gated channels and starts the action potential. Chloride channels open in response to inhibitory neurotransmitters, such as γ -aminobutyric acid (GABA) and glycine, leading to hyperpolarization of the membrane and the subsequent generation of an action potential.

Ligand-gated channels can be regulated by intracellular second messengers. Calcium-activated K⁺ channels are gated by internal calcium ions. In nerve cells, an influx of calcium during depolarization opens K⁺ channels to modulate the magnitude of the action potential (Ishi, T.M. et al. (1997) Proc. Natl. Acad. Sci. USA 94:11651-11656). Cyclic nucleotide-gated (CNG) channels are gated by cytosolic cyclic nucleotides. The best examples of these are the cAMP-gated Na⁺ channels involved in olfaction and the cGMP-gated cation channels involved in vision. Both systems involve ligand-mediated activation of a G-protein coupled receptor which then alters the level of cyclic nucleotide within the cell.

Ion channels are expressed in a number of tissues where they are implicated in a variety of processes. CNG channels, while abundantly expressed in photoreceptor and olfactory sensory cells, are also found in kidney, lung, pineal, retinal ganglion cells, testis, aorta, and brain. Calcium-activated K+ channels may be responsible for the vasodilatory effects of bradykinin in the kidney and for shunting excess K+ from brain capillary endothelial cells into the blood. They are also implicated in repolarizing granulocytes after agonist-stimulated depolarization (Ishi, supra). Ion channels have been the target for many drug therapies. Neurotransmitter-gated channels have been targeted in therapies for treatment of insomnia, anxiety, depression, and schizophrenia. Voltage-gated channels have been targeted in therapies for arrhythmia, ischemic stroke, head trauma, and neurodegenerative disease (Taylor, C.P. and L.S. Narasimhan (1997) Adv. Pharmacol. 39:47-98).

Disease Correlation

The etiology of numerous human diseases and disorders can be attributed to defects in the transport of molecules across membranes. Defects in the trafficking of membrane-bound transporters and ion channels are associated with several disorders, e.g. cystic fibrosis, glucose-galactose malabsorption syndrome, hypercholesterolemia, von Gierke disease, and certain forms of diabetes mellitus. Single-gene defect diseases resulting in an inability to transport small molecules across membranes include, e.g., cystinuria, iminoglycinuria, Hartup disease, and Fanconi disease (van't Hoff, W.G. (1996) Exp. Nephrol. 4:253-262; Talente, G.M. et al. (1994) Ann. Intern. Med. 120:218-226; and Chillon, M. et al. (1995) New Engl. J. Med. 332:1475-1480).

20

25

30

10

15

Protein Modification and Maintenance Molecules

The cellular processes regulating modification and maintenance of protein molecules coordinate their conformation, stabilization, and degradation. Each of these processes is mediated by key enzymes or proteins such as proteases, protease inhibitors, transferases, isomerases, and molecular chaperones.

Proteases

Proteases cleave proteins and peptides at the peptide bond that forms the backbone of the peptide and protein chain. Proteolytic processing is essential to cell growth, differentiation, remodeling, and homeostasis as well as inflammation and immune response. Typical protein half-lives range from hours to a few days, so that within all living cells, precursor proteins are being cleaved to their active form, signal sequences proteolytically removed from targeted proteins, and aged or defective proteins degraded by proteolysis. Proteases function in bacterial, parasitic, and viral invasion and replication within a host. Four principal categories of mammalian proteases have been identified based on active site structure, mechanism of action, and overall three-dimensional structure.

(Beynon, R.J. and J.S. Bond (1994) <u>Proteolytic Enzymes: A Practical Approach</u>, Oxford University Press, New York NY, pp. 1-5).

The serine proteases (SPs) have a serine residue, usually within a conserved sequence, in an active site composed of the serine, an aspartate, and a histidine residue. SPs include the digestive enzymes trypsin and chymotrypsin, components of the complement cascade and the blood-clotting cascade, and enzymes that control extracellular protein degradation. The main SP sub-families are trypases, which cleave after arginine or lysine; aspartases, which cleave after aspartate; chymases, which cleave after phenylalanine or leucine; metases, which cleavage after methionine; and serases which cleave after serine. Enterokinase, the initiator of intestinal digestion, is a serine protease found in the intestinal brush border, where it cleaves the acidic propeptide from trypsinogen to yield active trypsin (Kitamoto, Y. et al. (1994) Proc. Natl. Acad. Sci. USA 91:7588-7592).

Prolylcarboxypeptidase, a lysosomal serine peptidase that cleaves peptides such as angiotensin II and III and [des-Arg9] bradykinin, shares sequence homology with members of both the serine carboxypeptidase and prolylendopeptidase families (Tan, F. et al. (1993) J. Biol. Chem. 268:16631-16638).

Cysteine proteases (CPs) have a cysteine as the major catalytic residue at an active site where catalysis proceeds via an intermediate thiol ester and is facilitated by adjacent histidine and aspartic acid residues. CPs are involved in diverse cellular processes ranging from the processing of precursor proteins to intracellular degradation. Mammalian CPs include lysosomal cathepsins and cytosolic calcium activated proteases, calpains. CPs are produced by monocytes, macrophages and other cells of the immune system which migrate to sites of inflammation and secrete molecules involved in tissue repair. Overabundance of these repair molecules plays a role in certain disorders. In autoimmune diseases such as rheumatoid arthritis, secretion of the cysteine peptidase cathepsin C degrades collagen, laminin, elastin and other structural proteins found in the extracellular matrix of bones.

Aspartic proteases are members of the cathepsin family of lysosomal proteases and include pepsin A, gastricsin, chymosin, renin, and cathepsins D and E. Aspartic proteases have a pair of aspartic acid residues in the active site, and are most active in the pH 2 - 3 range, in which one of the aspartate residues is ionized, the other un-ionized. Aspartic proteases include bacterial penicillopepsin, mammalian pepsin, renin, chymosin, and certain fungal proteases. Abnormal regulation and expression of cathepsins is evident in various inflammatory disease states. In cells isolated from inflamed synovia, the mRNA for stromelysin, cytokines, TIMP-1, cathepsin, gelatinase, and other molecules is preferentially expressed. Expression of cathepsins L and D is elevated in synovial tissues from patients with rheumatoid arthritis and osteoarthritis. Cathepsin L expression may


20

10

15

20

25



يغ فيصا فيصدون سووفين الرفاع الما

also contribute to the influx of mononuclear cells which exacerbates the destruction of the rheumatoid synovium. (Keyszer, G.M. (1995) Arthritis Rheum. 38:976-984.) The increased expression and differential regulation of the cathepsins are linked to the metastatic potential of a variety of cancers and as such are of therapeutic and prognostic interest (Chambers, A.F. et al. (1993) Crit. Rev. Oncog. 4:95-114).

Metalloproteases have active sites that include two glutamic acid residues and one histidine residue that serve as binding sites for zinc. Carboxypeptidases A and B are the principal mammalian metalloproteases. Both are exoproteases of similar structure and active sites. Carboxypeptidase A, like chymotrypsin, prefers C-terminal aromatic and aliphatic side chains of hydrophobic nature, whereas carboxypeptidase B is directed toward basic arginine and lysine residues. Glycoprotease (GCP), or O-sialoglycoprotein endopeptidase, is a metallopeptidase which specifically cleaves O-sialoglycoproteins such as glycophorin A. Another metallopeptidase, placental leucine aminopeptidase (P-LAP) degrades several peptide hormones such as oxytocin and vasopressin, suggesting a role in maintaining homeostasis during pregnancy, and is expressed in several tissues (Rogi, T. et al. (1996) J. Biol. Chem. 271:56-61).

Ubiquitin proteases are associated with the ubiquitin conjugation system (UCS), a major pathway for the degradation of cellular proteins in eukaryotic cells and some bacteria. The UCS mediates the elimination of abnormal proteins and regulates the half-lives of important regulatory proteins that control cellular processes such as gene transcription and cell cycle progression. In the UCS pathway, proteins targeted for degradation are conjugated to a ubiquitin, a small heat stable protein. The ubiquitinated protein is then recognized and degraded by proteasome, a large, multisubunit proteolytic enzyme complex, and ubiquitin is released for reutilization by ubiquitin protease. The UCS is implicated in the degradation of mitotic cyclic kinases, oncoproteins, tumor suppressor genes such as p53, viral proteins, cell surface receptors associated with signal transduction, transcriptional regulators, and mutated or damaged proteins (Ciechanover, A. (1994) Cell 79:13-21). A murine proto-oncogene, Unp, encodes a nuclear ubiquitin protease whose overexpression leads to oncogenic transformation of NIH3T3 cells, and the human homolog of this gene is consistently elevated in small cell tumors and adenocarcinomas of the lung (Gray, D.A. (1995) Oncogene 10:2179-2183).

30 Signal Peptidases

The mechanism for the translocation process into the endoplasmic reticulum (ER) involves the recognition of an N-terminal signal peptide on the elongating protein. The signal peptide directs the protein and attached ribosome to a receptor on the ER membrane. The polypeptide chain passes through a pore in the ER membrane into the lumen while the N-terminal signal peptide remains

attached at the membrane surface. The process is completed when signal peptidase located inside the ER cleaves the signal peptide from the protein and releases the protein into the lumen.

Protease Inhibitors

Protease inhibitors and other regulators of protease activity control the activity and effects of proteases. Protease inhibitors have been shown to control pathogenesis in animal models of proteolytic disorders (Murphy, G. (1991) Agents Actions Suppl. 35:69-76). Low levels of the cystatins, low molecular weight inhibitors of the cysteine proteases, correlate with malignant progression of tumors. (Calkins, C. et al (1995) Biol. Biochem. Hoppe Seyler 376:71-80). Serpins are inhibitors of mammalian plasma serine proteases. Many serpins serve to regulate the blood clotting cascade and/or the complement cascade in mammals. Sp32 is a positive regulator of the mammalian acrosomal protease, acrosin, that binds the proenzyme, proacrosin, and thereby aides in packaging the enzyme into the acrosomal matrix (Baba, T. et al. (1994) J. Biol. Chem. 269:10133-10140). The Kunitz family of serine protease inhibitors are characterized by one or more "Kunitz domains" containing a series of cysteine residues that are regularly spaced over approximately 50 amino acid residues and form three intrachain disulfide bonds. Members of this family include aprotinin, tissue factor pathway inhibitor (TFPI-1 and TFPI-2), inter-α-trypsin inhibitor, and bikunin. (Marlor, C.W. et al. (1997) J. Biol. Chem. 272;12202-12208.) Members of this family are potent inhibitors (in the nanomolar range) against serine proteases such as kallikrein and plasmin. Aprotinin has clinical utility in reduction of perioperative blood loss.

A major portion of all proteins synthesized in eukaryotic cells are synthesized on the cytosolic surface of the endoplasmic reticulum (ER). Before these immature proteins are distributed to other organelles in the cell or are secreted, they must be transported into the interior lumen of the ER where post-translational modifications are performed. These modifications include protein folding and the formation of disulfide bonds, and N-linked glycosylations.

25 Protein Isomerases

20

Protein folding in the ER is aided by two principal types of protein isomerases, protein disulfide isomerase (PDI), and peptidyl-prolyl isomerase (PPI). PDI catalyzes the oxidation of free sulfhydryl groups in cysteine residues to form intramolecular disulfide bonds in proteins. PPI, an enzyme that catalyzes the isomerization of certain proline imidic bonds in oligopeptides and proteins, is considered to govern one of the rate limiting steps in the folding of many proteins to their final functional conformation. The cyclophilins represent a major class of PPI that was originally identified as the major receptor for the immunosuppressive drug cyclosporin A (Handschumacher, R.E. et al. (1984) Science 226: 544-547).

Protein Glycosylation

The glycosylation of most soluble secreted and membrane-bound proteins by oligosaccharides linked to asparagine residues in proteins is also performed in the ER. This reaction is catalyzed by a membrane-bound enzyme, oligosaccharyl transferase. Although the exact purpose of this "N-linked" glycosylation is unknown, the presence of oligosaccharides tends to make a glycoprotein resistant to protease digestion. In addition, oligosaccharides attached to cell-surface proteins called selectins are known to function in cell-cell adhesion processes (Alberts, B. et al. (1994) Molecular Biology of the Cell, Garland Publishing Co., New York NY, p.608). "O-linked" glycosylation of proteins also occurs in the ER by the addition of N-acetylgalactosamine to the hydroxyl group of a serine or threonine residue followed by the sequential addition of other sugar residues to the first. This process is catalysed by a series of glycosyltransferases each specific for a particular donor sugar nucleotide and acceptor molecule (Lodish, H. et al. (1995) Molecular Cell Biology, W.H. Freeman and Co., New York NY, pp.700-708). In many cases, both N- and O-linked oligosaccharides appear to be required for the secretion of proteins or the movement of plasma membrane glycoproteins to the cell surface.

An additional glycosylation mechanism operates in the ER specifically to target lysosomal enzymes to lysosomes and prevent their secretion. Lysosomal enzymes in the ER receive an N-linked oligosaccharide, like plasma membrane and secreted proteins, but are then phosphorylated on one or two mannose residues. The phosphorylation of mannose residues occurs in two steps, the first step being the addition of an N-acetylglucosamine phosphate residue by N-acetylglucosamine phosphotransferase, and the second the removal of the N-acetylglucosamine group by phosphodiesterase. The phosphorylated mannose residue then targets the lysosomal enzyme to a mannose 6-phosphate receptor which transports it to a lysosome vesicle (Lodish, supra, pp. 708-711). Chaperones

Molecular chaperones are proteins that aid in the proper folding of immature proteins and refolding of improperly folded ones, the assembly of protein subunits, and in the transport of unfolded proteins across membranes. Chaperones are also called heat-shock proteins (hsp) because of their tendency to be expressed in dramatically increased amounts following brief exposure of cells to elevated temperatures. This latter property most likely reflects their need in the refolding of proteins that have become denatured by the high temperatures. Chaperones may be divided into several classes according to their location, function, and molecular weight, and include hsp60, TCP1, hsp70, hsp40 (also called DnaJ), and hsp90. For example, hsp90 binds to steroid hormone receptors, represses transcription in the absence of the ligand, and provides proper folding of the ligand-binding domain of the receptor in the presence of the hormone (Burston, S.G. and A.R. Clarke (1995) Essays Biochem. 29:125-136). Hsp60 and hsp70 chaperones aid in the transport and folding of newly

ي بريد م در در در دولان در در در در

10

15 .

20

25

synthesized proteins. Hsp70 acts early in protein folding, binding a newly synthesized protein before it leaves the ribosome and transporting the protein to the mitochondria or ER before releasing the folded protein. Hsp60, along with hsp10, binds misfolded proteins and gives them the opportunity to refold correctly. All chaperones share an affinity for hydrophobic patches on incompletely folded proteins and the ability to hydrolyze ATP. The energy of ATP hydrolysis is used to release the hsp-bound protein in its properly folded state (Alberts, supra, pp 214, 571-572).

Nucleic Acid Synthesis and Modification Molecules Polymerases

DNA and RNA replication are critical processes for cell replication and function. DNA and RNA replication are mediated by the enzymes DNA and RNA polymerase, respectively, by a "templating" process in which the nucleotide sequence of a DNA or RNA strand is copied by complementary base-pairing into a complementary nucleic acid sequence of either DNA or RNA. However, there are fundamental differences between the two processes.

DNA polymerase catalyzes the stepwise addition of a deoxyribonucleotide to the 3'-OH end of a polynucleotide strand (the primer strand) that is paired to a second (template) strand. The new DNA strand therefore grows in the 5' to 3' direction (Alberts, B. et al. (1994) The Molecular Biology of the Cell, Garland Publishing Inc., New York NY, pp. 251-254). The substrates for the polymerization reaction are the corresponding deoxynucleotide triphosphates which must base-pair with the correct nucleotide on the template strand in order to be recognized by the polymerase. Because DNA exists as a double-stranded helix, each of the two strands may serve as a template for the formation of a new complementary strand. Each of the two daughter cells of the dividing cell therefore inherits a new DNA double helix containing one old and one new strand. Thus, DNA is said to be replicated "semiconservatively" by DNA polymerase. In addition to the synthesis of new DNA, DNA polymerase is also involved in the repair of damaged DNA as discussed below under "Ligases."

In contrast to DNA polymerase, RNA polymerase uses a DNA template strand to "transcribe" DNA into RNA using ribonucleotide triphosphates as substrates. Like DNA polymerization, RNA polymerization proceeds in a 5' to 3' direction by addition of a ribonucleoside monophosphate to the 3'-OH end of a growing RNA chain. DNA transcription generates messenger RNAs (mRNA) that carry information for protein synthesis, as well as the transfer, ribosomal, and other RNAs that have structural or catalytic functions. In eukaryotes, three discrete RNA polymerases synthesize the three different types of RNA (Alberts, supra, pp. 367-368). RNA polymerase I makes the large ribosomal RNAs, RNA polymerase II makes the mRNAs that will be translated into proteins, and RNA

10

15

PCT/US01/06059

polymerase III makes a variety of small, stable RNAs, including 5S ribosomal RNA and the transfer RNAs (tRNA). In all cases, RNA synthesis is initiated by binding of the RNA polymerase to a promoter region on the DNA and synthesis begins at a start site within the promoter. Synthesis is completed at a broad, general stop or termination region in the DNA where both the polymerase and the completed RNA chain are released.

Ligases

10

15

20

25

30

DNA repair is the process by which accidental base changes, such as those produced by oxidative damage, hydrolytic attack, or uncontrolled methylation of DNA are corrected before replication or transcription of the DNA can occur. Because of the efficiency of the DNA repair process, fewer than one in one thousand accidental base changes causes a mutation (Alberts, supra, pp. 245-249). The three steps common to most types of DNA repair are (1) excision of the damaged or altered base or nucleotide by DNA nucleases, leaving a gap; (2) insertion of the correct nucleotide in this gap by DNA polymerase using the complementary strand as the template; and '(3) sealing the break left between the inserted nucleotide(s) and the existing DNA strand by DNA ligase. In the last reaction, DNA ligase uses the energy from ATP hydrolysis to activate the 5' end of the broken phosphodiester bond before forming the new bond with the 3'-OH of the DNA strand. In Bloom's syndrome, an inherited human disease, individuals are partially deficient in DNA ligation and consequently have an increased incidence of cancer (Alberts, supra, p. 247).

Nucleases

Nucleases comprise both enzymes that hydrolyze DNA (DNase) and RNA (RNase). They serve different purposes in nucleic acid metabolism. Nucleases hydrolyze the phosphodiester bonds between adjacent nucleotides either at internal positions (endonucleases) or at the terminal 3' or 5' nucleotide positions (exonucleases). A DNA exonuclease activity in DNA polymerase, for example, serves to remove improperly paired nucleotides attached to the 3'-OH end of the growing DNA strand by the polymerase and thereby serves a "proofreading" function. As mentioned above, DNA endonuclease activity is involved in the excision step of the DNA repair process.

RNases also serve a variety of functions. For example, RNase P is a ribonucleoprotein enzyme which cleaves the 5' end of pre-tRNAs as part of their maturation process. RNase H digests the RNA strand of an RNA/DNA hybrid. Such hybrids occur in cells invaded by retroviruses, and RNase H is an important enzyme in the retroviral replication cycle. Pancreatic RNase secreted by the pancreas into the intestine hydrolyzes RNA present in ingested foods. RNase activity in serum and cell extracts is elevated in a variety of cancers and infectious diseases (Schein, C.H. (1997) Nat. Biotechnol. 15:529-536). Regulation of RNase activity is being investigated as a means to control tumor angiogenesis, allergic reactions, viral infection and replication, and fungal infections.

Methylases

Methylation of specific nucleotides occurs in both DNA and RNA, and serves different functions in the two macromolecules. Methylation of cytosine residues to form 5-methyl cytosine in DNA occurs specifically at CG sequences which are base-paired with one another in the DNA double-helix. This pattern of methylation is passed from generation to generation during DNA replication by an enzyme called "maintenance methylase" that acts preferentially on those CG sequences that are base-paired with a CG sequence that is already methylated. Such methylation appears to distinguish active from inactive genes by preventing the binding of regulatory proteins that "turn on" the gene, but permit the binding of proteins that inactivate the gene (Alberts, supra, pp. 448-451). In RNA metabolism, "tRNA methylase" produces one of several nucleotide modifications in tRNA that affect the conformation and base-pairing of the molecule and facilitate the recognition of the appropriate mRNA codons by specific tRNAs. The primary methylation pattern is the dimethylation of guanine residues to form N,N-dimethyl guanine.

Helicases and Single-Stranded Binding Proteins

Helicases are enzymes that destabilize and unwind double helix structures in both DNA and RNA. Since DNA replication occurs more or less simultaneously on both strands, the two strands must first separate to generate a replication "fork" for DNA polymerase to act on. Two types of replication proteins contribute to this process, DNA helicases and single-stranded binding proteins. DNA helicases hydrolyze ATP and use the energy of hydrolysis to separate the DNA strands. Single-stranded binding proteins (SSBs) then bind to the exposed DNA strands without covering the bases, thereby temporarily stabilizing them for templating by the DNA polymerase (Alberts, supra, pp. 255-256).

RNA helicases also alter and regulate RNA conformation and secondary structure. Like the DNA helicases, RNA helicases utilize energy derived from ATP hydrolysis to destabilize and unwind RNA duplexes. The most well-characterized and ubiquitous family of RNA helicases is the DEAD-box family, so named for the conserved B-type ATP-binding motif which is diagnostic of proteins in this family. Over 40 DEAD-box helicases have been identified in organisms as diverse as bacteria, insects, yeast, amphibians, mammals, and plants. DEAD-box helicases function in diverse processes such as translation initiation, splicing, ribosome assembly, and RNA editing, transport, and stability. Some DEAD-box helicases play tissue- and stage-specific roles in spermatogenesis and embryogenesis. Overexpression of the DEAD-box 1 protein (DDX1) may play a role in the progression of neuroblastoma (Nb) and retinoblastoma (Rb) tumors (Godbout, R. et al. (1998) J. Biol. Chem. 273:21161-21168). These observations suggest that DDX1 may promote or enhance tumor progression by altering the normal secondary structure and expression levels of RNA in cancer cells.

15



১১৩ জেন্ডিয় জেল্ফ **তথ্যসভ্**যা

Other DEAD-box helicases have been implicated either directly or indirectly in tumorigenesis (Discussed in Godbout, <u>supra</u>). For example, murine p68 is mutated in ultraviolet light-induced tumors, and human DDX6 is located at a chromosomal breakpoint associated with B-cell lymphoma. Similarly, a chimeric protein comprised of DDX10 and NUP98, a nucleoporin protein, may be involved in the pathogenesis of certain myeloid malignancies.

Topoisomerases

10

15

20

25

30

Besides the need to separate DNA strands prior to replication, the two strands must be "unwound" from one another prior to their separation by DNA helicases. This function is performed by proteins known as DNA topoisomerases. DNA topoisomerase effectively acts as a reversible nuclease that hydrolyzes a phosphodiesterase bond in a DNA strand, permitting the two strands to rotate freely about one another to remove the strain of the helix, and then rejoins the original phosphodiester bond between the two strands. Two types of DNA topoisomerase exist, types I and II. DNA Topoisomerase I causes a single-strand break in a DNA helix to allow the rotation of the two strands of the helix about the remaining phosphodiester bond in the opposite strand. DNA topoisomerase II causes a transient break in both strands of a DNA helix where two double helices cross over one another. This type of topoisomerase can efficiently separate two interlocked DNA circles (Alberts, supra, pp.260-262). Type II topoisomerases are largely confined to proliferating cells in eukaryotes, such as cancer cells. For this reason they are targets for anticancer drugs.

Topoisomerase II has been implicated in multi-drug resistance (MDR) as it appears to aid in the repair of DNA damage inflicted by DNA binding agents such as doxorubicin and vincristine.

Recombinases

Genetic recombination is the process of rearranging DNA sequences within an organism's genome to provide genetic variation for the organism in response to changes in the environment. DNA recombination allows variation in the particular combination of genes present in an individual's genome, as well as the timing and level of expression of these genes (see Alberts, supra, pp. 263-273). Two broad classes of genetic recombination are commonly recognized, general recombination and site-specific recombination. General recombination involves genetic exchange between any homologous pair of DNA sequences usually located on two copies of the same chromosome. The process is aided by enzymes called recombinases that "nick" one strand of a DNA duplex more or less randomly and permit exchange with the complementary strand of another duplex. The process does not normally change the arrangement of genes on a chromosome. In site-specific recombination, the recombinase recognizes specific nucleotide sequences present in one or both of the recombining molecules. Base-pairing is not involved in this form of recombination and therefore does not require DNA homology between the recombining molecules. Unlike general recombination, this form of



recombination can alter the relative positions of nucleotide sequences in chromosomes.

<u>Splicing Factors</u>

Various proteins are necessary for processing of transcribed RNAs in the nucleus. PremRNA processing steps include capping at the 5' end with methylguanosine, polyadenylating the 3' end, and splicing to remove introns. The primary RNA transcript from DNA is a faithful copy of the gene containing both exon and intron sequences, and the latter sequences must be cut out of the RNA transcript to produce an mRNA that codes for a protein. This "splicing" of the mRNA sequence takes place in the nucleus with the aid of a large, multicomponent ribonucleoprotein complex known as a spliceosome. The spliceosomal complex is composed of five small nuclear ribonucleoprotein particles (snRNPs) designated U1, U2, U4, U5, and U6, and a number of additional proteins. Each snRNP contains a single species of snRNA and about ten proteins. The RNA components of some snRNPs recognize and base pair with intron consensus sequences. The protein components mediate spliceosome assembly and the splicing reaction. Autoantibodies to snRNP proteins are found in the blood of patients with systemic lupus erythematosus (Stryer, L. (1995) <u>Biochemistry</u>, W.H. Freeman and Company, New York NY, p. 863).

Adhesion Molecules

10

The surface of a cell is rich in transmembrane proteoglycans, glycoproteins, glycolipids, and receptors. These macromolecules mediate adhesion with other cells and with components of the extracellular matrix (ECM). The interaction of the cell with its surroundings profoundly influences cell shape, strength, flexibility, motility, and adhesion. These dynamic properties are intimately associated with signal transduction pathways controlling cell proliferation and differentiation, tissue construction, and embryonic development.

Cadherins

25

BNSDOCID: <WO__0162927A2_I

Cadherins comprise a family of calcium-dependent glycoproteins that function in mediating cell-cell adhesion in virtually all solid tissues of multicellular organisms. These proteins share multiple repeats of a cadherin-specific motif, and the repeats form the folding units of the cadherin extracellular domain. Cadherin molecules cooperate to form focal contacts, or adhesion plaques, between adjacent epithelial cells. The cadherin family includes the classical cadherins and protocadherins. Classical cadherins include the E-cadherin, N-cadherin, and P-cadherin subfamilies. E-cadherin is present on many types of epithelial cells and is especially important for embryonic development. N-cadherin is present on nerve, muscle, and lens cells and is also critical for embryonic development. P-cadherin is present on cells of the placenta and epidermis. Recent studies report that protocadherins are involved in a variety of cell-cell interactions (Suzuki, S.T. (1996) J. Cell Sci.

109:2609-2611). The intracellular anchorage of cadherins is regulated by their dynamic association with catenins, a family of cytoplasmic signal transduction proteins associated with the actin cytoskeleton. The anchorage of cadherins to the actin cytoskeleton appears to be regulated by protein tyrosine phosphorylation, and the cadherins are the target of phosphorylation-induced junctional disassembly (Aberle, H. et al. (1996) J. Cell. Biochem. 61:514-523).

Integrins

Integrins are ubiquitous transmembrane adhesion molecules that link the ECM to the internal cytoskeleton. Integrins are composed of two noncovalently associated transmembrane glycoprotein subunits called α and β . Integrins function as receptors that play a role in signal transduction. For example, binding of integrin to its extracellular ligand may stimulate changes in intracellular calcium levels or protein kinase activity (Sjaastad, M.D. and W.J. Nelson (1997) BioEssays 19:47-55). At least ten cell surface receptors of the integrin family recognize the ECM component fibronectin, which is involved in many different biological processes including cell migration and embryogenesis (Johansson, S. et al. (1997) Front. Biosci. 2:D126-D146).

15 Lectins

10

- 20

25

30

Lectins comprise a ubiquitous family of extracellular glycoproteins which bind cell surface carbohydrates specifically and reversibly, resulting in the agglutination of cells (reviewed in Drickamer, K. and M.E. Taylor (1993) Annu. Rev. Cell Biol. 9:237-264). This function is particularly important for activation of the immune response. Lectins mediate the agglutination and mitogenic stimulation of lymphocytes at sites of inflammation (Lasky, L.A. (1991) J. Cell. Biochem. 45:139-146; Paietta, E. et al. (1989) J. Immunol. 143:2850-2857).

Lectins are further classified into subfamilies based on carbohydrate-binding specificity and other criteria. The galectin subfamily, in particular, includes lectins that bind β -galactoside carbohydrate moieties in a thiol-dependent manner (reviewed in Hadari, Y.R. et al. (1998) J. Biol. Chem. 270:3447-3453). Galectins are widely expressed and developmentally regulated. Because all galectins lack an N-terminal signal peptide, it is suggested that galectins are externalized through an atypical secretory mechanism. Two classes of galectins have been defined based on molecular weight and oligomerization properties. Small galectins form homodimers and are about 14 to 16 kilodaltons in mass, while large galectins are monomeric and about 29-37 kilodaltons.

Galectins contain a characteristic carbohydrate recognition domain (CRD). The CRD is about 140 amino acids and contains several stretches of about 1 - 10 amino acids which are highly conserved among all galectins. A particular 6-amino acid motif within the CRD contains conserved tryptophan and arginine residues which are critical for carbohydrate binding. The CRD of some galectins also contains cysteine residues which may be important for disulfide bond formation.

人们的是 trail__TONG CROCKERS

Secondary structure predictions indicate that the CRD forms several β -sheets.

Galectins play a number of roles in diseases and conditions associated with cell-cell and cell-matrix interactions. For example, certain galectins associate with sites of inflammation and bind to cell surface immunoglobulin E molecules. In addition, galectins may play an important role in cancer metastasis. Galectin overexpression is correlated with the metastatic potential of cancers in humans and mice. Moreover, anti-galectin antibodies inhibit processes associated with cell transformation, such as cell aggregation and anchorage-independent growth (See, for example, Su, Z.-Z. et al. (1996) Proc. Natl. Acad. Sci. USA 93:7252-7257).

Selectins

10

20

Selectins, or LEC-CAMs, comprise a specialized lectin subfamily involved primarily in inflammation and leukocyte adhesion (Reviewed in Lasky, <u>supra</u>). Selectins mediate the recruitment of leukocytes from the circulation to sites of acute inflammation and are expressed on the surface of vascular endothelial cells in response to cytokine signaling. Selectins bind to specific ligands on the leukocyte cell membrane and enable the leukocyte to adhere to and migrate along the endothelial surface. Binding of selectin to its ligand leads to polarized rearrangement of the actin cytoskeleton and stimulates signal transduction within the leukocyte (Brenner, B. et al. (1997) Biochem. Biophys. Res. Commun. 231:802-807; Hidari, K.I. et al. (1997) J. Biol. Chem. 272:28750-28756). Members of the selectin family possess three characteristic motifs: a lectin or carbohydrate recognition domain; an epidermal growth factor-like domain; and a variable number of short consensus repeats (scr or "sushi" repeats) which are also present in complement regulatory proteins. The selectins include lymphocyte adhesion molecule-1 (Lam-1 or L-selectin), endothelial leukocyte adhesion molecule-1 (ELAM-1 or E-selectin), and granule membrane protein-140 (GMP-140 or P-selectin) (Johnston, G.I. et al. (1989) Cell 56:1033-1044).

25 Antigen Recognition Molecules

All vertebrates have developed sophisticated and complex immune systems that provide protection from viral, bacterial, fungal, and parasitic infections. A key feature of the immune system is its ability to distinguish foreign molecules, or antigens, from "self" molecules. This ability is mediated primarily by secreted and transmembrane proteins expressed by leukocytes (white blood cells) such as lymphocytes, granulocytes, and monocytes. Most of these proteins belong to the immunoglobulin (Ig) superfamily, members of which contain one or more repeats of a conserved structural domain. This Ig domain is comprised of antiparallel β sheets joined by a disulfide bond in an arrangement called the Ig fold. Members of the Ig superfamily include T-cell receptors, major histocompatibility (MHC) proteins, antibodies, and immune cell-specific surface markers such as

10

15

20

25

30



South the Charles

CD4, CD8, and CD28.

MHC proteins are cell surface markers that bind to and present foreign antigens to T cells. MHC molecules are classified as either class I or class II. Class I MHC molecules (MHC I) are expressed on the surface of almost all cells and are involved in the presentation of antigen to cytotoxic T cells. For example, a cell infected with virus will degrade intracellular viral proteins and express the protein fragments bound to MHC I molecules on the cell surface. The MHC I/antigen complex is recognized by cytotoxic T-cells which destroy the infected cell and the virus within. Class II MHC molecules are expressed primarily on specialized antigen-presenting cells of the immune system, such as B-cells and macrophages. These cells ingest foreign proteins from the extracellular fluid and express MHC II/antigen complex on the cell surface. This complex activates helper T-cells, which then secrete cytokines and other factors that stimulate the immune response. MHC molecules also play an important role in organ rejection following transplantation. Rejection occurs when the recipient's T-cells respond to foreign MHC molecules on the transplanted organ in the same way as to self MHC molecules bound to foreign antigen. (Reviewed in Alberts, B. et al. (1994) Molecular Biology of the Cell, Garland Publishing, New York NY, pp. 1229-1246.)

Antibodies, or immunoglobulins, are either expressed on the surface of B-cells or secreted by B-cells into the circulation. Antibodies bind and neutralize foreign antigens in the blood and other extracellular fluids. The prototypical antibody is a tetramer consisting of two identical heavy polypeptide chains (H-chains) and two identical light polypeptide chains (L-chains) interlinked by disulfide bonds. This arrangement confers the characteristic Y-shape to antibody molecules. Antibodies are classified based on their H-chain composition. The five antibody classes, IgA, IgD, IgE, IgG and IgM, are defined by the α , δ , ϵ , γ , and μ H-chain types. There are two types of L-chains, κ and λ , either of which may associate as a pair with any H-chain pair. IgG, the most common class of antibody found in the circulation, is tetrameric, while the other classes of antibodies are generally variants or multimers of this basic structure.

H-chains and L-chains each contain an N-terminal variable region and a C-terminal constant region. The constant region consists of about 110 amino acids in L-chains and about 330 or 440 amino acids in H-chains. The amino acid sequence of the constant region is nearly identical among H- or L-chains of a particular class. The variable region consists of about 110 amino acids in both H- and L-chains. However, the amino acid sequence of the variable region differs among H- or L-chains of a particular class. Within each H- or L-chain variable region are three hypervariable regions of extensive sequence diversity, each consisting of about 5 to 10 amino acids. In the antibody molecule, the H- and L-chain hypervariable regions come together to form the antigen recognition site. (Reviewed in Alberts, supra, pp. 1206-1213 and 1216-1217.)

Both H-chains and L-chains contain repeated Ig domains. For example, a typical H-chain contains four Ig domains, three of which occur within the constant region and one of which occurs within the variable region and contributes to the formation of the antigen recognition site. Likewise, a typical L-chain contains two Ig domains, one of which occurs within the constant region and one of which occurs within the variable region.

The immune system is capable of recognizing and responding to any foreign molecule that enters the body. Therefore, the immune system must be armed with a full repertoire of antibodies against all potential antigens. Such antibody diversity is generated by somatic rearrangement of gene segments encoding variable and constant regions. These gene segments are joined together by site-specific recombination which occurs between highly conserved DNA sequences that flank each gene segment. Because there are hundreds of different gene segments, millions of unique genes can be generated combinatorially. In addition, imprecise joining of these segments and an unusually high rate of somatic mutation within these segments further contribute to the generation of a diverse antibody population.

T-cell receptors are both structurally and functionally related to antibodies. (Reviewed in Alberts, supra, pp. 1228-1229.) T-cell receptors are cell surface proteins that bind foreign antigens and mediate diverse aspects of the immune response. A typical T-cell receptor is a heterodimer comprised of two disulfide-linked polypeptide chains called α and β . Each chain is about 280 amino acids in length and contains one variable region and one constant region. Each variable or constant region folds into an Ig domain. The variable regions from the α and β chains come together in the heterodimer to form the antigen recognition site. T-cell receptor diversity is generated by somatic rearrangement of gene segments encoding the α and β chains. T-cell receptors recognize small peptide antigens that are expressed on the surface of antigen-presenting cells and pathogen-infected cells. These peptide antigens are presented on the cell surface in association with major histocompatibility proteins which provide the proper context for antigen recognition.

Secreted and Extracellular Matrix Molecules

Protein secretion is essential for cellular function. Protein secretion is mediated by a signal peptide located at the amino terminus of the protein to be secreted. The signal peptide is comprised of about ten to twenty hydrophobic amino acids which target the nascent protein from the ribosome to the endoplasmic reticulum (ER). Proteins targeted to the ER may either proceed through the secretory pathway or remain in any of the secretory organelles such as the ER, Golgi apparatus, or lysosomes. Proteins that transit through the secretory pathway are either secreted into the extracellular space or retained in the plasma membrane. Secreted proteins are often synthesized as inactive precursors that

30

10

15

are activated by post-translational processing events during transit through the secretory pathway. Such events include glycosylation, proteolysis, and removal of the signal peptide by a signal peptidase. Other events that may occur during protein transport include chaperone-dependent unfolding and folding of the nascent protein and interaction of the protein with a receptor or pore complex. Examples of secreted proteins with amino terminal signal peptides include receptors, extracellular matrix molecules, cytokines, hormones, growth and differentiation factors, neuropeptides, vasomediators, ion channels, transporters/pumps, and proteases. (Reviewed in Alberts, B. et al. (1994) Molecular Biology of The Cell, Garland Publishing, New York NY, pp. 557-560, 582-592.)

The extracellular matrix (ECM) is a complex network of glycoproteins, polysaccharides, proteoglycans, and other macromolecules that are secreted from the cell into the extracellular space. The ECM remains in close association with the cell surface and provides a supportive meshwork that profoundly influences cell shape, motility, strength, flexibility, and adhesion. In fact, adhesion of a cell to its surrounding matrix is required for cell survival except in the case of metastatic tumor cells, which have overcome the need for cell-ECM anchorage. This phenomenon suggests that the ECM plays a critical role in the molecular mechanisms of growth control and metastasis. (Reviewed in Ruoslahti, E. (1996) Sci. Am. 275:72-77.) Furthermore, the ECM determines the structure and physical properties of connective tissue and is particularly important for morphogenesis and other processes associated with embryonic development and pattern formation.

The collagens comprise a family of ECM proteins that provide structure to bone, teeth, skin, ligaments, tendons, cartilage, blood vessels, and basement membranes. Multiple collagen proteins have been identified. Three collagen molecules fold together in a triple helix stabilized by interchain disulfide bonds. Bundles of these triple helices then associate to form fibrils. Collagen primary structure consists of hundreds of (Gly-X-Y) repeats where about a third of the X and Y residues are Pro. Glycines are crucial to helix formation as the bulkier amino acid sidechains cannot fold into the triple helical conformation. Because of these strict sequence requirements, mutations in collagen genes have severe consequences. Osteogenesis imperfecta patients have brittle bones that fracture easily; in severe cases patients die in utero or at birth. Ehlers-Danlos syndrome patients have hyperelastic skin, hypermobile joints, and susceptibility to aortic and intestinal rupture. Chondrodysplasia patients have short stature and ocular disorders. Alport syndrome patients have hematuria, sensorineural deafness, and eye lens deformation. (Isselbacher, K.J. et al. (1994) Harrison's Principles of Internal Medicine, McGraw-Hill, Inc., New York NY, pp. 2105-2117; and Creighton, T.E. (1984) Proteins, Structures and Molecular Principles, W.H. Freeman and Company, New York NY, pp. 191-197.)

Elastin and related proteins confer elasticity to tissues such as skin, blood vessels, and lungs. Elastin is a highly hydrophobic protein of about 750 amino acids that is rich in proline and glycine

2 dest into diploma

10

15

20

25

residues. Elastin molecules are highly cross-linked, forming an extensive extracellular network of fibers and sheets. Elastin fibers are surrounded by a sheath of microfibrils which are composed of a number of glycoproteins, including fibrillin. Mutations in the gene encoding fibrillin are responsible for Marfan's syndrome, a genetic disorder characterized by defects in connective tissue. In severe cases, the aortas of afflicted individuals are prone to rupture. (Reviewed in Alberts, supra, pp. 984-986.)

Fibronectin is a large ECM glycoprotein found in all vertebrates. Fibronectin exists as a dimer of two subunits, each containing about 2,500 amino acids. Each subunit folds into a rod-like structure containing multiple domains. The domains each contain multiple repeated modules, the most common of which is the type III fibronectin repeat. The type III fibronectin repeat is about 90 amino acids in length and is also found in other ECM proteins and in some plasma membrane and cytoplasmic proteins. Furthermore, some type III fibronectin repeats contain a characteristic tripeptide consisting of Arginine-Glycine-Aspartic acid (RGD). The RGD sequence is recognized by the integrin family of cell surface receptors and is also found in other ECM proteins. Disruption of both copies of the gene encoding fibronectin causes early embryonic lethality in mice. The mutant embryos display extensive morphological defects, including defects in the formation of the notochord, somites, heart, blood vessels, neural tube, and extraembryonic structures. (Reviewed in Alberts, supra, pp. 986-987.)

Laminin is a major glycoprotein component of the basal lamina which underlies and supports epithelial cell sheets. Laminin is one of the first ECM proteins synthesized in the developing embryo. Laminin is an 850 kilodalton protein composed of three polypeptide chains joined in the shape of a cross by disulfide bonds. Laminin is especially important for angiogenesis and in particular, for guiding the formation of capillaries. (Reviewed in Alberts, <u>supra</u>, pp. 990-991.)

There are many other types of proteinaceous ECM components, most of which can be classified as proteoglycans. Proteoglycans are composed of unbranched polysaccharide chains (glycosaminoglycans) attached to protein cores. Common proteoglycans include aggrecan, betaglycan, decorin, perlecan, serglycin, and syndecan-1. Some of these molecules not only provide mechanical support, but also bind to extracellular signaling molecules, such as fibroblast growth factor and transforming growth factor β , suggesting a role for proteoglycans in cell-cell communication and cell growth. (Reviewed in Alberts, supra, pp. 973-978.) Likewise, the glycoproteins tenascin-C and tenascin-R are expressed in developing and lesioned neural tissue and provide stimulatory and anti-adhesive (inhibitory) properties, respectively, for axonal growth. (Faissner, A. (1997) Cell Tissue Res. 290:331-341.)

Cytoskeletal Molecules

The cytoskeleton is a cytoplasmic network of protein fibers that mediate cell shape, structure,

10

15

and the second of the second of

and movement. The cytoskeleton supports the cell membrane and forms tracks along which organelles and other elements move in the cytosol. The cytoskeleton is a dynamic structure that allows cells to adopt various shapes and to carry out directed movements. Major cytoskeletal fibers include the microtubules, the microfilaments, and the intermediate filaments. Motor proteins, including myosin, dynein, and kinesin, drive movement of or along the fibers. The motor protein dynamin drives the formation of membrane vesicles. Accessory or associated proteins modify the structure or activity of the fibers while cytoskeletal membrane anchors connect the fibers to the cell membrane.

Tubulins

10

15

20

25

30

Microtubules, cytoskeletal fibers with a diameter of about 24 nm, have multiple roles in the cell. Bundles of microtubules form cilia and flagella, which are whip-like extensions of the cell membrane that are necessary for sweeping materials across an epithelium and for swimming of sperm, respectively. Marginal bands of microtubules in red blood cells and platelets are important for these cells' pliability. Organelles, membrane vesicles, and proteins are transported in the cell along tracks of microtubules. For example, microtubules run through nerve cell axons, allowing bidirectional transport of materials and membrane vesicles between the cell body and the nerve terminal. Failure to supply the nerve terminal with these vesicles blocks the transmission of neural signals. Microtubules are also critical to chromosomal movement during cell division. Both stable and short-lived populations of microtubules exist in the cell.

Microtubules are polymers of GTP-binding tubulin protein subunits. Each subunit is a heterodimer of α - and β - tubulin, multiple isoforms of which exist. The hydrolysis of GTP is linked to the addition of tubulin subunits at the end of a microtubule. The subunits interact head to tail to form protofilaments; the protofilaments interact side to side to form a microtubule. A microtubule is polarized, one end ringed with α -tubulin and the other with β -tubulin, and the two ends differ in their rates of assembly. Generally, each microtubule is composed of 13 protofilaments although 11 or 15 protofilament-microtubules are sometimes found. Cilia and flagella contain doublet microtubules. Microtubules grow from specialized structures known as centrosomes or microtubule-organizing centers (MTOCs). MTOCs may contain one or two centrioles, which are pinwheel arrays of triplet microtubules. The basal body, the organizing center located at the base of a cilium or flagellum, contains one centriole. Gamma tubulin present in the MTOC is important for nucleating the polymerization of α - and β - tubulin heterodimers but does not polymerize into microtubules. Microtubule-Associated Proteins

Wheretubure-11880erated 1 Teteris

Microtubule-associated proteins (MAPs) have roles in the assembly and stabilization of microtubules. One major family of MAPs, assembly MAPs, can be identified in neurons as well as

non-neuronal cells. Assembly MAPs are responsible for cross-linking microtubules in the cytosol. These MAPs are organized into two domains: a basic microtubule-binding domain and an acidic projection domain. The projection domain is the binding site for membranes, intermediate filaments, or other microtubules. Based on sequence analysis, assembly MAPs can be further grouped into two types: Type I and Type II. Type I MAPs, which include MAP1A and MAP1B, are large, filamentous molecules that co-purify with microtubules and are abundantly expressed in brain and testes. Type I MAPs contain several repeats of a positively-charged amino acid sequence motif that binds and neutralizes negatively charged tubulin, leading to stabilization of microtubules. MAP1A and MAP1B are each derived from a single precursor polypeptide that is subsequently proteolytically processed to generate one heavy chain and one light chain.

Another light chain, LC3, is a 16.4 kDa molecule that binds MAP1A, MAP1B, and microtubules. It is suggested that LC3 is synthesized from a source other than the MAP1A or MAP1B transcripts, and that the expression of LC3 may be important in regulating the microtubule binding activity of MAP1A and MAP1B during cell proliferation (Mann, S.S. et al. (1994) J. Biol. Chem. 269:11492-11497).

10

15

25

BNSDOCID: <WO

0162927A2_l_:

Type II MAPs, which include MAP2a, MAP2b, MAP2c, MAP4, and Tau, are characterized by three to four copies of an 18-residue sequence in the microtubule-binding domain. MAP2a, MAP2b, and MAP2c are found only in dendrites, MAP4 is found in non-neuronal cells, and Tau is found in axons and dendrites of nerve cells. Alternative splicing of the Tau mRNA leads to the existence of multiple forms of Tau protein. Tau phosphorylation is altered in neurodegenerative disorders such as Alzheimer's disease, Pick's disease, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia and Parkinsonism linked to chromosome 17. The altered Tau phosphorylation leads to a collapse of the microtubule network and the formation of intraneuronal Tau aggregates (Spillantini, M.G. and M. Goedert (1998) Trends Neurosci. 21:428-433).

The protein pericentrin is found in the MTOC and has a role in microtubule assembly.

Actins

Microfilaments, cytoskeletal filaments with a diameter of about 7-9 nm, are vital to cell locomotion, cell shape, cell adhesion, cell division, and muscle contraction. Assembly and disassembly of the microfilaments allow cells to change their morphology. Microfilaments are the polymerized form of actin, the most abundant intracellular protein in the eukaryotic cell. Human cells contain six isoforms of actin. The three α -actins are found in different kinds of muscle, nonmuscle β -actin and nonmuscle γ -actin are found in nonmuscle cells, and another γ -actin is found in intestinal smooth muscle cells. G-actin, the monomeric form of actin, polymerizes into polarized, helical F-actin filaments, accompanied by the hydrolysis of ATP to ADP. Actin filaments associate to form

bundles and networks, providing a framework to support the plasma membrane and determine cell shape. These bundles and networks are connected to the cell membrane. In muscle cells, thin filaments containing actin slide past thick filaments containing the motor protein myosin during contraction. A family of actin-related proteins exist that are not part of the actin cytoskeleton, but rather associate with microtubules and dynein.

Actin-Associated Proteins

10

15

20

25

30

Actin-associated proteins have roles in cross-linking, severing, and stabilization of actin filaments and in sequestering actin monomers. Several of the actin-associated proteins have multiple functions. Bundles and networks of actin filaments are held together by actin cross-linking proteins. These proteins have two actin-binding sites, one for each filament. Short cross-linking proteins promote bundle formation while longer, more flexible cross-linking proteins promote network formation. Calmodulin-like calcium-binding domains in actin cross-linking proteins allow calcium regulation of cross-linking. Group I cross-linking proteins have unique actin-binding domains and include the 30 kD protein, EF-1a, fascin, and scruin. Group II cross-linking proteins have a 7,000-MW actin-binding domain and include villin and dematin. Group III cross-linking proteins have pairs of a 26,000-MW actin-binding domain and include fimbrin, spectrin, dystrophin, ABP 120, and filamin.

Severing proteins regulate the length of actin filaments by breaking them into short pieces or by blocking their ends. Severing proteins include gCAP39, severin (fragmin), gelsolin, and villin. Capping proteins can cap the ends of actin filaments, but cannot break filaments. Capping proteins include CapZ and tropomodulin. The proteins thymosin and profilin sequester actin monomers in the cytosol, allowing a pool of unpolymerized actin to exist. The actin-associated proteins tropomyosin, troponin, and caldesmon regulate muscle contraction in response to calcium.

Intermediate Filaments and Associated Proteins

Intermediate filaments (IFs) are cytoskeletal fibers with a diameter of about 10 nm, intermediate between that of microfilaments and microtubules. IFs serve structural roles in the cell, reinforcing cells and organizing cells into tissues. IFs are particularly abundant in epidermal cells and in neurons. IFs are extremely stable, and, in contrast to microfilaments and microtubules, do not function in cell motility.

Five types of IF proteins are known in mammals. Type I and Type II proteins are the acidic and basic keratins, respectively. Heterodimers of the acidic and basic keratins are the building blocks of keratin IFs. Keratins are abundant in soft epithelia such as skin and cornea, hard epithelia such as nails and hair, and in epithelia that line internal body cavities. Mutations in keratin genes lead to epithelial diseases including epidermolysis bullosa simplex, bullous congenital ichthyosiform



erythroderma (epidermolytic hyperkeratosis), non-epidermolytic and epidermolytic palmoplantar keratoderma, ichthyosis bullosa of Siemens, pachyonychia congenita, and white sponge nevus. Some of these diseases result in severe skin blistering. (See, e.g., Wawersik, M. et al. (1997) J. Biol. Chem. 272:32557-32565; and Corden L.D. and W.H. McLean (1996) Exp. Dermatol. 5:297-307.)

Type III IF proteins include desmin, glial fibrillary acidic protein, vimentin, and peripherin. Desmin filaments in muscle cells link myofibrils into bundles and stabilize sarcomeres in contracting muscle. Glial fibrillary acidic protein filaments are found in the glial cells that surround neurons and astrocytes. Vimentin filaments are found in blood vessel endothelial cells, some epithelial cells, and mesenchymal cells such as fibroblasts, and are commonly associated with microtubules. Vimentin filaments may have roles in keeping the nucleus and other organelles in place in the cell. Type IV IFs include the neurofilaments and nestin. Neurofilaments, composed of three polypeptides NF-L, NF-M, and NF-H, are frequently associated with microtubules in axons. Neurofilaments are responsible for the radial growth and diameter of an axon, and ultimately for the speed of nerve impulse transmission. Changes in phosphorylation and metabolism of neurofilaments are observed in neurodegenerative diseases including amyotrophic lateral sclerosis, Parkinson's disease, and Alzheimer's disease (Julien, J.P. and W.E. Mushynski (1998) Prog. Nucleic Acid Res. Mol. Biol. 61:1-23). Type V IFs, the lamins, are found in the nucleus where they support the nuclear membrane.

IFs have a central α -helical rod region interrupted by short nonhelical linker segments. The rod region is bracketed, in most cases, by non-helical head and tail domains. The rod regions of intermediate filament proteins associate to form a coiled-coil dimer. A highly ordered assembly process leads from the dimers to the IFs. Neither ATP nor GTP is needed for IF assembly, unlike that of microfilaments and microtubules.

IF-associated proteins (IFAPs) mediate the interactions of IFs with one another and with other cell structures. IFAPs cross-link IFs into a bundle, into a network, or to the plasma membrane, and may cross-link IFs to the microfilament and microtubule cytoskeleton. Microtubules and IFs are in particular closely associated. IFAPs include BPAG1, plakoglobin, desmoplakin I, desmoplakin II, plectin, ankyrin, filaggrin, and lamin B receptor.

Cytoskeletal-Membrane Anchors

Cytoskeletal fibers are attached to the plasma membrane by specific proteins. These attachments are important for maintaining cell shape and for muscle contraction. In erythrocytes, the spectrin-actin cytoskeleton is attached to cell membrane by three proteins, band 4.1, ankyrin, and adducin. Defects in this attachment result in abnormally shaped cells which are more rapidly degraded by the spleen, leading to anemia. In platelets, the spectrin-actin cytoskeleton is also linked to the membrane by ankyrin; a second actin network is anchored to the membrane by filamin. In

muscle cells the protein dystrophin links actin filaments to the plasma membrane; mutations in the dystrophin gene lead to Duchenne muscular dystrophy. In adherens junctions and adhesion plaques the peripheral membrane proteins α -actinin and vinculin attach actin filaments to the cell membrane.

IFs are also attached to membranes by cytoskeletal-membrane anchors. The nuclear lamina is attached to the inner surface of the nuclear membrane by the lamin B receptor. Vimentin IFs are attached to the plasma membrane by ankyrin and plectin. Desmosome and hemidesmosome membrane junctions hold together epithelial cells of organs and skin. These membrane junctions allow shear forces to be distributed across the entire epithelial cell layer, thus providing strength and rigidity to the epithelium. IFs in epithelial cells are attached to the desmosome by plakoglobin and desmoplakins. The proteins that link IFs to hemidesmosomes are not known. Desmin IFs surround the sarcomere in muscle and are linked to the plasma membrane by paranemin, synemin, and ankyrin. Myosin-related Motor Proteins

Myosins are actin-activated ATPases, found in eukaryotic cells, that couple hydrolysis of ATP with motion. Myosin provides the motor function for muscle contraction and intracellular movements such as phagocytosis and rearrangement of cell contents during mitotic cell division (cytokinesis). The contractile unit of skeletal muscle, termed the sarcomere, consists of highly ordered arrays of thin actin-containing filaments and thick myosin-containing filaments. Crossbridges form between the thick and thin filaments, and the ATP-dependent movement of myosin heads within the thick filaments pulls the thin filaments, shortening the sarcomere and thus the muscle fiber.

Myosins are composed of one or two heavy chains and associated light chains. Myosin heavy chains contain an amino-terminal motor or head domain, a neck that is the site of light-chain binding, and a carboxy-terminal tail domain. The tail domains may associate to form an α-helical coiled coil. Conventional myosins, such as those found in muscle tissue, are composed of two myosin heavy-chain subunits, each associated with two light-chain subunits that bind at the neck region and play a regulatory role. Unconventional myosins, believed to function in intracellular motion, may contain either one or two heavy chains and associated light chains. There is evidence for about 25 myosin heavy chain genes in vertebrates, more than half of them unconventional.

Dynein-related Motor Proteins

Dyneins are (-) end-directed motor proteins which act on microtubules. Two classes of dyneins, cytosolic and axonemal, have been identified. Cytosolic dyneins are responsible for translocation of materials along cytoplasmic microtubules, for example, transport from the nerve terminal to the cell body and transport of endocytic vesicles to lysosomes. Cytoplasmic dyneins are also reported to play a role in mitosis. Axonemal dyneins are responsible for the beating of flagella and cilia. Dynein on one microtubule doublet walks along the adjacent microtubule doublet. This sliding

n riangan kalimiran di Joseph Ing man a mayar

5

10

15

20

25

force produces bending forces that cause the flagellum or cilium to beat. Dyneins have a native mass between 1000 and 2000 kDa and contain either two or three force-producing heads driven by the hydrolysis of ATP. The heads are linked via stalks to a basal domain which is composed of a highly variable number of accessory intermediate and light chains.

Kinesin-related Motor Proteins

10

Kinesins are (+) end-directed motor proteins which act on microtubules. The prototypical kinesin molecule is involved in the transport of membrane-bound vesicles and organelles. This function is particularly important for axonal transport in neurons. Kinesin is also important in all cell types for the transport of vesicles from the Golgi complex to the endoplasmic reticulum. This role is critical for maintaining the identity and functionality of these secretory organelles.

Kinesins define a ubiquitous, conserved family of over 50 proteins that can be classified into at least 8 subfamilies based on primary amino acid sequence, domain structure, velocity of movement, and cellular function. (Reviewed in Moore, J.D. and S.A. Endow (1996) Bioessays 18:207-219; and Hoyt, A.M. (1994) Curr. Opin. Cell Biol. 6:63-68.) The prototypical kinesin molecule is a heterotetramer comprised of two heavy polypeptide chains (KHCs) and two light polypeptide chains (KLCs). The KHC subunits are typically referred to as "kinesin." KHC is about 1000 amino acids in length, and KLC is about 550 amino acids in length. Two KHCs dimerize to form a rod-shaped molecule with three distinct regions of secondary structure. At one end of the molecule is a globular motor domain that functions in ATP hydrolysis and microtubule binding. Kinesin motor domains are highly conserved and share over 70% identity. Beyond the motor domain is an α -helical coiled-coil region which mediates dimerization. At the other end of the molecule is a fan-shaped tail that associates with molecular cargo. The tail is formed by the interaction of the KHC C-termini with the two KLCs.

Members of the more divergent subfamilies of kinesins are called kinesin-related proteins (KRPs), many of which function during mitosis in eukaryotes (Hoyt, <u>supra</u>). Some KRPs are required for assembly of the mitotic spindle. <u>In vivo</u> and <u>in vitro</u> analyses suggest that these KRPs exert force on microtubules that comprise the mitotic spindle, resulting in the separation of spindle poles. Phosphorylation of KRP is required for this activity. Failure to assemble the mitotic spindle results in abortive mitosis and chromosomal aneuploidy, the latter condition being characteristic of cancer cells. In addition, a unique KRP, centromere protein E, localizes to the kinetochore of human mitotic chromosomes and may play a role in their segregation to opposite spindle poles.

Dynamin-related Motor Proteins

Dynamin is a large GTPase motor protein that functions as a "molecular pinchase," generating a mechanochemical force used to sever membranes. This activity is important in forming clathrin-coated vesicles from coated pits in endocytosis and in the biogenesis of synaptic vesicles in

neurons. Binding of dynamin to a membrane leads to dynamin's self-assembly into spirals that may act to constrict a flat membrane surface into a tubule. GTP hydrolysis induces a change in conformation of the dynamin polymer that pinches the membrane tubule, leading to severing of the membrane tubule and formation of a membrane vesicle. Release of GDP and inorganic phosphate leads to dynamin disassembly. Following disassembly the dynamin may either dissociate from the membrane or remain associated to the vesicle and be transported to another region of the cell. Three homologous dynamin genes have been discovered, in addition to several dynamin-related proteins. Conserved dynamin regions are the N-terminal GTP-binding domain, a central pleckstrin homology domain that binds membranes, a central coiled-coil region that may activate dynamin's GTPase activity, and a C-terminal proline-rich domain that contains several motifs that bind SH3 domains on other proteins. Some dynamin-related proteins do not contain the pleckstrin homology domain or the proline-rich domain. (See McNiven, M.A. (1998) Cell 94:151-154; Scaife, R.M. and R.L. Margolis (1997) Cell. Signal. 9:395-401.)

The cytoskeleton is reviewed in Lodish, H. et al. (1995) Molecular Cell Biology, Scientific American Books, New York NY.

Ribosomal Molecules

10

15

Ribosomal RNAs (rRNAs) are assembled, along with ribosomal proteins, into ribosomes, which are cytoplasmic particles that translate messenger RNA into polypeptides. The eukaryotic ribosome is composed of a 60S (large) subunit and a 40S (small) subunit, which together form the 20 80S ribosome. In addition to the 18S, 28S, 5S, and 5.8S rRNAs, the ribosome also contains more than fifty proteins. The ribosomal proteins have a prefix which denotes the subunit to which they belong, either L (large) or S (small). Ribosomal protein activities include binding rRNA and organizing the conformation of the junctions between rRNA helices (Woodson, S.A. and N.B. Leontis (1998) Curr. Opin. Struct. Biol. 8:294-300; Ramakrishnan, V. and S.W. White (1998) Trends 25 Biochem. Sci. 23:208-212.) Three important sites are identified on the ribosome. The aminoacyltRNA site (A site) is where charged tRNAs (with the exception of the initiator-tRNA) bind on arrival at the ribosome. The peptidyl-tRNA site (P site) is where new peptide bonds are formed, as well as where the initiator tRNA binds. The exit site (E site) is where deacylated tRNAs bind prior to their release from the ribosome. (The ribosome is reviewed in Stryer, L. (1995) Biochemistry W.H. 30 Freeman and Company, New York NY, pp. 888-908; and Lodish, H. et al. (1995) Molecular Cell Biology Scientific American Books, New York NY. pp. 119-138.)

Chromatin Molecules

The nuclear DNA of eukaryotes is organized into chromatin. Two types of chromatin are observed: euchromatin, some of which may be transcribed, and heterochromatin so densely packed that much of it is inaccessible to transcription. Chromatin packing thus serves to regulate protein expression in eukaryotes. Bacteria lack chromatin and the chromatin-packing level of gene regulation.

The fundamental unit of chromatin is the nucleosome of 200 DNA base pairs associated with two copies each of histones H2A, H2B, H3, and H4. Adjascent nucleosomes are linked by another class of histones, H1. Low molecular weight non-histone proteins called the high mobility group (HMG), associated with chromatin, may function in the unwinding of DNA and stabilization of single-stranded DNA. Chromodomain proteins function in compaction of chromatin into its transcriptionally silent heterochromatin form.

During mitosis, all DNA is compacted into heterochromatin and transcription ceases.

Transcription in interphase begins with the activation of a region of chromatin. Active chromatin is decondensed. Decondensation appears to be accompanied by changes in binding coefficient, phosphorylation and acetylation states of chromatin histones. HMG proteins HMG13 and HMG17 selectively bind activated chromatin. Topoisomerases remove superhelical tension on DNA. The activated region decondenses, allowing gene regulatory proteins and transcription factors to assemble on the DNA.

Patterns of chromatin structure can be stably inherited, producing heritable patterns of gene expression. In mammals, one of the two X chromosomes in each female cell is inactivated by condensation to heterochromatin during zygote development. The inactive state of this chromosome is inherited, so that adult females are mosaics of clusters of paternal-X and maternal-X clonal cell groups. The condensed X chromosome is reactivated in meiosis.

Chromatin is associated with disorders of protein expression such as thalassemia, a genetic anemia resulting from the removal of the locus control region (LCR) required for decondensation of the globin gene locus.

For a review of chromatin structure and function see Alberts, B. et al. (1994) Molecular Cell Biology, third edition, Garland Publishing, Inc., New York NY, pp. 351-354, 433-439.

Electron Transfer Associated Molecules

Electron carriers such as cytochromes accept electrons from NADH or FADH₂ and donate them to other electron carriers. Most electron-transferring proteins, except ubiquinone, are prosthetic groups such as flavins, heme, FeS clusters, and copper, bound to inner membrane proteins. Adrenodoxin, for example, is an FeS protein that forms a complex with NADPH:adrenodoxin reductase and cytochrome p450. Cytochromes contain a heme prosthetic group, a porphyrin ring

30

5

containing a tightly bound iron atom. Electron transfer reactions play a crucial role in cellular energy production.

Energy is produced by the oxidation of glucose and fatty acids. Glucose is initially converted to pyruvate in the cytoplasm. Fatty acids and pyruvate are transported to the mitochondria for complete oxidation to CO₂ coupled by enzymes to the transport of electrons from NADH and FADH₂ to oxygen and to the synthesis of ATP (oxidative phosphorylation) from ADP and P_i.

Pyruvate is transported into the mitochondria and converted to acetyl-CoA for oxidation via the citric acid cycle, involving pyruvate dehydrogenase components, dihydrolipoyl transacetylase, and dihydrolipoyl dehydrogenase. Enzymes involved in the citric acid cycle include: citrate synthetase, aconitases, isocitrate dehydrogenase, alpha-ketoglutarate dehydrogenase complex including transsuccinylases, succinyl CoA synthetase, succinate dehydrogenase, fumarases, and malate dehydrogenase. Acetyl CoA is oxidized to CO₂ with concomitant formation of NADH, FADH₂, and GTP. In oxidative phosphorylation, the transfer of electrons from NADH and FADH₂ to oxygen by dehydrogenases is coupled to the synthesis of ATP from ADP and P₁ by the F₀F₁ ATPase complex in the mitochondrial inner membrane. Enzyme complexes responsible for electron transport and ATP synthesis include the F₀F₁ ATPase complex, ubiquinone(CoQ)-cytochrome c reductase, ubiquinone reductase, cytochrome b, cytochrome c₁, FeS protein, and cytochrome c oxidase.

ATP synthesis requires membrane transport enzymes including the phosphate transporter and the ATP-ADP antiport protein. The ATP-binding casette (ABC) superfamily has also been suggested as belonging to the mitochondrial transport group (Hogue, D.L. et al. (1999) J. Mol. Biol. 285:379-389). Brown fat uncoupling protein dissipates oxidative energy as heat, and may be involved the fever response to infection and trauma (Cannon, B. et al. (1998) Ann. NY Acad. Sci. 856:171-187).

Mitochondria are oval-shaped organelles comprising an outer membrane, a tightly folded inner membrane, an intermembrane space between the outer and inner membranes, and a matrix inside the inner membrane. The outer membrane contains many porin molecules that allow ions and charged molecules to enter the intermembrane space, while the inner membrane contains a variety of transport proteins that transfer only selected molecules. Mitochondria are the primary sites of energy production in cells.

Mitochondria contain a small amount of DNA. Human mitochondrial DNA encodes 13 proteins, 22 tRNAs, and 2 rRNAs. Mitochondrial-DNA encoded proteins include NADH-Q reductase, a cytochrome reductase subunit, cytochrome oxidase subunits, and ATP synthase subunits.

Electron-transfer reactions also occur outside the mitochondria in locations such as the endoplasmic reticulum, which plays a crucial role in lipid and protein biosynthesis. Cytochrome b5 is a central electron donor for various reductive reactions occurring on the cytoplasmic surface of liver

La Burre Williams

10

15

20

25

endoplasmic reticulum. Cytochrome b5 has been found in Golgi, plasma, endoplasmic reticulum (ER), and microbody membranes.

For a review of mitochondrial metabolism and regulation, see Lodish, H. et al. (1995)

Molecular Cell Biology, Scientific American Books, New York NY, pp. 745-797 and Stryer (1995)

Biochemistry, W.H. Freeman and Co., San Francisco CA, pp 529-558, 988-989.

The majority of mitochondrial proteins are encoded by nuclear genes, are synthesized on cytosolic ribosomes, and are imported into the mitochondria. Nuclear-encoded proteins which are destined for the mitochondrial matrix typically contain positively-charged amino terminal signal sequences. Import of these preproteins from the cytoplasm requires a multisubunit protein complex in the outer membrane known as the translocase of outer mitochondrial membrane (TOM; previously designated MOM; Pfanner, N. et al. (1996) Trends Biochem. Sci. 21:51-52) and at least three inner membrane proteins which comprise the translocase of inner mitochondrial membrane (TIM; previously designated MIM; Pfanner, supra). An inside-negative membrane potential across the inner mitochondrial membrane is also required for preprotein import. Preproteins are recognized by surface receptor components of the TOM complex and are translocated through a proteinaceous pore formed by other TOM components. Proteins targeted to the matrix are then recognized by the import machinery of the TIM complex. The import systems of the outer and inner membranes can function independently (Segui-Real, B. et al. (1993) EMBO J. 12:2211-2218).

Once precursor proteins are in the mitochondria, the leader peptide is cleaved by a signal peptidase to generate the mature protein. Most leader peptides are removed in a one step process by a protease termed mitochondrial processing peptidase (MPP) (Paces, V. et al. (1993) Proc. Natl. Acad. Sci. USA 90:5355-5358). In some cases a two-step process occurs in which MPP generates an intermediate precursor form which is cleaved by a second enzyme, mitochondrial intermediate peptidase, to generate the mature protein.

Mitochondrial dysfunction leads to impaired calcium buffering, generation of free radicals that may participate in deleterious intracellular and extracellular processes, changes in mitochondrial permeability and oxidative damage which is observed in several neurodegenerative diseases. Neurodegenerative diseases linked to mitochondrial dysfunction include some forms of Alzheimer's disease, Friedreich's ataxia, familial amyotrophic lateral sclerosis, and Huntington's disease (Beal, M.F. (1998) Biochim. Biophys. Acta 1366:211-213). The myocardium is heavily dependent on oxidative metabolism, so mitochondrial dysfunction often leads to heart disease (DiMauro, S. and M. Hirano (1998) Curr. Opin. Cardiol 13:190-197). Mitochondria are implicated in disorders of cell proliferation, since they play an important role in a cell's decision to proliferate or self-destruct through apoptosis. The oncoprotein Bcl-2, for example, promotes cell proliferation by stabilizing

20

mitochondrial membranes so that apoptosis signals are not released (Susin, S.A. (1998) Biochim. Biophys. Acta 1366:151-165).

Transcription Factor Molecules

5

10

15

20

25

30

Multicellular organisms are comprised of diverse cell types that differ dramatically both in structure and function. The identity of a cell is determined by its characteristic pattern of gene expression, and different cell types express overlapping but distinctive sets of genes throughout development. Spatial and temporal regulation of gene expression is critical for the control of cell proliferation, cell differentiation, apoptosis, and other processes that contribute to organismal development. Furthermore, gene expression is regulated in response to extracellular signals that mediate cell-cell communication and coordinate the activities of different cell types. Appropriate gene regulation also ensures that cells function efficiently by expressing only those genes whose functions are required at a given time.

Transcriptional regulatory proteins are essential for the control of gene expression. Some of these proteins function as transcription factors that initiate, activate, repress, or terminate gene transcription. Transcription factors generally bind to the promoter, enhancer, and upstream regulatory regions of a gene in a sequence-specific manner, although some factors bind regulatory elements within or downstream of a gene's coding region. Transcription factors may bind to a specific region of DNA singly or as a complex with other accessory factors. (Reviewed in Lewin, B. (1990) Genes IV, Oxford University Press, New York NY, and Cell Press, Cambridge MA, pp. 554-570.)

The double helix structure and repeated sequences of DNA create topological and chemical features which can be recognized by transcription factors. These features are hydrogen bond donor and acceptor groups, hydrophobic patches, major and minor grooves, and regular, repeated stretches of sequence which induce distinct bends in the helix. Typically, transcription factors recognize specific DNA sequence motifs of about 20 nucleotides in length. Multiple, adjacent transcription factor-binding motifs may be required for gene regulation.

Many transcription factors incorporate DNA-binding structural motifs which comprise either α helices or β sheets that bind to the major groove of DNA. Four well-characterized structural motifs are helix-turn-helix, zinc finger, leucine zipper, and helix-loop-helix. Proteins containing these motifs may act alone as monomers, or they may form homo- or heterodimers that interact with DNA.

The helix-turn-helix motif consists of two α helices connected at a fixed angle by a short chain of amino acids. One of the helices binds to the major groove. Helix-turn-helix motifs are exemplified by the homeobox motif which is present in homeodomain proteins. These proteins are critical for specifying the anterior-posterior body axis during development and are conserved

throughout the animal kingdom. The Antennapedia and Ultrabithorax proteins of <u>Drosophila</u> melanogaster are prototypical homeodomain proteins (Pabo, C.O. and R.T. Sauer (1992) Annu. Rev. Biochem. 61:1053-1095).

The zinc finger motif, which binds zinc ions, generally contains tandem repeats of about 30 amino acids consisting of periodically spaced cysteine and histidine residues. Examples of this sequence pattern, designated C2H2 and C3HC4 ("RING" finger), have been described (Lewin, supra). Zinc finger proteins each contain an α helix and an antiparallel β sheet whose proximity and conformation are maintained by the zinc ion. Contact with DNA is made by the arginine prece ding the α helix and by the second, third, and sixth residues of the α helix. Variants of the zinc finger motif include poorly defined cysteine-rich motifs which bind zinc or other metal ions. These motifs may not contain histidine residues and are generally nonrepetitive.

The leucine zipper motif comprises a stretch of amino acids rich in leucine which can form an amphipathic α helix. This structure provides the basis for dimerization of two leucine zipper proteins. The region adjacent to the leucine zipper is usually basic, and upon protein dimerization, is optimally positioned for binding to the major groove. Proteins containing such motifs are generally referred to as bZIP transcription factors.

The helix-loop-helix motif (HLH) consists of a short α helix connected by a loop to a longer α helix. The loop is flexible and allows the two helices to fold back against each other and to bind to DNA. The transcription factor Myc contains a prototypical HLH motif.

Most transcription factors contain characteristic DNA binding motifs, and variations on the above motifs and new motifs have been and are currently being characterized (Faisst, S. and S. Meyer (1992) Nucleic Acids Res. 20:3-26).

Many neoplastic disorders in humans can be attributed to inappropriate gene expression. Malignant cell growth may result from either excessive expression of tumor promoting genes or insufficient expression of tumor suppressor genes (Cleary, M.L. (1992) Cancer Surv. 15:89-104). Chromosomal translocations may also produce chimeric loci which fuse the coding sequence of one gene with the regulatory regions of a second unrelated gene. Such an arrangement likely results in inappropriate gene transcription, potentially contributing to malignancy.

In addition, the immune system responds to infection or trauma by activating a cascade of events that coordinate the progressive selection, amplification, and mobilization of cellular defense mechanisms. A complex and balanced program of gene activation and repression is involved in this process. However, hyperactivity of the immune system as a result of improper or insufficient regulation of gene expression may result in considerable tissue or organ damage. This damage is well documented in immunological responses associated with arthritis, allergens, heart attack, stroke, and

30

15

infections (Isselbacher, K.J. et al. (1996) <u>Harrison's Principles of Internal Medicine</u>, 13/e, McGraw Hill, Inc. and Teton Data Systems Software).

Furthermore, the generation of multicellular organisms is based upon the induction and coordination of cell differentiation at the appropriate stages of development. Central to this process is differential gene expression, which confers the distinct identities of cells and tissues throughout the body. Failure to regulate gene expression during development can result in developmental disorders. Human developmental disorders caused by mutations in zinc finger-type transcriptional regulators include: urogenenital developmental abnormalities associated with WT1; Greig cephalopolysyndactyly, Pallister-Hall syndrome, and postaxial polydactyly type A (GLI3); and Townes-Brocks syndrome, characterized by anal, renal, limb, and ear abnormalities (SALL1) (Engelkamp, D. and V. van Heyningen (1996) Curr. Opin. Genet. Dev. 6:334-342; Kohlhase, J. et al. (1999) Am. J. Hum. Genet. 64:435-445).

Cell Membrane Molecules

10

15

20

25

30

Eukaryotic cells are surrounded by plasma membranes which enclose the cell and maintain an environment inside the cell that is distinct from its surroundings. In addition, eukaryotic organisms are distinct from prokaryotes in possessing many intracellular organelle and vesicle structures. Many of the metabolic reactions which distinguish eukaryotic biochemistry from prokaryotic biochemistry take place within these structures. The plasma membrane and the membranes surrounding organelles and vesicles are composed of phosphoglycerides, fatty acids, cholesterol, phospholipids, glycolipids, proteoglycans, and proteins. These components confer identity and functionality to the membranes with which they associate.

Integral Membrane Proteins

The majority of known integral membrane proteins are transmembrane proteins (TM) which are characterized by an extracellular, a transmembrane, and an intracellular domain. TM domains are typically comprised of 15 to 25 hydrophobic amino acids which are predicted to adopt an α-helical conformation. TM proteins are classified as bitopic (Types I and II) and polytopic (Types III and IV) (Singer, S.J. (1990) Annu. Rev. Cell Biol. 6:247-296). Bitopic proteins span the membrane once while polytopic proteins contain multiple membrane-spanning segments. TM proteins function as cell-surface receptors, receptor-interacting proteins, transporters of ions or metabolites, ion channels, cell anchoring proteins, and cell type-specific surface antigens.

Many membrane proteins (MPs) contain amino acid sequence motifs that target these proteins to specific subcellular sites. Examples of these motifs include PDZ domains, KDEL, RGD, NGR, and GSL sequence motifs, von Willebrand factor A (vWFA) domains, and EGF-like domains. RGD,

NGR, and GSL motif-containing peptides have been used as drug delivery agents in targeted cancer treatment of tumor vasculature (Arap, W. et al. (1998) Science 279:377-380). Furthermore, MPs may also contain amino acid sequence motifs, such as the carbohydrate recognition domain (CRD), that mediate interactions with extracellular or intracellular molecules.

5 <u>G-Protein Coupled Receptors</u>


G-protein coupled receptors (GPCR) are a superfamily of integral membrane proteins which transduce extracellular signals. GPCRs include receptors for biogenic amines, lipid mediators of inflammation, peptide hormones, and sensory signal mediators. The structure of these highly-conserved receptors consists of seven hydrophobic transmembrane regions, an extracellular N-terminus, and a cytoplasmic C-terminus. Three extracellular loops alternate with three intracellular loops to link the seven transmembrane regions. Cysteine disulfide bridges connect the second and third extracellular loops. The most conserved regions of GPCRs are the transmembrane regions and the first two cytoplasmic loops. A conserved, acidic-Arg-aromatic residue triplet present in the second cytoplasmic loop may interact with G proteins. A GPCR consensus pattern is characteristic of most proteins belonging to this superfamily (ExPASy PROSITE document PS00237; and Watson, S. and S. Arkinstall (1994) The G-protein Linked Receptor Facts Book, Academic Press, San Diego CA, pp. 2-6). Mutations and changes in transcriptional activation of GPCR-encoding genes have been associated with neurological disorders such as schizophrenia, Parkinson's disease, Alzheimer's disease, drug addiction, and feeding disorders.

20 <u>Scavenger Receptors</u>

Macrophage scavenger receptors with broad ligand specificity may participate in the binding of low density lipoproteins (LDL) and foreign antigens. Scavenger receptors types I and II are trimeric membrane proteins with each subunit containing a small N-terminal intracellular domain, a transmembrane domain, a large extracellular domain, and a C-terminal cysteine-rich domain. The extracellular domain contains a short spacer region, an α-helical coiled-coil region, and a triple helical collagen-like region. These receptors have been shown to bind a spectrum of ligands, including chemically modified lipoproteins and albumin, polyribonucleotides, polysaccharides, phospholipids, and asbestos (Matsumoto, A. et al. (1990) Proc. Natl. Acad. Sci. USA 87:9133-9137; and Elomaa, O. et al. (1995) Cell 80:603-609). The scavenger receptors are thought to play a key role in atherogenesis by mediating uptake of modified LDL in arterial walls, and in host defense by binding bacterial endotoxins, bacteria, and protozoa.

Tetraspan Family Proteins

The transmembrane 4 superfamily (TM4SF) or tetraspan family is a multigene family encoding type III integral membrane proteins (Wright, M.D. and M.G. Tomlinson (1994) Immunol.



agrant agreed by the property and the property of

Today 15:588-594). The TM4SF is comprised of membrane proteins which traverse the cell membrane four times. Members of the TM4SF include platelet and endothelial cell membrane proteins, melanoma-associated antigens, leukocyte surface glycoproteins, colonal carcinoma antigens, tumor-associated antigens, and surface proteins of the schistosome parasites (Jankowski, S.A. (1994) Oncogene 9:1205-1211). Members of the TM4SF share about 25-30% amino acid sequence identity with one another.

A number of TM4SF members have been implicated in signal transduction, control of cell adhesion, regulation of cell growth and proliferation, including development and oncogenesis, and cell motility, including tumor cell metastasis. Expression of TM4SF proteins is associated with a variety of tumors and the level of expression may be altered when cells are growing or activated. Tumor Antigens

Tumor antigens are cell surface molecules that are differentially expressed in tumor cells relative to normal cells. Tumor antigens distinguish tumor cells immunologically from normal cells and provide diagnostic and therapeutic targets for human cancers (Takagi, S. et al. (1995) Int. J.

Cancer 61:706-715; Liu, E. et al. (1992) Oncogene 7:1027-1032).

Leukocyte Antigens

10

15

20

25

Other types of cell surface antigens include those identified on leukocytic cells of the immune system. These antigens have been identified using systematic, monoclonal antibody (mAb)-based "shot gun" techniques. These techniques have resulted in the production of hundreds of mAbs directed against unknown cell surface leukocytic antigens. These antigens have been grouped into "clusters of differentiation" based on common immunocytochemical localization patterns in various differentiated and undifferentiated leukocytic cell types. Antigens in a given cluster are presumed to identify a single cell surface protein and are assigned a "cluster of differentiation" or "CD" designation. Some of the genes encoding proteins identified by CD antigens have been cloned and verified by standard molecular biology techniques. CD antigens have been characterized as both transmembrane proteins and cell surface proteins anchored to the plasma membrane via covalent attachment to fatty acid-containing glycolipids such as glycosylphosphatidylinositol (GPI). (Reviewed in Barclay, A.N. et al. (1995) The Leucocyte Antigen Facts Book, Academic Press, San Diego CA, pp. 17-20.)

30 Ion Channels

Ion channels are found in the plasma membranes of virtually every cell in the body. For example, chloride channels mediate a variety of cellular functions including regulation of membrane potentials and absorption and secretion of ions across epithelial membranes. Chloride channels also regulate the pH of organelles such as the Golgi apparatus and endosomes (see, e.g., Greger, R. (1988)



Annu. Rev. Physiol. 50:111-122). Electrophysiological and pharmacological properties of chloride channels, including ion conductance, current-voltage relationships, and sensitivity to modulators, suggest that different chloride channels exist in muscles, neurons, fibroblasts, epithelial cells, and lymphocytes.

Many ion channels have sites for phosphorylation by one or more protein kinases including protein kinase A, protein kinase C, tyrosine kinase, and casein kinase II, all of which regulate ion channel activity in cells. Inappropriate phosphorylation of proteins in cells has been linked to changes in cell cycle progression and cell differentiation. Changes in the cell cycle have been linked to induction of apoptosis or cancer. Changes in cell differentiation have been linked to diseases and disorders of the reproductive system, immune system, skeletal muscle, and other organ systems.

Proton Pumps

Proton ATPases comprise a large class of membrane proteins that use the energy of ATP hydrolysis to generate an electrochemical proton gradient across a membrane. The resultant gradient may be used to transport other ions across the membrane (Na⁺, K⁺, or Cl⁻) or to maintain organelle pH. Proton ATPases are further subdivided into the mitochondrial F-ATPases, the plasma membrane ATPases, and the vacuolar ATPases. The vacuolar ATPases establish and maintain an acidic pH within various organelles involved in the processes of endocytosis and exocytosis (Mellman, I. et al. (1986) Annu. Rev. Biochem. 55:663-700).

Proton-coupled, 12 membrane-spanning domain transporters such as PEPT 1 and PEPT 2 are responsible for gastrointestinal absorption and for renal reabsorption of peptides using an electrochemical H⁺ gradient as the driving force. Another type of peptide transporter, the TAP transporter, is a heterodimer consisting of TAP 1 and TAP 2 and is associated with antigen processing. Peptide antigens are transported across the membrane of the endoplasmic reticulum by TAP so they can be expressed on the cell surface in association with MHC molecules. Each TAP protein consists of multiple hydrophobic membrane spanning segments and a highly conserved ATP-binding cassette (Boll, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:284-289). Pathogenic microorganisms, such as herpes simplex virus, may encode inhibitors of TAP-mediated peptide transport in order to evade immune surveillance (Marusina, K. and J.J Manaco (1996) Curr. Opin. Hematol. 3:19-26).

30 ABC Transporters

The ATP-binding cassette (ABC) transporters, also called the "traffic ATPases", comprise a superfamily of membrane proteins that mediate transport and channel functions in prokaryotes and eukaryotes (Higgins, C.F. (1992) Annu. Rev. Cell Biol. 8:67-113). ABC proteins share a similar overall structure and significant sequence homology. All ABC proteins contain a conserved domain

5

10

20

25

30

The second with a second

of approximately two hundred amino acid residues which includes one or more nucleotide binding domains. Mutations in ABC transporter genes are associated with various disorders, such as hyperbilirubinemia II/Dubin-Johnson syndrome, recessive Stargardt's disease, X-linked adrenoleukodystrophy, multidrug resistance, celiac disease, and cystic fibrosis.

Peripheral and Anchored Membrane Proteins

Some membrane proteins are not membrane-spanning but are attached to the plasma membrane via membrane anchors or interactions with integral membrane proteins. Membrane anchors are covalently joined to a protein post-translationally and include such moieties as prenyl, myristyl, and glycosylphosphatidyl inositol groups. Membrane localization of peripheral and anchored proteins is important for their function in processes such as receptor-mediated signal transduction. For example, prenylation of Ras is required for its localization to the plasma membrane and for its normal and oncogenic functions in signal transduction.

Vesicle Coat Proteins

Intercellular communication is essential for the development and survival of multicellular organisms. Cells communicate with one another through the secretion and uptake of protein signaling molecules. The uptake of proteins into the cell is achieved by the endocytic pathway, in which the interaction of extracellular signaling molecules with plasma membrane receptors results in the formation of plasma membrane-derived vesicles that enclose and transport the molecules into the cytosol. These transport vesicles fuse with and mature into endosomal and lysosomal (digestive) compartments. The secretion of proteins from the cell is achieved by exocytosis, in which molecules inside of the cell proceed through the secretory pathway. In this pathway, molecules transit from the ER to the Golgi apparatus and finally to the plasma membrane, where they are secreted from the cell.

Several steps in the transit of material along the secretory and endocytic pathways require the formation of transport vesicles. Specifically, vesicles form at the transitional endoplasmic reticulum (tER), the rim of Golgi cisternae, the face of the Trans-Golgi Network (TGN), the plasma membrane (PM), and tubular extensions of the endosomes. Vesicle formation occurs when a region of membrane buds off from the donor organelle. The membrane-bound vesicle contains proteins to be transported and is surrounded by a proteinaceous coat, the components of which are recruited from the cytosol. Two different classes of coat protein have been identified. Clathrin coats form on vesicles derived from the TGN and PM, whereas coatomer (COP) coats form on vesicles derived from the ER and Golgi. COP coats can be further classified as COPI, involved in retrograde traffic through the Golgi and from the Golgi to the ER, and COPII, involved in anterograde traffic from the ER to the Golgi (Mellman, supra).

In clathrin-based vesicle formation, adapter proteins bring vesicle cargo and coat proteins

together at the surface of the budding membrane. Adapter protein-1 and -2 select cargo from the TGN and plasma membrane, respectively, based on molecular information encoded on the cytoplasmic tail of integral membrane cargo proteins. Adapter proteins also recruit clathrin to the bud site. Clathrin is a protein complex consisting of three large and three small polypeptide chains arranged in a three-legged structure called a triskelion. Multiple triskelions and other coat proteins appear to self-assemble on the membrane to form a coated pit. This assembly process may serve to deform the membrane into a budding vesicle. GTP-bound ADP-ribosylation factor (Arf) is also incorporated into the coated assembly. Another small G-protein, dynamin, forms a ring complex around the neck of the forming vesicle and may provide the mechanochemical force to seal the bud, thereby releasing the vesicle. The coated vesicle complex is then transported through the cytosol. During the transport process, Arf-bound GTP is hydrolyzed to GDP, and the coat dissociates from the transport vesicle (West, M.A. et al. (1997) J. Cell Biol. 138:1239-1254).

Vesicles which bud from the ER and the Golgi are covered with a protein coat similar to the clathrin coat of endocytic and TGN vesicles. The coat protein (COP) is assembled from cytosolic precursor molecules at specific budding regions on the organelle. The COP coat consists of two major components, a G-protein (Arf or Sar) and coat protomer (coatomer). Coatomer is an equimolar complex of seven proteins, termed alpha-, beta-, beta'-, gamma-, delta-, epsilon- and zeta-COP. The coatomer complex binds to dilysine motifs contained on the cytoplasmic tails of integral membrane proteins. These include the KKXX retrieval motif of membrane proteins of the ER and dibasic/diphenylamine motifs of members of the p24 family. The p24 family of type I membrane proteins represent the major membrane proteins of COPI vesicles (Harter, C. and F.T. Wieland (1998) Proc. Natl. Acad. Sci. USA 95:11649-11654).

Organelle Associated Molecules

Eukaryotic cells are organized into various cellular organelles which has the effect of separating specific molecules and their functions from one another and from the cytosol. Within the cell, various membrane structures surround and define these organelles while allowing them to interact with one another and the cell environment through both active and passive transport processes. Important cell organelles include the nucleus, the Golgi apparatus, the endoplasmic reticulum, mitochondria, peroxisomes, lysosomes, endosomes, and secretory vesicles.

Nucleus

The cell nucleus contains all of the genetic information of the cell in the form of DNA, and the components and machinery necessary for replication of DNA and for transcription of DNA into RNA. (See Alberts, B. et al. (1994) Molecular Biology of the Cell, Garland Publishing Inc., New

20

York NY, pp. 335-399.) DNA is organized into compact structures in the nucleus by interactions with various DNA-binding proteins such as histones and non-histone chromosomal proteins. DNA-specific nucleases, DNAses, partially degrade these compacted structures prior to DNA replication or transcription. DNA replication takes place with the aid of DNA helicases which unwind the double-stranded DNA helix, and DNA polymerases that duplicate the separated DNA strands.

Transcriptional regulatory proteins are essential for the control of gene expression. Some of these proteins function as transcription factors that initiate, activate, repress, or terminate gene transcription. Transcription factors generally bind to the promoter, enhancer, and upstream regulatory regions of a gene in a sequence-specific manner, although some factors bind regulatory elements within or downstream of a gene's coding region. Transcription factors may bind to a specific region of DNA singly or as a complex with other accessory factors. (Reviewed in Lewin, B. (1990) Genes IV, Oxford University Press, New York NY, and Cell Press, Cambridge MA, pp. 554-570.) Many transcription factors incorporate DNA-binding structural motifs which comprise either α helices or β sheets that bind to the major groove of DNA. Four well-characterized structural motifs are helix-turn-helix, zinc finger, leucine zipper, and helix-loop-helix. Proteins containing these motifs may act alone as monomers, or they may form homo- or heterodimers that interact with DNA.

Many neoplastic disorders in humans can be attributed to inappropriate gene expression. Malignant cell growth may result from either excessive expression of tumor promoting genes or insufficient expression of tumor suppressor genes (Cleary, M.L. (1992) Cancer Surv. 15:89-104). Chromosomal translocations may also produce chimeric loci which fuse the coding sequence of one gene with the regulatory regions of a second unrelated gene. Such an arrangement likely results in inappropriate gene transcription, potentially contributing to malignancy.

In addition, the immune system responds to infection or trauma by activating a cascade of events that coordinate the progressive selection, amplification, and mobilization of cellular defense mechanisms. A complex and balanced program of gene activation and repression is involved in this process. However, hyperactivity of the immune system as a result of improper or insufficient regulation of gene expression may result in considerable tissue or organ damage. This damage is well documented in immunological responses associated with arthritis, allergens, heart attack, stroke, and infections (Isselbacher, K.J. et al. (1996) <u>Harrison's Principles of Internal Medicine</u>, 13/e, McGraw Hill, Inc. and Teton Data Systems Software).

Transcription of DNA into RNA also takes place in the nucleus catalyzed by RNA polymerases. Three types of RNA polymerase exist. RNA polymerase I makes large ribosomal RNAs, while RNA polymerase III makes a variety of small, stable RNAs including 5S ribosomal

10

15

20

25

RNA and the transfer RNAs (tRNA). RNA polymerase II transcribes genes that will be translated into proteins. The primary transcript of RNA polymerase II is called heterogenous nuclear RNA (hnRNA), and must be further processed by splicing to remove non-coding sequences called introns. RNA splicing is mediated by small nuclear ribonucleoprotein complexes, or snRNPs, producing mature messenger RNA (mRNA) which is then transported out of the nucleus for translation into proteins.

Nucleolus

10

15

20

The nucleolus is a highly organized subcompartment in the nucleus that contains high concentrations of RNA and proteins and functions mainly in ribosomal RNA synthesis and assembly (Alberts, et al. supra, pp. 379-382). Ribosomal RNA (rRNA) is a structural RNA that is complexed with proteins to form ribonucleoprotein structures called ribosomes. Ribosomes provide the platform on which protein synthesis takes place.

Ribosomes are assembled in the nucleolus initially from a large, 45S rRNA combined with a variety of proteins imported from the cytoplasm, as well as smaller, 5S rRNAs. Later processing of the immature ribosome results in formation of smaller ribosomal subunits which are transported from the nucleolus to the cytoplasm where they are assembled into functional ribosomes.

Endoplasmic Reticulum

In eukaryotes, proteins are synthesized within the endoplasmic reticulum (ER), delivered from the ER to the Golgi apparatus for post-translational processing and sorting, and transported from the Golgi to specific intracellular and extracellular destinations. Synthesis of integral membrane proteins, secreted proteins, and proteins destined for the lumen of a particular organelle occurs on the rough endoplasmic reticulum (ER). The rough ER is so named because of the rough appearance in electron micrographs imparted by the attached ribosomes on which protein synthesis proceeds. Synthesis of proteins destined for the ER actually begins in the cytosol with the synthesis of a specific signal peptide which directs the growing polypeptide and its attached ribosome to the ER membrane where the signal peptide is removed and protein synthesis is completed. Soluble proteins destined for the ER lumen, for secretion, or for transport to the lumen of other organelles pass completely into the ER lumen. Transmembrane proteins destined for the ER or for other cell membranes are translocated across the ER membrane but remain anchored in the lipid bilayer of the membrane by one or more membrane-spanning α -helical regions.

Translocated polypeptide chains destined for other organelles or for secretion also fold and assemble in the ER lumen with the aid of certain "resident" ER proteins. Protein folding in the ER is aided by two principal types of protein isomerases, protein disulfide isomerase (PDI), and peptidyl-prolyl isomerase (PPI). PDI catalyzes the oxidation of free sulfhydryl groups in cysteine residues to

form intramolecular disulfide bonds in proteins. PPI, an enzyme that catalyzes the isomerization of certain proline imide bonds in oligopeptides and proteins, is considered to govern one of the rate limiting steps in the folding of many proteins to their final functional conformation. The cyclophilins represent a major class of PPI that was originally identified as the major receptor for the immunosuppressive drug cyclosporin A (Handschumacher, R.E. et al. (1984) Science 226:544-547). Molecular "chaperones" such as BiP (binding protein) in the ER recognize incorrectly folded proteins as well as proteins not yet folded into their final form and bind to them, both to prevent improper aggregation between them, and to promote proper folding.

The "N-linked" glycosylation of most soluble secreted and membrane-bound proteins by oligosacchrides linked to asparagine residues in proteins is also performed in the ER. This reaction is catalyzed by a membrane-bound enzyme, oligosaccharyl transferase.

سير سعاط

the season of the state of the state of

Golgi Apparatus

10

15

20

25

30

The Golgi apparatus is a complex structure that lies adjacent to the ER in eukaryotic cells and serves primarily as a sorting and dispatching station for products of the ER (Alberts, et al. supra, pp. 600-610). Additional posttranslational processing, principally additional glycosylation, also occurs in the Golgi. Indeed, the Golgi is a major site of carbohydrate synthesis, including most of the glycosaminoglycans of the extracellular matrix. N-linked oligosaccharides, added to proteins in the ER, are also further modified in the Golgi by the addition of more sugar residues to form complex N-linked oligosaccharides. "O-linked" glycosylation of proteins also occurs in the Golgi by the addition of N-acetylgalactosamine to the hydroxyl group of a serine or threonine residue followed by the sequential addition of other sugar residues to the first. This process is catalyzed by a series of glycosyltransferases each specific for a particular donor sugar nucleotide and acceptor molecule (Lodish, H. et al. (1995) Molecular Cell Biology, W.H. Freeman and Co., New York NY, pp.700-708). In many cases, both N- and O-linked oligosaccharides appear to be required for the secretion of proteins or the movement of plasma membrane glycoproteins to the cell surface.

The terminal compartment of the Golgi is the Trans-Golgi Network (TGN), where both membrane and lumenal proteins are sorted for their final destination. Transport (or secretory) vesicles destined for intracellular compartments, such as lysosomes, bud off of the TGN. Other transport vesicles bud off containing proteins destined for the plasma membrane, such as receptors, adhesion molecules, and ion channels, and secretory proteins, such as hormones, neurotransmitters, and digestive enzymes.

<u>Vacuoles</u>

The vacuole system is a collection of membrane bound compartments in eukaryotic cells that functions in the processes of endocytosis and exocytosis. They include phagosomes, lysosomes,

endosomes, and secretory vesicles. Endocytosis is the process in cells of internalizing nutrients, solutes or small particles (pinocytosis) or large particles such as internalized receptors, viruses, bacteria, or bacterial toxins (phagocytosis). Exocytosis is the process of transporting molecules to the cell surface. It facilitates placement or localization of membrane-bound receptors or other membrane proteins and secretion of hormones, neurotransmitters, digestive enzymes, wastes, etc.

A common property of all of these vacuoles is an acidic pH environment ranging from approximately pH 4.5-5.0. This acidity is maintained by the presence of a proton ATPase that uses the energy of ATP hydrolysis to generate an electrochemical proton gradient across a membrane (Mellman, I. et al. (1986) Annu. Rev. Biochem. 55:663-700). Eukaryotic vacuolar proton ATPase (vp-ATPase) is a multimeric enzyme composed of 3-10 different subunits. One of these subunits is a highly hydrophobic polypeptide of approximately 16 kDa that is similar to the proteolipid component of vp-ATPases from eubacteria, fungi, and plant vacuoles (Mandel, M. et al. (1988) Proc. Natl. Acad. Sci. USA 85:5521-5524). The 16 kDa proteolipid component is the major subunit of the membrane portion of vp-ATPase and functions in the transport of protons across the membrane.

15 Lysosomes

20

25

Lysosomes are membranous vesicles containing various hydrolytic enzymes used for the controlled intracellular digestion of macromolecules. Lysosomes contain some 40 types of enzymes including proteases, nucleases, glycosidases, lipases, phospholipases, phosphatases, and sulfatases, all of which are acid hydrolases that function at a pH of about 5. Lysosomes are surrounded by a unique membrane containing transport proteins that allow the final products of macromolecule degradation, such as sugars, amino acids, and nucleotides, to be transported to the cytosol where they may be either excreted or reutilized by the cell. A vp-ATPase, such as that described above, maintains the acidic environment necessary for hydrolytic activity (Alberts, supra, pp. 610-611).

Endosomes

Endosomes are another type of acidic vacuole that is used to transport substances from the cell surface to the interior of the cell in the process of endocytosis. Like lysosomes, endosomes have an acidic environment provided by a vp-ATPase (Alberts et al. supra, pp. 610-618). Two types of endosomes are apparent based on tracer uptake studies that distinguish their time of formation in the cell and their cellular location. Early endosomes are found near the plasma membrane and appear to function primarily in the recycling of internalized receptors back to the cell surface. Late endosomes appear later in the endocytic process close to the Golgi apparatus and the nucleus, and appear to be associated with delivery of endocytosed material to lysosomes or to the TGN where they may be recycled. Specific proteins are associated with particular transport vesicles and their target compartments that may provide selectivity in targeting vesicles to their proper compartments. A

cytosolic prenylated GTP-binding protein, Rab, is one such protein. Rabs 4, 5, and 11 are associated with the early endosome, whereas Rabs 7 and 9 associate with the late endosome.

Mitochondria ,

10

15

20

Mitochondria are oval-shaped organelles comprising an outer membrane, a tightly folded inner membrane, an intermembrane space between the outer and inner membranes, and a matrix inside the inner membrane. The outer membrane contains many porin molecules that allow ions and charged molecules to enter the intermembrane space, while the inner membrane contains a variety of transport proteins that transfer only selected molecules. Mitochondria are the primary sites of energy production in cells.

Energy is produced by the oxidation of glucose and fatty acids. Glucose is initially converted to pyruvate in the cytoplasm. Fatty acids and pyruvate are transported to the mitochondria for complete oxidation to CO_2 coupled by enzymes to the transport of electrons from NADH and FADH₂ to oxygen and to the synthesis of ATP (oxidative phosphorylation) from ADP and P_i.

Pyruvate is transported into the mitochondria and converted to acetyl-CoA for oxidation via the citric acid cycle, involving pyruvate dehydrogenase components, dihydrolipoyl transacetylase, and dihydrolipoyl dehydrogenase. Enzymes involved in the citric acid cycle include: citrate synthetase, aconitases, isocitrate dehydrogenase, alpha-ketoglutarate dehydrogenase complex including transsuccinylases, succinyl CoA synthetase, succinate dehydrogenase, fumarases, and malate dehydrogenase. Acetyl CoA is oxidized to CO_2 with concomitant formation of NADH, FADH₂, and GTP. In oxidative phosphorylation, the transfer of electrons from NADH and FADH₂ to oxygen by dehydrogenases is coupled to the synthesis of ATP from ADP and P_i by the F_0F_1 ATPase complex in the mitochondrial inner membrane. Enzyme complexes responsible for electron transport and ATP synthesis include the F_0F_1 ATPase complex, ubiquinone(CoQ)-cytochrome c reductase, ubiquinone reductase, cytochrome b, cytochrome c_1 , FeS protein, and cytochrome c oxidase.

25 Peroxisomes

Peroxisomes, like mitochondria, are a major site of oxygen utilization. They contain one or more enzymes, such as catalase and urate oxidase, that use molecular oxygen to remove hydrogen atoms from specific organic substrates in an oxidative reaction that produces hydrogen peroxide (Alberts, supra, pp. 574-577). Catalase oxidizes a variety of substrates including phenols, formic acid, formaldehyde, and alcohol and is important in peroxisomes of liver and kidney cells for detoxifying various toxic molecules that enter the bloodstream. Another major function of oxidative reactions in peroxisomes is the breakdown of fatty acids in a process called β oxidation. β oxidation results in shortening of the alkyl chain of fatty acids by blocks of two carbon atoms that are converted to acetyl CoA and exported to the cytosol for reuse in biosynthetic reactions.

Also like mitochondria, peroxisomes import their proteins from the cytosol using a specific signal sequence located near the C-terminus of the protein. The importance of this import process is evident in the inherited human disease Zellweger syndrome, in which a defect in importing proteins into perixosomes leads to a perixosomal deficiency resulting in severe abnormalities in the brain, liver, and kidneys, and death soon after birth. One form of this disease has been shown to be due to a mutation in the gene encoding a perixosomal integral membrane protein called peroxisome assembly factor-1.

The discovery of new human molecules satisfies a need in the art by providing new compositions which are useful in the diagnosis, study, prevention, and treatment of diseases associated with, as well as effects of exogenous compounds on, the expression of human molecules.

SUMMARY OF THE INVENTION

The present invention relates to nucleic acid sequences comprising human diagnostic and therapeutic polynucleotides (dithp) as presented in the Sequence Listing. The dithp uniquely identify genes encoding human structural, functional, and regulatory molecules.

The invention provides an isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-211; b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-211; c) a polynucleotide sequence complementary to a); d) a polynucleotide sequence complementary to b); and e) an RNA equivalent of a) through d). In one alternative, the polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-211. In another alternative, the polynucleotide comprises at least 60 contiguous nucleotides of a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-211; b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-211; c) a polynucleotide sequence complementary to a); d) a polynucleotide sequence complementary to b); and e) an RNA equivalent of a) through d). The invention further provides a composition for the detection of expression of human diagnostic and therapeutic polynucleotides comprising at least one isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-211; b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-211; c) a polynucleotide sequence complementary to a); d) a polynucleotide sequence complementary to b); and e) an RNA equivalent of a) through d);

10

,15

10

15

20

25

30



and a detectable label.

The invention also provides a method for detecting a target polynucleotide in a sample, said target polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-211; b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-211; c) a polynucleotide sequence complementary to a); d) a polynucleotide sequence complementary to b); and e) an RNA equivalent of a) through d). The method comprises a) amplifying said target polynucleotide or a fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

The invention also provides a method for detecting a target polynucleotide in a sample, said target polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-211; b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-211; c) a polynucleotide sequence complementary to a); d) a polynucleotide sequence complementary to b); and e) an RNA equivalent of a) through d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide, and b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.

The invention further provides a recombinant polynucleotide comprising a promoter sequence operably linked to an isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-211; b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-211; c) a polynucleotide sequence complementary to a); d) a polynucleotide sequence complementary to b); and e) an RNA equivalent of a) through d). In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide. In a further alternative, the invention provides a method for producing a human diagnostic and therapeutic polypeptide, the method comprising a) culturing a cell under conditions suitable for expression of the human diagnostic and therapeutic polypeptide,

10

20

25



wherein said cell is transformed with the recombinant polynucleotide, and b) recovering the human diagnostic and therapeutic polypeptide so expressed.

The invention also provides a purified human diagnostic and therapeutic polypeptide (DITHP) encoded by at least one polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEO ID NO:1-211. Additionally, the invention provides an isolated antibody which specifically binds to the human diagnostic and therapeutic polypeptide. The invention further provides a method of identifying a test compound which specifically binds to the human diagnostic and therapeutic polypeptide, the method comprising the steps of a) providing a test compound; b) combining the human diagnostic and therapeutic polypeptide with the test compound for a sufficient time and under suitable conditions for binding; and c) detecting binding of the human diagnostic and therapeutic polypeptide to the test compound, thereby identifying the test compound which specifically binds the human diagnostic and therapeutic polypeptide.

The invention further provides a microarray wherein at least one element of the microarray is an isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-211; b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEO ID NO:1-211; c) a polynucleotide sequence complementary to a); d) a polynucleotide sequence complementary to b); and e) an RNA equivalent of a) through d). The invention also provides a method for generating a transcript image of a sample which contains polynucleotides. The method comprises a) labeling the polynucleotides of the sample, b) contacting the elements of the microarray with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and c) quantifying the expression of the polynucleotides in the sample.

Additionally, the invention provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-211; b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-211; c) a polynucleotide sequence complementary to a); d) a polynucleotide sequence complementary to b); and e) an RNA equivalent of a) through d). The method comprises a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

The invention further provides a method for assessing toxicity of a test compound, said method

CONTRACTOR STATE

10

15

20

25

30

comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of i) a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-211; ii) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-211; iii) a polynucleotide sequence complementary to i), iv) a polynucleotide sequence complementary to ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence selected from the group consisting of i) a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-211; ii) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-211; iii) a polynucleotide sequence complementary to i), iv) a polynucleotide sequence complementary to ii), and v) an RNA equivalent of i)-iv), and alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i-v above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

The invention further provides an isolated polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:212-422, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:212-422, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:212-422, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:212-422. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:212-422.

DESCRIPTION OF THE TABLES

Table 1 shows the sequence identification numbers (SEQ ID NO:s) and template identification numbers (template IDs) corresponding to the polynucleotides of the present invention, along with their GenBank hits (GI Numbers), probability scores, and functional annotations corresponding to the GenBank hits.

Table 2 shows the sequence identification numbers (SEQ ID NO:s) and template identification

numbers (template IDs) corresponding to the polynucleotides of the present invention, along with polynucleotide segments of each template sequence as defined by the indicated "start" and "stop" nucleotide positions. The reading frames of the polynucleotide segments and the Pfam hits, Pfam descriptions, and E-values corresponding to the polypeptide domains encoded by the polynucleotide segments are indicated.

Table 3 shows the sequence identification numbers (SEQ ID NO:s) and template identification numbers (template IDs) corresponding to the polynucleotides of the present invention, along with polynucleotide segments of each template sequence as defined by the indicated "start" and "stop" nucleotide positions. The reading frames of the polynucleotide segments are shown, and the polypeptides encoded by the polynucleotide segments constitute either signal peptide (SP) or transmembrane (TM) domains, as indicated. The membrane topology of the encoded polypeptide sequence is indicated, the N-terminus (N) listed as being oriented to either the cytosolic (in) or non-cytosolic (out) side of the cell membrane or organelle.

Table 4 shows the sequence identification numbers (SEQ ID NO:s) corresponding to the polynucleotides of the present invention, along with component sequence identification numbers (component IDs) corresponding to each template. The component sequences, which were used to assemble the template sequences, are defined by the indicated "start" and "stop" nucleotide positions along each template.

Table 5 shows the tissue distribution profiles for the templates of the invention.

Table 6 shows the sequence identification numbers (SEQ ID NO:s) corresponding to the polypeptides of the present invention, along with the reading frames used to obtain the polypeptide segments, the lengths of the polypeptide segments, the "start" and "stop" nucleotide positions of the polynucleotide sequences used to define the encoded polypeptide segments, the GenBank hits (GI Numbers), probability scores, and functional annotations corresponding to the GenBank hits.

Table 7 summarizes the bioinformatics tools which are useful for analysis of the polynucleotides of the present invention. The first column of Table 7 lists analytical tools, programs, and algorithms, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between two sequences).

DETAILED DESCRIPTION OF THE INVENTION

Before the nucleic acid sequences and methods are presented, it is to be understood that this

15

20

invention is not limited to the particular machines, methods, and materials described. Although particular embodiments are described, machines, methods, and materials similar or equivalent to these embodiments may be used to practice the invention. The preferred machines, methods, and materials set forth are not intended to limit the scope of the invention which is limited only by the appended claims.

The singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. All technical and scientific terms have the meanings commonly understood by one of ordinary skill in the art. All publications are incorporated by reference for the purpose of describing and disclosing the cell lines, vectors, and methodologies which are presented and which might be used in connection with the invention. Nothing in the specification is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

Definitions

10

15

20

25

30

As used herein, the lower case "dithp" refers to a nucleic acid sequence, while the upper case "DITHP" refers to an amino acid sequence encoded by dithp. A "full-length" dithp refers to a nucleic acid sequence containing the entire coding region of a gene endogenously expressed in human tissue.

"Adjuvants" are materials such as Freund's adjuvant, mineral gels (aluminum hydroxide), and surface active substances (lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol) which may be administered to increase a host's immunological response.

"Allele" refers to an alternative form of a nucleic acid sequence. Alleles result from a "mutation," a change or an alternative reading of the genetic code. Any given gene may have none, one, or many allelic forms. Mutations which give rise to alleles include deletions, additions, or substitutions of nucleotides. Each of these changes may occur alone, or in combination with the others, one or more times in a given nucleic acid sequence. The present invention encompasses allelic dithp.

"Amino acid sequence" refers to a peptide, a polypeptide, or a protein of either natural or synthetic origin. The amino acid sequence is not limited to the complete, endogenous amino acid sequence and may be a fragment, epitope, variant, or derivative of a protein expressed by a nucleic acid sequence.

"Amplification" refers to the production of additional copies of a sequence and is carried out using polymerase chain reaction (PCR) technologies well known in the art.

"Antibody" refers to intact molecules as well as to fragments thereof, such as Fab, F(ab')₂, and Fv fragments, which are capable of binding the epitopic determinant. Antibodies that bind DITHP polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of

Compression Posts

interest as the immunizing antigen. The polypeptide or peptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

"Antisense sequence" refers to a sequence capable of specifically hybridizing to a target sequence. The antisense sequence may include DNA, RNA, or any nucleic acid mimic or analog such as peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothicates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine.

"Antisense sequence" refers to a sequence capable of specifically hybridizing to a target sequence. The antisense sequence can be DNA, RNA, or any nucleic acid mimic or analog.

"Antisense technology" refers to any technology which relies on the specific hybridization of an antisense sequence to a target sequence.

A "bin" is a portion of computer memory space used by a computer program for storage of data, and bounded in such a manner that data stored in a bin may be retrieved by the program.

"Biologically active" refers to an amino acid sequence having a structural, regulatory, or biochemical function of a naturally occurring amino acid sequence.

"Clone joining" is a process for combining gene bins based upon the bins' containing sequence information from the same clone. The sequences may assemble into a primary gene transcript as well as one or more splice variants.

"Complementary" describes the relationship between two single-stranded nucleic acid sequences that annual by base-pairing (5'-A-G-T-3' pairs with its complement 3'-T-C-A-5').

A "component sequence" is a nucleic acid sequence selected by a computer program such as PHRED and used to assemble a consensus or template sequence from one or more component sequences.

A "consensus sequence" or "template sequence" is a nucleic acid sequence which has been assembled from overlapping sequences, using a computer program for fragment assembly such as the GELVIEW fragment assembly system (Genetics Computer Group (GCG), Madison WI) or using a relational database management system (RDMS).

"Conservative amino acid substitutions" are those substitutions that, when made, least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids

15

20

which may be substituted for an original amino acid in a protein and which are regarded as conservative substitutions.

	Original Residue	Conservative Substitution
5	Ala	Gly, Ser
	Arg	His, Lys
	Asn	Asp, Gln, His
	Asp	Asn, Glu
	Cys	Ala, Ser
10	Gln	Asn, Glu, His
	Glu	Asp, Gln, His
	Gly	Ala
1	His	Asn, Arg, Gln, Glu
	lie	Leu, Val
15	Leu	Ile, Val
1	Lys	Arg, Gln, Glu
	Met	Leu, Ile
	Phe	His, Met, Leu, Trp, Tyr
1	Ser	Cys, Thr
20	Thr	Ser, Val
	Trp	Phe, Tyr
	Tyr	His, Phe, Trp
	Val	Ile, Leu, Thr

25

30

35

40

Conservative substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.

"Deletion" refers to a change in either a nucleic or amino acid sequence in which at least one nucleotide or amino acid residue, respectively, is absent.

"Derivative" refers to the chemical modification of a nucleic acid sequence, such as by replacement of hydrogen by an alkyl, acyl, amino, hydroxyl, or other group.

The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

"E-value" refers to the statistical probability that a match between two sequences occurred by chance.

A "fragment" is a unique portion of dithp or DITHP which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 10 to 1000 contiguous amino acid residues or nucleotides. A fragment used as a probe, primer,

antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous amino acid residues or nucleotides in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing and the figures, may be encompassed by the present embodiments.

A fragment of dithp comprises a region of unique polynucleotide sequence that specifically identifies dithp, for example, as distinct from any other sequence in the same genome. A fragment of dithp is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish dithp from related polynucleotide sequences. The precise length of a fragment of dithp and the region of dithp to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of DITHP is encoded by a fragment of dithp. A fragment of DITHP comprises a region of unique amino acid sequence that specifically identifies DITHP. For example, a fragment of DITHP is useful as an immunogenic peptide for the development of antibodies that specifically recognize DITHP. The precise length of a fragment of DITHP and the region of DITHP to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A "full length" nucleotide sequence is one containing at least a start site for translation to a protein sequence, followed by an open reading frame and a stop site, and encoding a "full length" polypeptide.

"Hit" refers to a sequence whose annotation will be used to describe a given template. Criteria for selecting the top hit are as follows: if the template has one or more exact nucleic acid matches, the top hit is the exact match with highest percent identity. If the template has no exact matches but has significant protein hits, the top hit is the protein hit with the lowest E-value. If the template has no significant protein hits, but does have significant non-exact nucleotide hits, the top hit is the nucleotide hit with the lowest E-value.

"Homology" refers to sequence similarity either between a reference nucleic acid sequence and at least a fragment of a dithp or between a reference amino acid sequence and a fragment of a DITHP.

"Hybridization" refers to the process by which a strand of nucleotides anneals with a complementary strand through base pairing. Specific hybridization is an indication that two nucleic acid sequences share a high degree of identity. Specific hybridization complexes form under defined annealing conditions, and remain hybridized after the "washing" step. The defined hybridization

30

15

conditions include the annealing conditions and the washing step(s), the latter of which is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid probes that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency.

Generally, stringency of hybridization is expressed with reference to the temperature under which the wash step is carried out. Generally, such wash temperatures are selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_m and conditions for nucleic acid hybridization is well known and can be found in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2^{nd} ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68° C in the presence of about $0.2 \times SSC$ and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65° C, 60° C, or 55° C may be used. SSC concentration may be varied from about 0.2 to $2 \times SSC$, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, denatured salmon sperm DNA at about $100\text{-}200 \,\mu\text{g/ml}$. Useful variations on these conditions will be readily apparent to those skilled in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their resultant proteins.

Other parameters, such as temperature, salt concentration; and detergent concentration may be varied to achieve the desired stringency. Denaturants, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as RNA:DNA hybridizations. Appropriate hybridization conditions are routinely determinable by one of ordinary skill in the art.

"Immunogenic" describes the potential for a natural, recombinant, or synthetic peptide, epitope, polypeptide, or protein to induce antibody production in appropriate animals, cells, or cell lines.

"Insertion" or "addition" refers to a change in either a nucleic or amino acid sequence in which at least one nucleotide or residue, respectively, is added to the sequence.

"Labeling" refers to the covalent or noncovalent joining of a polynucleotide, polypeptide, or antibody with a reporter molecule capable of producing a detectable or measurable signal.

10

15

20

25

"Microarray" is any arrangement of nucleic acids, amino acids, antibodies, etc., on a substrate. The substrate may be a solid support such as beads, glass, paper, nitrocellulose, nylon, or an appropriate membrane.

"Linkers" are short stretches of nucleotide sequence which may be added to a vector or a dithp to create restriction endonuclease sites to facilitate cloning. "Polylinkers" are engineered to incorporate multiple restriction enzyme sites and to provide for the use of enzymes which leave 5' or 3' overhangs (e.g., BamHI, EcoRI, and HindIII) and those which provide blunt ends (e.g., EcoRV, SnaBI, and StuI).

"Naturally occurring" refers to an endogenous polynucleotide or polypeptide that may be isolated from viruses or prokaryotic or eukaryotic cells.

"Nucleic acid sequence" refers to the specific order of nucleotides joined by phosphodiester bonds in a linear, polymeric arrangement. Depending on the number of nucleotides, the nucleic acid sequence can be considered an oligomer, oligonucleotide, or polynucleotide. The nucleic acid can be DNA, RNA, or any nucleic acid analog, such as PNA, may be of genomic or synthetic origin, may be either double-stranded or single-stranded, and can represent either the sense or antisense (complementary) strand.

"Oligomer" refers to a nucleic acid sequence of at least about 6 nucleotides and as many as about 60 nucleotides, preferably about 15 to 40 nucleotides, and most preferably between about 20 and 30 nucleotides, that may be used in hybridization or amplification technologies. Oligomers may be used as, e.g., primers for PCR, and are usually chemically synthesized.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to a DNA mimic in which nucleotide bases are attached to a pseudopeptide backbone to increase stability. PNAs, also designated antigene agents, can prevent gene expression by targeting complementary messenger RNA.

The phrases "percent identity" and "% identity", as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence

10

15

20

PCT/US01/06059 WO 01/62927

alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and Sharp, P.M. (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows:

Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequence pairs.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at http://www.ncbi.nlm.nih.gov/BLAST/. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to determine alignment between a known polynucleotide sequence and other sequences on a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 15 Sequences" can be accessed and used interactively at http://www.ncbi.nlm.nih.gov/gorf/bl2/. The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Reward for match: 1

Penalty for mismatch: -2

Open Gap: 5 and Extension Gap: 2 penalties

25 Gap x drop-off: 50

Expect: 10

Word Size: 11

Filter: on

Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over 30 the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences

10

shown herein, in figures or Sequence Listings, may be used to describe a length over which percentage identity may be measured.

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity", as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the hydrophobicity and acidity of the substituted residue, thus preserving the structure (and therefore function) of the folded polypeptide:

Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) with blastp set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Open Gap: 11 and Extension Gap: 1 penalty

Gap x drop-off: 50

Expect: 10

Word Size: 3

Filter: on

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length

10

20

supported by the sequences shown herein, in figures or Sequence Listings, may be used to describe a length over which percentage identity may be measured.

"Post-translational modification" of a DITHP may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu and the DITHP.

"Probe" refers to dithp or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. "Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the figures and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for example Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel et al., 1987, Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis et al., 1990, PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection

ومعواطبين عوادي أأماها والماري

5

10

15

20

25

program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

"Purified" refers to molecules, either polynucleotides or polypeptides that are isolated or separated from their natural environment and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other compounds with which they are naturally associated.

A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, <u>supra</u>. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be use to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

"Regulatory element" refers to a nucleic acid sequence from nontranslated regions of a gene, and includes enhancers, promoters, introns, and 3' untranslated regions, which interact with host proteins to carry out or regulate transcription or translation.

"Reporter" molecules are chemical or biochemical moieties used for labeling a nucleic acid, an amino acid, or an antibody. They include radionuclides; enzymes; fluorescent, chemiluminescent, or

15

20

25

chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

"Sample" is used in its broadest sense. Samples may contain nucleic or amino acids, antibodies, or other materials, and may be derived from any source (e.g., bodily fluids including, but not limited to, saliva, blood, and urine; chromosome(s), organelles, or membranes isolated from a cell; genomic DNA, RNA, or cDNA in solution or bound to a substrate; and cleared cells or tissues or blots or imprints from such cells or tissues).

"Specific binding" or "specifically binding" refers to the interaction between a protein or peptide and its agonist, antibody, antagonist, or other binding partner. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide containing epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

"Substitution" refers to the replacement of at least one nucleotide or amino acid by a different nucleotide or amino acid.

"Substrate" refers to any suitable rigid or semi-rigid support including, e.g., membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles or capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

A "transcript image" refers to the collective pattern of gene expression by a particular tissue or cell type under given conditions at a given time.

"Transformation" refers to a process by which exogenous DNA enters a recipient cell.

Transformation may occur under natural or artificial conditions using various methods well known in the art. Transformation may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method is selected based on the host cell being transformed.

"Transformants" include stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as cells which transiently express inserted DNA or RNA.

10

15

20

25

A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or <u>in vitro</u> fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, and plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), <u>supra</u>.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 25% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 30%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or even at least 98% or greater sequence identity over a certain defined length. The variant may result in "conservative" amino acid changes which do not affect structural and/or chemical properties. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

In an alternative, variants of the polynucleotides of the present invention may be generated through recombinant methods. One possible method is a DNA shuffling technique such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat.

25

Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of DITHP, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% or greater sequence identity over a certain defined length of one of the polypeptides.

20 THE INVENTION

5

10

15

25

30

In a particular embodiment, cDNA sequences derived from human tissues and cell lines were aligned based on nucleotide sequence identity and assembled into "consensus" or "template" sequences which are designated by the template identification numbers (template IDs) in column 2 of Table 1. The sequence identification numbers (SEQ ID NO:s) corresponding to the template IDs are shown in column 1. The template sequences have similarity to GenBank sequences, or "hits," as designated by the GI Numbers in column 3. The statistical probability of each GenBank hit is indicated by a probability score in column 4, and the functional annotation corresponding to each GenBank hit is listed in column 5.

The invention incorporates the nucleic acid sequences of these templates as disclosed in the Sequence Listing and the use of these sequences in the diagnosis and treatment of disease states characterized by defects in human molecules. The invention further utilizes these sequences in hybridization and amplification technologies, and in particular, in technologies which assess gene expression patterns correlated with specific cells or tissues and their responses in vivo or in vitro to

pharmaceutical agents, toxins, and other treatments. In this manner, the sequences of the present invention are used to develop a transcript image for a particular cell or tissue.

<u>Derivation of Nucleic Acid Sequences</u>

cDNA was isolated from libraries constructed using RNA derived from normal and diseased human tissues and cell lines. The human tissues and cell lines used for cDNA library construction were selected from a broad range of sources to provide a diverse population of cDNAs representative of gene transcription throughout the human body. Descriptions of the human tissues and cell lines used for cDNA library construction are provided in the LIFESEQ database (Incyte Genomics, Inc. (Incyte), Palo Alto CA). Human tissues were broadly selected from, for example, cardiovascular, dermatologic, endocrine, gastrointestinal, hematopoietic/immune system, musculoskeletal, neural, reproductive, and urologic sources.

Cell lines used for cDNA library construction were derived from, for example, leukemic cells, teratocarcinomas, neuroepitheliomas, cervical carcinoma, lung fibroblasts, and endothelial cells. Such cell lines include, for example, THP-1, Jurkat, HUVEC, hNT2, WI38, HeLa, and other cell lines commonly used and available from public depositories (American Type Culture Collection, Manassas VA). Prior to mRNA isolation, cell lines were untreated, treated with a pharmaceutical agent such as 5'-aza-2'-deoxycytidine, treated with an activating agent such as lipopolysaccharide in the case of leukocytic cell lines, or, in the case of endothelial cell lines, subjected to shear stress.

20

5

10

:15

Sequencing of the cDNAs

Methods for DNA sequencing are well known in the art. Conventional enzymatic methods employ the Klenow fragment of DNA polymerase I, SEQUENASE DNA polymerase (U.S. Biochemical Corporation, Cleveland OH), Taq polymerase (Applied Biosystems, Foster City CA), thermostable T7 polymerase (Amersham Pharmacia Biotech, Inc. (Amersham Pharmacia Biotech), Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies Inc. (Life Technologies), Gaithersburg MD), to extend the nucleic acid sequence from an oligonucleotide primer annealed to the DNA template of interest. Methods have been developed for the use of both single-stranded and double-stranded templates. Chain termination reaction products may be electrophoresed on urea-polyacrylamide gels and detected either by autoradiography (for radioisotope-labeled nucleotides) or by fluorescence (for fluorophore-labeled nucleotides). Automated methods for mechanized reaction preparation, sequencing, and analysis using fluorescence detection methods have been developed. Machines used to prepare cDNAs for sequencing can include the MICROLAB 2200 liquid transfer system (Hamilton Company

(Hamilton), Reno NV), Peltier thermal cycler (PTC200; MJ Research, Inc. (MJ Research), Watertown MA), and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing can be carried out using, for example, the ABI 373 or 377 (Applied Biosystems) or MEGABACE 1000 (Molecular Dynamics, Inc. (Molecular Dynamics), Sunnyvale CA) DNA sequencing systems, or other automated and manual sequencing systems well known in the art.

The nucleotide sequences of the Sequence Listing have been prepared by current, state-of-the-art, automated methods and, as such, may contain occasional sequencing errors or unidentified nucleotides. Such unidentified nucleotides are designated by an N. These infrequent unidentified bases do not represent a hindrance to practicing the invention for those skilled in the art. Several methods employing standard recombinant techniques may be used to correct errors and complete the missing sequence information. (See, e.g., those described in Ausubel, F.M. et al. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY; and Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY.)

15 Assembly of cDNA Sequences

5

10

20

25

30

Human polynucleotide sequences may be assembled using programs or algorithms well known in the art. Sequences to be assembled are related, wholly or in part, and may be derived from a single or many different transcripts. Assembly of the sequences can be performed using such programs as PHRAP (Phils Revised Assembly Program) and the GELVIEW fragment assembly system (GCG), or other methods known in the art.

Alternatively, cDNA sequences are used as "component" sequences that are assembled into "template" or "consensus" sequences as follows. Sequence chromatograms are processed, verified, and quality scores are obtained using PHRED. Raw sequences are edited using an editing pathway known as Block 1 (See, e.g., the LIFESEQ Assembled User Guide, Incyte Genomics, Palo Alto, CA). A series of BLAST comparisons is performed and low-information segments and repetitive elements (e.g., dinucleotide repeats, Alu repeats, etc.) are replaced by "n's", or masked, to prevent spurious matches. Mitochondrial and ribosomal RNA sequences are also removed. The processed sequences are then loaded into a relational database management system (RDMS) which assigns edited sequences to existing templates, if available. When additional sequences are added into the RDMS, a process is initiated which modifies existing templates or creates new templates from works in progress (i.e., nonfinal assembled sequences) containing queued sequences or the sequences themselves. After the new sequences have been assigned to templates, the templates can be merged into bins. If multiple templates exist in one bin, the bin can be split and the templates reannotated.

THE REPORT OF STREET

Once gene bins have been generated based upon sequence alignments, bins are "clone joined" based upon clone information. Clone joining occurs when the 5' sequence of one clone is present in one bin and the 3' sequence from the same clone is present in a different bin, indicating that the two bins should be merged into a single bin. Only bins which share at least two different clones are merged.

A resultant template sequence may contain either a partial or a full length open reading frame, or all or part of a genetic regulatory element. This variation is due in part to the fact that the full length cDNAs of many genes are several hundred, and sometimes several thousand, bases in length. With current technology, cDNAs comprising the coding regions of large genes cannot be cloned because of vector limitations, incomplete reverse transcription of the mRNA, or incomplete "second strand" synthesis. Template sequences may be extended to include additional contiguous sequences derived from the parent RNA transcript using a variety of methods known to those of skill in the art. Extension may thus be used to achieve the full length coding sequence of a gene.

Analysis of the cDNA Sequences

5

10

15

20

25

30

The cDNA sequences are analyzed using a variety of programs and algorithms which are well known in the art. (See, e.g., Ausubel, 1997, supra, Chapter 7.7; Meyers, R.A. (Ed.) (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853; and Table 7.) These analyses comprise both reading frame determinations, e.g., based on triplet codon periodicity for particular organisms (Fickett, J.W. (1982) Nucleic Acids Res. 10:5303-5318); analyses of potential start and stop codons; and homology searches.

Computer programs known to those of skill in the art for performing computer-assisted searches for amino acid and nucleic acid sequence similarity, include, for example, Basic Local Alignment Search Tool (BLAST; Altschul, S.F. (1993) J. Mol. Evol. 36:290-300; Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410). BLAST is especially useful in determining exact matches and comparing two sequence fragments of arbitrary but equal lengths, whose alignment is locally maximal and for which the alignment score meets or exceeds a threshold or cutoff score set by the user (Karlin, S. et al. (1988) Proc. Natl. Acad. Sci. USA 85:841-845). Using an appropriate search tool (e.g., BLAST or HMM), GenBank, SwissProt, BLOCKS, PFAM and other databases may be searched for sequences containing regions of homology to a query dithp or DITHP of the present invention.

Other approaches to the identification, assembly, storage, and display of nucleotide and polypeptide sequences are provided in "Relational Database for Storing Biomolecule Information," U.S.S.N. 08/947,845, filed October 9, 1997; "Project-Based Full-Length Biomolecular Sequence Database," U.S.S.N. 08/811,758, filed March 6, 1997; and "Relational Database and System for

Storing Information Relating to Biomolecular Sequences," U.S.S.N. 09/034,807, filed March 4, 1998, all of which are incorporated by reference herein in their entirety.

Protein hierarchies can be assigned to the putative encoded polypeptide based on, e.g., motif, BLAST, or biological analysis. Methods for assigning these hierarchies are described, for example, in "Database System Employing Protein Function Hierarchies for Viewing Biomolecular Sequence Data," U.S.S.N. 08/812,290, filed March 6, 1997, incorporated herein by reference.

Identification of Human Diagnostic and Therapeutic Molecules Encoded by dithp

The identities of the DITHP encoded by the dithp of the present invention were obtained by analysis of the assembled cDNA sequences.

SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, SEQ ID NO:218, SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, and SEQ ID NO:223, encoded by SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12, respectively, are, for example, human enzyme molecules.

SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227, and SEQ ID NO:228, encoded by SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17, respectively, are, for example, receptor molecules.

SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:240, and SEQ ID NO:241, encoded by SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, and SEQ ID NO:30, respectively, are, for example, intracellular signaling molecules.

SEQ ID NO:242, SEQ ID NO:243, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO:246, SEQ ID NO:247, SEQ ID NO:248, SEQ ID NO:249, SEQ ID NO:250, SEQ ID NO:251, SEQ ID NO:252, SEQ ID NO:253, SEQ ID NO:254, SEQ ID NO:255, SEQ ID NO:256, SEQ ID NO:257, SEQ ID NO:258, SEQ ID NO:259, SEQ ID NO:260, SEQ ID NO:261, SEQ ID NO:262, SEQ ID NO:263, SEQ ID NO:264, SEQ ID NO:265, SEQ ID NO:266, SEQ ID NO:267, SEQ ID NO:268, SEQ ID NO:269, SEQ ID NO:270, SEQ ID NO:271, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:275, SEQ ID NO:276, SEQ ID NO:277, SEQ ID NO:278, SEQ ID NO:279, SEQ ID NO:280, SEQ ID NO:281, SEQ ID NO:282, SEQ ID NO:283, SEQ ID NO:284, SEQ ID NO:285, SEQ ID NO:286, SEQ ID NO:290, SEQ ID NO:291, SEQ ID NO:292, SEQ ID NO:293, SEQ ID NO:295, SEQ ID

e extensive that is simple

10

15

20

25

NO:296, SEQ ID NO:297, SEQ ID NO:298, SEQ ID NO:299, SEQ ID NO:300, SEQ ID NO:301, SEQ ID NO:302, SEQ ID NO:303, SEQ ID NO:304, SEQ ID NO:305, SEQ ID NO:306, SEQ ID NO:307, SEQ ID NO:308, and SEQ ID NO:309, encoded by SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, and SEQ ID NO:98, respectively, are, for example, transcription factor molecules.

SEQ ID NO:310, SEQ ID NO:311, SEQ ID NO:312, SEQ ID NO:313, SEQ ID NO:314, SEQ ID NO:315, SEQ ID NO:316, and SEQ ID NO:317, encoded by SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, and SEQ ID NO:106, respectively, are, for example, membrane transport molecules.

SEQ ID NO:318, SEQ ID NO:319, SEQ ID NO:320, SEQ ID NO:321, SEQ ID NO:322, SEQ ID NO:323, SEQ ID NO:324, SEQ ID NO:325, SEQ ID NO:326, and SEQ ID NO:327, encoded by SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, and SEQ ID NO:116, respectively, are, for example, protein modification and maintenance molecules.

SEQ ID NO:328, SEQ ID NO:329, SEQ ID NO:330, SEQ ID NO:331, SEQ ID NO:332, SEQ ID NO:333, SEQ ID NO:334, SEQ ID NO:335, SEQ ID NO:336, SEQ ID NO:337, SEQ ID NO:338, SEQ ID NO:339, SEQ ID NO:340, and SEQ ID NO:341, encoded by SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, and SEQ ID NO:130, respectively, are, for example, nucleic acid synthesis and modification molecules.

SEQ ID NO:342, encoded by SEQ ID NO:131 is, for example, an adhesion molecule.

SEQ ID NO:343, SEQ ID NO:344, SEQ ID NO:345, SEQ ID NO:346, SEQ ID NO:347,

SEQ ID NO:348, and SEQ ID NO:349, encoded by SEQ ID NO:132, SEQ ID NO:133, SEQ ID

10

15

20

NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, and SEQ ID NO:138, respectively, are, for example, antigen recognition molecules.

SEQ ID NO:350, SEQ ID NO:351, SEQ ID NO:352, and SEQ ID NO:353, encoded by SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, and SEQ ID NO:142, respectively, are, for example, electron transfer associated molecules.

SEQ ID NO:354, SEQ ID NO:355, SEQ ID NO:356, SEQ ID NO:357, SEQ ID NO:358, and SEQ ID NO:359, encoded by SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, and SEQ ID NO:148, respectively, are, for example, secreted/extracellular matrix molecules.

SEQ ID NO:360, SEQ ID NO:361, SEQ ID NO:362, SEQ ID NO:363, SEQ ID NO:364, SEQ ID NO:365, SEQ ID NO:366, SEQ ID NO:367, SEQ ID NO:368, and SEQ ID NO:369, encoded by SEQ ID NO:149, SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153, SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, and SEQ ID NO:158, respectively, are, for example, cytoskeletal molecules.

SEQ ID NO:370, SEQ ID NO:371, SEQ ID NO:372, and SEQ ID NO:373, encoded by SEQ ID NO:159, SEQ ID NO:160, SEQ ID NO:161, and SEQ ID NO:162, respectively, are, for example, cell membrane molecules.

SEQ ID NO:374, SEQ ID NO:375, SEQ ID NO:376, SEQ ID NO:377, SEQ ID NO:378, SEQ ID NO:379, SEQ ID NO:380, SEQ ID NO:381, SEQ ID NO:382, SEQ ID NO:383, SEQ ID NO:384, SEQ ID NO:385, SEQ ID NO:386, SEQ ID NO:387, SEQ ID NO:388, SEQ ID NO:389, SEQ ID NO:390, SEQ ID NO:391, and SEQ ID NO:392, encoded by SEQ ID NO:163, SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, and SEQ ID NO:181, respectively, are, for example, ribosomal molecules.

SEQ ID NO:393, SEQ ID NO:394, SEQ ID NO:395, SEQ ID NO:396, SEQ ID NO:397, SEQ ID NO:398, SEQ ID NO:399, SEQ ID NO:400, SEQ ID NO:401, SEQ ID NO:402, and SEQ ID NO:403, encoded by SEQ ID NO:182, SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, and SEQ ID NO:192, respectively, are, for example, organelle associated molecules.

SEQ ID NO:404, SEQ ID NO:405, SEQ ID NO:406, SEQ ID NO:407, SEQ ID NO:408, SEQ ID NO:409, SEQ ID NO:410, SEQ ID NO:411, SEQ ID NO:412, SEQ ID NO:413, and SEQ ID NO:414, encoded by SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID

5

10

15

20

25

NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, and SEQ ID NO:203, respectively, are, for example, biochemical pathway molecules.

SEQ ID NO:415, SEQ ID NO:416, SEQ ID NO:417, SEQ ID NO:418, SEQ ID NO:419, SEQ ID NO:420, SEQ ID NO:421, and SEQ ID NO:422, encoded by SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, and SEQ ID NO:211, respectively, are, for example, molecules associated with growth and development.

Sequences of Human Diagnostic and Therapeutic Molecules

The dithp of the present invention may be used for a variety of diagnostic and therapeutic purposes. For example, a dithp may be used to diagnose a particular condition, disease, or disorder associated with human molecules. Such conditions, diseases, and disorders include, but are not limited to, a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, a cancer of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an autoimmune/inflammatory disorder, such as inflammation, actinic keratosis, acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, arteriosclerosis, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, bursitis, cholecystitis, cirrhosis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, paroxysmal nocturnal hemoglobinuria, hepatitis, hypereosinophilia, irritable bowel syndrome, episodic lymphopenia with lymphocytotoxins, mixed connective tissue disease (MCTD), multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, myelofibrosis, osteoarthritis, osteoporosis, pancreatitis, polycythemia vera, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, primary thrombocythemia, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, trauma, and hematopoietic cancer including lymphoma, leukemia, and myeloma; an infection caused by a viral agent classified

10

as adenovirus, arenavirus, bunyavirus, calicivirus, coronavirus, filovirus, hepadnavirus, herpesvirus, flavivirus, orthomyxovirus, parvovirus, papovavirus, paramyxovirus, picornavirus, poxvirus, reovirus, retrovirus, rhabdovirus, or togavirus; an infection caused by a bacterial agent classified as pneumococcus, staphylococcus, streptococcus, bacillus, corynebacterium, clostridium, meningococcus, gonococcus, listeria, moraxella, kingella, haemophilus, legionella, bordetella, gramnegative enterobacterium including shigella, salmonella, or campylobacter, pseudomonas, vibrio, brucella, francisella, yersinia, bartonella, norcardium, actinomyces, mycobacterium, spirochaetale, rickettsia, chlamydia, or mycoplasma; an infection caused by a fungal agent classified as aspergillus, blastomyces, dermatophytes, cryptococcus, coccidioides, malasezzia, histoplasma, or other mycosiscausing fungal agent; and an infection caused by a parasite classified as plasmodium or malariacausing, parasitic entamoeba, leishmania, trypanosoma, toxoplasma, pneumocystis carinii, intestinal protozoa such as giardia, trichomonas, tissue nematode such as trichinella, intestinal nematode such as ascaris, lymphatic filarial nematode, trematode such as schistosoma, and cestrode such as tapeworm; a developmental disorder such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism. Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Syndenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; an endocrine disorder such as a disorder of the hypothalamus and/or pituitary resulting from lesions such as a primary brain tumor, adenoma, infarction associated with pregnancy, hypophysectomy, aneurysm, vascular malformation, thrombosis, infection, immunological disorder, and complication due to head trauma; a disorder associated with hypopituitarism including hypogonadism, Sheehan syndrome, diabetes insipidus, Kallman's disease, Hand-Schuller-Christian disease, Letterer-Siwe disease, sarcoidosis, empty sella syndrome, and dwarfism; a disorder associated with hyperpituitarism including acromegaly, giantism, and syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIADH) often caused by benign adenoma; a disorder associated with hypothyroidism including goiter, myxedema, acute thyroiditis associated with bacterial infection, subacute thyroiditis associated with viral infection, autoimmune thyroiditis (Hashimoto's disease), and cretinism; a disorder associated with hyperthyroidism including thyrotoxicosis and its various forms, Grave's disease, pretibial myxedema, toxic multinodular goiter, thyroid carcinoma, and Plummer's disease; a disorder associated with hyperparathyroidism including Conn disease (chronic hypercalemia); a pancreatic disorder such as Type I or Type II diabetes mellitus and associated complications; a disorder associated

10

20

25

with the adrenals such as hyperplasia, carcinoma, or adenoma of the adrenal cortex, hypertension associated with alkalosis, amyloidosis, hypokalemia, Cushing's disease, Liddle's syndrome, and Arnold-Healy-Gordon syndrome, pheochromocytoma tumors, and Addison's disease; a disorder associated with gonadal steroid hormones such as: in women, abnormal prolactin production, infertility, endometriosis, perturbation of the menstrual cycle, polycystic ovarian disease, hyperprolactinemia, isolated gonadotropin deficiency, amenorrhea, galactorrhea, hermaphroditism, hirsutism and virilization, breast cancer, and, in post-menopausal women, osteoporosis; and, in men, Leydig cell deficiency, male climacteric phase, and germinal cell aplasia, a hypergonadal disorder associated with Leydig cell tumors, androgen resistance associated with absence of androgen receptors, syndrome of 5 α-reductase, and gynecomastia; a metabolic disorder such as Addison's disease, cerebrotendinous xanthomatosis, congenital adrenal hyperplasia, coumarin resistance, cystic fibrosis, diabetes, fatty hepatocirrhosis, fructose-1,6-diphosphatase deficiency, galactosemia, goiter, glucagonoma, glycogen storage diseases, hereditary fructose intolerance, hyperadrenalism, hypoadrenalism, hyperparathyroidism, hypoparathyroidism, hypercholesterolemia, hyperthyroidism, hypoglycemia, hypothyroidism, hyperlipidemia, hyperlipemia, lipid myopathies, lipodystrophies, lysosomal storage diseases, mannosidosis, neuraminidase deficiency, obesity, pentosuria phenylketonuria, pseudovitamin D-deficiency rickets; disorders of carbohydrate metabolism such as congenital type II dyserythropoietic anemia, diabetes, insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus, fructose-1,6-diphosphatase deficiency, galactosemia, glucagonoma, hereditary fructose intolerance, hypoglycemia, mannosidosis, neuraminidase deficiency, obesity, galactose epimerase deficiency, glycogen storage diseases, lysosomal storage diseases, fructosuria, pentosuria, and inherited abnormalities of pyruvate metabolism; disorders of lipid metabolism such as fatty liver, cholestasis, primary biliary cirrhosis, carnitine deficiency, carnitine palmitoyltransferase deficiency, myoadenylate deaminase deficiency, hypertriglyceridemia, lipid storage disorders such Fabry's disease, Gaucher's disease, Niemann-Pick's disease, metachromatic leukodystrophy, adrenoleukodystrophy, GM, gangliosidosis, and ceroid lipofuscinosis, abetalipoproteinemia, Tangier disease, hyperlipoproteinemia, diabetes mellitus, lipodystrophy, lipomatoses, acute panniculitis, disseminated fat necrosis, adiposis dolorosa, lipoid adrenal hyperplasia, minimal change disease, lipomas, atherosclerosis, hypercholesterolemia, hypercholesterolemia with hypertriglyceridemia, primary hypoalphalipoproteinemia, hypothyroidism, renal disease, liver disease, lecithin:cholesterol acyltransferase deficiency, cerebrotendinous xanthomatosis, sitosterolemia, hypocholesterolemia, Tay-Sachs disease, Sandhoff's disease, hyperlipidemia, hyperlipemia, lipid myopathies, and obesity; and disorders of copper metabolism such as Menke's disease, Wilson's disease, and Ehlers-Danlos syndrome type IX; a neurological

disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorder of the central nervous system, cerebral palsy, a neuroskeletal disorder, an autonomic nervous system disorder, a cranial nerve disorder, a spinal cord disease, muscular dystrophy and other neuromuscular disorder, a peripheral nervous system disorder, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathy, myasthenia gravis, periodic paralysis, a mental disorder including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, and Tourette's disorder; a gastrointestinal disorder including ulcerative colitis, gastric and duodenal ulcers, cystinuria, dibasicaminoaciduria, hypercystinuria, lysinuria, hartnup disease, tryptophan malabsorption, methionine malabsorption, histidinuria, iminoglycinuria, dicarboxylicaminoaciduria, cystinosis, renal glycosuria, hypouricemia, familial hypophophatemic rickets, congenital chloridorrhea, distal renaltubular acidosis, Menkes' disease, Wilson's disease, lethal diarrhea, juvenile pernicious anemia, folate malabsorption, adrenoleukodystrophy, hereditary myoglobinuria, and Zellweger syndrome; a transport disorder such as akinesia, amyotrophic lateral sclerosis, ataxia telangiectasia, cystic fibrosis, Becker's muscular dystrophy, Bell's palsy, Charcot-Marie Tooth disease, diabetes mellitus, diabetes insipidus, diabetic neuropathy, Duchenne muscular dystrophy, hyperkalemic periodic paralysis, normokalemic periodic paralysis, Parkinson's disease, malignant hyperthermia, multidrug resistance, myasthenia gravis, myotonic dystrophy, catatonia, tardive dyskinesia, dystonias, peripheral neuropathy, cerebral neoplasms, prostate cancer, cardiac disorders associated with transport, e.g., angina, bradyarrythmia, tachyarrythmia, hypertension, Long QT syndrome, myocarditis, cardiomyopathy, nemaline myopathy, centronuclear myopathy, lipid myopathy, mitochondrial myopathy, thyrotoxic myopathy, ethanol myopathy, dermatomyositis, inclusion body myositis, infectious myositis, and polymyositis, neurological disorders associated with transport, e.g., Alzheimer's disease, amnesia, bipolar disorder, dementia, depression, epilepsy, Tourette's disorder, paranoid psychoses, and schizophrenia, and other disorders associated with transport, e.g.,

Let 1970 E 44 A CHESPING

5

10

15

20

25

neurofibromatosis, postherpetic neuralgia, trigeminal neuropathy, sarcoidosis, sickle cell anemia, cataracts, infertility, pulmonary artery stenosis, sensorineural autosomal deafness, hyperglycemia, hypoglycemia, Grave's disease, goiter, glucose-galactose malabsorption syndrome, hypercholesterolemia, Cushing's disease, and Addison's disease; and a connective tissue disorder such as osteogenesis imperfecta, Ehlers-Danlos syndrome, chondrodysplasias, Marfan syndrome, Alport syndrome, familial aortic aneurysm, achondroplasia, mucopolysaccharidoses, osteoporosis, osteopetrosis, Paget's disease, rickets, osteomalacia, hyperparathyroidism, renal osteodystrophy, osteonecrosis, osteomyelitis, osteoma, osteoid osteoma, osteoblastoma, osteosarcoma, osteochondroma, chondroma, chondroblastoma, chondromyxoid fibroma, chondrosarcoma, fibrous cortical defect, nonossifying fibroma, fibrous dysplasia, fibrosarcoma, malignant fibrous histiocytoma, Ewing's sarcoma, primitive neuroectodermal tumor, giant cell tumor, osteoarthritis, rheumatoid arthritis, ankylosing spondyloarthritis, Reiter's syndrome, psoriatic arthritis, enteropathic arthritis, infectious arthritis, gout, gouty arthritis, calcium pyrophosphate crystal deposition disease, ganglion, synovial cyst, villonodular synovitis, systemic sclerosis, Dupuytren's contracture, hepatic fibrosis, lupus erythematosus, mixed connective tissue disease, epidermolysis bullosa simplex, bullous congenital ichthyosiform erythroderma (epidermolytic hyperkeratosis), non-epidermolytic and epidermolytic palmoplantar keratoderma, ichthyosis bullosa of Siemens, pachyonychia congenita, and white sponge nevus. The dithp can be used to detect the presence of, or to quantify the amount of, a dithp-related polynucleotide in a sample. This information is then compared to information obtained from appropriate reference samples, and a diagnosis is established. Alternatively, a polynucleotide complementary to a given dithp can inhibit or inactivate a therapeutically relevant gene related to the dithp.

Analysis of dithp Expression Patterns

The expression of dithp may be routinely assessed by hybridization-based methods to determine, for example, the tissue-specificity, disease-specificity, or developmental stage-specificity of dithp expression. For example, the level of expression of dithp may be compared among different cell types or tissues, among diseased and normal cell types or tissues, among cell types or tissues at different developmental stages, or among cell types or tissues undergoing various treatments. This type of analysis is useful, for example, to assess the relative levels of dithp expression in fully or partially differentiated cells or tissues, to determine if changes in dithp expression levels are correlated with the development or progression of specific disease states, and to assess the response of a cell or tissue to a specific therapy, for example, in pharmacological or toxicological studies. Methods for the analysis of dithp expression are based on hybridization and amplification technologies and include membrane-

10

115

based procedures such as northern blot analysis, high-throughput procedures that utilize, for example, microarrays, and PCR-based procedures.

Hybridization and Genetic Analysis

5

10

20

25

30

The dithp, their fragments, or complementary sequences, may be used to identify the presence of and/or to determine the degree of similarity between two (or more) nucleic acid sequences. The dithp may be hybridized to naturally occurring or recombinant nucleic acid sequences under appropriately selected temperatures and salt concentrations. Hybridization with a probe based on the nucleic acid sequence of at least one of the dithp allows for the detection of nucleic acid sequences, including genomic sequences, which are identical or related to the dithp of the Sequence Listing. Probes may be selected from non-conserved or unique regions of at least one of the polynucleotides of SEQ ID NO:1-211 and tested for their ability to identify or amplify the target nucleic acid sequence using standard protocols.

Polynucleotide sequences that are capable of hybridizing, in particular, to those shown in SEQ ID NO:1-211 and fragments thereof, can be identified using various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A.R. (1987) Methods Enzymol. 152:507-511.) Hybridization conditions are discussed in "Definitions."

A probe for use in Southern or northern hybridization may be derived from a fragment of a dithp sequence, or its complement, that is up to several hundred nucleotides in length and is either single-stranded or double-stranded. Such probes may be hybridized in solution to biological materials such as plasmids, bacterial, yeast, or human artificial chromosomes, cleared or sectioned tissues, or to artificial substrates containing dithp. Microarrays are particularly suitable for identifying the presence of and detecting the level of expression for multiple genes of interest by examining gene expression correlated with, e.g., various stages of development, treatment with a drug or compound, or disease progression. An array analogous to a dot or slot blot may be used to arrange and link polynucleotides to the surface of a substrate using one or more of the following: mechanical (vacuum), chemical, thermal, or UV bonding procedures. Such an array may contain any number of dithp and may be produced by hand or by using available devices, materials, and machines.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.)

Probes may be labeled by either PCR or enzymatic techniques using a variety of-commercially

Live Same Colored States

available reporter molecules. For example, commercial kits are available for radioactive and chemiluminescent labeling (Amersham Pharmacia Biotech) and for alkaline phosphatase labeling (Life Technologies). Alternatively, dithp may be cloned into commercially available vectors for the production of RNA probes. Such probes may be transcribed in the presence of at least one labeled nucleotide (e.g., ³²P-ATP, Amersham Pharmacia Biotech).

Additionally the polynucleotides of SEQ ID NO:1-211 or suitable fragments thereof can be used to isolate full length cDNA sequences utilizing hybridization and/or amplification procedures well known in the art, e.g., cDNA library screening, PCR amplification, etc. The molecular cloning of such full length cDNA sequences may employ the method of cDNA library screening with probes using the hybridization, stringency, washing, and probing strategies described above and in Ausubel, <u>supra</u>, Chapters 3, 5, and 6. These procedures may also be employed with genomic libraries to isolate genomic sequences of dithp in order to analyze, e.g., regulatory elements.

Genetic Mapping

15

25

Gene identification and mapping are important in the investigation and treatment of almost all conditions, diseases, and disorders. Cancer, cardiovascular disease, Alzheimer's disease, arthritis, diabetes, and mental illnesses are of particular interest. Each of these conditions is more complex than the single gene defects of sickle cell anemia or cystic fibrosis, with select groups of genes being predictive of predisposition for a particular condition, disease, or disorder. For example, cardiovascular disease may result from malfunctioning receptor molecules that fail to clear cholesterol from the bloodstream, and diabetes may result when a particular individual's immune system is activated by an infection and attacks the insulin-producing cells of the pancreas. In some studies, Alzheimer's disease has been linked to a gene on chromosome 21; other studies predict a different gene and location. Mapping of disease genes is a complex and reiterative process and generally proceeds from genetic linkage analysis to physical mapping.

As a condition is noted among members of a family, a genetic linkage map traces parts of chromosomes that are inherited in the same pattern as the condition. Statistics link the inheritance of particular conditions to particular regions of chromosomes, as defined by RFLP or other markers. (See, for example, Lander, E. S. and Botstein, D. (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.) Occasionally, genetic markers and their locations are known from previous studies. More often, however, the markers are simply stretches of DNA that differ among individuals. Examples of genetic linkage maps can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site.

In another embodiment of the invention, dithp sequences may be used to generate hybridization

probes useful in chromosomal mapping of naturally occurring genomic sequences. Either coding or noncoding sequences of dithp may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a dithp coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Meyers, supra, pp. 965-968.) Correlation between the location of dithp on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder. The dithp sequences may also be used to detect polymorphisms that are genetically linked to the inheritance of a particular condition, disease, or disorder.

In situ hybridization of chromosomal preparations and genetic mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending existing genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of the corresponding human chromosome is not known. These new marker sequences can be mapped to human chromosomes and may provide valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once a disease or syndrome has been crudely correlated by genetic linkage with a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequences of the subject invention may also be used to detect differences in chromosomal architecture due to translocation, inversion, etc., among normal, carrier, or affected individuals.

Once a disease-associated gene is mapped to a chromosomal region, the gene must be cloned in order to identify mutations or other alterations (e.g., translocations or inversions) that may be correlated with disease. This process requires a physical map of the chromosomal region containing the disease-gene of interest along with associated markers. A physical map is necessary for determining the nucleotide sequence of and order of marker genes on a particular chromosomal region. Physical mapping techniques are well known in the art and require the generation of overlapping sets of cloned

في المن والأنزاري المنافع والمن والمنافر الما

5

10

15

20

25

DNA fragments from a particular organelle, chromosome, or genome. These clones are analyzed to reconstruct and catalog their order. Once the position of a marker is determined, the DNA from that region is obtained by consulting the catalog and selecting clones from that region. The gene of interest is located through positional cloning techniques using hybridization or similar methods.

Diagnostic Uses

10

15

The dithp of the present invention may be used to design probes useful in diagnostic assays. Such assays, well known to those skilled in the art, may be used to detect or confirm conditions, disorders, or diseases associated with abnormal levels of dithp expression. Labeled probes developed from dithp sequences are added to a sample under hybridizing conditions of desired stringency. In some instances, dithp, or fragments or oligonucleotides derived from dithp, may be used as primers in amplification steps prior to hybridization. The amount of hybridization complex formed is quantified and compared with standards for that cell or tissue. If dithp expression varies significantly from the standard, the assay indicates the presence of the condition, disorder, or disease. Qualitative or quantitative diagnostic methods may include northern, dot blot, or other membrane or dip-stick based technologies or multiple-sample format technologies such as PCR, enzyme-linked immunosorbent assay (ELISA)-like, pin, or chip-based assays.

The probes described above may also be used to monitor the progress of conditions, disorders, or diseases associated with abnormal levels of dithp expression, or to evaluate the efficacy of a particular therapeutic treatment. The candidate probe may be identified from the dithp that are specific to a given human tissue and have not been observed in GenBank or other genome databases. Such a probe may be used in animal studies, preclinical tests, clinical trials, or in monitoring the treatment of an individual patient. In a typical process, standard expression is established by methods well known in the art for use as a basis of comparison, samples from patients affected by the disorder or disease are combined with the probe to evaluate any deviation from the standard profile, and a therapeutic agent is administered and effects are monitored to generate a treatment profile. Efficacy is evaluated by determining whether the expression progresses toward or returns to the standard normal pattern. Treatment profiles may be generated over a period of several days or several months. Statistical methods well known to those skilled in the art may be use to determine the significance of such therapeutic agents.

The polynucleotides are also useful for identifying individuals from minute biological samples, for example, by matching the RFLP pattern of a sample's DNA to that of an individual's DNA. The polynucleotides of the present invention can also be used to determine the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR

primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, an individual can be identified through a unique set of DNA sequences. Once a unique ID database is established for an individual, positive identification of that individual can be made from extremely small tissue samples.

In a particular aspect, oligonucleotide primers derived from the dithp of the invention may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from dithp are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSCCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in highthroughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP (isSNP), are capable of identifying polymorphisms by comparing the sequences of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).

DNA-based identification techniques are critical in forensic technology. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, etc., can be amplified using, e.g., PCR, to identify individuals. (See, e.g., Erlich, H. (1992) PCR Technology, Freeman and Co., New York, NY). Similarly, polynucleotides of the present invention can be used as polymorphic markers.

There is also a need for reagents capable of identifying the source of a particular tissue. Appropriate reagents can comprise, for example, DNA probes or primers prepared from the sequences of the present invention that are specific for particular tissues. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

The polynucleotides of the present invention can also be used as molecular weight markers on nucleic acid gels or Southern blots, as diagnostic probes for the presence of a specific mRNA in a particular cell type, in the creation of subtracted cDNA libraries which aid in the discovery of novel

in the LOW-AUCCORP

5

10

15

20

25

polynucleotides, in selection and synthesis of oligomers for attachment to an array or other support, and as an antigen to elicit an immune response.

Disease Model Systems Using dithp

5

20

25

The dithp of the invention or their mammalian homologs may be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent Number 5,175,383 and U.S. Patent Number 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination.

Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

The dithp of the invention may also be manipulated <u>in vitro</u> in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al. (1998) Science 282:1145-1147).

The dithp of the invention can also be used to create "knockin" humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of dithp is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress dithp, resulting, e.g., in the secretion of DITHP in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).

Screening Assays

DITHP encoded by polynucleotides of the present invention may be used to screen for molecules that bind to or are bound by the encoded polypeptides. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the bound molecule. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a ligand or fragment thereof, a natural substrate, or a structural or functional mimetic. (See, Coligan et al., (1991) <u>Current Protocols in Immunology</u> 1(2): Chapter 5.) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or to at least a fragment of the receptor, e.g., the active site. In either case, the molecule can be rationally designed using known techniques. Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, <u>Drosophila</u>, or <u>E. coli</u>. Cells expressing the polypeptide or cell membrane fractions which contain the expressed polypeptide are then contacted with a test compound and binding, stimulation, or inhibition of activity of either the polypeptide or the molecule is analyzed.

An assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. Alternatively, the assay may assess binding in the presence of a labeled competitor.

Additionally, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

Preferably, an ELISA assay using, e.g., a monoclonal or polyclonal antibody, can measure polypeptide level in a sample. The antibody can measure polypeptide level by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

All of the above assays can be used in a diagnostic or prognostic context. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.

Transcript Imaging and Toxicological Testing

Another embodiment relates to the use of dithp to develop a transcript image of a tissue or cell

Constitution Commission

10

15

20

25

type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent Number 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity pertaining to human molecules for diagnostics and therapeutics.

Transcript images which profile dithp expression may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect dithp expression <u>in vivo</u>, as in the case of a tissue or biopsy sample, or <u>in vitro</u>, as in the case of a cell line.

Transcript images which profile dithp expression may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E. F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and Anderson, N.L. (2000) Toxicol. Lett. 112-113:467-71, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at http://www.niehs.nih.gov/oc/news/toxchip.htm.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

In one embodiment, the toxicity of a test compound is assessed by treating a biological sample

containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

Another particular embodiment relates to the use of DITHP encoded by polynucleotides of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, supra). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

A proteomic profile may also be generated using antibodies specific for DITHP to quantify the levels of DITHP expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem. 270:103-11; Mendoze, L.G. et al. (1999) Biotechniques 27:778-88). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or aminoreactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

Toxicant signatures at the proteome level are also useful for toxicological screening, and should

والمستطيان المسترعية المحاولين والمراج والمراج

5

10

15

20

25

be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and Seilhamer, J. (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the DITHP encoded by polynucleotides of the present invention.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the DITHP encoded by polynucleotides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

Transcript images may be used to profile dithp expression in distinct tissue types. This process can be used to determine human molecule activity in a particular tissue type relative to this activity in a different tissue type. Transcript images may be used to generate a profile of dithp expression characteristic of diseased tissue. Transcript images of tissues before and after treatment may be used for diagnostic purposes, to monitor the progression of disease, and to monitor the efficacy of drug treatments for diseases which affect the activity of human molecules.

Transcript images of cell lines can be used to assess human molecule activity and/or to identify cell lines that lack or misregulate this activity. Such cell lines may then be treated with pharmaceutical agents, and a transcript image following treatment may indicate the efficacy of these agents in restoring desired levels of this activity. A similar approach may be used to assess the toxicity of pharmaceutical agents as reflected by undesirable changes in human molecule activity. Candidate pharmaceutical agents may be evaluated by comparing their associated transcript images with those of pharmaceutical agents of known effectiveness.

15

Antisense Molecules

5

10

20

25

30

The polynucleotides of the present invention are useful in antisense technology. Antisense technology or therapy relies on the modulation of expression of a target protein through the specific binding of an antisense sequence to a target sequence encoding the target protein or directing its expression. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa NJ; Alama, A. et al. (1997) Pharmacol. Res. 36(3):171-178; Crooke, S.T. (1997) Adv. Pharmacol. 40:1-49; Sharma, H.W. and R. Narayanan (1995) Bioessays 17(12):1055-1063; and Lavrosky, Y. et al. (1997) Biochem. Mol. Med. 62(1):11-22.) An antisense sequence is a polynucleotide sequence capable of specifically hybridizing to at least a portion of the target sequence. Antisense sequences bind to cellular mRNA and/or genomic DNA, affecting translation and/or transcription. Antisense sequences can be DNA, RNA, or nucleic acid mimics and analogs. (See, e.g., Rossi, J.J. et al. (1991) Antisense Res. Dev. 1(3):285-288; Lee, R. et al. (1998) Biochemistry 37(3):900-1010; Pardridge, W.M. et al. (1995) Proc. Natl. Acad. Sci. USA 92(12):5592-5596; and Nielsen, P. E. and Haaima, G. (1997) Chem. Soc. Rev. 96:73-78.) Typically, the binding which results in modulation of expression occurs through hybridization or binding of complementary base pairs. Antisense sequences can also bind to DNA duplexes through specific interactions in the major groove of the double helix.

The polynucleotides of the present invention and fragments thereof can be used as antisense sequences to modify the expression of the polypeptide encoded by dithp. The antisense sequences can be produced <u>ex vivo</u>, such as by using any of the ABI nucleic acid synthesizer series (Applied Biosystems) or other automated systems known in the art. Antisense sequences can also be produced biologically, such as by transforming an appropriate host cell with an expression vector containing the sequence of interest. (See, e.g., Agrawal, supra.)

In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J.E., et al. (1998) J. Allergy Clin. Immunol. 102(3):469-475; and Scanlon, K.J., et al. (1995) 9(13):1288-1296.)

Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) Blood 76:271; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY; Uckert, W. and W. Walther (1994) Pharmacol. Ther. 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J.J. (1995) Br. Med. Bull. 51(1):217-225; Boado, R.J. et al. (1998) J. Pharm. Sci. 87(11):1308-1315; and Morris, M.C. et al. (1997) Nucleic Acids Res. 25(14):2730-2736.)

Expression

10

15

In order to express a biologically active DITHP, the nucleotide sequences encoding DITHP or fragments thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding DITHP and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, supra, Chapters 4, 8, 16, and 17; and Ausubel, supra, Chapters 9, 10, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding DITHP. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal (mammalian) cell systems. (See, e.g., Sambrook, supra; Ausubel, 1995, supra, Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; Scorer, C.A. et al. (1994) Bio/Technology 12:181-184; Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659; and Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al., (1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R.M. et al. (1985) Nature 317(6040):813-815; McGregor, D.P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, I.M. and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.

For long term production of recombinant proteins in mammalian systems, stable expression of DITHP in cell lines is preferred. For example, sequences encoding DITHP can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Any number of

selection systems may be used to recover transformed cell lines. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.; Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14; Hartman, S.C. and R.C.Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051; Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Therapeutic Uses of dithp

5

10

15

20

25

30

The dithp of the invention may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) Science 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) Science 270:475-480; Bordignon, C. et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cell 75:207-216; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:643-666; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:667-703), thalassemias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) Science 270:404-410; Verma, I.M. and Somia, N. (1997) Nature 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords. protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci. USA. 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in dithp expression or regulation causes disease, the expression of dithp from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

In a further embodiment of the invention, diseases or disorders caused by deficiencies in dithp are treated by constructing mammalian expression vectors comprising dithp and introducing these vectors by mechanical means into dithp-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and Anderson, W.F. (1993) Annu. Rev. Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J-L. and Récipon, H. (1998) Curr. Opin. Biotechnol. 9:445-450).

Expression vectors that may be effective for the expression of dithp include, but are not limited

to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). The dithp of the invention may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β-actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and Bujard, H. (1992) Proc. Natl. Acad. Sci. U.S.A. 89:5547-5551; Gossen, M. et al., (1995) Science 268:1766-1769; Rossi, F.M.V. and Blau, H.M. (1998) Curr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX plasmid (Invitrogen); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and Blau, H.M. supra), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding DITHP from a normal individual.

Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and Eb, A.J. (1973) Virology 52:456-467), or by electroporation (Neumann, E. et al. (1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to dithp expression are treated by constructing a retrovirus vector consisting of (i) dithp under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus cis-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. U.S.A. 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M.A. et al. (1987) J. Virol. 61:1639-1646; Adam, M.A. and Miller, A.D. (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Patent Number 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of

cells (e.g., CD4⁺ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M.L. (1997) J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. U.S.A. 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

In the alternative, an adenovirus-based gene therapy delivery system is used to deliver dithp to cells which have one or more genetic abnormalities with respect to the expression of dithp. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) Annu. Rev. Nutr. 19:511-544 and Verma, I.M. and Somia, N. (1997) Nature 18:389:239-242, both incorporated by reference herein.

In another alternative, a herpes-based, gene therapy delivery system is used to deliver dithp to target cells which have one or more genetic abnormalities with respect to the expression of dithp. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing dithp to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res. 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent Number 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.S. Patent Number 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W. F. et al. 1999 J. Virol. 73:519-532 and Xu, H. et al., (1994) Dev. Biol. 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver dithp to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has

ENCLOSED THE CHANGE

5

10

15

20

25

been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H, and Li, K-J. (1998) Curr. Opin. Biotech. 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full-length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting dithp into the alphavirus genome in place of the capsid-coding region results in the production of a large number of dithp RNAs and the synthesis of high levels of DITHP in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of dithp into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

Antibodies

10

Anti-DITHP antibodies may be used to analyze protein expression levels. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, and Fab fragments. For descriptions of and protocols of antibody technologies, see, e.g., Pound J.D. (1998) Immunochemical Protocols, Humana Press, Totowa, NJ.

The amino acid sequence encoded by the dithp of the Sequence Listing may be analyzed by appropriate software (e.g., LASERGENE NAVIGATOR software, DNASTAR) to determine regions of high immunogenicity. The optimal sequences for immunization are selected from the C-terminus, the N-terminus, and those intervening, hydrophilic regions of the polypeptide which are likely to be exposed to the external environment when the polypeptide is in its natural conformation. Analysis used to select appropriate epitopes is also described by Ausubel (1997, supra, Chapter 11.7). Peptides used for antibody induction do not need to have biological activity; however, they must be antigenic. Peptides used to induce specific antibodies may have an amino acid sequence consisting of at least five amino acids, preferably at least 10 amino acids, and most preferably at least 15 amino acids. A peptide which mimics an antigenic fragment of the natural polypeptide may be fused with another protein such as keyhole limpet hemocyanin (KLH; Sigma, St. Louis MO) for antibody production. A peptide encompassing an antigenic region may be expressed from a dithp, synthesized as described above, or

purified from human cells.

5

10

15

20

25

30

Procedures well known in the art may be used for the production of antibodies. Various hosts including mice, goats, and rabbits, may be immunized by injection with a peptide. Depending on the host species, various adjuvants may be used to increase immunological response.

In one procedure, peptides about 15 residues in length may be synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using fmoc-chemistry and coupled to KLH (Sigma) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester (Ausubel, 1995, supra). Rabbits are immunized with the peptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity by binding the peptide to plastic, blocking with 1% bovine serum albumin (BSA), reacting with rabbit antisera, washing, and reacting with radioiodinated goat anti-rabbit IgG. Antisera with antipeptide activity are tested for anti-DITHP activity using protocols well known in the art, including ELISA, radioimmunoassay (RIA), and immunoblotting.

In another procedure, isolated and purified peptide may be used to immunize mice (about 100 µg of peptide) or rabbits (about 1 mg of peptide). Subsequently, the peptide is radioiodinated and used to screen the immunized animals' B-lymphocytes for production of antipeptide antibodies. Positive 'cells are then used to produce hybridomas using standard techniques. About 20 mg of peptide is sufficient for labeling and screening several thousand clones. Hybridomas of interest are detected by screening with radioiodinated peptide to identify those fusions producing peptide-specific monoclonal antibody. In a typical protocol, wells of a multi-well plate (FAST, Becton-Dickinson, Palo Alto, CA) are coated with affinity-purified, specific rabbit-anti-mouse (or suitable anti-species IgG) antibodies at 10 mg/ml. The coated wells are blocked with 1% BSA and washed and exposed to supernatants from hybridomas. After incubation, the wells are exposed to radiolabeled peptide at 1 mg/ml.

Clones producing antibodies bind a quantity of labeled peptide that is detectable above background. Such clones are expanded and subjected to 2 cycles of cloning. Cloned hybridomas are injected into pristane-treated mice to produce ascites, and monoclonal antibody is purified from the ascitic fluid by affinity chromatography on protein A (Amersham Pharmacia Biotech). Several procedures for the production of monoclonal antibodies, including in vitro production, are described in Pound (supra). Monoclonal antibodies with antipeptide activity are tested for anti-DITHP activity using protocols well known in the art, including ELISA, RIA, and immunoblotting.

Antibody fragments containing specific binding sites for an epitope may also be generated. For example, such fragments include, but are not limited to, the F(ab')2 fragments produced by pepsin digestion of the antibody molecule, and the Fab fragments generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, construction of Fab expression libraries in filamentous bacteriophage allows rapid and easy identification of monoclonal fragments with desired specificity

and the artist of the contraction of the contractio

(Pound, <u>supra</u>, Chaps. 45-47). Antibodies generated against polypeptide encoded by dithp can be used to purify and characterize full-length DITHP protein and its activity, binding partners, etc.

Assays Using Antibodies

Anti-DITHP antibodies may be used in assays to quantify the amount of DITHP found in a particular human cell. Such assays include methods utilizing the antibody and a label to detect expression level under normal or disease conditions. The peptides and antibodies of the invention may be used with or without modification or labeled by joining them, either covalently or noncovalently, with a reporter molecule.

Protocols for detecting and measuring protein expression using either polyclonal or monoclonal antibodies are well known in the art. Examples include ELISA, RIA, and fluorescent activated cell sorting (FACS). Such immunoassays typically involve the formation of complexes between the DITHP and its specific antibody and the measurement of such complexes. These and other assays are described in Pound (supra).

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications, and publications mentioned above and below, including U.S. Ser. No. 60/184,777, U.S. Ser. No. 60/184,797, U.S. Ser. No. 60/184,698, U.S. Ser. No. 60/184,770, U.S. Ser. No. 60/184,774, U.S. Ser. No. 60/184,693, U.S. Ser. No. 60/184,771,U.S. Ser. No. 60/184,813, U.S. Ser. No. 60/184,773, U.S. Ser. No. 60/184,776, U.S. Ser. No. 60/184,769, U.S. Ser. No. 60/184,768, U.S. Ser. No. 60/184,837, U.S. Ser. No. 60/184,697, U.S. Ser. No. 60/184,841, U.S. Ser. No. 60/184,772, U.S. Ser. No. 60/185,213, U.S. Ser. No. 60/185,216, U.S. Ser. No. 60/204,863, U.S. Ser. No. 60/205,221, U.S. Ser. No. 60/204,815, U.S. Ser. No. 60/203,785, U.S. Ser. No. 60/204,821, U.S. Ser. No. 60/204,908, U.S. Ser. No. 60/204,226, U.S. Ser. No. 60/204,525, U.S. Ser. No. 60/205,285, U.S. Ser. No. 60/205,232, U.S. Ser. No. 60/205,323, U.S. Ser. No. 60/205,287, U.S. Ser. No. 60/205,324, and U.S. Ser. No. 60/205,286, are hereby expressly incorporated by reference.

30

10

15

EXAMPLES

I. Construction of cDNA Libraries

RNA was purchased from CLONTECH Laboratories, Inc. (Palo Alto CA) or isolated from various tissues. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others

es it will be being

5

10

15

20

25

30

were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates

isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In most cases, RNA was treated with DNase. For most libraries, poly(A+) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega Corporation (Promega), Madison WI), OLIGOTEX latex particles (QIAGEN, Inc. (QIAGEN), Valencia CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Inc., Austin TX).

were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated with either

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene Cloning Systems, Inc. (Stratagene), La Jolla CA) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, Chapters 5.1 through 6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), or pINCY (Incyte Genomics, Palo Alto CA), or derivatives thereof. Recombinant plasmids were transformed into competent E. coli cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5α, DH10B, or ElectroMAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

Plasmids were recovered from host cells by <u>in vivo</u> excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: the Magic or WIZARD Minipreps DNA purification system (Promega); the AGTC Miniprep purification kit (Edge BioSystems, Gaithersburg MD); and the QIAWELL 8, QIAWELL 8 Plus, and QIAWELL 8 Ultra plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit (QIAGEN). Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format. (Rao, V.B. (1994) Anal. Biochem. 216:1-14.) Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Inc. (Molecular Probes), Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

10

20

cDNA sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 thermal cycler (Applied Biosystems) or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific Corp., Sunnyvale CA) or the MICROLAB 2200 liquid transfer system (Hamilton). cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, Chapter 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.

IV. Assembly and Analysis of Sequences

Component sequences from chromatograms were subject to PHRED analysis and assigned a quality score. The sequences having at least a required quality score were subject to various pre-processing editing pathways to eliminate, e.g., low quality 3'ends, vector and linker sequences, polyA tails, Alu repeats, mitochondrial and ribosomal sequences, bacterial contamination sequences, and sequences smaller than 50 base pairs. In particular, low-information sequences and repetitive elements (e.g., dinucleotide repeats, Alu repeats, etc.) were replaced by "n's", or masked, to prevent spurious matches.

Processed sequences were then subject to assembly procedures in which the sequences were assigned to gene bins (bins). Each sequence could only belong to one bin. Sequences in each gene bin were assembled to produce consensus sequences (templates). Subsequent new sequences were added to existing bins using BLASTn (v.1.4 WashU) and CROSSMATCH. Candidate pairs were identified as

all BLAST hits having a quality score greater than or equal to 150. Alignments of at least 82% local identity were accepted into the bin. The component sequences from each bin were assembled using a version of PHRAP. Bins with several overlapping component sequences were assembled using DEEP PHRAP. The orientation (sense or antisense) of each assembled template was determined based on the number and orientation of its component sequences. Template sequences as disclosed in the sequence listing correspond to sense strand sequences (the "forward" reading frames), to the best determination. The complementary (antisense) strands are inherently disclosed herein. The component sequences which were used to assemble each template consensus sequence are listed in Table 4, along with their positions along the template nucleotide sequences.

Bins were compared against each other and those having local similarity of at least 82% were combined and reassembled. Reassembled bins having templates of insufficient overlap (less than 95% local identity) were re-split. Assembled templates were also subject to analysis by STITCHER/EXON MAPPER algorithms which analyze the probabilities of the presence of splice variants, alternatively spliced exons, splice junctions, differential expression of alternative spliced genes across tissue types or disease states, etc. These resulting bins were subject to several rounds of the above assembly procedures.

Once gene bins were generated based upon sequence alignments, bins were clone joined based upon clone information. If the 5' sequence of one clone was present in one bin and the 3' sequence from the same clone was present in a different bin, it was likely that the two bins actually belonged together in a single bin. The resulting combined bins underwent assembly procedures to regenerate the consensus sequences.

The final assembled templates were subsequently annotated using the following procedure. Template sequences were analyzed using BLASTn (v2.0, NCBI) versus gbpri (GenBank version 120). "Hits" were defined as an exact match having from 95% local identity over 200 base pairs through 100% local identity over 100 base pairs, or a homolog match having an E-value, i.e. a probability score, of $\leq 1 \times 10^8$. The hits were subject to frameshift FASTx versus GENPEPT (GenBank version 120). (See Table 7). In this analysis, a homolog match was defined as having an E-value of $\leq 1 \times 10^8$. The assembly method used above was described in "System and Methods for Analyzing Biomolecular Sequences," U.S.S.N. 09/276,534, filed March 25, 1999, and the LIFESEQ Gold user manual (Incyte) both incorporated by reference herein.

Following assembly, template sequences were subjected to motif, BLAST, and functional analyses, and categorized in protein hierarchies using methods described in, e.g., "Database System Employing Protein Function Hierarchies for Viewing Biomolecular Sequence Data," U.S.S.N. 08/812,290, filed March 6, 1997; "Relational Database for Storing Biomolecule Information,"

The State of the Salara

10

15

20

25

U.S.S.N. 08/947,845, filed October 9, 1997; "Project-Based Full-Length Biomolecular Sequence Database," U.S.S.N. 08/811,758, filed March 6, 1997; and "Relational Database and System for Storing Information Relating to Biomolecular Sequences," U.S.S.N. 09/034,807, filed March 4, 1998, all of which are incorporated by reference herein.

The template sequences were further analyzed by translating each template in all three forward reading frames and searching each translation against the Pfam database of hidden Markov model-based protein families and domains using the HMMER software package (available to the public from Washington University School of Medicine, St. Louis MO). Regions of templates which, when translated, contain similarity to Pfam consensus sequences are reported in Table 2, along with descriptions of Pfam protein domains and families. Only those Pfam hits with an E-value of $\leq 1 \times 10^{-3}$ are reported. (See also World Wide Web site http://pfam.wustl.edu/ for detailed descriptions of Pfam protein domains and families.)

Additionally, the template sequences were translated in all three forward reading frames, and each translation was searched against hidden Markov models for signal peptides using the HMMER software package. Construction of hidden Markov models and their usage in sequence analysis has been described. (See, for example, Eddy, S.R. (1996) Curr. Opin. Str. Biol. 6:361-365.) Only those signal peptide hits with a cutoff score of 11 bits or greater are reported. A cutoff score of 11 bits or greater corresponds to at least about 91-94% true-positives in signal peptide prediction. Template sequences were also translated in all three forward reading frames, and each translation was searched against TMAP, a program that uses weight matrices to delineate transmembrane segments on protein sequences and determine orientation, with respect to the cell cytosol (Persson, B. and P. Argos (1994) J. Mol. Biol. 237:182-192; Persson, B. and P. Argos (1996) Protein Sci. 5:363-371). Regions of templates which, when translated, contain similarity to signal peptide or transmembrane consensus sequences are reported in Table 3.

The results of HMMER analysis as reported in Tables 2 and 3 may support the results of BLAST analysis as reported in Table 1 or may suggest alternative or additional properties of template-encoded polypeptides not previously uncovered by BLAST or other analyses.

Template sequences are further analyzed using the bioinformatics tools listed in Table 7, or using sequence analysis software known in the art such as MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Template sequences may be further queried against public databases such as the GenBank rodent, mammalian, vertebrate, prokaryote, and eukaryote databases.

The template sequences were translated to derive the corresponding longest open reading frame as presented by the polypeptide sequences. Alternatively, a polypeptide of the invention may begin at

25

PCT/US01/06059 WO 01/62927

any of the methionine residues within the full length translated polypeptide. Polypeptide sequences were subsequently analyzed by querying against the GenBank protein database (GENPEPT, (GenBank version 121)). Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

Table 6 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (GENPEPT) database. Column 1 shows the polypeptide sequence identification number (SEQ ID NO:) for the polypeptide segments of the invention. Column 2 shows the reading frame used in the translation of the polynucleotide sequences encoding the polypeptide segments. Column 3 shows the length of the translated polypeptide segments. Columns 4 and 5 show the start and stop nucleotide positions of the polynucleotide sequences encoding the polypeptide segments. Column 6 shows the GenBank identification number (GI Number) of the nearest GenBank homolog. Column 7 shows the probability score for the match between each polypeptide and its GenBank homolog. Column 8 shows the annotation of the GenBank homolog.

V. Analysis of Polynucleotide Expression

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel, 1995, supra, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

BLAST	Score x Percent	Identity
5 x minimum	{length(Seq. 1),	length(Seq. 2)}

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by

Control of the Committee

5

10

15

20

25

assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

10 VI. Tissue Distribution Profiling

A tissue distribution profile is determined for each template by compiling the cDNA library tissue classifications of its component cDNA sequences. Each component sequence, is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. Template sequences, component sequences, and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA).

Table 5 shows the tissue distribution profile for the templates of the invention. For each template, the three most frequently observed tissue categories are shown in column 3, along with the percentage of component sequences belonging to each category. Only tissue categories with percentage values of $\geq 10\%$ are shown. A tissue distribution of "widely distributed" in column 3 indicates percentage values of < 10% in all tissue categories.

25

20

VII. Transcript Image Analysis

Transcript images are generated as described in Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent Number 5,840,484, incorporated herein by reference.

30 VIII. Extension of Polynucleotide Sequences and Isolation of a Full-length cDNA

Oligonucleotide primers designed using a dithp of the Sequence Listing are used to extend the nucleic acid sequence. One primer is synthesized to initiate 5' extension of the template, and the other primer, to initiate 3' extension of the template. The initial primers may be designed using OLIGO 4.06 software (National Biosciences, Inc. (National Biosciences), Plymouth MN), or another appropriate

program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations are avoided. Selected human cDNA libraries are used to extend the sequence. If more than one extension is necessary or desired, additional or nested sets of primers are designed.

High fidelity amplification is obtained by PCR using methods well known in the art. PCR is performed in 96-well plates using the PTC-200 thermal cycler (MJ Research). The reaction mix contains DNA template, 200 nmol of each primer, reaction buffer containing Mg²⁺, (NH₄)₂SO₄, and β-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ are as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well is determined by dispensing 100 μ l PICOGREEN quantitation reagent (0.25% (v/v); Molecular Probes) dissolved in 1X Tris-EDTA (TE) and 0.5 μ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Incorporated (Corning), Corning NY), allowing the DNA to bind to the reagent. The plate is scanned in a FLUOROSKAN II (Labsystems Oy) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μ l to 10 μ l aliquot of the reaction mixture is analyzed by electrophoresis on a 1% agarose mini-gel to determine which reactions are successful in extending the sequence.

The extended nucleotides are desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides are separated on low concentration (0.6 to 0.8%) agarose gels, fragments are excised, and agar digested with AGAR ACE (Promega). Extended clones are religated using T4 ligase (New England Biolabs, Inc., Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent <u>E. coli</u> cells. Transformed cells are selected on antibiotic-containing media, individual colonies are picked and cultured overnight at 37°C in 384-well plates in LB/2x carbenicillin liquid media.

The cells are lysed, and DNA is amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1:

10

15

20

25

94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA is quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries are reamplified using the same conditions as described above. Samples are diluted with 20% dimethysulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).

In like manner, the dithp is used to obtain regulatory sequences (promoters, introns, and enhancers) using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.

IX. Labeling of Probes and Southern Hybridization Analyses

Hybridization probes derived from the dithp of the Sequence Listing are employed for screening cDNAs, mRNAs, or genomic DNA. The labeling of probe nucleotides between 100 and 1000 nucleotides in length is specifically described, but essentially the same procedure may be used with larger cDNA fragments. Probe sequences are labeled at room temperature for 30 minutes using a T4 polynucleotide kinase, γ^{32} P-ATP, and 0.5X One-Phor-All Plus (Amersham Pharmacia Biotech) buffer and purified using a ProbeQuant G-50 Microcolumn (Amersham Pharmacia Biotech). The probe mixture is diluted to 10^7 dpm/ μ g/ml hybridization buffer and used in a typical membrane-based hybridization analysis.

The DNA is digested with a restriction endonuclease such as Eco RV and is electrophoresed through a 0.7% agarose gel. The DNA fragments are transferred from the agarose to nylon membrane (NYTRAN Plus, Schleicher & Schuell, Inc., Keene NH) using procedures specified by the manufacturer of the membrane. Prehybridization is carried out for three or more hours at 68°C, and hybridization is carried out overnight at 68°C. To remove non-specific signals, blots are sequentially washed at room temperature under increasingly stringent conditions, up to 0.1x saline sodium citrate (SSC) and 0.5% sodium dodecyl sulfate. After the blots are placed in a PHOSPHORIMAGER cassette (Molecular Dynamics) or are exposed to autoradiography film, hybridization patterns of standard and experimental lanes are compared. Essentially the same procedure is employed when screening RNA.

X. Chromosome Mapping of dithp

The cDNA sequences which were used to assemble SEQ ID NO:1-211 are compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that match SEQ

30

10

ID NO:1-211 are assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as PHRAP (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon are used to determine if any of the clustered sequences have been previously mapped. Inclusion of a mapped sequence in a cluster will result in the assignment of all sequences of that cluster, including its particular SEQ ID NO:, to that map location. The genetic map locations of SEQ ID NO:1-211 are described as ranges, or intervals, of human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's parm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters.

XI. Microarray Analysis

10

15

20

25

30

Probe Preparation from Tissue or Cell Samples

Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and polyA+ RNA is purified using the oligo (dT) cellulose method. Each polyA+ RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/µl oligo-dT primer (21mer), 1X first strand buffer, 0.03 units/ μ 1 RNase inhibitor, 500 μ M dATP, 500 μ M dGTP, 500 μ M dTTP, 40 μ M dCTP, 40 µM dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng polyA+ RNA with GEMBRIGHT kits (Incyte). Specific control polyA+ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA (W. Lei, unpublished). As quantitative controls, the control mRNAs at 0.002 ng, 0.02 ng, 0.2 ng, and 2 ng are diluted into reverse transcription reaction at ratios of 1:100,000, 1:10,000, 1:1000, 1:100 (w/w) to sample mRNA respectively. The control mRNAs are diluted into reverse transcription reaction at ratios of 1:3, 3:1, 1:10, 10:1, 1:25, 25:1 (w/w) to sample mRNA differential expression patterns. After incubation at 37°C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85°C to the stop the reaction and degrade the RNA. Probes are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The probe is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14 µl 5X SSC/0.2%

SDS.

10

20

25

Microarray Preparation

Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μ g. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester, PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.

Array elements are applied to the coated glass substrate using a procedure described in US Patent No. 5,807,522, incorporated herein by reference. 1 µl of the array element DNA, at an average concentration of 100 ng/µl, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford, MA) for 30 minutes at 60°C followed by washes in 0.2% SDS and distilled water as before.

Hybridization

Hybridization reactions contain 9 μ l of probe mixture consisting of 0.2 μ g each of Cy3 and Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The probe mixture is heated to 65°C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm² coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μ l of 5x SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60°C. The arrays are washed for 10 min at 45°C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45°C in a second wash buffer (0.1X SSC), and dried.

Detection

Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the probe mix at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two probes from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood, MA) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

10

15

20

25

XII. Complementary Nucleic Acids

Sequences complementary to the dithp are used to detect, decrease, or inhibit expression of the naturally occurring nucleotide. The use of oligonucleotides comprising from about 15 to 30 base pairs is typical in the art. However, smaller or larger sequence fragments can also be used. Appropriate oligonucleotides are designed from the dithp using OLIGO 4.06 software (National Biosciences) or other appropriate programs and are synthesized using methods standard in the art or ordered from a commercial supplier. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent transcription factor binding to the promoter sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding and processing of the transcript.

XIII. Expression of DITHP

Expression and purification of DITHP is accomplished using bacterial or virus-based expression systems. For expression of DITHP in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the trp-lac (tac) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the lac operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express DITHP upon induction with isopropyl beta-Dthiogalactopyranoside (IPTG). Expression of DITHP in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding DITHP by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See e.g., Engelhard, supra; and Sandig, supra.)

In most expression systems, DITHP is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from DITHP at

specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak Company, Rochester NY). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, Chapters 10 and 16). Purified DITHP obtained by these methods can be used directly in the following activity assay.

XIV. Demonstration of DITHP Activity

5

10

15

20

25

30

DITHP activity is demonstrated through a variety of specific assays, some of which are outlined below.

Oxidoreductase activity of DITHP is measured by the increase in extinction coefficient of NAD(P)H coenzyme at 340 nm for the measurement of oxidation activity, or the decrease in extinction coefficient of NAD(P)H coenzyme at 340 nm for the measurement of reduction activity (Dalziel, K. (1963) J. Biol. Chem. 238:2850-2858). One of three substrates may be used: Asn- β Gal, biocytidine, or ubiquinone-10. The respective subunits of the enzyme reaction, for example, cytochtome c_1 -b oxidoreductase and cytochrome c, are reconstituted. The reaction mixture contains a)1-2 mg/ml DITHP; and b) 15 mM substrate, 2.4 mM NAD(P)+ in 0.1 M phosphate buffer, pH 7.1 (oxidation reaction), or 2.0 mM NAD(P)H, in 0.1 M Na₂HPO₄ buffer, pH 7.4 (reduction reaction); in a total volume of 0.1 ml. Changes in absorbance at 340 nm (A₃₄₀) are measured at 23.5° C using a recording spectrophotometer (Shimadzu Scientific Instruments, Inc., Pleasanton CA). The amount of NAD(P)H is stoichiometrically equivalent to the amount of substrate initially present, and the change in A₃₄₀ is a direct measure of the amount of NAD(P)H produced; Δ A₃₄₀ = 6620[NADH]. Oxidoreductase activity of DITHP activity is proportional to the amount of NAD(P)H present in the assay.

Transferase activity of DITHP is measured through assays such as a methyl transferase assay in which the transfer of radiolabeled methyl groups between a donor substrate and an acceptor substrate is measured (Bokar, J.A. et al. (1994) J. Biol. Chem. 269:17697-17704). Reaction mixtures (50 μl final volume) contain 15 mM HEPES, pH 7.9, 1.5 mM MgCl₂, 10 mM dithiothreitol, 3% polyvinylalcohol, 1.5 μCi [methyl-³H]AdoMet (0.375 μM AdoMet) (DuPont-NEN), 0.6 μg DITHP, and acceptor substrate (0.4 μg [³5S]RNA or 6-mercaptopurine (6-MP) to 1 mM final concentration). Reaction mixtures are incubated at 30 °C for 30 minutes, then 65 °C for 5 minutes. The products are separated by chromatography or electrophoresis and the level of methyl transferase activity is determined by quantification of methyl-³H recovery.

DITHP hydrolase activity is measured by the hydrolysis of appropriate synthetic peptide substrates conjugated with various chromogenic molecules in which the degree of hydrolysis is

quantified by spectrophotometric (or fluorometric) absorption of the released chromophore. (Beynon, R.J. and J.S. Bond (1994) <u>Proteolytic Enzymes: A Practical Approach</u>, Oxford University Press, New York NY, pp. 25-55) Peptide substrates are designed according to the category of protease activity as endopeptidase (serine, cysteine, aspartic proteases), animopeptidase (leucine aminopeptidase), or carboxypeptidase (Carboxypeptidase A and B, procollagen C-proteinase).

DITHP isomerase activity such as peptidyl prolyl *cis/trans* isomerase activity can be assayed by an enzyme assay described by Rahfeld, J.U., et al. (1994) (FEBS Lett. 352: 180-184). The assay is performed at 10°C in 35 mM HEPES buffer, pH 7.8, containing chymotrypsin (0.5 mg/ml) and DITHP at a variety of concentrations. Under these assay conditions, the substrate, Suc-Ala-Xaa-Pro-Phe-4-NA, is in equilibrium with respect to the prolyl bond, with 80-95% in *trans* and 5-20% in *cis* conformation. An aliquot (2 ul) of the substrate dissolved in dimethyl sulfoxide (10 mg/ml) is added to the reaction mixture described above. Only the *cis* isomer of the substrate is a substrate for cleavage by chymotrypsin. Thus, as the substrate is isomerized by DITHP, the product is cleaved by chymotrypsin to produce 4-nitroanilide, which is detected by it's absorbance at 390 nm. 4-Nitroanilide appears in a time-dependent and a DITHP concentration-dependent manner.

An assay for DITHP activity associated with growth and development measures cell proliferation as the amount of newly initiated DNA synthesis in Swiss mouse 3T3 cells. A plasmid containing polynucleotides encoding DITHP is transfected into quiescent 3T3 cultured cells using methods well known in the art. The transiently transfected cells are then incubated in the presence of [³H]thymidine, a radioactive DNA precursor. Where applicable, varying amounts of DITHP ligand are added to the transfected cells. Incorporation of [³H]thymidine into acid-precipitable DNA is measured over an appropriate time interval, and the amount incorporated is directly proportional to the amount of newly synthesized DNA.

Growth factor activity of DITHP is measured by the stimulation of DNA synthesis in Swiss mouse 3T3 cells (McKay, I. and I. Leigh, eds. (1993) Growth Factors: A Practical Approach, Oxford University Press, New York NY). Initiation of DNA synthesis indicates the cells' entry into the mitotic cycle and their commitment to undergo later division. 3T3 cells are competent to respond to most growth factors, not only those that are mitogenic, but also those that are involved in embryonic induction. This competence is possible because the <u>in vivo</u> specificity demonstrated by some growth factors is not necessarily inherent but is determined by the responding tissue. In this assay, varying amounts of DITHP are added to quiescent 3T3 cultured cells in the presence of [³H]thymidine, a radioactive DNA precursor. DITHP for this assay can be obtained by recombinant means or from biochemical preparations. Incorporation of [³H]thymidine into acid-precipitable DNA is measured over an appropriate time interval, and the amount incorporated is directly proportional to the amount of

30

newly synthesized DNA. A linear dose-response curve over at least a hundred-fold DITHP concentration range is indicative of growth factor activity. One unit of activity per milliliter is defined as the concentration of DITHP producing a 50% response level, where 100% represents maximal incorporation of [³H]thymidine into acid-precipitable DNA.

Alternatively, an assay for cytokine activity of DITHP measures the proliferation of leukocytes. In this assay, the amount of tritiated thymidine incorporated into newly synthesized DNA is used to estimate proliferative activity. Varying amounts of DITHP are added to cultured leukocytes, such as granulocytes, monocytes, or lymphocytes, in the presence of [³H]thymidine, a radioactive DNA precursor. DITHP for this assay can be obtained by recombinant means or from biochemical preparations. Incorporation of [³H]thymidine into acid-precipitable DNA is measured over an appropriate time interval, and the amount incorporated is directly proportional to the amount of newly synthesized DNA. A linear dose-response curve over at least a hundred-fold DITHP concentration range is indicative of DITHP activity. One unit of activity per milliliter is conventionally defined as the concentration of DITHP producing a 50% response level, where 100% represents maximal incorporation of [³H]thymidine into acid-precipitable DNA.

An alternative assay for DITHP cytokine activity utilizes a Boyden micro chamber (Neuroprobe, Cabin John MD) to measure leukocyte chemotaxis (Vicari, supra). In this assay, about 10⁵ migratory cells such as macrophages or monocytes are placed in cell culture media in the upper compartment of the chamber. Varying dilutions of DITHP are placed in the lower compartment. The two compartments are separated by a 5 or 8 micron pore polycarbonate filter (Nucleopore, Pleasanton CA). After incubation at 37 °C for 80 to 120 minutes, the filters are fixed in methanol and stained with appropriate labeling agents. Cells which migrate to the other side of the filter are counted using standard microscopy. The chemotactic index is calculated by dividing the number of migratory cells counted when DITHP is present in the lower compartment by the number of migratory cells counted when only media is present in the lower compartment. The chemotactic index is proportional to the activity of DITHP.

Alternatively, cell lines or tissues transformed with a vector containing dithp can be assayed for DITHP activity by immunoblotting. Cells are denatured in SDS in the presence of β -mercaptoethanol, nucleic acids removed by ethanol precipitation, and proteins purified by acetone precipitation. Pellets are resuspended in 20 mM tris buffer at pH 7.5 and incubated with Protein G-Sepharose pre-coated with an antibody specific for DITHP. After washing, the Sepharose beads are boiled in electrophoresis sample buffer, and the eluted proteins subjected to SDS-PAGE. The SDS-PAGE is transferred to a nitrocellulose membrane for immunoblotting, and the DITHP activity is assessed by visualizing and quantifying bands on the blot using the antibody specific for DITHP as the primary antibody and ¹²⁵I-

A ST COLL TOWN IN WASHINGTON

5

10

20

25

labeled IgG specific for the primary antibody as the secondary antibody.

DITHP kinase activity is measured by phosphorylation of a protein substrate using γ -labeled [32 P]-ATP and quantitation of the incorporated radioactivity using a radioisotope counter. DITHP is incubated with the protein substrate, [32 P]-ATP, and an appropriate kinase buffer. The [32 P] incorporated into the product is separated from free [32 P]-ATP by electrophoresis and the incorporated [32 P] is counted. The amount of [32 P] recovered is proportional to the kinase activity of DITHP in the assay. A determination of the specific amino acid residue phosphorylated is made by phosphoamino acid analysis of the hydrolyzed protein.

In the alternative, DITHP activity is measured by the increase in cell proliferation resulting from transformation of a mammalian cell line such as COS7, HeLa or CHO with an eukaryotic expression vector encoding DITHP. Eukaryotic expression vectors are commercially available, and the techniques to introduce them into cells are well known to those skilled in the art. The cells are incubated for 48-72 hours after transformation under conditions appropriate for the cell line to allow expression of DITHP. Phase microscopy is then used to compare the mitotic index of transformed versus control cells. An increase in the mitotic index indicates DITHP activity.

In a further alternative, an assay for DITHP signaling activity is based upon the ability of GPCR family proteins to modulate G protein-activated second messenger signal transduction pathways (e.g., cAMP; Gaudin, P. et al. (1998) J. Biol. Chem. 273:4990-4996). A plasmid encoding full length DITHP is transfected into a mammalian cell line (e.g., Chinese hamster ovary (CHO) or human embryonic kidney (HEK-293) cell lines) using methods well-known in the art. Transfected cells are grown in 12-well trays in culture medium for 48 hours, then the culture medium is discarded, and the attached cells are gently washed with PBS. The cells are then incubated in culture medium with or without ligand for 30 minutes, then the medium is removed and cells lysed by treatment with 1 M perchloric acid. The cAMP levels in the lysate are measured by radioimmunoassay using methods well-known in the art. Changes in the levels of cAMP in the lysate from cells exposed to ligand compared to those without ligand are proportional to the amount of DITHP present in the transfected cells.

Alternatively, an assay for DITHP protein phosphatase activity measures the hydrolysis of P-nitrophenyl phosphate (PNPP). DITHP is incubated together with PNPP in HEPES buffer pH 7.5, in the presence of 0.1% β -mercaptoethanol at 37°C for 60 min. The reaction is stopped by the addition of 6 ml of 10 N NaOH, and the increase in light absorbance of the reaction mixture at 410 nm resulting from the hydrolysis of PNPP is measured using a spectrophotometer. The increase in light absorbance is proportional to the phosphatase activity of DITHP in the assay (Diamond, R.H. et al (1994) Mol Cell Biol 14:3752-3762).

An alternative assay measures DITHP-mediated G-protein signaling activity by monitoring the mobilization of Ca⁺⁺ as an indicator of the signal transduction pathway stimulation. (See, e.g., Grynkievicz, G. et al. (1985) J. Biol. Chem. 260:3440; McColl, S. et al. (1993) J. Immunol. 150:4550-4555; and Aussel, C. et al. (1988) J. Immunol. 140:215-220). The assay requires preloading neutrophils or T cells with a fluorescent dye such as FURA-2 or BCECF (Universal Imaging Corp, Westchester PA) whose emission characteristics are altered by Ca⁺⁺ binding. When the cells are exposed to one or more activating stimuli artificially (e.g., anti-CD3 antibody ligation of the T cell receptor) or physiologically (e.g., by allogeneic stimulation), Ca⁺⁺ flux takes place. This flux can be observed and quantified by assaying the cells in a fluorometer or fluorescent activated cell sorter. Measurements of Ca⁺⁺ flux are compared between cells in their normal state and those transfected with DITHP. Increased Ca⁺⁺ mobilization attributable to increased DITHP concentration is proportional to DITHP activity.

DITHP transport activity is assayed by measuring uptake of labeled substrates into Xenopus laevis oocytes. Oocytes at stages V and VI are injected with DITHP mRNA (10 ng per oocyte) and incubated for 3 days at 18°C in OR2 medium (82.5mM NaCl, 2.5 mM KCl, 1mM CaCl₂, 1mM MgCl₂, 1mM Na₂HPO₄, 5 mM Hepes, 3.8 mM NaOH, 50μg/ml gentamycin, pH 7.8) to allow expression of DITHP protein. Oocytes are then transferred to standard uptake medium (100mM NaCl, 2 mM KCl, 1mM CaCl₂, 1mM MgCl₂, 10 mM Hepes/Tris pH 7.5). Uptake of various substrates (e.g., amino acids, sugars, drugs, ions, and neurotransmitters) is initiated by adding labeled substrate (e.g. radiolabeled with ³H, fluorescently labeled with rhodamine, etc.) to the oocytes. After incubating for 30 minutes, uptake is terminated by washing the oocytes three times in Na⁺-free medium, measuring the incorporated label, and comparing with controls. DITHP transport activity is proportional to the level of internalized labeled substrate.

DITHP transferase activity is demonstrated by a test for galactosyltransferase activity. This can be determined by measuring the transfer of radiolabeled galactose from UDP-galactose to a GlcNAc-terminated oligosaccharide chain (Kolbinger, F. et al. (1998) J. Biol. Chem. 273:58-65). The sample is incubated with 14 μl of assay stock solution (180 mM sodium cacodylate, pH 6.5, 1 mg/ml bovine serum albumin, 0.26 mM UDP-galactose, 2 μl of UDP-[³H]galactose), 1 μl of MnCl₂ (500 mM), and 2.5 μl of GlcNAcβO-(CH₂)₈-CO₂Me (37 mg/ml in dimethyl sulfoxide) for 60 minutes at 37°C. The reaction is quenched by the addition of 1 ml of water and loaded on a C18 Sep-Pak cartridge (Waters), and the column is washed twice with 5 ml of water to remove unreacted UDP-[³H]galactose. The [³H]galactosylated GlcNAcβO-(CH₂)₈-CO₂Me remains bound to the column during the water washes and is eluted with 5 ml of methanol. Radioactivity in the eluted material is measured by liquid scintillation counting and is proportional to galactosyltransferase activity in the starting

La estado Labora de Adela de La Caldada de L

10

15

20

25

sample.

In the alternative, DITHP induction by heat or toxins may be demonstrated using primary cultures of human fibroblasts or human cell lines such as CCL-13, HEK293, or HEP G2 (ATCC). To heat induce DITHP expression, aliquots of cells are incubated at 42 °C for 15, 30, or 60 minutes. Control aliquots are incubated at 37 °C for the same time periods. To induce DITHP expression by toxins, aliquots of cells are treated with 100 µM arsenite or 20 mM azetidine-2-carboxylic acid for 0, 3, 6, or 12 hours. After exposure to heat, arsenite, or the amino acid analogue, samples of the treated cells are harvested and cell lysates prepared for analysis by western blot. Cells are lysed in lysis buffer containing 1% Nonidet P-40, 0.15 M NaCl, 50 mM Tris-HCl, 5 mM EDTA, 2 mM N-ethylmaleimide, 2 mM phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin, and 1 mg/ml pepstatin. Twenty micrograms of the cell lysate is separated on an 8% SDS-PAGE gel and transferred to a membrane. After blocking with 5% nonfat dry milk/phosphate-buffered saline for 1 h, the membrane is incubated overnight at 4°C or at room temperature for 2-4 hours with a 1:1000 dilution of anti-DITHP serum in 2% nonfat dry milk/phosphate-buffered saline. The membrane is then washed and incubated with a 1:1000 dilution of horseradish peroxidase-conjugated goat anti-rabbit IgG in 2% dry milk/phosphate-buffered saline. After washing with 0.1% Tween 20 in phosphate-buffered saline, the DITHP protein is detected and compared to controls using chemiluminescence.

Alternatively, DITHP protease activity is measured by the hydrolysis of appropriate synthetic peptide substrates conjugated with various chromogenic molecules in which the degree of hydrolysis is quantified by spectrophotometric (or fluorometric) absorption of the released chromophore (Beynon, R.J. and J.S. Bond (1994) Proteolytic Enzymes: A Practical Approach, Oxford University Press, New York, NY, pp.25-55). Peptide substrates are designed according to the category of protease activity as endopeptidase (serine, cysteine, aspartic proteases, or metalloproteases), aminopeptidase (leucine aminopeptidase), or carboxypeptidase (carboxypeptidases A and B, procollagen C-proteinase). Commonly used chromogens are 2-naphthylamine, 4-nitroaniline, and furylacrylic acid. Assays are performed at ambient temperature and contain an aliquot of the enzyme and the appropriate substrate in a suitable buffer. Reactions are carried out in an optical cuvette, and the increase/decrease in absorbance of the chromogen released during hydrolysis of the peptide substrate is measured. The change in absorbance is proportional to the DITHP protease activity in the assay.

In the alternative, an assay for DITHP protease activity takes advantage of fluorescence resonance energy transfer (FRET) that occurs when one donor and one acceptor fluorophore with an appropriate spectral overlap are in close proximity. A flexible peptide linker containing a cleavage site specific for PRTS is fused between a red-shifted variant (RSGFP4) and a blue variant (BFP5) of

Green Fluorescent Protein. This fusion protein has spectral properties that suggest energy transfer is occurring from BFP5 to RSGFP4. When the fusion protein is incubated with DITHP, the substrate is cleaved, and the two fluorescent proteins dissociate. This is accompanied by a marked decrease in energy transfer which is quantified by comparing the emission spectra before and after the addition of DITHP (Mitra, R.D. et al (1996) Gene 173:13-17). This assay can also be performed in living cells. In this case the fluorescent substrate protein is expressed constitutively in cells and DITHP is introduced on an inducible vector so that FRET can be monitored in the presence and absence of DITHP (Sagot, I. et al (1999) FEBS Lett. 447:53-57).

A method to determine the nucleic acid binding activity of DITHP involves a polyacrylamide gel mobility-shift assay. In preparation for this assay, DITHP is expressed by transforming a mammalian cell line such as COS7, HeLa or CHO with a eukaryotic expression vector containing DITHP cDNA. The cells are incubated for 48-72 hours after transformation under conditions appropriate for the cell line to allow expression and accumulation of DITHP. Extracts containing solubilized proteins can be prepared from cells expressing DITHP by methods well known in the art. Portions of the extract containing DITHP are added to [³²P]-labeled RNA or DNA. Radioactive nucleic acid can be synthesized in vitro by techniques well known in the art. The mixtures are incubated at 25 °C in the presence of RNase- and DNase-inhibitors under buffered conditions for 5-10 minutes. After incubation, the samples are analyzed by polyacrylamide gel electrophoresis followed by autoradiography. The presence of a band on the autoradiogram indicates the formation of a complex between DITHP and the radioactive transcript. A band of similar mobility will not be present in samples prepared using control extracts prepared from untransformed cells.

In the alternative, a method to determine the methylase activity of a DITHP measures transfer of radiolabeled methyl groups between a donor substrate and an acceptor substrate. Reaction mixtures (50 μl final volume) contain 15 mM HEPES, pH 7.9, 1.5 mM MgCl₂, 10 mM dithiothreitol, 3% polyvinylalcohol, 1.5 μCi [methyl-³H]AdoMet (0.375 μM AdoMet) (DuPont-NEN), 0.6 μg DITHP, and acceptor substrate (e.g., 0.4 μg [³5S]RNA, or 6-mercaptopurine (6-MP) to 1 mM final concentration). Reaction mixtures are incubated at 30°C for 30 minutes, then 65°C for 5 minutes. Analysis of [methyl-³H]RNA is as follows: 1) 50 μl of 2 x loading buffer (20 mM Tris-HCl, pH 7.6, 1 M LiCl, 1 mM EDTA, 1% sodium dodecyl sulphate (SDS)) and 50 μl oligo d(T)-cellulose (10 mg/ml in 1 x loading buffer) are added to the reaction mixture, and incubated at ambient temperature with shaking for 30 minutes. 2) Reaction mixtures are transferred to a 96-well filtration plate attached to a vacuum apparatus. 3) Each sample is washed sequentially with three 2.4 ml aliquots of 1 x oligo d(T) loading buffer containing 0.5% SDS, 0.1% SDS, or no SDS. and 4) RNA is eluted with 300 μl of water into a 96-well collection plate, transferred to scintillation vials containing liquid scintillant, and

្រស់ សាល់ 🔩 ក្រុំវិកភា 🕮 សិខភាព

10

15

20

25

radioactivity determined. Analysis of [methyl-³H]6-MP is as follows: 1) 500 µl 0.5 M borate buffer, pH 10.0, and then 2.5 ml of 20% (v/v) isoamyl alcohol in toluene are added to the reaction mixtures.

2) The samples mixed by vigorous vortexing for ten seconds. 3) After centrifugation at 700g for 10 minutes, 1.5 ml of the organic phase is transferred to scintillation vials containing 0.5 ml absolute ethanol and liquid scintillant, and radioactivity determined. and 4) Results are corrected for the extraction of 6-MP into the organic phase (approximately 41%).

An assay for adhesion activity of DITHP measures the disruption of cytoskeletal filament networks upon overexpression of DITHP in cultured cell lines (Rezniczek, G.A. et al. (1998) J. Cell Biol. 141:209-225). cDNA encoding DITHP is subcloned into a mammalian expression vector that drives high levels of cDNA expression. This construct is transfected into cultured cells, such as rat kangaroo PtK2 or rat bladder carcinoma 804G cells. Actin filaments and intermediate filaments such as keratin and vimentin are visualized by immunofluorescence microscopy using antibodies and techniques well known in the art. The configuration and abundance of cytoskeletal filaments can be assessed and quantified using confocal imaging techniques. In particular, the bundling and collapse of cytoskeletal filament networks is indicative of DITHP adhesion activity.

Alternatively, an assay for DITHP activity measures the expression of DITHP on the cell surface. cDNA encoding DITHP is transfected into a non-leukocytic cell line. Cell surface proteins are labeled with biotin (de la Fuente, M.A. et al. (1997) Blood 90:2398-2405). Immunoprecipitations are performed using DITHP-specific antibodies, and immunoprecipitated samples are analyzed using SDS-PAGE and immunoblotting techniques. The ratio of labeled immunoprecipitant to unlabeled immunoprecipitant is proportional to the amount of DITHP expressed on the cell surface.

Alternatively, an assay for DITHP activity measures the amount of cell aggregation induced by overexpression of DITHP. In this assay, cultured cells such as NIH3T3 are transfected with cDNA encoding DITHP contained within a suitable mammalian expression vector under control of a strong promoter. Cotransfection with cDNA encoding a fluorescent marker protein, such as Green Fluorescent Protein (CLONTECH), is useful for identifying stable transfectants. The amount of cell agglutination, or clumping, associated with transfected cells is compared with that associated with untransfected cells. The amount of cell agglutination is a direct measure of DITHP activity.

DITHP may recognize and precipitate antigen from serum. This activity can be measured by the quantitative precipitin reaction (Golub, E.S. et al. (1987) <u>Immunology: A Synthesis</u>, Sinauer Associates, Sunderland MA, pages 113-115). DITHP is isotopically labeled using methods known in the art. Various serum concentrations are added to constant amounts of labeled DITHP. DITHP-antigen complexes precipitate out of solution and are collected by centrifugation. The amount of precipitable DITHP-antigen complex is proportional to the amount of radioisotope detected in the

5

10

15

20

25

30

precipitate. The amount of precipitable DITHP-antigen complex is plotted against the serum concentration. For various serum concentrations, a characteristic precipitation curve is obtained, in which the amount of precipitable DITHP-antigen complex initially increases proportionately with increasing serum concentration, peaks at the equivalence point, and then decreases proportionately with further increases in serum concentration. Thus, the amount of precipitable DITHP-antigen complex is a measure of DITHP activity which is characterized by sensitivity to both limiting and excess quantities of antigen.

A microtubule motility assay for DITHP measures motor protein activity. In this assay, recombinant DITHP is immobilized onto a glass slide or similar substrate. Taxol-stabilized bovine brain microtubules (commercially available) in a solution containing ATP and cytosolic extract are perfused onto the slide. Movement of microtubules as driven by DITHP motor activity can be visualized and quantified using video-enhanced light microscopy and image analysis techniques. DITHP motor protein activity is directly proportional to the frequency and velocity of microtubule movement.

Alternatively, an assay for DITHP measures the formation of protein filaments <u>in vitro</u>. A solution of DITHP at a concentration greater than the "critical concentration" for polymer assembly is applied to carbon-coated grids. Appropriate nucleation sites may be supplied in the solution. The grids are negative stained with 0.7% (w/v) aqueous uranyl acetate and examined by electron microscopy. The appearance of filaments of approximately 25 nm (microtubules), 8 nm (actin), or 10 nm (intermediate filaments) is a demonstration of protein activity.

DITHP electron transfer activity is demonstrated by oxidation or reduction of NADP. Substrates such as Asn- β Gal, biocytidine, or ubiquinone-10 may be used. The reaction mixture contains 1-2 mg/ml HORP, 15 mM substrate, and 2.4 mM NAD(P)+ in 0.1 M phosphate buffer, pH 7.1 (oxidation reaction), or 2.0 mM NAD(P)H, in 0.1 M Na₂HPO₄ buffer, pH 7.4 (reduction reaction); in a total volume of 0.1 ml. FAD may be included with NAD, according to methods well known in the art. Changes in absorbance are measured using a recording spectrophotometer. The amount of NAD(P)H is stoichiometrically equivalent to the amount of substrate initially present, and the change in A₃₄₀ is a direct measure of the amount of NAD(P)H produced; Δ A₃₄₀ = 6620[NADH]. DITHP activity is proportional to the amount of NAD(P)H present in the assay. The increase in extinction coefficient of NAD(P)H coenzyme at 340 nm is a measure of oxidation activity, or the decrease in extinction coefficient of NAD(P)H coenzyme at 340 nm is a measure of reduction activity (Dalziel, K. (1963) J. Biol. Chem. 238:2850-2858).

DITHP transcription factor activity is measured by its ability to stimulate transcription of a reporter gene (Liu, H.Y. et al. (1997) EMBO J. 16:5289-5298). The assay entails the use of a well

Ş

characterized reporter gene construct, $LexA_{op}$ -LacZ, that consists of LexA DNA transcriptional control elements ($LexA_{op}$) fused to sequences encoding the <u>E. coli</u> LacZ enzyme. The methods for constructing and expressing fusion genes, introducing them into cells, and measuring LacZ enzyme activity, are well known to those skilled in the art. Sequences encoding DITHP are cloned into a plasmid that directs the synthesis of a fusion protein, LexA-DITHP, consisting of DITHP and a DNA binding domain derived from the LexA transcription factor. The resulting plasmid, encoding a LexA-DITHP fusion protein, is introduced into yeast cells along with a plasmid containing the LexA_{op}-LacZ reporter gene. The amount of LacZ enzyme activity associated with LexA-DITHP transfected cells, relative to control cells, is proportional to the amount of transcription stimulated by the DITHP.

Chromatin activity of DITHP is demonstrated by measuring sensitivity to DNase I (Dawson, B.A. et al. (1989) J. Biol. Chem. 264:12830-12837). Samples are treated with DNase I, followed by insertion of a cleavable biotinylated nucleotide analog, 5-[(N-biotinamido)hexanoamido-ethyl-1,3-thiopropionyl-3-aminoallyl]-2'-deoxyuridine 5'-triphosphate using nick-repair techniques well known to those skilled in the art. Following purification and digestion with EcoRI restriction endonuclease, biotinylated sequences are affinity isolated by sequential binding to streptavidin and biotincellulose.

Another specific assay demonstrates the ion conductance capacity of DITHP using an electrophysiological assay. DITHP is expressed by transforming a mammalian cell line such as COS7, HeLa or CHO with a eukaryotic expression vector encoding DITHP. Eukaryotic expression vectors are commercially available, and the techniques to introduce them into cells are well known to those skilled in the art. A small amount of a second plasmid, which expresses any one of a number of marker genes such as β -galactosidase, is co-transformed into the cells in order to allow rapid identification of those cells which have taken up and expressed the foreign DNA. The cells are incubated for 48-72 hours after transformation under conditions appropriate for the cell line to allow expression and accumulation of DITHP and β-galactosidase. Transformed cells expressing βgalactosidase are stained blue when a suitable colorimetric substrate is added to the culture media under conditions that are well known in the art. Stained cells are tested for differences in membrane conductance due to various ions by electrophysiological techniques that are well known in the art. Untransformed cells, and/or cells transformed with either vector sequences alone or β -galactosidase sequences alone, are used as controls and tested in parallel. The contribution of DITHP to cation or anion conductance can be shown by incubating the cells using antibodies specific for either DITHP. The respective antibodies will bind to the extracellular side of DITHP, thereby blocking the pore in the ion channel, and the associated conductance.

XV. Functional Assays

25

'WO 01/62927 PCT/US01/06059

DITHP function is assessed by expressing dithp at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT (Life Technologies) and pCR3.1 (Invitrogen Corporation, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 μ g of recombinant vector are transiently transfected into a human cell line, preferably of endothelial or hematopoietic origin, using either liposome formulations or electroporation. 1-2 μ g of an additional plasmid containing sequences encoding a marker protein are co-transfected.

Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector.

Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; CLONTECH), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties.

FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of DITHP on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding DITHP and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Inc., Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding DITHP and other genes of interest can be analyzed by northern analysis or microarray techniques.

XVI. Production of Antibodies

DITHP substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g.,

5

10

15

20

25

30

WO 01/62927 PCT/US01/06059

Harrington, M.G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the DITHP amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding peptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, Chapter 11.)

Typically, peptides 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using fmoc-chemistry and coupled to KLH (Sigma) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, supra.) Rabbits are immunized with the peptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide activity by, for example, binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG. Antisera with antipeptide activity are tested for anti-DITHP activity using protocols well known in the art, including ELISA, RIA, and immunoblotting.

XVII. Purification of Naturally Occurring DITHP Using Specific Antibodies

Naturally occurring or recombinant DITHP is substantially purified by immunoaffinity chromatography using antibodies specific for DITHP. An immunoaffinity column is constructed by covalently coupling anti-DITHP antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing DITHP are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of DITHP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/DITHP binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and DITHP is collected.

XVIII. Identification of Molecules Which Interact with DITHP

DITHP, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter reagent. (See, e.g., Bolton, A.E. and W.M. Hunter (1973) Biochem. J. 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled DITHP, washed, and any wells with labeled DITHP complex are assayed. Data obtained using different concentrations of DITHP are used to calculate values for the number, affinity, and association of DITHP with the

30

10

15

20

WO 01/62927 PCT/US01/06059

candidate molecules.

5

10

15

Alternatively, molecules interacting with DITHP are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) Nature 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (CLONTECH).

DITHP may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Patent No. 6,057,101).

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

									•				, •								_											,			
		Human aldehyde reductase mRNA, complete cds.		nidinase	carbonic anhydrase I (AA 1-261)	acetyl-CoA synthetase	alpha glucosidase II, alpha subunit	omithine decarboxylase	unnamed protein product (Homo sapiens)	unnamed protein product (Homo sapiens)	Itansglutaminase E3 (Homo sapiens)	M2-type pyruvate kinase (Homo saplens)	aryisulphatase (Homo sapiens)	similar to Achlya ambisexualis antheridioi steroid receptor (NID:g166306)	Human chromosome 3, olfactory receptor pseudogene cluster 1,	complete sequence, and myosin light chain kinase (MLCK)	bseudogene, bartial seguence. Urman I coll recorder Alpha delta loci is from bases 501413 to 752734	il receptior diplica della locus illam puses doro i o 702/30	(section 3 of 5) of the Complete Nucleotide Sequence.	unnamed protein product (Homo saplens)	Human T-cell receptor alpha delta locus from bases 501613 to 752736	(section 3 of 5) of the Complete Nucleotide Sequence,	serine/threonine kinase	Ras like GTPase (Homo saplens)	dJ593C16.1 (ras GTPase activating protein)	The KIAA0147 gene product is related to adenylyl cyclase.	kappa B-ras 1 (Homo saplens)	use C-1	aciogenital dysplasia protein 2 (Mus musculus)	myocyte nuclear factor (Mus musculus)	Juman guanine nucleotide-binding protein alpha-subunit gene (G-s-	J.3.	hook1 protein (Homo saplens)	neuronal tyrosine threonine phosphatase I (Mus musculus)	Potein Kinase (Kattus norvegicus)
	re Annotation	Human ald	Glyoxalase	dihydropyrimidinase	carbonica	acetyl-CoA	alpha gluc	omithine de	nunamed	d pewbuun	transglutan	M2-type py	aryisulphate	similar to Ac	Human chi	complete s	pseudoder U. imain T. O.		(section 3 c	nunamed	Human 1-c	(section 3 c	serine/threc	Ras like GTF	dJ593C16.1	The KIAA01	kappa B-ra	phospholipase C-1	faciogenito	myocyte n	Human gu	alpha), exon 3	hook1 prof	neuronal ty	Protein Kind
	Number Probability Score Annotation	1.00E-92	2.40E-65	4.40E-74	5.00E-85	2.00E-63	, 0	4.00E-23	0	4.00E-92	0	9.00E-65	1.00E-172	1.20E-11			O	•	0	2.00E-19		0	1.10E-31	1.00E-160	9.70E-49	0	2.00E-89	4.50E-87	3.00E-57	5.00E-58	l	1.00E-142	1.00E-177	0 100	1.00E-164
	GI Number F	g178480	g2909424	g3608122	g29600	g1835116	g2104689	g63713	g10435462	g7023634	g307504	g189998	g2576305	g2088668			g3861482	1	g2358042	g10439739		g2358042	g404634	g2117166	g5763838	g1469876	g7008402	g206218	g3599940	g508528		g183399	g3005085	g1781037	g2077934
IABLE 1	Template ID	LG:1040582.1:2000FEB18	LG:453570.1:2000FEB18	LG:408751.3:2000FEB18	LI:090574.1:2000FEB01	LI:229932.2:2000FEB01	LI:332176.1:2000FEB01	LI:403248.2:2000FEB01	LG:220992.1:2000MAY19	LG:1094571.1:2000MAY19	LI:350754.4:2000MAY01	LI:255828.29:2000MAY01	LI:1190263.1:2000MAY01	LG:270916.2:2000FEB18			LG:999414.3:2000FEB18		LG:429446.1:2000FEB18	LI:057229.1:2000FEB01		LI:351965.1:2000FEB01	LG:068682.1:2000FEB18	LG:242665.1:2000FEB18	LG:241743.1:2000FEB18	LI:034212.1:2000FEB01	LG:344886.1:2000MAY19	LG:228930.1:2000MAY19	LG:338927.1:2000MAY19	LG:898771.1:2000MAY19		LI:257664.67:2000MAY01	LI:001496.2:2000MAY01	LI:1085273.2:2000MAY01	LI:333138.2:2000MAY01
	SEQ ID NO:	_	8	်က	4	ഹ	9	7	ω	တ	5	1	12	13			₹		5	16		17	18	19	20	21	23	23	24	22		5 9	. 27	58	23

a some filter care care

•	•	1	•		
faciogenital dysplasia protein 2 (Mus musculus) a variant of TSC-22 (Gallus gallus) bromodomain PHD finger transcription factor (Homo sapiens) AhR repressor Y box transcription factor supported by Genscan and several ESTs: C83049 (NID:g3062006),	(NID:a3434464), and AA969095 (NID:a3144275) (Homo sapiens) franscription factor Elongin A2 (Homo sapiens) enhancer of polycomb (Mus musculus) zinc finger protein AP136.	zinc-finger protein 7 BWSCR2 associated zinc-finger protein BAZ2 similarto human ZFY protein. Human HZF10 mRNA for zinc finger protein. Human mRNA for KIAA0065 gene, partial cds.	Human Kruppel related zinc tinger protein (HIF IV) mikNA, complet cas. Human repressor transcriptional factor (ZNF85) mRNA, compl. te cds. KIAA1473 protein (Homo saplens) Human Krueppel-related DNA-binding protein (TF9 PF4) mRNA, 5' cds. NK10 unnamed protein product (Homo saplens)	Human zinc iinger protein (ZNF141) mikinA, complete cas. Human zinc finger protein (ZNF141) mRNA, complete cds. Human Krueppel-related DNA-binding protein (PF4) mRNA, 5' nd. ha0946 protein is Kruppel-related. Zfp-29 zinc finger protein	zinc finger protein zinc finger protein pMLZ-4 Eos protein KRAB zinc finger protein; Method: conceptual translation supplied by DNA binding protein
6.00E-45 5.00E-97 1.00E-105 6.00E-34 2.00E-11	1.00E-59 2.00E-52 4.00E-66 1.40E-60 5.00E-36	3.60E-11 2.60E-39 3.20E-25 2.00E-33	2.00E-47 0 1.00E-19 0 3.50E-36 1.00E-14	2.00E-40 2.00E-24 1.00E-98 4.00E-16 0 2.00E-96 8.00E-42	2.00E-22 4.00E-24 0 3.00E-67 2.00E-26 1.00E-53
g359940 g1181619 g6683492 g4164151 g2745892	g3924670 g6939732 g3757892 g984814 g487784	g4325310 g6002480 g1504006 g498720 g498151	g186773 g1017721 g7959207 g184451 g506502 g7023216	934/905 9347905 9454818 9498152 955471 9984814	9498721 9498719 9200407 94062983 91049301
LI:338927.1:2000MAY01 LG:33558.1:2000FEB18 LG:998283.7:2000FEB18 LI:402739.1:2000FEB01 LI:175223.1:2000FEB01	LG:981076.2:2000MAY19 LI:1008973.1:2000MAY01 LI:1190250.1:2000MAY01 LG:021371.3:2000FEB18 LG:475404.1:2000FEB18	LG:979406.2:2000FEB18 LG:410726.1:2000FEB18 LG:200005.1:2000FEB18 LG:1076828.1:2000FEB18 LG:1076931.1:2000FEB18	LG:1078121.1:2000FEB18 LG:1079203.1:2000FEB18 LG:1082586.1:2000FEB18 LG:1082774.1:2000FEB18 LG:1083120.1:2000FEB18	LG:1087707.1:2000FEB18 LG:1090915.1:2000FEB18 LG:1094230.1:2000FEB18 LG:474848.3:2000FEB18 LI:251656.1:2000FEB01 LI:021371.1:2000FEB01 LI:133095.1:2000FEB01	LI:236654.2:2000FEB01 LI:200009.1:2000FEB01 LI:344772.1:2000FEB01 LI:789445.1:2000FEB01 LI:789657.1:2000FEB01
33 33 33	36 33 39 39	6 1 5 5 4 5 5	5 4 4 4 4 6 5 2 2 4 4 4 4 4 6 5	55 55 57 57	58 60 62 63

Human ZNF37A mRNA for zinc finger protein.	Human zinc finger protein (FDZF2) mRNA, complete cds.	Human repressor transcriptional factor (ZNF85) mRNA, complete cds.	otein ZFP113	Human ZNF37A mRNA for zinc finger protein.	Human ZNF37A mRNA for zinc finger protein.	protein	Human mRNA for KIAA0065 gene, partial cds.	Human HKL1 mRNA, complete cds.	otein	unnamed protein product (Homo saplens)	Human hematopoietic cell derived zinc finger protein mRNA, complete	zinc finger protein ZNF136 (Homo sapiens)	otein ZNF135	na0946 protein is Kruppel-related.	epressor transcriptional factor	Human mRNA for KIAA0065 gene, partial cds.	Human zinc finger protein (FDZF2) mRNA, complete cds.	BC37295_1 (Homo saplens)	Human zinc finger protein ZNF136.	Human HZF1 mRNA for zinc finger protein.	Human ZNF37A mRNA for zinc finger protein.	protein	Human Y-linked zinc finger protein (ZFY) gene, complete cds.	hypothetical protein (Homo sapiens)	nypothetical protein (Homo saplens)	KIAA1611 protein (Homo sapiens)	dJ228H13.3 (zinc finger protein) (Homo sapiens)	sculus)	unnamed protein product (Homo sapiens)	unnamed protein product (Homo sapiens)	no sapiens)	putative kruppel-related zinc finger protein NY-REN-23 antigen (Homo		norvegicus)	zinc finger protein ZNF140 (Homo sapiens)
Human ZNF37	Human zinc fi	Human repre	zínc finger protein ZFP113	Human ZNF37	Human ZNF37	DNA binding protein	Human mRN	Human HKL1	zinc finger protein	unnamed pro	Human hemo	zinc finger pre	zinc finger protein ZNF135	ha0946 prote	repressor tran	Human mRN	Human zinc f	BC37295_1 (F	Human zinc f	Human HZF1	Human ZNF37	DNA binding protein	Human Y-link	hypothetical	hypothetical	KIAA1611 pro	dJ228H13.3 (2	NK10 (Mus musculus)	unnamed pro	unnamed pro	PRO2032 (Homo sapiens)	putative krup	saplens)	Roaz (Rattus norvegicus)	zinc finger pr
0	0	3.00E-53	4.00E-45	o	0	9.00E-36	4.00E-28	0	2.00E-55	7.00E-18	0	4.00E-16	4.00E-48	1.00E-20	1.00E-53	9.00E-27		3.00E-33	3.00E-38	0	0	1.00E-51	2.00E-95	2.00E-40	3.00E-35	2.00E-23	8.00E-79	1.00E-141	1.00E-142	7.00E-18	1.00E-18		0	0	1.00E-45
g288424	g2232012	g1017721	g5640017	g288424	g288424	g1020145	g498151	g2970037	g538413	g7023216	g3342001	g487785	g488555	g498152	g1017722	g498151	g2232012	g4567179	g487784	g498718	g288424	g1020145	g6650686	g5262560	g5262560	g10047297	g5931821	g506502	g7023216	g7023216	g7959865		g5360097	g2149792	g487787
LI:789808.1:2000FEB01	LI:792919.1:2000FEB01	LI:793949.1:2000FEB01	LI:794389.1:2000FEB01	LI:796010.1:2000FEB01	LI:796324.1:2000FEB01	LI:796373.1:2000FEB01	LI:796415.1:2000FEB01	LI:798636.1:2000FEB01	LI:800045.1:2000FEB01	LI:800680.1:2000FEB01	LI:800894.1:2000FEB01	LI:801015.1:2000FEB01	LI:801236.1:2000FEB01	LI:803335.1:2000FEB01	Li:803998.1:2000FEB01	LI:478757.1:2000FEB01	LI:808532.1:2000FEB01	LI:443073.1:2000FEB01	LI:479671.1:2000FEB01	LI:810078.1:2000FEB01	LI:810224.1:2000FEB01	LI:817052.2:2000FEB01	LG:892274.1:2000MAY19	LG:1080959.1:2000MAY19	LG:1054900.1:2000MAY19	LG:1077357.1:2000MAY19	LG:1084051.1:2000MAY19	LG:1076853.1:2000MAY19	LG:481631.10:2000MAY19	LG:1088431.2:2000MAY19	LI:401619.10:2000MAY01		LI:1144007.1:2000MAY01	LI:331074.1:2000MAY01	LI:1170349.1:2000MAY01
64	65	99	29	89	69	2	71	72	73	74	75	92	11	82	79	80	81	85	83	84	82	98	87	88	83	8	91	35	83	94	92		96	97	86

and the company that the same

unnamed protein product (Homo saplens) Human hereditary haemochromatosis region, histone 2A-like protein	gene, hereditary haemochromatosis (HLA-H) gene, koket gene, and sodium phosphate fransporter (NPT3) aene, complete cds. Human hereditary haemochromatosis region, histone 2A-like protein	sodium phosphate transporter (NPT3) aene, complete cds. inc. inwardly rectifying potassium channel Kir5.1	calcium channel alpha-2-delta-C subunit (Mus musculus)	tetrodotoxin-resistant voltage-gated sodium channel (Homo sapiens) heta-clanine-sensitive nei ronal GABA transporter (Ratti is noivealcus)	CTL1 protein (Homo saplens) Ests A Insana (F30812), A I058345(F50679), AU030138(F50679), correspond	to a region of the predicted gene Similar to Spinacla oleracea mRNA	for protectsome 37kD subunit.(X96974) Rhesus monkey cyclophilin A mRNA, complete cds.	Similarity to B.subtilis DNAJ profein (SW:DNAJ_BACSU); CUNA EST	Method: conceptual translation supplied by author; putative hybrid	protein similar to HERV-H protease and HERV-E integrase (Human	endoaenous retrovirus) testis specific DNAJ-homolog	dnaJ protein (Thermotoga maritima)	25 kDa trypsin Inhibitor (Homo sapiens)	putative chaperonin (Arabidopsis thalland)	similar to Homo saplens mRNA for KIAA0/23 protein with Genbank	protects PC6 isoform A (Homo saplens)	lymphocyte specific helicase	ORF derived from D1 leader region and integrase coding region (Homo	saplens)	Human mariner 1 transposase gene, complete consensus sequence.	Cikt denved nom d'i leader region and maegrase coding region (mondo	sapiens) similar to mitochondrial RNA splicing MSR4 like protein; cDNA EST	EMBL:C09217 comes from this gene	
6.00E-25	0	0 2.10E-56	3.00E-41	0 0	1.00E-48		3.00E-75 0	9 BOE.34	6.00E-04		4.00E-33 3.00E-50	1.00E-11	4.00E-67	1.00E-128	1 00E-144	2.00E-16	3.40E-176		3.00E-23	0	1 00 5	1.005-20	3.00E-12	
g7020440	g2088550	g2088550 g3953533	g4186073	g4838145 g204220	g6996442		g5091520 g2565302	70727850	10.75.70cg		g1049231 g2286123	g4981382	g2943716	g6957716	02088070	9296929	g805296)	g2104910	g1263080	0107010	96.049	g3880433	
LG:335097.1:2000FEB18	LG:1076451.1:2000FEB18	LI:805478.1:2000FEB01 LG:101269.1:2000MAY19	LI:331087.1:2000MAY01	LI:410188.1:2000MAY01	LI:427997.4:2000MAY01		LG:451682.1:2000FEB18 LG:1077283.1:2000FEB18	1 C:491496 F:0000EEB18	LG:461436.3.2000FEB10		LI:793701.1:2000FEB01 LI:373637.1:2000FEB01	LG:239368.2:2000MAY19	LI:053826.1:2000MAY01	LI:449393.1:2000MAY01	11.4074407 06.0000MAV04	11:336338 8:2000MAY01	LG:345527.1:2000FEB18		LG:1089383.1:2000FEB18	LG:1092522.1:2000FEB18		LG:1093210.1.2000rED10	LI:270318.3:2000FEB01	
66	100	101	103	4 4 5	106	, - -	107 108	Q C			119	112	113	114	4	116	112		118	119	5	2	121	

lymphocyte specific helicase ORF derived from D1 leader region and integrase coding region (Homo	saplens) ORF derived from D1 leader region and integrase coding region (Homo	sapiens)	Human mariner 1 transposase gene, complete consensus sequence.	unnamed protein product (Homo sapiens)	KIVA Nelicase 2 (2007) 12 (2007) Holledin C tominal domain and SNEO N tominal	GUOZUETT, 10 (NOVE) MERCASE C-REMINAL ACTION AND SINFA IN-TERMINAL	domains containing protein, similar to KIAAU3U8)	Human mkNA for U. small nuclear kNP-specific C profein.	umamed protein product (nomo sapiens) protocodpein 48 (Homo sapiens)	unnamed protein product (Homo caplens)	Human genomic DNA, chromosome 6p21.3, HLA Class I region, section	8/20.	Human genomic DNA, chromosome 6p21.3, HLA Class I region, section	8/20.	Human genomic DNA, chromosome 6p21.3, HLA Class I region, section	20/20.	Human genomic DNA, chromosome 6p21.3, HLA Class I region, s ction	15/20.	unnamed portein product (Macaca fascicularis)	class II antigen (Homo saplens)	cytochrome P-450 2B-Bx	cytochrome P-450(1)	cytochrome c oxidase subunit IV	cytochrome P-450p-2 (Oryctolagus cuniculus)	collagen subunit (alpha-1 (X)) 3	hikaru genki type 1 product	SULFATED SURFACE GLYCOPROTEIN 185	Human mucin mRNA, partial cds	dJ708F5,1 (PUTATIVE novel Collagen alpha 1 LIKE proteln) (Homo	keratin (Homo sapiens)	NBL4	l nigotim
1.00E-83	4.00E-26	3.00E-23	4.00E-93	3.00E-12	5.00E-25	2 COT 103	3.00E-12/	2.00E-57	3.00E-12	1 OOF-25		. 0		0		0		0	7.00E-23	1.00E-112	4.80E-84	4.00E-58	1.50E-29	2.00E-06	9.00E-48	7.00E-06	1.00E-05	0	1.00E-168	0	1.00E-46	1.00=06
g805296	g2104910	g2104910	g1263080	g/020440	93776011	00000000	ge016932	g3/542	97020440	n10436424		g5926696		g5926696		g5926710		g5926703	g9280152	g673417	g404777	g203759	g2809498	g164981	g30095	g391663	g1405821	g292045	g4582324	g7161771	g466548	g3/24141
LI:335671.2:2000FEB01	LI:793758.1:2000FEB01	LI:803718.1:2000FEB01	LI:412179.1:2000FEB01	LI:8156/9.1:2000FEB01	LI:481361.3:2000FEB01	0.04704 4.00000 L	LG:24/388.1:2000IMAY19	LG:255789.10:2000MAY19	L:787616.1.2000MAT01	1 G-982697 1-2000FFB18		LG:1080896.1:2000FEB18		LI:811341.1:2000FEB01		LI:903225.1:2000FEB01		LI:242079.2:2000FEB01	LG:979580.1:2000MAY19	LI:1169865.1:2000MAY01	LG:337818.2:2000FEB18	LI:337818.1:2000FEB01	LG:241577.4:2000MAY19	LG:344786.4:2000MAY19	LI:414307.1:2000FEB01	LI:202943.2:2000FEB01	LI:246194.2:2000FEB01	LI:815961.1:2000FEB01	LG:120744.1:2000MAY19	LI:757520.1:2000MAY01	LG:160570.1:2000FEB18	LI:350398.3:2000FEB01
122	123	124	125	1 <u>7</u>	12/	0	200	2 5	5 5	133	!	133		134		135		136	137	138	139	140	141	142	143	144	145	146	147	148	149	20

													•														-							
spoke protein	PF20	Macaque mRNA for alpha-tubulin.	Khc-73 gene product (Drosophila melanogaster)	ankyrin 1 (Bos taurus)	dystrophin-related protein 2 (Homo saplens)	desmoglein 3 (Mus musculus)	64 Kd autoantigen	The KIAA0143 gene product is related to a putative C. elegans gene	encoded on cosmid C32D5, (Homo saplens)	DM-20 protein (Mus musculus)	defender against death 1 protein (Homo saplens)	ribosomal protein L32-like protein	putative 40S ribosomal protein s12	RL5 ribosomal protein	Human mRNA for ribosomal protein S26.	ribosomal protein L7	Human ribosomal protein L7 antisense mRNA gene, partial sequ nce.	Human ribosomal protein \$10 mRNA, complete cds.	Human mRNA for ribosomal protein L7.	Human mRNA for HBp15/L22, complete cds.	putative ribosomal protein S14 (Arabidopsis thaliana)	putative 40S ribosomal protein s12 (Fragaria x ananassa)	putative 40S ribosomal protein s12 (Fragaria x ananassa)	Human mRNA for ribosomal protein L31.	rlbosomal protein S4 type I (Zea mays)	rlbosomal protein L17 (Zea mays)	ribosomal protein S16 (AA 1-146) (Rathus rathus)	putative 40S ribosomal protein s12 (Fragaria x ananassa)	Human mRNA for ribosomal protein \$12.	ribosomal protein L37 (Rattus norvegicus)	tricarboxylate carrier (rats, liver, Peptide Mitochondrial Partial, 357 aa)	peroxisomal Ca-dependent solute carrier	nuclear body associated kinase 1b	
2.00E-74	2.00E-51	2.00E-30	0	2.00E-18	0	0	5.30E-44		0	1.00E-123	3.00E-24	2.40E-42	1.70E-59	1.90E-62	0	1.80E-16	0	0	0	0	5.00E-66	1.00E-70	6.00E-76	4.00E-54	1.00E-130	2.00E-95	1.00E-62	6.00E-76	2.00E-59	8.00E-29	2.50E-67	9.40E-29	0	
g18218 41755049	g1813638	g38076	g7303061	g7385113	g1353782	g2290200	g28969		g1469868	g387514	g2149291	g5816996	g643074	g463252	g296451	g200785	g1800114	g550024	g36139	g409069	94886269	g643074	g643074	g36129	g2331301	g2668748	g57714	g643074	g36145	g57121	g545998	g2352427	g5815141	
LI:221285.1:2000FEB01			LG:403409.1:2000MAY19	LG:233933.5:2000MAY19	LI:290344.1:2000MAY01	LI:410742.1:2000MAY01	LG:406568.1:2000MAY19		LI:283762.1:2000MAY01	LI:347687.113:2000MAY01	LI:1146510.1:2000MAY01	LG:451710.1:2000FEB18	LG:455771.1:2000FEB18	LG:452089.1:2000FEB18	LG:246415.1:2000FEB18	LG:414144.10:2000FEB18	LG:1101445.1:2000FEB18	LG:452134.1:2000FEB18	LI:903021.1:2000FEB01	LI:246422.1:2000FEB01	LG:449404.1:2000MAY19	LG:449413.1:2000MAY19	LG:450105.1:2000MAY19	LG:460809.1:2000MAY19	LG:481781.1:2000MAY19	LG:1101153.1:2000MAY19	LI:257695.20:2000MAY01	LI:455771.1:2000MAY01	LI:274551.1:2000MAY01	LI:035973.1:2000MAY01	LG:978427.5:2000FEB18	LG:247781.2:2000FEB18	LI:034583.1:2000FEB01	
151	<u> </u>	154	155	156	157	158	159		160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	171	178	179	180	181	182	183	184	

selected as a weak suppressor of a mutant of the subunit AC40 of DNA dependant RNA polymerase I and III AHNAK nucleoprotein beta-glucuronidase precursor (EC 3.2.1.31) unnamed protein product (Homo sapiens) Human beta-glucuronidase mRNA, complete cds. pyruvate dehydrogenase phosphatase (Bos taurus) RNA-binding protein Nova-2 (Homo sapiens) ventral neuron-specific protein 1 NOVA1 (Mus musculus)	dehydrin 6 acyl carrier protein Human endozepine (putative ligand of benzodiazepine receptor)	mRNA, complete cds. E3 ubiquitin ligase SMURF1 (Homo sapiens) sorting nexin 15A (Homo sapiens) dJ20B11.1 (ortholog of rat RSEC5 (mammallan exocyst complex subunit))	(Homo saplens) Ilpase (Homo saplens) syntaxin 11 rab11 binding protein (Bos taurus) gamma-thionin (Hordeum vulgare) protein synthesis elongation factor 1-alpha (Rhodotorula mucilaginosa) Fas-ligand associated factor 3 Fuman genomic DNA of 8p21.3-p22 anti-oncogene of hepatocellular	colorectal and non-small cell lung caricer, securing in 77 1.1. prohibitin (Human, mRNA, 1043 nt). mitogen inducible gene mig-2 (Homo sapiens) Human endogenous retrovirus type C oncovirus sequence. pva1 (Plasmodium vivax) hepatoceliular carcinoma-related putative tumor suppressor (Homo apoptosis related protein APR-3 (Homo sapiens)
0.0003 1.00E-46 2.00E-54 1.00E-109 0 2.00E-81 5.00E-34	2.10E-20 3.30E-41	2.00E-35 0 1.00E-33	3.00E-87 4.00E-54 5.10E-41 3.00E-81 2.00E-21 4.00E-21 6.10E-13	0 0 8.00E-62 0 8.00E-10 3.00E-88
g295671 g178281 g183233 g7022046 g183232 g414797	g4105111 g453189	g181960 g6446606 g9622856	g5823961 g9963839 g3243240 g4512103 g790641 g2367625	g4003386 g246482 g505033 g325464 g1177607 g10504238
LI:333307.2:2000FEB01 LI:814710.2:2000FEB01 LG:414732.1:2000MAY19 LG:413910.6:2000MAY19 LI:900264.2:2000MAY01 LI:335593.1:2000MAY01	LG:1040978.1:2000FEB18 LG:1040978.1:2000FEB18	LG:446649.1:2000FEB18 LG:132147.3:2000FEB18 LI:036034.1:2000FEB01	LG:162161.1:2000MAY19 LG:407214.10:2000MAY19 LG:204626.1:2000MAY19 LI:007401.1:2000MAY01 LI:476342.1:2000MAY01 LI:1072759.1:2000MAY01 LG:998857.1:2000FEB18	LG:482261.1:2000FEB18 LG:480328.1:2000FEB18 LG:31197.1:2000MAY19 LG:399395.1:2000MAY19 LG:390395.1:2000MAY19 LG:380497.2:2000MAY19 LI:272913.22:2000MAY19
185 186 187 188 190 191	192 193 194	195 196 197	198 200 201 202 203 203	205 206 207 208 209 210

	E-value	2.50E-51	3.80E-72	1.40E-19	9.70E-144	4.10E-144	1.40E-12	1.10E-153	2.30E-42	2.90E-47	3.20E-106	2.50E-63	7.00E-71	5.70E-24	8.60E-66	3.60E-13	4.30E-07	1.70E-65	2.30E-34	8.00E-06	1.70E-17	1.70E-25	1.30E-39	2.00E-90	2.60E-29	1.90E-12	1.40E-18	2.10E-04	1.10E-15	2.40E-34	2.10E-17	8.90E-55	2.00E-07	3.40E-21	2.80E-41
	Pfam Description	Aldo/keto reductase family	Glyoxalase	Dihydroorotase-like	Eukaryotic-type carbonic anhydrase	Glycosyl hydrolases family 31	3 Pyridoxal-dependent decarboxylase	-	Riboflavin kinase / FAD synthetase	Transglutaminase-like superfamily	Transglutaminase family	Transglutaminase family	Pyruvate kinase	Pyruvate kinase	Sulfatase	7 transmembrane receptor (rhodopsin family)	7 transmembrane receptor (rhodopsin family)	Eukaryotic protein kinase domain	Ras family	PH domain	Ras family	Fork head domain	Dual specificity phosphatase, catalytic domain	Eukaryotic protein kinase domain	Bromodomain	PHD-finger	'Cold-shock' DNA-binding domair	Zinc finger, C2H2 type	KRAB box	KRAB box	KRAB box	SCAN domain	Zinc finger, C2H2 type	KRAB box	KRAB box
TABIE2	Template ID Start Stop Frame Pfam Hit	LG:1040582.1:2000FEB18 267 539 forward 3 aldo_ket_red	LG:453570.1:2000FEB18 186 605 forward 3 Glyoxalase	LG:408751.3:2000FEB18 194 1345 forward 2 Dihydrooratase	Ll:090574.1:2000FEB01 60 776 forward 3 carb_anhydrase	LI:332176.1:2000FEB01 2 961 forward 2 Glyco_hydro_31	LI:403248.2:2000FEB01 191 367 forward 2 Orn_DAP_Arg_deC	1556 forward 3	LG:1094571.1:2000MAY19 328 720 forward 1 FAD_Synth	LI:350754.4:2000MAY01 855 1121 forward 3 Transglut_core	LI:350754.4:2000MAY01 1455 2132 forward 3 Transglutamin_C	LI:350754.4:2000MAY01 54 413 forward 3 Transglutamin_N	LI:255828.29:2000MAY01 2 367 forward 2 PK	LI:255828.29:2000MAY01 348 512 forward 3 PK	LI:1190263.1:2000MAY01 281 1750 forward 2 Sulfatase	LG:999414.3:2000FEB18 718 1038 forward 1 7tm_1	LG:999414.3:2000FEB18 1115 1453 forward 2 7tm_1	LG:068682.1:2000FEB18 176 883 forward 2 pkinase	LG:242665.1:2000FEB18 190 747 forward 1 ras	199		662 forward 3	LI:1085273.2:2000MAY01 285 1070 forward 3 DSPc	LI:333138.2:2000MAY01 291 1016 forward 3 pkinase	370 630 forward 1	3 4 153 forward 1	431	LG:021371.3:2000FEB18 932 1000 forward 2 zf-C2H2	LG:475404.1:2000FEB18 176 328 forward 2 KRAB	LG:979406.2:2000FEB18 85 273 forward 1 KRAB	LG:410726.1:2000FEB18 646 834 forward 1 KRAB	LG:410726.1:2000FEB18 274 558 forward 1 SCAN		173 310 forward 2	LG:1078121.1:2000FEB18 186 374 forward 3 KRAB
	SEQ ID NO:	-	8	თ	4	ဖ	7	ω	တ	9	9	1	=	Ξ	2	. 14	Į, 4	<u>∞</u> 89	19	20	- 5 5	52	88	53	35	32	34	38	99	40	4	41	43	44	45

6.00E-06	9.20E-05	6.80E-12	1.30E-40	7.10E-39	4.40E-05	5.10E-22	2.80E-40	7.40E-22	3.70E-41	2.10E-38	3.90E-08	2.10E-04	4.30E-06	1.40E-04	1.80E-05	2.50E-07	1.60E-27	2.60E-06	1.00E-07	3.40E-04	5.30E-06	1.70E-41	8.70E-06	1.00E-07	3.40E-04	1.00E-07	3.40E-04	1.10E-06	7.10E-39	2.60E-07	5.30E-07	5.00E-21	6.50E-40	3.00E-24	4.40E-07
				-		1	٠.	•				•.										٠													
			÷									ů.											•							1	•	,			
																	•		•	•		· .										,			,
Zinc finger C2H2 type	Zinc finger, C2H2 type		KRAB box	KRAB box	Zinc finger, C2H2 type	KRAB box	KRAB box	KRAB box	KRAB box	KRAB box	Zinc finger, C2H2 type	Zinc finger, C2H2 type			\sim	$\overline{}$	KRAB box	Zinc finger, C2H2 type	_	$\overline{}$	Zinc finger, C2H2 type	KRAB box	Zinc finger, C2H2 type	_		_	Zinc finger, C2H2 type	Zinc finger, C2H2 type	KRAB box	Zinc finger, C2H2 type	Zinc finger, C2H2 type	KRAB box	KRAB box	KRAB box	Zinc finger, C2H2 type
489 forward 1 zf-C2H2	forward 2	-	326 forward 3 KRAB	forward 3	908 forward 3 zf-C2H2	266 forward 3 KRAB	350 forward 3 KRAB -:	251 forward 3 KRAB	308 forward 3 KRAB	441 forward 1 KRAB	310 forward 2 zf-C2H2	785 forward 3 zf-C2H2	607 forward 2 zf-C2H2	873 forward 1 zf-C2H2	632 forward 3 zf-C2H2	701 forward 3 zf-C2H2	262 forward 2 KRAB	610 forward 2 zf-C2H2	340 forward 2 zf-C2H2	494 forward 3 zf-C2H2	99 forward 1 zf-C2H2	308 forward 3 KRAB	143 forward 3 zf-C2H2	344 forward 3 zf-C2H2	501 forward 1 zf-C2H2	358 forward 2 zf-C2H2	518 forward 3 zf-C2H2	249 forward 1 zf-C2H2	forward 3	397 forward 2 zf-C2H2	432 forward 1 zf-C2H2	319 forward 2 KRAB	313 forward 2 KRAB	216 forward 1 KRAB	293 forward 3 zf-C2H2
421	647	414	138	45	840	117	162	129	120	253	242	717	539	802	564	633	7	545	272	426	ઝ	120	75	276	433	290	450	181	45	329	364	155	125	23	222
I G-1079203 1-2000FEB18	LG:1079203.1:2000FEB18	LG:1082586.1:2000FEB18	LG:1082774.1:2000FEB18	LG:1082775.1:2000FEB18	LG:1082775.1:2000FEB18	LG:1083120.1:2000FEB18	LG:1087707,1:2000FEB18	LG:1090915.1:2000FEB18	LG:1094230.1:2000FEB18	LG:474848.3:2000FEB18	LI:251656.1:2000FEB01	LI:021371.1:2000FEB01	LI:133095.1:2000FEB01	LI:236654.2:2000FEB01	LI:200009.1:2000FEB01	LI:758502.1:2000FEB01	LI:789445.1:2000FEB01	LI:789657.1:2000FEB01	LI:789808.1:2000FEB01	Li:789808.1:2000FEB01	LI:792919.1:2000FEB01	LI:793949.1:2000FEB01	LI:794389.1:2000FEB01	LI:796010.1:2000FEB01	LI:796010.1:2000FEB01	LI:796324.1:2000FEB01	LI:796324.1:2000FEB01	LI:796373.1:2000FEB01	LI:796415.1:2000FEB01	LI:798636.1:2000FEB01	LI:800045.1:2000FEB01	LI:800680.1:2000FEB01	LI:800894.1:2000FEB01	LI:801015.1:2000FEB01	LI:801236.1:2000FEB01
46	. 46	47	48	49	49	20	51	52	53	54	22	26	22	28	29	9	62	63	64	64	65	99	29	89	89	69	69	2	7	72	73	74	75	92	11

1	2.10E-38	1.20E-05	2.40E-21	5.70E-05	2.50E-05	1.70E-19	1.80E-06	1.20E-05	1.00E-07	8.90E-08	9.20E-27	5.30E-11	2.00E-16	2.30E-17 .	4.80E-31	1.80E-06	1.50E-07	5.70E-25	1.70E-05	5.00E-21	5.90E-05	4.10E-60:	1.00E-03	2.50E-29	5.80E-05	3.50E-65	3.70E-97	3.30E-66	8.50E-113	8.60E-74	5.50E-52	4.40E-59	1.80E-37	1.30E-18	2.80E-28 8.30E-30	0.000
		Zinc finger, C2H2 type	KRAB box	Zinc finger, C2H2 type	Zinc finger, C2H2 type		Zinc finger, C2H2 type			C2H2 type ·		il aspartyl protease	KRAB box	KRAB box	KRAB box	Zinc finger, C2H2 type	Zinc finger, C2H2 type	KRAB box	Zinc finger, C2H2 type	KRAB box	KRAB box	SCAN domain	Zinc finger, C2H2 type	KRAB box	Zinc finger, C2H2 type	Inward rectifier potassium channel	Ion transport protein	Ion transport protein	Sodium:neurotransmitter symporter family	Sodium:neurotransmitter symporter family	Sodium:neurotransmitter symporter family	Proteasome A-type and B-type	Cyclophilin type peptidyl-prolyl cis-frans isomerase.	Cyclophilin type peptidyl-prolyl cis-trans isomerase	DnaJ domain	Unas domain
	408	130 forward 2	467 643 forward 2 KRAB	53 121 forward 2 zf-C2H2	176 244 forward 2 zf-C2H2	160 312 forward 1 KRAB	424 492 forward 1 zf-C2H2	587 655 forward 2 zf-C2H2	171 239 forward 3 zf-C2H2	901 969 forward 1 zf-C2H2	96 461 forward 3 dUTPase	489 752 forward 3 rvp	182 322 forward 2 KRAB	78 218 · forward 3 KRAB	94 282 forward 1 KRAB	195 263 forward 3 zf-C2H2	706 774 forward 1 zf-C2H2	96 263 forward 3 KRAB	882 950 forward 3 zf-C2H2	175 339 forward 1 KRAB	914 1108 forward 2 KRAB	323 610 forward 2 SCAN	194 262 forward 2 zf-C2H2	185 370 forward 2 KRAB	740 808 forward 2 zf-C2H2	556 831 forward 1 IRK	4569	5314 forward 2	1215 forward 1	782 forward 3	1187 1438 forward 2 SNF	260	427	278 forward 3	351 539 forward 3 DnaJ	ZI/ IOIWard Z
	LI:803335.1:2000FEB01	LI:803998.1:2000FEB01	LI:478757.1:2000FEB01	LI:808532.1:2000FEB01	LI:443073.1:2000FEB01	LI:479671.1:2000FEB01	LI:810078.1:2000FEB01	LI:810078.1:2000FEB01	LI:810224.1:2000FEB01	LI:817052.2:2000FEB01	LG:892274.1:2000MAY19	LG:892274.1:2000MAY19	LG:1080959.1:2000MAY19	LG:1054900.1:2000MAY19	LG:1077357.1:2000MAY19	LG:1084051.1:2000MAY19	LG:1076853.1:2000MAY19	LG:481631.10:2000MAY19	LG:481631.10:2000MAY19	LG:1088431.2:2000MAY19	LI:1144007.1:2000MAY01	LI:1144007.1:2000MAY01	LI:331074.1:2000MAY01	LI:1170349.1:2000MAY01	LI:1170349.1:2000MAY01	LG:101269.1:2000MAY19	LI:410188.1:2000MAY01	LI:410188.1:2000MAY01	LI:1188288.1:2000MAY01			LG:451682.1:2000FEB18	LG:1077283.1:2000FEB18	LG:1077283.1:2000FEB18	LG:481436.5:2000FEB18	LI:3/363/.1:2000FEBU1
į	28	29	8	81	82	83	8	84	82	98	87	87	88	88	8	91	35	83	93	94	96	96	26	86	98	102	104	104	105	105	105	107	108	108	1	=

1.10E-17 9.80E-66 7.20E-21 7.20E-44 9.10E-13 7.10E-06	2.70E-19 1.60E-14 6.00E-20 4.80E-14	2.30E-08 1.80E-65 1.50E-173 3.50E-45	4.40E-27 5.40E-27 2.30E-38	2.50E-10 1.40E-09 2.00E-51 7.10E-157 1.60E-22	5.90E-07 5.10E-06 7.10E-20 2.50E-06 3.00E-04 6.80E-172	4.90E-06 4.10E-07 5.40E-08 1.80E-21 9.90E-04 7.10E-160 4.80E-57 6.60E-78
SCP-like extracellular protein TCP-1/cpn60 chaperonin family Helicases conserved C-terminal domain SNF2 and others N-terminal domain Helicases conserved C-terminal domain SNF2 and others N-terminal domain	Helicases conserved C-terminal domain SNF2 and others N-terminal domain Cadherin domain Ribosomal protein 123	Immunoglobulin domain Class II histocompatibility antigen, alpha domain Cytochrome P450 Cytochrome P450	Cytochrome P450 Cytochrome P450 C1q domain	Collagen triple helix repeat (20 coples) Sushi domain (SCR repeat) von Willebrand factor type A domain Intermediate filament proteins FERM domain (Band 4.1 family)	Myosin head (motor domain) WD domain, G-beta repeat Tubulin/FtsZ family Tubulin/FtsZ family FHA domain	Ank repeat Spectrin repeat WW domain Cadherin domain Cadherin domain Myelin proteolipid protein (PLP or lipophilin) Ribosomal protein L32 Ribosomal protein S12
1106 forward 3 SCP 788 forward 3 cpn60_TCP1 7957 forward 1 helicase_C 631 forward 2 SNF2_N 8 475 forward 2 helicase_C 95 forward 3 SNF2 N	600 forward 1 173 forward 3 1699 forward 2 764 forward 3	790 forward 2 ig 547 forward 2 MHC_II_al 1518 forward 1 p450 998 forward 3 p450	384 forward 1 673 forward 2 964 forward 2	 544 forward 2 Collagen 209 forward 3 sushi 813 forward 1 wwa 7362 forward 1 filament 562 forward 2 Band_41 	129 forward 1 336 forward 1 341 forward 3 478 forward 2 1652 forward 3 1193 forward 3	356 forward 3 1312 forward 2 1450 forward 2 889 forward 2 1520 forward 1 459 forward 1 473 forward 3
LI:053826.1:2000MAY01 834 LI:449393.1:2000MAY01 90 LG:345527.1:2000FEB18 667 LG:34557.1:2000FEB18 8 LI:335671.2:2000FEB01 38 LI:335671.2:2000FEB01 3	· o o — _	T T W		LI:414307.1:2000FEB01 365 LI:202943.2:2000FEB01 36 LG:120744.1:2000MAY19 301 LI:757520.1:2000MAY01 427 LG:160570.1:2000FEB18 260		
113 LL 114 LL; 117 LG 117 LG 122 LG				143 144 147 148 169 149		

EMSCOSPOLARD BIRELE


2.40E-25 2.70E-60	2.40E-59	4.20E-28	4.30E-28	7.70E-07	6.90E-77	6.10E-47	3.20E-21	6.60E-78	6.00E-17	1.40E-97	5.20E-76	1.60E-40	6.60E-78	1,60E-13	1.80E-24	2.90E-11	2.50E-13	5.40E-13	4.20E-41	3.90E-14	1.60E-44	9.90E-138	1.50E-12	5.50E-15	8.60E-44	1.70E-19	6.80E-31		,	2.60E-39	1.60E-06	7.00E-17
Ribosomal protein L5	Ribosomal protein S26e	Ribosomal protein L30p/L7e	Ribosomal L22e protein family	Ribosomal L22e protein family	Ribosomal protein S11	Ribosomal protein S12	Ribosomal protein \$12	Ribosomal protein S12	Ribosomal protein L31e	Ribosomal family S4e	Ribosomai protein L22p/L17e	Ribosomal protein S9/S16	Ribosomal protein \$12	Ribosomal protein L37e	Mitochondrial carrier proteins	Protein phosphatase 2C	KH domain	KH domain	Dehydrins	Phosphopantetheine attachment site	Acyl CoA binding protein	HECT-domain (ubiquitin-transferase):	WW domain	IPT/TIG domain	Syntaxin	Gamma-thionins family	Retroviral GAG p10 protein	gag gene protein p24 (core nucleocapsid	gag gene protein p24 (core nucleocapsid	SPFH domain / Band 7 family	Zinc finger, C2H2 type	G-patch domain
268 forward 2 Ribosomal_L5 577 forward 2 Ribosomal_L5 C	forward 3	forward 3	397 forward 2 Ribosomal_L22e	318 forward 1 Ribosomal_L22e	531 forward 1 Ribosomal_S11	368 forward 3 Ribosomal_S12	504 forward 1 Ribosomal_S12	490 forward 2 Ribosomal_S12	236 forward 3 Ribosomal_L31e	671 forward 3 Ribosomal_S4e	499 forward 2 Ribosomal_L22	673 forward 2 Ribosomal_S9	473 forward 3 Ribosomal_S12	479 forward 3 Ribosomal_L37e	426 forward 1 mito_carr	1555 forward 2 PP2C	1447 forward 2 KH-domain	744 forward 1 KH-domain	426 forward 1 dehydrin	481 forward 2 pp-binding	316 forward 2 ACBP	2414 forward 3 HECT	1154 forward 3 WW	385 forward 2 TIG	1212 forward 1 Syntaxin	299 forward 3 Gamma-thionin	552 forward 1 Gag_p10	1229 forward 3	1545 forward 1	1515 forward 1 Band_7	117 forward 1 zf-C2H2	336 forward 1 G-patch
107	27	306	53	8	175	8	367	88	က	243	8	110	69	318	142	1151	1292	592		278	8	1497	1065	128	322	159	286	1044	1375	985	49	202
LG:452089.1:2000FEB18 LG:452089.1:2000FEB18	LG:246415.1:2000FEB18	LG:1101445.1:2000FEB18	LI:246422.1:2000FEB01	L1:246422.1:2000FEB01	LG:449404.1:2000MAY19	LG:449413.1:2000MAY19	LG:449413.1:2000MAY19	LG:450105.1:2000MAY19	LG:460809.1:2000MAY19	LG:481781.1:2000MAY19	LG:1101153.1:2000MAY19	LI:257695.20:2000MAY01	LI:455771.1:2000MAY01	LI:035973.1:2000MAY01	LG:247781.2:2000FEB18	LI:900264.2:2000MAY01	LI:1189543.1:2000MAY01	LI:1189543.1:2000MAY01	LG:455450.1:2000FEB18	LG:1040978.1:2000FEB18	LG:446649.1:2000FEB18	LG:132147.3:2000FEB18	LG:132147.3:2000FEB18	LG:162161.1:2000MAY19	LG:204626.1:2000MAY19	LI:476342.1:2000MAY01	LG:482261.1:2000FEB18	LG:482261.1:2000FEB18	LG:482261.1:2000FEB18	LG:480328.1:2000FEB18	LG:480328.1:2000FEB18	LG:380497.2:2000MAY19
165 165	166	168	171	171	172	173	173	174	175	176	177	178	179	181	183	 130	192	192	193	194	195	196	196	198	200	202	205	202	202	506	506	210

BL	E.	3

	TABLE 3					
	Template ID	Start	Stop	Frame	Domain	Topology
SEQ ID NO:			4		' Type	
1	LG:1040582.1:2000FEB18	31	117	forward 1	TM	N in
1	LG:1040582.1:2000FEB18	319	405	forward 1	TM	N in
1	LG:1040582.1:2000FEB18	108	155	forward 3	TM	N out
2 ·	LG:453570.1:2000FEB18	361	447	forward 1	TM	N in
3	LG:408751.3:2000FEB18	1318	1404	forward 1	TM	N in
3	LG:408751.3:2000FEB18	1025	1099	forward 2	TM	N in
3	LG:408751.3:2000FEB18	1298	1360	forward 2	TM	N in
3	LG:408751.3:2000FEB18	1379	1441	forward 2	TM	N in
3	LG:408751.3:2000FEB18	1463	1537	forward 2	TM	N in
3	LG:408751.3:2000FEB18	1047	1133	forward 3	TM	N in
3	LG:408751.3:2000FEB18	1266	1352	forward 3	TM	N in
3	LG:408751.3:2000FEB18	1419	1469	forward 3	TM	N in
4	LI:090574.1:2000FEB01	79	144	forward 1	TM	N in
4	LI:090574.1:2000FEB01	607	678	forward 1	TM	N in
4	LI:090574.1:2000FEB01	1009	1080	forward 1	TM	N in
4	LI:090574.1:2000FEB01	497	583	forward 2	TM	N out
4	LI:090574.1:2000FEB01	743	829	forward 2	TM	N out
4	LI:090574.1:2000FEB01	1026	1085	forward 3	TM	N out
5	LI:229932.2:2000FEB01	76	162	forward 1	TM	N out
5	LI:229932.2:2000FEB01	190	276	forward 1	TM	N out
5	LI:229932.2:2000FEB01	1237	1323	forward 1	TM	
. 5	LI:229932.2:2000FEB01	68	142	forward 2	TM	N out N in
, 5 5	LI:229932.2:2000FEB01	335	412	forward 2		N in
5		335 758	412 844		TM	
5 5	LI:229932.2:2000FEB01 LI:229932.2:2000FEB01	736 1229	1288	forward 2	TM	N in
5	LI:229932.2:2000FEB01	60	146	forward 2 forward 3	TM TM	N in N in
5	LI:229932.2:2000FEB01	216	302	forward 3	TM	N in
5	Ll:229932.2:2000FEB01	690	752	forward 3	TM	N in
5	LI:229932.2:2000FEB01	765	827	forward 3	TM	N in
5	LI:229932.2:2000FEB01	1209	1289	forward 3	TM	N in
6	LI:332176.1:2000FEB01	343	399	forward 1	TM	N in
6	LI:332176.1:2000FEB01	1078	1131	forward 1	TM	N in
6	LI:332176.1:2000FEB01	1606	1692	forward 1	TM	N in
6	LI:332176.1:2000FEB01	2218	2274	forward 1	TM	N in
6	LI:332176.1:2000FEB01	2383	2433	forward 1	TM	N in
6	LI:332176.1:2000FEB01	110	196	forward 2	TM	N in
6	Ll:332176.1:2000FEB01	1307	1378	forward 2	TM	N in
6	LI:332176.1:2000FEB01	1640	1726	forward 2	TM -	N in
6	LI:332176.1:2000FEB01	1946	2005	forward 2	TM	N in
6	LI:332176.1:2000FEB01	135	2003	forward 3	TM	N in
6	LI:332176.1:2000FEB01	693	752	forward 3	TM	N in
6	LI:332176.1:2000FEB01	777	839	forward 3	TM	N in
6	LI:332176.1:2000FEB01	867	929	forward 3	TM	N in
6	LI:332176.1:2000FEB01	1035	1118	forward 3	TM	N in
6	LI:332176.1:2000FEB01	1173	1253	forward 3	TM	N in
6	LI:332176.1:2000FEB01	1572				N in
6	LI:332176.1:2000FEB01	2121	1658 2180	forward 3 forward 3	TM TM	N in
6	LI:332176.1:2000FEB01	2277		forward 3		N in
6	LI:332176.1:2000FEB01	2400	2363		TM	
8	LG:220992.1:2000MAY19		2456 393	forward 3	TM	N in
8	LG:220992.1:2000MAY19	343 646		forward 1	TM	
8 8	LG:220992.1:2000MAY19	646	732	forward 1	TM	
8 8	LG:220992.1:2000MAY19	1639	1725	forward 1	TM	
O	LG.220032.1.2000IVIAY19	1879	1965	forward 1	TM	

_	1.0.000000 4.0000044440	0005	0000	formulated 4	773.4	
8	LG:220992.1:2000MAY19	2005 17	2088 76	forward 1 forward 2	TM TM	N in
8 8	LG:220992.1:2000MAY19 LG:220992.1:2000MAY19	4040	1732	forward 2	TM	N in
8	LG:220992.1:2000MAY19	1850	1933	forward 2	TM	N in
8	LG:220992.1:2000MAY19	1434	1484	forward 3	TM	N out
8	LG:220992.1:2000MAY19	1734	1820	forward 3	TM .	N out
8	LG:220992.1:2000MAY19	1974	2036	forward 3	TM	N out
8	LG:220992.1:2000MAY19	2067	2129	forward 3	TM	N out
8	LG:220992.1:2000MAY19	2151	2237	forward 3	TM	N out
9	LG:1094571.1:2000MAY19	781	867	forward 1	TM	N in
9	LG:1094571.1:2000MAY19	419	50 5	forward 2	TM	N in
9	LG:1094571.1:2000MAY19	767	853	forward 2	TM	N in
9	LG:1094571.1:2000MAY19	757 756	842	forward 3	TM	N in
10	LI:350754.4:2000MAY01	277	348	forward 1	TM	N in
10	LI:350754.4:2000MAY01	583	651	forward 1	TM	N in
10	LI:350754.4:2000MAY01	670	747	forward 1	TM	N in
10	LI:350754.4:2000MAY01	381	467	forward 3	TM	N in
10	LI:350754.4:2000MAY01	2469	2555	forward 3	TM	Nin
12	LI:1190263.1:2000MAY01	664	735	forward 1	TM	N in
12	LI:1190263.1:2000MAY01	787	861	forward 1	TM	N in
12	LI:1190263.1:2000MAY01	901	954	forward 1	TM	N in
12	LI:1190263.1:2000MAY01	188	274	forward 2	TM	N in
12	LI:1190263.1:2000MAY01	455	508	forward 2	TM	N in
12	LI:1190263.1:2000MAY01	809	895	forward 2	TM	N in
12	LI:1190263.1:2000MAY01	1616	1663	forward 2	TM	N in
12	LI:1190263.1:2000MAY01	183	251	forward 3	TM	N in
12	LI:1190263.1:2000MAY01	648	704	forward 3	TM	N in
12	LI:1190263.1:2000MAY01	1149	1235	forward 3	TM	N in
13	LG:270916.2:2000FEB18	173	259	forward 2	TM	N out
14	LG:999414.3:2000FEB18	109	195	forward 1	TM	N out
14	LG:999414.3:2000FEB18	358	438	forward 1	TM	N out
14	LG:999414.3:2000FEB18	520	591	forward 1	TM	N out
14	LG:999414.3:2000FEB18	661	744	forward 1	TM	N out
14	LG:999414.3:2000FEB18	883	969	forward 1	TM	N out
14	LG:999414.3:2000FEB18	976	1062	forwa rd 1	TM	N out
14	LG:999414.3:2000FEB18	302	388	forward 2	TM	N in
14	LG:999414.3:2000FEB18	533	613	forward 2	TM	N in
14	LG:999414.3:2000FEB18	992	1048	forward 2	TM	N in
14	LG:999414.3:2000FEB18	1169	1246	forward 2	TM	N in
14	LG:999414.3:2000FEB18	1307	1366	forward 2	TM	N in
14	LG:999414.3:2000FEB18	207	284	forward 3	TM	N out
14	LG:999414.3:2000FEB18	324	404	forward 3	TM	N out
14	LG:999414.3:2000FEB18	540	599	forward 3	TM	N out
14	LG:999414.3:2000FEB18	1029	1115	forward 3	TM	N out
14	LG:999414.3:2000FEB18	1167	1253	forward 3	TM	N out
14	LG:999414.3:2000FEB18	1314	1373	forward 3	TM	N out
15	LG:429446.1:2000FEB18	628	699	forward 1	TM	N out
15	LG:429446.1:2000FEB18	629	682	forward 2	TM	N in
15	LG:429446.1:2000FEB18	627	713	forward 3	TM	N in
16	LI:057229.1:2000FEB01	10	69	forward 1	TM	
16	LI:057229.1:2000FEB01	118	198	forward 1	TM	
16	LI:057229.1:2000FEB01	292	360	forward 1	TM	
16	LI:057229.1:2000FEB01	11	67	forward 2	TM	
16	LI:057229.1:2000FEB01	146	226	forward 2	TM	
16	LI:057229.1:2000FEB01	290	355	forward 2	MT	
16	LI:057229.1:2000FEB01	12	71	forward 3	TM	N out

16	LI:057229.1:2000FEB01	114	176	forward 3	TM	N out
17	LI:351965.1:2000FEB01	487	573	forward 1	TM	•
17	LI:351965,1:2000FEB01	1036	1098	forward 1	TM	
17	LI:351965.1:2000FEB01	492	578	forward 3	TM	N in
17	LI:351965.1:2000FEB01	969	1055	forward 3	TM	N in
17	LI:351965.1:2000FEB01	1098	1184	forward 3	TM	N in
18	LG:068682.1:2000FEB18	707	793 ·	forward 2	TM	N out
19	LG:242665.1:2000FEB18	10	63	forward 1	TM	N out
19	LG:242665.1:2000FEB18	12	62	forward 3	TM	N out
19	LG:242665.1:2000FEB18	333	39 8	, forward 3	TM .	N out
20	LG:241743.1:2000FEB18	43	99	forward 1	ŤM	N out
21	LI:034212.1:2000FEB01	1300	1365	forward 1	, TM	, N _i n
21	LI:034212.1:2000FEB01	1570	1647	forward 1	TM	N in
21	LI:034212.1:2000FEB01	2386	2472	forward 1	TM ·	N in
21	LI:034212.1:2000FEB01	2533	259 8	forward 1	TM	N in
21	LI:034212.1:2000FEB01	2620	2706	forward 1	TM I	N in
21	LI:034212.1:2000FEB01	2740	28 26	forward 1	' TM	N in
21	LI:034212.1:2000FEB01	719	805	forward 2	TM	
21	Ll:034212.1:2000FEB01	1205	1291	forward 2	TM	
21	LI:034212.1:2000FEB01	1460	1546	forward 2	TM	
21	LI:034212.1:2000FEB01	1685	1768	forward 2	TM	•
21	LI:034212.1:2000FEB01	1814	1882	forward 2	' TM	
21	LI:034212.1:2000FEB01	2066	2128	forward 2	TM	
21	LI:034212.1:2000FEB01	2156	2218	forward 2	TM	
21	LI:034212.1:2000FEB01	2540	2626	forward 2	TM	
21	LI:034212.1:2000FEB01	2657	2734	forward 2	TM	
21	LI:034212.1:2000FEB01	12	62	forward 3	TM	N out
21	LI:034212.1:2000FEB01	1236	1301	forward 3	TM	N out
21	LI:034212.1:2000FEB01	1590	1646	forward 3	TM	N out
21	LI:034212.1:2000FEB01	1668	1721	forward 3	TM	N out
21	LI:034212.1:2000FEB01	2130	2216	forward 3	TM	N out
21	LI:034212.1:2000FEB01	2295	2381	forward 3	TM	N out
21	LI:034212.1:2000FEB01	2436	2513	forward 3	TM	N out
21 21	L1:034212.1:2000FEB01 L1:034212.1:2000FEB01	2538 2667	2624 2735	forward 3	TM TM	N out
22	LG:344886.1:2000MAY19	937	1002	forward 3	TM	N out N in
22	LG:344886.1:2000MAY19	1081	1155	forward 1	TM	· N in
22	LG:344886.1:2000MAY19	1696	1782	forward 1 forward 1	TM	N in
22	LG:344886.1:2000MAY19	413	463	forward 2	TM	N in
22	LG:344886.1:2000MAY19	551	637	forward 2	TM	N in
22	LG:344886.1:2000MAY19	950	1012	forward 2	TM	N in
22	LG:344886.1:2000MAY19	1031	1093	forward 2	TM .	N in
22	LG:344886.1:2000MAY19	1112	1183	forward 2	TM	N in
22	LG:344886.1:2000MAY19	1271	1348	forward 2	TM	N in
22	LG:344886.1:2000MAY19	1634	1720	forward 2	TM	N in
22	LG:344886.1:2000MAY19	567	626	forward 3	TM	N in
22	LG:344886.1:2000MAY19	1011	1073	forward 3	TM	N in
22	LG:344886.1:2000MAY19	1089	1151	forward 3	TM	N in
22	LG:344886.1:2000MAY19	1707	1757	forward 3	TM	N in
23	LG:228930.1:2000MAY19	111	167	forward 3	TM	N in
24	LG:338927.1:2000MAY19	934	1020	forward 1	TM	N out
24	LG:338927.1:2000MAY19	1133	1219	forward 2	TM	N in
24	LG:338927.1:2000MAY19	1170	1250	forward 3	TM	N in
25	LG:898771.1:2000MAY19	1261	1314	forward 1	TM	N out
25	LG:898771.1:2000MAY19	1397	1450	forward 2	TM	N out
26	LI:257664.67:2000MAY01	280	366	forward 1	TM	N in
						•••



•						
50	LG:1083120.1:2000FEB18	214	291	forward 1	TM	N out
50	LG:1083120.1:2000FEB18	233	319	forward 2	TM·	N out
50	LG:1083120.1:2000FEB18	252	320	forward 3	· TM	N in
51	LG:1087707.1:2000FEB18	367	453	forward 1	TM	N out
51	LG:1087707.1:2000FEB18	469	531	forward 1	TM	N out
51	LG:1087707.1:2000FEB18	667	729	forward 1	TM	N out
51 ·	LG:1087707.1:2000FEB18	742	804	forward 1	TM	N out
51	LG:1087707.1:2000FEB18	407	481	forward 2	TM	N in
51	LG:1087707.1:2000FEB18	671.	739	forward 2	TM	N in
51	LG:1087707.1:2000FEB18	743	811	forward 2	TM	N in
51	LG:1087707.1:2000FEB18	570	641	forward 3	TM	N out
51	LG:1087707.1:2000FEB18	747	833	forward 3	TM .	N out
52	LG:1090915.1:2000FEB18	11	61	forward 2	TM	N out
53	LG:1094230.1:2000FEB18	469	555	forward 1	TM	N out
53	LG:1094230.1:2000FEB18	449	535	forward 2	TM	N out
54	LG:474848.3:2000FEB18	445	531	forward 1	TM	N out
54	LG:474848.3:2000FEB18	456	518	forward 3	TM	N out
58	LI:236654.2:2000FEB01	221	307	forward 2	TM	N out
59	LI:200009.1:2000FEB01	1045	1131	forward 1	TM	N out
59	LI:200009.1:2000FEB01	1171	1233	forward 1	TM	N out
59	LI:200009.1:2000FEB01	1076	1162	forward 2	TM	N in
59	Ll:200009.1:2000FEB01	1044	1130	forward 3	TM	N in
60	LI:758502.1:2000FEB01	286	369	forward 1	TM	N out
60	LI:758502.1:2000FEB01	755	805	forward 2	TM	N in
60	LI:758502.1:2000FEB01	780	833	forward 3	TM	N in
62	LI:789445.1:2000FEB01	9	80	forward 3	TM	N out
63	LI:789657.1:2000FEB01	854	937	forward 2	TM	N in
64	LI:789808.1:2000FEB01	347	400	forward 2	TM	N in
65	LI:792919.1:2000FEB01	176	256	forward 2	TM	••••
65	LI:792919.1:2000FEB01	371	427	forward 2	TM	
66	LI:793949.1:2000FEB01	208	282	forward 1	TM	N out
66	LI:793949.1:2000FEB01	472	558	forward 1	TM	N out
66	LI:793949.1:2000FEB01	455	541	forward 2	TM	N out
67	LI:794389.1:2000FEB01	265	333	forward 1	TM	N out
67	LI:794389.1:2000FEB01	424	477	forward 1	TM	N out
67	LI:794389.1:2000FEB01	384	455	forward 3	TM	N in
68	LI:796010.1:2000FEB01	351	404	forward 3	TM	N in
69	LI:796324.1:2000FEB01	365	418	forward 2	TM	N in
72	LI:798636.1:2000FEB01	490	543	forward 1	TM	N in
73	LI:800045.1:2000FEB01	627	701	forward 3	TM	N in
74	LI:800680.1:2000FEB01	334	411	forward 1	TM	N out
74	LI:800680.1:2000FEB01	359	421	forward 2	TM	N out
75	LI:800894.1:2000FEB01	536	592	forward 2	TM	N in
75	LI:800894.1:2000FEB01	300	374	forward 3	TM	N out
75	LI:800894.1:2000FEB01	396	482	forward 3	TM	N out
77	LI:801236.1:2000FEB01	262	318	forward 1	TM	N out
78	LI:803335.1:2000FEB01	412	498	forward 1	TM	N out
78	LI:803335.1:2000FEB01	423	485	forward 3	TM	N out
79	LI:803998.1:2000FEB01	221	307	forward 2	TM	N out
81	LI:808532.1:2000FEB01	472	558	forward 1	TM	N in
81	LI:808532.1:2000FEB01	117	203	forward 3	TM	N in
81	LI:808532.1:2000FEB01	363	443	forward 3	TM	N in
81	LI:808532.1:2000FEB01	558	623	forward 3	TM	N in
82	LI:443073.1:2000FEB01	293	379	forward 2	TM	N in
82	LI:443073.1:2000FEB01	81	152	forward 3	TM	N in
82	Ll:443073.1:2000FEB01	189	260	forward 3	TM	N in
		= -				

						,
83	LI:479671.1:2000FEB01	523	579	forward 1	TM	N out
85	LI:810224.1:2000FEB01	246	299	forward 3	TM	
87	LG:892274.1:2000MAY19	49	105	forward 1	TM	N out
87	LG:892274.1:2000MAY19	613	681	forward 1	TM	N out
87	LG:892274.1:2000MAY19	506	589	forward 2	TM	N in
91	LG:1084051.1:2000MAY19	301	363	forward 1 -	TM	· N in
92	LG:1076853.1:2000MAY19	964	1050	forward 1	TM	N in
92	LG:1076853.1:2000MAY19	56	130	forward 2	TM	N out
92	LG:1076853.1:2000MAY19	741	818	forward 3	TM '	N in
93	LG:481631.10:2000MAY19	298	357	forward 1	TM	N out
93	LG:481631.10:2000MAY19	598	654	forward 1	· TM	N out
94	LG:1088431.2:2000MAY19	379	441	forward 1	TM	N out
94	LG:1088431.2:2000MAY19	354	431	forward 3	TM	N out
95	LI:401619.10:2000MAY01	157	219	forward 1	TM	N out
95	LI:401619.10:2000MAY01	232	294	forward 1	, TM ¹	N out
95	LI:401619.10:2000MAY01	502	576	forward 1	TM	N out
95	LI:401619.10:2000MAY01	146	232	forward 2	TM	N in
95	LI:401619.10:2000MAY01	326	412	forward 2	TM	N in
95	LI:401619.10:2000MAY01	440	490	forward 2	TM	N in
95	LI:401619.10:2000MAY01	512	580	forward 2	TM	N in
95	LI:401619.10:2000MAY01	186	257	forward 3	TM'	N in
95	LI:401619.10:2000MAY01	528	599	forward 3	TM	N in
96	Ll:1144007.1:2000MAY01	2833	2910	forward 1	TM	N in
96	LI:1144007.1:2000MAY01	3301	3378	forward 1	TM	N in
96	LI:1144007.1:2000MAY01	3511	3597	forward 1	TM	N in
96	LI:1144007.1:2000MAY01	3634	3696	forward 1	TM	N in
96	LI:1144007.1:2000MAY01	3736	3801	forward 1	TM	N in
96	LI:1144007.1:2000MAY01	2645	2725	forward 2	TM	N out
96	LI:1144007.1:2000MAY01	2879	2965	forward 2	TM	N out
96	LI:1144007.1:2000MAY01	3356	3433	forward 2	TM	N out
96	LI:1144007.1:2000MAY01	3476	3523	forward 2	TM	N out
96	LI:1144007.1:2000MAY01	2772	2858	forward 3	TM	N in
96	LI:1144007.1:2000MAY01	3258	3332	forward 3	TM	N in
96	LI:1144007.1:2000MAY01	4017	4097	forward 3	TM	N in
97	LI:331074.1:2000MAY01	1264	1326	forward 1	TM	N in
97	LI:331074.1:2000MAY01	1357	1419	forward 1	TM	N in
97	LI:331074.1:2000MAY01	1450	1512	forward 1	TM	N in
97	LI:331074.1:2000MAY01	1540	1626	forward 1	TM	N in
97	LI:331074.1:2000MAY01	1433	1513	forward 2	TM	N in
97	LI:331074.1:2000MAY01	1574	1660	forward 2	TM	N in
97	LI:331074.1:2000MAY01	1461	1529	forward 3	TM	N in
97	LI:331074.1:2000MAY01	1560	1646	forward 3	TM	N in N in
98	LI:1170349.1:2000MAY01	34	102	forward 1	TM	
99	LG:335097.1:2000FEB18	601 847	672	forward 1	TM	N out
99	LG:335097.1:2000FEB18	847	909	forward 1	TM	N out
99	LG:335097.1:2000FEB18	928	981	forward 1	TM	N out N out
99	LG:335097.1:2000FEB18	164	244	forward 2	TM	
99	LG:335097.1:2000FEB18	623	682 74	forward 2	TM TM	N out N in
99	LG:335097.1:2000FEB18	12		forward 3		
99	LG:335097.1:2000FEB18	219	299 690	forward 3	TM TM	N in N in
99	LG:335097.1:2000FEB18	594 94	680 156	forward 3	TM	N in
100	LG:1076451.1:2000FEB18 LG:1076451.1:2000FEB18		156 187	forward 1 forward 2	TM	N out
100	LG:1076451.1:2000FEB18 LG:1076451.1:2000FEB18	101 18	187 98		TM	N out
100	LG:1076451.1:2000FEB18 LG:1076451.1:2000FEB18	96	98 164	forward 3 forward 3	TM	N out
100	LG:1076451.1:2000FEB18		290	forward 3	TM	N out
100	LG. 1070431.112000FEB18	216	230	ioiwaru 3	t IVI	14 Out

WO 01/62927 PCT/US01/06059

		•				
101	LI:805478.1:2000FEB01	83	136	forward 2	TM	N-out
101	LI:805478.1:2000FEB01	212	298	forward 2	TM	N out
102	LG:101269.1:2000MAY19	655	741	forward 1	. TM	N in
102	LG:101269.1:2000MAY19	650	736	forward 2	TM	N in
102	LG:101269.1:2000MAY19	96	182	forward 3	TM .	N in
102	LG:101269.1:2000MAY19	249	335	forward 3	TM	N in
102	LG:101269.1:2000MAY19	663	740	forward 3	TM	N in
103	LI:331087.1:2000MAY01	251	298	forward 2	TM	N out
103	LI:331087.1:2000MAY01	237	311	forward 3	TM	
104	LI:410188.1:2000MAY01	520	591	forward 1	TM	N in
104	LI:410188.1:2000MAY01	640	· 711	forward 1	TM	N in
104	LI:410188.1:2000MAY01	724	810	forward 1	TM .	N in
104	LI:410188.1:2000MAY01	832	879	forward 1	TM	N in
104	LI:410188.1:2000MAY01	883	969	forward 1	TM	' N in
104	LI:410188.1:2000MAY01	1171	1257	forward 1	TM	N in
104	LI:410188.1:2000MAY01	1303	1389	forward 1	TM	N in
104	LI:410188.1:2000MAY01	2290	2361	forward 1	TM	N in
104	LI:410188.1:2000MAY01	2389	2460	forward 1	TM	N in
104	LI:410188.1:2000MAY01	2470	2556	forward 1	TM	N in
104	LI:410188.1:2000MAY01	2635	2721	forward 1	TM	N in
104	LI:410188.1:2000MAY01	2794	2862	forward 1	TM	N in
104	LI:410188.1:2000MAY01	2878	2964	forward 1	TM	N in
104	LI:410188.1:2000MAY01	3757	3837	forward 1	TM	N in
104	LI:410188.1:2000MAY01	3871	3957	forward 1	TM	N in
104	LI:410188.1:2000MAY01	3961	4047	forward 1	TM	N in
104	LI:410188.1:2000MAY01	4111	4194	forward 1	TM	N in
104	LI:410188.1:2000MAY01	4342	4428	forward 1	TM .	N in
104 104	LI:410188.1:2000MAY01 LI:410188.1:2000MAY01	4492 4714	4578	forward 1	TM TM	N in
104	LI:410188.1:2000MAY01	6439	4794 6519	forward 1 forward 1	TM	N in N in
104	LI:410188.1:2000MAY01	7492	7575	forward 1	TM	N in
104	LI:410188.1:2000MAY01	7432 7783	7845	forward 1	TM	N in
104	LI:410188.1:2000MAY01	4673	4735	forward 2	TM	Nin
104	LI:410188.1:2000MAY01	4766	4828	forward 2	TM	N in
104	LI:410188.1:2000MAY01	4928	5014	forward 2	TM	N in
104	LI:410188.1:2000MAY01	5231	5317	forward 2	TM	N in
104	LI:410188.1:2000MAY01	6341	6409	forward 2	TM	N in
104	Ll:410188.1:2000MAY01	7655	7741	forward 2	TM	N in
104	LI:410188.1:2000MAY01	8060	8146	forward 2	TM	N in
104	Ll:410188.1:2000MAY01	4776	485 9	forward 3	TM	N in
104	LI:410188.1:2000MAY01	6309	6371	forward 3	TM	N in
104	LI:410188.1:2000MAY01	7704	7775	forward 3	TM	N in
105	LI:1188288.1:2000MAY01	457	519	forward 1	TM	
105	LI:1188288.1:2000MAY01	841	915	forward 1	TM	
105	LI:1188288.1:2000MAY01	958	1038	forward 1	TM	
105	LI:1188288.1:2000MAY01	1072	1140	forward 1	TM	
105	LI:1188288.1:2000MAY01	1477	1539	forward 1	TM	
105	LI:1188288.1:2000MAY01	1564	1626	forward 1	TM	
105	LI:1188288.1:2000MAY01	1810	1896	forward 1	TM	
105	LI:1188288.1:2000MAY01	2134	2220	forward 1	TM	
105	LI:1188288.1:2000MAY01	2734	2820	forward 1	TM	
105	LI:1188288.1:2000MAY01	1067	1147	forward 2	TM	N out
105	LI:1188288.1:2000MAY01	1157	1243	forward 2	TM	N out
105 105	LI:1188288.1:2000MAY01	1313	1399	forward 2	MT	N out
105	LI:1188288.1:2000MAY01 LI:1188288.1:2000MAY01	1556	1618 2368	forward 2	TM	N out
105	LI.1 100200.1:2UUUMAYU1	2294	∠305	forward 2	TM	N out
		200		1		
	i			l .		

			•			
105	LI:1188288.1:2000MAY01	435	521	forward 3	TM	N in
105	LI:1188288.1:2000MAY01	597	683	forward 3	' TM	N in
105	LI:1188288.1:2000MAY01	2301	2354	forward 3	TM	N in
105	LI:1188288.1:2000MAY01	2700	2753	forward 3	TM ·	N in
106	LI:427997.4:2000MAY01	148	222	forward 1	TM	N in
106	LI:427997.4:2000MAY01	745	828	forward 1	TM	N in
106	LI:427997.4:2000MAY01	1192	1278	forward 1	TM	N in
106	LI:427997.4:2000MAY01	1351	1434	forward 1	TM	N in
106	LI:427997.4:2000MAY01	1450	1518	forward 1	TM ·	N in
106	LI:427997.4:2000MAY01	1759	1845	forward 1	TM	N in
106	LI:427997.4:2000MAY01	134	220	forward 2	TM	N in
106	LI:427997.4:2000MAY01	749	832	forward 2	TM	N in
106	LI:427997.4:2000MAY01	1031	1087	forward 2	TM	N in
106	LI:427997.4:2000MAY01	1607	1693	forward 2	TM	N in
106	LI:427997.4:2000MAY01	1730	1816	forward 2	TM	N in
106	LI:427997.4:2000MAY01	2111	2191	forward 2	TM	N in
106	LI:427997.4:2000MAY01	150	236	forward 3	TM	N in
106	LI:427997.4:2000MAY01	681	767	forward 3	TM	N in
106	LI:427997.4:2000MAY01	765	851	forward 3	TM	N in
106	LI:427997.4:2000MAY01	1068	1124	forward 3	TM	N in
106	LI:427997.4:2000MAY01	1.665	1751	forward 3	TM	N in
106	LI:427997.4:2000MAY01	1782	1856	forward 3	TM	N in
107	LG:451682.1:2000FEB18	93	155	forward 3	TM	
109	LG:481436.5:2000FEB18	583	669	forward 1	TM	N in
109	LG:481436.5:2000FEB18	7 69	834	forward 1	TM	N in
109	LG:481436.5:2000FEB18	1111	1176	forward 1	TM	N in
109	LG:481436.5:2000FEB18	575	655	forward 2	TM	N out
109	LG:481436.5:2000FEB18	764	826	forward 2	TM	N out
109	LG:481436.5:2000FEB18	1091	1153	forward 2	TM	N out
109	LG:481436.5:2000FEB18	1187	1249	forward 2	TM	N out
109	LG:481436.5:2000FEB18	84	170	forward 3	TM	N in
109	LG:481436.5:2000FEB18	753	833	forward 3	TM	N in
109	LG:481436.5:2000FEB18	1164	1241	forward 3	TM	N in
110	LI:793701.1:2000FEB01	352	405	forward 1	TM	N in
110	LI:793701.1:2000FEB01	389	475	forward 2	TM	N in
111	LI:373637.1:2000FEB01	412	498	forward 1	TM	
111	LI:373637.1:2000FEB01	434	520	forward 2	MT	N out
111	LI:373637.1:2000FEB01	866	919	forward 2	TM	N out
111	LI:373637.1:2000FEB01	423	473	forward 3	TM	N in
111	LI:373637.1:2000FEB01	867	920	forward 3	TM	N in
112	LG:239368.2:2000MAY19	241	327	forward 1	TM	N out
113	LI:053826.1:2000MAY01	31	117	forward 1	TM	N out
113	LI:053826.1:2000MAY01	1102	1188	forward 1	TM	N out
113	LI:053826.1:2000MAY01	1282	1350	forward 1	TM	N out
113	LI:053826.1:2000MAY01	41	112	forward 2	TM TM	N out
113	LI:053826.1:2000MAY01 LI:053826.1:2000MAY01	164	238	forward 2	TM	N out N out
113		461	538	forward 2 forward 2	TM	N out
113	LI:053826.1:2000MAY01 LI:053826.1:2000MAY01	1130 1214	1192 1276	forward 2	TM	N out
113	LI:053826.1:2000MAY01 LI:053826.1:2000MAY01	1307	1378	forward 2	TM	N out
113	LI:053826.1:2000MAY01 LI:053826.1:2000MAY01	126	200	forward 3	TM	N in
113	LI:053826.1:2000MAY01	348	200 416	forward 3	TM	N in
113	LI:053826.1:2000MAY01 LI:053826.1:2000MAY01	346 624	683	forward 3	TM	N in
113 113	LI:053826.1:2000MAY01	1215	1277	forward 3	TM	N in
113	LI:053826.1:2000MAY01	1213	1352	forward 3	TM	N in
115	LI:1071427.96:2000MAY01	1072	1140	forward 1	TM	
		,				

115	LI:1071427.96:2000MAY01	1297	1383	forward 1	TM	
115	LI:1071427.96:2000MAY01	1459	1536	forward 1	TM	
115	LI:1071427.96:2000MAY01	1765	1851	forward 1	TM	
115	LI:1071427.96:2000MAY01	1909	1971	forward 1	TM	
115	LI:1071427.96:2000MAY01	2002	2064	forward 1	TM	
115	'LI:1071427.96:2000MAY01	1562	1648	forward 2	TM	N out
115	LI:1071427.96:2000MAY01	1706	1792	forward 2	TM	N out
115	LI:1071427.96:2000MAY01	1823	1885	forward 2	TM	N out
115	LI:1071427.96:2000MAY01	1913	1975	forward 2	TM	N out
115	LI:1071427.96:2000MAY01	2045	2098	forward 2	TM	N out
115	LI:1071427.96:2000MAY01	384	470	forward 3	TM	N out
115	LI:1071427.96:2000MAY01	840	926	forward 3	TM	N out
115	LI:1071427.96:2000MAY01	987	1049	forward 3	TM	N out
115	LI:1071427.96:2000MAY01	1092	1154	forward 3	TM	N out
		1383	1454	•		
115	LI:1071427.96:2000MAY01			forward 3	TM	N out
115	LI:1071427.96:2000MAY01	1599	1655	forward 3	TM '	N out
115	LI:1071427.96:2000MAY01	1767	1844	forward 3	TM	N out
115	LI:1071427.96:2000MAY01	1884	1952	forward 3	TM	N out
115	LI:1071427.96:2000MAY01	2013	2099	forward 3	TM	N out
115	LI:1071427.96:2000MAY01	2127	2189	forward 3	TM	N out
116	LI:336338.8:2000MAY01	100	186	forward 1	TM	N out
116	LI:336338.8:2000MAY01	427	513	forward 1	TM'	N out
116	LI:336338.8:2000MAY01	110	196	forward 2	TM	
116	LI:336338.8:2000MAY01	281	367	forward 2	TM	
116	Ll:336338.8:2000MAY01	422	508	forward 2	TM	
116	LI:336338.8:2000MAY01	354	416	forward 3	TM	N out
116	LI:336338.8:2000MAY01	432	494	forward 3	TM	N out
117	LG:345527.1:2000FEB18	46	120	forward 1	TM	N out
117	LG:345527.1:2000FEB18	917	979	forward 2	TM	N out
117	LG:345527.1:2000FEB18	1010	1072	forward 2	TM	N out
117	LG:345527.1:2000FEB18	1112	1198	forward 2	TM	N out
117	LG:345527.1:2000FEB18	96	182	forward 3	TM	N out
117	LG:345527.1:2000FEB18	474	536	forward 3	TM	N out
117	LG:345527.1:2000FEB18	552	614	forward 3	TM	N out
118	LG:1089383.1:2000FEB18	43	126	forward 1	TM	N out
118	LG:1089383.1:2000FEB18	14	100	forward 2	TM	
118	LG:1089383.1:2000FEB18	140	205	forward 2	TM	
118	LG:1089383.1:2000FEB18	12	59	forward 3	TM	N out
120	LG:1093216.1:2000FEB18	31	117	forward 1	TM.	N out
120	LG:1093216.1:2000FEB18	151	234	forward 1	TM	N out
120	LG:1093216.1:2000FEB18	283	348	forward 1	TM	N out
120	LG:1093216.1:2000FEB18	23	109	forward 2	TM	N in
120	LG:1093216.1:2000FEB18	143	193	forward 2	TM	N in
120	LG:1093216.1:2000FEB18	48	122	forward 3	TM	N out
120	LG:1093216.1:2000FEB18	180	263	forward 3	TM	N out
122	LI:335671.2:2000FEB01	22	108	forward 1	TM	N out
122	LI:335671.2:2000FEB01	1048	1134	forward 1	TM	N out
122	LI:335671.2:2000FEB01	854	916	forward 2	TM	N in
122	LI:335671.2:2000FEB01	926	988	forward 2	TM	N in
122	LI:335671.2:2000FEB01	998	1072	forward 2	TM	N in
122	LI:335671.2:2000FEB01	399	461	forward 3	TM	N out
122	LI:335671.2:2000FEB01	480	542	forward 3	TM	N out
122	LI:335671.2:2000FEB01	576	662	forward 3	TM	N out
122	LI:335671.2:2000FEB01	1023	1085	forward 3	TM	N out
122	LI:335671.2:2000FEB01	1098	1160	forward 3	TM	N out
122	LI:335671.2:2000FEB01	1173	1235	forward 3	TM	N out

A contract to the contract success.

123	LI:793758.1:2000FEB01	31	117	forward 1	TM ·	N out
123	LI:793758.1:2000FEB01	151	234	forward 1	TM	N out
123	LI:793758.1:2000FEB01	283	348	forward 1	TM	N out
123	LI:793758.1:2000FEB01	23	109	forward 2	· TM	N in
123	LI:793758.1:2000FEB01	143	193	forward 2	TM	N in
123	LI:793758.1:2000FEB01	48	122	forward 3	TM	N out
123	LI:793758.1:2000FEB01	180	263	forward 3	TM	N out
124	LI:803718.1:2000FEB01	43	126	forward 1	TM	N out
124	LI:803718.1:2000FEB01	14	100	forward 2	TM '	
124	LI:803718.1:2000FEB01	140	205	forward 2	TM	
124	LI:803718.1:2000FEB01	12	59	forward 3	' TM	N out
125	LI:412179.1:2000FEB01	328	414	forward 1	TM	
125	LI:412179.1:2000FEB01	436	504	forward 1	TM '	
125	LI:412179.1:2000FEB01	56	115	forward 2	TM	N out
125	LI:412179.1:2000FEB01	413	475	forward 2	TM '	N out
125	LI:412179.1:2000FEB01	512	574	forward 2	TM	N out
125	LI:412179.1:2000FEB01	96	176	forward 3	TM	N out
125	LI:412179.1:2000FEB01	384	446	forward 3	TM	N out
125	LI:412179.1:2000FEB01	462	524	forward 3	TM	N out
126	LI:815679.1:2000FEB01	10	84	forward 1	TM	N out
126	LI:815679.1:2000FEB01	313	399	forward 1	TM'	N out
126	LI:815679.1:2000FEB01	946	1032	forward 1	TM	N out
126	LI:815679.1:2000FEB01	1171	1248	forward 1	TM	N out
126	LI:815679.1:2000FEB01	323	409	forward 2	TM	N in
126	LI:815679.1:2000FEB01	500	568	forward 2	TM	N in
126	LI:815679.1:2000FEB01	971	1021	forward 2	TM	N in
126	LI:815679.1:2000FEB01	1493	1561	forward 2	TM	N in
126	LI:815679.1:2000FEB01	15	92	forward 3	TM	N in
126	LI:815679.1:2000FEB01	285	356	forward 3	TM	N in
126	LI:815679.1:2000FEB01	690	764	forward 3	TM	N in
126	LI:815679.1:2000FEB01	993	1076	forward 3	TM	N in
126	LI:815679.1:2000FEB01	1626	1712	forward 3	TM	N in
127	LI:481361.3:2000FEB01	199	252	forward 1	TM	N out
128	LG:247388.1:2000MAY19	190	240	forward 1	TM	N out
128	LG:247388.1:2000MAY19	233	319	forward 2	TM	N out
128	LG:247388.1:2000MAY19	446	532	forward 2	TM	N out
130	LI:787618.1:2000MAY01	10	84	forward 1	TM	N in
130	LI:787618.1:2000MAY01	313	399	forward 1	TM	N in
130	LI:787618.1:2000MAY01	679	750	forward 1	TM	N in
130	LI:787618.1:2000MAY01	1018	1098	forward 1	TM	N in
130	LI:787618.1:2000MAY01	1189	1266	forward 1	TM	N in
130	LI:787618.1:2000MAY01	323	409	forward 2	TM	Ņ out
130	LI:787618.1:2000MAY01	500	5 68	forward 2	TM	N out
130	LI:787618.1:2000MAY01	944	1030	forward 2	TM	N out
130	LI:787618.1:2000MAY01	1508	1582	forward 2	TM	N out
130	LI:787618.1:2000MAY01	1616	1702	forward 2	TM	N out
130	LI:787618.1:2000MAY01	15	92	forward 3	TM	N out
130	LI:787618.1:2000MAY01	285	356	forward 3	TM	N out
131	LI:331610.2:2000MAY01	91	156	forward 1	TM	
131	LI:331610.2:2000MAY01	277	363	forward 1	TM	
131	LI:331610.2:2000MAY01	682	744	forward 1	TM	
131	LI:331610.2:2000MAY01	4126	4212	forward 1	TM	
131	LI:331610.2:2000MAY01	4951	5001	forward 1	TM	
131	LI:331610.2:2000MAY01	5023	5109	forward 1	TM	
131	LI:331610.2:2000MAY01	5128	5190	forward 1	TM	
131	LI:331610.2:2000MAY01	5407	5469	forward 1	TM	

					ė	ş ·
131	LI:33	5485	5547	ward 1	TM	
131	LI:331610.2:2000MAY01	5563	5625	forward 1	TM	
131	LI:331610.2:2000MAY01	5728	58 05	forward 1	TM	
131	LI:331610.2:2000MAY01	5896	594 9	forward 1	TM	
131	LI:331610.2:2000MAY01	6268	6327	forward 1	TM	
131	LI:331610.2:2000MAY01	6454	6522	forward 1	TM	
131	LI:331610.2:2000MAY01	6559	6645			
	LI:331610.2:2000MAY01			forward 1	TM	
131	LI:331610.2:2000MAY01	7477	7539	forward 1	TM	
131		7552	7614	forward 1	TM	N
131	LI:331610.2:2000MAY01	671	724	forward 2	TM	N out
131	LI:331610.2:2000MAY01	4127	4213	forward 2	TM	N out
131	LI:331610.2:2000MAY01	4928	5011	forward 2	TM	N out
131	LI:331610.2:2000MAY01	5051	5113	forward 2	TM	N out
131	LI:331610.2:2000MAY01	5135	5197	forward 2	TM	N out
131	LI:331610.2:2000MAY01	5207	5269	forward 2	TM	N out
131	LI:331610.2:2000MAY01	5537	5611	forward 2	TM	N out
131	LI:331610.2:2000MAY01	5726	5797	forward 2	TM	N out
131	Ll:331610.2:2000MAY01	5903	5989	forward 2	TM	N out
131	LI:331610.2:2000MAY01	6392	6478	forward 2	TM	N out
131	LI:331610.2:2000MAY01	6746	6814	forward 2	TM	N out
131	LI:331610.2:2000MAY01	7295	7381	forward 2	TM	N out
131	LI:331610.2:2000MAY01	7586	7633	forward 2	TM.	N out
131	LI:331610.2:2000MAY01	2763	2849	forward 3	TM	
131	LI:331610.2:2000MAY01	4527	4595	forward 3	TM	
131	LI:331610.2:2000MAY01	5079	5165	forward 3	TM	
131	LI:331610.2:2000MAY01	5445	5516	forward 3	TM	•
131	LI:331610.2:2000MAY01	5676	5759	forward 3	TM	
131	LI:331610.2:2000MAY01	6255	6341	forward 3	TM	
131	LI:331610.2:2000MAY01	6378	6464	forward 3	TM	
131	LI:331610.2:2000MAY01	6624	6692	forward 3	TM	•
131	LI:331610.2:2000MAY01	6705	6779	forward 3	TM	
131	LI:331610.2:2000MAY01	6810	6884	forward 3	TM	
131	LI:331610.2:2000MAY01	7062	7133	forward 3	TM	
131	LI:331610.2:2000MAY01	7677	7748	forward 3	TM	
131	LI:331610.2:2000MAY01	7833	7919	forward 3	TM	
132	LG:982697.1:2000FEB18	355	441	forward 1	TM	N in
132	LG:982697.1:2000FEB18	946	993	forward 1	TM	N in
132	LG:982697.1:2000FEB18	897	983	forward 3	TM	N in
132	LG:982697.1:2000FEB18	1215	1301	forward 3	TM	N in
133	LG:1080896.1:2000FEB18	367	426	forward 1	TM	N in
133	LG:1080896.1:2000FEB18	476	562	forward 2	TM	N in
133	LG:1080896.1:2000FEB18	815	901	forward 2	TM	N in
133	LG:1080896.1:2000FEB18	342	395	forward 3	TM	N in
134	LI:811341.1:2000FEB01	562	615	forward 1	TM	N out
134	LI:811341.1:2000FEB01	691	777	forward 1	TM	N out
135	LI:903225.1:2000FEB01	20	100	forward 2	TM	N out
135	LI:903225.1:2000FEB01	12	83	forward 3	TM	N out
135	LI:903225.1:2000FEB01	768	827	forward 3	TM	N out
137	LG:979580.1:2000MAY19	298	354	forward 1	TM	N in
137	LG:979580.1:2000MAY19	826	909	forward 1	TM	N in
137	LG:979580.1:2000MAY19	934	1020	forward 1	TM	- N in
137	LG:979580.1:2000MAY19	233	289	forward 2	TM	N out
137	LG:979580.1:2000MAY19	338	418	forward 2	TM	N out
137	LG:979580.1:2000MAY19	201	272	forward 3	TM	N in
138	LI:1169865.1:2000MAY01	197	283	forward 2	TM	N in
138	LI:1169865.1:2000MAY01	863	949	forward 2	TM	N in

139	LG:337818.2:2000FEB18	40	117	forward 1	TM ·	N out
139	LG:337818.2:2000FEB18	532	618	forward 1	' TM	N out
139	LG:337818.2:2000FEB18	, 907	993	forward 1	TM	N out
139	LG:337818.2:2000FEB18	1372	1425	forward 1	TM	N out
140	LI:337818.1:2000FEB01	40	114	forward 1	TM -	N in
140	LI:337818.1:2000FEB01	401	466	forward 2	TM	N in
140	LI:337818.1:2000FEB01	852	905	forward 3	TM	N in
141	LG:241577.4:2000MAY19	496	582	forward 1	TM	N in
142	LG:344786.4:2000MAY19	19	105	forward 1	TM	N out
142	LG:344786.4:2000MAY19	14	88	forward 2	TM	N in
142	LG:344786.4:2000MAY19	173	247	forward 2	TM	N in
142	LG:344786.4:2000MAY19	21	107	forward 3	TM	,,,,,,,,,
143	LI:414307.1:2000FEB01	116	202	forward 2	TM	N in
144	LI:202943.2:2000FEB01	166	237	forward 1	TM	N in
144	LI:202943.2:2000FEB01	263	313	forward 2	TM	N out
144	LI:202943.2:2000FEB01	203 276	326	forward 3	TM	N in
	LI:815961.1:2000FEB01	232	291	forward 1	TM	N out
146	LI:815961.1:2000FEB01		167	forward 3	TM	N out
146		81		forward 3	TM	N out
146	LI:815961.1:2000FEB01	243	329 422	forward 3	TM	N out
1.46	LI:815961.1:2000FEB01	354 570	422 659		TM	N out
146	LI:815961.1:2000FEB01	573		forward 3 forward 3	TM	N out
. 146	LI:815961.1:2000FEB01	741	803			N out
147	LG:120744.1:2000MAY19	181	249	forward 1	TM	N Out
147	LG:120744.1:2000MAY19	188	256	forward 2	TM TM	
147	LG:120744.1:2000MAY19	275	328	forward 2		NI in
148	LI:757520.1:2000MAY01	2140	2220	forward 1	TM	N in
148	LI:757520.1:2000MAY01	2293	2379	forward 1	TM	N in
148	LI:757520.1:2000MAY01	1988	2059	forward 2	TM	N in
148	LI:757520.1:2000MAY01	2285	2359	forward 2	TM	N in
148	LI:757520.1:2000MAY01	1677	1763	forward 3	TM	
148	LI:757520.1:2000MAY01	1995	2066	forward 3	TM	31
149	LG:160570.1:2000FEB18	345	413	forward 3	TM	N out
149	LG:160570.1:2000FEB18	462	518	forward 3	TM	N out
151	LI:221285.1:2000FEB01	1375	1452	forward 1	TM	N out
152	LI:401605.2:2000FEB01	235	321	forward 1	TM	N in
152	LI:401605.2:2000FEB01	192	263	forward 3	TM	N in
152	LI:401605.2:2000FEB01	489	563	forward 3	TM	N in
153	LI:329017.1:2000FEB01	179	235	forward 2	TM	N in
153	LI:329017.1:2000FEB01	359	433	forward 2	TM	N in
153	LI:329017.1:2000FEB01	449	526	forward 2	TM	N in
153	LI:329017.1:2000FEB01	617	703	forward 2	TM	N in
153	LI:329017.1:2000FEB01	920	973	forward 2	TM	N in
155	LG:403409.1:2000MAY19	136	222	forward 1	TM	N out
155	LG:403409.1:2000MAY19	973	1029	forward 1	TM	N out
155	LG:403409.1:2000MAY19	1285	1371	forward 1	TM	N out
155	LG:403409.1:2000MAY19	182	268	forward 2	TM	N in
156	LG:233933.5:2000MAY19	148	234	forward 1	TM	N out
156	LG:233933.5:2000MAY19	39	125	forward 3	TM	N out
157	LI:290344.1:2000MAY01	232	312	forward 1	TM	N out
157	LI:290344.1:2000MAY01	1258	1311	forward 1	TM	N out
157	LI:290344.1:2000MAY01	3640	3714	forward 1	TM	N out
157	LI:290344.1:2000MAY01	4366	4449	forward 1	TM	N out
157	LI:290344.1:2000MAY01	4468	4548	forward 1	TM	N out
157	LI:290344.1:2000MAY01	146	226	forward 2	TM	N out
157	LI:290344.1:2000MAY01	3122	3196	forward 2	TM	N out
157	LI:290344.1:2000MAY01	3833	3919	forward 2	TM	N out

157	LI:290544.1:2000MAY01	4457	4537	forward 2	TM	N out
157	LI:290344.1:2000MAY01	4760	4846	forward 2	TM	N out
157	LI:290344.1:2000MAY01	432	503	forward 3	TM	N out
157	LI:290344.1:2000MAY01	1647	1733	forward 3	TM	N out
157	LI:290344.1:2000MAY01	3177	3248	forward 3	TM.	N out
157	LI:290344.1:2000MAY01	3594	3680	forward 3	TM	N out
157	LI:290344.1:2000MAY01	3753	3815	forward 3	TM	N out
157	LI:290344.1:2000MAY01	3864	3926	forward 3	TM	N out
157	LI:290344.1:2000MAY01	4443	4526	forward 3	TM	N out
158	LI:410742.1:2000MAY01	136	210	forward 1	TM .	N out
158	LI:410742.1:2000MAY01	2200	2286	forward 1	TM	N out
158	LI:410742.1:2000MAY01	2437	2514	forward 1	, TM	N out
158	LI:410742.1:2000MAY01	3149	3229	forward 2	TM	N'in
158	LI:410742.1:2000MAY01	3437	35 05	forward 2	TM ·	N in
158	LI:410742.1:2000MAY01	510	578	forward 3	TM	N in
158	LI:410742.1:2000MAY01	1905	1991	forward 3	TM:	N in
158	LI:410742.1:2000MAY01	2811	2897	forward 3	· TM	N'in
158	LI:410742.1:2000MAY01	3168	3254	forward 3	TM	N in
159	LG:406568.1:2000MAY19	490	549	forward 1	TM	N in
159	LG:406568.1:2000MAY19	1732	1818	forward 1	TM ·	N in
159	LG:406568.1:2000MAY19	1825	1899	forward 1	TM	N in
159	LG:406568.1:2000MAY19	1918	2004	forward 1	· TM:	N in
159	LG:406568.1:2000MAY19	12	59	forward 3	TM	N in
159	LG:406568.1:2000MAY19	1935	2018	forward 3	TM	N in
159	LG:406568.1:2000MAY19	2094	2174	forward 3	TM	N in
160	LI:283762.1:2000MAY01	1675	1746	forward 1	TM	
160	LI:283762.1:2000MAY01	2095	2181	forward 1	TM	•
160	LI:283762.1:2000MAY01	2632	2718	forward 1	TM	
160	Ll:283762.1:2000MAY01	2830	2916	forward 1	TM	
160	LI:283762.1:2000MAY01	2941	3027	forward 1	TM	
160	LI:283762.1:2000MAY01	3235	3321	forward 1	TM	
160	LI:283762.1:2000MAY01	3328	3414	forward 1	TM	
160	LI:283762.1:2000MAY01	3592	3666	forward 1	TM	
160	LI:283762.1:2000MAY01	3682	3768	forward 1	TM	
160	LI:283762.1:2000MAY01	4153	4224	forward 1	TM	
160	LI:283762.1:2000MAY01	4360	4434	forward 1	TM	
160	LI:283762.1:2000MAY01	4594	4656	forward 1	TM	
160	LI:283762.1:2000MAY01	4681	4743	forward 1	TM	
160 160	LI:283762.1:2000MAY01	4885	4962 5061	forward 1	TM	
160	L1:283762.1:2000MAY01 L1:283762.1:2000MAY01	5011 92	5061 178	forward 1	TM	NI im
160	LI:283762.1:2000MAY01	92 278	364	forward 2	TM TM	N in N in
160	Li:283762.1:2000MAY01	995	1075	forward 2 forward 2	TM	N in
160	Li:283762.1:2000MAY01	1523	1597	forward 2	TM	N in
160	LI:283762.1:2000MAY01	1817	1903	forward 2	TM	N in
160	LI:283762.1:2000MAY01	2522	2599	forward 2	TM	N in
160	LI:283762.1:2000MAY01	2666	2752	forward 2	TM	· N in
160	LI:283762.1:2000MAY01	2837	2887	forward 2	TM	N in
160	LI:283762.1:2000MAY01	3038	3097	forward 2	TM	N in
160	LI:283762.1:2000MAY01	3563	3625	forward 2	TM	N in
160	LI:283762.1:2000MAY01	3638	3700	forward 2	TM	N in
160	LI:283762.1:2000MAY01	4067	4144	forward 2	TM	N in
160	LI:283762.1:2000MAY01	4439	4522	forward 2	TM	N in
160	LI:283762.1:2000MAY01	4685	4765	forward 2	TM	N in
160	LI:283762.1:2000MAY01	4784	4843	forward 2	TM	N in
160	LI:283762.1:2000MAY01	4973	5050	forward 2	TM	N in

160	LI:283762.1:2000MAY01	5072	5125	forward 2	TM	N in
160	LI:283762.1:2000MAY01	693	755	forward 3	TM	N out
160	LI:283762.1:2000MAY01	765	827	forward 3	TM	N out
160	LI:283762.1:2000MAY01	840	902	forward 3	TM	N out
160	Ll:283762.1:2000MAY01	1623	1694	forward 3	TM	N out
160	LI:283762.1:2000MAY01	1800	1880	forward 3	TM .	N out
160	LI:283762.1:2000MAY01	2622	2708	forward 3	TM	N out
160	LI:283762.1:2000MAY01	2778	2861	forwa rd 3	TM	N out
160	LI:283762.1:2000MAY01	3144	3230	forward 3	TM	N out
160	LI:283762.1:2000MAY01	3276	3362	forward 3	TM	N out
160	LI:283762.1:2000MAY01	3441	3527	forward 3	TM	N out
160	LI:283762.1:2000MAY01	3666	3752	forward 3	TM	N out
160	LI:283762.1:2000MAY01	4077	4163	forward 3	TM .	N out
160	LI:283762.1:2000MAY01	4245	4331	forward 3	TM	N out
160	LI:283762.1:2000MAY01	4395	4481	forward 3	TM	N out
160	LI:283762.1:2000MAY01	4584	4646	forward 3	TM	N out
160	LI:283762.1:2000MAY01	4662	4724	forward 3	TM	N out
160	LI:283762.1:2000MAY01	4845	4892	forward 3	TM	N out
161	LI:347687.113:2000MAY01	319	405	forward 1	TM	N out
1.61	LI:347687.113:2000MAY01	463	549	forward 1	TM	N out
161	LI:347687.113:2000MAY01	733	819	forward 1	TM	N out
161	LI:347687.113:2000MAY01	1240	1293	forward 1	TM	N out
161	LI:347687.113:2000MAY01	1720	1797	forward 1	TM	N out
161	LI:347687.113:2000MAY01	1861	1908	forward 1	TM	N out
161	LI:347687.113:2000MAY01	1972	2034	forward 1	TM	N out
161	LI:347687.113:2000MAY01	2050	2112	forward 1	TM	N out
161	LI:347687.113:2000MAY01	2308	2394	forward 1	TM	N out
161	LI:347687.113:2000MAY01	977	1057	forward 2	TM	N in
161	LI:347687.113:2000MAY01	1250	1309	forward 2	TM	N in
161	LI:347687.113:2000MAY01	1730	1792	forward 2	TM	N in
161	LI:347687.113:2000MAY01	1808	1870	forward 2	TM	N in
161	LI:347687.113:2000MAY01	1886	1948	forward 2	TM	N in
161	LI:347687.113:2000MAY01	324	398	forward 3	TM	N in
161	LI:347687.113:2000MAY01	948	1034	forward 3	TM	N in
161	LI:347687.113:2000MAY01	1686	1763	forward 3	TM	N in
161	LI:347687.113:2000MAY01	1791	1874	forward 3	TM	N in N in
161	LI:347687.113:2000MAY01	2025	2108	forward 3	TM TM	N in
163	LG:451710.1:2000FEB18	502 453	588 515	forward 1 forward 3	TM	N in
163 164	LG:451710.1:2000FEB18 LG:455771.1:2000FEB18	455 199	515 285	forward 1	TM	N out
165	LG:452089.1:2000FEB18	695	772	forward 2	TM	N out
165	LG:452089.1:2000FEB18	708	764	forward 3	TM	N out
166	LG:246415.1:2000FEB18	196	246	forward 1	TM	N in
167	LG:414144.10:2000FEB18	589	672	forward 1	TM	N in
167	LG:414144.10:2000FEB18	615	692	forward 3	TM	N out
168	LG:1101445.1:2000FEB18	787	858	forward 1	TM	N out
	LG:1101445.1:2000FEB18	506	592	forward 2	TM	N out
168 169	LG:452134.1:2000FEB18	276	326	forward 3	TM	N out
170	LI:903021.1:2000FEB01	109	162	forward 1	TM	N out
172	LG:449404.1:2000MAY19	163	219	forward 1	TM	N out
172	LG:449404.1:2000MAY19	200	280	forward 2	TM	N out
173	LG:449413.1:2000MAY19	353	439	forward 2	TM	N out
173	LG:1101153.1:2000MAY19	520	600	forward 1	TM	N in
177	LG:1101153.1:2000MAY19	585	671	forward 3	TM	N in
178	LI:257695.20:2000MAY01	433	516	forward 1	TM	N in
179	LI:455771.1:2000MAY01	199	285	forward 1	TM	N out
113	LOUDINIA I U I	100	200			

						•
180	LI:274551.1:2000MAY01	81	152	forward 3	TM	N out
180	LI:274551.1:2000MAY01	216	269	forward 3	TM	N out
181	LI:035973.1:2000MAY01	622	708	forward 1	TM	. N out
181	LI:035973.1:2000MAY01	596	682	forward 2	TM	N out
181	LI:035973.1:2000MAY01	588	674	forward 3	TM	N out
182	LG:978427.5:2000FEB18	.221	295	forward 2	TM	N out
182	LG:978427.5:2000FEB18	365	433	forward 2	TM	N out
182	LG:978427.5:2000FEB18	198	284	forward 3	TM	N out
183	LG:247781.2:2000FEB18	22	108	forward 1	TM	N in
183	LG:247781.2:2000FEB18	1114	1200	forward 1	TM	N in
183	LG:247781.2:2000FEB18	1149	1235	forward 3	TM	N in
185	LI:333307.2:2000FEB01	24	98	forward 3	, TM	N out
187	LG:414732.1:2000MAY19	40	93	forward 1	TM	N out
187	LG:414732.1:2000MAY19	156	233	forward 3	TM ·	N out
188	LG:413910.6:2000MAY19	385	441	forward 1	TM	N out
188	LG:413910.6:2000MAY19	886	948	forward 1	TM +	N out
188	LG:413910.6:2000MAY19	104	190	forward 2	¹ TM	N out
188	LG:413910.6:2000MAY19	387	461	forward 3	TM	N out
188	LG:413910.6:2000MAY19	921	1007	forward 3	TM	N out
189	LI:414732.2:2000MAY01	34	93	forward 1	TM	N out
189	LI:414732.2:2000MAY01	24	110	forward 3	TM	N out
189	LI:414732.2:2000MAY01	159	236	forward 3	¹ TM₁	N out
190	LI:900264.2:2000MAY01	730	807	forward 1	TM	N in
190	LI:900264.2:2000MAY01	1018	1092	forward 1	TM	N in
190	LI:900264.2:2000MAY01	1294	1350	forward 1	TM	N in
190	LI:900264.2:2000MAY01	1519	1578	forward 1	· TM	N in
190	LI:900264.2:2000MAY01	2311	2397	forward 1	TM	Nin
190	LI:900264.2:2000MAY01	2509	2562	forward 1	TM	N in
190	LI:900264.2:2000MAY01	2752	2808	forward 1	TM	N in
190	LI:900264.2:2000MAY01	3103	3165	forward 1	TM	N in
190	LI:900264.2:2000MAY01	3178	3240	forward 1	TM	N in
190	LI:900264.2:2000MAY01	3253	3315	forward 1	TM	N in
190	LI:900264.2:2000MAY01	3424	3510	forward 1	TM	N in
190	Ll:900264.2:2000MAY01	3520	3603	forward 1	TM	N in
190	LI:900264.2:2000MAY01	3883	3945	forward 1	TM	N in
190	LI:900264.2:2000MAY01	3982	4044	forward 1	TM	N in
190	LI:900264.2:2000MAY01	68	154	forward 2	TM	•
190	LI:900264.2:2000MAY01	188	274	forward 2	TM	•
190	LI:900264.2:2000MAY01	1079	1165	forward 2	TM	
190	LI:900264.2:2000MAY01	2285	2359	forward 2	TM	
190	LI:900264.2:2000MAY01	2732	2812	forward 2	TM	
190	LI:900264.2:2000MAY01	3095	3172	forward 2	TM .	
190	LI:900264.2:2000MAY01	3260	3319	forward 2	TM	
190	LI:900264.2:2000MAY01	3434	3505	forward 2	TM	
190	LI:900264.2:2000MAY01	3515	3601	forward 2	TM	
190	LI:900264.2:2000MAY01	3662	3748	forward 2	TM	
190	LI:900264.2:2000MAY01	3842	3913	forward 2	TM	
190	LI:900264.2:2000MAY01 LI:900264.2:2000MAY01	3992	4063	forward 2	TM	N1 :
190	LI:900264.2:2000MAY01	198	248	forward 3	TM	N in
190 190	LI:900264.2:2000MAY01	1080 1431	1133 1517	forward 3 forward 3	TM TM	N in
190	Ll:900264.2:2000MAY01	1518	1571	forward 3	TM	N in
190	L1:900264.2:2000MAY01	1740	1814	forward 3	TM	N in N in
190	LI:900264.2:2000MAY01	2409	2480	forward 3	TM	N in
190	LI:900264.2:2000MAY01	2409 2928	2993	forward 3	TM	N in
190	LI:900264.2:2000MAY01	3096	2953 3161	forward 3	TM	N in
130	LI.OUCEUT.E.ZUUUIVIA TUI	3030	3101	ioi waiu 3	1 (7)	141 1/1

	,					
190	LI:900264.2:2000MAY01	3342	3404	forward 3	TM	N in
190	LI:900264.2:2000MAY01	3447	3509	forward 3	TM	N in
190	LI:900264.2:2000MAY01	3531	3614	forward 3	TM	N in
190	LI:900264.2:2000MAY01	3987	4064	forward 3	TM	N in
191	LI:335593.1:2000MAY01	685	771	forward 1	TM	N in
191	LI:335593.1:2000MAY01	1273	1335	forward 1	TM	N in
191	LI:335593.1:2000MAY01	1366	1428	forward 1	TM	N in
191	LI:335593.1:2000MAY01	710	757	forward 2	TM	N in
191	LI:335593.1:2000MAY01	1250	1336	forward 2	ŢM '	N in
191	LI:335593.1:2000MAY01	1358	1408	forward 2	TM	N in
191	LI:335593.1:2000MAY01	1448	1525	forward 2	· TM	N in
191	LI:335593.1:2000MAY01	1604	1690	forward 2	TM	N in
191	LI:335593.1:2000MAY01	81	128	forward 3	TM	N in
191	LI:335593.1:2000MAY01	246	296	forward 3	TM	N in
191	LI:335593.1:2000MAY01	807	866	forward 3	TM	N in
191	LI:335593.1:2000MAY01	876	947	forward 3	TM	N in
191	LI:335593.1:2000MAY01	1155	1217	forward 3	TM	N in
191	LI:335593.1:2000MAY01	1233	1295	forward 3	TM	N in
191	LI:335593.1:2000MAY01	1359	1445	forward 3	TM	N in
192	LI:1189543.1:2000MAY01	1765	1842	forward 1	TM	
192	LI:1189543.1:2000MAY01	1861	1935	forward 1	TM'	
192	LI:1189543.1:2000MAY01	2236	2307	forward 1	TM	
192	LI:1189543.1:2000MAY01	2356	2442	forward 1	TM	
192	LI:1189543.1:2000MAY01	2476	2544	forward 1	TM	
192	LI:1189543.1:2000MAY01	2659	2712	forward 1	TM	
192	LI:1189543.1:2000MAY01	3097	3174	forward 1	TM	
192	LI:1189543.1:2000MAY01	3217	3288	forward 1	TM	
192	LI:1189543.1:2000MAY01	3439	3492	forward 1	TM	
192	LI:1189543.1:2000MAY01	860	946	forward 2	TM	
192	LI:1189543.1:2000MAY01	1016	1099	forward 2	TM	
192	LI:1189543.1:2000MAY01	1145	1216	forward 2	TM	
192	LI:1189543.1:2000MAY01	1601	1672	forward 2	TM	
192	LI:1189543.1:2000MAY01	1691	1768	forward 2	TM	
192	LI:1189543.1:2000MAY01	2411	2485	forward 2	TM	
192	LI:1189543.1:2000MAY01	2831	2917	forward 2	TM	
192	LI:1189543.1:2000MAY01	3080	3166	forward 2	TM	
192	LI:1189543.1:2000MAY01	3227	3310	forward 2	TM	
¹⁹²	LI:1189543.1:2000MAY01	1155	1229	forward 3	TM	N out
192	LI:1189543.1:2000MAY01	1683	1766	forward 3	TM	N out
192	LI:1189543.1:2000MAY01	1770	1838	forward 3	TM	N out
192	LI:1189543.1:2000MAY01	2019	2069	forward 3	TM	N out
192	LI:1189543.1:2000MAY01	2352	2438	forward 3	TM	N out
192	LI:1189543.1:2000MAY01	2508	2594	forward 3	TM	N out
192	LI:1189543.1:2000MAY01	3030	3101	forward 3	TM	N out
192	LI:1189543.1:2000MAY01	3183	3263	forward 3	TM	N out
192	LI:1189543.1:2000MAY01	3360	3446	forward 3	TM	N out
193	LG:455450.1:2000FEB18	422	490	forward 2	TM	N out
194	LG:1040978.1:2000FEB18	500	586	forward 2	TM	N out
194	LG:1040978.1:2000FEB18	276	332	forward 3	TM	N out
196	LG:132147.3:2000FEB18	259	345	forward 1	TM	N out
196	LG:132147.3:2000FEB18	418	504	forward 1	TM	N out
196	LG:132147.3:2000FEB18	718	780	forward 1	TM	N out
196	LG:132147.3:2000FEB18	1477	1548	forward 1	TM	N out
196	LG:132147.3:2000FEB18	1585	1647	forward 1	TM	N out
196	LG:132147.3:2000FEB18	1690	1752	forward 1	TM	N out
196	LG:132147.3:2000FEB18	2560	2637	forward 1	TM	N out

				_
wo	Λı	IZ 7	กา	7
wu	171	MZ	7 L	. ,

196	LG:132147.3:2000FEB18	2731	2790	forward 1	TM	N out
196	LG:132147.3:2000FEB18	2908	2976	forward 1	TM	N out
196	LG:132147.3:2000FEB18	3082	3168	forward 1	- TM	N out
196	LG:132147.3:2000FEB18	3184	3243	forward 1	TM	N out
196	LG:132147.3:2000FEB18	3376	3462	forward 1	TM	N out
196	LG:132147.3:2000FEB18	1451	1531	forward 2	- TM	N out
196	LG:132147.3:2000FEB18	1538	1615	forward 2	TM	N out
196	LG:132147.3:2000FEB18	2741	2827	forward 2	TM	N out
196	LG:132147.3:2000FEB18	2960	3031	forward 2	TM	N out
196	LG:132147.3:2000FEB18	3050	3112	forward 2	TM	N out
196	LG:132147.3:2000FEB18	1626	1703	forward 3	TM	N in
196	LG:132147.3:2000FEB18	2508	2594	forward 3	TM .	N in
196	LG:132147.3:2000FEB18	2919	2987	forward 3	TM	N in
196	LG:132147.3:2000FEB18	3177	3263	forward 3	TM	N in
196	LG:132147.3:2000FEB18	3372	3422	forward 3	TM	N in
197	LI:036034.1:2000FEB01	157	219	forward 1	TM	N out
197	LI:036034.1:2000FEB01	395	457	forward 2	TM	N in
197	LI:036034.1:2000FEB01	479	541	forward 2	TM	N in
197	LI:036034.1:2000FEB01	563	625	forward 2	TM	N in
197	LI:036034.1:2000FEB01	647	709	forward 2	TM	N in
198	LG:162161.1:2000MAY19	372	458	forward 3	TM	N in
199	LG:407214.10:2000MAY19	34	120	forward 1	TM	N out
199	LG:407214.10:2000MAY19	44	124	forward 2	TM	N out
199	LG:407214.10:2000MAY19	203	289	forward 2	TM	N out
200	LG:204626.1:2000MAY19	19	99	forward 1	TM	N out
202	LI:476342.1:2000MAY01	39	122	forward 3	TM	N out
203	LI:1072759.1:2000MAY01	409	495	forward 1	TM	N in
203	LI:1072759.1:2000MAY01	889	951	forward 1	TM	N in
203	LI:1072759.1:2000MAY01	1387	1458	forward 1	TM	N in
203	LI:1072759.1:2000MAY01	1687	1770	forward 1	TM	N in
203	. LI:1072759.1:2000MAY01	392	478	forward 2	TM	N out
203	LI:1072759.1:2000MAY01	1055	1132	forward 2	TM	N out
203	LI:1072759.1:2000MAY01	1424	1507	forward 2	TM	N out
203	LI:1072759.1:2000MAY01	1694	1768	forward 2	TM	N out
203	LI:1072759.1:2000MAY01	1191	1277	forward 3	TM	N out
203	LI:1072759.1:2000MAY01	1677	1760	forward 3	TM	N out
204	LG:998857.1:2000FEB18	1195	1281	forward 1	TM	N in
204	LG:998857.1:2000FEB18	164	226	forward 2	TM	N out
204	LG:998857.1:2000FEB18	344	400	forward 2	TM	N out
204	LG:998857.1:2000FEB18	398	460	forward 2	TM	N out
204	LG:998857.1:2000FEB18	1478	1561	forward 2	TM	N out
205	LG:482261.1:2000FEB18	19	93	forward 1	TM	N out
205	LG:482261.1:2000FEB18	890	961	forward 2	TM	N out
205	LG:482261.1:2000FEB18	1070	1123	forward 2	TM	N out
205	LG:482261.1:2000FEB18	21	89	forward 3	TM	N out
205	LG:482261.1:2000FEB18	1242	1292	forward 3	TM	N out
206	LG:480328.1:2000FEB18	436	522	forward 1	TM	N out
206	LG:480328.1:2000FEB18	568	642	forward 1	TM	N out
206	LG:480328.1:2000FEB18	769	849	forward 1	TM	N out
206	LG:480328.1:2000FEB18	967	1029	forward 1	TM	N out
206	LG:480328.1:2000FEB18	56	130	forward 2	TM	N in
206	LG:480328.1:2000FEB18	194	280	forward 2	TM	N in
206	LG:480328.1:2000FEB18	396	482	forward 3	TM	N out
206	LG:480328.1:2000FEB18	747	818	forward 3	TM	N out
207	LG:311197.1:2000MAY19	241	315	forward 1	TM	N in
207	LG:311197.1:2000MAY19	527	613	forward 2	TM	N out
201	EG.S.T. TOT.T.EUUUIVIA I 13	JLI	0.0	ioi waid Z	1 141	14 541

208	LG:1054883.1:2000MAY19	76	129	forward 1	TM	N out
208	LG:1054883.1:2000MAY19	83	145	forward 2	' TM	N out
209	LG:399395.1:2000MAY19	163	216	forward 1	TM	N out
211	LI:272913.22:2000MAY01	37	123	forward 1	TM	N in

WO 01/62927 PCT/US01/06059

Decemporate Decemporate	TABLE 4 SEQ				SEQ ID	Component				SEO LI	Component		
Steart Stop 4 70513533D1 496 5 60123162B1 144 1 397 4 703758353D1 486 169 5 60123162B1 603 215 655 4 6338333H1 640 1159 5 6217784H1 857 244 453 4 638333H1 60 1159 5 6217784H1 857 244 453 4 653966f6 1 194 5 6217784H1 408 303 633 4 70514050D1 31 595 6012485B2 92 304 633 4 70514050D1 31 595 6012485B2 92 1261 1340 4 70514050D1 31 595 6012485B2 92 1261 1340 4 70514050D1 31 595 6012486B2 92 1261 1340 4 7051405D1 31 40 7051405D1 31	nodim	ent			NO:	a	Start	Stop		NO:		Start	Stop
2 316 4 7031760ED1 52.5 961 5 1602161H1 603 215 655 4 129689H1 26.2 495 5 1602161H1 603 244 543 4 633833H1 26.2 495 5 6177954H1 87 1 244 543 4 64332126 1 494 5 6177954H1 897 1 271 4 26596676 1 192 5 617734H1 408 5 617488B2 5 617484H1 408 5 617484H1 408 </td <td>_</td> <td></td> <td>Start</td> <td>Stop</td> <td>4</td> <td>05135</td> <td>496</td> <td>1069</td> <td></td> <td>2</td> <td>ന</td> <td>714</td> <td>1379</td>	_		Start	Stop	4	05135	496	1069		2	ന	714	1379
1 397 4 126898H1 262 495 5 62177384H1 877 244 555 4 638333H1 640 1159 5 62177354H1 859 244 555 4 638333H1 640 192 5 1473544R6 214 1 467 4 265996ff 1 194 - 5 1473544R1 249 303 633 4 7051364V1 31 589 5 1473544R1 249 501 4 7051364V1 31 589 5 1473544R6 244 501 4 7051364V1 31 589 5 60124888 282 784 133 4 70514030U1 31 577 5 60124486 222 1261 146 70513401 31 569 5 60123139B1 249 127 147 70512591V1 31 569 5 601	2604	46	7	316	7	3	522	961		വ	1602161H1	603	798
215 655 4 633833341 640 1159 5 6217935411 859 244 543 4 633833341 640 1159 5 6217354411 240 1 271 4 26595676 1 194 5 147354411 408 303 633 4 705136401 31 577 5 601231391 240 591 733 4 7051402001 31 577 5 60124868B2 92 784 1388 4 7051402001 31 577 5 60124868B2 92 1261 156 5 601231391 4 705140201 31 577 5 60124868B2 22 1261 1574 4 705140201 31 547 5 6012488B2 22 1274 4 705140201 31 577 5 6012488B2 22 22 4 7051259101	9137	9H1		397	4	296	262	495		ഹ.	6217784H1	857	1351
244 543 4 gd332226 1 454 5 1473544H1 408 1 467 4 26599676 1 192 5 1473544H1 408 303 633 4 7651403001 31 585 5 1473544H1 408 303 633 4 7051403001 31 577 5 60124858B2 224 281 138 4 7051403001 31 577 5 6012485B2 282 1261 1340 4 70512041V1 31 5 6012485B2 282 1261 1340 4 70512591D1 31 47 5 693564 15 1 436 4 70512591D1 31 47 5 693564 15 2 540 4 70512591D1 31 47 47 47 47 47 47 47 47 47 47 47 47 </td <td>6148</td> <td>19</td> <td>\vdash</td> <td>655</td> <td>4</td> <td></td> <td>640</td> <td>1159</td> <td></td> <td>2</td> <td>~</td> <td>859</td> <td>1356</td>	6148	19	\vdash	655	4		640	1159		2	~	859	1356
1 467 4 2659966ff 1 1 92 5 147344T1 249 30 633 4 7051346ff 1 1 94 5 1473544T1 248 591 753 4 705134001 31 577 5 60124858E2 982 591 753 4 70513401 31 589 5 60124858E2 982 784 1388 4 705130401 31 589 5 60124858E2 982 1291 164 705130401 31 589 5 60124858E2 982 1291 164 7051259101 31 247 5 64457589 222 24 504 4 7051259101 31 477 5 66620341 459 24 504 4 7051342601 4 7051342601 4 7051342601 4 7051342601 4 7051382901 4 7051342601 4 <t< td=""><td>6475</td><td>14</td><td>244</td><td>543</td><td>4</td><td>g4332126</td><td>-</td><td>454</td><td>٠</td><td></td><td><# ■</td><td>214</td><td>653</td></t<>	6475	14	244	543	4	g4332126	-	454	٠		<# ■	214	653
1 271 4 26596676 1 194 5 147754411 408 93 633 4 7051354571 31 585 5 6012313911 948 591 753 4 7051403001 31 577 5 6012485892 282 784 1388 4 7051403001 31 577 5 6012485892 282 1261 1340 4 7051403001 31 566 5 64477589 282 1274 4 7051259101 31 171 5 6935694 25 1 436 4 7051259101 31 169 5 6935694 25 2 500 4 705131201 31 171 5 6935694 25 2 500 4 705131201 31 60 43513293 14 2 6 6 70320491 34 703132201 24	1149	2F8 -	-	467	4	2659966 <u>ř</u> 6	н	192		ιΩ	1473544T1	249	653
303 633 4 7051354571 31 585 5 60124858B2 948 313 633 4 7051403001 31 597 5 60124858B2 222 784 1388 4 7051403001 31 599 5 6147354T6 247 1261 1340 4 70512591V1 31 569 5 147354T6 247 1 315 4 70512591V1 31 171 5 6993694 25 2 540 4 70512591V1 31 171 5 6993694 25 2 540 4 70512591V1 31 171 5 6993694 45 2 540 4 70512591V1 31 447 5 6682774 196 2 504 4 70512450V1 4 70512450V1 4 70512450V1 4 70512450V1 4 70512450V1 4 70512450V1	1149	2H1	႕	271	4	2659966T6	7	194	1	ς,	1473544H1	408	653
591 753 4 70514030D1 31 577 5 60124858B2 982 784 1388 4 70514030T1 31 589 5 6445789 222 1201 1674 4 705124030T1 31 566 5 1475476 247 1201 1674 4 70512591V1 31 171 5 9643576 247 2 5 4 70512591V1 31 169 5 9715576 191 2 4 70512591V1 31 171 5 9645774 196 2 5 6 4 70513426V1 61 680 5 9714379 14 2 5 6 4 70513426V1 61 680 5 9714379 14 2 6 6 4 70513426V1 61 680 5 9714379 14 3 3 5 6 <	11149	2T8		633	7	70513545V1	31	585		ഹ	60123139B1	948	1362
784 1388 4 70514030V1 31 589 5 64457589 222 1261 1340 4 7051240V1 31 366 5 147354476 247 1291 1674 4 265966H1 31 366 5 2866203H1 459 1 436 4 70512591D1 31 169 5 2866203H1 459 24 504 4 7051242CV1 61 680 5 2866203H1 459 24 504 4 7051342CV1 61 680 5 63148379 141 25 170 4 7051342CV1 61 60 423148379 141 25 170 4 7051342CV1 24 50 612 6 63148379 141 25 170 4 7051426V1 24 705148379 141 250 612 612020505 141 25 170 <	11105	6н1		753	4	70514030D1	31	577		Ŋ	\mathbf{z}	982	1362
1261 1340 4 70513041V1 31 366 5 147354476 247 1291 1674 4 2659966H1 1 247 5 9715576 191 1201 1674 4 70512591D1 31 171 5 993644 255 1 436 4 70512591D1 31 169 5 2866203H1 459 24 504 4 705124591D1 31 169 5 2866203H1 459 24 504 4 70513426V1 61 680 5 96213233 1 25 170 4 7051426V1 61 680 6 4835189H1 679 31 344 4 70514268V1 24 612 680 6 48318379 141 25 170 4 70514482D1 24 783 6 5330975H1 141 31 5 4 70514482D1 </td <td>36621</td> <td></td> <td></td> <td>1388</td> <td>4</td> <td>70514030V1</td> <td>31</td> <td>589</td> <td></td> <td>വ</td> <td>1575</td> <td>222</td> <td>601</td>	36621			1388	4	70514030V1	31	589		വ	1575	222	601
1291 1674 4 265986H1 1 247 5 9715576 191 1 315 4 70512251V1 31 171 5 9938694 255 1 315 4 70512251V1 31 169 5 286203H1 459 24 504 4 70513426V1 61 680 5 9313233 1 24 504 4 70513426V1 61 680 5 9313233 1 24 504 4 70513426V1 61 680 5 9313233 1 24 500 4 70515523V1 24 61 60 4541025H1 196 33 570 4 7051785D1 29 78 6 4541025H1 804 45 505 4 70514482V1 24 278 6 4541025H1 144 71 625 4 70514482V1 24 2	55910			1340	4	70513041V1	31	366		ഹ	1473544T6	247	569
1 315 4 70512591V1 31 171 5 9935094 255 2 540 4 70512591V1 31 169 5 2866203H1 459 2 540 4 70512591D1 37 447 5 9682744 196 24 504 4 705132401 1 290 6 4831839H 196 25 170 4 7051324V1 24 612 6 483189H 679 25 170 4 70515524V1 24 612 6 483189H 679 33 250 4 70317785D1 29 6 483189H 679 33 550 4 70317785D1 24 391 6 451025H 952 45 421 4 70514482D1 24 778 6 2330975H 94 55 421 4 70514482D1 24 278 6	19838			1674	4	2659966Н1	н	247		ហ	g715576	191	267
1 436 4 70512591D1 31 169 5 2866203H1 459 22 540 4 70318172D1 57 447 5 2682774 196 24 504 4 70318172D1 57 638 5 91213293 1 24 500 4 70312426V1 61 638 5 91418379 141 25 170 4 70312426V1 24 612 6 4835189H1 679 31 344 4 70317785D1 295 738 6 4835189H1 679 33 570 4 70317785D1 24 391 6 4541025H1 804 45 421 4 70314482V1 24 378 6 4541025H1 804 5 4 70318442V1 24 278 6 230975K6 952 41 70318245D1 25 395 6 2571536T6	55532	87		315	4	70512591V1	31	171		S	g993694	255	260
22 540 4 70318172D1 57 447 5 9682774 196 24 504 4 70318172D1 57 447 5 9682774 196 24 500 4 70313426V1 61 680 5 93132393 1 25 500 4 70317485D1 24 612 6 4835188H3 14 33 570 4 70317785D1 29 6 4835188H3 14 45 421 4 70317785D1 29 6 4541025H1 952 45 421 4 70314482D1 24 391 6 4541025H1 952 45 421 4 70314482D1 24 78 6 243065H2 144 71 625 4 703148245D1 24 78 6 243065H2 144 71 625 4 703148245D1 24 78 6	98985	7H1		436	4	70512591D1	31	169		ഗ	2866203H1	459	557
24 504 4 70513426V1 61 680 5 93213293 1 24 500 4 70320498D1 247 638 5 93148379 141 25 170 4 70312785D1 290 6 91920265 798 33 250 4 70317785D1 295 61 6 4541025H1 679 45 421 4 70317785D1 295 6 4541025H1 679 45 421 4 70317785D1 24 391 6 4541025H1 679 45 421 4 7031122D1 37 783 6 2330975H1 952 41 70318482D1 24 278 6 2430651T6 1141 71 625 4 70318482D1 25 395 6 2430651T6 1144 381 985 4 70318482D1 25 395 6 2571330975K	95537			540	4	70318172D1	57	447	•	, C	g682774	196	472
24 500 4 70320498D1 247 638 5 93148379 141 25 170 4 70320498D1 247 638 5 93148379 141 25 170 4 70312071 24 612 6 454102541 679 33 250 4 70317185D1 24 612 6 454102541 679 45 421 4 705164871 24 31 6 233097586 952 45 421 4 7051448201 24 278 6 233097586 952 61 213 4 7051448201 24 278 6 233097586 952 61 213 4 7051448201 24 278 6 233097586 952 51 625 4 7051448201 24 278 6 233097586 952 52 1069 4 7051448201 24<	15345			504	4	70513426V1	61	980		ഗ	g3213293	-1	454
25 170 4 034207H1 1 290 6 4835189H1 679 31 344 4 70515532V1 24 612 6 91920265 798 33 250 4 70317785D1 295 738 6 91920265 798 45 421 4 7031122D1 370 783 6 2330975H2 952 45 421 4 70514482D1 24 278 6 2330975H2 1141 71 625 4 70514482D1 24 278 6 243065T6 1144 71 625 4 7051482D1 24 278 6 257153GF6 1144 381 973 4 7051482D1 25 395 6 257153GF6 1144 381 973 4 7051482D1 24 278 6 257153GF6 1144 381 973 4 70514842D1	43900			500	4	70320498D1	247	638		س	g3148379	141	356
31 344 4 70515532V1 24 612 6 91920265 798 33 250 4 70317785D1 295 738 6 4541025H1 804 45 70317785D1 24 391 6 2330975H1 952 45 421 4 70514482D1 24 278 6 2330975H6 952 71 625 4 70514482D1 24 278 6 2330975H6 952 71 625 4 70514482D1 24 278 6 2430651T6 1144 71 625 4 70514482D1 25 395 6 2430651T6 1144 381 885 4 70514959V1 1 30 6 2530491 1302 525 1069 4 70514959V1 1 30 6 62359341 1445 573 811 5 60123139D2 1 30	11929			170	4	034207H1	-	290		ဖ	4835189H1	619	932
33 250 4 70317785D1 295 738 6 4541025H1 804 33 570 4 70516168V1 24 391 6 2330975H1 952 45 421 4 70516168V1 24 378 6 2330975H 952 61 213 4 70514482D1 24 278 6 2430651T6 1141 71 625 4 70514482D1 24 278 6 2430651T6 1144 381 985 4 70514482D1 25 395 6 2430651T6 1144 525 1069 4 7051495V1 1 300 6 2230491 1302 573 811 5 405 6 66235931 1445 573 814 5 60123139D1 1 37 6 557711H1 14 442 78 6 622183982 84 4 4724029H<	20030			344	4	70515532V1	24	612		.9	· g1920265	798	1061
33 570 4 70516168V1 24 391 6 2330975H1 952 45 421 4 70321122D1 370 783 6 2330975K6 952 61 213 4 70514482D1 24 278 6 2430651T6 1141 71 625 4 70514482D1 25 395 6 2430651T6 1144 383 885 4 70514482D1 25 395 6 257153GT6 1144 381 973 4 70318040D1 29 409 6 257153GT6 1144 55 165 4 70514959V1 1 300 6 623593H1 104 573 811 5 6023593V1 1 307 6 623593H1 1445 573 845 5 60123139D2 1 368 6 62183982 84 442 6 6 6 6	31898			250	4	70317785D1	295	738		9	4541025H1	804	1057
45 421 4 70321122D1 370 783 6 2330975R6 952 61 213 4 70514482D1 24 278 6 2430651T6 1141 71 625 4 70514482D1 24 278 6 2571536T6 1144 383 885 4 70318245D1 25 395 6 2571536T6 1144 381 973 4 70318040D1 29 409 6 25930491 1302 525 1069 4 70514959V1 1 300 6 62359341 104 573 1055 5 92958900 175 294 6 62359341 104 573 811 5 60123139D2 1 307 6 62359341 14 198 445 5 60123135D1 1 368 6 5577111H1 14 4 45 962 5 6127857H1	31843			570	4	70516168V1	24	391		9	2330975H1	952	1172
61 213 4 70514482D1 24 278 6 243065176 1141 71 625 4 70514482V1 24 278 6 257153676 1144 383 885 4 70318245D1 25 395 6 257153676 1144 381 973 4 70318040D1 29 409 6 387885076 1244 525 1069 4 70514959V1 1 300 6 62235931 1455 573 1055 5 62258900 175 294 6 6235931 104 573 811 5 60123139D2 1 307 6 62359371 6 198 445 5 60123139D2 1 368 6 557711111 14 1 412 733 5 60123139D1 1 475 6 62183982 84 464 962 5 6127857H	20034			421	4	70321122D1	370	783	·.	, 9	2330975R6	952	1311
71 625 4 70514482V1 24 278 6 2571536T6 1144 383 885 4 70318245D1 25 395 6 3878850T6 1244 381 973 4 70318040D1 29 409 6 62930491 1302 525 1069 4 70514959V1 1 300 6 623593H1 104 573 1055 5 62958900 175 294 6 623593H1 104 573 811 5 60123139D2 1 37 6 623593H1 104 198 445 5 60123139D2 1 36 6 577111H1 14 1 412 733 5 60123139D1 1 475 6 577111H1 14 445 809 5 6127857H1 1 475 6 52183982 84 1 462 809 5	15514			213	4	70514482D1	24	278		9	2430651T6-	1141	1667
383 885 4 70318245D1 25 395 6 3878850T6 1244 381 973 4 70318040D1 29 409 6 92930491 1302 525 1069 4 70514959V1 1 300 6 92844521 1455 573 1055 5 92958900 175 294 6 6623593H1 104 573 811 5 167606H1 1 173 6 623593H1 104 198 445 5 60123139D2 1 307 6 4724029H1 1 1 412 734 5 60123139D1 1 368 6 5577111H1 14 462 809 5 6127857H1 1 475 6 3878850F6 119 464 962 5 9706800 1 340 6 9218398 239 184 713 5 9454268H1	14760			625	4	70514482V1	24	278	,	9	2571536T6	1144	1680
381 973 4 70318040D1 29 409 6 g2930491 1302 525 1069 4 70514959V1 1 300 6 g3844521 1455 573 1055 5 g2958900 175 294 6 6623593H1 104 573 811 5 167606H1 1 173 6 623593H1 104 198 445 5 60123139D2 1 307 6 4724029H1 1 1 412 733 5 60123139D1 1 475 6 577111H1 14 4 462 809 5 6127857H1 1 475 6 3878850F6 119 4 464 962 5 9706800 1 340 6 378850H1 120 184 713 5 9690740 11 385 6 9278338 239 88 362 5 </td <td>06066</td> <td></td> <td></td> <td>885</td> <td>7</td> <td>70318245D1</td> <td>25</td> <td>395</td> <td>•</td> <td>9</td> <td>3878850T6</td> <td>1244</td> <td>1662</td>	06066			885	7	70318245D1	25	395	•	9	3878850T6	1244	1662
525 1069 4 70514959V1 1 300 6 g3844521 1455 573 1055 5 g2958900 175 294 6 6623593H1 104 573 811 5 167606H1 1 173 6 6623593H1 104 198 445 5 60123139D2 1 307 6 4724029H1 1 1 412 734 5 60123152D1 1 368 6 557711H1 14 1 42 809 5 6127857H1 1 475 6 3878850F6 119 1 44 962 5 9706800 1 340 6 3878850F1 120 184 713 5 9690740 11 385 6 92783388 239 88 362 5 4454268H1 377 645 6 92785249 239	36602			973	4	70318040D1	29	409		ဖ		1302	1714
573 1055 5 g2958900 175 294 6 6623593H1 104 573 811 5 167606H1 1 173 6 6623593H1 104 198 445 5 60123139D2 1 307 6 4724029H1 1 1 412 734 5 60123135D1 1 368 6 557711H1 14 1 42 809 5 6127857H1 1 475 6 3878850F6 119 1 464 962 5 9706800 1 340 6 3878850F1 120 184 713 5 9690740 11 385 6 9278338 239 88 362 5 4454268H1 377 645 6 92785249 239	06712			1069	4	70514959V1		300		9	g3844521	1455	1711
573 811 5 167606H1 1 173 6 6623593J1 634 12 198 445 5 60123139D2 1 307 6 4724029H1 1 13 1 397 784 5 60123152D1 1 368 6 5577111H1 14 20 1 412 733 5 60123139D1 1 156 6 92183982 84 44 1 462 809 5 6127857H1 1 475 6 3878850F6 119 52 1 464 962 5 9706800 1 340 6 3878850F1 120 39 184 713 5 9690740 11 385 6 92783388 239 72 88 362 5 4454268H1 377 645 6 92785249 239 71	19838			1055	ς,	g2958900	_	294		•	6623593H1	104	689
198 445 5 60123139D2 1 307 6 4724029H1 1 13 1 397 784 5 60123152D1 1 368 6 557711H1 14 20 1 412 733 5 60123139D1 11 156 6 92183982 84 44 1 462 809 5 6127857H1 1 475 6 3878850F6 119 52 1 464 962 5 9706800 1 340 6 3878850F1 120 39 184 713 5 9690740 11 385 6 92783388 239 72 88 362 5 4454268H1 377 645 6 92785249 239 71	88861			811	ഹ	167606H1	н	173		ဖ	6623593J1	m	1236
11 397 784 5 60123152D1 1 368 6 5577111H1 14 20 11 412 733 5 60123139D1 11 156 6 92183982 84 44 11 462 809 5 6127857H1 1 475 6 3878850F6 119 52 11 464 962 5 9706800 1 340 6 3878850H1 120 39 184 713 5 9690740 11 385 6 92785249 239 71 88 362 5 4454268H1 37 645 6 92785249 239 71	70902			445	Ŋ	60123139D2	⊣	307	1	- 9	4724029H1	-1	133
412 733 5 60123139D1 11 156 6 92183982 84 44 462 809 5 6127857H1 1 475 6 3878850F6 119 52 464 962 5 9706800 1 340 6 3878850H1 120 39 184 713 5 9690740 11 385 6 92783388 239 72 88 362 5 4454268H1 377 645 6 92785249 239 71	13199	ᅺ		784	ហ	60123152D1	⊣	368		9	5577111H1	14	200
462 809 5 6127857H1 1 475 6 3878850F6 119 52 464 962 5 9706800 1 340 6 3878850H1 120 39 184 713 5 9690740 11 385 6 92783388 239 72 88 362 5 4454268H1 377 645 6 92785249 239 71	3205	92D1		733	ហ	60123139D1	11	156	1		2183	84	445
464 962 5 g706800 1 340 6 3878850H1 120 39 184 713 5 g690740 11 385 6 g2783388 239 72 88 362 5 4454268H1 377 645 6 g2785249 239 71	3207	69D1		808	'n	12		475	,	9	878850F	119	524
83492H1 184 713 5 g690740 11 385 6 g2783388 239 72 06925H1 88 362 5 4454268H1 377 645 6 g2785249 239 71	3116	87D1	4	962	ហ	g706800	പ	340		ဖ	8788	120	399
06925H1 88 362 5 4454268H1 377 645 6 g2785249 239 7	18349	2H1	₽	713	ιń	g690740	11	œ		g	278338	239	721
	0692	5H1		362	ř	4454268H1	377		,	ဖ	278524	239	710

1700	1763	1714	1765	1714	1714	1.714	1969	2145	2309	2309	807	787	863	926	1178	537	601	654	720	878	531	606	614	930	714	710	922	940	763	735	793	592	4	259	വ	2639	2638
1460	1504	1575	1583	1587	1623	1654	1718	1916	1971	1971	537	561	618	670	832	-1	101	110	151	350	351	351	351	-401	427	437	479	481	514	520	536	14	4	-		2430	2451
3881903H1	3014303T6	490059A1 1803962T6	74H1	2313878T6	g2436491	g3277091	3319247H1	4917483H1	6826179J1	6826179H1	3088820H1	2012535H1 -	3232447H1	2536817H2	g2209764	7260050H1	2457623F6	6987326H1	7032756H1	6457158H1	2890632F6	2893095F6	2893095H1	7166124H1	4760777H1	3160745H1	g2006716	g2209659	3362481H1	1751755H1	6141843H1	6584158H1	-3401851H1	3403550H1	3404251H1	g1137215	3378612H1
& (20 0	o co	· •	ထ	&	œ	∞	80	φ	œ	0	6	6	6	6	<u>ص</u>	6	o,	σ.	0	6	6	σ	σ	6	σ	თ	9	თ	σ	6	10	10	10	70	10	10
								'	•								•					,	`, ,		,					Ť	i		ı	•			
442	495 225	720 476	935	675	837	684	905	841	160	746	819	695	779	877	964	1096	885	766	1430	1089	1389	1476	1225	1171	1299	1266	1230	1230	1412	1310	1460	1303	1400	1701	1493	1714	1687
167	229	306	401	407	413	416	483	483	483	483	529	553	555	615	667	667	672	725	881	907	907	935	962	970	974	974	974	983	991	1010	1083	1095	1133	1228	1385	1385	1429
2346879T6	2313878H1	3773491H1	ന	4212712H1	6918705H1	3014942H1	١,	1803962F6	1803962H1	1807684H1	3876768H1	6024789H1	4062033H1	4634711HI	3014303H1	3014303F6	1633402H1	5865873H1	6552378H1	2892794H1	2892794F6	6406936H1	4902732H1	1492959H1	g1686447	5929258H1	3509940H1	4588644H1	6979634H1	946914H1	g5854943	5544986H1	3860122H1	g4260489	1724521H1	1724521F6	3026692H1
ω (жо с	∞ α	- σ	œ	œ	8	œ	œ	œ	∞	œ	∞	œ	∞	80	80	80	80	œ	ω	œ	80	80	œ	80	80	œ	œ	œ	æ	∞	œ	80	∞	œ	œ	©
439	828	951 1042	957	606	703	680	759	787	219	606	438	306	208	146	491	280	283	239	95	212	278	237	320	210	623	423	157	163	224	247	442	366	155	297	388	189	433
284	388	429	429	447	448	448	471	485	-	585	ㄷ	œ	25	34	7	-	30	н	7	11	12	13	13	15	15	16	16	16	17	18	18	19	21	22	41	42	28
g1920471	g1/84782	655110ZH1 6550902H1	6551002H1	g3645387	2430651H1	2430651R6	3712318H1	g981405	g1975879	g1784993	1467511T7	6326238H1	526662H1	2856544H1	1980062R6	1980059H1	5573392H1		2662640H1	2523793H1	3155877H1	3539049H1	3179390H1	5543678H1	6834974H1	257055R6	133343H1	484198H1	257055H1	2346879H1	2346879F6	g1985882	3156918H1	4934879H1	g1751206		258140H1
9 (۰ م	ט פ	· •	9	9	9	9	9	9	9	9	9	9	9	7	7	7	œ	ω	80	æ	80	80	œ	8	œ	œ	ω	&	œ	œ	œ	80	œ	œ	ထ	œ

																															- 1							
637	450	450	- 351	351	263	255	254	253	173	159	259	645	849	443	144	443	443	443	531	604	1132	889	1061	1267	1271	1144	1242	1241	367	1241	1169	1089	1393	472	258	312	617	493
79	` ,	344	11	96	~	25	11	30	11	11	н	137	298		72	388	388	388	236	378	527	661	781	822	823	825	824	847	151	896	1018	979	1202	-1	09	09	152	160
6420632H1	2195346F6	195	3933140F6	3933140H1	6020638H1	g5880310	g2156573	g2264198	6936789H1	5043956H1	1897573H1	4337619T6	5436383H1	1671029F6	1671029H1	1671029T6	g2238932	g2243675	g2219785	5099781H1	3254347R6	5668261H1	4289028H1	g3931955	g3401348	g2825326	.2750359R6	2750359T6	2351445H1	2750359H1	2203345H1	3254347H1	4822216H1	3184753F6	5108214T6	33	g4287070	1
14	14	- 14	14	14	14	14	14	14	14	14	15	15	15	16	16	16	. 16	16	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17
				:									•	•											. •													
	٠																																					
ή ο ξ	819	894	895	840	841	939	888	824	611	1033	852	066	1066	1032	894	1253	2173	1731	2025	2172	2172	2195	2147	2188	2175	2199	435	252	1574	1492	1386	1268	1222	1203	1079	922	833	795
221		ນ		54																							~				1137	1140	724			969	675	546
7055704311	, u,	S	u)	55	05	70561793V1	70559002V1	6127888H1	70557039V1	70559636V1	70561656V1	70560742V1	70561641V1	g873095	70449484V1	6848717H1	70558944V1	70450051V1	70561063V1	g5361507	g4735148	g4875543	758040T6	g872996	g3840560	g4333943	2734453F6	2734453H1	4860612T7	g902319	g778351	g1638619	6929341H1	1675892T6	1720010F6	200	\leftarrow	5496406H1
12	17	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	13	13	14	14	14	14	14	14	14	14	14	14
																									ı													
2,42	229	2638	2632	2603	2252	2553	2659	2641	2701	2601	2700	2654	2562	2519	2640	2569	2287	260	267	534	628	538	275	269	383	511	575	582	631	687	272	605	310	585	384	2175	812	834
v	, OT	16	2077	2121	2130	2152	2159	2394	2170	2171	2202	2348	1884	1981	2022	2035	2050	15	18	-	-		2	12	12	12	12	12	13	12	12	13	12	13	35	119	150	217
6584049H1	3402034H1	g307503	70779637V1	7258175H1	3961980H1	6584189T1	6584158T1	g3785069	981592T6	3385383T6	1221889T6	70779908V1	70776665V1	70775642V1	70776673V1	6584049T1	3401765H1	3401379H1	3404170H1	6905943H1	70562343V1	70560334V1	70559056V1	70560532V1	70559641V1	70559213V1	70561550V1	70561738V1	70559422V1	70559480V1	758040H1	70559415V1	758040R6	70561876V1	70559130V1	g2576304	561	70560479V1
5	2 6				10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	11	12	12	12	12	12	12	13	12	12	12	12	12	12	12	12	12	12	12

																									•												
974	1013 968	1107	1134	1226	1233	1264	1288	1225	1293	1565	1588	1330	1336	1422	1754	1357	1679	1713	1625	1702	1651	1673	1750	2172	1793	1874	1773	1896	1913	1779	1875	2159	1945	2047	2160	2077	2020
722	784	787	879	926	950	997	1010	1021	1038	1064	1085	1085	1112	1144	1249	1287	1363	1399	1400	1401	1424	1436	1481	-1571	1572	1583	1631	1648	1664	1665	1672	1693	-1695	1753	1803	m	1850
2670050H1	41189/3H1 2744119H1	g1081212	5576610H1	6418368H1	5864111H1	5033538H1	3511167H1	5805062H1	4873652H1	6614566Н1	2645969F6	2645969H1	g2112831	3742279H1	6334985H1	5292787H2	g853299	5742830H1	777713H1	777713R6	2291319H1	3241291H1	-1832630H1	1804812T6	1481768H1	3730896Н1	4442950H1	2794894H1	4161422H1	4163675H1	g2787436	1898917T6	26	3726809H1	σ	2293309H1	1214225H1
21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21
						٠		•														,	·		•						1		ı	•			
																										1											
427	494 451	585	2463	2211	2187	2159	2198	2198	2198	2317	2693	2207	2365	2431	2718	2448	2461	2953	2950	3020	417	285	609	871	582	530	588	809	645	672	671	864	206	889	882	926	1180
177	211	3.73	2017	2040	2042	2045	2052	2052	202	2056	2092	2101	2134	2184	2250	2250	2266	2658	2713	2748	ᆏ	႕	215	311	311	311	346	365	380	386	402	205	502	547	585	652	889
3456613H1	4923878HI 6847871H1	15	g4281322	3934096H1	3934274H1	1648485T6	1648242H1	1648485H1	1648485F6	4676772H1	1004843T6	g4533314	3416826H1	5304471H1	1310089F6	1310089H1	2461918H1	g4330296	g3178479	g856243	3951063F6	3951063H1	g2114724	1804812F6	1804812H1	1804772H1	2662164H1	2011927H1	4863613H1	3934325H1	3763239H1	1004843R6	1004843H1	g846375	5810205H1	384851H1	g1861137
20	7 7 7 0 7 0	20	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21	21
472	513 884	811	650	423	423	423	423	423	422	344	263	1023	1150	1132	1159	179	269	452	301	685	731	675	934	797	1116	916	945	558	448	198	331	248	652	490	368	543	388
	236 314															-																			94		
	_									g3307490						g892900	3436153H1	g4737696	839090H1	6938671H1	6939071H1	g646973	g1277657	2755039H1	838332T6	4800144H1	2084151H1	6199407H1	2519336F6	2519336H1	6793417H1	1639314H1	6818283H1	1984661R6	1984662H1	1984661T6	4021069H1
17	1. 18	18	18	18	18	18	18	18	18	18	18	19	19	13	19	19	19	19	19	19	19	19	19	19	19	19	19	20	20	20	20	20	20	20	20	20	20

																																,							
-	1759	1839	- 1665	1765	1616	1552	1603	1647	1627	1559	1785	1945	1766	1772	1785	1756	1772	1738	1988	1757	1977	1843	1977	1984	1831	1915	2004	11	1756	98	1946	œ	1973	3	190	279	613	619	
1357	1361	1371	1373	1379	1382	1388	1388	1388	1400	1408	1408	1428	1441	1471	1473	1474	1479	1513	1525	1559	1559	1568	1580	1620	1650	1671	1686	1686	1701	2	1730	9	1841	9	₽,	121	122	183	
g3147585						2292948H1	1373715H1	4742391H1	2749392H1	g1241849	g6046888	2294209T6	g1471742	g4332659	g3842415	g2841585	g2003011	2501320H1	g3961438	g2022791	g6132921	5690247H1	g1496515	g2252260	g3739177	5338636H1	5710854H2	3223930H1	4255692H1	g1210253	g920434	g1210208	4320678H1	g884068	6991066н1	4753733H1	4753733F8	7065882H1	
22	22	. 22	22	22	22	22	22	22	22	22	22	22	. 22	22	22	22	22	. 22	22	22	55	- 22	. 25	22	22	22	22	22	22	22	. 22	22	22	22	23	23	23	23	
	1																																						
889	892	921	1000	963	961	1022	1123	1252	1217	1256	1222	1252	1155	1051	1144	1210	1244	1491	1153	1440	1593	1481	1688	1444	1600	1712	1822	1505	1760	1776	1448	1779	1778	1773	1762	1730	1766	1772	
629	637	629	705	705	713	754	771	96/	801	804	850	865	870	887	922	952	953	1013	1068	1107	1122	1143	1179	1179	1213	1213	1214	1229	1310	1309	1317	1326	1328	1332	1331	1355	1356	S	
5681165H1	5277977H1	4645753H1	34	934	746066H1	4771093H1	g2054100	g4762720	g2321843	g3017276	g483457	g4762705	4338534H1	628211H1	5563275H1	5286207H1	6160626H1	6838871H1	2400686H1	g866503	6747627H1	g920433	2294209R6	2294209H1	g1471741	g1332314	6021757H1	2189963H1	g5766946	g2524669	g2178309	g4762067	g5361693	g4074013	g5849550	6736883H1	g2183535	g4332913	
22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	
																		•							ı														
2128	2198	2386	2048	2201	2222	2387	2420	2203	2292	242	232	328	581	234	624	234	234	232	609	232	232	234	231	415	680	232	483	644	514	493	648	782	759	853	824	844	902	764	
1855	1913	1917	1925	1942	1964	1970	1983	1984	1994	7	-1	47	49	20	75	75	83	90	100	102	105	110	113	130	145	150	180	346	367	367	381	503	260	260	561	574	622	622	
6337	373390	38907	5696574H1	g1081162	2645969T6	g1860963	777713T6	g4149122	4875545H1	487652H1	487652R6	g2003010	6442754H1	6152037H1	7072795H1	3126080H1	491193H1	4751976H1	7100707H1	2292643H1	6140970H1	4066069H1	5007390H1	4773161H1	6993149H1	572575H1	5756677H1	6064882H1	5372689H1	3123257H1	g2022792	5068149H1	5894157H1	988	2621801H1	6401738H1	245	2122453F6	
21	21	21	21	21	21	21	21	21	21	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	22	

1627	1961	1630	1962	1901	1961	1796	1943	1797	2184	200	319	308	617	433	328	487	320	2457	414	594	814	096	978	1529	2219	2245	2188	2239	2239	2361	22	2365	2409	29	2459	2386	2458	2419	
1421	1500	1505	1512	1559	1266	1266	1574	1574	1766	⊣	56	55	. 89	166	-	7	ᆏ	89	238	460	675		878	1389	1759	1818	1835	1864	1864	1898	1915	1994	2020	2019	2029	2045	2061	2061	(
2966432H1	くな	$^{\circ}$	g2715860	91858T	3891858F6	3891858H1	925628T6	925628H1	g5113339	7286802H1	3490274H1	6817649H1	6779822H1	1343838H1	682774611	g4372436	7277307H1	g1109781	g2987914	3242379H1	5843682H1		3560794H1	6146228H1	g5454470	g5634013	g3933775	6824121H1	<==	6789580H1	g5596185	13766	g3917233	3222719H1	g4487317	28	925319R6	925319T6	
7.0	27	27	27	27	27	27	27	27	27	27	27	27	27	. 27	28	78	28	28	28	78	28	28	78	28	28	28	78	28	28	28	28	28	78	28	5 8	28	58	28	
	•			•									,																										
, 908	2 00	821	982	923	1018	1024	887	666	954	730	296	931	863	978	1041	1308	1322	978	970	1508	1569	439	574	1961	746	638	896	762	1069	892	856	1025	1101	1082	1190	1380	1470	1969	-
210	541	541	541	541	541	577	589	587	605	629	641	663	663	669	809	815	841	862	898	940	1092	-1		1574	228	483	571	571	217	577	298	697	825	825	836	1016	1163	1402	
, 6962196u1	2 4	419	563612	ന	g5636142	g2568732	3747228H1	6600395H1	6978931H1	2240520H1	2240520F6	5626829H1	g2162199	6862047H1	7281807H1	g2209650	6216076H1	7238641H1	6210267H1	7039186H1	g2209760	7281748H1	7281705H1	925628R6	6466550H1	035057H1	2173285F6	2173285H1	1743077R6	1743077H1	3344276H1	6579246H1	5637939F8	5637939H1	5624530R8	5637939R8	3483518H1	6817649J1	
25	52 22	25	25	25	25	25	25	25	25	25	25	25	25	22	22	22	25	25	25	25	25	3 6	5 6	27	- 27	27	27	27	27	27	27	27	27	27	27	27	27	27	
722	, 2 2 6 6 1	349	683	724	722	584	381	504	574	1021	099	339	748	1081	1131	1390	1248	1248	315	257	271	587	292	259		1435	1390	1361	1390	1393	1390	1390	536	9	9	516	ω	9	
	270												625								33										1325					434			
270767	76986	1576986H1	1576986T6	g3843718	g3750491	3604635H1	g793096	6756043H1	3845553H1	5057288F9	5057288H1	5065461F8	2359950H1	6112349H1	5444375H1	g4264503	3385663T6	3845553T6	3385663F6	3385663H1	5468404H1	5468404F8	5072501H1	6917202H1	4148204T6	4148204H1	4148204F6	g4532148	213841R6	213841T6	213841H1	213833H1	7204172H1	6819816H1	6836688H1	6349781H2	7280863H1	g4081510	
,	23	23		e	e		m	24	24	24	24	24	24			24		24	24	24			24	24			24	24	24		24		25			25	25		

	-									•						,																							
	1604	1111	1103	7677	2390	- 2586	2231	2197	2603	2430	2632	2625	2669	2344	2682	2689	2671	2671	2623	2688	2517	2458	2394	2685	2622	2671	2559	2671	2681	2629	2458	2671	2543	2391	2570	2671	2639	2682	2671
	1486	219	170	1061	1926	1976	1979	1979	2006	2023	2038	2052	2130	2070	2110	2110	2110	2110	2111	2152	2158							2209					226	2264	2288	2316	3	'n	9
	70248162V1	7025464/VI	10//3/9HI	173/79/HT	70660270V1	70255193V1	. 70656301V1	71273576V1	6620779H1	70655675V1	70255204V1	1741694T6	6121206F8	5267406H1	6120592H1	6128080H1	6120292H1	6127177H1	3269702T6	70254909V1	4001246R6	4001246H1	70659041V1	g5864796	g2913171	6752303H1	70658326V1	70256172V1	2287809R6	2287809T6	2287809H1	6834934H1	2255790H1	70657495V1	m	70254456V1	61	70249168V1	
٠	29	א כ	, v	7	29	53	59	. 62	29	53	29	29	59	59	59	59	29	29	29	29	53	29	29	29	- 62	53	59	29	53	50	5	53	59	29	29-	29	29	29	29
											•								•	٠		•			,										ı	1			
	930	928	636	7007	286	198	254	374	402	755	446	702	949	2119	1617	1413	1601	1420	1524	1679	1485	1573	1720	1860	1525	1753	1576	1462	1435	1869	1903	1870	2218	1916	36	1866	œ	1915	
	444	463	15C	50 y	-1	-	œ	142	165	175	175	398	413	1672	1165	1166	1171	1202	1247	1304	1310	1314	1326	1330	1339	1341	1345	1347	1351	1361	1392	1366	1690	1671	1691	1410	1410	1414	1418
	70254664V1	70254648V1	/U25/2/3VI	g3//8/32	4023624H1	70249613V1	3269702H1	70249634V1	1286494H1	7191139H2	5841654H1	7120789H1	70255670V1	70255767V1	3272240F6	3272240H1	70257558V1	70248599V1	70250795V1	70249059V1	70250085V1	70251290V1	70255060V1	70254762V1	70257824V1	70255199V1	70250692V1	70257468V1	70251556V1	70255729V1	70255867V1	70255422V1	70254725V1	02	7033280H1	1741694R6	74	70256209V1	7079231H1
	29	29	67	67	29	29	29	29	29	29	29	29	29	29	29	29	29	29	. 29	29	29	29	29	29	29	29	29	29	29	29	29	29	29	29	29	29	29	29	. 29
	2370	2467	2397	7458	2444	2458	2534	2476	1374	1539	1299	1570	1409	1378	1269	1541	1311	1638	1333	2219	1986	2224	2329	2103	2379	1933	2347	2007	2279	2268	2506	1948	2335	2417	2117	1239	1401	1233	Н
	2061	2103	2139	2165	2165	2203	2265	2276	992	1036	1050	1073	1088	1116	1117	1130	1132	1149	1157	1723	1723	1723	1742	1769	1771	1775	1787	1791	1805	1838	1854	1865	1872	1879	1879	764	842	9	Н
	5319H	637			g1114183	g3844190	6193937H1	g5364673	6450124H1	70254601V1	70250522V1	70255407V1	g2004277	70247748V1	70249044V1	70256246V1	70248757V1	7331424H1	70248822V1	70656623V1	661089H1	661089R6	6444789H1	70248827V1	6551207H1	6745795H1	6977014H1	70258294V1	70254633V1	70255157V1	6746363H1	70655542V1	6561163H1	7239061H1	A.	70255827V1	025	70248754V1	563
	78	20 00	87.0	87	28	28	28	28	29	29	29	29	29	29	29	29	29	29	29	29	53	59	59	59	59	59	29	59	59	53	59	29	53	59	59	29	59	59	29

	'V0 F-1 F		ン 4.
263 261 261 319 416 577 568 538 538 645	353 205 205 205 306 358 456 1296		1229 1714 282 254 262 178 613 606
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1520 1578 1578 1632 443 622 899 899	959 11197 17 17 17 56 60 60 173
6917202H1 3385663H1 5468404F8 3385663F6 70775648V1 70778292V1 70779496V1 70775549V1 70775549V1 93254719	9375300 93959110 9897505 95233046 92929868 93016800 6202689H1 92435161 4707801H1	5915008H1 3036834H1 3036834F6 5387714H1 7122625H1 6915116J1 5092947H1 5370334H1 5092947F6	50177 47078 55051 55140 55051 12250 92929 63146 63146
30 30 30 30 31 31		, 1	
			•
			• •
1284 1284 1284 1284 1389 1433 1359 641 581	4 4 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	442 547 1043 669 933 737	1081 1128 1093 740 1166 766 1388 1391
1033 1031 1086 1087 1174 1181 1181 1254 11 207	24 3337 1102 44 44 44 44	4 4 2 3 3 3 4 4 2 3 3 3 4 4 2 3 3 8 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	476 503 513 541 576 613 1323 1323
3385663T6 3845553T6 70776533V1 70776877V1 4148204T6 4148204F6 4148204H1 94532148 5072501H1 70770035V1	70779544V1 70776851V1 70776851V1 70779695V1 5468404H1 6756043H1 7190732H1 71087882V1 70777729V1	70780840V1 70779497V1 384553H1 5057288F9 5057288H1 70776801V1 5065461F8 70777098V1	70780976V1 7077266V1 70772943V1 7077725V1 70779028V1 213833H1 213841R6 213841R6 213841R6
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0			
2682 1493 1951 1604 1980 2172 1928 2113 2113	1900 1900 1970 1875 1980 2113 2145	2028 1188 905 1108 1122 464 758 1111	1217 1195 1207 1132 1127 1108 1239 1164 1251
2606 977 1692 1397 1653 1663 1487 1487 1509	1538 1570 1571 1609 1659 1694 1704	672 651 672 672 672 673 648 653	697 715 716 751 764 809 839 933 997
6059196H1 70255727V1 70257455V1 70257088V2 70255058V1 5779331H1 70248161V1 6536779H1 70254435V1	70254449V1 70257853V1 7025434V1 5191169H1 70257088V1 70255260V1 70255174V1 9756281	70659718V1 70254418V1 70258031V1 7178470H1 70256308V1 70780965V1 2359950H1 70777278V1	70779952V1 70777355V1 70771142V1 70775784V1 70769785V1 6112349H1 70776223V1 5444375H1 5057288T8 94264503
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	, , , , , , , , , , , , , , , , , , ,	8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	00000000000000000000000000000000000000

																							21																
2	- 589	423	- 310	307	183	268	549	220	593	324	622	364	285	1066	949	823	1013	1315	1049	1261	1293	1008	1068	765	652	841	840	1051	84	326	868	669	009	818	802	813	501	634	
⊣	ო	m	82	107	-1	4	σ	28	29	29	-1	81	.7	627	643	715	835	894	986	1053	1053										353	37	373	337	296	302	-	277	
6769153J1	6764824J1	g6048166	653157H1	509350H1	3386816H1	3888124H1	6779840H1	3159561H1	6250084H1	2809974H1	3386816F6	3672749H1	4005442H1	70821167V1	70822737V1	70832705V1	412478T6	6779840J1	g2631213	5501816H1	5501816F6	4005442T6	70818940V1	059074H1	2862291H1	93934153	93900180	391612F1	g895347	4005442F6	391612R1	412478R6	247	3868	1951349T6	6947424H1	6980110H1	g1897936	
36	36	. 36	37	37	37	37	37	37	37	37	37	37	37	37	37	37	. 37	37	37	37	37	37	37	37	37	37	37	37	37	37	37	37	37	37	37	37	38	38	
				:									,									•			. •														
	1																										,												
561	662	524	705	099	9/9	966	969	940	979	930	1000	881	867	926	882	606	362	419	613	417	315	463	455	522	653	621	667	477	415	278	477	292	320	551	326	550	595	579	
310	316	319	340	340	340	368	374	379	564	266	575	622	631	671	671	969	⊣	7	322	ᆏ	7	31	28	103	332	332	190	162	123	~	⊣			99		-	-	m	
042027H1	•	999	g897225	05		5018641T6	g2933440	1876772T6	g2703395	2652012T6	g1858336	3124683H1	g1313829	4200739H1	2244549H1	2684460H1	g3232386	g3181700	6109493H1	3081155F6	3081155H1	3081155T6	g1648354	5800009H1	3517533R6	3517533H1	g5178468	3504115H1	3082646H1	259700H1	7169509H1	6768733H1	3176620H1	3176620F6	4613367H1	6753724J1	6769683J1	6772986J1	
32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	33	33	33	34	34	34	34	34	35	35	35	35	35	35	35	35	35	35	35	36	36	36	
																									ı														
599	909	823	211	950	947	716	1308	996	1259	1540	1588	314	232	415	588	457	563	664	816	826	792	976	801	978	979	792	878	978	705	969	688	693	685	723	737	519	932	504	
312	324	206	903	904	731	904	911	911	1000	1024	1318	⊣	⊣	98	238	255	254	267	503	505	536	518	536	525	540	552	527	564	413	416	426	421	454	478	480	273	279	285	
6201718H1	2682720H1	3665294H1	g1139437	3663680H1	5040414H1	g1139431	1772915R6	1772915H1	4849209H1	1772915T6	g4691031	6298418H1	3403590H1	6327716H1	g1068995	6921019H1	4307678H1	g1858272	2812311H1	2812294H1	4976432H1	g5037963	4976496H1	g3736768	g4986041	4124067H1	g4073888	g5526438	5209523H1	4109819H1	3726063H1	4671035H1	2311003H1	5206768H1	679406H1	829499H1	2655709T6	1494347H1	
31	31	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	32	

																	- 1		1																				
420	439 674	738	.823	583	524	520	320	283	404	582	1179	664	605.	609	664	557	353	619	1027	633	364	901	509	239	227	238	329	254	442	551	594	366	366	425	479	597	637	403	
	171	271	404	113	75	73	28	Н	1	166	547	578	, H	493	542	н	~	256	591	-	႕	377	-	⊣	ᅮ	႕	႕	7	13	98	123	131	208	228	-	398	126	н	
07.40	4229003F6	22900	g3895952	\sim	10	\sim	3817246H1	2895718H1	4295967F8	g5811741	6708077H1	5352502H1	6819988J1	6292367H1	g4900516	2607525T6	5120882F6	g4072524	-4936033R6	5387945T6	5401502T6	2205615T6	4150193F6	g2005559	1399832H1	1398471H1	g2027783	1322674H1	g2278640	g2159473	w	g2156015	ம	ഥ	3743	2737435T6	5477	3796761F6	
Ç	4 43 43	43	43	44	44	44	44	44	45	45	46	46	46	- 46	46	47	48	48	49	49	20	51	51	52	52	52	52	52	52	52	52	52	52	52	53	53	54	54	
																			. '																				
000	428 448	584	475	944	999	1111	1156	1151	1:142	1307	1088	1214	2414	2263	1996	2456	1874	1791	1690	1516	1515	1439	1413	2431	1290	1290	1290	1271	1271	1161	1101	1070	1065	4	2	568	541	357	
ç	23 184	285	285	351	378	9/9	713	731	824	837	974	1135	1927	1837	1385	1986	1404	1372	1147	1339	949	1187	818	2124	869	874	1009	809	1109	911	733	069	818	673	236	275	- 1	192	
0	g1048352 3023715H1	2071327F6	=	29	4583753H1	2071327T6	g4176194	g3178308	g4149782	6912958H1	g3797002	g3180193	6937854H1	7032292H1	7002267H1	7153478H1	7100968H1	7035269H1	7166089H1	5637088H1	6778731H1	2689778H1	4293860F6	5975002H1	g1423371	g3424813	g1859062	1809216F6	1809216H1	4290553H1	6932930H1	g1858731	4293860H1	\sim	\sim	6132451H1	6781622H1	5966128H1	
,	4 7 7	41	41	41	41	41	41	41	41	41	41	41	42	42	42	42	42	42	42	42	42	42	42	42	- 42	42	42	42	42	42	42	42	42	42	42	42	42	42	
773	41/ 614	689	166	755	556	718	912	1132	954	1075	1335	1434	1387	1149	1297	1614	1569	1616	484	259	272	326	255	521	245	202	289	278	486	272	486	400	386	327	483	799	848	434	
0	300	.438	452	452	494	507	640	658	701	847	847	894	893	942	1017	1089	1298	1350	н	20	20	20	20	20	20	25	37	81	129	155	180	-	84	84	0	268	7	႕	
1101010111	8264019H1 3099905H1	g2329399	2821248F6			6291249H1	5636134H1	6758395H1	1903638H1	4991026H1	4991026F6	2821248T6	6208066H1	4453533H2	5621950H1	6827666Н1	3165907H1	4982360H1	5998240H1	458061H1	455162H1	460544R6	455966H1	455162R6	460544H1	3206542H1	4663964H1	g1807165	g2401959	3614680H1	g5101146	6927079H1	g922215	g922268	g991321	4991883T6	1958936H1	6033171H1	
0	2 8 23 6	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	38	39	39	39	39	39	39	39	39	39	39	39	39	39		40	40	40	40	40	41	

															•																								
1	618 589	851		824	839	1111	894	1569	1291	1353	1745	1757	1572	1758	1758	1646	1592	1745	1748	1775	954	905	397	308	750	490	751	502	298	137	298	241	397	653	629	569	252	2056	
1	162	460	460	501	584	601	601	62	1048	12	1216	1226	1284	1301	1307	1398	1399	1452	1580	1655	296	399	러	+	375	-	409	-	-	, ,		.	-		33	-		1723	
	g3057535 6429507H1	2865771F6	65	91	g1258980	3569914F6	2	3569914T6	5327014H1	1320957H1	2971828F6	g3049125	3077923H1	g4069747	g3417824	5732379H1	5732479H1	2971828H2	g1201083	4459657H1	6020692201	368741T6	368741R6	368741H1	g4187853-	368741R1	g3838805	5963989H1	3593809H1	g1059739	1850713F6	1850713H1	872	872	2872408T6	2862618T6	83	287364H1	
	n o	200		29	29	29	. 69	29	29	59	29	29	23	29	29	59	.59	29		29	60	.09	9	. 09	9	9	90	61	61	61	61	61	62	- 29	62	63	63		
										· · · · · · · · · · · · · · · · · · ·									٠				,												,				
																								•			,					•		ı				٠	
1	564 526	≀ ⊶	416	384	383	382	296	267	264	194	129	127	125	188	325	468	367	499	732	505	577	912	718	1136	1148	4	1186	1152	1149	1071	1055	1186	1187	1178	1187	8		524	
	304	, , ,	н	~	က	-	7	⊣	-	70	ᇊ	28	20			19	81	232	288	288	365	403	520	645	733	166	800	800	800	800	800	840	204	945	1081	3	126	133	
	g1962414 g1376321	g4110945	g4310623	33	83516	1148	376	S	3351668H1	1785191H1	\leftarrow	4050289H1	4144289H1	g1979821	g3835204	g4072180	3519808H1	g843784	1614746F6	1614746H1	1575232H1	g2209653	6322462H1	56	1614746T6	g3644249	33	7	~	677184H1	670448H1	g2810503	g2336018	926	899	83893	085	g1148294	
ļ	57	57	57	57	57	57	57	57	57	57	57	57	57	58	28	58	28	58	58	58	28	58	58	58	28	58	28	58	58	58	28	58	28	28	28	59	59	. 59	
																		•						•															
,	306 285	415	280	388	427	470	427	414	754	665	267	354	334	409	486	475	276	438	632	674	1055	795	1163	1154	869	1017	1289	1335	1610	1059	1041	618	951	891	891	411	724	682	
	٦ ۾	34	52	59	-1	20	169	211	212	356	٦,	-	19	158	172	172	214	227	360	421	267	267	629	614	662	737	1018	1070	1325	753	798	20	689	482	645	310	233	284	
	3796761H1	4654776F6	1729735H1	g895564	2920075R6	784499T6	2920075H1	269219H1	269219R1	g1978467	6183766н1	g1897936	3099905H1	g2329399	2821248F6	2821248H1	g954493	6291249H1	5636134H1	1903638H1	4991026F6	4991026H1	6208066Н1	2821248T6	4453533H2	5621950H1	3165907H1	4982360H1	6417723H1	6061626H1	5425067H1	6331039H1	6132218H1	2	3499278H1	65	30	6538713H1	
	5.4	54	54	54	52	55	22	55	55	55	26	99	26	99	26	26	26	26	26	26	26	26	26	26	26	99	26	26	26	57	57	21	57	57	21	57	21	57	

Section 1980 Contractor

																ı		1																			
692	656	626	786	605	437	437	1510	1479	772	772	1852	766	747	2066	2039	947	947	947	947	947	947	946	1992	867	1923	837	1919	800	800	791	787	2175	1098	2175	2166	2166	2160
304	, , ,	378	400	303	304	304	1256	1233	380	304	1579	472	102	1733	1651	404	393	472	699	782	789	868	1844	909	1651	304	1651	300	340	353	359	1871	979	1942	1871	1715	1710
60203050V1 70374630D1	60209436U1	70373679D1	70373094D1	70375597D1	70373898D1	70373514D1	819073H1	2831185H1	70375782D1	70374947D1	g824801	70376281D1	60209435U1	g2780043	2751856R6	70374895D1	70376064D1	-70374077D1	70373091D1	70373401D1	70376523D1	70375900D1	3999158H1	70376383D1	2751856H1	70374800D1	2751062H1	70373252D1	70375702D1	60203054V1	70373230D1	5822141H1	6332621Н1	1689922F6	5820119H1	22274	g3594875
86 86	98	86	98	98	98	98	98	98	86	98	86	98	98	98	98	86	86	98	98	98	98	98	98	86	98	98	98	98	98	98	86	98	98	98	98	98	98
												1																									
449	2221	415	285	637	548	205	207	85	639	292	830	220	508	989	1125	390	1046	216	256	198	1298	1297	590	629	78	721	721	204	208	317	543	1024	446	1959	741	1830	730
225	1764	34	34	126	⊣	~	-	7	120	98	591	-	-	371	619	ᠬ	619	ᆸ	7	ᆸ	721	788	210	210	~	147	433	Н	63	63	႕	881	98	1523	365	1617	286
2007652T6	3325402T7	4654776F6	4654776H1	4654776T6	1476477F6	1476477H1	1476477H6	1476485H1	1476477T6	1500139H1	1496323H1	5200862H1	5200862F6	5200862T6	450278R6	448904R6	450278R7	448904H1	446282H1	450278H1	448904T6	450278T7	807409T6	807409R6	807409H1	3844814F6	3844814H1	3779417H1	3769201H1	3844814T6	1224910R6	1224910H1	1224910T6	5296190T6	70375800D1	5884784H1	60203053V1
76	77	78	78	78	79	79	79	79	79	79	79	80	80	80	81	81	81	81	81	81	81	81	82	. 82	82	83	83	. 83	83	83	84	84		85	98	98	98
481 792	, H	2320	1994	548	1284	102	402	354	260	207	501	119	245	395	344	385	571	617	523	1975	1940	009	1317		1401	438	276	754	688	303	501	279	292	490	182	740	411
198								ر ک	4		19						438				1397							227		-	8						225
2867867H1 2828380H1	2881835T6	2882345T6	2820130T6	2837371H1	222227T6	270908H1	2698411H1	269967H1	2778926H1	2737435H1	2737435F6	2753160H1	2718845H1	2718845F6	2729146H1	2690266H1	2782984H1	2737435T6	2666231T6	1729868T6	3256037T6	3394349T6	5387945T6	394892F1	402386T6	3318809F6	3318809H1	3318809T6	3255863H1	3685359H1	3685359F6	3685359T6	63	3637162F6		6371	2007652H1
63		64	64	64	65	99	99	99	99		99			99	99	99	99	99	29	89	69	70	71	72	72	73	73		73	74	74	74	75	75		75	92

										•																													
	246	7 5 7 7	173	905	. 218	167	280	480	323	521	143	387	370	287	681	401	471	487	200	441	480	584	845	817	1123	916	1110	1027	1283	1243	2784	2951	3092	2776	2989	2875	2819	2838	
,	-	-1 		628	11	-, -,	H	2.1	21	243	႕	16	16	28	186	186	192	248	249	249	326	378	565	572	719	719	781	784	896	1007	2484	2486	2503	2512	2525	2538	2539	2540	
	5767313H1	257941H1	2727658H1	5511002F6	g1977359	894136H1	893591H1	3685359F6	3685359H1	3685359T6	g1925745	g2752333	g2881366	3257022H1	2380565F6	2380565H1	6354028H1	2809746H1	5110009H1	5110002H1	6354128H1	1546477H1	5055767H1	3413877H1	2360256R6	2360256H1	g1688388	1330559H1	g844802	g1640803	4895030H1	g1941651	70657184V1	g658182 -	g2718978	g715365	5298571H1	4749511H1	
	93	2 6	, e	93	93	94	. 76	94	94	94	95	92	95	92	92	92	95	95	95	95	95	95	95	95 -	95	92	92	95	95	92	96	96	96	- 96	96		96	. 96	
																			٠												,								
									•									٠						ʻ. ,	,							í		ı					
	370	#00 200	407	272	235	198	137	546	264	335	348	347	494	289	737	775	1266	1320	1386	381	160	550	314	689	678	563	599	935	1159	1118	1319	252	259	692	1039	1022	149	880	
		120	140	19	98	~	~ 1	7	19	46	78	155	171		515	535	736	808	828	7	7	56	25	119	125	301	315	491	653	899	808	-	19	149	541	290	႕	628	
	6779728J1	62450030	\sim	1895443H1	4729485H1	5217490H1	1542833H1	3836068F6	1891884H1	3052342H1	5735738H1	g5661058	3525414H1	3836068H1	1335071H1	1353732H1	6166536H1	6483617F9	6483617F8	4326477F6	4326477H1	4140846T9	3888314H1	7073510H1	7081835H1	2079383H1	6405368H1	7254119H1	2	6759433J1	6483617H1	257941R6	2764170H1	7040554H1	6477351H1	g3163349	3209591H1	5511002H1	
	0 0	0 0	06	91	91	91	91	91	91	91	91	91	91	91	92.	92	92	92	92	92	92	92	. 92	. 92	92	92	92	92	92	92	92	93	93	93	93	93	93	. 93	
	2160	2160	2160	2153	2151	2146	2145	2132	2117	2117	2117	2117	2117	2117	2117	2117	2113	1018	2184	257	581	529	595	457	529	807	759	63	439	99	481	570	248	364	288	408	402	408	
	1700	1063	1891	1857	1942	1770	1928	1832	1694	1788	1799	1756	1834	1651	1783	1673	2002	590	1751	~	7	84	125	286	329	482	539	12	360	1	12	51	15	~	ᆸ	13	13	26	
		9364/43/ ~2675135	926/3133 q4524280		1689922H1	g1501747	g2342389	g846897	94264802	g3693061	94269694	g2269848	9824800	g3069508	g2055928	g2539104	g2901266	70375731D1	g4390710	5059054H1	5059022F9	179544R6	1227952T6	064418H1	179544H1	g1011391	4667922H1	g4189831	4721701H1	3123901H1	6785315H1	7201126H2	2327449H1	2327457T6	2327449T6	27	2327457R6	369	
	98	0 0	98	86	98	98	98	98	98	98	98	98	98	98	98	98	98	86	98	87	87	87	87	87	87	87	87	88	88	88	88	88	83	89	83	83	89	90	

4338	'n	1122	1099	1519	1359	1673	1763	1782	1682	1559	2033	2000	2005	1845	1890.	2122	1921	2115	2062	1921	2078	2255	2006	2047	2008	2241	2222	2075	2480	2182	2529	2097	2525	25	53	2527	2714	
202			838	926	1050	1215	1264	1304	1305	1305	1438	1487	1489	1489	1535	1644	1684	1689	1689	1689	1698	1733	1733	1778	-1783	1783	1789	1791	1851	1863	1859	1863	1962	ð	2034	2043	2095	
93869256	93067	45	5356	70837439V1	3502278H1	g1779649	60209482U1	495759R1	495759R6	495759H1	70375665D1	60207458U1	60209492U1	60209480U1	7006928H1	70375676D1	70375660D1	494011R1	494011R6	494011H1	g3896433	994895R1	994895H1	680754H1	70374292D1	70375422D1	70375842D1	3488220H1	71220762V1	1332986F6	71221685V1	1332986Н1	70838337V1	-1964279H1	71221831V1	70375269D1	g1357787),
96	96		96	96	96		96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	- 96	96	96	96	96	96	
									1							•		•					•			•						,		ı				
50	œ	27	41	445	85	445	65	45	49	55	440	35	80	96	893	66	87	04	86	58	98	868	893	94	93	893	77	849	93	873	868	944	056	43	4	7	4	
34	36		ന	m	m	'n	ന	ന	m	m	m	ന	ന	m	m	ന	m	ന	ന	m	m	ന	സ	ന	ന	ന	ന	ന	m	8 38	8 38	9 39	1 40	4	57	25	7	
306	3118	3113	3148	315	3157	315	3163	3178	318	318	3218	325	3308	330	332	3341	3428	342	346	3493	351.	354	359	360:	362(362(3619	3643	3648	364	364	99	80	91	Н		61	
g1780421	93	6500625H1	g654349	g5747781	75897	56498	13577	g2931035	155875T6	3874011H1	g1190099	3117949H1	2756752H1	70837859V1	495759F1	1332986T6	3297117H1	g2959267	.,,	154612T6	w	g3838447	g1187596	7004590H1	6192804H1	6194735H1	6194703H1	495759T6	g4737879	g758939	g3895731	g1079906	767355H1	g1115031	7337250H1	2485552H1	7235980H1	
96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	
2804	2664	3199	2990	3127	3092	2878	3122	2806	3091	3185	3131	3131	2989	3193	3435	3294	3079	3428	3400	3434	3445	3534	3187	3555	3189	3229	3552	3147	3405	3448	3519	3447	3108	3445	3445	3446	3449	
	2540																																					
5298771H1	298612H1	70H1	133					-							70657566V1											5138789H1			يو	391	SH1	183	덮	g3419253	5656805	1444847	3416160	
96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	

WO 01/62927 PCT/US01/06059

																								11																
1	759	318	849	-811	1100	775	928	1055	1004	1062	1100	983	1100	1102	1100	584	1583	465	722	597	643	455	169	826	601	398	678	523	482	635	811	271	814	708	856	813	848	847	812	
,	183	268	285	613	616	616	671	681	702	719	726	726	745	748	1004	~	1192	-1	224	237	346	346	346	597	പ	251	273	273	351	353	394	~	430	434	614	618	618	618	627	
	3016435T6	094	4587201H1	762	1495146R6	1495146H1	5326946H1	1495146T6	3703757H1	2948181T6	2948181F6	2948181H1	g4620028	g928615	677653H1	5901489T6	2025051T6	g2932743	7165328H1	g5664446	2863343H1	4030732H1	2863343F6	3323244H1	4987160F6	4986076H1	2753343R6	2753343H1	4793432H1	4793224H1	2753343T6	4987160H1	3343341T6	4228058H1	86467.7H1	755	755913н	2755913R6	197185516	•
į	66	66	- 99	66	66	66	66	66	66	66	66	66	66	66	66	100	101	. 102	102	102	102	102	102	102	103	103	103	103	103	103	103	103	103	103	103	103	103	103	103	
					•										. '																									
	1220	1192	943	940	1108	1360	1431	461	811	1445	1503	1429	1503	1835	1774	1689	1528	1643	1582	1639	1827	1671	1704	1854	1832	1177	1116	1131	1402	1530	1184	929	377	273	368	825	S	138		
	680	680	754	807	819	828	925	300	544	1164	1199	1145	1269	1597	1598	1279	1308	1353	1387	1412	1415	1497	1574	1628	1650	860	860	895	806	908	625	637	7	-	18	213	н	н	28	
	60264804D1	60264819D1	g2011093	069791H1	യ		on	6337692H1	3371311H1	3091243H1	3915431H1	1954644H1	2596935H1	4719538T6	g812717	60100951B1	2410012H1	5781437H1	1499912H1	2777329H1	60100952B1	g2577280	g3648252	g1128730	g2837364	60100950D1	60100952D1	1264982H1	6120149H1	6119056Н1	60264817D1	60100951D1	6197337H1	6198216T8	6197337F8	6331250H1	01643	3016435H1	5964071H1	
	97	97	97	97	97	97	97	97	97	97	97	97	24	97	97	97	97	97	97	97	97	97	97	97	97	97	97	97	97	97	97	97	86	86	86	86	66	66	66	
																										1														
	28	2490	2790	2286	2536	2783	2539	2794	2887	2826	2587	2793	2962	2950	2627	2906	2962	2679	3045	2804	1185	1239	1228	1306	1422	1564	1506	1642	1372	283	315	334	705	418	466	424	493	899	1235	
	2117	2146	2168	2168	2168	2218	2282	2283	2299	2308	2308	2344	2397	2404	2404	2404	2403	2466	2484	2484	925	964	984	1027	1034	1061	1076	1077	1125	႕	73	74	151	169	211	228	257	641	089	
	71221729V1	70838208V1	2598088F6	2598088H1	g573567	6409839H1	5035552H1	70658011V1	70656808V1	1997937R6	1997937H1	g3887783	1997937T6	g1280977	155875H1	155875R6	70839485V1	6096636H1	7126727H1	5876310H1	4719538H1	4911350H1	1903472H1	3639862H1	4541862F6	6907459H1	g5657760	6908516J1	4697720H1	4238385H1	3403365H1	3403365F6	6907459J1	4551324H1	3374712H1	. 60264809D1	1954023H1	g792057	60264821D1	
	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	96	97	97	97	97	97	97	97	97	97	97	97	97	97	97	97	26	24	97	93	

1	2175	1895	\leftarrow	α	2227	2086	1907	1941	1892	S	1763	1833	1932	1725	1205	2132	2222	2223	2224	2367	2121	2090	2151	2080	2222	2222	2268	2177	17	2208	2222	2222	2222	2074	2220	22	2222	2160
	1584	1623	1657	1657	1671	1671	1671	1698	1447	1469	1494	1540	1546	1559	558	1882	1888	1901	1901	1911	1931	1793	1800	1802	1811	1816	1815	1819	1818	1821	1826	1835	1853	1853	1858	1859	9	1859
1	3173959T6 2298374R6	298374H	1361272F1	1361366H1	1683557F6	1683573F6	1683573H1	1336611H1	71265365V1	70062844V1	2273538H1	3022474H1	71120676V1	70524882V1	70528634V1	2408847H1	70059242V1	g5855887	-g5858285	3409241T6	5669576H1	70062956V1	70061871V1	4778510H1	70061698V1	g4901915	70060889V1	1623591T6	1915736T6	g3155476	g5392637	70061837V1	ന	1623591H1	g2198272	_	70062540V1	960516Н1
	106	106	106	106	106	106	106	106	106	106	106	1.06	106	106	106	106	106	106	106	1,06	106	106	1,06	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106
	- T	82	82	9(96	*	9.	99	14	73	35	52	0.7	60	7.5		73	7.	. 91	86		31	•	~				96	66	71	68	37	74	33	62	35	57	[3
		2938		~	-		7				2725			2409				~		7		2181	599	847	460	578		, 	~		-	-	-		~	~	4 2157	2 1812
	2540	2671	2772	1746	1745	1780	1864	1885	191	1931	1952	2005	2013	2192	2198	2200	223	2248	226(2358	H	159	164	245	266	357	114	1204	1205	1213	1213	1214	1252	143	1481	154	Ó	156
	70523321V1	70523241V1	g561027	g875594	g669502	70525213V1	70522841V1	70524066V1	70524543V1	7238311H1	70522425V1	70525244V1	70526939V1	70526388V1	70524889V1	70526612V1	70522907V1	70522785V1	70526373V1	7086069H1	7071063H1	g913241	g6299529	7091369H1	7347105H1	5312260H1	7090770H1	70525682V1	70526748V1	2707682H1	2707682F6	70522990V1	1569986H1	70529862V1	70522200V1	70525480V1	6449560H1	3408296H1
	105	105	105	105	105	105	105	105	105	105	105	105	105	105	105	105	105	105	105	105	105	105	105	105	- 105	105	105	105	105	105	105	105	105	105	105	105	105	1.06
		6875	2	13		8524	O.	7745	8487	8197	8337	8524	8524	8530	8530	8524	8518	8521	428	836	664	1544	1373	2134	2612	4813	6705	2395	2253	1909	1909	2188	2259	2603	2903	2965	2939	2939
	661	6610	7598	307	8369	8369	7598	7598	7859	7988	8062	8121	8183	8263	8263	8287	8287	7	343	445	445	1141	1141	1716	2112	4291	6436	1630	1639	1689	1689	1716	1746	2383	2410	2420	2426	2426
	6161690H1	3957372H2	86558	g4838144	17	g3861906	185105H1	186558H1	186558T6	q1635936	4619766H1	7356046H1	g3797365	6432853H1	6434079H1	756968R6	756968H1	g184038	7000401H1	1608059F6	1608059H1	2169635F6	2169635H1	2169635T6	7229203H1	g314259	3960183H1	70524885V1	70524843V1	6643169V1	70646269V1	70525307V1	g880693	70533384V1	2707682T6	70523481V1	70525826V1	(V
	103	104	104	104	104	104	104	104	104	104	104	104	104	104	104	104	104	104	104	104	104	104	104	104	104	104	104	105	105	105	105	105	105	105	105	105	105	105

														- 1																							
1882	1762	1729	2182	2333	2047	2225	2376	2221	1411 -	1499	1492	1575	1263	1013	696	1202	1246	1180	2424	2225	1182	1200	1195	1200	1254	1601	1689	1325	1749	1594	1765	1363	1589	1585		1794	283
1322	1322	1322	1735	1747	1758	1775	1.781	1794	895	846	884	889	753	731	731	731	732	695	2106	2147	968	895	895	895	1006	1009	1031	1044	1097	1102	1097	1100	1322	1322		1326	- 1
70061612V1 70059581V1	5892	9	2983	70061519V1	149	g2879046	1853191T6	g2444573	3934758F6	70527491V1	71119165V1	71265279V1	71264808V1	71265724V1	1915736H1	71265549V1	71266530V1	2681128F6	g2541182	g3039868	3931985H1	3934538H1	3934758H1	3934357H1	3662984Н1	70529227V1	71265619V1	5946829H1	S	\sim	71266010V1	9478	m	50	198167	620	5913661H1
106 106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	1.06	106	106	106	106	106	107
								1										•	٠				i ,		,					•	•		ı				
2226	2222	2222	2222	579	824	1041	358	296	497	350	099	1368	1103	1037	1271	1323	1700	1448	1220	1424	1420	1724	1825	1433	1780	1954	1741	1501	1481	1960	1969	1885	1871	1610	1441		1886
1960	2064	2063	2064	461	493	467	- 1	7	103	104	329	801	808	991	799	1101	1118	1121	1133	1134	1137	1153	1197	1224	1235	1267	1275	1277	1282	1295	1301	1306	1311	1314	1314	1320	1322
g3151378 g1980460	223027R1	223027H1	3027	70529734V1	g850466	70530256V1	3751266F6	3751266H1	3321818F6	3321818H1	6351045H2	71265775V1	4177726H1	5296714H1	7059995H1	096309H1	71118507V1	71120385V1	g2198304	71119740V1	4174878H1	71117317V1	71119085V1	3792653H1	6329373H1	71119545V1	71120838V1	4717156H1	5391806H1	71118747V1	70527304V1	71120713V1	Н	5290693H1	~	d.	3173959F6
106	106	106	106	106	106	901	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	. 106	106	106	106	106	106	106	106	106	106	106	106	106	106	106
2185	2294	950	892	911	22.18	1960	1922	1933	2222	2175	2187	2185	1862	1909	1605	1816	1857	2023	1751	1261	1234	1366	1311	1292	1260	1137	984	1260	1481	1608	1580	1168	1537	1452	1294	2251	2222
1859	1884	683	650	650	1706	1706	1705	1706	1719	1725	1725	1730	1341	1346	1348	1403	1404	1408	1448	731	731	732	731	731	731	731	969	206	725	922	921	937	896	973	1006	1936	1938
960387T1 2086141H1	4239442T8	37	577	S	8531	1853191H1	1632340H1 -	614199H1	70059326V1	1683573T6	3751266T6	3321818T6	70062398V1	71118139V1	1865168H1	71294927V1	71120506V1	71118652V1	71266623V1	71265047V1	71119759V1	71266124V1	71118641V1	71118731V1	71265792V1	1915736R6	2681128H1	70531848V1	71264971V1	71266413V1	71117117V1	3672409H1	11185	71119741V1	96408	28624	g2969311
106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106	106

																	•									•													
1912	1903	1882	2125	1877	1913	1898	1918	1914	1901	1928	1880	1920	1976	2029	2020	1834	1900	1920	2032	2136	2081	2079	2011	2209	2132	2136	2135	2136	2136	2136	2136	2106	2321	2238	2136	2251	2137	2215	
1645	1653	1653	1654	1655	1654	1656	1666	1668	1669	1675	1677	1678	1686	1694	1697	1708	1724	1750	1779	1858	1872	1907	1918	1922	- 1933	1933	1933	1940	1939	1950	1966	1966	1988	-1989	1994	1995	2021	2025	
g990246	957795H1	472488H1	472488R1	302216н1	1876833H1	2697195H1	5377444H1	2431879H1	777024H1	3236114H1	1641892H1	5569350H1	3857806H1	g2751499	g876527	4069649H1	4307481H1	031299H1	3623362H1	g5036497	3624213H1	g2411009	4721623H1	2839772H2	6056374H1	6056674H1	3802178H1	4371036H1	412662H1	1907478H1	5050475H1	6447704H1	g3888474	-5379172H1	5015647H1	3327673Н1	3567634H1	1739210H1	
115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	
									1	•								,					•			1	•					1			•				
503	501	750	1106	1106	166	440	417	338	401	461	205	304	288	439	1450	1161	1207	1244	1178	1181	1164	868	1327	1079	1525	507	989	662	793	9/9	1845	1873	1915	1955	1903	1756	1891	1910	
248	251	368	635	884	-1	-	-1	7	-	-	71	90	94	147	-1	657	657	692	692	692	692	692	879	950	966	-	365	365	365	365	1625	1625	1631	1631	1636	1636	1637	1643	
g3040122	g3051904	g3804542	5282615F6	5282615H1	g2563121	2792728F6	2792728T6	g3040744	g2714186	7157205H1	g4371924	1394888T6	1624877H1	2792728H1	g2943715	6487571H1	6487571F9	70681361V1	70681601V1	1544823R6	70681277V1	1544823H1	g4686743	70680264V1	6476403H1	6272292H2	5910821T8	5910821T9	5910821F8	5910821H1	1551035H1	2716914H1	4876737H1	7091270H1	674945H1	670546H1	2119143H1	2815231H1	
111	111	111	111	111	112	112	112	112	112	112	112	112	112	112	113	113	113	113	113	113	113	113	113	113	113	114	114	114	114	114	115	115	115	115	115	115	115	115	
569	575	821	435	559	1430	1187	1379	1201	1220	1213	1304	1349	1411	1257	1341	1286	432	226	233	240	624	1001	715	1072	259	909	323	954	624	505	208	509	583	429	562	751	563	509	
н		213		111	918	918	932	933	993	993	1010	1010	1080	1081	1106	1209	-	-	99	29	255	461	462	800	-	27	56	367	н	134	134	135	139	142	142	168	248	248	
913	5913661F6	5913661T6	96	ഗ	2536867F6	2536867H2	g1926046	g1925836	3244923F6	3244923H1	2878889H1	2878889F6	g858504	5567006H1	1896278H1	g784668	3364252F6	3364252H1	096666н1	096675H1	7132087H1	4030547F8	4030547H1	5077091H1	2717953H1	2806157F6	2806157H1	2724233T6	166942F1	g3755789	g3109437	g3037830	g3180013	g4270829	g3594985	826	94253	5383	
107	107	107	108	108	109	109	109	109	109	109	109	109	109	109	109	109	109	109	109	109	109	109	109	109	110	110	110	110	111	111	111	111	111	111	111	111	111	111	

																														-	1						
1744 1739	1707	- 2097	1772	1559	1790	1756	2067	1816	1808	2096	1782	2006	1809	2104	1639	1858	2079	1837	1775	1753	1767	1773	1778	2096	2068	1869	2099	1848	1721	1846	1859	2101	1861	1852	1854	1833	1847
1493 1495	1498	1500	1501	1502	1504	1509	1513	1517	1522	1523	1523	1524	1530	1538	1538	1541	1548	1548	1550	1551	1553	1553	1556	1560	1563	1566	1569	1573	1578	1577	1583	1584	1591	1593		1596	1596
2886241H1 1222871H1	4193226H1	7065251H1	2152140H1	3763167H1	3571390H1	942026H1	4533306T1	2124615H1	3684042H1	6715567H1	3322645H1	g1873672	3590863H1	60123902B1	1002539H1	6077425H1	6513731H1	3785763H1	538349H1	1832140H1	1669989H1	450252H1	737082H1	7065802H1	6741001H1	.835332H1	1599938T6	4226362H1	529930H1	4771124H1	4715169H1	4533768T1	4895425H1	4348930H1	4348733H1	g2616416	5698825H1
115 115	. 115	115	115		115	115	115	115	115	115	115	115	115	115	115	. 115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115
			:									,	. •		٠									. •													
,																																					
433 554	618	694	219	869	709	726	176	968	982	1087	1011	982	1454	1084	1504	1469	1440	1469	1464	1482	1938	1922	1849	1699	1702	1656	1712	2086	1902	1706	1970	1758	2051	1812	2031	1978	1912
245 289	370	418	466	480	480	481	525	620	647	647	751	768	837	1011	1087	1206	1238	1239	1244	1255	1349	1401	1427	1436	1436	1439	1450	1458	1466	1461	1461	1461	1466	1469	1481	1486	1495
4696530H1 928643H1	4529248H1	3942806H1	7280921H1	g2013891	g2013455	5422141H1	3110608H1	5659913H1	5545664F8	5545664F6	3163564H1	761584H1	6887167J1	1852303H1	6948478H1	4158605H1	5270074H1	2365846H1	2444605H1	3115706H1	6728257H1	5717548H1	5796003H1	779492H1	2279382H1	5370473H1	4152676H1	60123909B1	6960268Н1	3449619H1	7039654H1	3890456H1	6966324H1	765511H1	4940482T9	95	6734637H1
115 115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115
					•																			i													
2132 2132	2132	2132	2421	2132	2329	2494	2420	2464	2356	2476	2491	2513	2463	2468	2496	2483	2496	2496	2496	2496	2496	243	640	410	909	197	385	372	431	361	374	444	433	496	449	473	504
2032 2037	2060	2062	2072	2084	2116	2153	2155	2185	2193	2232	2244	2245	2255	2262	2295	2336	2360	2377	2404	2408	2439	т	96	86	100	120	146	157	161	160	163	187	189	215	219	230	230
880124H1 2354054H1	1235532H1	2350867H1	g983285	4190021H1	g2017399	6550613H1	5195955H1	3907635H1	g3166884	g994523	g1099949	g757333	4534796H1	1543657H1	4754806H1	1947635H1	3930538H1	2760689H1	5563236H1	4310883H1	2778679H1	725638H1	6733284H1	3096672H1	7034622H1	g777461	5198834H1	2394482H2	4970513H1	4969579H1	377654H1	305879H1	307158H1	3319063H1	5504343H1	3513751H1	4775727H1
115 115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115	115

																									•												
1287	70 to	282	411	701	249	280	161	499	2053	352	349	2022	555	555	165	186	595	927	256	1422	906	206	366	734	889	849	1297	1369	349	1066	1286	955	1457	293	1531	754	1598
1164	٦,-	. ⊢	,	194	~	31	78	374	1824	128	82	1824	220	44	-	317	330	414	414	1354	421	H	71	- 181	693	693	718	825	181	825	966	522	.1137	-	1198	522	1333
60110854B2	92004102	g2223423 q1267721	93918260	2807456F6	2807456H1	2807456T6	270567H1	269931H1	269626H1	269080H1	270403H1	270910R1 ·	587588R6	587588T6	587588H1	3321035F6	3321035H1	g1319620	g2741801	g2841030	g2933104	5259815H1	3568526H1	1289824F6	g928730	764159H1	6620992H1	839936R1	1289824H1	839936H1	3869224H1	1685280F6	-3223525H1	3843717H1	g1395923	1685280H1	S028090H1
122	122	122	122	123	123	123	123	123	.123	123	123	123	124	124	124	125	125	125	125	125	125	126	126	126	126	126	126	126	126	126	126	126	126	126	126	126	126
								,									•								,	,					1		1	,			
530	07C	249	671	357	257	917	822	1199	1090	1022	548	507	846	801	793	1219	438	338	546	621	1018	638	986	424	316	365	446	102	1356	1353	316	1335	1329	1329	270	315	618
274	336 1	-1	122	- -1	ч	587	266	955	955	168	H	118	579	526	484	797	140	198	256	334	391	364	419	-1	ᆸ	₹₹	4	4	960	828	14	828	870	924	37	38	45
3437984H1	25441/5HI	2807456H1	2807456T6	g3595066	4665764H1	70151773V1	60203477UI	522228H1	522135H1	026879H1	6020362101	60203622U1.	4401727H1	g2540618	2807905H1	70152547V1	3812508H1	g1265991	3860472H1	3520754H1	70152228V1	4350225H1	70155823V1	g3919706	2512390F6	g1792877	g4187765	g2905531	70156040V1	70151954V1	2512390H1	60202389B1	60202388B1	60202388B2	999391H1	2512390T6	4970577T6
119	120	120	120	121	121	122	122	122	122	122	122	122	122	122	122	122	122	122	122	122	122	122	122	122	122	122	122	122	122	122	122	122	122	122	122	122	122
							_	_														į	•			10				_	•						
1844	1007	1897	1835	1837	1860	1841	1744	1863	1921	957	523	9/9	996	772	788	513	520	520	381	483	637	647	863	871	916	1236	1245	1092	1111	1160	1269	336	512	539	443	387	481
1597	1501	1598	1600	1601	1601	1600	1601	1608	1618	699	 1	141	534	534	537	⊣	72	72	120	120	423	423	555	597	650	731	787	838	897	1025	1025	1	-1	229		89	220
2288814H1	20000000000000000000000000000000000000	3062229T6	883098H1	5336847H1	2741220H1	880546H1	6398288H1	3252954H1	3779658H1	g1891130	7333578H1	6545439H1	g3805536	g3322110	5610773H1	6929774H1	6052078J1	6052078H1	4970577H1	4970577F6	6292129H1	6294687H1	2807905H1	g2540618	4401727H1	5729803H1	g1301257	026879H1	g1303063	522135H1	522228H1	587588R6	587588T6	g1069975	g2809760	g2934256	2785236н2
115	115	115	115	115	115	115	115	115	115	116	116	116	116	116	116	117	117	117	117	117	117	117	117	117	117	117	117	117	117	117	117	118	118	118	119	119	119

	3266	8265	- 7418	7382	7421	7069	7468	7317	7469	7465	7369	7465	7465	7424	7369	7469	7468	7437	7465	7469	7470	2981	8265	8268	8277	8265	3669	3606	4085	2856	2839	2828	8220	671	4447	8237	8262	8008
	2681 7992	8059	6903	6914	6942	6962	7015	7053	7067	7123	7123	7124	7127	7128	7142	7147	7149	7200	7080	7082	7111	2813	7994	8006	8011	8034	3434	3458	3509	2524	2531	2708	7755	218		7709	8140	7763
,	6881955J1 2825680F6	g5036098	4027974T6	5717756H1	2717848T6	4722802H1	g3594812	6403421H1	g3163456	2649733F6	2649733H1	7003170H1	g683322	2649733T6	2484677H1	g6075627	g3048962	212391H1	g6506945	g6073337	g2630574	5207126H2	2825680H1	g560960	g796025	1415181H1	3336518H1	4723427H1	70390598D1	648	357277	5544294H1	101	ũ	g2599501	6044517J1	810518H1	2101112H1
	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131
	,																																					
	1700 1628	1957	1900	1997	2002	2002	861	892	1474	206	366	737	349	006	1676	1733	1682	2036	1477	1616	1803	1549	891	855	1448	852	1213	891	892	1189	1932	90	2002	1949	1277	2103	2358	7881
	1443 1442	1483	1491	1564	1574	1621	689	693	1152		71	181	181	009	1421	1437	1437	1442	1243	1348	1225	1213	969	249	1153	693	664	665	689	929	1701	1701	1690	1701	717	1921	2177	7624
	4032140H1 1597096H1	3438058T6	4032240T9	g3804916	g3432508	g3254781	1947742T6	g928730	3223525H1	5259815H1	3568526H1	1289824F6	1289824H1	g2540596.	4216695H1	3438058F6	3438058H1	1597096F6	1685280H1	5028090H1	7213258H1	g1395923	3928775H1	1289824T6	3843717H1	764159H1	5724304H1	6040888H1	g1225270	7153412H1	3640283T9	3640283T8	g3538751	3640283F8	6620992H1	40	5665320H1	872922H1
	130	130	130	130	130	130	130	130	130	130	130	130	130	130	130	130	130	130	130	130	130	130	130	130	130	130	130	130	130	130	130	130	130	130	130	131	131	131
																								٠	1													
	1656 852	897	1233	828	889	295	562	516	436	379	1216	1358	1374	1405	1490	1484	1519	1718	1557	1691	766	971	971	971	888	878	792	009	520	474	192	182	895	852	1385	1073	1477	1301
	1404	009	664	688	688	269	318	45	9	-	910	1038	1025	1137	1144	1197	1212	1316	1401	1492	919	747	507	359	629	602	433	167		207	⊢	40	709	708	828	828	1040	1001
	4216695H1 1289824T6	g2540596	5724304H1	1947742T6	g1225270	3438058F6	3438058H1	3438058T6	93804916	g3254781	3504571H1	g2055741	g1270278	2733544H1	g1162686	g1109059	g1774715	g3897241	5854467H1	g1898243	g2358498	183176H1	183176R6	183176R1	2733388H1	5616358H1	g2824012	g4762579	7104793H1	4004284H1	3928775H1	2562126T6	g4902006	2562126T6	839936R1	839936H1	1685280F6	3869224H1
	126 126	126	126	126	126	126	126	126	126	126	127	127	127	127	127	127	127	127	127	127	128	128	128	128	128	128	128	128	128	128	129	129	130	130	130	130	130	130

7961	7465	40	S	46	7591	7464	52	7592	7469	47	7465	9092	3236	3347	7667	7721	7784	7802	7874	7881	7692	7784	6658	. 6568	6619	6913	6946	6662	6705	0.099	7110	6852	6873	1351	18	04	6832	6895	
1696		7255	7271	7301	7313	7317	7330	7332	7357	7391	7390	7394	3040	3040	7499	7499	7561	7571	7593	7612	7499	7522	6136	6238	6336	6370	6416	6416	6428	6442	6547	6581	6583	1058	1921	28	6584	6299	
5036970H1	g2212423	3282024T6	3323350H1	g2768029	3322677H1	g1515911	3865622H1	g317850	g3174898	4253321H1	4244366H1	3334656H1	6355568H1	g1881143	1372008H1	2292865H1	g91:5845	2289132H1	-5832896H1	4774272H1	1393295H1	1772773H1	6269862H1	g1975380	3389337H1	6706684н1	3282024F6	3282024H1	3854583H1	2509302H1	7225908H1	3147875H1	3797563H1	g2398342	6881955H1	2717848F6	2717848H1	4058694H1	
131	131	131	131	131	131	131	131	131	131	131	131	131	131	- 131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	
													•														ı												
4452	4472	4452	4441	4666	4526	4520	4498	4819	4636	4466	4773	4801	4888	4766	4881	4822	4923	2006	5084	5518	5271	5459	5352	5226	5635	5610	5787	5886	6052	5974	8909	6448	6178	6205	6335	6392	6274	6419	
3974	3991	4048	4080	4273	4273	4273	4275	4364		4395	4479	4511		4527		4592			4839							5346	5545	5702	5783	5815	5855	5903	5974	6029	6044	6063	6063	909	
g5675561	6618788H1	g3144228	g2751511	1863153F6	1863161F6	1863153H1	385245H1	g4970402	5857654H1	g1624652	g1023422	g1023318	3341807F6	3341807H1	4027974F6	4027926H1	6024929H1	2203255H1	4184071H1	3322055F6	3322055H1	1863161T6	811828H1	789137H1	g3077295	3242918H1	4578433H1	5694130H1	4255728H1	5673677H1	g1880292	5768386H1	g1442274	g1678263	3607889H1	g709099	g769480	g692094	
131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	
																									1			•											
m	8284	8165	12	8046	8181	8266	8265	8265	8265	8268	8268	8226	7959	7844	7654	7723	7765	7765	7643	8049	4007	3803	3803	4161	3798	3902	3865	3890	4204	4207	4206	4151	4212	4265	4106	N	4321		
7764	7774	7774	7815	\leftarrow	7821	7831	7834	7843	7870	7964	7984	7985	7719	7619	7405	7445	7488	7488	7499	7497	3583	3583	3583	3664	3665	3680	3698	3734	3746	3779	3780	3835	3859	3867	3867		3896	3964	
2101112R6	6559424H1	g2140984	3781662H1	744157H1	4774224T9	g2324704	g3796940	g5839127	g3932489	g683058	g1225252	2825680T6	3278368H1	4726587H1	2108075H1	g1241115	4632120H1	4632247H1	7154510H1	6162751H1	1593082F6	1593043H1	1593082H1	7236349H1	4004354H1	439020H1	3480603H1	g1678362	g4691014	g6132554	g3756265	g1199039	g819518	2155889F6	2155889H1	513	70391721D1	2155889T6	
131	C	ന	131	131	131	131	131	131	r	3	131	B	131	131	131	131	സ	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	131	3	131	3	

926	1055	1053	1011	1052	-869	926	1036	1227	1055	1001	1009	213	468	755	749	488	528	864	932	1259	2604	1152	1251	1120	1086	986	1191	1429	1453	1370	1610	2566	2562	2433	S	2551	2509	2604
333	609	744	744	744	744	744	763	763	865	874	887		151	166	166	208	383	570	. 029	846	2466	893	919	958	882	882	1029	1091	1295	893	1313	2212	2212	2212	2215	2219	2228	2253
3960046F8	g4114677	g3674688	2705604T6	g3429159	1871586H1	. 1998855H1	2135293H1	2135293F6	2100630H1	292419T6	3960046T8	6100950H1	6302544H1	6144369H1	6144369F8	6099148H1	6281896H1	6111359H1	6028709H1	6144369T8	5056523H1	2271032H1	4243388H1	4552488H1	g1953334 -	g1953371	g713204	g1967839	3737077H1	2271032R6	6326476H1	1845337T6	1845337R6	_	859	g5659132	913114H1	g1960980
137	137	137	137	137	137	137	137	137	137	137	137	138	138	138	138	138	138	138	138	138	139	139	139	139	139	139	139	139	139	139	139	139	139	139-	139	139	139	139
							,												•	٠			,								•	ı						
				₹!	-	7																٠			•							·						
863	841	725	450	102	1091	128.	955	231	379	230	353	521	579	507	882	763	929	923	292	502	522	440	450	465	565	565	565	565	565	563	508	565	546	969	502		486	473
443	420	303	ન	683	683	921	674	Н	⊣	37	142	157	157	262	334	520	809	069	Ä	260	375	78	135	77	450	450	450	450	452	455	457	450	398	491	H	194	196	333
a5109774	g5526440	g4599202	6306770H1	4186114H1	4186114F6	4186114T6	4165023H1	2268189H1	2268189R6	1470335H1	g2505442	g2505398	g2458763	1445774H1	2268189T6	368103H1	g2328398	2322571H1	6114201H1	3287273H1	g779441	g879517	g870148	g883117	2120815H1	1631555H1	1631555F6	g705961	1547031H1	4796579H1	5081193H1	1630826F6	1630826H1	g2023471	6864812H1	292419H1	292419R6	3960046H2
133	133	133	133	134	134	134	134	135	135	135	135	135	135	135	135	135	135	135	136	136	136	136	136	136	136	136	136	136	136	136	136	136	136	136	137	137	137	137
6932	6955	7417	41	7361	7235	7102	7171	7098	7030	1410	1255	1410	1271	1281	1284	1417	247	445	151	358	697	455	704	582	740	1047	212	1060	1088	1094	1088	196	1089	1089	1088	1089	1252	1143
6665	6782	6814	6820	6822	6874	6873	6874	6874	6888	13	1172	1194	1210	1210	1210	1214		7	-	150	150	192	192	196	348	519	535	269	652	687	689	836	860	950	950	950	957	717
025240H1	4270965H1	3341807T6	3322055T6	4027974T9	g691854	4029613H1	g708808	g565754	124772H1	1630826T6	g5813217	1631555T6	3878121H1	1986029H1	2956806H1	1372584H1	854216H1	854312R6	854312H1	2465049H1	2465049F6	2271395H1	2271395R6	g2184123	g1692736	2465049T6	1601994H1	5274102T6	g3413112	g1692707	g3428202	g1686359	-	g3843958	g4394372	~1	g661412	g5438299
131	131	131	131	131	131	G	m	131	131	132	132	132	132	132	132	132	132	132	132	132	132	132	132	132	132	132	132	132	132	132	132	132	132	132	132	132	132	133

																									•												
880	761	629	701	939	963	1120	1322	1302	1165	1033	1208	1402	1322	1345	1480	1687	1510	1501	1474	44	1576	1632	1878	1656	1625	1655	1943	1631	2064	1618	2081	1883	1768	2073	2072	1850	1908
402	428	467	538	009	802	823	855	870	899	943	1006	1052	1052	1088	1208	1208	1244	1244	1244	1247	1327	1382	1396	-1398	1418	1420	43	1432	1461	1493	1549	- 1569	1559	1573	9	1635	1662
2271032R6 2271032H1	4243388H1	4552488H1	g713204	g1967839	3737077H1	6326476H1	g1968949	g2229641	476160H1	6158833H1	794690H1	1889107F6 -	1889107H1	5840503H2	2061567H1	2061567R6	4399331H1	4399135H1	2250985H1	1501428H1	4516041H1	4180584H1	g1968950	5038396H1	3254138H1	5946104H1	2700155F6	2700155H1	2061567T6	3365965H1	1749882T6	70366789D1	1752020H1	2700155T6	8891	3236592H2	5291302H1
140	140	140	140	140	140	140	140	140	140	140	140	140	140	140	140	140	140	140	140	140	140	140	140	140	140	140	140	140	140	140	140 -	140	140	140	140	140	140
								l	•							•	•						•		,						ı		1				
1970	1698	1850	1812	1964	1892	1991	2000	1930	2162	2378	2066	245	593	331	218	263	268	663	188	747	747	1240	1106	1171	1085	1357	331	587	245	218	263	268	615	680			495
1698	1496	1513	1542	1734	1542	1734	1734	1737	1549	1812	1817	-	-	-	21	24	25	33	34	422	422	672	797	811	811	860	~	⊣	⊣	21	24	25	306	320	320	394	394
2061567H1 6158833H1	794690H1	6576416H1	1889107H1	2250985H1	1889107F6	4399135H1	4399331H1	1501428H1	6823952J1	6018675H1	4516041H1	1272843H1	1272843F6	1272843F1	1274319H1	2598183H1	3256051H1	6826541J1	6823903H1	6820526H1	6820526J1	6826541H1	3857549H1	1749882F6	1749882H1	6829715H1	1272843F1	1272843F6	1272843H1	1274319H1	2598183H1	3256051H1	3857549H1	1749882F6	98	53	g1953371
139	139	139	139	139	139	139	139	139	139	139	139	139	139	139	139	139	139	139	139	139	139	139	139	139	139	139	140	140	140	140	140	140	140	140	140	140	140
2601	61	2604	61	60	9	59	59	59	56	2604	12	36	14	45	1	14	43	12	55	10	22	57	25	56	56	34	39	8	58	2604	69	81	83	79	29	1655	17
2244	25.	25	25	29	31	34	35	36	36	41	87	88	88	90	90	91	92	92	95	98	90	03	04	90	9	12	15	16	20	2200	1567	സ	1578	36	67	1389	9
g5887689	838	913	741	785	463	312	8	4519262H1	1272843T6	6104909H1	4180584H1	589	339	6576957H1	3254138H1	5946104H1	2700155F6	2700155H1	2061567T6	3365965H1	g5591869	1749882T6	1752020H1	2700155T6	1889107T6	3236592H2	5291302H1	3816	g2355286	14656	07668	g1968949	5840503H2	g2229641	6725031H1	16	2061567R6
139	139	m	സ	139	3	m	m	139	S	139	S.	E	139	3	139	S	n	3	139	സ	139	ന	139	ຕ	139	ന	n	m	139	139	139	ന	139	139	ന	ന	139

																							.,																
;	463	211	- 393	782	946	1097	1114	1115	2440	2439	319	2440	2439	2439	2448	2439	2188	532	440	747	2451	617	650	578	430	436	511	286	551	272	279	468	446	410	661	713	714	880	
,	19 34	42	128	492	672	816	2	939	2099	~	႕	2048	2330	2387	2284	1897	1978	7	ဖ	265	1875	,	169	169	169	-	255	ᆏ	-	14	3 6	168	168	322	378	426	427	469	
	7008530HI 7161666H1	7017571H1	3277305H1	3565182H1	g4293857	2992317H1	5643301R6	5643301R8	g3742856	g1903217	7183853H1	g3665358	6282319H1	g3931095	g1487041	g1365146	g1487088	7183071H1	7184162H1	7182312H1	g1365200	6807937J1	934453R6	934453T6	934453H1	g2356671	3878737H1	3613937H1	3613937F6	3356375H1	4365653H1	3133682F6	3133682H1	2784431H2	4760428H1	g1987179	3985930H1	93840682	
. ,	147	147	147	147	147	147	147	147	148	148	148	148	148	148	148	148	. 148	148	148	148	148	149	149	149	149	150	150	151	151	151	151	151	151	151	151	151	151	151	
												•		•		•									:•														
	٠																																						
	530 355	370	415	738	738	738	645	1158	495	468	451	451	451	451	450	420	335	329	325	313	283	217	194	374	226	336	329	329	278	329	337	288	329	573	927	266	412	557	
,	60 63	78	122	261	489	492	376	638	39	45	39	135	7	149	233	Ŋ	-	ᆔ	-	'n	20	.	. 7	٦,	-1	198	-	12	36	162	162	169	231	-1	290	₽	٠ ٦	12	
	6338721H1 3722062H1	356468BH1	908	145	445	5155056H1	5440206H1	6206972H1	2240790T6	g2155919	3219860T6	3219860H1	3219860R6	3221716H1	2412827H1	g3932128	g2155881	g2775288	g3277838	g1390787	2532555T6	g1422648	g1783871	6021058201	g857093	60124509B1	g2324899	g4525985	3516332H1	3012696F6	3012696Н1	3012696T6	561748H1	6623203J1	3538176T6	643	5643301F6	7007819H1	
,	143	143	143	143	143	143	143	143	143	143	143	143	143	143	143	143	143	143	143	143	143	143	143	144	144	144	145	145	145	145	145	145	145	146	146	147	147	147	
																									,														
	2099 2114	2072	2076	1943	2109	2019	2114	2013	2121	2112	2117	2109	2101	2109	2072	2114	2114	511	778	497	608	768	773	241	218	343	275	296	264	245	202	223	551	246	455	302	294	161	
,	1710	1722	1722	1722	1725	1738	1763	1759	1764	1807	1822	1857	1868	1870	1878	1923	1976	-	σ	9	540	Ω	2	Н	⊣	44	45	25	н	-1	ન	7	œ	7	7	6	38	-	
į	g2355286 g3146568	1845337R6	453	1845337H1	g4288591	913114H1	g1960980	911966H1	g3741346	g3785022	g2463906	g4312734	g2100983	4519262H1	1272843T6	6104909H1	5056523H1	2211487F6	2211487T6	2412148H1	2564905H1	125647H1	2242295T6	2211487H1	3404890H1	3387263H1	g1225131	2745513H1	3330364H1	2532555H1	2532555F6	3452732H1	6206478H1	2240790H1	2240790F6	4052530H1	2119	2207141H1	
,	140	140	140	140	140	140	140	140	140	140	140	140	140	140	140	140	140	141	141	141	141	141	141	141	142	142	142	142	143	143	143	143	143	143	143	143	143	143	

C	23 <i>5</i>	633	370	592	361	401	461	618	1108	804	835	488	5300	3885	3912	3492	4028	3932	3932	3934	3964	3716	3954	4142	4177	4148	4249	4079	4175	3776	4306	4142	4322	3792	4400		4394	4224	
Č	26 26	28	28	47	83	110	192	357	515	517	260	+	4960-	3224	3308	3325	3365	3406	3407	3407	3410	3462	3464	3487	3548	3565	3574	3590	3600	9	3605	64	3692	3699	3759	78	œ	3832	
27500011	1728945H1	6141236F8	6141236H1	882	3388023H1	6134014H1	3323733H1	3409854H1	4068325F6	4068325H1	3629455H1	7006557H1	6459173H2	71034189V1	71033929V1	g2166710	71239210V1	71035047V1	.71035847V1	71239003V1	7252515J2	617587H1	617587R6	71035452V1	71239589V1	71034494V1	71036467V1	71019079V1	71034628V1	71033566V1	71033563V1	~	71034052V1	2852347H1	71034523V1	71021626V1	71033276V1	71035439V1	
7.	155	155	155	155	155	155	155	155	155	155	155	156	157	. 157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	
				•									,						. •																			-	
	402	384	564	737	784	176	867	840	845	744	880	1240	1325	1170	1384	1579	1641	1483	1554	1682	1682	1696	1931	1820	2275	2272	2146	2275	2272	255	227	161	206	243	333	276	298	296	
, t	125	239	273	344	457	574	577	644	644	657	663	705	705	760	803	989	1018	1069	1308	1337	1346	1395	1494	1578	1717	1831	1871	1973	1991		-	ᆏ	7	-	н	22	22	22	
1110000	5950630A1 5950410H1	9	3533254H1	4875149T6	g3202357	748032H1	3751233H1	5812189H1	5812190H1	311752H1	373638H1	6333709H1	6329688H1	7080559H1	6532643H1	6141236T8	4068325T6	7068876H1	3256362H1	g1400213	g3254782	g1383466	6412487H1	5534143H1	6869946H1	g4510725	6298042H1	g1998847	3541104H1	5499626H1	5500309H1	50	5499909H1	2723940H1	72	6432	2670	g1998848	
70.	154	154	154	154	154	154	155	155	155	155	155	155	155	155	155	155	155	155	155	155	155	155	155	155	- 155	155	155	155	155	155	155	155	155	155	155	155	155	155	
,	1081 876	835	1299	243	298	533	290	485	324	627	607	517	265	565	565	458	471	421	518	736	652	553	540	533	515	492	406	414	228	157	94	183	323	333	195	257	633	372	
i	524 524	562	732	ન	33	33	104	-	70	114	114	137	244	507	514	⊣	ო	2	46	217	102	86	-	96	24	~	119	11	-1	-	11	н	42	61	70	70	71	121	
***************************************	6619463A1 g3594561	3613937T6	6148958H1	5067091H1	2583002H1	2583002F6	g273554	70255820V1	70249242V1	70254597V1	70254754V1	70254688V1	70255790V1	70255539V1	70255201Vl	g4194301	g3244448	g3804087	2383032T6	70046632V1	70046986V1	70047134V1	6208108H1	70046575V1	70047390V1	2383032F6	4938245H1	70047509V1	2383032H1	1952540H1	70046695V1	750543H1	g1474315	3722596H1	4875149F6	4875149H1	6561179Н1	2029094H1	
	151	151	151	151	151	151	151	152	152	152	152	152	152	152	152	153	153	153	153	153	153	153	153	153	153	153	153	153	153	153	153	154	154	154	154	154	154	154	

WO 01/62927 PCT/US01/06059

					•			-						٠,																								
3562	3662	3365	3732	63	3240	2177	2199	2192	2183	2312	2732	2649	2409	2736	3476	3511	3206	3447	3146	3513	3450	3426	3432	3609	3594	3697	3605	3697	3600	3697	3697	3654	3697	3697	3697	3697	3666	
3061	3098	3087	3018	3019	3015	1905	1907	1907	1907	2044	2168	2168	2168	2298	2823	2857	2850	2859	2790	2775	2765	2806	2704	3293	3297	3309	3311	3311	3317	3271	3270	3293	28	20	21	23	3235	
70479313V1	70480157V1	4564168H1	70466004V1	70478380V1	. 4557976н1	3618747H1	6510691H1	6510634H1	6510739H1	4554621H1	70464785V1	4554554F6	4554554H1	70466681V1	70467583V1	70480720V1	70479363V1	70476260V1	70481657V1	70466450V1	70476879V1	70477920V1	70466934V1	70465560V1	70476467V1	70479516V1	4792962H1	70467134V1	4554470H1	046640	70480199V1	70469816V1		70481137V1	70466975V1	046604	70478359V1	_
158	158	158	158	158		158	158	158	158	158	158	158	158	158	158	158	158	158	158	158	158	158	158	158	158	158	158	158	158	158	158	158	158	158	158	158	158	
															,																							
						•		ı									•					•											ı	,				
3457	3542	3512	3682	3655	3600	3174	3173	3576	3575	3590	3656	3535	3663	3650	3794	3763	3690	3414	3581	3899	3692	3674	3974	3551	3664	3697	3695	3682	4154	2592	2687	3117	79	23	3708	3550	3634	
2922	3000	02	3037	3060	3064	3064	3064	3068	3070	3074	3096	3098	3107	3116	3130	3136	3150	3163	3177	3225	3382	3382	3384	3362	3358	3382	3532	3542	3600	2336	2407	2535	2535	2538	3029	3029	3050	
71036110V1	71238907V1	103	71239855V1	71035104V1	71240132V1	71022089V1	71020694V1	71033750V1	71036780V1	124	71035904V1	71239106V1	71239593V1	71036268V1	71033766V1	71036727V1	71036255V1	3246035H1		71034117V1			٠		70464393V1	2028546R6	897912H1	2657383H1	70466432V1	3405032H1	09941	78	93661	4686	46573	456814	70477055V1	
157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	158	158	158	158	158	158	158	158	158	158	158	S	S	S	158	158		
σ,	453 <i>2</i> 4325	4596	4694	4499	4718	4729	4415	4723	4873	4724	5071	4713	5106	3523	510	589	467	300	1063	2130	2207	2304	2273	2833	2971	2844	2836	2755	2556	3009	2877	3427	3427	14	3524	3495	3457	
3841	4020	4052	4094	4243	4251	4264	4263	4274	4473	4473	4517	4552	4758	-	œ	38	38	40	465	1537	1721	1744	2069	2217	2382	2382	2382	2382	2382	2421	2459	2859	2861	2871	2880	2904	2922	
71239794V1	/1036851V1 2902436H1	103	617587T6	71240672V1	g2839119	71239718V1	71240638V1-	g2716554	2839872F6	2839872H2	6701187H1	71033989V1	6700916н1	g1353781	7183461H1	5878868F8	5878868T9	5878868H1	6621194J1	7044151H1	7115836H2	6891967Н1	7112010H2	7115993H2	71036402V1	71036528V1	71036302V1	5682881F6	5682881H1	7121747H1	6554467H1	71035730V1	103	5693974H1	03	71239770V1	71036410V1	
157	157	157	157	157	157	157	157	157	157	157	157	157	157	İ57	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	157	

. 	7 4 6 4 6 8 4 6 6 7	001770045	4071601400
841. 807 889 1061 1125 1335 1335 1336 1347 1347	76113333374	1495 1600 1661 1587 1647 1459 1474 1535	1634 1669 1507 1881 1883 1695 1641 1714 1610 1705
505 509 509 801 912 950 1063 11064	1129 1129 1177 1247 1308 1331 1328 1337 1340	1339 1348 1351 1363 1376 1376 1377 1376	1382 1383 1390 1390 1398 1401 1439 1475
3028782F6 3028782H1 1005592H1 4646393H1 5278286H1 2521969F6 983403H1 983403H6 188949H1 983403T6	2521969H1 2639257H1 983273H1 3692640T6 4013213H1 3877453H1 4010336H1 2324266H1	3576519H1 5176829H1 3873606H1 4852614H1 3016113F6 3011865H1 058529H1 3958442H1 5276870H1	3578346H1 3016113H1 6337413H1 6338013H1 6335720H1 368195H1 4151882H1 3874704H1 5278359H1
159 159 159 159 159 159	159 159 159 159 159	159 159 159 159 159 159	159 159 159 159 159 159 159 159
		•	
3570 3570 3466 3528 3529 3208 3368 3697	33705 3430 3430 3178 3178 3359	3354 3434 3428 3682 3697 3667 296 271	342 264 264 386 386 293 291 519 619 825
2901 2900 2923 2927 2992 2746 2746 3467 3496	2440 3457 3171 3208 2883 2883 2882 2886 2708	2722 2732 2742 3334 3348 1 1 1	4 4 6 113 119 179 250 350
70478180V1 70465864V1 70476782V1 70469166V1 70480392V1 70480392V1 70478255V1 70478255V1 70478255V1	70465130V1 2301520H1 70467663V1 70467111V1 4562810H1 70473226V1 2620793H1 70464811V1	70478794V1 70467700V1 70481589V1 70466101V1 70479545V1 3874759H1 3685395H1 3692640H1	3692640F6 g3116688 3445829H2 306745H1 945423H1 988248R1 4454887H1 3877090H1 6901148H1
158 158 158 158 158 158 158 158	158 158 158 158 158 158 158	158 158 158 158 158 159 159	159 159 159 159 159 159 159
		,	
00044540000	3657 3657 3657 3682 3697 3697 3682 3682	. 666668848	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
3242 3217 1289 1904 50 979 1016 3129 3129	3142 3142 3322 3328 3328 3328 3329	3408 3429 3435 3440 2697 2699 2765 2765	2769 2644 2650 2650 2650 2607 2630 2624 1
6515587H1 70478211V1 4558722H1 3618747F6 9190751 91736195 2624295R6 2624295R6 2624295H1 70466944V1	70468/18V1 70469007V1 70469207V1 70466503V1 70479148V1 70464268V1 70467743V1	70481575V1 3381962H1 70468987V1 70465226V1 70469171V1 70469220V1 70481022V1 2624295T6	70469934V1 70480048V1 70478224V1 70467878V1 70467582V1 70465805V1 70481125V1 70469427V1 6287762H2
158 158 158 158 158 158	158 158 158 158 158 158	158 158 158 158 158 158	158 158 158 158 158 158 158 158

												,																							
4933	4927	4908	4921	4906	4890	4971	4924 -	4902	4986	4932	4924	4939	4940	4991.	5202	4968	4976	4974	4936	4923	4947	5145	2067	5241	5278	2060	4942	5234	5080	5287	5282	5285	5285	N	5285
4622	4644	4644	4658 4651	4663	4669	4671	4672	4678	4680	4690	4694	4702	4705	4707	4713	4713	4719	4719	4724	4726	4729	4747	4747	4747	4762	4764	4773	4773	4775	4799	4804	4806	4807	0	4810
g1525497 5704503H1	4060183H1 1416579H1	4 1	4569760H2 3721940H1	g852574	g1023637	3712504H1	4825195H1	g985536	3568055H1	g2819448	g1024915	g4125247	4254485T8	5714026H1	770816R1	770816H1	1901241H1	1898941H1	g2903316	6715734H1	2897118H1	986309R1-	.986309H1	986309T1	g2837150	2027901H1	2654529H1	g3057209	87191	73578	24	23	84	g5367615	g4437224
160	160 160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	1.60	160	160	160	160	160	160	160	160	160	160	1.60	160	160	160	160	160	160
						1										٠					,		,						1		ı	,			
2201	2207 4929	4936	4930	4765	4835	4780	4894	4719	4961	4780	4749	4740	4830	4951	4929	4929	4936	4861	4749	4962	4910	4854	4881	4943	4905	4764	4863	4852	4916	4930	4864	4876	4941	4910	4912
1998 2013	2048 4494	4498	4500	4519	4524	4524	4532	4533	4536	4536	4536	4536	4538	4546	4553	4554	4558	4561	4568	4575	4586	4584	4589	4598	4598	4597	4598	4599	4602	4610	4607	4615	4615	4615	4621
058768H1 3045908H1	g2787073 g6086623	92569620	g2754538 302246541	2448511H1	3760535H1	2640174H1	517085T6	5338680H1	1.1	735966н1	1592447H1	1591916H1	5022872H1	g3253612	g3843392	g3843398	g4080952	3814494H1	2009809H1	g1271129	g1068131	2096906H1	2603246H1	g829798	g1068126	2006525H1	628342H1	1943588H1	g1044543	g777642	2685217H1	1365826H1	9	ന	6371841H1
159	159 160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160
1783	1624 1854	1804	1792	1842	1839	1923	1800	1923	1972	2155	1935	1929	1889	1931	2044	1990	1973	2024	2025	2179	2001	2075	2143	2194	2054	2014	2011	2109	2024	2120	2026	2169	2214	2204	\leftarrow
1486	1495 1513	1512	1520	1548	1582	1591	1592	1611	161.8	1674	1697	1700	1706	1706	1706	1721	1723	1739	1739	1764	1761	1764	1764	1767	1765	1817	1823	1823	1826	1836	1852	1877	1888	1888	σ
332	5531678H1 g5395484	693	4152946H1	890	4466716H1	g395449	5167337H1	920392H1	3011865T6	3016113T6	5277911H1	2636153H1	1567405H1	462513H1	462513R6	3877471H1	5277625H1	3016674H1	3045188H1	977605T1	5299216H1	977605H1	977605R1	3028782T6	3487465H1	6	Ξ	3683935H1		979691H1	g434193	3013979H1	80	æ	5278931H1
159	159 159	159	159	159	159	159	159	159	159	159	159	159	159	159	159	159	159	159	159	159	159	159	159	159	159	159	159	159	159	159	159	159	159	159	159

																	•																						
5404	5394	5163	5403	5294	5252	5159	5352	5339	5295	5350	5277	4005	4195	4118	4023.	4117	4049	4068	4063	4048	4086	4088	4152	4104	4145	4196	4122	4101	4202	4159	4460	4238	4205	4227	4231	4363	4318	4165	
5258	5261	4959	4967	4969	4971	4974	4981	4988	4991	4997	4997	3755	3765	3767	3767	3805	3812	3817	3821	3821	3822	3831	3838	3858	-3862	3871	3873	3903	3904	3913	3939	3935	3936	-3941	3942	97	_	3982	
g810674	g944127	4125568H1	g6464630	g1501886	4537948H1	4699937H1	g3038275	g1664143	1283369T6	1283369F6	1283369H1	056712H1	g829797	g852673	g775984	2967706H1	2539208H1	2443012H1	988892H1	2291992H1	4178688H1	1833818H1	6368013H1	-2134837H1	5657126H1	g1665244	2288056H1	3740644H1	4714119H1	5352624H1	g1272802	6388078H1	3056718H1	-g1044542	g1525554	g1625857	g1977647	056202H1	
160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	
							· i									,		•					•			,						1		1	,				
5285	5285	5237	5170	5116	5211	5138	5207	5202	5285	5165	5285	5285	5232	5403	5285	5257	5345	5285	5403	5269	5406	5408	5271	5403	5293	5289	5403	5406	5319	5288	5271	5285	5339	5279	5354	5339	5339	2302	
4932	4934	4940	4940	4940	4950	4952	4957	4999	5014	5033	5036	5037	5040	5047	5046	5046	5058	5071	5084	5084	5087	5098	5102	5131	5128	5134	5139	5143	5146	5145	5149	5151	5161	5176	5216	5216	5216	5216	
g4089434	g1484540	1739863R6	1739863H1	4207604H1	5578672H1	1689363H1	2606160H1	Ħ	g795782	6613821H1	4772611H1	4923819H1	g1188096	g2540711	g2022546	3445038H1	g5447532	3486818H1	g1479409	g1064422	g2821180	g1543936	2769102H1	g815309	g4893445	1923809H1	g29237	g1548590	g1202222	g3202374	g1665338	g1228664	7336808H1	2807655H1	1741769R6	1741769H1	1741195H1	1741769T6	
160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	
4940	5285	5002	5285	5285	5098	5290	5287	5287	5313	5293	5287	5285	5285	5291	5286	4946	5290	5286	5270	5127	5278	5276	5288	5291	5149	4936	5086	5129	5287	5285	5285	5285	5285	5186	5285	5186	5285	5287	
4810	4812	4813	4815	4816	4817	4821	4823	4823	4828	4829	4843	4843	4842	4846	4848	4848	4853	4854	4854	4854	4855	4856	4857	4857	4856	4863	4867	4872	4879	4892	4895	4903	4906	4911	4912	4911	4920	4930	
4790610H1	34129	1236	41535	g3050313	4340133H1	g4071897	g4762931	g4393968	6872074H1	g3308744	g3887256	g5811461	g4372712	g3597624	g3869879	4201581H1	g4081955	q3840562	g5809990	4129277H2	g5904237	g4969558	g4292330	g5849107	3621721H1	g4987769	347302H1	5408358H1	g3896761	3279	g4244340	3658	4983	3887	21553	3876	g2816194	g5547017	
160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	

WO 01/62927 PCT/US01/06059

																							-1									,						
749	761	931	-831	841	845	981	1600	1308	1587	1460	62	1536	1626	1619	1701	1717	1616	1672	1665	1625	1852	1803	1799	2124	2062	2043	2259	2018	2182	2323	2155	2659	34	2330	35	2352	2364	2627
480		. 2				741		~			1169	1232	1305	1367	1415	1439	1439	1447	1488	1534	1546	1546	1643	1722	1722	1722	1732	1775	1859	1887	1915	2044	2065	2065	2082	60	2153	2174
5643561H1	4960333H1	g2277376	5090209H1	525014H1	525014R6	162678H1	6332784H1	3872857H1	525014T6	g395681	g6086016	g2779861	g1057696	4806634H1	5864502H1	156350R6	156350H1	5502785H1	4696595H1	g3701554	3825811H1	3825859H1	g1880691	g691032	g573544	g708679	6610185H1	1257342H1	2532881H1	g3416512	2722041H1	7191660H2	1804357H1	1806920H1	5602907H1	2830493H1	5542070H1	7171003H1
160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160
	,	•										•						٠							•													
4553	4536	S	4620	4709	4600	4764	4	4	46			Ţ	Q	4482	4873	4872	4710	4671	4685	4930	4687	4939	4933	4747	4748	4933	4623	4747	4941	4929	5285	516	248	456	523	440	603	747
4205	4295	4327	4331	4341	4342	4342	4347	4361	4370	4376	4377	4376	4378	4392	4392	4396	4397	4431	4437	4447	4448	4448	4460	4465	4466	4469	4480	4484	4488	4491	-	H	œ	81	186	189	279	455
147283441	42006388	g810580	4140391H1	ഥ	g815902	g2898761	6601487H1	3812509H1	5605594H1	5401012H1	g1023636	056184H1	g1060832	3253684H1	g1501988	293402T6	g2825431	4421168H1	2436027H1	g5177561	g797106	g2874401	g3597789	4649987H1	2920060H1	g3675776	986389H1	6291011H1	g5527815	g6086615	g1469867	7086887H1	w	g273451	g1057697	3903676H1	434	3698379H1
1,60	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160
																									ı													
776	4527	4492	4274	4192	4572	4388	4381	4202	4340	4243	4335	4551	4227	4346	4343	4424	4407	4478	4491	4422	4624	4413	4622	4447	4640	4394	4628	4465	4584	4423	4464	4434	4491	4471	4550	4552	4510	4433
4000	4000	4000	4010	4032	4048	4051	4064	4066	4076	4088	4093	4110	4110	4110	4125	4126	4131	4133	4145	4144	4149	4149	4149	4153	4161	4167	4168	4169	4169	4171	4188	4197	4199	4235				88
125062011	1259479F1	1259638F1	4383783H1	g1440113	6856341H1	g944630	5950009H1	g1240400	5387777H1	4342232H1	3022534H1	293402R6	293402H1	2772843H1	2411009H1	2819785H1	4512962H1	g1978183	g4152729	1690358H1	6334629H1	5387664H1	6334630H1	4600162H1	g5673211	055138H1	g4648135	986584H1	986584R1	2290964H1	3056037H1	2784447H2	3567327H1	4135683H1	3789022H1	4833507H1	2285967H1	3469203H1
160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160

																٠.																						
2140	2331	.2323	2530	2555	2384	2352	2269	26	26	57	2319	2371	2371	2180	2385	2490	2316	2518	2379	2467	35	38	37	2253	2344	2422	2377	42	49	2350	2405	2265	2389	2343	2367	2344	2487	
2068	2068	2073	2085	2068	2070	2073	2073	2078	2081	2081	2096	2081	2082	2085	2106	2213	2214	2215	2096	2219	2097	2100	2099	2106	2127	2114	2123	2219	2219	2127	2132	15	13	2139	2142	4	2219	
6517527H1	3468616H1	5451867H1	6441810H1	7076574H1	70346502D1	4772876H1	805234H1	6763871H1	7079082H1	6996593H1	5693746H1	4760746H1	4760754H1	3466673H1	3955495H1	3945275H1	6891449H1	-4195061H1	3781801H1	2570710H1	4690839H1	g683009	5682533H1	5575001H1	1505114H1	4091605H1	5832027H1	5401121H1	5388353H1	2704568H1	5834524H1	7103141H1	4315855H1	5834443H1	664952H1	1992383H1	3468549H1	
161	161	161	161	161	161	191	161	161	161	161	161	161	. 161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	
,												,			•			,																				
3676	62	3838	3783	3790	3511	3645	3714	3674	3719	3598	3785	4011	3727	3982	3710 .	3865	3800	3795	3846	3859	3699	3850	3871	3885	3889	3937	4014	3817	3844	4010	4101	4082	3928	2389	2269	2243	2316	
3406	404	3410	3410	3414	3420	3421	3421	3442	3446	3458	3477	3483	3502	3503	3524	3525	3540			598	615	3622	3627	3628	3629	3636	3641	3654	3687	3721	3740	3749	3750	2061	2061	2063	2063	
2029016H1	5544787H1	(2)	g1225697	g985312	g944631	2471283H1	3561909H1	g965314	2748973H1	5621772H1	g1064141	7033911H1	517085H1	517085R6	4655472H1	3521721H1	2668464H1	2285765H1	2796870H1	2761118H1	5544423H1	338142H1	4545187H1	2243019H1	2772059H1	2960117H1	g1969950	g1947603	5002748H1	4062722H1	7107841H1	g1024914	5546516H1	g1219848	5406570H1	5451646H1	g2000931	
160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	- 160	160	160	160	160	160	160	160	160	160	161	161	161	161	
2486	2417	2880	2674	2678	2875	2861	3021	3287	2941	3062	3068	3061	3086	3338	3109	3404	3191	3116	3265	3259	3245	3630	3222	3471	3359	3463	3502	3446	3473	3589	3560	3626	3559	3571	3396	3656	3626	
2202	3 6	37	40	45	9	62	64	68	89	70	7.1	77	73	83	85	90	92	96	8	딩	0	02	04	07	12	17	3197	19	22	23	25	25	25	25	2	3	38	
3109807H1	200	200	5092027H1	3595466H1	8	4028493H1	6918376H1	833106R1	833106H1	g1068214	g1068219	386166H1	3163260H1	6490409H1	2122144H1	g1484539	3120466H1	g1062289	4178517H1	2505067H1	2505367H1	7034903H1	g1259693	7315867H1	5370265H1	g2022547	2707316H1	2894887H1	g796865	3523324H1	5	g1548639	g943258	g1067965	2	4441134H1	g682946	
160	o v	160		9	160	9	9	160	9	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	160	

															•																							
1630	1855	1822	2069	1783	1775	1812	1850	1687	1797	1827	1750	1855	1803	1931	1813	2028	2020	2022	2023	2007	1838	2046	2083	2298	2036	2192	2088	2569	2246	2568	.2481	2531	2272	2342	2265	2568	2578	2149
	1508	1519	52	1533	1538	1540	1554	1577	1578	1580	1585	1597	1635	1647	1648	1724	1724	1744	1749	1751	1757	1772	1800	1790	1820	1896	1979	1988	1992	1996	2001	2024	02		03	2023	2031	2046
******	7070664H1	6416952H1	6894069H1	5013816H1	533363H1	4761822H1	2904083H1	4306790H1	1991775H1	4337965H1	5833237H1	3469095H1	4316943H1	5876761H1	5015603H1	2963466H1	4316745H1	4315891H1	4091142H1	4753020H1	6518022H1	4316639H1	2705655H1	5961924H1	4695643HL	2707689H1	4342587H1	6770516H1	4342620H1	6882093J1	6886296J1	7253724H1	2423349H1	4316734H1	4256579H1	6763709H1	6771870J1	477277H1
,	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	191	161	161	161	161	161-	161	161	161	161
							,		ı										•		-				٠	,					•	ı		1	,			
,	1143 924	910	1230	1507	1202	1498	1478	1337	1361	1416	1438	1456	1378	1468	1485	1475	1392	1459	1433	1480	1440	1464	1490	1355	1487	1505	1459	1489	1491	1543	1564	1570	1546	1831	1576	1851	1663	1580
L	762	780	186	877	981	988	1024	1056	1105	1117	1118	1117	1117	1143	1172	1174	1178	1182	1193	1194	1193	1203	1221	1238	1238	1238	1257	1259	1264	1278	1281	1298	1304	1304	1303	1308	1308	1317
	1476202H1	865333H1	7193726H2	6891594J1	4031012H1	6446990H1	g6133077	3941692H1	4772703H1	g668477	g870488	g698735	g669863	g768138	g1062711	g875401	1617044H1	5781411H1	532473H1	3945042H1	4758039H1	3466710H1	5860513H1	6770719H1	5656957H1	5204013H1	4254309H1	5578708H1	5013751H1	4019484H1	6063870H1	3471004H1	5206590H1	6746950H1	5857309H1	5968610H1	g2012398	3469688H1
,	161	191	161	161	161	161	161						161		191	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161
	2426 2573	2414	2421	2420	2347	2445	2452	2426	2450	2750	2747	2390	2800	2495	2569	2315	2438	2435	2805	2424	2454	2744	2692	2384	2365	2418	552	726	096	990	992	961	925	1180	1180	Н	884	Н
١,	161 148	26																													479			582	629	979	664	929
1	4256959HL 6993692H1	534218H1	664384H1	4713170H1	663504H1	2247226H1	2245218H1	531779H1	2042975H1	6741472H1	4490622H1	4063891H1	5960583H1	3781135H1	7071563H1	6891449J1	554022H1	4532533H1	6739828H1	4691246H1	3470773H1	5967249H1	6765073J1	666644H1	5579450H1	1618034H1	7088449H1	7073146H1	678488H1	6882093Н1	6882161H1	6766193H1	6977268H1	7230035H1	7075220H1	1485846F6	g1975476	1486578H1
į	161 161	161	161	161	161	161	161	161	161	161	191	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	161	191	61		61

0	282 284 284	211	275	919	289	275	249	288	282	258	197	275	310	264	257	304	336	289	218	271	278	280	353	318	270	286	277	797	172	326	191	272	634	312	692	717	595	609	
•	8 1 18 18	18	13	13	20	19	19	19	20	20	13	13	20	21	22	23	22	20	23	22	21	24	24	25	- 22	56	31	32	36	37	126	126	166	-173	330	330		349	
	5587272H1 4997069H1	1551008H1	5347226H1	6819761H1	5117110H1	3447366H2	2445594H1	4622780H1	2111981H1	552401H1	2461616H1	5379341H1	3820792H1 -	4347282H1	1322148H1	4222393H1	4223817H1	5843163H1	3657588H1	4721051H1	4790883H1	5377733H1	g1638522	3596245H1	781633H1	5374490H1	2161371Hİ	3597248H1	2934534H1	4386768H1	3399780H1	6399947H1	6897251H1	-4431669H2	g1779781	g826488	4794163H1	4880181H1	
,	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167 -	167	167	167	167	167	167	
									ì									•								,								ı					
																											•												
	460	570	497	576	313	821	391	173	146	115	503	435	435	89	272	294	77	250	255	119	240	234	74	226	106	197	248	270	327	213	271	272	256	279	286	306	278	293	
,	~ 1 ~ −1	78	႕	35	35	376	~	ᆸ	~	H	9	129	313	ч	12	19	- 1	n	28	က	က	4	9	6	13	10	11	12	12	12	12	35	12	12	12	15	15	15	
,	5911540F8 5911540H1	5911540T8	5905252F8	5905252F6	5905252H1	5905252T6	4020439F8	2773907F6	2773907H1	4020439H1	4020439T8	2773907T6	g820143	6919815H1	6100456H1	5840353H1	3055393H1	4528621H1	482608H1	3477717H1	2472906H1	2444808H1	3167552H1	2615139H1	3199504H1	2455307H1	2428111H1	3458104H1	3596416H1	2453021H1	4298232H1	g1956274	g1880655	3458004H1	5694361H1	g2026069	477069H1	1918196H1	
,	164 164	164	165	165	165	165	166	166	166	166	166	166	166	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	167	
																																					•		
	2522 2293	2293	2251	2306	2492	2479	2566	2825	2647	2887	2887	2887	2791	2801	2887	2840	2895	2877	2887	2858	2887	2826	2874	2887	2887	2887	2886	2906	2887	2883	2887	306	561	282	630	537	391	609	
	2041 2058	2058	2060	2061	2315	2316	2311	2347	2408	2494	2494	2494	2571	2566	2595	2604	2614	2619	2629	2650	2681	2681	2694	2694	2694	2699	2713	2737	2739	2789	79		108	← 1	- -1	~	1	52	
	6740527H1 4691683H1	5205527H1	5575884H1	3466389H1	5955966H1	5205250H2	4776444H1	6517485H1	2292420H1	6552809H1	6552988H1	6552963H1	4619412H1	4775811H1	g1194667	5405506H1	4314575H1	1289406H1	g1190424	g1071637	4773458H1	4756793H1	4341024H1	4298642H1	1596024H1	552947H1	5371715H1	5447990H2	667160H1	668331H1	5657894H1	6127609T8	6959915H1	914	4133F	321108F	914	914133T	
,	161 161	161	161	161	161	191	161	161	161	161	191	161	161	161	161	161	161	161	161	161	191	161	161	161	161	161	161	161	161	161	161	162	162	163	163	163	163	163	

353	124	444	- 412	105	643	999	782	779	524	376	1748	1657	1768	1896	1708	1680	1859	2080	1841	1981	1763	1769	1762	1851	1852	1881	1927	2035	518	259	452	359	406	469	517	447	785	739
Н	⊣	175	н	~	26	83	406	479	-1	ო	1485	1485	1486	1492	1496	1496	1533	1537	1537	1542	1549	1554	1557	1559	1565	1566	1569	1570	⊣	91	104	107	172	224	258	361	437	487
4290049F6	4290049H1	5493752H1	6729842H1	5401350H1	6057617н1	5401350T9	g3214092	3524102H1	7030475H1	7030327H1	5271230H1	240641H1	2948213H1	g1291432	353018H1	349497H1	g2276981	6804414J1	3499213H1	g2537462	1551014H1	808076H1	2307944H1	g2222952	2804178H1	680150571	.g888315	g2056786	6901949H1	4183549H1	6980581H1	5839778H1	808102H1	4323252H1	g2003585	g900863		582110H1
180	180	180	181	181	181	181	181	181	182	182	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183
		•											1	. •											. •													
	٠																																					
311	492	586	517	551	310	483	376	299	565	535	336	336	175	564	271	932	360	280	305	682	733	144	235	169	271	130	276	317	287	869	669	491	662	460	250	268	269	103
н	24	248	-	ㄷ	н	10	⊣	н	12	99	H		-	7	-	411	7	-	-	155	248	-	. 73	ч	↤	7	17	28	151	194	207	225	388	-	~1	27	78	₽
5908301H1	6271267H2	5908301T9	5907939T9	5907939F8	5907939H1	6271008H2	5912415F8	5912415H1	5912415F6	5912415T9	4119207F6	4119207T6	4119207H1	5905477F6	5905477H1	5905477T9	5907791F8	5907791H1	5907791F6	5907791T9	5907791T6	4770137H1	5564253H1	606101H1	4650476H1	592893H1	781453H1	2793564H1	888943H1	6589872H1	2190828T6	1503654H1	4200384H1	5911540F8	5911540H1	5911540T9	5911540T8	g4325750
172	172	172	173	173	173	173	174	174	174	174	175	175	175	176	176	176	177	177	177	177	177	178	178	178	178	178	178	178	178	178	178	178	178	179	179	179	179	180
																									ı													
638	1013	513	539	800	709	753	753	753	753	753	869	546	563	523	315	287	635	804	669	885	522	303	492	557	562	523	286	557	553	556	365	267	268	629	272	216	445	519
366	396	408	452	584	624	648	9/9	692	697	697	184	⊣	8	∞	26	112	184	238	239	869		11	213	277	464	464	464	223	464	501	⊣	, ,	14	23		7	129	- -
9889083	6819761J1	g916666	4249123H1	6481276H1	4191747H1	638004H1	1452178H1	g2615681	g1665347	g2558364	6795278H1	6796542H1	6796380H1	6795463H1	3941984H1	g1260435	6798249H1	6791366H1	6790685H1	1242854H1	2904954T6	4739603H1	5614905H1	g2006850	2008385H1	2014576T6	2014576H1	3294227T6	2014576R6	1716729H1	3966795F6	3966795H1	3274864H1	3966795T6	3033193F6	3033193H1	8	90830
29	.67	797	191	167	167	167	167	.67	191	.67	.68	.68	.68	.68	89.	.68	89	.68	89.	891	691	691	691	691	691	69	69.	69	69	69	.70	.70	70	.70	.71	.71	.71	72

																	'																					
1	1501 1641	1714	1554	1751	1586	1680	1989	1767	1708	1629	1748	1979	1888	1929	1754.	2292	2349	2291	2324	2338	2300	2294	2298	2338	2300	2265	2280	2338	34	34	2343	2338	33	33	31	m	2338	2340
,	1402	1409	1415	1415	1434	1434	1465	1465	1465	1473	1480	1480	1480	1481	1482	2032	2044	2046	2048	2051	2055	2058	2060	2060	-2061	2066	2067	2069	2077	2081	2082	2105	2106	-2106	2107	급	Ñ	2158
	5483319H1 5322481H1	5948083H1	1996549Hl	1996549R6	5405753H1	5293687H2	935623R1	936611H1	935623H1	3409340H1	1819126H1	1819126F6	g2053565	g2209615	5879274H1	4570795H1	g1046490	1416514H1	4193606H1	g1858344	5021880T1	1281333H1	2222539H1	-2222539F6	2222539T6	5341229H1	2659133H1	g3871000	g4524292	g1858279	1301182H1	2256984H1	6498361H1	-2574115H1	~~		g3051313	3142955Hl
	183 183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183
			•			,	٠																	1		,	í					ı		i	٠			
	1179 1179	1179	1163	1601	1327	1348	1304	1413	1367	1320	1438	1261	1470	1455	1390	1658	1487	1778	1485	1481	1481	1764	1761	1583	1538	1553	1887	1601	1591	1904	1625	1857	1468	1669	1950		1608	1635
	962 981	1018	1046	1065	1074	1104	1108	1120	1121	1121	1121	1124	1143	1143	1202	1202	1206	1214	1259	1259	1259	1261	1290	1308	1328	1328	1334	1344	1343	1351	1363	1372	~	1386	1386	1392	1401	1402
	3697260H1 1331860H1	g1644929	g1880762	6804414H1	1722938H1	5451478H1	σ	5950551H1	3376840H1	5950519H1	4193013H1	4556920H1	g1046489	g1046497	1283213H1	1283213F6	4225341H1	671488H1	1346996H1	1348304H1	1348303H1	6954001H1	g2107139	4720048H1	1720725H1	1722139H1	5970873H1	4693221H1	2571078H1	6121921H1	4215895H1	g2188904	g1646485	004844H1	6313521H1	2427675H1	5478565H1	5480821H1
	183 183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183
1	778 913	793	808	893	797	851	1078	855	913	864	797	832	993	931	991	1180	975	955	1179	991	991	1045	1078	1006	866	1059	1419	1058	366	1068	1103	1137	1013	1101	1195	1257	1166	1119
	499 515	538	552	552	584	614	636	648	655	699 .	989	702	713	715	740	752	752	752	772	778	778	784	782	795	795	802	908	908	808	821	822	843	845	860	895	897	901	903
	3323870H1 2115479R6	4779981H1	1818066H1	1818066F6	g4438745	5450643H1	0662	3538459H1	2115479H1	4090518H1	6077621H1	4947628H1	4759655H1	1699317H1	4303659H1	591324R6	591324H1	591174H1	5998787H1	1672160H1	1672152H1	4694794H1	2972664Н2	1718469H1	1718480H1	3270027H1	927251R1	927251H1	g1986696	5102583H1	7094153H1	5948962H1	1571253H1	37	3784982H1	6980693H1	4770011H1	1695218H1
,	183 183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183

																						**								•								
2301	29	33	28	ന	g)	436	444	484	634	921	792	1007	733	897	823	882	888	1018	1072	1018	1200		1403	1333	294	243	350	427	363	412	369	424	Н.	403	9	4	528	
2000	2012	01	02	02		Н	\vdash	239	239	459	473	474	474	488	542	598	909	664	723	793	876	943	1031	1149	-	-1		126	130	139	139	154	9	21.4	4	265	267	
953800T1 q895530	538	953800R1	128	g1046498	3497339T6	g1060678	6258709H1	2570554H1	2570554R6	6200064H1	g734035	1400373F6	1400373H1	g2167556	6389638H1	6344656H1	634468BH1	6328470H1	g4148622	6338470H1	3784456H1	3781165H1	g733951	g734304	3554877H1	4111213H1	5624259R8	3139315H1	5545642H1	3141553H1	g564381	987690H1	4833664H1	116132H1	3691576H1	ø	3283023H1	
183	183	183	183	183	184	184	184	184	184	184	184	184	184	184	184	184	184	184	184	184	184	184	184	184	184	185	185	185	185	185	185	185	185	185	185	185	185	
			:								•	,												. ,						,								
1					٠													, ·							,													
2036 2013	03	11	2040	04	1919	2034	2066	2096	2091	2105	2042	2298	2095	2298	2033	2039	2033	2040	2002	2340	2095	2339	2341	1977	2033	2340	2338	2342	2340	2341	4	7	33	3	33	4	3	
1797	1798	1801	1805	1808	1811	1816	1825	1819	1826	1828	1831	1843	1847	1851	1859	1860	1872	1872	1872	1876	1885	1886	1886	1889	1894	1905	1910	1912	1912	1916	1919	3	93	3	S		1998	
3246162H1 1344364H1	134438H1	$^{\circ}$	683816Н1	5451469H1	2402750H1	1851976H1	3702341H1	2963989H1	g1441785	5777701H1	g3898324	1819126T6	148498H1	2106229T6	g4762523	g4620507	1964264H1	1964264R6	1964264T6	g2945963	4696529H1	g4564438	g3741810	2913361H1	6862628H1	g3742173	g4083420	g3678703	6327536н1	g2910125	g3308355	2556534H1	g3922126	40	g4083582		g2902884	
183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183		183	183	
																								1														
2339	2340	2344	2339	2339	2338	2339	2105	1827	1854	2036	1804	2033	1849	2060	1904	2033	1907	1849	1903	1936	1939	2024	1978	2033	1926	2038	2033	1972	1913	2048	2036	2125	1850	2061	2060	2033	1957	
2164	2190	2197	2225	2254	2274	2283	1575	1579	1581	1586	1589	1588	1589	1591	1605	1633	1649	1663	1664	1669	1671	1690	1712	1737	1741	1745	1749	1754	1754	1759	1759	1759	1785	1788	1790	1791	1797	
2878176H1 3271618H1	29581	2247168H1	2246357H1	2247256H1	3812939H1	5103254H1	7064872H1	6818666H1	4726069H1	g4662834	g1182379	g4874675	5661656H1	6868292H1	3706916H1	g2208265	2424009H1	1470490H1	797359H1	3245252H1	4781187H1	g1688385	1413737H1	g2279273	g1146486	g1644873	g888316	099594H1	3996904H1	3916961H1	3917411H1	6801505H1	910557H1	2921975H1	5003193H1	g1442965	5018209H1	
183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	183	

	4460	4451	4431	4458	4415	4386	4319	4460	4442	4347	4457	4458	4453	4454	4457	4343	4458	4456	4461	4461	4457	4457	4419	4182	4452	4174	4457	4048	4417	4085	4433	4418	4020	4119	4077	4130	4422	3984	4083	
	4165	4157	4063	4182	4063	4063	4063	4184	4187	4204	4210	4210	4210	4212	4245	4063	4259	4272	4292	4292	4327	4389	4069	4066	4069	4069	4083	3788	3815	3816	3822	3824	3832	3844	3847	3850	86	3868	3881	,
	g816766	3041690H1	977648R1	g1193159	977648T1	977648H1	978306H1	g2051455	5280171H1	g3886427	1381539H1	552969H1	2760603H1	g3647431	1917113H1	4787118H1	g892648	g2229339	1942308H1	1942315H1	1941519H1	5007945H1	197971816	240941H1	1979718R6	1979718H1	g682911	4465894H1	2819748T6	3445036H1	6735779H1	2279717T6	3720714H1	4828820H1	1369089H1	1833781H1	1965941T6	2559627H1	2285422H1	
	1:90	190	190	190	190	190	190	190	190	190	190	190	190	190	190	130	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	
	42	. 25	246	42	289	616	478	654	585	81	26	680	619	768	089	680	. 929	92	46		564	751	9/9	9/9	680	9/9	92	897	4349	4319	4475	4414	4451	4458	4352	4450	4457	4466	453	
	ν	4	Š	_	59 5							256 6									292 5			307 6											4120 4		m	4156 4	1061 4	
	70395867D1 1	2525961F6 4	2525961H1 5	70395557D1 4(6560586H1 6	70396453D1 7	70396167D1 1	70396459D1 1	70396121D1 1	g1357976 2	5961T6		70396654D1 2	70395799D1 2	70395826D1 2	70397446D1 2			70397538D1 2				70395110D1 3		70397165D1 3	겁		2402420H1 4	_	2791792R6 ¢	9			2005H1	54871	_	52773	-41	
	189	189	189	189	189	189	1.89	189	189	189	189	189	189	189	189	189	189	189	189	189	189	189	189	189	189	189	189	189	190	190	190	190	190	190	190	190	190	190	190	
	564	296	594	591	569	567	626	689	705 -	711	721	648	255	249	1184	449	243	613	523	211	894	322	442	268	287	276	303	301	291	159	762	1192	1210	1124	1114	1115	1185	1295	-	•
	290	347	347	347	387	387	456	459	459	464	490	498	⊣	⊣	867	Н	7	64	235	253	532	-1	н	-1	23	22	23	23	23	23	196	603	732	845	845	851	905	1078	1093	
•	3959293H2	2675859H1	2676108H1	2676122H1	5301231H1	1598950H1	2352332H1	5038795H1	2534205H1	3252993H1	1742040H1	4592168H1	g29244	2635196H1	6428735H1	2525961F6	2525961H1	6560586H1	q1357976	2525961T6	q3245391	g1277774	g2186366	5533987H1	5320656H1	985175H1	5478163H1	5476045H1	5325512H1	5479637H1	7289635H1	6559813H1	6858544H1	293	7	4017917H1	5206602H1	4776841H1	6314480H1	
	185	185	185	185	185	185	185	185	185	185	185	185	185	185	186	187	187	187	187	187	187	188	188	188	188	188	188	188	188	188	188	188	188	188	188	188	188	188	188	

															•																								
2714	2721	2721	2713	2618	-2978	2721	2638	2634	2984	5666	2.722	2717	2719	2720	3045	2713	2833	. 2658	2721	2858	3033	2932	2716	3160	2702	2713	2722	2837	2942	3124	2979	2925	2988	2808	3320	3268	3035	3000	
c		co.	36	36	2369	2373	2371	2371.	2391	2405	2421	2418	2426	2442	2465	2498	2530	2542	2547	2550	2559	2573	2577	2586	2619	2633	2650	2655	2661	2688	2688	2726	2731	2731	4	S		2797	
g3228885	g2541163	g3884137	1819282F6	1819282H1	6492522H1	. g875856	4176829H1	4176860H1	70864219V1	1819282T6	g819854	g561301	70145373V1	4670647H1	70855556V1	6844792H1	3724780H1	4822074H1	g794631	g708639	70146025V1	g691143	g3096354	70855455V1	4259987H1	6545104H1	g874560	4612918H1	4144852H1	985756R1	985756H1	5570469H1	6323423HI	985756R6 -	6835880H1	7	3506	7122.7966V1	
190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190-	190		190	190	
									1										•				,	1								•		i					
3923	3919	3916	3890	3966	m	4233	4417	3962	3969	4037	4264	4329	4255	3976	4029	2748	2371	2716	2513	2367	2701	2782	2277	2726	2355	2707	2718	2637	2567	2504	2503	2721	2489	2674	2712	2563	2713	2531	
3692	3692	3692	3692	3696	3696	3703	3716	3731	3734	3740	3753	3753	3753	3755	3772	2110	2129	2130	2130	2130	2173	2176	2180	2191	2218	2225	2245	2249	2249	2257	2257	2277	2276	2	2296	2315	2316	2326	
1923669H1	3010	965	1833543H1	927374H1	4511590H1	6517421H1	1551235T6	2674692H1	2288745H1	4311971H1	6118751H1	6119992H1	6126908H1	g4629955	2157206H1	71226132V1	g3092783	70863741V1	2079255F6	2079255H1	6167128H1	70856205V1	6482958H1	70149143V1	5372491H1	71226268V1	g5234288	g389953	g769298	579131H1	579198H1	g3308511	083837H1	g4534587	g4188225	380	g3870352	3086136H1	•
190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	
œ	4157	N	4433	9	4221	4223	4416	4419	4452	4465	4459	4	4457	4460	4459	4456	4453	4314	4126	4457	3813	3683	3663	3911	3913	3659	3663	3749	3760	3663	3663	3817	3748	3641	3739	3918	4177	3981	
90	3904	92	σ	σ	σ	σ	σ	3967	σ	ത	σ	0	0	0	4020	4021	4026	4040	4042	4047	3411	3411	3442	3446	3446	3446	3453	3473	3491	3491	3491	3498	3514	3584	3610	3663	3692	3692	
4835	259	264	03	651	5013604H1	245864H	2301055T6	2292517T6 -	g5444044	g5436138	g3427279	6612393H1	g6044228	g4650722	g5109970	g2656315	g3277136	615565H1	g1192291	g4002109	933913R1	933913H1	3056157H1	6853558H1	1267149F1	1267149H1	1413302H1	4092170H1	1961533H1	1961533R6	464481H1	_	1373705H1	w	8228	105	65941R	91	
190	190	σ	190	σ	σ	9	σ	190	σ	σ	σ	9	6	9	9	190	σ	σ	σ	σ	σ	ത	σ	σ	6	σ	190	9	σ	σ	σ	190	190	190	190	190	190	190	

																•																						
941 1021	1297	1196	1129	1176	1352	1627	1060	1629	1612	1289	1319	1361	1456	1758.	1468	1383	1461	1743	1430	1824	1654	1774	1490	1804.	1935	1903	1926	1505	1996	2008	1993	1664	2078	2064	2100	2020	2044	
798 819	870	873	874	874	891	964	1008	1036	1056	1054	1079	1120	1127	1134	1134	1134	1141	1151	1157	1203	1215	1220	1221	- 1274	1290	1303	1307	1323	1330	1366	1396	1416	-1421	1437	1450		1463	
1305496H1 3617505H1	70861843V1	g669800	g875546	g874649	70862573V1	70856733V1	g771213	7048824H1	71225244V1	3211592H1	093259H1	926880H1	6163034H1	70860860V1	1366443R6	1366443H1	70145966V1	6448764H1	4960778H1	71226715V1	71228090V1	70857707V1	4625867H1	71225380V1	70858188V1	70858768V1	70864189V1	6911209H1	70858579V1	70858582V1	71224853V1	5640688H1	-71226033V1	7359924H1	70861230V1	71226687V1	70864162V1	
190	190	190	190	190	190	190	190	190	.190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	σ	190	190	190	190	190	190	190	190	190	190	190	190	
					•												٠					,	,		,	,					1		ı					
3669 3405	3493	3515	3628	3559	3583	3577	3624	3615	3591	3447	3579	3641	3628	3639	3574	3653	3864	402	201	512	371	187	477	464	435	473	504	854	648	286	823	565	S	575	961	1267	1046	-
3278	3292	3301	31	3313	3313	3314	3325	3328	3345	3349	3359	3360	3380	3382	3393	3404	3409	~ 1	⊣	41	127	127	192	203	219	219	271	286	293	299	302	320	364	491	491	798	798	
g1893973 3992283H1	793	325	008	2637310F6	2637310H1	4623479H1	3769624H1	3725948H1	3433892H1	3919666н1	5732787H1	3741626H1	5874821H1	2292517H1	3559065H1	3778532H1	6520495H1	5510632F6	5510632H1	6780915H1	4782751H1	4782751F6	2987413H1	6064208H1	5336504H1	5337416H1	g1984325	7245264H1	g3239921	g2026718	7245164H1	g2816869	5510632R6	4760384H1	4760384F6	1305496F6	70145686V1	•
190 190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190		190	
3085 3266	N	3306	3163	3153	3301	3252	3263	3460	3279	3153	3299	3090	3523	3241	3449	3264	3244	3268	3288	3394	3231	3330	3768	3301	3448	3424	3373	3464	3470	3479	3272	46	3448	75	45	9	65	
2803 2829	2825	2871	2881	2893	2895	2909	2927	2945	2945	2945	2976	2985	2989	2986	2989	2998	3002	3018	3032	3075	3077	3096	3132	3133	3154	3183	3183	3207	3209	3212	3214	23	23	25	26	3269	27	
3091359H1 985756T6	g1198696	10	3695945H1	377540	m	g618368	1305496T6	1551235R6	g530325	1551235H1	4311884H1	3659340H1	6125263H1	1984710H1	6124418H1	1008121H1	4402539H1	3518554H1	3345944H1	2819748F6	2819748H1	5660765H1	71225736V1	70857262V1	2	2279717H1	2	3469571H1	3356238H1	1805536H1	4160048H1	4942785H1	5585444H1	6269078H1	\sim	7290084H1	7011256H1	
190 190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	190	

WO 01/62927 PCT/US01/06059

																							41								t							
843	474	692	-1009	1039	712	685	989	931	1004	749	1233	1308	1182	1297	1488	1448	1488	1798	1757	1457	1460	1818		1121	2353	2223	2725	2228	2259	1911	1866	2202	2784	2564	2687	9	2711	2772
512	398	413	563	565	582	512	512	534	295	295	069	682	808	873	1204	1204	1343	1441	1442	862	921	1366	826	826	1984	2002	2259	1952	1752	1653	1698	1740	31	2311	42	43	4	2522
1965957R6	\sim	6843692H1	g3433649	6883312H1	70747238V1	1965957H1	2301872H1	6202014H1	g4113683	70749633V1	71129118V1	5769401H1	g611097	70641000V1	2106710H1	2106710T6	861904H1	2709045F6	2709045H1	7345973H1	7322101H1	6850665H1	2654475F6	2654475H1	g831331	1787542H1	6930205H1	4020229H1	6894957J1	5269	3246645H1	g4901556	2740754F6	2740754H1	1834220H1	4941620H1	4941983H1	2072075H1
191	191	191	191	191	191	191	191	191	191	191	191	191	191	191	191	191	. 191	191	191	192	192	192	192	192	192	192	192	192	192	192	192	192	192	192	192	192	192	192
	•											·	,	•		•									. •	,												
2704	2280	2280	2785	2683	2596	2240	2326	2351	2687	2744	2685	2729	1492	928	441	1489	1490	1488	1509	1011	931	810	829	1365	1276	416	467	473	473	210	163	401	700	833	930	1472	813	671
2033	2050	2050	2048	2059	2060	2069	2070	2070	2072	2086	2095	2110	1204	417	381	928	1003	1016	1088	591	605	613	613	653	657	143	176	212	255	-	œ	127	399	399	406	119	503	202
70855603V1	70858486V1	70858723V1	70861733V1	70855437V1	70858374V1	449622H1	71228093V1	71227893V1	71227986V1	71225556V1	70864357V1	70855127V1	2106710R6	71032896V1	2004771H1	71134281V1	71130579V1	71129556V1	71133640V1	g3427925	71133255V1	70643569V1	70639731V1	71133577V1	71134103V1	968289H1	7212584H1	g4735242	g4533052	2705278H1	2427258H1	991952H1	3070166H1	113	71130961V1	71133228V1	2301872R6	g1263124
190	190	190	190	190	190	190	190	190	190	190	190	190	191	191	191	191	191	191	191	191	191	191	191	191	191	191	191	191	191	191	191	191	191	191	191	191	191	191
																	-								ŧ													
2187	2076	2062	1993	2169	2133	2227	2117	2147	2109	1963	1845	2119	1887	2284	2167	2354	1956	2409	2302	2382	2053	2413	2415	2439	2409	2491	2474	2422	2394	2131	2563	2315	2297	2402	2660	2639	2644	2573
1491	1507	1539	1520	1520	1526	1541	1548	1558	1568	1573	1573	1611	1626	1651	1689	1722	1730	1740	1745	1755	1752	1822	1830	1869	1869	1877	1889	1929	1936	1936	1973	2000	2000	2001	2013	2015	2015	2016
70855640V1	71225393V1	70858387V1	70855984V1	48	70855452V1	70861672V1	70861119V1	71225746V1	70856590V1	4030718F6	4030718H1	70856815V1	2742284H1	71228652V1	70855093V1	70863689V1	6412316H1	70857818V1	70860827V1	70864783V1	70863459V1	70858650V1	6911209J1	70146804V1	70146516V1	70863645V1	71225144V1	71224913V1	70146682V1	060994H1	70861917V1	2791792F6	2791792H1	70857602V1	71225364V1	70858585V1	96	70860984V1
6	190	ത	σ	σ	σ	σ	σ	0	ര	6	σ	σ	σ	σ	σ	σ	σ	σ	σ	σ	190	σ	σ	σ	g	σ	9	g	9	9	190	σ	190	g	190	σ	190	σ

	3495 3493	3548	3854	3611	3807	3621	3736	3755	3895	3895	289	305	411	271	251	727	528	206	409	614	729	727	1106	1266	965	882	1284	1210	1272	1293	1306	1557	1453	1633	1456	1468	1331	1450	
ć	3236 3251	29	30	35	35	39	43	47	53	56				-1	Ŋ			272	276	375	380	403	603	629	704	704	910	953	966	1055	1083	1121	1189	1189	1202	\vdash	Ť	1293	
ı	5592052HI 996009H1	5041507H1	7032868H1	1665916H1	1665916F6	1304	96	3978484H1	g831015	g821280	g1885508	g1110043	3349547F6	3349547H1	2741917H1	6991627H1	1434004H1	5587446H1	g2880882	349280H1	g713456	g698683	6916554H1	6719552H1	4384945H1	4384979H1	g1885551	5019503H1	87	2479328H1	037774H1	g1717439	4840554H1	4840554F6	3279387H1	5373713H1	56	4916687H1	
	196 196		6	196	196	196	σ	196	9	σ	ဖ	96	9	9	ø	9	9	196	196	196	196	196	196	196	σ	196	σ	9	σ	196	196	196	196	196	196	σ		196	
	•												1																										
ī	575 194	380	154	512	2884	2924	2909	2931	2878	2923	2887	2903	2909	2926	2925	2888	2917	2879	2909	2910	2879	2899	2867	2907	2909	3047	3033	3025	2878	2906	2906	2899	18	3277	3294	3177		3451	
. •	⊢ ←	ı	29	89	2556	2558	2558	2567	2570	2587	2604	61	2639	2645	2649	2664	2664	2666	2690	2691	2696	2712	2716	2730	2738	2771	2771	2781	2784	2792	2792	2	2857	99	3012	3028	3208	3217	
	5910555T6 5910555H1	79(16889	567	444	051	g1859536	\sim	g1783714	g823824	g2782889	4840554T6	g565986	g3277818	g4149369	1575363H1	1575363F6	1575363T6	g788188	g1482370	g864606	2006905H1	806183H1	g842117	g3742246	4882821H1	4884359H1	5090054H1	27783	2343515H1	マ	88	9	13	3369954H1	5346406H1		3077845H1	
		195	195	195	196	196	196		196	196	196	196	196	196		9	9		ဖ	ဖ	9		196	196		196	196	196	196	196	196	196	196	196	196	196	196	196	
																									1														
- 1	2779	96	28	8	13	13	17	90	23	24	64	37	63	39	47	65	63	89	54	68	69	538	657	3683	68	68	3550	62	67	69	432	588	484	254	443	587	489	640	
١	2564	70	73	76	88	91	94	94	97	01	13	14	17	17	13	13	21	24	32	32	H	141	489	3487	49	54	3347	38	43	46		-	~	-	22	-	82	ન	
1	5373319H1 3619907H1	543335	89495	69427	ω	_	28411	87857	77577	\sim	74075	21428	3732858F6	3732858H1	4136158H1	2654475T6	3732858T6	g4189007	856846H1	g4076116	g440877	g5544790	7106835H1	2313806Н1	2841392H1	2097796H1	666777H1	815360H1	2104253H1	83127	σ	91184	91184	91184	σ	55F	910555	10555F	
•	192 192	192	6	9	192	192	192	192	192	σ	192	σ	σ	192	0	0	ത	192	g	ര	g	192	192	σ	σ	192	192	σ	O)	192	တ	193	193	193	193	O.	194	194	

																1																						
2910	28/8	564	146	322	566	353	585	479	303	260	999	377	370	320	313	293	518 -	226	437	416	542	440	217	307	209	752	397	372	605	1136	1221	1046	1233			422	400	589
2555	n	-1	-	H		53	, H	ம	N	œ	75	122	122	, -1	н	~	⊣	25	. 691	169	പ	24	24	38	38	126	126	137	339	559	610	832	833	7	7	7	7	10
g3280248	92208127	5965475H1	g1162029	184	313	6151063H1	6764201J1	986476R6	986476H1	4180212H1	g3933038	4029248H1	4029227H1	g4196260	g2218495	3685061H1	6821713J1	5372078H1	4205860H1	4205654H1	6868907H1	1543453R6	1543453H1	5055563H1	5055563F9	4778273F8	4778273H1	2724784H1	2925738H1	4778273T9	1543453T6	1921258H1	2	v	9	6144	13995	6764092J1
196	196	197	197	197	197	197	198	198	198	198	198	198	198	199	199	199	199	199	199	199	200	200	200	200	200	200	200	200	200	200	200	200	200	201	201	0	201	201
																		,																				
									,									•						· .		•						ı		1				
2483	5 (2469	40	43	35	2516	2518	2516	2285	2467	2439	2520	2501	2632	2636	2794	2644	2660	2516	2906	2923	2922	2834	2993	3007	2833	2923	2904	2876	2911	2770	2713	2917	2877	2916	2878	σ	2921
2140	2140	2142	2150	2156	2174	2175	2175	2180	2180	2199	2200	2231	2244	2320	2319	2330	2353	2391	2391	2437	2523	2545	2547	2547	2547	2547	2548	2548	2549	2555	2555	2555	2555	2555	2555	2557	2555	2555
8	7	ω 	4324610H1	8	4834124H 1	g1783896	g2207390	908344R2	908344H1	4748325H1	4746557H1	g1859648	5565332H1	g778446	g831074	g2053046	3031124H1	2277831H1	2277831R6	g2552923	g832055	g1329627	g4990052	g4311136	g4988520	g4740301	g3422370	g4289096	g3431513	000140H1	2543809H1	13	g5113593	18956	S	7	1287	g4565709
196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196
1543	9 1	65	63	02	1623	1693	11	1896	1820	1840	1841	1884	1825	1955	1840	2034	1965	2321	2009	2053	2024	2047	2030	2062	2217	2151	2009	2272	2281	2225	2284	2353	2373	2304	2331	2391	2462	2408
1328	1330	37	37	1426	1438	1473	1498	1511	1513	1512	1513	1513	1566	1590	1608	1668	1735	1739	1779	1779	1779	1778	1784	1803	1843	1894	1945	1966	1965	1966	2028	2055	2063	2063	07	11	12	13
4581558H1	23070	604	700	9	48432	1912429H1	g1440342	g4524899	g768901	g571029	g880779	g832097	4623266H1	3519427H1	3680478H1	6332293H1	4832174H1	g1329683	g787502	g864605	196 g787457	g841915	5589418H1	5071250H1	3865563H1	1955962H1	4750673H2	442154H1	261197H1	433	4515301H1	805	2191782F6	19	3735668H1	3038357H1	129	4633908H1
196	ס עכ	0	σ	σ	ത	σ	9	σ	9	σ	g	σ	9	σ	196	196	196	196	196	196	196	196	196	196	196	196	196	9	σ	σ	9	σ	σ	9	9	σ	σ	9

																																					•		
1465	78/T	eg P	1675	1499	1487	1465	1541	1760	1479	1778	1463	1513	1502	1757	1655	1515	1502	1909	1806	1756	1868	1569	1747	1912	1803	1582	1713	1905	1885	1571	1859	1599	1915	1611	1594	1885	1827	1582	
1165	1169	1169	1169	1169	1170	1169	1173	1177	1187	1194	1197	1193	1198	1199	1200	1200	1204	1219	1220	1218	1221	1233	1236	1239	1243	1244	1258	1248	1252	1256	1254	1255	1257	1255	1256	1261	1263	1262	
5803566н1	6040276H1	973	5973594HI	5995226H1	5993875H1	6078894H1	5825616H1	5921387T8	6042666H1	7185125H1	5993778H1	5993775H1	6168554H1	60047572D4	5824125H1	5994991H1	6112929Н1	7330358H1	.5768301H1	5769260H1	7330481H1	5995163H1	6959960H1	60206936U1	6034683H1	6169613H1	4294314T9	6041063H1	71035949V1	5952448H1	5974564H1	5991486H1	7264840H1	5991328H1	6112291H1	7080084H1	5771870H1	6170079Н1	
203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	
	ı												,			•			. "																				
1322	1308	1610	1617	1615	1353	1418	1723	1676	1386	1395	1470	1461	1685	1633	1618	1743	1454	1394	1709	1351	1725	1428	1752	1712	1687	1401	1719	1678	1656	1460	1760	1770	1429	1778	1729	1720	1505	1461	
					1078		1093	1094	1094	1095				1102	1102								•	1114	1118			1117			1122	1134		1145	1145	1146	1162	1162	
6183568H1	6183681H1	71001091V1	6217476H1	6148902H1	6114310H1	5806522H1	6146547H1	7220801H1	6132328H1	5995785H1	7322507H1	6113383H1	5975102H1	6148050H1	5977862H1	6038505H1	7080569H1	6116490H1	71360704V1	5892681H1	6164075H1	6181324H1	5770720H1	5797766H1	5826374H1	5796423H1	6036824H1	6034194H1	5769794H1	6134213H1	5770890H1	5976811H1	6178910H1	5975668H1	5975687H1	6214924H1	6183602H1	6183689Н1	
203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	- 203	203	203	203	203	203	203	203	203	203	203	203	203	203	
																									•								•						
537	315	331	296	474	375	913	944	870	1127	972	1002	954	972	972	281	372	358	484	264	444	431	200	444	444	1616	1635	1230	1168	1270	1477	1299	1193	1567	1221	1323	1600	1604	1629	
59	67	69	98	83	108	384	422	430	537	661	732	753	810	814	-	⊣	4	9	9	9	28	27	36	59	961	971	971	896	971	976	976	916	984	982	1003	1022	1027	1031	
g2910438	4570842H1	4921180H1	5955592H1	g2904695	g2841122	6982639H1	1570643T6	g5232046	7377338H1	1570643F6	3119826H1	6097252H1	1570316H1	1570643H1	5913683H1	5320619F9	5913683F6	5321234F9	5914061H1	5914061F8	5913683T6	5913683F8	6269343H1	6269670H1	71035493V1	577173H1	5952931H1	5989634H1	5800985H1	5800543H1	5805534H1	5831382H2	6166604H1	6153585H1	5804655H1	7075719H1	5798865H1	6964153H1	
201	201	201	201	201	201	201	201	201	201	201	201	201	201	201	202	202	202	202	202	202	202	202	202	202	203	203	203	203	203	203	203	203	203	203	203	203	203	203	

					•									١,																								
1069 1061	1259	1336	1255	- 1018	1320	1083	1118	1081	1129	1419	1105	997	1129	1081	1105	1170	1090	1095	1427	1396	1364	1459	1480	1457	1148	1124	917	1459	1130	1196	1162	1477	1166	1368	1096	1499	1046	
754 757	759	764	160	763	777	773	787	793	792	197	197	797	803	802	804	908	815	813	820	820	820	827	829	839	835	836	836	848	849	851	853	828	856	861	828	863	870	
6110012H1 6135068H1	6035941H1	6163478H1	5968127H1	6178490H1	60204862U1	6108986Н1	6097994H1	6165174H1		5798369H1	5801102H1	6112951H1	6109295H1	6110881H1	6179893H1	5955376H1	7359669H1	6176408H1	7004683H1	7004582H1	71033163V1	5974746H1	7325468H1	6035163H1	6112093H1	6177785H1	5798782H1	6150235H1	5952964H1	6218804H1	5804744H1	5771556H1	5994894H1	71036246V1	5915476H1	6163363H1	5796628H1	-
203 203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	
																	•																					
								ı									٠														,		ŧ	,				
898 1211	950	955	696	1020	974	917	1176	1176	889	1250	1098	1001	994	. 926	1277	1238	1173	1046	1001	983	1298	1023	1001	1074	1236	982	1044	866	1001	1199	1085	1069	1031	983	1095	1336	1359	
647 648	648	653	929	629	629	629	664	664	999	664	999	671	671	671	672	681	684	691	669	669	701	701	702	904	710	710	723	726	732	736	740	740	741	741	741	747	750	
6150959H1 6162572H1	5803707H1	6111936Н1	6111235H1	341	5995735H1	6002288H1	6144013H1	6166779H1	6052294H1	6053478J1	6052294J1	599522H1	5990146H1	6079085H1	5798802H1	5975323H1	7327981H2	6155086H1	6183751H1	6183830H1	6215696H1	6109481H1	6030242H2	6163760H1	6153438H1	6111179H1	6116630H1	6151576H1	6111753H1	5824855H1	5991422H1	6180759H1	ന	5954296H1	6154930H1	6145090H1	7215869H1	
203 203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	
																							•															
1862 1837	1662	1677	1909	1912	1881	1900	1807	1929	1907	1912	1919	1561	1601	1550	1639	1935	1918	1856	1896	1640	1633	1916	1668	1646	1636	1639	1684	1935	1756	1197	926	859	974	926	966	944	922	
1264 1269	1274	1274	1284	1286	1290	1297	1299	1306	1319	1322	1327	1327	1328	1331	1330	1332	1333	1333	1337	1338	1338	1339	1338	1338	1340	1340	1351	1354	1356	628	630	m	4	4	647	647	647	
6080872H1 5824738H1	3390106T6	60221621V1	7004345H1	60109238B1	7186303H1	7025213H1	7182261H1 -	7193486H2	6736012Н1	5970654H1	5770017H1	5802957H1	5800770H1	5804521H1	5995788H1	7331927H1	5769517H1	5967562H1	6163438H1	5953896H1	5789044H1	5975734H1	6078714H1	5786342H1	6175953H1	5805592H1	5952736H1	3693154F6	6217933H1	7160128H1	6117709H1	6180232H1	73	6132472H1	6150854H1	8044	6043158H1	
203 203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	

302	674	, 0, 7	210	7 6 7	543	481	546	448	751	578	893	837	545	596	296	268	856	899	585	858	639	828	764	644	932	425	216	954	994	299	674	1002	923	729	1031		744	
186	7 00	194	201	204	210	214	218	226	228	242	250	253	257	265	265	265	265	294	296	304	310	313	320	-336	326	329	328	354	357	360	367	387	-396	393	411	421	423	
6172501H1	7183712H1	7025064H1	7225279H1	6116494H1	5953527H1	5892842H1	5993811H1	6109818H1	6044864H1	6182368H1	7326560H2	6033805H1-	6101869H1	6170505H1	6152125H1	6137458H1	5958352H1	5975525H1	5838053H1	5796171H1	6112187Н1	6165284H1	-5826529H1	6172048H1	6035764H1	6966778Н1	6172080H1	7182401H1	7269240H1	6029089Н1	6100553H1	5825841H1	-7214023H1	6109604H1	6143986H1	\leftarrow	6136677H1	
203	202	203	200	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203 -	203	203	203	203	203	203	
					,	٠		1														,	•								í		ł					
255	040	647	ה ה ה	979	6,0 818	395	393	393	384	694	290	317	615	662	675	170	429	474	394	219	287	403	467	719	381	728	278	616	425	630	416	465	830	467	658	480	509	
67	א כ	۲ ا ا	ה	0 6	0 6	79	79	79	79	79	79	84	84	98	88	90	90	91	91	91	96	66	104	104	106	118	108	122	133	137	144	148	147	166	168	177	179	-
6107796H1	/221886H1	5/69589HI	7240000111	45/1391F6	5174042H1	6176812H1	6177958H1	6179512H1	6181431H1	7008218H1	6215727H1	6151732H1	5973312H1	60126922U1	5974449H1	6111184H1	6113115H1	6000095H1	6182051H1	7272693H1	7385648H1	6135054H1	6182449H1	5775693H1	6175825H1	5968167H1	60120598D1	6147691H1	6115311H1	5975411H1	5915392H1	13	7328558H1	5996192H1	97	5989334H1	6109928H1	
203	203	203	202	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	. 203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	
و بد	_ 1.							10		10	~ 1	~ 1	_	10		~	_	•	_	١0			_	_	~	•	١0	~1	- 1 1	~	9							
1144	107	1510	# 6	113/	1168	1275	1459	1245	1264	1525	1542	1222	1214	1026	151	1523	1548	1529	151(1026	152	988	1589	121(1263	148	122	1533	1554	1173	123	390	613	387	615	610	430	
872	8/6	884	0 0	0 0	000	906	906	806	913	915	914	912	924	913	920	923	924	925	924	923	932	935	940	936	942	947	941	957	948	946	948	62	65	65	99	29	29	
6115353Н1	6115444H1	6033285H1	014341/HL	61728/8H1	5801236H1	6113354H1	6032732H1	6130142H1	6168522H1	6037518H1	6032546H1	60104786D4	6176164H1	6133149H1	7320972H1	6033149H1	5970892H1	6036731H1	5970884H1	6113366н1	7185073H1	5827058H1	5770524H1	6114346H1	5990721H1	5975145H1	6044290H1	5768644H1	5971326н1	6110988H1	6099321H1	6173091H1	6036155H1	6180780H1	5770305H1	7215805H1	7024381H1	
203	203	203	202	203	202	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	

																							*1															
340	328	328	, 55 y	797	5.78	685	673	685	682	557	552	645	444	387	363	350	322	379	384	362	337	644	636	385	377	372	365	374	359	S	353	347	339	œ	675	Н	283	685
39	5 G	ა თ (ָ אַ נ	יי פונס	2.	39	40	39	39	39	39	20	39	39	40	39	39	62	42	42	42	43	43	43	43	43	43	43	43	43	44	43	43	43	45	44	43	
6136114H1	13255	9,50	770	6028575HI	5914782H1	7359725H1	6084122H1	7083662H1	7358734H1	7181284H1	60264004D1	6080769H1	7212965H1	6174304H1	6117564H1	6132067H1	6099630H1	6134055H1	5994380H1	6098224H1	6132993H1	7213881H1	6081567H1	6132164H1	6101109H1	5992072H1	6078760H1	5995191H1	1719	9898	6181359H1	6110331H1	6111434H1	6168435H1	7268992H1	6081557H1	6110567H1	7272829H1
203	203	203	203	9	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203		203	203
479	249	2	177	531	569	358	686	619	645	637	592	578	341	644	372	340	648	636	616	324	675	709	673	643	615	623	613	643	555	420	380	375	358	372	358	350	347	4
12	ر ور رو	35	ָ מ	66	32	44	41	34	35	36	36	36	36	36	37	37	39	38	39	39	39	39	39.	39	39	39	39	39	39	39	39	39	39	39	39	39	39	39
341								6H1																											9H1			
97693	0246	731	3	7279008H1	02	7079629H2	5972573H1	7160586	Ξ	7083178H1	7182216H1	7184701	6170753	· 7261837H1	6180976H1	6170740	7262607	7220667	7182859	6099372H1	7260783H1	7316234H1	4625563F9	7160372H1	7160758	7216608H1	7219614	7213493H1	7160235H1	7317368H1	O)	81	6171834	6169216Н1	6131659	6177913H1	6109871H1	6132882Н1
203	203	203	\supset	0	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	
																									1													
1047		1086		1098		930	756	772	1055	793	718	775	1096	694	1087	897	898	804	726	886	888	769	881	1094	897	1133	1225	868		1060	1092	905	1260	937	1188	156	324	301
430	448	452	453	455	457	461	461	468	474	478	491	517	524	525	539	534	534	534	534	543	543	544	546	577	586	589	590	296	599	909	612	617	626	624	628	-	~	8
6041789H1	5989594H1	6053478H1	967	486	808	785	584	6137438H1	197	6108268H1	6115462H1	5891369H1	6001442H1	7360854H1	5974453H1	6109032H1	5892176H1	5953990H1	5831262H1	5955474H1	5955458H1	6111439H1	6111316H1	5797137H1	6133207H1	7328606H1	7261854H1	6100514H1	6040074H1	5824550H1	8149	6181437H1	5771704H1	13136	71216557V1	6141011H1	6108212H1	w
203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203

																					11								,							
1799	1933	σ	1937	1869	1928	1854	1861	1840	1928	1928	1928	1889	1866	1926	1933	1813	1920 -	1928	1928	1930	1934	1928	92	93	1784	1863	1832	1715	1652	1921	1825	1883	1746	1928	1832	1937
1456 1459 1555	1555	55	1561	1564	1565	1566	1566	1565	1566	1568	1567	1568	1571	1571	1574	1579	1580	1587	1588	1511	1513	1524	1523	1528	1526	1528	1530	1530	1532	1534	1547	1550	1550	55	1550	1552
5990839H1 5768633H1		g6030521	g6197062	6152884H1	g6471957	5955189H1	6030104H2	5805947H1	5771690H1	g6030549	g6198562	6097965H1	6151677H1	5974518H1	g6229210	6028702H1	g6470581	g6198908	g6044672	g6470803	g6027906	g6074740	516	g6133768	6179968H1	5991468H1	5786634H1	5786701H1	5786734H1	g6047869	6176458H1	5816770H1	17	64710	5817174H1	g6471718
203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203
,		•									1						-																			
683 524	640 1910	1657	83	1676	1661	1929	1682	1667	1676	1927	1699	1666	1721	1700	1699	1548	1918	1722	1725	1477	1784	1937	1938	1938	1887	1747	1920	1938	1936	1530	1927	1907	1936	1778	1932	1938
588	1354	1353	1360	1364	1364	1366	1365	1365	1367	1372	1377	1375	1382	1383	1393	1401	1403	1404	1405	1404	1415	1428	1432	1431	1434	1434	1434	1436	1437	1440	1440	1440	1443	1444	1445	1453
6034778H1 7330333H1	60104786B2	6177422H1	5824565H1	6110675H1	6042367Н1	6035204H1	6170972H1	6181601H1	5802968H1	4362784F8	5996082H1	5996003H1	5995203H1	6133437H1	6178414H1	6179001H1	5769429H1	5785086H1	5801902H1	5792833H1	5949501H1	g6228962	g6228709	g6300732	60126922B1	6173439H1	5769804H1	g6301637	g6302015	5953730H1		7082145H1	g6301063	6133907H1	g6039672	g6301561
203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203		203	203
																							ı													
388	103 647	588	393	404	353	235	644	919	616	388	373	347	243	718	650	375	387	363	348	635	389	331	306	687	619	733	230	630	412	419	644	647	593	635	399	643
45	45	46	47	46	47	47	48	49	49	48	48	48	48	49	49	49	49	49	48	20	20	89	20	51	51	54	54	54	54	73	52	54	28	28	26	26
5992910H1 6131653H1	7263260H1	7158311H1	6097721H1	6136962H1	6170754H1	0	7275183H1	7182041H1	7182971H1	5991415H1	6112705H1	6098861H1	6099983H1	7283631H1	6039521H1	5992224H1	6170022H1	5992273H1	6114538H1	7272102H1	6136863H1	6085163H1	6115314H1	7270954H1	7190289H2	4624253F8	6037863H1	5973394H1	6168342H1	6733426H1	5770643H1	6733166H1	7321688H1	6038935H1	6134077H1	7185189H1
203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203

														,																								
1917	1850	1920	1920	- 1912	1934	1920	1938	1932	1936	1938	1938	1827	1928	1928	1928	1928	1926	1926	1925	1937	1929	1928	1929	1806	1928	1932	1929	1929	1929	1928	1928	1930	1928	1804	1930		1928	
1668 1668	1668	99	67	1670	1672	1674	1676	1680	1686	1686	1686	1686	1687	1691	1692	1693	1695	1695	1695	1708	1710	1721	1465	1466	46	1466	1468	1468	1468	1468	1469	1470	1468	1470		1470	1469	
5946071H1 5950118H1	6157445H1	97	5767935H1	5767973H1	5947508H1	5790266H1	g6400408	7338126H1	7350525H1	g6398110	g6402278	6157246H1	g6197883	g6046641	g6400764	g6076220	5794559H1	g6033633	5787563H1	g6117328	g6044253	g6398246	g6131945	6181714H1	g6048081	g6047077	g6132102	g6398647	g6400444	g6086266	g6132321	g6132239	g6074116 -	5990574H1	962	g6074889	356	
203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203-	203	203	203	203	
														,				•				•	•								ı		ı	,				
1935	1911	1933	1928	1928	1928	1930	1936	1936	1932	1932	1930	1928	1929	1933	1938	1932	1926	1934	1937	1934	1920	1920	1920	1928	1928	1930	1925	1926	1981	1927	1938	1956	1876	1926	1928		1940	
1480 1480	1482	1481	1481	1481	1481	1482	1482	1480	1482	1482	1483	1484	1484	1485	1484	1485	1485	1486	1487	1489	1815	1815	1815	1823	1833	1841	1844	1856	1722	1722	1728	74	1746	1754	S	9	1865	
g6131743 g6044247	6034847H1	g6117455	g6464482	g6036141	g6047637	g6117632	g6463078	g6035703	g6076131	g6196780	g6031028	g6464375	g6043231	g6117300	g6200216	g6040103	g6399002	g6029144	g6043655	g6196472	g6034277	g6117025	g6199037	g6198912	g6473327	g6463164	5920960H1	g6198784	5787770H1	5789227H1	g6074506	6166065H1	g6029762	5786021H1	64388	99258	6158235H1	•
203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	
1937	192	193	193	193	193	193	193	193	192	193	192	181	1928							192	181	1928	192	1787	193	1806	192	192	13	1933	1936	1935	1934	1934	1937	1938	C	
1552	1553	1488	1488	1489	1490	1490	1490	1490	1489	1492	1492	1492	1493	1493	1500	1501	1505	1501	1502	1502	1503	503	504	519	1509	511	476	476	1477	1477	1478	47	47	47	1480	48	1479	
g6464005 6108818H1	7181625H1	g6043984	g6476041	17539	g6028910	g6073495	g6401184	g6073672	g6036791	614	g6036640	6157091H1	g6033899	g6198865	6219812H2	6192668H1	5768793H1	6191666Н1	g6473184	g6476087	5993364H1	g6438645	g6076043	6043152H1	g6472040	_	5	7	3633	1	1423	602946	643951	646295	64396	619663	643964	
203	03	03	03	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	203	

		-																																					
4	40T	775	304	843	783	<u> 196</u>	175	298	1619	1679	1618	1484	1385	1392	1309	1275.	1289	1299	1315	1285	1302	1301	1284	1284	1267	951	920	928	991	879	1695	1691	1683	1679	1679	1726	1583	1586	1506
•	191	156 156	13	621	448	147	541	94	1303	1438	1303	875	802	786	886	1112	833	929	1075	929	1064	1157	823	747	705	- 514	535	424	498	335	1455	1157	1404	1335	-1439	1158	1354	1360	1281
	1299074H1	~ •	3698810H1	1751671H1	g1616031	6824349J1	4516155H1	4672305H1	6829925Н1	1426502H1	6829925J1	6824269J1	6824288J1	6825511J1-	g5856181	g824615	6802929J1	g5127144	g2344128	6458046H1	g2397910	g2278427	g3058045	6820991H1	2255054T6	6822128H1	6802929H1	6825384HI	6824288H1	6824091J1	3512547H1	6804257H1	3700061H1	1426502F6 -	-755545H1	6498381H1	1858538T6	1810993T6	1810792H1
	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204 -	204	204	204	205	202	205
								٠		•															·								,		ı				
•	φ, .	241	15	55	1145	1116	15	14	1076	1051	1007	1756	4	1742	1305	1289	97	78	97	1287	87	02	7	7	7	2	7	e	e	8	Q	e	0	7	3	8	3	32	. 2
,	12	17	1115	11	11	11	1115	1114																				713				453	88	82	46	80	46	43	43
	979	984	594	9/9	813	823	822	921	434	808	729	1157	829	1143	1065	816	1027	845	1227	914	899	1021	393	312	549	357	357	502	474	315	329	185	386	350	179	235	-	234	255
1	ശ	വ	6825511H1	6827717H1	6828967J1	6825030H1	6825030J1	1470306H1	682771751	1945447H1	5870352H1	6826536J1	6822128J1	6826536H1	g3056033	g5837846	g2986193	6831310H1	1631532H1	g3150672	g2236974	g4889379	2255054R6	6498130H1	2255054H1	6826447H1	6826447J1	1579339H1	4443559H1	2042892H1	3358238H1	4750087H1	6824269H1	6824349H1	2184748H1	6756704J1	2184748F6	6756496H1	6756704H1
•	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204	204
•	1936	1930	1938	1928	1928	1930	1928	1916	1928	1928	1930	1937	1928	1888	1928	1920	1928	1904	1906	1915	1928	1932	1935	1912	1929	1928	1911	1946	1920	1930	1932	1891	1928	1928	1928	1221	1264	1258	1245
	1472	1472	1472	1472	1473	1474	1459	1464	1475	1475	1475	1476	1600	1603	1605	1604	1611	1615	1615	1615	1619	1653	1656	1656	1665	1665	1666	1668	1668	1588	1593	1593	1594	1597	1596	9	↤	860	9
	g6400824	g6132812	g6400805	g6400717	g6030907	g6047234	7180844H1	g6035938	g6439666	g6036991	g6047968	g6036801	g6196212	6177877H1	g6039199	g6438679	g6400557	5817262H1	5817362H1	5820474H1	6102129H1	g6074067	g6132060	3775108F9	g6198405	6178153H1	g6045038	5770026H1	5792284H1	g6028253	g6475978	6175948H1	g6132639	g6463340	g6046756	6844571H1	1299074T6	1751671T6	6941680Н1
	_	m	ო	ლ	٠ ٣	33	33	03	03	03	03	33	03	03	03	03	03	03	03	03	03	03	03	03	03	03	03	203	03	03	03	03	03	03	03	04	04	204	0.4

																								1															
	675	0/0	0/0	9/9	6/5	545	297	246	183	265	267	156	267	219	393	276	382	540	238	220	432	212	326	321	272	277	324	251	280	512	316	382	247	355	182	275	282	340	365
	277	202	197	2 7 8	273	354	-1	Н	H.	~	т	٦	~	÷	~	-1	20	20	20	21	21	20	24	24	27	28	31	32	35	38	38	38	38	26	62	99	99	36	99
	900	93090059	7 7	176	95630519	574367417	5743674H1	4127943H1	5743674R7	1952854T6	2917244T6	2917244H1	2917244F6	5507875H1	5507875F6	3510289H1	6985373H1	6985355H1	4715879H1	645341H1	645341R6	4551228H1	3182009H1	3182022H1	5156573H1	4800844H1	5864355H1	.6219781Н1	3375196Hl	6306192H1	g575091	92	2924014H1	2825826H1	3695750H1	941644R6	3104	3580982H1	941644R1
	207	N C		707	207	202	207	207	207	208	209	209	209	210	210	210	210	210	210	210	210	210	210	210	210	210	210	210	210	210	210	210	210	210	210	210	210	210	210
			•																							•													
	,																																						
	61	נ	~ c	ָ ה	82	90	9/	64	45	18	88	83	96	46	00	23	22	7.1	60	90	86	47	20	20	92	. 08	35	17	23	₩.	~	σ.		₹#	~	o o	σ.	က	7
,	Ö	2 4 4	1;	777	102	11	17	124	134	14.	16	1489	14	15	12	15,	15.	12	19(20	17	207	20	20	200	20.	20(207	20	86	82.	79	68	89	67	67	67	67	. 19
	672	7/9	200	6/5	97.8	912	953	1005	1104	1144	1173	1223	1223	1228	1238	1278	1316	1331	1418	1441	1482	1596	1631	1700	1749	1798	1809	1885	1942	503	242	316	260	209	286	451	263	299	224
	2487001F6	4 8 7 7 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	2	762060/HI	317	7.2	5591	365	5064775H1	g1014062	6249620H1	2881132F6	2881132H1	g1949025	4552262H1	950155H1	1705026H1	4398180H1	3179825T6	2487001T6	6097383H1	g2251371	94072810	g3889774	g4087488	g1014063	2881132T6	g1195443	g2155148	m	6803514J1	เด	g4568721	CII	g5365250	567660	g4111591	253949	76
	206	902	907	907	206	206	206	206	206	206	206	206	206	206	206	206	206	206	206	206	206	206	206	206	206	206	206	206	206	207	207	207	207	207	207	207	207	207	207
																										ı													
	1595	1586	1586	1286	511	265	563	163	341	402	682	916	806	714	852	852	866	841	1096	1419	1261	1558	1518	364	364	424	672	409	484	481	619	558	731	787	731	851	865	928	846
	3	1368	ς α	33		← 1	m	17	89	351	400	474	474	474	642	642	642	642	642	1002	1024	1281	1281	.	⊣	120	120	141	222	327	359	425	463	519	563	268	602	633	642
	2625825H1	2228636T6	1724417T6	Z689550T6	2689550F6	2689550H1	6476804H1		g2244465	1494653H1	1858538H1	2218749F6	2228636F6	2228636H1	1724288H1	1724417H1	1724417F6	1724064H1	1724064F6	6549336H1	4822845H1	1810993F6	1810993H1	6045641H1	6045641J1	3179825H1	3179825F6	4758644H1	2966833H1	5372448H1	2686267H1	3722865H1	5036810H1	4164428H1	3799675H1	4708839H1	2952970H1	3561988H1	856538H1
	205	\circ	9	\circ	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	05	90	90	90	90	90	90	90	90	90	90	90	90	90	90	90	90

_	4	9	4	œ	9	-	866	S	œ	
70	82	131	218	234	308	354	543	260	ᆏ	
96775	83105	72785	05343	46825	50787	87449	g5109730	13919	40998	
210	210	210	210	210	210	210	210	210	211	

WO 01/62927 PCT/US01/06059

	TABLE 5	
SEQ ID NO:	Template ID	Tissue Distribution .
OLG ID 110.	remplate ib	Liver - 41%, Pancreas - 34%, Cardiovascular System
1	LG:1040582.1:2000FEB18	-, 14%
2	LG:453570.1:2000FEB18	Nervous System - 100%
3	LG:408751.3:2000FEB18	Sense Organs - 63%, Nervous System - 22%
• 4	LI:090574.1:2000FEB01	Nervous System - 46%, Unclassified/Mixed - 36%
5	LI:229932.2:2000FEB01	Musculoskeletal System - 80%
6	LI:332176.1:2000FEB01	Urinary Tract - 95%
-		Respiratory System - 60%, Hemic and Immune
7	LI:403248.2:2000FEB01	System - 40%
. 8	LG:220992.1:2000MAY19	Embryonic Structures - 17%, Male Genitalia - 12%
		Liver - 19%, Embryonic Structures - 16%,
9	LG:1094571.1:2000MAY19	· · · · · · · · · · · · · · · · · · ·
		Skin - 47%, Stomatognathic System - 27%, Sense
10	LI:350754.4:2000MAY01	Organs - 14%
11.	LI:255828.29:2000MAY01	Musculoskeletal System - 100%
12	Ll:1190263.1:2000MAY01	Urinary Tract - 80%, Urinary Tract - 15%
13	LG:270916.2:2000FEB18	Female Genitalia - 100%
:		Embryonic Structures - 30%, Urinary Tract - 13%,
i		Digestive System - 11%, Musculoskeletal System -
14	LG:999414.3:2000FEB18	11%
		Urlnary Tract - 80%, Hemic and Immune System -
15	LG:429446.1:2000FEB18	20%
		Male Genitalia - 71%, Hemic and Immune System -
16	LI:057229.1:2000FEB01	29%
17	LI:351965.1:2000FEB01	Unclassified/Mixed - 53%, Male Genitalia - 12%
18	LG:068682.1:2000FEB18	Unclassified/Mixed - 49%, Male Genitalia - 27%
40	10.0400054.000055540	Germ Cells - 47%, Female Genitalia - 13%, Male
19	LG:242665.1:2000FEB18	Genitalia - 12%
20	I C:041740 1:0000FEB18	Liver - 27%, Urinary Tract - 27%, Respiratory System -
20	LG:241743.1:2000FEB18	14%
21	LI:034212.1:2000FEB01	Digestive System - 24%, Musculoskeletal System -
22	LG:344886.1:2000MAY19	22%, Nervous System - 11% Germ Cells - 24%, Nervous System - 12%
22	EG.344000.1.2000WA119	Embryonic Structures - 43%, Nervous System - 29%,
		Respiratory System - 14%, Hemic and Immune
23	LG:228930.1:2000MAY19	System - 14%
20	24.22000.1.2000	Digestive System - 23%, Unclassified/Mixed - 21%,
		Embryonic Structures - 19%, Hemic and Immune
24	LG:338927.1:2000MAY19	System - 19%
		Pancreas - 13%, Embryonic Structures - 11%,
		Female Genitalia - 10%, Urinary Tract - 10%, Hemic
	·	and Immune System - 10%, Cardiovascular System -
25	LG:898771.1:2000MAY19	10%
26	LI:257664.67:2000MAY01	Hemic and Immune System - 100%
		Endocrine System - 27%, Female Gentfalla - 25%,
27	LI:001496.2:2000MAY01	Embryonic Structures - 25%
		Digestive System - 29%, Skin - 24%, Endocrine
28	LI:1085273.2:2000MAY01	System - 16%
		Exocrine Glands - 61%, Nervous System - 13%,
29	LI:333138.2:2000MAY01	Nervous System - 11%
		Embryonic Structures - 51%, Digestive System - 17%
30	LI:338927.1:2000MAY01	
	1 A AARMES	Endocrine System - 45%, Nervous System - 18%,
31	LG:335558.1:2000FEB18	Exocrine Glands - 11%
•	, . 	

32	LG:998283.7:2000FEB18	Sense Organs - 33%, Germ Cells - 18% Unclassified/Mixed - 78%, Male Genitalia - 11%,
00	11.400700 4.000055004	•
33	LI:402739.1:2000FEB01	Hemic and Immune System - 11%
34	LI:175223.1:2000FEB01	Embryonic Structures - 99%
		Endocrine System - 28%, Nervous System - 22%,
•	•	Respiratory System - 17%, Female GenItalia - 17%,
35	LG:981076.2:2000MAY19	Hemic and Immune System - 17%
36	LI:1008973.1:2000MAY01	Nervous System - 57%, Digestive System - 41%
37	LI:1190250.1:2000MAY01	Female Genitalia - 48%, Respiratory System - 25%
••		Liver - 23%, Endocrine System - 17%, Hemic and
38	LG:021371.3:2000FEB18	
		Immune System - 17%
39	LG:475404.1:2000FEB18	Skin - 82%
		Liver - 46%, Connective Tissue - 31%, Nervous
40	LG:979406.2:2000FEB18	System - 15%
		Embryonic Structures - 52%, Endocrine System -
41	LG:410726.1:2000FEB18	26%
'		Unclassified/Mixed - 26%, Cardiovascular System -
42	LG:200005.1:2000FEB18	14%, Female Genitalia - 13%
43	LG:1076828.1:2000FEB18	Unclassified/Mixed - 69%, Urinary Tract - 25%
		Unclassified/Mixed - 63%, Musculoskeletal System -
44	LG:1076931.1:2000FEB18	20%, Urinary Tract - 11%
45	LG:1078121.1:2000FEB18	Female Genitalia - 75%, Nervous System - 25%
75	Ed. 10.70121.11.20001 EB10	Female Genitalia - 42%, Cardiovascular System -
46	LG:1079203.1:2000FEB18	33%, Hemic and Immune System - 17%
46	LG:1079203.1.2000FEB18	· · · · · · · · · · · · · · · · · · ·
47		Respiratory System - 100%
48	LG:1082774.1:2000FEB18	Respiratory System - 50%, Female Genitalia - 50%
49	LG:1082775.1:2000FEB18	Female Genitalia - 75%, Nervous System - 25%
50	LG:1083120.1:2000FEB18	Nervous System - 100%
51	LG:1087707.1:2000FEB18	Stomatognathic System - 98%
		Embryonic Structures - 44%, Connective Tissue -
52		19%
53	LG:1094230.1:2000FEB18	
		Connective Tissue - 44%, Exocrine Glands - 44%,
54	LG:474848.3:2000FEB18	Hemic and Immune System - 11%
		Nervous System - 38%, Digestive System - 38%, Male
55	LI:251656.1:2000FEB01	Genitalia - 25%
		Hemic and Immune System - 69%, Endocrine
56	LI:021371.1:2000FEB01	System - 14%
57	LI:133095.1:2000FEB01	Respiratory System - 67%, Nervous System - 13%
		Unclassified/Mixed - 30%, Respiratory System - 19%,
		Nervous System - 13%, Digestive System - 13%
58	LI:236654.2:2000FEB01	
-		Unclassified/Mixed - 37%, Urinary Tract - 16%,
59	LI:200009.1:2000FEB01	Cardiovascular System - 15%
-00	E20000.1.20001 E.Du 1	Unclassified/Mixed - 78%, Musculoskeletal System -
60	LI:758502.1:2000FEB01	·
00	LI.7 30302. 1.2000FEDU1	Noncour System 56% Skip 27% Connective Tissue
64	11:044770 1:000055004	Nervous System - 56%, Skin - 27%, Connective Tissue
61 62	LI:344772.1:2000FEB01	- 13%
62	LI:789445.1:2000FEB01	Endocrine System - 100%
		Urinary Tract - 31%, Female Genitalia - 19%,
		Digestive System - 19%, Hemic and Immune System
63	LI:789657.1:2000FEB01	- 19%
		Exocrine Glands - 44%, Female Genitalia - 33%,
64	LI:789808.1:2000FEB01	Nervous System - 22%
65	LI:792919.1:2000FEB01	Respiratory System - 100%

WO 01/62927 PCT/US01/06059

	•	Female Genitalia - 42%, Endocrine System - 19%,
66	LI:793949.1:2000FEB01	Exocrine Glands - 13%
67	LI:794389.1:2000FEB01	Endocrine System - 100%
68	LI:796010.1:2000FEB01	Exocrine Glands - 100%
69	LI:796324.1:2000FEB01	Female Genitalia - 100%
70	LI:796373.1:2000FEB01	Respiratory System - 100%
71	LI:796415.1:2000FEB01	Nervous System - 100%
72	LI:798636.1:2000FEB01	Hemic and Immune System - 100%
73	LI:800045.1:2000FEB01	Female Genitalia - 60%, Male Genitalia - 40%
74	LI:800680.1:2000FEB01	Cardiovascular System - 100%
75	LI:800894.1:2000FEB01	Respiratory System - 50%, Digestive System - 50%
76	LI:801015.1:2000FEB01	Male Genitalia - 100%
77	LI:801236.1:2000FEB01	Endocrine System - 100%
78	LI:803335.1:2000FEB01	Connective Tissue - 100%
		Nervous System - 38%, Digestive System - 38%, Male
79	LI:803998.1:2000FEB01	Genitalia - 25%
80	LI:478757.1:2000FEB01	Digestive System - 100%
81	LI:808532.1:2000FEB01	Hemic and Immune System - 100%
82	LI:443073.1:2000FEB01	Digestive System - 100%
	· _ 1	Exocrine Glands - 80%, Hemic and Immune System
83	LI:479671.1:2000FEB01	- 20%
84	LI:810078.1:2000FEB01	Digestive System - 100%
85	LI:810224.1:2000FEB01	Digestive System - 100%
		Nervous System - 24%, Unclassified/Mixed - 18%,
86	LI:817052.2:2000FEB01	Exocrine Glands - 14%
		Embryonic Structures - 63%, Digestive System - 30%
87	LG:892274.1:2000MAY19	
		Digestive System - 40%, Respiratory System - 30%,
88	LG:1080959.1:2000MAY19	Hemic and Immune System - 30%
89	LG:1054900.1:2000MAY19	
		Nervous System - 38%, Female Genitalia - 38%,
90	LG:1077357.1:2000MAY19	
	10400405440000440440	Pancreas - 31%, Digestive System - 22%, Hemic and
91	LG:1084051.1:2000MAY19	
		Female Genitalia - 23%, Unclassified/Mixed - 23%,
00	10.4070000 4.0000144\/40	Cardiovascular System - 18%, Exocrine Glands -
92	LG:1076853.1:2000MAY19	
02	LC:481631 10:3000MAV10	Female Genitalia - 22%, Nervous System - 17%,
93	LG.461631.10:2000WA119	Exocrine Glands - 17%, Urinary Tract - 17%
94	LG:1088431.2:2000MAY19	Exocrine Glands - 67%, Cardiovascular System -
34	LG. 1000431.2.2000WAT19	
95	LI:401619.10:2000MAY01	Endocrine System - 18%, Embryonic Structures -
33	LI.401019.10.2000IMA101	16%, Pancreas - 15% Hamia and Immuna System 27% Famala
96	LI:1144007.1:2000MAY01	Hemic and Immune System - 27%, Female
30	LI.1144007.1.2000WA101	Genitalia - 13% Endocrine System - 28%, Sense Organs - 22%,
97	Ll:331074.1:2000MAY01	
98	LI:1170349.1:2000MAY01	Connective Tissue - 10% Endocrine System - 91%
55	EI.1170070.1.2000IVIA101	Embryonic Structures - 24%, Musculoskeletal System
99	LG:335097.1:2000FEB18	- 19%, Nervous System - 16%
100	LG:1076451.1:2000FEB18	- 17 0, 14010003 System - 1076
101	LI:805478.1:2000FEB01	Skin - 100%
101	-1.000-7.0.1.20001 LD01	
		Endocrine System - 3396 Embryonic Structures -
102	LG:101269 1·2000MAY19	Endocrine System - 33%, Embryonic Structures - 33%, Uringay Tract - 30%
102 103	LG:101269.1:2000MAY19 LI:331087.1:2000MAY01	Endocrine System - 33%, Embryonic Structures - 33%, Urinary Tract - 30% Liver - 82%, Hemic and Immune System - 13%



,		Cardiovascular System - 81%, Cardiovascular
104	LI:410188.1:2000MAY01	System - 12%
105	LI:1188288.1:2000MAY01	Nervous System - 73%
	· · ·	Liver - 16%, Male Genitalia - 13%, Embryonic
106	LI:427997.4:2000MAY01	Structures - 11%
107	LG:451682.1:2000FEB18	Nervous System - 100%
108	LG:1077283.1:2000FEB18	Liver - 86%, Hemic and Immune System - 14%
		Embryonic Structures - 41%, Endocrine System -
109	LG:481436.5:2000FEB18	20%, Hemic and Immune System - 13%
	•	Endocrine System - 43%, Urinary Tract - 36%,
110	LI:793701.1:2000FEB01	Respiratory System - 21%
111	LI:373637.1:2000FEB01	Germ Cells - 74%, Unclassified/Mixed - 16%
		Digestive System - 43%, Male Genitalia - 24%,
112	LG:239368.2:2000MAY19	Endocrine System - 24%
		Germ Cells - 66%, Unclassified/Mixed - 22%, Male
113	LI:053826.1:2000MAY01	Genitalia - 12%
114	LI:449393.1:2000MAY01	Nervous System - 100%
115	LI:1071427.96:2000MAY01	,
116	LI:336338.8:2000MAY01	Unclassified/Mixed - 55%, Connective Tissue - 26%
	·	Urinary Tract - 24%, Hemic and Immune System -
117	LG:345527.1:2000FEB18	24%, Respiratory System - 18%
118	LG:1089383.1:2000FEB18	
		Female Genitalia - 38%, Exocrine Glands - 31%,
440	1.0.4000000.4.000000000	Male Genitalia - 15%, Hemic and Immune System -
119	LG:1092522.1:2000FEB18	15%
120	LG:1093216.1:2000FEB18	Urinary Tract - 100%
404	11.070040 0.0000EEB04	Embryonic Structures - 86%, Hemic and Immune
121	LI:270318.3:2000FEB01	System - 14% Unalgorited (Mixed 24% Hemio and Immune
122	LI:335671.2:2000FEB01	Unclassified/Mixed - 34%, Hemic and immune
123	LI:793758.1:2000FEB01	System - 20%, Urinary Tract - 17% Nervous System - 62%, Urinary Tract - 38%
123	LI:803718.1:2000FEB01	Female Genitalia - 100%
125	LI:412179.1:2000FEB01	Endocrine System - 100%
126	LI:815679.1:2000FEB01	Digestive System - 75%
120	21.01.007.011.20001.2001	Embryonic Structures - 28%, Skin - 20%,
127	LI:481361.3:2000FEB01	Unclassified/Mixed - 16%
	2.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Cardiovascular System - 33%, Endocrine System -
128	LG:247388.1:2000MAY19	21%, Male Genitalia - 21%
129	LG:255789.10:2000MAY19	
		Endocrine System - 22%, Digestive System - 13%,
130	LI:787618.1:2000MAY01	Endocrine System - 12%
		Sense Oraans - 18%. Nervous System - 11%.

	_	Digestive System - 34%, Liver - 17%, Female
139	LG:337818.2:2000FEB18	Genitalia - 11%
		Digestive System - 27%, Liver - 19%, Female
140	Ll:337818.1:2000FEB01	Genitalia - 15%
		Pancreas - 48%, Endocrine System - 24%,
141	LG:241577.4:2000MAY19	Respiratory System - 14%
		Respiratory System - 67%, Digestive System - 22%,
142	LG:344786.4:2000MAY19	Nervous System - 11%
		Endocrine System - 44%, Unclassified/Mixed - 17%,
143	LI:414307.1:2000FEB01	Nervous System - 11%
144	LI:202943.2:2000FEB01	Embryonic Structures - 100%
145	LI:246194.2:2000FEB01	Germ Cells - 75%, Pancreas - 13%
146	LI:815961.1:2000FEB01	Digestive System - 99%
		Skin - 33%, Embryonic Structures - 21%, Digestive
147	LG:120744.1:2000MAY19	System - 21%
		Musculoskeletal System - 45%, Cardiovascular
148	LI:757520.1:2000MAY01	System - 26%, Skin - 24%
149	LG:160570.1:2000FEB18	Skin - 84%, Female Genitalia - 16%
		Male Genitalia - 50%, Hemic and Immune System -
150	LI:350398.3:2000FEB01	50%
151	LI:221285.1:2000FEB01	Endocrine System - 42%, Nervous System - 21%
153	LI:329017.1:2000FEB01	Endocrine System - 62%, Unclassified/Mixed - 24%
154	LI:401322.1:2000FEB01	Sense Organs - 44%, Liver - 22%, Skin - 14%
		Respiratory System - 18%, Female Genitalia - 16%,
155	LG:403409.1:2000MAY19	Cardiovascular System - 13%
156	LG:233933.5:2000MAY19	Digestive System - 100%
		Connective Tissue - 40%, Nervous System - 19%,
157	LI:290344.1:2000MAY01	Embryonic Structures - 12%
158	LI:410742.1:2000MAY01	Respiratory System - 47%, Skin - 42%
	•	Stomatognathic System - 57%, Musculoskeletal
159	LG:406568.1:2000MAY19	System - 21%, Cardiovascular System - 16%
160	LI:283762.1:2000MAY01	Sense Organs - 25%
161	LI:347687.113:2000MAY01	Nervous System - 45%, Nervous System - 38%
162	LI:1146510.1:2000MAY01	Skin - 94%
163	LG:451710.1:2000FEB18	Connective Tissue - 89%, Nervous System - 11%
164	LG:455771.1:2000FEB18	Nervous System - 100%
165	LG:452089.1:2000FEB18	Nervous System - 100%
166	LG:246415.1:2000FEB18	Pancreas - 83%, Nervous System - 17%
		Cardiovascular System - 17%, Connective Tissue -
167	LG:414144.10:2000FEB18	12%
168	LG:1101445.1:2000FEB18	Liver - 91%
		Hemic and Immune System - 64%, Male Genitalia -
169	LG:452134.1:2000FEB18	36%
170	LI:903021.1:2000FEB01	Male Genitalia - 100%
171	LI:246422.1:2000FEB01	Hemic and Immune System - 100%
172	LG:449404.1:2000MAY19	Nervous System - 100%
173	LG:449413.1:2000MAY19	Nervous System - 100%
174	LG:450105.1:2000MAY19	Nervous System - 100%
175	LG:460809.1:2000MAY19	Exocrine Glands - 100%
176	LG:481781.1:2000MAY19	Nervous System - 100%
177	LG:1101153.1:2000MAY19	
		Exocrine Glands - 28%, Endocrine System - 19%,
178	LI:257695.20:2000MAY01	Nervous System - 16%, Digestive System - 16%
179	LI:455771.1:2000MAY01	Nervous System - 100%
		Nervous System - 60%, Hemic and Immune System -
180	LI:274551.1:2000MAY01	40%

•	•	Embryonic Structures - 58%, Digestive System - 26%,
181	LI:035973.1:2000MAY01	Nervous System - 16%
182	LG:978427.5:2000FEB18	Nervous System - 100%
183	LG:247781.2:2000FEB18	Nervous System - 11%
184	LI:034583.1:2000FEB01	Nervous System - 35%, Endocrine System - 35%
٠.		Cardiovascular System - 28%, Urinary Tract - 27%,
185	LI:333307.2:2000FEB01	Musculoskeletal System - 17%
186	LI:814710.2:2000FEB01	Respiratory System - 100%
187	LG:414732.1:2000MAY19	Endocrine System - 82%, Nervous System - 18%
		Connective Tissue - 55%, Nervous System - 15%,
188	LG:413910.6:2000MAY19	Embryonic Structures - 13%
18 9	LI:414732.2:2000MAY01	Endocrine System - 80%, Nervous System - 20%
190	LI:900264.2:2000MAY01	Urinary Tract - 15%, Male Genitalia - 12%
•		Urinary Tract - 46%, Endocrine System - 17%, Germ
191	LI:335593.1:2000MAY01	Cells - 14%
		Stomatognathic System - 35%, Digestive System -
192	LI:1189543.1:2000MAY01	14%
193	LG:455450.1:2000FEB18	Nervous System - 100%
194	LG:1040978.1:2000FEB18	Nervous System - 100%
195	LG:446649.1:2000FEB18	Liver - 80%, Hemic and Immune System - 13%
		Unclassified/Mixed - 17%, Sense Organs - 16%,
196	LG:132147.3:2000FEB18	Embryonic Structures - 10%
197	LI:036034.1:2000FEB01	Nervous System - 80%
		Unclassified/Mixed - 53%, Cardlovascular System -
198	LG:162161.1:2000MAY19	21%, Nervous System - 16%
		Unclassified/Mixed - 40%, Respiratory System - 24%,
199	LG:407214.10:2000MAY19	
	1.0.00.1.000.1.000.1.1.1.1.1.0	Digestive System - 41%, Exocrine Glands - 24%,
200	LG:204626.1:2000MAY19	Female Genitalia - 18%
004	11007404 4 00001411/04	Unclassified/Mixed - 31%, Nervous System - 25%,
201	LI:007401.1:2000MAY01	Urinary Tract - 11%
202	LI:476342.1:2000MAY01	Connective Tissue - 77%, Nervous System - 23%
000	11.4070750 4.00001441/04	Hemic and Immune System - 27%, Musculoskeletal
203	LI:1072759.1:2000MAY01	System - 19%, Endocrine System - 11%
204	LG:998857.1:2000FEB18	Digestive System - 58%, Pancreas - 12%
205	LG:482261.1:2000FEB18	Male Genitalia - 85%, Respiratory System - 15%
206	LG:480328.1:2000FEB18	Skin - 20%, Germ Cells - 18%, Female Genitalia -
206	LG.400326.1.2000FEB16	10% - Lacetive System 15% Male
207	LG:311197.1:2000MAY19	Germ Cells - 44%, Digestive System - 15%, Male
208	LG:1054883.1:2000MAY19	Genitalia - 11% Endocrine System - 100%
209	LG:399395.1:2000MAY19	Hemic and Immune System - 100%
200	EG.000000.1.2000WF(119	Germ Cells - 23%, Exocrine Glands - 14%,
210	LG:380497.2:2000MAY19	Connective Tissue - 13%
211	LI:272913.22:2000MAY01	Female Genitalia - 100%
2.11	LILE ZU I GLEZ ZUUUIVIA I U I	remaie Gennana - 10070

	nnotation	aldehyde reductase [Hattus norvegicus]	aidehyde reductase [Mus musculus]	aldehyde reductase [Homo sapiens]	Glyoxalase I [Cicer arietinum]	Glyoxalase I (Brassica juncea)	glyoxalase-I [Lycopersicon esculentum]	луроthetical protein [Ното saplens]	collapsin response mediator protein-5 [Homo sapiens]	Jlip-like protein [Rattus norvegicus]	carbonic anhydrase I (AA 1-261) [Homo sapiens]	carbonic anhydrase I (EC 4.2.1.1) [Homo sapiens]	carbonic anhydrase II (AA 1-260) [Homo sapiens]	unnamed protein product [Homo sapiens]	probable acetyl-coa synthetase [Pseudomonas aeruginosa]	prpE protein [Vibrio cholerae]	alpha glucosidase II, alpha subunit [Mus musculus]	glucosidase II alpha subunit [Homo sapiens]	The ha1225 gene product is related to human alpha-glucosidase. [Homo	sapiens]	ornithine decarboxylase-2 [Xenopus laevis]	omithine decarboxylase [Mus pahari]	ornithine decarboxylase [Mus musculus]	unnamed protein product [Homo sapiens]	similar to C. elegans R10H10.6 and S. cerevisiae YD8419.03c [Drosophila	melanogaster]	CG2846 gene product [Drosophila melanogaster]	fransglutaminase E3 [Homo sapiens]	IGM3 (PHOLEIN-GLUTAMINE GLUTAMYLI HANSFEHASE E3 PRECURSOR (EC 2.3.2.13) (TGASE E3) (TRANSGLUTAMINASE 3).) [Homo	sapiens]	ıransglutaminase E3 [Mus musculus]			
	core			-	2.00E-60 G	2.00E-58 G	4.00E-57 g	<u> </u>	•	_				_			1.00E-111 a	1.00E-111 g	_	~			1.00E-17 o	л О		1.00E-164 u	3.00E-92 u		_	3.00E-49 C	0	~ CL	s 0	. O
	GI Number	9399660	g7677318	g6013149	g2909424	g2113825	g1177314	g8671168	g8886025	g8671360	g29600	g179793	g29587	g10438188	g9949721	g9655831	g2104689	g7672977		g577295	g9653274	g200124	g53518	g10435462	g7023375	g10433608	g7023634		g3213202	g7298960	g307504		g4467804	g309521
	Stop	542	542	545	485	485	485	266	266	266	833	833			1287	1287	1078	1078		1078	490	490							792	792	2135		2135	2135
	Start	198	198	198	က	က	က	0	0	0	42	12	12	742	742	742	Ø	N		7	161	161	161	98	98	ဗ္တ	-		-	-	33		88	33
	Length	115	115	115	161	161	161	332	332	332	274	274	274	182	182	182	329	329		329	110	110	110	549	549	549	264		264	264	701		701	701
TARIER	Frame	က	က	က	က	က	က	8	α	8	က	က	က	-	· •	-	8	7		8	8	٥	Q	က	က	က	-		-	•	က		က	ღ
-	SEQ ID NO:	212	212	212	213	213	213	214	214	214	215	215	215	216	216	216	217	217		217	218	218	218	219	219	219	220		220	220	221		221	221

	•																																	
miz-type pyruvate kiriase [norm sapterts] pyruvate kinase; ATP:pyruvate 2-o-phosphotransferase [Oryctolagus	cuniculus]	arylsulphatase [Homo sapiens]	ARSD [Homo sapiens]	ARSE [Homo sapiens]		BC319430_7 [Homo sapiens]	olfactory receptor [Homo sapiens]	BC319430_5 [Homo sapiens]	envelope protein [Homo sapiens]	envelope protein precursor [Homo sapiens]	envelope protein [Homo sapiens]	hypothetical protein [Macaca fascicularis]	unnamed protein product [Homo sapiens]	unnamed protein product [Homo sapiens]	unknown protein U5/2 [multiple sclerosis associated retrovirus element]	serine/threonine kinase [Mus musculus]	protein kinase [Mus musculus]	testis specific serine kinase-3 [Mus musculus]	Ras like GTPase [Homo sapiens]	Rar protein [Homo sapiens]	match: multiple proteins; RAR (RAS like GTPASE) like [Homo sapiens]	dJ593C16.1 (ras GTPase activating protein) [Homo sapiens]	synGAP-d [Rattus norvegicus]	nGAP [Homo sapiens]	The KIAA0147 gene product is related to adenylyl cyclase. [Homo sapiens]	vartul-2 protein [Drosophila melanogaster]	Vartul-1 protein [Drosophila melanogaster]	kappa B-ras 1 [Homo sapiens]	kappaB-Ras1 [Mus musculus]	kappa B-ras 2 [Homo sapiens]	phospholipase C-beta-1a [Homo sapiens]	phospholipase C-beta-1b [Homo sapiens]	phospholipase C-1 [Rattus sp.]	
CO-3007	3.00E-64	1.00E-128	3.00E-82	4.00E-75		8.00E-62	2.00E-54	2.00E-54	4.00E-15	4.00E-15	4.00E-15	1.00E-11	3.00E-10	2.00E-09	3.00E-18	1.00E-59	3.00E-59	2.00E-54	1.00E-160	1.00E-140	1.00E-102	1.00E-66	1.00E-66	1.00E-66	1.00E-103	1.00E-86	1.00E-86	1.00E-107	1.00E-103	8.00E-75	1.00E-111	1.00E-111	1.00E-110	
0 (03330	g2623945	g2576305	g791002	g791004		g4092820	g2792016	g4092819	g8272468	g4773880	g4262296	g11231093	g10435559	g7020625	g5726235	g404634	g2738898	g8101585	g2117166	g466271	g3036779	95763838	g4417207	g4105589	g1469876	g6850952	g6782322	g7008402	g7239257	g7008404	g9368448	g9368450	g206218	
0																																		
V	8	998	998	998	8	1049	1049	1049	86	88	86	79	79	79	836	α	7	~	-		-	40	6	4	28	28	28	370	370	370	17	17	17	
2	150	234	234	234	88	173	173	173	89	99	89	2	20	20	117	294	294	294	326	326	326	182	182	182	358	358	358	194	194	194	222	222	222	
N	8	8	8	8	8	8	7	8	8	7	8	-		-	8	8	01	7	-	-	-	-	-	-	-	-	,- -	-	-		8	α	8	
7	222	223	223	223	224	225	225	225	226	226	526	227	227	227	228	529	229	529	230	230	230	231	231	23-	232	232	232	233	233	233	234	234	234	
	2 150 2 451 g189998 7.00E-65	2 150 2 451 g169996 7.00E-65 2 150 2 451 g2623945 3.00E-64	2 150 2 451 g169998 7.00E-65 2 150 2 451 g2623945 3.00E-64 2 234 866 1567 g2576305 1.00E-128	2 150 2 451 g169598 7.00E-65 2 150 2 451 g2623945 3.00E-64 2 234 866 1567 g2576305 1.00E-128 2 234 866 1567 g791002 3.00E-82	2 150 2 451 g169998 7.00E-65 2 150 2 451 g2623945 3.00E-64 2 234 866 1567 g2576305 1.00E-128 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791004 4.00E-75	2 150 2 451 g169998 7.00E-65 2 234 866 1567 g2576305 1.00E-128 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791004 4.00E-75 2 86 2 259	2 150 2 451 g169598 7.00E-65 2 234 866 1567 g2576305 1.00E-128 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791004 4.00E-75 2 23 86 2 259 2 173 1049 1567 g4092820 8.00E-62	2 150 2 451 g169598 7.00E-65 2 234 866 1567 g2576305 1.00E-128 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791004 4.00E-75 2 234 866 1567 g791004 4.00E-75 2 86 2 259 2 173 1049 1567 g4092820 8.00E-62 2 173 1049 1567 g2792016 2.00E-54	2 150 2 451 g169598 7.00E-65 2 234 866 1567 g2576305 1.00E-128 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791004 4.00E-75 2 86 2 259 2 173 1049 1567 g4092820 8.00E-62 2 173 1049 1567 g4092819 2.00E-54	2 150 2 451 g169598 7.00E-65 2 234 866 1567 g2576305 1.00E-128 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791004 4.00E-75 2 86 2 259 2 173 1049 1567 g4092820 8.00E-62 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 68 86 289 g8272468 4.00E-15	2 150 2 451 g169598 7.00E-65 2 234 866 1567 g2576305 1.00E-128 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791004 4.00E-75 2 86 2 259 2 173 1049 1567 g4092820 8.00E-62 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 68 86 289 g8272468 4.00E-15 2 68 86 289 g4773880 4.00E-15	2 150 2 451 g169598 7.00E-65 2 234 866 1567 g2576305 1.00E-128 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791004 4.00E-75 86 2 259 2 173 1049 1567 g4092820 8.00E-62 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 173 86 289 g8272468 4.00E-15 2 68 86 289 g4773880 4.00E-15 2 68 86 289 g4262296 4.00E-15	2 150 2 451 g169598 7.00E-65 2 234 866 1567 g2576305 1.00E-128 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791004 4.00E-75 8 2 259 2 173 1049 1567 g4092820 8.00E-62 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 68 86 289 g4262296 4.00E-15 2 68 86 289 g4262296 4.00E-15 1 70 79 288 g11231093 1.00E-11	2 150 2 451 g169598 7.00E-65 2 234 866 1567 g2576305 1.00E-128 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791004 4.00E-75 8 2 259 2 173 1049 1567 g4092820 8.00E-62 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 68 86 289 g4773880 4.00E-15 68 86 289 g4773880 4.00E-15 1 70 79 288 g11231093 1.00E-11 1 70 79 288 g11231093 1.00E-11	2 150 2 451 g163936 7.00E-63 2 234 866 1567 g2576305 1.00E-128 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791004 4.00E-75 2 234 866 1567 g791004 4.00E-75 2 173 1049 1567 g4092820 8.00E-62 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 68 86 289 g4272468 4.00E-15 2 68 86 289 g4262236 4.00E-15 1 70 79 288 g10435559 3.00E-10 1 70 79 288 g10435559 2.00E-09	2 150 2 451 g169596 7.00E-65 2 234 866 1567 g2576305 1.00E-128 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791004 4.00E-75 86 2 259 2 173 1049 1567 g4092820 8.00E-62 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 68 86 289 g8272468 4.00E-15 68 86 289 g4262296 4.00E-15 1 70 79 288 g11231093 1.00E-11 1 70 79 288 g10435559 3.00E-10 1 70 79 288 g7020625 2.00E-09 2 117 836 1186 g5726235 3.00E-18	2 150 2 451 g163936 7.00E-63 2 234 866 1567 g2576305 1.00E-128 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791004 4.00E-75 8 2 259 8.00E-62 2 173 1049 1567 g4092820 8.00E-62 1 173 1049 1567 g2792016 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 68 86 289 g4262296 4.00E-15 68 86 289 g4262296 4.00E-15 1 70 79 288 g11231093 1.00E-11 1 70 79 288 g10435559 3.00E-10 1 70 79 288 g7020625 2.00E-09 2 294 2 883 g404634 1.00E-59	2 150 2 451 g163936 7.00E-63 2 234 866 1567 g2576305 1.00E-128 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791004 4.00E-75 8 2 259 8.00E-62 173 1049 1567 g4092820 8.00E-62 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 68 86 289 g4272468 4.00E-15 68 86 289 g4773880 4.00E-15 68 86 289 g4773880 4.00E-15 1 70 79 288 g11231093 1.00E-11 1 70 79 288 g10435559 3.00E-10 1 70 79 288 g7020625 2.00E-09 2 294 2 883 g404634 1.00E-59 2 294 2 883 g2738898 3.00E-18	2 150 2 451 g163936 7.00E-63 234 866 1567 g2576305 1.00E-128 234 866 1567 g791002 3.00E-82 234 866 1567 g791004 4.00E-75 86 2 259 86 2 259 800E-62 173 1049 1567 g4092820 8.00E-62 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 68 86 289 g4262296 4.00E-15 68 86 289 g4262296 4.00E-15 1 70 79 288 g11231093 1.00E-11 1 70 79 288 g10435559 3.00E-10 1 70 79 288 g7020625 2.00E-09 117 836 1186 g5726235 3.00E-18 2 294 2 883 g2738898 3.00E-59 294 2 883 g8101585 2.00E-54	2 150 2 451 g163936 7.00E-63 2 234 866 1567 g2576305 1.00E-128 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791004 4.00E-75 8 2 259 8.00E-62 173 1049 1567 g4092820 8.00E-62 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 68 86 289 g4262296 4.00E-15 68 86 289 g4262296 4.00E-15 1 70 79 288 g10435559 3.00E-10 1 326 1186 g5726235 3.00E-18 2 294 2 883 g8101585 2.00E-59 1 326 1 978 g2117166 1.00E-160	2 150 2 451 g163936 7.00E-63 2 234 866 1567 g2576305 1.00E-128 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791004 4.00E-75 8 2 259 8.00E-62 2 173 1049 1567 g4092820 8.00E-62 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-15 6 8 86 289 g4262296 4.00E-15 6 8 86 289 g4262296 4.00E-15 1 70 79 288 g10435559 3.00E-10 1 70 79 288 g10435559 3.00E-10 1 70 79 288 g10435559 3.00E-10 2 294 2 883 g404634 1.00E-59 2 294 2 883 g2738898 3.00E-59 2 294 2 883 g2738898 3.00E-59 1 326 1 978 g2117166 1.00E-140	2 150 2 451 g168936 7.00E-65 2 234 866 1567 g2576305 1.00E-128 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791004 4.00E-75 86 2 259 3.00E-82 2 173 1049 1567 g4092820 8.00E-62 1 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 1.00E-15 68 86 289 g4262296 4.00E-15 68 86 289 g4262296 4.00E-15 1 70 79 288 g10435559 3.00E-10 1 70 79 288 g10435559 3.00E-10 1 70 79 288 g10435559 3.00E-10 2 294 2 883 g404634 1.00E-59 2 294 2 883 g2738898 3.00E-54 2 294 2 883 g2738898 3.00E-54 1 326 1 978 g2117166 1.00E-160 1 326 1 978 g3036779 1.00E-102	2 150 2 451 g168986 7.00E-65 2 234 866 1567 g2576305 1.00E-128 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791004 4.00E-75 8 2 259 8.00E-62 2 173 1049 1567 g4092820 8.00E-62 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 68 86 289 g4262296 4.00E-15 68 86 289 g4262296 4.00E-15 68 86 289 g4262296 4.00E-15 1 70 79 288 g11231093 1.00E-11 1 70 79 288 g10435559 3.00E-10 1 70 79 288 g7020625 2.00E-09 2 294 2 883 g404634 1.00E-59 2 294 2 883 g2738898 3.00E-16 1 326 1 978 g2117166 1.00E-160 1 326 1 978 g3036779 1.00E-140 1 326 1 978 g3036779 1.00E-140	2 150 2 451 g168398 7.00E-65 2 234 866 1567 g2576305 1.00E-128 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791004 4.00E-75 86 2 259 8.00E-62 2 173 1049 1567 g4092820 8.00E-62 1 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-15 68 86 289 g4262296 4.00E-15 68 86 289 g4773880 4.00E-15 1 70 79 288 g11231093 1.00E-11 1 70 79 288 g10435559 3.00E-10 1 70 79 288 g10435559 1.00E-16 2 294 2 883 g2738898 3.00E-16 1 326 1 978 g2117166 1.00E-160 1 326 1 978 g2036779 1.00E-160 1 182 40 585 g5763838 1.00E-66	2 150 2 451 g168986 7.00E-05 150 2 234 866 1567 g2576305 1.00E-128 234 866 1567 g791002 3.00E-64 6 234 866 1567 g791004 4.00E-75 7 86 2 259 3.00E-62 173 1049 1567 g792016 2.00E-54 6 8 86 289 g4272468 4.00E-15 6 8 86 289 g4272380 4.00E-15 6 8 86 289 g4262296 4.00E-15 6 8 86 289 g4262296 4.00E-15 6 8 86 289 g4262296 4.00E-15 6 8 86 289 g4262296 4.00E-15 6 1 70 79 288 g10231093 1.00E-11 70 79 288 g7020625 2.00E-09 1 70 79 288 g7020625 2.00E-09 1 1 326 1186 g5726235 3.00E-18 1 326 1 978 g46271 1.00E-160 1 326 1 978 g46271 1.00E-160 1 326 1 978 g4773838 1.00E-160 1 326 1 978 g4773838 1.00E-66 1 182 40 585 g471207 1.00E-66 1 182 40 585 g471207 1.00E-66 1	2 150 2 451 g168998 7.00E-69 2 234 866 1567 g2576305 1.00E-128 2 234 866 1567 g791002 3.00E-64 2 234 866 1567 g791004 4.00E-75 8 2 259 8.00E-62 2 173 1049 1567 g4092820 8.00E-62 1 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 1 70 79 288 g10435559 3.00E-10 1 70 79 288 g1043559 3.00E-10 2 294 2 883 g404634 1.00E-59 2 294 2 883 g2738898 3.00E-59 2 294 2 883 g2738898 3.00E-59 2 294 2 883 g2738898 3.00E-160 1 326 1 978 g266271 1.00E-160 1 326 1 978 g466271 1.00E-160 1 326 1 978 g471707 1.00E-66 1 182 40 585 g4417207 1.00E-66 1 182 40 585 g4105589 1.00E-66 1 358 58 1131 g1469876 1.00E-103	2 150 2 451 g2623945 7.00E-69 150 2 234 866 1567 g2576305 1.00E-128 2 234 866 1567 g791002 3.00E-82	2 150 2 451 g168986 7.00E-05 150 2 234 866 1567 g2576305 1.00E-128 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791004 4.00E-75 2 234 866 1567 g791004 4.00E-75 2 234 866 1567 g791004 4.00E-75 2 234 866 1567 g791004 4.00E-75 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 173 1049 1567 g4092819 2.00E-54 2 68 86 289 g4262296 4.00E-15 6 8 86 289 g473380 4.00E-15 6 8 86 289 g473380 4.00E-15 6 1 70 79 288 g11231093 1.00E-11 1 70 79 288 g10435559 3.00E-10 1 1 70 79 288 g10435559 3.00E-10 1 1 20 1 978 g2117166 1.00E-59 1 326 1 978 g2117166 1.00E-16 1 1 82 40 585 g417207 1.00E-16 1 1 82 40 585 g417207 1.00E-16 1 1 82 40 585 g417207 1.00E-66 1 358 58 1131 g6850952 1.00E-86	2 150 2 451 g169398 7.00E-69 150 2 345 g2623945 3.00E-64 2 234 866 1567 g791004 4.00E-75 8 234 866 1567 g791004 4.00E-75 8 2 234 866 1567 g791004 4.00E-75 8 2 234 866 1567 g791004 4.00E-75 8 6 2 259 g477380 8.00E-62 173 1049 1567 g2792016 2.00E-54 2 68 86 289 g477380 4.00E-15 6 8 86 289 g477380 4.00E-15 6 8 86 289 g477380 4.00E-15 6 8 86 289 g477380 4.00E-15 6 170 79 288 g11231093 1.00E-11 1 70 79 288 g7020625 2.00E-09 1 70 79 288 g7020625 2.00E-09 1 70 79 288 g7020625 2.00E-09 1 326 1 978 g2738898 3.00E-16 1 326 1 978 g2738898 1.00E-16 1 326 1 978 g3036779 1.00E-160 1 182 40 585 g417207 1.00E-102 1 182 40 585 g417207 1.00E-103 1 358 58 1131 g6850952 1.00E-86 1 358 58 1131 g6850952 1.00E-86 1 358 58 1131 g6850952 1.00E-86 1 194 370 951 g7008402 1.00E-107 1	2 150 2 451 g168986 7.00E-05 7.00E-05 234 866 1567 g2576305 1.00E-128 234 866 1567 g791004 4.00E-75 8 234 866 1567 g792820 8.00E-62 173 1049 1567 g2792016 2.00E-54 2 173 1049 1567 g2792016 2.00E-54 2 88 6 289 g4272468 4.00E-15 6 8 86 289 g4773880 4.00E-15 6 8 86 289 g4773880 4.00E-15 1 70 79 288 g11231093 1.00E-11 1 70 79 288 g7020625 2.00E-09 1 70 79 288 g7020625 2.00E-09 1 70 79 288 g7020625 2.00E-09 1 326 1 978 g2738898 3.00E-16 1 326 1 978 g2738898 3.00E-16 1 326 1 978 g3036779 1.00E-160 1 182 40 585 g417207 1.00E-160 1 182 40 585 g417207 1.00E-102 1 182 40 585 g4105589 1.00E-66 1 358 58 1131 g6850952 1.00E-86 1 358 58 1131 g6850952 1.00E-86 1 194 370 951 g7038475 1.00E-103 1 194 370 951 g7239257 1.00E-103	2 150 2 451 g2623945 7.00E-05 2 451 g2623945 3.00E-64 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791004 4.00E-75 2 234 866 1567 g791004 4.00E-75 2 234 866 1567 g292016 2.00E-54 2 173 1049 1567 g292016 2.00E-54 2 173 1049 1567 g292016 2.00E-54 2 88 g2722016 2.00E-54 2 88 g2722016 2.00E-15 1 70 79 288 g11231093 1.00E-11 1 70 79 288 g1043559 3.00E-10 1 70 79 288 g10435559 3.00E-10 1 70 79 288 g10435559 3.00E-10 1 326 1 978 g26177166 1.00E-160 1 326 1 978 g26177166 1.00E-160 1 1 82 40 585 g477207 1.00E-160 1 1 82 40 585 g4705889 1.00E-102 1 182 40 585 g470589 1.00E-66 1 1 82 40 585 g470589 1.00E-103 358 58 1131 g6850952 1.00E-86 1 194 370 951 g7008404 8.00E-75 1 194 370 951 g7008404 8.00E-75 1	2 150 2 451 g2623945 7.00E-05 234 866 1567 g2576305 1.00E-128 234 866 1567 g791002 3.00E-82 234 866 1567 g791002 3.00E-82 234 866 1567 g791004 4.00E-75 2 234 866 1567 g791004 4.00E-75 2 234 866 1567 g791004 4.00E-75 2 234 866 1567 g791004 4.00E-62 2 173 1049 1567 g2792016 2.00E-54 2 173 1049 1567 g2792016 2.00E-54 2 173 1049 1567 g2792016 2.00E-54 2 88 g2722635 3.00E-15 1 70 79 288 g11231093 1.00E-11 1 70 79 288 g1043559 3.00E-10 1 70 79 288 g10435559 3.00E-10 1 70 79 288 g10435559 3.00E-10 1 326 1 978 g2738898 3.00E-59 1 326 1 978 g26177166 1.00E-160 1 326 1 978 g26177166 1.00E-160 1 182 40 585 g477207 1.00E-160 1 182 40 585 g4705897 1.00E-102 1 182 40 585 g4105589 1.00E-66 1 1 958 58 1131 g6850952 1.00E-86 1 1 958 59388448 1.00E-103 1 958 58 1131 g6850952 1.00E-103 1 958 59388448 1.00E-103 1 958 593884	2 150 2 451 g2623945 7.00E-05 2 451 g2623945 3.00E-64 2 234 866 1567 g2576305 1.00E-128 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791002 3.00E-82 2 234 866 1567 g791004 4.00E-75 8 2 259 2 259 2 259 2 259 2 259 2 259 2 2792016 2.00E-54 1 70 79 288 g11231093 1.00E-15 6 8 86 289 g4262296 4.00E-15 6 8 8 289 g4262296 4.00E-15 6 8 8 2 294 2 88 g1043559 3.00E-10 1 70 79 288 g1043559 3.00E-10 1 326 1 978 g2177166 1.00E-160 1 326 1 978 g2177167 1.00E-160 1 326 1 978 g2177167 1.00E-160 1 326 1 978 g2177167 1.00E-160 1 326 1 978 g2177167 1.00E-160 1 326 1 978 g2177167 1.00E-160 1 326 1 978 g217207 1.00E-160 1 326 1 970 951 g7008404 8.00E-75 1 1 194 370 951 g7008404 8.00E-75 1 1 194 370 951 g7008404 8.00E-75 1 1 194 370 951 g7008404 8.00E-75 1 10E-111 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	150 2 451 g2623945 7.00E-05 234 866 1567 g2576305 1.00E-128 234 866 1567 g791002 3.00E-62 234 866 1567 g791004 4.00E-75 86 2 259 3791004 4.00E-75 86 2 259 3791004 4.00E-75 173 1049 1567 g2792016 2.00E-54 173 1049 1567 g2792016 2.00E-54 173 1049 1567 g2792016 2.00E-54 173 1049 1567 g2792016 2.00E-54 173 1049 1567 g2792016 2.00E-54 173 1049 1567 g2792016 2.00E-54 173 1049 1567 g2792016 2.00E-54 173 1049 1567 g2792016 2.00E-54 173 1049 1567 g2792016 2.00E-65 117 836 1186 g5726235 3.00E-15 68 86 289 g4773880 4.00E-15 68 86 289 g4773880 4.00E-15 68 86 289 g4773880 4.00E-15 68 86 289 g4773880 1.00E-10 17 836 1186 g5726235 3.00E-10 182 40 585 g4417207 1.00E-66 182 40 585 g4417207 1.00E-66 182 40 585 g4417207 1.00E-66 184 370 951 g7008404 1.00E-10 194 370 951 g7008404 1.00E-11 1222 17 682 g9368450 1.00E-11 1222 17 682 g9368450 1.00E-110 1222 17 682 g9368450 1.00E-110

faciogenital dysplasia protein 2 [Mus musculus] FLJ00048 protein [Homo sapiens] FGD1 [Homo sapiens]	hook1 protein [Homo sapiens] dJ782L23.1 (HOOK1) [Homo sapiens]	nookz protein (nomo sapiens) protein-tyrosine phosphatase [Homo sapiens] neuronal tyrosine threonine phosphatase 1 (Mus musculus)	hypothetical protein SCE41.24c [Streptomyces coelicolor]	hypothetical protein [Homo sapiens] dJ272L16.1 (Rat Ca2+/Calmodulin dependent Protein Kinase LIKE protein)	[Homo sapiens]	Protein Kinase [Rattus norvegicus] Fl.100048 protein (Homo sapiens)	faciogenital dysplasia protein 2 [Mus musculus]	TSC22-related inducible leucine zipper 1b [Mus musculus]	a variant of TSC-22 [Gallus gallus]	KIAA0669 protein [Homo sapiens]	bromodomain PHD finger transcription factor [Homo sapiens]	contains similarity to Pfam domain: PF00439 (Bromodomain), Score=125.5, Evalue=1.59-35, N=1; PF00628 (PHD-finger), Score=102.0, E-value=3.89-27,	N=2 [Caenorhabditis elegans]	predicted using Genefinder~contains similarity to Pfam domain; PF00439 (Bromodomain) Score=125.5. F-value=1.5e-35. N=1: PF00628 (PHD-finger)	Score=102.0, E-value=3.8e-27, N=2 [Caenorhabditts elegans]	KIAA1234 protein [Homo sapiens]	dioxin receptor repressor [Homo sapiens]	AhB repressor [Mus musculus]	unnamed protein product [Homo sapiens]	CG17334 gene product [Drosophila melanogaster]	Y box transcription factor [Mus musculus]	supported by Genscan and several ESTs: C83049 (NID:g3062006), AA823760 (NID:g2893628), AA215791 (NID:g1815572), AI095488	(NID:9343464), and AA969095 (NID:93144275) [Homo sapiens]
1.00E-57 8.00E-42 4.00E-20	2.00E-92 2.00E-92	2.00E-70 1.00E-105 1.00E-76	5.00E-11	1.00E-156	1.00E-153	1.00E-152 1.00F-34	2.00E-16	1.00E-143	1.00E-106	9.00E-16	1.00E-105		9.00E-53		9.00E-53	1.00E-42	1.00E-40	4.00E-35	9.00E-44	1.00E-16	1.00E-12		4.00E-68
g3599940 g10440426 g595425	g3005085 g5706448	g300508/ g1109782 g1781037	g10241798	g4678722	g4007153	g2077934 g10440426	g3599940	g11907572	g1181619	g3327152	g6683492	•	g3876452		g3876449	g6330736	g11244871	g4164151	g10433955	g7295442	g2745892		g3924670
680 680 680 1282 386	1021	1021 2298 2298	2298	1040	1040	1040 531	531	1882	1882	1882	711		711		711	483	483	483	506	206	206		652
126 126 126 707 204	144	17/1261	1261	147	147	147	33	821	821	821	-		-		*	-	-	-	54	54	24		173
185 185 192 61	335	335 346 346	346	298	298	298 133	133	354	354	354	237		237		237	161	161	161	151	151	151		160
ოოოოო	N N 0	N		က	က	ი -		8	8	ત્ય	-		-		-	-	-	-	က	က	က		N
235 235 235 236 237	238	730 8 730 8	236 236	240	240	240 241	241	242	242	242	243		243		243	244	244	244	245	245	245		246

homeobox protein LSX [Homo sapiens] phtf protein [Mus musculus] transcription factor Elongin A2 [Homo sapiens] dJ886K2.1 (elongin A; RNA polymerase; RNA polymerase	Il elongation factor.) [Homo sapiens] elongin A [Homo sapiens] enhancer of polycomb [Homo sapiens]	enhancer of polycomb [Drosophila melanogaster]	E(Pc) gene product [Drosophila melanogaster] bA465L10.2 (novel C2H2 type zinc finger protein similar to chicken FZF-1)	[Homo sapiens]	unnamed protein product [Homo sapiens]	zinc finger protein [Gallus gallus]	unnamed protein product [Homo sapiens]	gonadotropin inducible transcription repressor-4 [Homo sapiens]	KIAA1198 protein [Homo sapiens]	zinc finger protein 7 (ZFP7) [Homo sapiens]	zinc-finger protein 7 [Homo sapiens]	KID2 [Mus musculus]	BWSCR2 associated zinc-finger protein BAZ2 [Homo sapiens]	zinc finger protein ZNF287 [Homo sapiens]	zinc finger protein SKAT2 [Mus musculus]	KIAA1629 protein [Homo sapiens]	similarto human ZFY protein. [Homo sapiens]	KIAA1441 protein [Homo sapiens]	KIAA1559 protein [Homo sapiens]	BC331191_1 [Homo sapiens]	zinc finger proteln [Homo sapiens]	ha0946 protein is Kruppel-related. [Homo sapiens]	bA393J16.1 (zinc finger protein 33a (KOX 31)) [Homo sapiens]	unnamed protein product [Homo sapiens]	zinc finger protein [Homo sapiens]	hematopoietic cell derived zinc finger protein [Homo sapiens]	krueppel-like zinc finger protein HZF2 [Homo sapiens]	unnamed protein product [Homo sapiens]	repressor transcriptional factor [Homo sapiens]
2.00E-59 6.00E-59 1.00E-52	1.00E-29 1.00E-29 4.00E-29	3.00E-18	3.00E-18	0	0	8.00E-98	2.00E-64	3.00E-36	4,00E-34	2.00E-17	2.00E-17	5.00E-17	3.00E-49	3.00E-47	8.00E-43	0	1.00E-96	4.00E-66	3.00E-49	2.00E-45	3.00E-44	2.00E-20	2.00E-20	2.00E-19	2.00E-26	1.00E-25	5.00E-25	4.00E-74	8.00E-73
g5640105 g6523391 g6939732	g4581412 g992563	g3757890	g7303589	g10443047	g10438918	g984814	g10434195	g6467206	g6330394	g340446	g4325310	g6007771	g6002480	90863806	g11527849	g10047335	g1504006	g7243280	g10047183	g5080758	g498721	g498152	g7576272	g10440081	g347906	g3342002	g8163824	g10435738	g1017722
652 652 587	587 587 537	537	537	1612	1612	1612	220	220	220	471	471	471	1059	1059	1059	2455	2455	2455	633	633	633	310	310	310	386	386	386	684	684
173 173 108	108 108 7	8 8	22	266	266	266	140	4	140	-	-	-	145	145	145	305	305	305	~	_	-	8	~	8	135	135	135	1 33	103
160 160 160	160 160 171	<u> </u>	171	449	449	449	127	127	127	157	157	157	305	305	305	717	717	717	211	211	211	103	103	103	84	84	84	194	194
ଷଷଟ	თ n +		-	8	7	C)	ω.	8	8	-	-	-	-	-	-	0	8	8	-	-	-	8	67	7	က	ო	က	-	
246 246 247	247 247 248	548 548	248	249	249	249	250	250	250	251	251	251	252	252	252	253	253	253	254	254	254	255	255	255	256	256	256	257	257

		iens]	iens]			sapiens]								iens]	sapiens]	,	1			1	sapiens]		Mus musculus]	l) [Homo sapiens]			[Homo sapiens]	ein similar to chicken FZF-1)			•	lus]		•	gallus]
KIAA1473 protein [Homo sapiens]	p40 [Homo sapiens]	ORF1, encodes a 40 kDa product [Homo sapiens]	ORF1 codes for a 40 kDa product [Homo sapiens]	DNA-binding protein [Homo sapiens]	KIAA1473 protein [Homo sapiens]	Krueppel-related DNA-binding protein [Homo sapiens]	zinc finger protein [Homo sapiens]	Kruppel-type zinc finger [Homo sapiens]	ZNF180 [Homo sapiens]	unnamed protein product [Homo sapiens]	zinc finger protein 54 [Mus musculus]	zinc finger protein SBZF3 [Homo saplens]	zinc finger protein [Homo sapiens]	Krueppel family zinc finger protein [Homo sapiens]	krueppel-like zinc finger protein HZF2 [Homo saplens]	HSPC059 [Homo sapiens]	zinc finger protein [Homo sapiens]	unnamed protein product [Homo sapiens]	DNA-binding protein [Homo sapiens]	BC273239_1 [Homo sapiens]	Krueppel-related DNA-binding protein [Homo sapiens]	KIAA0972 protein [Homo sapiens]	KRAB-containing zinc-finger protein KRAZ2 [Mus musculus]	bA393J16.1 (zinc finger protein 33a (KOX 31)) [Homo saplens]	Zfp-29 [Mus musculus]	DNA binding protein [Homo sapiens]	BWSCR2 associated zinc-finger protein BAZ1 [Homo sapiens]	bA465L10.2 (novel C2H2 type zinc finger protein similar to chicken FZF-1)	[Homo sapiens]	unnamed protein product [Homo sapiens]	zinc finger protein [Gallus gallus]	zinc finger protein 276 C2H2 type [Mus musculus]	hypothetical protein [Macaca fascicularis]	zinc finger protein PZF [Mus musculus]	high molecular mass nuclear antigen [Gallus gallus]
3.00E-71	6.00E-07	8.00E-07	8.00E-07	4.00E-36	1.00E-33	3.00E-33	1.00E-38	2.00E-38	4.00E-38	1.00E-14	6.00E-14	3.00E-13	1.00E-26	6.00E-26	6.00E-26	2.00E-15	4.00E-15	2.00E-14	8.00E-35	7.00E-32	9.00E-32	5.00E-22	6.00E-22	2.00E-21	1.00E-134	3.00E-73	3.00E-72		0	0	2.00E-97	4.00E-45	3.00E-43	4.00E-43	9.00E-08
g7959207	g2072955	g483915	g339776	g3329372	g7959207	g184452	g8099348	g5730196	g8050899	g7023216	g3406676	g9802037	g186774	g2384653	g8163824	g7239109	g347906	g7023216	g3329372	g4559318	g184452	g4589588	ğ4514561	g7576272	g55471	g1020145	g6002478		g10443047	g10438918	g984814	g9886891	g11611571	g453376	g2754696
684	414	414	414	353	353	353	947	947	947	335	335	335	485	485	485	254	254	254	392	392	392	471	471	471	754	754	754		1601	1601	1601	805	802	802	829
103	88	88	83	72	72	75	369	369	369	က	က	က	72	72	72	ટ	21	2	8	8	8	184	184	184	N	~	7		36	36	ဗ္တ	8	~	લ	Ø
194	129	129	129	93	93	93	193	193	193	11	==	=	137	137	137	89	89	89	101	101	101	96	96	96	251	251	251		255	522	255	267	267	267	286
-	-	Ψ-	-	က	က	က	က	က	က	က	က	က	က	က	ო	က	က	ო	က	က	က	- -	-	-	0	7	8		က	ო	က	0	8	Ø	Ø
257	258	258	258	259	259	259	260	260	260	261	261	261	262	5 85	262	263	263	263	264	264	264	265	265	265	566	566	566		267	267	267	268	268	5 68	569

antifreeze glycopeptide AFGP polyprotein precursor [Boreogadus salda] PR-domain zinc finger protein 6 isoform A: PR-domain family protein 3 isoform		unnamed protein product [Homo sapiens]		zinc finger protein ZNF180 [Homo sapiens]	ZNF180 [Homo sapiens]	pMLZ-4 [Mus musculus]	Eos protein [Mus musculus]	eos [Raja eglanteria]	zinc finger transcription factor Eos [Homo sapiens]	KRAB zinc finger protein; Method: conceptual translation supplied by author	[Homo sapiens]	KIAA1588 protein [Homo sapiens]	KRAB zinc finger protein [Mus musculus]	zinc finger protein [Cavia porcellus]	unnamed protein product [Homo sapiens]	HPF1 protein [Homo sapiens]	bA508N22.2 (zinc finger protein 37a (KOX 21)) [Homo sapiens]	ZNF37A [Homo sapiens]	Kruppel-type zinc finger [Homo sapiens]	Zinc finger protein 222 [Homo sapiens]	zinc finger protein ZNF222 [Homo sapiens]	•		BC273239_1 [Homo sapiens]	Krueppel-related DNA-binding protein [Homo sapiens]	bA245E14.1 (novel zinc finger protein similar to ZFP47) [Homo sapiens]	zinc finger protein ZFP113 [Mus musculus]	zinc finger protein [Homo sapiens]	ZNF37A [Homo sapiens]	bA508N22.2 (zinc finger protein 37a (KOX 21)) [Homo sapiens]	dJ733D15.1 (Zinc-finger protein) [Homo sapiens]	bA508N22.2 (zinc finger protein 37a (KOX 21)) [Homo saplens]	ZNF37A [Homo sapiens]	pMLZ-4 [Mus musculus]
9.00E-06	1.00E-112	1.00E-26	9.00E-26	1.00E-107	1.00E-107	1.00E-101	5.00E-65	4.00E-46	3.00E-42		3.00E-25	9.00E-25	1.00E-19	2.00E-36	4.00E-36	5.00E-36	2.00E-51	2.00E-51	4.00E-36	3.00E-91	3.00E-91	1.00E-81	1.00E-30	3.00E-29	5.00E-29	2.00E-46	2.00E-46	5.00E-46	2.00E-27	2.00E-27	9.00E-20	4.00E-29	4.00E-29	4.00E-21
g2078483	g8575782	g10437767	g7295698	g6409345	g80508g	g200407	g4062983	g9408382	g11612390		g1049301	g10047251	g8809810	g1237278	g7023417	g11917507	g9801232	g829151	g5730196	g7656698	g6118381	g6118383	g3329372	g4559318	g1124876	g11062533	g5640017	g186774	g829151	g9801232	g3702137	g9801232	g829151	g200407
829	851	821	851	791	791	791	715	715	715		493	493	493	829	829	829	650	650	650	447	447	447	392	392	392	416	416	416	455	455	455	472	472	472
8	270	270	270	က	က	က	230	230	290		α	8	0	203	509	509	336	336	336	-		<u>_</u>	8	8	8	9	9	9	165	165	165	182	182	182
286	194	194	194	263	263	263	142	142	142		164	164	164	107	107	107	105	105	105	149	149	149	5	1 0	101	137	137	137	26	26	26	26	6	97
87	ო	က	က	က	က	က	84	N	~		7	8	Ø	2	2	7	က	က	က	-	-		က	က	က	က	က	က	က	က	က	7	α	8
269	270	270	270	271	271	271	272	272	272		273	273	273	274	274	274	275	275	275	276	276	276	277	277	277	278	278	278	279	279	279	280	280	280

														•				•																	
zinc-finger protein ZBRK1 [Homo sapiens]	unnamed protein product [Homo sapiens]	KRAB zinc finger protein ZFQR [Homo sapiens]	zinc finger protein [Homo sapiens]	zinc finger protein [Homo sapiens]	zinc finger protein [Homo sapiens]	KID2 [Mus musculus]	HKL1 [Homo sapiens]	zinc finger protein [Rattus norvegicus]	zinc finger protein [Mus musculus]	zinc finger protein [Mus musculus]	zinc finger protein [Homo sapiens]	unnamed protein product [Homo sapiens]	zinc finger protein SBZF3 [Homo sapiens]	HSPC059 [Homo sapiens]	ZNF91L [Homo sapiens]	KIAA1473 protein [Homo sapiens]	hematopoietic cell derived zinc finger protein [Homo sapiens]	zinc finger protein ZNF136 [Homo sapiens]	hypothetical protein [Homo sapiens]	unnamed protein product [Homo sapiens]	zinc finger protein ZNF286 [Homo sapiens]	zinc finger protein ZFP113 [Mus musculus]	unnamed protein product [Homo sapiens]	KIAA0972 protein [Homo sapiens]	KRAB-containing zinc-finger protein KRAZ2 [Mus musculus]	bA393J16.1 (zinc finger protein 33a (KOX 31)) [Homo sapiens]	KIAA1473 protein [Homo sapiens]	zinc finger protein [Homo sapiens]	zinc finger protein 4 [Homo sapiens]	ha0946 protein is Kruppel-related. [Homo sapiens]	unnamed protein product [Homo sapiens]	bA393J16.1 (zinc finger protein 33a (KOX 31)) [Homo sapiens]	Zinc finger protein 222 [Homo sapiens]	zinc finger protein ZNF222 [Homo sapiens]	zinc finger protein ZNF223 [Homo sapiens]
3.00E-61	3.00E-61	3.00E-61	2.00E-14	2.00E-14	2.00E-13	4.00E-97	2.00E-93	2.00E-93	5.00E-57	5.00E-57	3.00E-55	2.00E-18	4.00E-16	7.00E-15	7.00E-56	5.00E-50	7.00E-50	4.00E-16	7.00E-15	9.00E-15	4.00E-47	2.00E-46	4.00E-46	5.00E-22	6.00E-22	2.00E-21	1.00E-26	3.00E-26	4.00E-23	1.00E-06	1.00E-06	1.00E-06	1.00E-133	1.00E-133	1.00E-122
g10442700	g10435411	g10954044	g8099348	g498725 _.	g495568	g6007771	g2970038	g205067	g1806134	g538413	g186774	g7023216	g9802037	g7239109	g2739353	g7959207	g3342002	g487785	g5262560	g10434856	99963804	g5640017	g7020166	g4589588	g4514561	g7576272	g7959207	g498736	g4454678	g498152	g10440081	g7576272	g7656698	g6118381	g6118383
267	267	267	629	629	629	517	517	517	453	453	453	349	349	349	499	499	499	234	234	234	455	455	455	438	438	438	564	564	564	553	553	553	637	637	637
31	31	31	369	369	369	8	Q	0	-	_	-	83	83	83	62	62	62	-	-	-	28	28	78	151	151	151	118	118	118	152	152	152	Q	0	0
179	179	179	87	87	87	172	172	172	151	151	151	83	83	83	146	146	146	28	78	. 78	126	126	126	96	96	96	149	149	149	134	2 8	134	212	212	212
-	-	-	က	က	က	8	~	81	_	-	-	Ø	Q1	7	7	7	ત	-	_	-	က	က	က	-	-	-	-		-	ત	N	ત	Ø	8	,cv
281	281	281	282	282	282	283	283	283	284	284	284	285	285	285	286	286	286	287	287	287	288	288	288	289	289	289	290	290	.290	291	291	291	292	292	292

										,				'	•	•							•			•									
BC37295_1 [Homo sapiens]	unnamed protein product [Homo saplens]	nypothetical protein [Homo sapiens]	zinc finger protein (583 AA) [Homo sapiens]	zinc finger protein ZNF136 [Homo sapiens]	hypothetical protein [Homo sapiens]	zinc finger protein [Homo sapiens]	Zinc finger protein s11-6 [Mus musculus]	gonadotropin inducible transcription repressor-4 [Homo sapiens]	bA508N22.2 (zinc finger protein 37a (KOX 21)) [Homo saplens]	ZNF37A [Homo sapiens]	ZNF157 [Homo sapiens]	KIAA1285 protein [Homo sapiens]	DNA binding protein [Homo sapiens]	KIAA0326 [Homo sapiens]	protease [Homo sapiens]	protease [Homo sapiens]	protease [Human endogenous retrovirus K]	unnamed protein product [Homo sapiens]	nypothetical protein [Homo sapiens]	zinc finger protein (583 AA) [Homo sapiens]	unnamed protein product [Homo sapiens]	hypothetical protein [Homo sapiens]	unnamed protein product [Homo sapiens]	KIAA1611 protein [Homo sapiens]	unnamed protein product [Homo sapiens]	zinc finger protein [Homo sapiens]	dJ228H13.3 (zinc finger protein) [Homo sapiens]	nypothetical protein [Homo sapiens]	zinc finger protein ZNF135 [Homo sapiens]	NK10 [Mus musculus]	zinc finger protein ZNF135 [Homo sapiens]	zinc finger protein [Homo sapiens]	unnamed protein product [Homo sapiens]	unnamed protein product [Homo sapiens]	unnamed protein product [Homo sapiens]
2.00E-33 BC37	_	9.00E-31 hypot	9.00E-24 zinc f	8.00E-23 zinc f	1.00E-22 hypot	2.00E-83 zinc f	3.00E-69 Zinc I	4.00E-68 gona	3.00E-28 bA50		4.00E-20 ZNF1	1,00E-131 KIAA	6.00E-53 DNA		_	4.00E-20 prote		2.00E-40 unna	2.00E-40 hypol		_	3.00E-35 hypol	2.00E-27 unna	_	2.00E-22 unna			_	2.00E-63 zinc f	_		•	~	_	7.00E-54 unna
	•	g5817149 9.00			_	g498719 2.0						•						g10434856 2.0	g5262560 2.0		.	g5262560 3.0								·			•		g10436789 7.0
																					_														
							540								425		425						407		531		545			789					1037
																																		<u>æ</u>	
108	108	108	83	83	83	180	180	180	97	97	97	217	217	217	137																		340	340	340
33 2	33 2	33 2	34 1	1 1	1 1	35 1	35 1	35 1	36 3	36 3	36 3	1 1	76	1 1	38 3																33 1		34 3	304 3	3 4
స	స	ĭĭ	ĭί	ŭ	స	స	స	ಸ	ಸ	ŭ	స	ಭ	స	స	Κί	ά	ณ์	ิ	ถึ	ŭ	്	ਲ	്	്	്	്	ಹ	ĕ	്	്	്	്	က	ਲ	ਲ

			-					0													*1								1	3, GAT-3		·~			
unnamed protein product [Homo sapiens]	zinc finger protein SBZF3 [Homo sapiens]	HSPC059 [Homo sapiens]	PRO2032 [Homo sapiens]	muscleblind [Mus musculus]	EXP35 [Homo sapiens]	ZNF202 beta [Homo sapiens]	hypothetical protein [Homo sapiens]	putative kruppel-related zinc finger protein NY-REN-23 antigen [Homo	sapiens]	KIAA0760 protein [Homo sapiens]	Smad- and Olf-interacting zinc finger protein [Homo sapiens]	Roaz [Rattus norvegicus]	zinc finger protein ZNF140 [Homo sapiens]	KIAA1559 protein [Homo sapiens]	BC37295_1 [Homo sapiens]			HERV-E envelope glycoprotein [Homo sapiens]	HERV-E envelope glycoprotein [Homo sapiens]	HERV-E envelope protein [Human endogenous retrovirus]	inwardly-rectifying potassium channel Kir5.1 [Homo sapiens]	inwardly-rectifying potassium channel Kir5.1 [Homo sapiens]	inwardly-rectifying potassium channel Kir5.1 [Homo sapiens]	calcium channel alpha2-delta3 subunit [Homo sapiens]	calcium channel alpha-2-delta-C subunit [Mus musculus]	hypothetical protein [Macaca fascicularis]	sodium channel alpha subunit [Homo sapiens]	voltage-gated sodium channel [Mus musculus]	sodium channel alpha-subunit [Rattus norvegicus]	gamma-aminobutyric acid transporter type 3, GABA transporter type 3, GAT-3	[human, fetal brain, Peptide, 632 aa] [Homo sapiens]	beta-alanine-sensitive neuronal GABA transporter [Rattus norvegicus]	GABA transporter [Rattus norvegicus]	CTL1 protein [Homo sapiens]	CTL1 protein [Rattus norvegicus]
2.00E-18	4.00E-16	7.00E-15	9.00E-20	6.00E-11	2.00E-10	0	0		1.00E-123	0	0	0	8.00E-15	9.00E-31	2.00E-29			4.00E-13	4.00E-13	2.00E-10	2.00E-74	2.00E-74	2.00E-74	2.00E-22	2.00E-22	2.00E-22	0	0	0		5.00E-71	2.00E-69	2.00E-69	4.00E-61	1.00E-59
g7023216	g9802037	g7239109	g7959865	g8099520	g8515711	g3869259	g7328045	ı	g5360097	g3882241	g6760445	g2149792	g487787	g10047183	g4567179			g2587027	g2587024	g1049232	g8132311	g8132295	g8132293	g7105926	g4186073	g9929977	g184039	g6782382	g206858		g913242	g204220	g202535	g6996442	g6996589
369	369	369	240	240	240	1333	1333		1333	1174	1174	1174	715	715	715	754	576	330	330	330	855	852	855	820	820	820	4809	4809	4809		839	839	839	686	989
103	103	103	•	Ψ-	-	176	176		176	7	7	7	191	191	191	521	394	172	172	172	304	304	304	1	164	164	-	-	-		240	240	240	က	က
83	88	83	8	8	8	386	386		386	368	368	368	175	175	175	78	6	73	73	73	184	184	184	219	219	219	1603	1603	1603		200	200	200	329	329
-	-	-	_	-	_	7	8		8	7	8	8	8	8	7	Ø	-	-	-	-	-	-		7	7	8		-	-		က	က	က	က	က
305	305	305	306	306	306	307	307		307	308	308	308	309	309	309	310	311	312	312	312	313	313	313	314	314	314	315	315	315		316	316	316	317	317

						- 1	,				·																	
CTL1 protein [Torpedo marmorata] ESTs AU058081(E30812),AU058365(E50679), AU030138(E50679)	mRNA for proteasome 37kD subunit.(X96974) [Oryza sativa] ESTs AU058081(E3082),AU075427(E30384) correspond to a region of the predicted gene. Similar to Spinacla oleracea proteasome 27 kD subunit	(P52427) [Oryza sativa] ESTs AU058081(E3082),AU075427(E30384) correspond to a region of the predicted gene a Similar to Spinacia pleracea proteasome 27 kD subunit	(P52427) [Oryza sativa]	cyclophilin A [Mus musculus]	cyclophilin (AA 1 - 164) [Mus musculus]	unnamed protein product [Homo sapiens]	mDj10 [Mus musculus]	unnamed protein product [Homo sapiens]	HERV-E envelope protein [Human endogenous retrovirus]	HERV-E envelope glycoprotein [Homo sapiens]	HERV-E envelope glycoprotein [Homo sapiens]	testis specific DNAj-homolog [Mus musculus]	DnaJ homolog [Homo sapiens]	DNAj homolog [Homo sapiens]		25 kDa trypsin inhibitor [Homo sapiens]	dJ881L22.3 (novel protein similar to a trypsin inhibitor) [Homo sapiens]	late gestation lung protein 1 [Rattus norvegicus]	putative chaperonin [Arabidopsis thaliana]	TCP-1 chaperonin-like protein [Arabidopsis thaliana]	chaperonin containing TCP-1 zeta-1 subunit [Mus musculus]	KIAA0723 protein [Homo sapiens]	similar to Homo sapiens mRNA for KIAA0723 protein with GenBank	Accession Number AB018266.1 []	matrin 3 [Homo sapiens]		proliferation-associated SNF2-like protein [Homo sapiens]	lymphocyte specific helicase [Mus musculus]
. 2.00E-51	1.00E-134	1.00E-134	1.00E-134	2.00E-07	2.00E-07	1.00E-84	7.00E-84	5.00E-81	3.00E-24	2.00E-23	2.00E-23	6.00E-33	1.00E-32	1.00E-32		5.00E-81	5.00E-54	2.00E-52	1.00E-135	1.00E-132	2.00E-93	1.00E-171		1.00E-171	1.00E-170		1.00E-158	1.00E-149
g6996587	g5091520	98096329	g8096319	g5759144	g50621	g7019854	g6567172	g10436329	g1049232	g2587024	g2587027	g2286123	g6681592	g6648623	,	g2943716	g9885193	g4324682	g6957716	g9755653	g5295933	g3882167		g9956070	g6563246		98980660	g805296
686	770	770	220	529	229	1181	1181	1181	672	672	672	683	683	683	452	1265	1265	1265	791	791	791	1093		1093	1093	955	910	910
က	က	က	ლ ი	1 0	8	354	354	354	328	328	328	က	က	က	153	840	840	840	က	က	က	ຊ		83	g	656	~	ଧ
329	256	256	256 76	92	9/	276	576	276	15	115	115	227	227	227	100	142	142	142	263	263	263	357		357	357	100	303	303
က	က	က	ကင	1 01	8	က	က	က	-	-	-	က	က	က	က	က	က	က	က	က	က	8		N	0	Q	2	0
317	318	318	318	319	319	320	320	320	321	321	321	322	322	322	323	324	324	324	325	325	325	326		326	326	327	328	328

similar to Mus musculus lymphocyte specific helicase mRNA with GenBank Accession Number U25691.1 [Homo sapiens]			ORF derived from D1 leader region and integrase coding region [Homo	sapiens]	ORF derived from protease and integrase coding regions [Homo sapiens]	pol protein [Homo sapiens]		proliferation-associated SNF2-like protein [Homo saplens]	similar to Mus musculus lymphocyte specific helicase mRNA with GenBank	Accession Number U25691.1 [Homo sapiens]	unnamed protein product [Homo sapiens]	ORF derived from D1 leader region and integrase coding region [Homo	sapiens]	ORF derived from protease and integrase coding regions [Homo saplens]	pol protein [Homo sapiens]		orf; encodes putative chimeric protein with SET domain in N-terminus with	similarity to several other human, Drosophila, nematode and yeast proteins	[Homo sapiens]	unknown [Homo sapiens]	mariner transposase [Homo sapiens]		KIAA1595 protein [Homo sapiens]	ATP-dependent RNA helicase-like protein [Arabidopsis thaliana]	RNA helicase [Arabidopsis thaliana]	unnamed protein product [Homo sapiens]	KIAA1416 protein [Homo sapiens]	dJ620E11.1 (novel Helicase C-terminal domain and SNF2 N-terminal domains	containing protein, similar to KIAA0308) [Homo sapiens]			protocadherin 68 [Homo sapiens]	KIAA1400 protein [Homo sapiens]	OL-protocadherin [Mus musculus]
8.00E-86				1.00E-29	5.00E-21	5.00E-21		8.00E-92		8.00E-92	1.00E-89		1.00E-30	5.00E-21	5.00E-21				8.00E-12	8.00E-12	1.00E-11		7.00E-81	3.00E-26	3.00E-26	1.00E-128	1.00E-126		1.00E-120			0	4.00E-49	5.00E-48
g9956001	•			g2104910	g2104914	g4959374	•	g8980660	ı	g9956001	g7022306	•	g2104910	g2104914	g4959374	•			g2231380	g3005702	g1263081	ŧ	g10047265	g10176757	g3776011	g10434055	g7243213		g11345539			g2599502	g7243181	g4099551
910	382	307		299	299	299	257	877		877	877		299	299	299	382			721	721	721	1934	503	503	503	696	696		696	191	1974	3377	3377	3377
Ø	167	8		446	446	446	22	302		302	302		446	446	446	167			557	222	557	1614	83	63	83	199	199		199	က	623	2097	2097	2097
303	72	9/		74	74	74	29	192		192	192		74	74	74	72			22	55	22	107	147	147	147	257	257		257.	63	112	427	427	427
ત	8	ď		લ	N	8	ო	8		8	α.		8	9	٥,	ď			α,	Ø	લ	က	က	က	က	-	-		-	ო	-	က	က	က
328	329	330		331	331	331	332	333		333	333		334	334	334	335			336	336	336	337	338	338	338	339	339		339	340	341	342	342	342

		•	• •	
unnamed protein product [Homo sapiens] HERV-E envelope glycoprotein [Homo sapiens] HERV-E envelope glycoprotein [Homo sapiens] HERV-E envelope protein [Human endogenous retrovirus] hypothetical protein [Homo sapiens] ribosomal protein L23A [Homo sapiens]	PRO2852 [Homo sapiens] unnamed portein product [Macaca fascicularis] unnamed protein product [Homo sapiens] class II antigen [Homo sapiens] MHC class II DP3-alpha [Homo sapiens] SB classII histocompatibility antigen alpha- chain [Homo sapiens] cytochrome P450 2B-Bx=phenobarbital-inducible [rabbits, kidney, Peptide, 491 aa] [Oryctolagus cuniculus] cytochrome P-450 2B-Bx [Oryctolagus cuniculus] cytochrome P-450 [Oryctolagus cuniculus]	dJ857M17.2 (novel protein similar to cytochrome c oxidase subunit IV (COX4)) [Homo sapiens] cytochrome c oxidase subunit IV isoform 2 precursor [Thunnus ob sus] cytochrome c oxidase subunit IV [Gorilla gorilla] unnamed protein product [Homo sapiens]	collagen subunit (alpha-1 (X)) 3 [Homo sapiens] polydom protein [Mus musculus] hikaru genki type4 product precursor [Drosophila melanogaster] hikaru genki type3 product precursor [Drosophila melanogaster]	dJ708F5.1 (PUTATIVE novel Collagen alpha 1 LIKE protein) [Homo sapiens] cartilage matrix protein [Homo sapiens]
1.00E-10 4.00E-13 4.00E-13 2.00E-10 6.00E-58 6.00E-58	2.00E-22 5.00E-22 5.00E-21 1.00E-152 1.00E-147 1.00E-144 1.00E-144	2.00E-80 9.00E-42 3.00E-41 1.00E-176	6.00E-49 4.00E-12 4.00E-07	1.00E-129 4.00E-36
g10436424 g2587027 g2587024 g1049232 g9368839 g2739452 g1399086	g11493463 g9280152 g10437485 g673417 g703089 g758100 g402843 g404777 g164959	g11863734 g8809758 g2809498 g11229985	g30095 g30095 g311177164 g391667	g4582324 g1732121
1066 847 899 899 803 803 803	811 811 811 994 994 994 1551 1551	1995 726 726 726 285 994	332 332 332 332 336 410	897 897
635 557 675 675 675 339 339 339	425 425 122 122 122 123 124 125	1300 67 67 1 1 2	1 2 2 2 5 1 6 1 6 1 6 1 6 1 6 1 6 1 6 1 6 1 6 1 6	18 18 18
144 97 75 75 75 135 135	129 129 129 291 291 291 517 517	220 220 220 331 331	331 93 93 112 73	239
८ ८ ८ ८ ८ ८ ८ ८ ८ ८	1000000		v d w w w ← w	
343 345 345 346 346 346 346	348 348 349 350 350 350	351 352 352 353 354	354 355 355 355 356 357	358 358

cartilage matrix protein [Homo sapiens]	type II intermediate filament of hair keratin [Homo sapiens]	keratin [Homo sapiens]	hair keratin basic 5; keratin Hb5 [Mus musculus]	hNBL4 [Homo sapiens]	NBL4 [Mus musculus]	band 4.1-like protein 4 [Danio rerio]	myosin I [Rattus norvegicus]	KIAA0727 protein [Homo sapiens]	dJ111C20.1 (similar to Chlamydomonas radial spoke protein 3) [Homo		spoke protein [Chlamydomonas reinhardtii]	CG10099 gene product [Drosophila melanogaster]		PF20 [Chlamydomonas reinhardtii]	pf20 homolog [Trypanosoma brucei]	beta transducin-like protein [Podospora anserina]		kinesin-like protein GAKIN [Homo sapiens]	KIF13A [Mus musculus]	kinesin-like protein RBKIN2 [Homo sapiens]	hypothetical protein [Macaca fascicularis]	ankyrin 1 [Bos taurus]	alt. ankyrin (variant 2.2) [Homo sapiens]	dystrophin-related protein 2 [Homo sapiens]	dystrophin-related protein 2 A-form splice variant [Rattus norvegicus]	dystrophin-related protein 2 B-form splice variant [Rattus norvegicus]	pemphigus vulgaris antigen [Homo sapiens]	desmoglein 3 [Mus musculus]	desmoglein 2 [Homo sapiens]	64 Kd autoantigen [Homo sapiens]	tropomodulin 2 [Homo sapiens] -	neural tropomodulin N-Tmod [Mus musculus]	_	KIAA0953 protein [Homo sapiens]
2.00E-35	0	0	0	2.00E-64	3.00E-63	5.00E-54	6.00E-08	6.00E-08		1.00E-120	1.00E-75	9.00E-47	•	9.00E-53	2.00E-47	1.00E-37		0	0	0	1.00E-56	2.00E-18	2.00E-18	0	0	0	0	1.00E-176	2.00E-58	7.00E-71	8.00E-61	3.00E-60	1.00E-124	4.00E-82
g180654	g1903218	g7161771	g4103156	g11034725	g466548	g2822458	g3724141	g3882175		g6855339	g18218	g7295323		91813638	g3983133	g607003		g8896164	g10697238	g11761613	g11231085	g7385113	g747710	g1353782	g11066165	g11066167	g190752	g2290200	g416178	g28969	g6934240	g7288857	g1469868	g4589550
897	1587	1587	1587	631	631	631	248	248		1553	1553	1553	493	843	843	843	480	2273	2273	2273	488	488	488	2212	2212	2212	2297	2297	2297	1595	1595	1595	1153	1153
181	4	4	4	161	161	161	54	54		က	က	က	314	127	127	127		က	က	က	က	က	က	308	308	308	666	66 6	666	က	က	က	383	383
239	528	528	528	157	157	157	65	8		517	517	517	09	239	239	239	160	757	757	757	162	162	162	635	635	635	433	433	433	531	531	531	257	257
~	-	—	÷	Ø	2	8	က	က		က	က	က	Ø	-	-	-	-	က	က	က	က	က	က	7	~1	8	က	ო	က	ო	က	ო	8	0
358	329	329	329	360	360	360	361	361		362	362	362	363	364	364	364	365	366	366	366	367	367	367	368	368	368	369	369	369	370	370	370	371	371

January Bulletin Buckey bus

							٠.	r					,			_																		
				•		<i>*</i> ,	•				٠.		•		1	al protein L7A)									ensj		1.5						psis thaliana]	
cmp44E gene product [alt 1] [Drosophila melanogaster] DM-20 protein [Mus musculus]	DM-20 [Homo sapiens]	proteolipid protein variant Dm-20 [Mus musculus]		ribosomal protein L32-like protein [Arabidopsis thaliana]	ribosomal protein L32-like protein [Arabidopsis thaliana]	ribosomal protein L32 [Arabidopsis thaliana]	putative 40S ribosomal protein s12 [Fragaria x ananassa]	40s ribosomal protein S23 [Euphorbia esula]	putative protein [Arabidopsis thaliana]	ribosomal protein L11-like [Nicotiana tabacum]	ribosomal protein L11-like [Arabidopsis thaliana]	ribosomal protein L11, cytosolic [Arabidopsis thallana]	ribosomal protein S26 [Rattus norvegicus]	ribosomal protein S26 [Homo sapiens]	ribosomal protein S26 [Homo sapiens]	dJ475N16.3 (novel protein similar to RPL7A (60S ribosomal protein L7A))	[Homo sapiens]	60S ribosomal protein L7 [Cyanophora paradoxa]	ribosomal protein L7 [Mus musculus]	ribosomal protein L7 [Rattus norvegicus]	ribosomal protein L7 [Mus musculus]	ribosomal protein L7 [Mus musculus]	ribosomal protein S10 [Homo sapiens]	ribosomal protein S10 (AA 1-165) [Rattus norvegicus]	bA371L19.2 (similar to ribosomal protein S10) [Homo sapiens]	ribosomal protein L7 [Homo sapiens]	ribosomal protein L7 [Homo sapiens]	ribosomal protein L7 [Homo sapiens]	HBp15/L22 [Sus scrofa]	HBp15/L22 [Mus musculus]	HBp15/L22 [Homo sapiens]	putative ribosomal protein S14 [Arabidopsis thaliana]	putative 40S ribosomal protein s14; 67401-66292 [Arabidopsis thaliana]	40S ribosomal protein S14 [Arabidopsis thaliana]
1.00E-55 1.00E-123	1.00E-123	1.00E-122		1.00E-59	1.00E-59	7.00E-59	4.00E-76	1.00E-75	6.00E-75	1.00E-93	4.00E-93	4.00E-93	7.00E-41	7.00E-41	7.00E-41		6.00E-53	2.00E-21	1.00E-20	1.00E-82	2.00E-80	2.00E-80	2.00E-31	3.00E-30	3.00E-29	2.00E-31	2.00E-31	2.00E-31	2.00E-19	2.00E-19	2.00E-19	2.00E-75	6.00E-75	3.00E-74
g7304005 g387514	g190088	g200409		g7268562	g5816996	g10177580	g643074	g6716785	g7413571	g10799832	g7630065	g11908058	g57131	g296452	g3335024		g6969165	g6687301	g200785	g206736	g200785	g554269	g550025	g57127	g9581772	g36140	g307388	g1335288	g409074	g409072	g409070	g4886269	0689009b	g4678226
1153 864	864	864	559	492	492	492	476	476	476	727	727	727	308	308	308		621	621	621	533	533	533	514	514	514	576	576	576	315	315	315	585	585	585
383 139	139	139	380	22	22	22	က	က	က	7	4	4	က	က	က		316	316	316	က	က	က	257	257	257	286	286	286	2	2	2	46	46	46
257 242	242	242	9	157	157	157	158	158	158	238	238	238	102	102	102		102	102	102	177	177	177	88	98	98	26	4	26	82	82	82	180	180	180
o -		-	8	-	-	-	က	က	က	0	8	0	က	က	က			-	•	က	က	က	α	7	01	-	-	-	_	-	-	-	. —	-
371 372	372	372	373	374	374	374	375	375	375	376	376	376	377	377	377		378	378	378	379	379	379	380	380	380	381	381	381	382	382	382	383	383	383

F 1	issa]	, ,		ISSA]															issa]			ч			n, HeLa cells, Peptide, 97					ī						
	putative 40S ribosomal protein s12 [Fragana x ananassa]	40s ribosomal protein S23 [Euphorbia esula]	putative protein [Arabidopsis thaliana]	putative 40S ribosomal protein s12 [Fragaria x ananassa]	40s ribosomal protein S23 [Euphorbia esula]	putative protein [Arabidopsis thaliana]	ribosomal protein L31 (AA 1-125) [Homo saplens]	ribosomal protein L31 [Homo sapiens]	ribosomal protein L31 (AA 1-125) [Rattus norvegicus]	ribosomal protein S4 type I [Zea mays]	ribsomal protein S4 [Zea mays]	ribosomal protein S4 [Arabidopsis thaliana]	ribosomal protein L17 [Zea mays]	ribosomal protein L17-2 [Hordeum vulgare]	ribosomal protein L17-1 [Hordeum vulgare]	RPS16 [Homo sapiens]	ribosomal protein S16 (AA 1-146) [Rattus rattus]	16S ribosomal protein [Mus musculus]	putative 40S ribosomal protein s12 [Fragaria x ananassa]	40s ribosomal protein S23 [Euphorbia esula]	putative protein [Arabidopsis thaliana]		ribosomal protein L37 [Rattus norvegicus]	ribosomal protein L37 [Homo sapiens]	ribosomal protein L37 (C2-C2 zinc-finger-like) [human, HeLa cells, Peptide, 97	aa] [Homo sapiens]	unnamed protein product [Homo sapiens]	unnamed protein product [Homo sapiens]	tricarboxylate carrier [Rattus sp.]		protein kinase HIPK2 [Homo sapiens]	nuclear body associated kinase 1b [Mus musculus]	nuclear body associated kinase 1a [Mus musculus]	PC326 protein [Homo sapiens]	Mus musculus Dentin Matrix Protein 1 []	dentin matrix protein-1 [Mus musculus]
	2.00E-49	6.00E-49	3.00E-48	4.00E-76	1.00E-75	6.00E-75	1.00E-22	1.00E-22	1.00E-22	1.00E-122	1.00E-120	1.00E-116	1.00E-95	8.00E-85	1.00E-82	5.00E-28	5.00E-28	2.00E-27	4.00E-76	1.00E-75	6.00E-75		3.00E-18	3.00E-18		3.00E-18	3.00E-80	3.00E-80	6.00E-79		0	0	0	1.00E-161	1.00E-08	1.00E-08
1	g643074	g6716785	g7413571	g643074	g6716785	g7413571	g36130	g1655596	g57115	g2331301	g2345154	g7546687	g2668748	g19104	g19102	g338447	g57714	g200796	g643074	g6716785	g7413571		g57121	g292441		g1839334	g10433651	g10434617	g545998	•	g11907599	g5815141	g5815139	g7688667	g2734854	g6137020
1	374	374	374	493	493	493	305	305	305	779	779	779	553	553	553	457	457	457	476	476	476	315	551	551		551	523	523	523	551	1197	1197	1197	1011	1011	101
	2	7	2	0	8	Q	က	က	က	က	က	က	N	8	8	ଧ	8	8	ო	က	က	34	303	303		303	8	N	8	က	-	_	-	109	109	109
	118	118	118	164	164	164	101	101	101	259	259	259	184	184	184	152	152	152	158	158	158	94	83	83		ဆ	174	174	174	183	338	333	338	301	301	301
,	က	ო	က	8	8	N	ო	က	က	က	ო	က	8	N	8	~	8	ત્ય	က	က	က	-	က	က		က	8	N	ત્ય	က	-	-	-	-	-	-
,	384	384	384	385	385	385	386	386	386	387	387	387	388	388	388	389	389	389	390	330	390	391	392	392		392	393	393	393	394	395	395	395	396	396	396

AHNAK nucleoprotein [Homo sapiens]	desmoyokin [Mus musculus]	AHNAK gene product [Homo sapiens]	beta-glucuronidase precursor (EC 3.2.1.31) [Homo sapiens]	beta-glucuronidase [Cercopithecus aethiops]	mutant beta-glucuronidase [Felis catus]	unnamed protein product [Homo sapiens]	unnamed protein product [Mus musculus]	ataxin 2-binding protein [Homo sapiens]	beta-glucuronidase precursor (EC 3.2.1.31) [Homo sapiens]	beta-glucuronidase [Cercopithecus aethiops]	mutant beta-glucuronidase [Felis catus]	pyruvate dehydrogenase phosphatase [Bos taurus]	pyruvate dehydrogenase phosphatase isoenzyme 1 [Rattus norvegicus]	byruvate dehydrogenase [Homo sapiens]		onconeural ventral antigen-1 [Homo sapiens]	ventral neuron-specific protein 1 NOVA1 [Mus musculus]	astrocytic NOVA-like RNA-binding protein [Homo sapiens]	dehydrin 6 [Hordeum vulgare]	dehydrin; DHN6 [Hordeum vulgare]	abscisic acid response protein [Prunus dulcis]	acyl carrier protein [Zea mays]	acyl carrier protein III [Hordeum vulgare]	acyl carrier protein II [Hordeum vulgare]	diazepam binding inhibitor [Rattus norvegicus]	multifunctional acyl-CoA-binding protein [Rattus norvegicus]	diazepam binding inhibitor [Rattus norvegicus]	ubiquitin E3 ligase SMURF2 [Homo sapiens]	KIAA1625 protein [Homo sapiens]	E3 ubiquítin ligase SMURF1 [Homo sapiens]	sorting nexin 15A [Homo sapiens]	unknown [Homo sapiens]	sorting nexin 15 [Homo sapiens]	[Homo sapiens]
1.00E-47	2.00E-47	5.00E-47	1.00E-34	2.00E-33	3.00E-29	1.00E-36	5.00E-34	1.00E-29	1.00E-34	2.00E-33	3.00E-29	9.00E-58	3.00E-56	3.00E-53		1.00E-149	1.00E-137	9.00E-99	1.00E-43	4.00E-43	1.00E-28	9.00E-59	4.00E-49	6.00E-41	1.00E-40	1.00E-40	1.00E-40	0	0	0	9.00E-24	1.00E-23	1.00E-23	2.00E-87
g178281	g50675	g897824	g183233	g3549609	g4102553	g7022046	g7670456	g8671586	g183233	g3549609	g4102553	g414797	g3298607	g7688679		g440878	g7025507	g2673961	g4105111	g6017938	g5738195	g453189	g166971	g166969	g203923	g1228089	g203925	g10953883	g10047327	g6446606	g9622856	g2529709	g9622854	g5823961
316	316	316	099	999	999	588	588	588	663	663	663	1055	1055	1055	416	897	897	897	426	426	426	505	505	505	352	352	352	2414	2414	2414	903	80 80	903	583
8	~	7	202	202	202	106	106	106	205	202	205	651	651	651	စ္တ	-	-	~ -	-	₩.	-	~	8	α	જ	~	7	က	က	က	244	244	244	8
105	105	105	153	153	153	161	161	161	153	153	153	135	135	135	129	299	299	299	142	142	142	168	168	168	117	117	117	804	804	804	220	220	220	168
8	87	8	-	-	-	-	-	-	-	-	-	က	က	က	က	~ -	- -	•		-	-	8	~	8	8	7	8	က	က	က	- -		-	0
397	397	397	398	398	398	333	399	399	400	400	400	401	401	401	402	403	403	403	404	404	404	405	405	405	406	406	406	407	407	407	408	4 08	408	409

rsec5 [Rattus norvegicus] CG8843 gene product [Drosophila melanogaster]	lipase [Homo sapiens]	syntaxin 11 [Homo sapiens]	syntaxin 11 [Homo sapiens]	syntaxin 11 [Homo sapiens]	rab11 binding protein [Bos taurus]	WD-containing protein [Rattus norvegicus]				gag [Homo sapiens]	Gag-Pro-Pol protein [Homo sapiens]	Gag-Pro-Pol protein [Homo sapiens]	prohibitin [human, Peptide, 272 aa] [Homo sapiens]	prohibitin [Rattus norvegicus]	prohibitin or B-cell receptor associated protein (BAP) 32 [Mus musculus]	mitogen inducible gene mig-2 [Homo sapiens]	CG14991 gene product [alt 2] [Drosophila melanogaster]	CG14991 gene product [alt 1] [Drosophila melanogaster]	HERV-E envelope glycoprotein [Homo sapiens]	HERV-E envelope glycoprotein [Homo sapiens]	HERV-E envelope protein [Human endogenous retrovirus]		hepatocellular carcinoma-related putative tumor suppressor [Homo sapiens]	unnamed protein product [Homo sapiens]	contains similarity to Pfam domain: PF01585 (G-patch domain), Score=67.0, E	value=1.3e-16, N=1 [Caenorhabditits elegans]	apoptosis related protein APH-3 [Homo sapiens]	HSPC013 [Homo sapiens]
2.00E-84 8.00E-29	1.00E-50	4.00E-56	1.00E-53	8.00E-46	3.00E-57	8.00E-43	1			3.00E-31	3.00E-31	3.00E-31	1.00E-63	2.00E-63	2.00E-63	6.00E-75	5.00E-33	5.00E-33	3.00E-34	3.00E-34	2.00E-31		1.00E-101	7.00E-75		1.00E-28	7.00E-55	3.00E-49
g2827158 g7295804	g9963839	g3243240	g4104685	g3248918	g4512103	g6049150				g9558701	g5802824	g5802821	g246483	g206384	g541732	g505033	g10727293	g7292434	g2587027	g2587024	g1049232		g10504238	g7020759		g3880143	g4982485	g4689122
583 583	517	1218	1218	1218	640	640	366	880	821	828	828	828	1464	1464	1464	982	982	982	516	516	516	403	648	648		648	486	486
8 8	194	277	277	277	212	212	-	623	183	40	40	40	940	940	940	167	167	167	16	16	16	227	-	- -		-	-	-
168 168	108	314	314	314	143	143	122	98	213	263	263	263	175	175	175	272	272	272	167	167	167	29	216	216		216	162	162
N N	α	-	-	-	8	Q	-	8	က	-	-	-	~ -		-	Ø	8	8	-	Ψ-	-	ય	-	-		-	_	-
409 409	410	411	411	411	412	412	413	414	415	416	416	416	417	417	417	418	418	418	419	419	419	420	421	421		421	422	422

Table 7

Program	Description	Reference	Parameter Threshold
JKA	A program mar removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Applied Diosystells, Foster City, CA.	;
ABIPARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
•	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25:3389-3402.	ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less
	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises as least five functions: fasta, ffasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad Sci. USA 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183:63-98; and Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value=1.06E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less Full Length sequences: fastx score=100 or greater
	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff (1991) Nucleic Acids Res. 19:6565-6572; Henikoff, J.G. and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37:417-424.	Probability value= 1.0E-3 or less
	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) J. Mol. Biol. 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322; Durbin, R. et al. (1998) Our World View, in a Nutshell, Cambridge Univ. Press, pp. 1-350.	PFAM hits: Probability value=1.0E-3 or less Signal peptide hits: Score=0 or greater

Table 7 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, M. et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221.	Normalized quality score2GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M.S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies.	Gordon, D. et al. (1998) Genome Res. 8:195-202.	2.
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12:431-439.	Score=3.5 or greater
TMAP	A program that uses weight matrices to delineate transmembrane segments on protein sequences and determine orientation.	Persson, B. and P. Argos (1994) J. Mol. Biol. 237:182-192; Persson, B. and P. Argos (1996) Protein Sci. 5:363-371.	
TMHMMER	A program that uses a hidden Markov model (HMM) to delineate transmembrane segments on protein sequences and determine orientation.	Sonnhammer, E.L. et al. (1998) Proc. Sixth Intl. Conf. on Intelligent Systems for Mol. Biol., Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence Press, Menlo Park, CA, pp. 175-182.	ial 2.
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	217-221; page VI.

CLAIMS

What is claimed is:

10

15

- An isolated polynucleotide comprising a polynucleotide sequence selected from the group
 consisting of:
 - a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-211,
 - b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-211,
 - c) a polynucleotide sequence complementary to a),
 - d) a polynucleotide sequence complementary to b), and
 - e) an RNA equivalent of a) through d).
 - 2. An isolated polynucleotide of claim 1, comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:1-211.
 - 3. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 1.
- 4. A composition for the detection of expression of diagnostic and therapeutic polynucleotides comprising at least one of the polynucleotides of claim 1 and a detectable label.
 - 5. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 1, the method comprising:
 - a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
 - b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
- 6. A method for detecting a target polynucleotide in a sample, said target polynucleotide comprising a sequence of a polynucleotide of claim 1, the method comprising:
 - a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and

b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

- 7. A method of claim 5, wherein the probe comprises at least 30 contiguous nucleotides.
- 8. A method of claim 5, wherein the probe comprises at least 60 contiguous nucleotides.
- 9. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 1.
 - 10. A cell transformed with a recombinant polynucleotide of claim 9.
 - 11. A transgenic organism comprising a recombinant polynucleotide of claim 9.
- 15 12. A method for producing a diagnostic and therapeutic polypeptide, the method comprising:
 - a) culturing a cell under conditions suitable for expression of the diagnostic and therapeutic polypeptide, wherein said cell is transformed with a recombinant polynucleotide of claim 9, and
 - b) recovering the diagnostic and therapeutic polypeptide so expressed.
- 13. A purified diagnostic and therapeutic polypeptide (DITHP) encoded by at least one of the polynucleotides of claim 2.
 - 14. An isolated antibody which specifically binds to a diagnostic and therapeutic polypeptide of claim 13.
 - 15. A method of identifying a test compound which specifically binds to the diagnostic and therapeutic polypeptide of claim 13, the method comprising the steps of:
 - a) providing a test compound;
 - b) combining the diagnostic and therapeutic polypeptide with the test compound for a sufficient time and under suitable conditions for binding; and
 - c) detecting binding of the diagnostic and therapeutic polypeptide to the test compound, thereby identifying the test compound which specifically binds the diagnostic and therapeutic polypeptide.

25

30

5

16. A microarray wherein at least one element of the microarray is a polynucleotide of claim 3.

- 17. A method for generating a transcript image of a sample which contains polynucleotides,5 the method comprising the steps of:
 - a) labeling the polynucleotides of the sample,
 - b) contacting the elements of the microarray of claim 16 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and
 - c) quantifying the expression of the polynucleotides in the sample.

10

15

- 18. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence of claim 1, the method comprising:
- a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,
 - b) detecting altered expression of the target polynucleotide, and
- c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.
- 20

25

- 19. A method for assessing toxicity of a test compound, said method comprising:
- a) treating a biological sample containing nucleic acids with the test compound;
- b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 1 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 1 or fragment thereof;
 - c) quantifying the amount of hybridization complex; and
- d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.
- 20. An array comprising different nucleotide molecules affixed in distinct physical locations on a solid substrate, wherein at least one of said nucleotide molecules comprises a first oligonucleotide or polynucleotide sequence specifically hybridizable with at least 30 contiguous nucleotides of a target

polynucleotide, said target polynucleotide having a sequence of claim 1.

21. An array of claim 20, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 30 contiguous nucleotides of said target polynucleotide.

5

- 22. An array of claim 20, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 60 contiguous nucleotides of said target polynucleotide
 - 23. An array of claim 20, which is a microarray.

10

20

- 24. An array of claim 20, further comprising said target polynucleotide hybridized to said first oligonucleotide or polynucleotide.
- 25. An array of claim 20, wherein a linker joins at least one of said nucleotide molecules to said solid substrate.
 - 26. An array of claim 20, wherein each distinct physical location on the substrate contains multiple nucleotide molecules having the same sequence, and each distinct physical location on the substrate contains nucleotide molecules having a sequence which differs from the sequence of nucleotide molecules at another physical location on the substrate.
 - 27. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 - a) an amino acid sequence selected from the group consisting of SEQ ID NO:212-422,
 - b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:212-422,
 - c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:212-422, and
- d) an immunogenic fragment of an amino acid sequence selected from the group consisting
 of SEQ ID NO:212-422.

NATIONAL MODERNINGS

```
<110> INCYTE GENOMICS
                             PANZER, Scott R.
                            SPIRO, Peter A. BANVILLE, Steven C.
                             SHAH, Purvi
                             CHALUP, Michael S.
                             CHANG, Simon C.
                            CHEN, Alice
D'SA, Steven A.
                            AMSHEY, Stefan
                            DAHL, Christopher R. DAM, Tam C.
                             DANIELS, Susan E.
                            DUFOUR, Gerard E. FLORES, Vincent
                            FONG, Willy T.
                             GREENAWALT, Lila B.
                             HILLMAN, Jennifer L.
                             JONES, Anissa L.
                             LIU, Tommy F.
                             ROSEBERRY, Ann M.
                             ROSEN, Bruce H.
                             RUSSO, Frank D.
                             STOCKDREHER, Theresa K.
                             DAFFO, Abel
                             WRIGHT, Rachel J.
                             YAP, Pierre E.
YU, Jimmy Y.
                             BRADLEY, Diana L. BRATCHER, Shawn R.
                              CHEN, Wensheng
                             COHEN, Howard J.
                             HODGSON, David M.
LINCOLN, Stephen E.
<120> MOLECULES FOR DIAGNOSTICS AND THERAPEUTICS
<130> PT-1113 PCT
 <140> To Be Assigned
<141> Herewith
<150> 60/184,777; 60/184,797; 60/184,698; 60/184,770; 60/184,774;
                              60/184,693; 60/184,771; 60/184,813; 60/184,773; 60/184,776;
                             60/184,769; 60/184,768; 60/184,837; 60/184,697; 60/184,841; 60/184,772; 60/185,213; 60/185,216; 60/204,863; 60/205,221; 60/204,815; 60/203,785; 60/204,821; 60/204,908; 60/204,226; 60/205,25; 60/205,285; 60/205,232; 60/205,323; 60/205,287;
                              60/205,324; 60/205,286
<151> 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 
                             2000-02-24; 2000-02-24; 2000-02-24; 2000-02-24; 2000-05-17; 2000-05-17; 2000-05-12; 2000-05-16; 2000-05-16; 2000-05-17; 2000-05-17; 2000-05-16; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17; 2000-05-17;
 <160> 422
 <170> PERL Program
```

<210> 1 <211> 543

```
<212> DNA
<213> Homo sapie
<220>
<221> misc_feature
<223> Incyte ID No: LG:1040582.1:2000FEB18
cggccgtcca gacgtcgtgg tggagtgaga ggttcccagg gaggaatgtg caaagtcctg 60 ttggttctac ccctcttcta cttcgaggaa ggggtccgcg tcgcgcgttt ctggaacggg 120
ctctctccct ggggtggctg ctgttctccg ccagattaag ccgggcctgc tggctcagta 180
ctggagtgca gagctgaatt ctggccactt tgtcttctcc acagcctgtg ctcattgcca 240
aggggacaat gacggectec agtgteetee tgeacactgg acagaagatg cetetgattg 300
gtctggggac atggaagagt gagcctggtc aggtgaaagc agctattaaa tatgccctta 360
gcgtaggcta ccgccacatt gactgtgctt ctgtatatgg caatgaaact gagattgggg 420
aggcectgaa ggagagtgtg gggtcaggca aggcagtccc tcgagaggag ctgtttgtga 480
catccaagct gtggaatact aagcaccace ctgaggatgt agaacctgcc ctccggaaga 540
                                                                             543
<210> 2
<211> 633
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:453570.1:2000FEB18
cctgcacgct cctccgcctg attcccagcg cgtcgcactt caagagattc gatcgggttc 60 gccggttcgc gcccgccgcc atggcgactt cctcaggacc aaaggaggcg ccagcgaata 120
accetggget ceagacegag gtegaceeeg ceaceaaagg etacttettg caacaaacga 180
tgttacgtgt gaaggaccca aaagtgagcc ttgacttcta ctcacgtgtg atgggcatgt 240 cgttgctgaa aaggttggat tttgaagaga tgaaattcag tttgtatttt ctaggttacg 300 aggatgtgac cttagcccct gatgatcata tcaagcggac tgaatggact tttaggcaaa 360
aagctactet tgageteace cacaactggg geacggaaaa tgaccetgaa ttcaaaggtt 420
accataatgg gaactcagac cctcgtggtt ttggtcatat aggagtaact gtggatgatg 480
tocactagge atgtgaacge tttgaacgte ttggggttga gtttgtgaag aaacctgatg 540
atggaaaaat caatggcatc gctttcatca aagatcctga tggttatgga tcgaaatatt 600
tgaccagacg attgggacgg ttacttcttc agc
<210> 3
<211> 1674
<212> DNA
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: LG:408751.3:2000FEB18
ctcagccagc gtgaggatcc tcatcaaggg aggcaaggtg gtgaacgatg actgcaccca 120
cgaggctgac gtctacatcg agaatggcat catccagcag gtgggccgcg agctcatgat 180
ccctggcggg gccaaggtga ttgatgccac aggaaaactg gtgatccctg gtggcatcga 240 caccagcacc cacttccacc agacettcat gaatgccacg tgcgtggacg acttctacca 300
tgggaccaag gcagcacteg teggaggeac caccatgate ateggecaeg teetgeeega 360
caaggagace teeettgtgg aegettatga gaagtgeega ggtetggeeg aeeeceaaggt 420
ctgctgtgat tacgccctcc acgtggggat cacctggtgg gcacccaagg tgaaagcaga 480 aatggagaca ctggtgaggg agaagggtgt caactcgttc cagatgttca tgacctacaa 540
ggacetgtae atgettegag acagtgaget gtaccaagtg ttgcaegett gcaaggacat 600
tggggcaatc gcccgcgtcc atgctgaaaa tggggagctt gtggccgagg gtgctaagga 660
ggcactggat ttggggatca caggcccaga aggaatcgag atcagccgtc cagaggagct 720
ggaagetgaa gecaeteate gtgttateae cattgeaaae aggaeteaet gtecaateta 780
cctggtcaac gtgtccagta tctcggctgg tgacgttatc gcagctgcta agatgcaagg 840
gaaggttgtg ctggcggaga ccaccactgc acatgccacg ctgacaggct tacactacta 900
```

ccaccaggac tggtcccacg cggctgccta tgtcacggtg cctcccctga gactggacac 960

WO 01/62927 PCT/US01/06059 caacacctca acctacctca agcetget ggccaagtaa ggcgtttcag gcacattg 1020 cagggatgtg tacatettta ggaagacgte atagagggee caggaaacaa atetgageta 1080 ggtttgattt cattgtgccc ataggateat tgtgcttttc ttaccttctc tgagcccatc 1140 agataattgc catcetattg ggattttatg accgettgat atggagtgag atettetgaa 1200 gtataagagt gaagageaca tatagaactg tgaacegtgg ttatteggaa ttteaaagga 1260 cattgatete ttaetgetaa ageecagtgg ggagetgeag aaegtggeet gtgaettate 1320 ctagaatgta ggggteettt etgtteett tgtteaecte teeetettet tgttggetee 1380 cgtgtgcccc ttgtctgtac atccctcctt ctgtgggttt ctcctccttt ccttccctt 1440 tecettttte ttetgeactt tetececett teetteecae accetteete cagateteet 1500 ttctccagct cttctatttc tgacactgct ttttccccat gcaatcccaa tctaaaggaa 1560 atggtttgat gaacggtctg aattcagtgg gacccaatta tggaagggtt tctgttttat 1620 cccaataact gcttgcagct tctttctctc tcctattaac atttttgggg ccag 1674 <210> 4 <211> 1248 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:090574.1:2000FEB01 <221> unsure <222> 1148, 1234 <223> a, t, c, g, or other <400> 4 cgcgtacgta agctcggaat tcggctcgag ttccaccccg agggaccatg tcgaggctca 60 gctggggata ccgcgagcac aacggtccta ttcactggaa ggaatttttc cctattgctg 120 atggtgatca gcaatctcca attgagatta aaaccaaaga agtgaaatat gactcttccc 180 tecgaceact tagtateaag tatgaceeaa geteagetaa aateateage aacageggee 240 attectteaa tgttgaettt gatgaeacag agaacaaate agttetgegt ggtggteete 300 tcactggaag ctacaggtta cggcaggttc accttcactg ggggtccgct gatgaccacg 360 gctccgagca catagtagat ggagtgagct atgctgcaga gctccatgtt gttcactgga 420 attcagacaa ataccccagc tttgttgagg cagctcatga accagatgga ctggctgtct 480 tgggagtgtt tttacagatt ggtgaaccta attcccaact gcaaaagatt actgacactt 540 tggattccat taaagaaaag ggtaaacaaa ctcgattcac aaattttgac ctattgtctc 600 tgcttccacc atcctggac tactggacat atcctggttc tcttacagtt ccacctcttc 660 ttgagagtgt cacatggatt gttttaaagc aacctataaa catcagctct caacagctgg 720 ccaaatttcg cagttcctg tgcacaagcgg agggtgaagc agcagcttt ctggtgcatc 780 acttggccac cattccctgt gggagcagct ctgccacctg ctctgggcat tgttaatcct 840 ctggtccca aactgaatcc actgggcctt gcttttgctg ctgctaggga agagaaggca 900 gagaagtatt cattaacagt aaacattagt tgtgctcagc cctctgcagt ctacctctgc 960 taggcataaa ataaggagaa gtggcctcgg gtgaaagcag gtttggatta aaatttccta 1020 atgccaggc tgctgaacg ttggattact cttcacctat acttctataa atggtaatc 1080 ttgttataag ttttccacaa gtggcataga gtctcttctg tgaacactgt tcttctgtgc 1140 aggtgggntg gactagatca agggtcttca gcagttttga tcagccagtg gatttcaaag 1200 acccattaat taaaagcttt ttaatcaaaa gctntcttac aaagggcg 1248 <210> 5 <211> 1451 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:229932.2:2000FEB01 taatgattca aagataattt tataaaagcc aaagtaactt gtagctaata tataaaatac 60 ttttgaccag gaacttttaa agtggatgct atgaagatag agagtgtttt tacacattgt 120 ttattgattt taatttcact ttttctctcc ttagggtgtg attaggccca ctggggggata 180

all the day to the the Designation

cgctgtcatg ctacactggt caatgtcttc catatacgga cttcaacccg gagaggtgtg 240 gtgggcagct tctgacttag gctgggttgt tggacattcc tatatctgct atggacctct 300 tcttcatggg aacacaacag ttttatatga ggggaagcct gtgggaacac cagatgctgg 360 cgcttatttc cgtgtgcttg cagagcatgg agtagctgcc ttgtttacag caccaactgc 420

WO 01/62927 PCT/US01/06059

```
aattagagca atcd maac aggaccetgg ggcagctttg ggga agt actctetgac 480 aaggttcaaa acattatttg tggctggaga acgatgtgat gtagagacce tggaatggte 540
caaaaatgtc ttcagagtac ctgtcttaga ccattggtgg caaactgaga ctggatctcc 600
aattactgcg tcatgtgttg gattaggcaa ttctaaaaca cctccaccag ggcaagcagg 660
aaaaagegee caggatacaa tgttatgatt ttggatgaca acatgeaaaa ctgaaggete 720
ggtgtttagg aaatattgtg gtaaaagtta ccattgccac ctggggcttt ttcaggactc 780
tggaagaatc aggaagcatt caagcattta tactttgaaa aatttcctgg atattatgat 840
accatggatg ctggttacat ggatgaagaa ggctatttgt atgttatgtc tcgagtggat 900
gatgtaataa atgttgcagg tcacagaatt tctgcaggcg ccattgaaga gtcaatcctt 960
teceatggta cegtggeaga etgtgetgtt gttggeaagg aagateeett aaaaggteat 1020
gtccccttag cactctgtgt attgagaaaa gatataaatg caacagagga gcaagttttg 1080
gaagaaattg tgaaacacgt tagacagaac attggccctg tggctgcttt tcgaaatgca 1140
gtgtttgtca aacagctacc caaaaccaga tctggcaaga tcccccgatc agctttatct 1200
gccattgtca atggcaagcc atacaagata acttctacaa ttgaagaccc cagcattttt 1260
ggccacgtag aagaaatgct gaagcaagca taatgagttt gtcttattcc tattttgagt 1320
tgatttaatt tettaattga aattaaatta tttgagttgt tteteagaaa taaatatte 1380
agtagaaatt acttgcaaaa tgaaatgtga attgtaaaac ttggcctaaa caaatctaat 1440
gaaaacatgt g
<210> 6
<211> 2615
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:332176.1:2000FEB01
actgataaaa cgatctaaag ggaaggagag accetttgtt ettacacgtt etttetttge 60
tggatcacaa aagtatggtg ccgtgtggac aggcgacaac acagcagaat ggagcaactt 120 gaaaatttct atcccaatgt tactcactct cagcattact gggatctctt tttgcggagc 180
tgacatagge gggttcattg ggaatecaga gacagagetg ctagtgegtt ggtaceagge 240 tggageetae cagecettet teegtggeea tgecaceatg aacaceaage gacgagagee 300
etggetettt ggggaggaac acaccegact cateegagaa geeateagag agegetatgg 360
cctcctgcca tattggtatt ctctgttcta ccatgcacac gtggcttccc aacctgtcat 420
gaggectetg tgggtagagt tecetgatga actaaagaet tttgatatgg aagatgaata 480
catgctgggg agtgcattat gggttcatcc agtcacagaa ccaaaagcca ccacagttga 540
tgtgtttctt ccaggatcaa atgaggtctg gtatgactat aagacatttg ctcatgggga 600 aggagggtgt actgtaaaga tcccagtagc cttggacact attccagtgt ttcagcgagg 660
tggaagtgtg ataccaataa agacaactgt aggaaaatcc acaggctgga tgactgaatc 720
ctectatgga cteegggttg ctetaageae taagggttet teagtgggtg agttatatet 780
tgatgatggc cattcattcc aatacctcca ccagaagcaa tttttgcaca ggaagttttc 840
attetgttee agtgttetga teaatagttt tgetgaecag aggggteatt ateccageaa 900
gtgtgtggtg gagaagatet tggtettagg etteaggaag gageeatett etgtgaetae 960
ccactcatct gatggtaaag atcagcctgt ggcttttacg tattgtgcca aaacatccat 1020 cctgagcctg gagaagctct cactcaacat tgccactgac tgggaggtcc gcatcatatg 1080
acaaagaact gccctggtg atgtgagcag ggacctgcct gcccctttca acctttcccc 1140
teacettttt tgagattttt getgeaatet gtttgeette eetgaateaa aataatettt 1200
cattegteac cattatacta atgaacaata gattteatgt tteaaaattt cagattttac 1260
atgttataga tgtactaaca atattcettg tatcaaacat etcetttet ceetgataca 1320 tageeetgag acatttatag egtteaggag tettetattg ettecattee tteageaggg 1380
ctgcgtgggt ctgttttaac gtgggccaag cctacctggg cagcccattt gccagggctt 1440
geeteaggee atgeageatt ggegetetgg etgeageage tgagttgete aaggeeagtg 1500
tecaagtgga cageageete tggtaeteee eecatttate ttecaeceae atggagetgg 1560 geagageage cetettetgt gtgeaetgea taegetgeag cegtgggagt tatteteee 1620
tagagatega ettggeagea egaaggatte ttttetettt catgettete aggeteaata 1680
gtttctaatt aatcttaaaa tccatgtctt ttacattgtt tttttaatta agtgctgttt 1740
actaaccaaa taatatttat aacatgagta agctataatt aataacaatg aaataaatac 1800
ccatgtaccc accactggac ttcagaagta gaactcatga ctgggactag gatgaggcaa 1860
gggagaccet ggcettgggc acaaaatgta agggatgeca aaaaaataca gtaatcaaag 1920
taagtaatat ttcaatccaa tatttttaaa aatcagaatt aatgcaaaaa aaaccatgat 1980
gaacaaaata ttaaaattta aaataaagac aggattagta ttactgagtt ttccttttgt 2040
cccaggetet aatatggett ggeatgggge agaacattac aacataccag tegtgteatg 2100 gtgeecaagg etccacagae etcagtgget ecetgetgee tgecacagea tetgttttag 2160 cageetegae tecteageae tecteageae acacetette ttateagget teetecaett 2220
agcaacttge taacggccac ctctgtgcct tctgatccct gggcgccaat atcctcctgc 2280
```

PCT/US01/06059 WO 01/62927 cettaceate ettecagged acttaaat eccaettee catgaagee etgegtga 2340 acaeceetae ecceatacee attageagtg attttgeeet teecegtaat getgteecae 2400

ttataactgt getetaetta geatteteag ggateatace ttaatgtttt cagtatgtet 2460 gegttetect actagattgt atgtecetca agageatgtt etgtttetet tetgtetgae 2520 agagcactat tatacctgac tttcagtaac tgttagctgt gattagttag ctggtggatt 2580 taattgatta aaaaattacg attgaatgta aaaaa 2615

<210> 7 <211> 491 <212> DNA <213> Homo sapiens

<220> <221> misc_feature

<223> Incyte ID No: LI:403248.2:2000FEB01

<400> 7 gcctggcagg aggaggaaaa tggttccacc tccaagacca tcgtgtacca ccttgatgag 60 ggcgtgtatg ggatcttcaa ctcagtcctg tttgacaaca tctgccctac ccccatcctg 120 cagaagteta agaaccaete accetgetae atgtetetag agteeattea ttteattgee 180 gtgtageget ettttgaaac cateeaegga geageeetg tacageagea geetgtgggg 240 ceeggeggtt gatggetgtg attgegtgge tgagggeetg tggetgeege aactacaegt 300 aggggaetgg etggtetttg acaacatggg egeetacaet gtggeatgg gtteeeett 360 ttgggggacc caggectgec acateaccta tgccatgtec cgggtggcet gggaagcget 420 gcgaaggcag ctgatggctg cagaacagga ggatgacgtg gagggtgtgt gcaagcctct 480 gtcctgcggc t

<210> 8 <211> 2309 <212> DNA <213> Homo sapiens <220>

<221> misc_feature <223> Incyte ID No: LG:220992.1:2000MAY19

<220> <221> unsure <222> 1738 <223> a, t, c, g, or other

aattaaagat ggctgcgccc atgtaacatc actagcgacc ggtgacctct ttttccccct 60 tgcctggctc ctgtggtggc aggctgggca cgaggaccat gctgggccgg agcctccgag 120 aagtttctgc ggcactgaaa caaggccaaa ttacaccaac agagctctgt caaaaatgtc 180 tctctcttat caagaagacc aagtttctaa atgcctacat tactgtgtca gaagaggtgg 240 ccttaaaaca agctgaagaa tcagaaaaga gatataagaa tggacagtca cttggggatt 300 tagatggaat teetattgea gtaaaagaea attteageae ttetggeatt gagaeaacat 360 gtgcatcaaa tatgctgaaa ggttatatac caccttataa tgctacagta gttcagaagt 420 tgttggatca gggagctcta ctaatgggaa aaacaaattt agatgagttt gctatgggat 480 ctgggagcac agatggtgta tttggaccag ttaaaaaccc ctggagttat tcaaaacaat 540 atagagaaaa gaggaagcag aatccccaca gcgagaatga agattcagac tggctgataa 600 ctggaggaag ctcaggtggg agtgcagctg ctgtatcggc gttcacatgc tacgcggctt 660 taggatcaga tacaggagga tcgaccagaa atcctgctgc ccactgtggg cttgttggtt 720 tcaaaccaag ctatggctta gtttcccgtc atggtctcat tcccctggtg aattcgatgg 780 atgtgccagg aatcttaacc agatgtgtgg atgatgcagc aattgtgttg ggtgcactgg 840

ccggacctga ccccagggac tctaccacag tacatgaacc tattaataaa ccattcatgc 900 ttcccagttt ggcagatgtg agcaaactat gtataggaat tccaaaggaa tatcttgtac 960 cggaattate aagtgaagta cagtetettt ggteeaaage tgetgacete tttgagtetg 1020 agggggeeaa agtaattgaa gtateeette eteacaceag ttatteaatt gtetgetace 1080 atgtattgtg cacateagaa gtggeatega atatggeaag atttgatggg etacaatatg 1140 gtcacagatg tgacattgat gtgtccactg aagccatgta tgctgcaacc agacgagaag 1200 ggtttaatga tgtggtgaga ggaagaattc tctcaggaaa ctttttctta ttaaaagaaa 1260 actatgaaaa ttattttgtc aaagcacaga aagtgagacg cetcattgct aatgactttg 1320 taaatgettt taactetgga gtagatgtet tgetaactee caccacettg agtgaggeag 1380 taccatactt ggagtteate aaagaggaca acagaaceeg aagtgeeeag gatgatattt 1440 ttacacaage tgtaaatatg geaggattge cagcagtgag tatecetgtt geacteteaa 1500

Committee to the Continues

WO 01/62927 PCT/US01/06059 accaagggtt gccaaggga ctgcagttta ttggacgtgc gtt ggac cagcagcttc 1560 ttacagtagc caaatggttt gaaaaacaag tacagtttcc tgttattcaa cttcaagaac 1620 tcatggatga ttgttcagca gtccttgaaa atgaaaagtt agcctctgtc tctctaaaac 1680 agtaaacata tettacaaat taaaatgact tttaggetgg gattacagge gttagcanee 1740 atgeeegget taaaactgge tttttaaatg gaacttttgt ttattttatt ttatteette 1800 etteeettt tttacaatt gaatggaact tttagetttg cegtgetgeg ttaggaaatg 1860 aagacacatc ctgaactgga acaagacttg ccaggggtga actggcaaac tttcctgtac 1920 taacttcaca atccaaacca cacgatgtta tttcttatag tggctgtaaa ggaagaagct 1980 geagggetta aatgtactet ttteeagttt etggatttat etgtagttta ettttatttt 2040 gtegetttgg tegtgeattg aatgttetet tgaettteaa agatttgaaa atatatttaa 2100 tatagtaatt cagagggggt gaactettge atggtttgat taaaattata geettaaaaa 2160 gcattgttag ttttagggca gatagccttt ggattcaagt atatcttgtc tttcatgtat 2220 caattcaact gaccattiga cettaaaagt tggtattitt aatteegaat tattigtgig 2280 ctaccgtaaa tcaggcgtat tgcttgtca <210> 9 <211> 930 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:1094571.1:2000MAY19 <400> 9 cgcacgccgg cggcgcggag gccggctctg cgcttcgggc cgcccctcc cccaccccg 60 ctcacactcg gcacttactt cggctgtctc cgctgccctc cagcggagac gcagctcctc 120 aggcgcccgg cggtatttgt tgggtcggcg gcgtcaggga ttcgcagtgg cctgtggtcg 180 gcgtcgtccg gccactggtg cgcccccgcg gcaggcagag ctcacgctcc tgtcccccgg 240 ctggtccggg gtctgggcgc cgcgtcgacg gcggctccgc aggacgcgca gaccgggccg 300 cagcccatgc cccgagcgga ctgcattatg aggcacctgc cttacttctg ccggggtcaa 360 gtggtgcggg gcttcggcg cggctccaag cagctgggca tccccacagc taattttcct 420 gagcaagtgg tagataatct tccagctgat atatccactg gtatttacta tggttgggcc 480 agtgttggaa gtggagatgt ccataagatg gtggtgagca taggatggaa cccatattac 540 aagaatacga agaagtctat ggaaacacat atcatgcata ccttcaaaga ggacttctat 600 ggggaaatcc tcaatgtggc cattgttggc tacctgagac cagaaaagaa ctttgattct 660 ttagagtcac ttatttcagc aattcaaggt gatattgaag aagctaagaa acgactagag 720 ttaccagaac atttgaaaat caaagaagac aatttcttcc aggtttctaa aagcaaaata 780 atgaatggcc actgatgaaa aattgtatta tttattcatt cactgttttc tagtgtttct 840 gtgtttatta ctgttcagca tcatcttggt tatatactga aaatcaaaca ctttactaca 900 gttgtgaatt agtttaaacc gtacaatgtt <210> 10 <211> 2700 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:350754.4:2000MAY01 gcactgtccg tgccattccc agaggagcct gagaagaggc agaggaaggg cgaaacatgg 60 ctgctctagg agtccagagt atcaactggc agaaggcctt caaccgacaa gcgcatcaca 120 cagacaagtt ctccagccag gagctcatct tgcggagagg ccaaaacttc caggtcttaa 180 tgatcatgaa caaaggcctt ggctctaacg aaagactgga gttcattgac accacagggc 240 cttacccctc agagtcggcc atgacgaagg ctgtgtttcc actctccaat ggcagtagtg 300 gtggctggag tgcggtgctt caggccagca atggcaatac tctgactatc agcatctcca 360 gtcctgccag cgcacccata ggacggtaca caatggccct ccagatette tcccagggeg 420 gcatctcctc tgtgaaactt gggacgttca tactgctttt taacccctgg ctgaatgtgg 480 atagegtett tatgggtaac catgetgaga gagaagagta tgttcaggaa gatgeeggea 540 tcatctttgt gggaagcaca aaccgaattg gcatgattgg ctggaacttt ggacagtttg 600 aagaagacat totoagcato tgoototoaa tottggatag gagtotgaat ttoogcogtg 660 acgetgetae tgatgtggee ageagaaatg accecaaata egttggeegg gtgetgagtg 720 ceatgateaa tageaatgat gacaatggtg tgettgetgg gaattggage ggeacetaea 780 ceggtggeeg ggacceaagg agetgggaeg geagegtgga gateetcaaa aattggaaaa 840

aatctggctt cagcccagtc cgatatggcc agtgctgggt ctttgctggg accctcaaca 900

WO 01/62927 PCT/US01/06059 cagogotgog gtotttgggg toottooc gggtgatoac caacttcaac agotcatg 960 acacagacog aaatotcagt gtggatgtgt actacgacoc catgggaaac cocctggaca 1020 agggtagtga tagogtatgg aatttccatg totggaatga aggctggttt gtgaggtotg 1080 acctgggccc cccgtacggt ggatggcagg tgttggatgc taccccgcag gaaagaagcc 1140 aaggggtgtt ccagtgcggc cccgcttcgg tcattggtgt tcgagagggt gatgtgcagc 1200 tgaacttcga catgcccttt atcttcgcgg aggttaatgc cgaccgcatc acctggctgt 1260 acgacaacac cactggcaaa cagtggaaga attccgtgaa cagtcacacc attggcaggt 1320 acatcagcac caaggeggtg ggcagcaatg ctegcatgga egtcaeggac aagtacaagt 1380 acccagaagg ctctgaccag gaaagacaag tgttccaaaa ggctttgggg aaacttaaac 1440 ccaacacgcc atttgccgcg acgtcttcga tgggtttgga aacagaggaa caggagccca 1500 gcatcatcgg gaagctgaag gtcgctggca tgctggcagt aggcaaagaa gtcaacctgg 1560 tcctactgct caaaaacctg agcagggata cgaagacagt gacagtgaac atgacagcct 1620 ggaccatcat ctacaacggc acgettgtac atgaagtgtg gaaggactct gccacaatgt 1680 ccetggacce tgaggaagag geagaacate ccataaagat etegtaeget eagtatgaga 1740 ggtacctgaa gtcagacaac atgatccgga tcacagcggt gtgcaaggtc ccagatgagt 1800 ctgaggtggt ggtggagcgg gacatcatcc tggacaaccc caccttgacc ctggaggtgc 1860 tgaacgagge tcgtgtgcgg aagcctgtga acgtgcagat gctcttctcc aatccactgg 1920 atgagccggt gagggactgc gtgctgatgg tggagggaag cggcctgctg ttgggtaacc 1980 tgaagatega egtgeegace ctagggeeca aggageggte eegggteegt tttgatatee 2040 tgeceteceg gagtggeace aageaactge tegeegactt eteetgeaac aagtteeetg 2100 caateaagge catgttgtee ategaegtag cegaatgaag ggegetggtg geeteeegta 2160 caaacttgga caacaeggag cagggagage teaceatggg aatgaacee cegeecatge 2220 tgteegeet gggtaaacee teteeatete ceaaggetge cagacatgga ceteeagget 2280 ccagcacate eccetetect etececeagg ttgggtetgg gtecaccetg tectatgact 2340 tgatcacttt tgcacattgc ctggccgctt ctccccagag ctgcctgctc tgtgagcccc 2400

acagecetge teattectea egecetteaa tgetgeagga tggaetgget eetgaeceag 2460 ggaeteteea aaegggatae aggagagaag etggtetaga etgtttgetg ateceeaace 2520 tgeaegggge atteetgett eteateteag gecaecacag agggeagggg atggttagte 2580 acetgeecea geaeteacae eetaaeteaa aataaatgtt aaataagtge gateacacag 2640 eaeeggaetet aeetgaetge tgttgeaeet aaggtggtga aggagaggg aggetgtgge 2700

```
<210> 11

<211> 534

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: LI:255828.29:2000MAY01
```

ctgtaccatt ggeccagett ecegateagt ggagacgttg aaggagatga ttaagtetgg 60 aatgaatgtg getegtetga actteteta tggaacteat gagtaccatg eggagaccat 120 caagaatgtg egcacageca eggaaagett tgettetgae eceateetet aeeggecegt 180 tgetgtgget etagacaeta aaggacetga gateegaaet gggeteatea agggeagegg 240 caetgeagag gtggagetga agaaggeage eaeteeteaa ateaegetgg ataaegeeta 300 eatggaaaag tgtgacgag acateetgtg getggaetae aagaacatet geaaggtggt 360 ggaagtgage egaetgeate atgetgtetg gagaaaeage eaaaggggae tateetetgg 420 aggetgttga gaaacttgtg eatgeagea etgatagete gtgaggetga ggeageeatg tteeaeega 480 agetgtttga agaacttgtg egageettaa gteaeteeae agaeeteatg gaag

```
<210> 12
<211> 2195
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:1190263.1:2000MAY01
```

ccacgetyte gggacattaa tttggtycce tacactytyg gycctcayaa aayactcaya 60 atccttygac gcayttygce gaacccyyay cttayttaac ccycayyycc atttygaayc 120 cctcccytyg ctttayytt ctcctccaty tygaacctya acaacaayaa gytattccaa 180 ycttycacaa tygaytcycc cayyayaccc ttyytettt catyttett gytytyyc 240 acttettya acactatyyc caytycacac atygytycat tyacyacaay ycctaatatt 300 ytcctaaatc catyytyat yacctyyyyt atygyayatc tygyctycta cyycaatyac 360

on the second State of the state states

WO 01/62927 PCT/US01/06059 accatgcagg acgc ca ttcgaccgcc ttgccaggga agg cag actgactcag 420 cacatetety coggeteect etgeageeca aageeggtee eggeteetgt gagggagaag 480 ataccccatc cggatcacgg taataggtta ctagtgggta atagaagtgt gtttccaaat 540 atettgeagt eccegegagg ceteectett aatgagacaa caettgeage ettgttaaaa 600 gaagcaagga tacagcacgg ggcttatagg caaatggcac caaaggtttg cactggcgat 660 tcccagaagt gagccatgtg ccacccatcc atataattag tggcgttttg actaactaac 720 taatgtgcat gcctgttcac ctctctgttg acatgctgct ggccgggacc ccctctcgtt 780 acaacggaat tagcctttga gagtcagctc tggctctgtg tgcagctagt tgccattgcc 840 atcctcaccc taacctttgg gaagctgagc ggctgggtct ctgttccctg ggctcctgat 900 ettetecatg attetgttta ttttectett gggetatget tggtteteca gecacaegte 960 ccctttatac tgggactgcc tcctcatgcg ggggcacgag atcacggagc agcccatgaa 1020 ggctgaacga gctggatcca ttatggtgaa ggaggcgatt tcctttttag aaaggcacag 1080 taaggaaact ttccttctct ttttctcctt tcttcacgtg cacacacctc tccccaccac 1140 ggacgatttc actggcacca gcaagcatgg cttgtatggg gataatgtgg acgagatgga 1200 ctccatggtg ggcaagattc ttgatgctat cgatgatttt ggcctaagga acaacaccct 1260 tgtctacttt acatcagatc acggagggca tttggaagct aggcgagggc atgcccaact 1320 tggtggatgg aatggaatat acaaaggtgg aaaaggcatg gggggctggg aaggtggaat 1380 ccgcgtccca ggaattgtcc gatggcctgg aaaggtacca gctggacggt tgattaagga 1440 acctacaagt ttaatggata ttttaccaac tgtcgcatca gtgtcaggag gaagtctccc 1500 tcaggacagg gtcattgacg gccgagacct catgcccttg cttgcagggc aacgtcaggc 1560 actcggagca tgaattctt ttccactact gtggctccta cctgcacgcc gtgcggtgga 1620 tececaagga egacagtggg teagtttgga aggeteagta tgtgaceegg gtatteaage 1680 caccagette tggtggetge tatgteacet cattatgeag atgtteegga gaacagggtt 1740 acetaceaa accceettet tgettetteg ateteteeag gaacecetea gagteeacac 1800 cettgacaeg tgecacagag eccetetatg atttggtgat taaaaaggtg gecaacgeec 1860 tgaaggaaca cccaggaaac catcgtgctt gtgaccatac caactttcag aaattgaatc 1920 agggcaggag gtggttgaag ctttggtggt ggggtgtccc cattgggtct gtgtgacagg 1980 gaagaggaag tctctaagcc tcggggtcct aaggagaaga gatatttaca atcaggctac 2040 cagaggaagc ctggggtcct aacgagaaga gataattaca atcaggctac caaaggaagc 2100 actaactttg gtgctttcaa gttggcaagg agtgcattta atagtcaata aattcatcta 2160 ccattccaga ttattaaagg cccactggta gttcc 2195 <210> 13 <211> 435 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:270916.2:2000FEB18

```
<400> 13
gaagttttce tccaacgget tatggeecte tacgtggett ctcactacaa gaactetece 60
aatgatetee agatgetete cgatgeacet geteaceate tettetgeet tetgeeteet 120
gtgeececca eccagaatge cettecagaa gtgettgetg ttatecaggt ataggageag 180
aggegteett gtggeagtga tttggggaac cactgaggea teaggaatta gtggettaat 240
aactgeattg tgggagttat gaaactgtgg agteetggte tggaaceaag gggetgggte 300
tgetgagaca ggtgactagg gtgeactgga agaggttage gecactagac acceaaaget 360
ccactgttga eggacggggg aaaagecaga accgaceget etettatttg acteacaget 420
tcettecaca aacag 435

<210> 14

<211> 1574

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature
<223> Incyte ID No: LG:999414.3:2000FEB18
```

tagattcaat tcatttggaa acacagctcc catttttgag tgtgcatgta cttttatgaa 60 gaaatgatgt cagaaaaccg aaggatgatg ataaatacta aaagtaacag gcatgtgaaa 120 aggtcttccg attgagaact ataaggtttg atttcatttt cagataatgg ggtcctagct 180 cttgtgtcgt ccttttacat attctacatc aatggaagtt gtagcaccgt gtcagaataa 240 agtagagtgt atttcatggc ttcttaattt ctttcaatta gactgagatc ttttcttca 300 agagagaagg acactgtcat tgcattgtat tttttctga aaagagtagg ccgtattta 360

WO 01/62927 PCT/US01/06059 ctgagatcac ggagttgtta atgtgacgt tttggtcttc taatattcti agtggattt 420 tctctaaagt agtatgaaca gaaagcettg tatagcaaaa agtaaatcac gtaataatte 480 tgagattttt ggaattgtca caactgagaa acattgctgg cggtgtatgg tccgcaagtg 540 tcaagatgtt ccttgtgaat tgctcgcatc cagcattaag ggctggtttt tatcttttat 600 ttttccaate etettteett eteaaggtgt 'eeaagacaca eggageeaeg gaateteaca 660 cttgttgcat gtatagaagg catgctcctg actgtgatgg cctatgactg ctttgtagcc 1020 atetgtegee etetgeacta eccagteate gtgaateete acetetgtgt ettettegtt 1080 ttggtgteet tttteetta geetgttgga tteccagetg cacagttgga ttgtgttaca 1140 attaaceate ateaagaatg tggaaatete taatttggte tgtgacecat eteaacttet 1200 caacettgee tgttetgaca gegteatega tageatatte atatatttag atagtaetat 1260 atttggttt cttccatct cagggatcct tttgtcttac tataaaattg tcccctcat 1320 tctaagaatt tcatcatcag atgggaagta taaagccttc tccacctgtc gctctcacct 1380 ggcagttgtt tgcttatttt atggaacagg cattggcgtg tacctgactt cagctgtggc 1440 accagccccc aggagtggtg tggtggtgt agtgatgtac actgtggtca ccccatgct 1500 gaaccctttc atctactgcc tgagaaaaca gggacattca aagcgcctgt ggaggtgcgc 1560 agcagaacag tcga <210> 15 <211> 849 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:429446.1:2000FEB18 <400> 15 caggtcagag aacaaaaggc ttgctgccat cttgggagtg gccgccacca tcttgggagc 60 tctaagaaca aagacccacc cgtaacattt ggtggcaact gtacggggat tctccaaagt 120 gtttgtctct tccagaatca aaactgtaaa actacaaatt gttcttcaaa tggagcccca 180 gatgcagtct atgactaaga tctaccacag accettggac eggeetgeta geceatgete 240 egatgttgat gacategaag gegeeeetee caaggaaate tcaactgcat gacceetact 300 aegeeecaat teegeaggaa geagttagag eagteattgg ceaaceteee caacagcact 360 tgagttttcc tgttgagagg gagaactgag agacaggact agctggattt cccaggccaa 420 ctaagaatec ctaagectat etgggaaggt gaccgtatec acetttaaac atagggettg 480 caacttaget cacacccgac taatcagata gtaaggagag ctcactaaaa tgctaattag 540 gcaaaaacag gaggtaaaga aatagccaat catctattgc ctgagagcac agcaggaggg 600 acaatgatca ggatataaac ccaggcattc aagccagcaa tggctaccct ctttgggtcc 660 cctccgtttg tatgggagct ctgttttcat gctattttaa agtcttgcaa ctgcacactc 720 ttctgatcca tgtttgttac agcttgagct gagcttttgc tcaccatcca gcaatgctct 780 ttgccaccat cacagacccg ccactgactt ccatccctct ggatccagca gggtgttcag 840 ctgtgctca <210> 16 <211> 443 <212> DNA <213> Homo sapiens <221> misc_feature <223> Incyte ID No: LI:057229.1:2000FEB01 aaactateet ggattgtata tatatgtata tattgtgtat atatatgtat atattatata 60 cacatatata taaaataaca acccagtcta cctgaatttt cacattttca gaaaactgta 120 ttgagacaga gtcttgctct gtttcccagg ttggagtgcg gtggtgcggt cttggctcac 240 tgcaacctct gccttctggg atcaagtgat tctcctgcct cagcctcctg agtagctggg 300 attatagaca tgcgccaccg tgcccagctg atttttgtat ttttagtaga gatggggttt 360 cgccatgtta gccaggctgg tctggaagca ttttaaaacc aaaaggtttg tatttaactt 420

443

acttactaag attattgtat tcc

```
- WO 01/62927
                                                                  PCT/US01/06059
<210> 17
<211> 1393
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte ID No: LI:351965.1:2000FEB01
<221> unsure
<222> 120, 765
<223> a, t, c, g, or other
gaagetgtaa aactactaat tgttetteaa aaggageeee agatgeagte catgactaag 60
atctaccaca gacccctgga ccggcctgct agcccatgca ccgatgttaa tgatatcgan 120
ageactecce caaggaaatt teaactgeac aaccectact acaccecaat teagcaggaa 180
gcagttagag cggtcgtcag ccaacctccc cagcagcact tgggttttcc tgttgagagc 240
ggggactgag agacaggact agctggattt cctaggctga ctaagaatcc ctaagcctag 300
ctgggaaggt gaccgcgtct acctttaaac acggggcttg caacttagct cacacccaac 360
caatcaggta gtaaagagag ctcactaaaa tgctaattag gcaaaaacag gaggtagaga 420 aatagccaat catctatcgc ctgagagcac agcaggaggg acaatgatcc ggatataaac 480
ccaagcatte gagecagcaa eggetgeee etttgtgtee ecteetttg tatgggaget 540
ctgttttcac tctattaaat cttgcaactg cactcttctg gtctgtgttt gttacggttt 600
gagetgaget ttegetegee gtecaceact getgtttgee gecateggag acetgeeget 660 gaettecate ceteeggate tggeagggtg tteatgtget cetgatecag agaggeacee 720
attgccattc ctgattgggc taaaggcttg ccattgttcc tgcangacta agtgcccggg 780
ttcatcctaa tcgagctgaa cactagtcgc tgggttccac gattctcttc cgtgacccac 840
gacttctaat agagetataa cactcaccge aeggeecaag attecattee ttegaateeg 900
tgaggccaag aaccccaggt cagagaacat gaggcttgcc accattttgg aagtggcctg 960
ccgccatttt ggaagtggcc tgccaccatc ttgggagctc tgggagcaag gaccccctgg 1020
taacagtagt agatacatag aatttttaaa taaacatact tatattaagg gtactcttag 1080
ggtctatact aagaaatttt gcatgettgt cattaaaagc tttgagtcca agtcctgtgt 1140 gtgtgtatat gactttgact ctaagtcaag tgtaaatgta actgtataga tatgccatgt 1200
atataatgta aataaaatat atacatatat ttataaataa ggcagtctga aaacttgctt 1260
gctggtgaac tttaaaacag cctctttctc gtgatatacc cctccagttt atccagtgga 1320
aaagaaaatt actgctggat taaaaacaag tgcttaggct aggtgtggta cctcatgcct 1380
gtaatttcag cac '
<210> 18
<211> 884
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:068682.1:2000FEB18
<400> 18
acageggeea atgtetggea gtgggeacat gggggtgegg gggtgtaggt geeaagegee 60
atggettaga eeegagattg gagteeggee geeeeeeege ageeaageeg eeteetgeee 120
cccgtgegcc ctaggegcca ccatgteggg agacaaactt etgagegaac teggttataa 180
getgggeege acaattggag agggeageta etecaaggtg aaggtggeea eatecaagaa 240
gtacaagggt accgtggcca tcaaggtggt ggaccggcgg cgagcgcccc cggacttcgt 300
caacaagttc ctgccgcgag agctgtccat cctgcggggc gtgcgacacc cgcacatcgt 360
geacgtette gagtteateg aggtgtgeaa egggaaactg tacategtga tggaagegge 420
cgccaccgac ctgctgcaag ccgtgcagcg caacgggcgc atccccggag ttcaggcgcg 480 cgacctcttt gcgcagatcg ccggcgccgt gcgctacctg cacgatcatc acctggtgca 540
ccgcgacctc aagtgcgaaa acgtgctgct gagcccggac gagcgccgcg tcaagctcac 600
cyacttegge tteggeegee aggeecatgg etacceagae etgageacea cetactgegg 660
ctcagccgcc tacgcgtcac ccgaggtgct cctgggcatc ccctacgacc ccaagaagta 720
cgatgtgtgg agcatgggcg tcgtgctcta cgtcatggtc accgggtgca tgcccttcga 780
cgactcggac atcgccggcc tgccccggcg ccagaaacgc ggcgtgctct accccgaagg 840
cctcgagctg tccgagcgct gcaaggccct gatcgccgag ctgc
```

<210> 19

WO 01/62927 PCT/US01/06059 <211> 1116 <212> DNA <213> Homo sapiens <221> misc_feature <223> Incyte ID No: LG:242665.1:2000FEB18 <220> <221> unsure <222> 1087, 1090 <223> a, t, c, g, or other caccacctca tttcgcttta tttcacagac ttccccatct cattttttat gttctatgct 60 aattteteaa gaagaacagg eeeggeacea eetetgegea caacceegeg ggeetggete 120 aggeggagt geggggeeag caccatgage geceegggea geceegacea ggeetatgae 180 tteetgetea agtteetget ggtgggegae agggaegtag geaagagtga gateetggag 240 ageetgeagg atggtgeage tgagteeeeg tacageeate teggggggat egactacaag 300 acgaccacca tectgetgga eggecagegg gtgaagetga agetetggga taegtegggg 360 cagggaagat titgtaccat attccgctcc tactctcgtg gtgcacaagg agtgatcctg 420 gtctacgaca ttgcaaaccg ctggtctttc gagggtatgg atcgatggat taagaagatt 480 gaggaacatg cccctggtgt ccctaaaatc ctggtgggga atcgcctaca tctggcattc 540 aagaggcagg tgcccaggga gcaggcccag gcctacgccg agcgcctggg tgtgaccttc 600 tttgaggtca gccctctgtg caatttcaac atcatagagt ctttcacgga gctggccagg 660 atagtgetge tgeggeacag gatgaattgg etegggagge egageaaggt actgagettg 720 caagacetet getgeegeac categtgtee tgeacacetg tgeatetggt ggacaagete 780 cegeteecea gtacettaag aagecacete aagteettet ecatggetaa gggeetgaat 840 gecaggatga tgegaggeet etectaetee eteacacea getecaetea caaaaggage 900 agoctotgoa aagtgaagat ogtotgocca coccagagoo cacccaaaaa otgoaccaga 960 aacagetgea aaatttetta aggaaggeac caaaaggaaa caagetggaa tegetecagg 1020 aaaaactetg gttacacetg gaagatggaa gtegeattgt agatteaaga aattagtttt 1080 cagtttntcn cgggaaccat gctgcttggg aatgtg <210> 20 <211> 585 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:241743.1:2000FEB18 <400> 20 ccggcccaga atgtagaaac ggttaggagg gacctgtgaa aaagcgggac accaagaaga 60 gcactgttgc tgtttttagt ttttaaaata agaggaagcc cagtgtccca tctgatgccg 120 aggetgaagg agtetegete ceaegagtee etgeteagee ceageagtge ggtggaggeg 180 ctggacctca gcatggagga agaggtggtc atcaagcccg tgcacagcag catccttggc 240 caggactact gettegaggt gacgacgtea teaggaagea agtgetttte etgeeggtet 300 gcagctgagc gggataagtg gatggagaac ctccggcgag cggtgcatcc caacaaggac 360 aacagccggc gtgtggagca catcctgaag ctgtgggtga tcgaggccaa ggacctgcca 420 gccaagaaga agtacctgtg cgagctgtgc ctggacgatg tgctctatgc ccgcaccacg 480 ggcaagctca agacggacaa tgttttctgg ggcgagcact tcgagttcca caacttgccg 540 cctctgcgca cggtcactgt ccacctgtac cgggagaccg acaag <210> 21 <211> 2950 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:034212.1:2000FEB01 <220> <221> unsure

<222> 52, 132

<223> a, t, c, r other

```
<400> 21
tactatattg ctcagcattt ctaagtattc tctaagtgct ctttatttat gntttaaaat 60
agetetetta eccagetgeg aagaetagaa gaaettgatt taggaaacaa tgaaatatat 120
aatttgccag antcaattgg agccctctta catctaaaag atctctggtt ggatggaaat 180
caactgtcag aattacctca ggaaatagga aatctgaaga acctgctgtg titagatgtc 240
tetgaaaaca ggttggaaag actteetgaa gaaateagtg geetgaette attaaeggat 300
ttagtcattt cccagaactt attagaaacg attccggatg gcattggaaa actaaagaaa 360 ctgtcaatct tgaaggtgga tcagaataga ctcacacagt tgcctgaagc agttggggaa 420
tgtgaaagtc tcactgagtt agttcttaca gaaaatcagc tcctgaccct gcctaaaagc 480
attggaaaac taaagaagtt gagcaacttg aatgcagaca gaaataaatt agtgtcctta 540
ccaaaagaga tcggcgggtg ctgcagcctc actgtgttct gtgtacgtga caacagacta 600
acteggatac etgeagaggt gteacaggea acagaactte atgteetgga tgtggeaggg 660 aacaggttge tgeatetace tttateeetg actgeettga agttgaagge tetgtggeta 720
tetgacaace agteccagee eetgettaca ttecagacag acacagacta caccacagga 780
gagaagattt taacctgtgt ettactteet eagetgeett etgaacctae ttgteaagag 840
aatctgcctc gctgtggtgc actggagaac ttggtaaatg atgtctctga tgaagcctgg 900 aacgagcgtg ctgtcaacag agtcagtgcg atccgatttg tggaggatga gaaagatgaa 960
gaagacaatg agacgagaac acttetaagg cgagccacte cacacccagg ggagttaaag 1020
cacatgaaaa agacagtgga gaatttacgg aatgacatga atgctgctaa aggactggac 1080
tcaaacaaaa acgaggtcaa tcatgccatt gaccgagtga ccacttctgt gtagagtttc 1140 acctccaagt tttacctcct gtgtcttcct ctgctgtcga gacgttcctg tctgcttccc 1200
gggagectea egtgeteett gteetaacea geeeeegege geeatettee egtggagtgt 1260
ggggaagetg etgtetecca ggaagtgeet tacteatece gcaaceagte agegeaceag 1320
tggtctcccg gtgtgatttt tttttttta atttcagttg tttgtaataa gtagaataca 1380
ctactgtaaa catacgacct ttgtttttgt cttatgttgg ggtaaaggaa agcaggaagg 1440 ggaattttta teeteetee tteegtaaag tgetgggata ttttgaatee eccaagttee 1500
cttggaccta ctgatgagag atagttttat gtatggggaa aaatggatac tttttaaacc 1560
ttttttggca getcagatgg tgtaaatttt aaaattttgt ataggtattt cataacaaaa 1620
atatgtattt cttttttgtt attttatctt gaaaacggta catattttag tatttgtgca 1680 gaaaaacaag tectaaagta tttgtttta tttgtaccat ccaettgtge cttactgtat 1740
cctgtgtcat gtccaatcag ttgtaaacaa tggcatcttt gaacagtgtg atgagaatag 1800
gaatgtggtg ttttaaagca gtgttgcatt ttaatcagta atctacctgg tggatttgtt 1860 tttaaccaaa aagatgaatt atcaatgatt tgtaattata tcggttgatt ttttttgaaa 1920 agatgaacca aaggatttga ctgctaatat tttattcctt acacttttt tctgaataag 1980
teteteataa tgagtgeagt gteagaetgt geetaetetg atggtatgtg ceatttgtaa 2040
aataaaatag agcagaaaaa cacaaaaaga gaacactggt tcagacattc agtgggcaag 2100
taaattatgg actgcaaaat aatgattttt attcaagaaa gctttaaaag ttttatatcc 2160
agatatacaa ccacaataaa gcaaaataac ctactatcaa aatagaaatg ttgctatctt 2220
tataagtgca atttaatttg taaatagagt ttgaatcaaa gtatcacaaa atactgcttc 2280
aagatttaat tttaaatctg ctaatttaag ggatattggg aaaagttttg gtgtgtttct 2340 gttgatttct tttttgtatg ctgtgataaa agagaaatga aaagtgccag tcactgtgtg 2400
gtgtctagga aaatcatata tatttttttc tccaagaaat aaattcatcc tggacattgg 2460
ccatacaget ttttaaaatt attactttgt atgttcaagt gatagcaggt agccaaattc 2520
tttgacagtg tgctctggtc tgttaaatat ctaaattacc cgtcagttgt gagtgacctc 2580 ctgtgggact tgcattcaca tggggcagag cccagaattg cctttgactc tggctagtaa 2640
ttttgggttg tggctatctg gccaattgga ctccttataa acccgtcttc aaccaaccaa 2700
ataccatact tttttttact tcctatacat ttacttattg ggttcactta gctttttagt 2760
ctgtgtgtat gtaaatatgt gtgtatttta aaaactattt atggagctga aagtacataa 2820
cacataagtg agtttcggct ggtcagtttt ataccttgtt ccctaatctg tgcataccaa 2880
ttttcttttc tctgttttaa gatttttgac atcctctatt ttgttttaag cttataaaga 2940
taatgccact
                                                                                  2950
<210> 22
<211> 1973
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:344886.1:2000MAY19
<400> 22
gttctgccga gtggggcgcc gcggccgcta ttgtcccgcc ccctgctccg caagattcga 60
geetgagegg cetgggegte tegagaggtg agagagttgg eggegaggte teggeggeta 120
```

agegagegte ggegaetgte teteegegag aggaggeaag ttggggteea ggeteeaaag 180

WO 01/62927 PCT/US01/06059 ceggtggeeg egtacegegg gageeget gtetttgagg tetgaggaga acagacag 240 agtetagete ttteacecag getggagtga agtggtgeaa teteagetea gtgeaacete 300 egeeceetgg gtteaagtga tteteetgee teageeteee eagtggetgg gattacagtg 360 atatoctgag agaagatggg aaagggctgc aaggttgtgg tttgtggatt gttatotgtg 420 gggaaaactg caattttgga gcagctcctt tatggaaatc atactattgg aatggaagat 480 tgcgaaacaa tggaagatgt atacatggct tcagtagaaa cagaccgagg agtaaaagaa 540 cagttacatc tttatgacac cagaggtcta caggaaggcg tggagctgcc aaagcattat 600 ttttcattg agagtggagc ttctgaagaa agaaatcgat aagttcaaag acaaaaaaga ggtagcaatt 720 gtggtattag gaaacaaaat cgacctttct gagcagagac aagtggacgc tgaagtggca 780 cagcagtggg caaaaagtga gaaagtaaga ctgtgggagg tgactgttac agatcggaaa 840 actctgattg aaccattcac tttattagcc agtaaacttt ctcaacccca gagcaaatca 900 agctttcctt tgcctgggag gaaaaacaaa gggaactcta attctgagaa ctaaaaatca 960 gtaatttcca caattgtatg ttgaatagtg attgccttta agtgtctgtg aacatggagt 1020 aatattacta tttaaaatag gccatttgta tctacctttg gtccttagga aaattcctaa 1080 ggaagtcaat taatgcactt tagatgttaa aagtatttgg gctaaggtta ttattgcctg 1140 atatgaaata atatattctt attctcattg tttgaaacct gtctttgaaa ttagcacctt 1200 tgttatttat gttgtacttg tgaaaacagt aaaatagttt ggatagttat gcaaatgcac 1260 ctatgtgtaa cttcccccca accccaagct gtttcggaag atatcataat cattctgtgt 1320 aacattatgc aaacttctaa gcccaaacat gactttgttt ttaaaaagtt cattaatcta 1380 atgtctagga ttataaaaca tttttttgtg tctaaattgg acccaaaaca ttgaacagtt 1440 tggggtagta agctaaattt catcttgtgg agattttgct aaacagacta agacccatga 1500 tttagctttg ctcaaattag aatgtttagc atgagttgag gtaccaggta gtgttaagta 1500 ggttcatcac gctctaaggc cgttttttcc ttagccagac ccctgttgat agaccagata 1620 cttgagggca aactgtttgc tcctccttt gaaaatgatt aggcacttaa ggacagtaaa 1680 gctgtatttt ctggaaggaa gactgtatct tctggaatag ttttctagaa aactagtcat 1740 atacaataaa agtatcaaaa atattgggct ctaatttgat ctgacttaga tgtctgagtt 1800 tgtgttgttt ctctaaagat tttggcaaga ctcaagcaat gtggctgact gtaactttat 1860 taatttaaaa ggtaggaagt aagctactta gtggtttcac ctgtgaaata actattttga 1920 ctgaaatgta aaataagcta ttcaacaaag aacatattaa aacatcaagt aat <210> 23 <211> 683 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:228930.1:2000MAY19 geeggageee agatgageee agatggeegg ggeteaacce ggagtgeacg cettgeaact 60 caagecegtg tgcgtgteeg acagecteaa gaagggeace aaattegtea agtgggatga 120 tgactcaact attgttactc caattatttt gaggactgac cctcagggat ttttctttta 180 ctggacagat caaaacaagg agacagagct actggatctc agcettgtca aagatgccag 240 atgtgggaga cacgccaaag ctcccaagga ccccaaatta cgtgaacttt tggatgtggg 300 gaacatcggg cgcctggagc agcgcatgat cacagtggtg tatgggcctg acctcgtgaa 360 catctcccat ttgaatctcg tggctttcca agaagaagtg gccaaggaat ggacaaatga 420 ggttttcagt ttggcaacaa acctgctggc ccaaaacatg tccagggatg catttctgga 480 aaaagcctat actaaactta agctgcaagt cactccagaa gggcgtattc ctctcaaaaa 540 catatatcgc ttgttttcag cagatcggaa gcgagttgaa actgctttag aggcttgtag 600 tettecatet teaagggtgg aaaaagetaa tgaggetgeg aaaagtgage agagetgtgg 660 aaaggctccc ccaaaacatt ttc <210> 24 <211> 1435 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:338927.1:2000MAY19 <220> <221> unsure <222> 1409, 1432 <223> a, t, c, g, or other

WO 01/62927 PCT/US01/06059

```
<400> 24
gtgageegae ettetgagee etcaagaaag atcagaacag atteatgggt gatttageet 60
atetytecca ggecagegty getyagtyty etygetygag geetetetet etyettegag 120
ggtagetgag atceaeccg gaaaccggca ggatgaaggg ggcaagtgag gagaagetgg 180
catctgtgtc caacctggtc actgtgtttg agaatagcag gaccccagaa gcagcaccca 240
gaggccagag gctagaggac gtgcatcacc gccctgagtg caggcctccc gagtccccag 300 gaccacggga gaagacgaat gtcggggagg ccgtggggtc tgagcccagg acagtcagca 360 ggaggtacct gaactccctg aagaacaagc tgtccagcga agcctggagg aaatcttgcc 420
agoctgtgac cototoagga toggggacgo aggagocaga gaagaagato gtocaggago 480
tgctggagac agagcaggcc tatgtggcgc gcctccacct gctagaccag gtgtttttcc 540
aggagetget gaagacagee egeageagea aggeetteee agaggatgtg gteagggtea 600 tetteteeaa cateteetee atetateagt teeattetea gttetteete ceagagetge 660
ageggegeet ggacgactgg tgaggteeac caggageeec tgaggeetea gaecacagee 720
ctggccaggt ggaggtgggg agaccccagg gcgctaggtt cagcctccta ggcccaggcc 780 cttattgtgt ggccatgcct ccctggggct cggtctgtct gcacagtgaa gggcttgggt 840 gaatgagctc tgagaggctg tgtgtgtgca gactgcttcc tggggaaagg ggtggatcag 900
gtcctggcca agccaagtga ccaagtgact ttgggacagt gaaaatagec agtgccaact 960
gagggettee tacacgeetg geettggget tteeetetat taacteeete aatetteaca 1020
teageetget gtgtgatgae ggeateatgg ttatgeaaga aaccetettg ttttcacaga 1080
tggccactaa agcatttaac agtgaagtta cttgccttat atagtttgcc acgaagtcta 1140
ggatgtcctt taagatcttt ggcaaagaag aatgctagta attgttaaac ctagtgatgt 1200
attgattgct taaaacattt ataataaact gttgtttttt tttaagataa taatagccac 1260
catacctggc gcatgcatat titttaagag tacccactgg agtctaatat atagcctggg 1320 ttacctggga tgaagaataa agagagcaaa ctaccacaag caatggttga gcccctgtca 1380 agtgccagtc atgatagtag taataatant aataaacatc tattgggcca anaaa 1435
<210> 25
<211> 1508
<212> DNA
<213> Homo sapiens
'<220>
<221> misc_feature
<223> Incyte ID No: LG:898771.1:2000MAY19
ggtgacccag cgacctgtgt gtcccacagc ccgtccgtcc ctctgtcagt ctccctgtca 60
ctggcatgtc ctgggtggtc ccagtggcac cttctaggcc cggcccctgg atgcggtgga 120
ggetgecegg ggtgggtcag catggggttg teeetgtgag cacageteeg ggagaceegt 180 acteagaate etcagetet etegeetgag geggaaatgt gaettgggaa ttgteeteea 240 tataaaggaa gcaaaateag ggeetagggg ctagagtgea gtggtgtgat catageteac 300
tgcagcctcg acctcccagg ctcaagccat cttcctgcct cagcctcctg aacagctgga 360
actgcagtgt coccaactcc tgcccagcca gtccacgcgg tgccggctcc tccagttacc 420
getttgtgea gaacgtgace teggaeetge agetggeage agagtttgea geaaaggeeg 480
cgtcggagca gcaggcagac acgtctggag gagacagccc caaggatgag tcaaagccgc 540
egttetecta egegeagetg ategtgeagg ceatetecte egeceaggae eggeagetga 600
ccctgagegg gatetacgec cacateacca agcattacec ctactacegg acggecgaca 660
aaggetggea getgaageeg agteeceagg geeggatege etetgaagge eettagaaca 720 tggaacteac aggeatattg etteeettaa aacagaagag aegeggegeg eeegeeetge 780
agctgcccaa gcagtgtacc ttccggtttc ccagcacggc catcaagatc cagttcactt 840
cgctctatca caaagaagag gcccagcct cccgctgcg gccactgtac ccccagatct 900 cccctctgaa gatccacatc ccggagccgg acctccggag catggtcagc cccgtcccct 960 ccccgacggg caccatcagt gtccccaact cctgccagc cagtccacgc ggtgccggct 1020
cctccagtta ccgctttgtg cagaacgtga cctcggacct gcagctggca gcagagtttg 1080
cagcaaaggc cgcgtcggag cagcaggcag acacgtctgg aggagacagc cccaaggtct 1140
gageceacet ggegeegtgg tgeacetggt gacecaggat egggeeatag tgacecggeg 1200 egggeggeac agacagecea gggeetgegg gegtgtgete gaggtggtet eageceacag 1260 ggaatggage egcagetgge ggtagageeg teggeeettt etegttteg tgeecaaate 1320
atcceegttg gtcatttget ggtgacaggg gtggegeegt cacegaggge eceteeegee 1380
acgctccttg ttcatctgcc gctggcagcc cggcgtcaaa gccttcatac agcccttgag 1440
caggatggcg ttctccttat aactitgtct tagttcattt ttgtccaata gctgttttca 1500
aattgatt
<210> 26
<211> 574
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> misc_feature
<223> Incyte ID No: LI:257664.67:2000MAY01 "
cgacctaaga attgccggga ggatggatgg ctggcgcgcg aattgttgct tttgctcttg 60 gctgatggtt gaggaatgta gagagactgt gtggggtttg tgtgacactg cggtgccttg 120 cagattaggt gagctttcaa tctctcttta aaaggggcgg cgaagaggac ccgcaggctg 180
caaggagcaa cagcgatggg taggcacatt caaaaccaga aaaaattgtt aacaaaccaa 240
acaaacatga agatcatact gggaaactga ggccagagac ccgggaagaa aataaaaatc 300
atttaaagga ccatcagcca tattggcata catttgtgaa taacacacaa tttcctgaca 360
tttgggagca agtaaagtgc gtaacataaa tttttttggc catgcttaaa gtagaatgag 420 atccagctgg gggaaagtta tagatttcag ccttggatga tcagtttagg atttcgagaa 480 ttgatgttt tccatatggt ttctgtttc ccccagctct ccatttgaac cagctgcttg 540
ttttaaaact atctactaaa ttccatctac ccac
<210> 27
<211> 1969
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:001496.2:2000MAY01
<400> 27
ggggegetgg gggtgacggt geggageege tgccageget gggegagagt eggeggeegg 60 atccgaggag caggegggee tgaggeegag teagetgege gggeeeeegg atcccegae 120
agagacggcg gcggtgtctg gccaggcggt aggcgctgcc tggcccgcgg cggggaagat 180
gttcagegta gagtcgctgg agcgggggga gctgtgcgag agcctcctca cttggatcca 240
gacatttaat gttggatgca ccatgccaga acccgtggaa gatttaacga atggggttgt 300
gatggcccag gttcttcaaa agatagatcc tgcatatttt gatgaaaatt ggctaaacag 360 aatcaaaact gaagtaggag ataattggag gctaaagata agcaatttaa agaaaatttt 420 aaaaggaatc ttggattata atcatgagat tttaggacag caaattaatg actttaccct 480
tcctgatgtg aaccttattg gggagcattc tgatgcagca gagcttggaa ggatgcttca 540 gctcatctta ggctgtgctg tgaactgtga acagaagcaa gagtacatcc aagccattat 600 gatgatggag gaatctgttc aacatgttgt catgacagcc attcaagagc tgatgagtaa 660 agaatctcct gtctctgctg gaaatgatgc ctatgttgac cttgatcgtc agctgaagaa 720 aactacagag gaactaaatg aagctttgtc agcaaaggaa gaaattgctc aagaaggca 780
tgaactggat atgeaggttg cagcattgea ggaagagaaa agtagtttgt tggcagagaa 840 teaggtatta atggaaagae teaateaate tgattetata gaagaeceta acagtecage 900 aggaagaagg catttgeage tecagaetea attagaacag etceaagaag aaacatteag 960
actagaagca gccaaagatg attatcgaat acgttgtgaa gagttagaaa aaggagatct 1020
ctgaacttcg gcaacagaat gatgaactga ccactttggc agatgaagct cagtctctga 1080 aagatgagat cgacgtgctg agacattctt ctgataaagt atctaaacta gaaggtcaag 1140 tagaatctta taaaaagaag ctagaagacc ttggtgattt aaggcggcag gttaaactct 1200 tagaagagaa gaataccatg tatatgcaga atactgtcag tctagaggaa gagttaagaa 1260
aggecaaege agegegaagt caaettgaaa eetacaagag acaggtagta gaactacaaa 1320
acagattato ogaagaatoa aagaaagoag ataaactaga ttttgaatat aagoggotaa 1380
aagaaaaagt tgacagtett caaaaagaaa aggacagget gagaacagaa agggattete 1440
tgaaggaaac cattgaagag cttcgttgtg tacaagctca agaaggccag ctcacaacac 1500 aagggttaat gcctcttgga agtcaggagt cttcagacag tctagctgca gagattgtta 1560
cacctgaaat cagggagaaa citattegte tteageatga gaataagatg ttaaagetta 1620
accaagaagg ttcggacaat gaaaaaatag ccttattgca gagccttcta gatgatgcaa 1680
atctacgcaa gaatgaactg gagacagaga ataggctggt gaatcaaaga cttctggaag 1740 tacagtcaca agttgaagaa ttacaaaaat ctttacagga tcaaggctca aaagcagaag 1800
atgetattte agteetteta aaaaagaage ttgaagaaca tetagagaag etgeatgagg 1860
ccaataatga actacagaag aagagagcca ttattgaaga tctcgagcca agatttaaca 1920
                                                                                                              1969
acageteett aaaaattgaa gaattaecaa gaagetttae gaaagaaag
<210> 28
<211> 2476
<212> DNA
<213> Homo sapiens
<220>
```

e i sesso e la Maria dell'income

<221> misc_feature

<223> Incyte ID

LI:1085273.2:2000MAY01

```
<400> 28
egggeeeege egggeeeatg gaeggegegg eegagegge geeetgageg eggtgegggt 60
cctcggagca cccccgaggt gagcgcaagc aaggtccggc atcatgtgct aggttattcc 120
cagtgcgagg ccacacttgg gccgtcggag cagcccctcc tcacttcagg ggtcaccctc 180
cccaagaccc attgccccat gatggccggg gaccggctcc ccaggaaggt gatggacgcc 240
aagaagetgg ceageetget gegggggggg cetgggggge egetggteat egacageege 300 teettegtgg agtacaacag etggcatgtg etcageteeg teaacatetg etgetecaag 360
ctggtgaagt ggcggttgca gaagggcaag gtgaccattg tggagttcat ccagccggct 420
gcacgcagcc aggtggaggc cactgagcca caggacgtgg tggtctatga ccagagcacg 480
egggaegeca gegtgetgge egeagaeage tteeteteea teetggetga geaagetgga 540
eggetgette gacagegtgg ceatecteae tgggggette geeacettet ecteetgett 600 ecceggeete tgegagggea ageetgetge cetgetaeee atgageetet eccageeetg 660
cetgeetgtg cecagegtgg geetgaeeeg cateetgeet caectetace tgggetegea 720
gaaggacgtc ctaaacaagg atctgatgac gcaaaatgga ataagctacg tcctcaacgc 780
cagcaactec tgccccaage etgactteat actgcgagag ecgetteatg egggteecca 840
tcaacgacaa ctactgtgaa aaactgctgc cctggctgga caagtccatc gagtacatcg 900
ataaagccaa getetecage tgecaagtca tegtecactg tetggetgge ateteceget 960
etgecaccat egecategee tacatcatga agaccatggg catgteetee gaegaegeet 1020,
acaggttegt gaaggacagg egecegteea tetegeecaa etteaaette etgggeeage 1080 tgetggagta egagegeaeg etgaagetge tggeegeeet geagggegae eegggeacee 1140
cctcagggac geeggagect ecgeecagte etgeegeegg ggeecegetg ecaeggetge 1200
caccacctac ctcagagage getgecacag ggaatgegge tgccagggag ggeggeetga 1260
gegegggegg ggagececec gegeececea egeeceegge gaccagegca etgeageagg 1320 geetgegegg cetgeaecte teeteggaec geetgeagga cactaacege etcaageget 1380
cetteteet ggacateaag tetgeetaeg eccetageag geggeeegae ggeeeeggge 1440
cccccgaccc cggcgaggcc ccgaagctct gcaagctgga cagcccgtcg ggggccgcgc 1500
tgggcctgtc ctcgcccage ccggacagcc cggacgcgc gcctgaggcg cggcccacgg 1560 ccccgccggc ggccccggcc ccccgccggc tcccccgcg gctccccgc gcacagcctc 1620 ggcctgaact tcggcgatgc ggcccggcag actccgcggc acggcctctc ggccctgtcg 1680
gegeeeggge tgeeeggee tggeeagegg geeggeeeeg gggeetggge accgeett 1740 gaeteeceag geacgeegte geeegaeggg ceetggtget teageeeega gggegeacag 1800 ggggegggg gggtgetgtt tgegeeette ggeegggegg gegeeeeggg accaggegge 1860 ggeageagec tgeggegge ggaageageg agggetgage ceegggaegg eggaeegge 1920
tggcccgagg agccggcccc ggagacgcag ttcaagcgcc gcagctgcca gatggagttc 1980
gaggagggca tggtggaggg gcgcgcgcgc ggcgaggagc tggccgccct gggcaagcag 2040 gcgagcttct cgggcaacgt tgaagtcatc caagttgtct ctgacccttc ggctgccttc 2100
ggccccgccg cccgcagcca ggcccgtaat aaatgtatat tatatataat gcaaagaaag 2160
gtaaatggtt taactgggaa ttttaatccg agaagtaaaa taatttcgat tttttattta 2220
tttaagetgt teattetgge aatggatttg geaacagtge gggtggteet egagetteea 2280 tttttaetgt etggtattta aactgaaaca taegttteta ageaataega ggeeacette 2340
cagtegeaag etgggtgeea ggeetgggge ceetcecagt teceeegeee caggaaacae 2400
tgctgacctt tgcaaaggct gccgagcttt cgtgcacttt ttacataaca aaaaggtgaa 2460
                                                                                            2476
aaaaaggaaa aaaaaa
<210> 29
<211> 2689
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:333138.2:2000MAY01
<400> 29
aggagetgga gtgggagete aageaggatt etteeegagt eeetgggtaa gacaaceetg 60
gettetttte ttggetttag agggteteet tgettaatgg gaagegtgea geacetagtg 120 agtggatttg aagageeact ttgtaageaa ettgggeatt tattteagee ceagtteeag 180
tettecetga etetittgge atcaaggeat cetcagaage tteaactetg gaggeaatgg 240
gtcgaaagga agaagatgac tgcagttcct ggaagaaaca gaccaccaac atccggaaaa 300 ccttcatttt tatggaagtg ctgggatcag gagctttctc agaagttttc ctggtgaagc 360 aaagactgac tgggaagctc tttgctctga agtgcatcaa gaagtcacct gccttccggg 420
acagcagcct ggagaatgag attgctgtgt tgaaaaagat caagcatgaa aacattgtga 480
ccctggagga catctatgag agcaccaccc actactacct ggtcatgcag cttgtttctg 540
gtggggaget etttgacegg ateetggage ggggtgteta cacagagaag gatgecagte 600 tggtgateca geaggtettg teggeagtga aatacetaca tgagaatgge ategtecaca 660
```

WO 01/62927 PCT/US01/06059

```
gagacttaaa gcccgaaaac
                                                 getttace ttaccectga agagaactet gateatga 720
tcactgactt tggtctgtcc aagatggaac agaatggcat catgtccact gcctgtggga 780
ccccaggeta egtggeteca gaagtgetgg cccagaaace etacagcaag getgtggatt 840 getggtecat eggegteate acetacatat tgetetgtgg atacceccca ttetatgaag 900
aaacggagte taagetttte gagaagatca aggagggeta etatgagttt gagtetecat 960
tctgggatga catttctgag tcagccaagg actttatttg ccacttgctt gagaaggatc 1020
cgaacgaggg ggtaacactg tgagaagggc ttgagtcatc cctggattga cggtaacaca 1080 gccctccacc gggacatcta cccatcagtc aggcgtccag atccagaaga actttgctaa 1140 gagcaagtgg aggcaagcct tcaacgcagc agctgtggta gcacacaatg aggaagctac 1200
acatgaacct gcacacgccc gggcgtccgc ccagaggtgg agaacaggcc gcctgaaact 1260
caageeteag aaacetetag acceagetee cetgagatea ceateacega ggeacetgte 1320 etggaceaca gtgtageact ceetgeetet gaceeatat accetgeeca geategeege 1380 eggeecaetg ceettggtgg caggteecte aactgeetgg teaatggete cetecacate 1440 ageageagee tggtgeecat geateagggg teeetggeeg eegggeeetg tggetgetge 1500
tocaagetge etgaacattg ggagcaaagg aaagteetee taetgetetg ageccacact 1560
ceteaaaaa gecaacaaa aacagaactt caagteggag gtcatggtae eggttaaage 1620 cagtggcatg ettecaetge egggcaggge agactggagt etgteteatt atgtgattee 1680 tggageetgt gectatgtea egtgcaattt tecaggagae atatteaact eetetgetee 1740 tecaaacetg gtgtetatee ggcagaggga ggaaggeaga gcaagtggag eagggettag 1800 caggageagt teetgggea gaagcaccat geetgetee eagetgggge ageceegtea 1860
taggaggec aggaggage cccaaggegt agaagcettg gttgaagetg tgagcaggag 1920 aageggtge caccagette cagtgtetee egtgacetgg cetgetetat geceeacace 1980 ctacagtgge egtggetetg tgeagtgtta egttagatag etetegeeet gggtetgtge 2040 tgtttgtegt gaaaagetta aatgggetgg gecaggetgt gteacettet ecaaageaaa 2100 geceatatgt gagcatetat ecaagtgte caaactetet etecaatete 2160
taaagtetee aacetettgg ceagattgeg eteattaatg gtegttgeet geeeatetge 2220
catgaatace agceagetee ceatggtggt etecetggtg agetetteaa gttetaatee 2280 ttaaeteeag gattagetee caagtgeget gagaaceaag caagcacact ttettggeee 2340 tteteeetge eteaatetaa aagcagtgee acaeceteea aaggtggaat agaaagaagt 2400
teatgagtaa gaggetgeaa egitgaaeta ettagteeat gagteeagea etgteeteeg 2460
tgcacagcag cccaaatgga cgttaacctt ggaagttgac ttatatttaa gtgtctgcca 2520 ggaggttcta agtcctgcct ctggttcccg ttttctctcc ttgaaatgtg ccagtcgaca 2580 tccatatctt ggtccgttcc ccaggtatgt cctcggcccg tcgcaccccg tccaggcttc 2640
atgctcagag ttgtgcttaa taaaatggac atattttct ctaaaaaaa
```

```
<210> 30
<211> 1391
<212> DNA
```

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: LI:338927.1:2000MAY01

<400> 30

WO 01/62927 PCT/US01/06059 acctgggatg aaga ag agagcaaact accccaagca atg agc ccctgtcaag 1380 tgccagtcat g 1391 <210> 31 <211> 1886 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:335558.1:2000FEB18 <221> unsure <222> 1844 <223> a, t, c, g, or other <400> 31 cattageget aggaagatge geacceggea atgtteeete gaaggggeag eggtagtgge 60 agegeetetg eteteaatge ageaggtace ggegteggta gtaatgeeae atetteegag 120 gatttteege eteegteget getteageeg eegeeeettg eageatette taegteggga 180 ccacagcete egectecaca aageetgaae eteetttege aggeteaget geaggeacag 240 cetettgege caggeggaac teaaatgaaa aagaaaagtg gettecagat aactagegtt 300 actcctgctc agatctccgc tagtatcagc tctaacaaca gtatagcaga ggacactgag 360 agctatgatg atctggatga atctcacacg gaagatctct cttcttcgga gatccttgat 420 gtgtcacttt ccagggctac tgacttaggg gagcccgaac gcagctcctc agaagagacc 480 ctaaataact tccaggaagc cgagacacct ggggcagtct ctcccaacca gccccacctt 540 cctcagcctc atttgcctca ccttccacaa cagaatgttg tgatcaatgg gaatgctcat 600 ccacaccacc tccatcacca ccatcagatt catcatgggc accacctcca acatggtcac 660 caccatccat ctcatgttgc tgtggccagt gcatccatta ctggtgggcc accctcaagc 720 ccagtatcta gaaaactctc tacaactgga agctctgaca gtatcacacc agttgcacca 780 acttctgctg tatcatccag tggttcacct gcatctgtaa tgactaatag gcgtgctcca 840 agtactacag gtggaactag gtataaattc tgttactggc actagtacag taaataatgt 900 taacattact gctgtgggta gttttaatcc taatgtgaca agcagcatgc ttggtaatgt 960 taatataagt acaagcaata ttoctagtgc tgctggtgtg agtgttgggc ctggagttac 1020 cagtggtgtt aatgtgaata tettgagtgg catgggcaat ggtactattt etteetetge 1080 tgetgttage agtgtteeta atgeagetge agggatgaet gggggategg ttteaagtea 1140 gcagcaacaa ccaacagtta acacttegag gttcagagtt gtgaagttag attetagtte 1200 tgagcccttt aaaaaaggta gatggacttg cactgagttc tatgaaaaag aaaatgctgt 1260 acctgctaca gaaggtgtgc tgataaataa agtggtggag actgtaaagc aaaatccgat 1320 agaagtgact tctgaaaggg agagcactag tgggagttca gtgagcagta gtgtcagcac 1380 actgagtcac tatacagaga gtgtgggaag tggagagatg ggagccccta ctgtggtggt 1440 gcagcagcag cagcagcaac aacgactact acagcaacaa ccagctctcc aaggtgtgac 1500 cetecaacag atggattttg gtageactgg tecacagagt attecageag ttagtatace 1560 acagagtatt teteagteac agateteaca agtaeaatta cagteteaag aactgageta 1620 teageaaaag caaggtette agecagtace tetgeaagee actatgagtg etgeaactgg 1680 tatecageca tegeetgtaa atgtggttgg tgtaaettea getttaggte ageageette 1740 catttecagt ttggeteaac eccagetace atatteteag geggeteete eagtgeaaac 1800 teeeetteea ggggeaceac caececaaca gttacagtat gganaacage aaceaatggt 1860 ttctacacag atggccccag gcatga <210> 32 <211> 1540 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:998283.7:2000FEB18 ctttactgta tctgtaaaac gccttatgat gaatctaagt tctatattgg ctgtgatctt 60 tgtactaact ggtatcatgg agaatgtgtt ggcatcacag aaaaggaggc taagaaaatg 120 gatgtgtaca tetgtaatga ttgtaaacgg geacaagagg geageagtga ggaattgtac 180 tgtatetgea gaacacetta tgatgagtea caattttata ttggetgtga teggtgteag 240

aattggtace atgggcgetg cgttggcate ttgcaaagtg aggcagaget cattgatgag 300 tatgtetgte cacagtgeca gtcaacagag gatgccatga cagtgetcae gccactaaca 360

```
PCT/US01/06059
  WO 01/62927
gagaaggatt atgaggggtt agagggtg ctccgttcct tacaggccca agatggcc 420 tggcctttcc ttgaaccagt agaccctaat gatgcaccag attattatgg tgttattaag 480
                               agagggtg ctccgttcct tacaggccca
gaacctatgg accttgccac catggaagaa agagtacaaa gacgatatta tgaaaagctg 540
acggaatttg tggcagatat gaccaaaatt tttgataact gtcgttacta caatccaagt 600
gactcccat tttaccagtg tgcagaagtt ctcgaatcat tctttgtaca gaaattgaaa 660 ggcttcaaag ctagcaggtc tcataacaac aaactgcagt ctacagcttc ttaaagttca 720 gcgtgttaac ctaacataaa acacagcaag aatctggttg tctgaactat tttaaattaa 780 ggaggccagat gtttttagtc aggctatcct gacaagactt gacctaaact tcgttttta 840
tggtcataac agtccaatta tattcttggc caattttgtc caacggacaa gaaaaaagca 900
tgctgccctc atttgtcaac taattatttt ttcttataaa atccagccac ggttacatat 1200
aatccatcca tatcttatca atgattcctg tacgtaaaag tacaagacaa cctctagatg 1260 tcttttcttt ctatgaaagg agctgctatg tacacatgtg cacacacaca caactgcgaa 1320 tcaacaatga gtttattgtt catggtagat taaaattaag cttgcataaa ggttgggcta 1380
agtggtcctg gactacagac tctggtgact tgaatataac agtacaattt gtcaattact 1440 ccacaccagg ttgaaatgag taaaatctat ttgaaggtat cttctttgta aacatttgtc 1500
agattctaat ttttcttttt gtattaaaat tcaactatgg
<210> 33
<211> 613
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:402739.1:2000FEB01
ccgccgtggg ggcagagaag tccaacccct ccaagcgaca ccggcgggac atcaaggccg 60
aggacgatga tecegeeggg ggagtgeaeg tacgegggee ggaageggag gaggeeeetg 120
cagaaacaga ggcccgccgt gggggcagag aagtccaacc cctccaagcg acaccgggac 180
cgcctcaacg ccgagttgga ccacctggcc agcctgctgc cgttcccgcc tgacatcatc 240
tecaagetgg acaagettte tgteetgege eteagtgtea gttaceteeg ggtgaagage 300
ttcttccaag gacaggggtt ggcagtggca gatgccgaag atgtggatga ccacacgggc 360
gaacgaaggc ccatgtcgtt caggaggccc cgagcattgg acacccaggc cctgagacgt 420
actcagttcg gtctgcatct gttgatggtg aatattgcag gactgatagc cactgaccgc 480 ctgtagtgat gtgtgaggac aatgaaggca atggtgattc acaggcaggc cagcaccata 540 tgggtgttag ttgtaaattc atggttacat aacataataa atttacctac gaattcatta 600
tttataaaca aaa
<210> 34
<211> 507
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:175223.1:2000FEB01
<400> 34
gcacattaga ccatgcgagc taaatttgtg atcgcacaaa atcaagatgt tagattgatg 60 cagaagatca ctccgttcca aagggaaagt tttcatctca cgagtttgga gctgagggcc 120
cgtggggcaa catggccgaa ggcggggcta gcaaaggtgg tggagaagag cccgggaagc 180
tgccggagcc ggcagaggag gaatcccagg ttttgcgcgg aactggccac tgtaagtggt 240
tcaatgtgcg catgggattt ggattcatct ccatgataaa ccgagaggga agccccttgg 300
atattccagt cgatgtattt gtacaccaaa gcaaactatt catggaagga tttagaagcc 360
taaaagaagg agaaccagtg gaattcacat ttaaaaaatc ttccaaaggc cttgagtcaa 420
tacgggtaac aggacctggt gggagccct gtttaggaag tgaaagaaga cccaaaggga 480
agacactaca gaaaagaaaa ccaaagg
<210> 35
<211> 653
<212> DNA
<213> Homo sapiens
```

WO 01/62927 PCT/US01/06059 <220> <221> misc feature <223> Incyte ID No: LG:981076.2:2000MAY19 <220> <221> unsure <222> 642 <223> a, t, c, g, or other <400> 35 gggcaacccg tetggaggca gegegeeege gggeageete gttgtggete ettgggetet 60 gttggeggeg gegetagett eggagtetee egegegeace teageegeet eetageggeg 120 cggcgctcgc tectacgect aaaatgacca atgtgtgatt teagtggaat aaatggcgtc 180 caaagtcaca gatgctatag tetggtatea aaagaagatt ggagcatatg atcaacaaat 240 atgggaaaaa tetgttgaac agagagaaat caaggggeta aggaataaac caaagaaaac 300 agcacatgtg aaaccagacc tcatagatgt tgatcttgta agagggtctg catttgcaaa 360 ggcaaagcct gaaagtcctt ggacttctct gaccagaaag ggaattgttc gagttgtatt 420 titeccettt iteticeggt ggtggttaca agtaacatca aaggteatet titteigget 480 tetigteett tatettette aagtigetgt aatagtatta tietgeteea ettetagece 540 acacagcata cetetgacag aggtgattgg geegatatgg etgatgetge teetgggaac 600 tgtgcattge cagattgttt ceacaagaac acceaaacet entetaagta cag 653 <210> 36 <211> 589 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:1008973.1:2000MAY01 <400> 36 cacatcccga ggaacagaag cgggcctgct cagcatgtct gcaaggaccg gcgttccaga 60 ccaagatggc ccgctgctcc gaggacccag ctcgctccag gctgtgactc cacatcccga 120 ggtcgccgcc tggcgaccgg gcagcgagga ccggccaccc cagactgcct gtgccgccgc 180 cccgagctcg gacagagccg cgaccgcgag gacagcgacg cctgcacagc tctggcgaga 240 tggcggcagg gtccactacg ctgcgcgcag tggggaagct gcaggtgcgt ctggccacta 300 agacggagcc gaaaaagcta gagaaatatt tgcagaaact ctccgccttg cccatgaccg 360 cagacatect ggeggagaet ggaeteagaa agaeggtgaa gegeetgegg aageaecage 420 acgtgggcga ctttgccaga gacttagcgg cccggtggaa gaagctggtg ctcgtggacc 480 gaaacaccgg gcctgacccg caggaccctg aggagagcgc ttcccgacag cgctacgggg 540 aggetettea ggagegggaa aagggetggg ggetteecag aaaaegega <210> 37 <211> 1315 <212> DNA <213> Homo sapiens <221> misc_feature <223> Incyte ID No: LI:1190250.1:2000MAY01 tagggaatgg ctggggttgg ctgaagagcg cacagtggag ttttaatgtc cgccatgttg 60 agceatggcg tattgaagag agcgagcgag agaggagcgg agcggcacag cctcccaccc 120 teceggetgg tgttagtgee eggacggegg getetgeget eegeceetea agteceegge 180 ageggttgge gagtggggae egaaceeeg gttetecatg atecegetgg eeggggeegt 240 tteeeceaga geggagaggt atetgetgeg eetgagatga gtaaactgte gtttegggeg 300 egggegetag aegeetegaa geegetgeeg gtttteeget gtgaggatet geeegaeetg 360 cacgaatacg cetegataaa cagggeegtg cegeagatge ceaceggaat agagaaggaa 420 gaggagtegg aacateatet teeageggge ttattteage acageaggtg tatggegaga 480 agagggattt atatggttat accggtccca gaggcagaaa gtaattattg cttactatga 540 agtetataat ateetgggga atttaagatg eeaaaageag etteatttea eataeageet 600' tttagtttgg atgctgaaca gcctgattat gatttggatt tctgaagatg aagatatttg 660 tgaatataac tgttaaaaga aaaatggaac acttctgccc ccttgcccat ttgtaggcaa 720 atggattgac ccccctagaa aaaggcagtg gtcagcagcc agtcagtctg caggaagcca 780 aactactgct aaaagaagat gatgaactaa ttagagaagt ttatgaatat tggattaaaa 840

WO 01/62927 PCT/US01/06059

```
cgagatg 900
gaaaaaatcg caaaaatgat gaagcctctt acgtaaatat gcttaagctg cgacgagatc 1020
taagtcgagc tgttactatt ctagagatga taaaaagaag agataaaagt aaaaggagag 1080
ctattgcact taacactgga aattatggaa aagaggtata atttgggcga ctacaatgga 1140 gagatcatgt ctgaggttat ggcacagaga cagccaatga aacctactta tgcatcccc 1200 atcatcccta ttactatata gcagtctatt taaacaccat ggaaggaatat ggatgaag 1260
gagttcaaat gttaataagc aagattatag tccgatctta tccgaccgat acggt
<210> 38
<211> 1616
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:021371.3:2000FEB18
<400> 38
gtgacagage cgtgcctgga acccaggtct cctgactggg aggtcccage tctcgccgtt 60
getetaatee aggeeaggte etactgtget gacagaatgt eggetgttgg geggtagtat 120 ceatgetgee etetaaceae aggetgtetg tgteatgtga eteaatgeae ecateagtgg 180
tetgtgatga gtgggtggga ggatattttg getggeetet ggeecaettg tecaegtetg 240
teetggtgtg teagtggetg gettgtgace tggcatgtee gtggcaggtg tggaaggaga 300
gcctctagtg agttcccaga gtggacagag ccctccagag ccacaggatc ccgaggetcc 360
cageteetea ggeeeaggae acetggtgge catgggeaag gtgageagga ceeetgtgga 420 agetggtgtg ageeagteag atgeagagaa egeageeee teetgeeegg atgageatga 480
cactetgece eggegeegag gregacette caggegette etaggeaaga aatacegeaa 540
gtactattac aagtcgccca aaccactttt gaggcccttc ctgtgccgca tctgtggttc 600 tcgctttctg tcccacgagg acctgcgctt ccacgtcaac tcccatgagg ctggcgatcc 660 ccagctcttc aagtgcctgc agtgcagcta tcgttcccgc cgctggtcct cgctcaagga 720
gcacatgttc aaccacgtgg gcagcaagcc ctacaagtgt gacgagtgca gctacaccag 780
tgtctaccgg aaggacgtca ttcggcacgc cgctgtgcac agccgggacc ggaagaagag 840
gccagatccg actccaaage tgagctcttt cccctgccct gtgtgtggcc gtgtgtaccc 900
catgcagaaa agactcacgc agcacatgaa gacgcacagc actgagaagc cccacatgtg 960 tgacaagtgt ggaaagtcct ttaagaagcg ctacaccttc aaaatgcacc tgctcacgca 1020
catccagget gitgecaace geaggiteaa gigtgagite tgigagitig titgigaaga 1080
caagaaggca ctgctgaacc accagttgtc ccacgtcagt gacaagccct tcaaatgcag 1140
cttttgtccc taccgcacct tccgagagga cttcttgctg tcccatgtgg ctgtcaagca 1200
cacaggggee aagecetteg cetgtgagta etgecaette ageacaegge acaagaagaa 1260 cetgegeetg cacgtaeggt geegacaege aageagette gaggaatggg ggaggegeea 1320
ccctgaggag ccccctccc gccgtcgccc cttcttctct ctgcagcaga ttgaggagct 1380
gaagcagcag cacagtgcgg cccctggacc acctcccagt tccccaggac ctcctgagat 1440 acccccagag gcgacaactt tccagtcatc tgaggctccc tcattgctct gttctgacac 1500 cctgggcggc gccaccatca tctaccagca aggagctgag gagtcgacag cgatggccac 1560 gcagacagcc ttggatcttc tgctgaacat gagtgctcag cgggaactgg ggggca 1616
<210> 39
<211> 521
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:475404.1:2000FEB18
<400> 39
ggeggttget ttgtetetee ttegeeggag eeggetette etgttagtet eegetgetag 60
ttettggete tgggaggeee aggtggetet geageageet etgeeaceet gtgacetgeg 120
agtattggga catccetage tgacgccagg acacceggga agccgaggaa tggactcggt 180 ggcttttgag gatgtggctg tgaactttac ccaggaggaa tgggctttgc tagattcttc 240 tcagaagaat ctctacagag aagtgatgca ggaaacctgc aggaacctgg cttctgtagg 300
aagccaatgg aaagaccaga atattgaaga tcacttcgaa aaacctggga aagatataag 360
aaatcatatc gtacagagac tgtgtgaaag taaagaagat ggtcagtatg gagaagttgt 420
cagccaaatt ccaaatcttg atctgaacga gaacatttct actggattaa aaccatgtga 480
                                                                                           521
atgcagtatt tgtggaaaag tctttgtacg tcattccctc c
```

```
WO 01/62927
                                                                     PCT/US01/06059
<210> 40
<211> 848
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:979406.2:2000FEB18
<220>
<221> unsure
<222> 407, 509, 590, 645, 689, 707, 829
<223> a, t, c, g, or other
<400> 40
aattcactgt ctgtagcatc tgctcctcca cagagggacc ctggaatggc gatggcactc 60
cegatgeetg gaceteagga ggeggttgtg ttegaggatg tggetgtgta etteaeaagg 120
atagagtgga gttgcctggc ccccgaccag caggcactct acagggacgt gatgctggag 180
aactatggga acctggcctc actaggcttt cttgttgcca aaccagcact gatctcccta 240
ttggagcaag gagaggagee gggggeettg attetgeagg tggetgaaca gagegtggee 300 aaageeagee tgtgeacaga ggaccetaat acaetgeeca geagaageea ggaaggaage 360
cctgccagct cagaaggtgg gccaggagag aagggtgtgg ccggaanggt agccggtggg 420
ggtgctgcat cetettggcc ccacggggag caccetgtca cccctaacag atgaagagaa 480
ggtgaggggg gattgagtta cetgeceant ggtgtgteaa aeteeatgat gggggtggga 540
acatgcagac etggcccete caaggcccae tgeteceegg getgtgegen ceacagtetg 600 tgecagggge tgcagaaaga gecatgggaa geetggccet ggtanggcae caagatgggg 660
agggetggat ccacceteca gagaacaana atcetgggea gtageengga catggtgggg 720
gaagetgaag ggttgtccct gagcatcccc aacatggagc tcggaagtct gggccatggg 780
caggaaagca cgaaggtcag ggccagcctg gggaaccaag agctgtgcna cgatcccttc 840
cacctggg
<210> 41
<211> 1307
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:410726.1:2000FEB18
<400> 41
tgctgttgcg gatgctgatg cgtttctgca ggactgtaaa ctggattcct ggaacctttg 60
atatteetgg etgtgtatag tgeetgttgg tggaetgtae tgataeteaa etagagtgtg 120
aagggactgg attcctgccc ctgagacaca atgcaagctg tagtgccctt gaacaagatg 180
acagccatct caccagaacc tcaaactctg gcctcgactg aacaaaatga ggtcccaaga 240 gtggttactt ctggggaaca agaagctatt ttaagaggaa atgctgctga tgcagagtct 300
ttcagacaga ggtttaggtg gttttgttac tcagaagtag ctggacccag gaaagctctg 360
agtcaactct gggagctctg caatcagtgg ctgagaccag acattcacac gaaagaacag 420 attttagagc ttctggtgtt tgagcagttc ctgaccattt tgectgggga gatcaggatt 480
tgggtaaagt cacaacatcc tgagagtagt gaggaagtgg tgaccctaat agaagatttg 540
acccagatgc ttgaagaaaa agatccagtc tctcaagatt ctactgtttc ccaagaggag 600
aactcaaaag aggataaaat ggtcactgtt tgtcccaata ctgagtcctg tgaatctata 660
acattgaagg atgtagctgt gaacttttca agaggagagt ggaagaagct ggagcctttt 720
caaaaggagc tatataagga agtgctactg gaaaacctca ggaacctaga atttctggac 780
tttccagttt caaaattaga gttgatttcc cagctaaagt gggttgaatt gccatggctg 840
ctggaagaag tctcaaaaag ctcccgacta gatgaatcag ctttagataa aataatagaa 900
aggtgcctca gggatgatga tcatggcttg atggaagaat cccagcaata ttgtggcagc 960 tcagaggagg atcacggtaa tcagggaaat tcaaaaggaa gagtcgcaca atacaaaact 1020
cttgggagtg gcagtagggg taagaaattt gacccagatt aaagcccctt tggacatgat 1080
ttcaaagaaa cttcagacgt aattaaacat ctgagagtct acttgaggaa gaaatctcgg 1140
aggtataatg aaagcaagaa accettcagt tttcattcag acettgttct gaccagcaag 1200
gagaaaaccg ccggagataa gtcacggaaa tctaatgatg gtgggaaagt cctgagtcac 1260
tcttcagetc gtactgaaca tcagaaacgt cagaagattc atttttg
                                                                            1307
<210> 42
<211> 2456
```

22/228

<212> DNA

<213> Homo sapiens

```
<221> misc_feature
<223> Incyte ID No: LG:200005.1:2000FEB18
ggagcctggt caacaagcca gcaccactgt gctaggaggc caggccggct ctgcagccga 60
cgcatcccgt gtgagcagac acacatagct cgctttcttg ggggctcttt gtcagccacc 120
aacacagaa gcacacactg acacacacgt acacaaagat ctgagccagg ttgtgggagg 180 gtatgttctg tcttgtgctt tttcttttag aagctactaa agggtgttgg ggatgcttct 240 gactattatg aaggccaaaa ggcctgttga ctggggctgc ttttaaccct ttcctatttg 300 ctgagaatgc agccgtgtga cagtaactga acattggtct aaagtctttc caaaaggtca 360
aggitcacaa gaacatcigc tcaaattaat gaccatgggg gatatgaaga ccccagactt 420
tgatgacete etggeageat ttgacatece agatatggte gatectaaag cagetattga 480
gtctggacac gatgaccatg aaagccacat gaagcagaat gctcacggag aggatgactc 540 ccacgcacca tcatcttctg atgtgggtgt cagcgttatc gtcaagaatg ttcggaacat 600 tgactcttcc gagggcgggg agaaagacgg ccacaaccc actggcaatg gcttacataa 660 tgggtttctc acagcatcct cccttgacag ttacagtaaa gatggagcaa agtccttgaa 720
aggagatgtg cetgeetetg aggtgacact gaaagaeteg acatteagee agtttageee 780 gatetecagt getgaagagt ttgatgaega egagaagatt gaggtggatg acceeeetga 840
caaggaggac atgcgatcaa gcttcaggtc gaatgtgttg acggggtcgg ctccccagca 900 ggactacgat aagctgaagg cactcggagg ggaaaactcc agcaaaactg gactctctac 960 gtcaggcaat gtggagaaaa acaaagctgt taagagagaa acagaagcca gttctataaa 1020
cctgagtgtt tatgaacctt ttaaagtcag aaaagcagag gataaattga aggaaagctc 1080
tgacaaggtg ctggaaaaca gagtcctaga tgggaagctg agctccgaga agaatgacac 1140 cagcctcccc agcgttgcgc catcaaagac aaagtcgtcc tccaagctct cgtcctgcat 1200
cgctgccatc gcggctctca gcgctaaaaa ggcggcttca gactcctgca aagaaccagt 1260;
ggccaattcg agggaatcct ccccgttacc aaaagaagta aatgacagtc cgagagccgc 1320
tgacaagtet cetgaatece agaateteat egaegggace aaaaaaceat eeetgaagea 1380
accggatagt cccagaagca tctcaagtga gaacagcagc aaaggatccc cgtcctctcc 1440
cgcagggtcc acaccagcaa tccccaaagt ccgcataaaa accattaaga catcttctgg 1500
ggaaatcaag agaacagtga ccagggtatt gccagaagtg gatcttgact ctggaaagaa 1560
accttccgag cagacagcgt ccgtgatggc ctctgtgaca tcccttctgt cgtctccagc 1620
atcagecgee gteettteet etececeaa ggegeetete eagtetgegg tegtgaceaa 1680 tgeagtttee eetgeagge teaececeaa acaggteaca atcaageetg tggetactge 1740 ttteeteea gtgtetgetg tgaagaegge aggateeaa gteattaatt tgaagetege 1800
taacaacacc acggtgaaag ccacggtcat atctgctgcc tctgtccaga gtgccagcag 1860
cgccatcatt aaagctgcca acgccatcca gcagcaaact gtcgtggtgc cggcatccag 1920 cctggccaat gccaaactcg tgccaaagac tgtgcacctt gccaacctta accttttgcc 1980 tcagggtgcc caggccacct ctgaactccg ccaagtgcta accaaacctc agcaacaaat 2040 aaagcaggca ataatcaatg cagcagcctc gcaaccccc aaaaaggtgt ctcgagtcca 2100
ggtggtgteg teettgeaga gttetgtggt ggaagettte aacaaggtge tgageagtt 2160 caatecagte ectgtttaca teecaaacet cagteetee gecaatgeag ggateacgtt 2220 acegaegegt gggtacaagt gettggagtg tggggaetee tttgcaettg aaaagagtet 2280 gaeceageae tacgaeagae ggagegtgeg catcgaagta acgtgeaee attgtacaaa 2340 gaacetegtt ttttacaaca aatgeageet eettteeeat geeegtggge ataaggagaa 2400
aggggtggta atgcaatgct cccacttaat tttaagccag tcccagcaga tcaaat
<210> 43
<211> 738
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1076828.1:2000FEB18
<220>
<221> unsure
<222> 74, 161, 279, 339, 346, 362
<223> a, t, c, g, or other
<400> 43
actectaage etcaagtgat etcettattg gaacaaggga aagageeetg gatggttgge 60 agagagetta caanaggeet gtgtteagat etggaatega tgtgtgaaac caagttatta 120
tetetaaaga aggaagitta igaaatagaa tiaigeeaga nggagataai gggaettaca 180
```

```
WO 01/62927
                                                                     PCT/US01/06059
aagcatggcc ttga
                     ctc cagttttgga gatgttttgg aat
                                                          gaag ccaccttgca 240
aaacaactgg gatarccaaa tgggcatttt agtcaagana tattcactcc tgaatacatg 300
cccacattta ttcaacagac attccttact ctccatcana taattnataa tgaagacaga 360
cnctatgaat gtaaggaatg tggaaagatg tttagtcatg gctcacaact tactcaacat 420
cagagaatac acactggtga gaaaccctat caatgtaagg aatgtggaaa agcgtttaat 480
cgtggctcac tccttacacg acaccagagg attcatactg gtgagaaacc ctatgaatgt 540 aaagaatgtg gaaaaacctt tagtcgtggc tcagaactta ctcaacatga gcgaattcac 600
acagetggag etcegttact etcatgggga etttgagaat ggtatetggg tgttatggat 660
catggagcag aaatacagaa ggagtctgca accctgatga ctttgtggaa cagccatact 720
agctctggtc tgcttgcc
<210> 44
<211> 310
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1076931.1:2000FEB18
<400> 44
gggcggtgaa ggtcagagtg cagacctgag accactgctc accgacttca gactccagtt 60
tatctgtgcc ccagcttcct cacttagtct cagaagactt aggctgaggc ctcagaagga 120
gatetecate ettigtecag ageagaacag gatggecatg teccaggaat cattgacett 180 caaggacgtg tttgtggget teaccetgga ggagtggeag caactggace etagteagag 240
ggetetgtat agagatgtga tgetggagaa etacageaac ettgtetcag tggggtattg 300
tgctcacaaa
<210> 45
<211> 404
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1078121.1:2000FEB18
tgctcgggga agctcaggtg gccgccacag cctcttgccc tctgacctgc aggtatcagg 60
agatccatag ctaagcagcc tggacacccg ggaagctggg aaatggtgtg atttgtccag 120 ataatctcac ctgagaagga atcccagaga agaaggaaga agaggaagaa atggctggtt 180
ctcagggact gttgatattc agggatgtgg ccatagaatt ctctccggag gagtggagct 240
atctggaccc tgctcagcag aatctgtata gggacgtgat gttagaaaac tacagaaacc 300
tggtctccct gggtattgct gtctctaagc cagaactgat cacctgtcta gagcaaagga 360
atgagccctg gaatgtgaag aaacattgag acagtagcca gaca
                                                                             404
<210> 46
<211> 1179
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1079203.1:2000FEB18
<400> 46
gggageteta ggtetagtet ttactgetet gtgtattetg etcetagagg eccageetet 60
gtgactccgt tatctggcag gtattgggag atgcacagct aagatgccag gaccacctgg 120
aageetagaa atgttatata tteteattte aetgaagace tttggeeaga geatageata 180
aaagattett tteaaaaagt gataetgaga ggatatggaa aatgtggaea tgagaattta 240
caattaagaa taagttgtaa aagtgtggat gagtctaagg tgttcaaaga aggttataat 300 gaacttaacc aatgtttgag aactacccag agcaaaatat ttcaatgtga taaatacgtg 360
aaagtettte ataaattite aaatteaaac agteataaga aaagaaatac tggaaagaag 420
gttttcaaat gtaaagaatg tggcaaatca ttttgcatgc tttcacatct aacacacat 480
ataagaatte acactagaga gaattettac aaatgtaaag aatgtggcaa agttettaac 540
caatcctcag agcttattaa acataagaaa attcatactg gagagaaacc ctacacgtgt 600 gaaaaaatgtg gcaaaacctt taaccagtct gcaaatcttt atgcacataa gaaaattcat 660
```

WO 01/62927 PCT/US01/06059

```
actggagata aaaccataca agtgtaaaga atgtggcaaa gcctttaagt catactacag 720
cattettaaa cataagagaa ctcataccag gggaatgtet tacgaaggtg acgaatgteg 780
cggtctttaa atgctcctca atcctttcta atcataagat aattcataat gaagagaaac 840
tctaaaatgt gaaaaatgtg agaaggcttt taatcacacc tcaatctgtt gtagacataa 900
gagtaattat attgatgaga agccaaatta aaattaaaaa tgtggcaaag acttccaatt 960
ctagtcagtt cttaatgtaa ttcctactga agaaaacacc tggaaataca aaaaatgtgg 1020
caaaactigt aaccaaigct tagcatttit gcacatgata gtatttatat gtgagactac 1080
ttgtacaaac ataaaaatat acaaaagcta ttgtctactt gaaatttata gttaataaaa 1140
                                                                       1179
gcaaataaat gtatttctgt tgaaagacct ttagaaata
<210> 47
<211> 557
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1082586.1:2000FEB18
<220>
<221> unsure
<222> 42
<223> a, t, c, g, or other
<400> 47
gaaaggaaaa agattgaaga aaagtaagca cagcctagga gncccatggg acaatatcaa 60
gcagaccaat atatacateg taggagtice agcagaagag agaaagggge agagagaata 120
ttggaagaaa taatggctga aaacttttca agtttgataa aagacatgaa tataaacatc 180
caagaagete aacaaactee aagtatgatg aacteaaaga tagecacatt gagacatatt 240
ataatcaaac tgtcaaaaga caaacacagg cetttgtete teactgeage cagageteec 300 agtettgtgt ttacttetet gtttettetg ettetagagg eecageetet gtggeeetgt 360
gacctgcagg tattgggaga tccactgcta agatgccagg accccctgga agcctagaaa 420
tgagatcatt gacatttagg gaggtggcca tagaattatc tctggaggaa tggcaatgcc 480
tggacactgc acagcagaat ttatatagga atgtgatgtt agggaactac agaaacctgg 540
tcttcctggg tatattg
<210> 48
<211> 353
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1082774.1:2000FEB18
cagagatecg agetategat ettaaetget etgtgeegte ageteetaga ggeecageet 60
ctgtggccct gtgacctgca ggtattagga gggtcacagc taggacgccg ggaccccctg 120 gaagcctaga aatgggacca ttgcaattta gagatgtggc catagaattc tctctggagg 180
agtggcattg cctggacgct gcacagcgga atctatatag ggatgtgatg ttagagaact 240
acagaaacct gatetteett ggtattgttg tetetaaacc aaacctgate acctgtetgg 300
agcaaggaaa aaaaccttta actatgaaga ggcatgagat gattgccaaa ccc
<210> 49
<211> 1027
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1082775.1:2000FEB18
<400> 49
ctctgctctg ccaacactag tggaatatga tcacatccca gggatcagtg tcatttaggg 60
atgtgactat gggcttcact caagaggagt ggcatcatct ggaccctgct cagaggaccc 120
tgtagaggaa tgtgatgctg gagaactaca gccaccttgt ctcagtaggg tattgcattc 180
ctaaaccaga agtgatcctc aaattggaga caggcaagga gccatggata ttagaggaaa 240
```

```
PCT/US01/06059
  WO 01/62927
aatttcgaag ccad
                    cat ctgggtgagt tagtgccaga tgg.
                                                        taa agaattaatt 300
aataccagta gaaactattc aagaatgaag ttcaatgagt ttaacaaagg tggaaaatgt 360
ttctgtgatg aaagcatgaa ataattcatt ttgaagagga accttctgaa tataataaca 420 atgggaacag cttctggctg aatgaagacc tcatttggca tcagaagatt aaaaattggg 480
agcaacettt tgaatacaat gaatgtggga aagettteee tgagaattea etetteettg 540
tacataagag agettacaca ggacagaaaa catgcaaata tactgaacat gggaaaacet 600
gttatatgtc atttttatt actcatcagc aaacacatcc aagagagaac cactatgaat 660
gtaatgaatg tggagaaagt atctttgagg aatccattct ctttgaacat cagaatgttt 720
acccattcag ccagaattta aatcccactc taattcagag aacccactca attagcaata 780
ttattgaata taatgaatgt ggaacetttt teagtgaaaa attageeett catttacaac 840
agagaacaca tccaggggaa aaaccttatg aatgtcatga atgtggaaaa accttcaccc 900
agaagtcagc ccacacaaga catcagagaa cacacacagg gaaaacccta tgaatgtcac 960
ggatgtggga agaccttgta taagaattca gacctcatta gaaatcaaag aattcacaca 1020
gggagtt
<210> 50
<211> 364
<212> DNA
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: LG:1083120.1:2000FEB18
cgccaggcct acgagatttg acttgtaaag aattacttat attgactgag agagaagccc 60
agaagaggaa gaagaggaaa gaaaaggagt cagggatggc tettacacag ggacetttga 120
cattcaggga tgtagccata gaattctctc aggaggagtg gaaatccctg gaccctgtgc 180 agaaagcttt gtactgggat gtgatgttgg agaactacag gaacctggtc ttcctgggta 240
aggataattt tgctctagaa gttaagatct gccctcgtgt atttttgtat tttctctgtt 300
gtctttctgt gggagcccgt tccattcatt tgcactgaga ctgaagcctt gttgagacac 360
<210> 51
<211> 901
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1087707.1:2000FEB18
<400> 51
cctagettct aggetetgag tecagtacce gtetgtacta ttecatetet tecgetecat 60
tagetecteg gtgactecae catageceet gttateetgt gaeetgeagg taetgggaca 120
tecataggga agaaggegga acateeggag getgggaaat gegagtgeta acatteaggg 180
atgtggctgt agaattctcc ccagaagagt gggaatgcct ggactctgct cagcagcgtt 240 tgtataggga tgtgatgtta gagaactacg gaaacctgtt ctccttgggt cttgctatct 300
agaagacagt agccaaacac ccagattatt atgatgtttg taatgaagat tatgagtata 420
attggagcta tatgtttctg aattctgaac aactatttat aaaattttat cctacttttt 480 tctgttgaac atatgacttc tctcgtctgc taaacacata cagaccttta gttttggttt 540
acatggattt aaatatatag atatatcact gtaaaataaa cttcaggtgt aacagattta 600
tagagaaagt aatcatattt gtttatggtt gtgtacctac tttgagaaga aaagaaaaat 660 attagaatga acagataatt ttacaagtgt tgatcactta ccagcaaacc agaaacttca 720
gagattttga aagcaaatct attttctctg ctgtgtatta aattcattta tctaaaatgt 780
tattgctcct ggcttagaat catcttgtgc aaattctctt tttttgttgt ttgtctgttt 840
geetgttget caccatagae ataattitet titeataaaa cattettigt ataateacet 900
<210> 52
<211> 254
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
```

26/228

18 1 Bury to 10

```
<223> Incyte ID No: LG:1090915.1:2000FEB18
<400> 52
ttccgttttc gcgtggttct tttgcaagct ctggattctc tggagtttga atgtttccag 60
tattggaacc ccaccaagta ggactgatca ggtcttacaa ttctaaaacc atgacctgtt 120
ttcaggaatt agtgacattc agggatgtgg ccatagactt ctctcggcag gagtgggaat 180 gcctggaccc taatcagagg gacttataca gggatgtgat gttggagaac tacaggaacc 240
tggtctccct ggga
<210> 53
<211> 597
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1094230.1:2000FEB18
<400> 53
tgcagtcaga gctccaggtc tggttcttct cctaaaggcc caggctgtgt ggccccgtgt 60
cctgcaggta ttgggagatc cacagctaag acaccgggac ctcctggaag ccaaaaatgg 120 gaccattgca atttagagat gtggccatag aattctctct ggaggagtgg cattgcctgg 180
acactgcaca geggaattta tataggaatg tgatgttaga gaactacagt aacctggtct 240
tecttggtat tactgtttet aagecagace tgateacetg tetggageaa ggaagaaaac 300
ctttgaccat gaagagaaat gagatgatag ccaaaccctc agtgagcttc cttcaagttc 360 acagtgagag ccaaagtcct cttcatgaca tataagagac tgcacagtgt ggctgcttt 420 ccataatttt tgggacgcac aaatgtctgc atgattttga gaaactaaaa ttactctcaa 480
agttetettt tigeateaga tetgaaatgt etgagagtaa tagttetgt tgaattttt 540
titgttcatt tttctgcaca gtccattctg tttttattac tatctaggct tgaaata
<210> 54
<211> 637
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:474848.3:2000FEB18
<400> 54
ggaagtgcgg cacccagagg cggtcttgta gctgggccag cctggggctt ggttctatgt 60
ccctgcgggt cggtgcgagg gcgaagagga acccgtgggc ccggggggatc ccggggggcc 120
ggaccagtgt tccccagttg tgggagcaga cgcgtgggcg catcgcgggc gggcagggcc 180
tgaagtgcag ctatgtttcc agtgttctct ggctgtttcc aagagctaca agaaaagaat 240
aaatetetgg agttggtgte etttgaggag gtagetgtge aetteacetg ggaggagtgg 300 caggacetgg atgaegetea gaggaeeetg tacagggaeg tgatgetgga gaeetacage 360
agectggtat cattggggea ttgcattacc aaacctgaga tgatettcaa getagagcaa 420
ggagcagagc catggatagt agaagaaacc ctaaacctga gactttcagg ctaagcctcc 480
ctccttttgg tagaggcttt tttataccat ttgggaactg gtttggataa gctaccttaa 540 tgaaggacga cacatccctc cagagatgat aaaagacttt ttgtcttttc tgatttaaga 600
aaactttatc tcgtaagcta cctatagttt acaaaaa
<210> 55
<211> 754
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:251656.1:2000FEB01
<220>
<221> unsure
<222> 702
<223> a, t, c, g, or other
```

<400> 55

WO 01/62927 PCT/US01/06059 gta atcaagacat gtttgagaat gaa gta agatattctc 60 tgaaaatggg gagd ggaaatgcct gaaggtgaaa gtgctcagca ctccgatggg gaaagtgact ttgagagaga 120 tgctggcatc cagaggctcc agggacacac cccaggtgag gaccacgggg aggtggtttc 180 tcaggacagg gaagttggcc agctcatagg cctgcagggc acctacctag gggagaagcc 240 ctacgaatgt ccccagtgtg ggaagacctt cagccggaaa tcccacctca tcacacacga 300 gaggacccac acaggagaga aatactacaa atgtgatgaa tgtggaaaaa gctttagtga 360 tggttcaaat tttagtagac accaaaccac tcacaccggg gagaagccct acaaatgcag 420 agactgtggg aagagettta geeggagtge caaceteata acceaceaga ggatecacae 480 gggggaaaag ceettecagt gtgeegagtg tggeaagage tteageagga gteecaacet 540 cattgcacat cagegeacee acacaggaga gaaaceetae tegtgeeceg agtgtggaaa 600 gagetttgge aacegateca geettaacae geateagggg atecacaetg gagaaaagee 660 ctacgaatgt aaagaatgcg gcgaaagttt tagttacaac tncaatctaa tcagacaaca 720 gagaattcac acaggagaga aaccctacaa atgt <210> 56 <211> 1601 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:021371.1:2000FEB01 acgtctgtcc tggtgtgtca gtggctggct tgtgacctgg catgtccgtg gcaggtgtgg 60 aaggagagee tetagtgagt teecagagtg gacagageee tecagageea caggateeeg 120 aggeteecag eteeteagge ceaggacaee tggtggeeat gggcaaggtg agcaggaeee 180 ctgtggaage tggtgtgage cagtcagatg cagagaacge agececetee tgeeeggatg 240 agcatgacac tetgeceegg egeegaggte gaeetteeag gegetteeta ggeaagaaat 300 accgcaagta ctattacaag tegeccaaac caettttgag geeetteetg tgeegcatet 360 gtggtteteg etttetgtee caegaggace tgegetteea egteaactee catgaggetg 420 gegatececa getetteaag tgeetgeagt geagetateg tteeegeege tggteetege 480 tcaaggagca catgttcaac cacgtgggca gcaagcccta caagtgtgac gagtgcagct 540 acaccagtgt ctaccggaag gacgtcattc ggcacgccgc tgtgcacagc cgggaccgga 600 agaagaggcc agatccgact ccaaagctga gctctttccc ctgccctgtg tgtggccgtg 660 tgtaccccat gcagaaaaga ctcacgcagc acatgaagac gcacagcact gagaagcccc 720 acatgtgtga caagtgtgga aagteettta agaagegeta caeetteaaa atgeaeetge 780 teacgeacat ceaggetight gecaacegea gitteaagtg tgagttetgt gagtttgttt 840 gtgaagacaa gaaggcactg ctgaaccacc agttgtccca cgtcagtgac aagcccttca 900 aatgcagctt ttgtccctac cgcaccttcc gagaggactt cttgctgtcc catgtggctg 960 teaageaeae aggggeeaag eeettegeet gtgagtaetg eeactteage acaeggeaea 1020 agaagaacct gcgcctgcac gtacggtgcc gacacgcaag cagcttcgag gaatggggga 1080 ggcgccaccc tgaggagccc ccctcccgcc gtcgcccctt cttctctctg cagcagattg 1140 aggagetgaa geageageae agtgeggeee etggaceaee teecagttee ceaggaeete 1200 ctgagatacc cccagaggcg acaactttcc agtcatctga ggctccctca ttgctctgtt 1260 ctgacaccct gggcggcgcc accatcatct accagcaagg agctgaggag tcgacagcga 1320 tggccacgca gacagccttg gatcttctgc tgaacatgag tgctcagcgg ggaccggggg 1380 gcacagccct gcaggtgtgc tgcctgggaa cctgctcccc ttcccagcta ccgcagtacc 1440 cagccctgca ctggacactg ggactagagg aaaacagtgt atcagagctt ctccgccctt 1500 gggggctccc aggcagtgga ggagacagat ctgctgaagt ctggtgggca aacagagagg 1560 aacaggcttt gccacggagg ccgcagggta tcccatccat t 1601 <210> 57 <211> 1059 <212> DNA <213> Homo sapiens <221> misc_feature <223> Incyte ID No: LI:133095.1:2000FEB01 <220> <221> unsure <222> 107 <223> a, t, c, g, or other

28/228

<400> 57

WO 01/62927 PCT/US01/06059

```
tggactgggc gaggaggtgc cetgtgccat gatggagggt gtggcagcct cacaccagac 60
agagecegag ggtagecage ctageaceat ggaegecace geagtaneag geategagae 120
caagaaagag aaggaggacc tgtgcttgct aaagaaggag gagaaggagg agccagtagc 180
cccggagctg gcaacaacgg tgcctgagag cgcagagcct gaggcagagg cggacgggga 240 ggagctggac ggcagcgaca tgtcagccat catctatgaa atccccaagg agcctgagaa 300
gaggeggegg, ageaageggt egegggtgat ggatgetgae ggeetgeteg agatgtteea 360
ctgcccatac gagggctgca gccaagtcta cgtggccctc agcagcttcc agaaccacgt 420
caatettgtg categgaaag gaaagaccaa agtgtgcect cateetgget gtggcaagaa 480 gttetattta tecaaecaec tgeggeggea catgateate catteaggtg teegtgaatt 540 caectgegag acetgeggea agteetteaa gaggaagaac caectggagg tacateggeg 600 caecaeaec ggeggagaece ceetgeagtg egagatetgt ggetaecagt geeggeageg 660
cgcgtcgctc aactggcaca tgaagaagca cactgcggag gtgcagtaca acttcacgtg 720
cgatcgctgc gggaagcgct tcgagaagct ggacagcgtc aagttccaca cgctcaaaag 780 ccacccggat cacaagccca cctgacccac ctgaccactg accgccccta tttattcgtc 840
cgctcggaca ccacgcccgg gcttgccggg gcctggacag ctgcgagggc cgcccggacc 900 gcgggccgga aggaggcgcc cccgcccgc cccagagctg ggccccctgg gcaggttccc 960
caccecgece cacegeatee tteteggage tggtgeetgg ggetgeattg etggaactgt 1020
                                                                                               1059
gtcaagagag cagagtgaga ttaaagagcg agaaaggag
<210> 58
<211> 1187
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:236654.2:2000FEB01
<400> 58
geggeegetg cetgeagace ttecegttgg aggeeateae tgeetteatg gaceaeaaga 60 agetgggetg teagetette agaggeecea gegggeea gggeteagaa egagaggage 120
tgaaggeett gagetgeetg egetgtggea aacagtteae agtggeetgg aagetgetge 180
gtcacgccca gtgggaccac ggactgtcca tctaccagac agaatcagag gccccggagg 240
cecegtectg ggeetggeeg aggtggetge ageegtgteg geagtggtgg ggeeageage 300 tgaggeeaag ageeceegtg caagtggeag eggeeteace eggeggagee caectgteet 360 gtgtgeaaga agaeceteag eteetteage aaceteaaag tgeacatgeg eteacacaca 420
ggcgagcgge cetatgettg cgaccagtgt cectacgeet gegeecagag cagcaagete 480
aaccgccaca agaagaccca ccggcaggtg ccgcccaga gccccctcat ggccgacacc 540 agccaggage aggcctctge agcccctccg gagccggctg tccatgctgc tgccccacc 600 agcacccttc catgcagcg tggtgagggg gctggagccg ccgccacagc aggtgtccag 620 gaacccggggg tccttggaggggtcaa gccggccctg gtggagacac ttggggagcc 720
atcaccacgg aacaaagaac tgaccctgca aacagccaga aggcatcacc caaaaagatg 780
cccaagtcag ggggcaagag ccgcgggccc gggggcagct gtgagttctg cgggaagcat 840
tttaccaaca gcagcaacct gacggtgcac cggcgctcac acaccgggga gcgcccctac 900
acctgtgagt tetgeaacta egectgegee cagageagta ageteaaceg ceacegeege 960
atgcacggca tgacgcctgg cagcacccgc ttcgagtgcc cccactgcca tgtgcccttc 1020
ggcctgcgag ccaccctgga caaacacctg cggcagaagc accctgaggc ggccggcgag 1080
gcctgagccc aggaaagccc ccctcactgt ccctggtacc gctgccaaca cccattgacc 1140 tcctcgtttt tgcccgcctt ctccaagtaa attttccctt ttattta 1187
<210> 59
<211> 1671
<212> DNA
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: LI:200009.1:2000FEB01
<220>
<221> unsure
<222> 1663
<223> a, t, c, g, or other
geggeegeeg egeeceegee ggagetgeeg gagtggetge gggaeetgee tegegaggtg 60
```

tgcctctgca ccagtactgt gcccggcctg gcctacggca tctgcgcggc gcagaggatc 120

PCT/US01/06059 WO 01/62927 cagcaaggca ccts tgg acctttccaa ggcgtgcttc tgc caga gaaggtgcag 180 gcaggcgccg tgaggaacac gcagcatete tgggagtaaa tgtcccttca acggtaatgg 240 aagccatgtt geegaccaga agccettgag geettteace aaaggeggea aatetegeee 300 ctaccacca geagegetee gttgttttee eecagactee gtgcagcagg aacttetete 360 ttctggataa gtctgggccc attgaatcag gatttaatca aatcaacgtg aaaaaccagc 420 gagtectgge aageccaact tecacaagec agetecaete ggagtteagt gaetggeate 480 tttggaaatg tgggeagtge tttaagaett teacecageg gatectetta cagatgeaeg 540 tgtgeaegea gaacecegae agaecetaee aatgeggeea etgeteceag teetttteee 600 agcetteaga aetgaggaae eaegtggtea eteactetag tgaceggeet tteaagtgeg 660 getactgtgg tegtgeettt geeggggeea ceacceteaa caaccacate egaacceaca 720 ctggagaaaa gcccttcaag tgcgagaggt gtgagaggag cttcacgcag gccacccage 780 tgagccgaca ccagcggatg cccaatgagt gcaagccaat aactgagagc ccagaatcaa 840 togaagtgga ttaacggatt gatggttgga attaaactgo aaggaaagto atgattaaat 900 gtcacggaca cttaagcaaa accaaagatt tcctctgagc aactttcaat cagtcccaga 960 aaaccaaaag cagtaataaa ataagtaaga tgttaagaga tattgatcct ggcatggaag 1020 tcagaccagg aaagagatta tttatttatg acttagggat gagacttatt tcagtggaca 1080 actaacctgg gatggttaac atttccagtc ccaccatgta ttttgctttg tttctaaaaa 1140 gctttttaaa aactgttatt taataccaaa gggaggaatc gtatgggttc ttctgcccac 1200 cgttgtgact aagaatgcac agggacttgg ttctcgttgc acctttttt agtaacatgt 1260 ttcatgggga cccactgtac agcccttcat tctgctgtgt cagtttggcc tggcctgaca 1320 ctggctgccc cagcggggac cacggaagca gagtgagagc cttcgctgag tcaatgctac 1380 cttcagcccc agacgcatcc catttccatg tettccatge teactgetca tgcacttttt 1440 acacggtttc ttccaaacag cccggtcttg atgcaggaga gtctggaaaa ggaagaaaat 1500 ggtttcagtt tcaaaattca aaggaaaaag ttgaggactt attttgtcct gtcaagattg 1560 caagaacatg taaaatgtac ggagcttcat aatacgttat attgttccga agcagctcgt 1620 tgagaaacat ttgttttcaa taacatttta gcttaaaaaa aanaaaggaa a <210> 60 <211> 952 <212> DNA <213> Homo sapiens <221> misc_feature <223> Incyte ID No: LI:758502.1:2000FEB01 caacactcat caaacatcag agaacccaca caggggagag accctatgag tgcccagagt 60 gtggaaagac ttttgggcgg aagccacacc tcataatgca ccaaagaacc cacacaggcg 120 agaagcccta cgcgtgcctg gaatgtcaca aaagcttcag tcgaagctca aatttcatca 180 ctcaccagag gacccacaca ggggtgaagc cttacaggtg taatgactgt ggggagagtt 240 ttagccagag ctcggatttg attaagcacc aacgaaccca cacgggagaa cggcccttca 300 aatgeeegga gtgegggaag ggetteagag atagttetea ttttgtaget eacatgagea 360 eteatteagg agagaggeet tteagttgte etgaetgeea caaaagette agteagaget 420 cacatttggt cacgcaccaa agaacacaca caggtgagag accttttaag tgcgaaaact 480 gtgggaaagg attegeegae ageteegeee teaetaagea eeaaegaate caeaeeggag 540 aaagacccta caaatgtgga gagtgtggga agagcttcaa tcagagctcc cactttatta 600 cccatcagcg aatccactta ggagacaggc cctatcgatg tcctgagtgt ggcaagacct 660 tcaatcagcg ttcccatttc ctcacacacc agagaacgca tacaggagaa aaacctttcc 720 actgtagtaa atgtaacaag agcttccgtc agaaagcgca tcttttatgc catcaagaca 780 cccatttgat ttaggaagta gtctttggtg ttcagctgct cccttgcaca ttttcattgc 840 tactgtcttc aagcaccca aatagagaaa acctgggcgt cagtggctca atttgggccc 900 tgatctattc tccctctttc ttgtctatgt tataacagag aggatagact ta <210> 61 <211> 749 <212> DNA <213> Homo sapiens <221> misc_feature <223> Incyte ID No: LI:344772.1:2000FEB01 <221> unsure

30/228

<222> 713

<223> a, t, c, g, or other

group to the service of the fit of the service of the fit

```
<400> 61
cgcaaaaggc tgtccctccc aaacctggga ttctgggctc actgagttca cctgcgagtc 60
agecetacet geactgetet ggtetagtae aaacaggetg etggeattga gagactggee 120
attectagga tgacetggga atttatecec tetgeactge tececaagea ettggataat 180 gaagetgage tgtetteaac tgtattatat gtagacagaa ggteaceate tacageetgg 240 tgaaaaatga gteagacett tecaetgtaa agacaaacae atgagetgag etaagaatet 300 etttaaaatg gacatagaag actgeaatgg eegeteetat gtgtetggta geggggaete 360
atctctggag aaggagttcc tcggggcccc agtggggccc tcggtgagca cccccaacag 420
ccagcactet tetectagec geteacteag tgccaactee atcaaggtgg agatgtacag 480
cgatgaggag tcaagcagac tgctggggcc agatgagcgg ctcctggaaa aggacgacag 540 cgtgattgtg gaagattcat tgtctgagcc cctgggctac tgtgatggga gtgggccaga 600 gcctcactcc cctggggca tccggctgcc caatggcaag ctcaagtgtg acgtctgcg 660
catggtctgt attggaccca acgtgctcat ggtgcacaag cgcagtcaca ctnggtgaaa 720
ggcccttcca ttgcaaccag tgtggtgcc
<210> 62
<211> 620
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:789445.1:2000FEB01
<400> 62
ggaacatcga gaagccaagg ctagtggctg ggttactgat ggattactga tggattcttc 60 tcagcactta gtgacctttg aggatgtggc tgtggacttt acccaggagg agtggacttt 120
gttggatcaa gcccagagag atctctacag agatgtgatg ttggagaact acaagaatct 180
cattatacta gragggtetg aattatteaa acgtagtete atgtetggat tggaacaaat 240
ggaagagetg aggacaggag tgacaggagt tetgeaggaa ttggatttge aactcaaaac 300 caaaggetee ceaetgetge aagatattte tgeagaaaga teaecaaatg gagtacaatt 360
ggagagaagc aatactgcag agaaactgta tgactctaac cattctggaa aagtcttcaa 420
tgaacaccca tttcttatga ctcacatgat aactcacatt ggagagaaaa cttctgagga 480 taatcagagt ggataagcct taagaaagaa ctttcctcat agtttttaca agaaaagtca 540
tgctgaggga aaaatgccta agtgtgttaa acatgaaaaa gccttcaacc agtttccaaa 600
tcttactagg cagaataaaa
<210> 63
<211> 1110
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:789657.1:2000FEB01
<220>
<221> unsure
<222> 449, 530
<223> a, t, c, g, or other
<400> 63
ttagcagtgt aatgaacgtg gcaaaggttt taaatcaaaa agcaaagctt gcacatcagc 60
atagaattca tactggagat aaacgttaca aatgtgaagc atgtgacaaa gtttacagtc 120
gcaaatcaag cetegaaaga caggagaatt catactggag agaaagetta catatgtgaa 180
gaatgtcacc aagttttcag tcacactcaa accttgaaag acacagcaga attcctactg 240
gagagatage ataaaaatgt aagagtttgt gacaaggett teaggeataa ttegeacetg 300
gcacaacatc ctagaattca cattggagag aaagcttaca agtataatga atgtgacagg 360 tctttagtgg gcagtcaaca cttgtttacc atcaggcaat ccatggtgta gggaaacttt 420
acttatgtaa tgattgtcac aaagtcttna gttacactac aaccattgcg aatcattgga 480
gaatccataa tgaataaaga tctaacaagt gtaatgaatg tggcaagtcn ttagtaaaag 540
ttcccacctt gcagttcatc agagaattca tactggagag aaaccttaca aatgtaatcg 600
atgtggcaag tgcttcagtc aaagttcctc tcttgcaagg catcagacag ttcatacagg 660 agagaaacct tacatatgtg ctgaatgtgg aaaggccttt tctcagaagt cagaccttgt 720
tgtacatcag ataattcata ctggagagaa acctgatcga tgtactgtat gtgggaaggc 780 cttcatccag aagtcccaac tcactgtaca tcagagaatt catacactaa tgaaatcata 840
agaatggtet gaacacagaa aagcettcag ggtcagttca agcettaata gatagtgcaa 900
```

PCT/US01/06059 WO 01/62927 Rgat tttggggact acatctttgt tgal aatt ttacaagtga 960 caaccaatgg attt agtcatgttc ctaatgtatt tcattcttta tcaaagataa tagagaagtc aatacgtaaa 1020 tgatggacat tttcactatg gcatataaaa gtttttaaat tgagaaatga atgattagca 1080 taacagaacg aattgcatgt acatctcttt <210> 64 <211> 899 <212> DNA ' <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:789808.1:2000FEB01 gaaatcaaga attcacacag gggagagcct ttacagatgt catgaatgga gaaatccttc 60 agtgaaaagt catcccttac tcaaaatcag agaacacacg tggggagaaa tcatgaatgt 120 catgaatgtg ggaaaacctc gtttaagtca gttctaactg tgcatcagaa aacacacagg 180 ggagaagccc tatgaatgct atgcatgtgg caacaccttt ctcagaaaat ccgacctcat 240 taaacatcag agaattcaca caggagaaaa accttatgaa tgtaatgaat gtgggaagtc 300 atteteegag aagteaacce ttaetaaaca tetaagaaca cacagatggg aaatettatg 360 catgtattca atgtggaaaa tttttctgct gctactacag tttcacagaa catctgagaa 420 gacacacagg ggagaaacct tttggatgta atgaatgtgg gaaaaccttc catcagaagt 480 tggccctaat tgttcaccag agaactcata taagacagaa accctatgga tgtaatgaat 540 gtggaaaatc attctgtgtg aagtcaaaac tcattgcaca tcatagaaca tacacagggg 600 agaaacccta tgaatgtaat gtttgtggaa aattattatt aagtcaaaac taactgtaca 660 tcacagaaca cacttgaggt gaaaccctat aaatgtagta agtgagggaa attactctgg 720 gtgaagtcag aactttgtag agcagagaac ataaagggtg agagaaatct gttaatataa 780 tgataatgag aacacctttg ccctgaagtc agttctcaca gtagagaaga gaacttaaag 840 agggaaaaaa caatatgaag atatggaatg caggaaaaca ttattctggg atttgggcc 899 <210> 65 <211> 476 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:792919.1:2000FEB01 catcagatga ttcatatggg acagaaccca tataattgta aagaatgtgg gaagagcttc 60 aaatggteet catatetttt ggteeateaa egagteeaca etggagaaaa geeatacaaa 120 tgtgaggagt gtgggaaggg ctacattagt aagtcaggtc ttgacttcca ccatagaacc 180 cacacgggag agagatetta taactgtgat aactgeggga agagetttag acatgettet 240 agtattttga atcataagaa actccactgc caaagaaagc cattgaaatg tgaagactgt 300 ggaaagagge ttgtatgccg gtcatactgt aaagaccaac aaagagacca cagtggagaa 360 aacccatcca aatgtgagga ctgtgggaag cgctacaaga ggcgcttgaa tctggatata 420 attttatcat tattttaaa tgacatataa gttatacata tttatggagt gtgaaa <210> 66 <211> 597 <212> DNA

<221> misc_feature
<223> Incyte ID No: LI:793949.1:2000FEB01
<400> 66
tgcagtcaga gctccaggtc tggttcttct cctaaaggcc caggctgtgt ggccccgtgt 60
cctgcaggta ttgggagatc cacagctaag acaccgggac ctcctggaag ccaaaaatgg 120
gaccattgca atttagagat gtggccatag acttctccca ggaggagtgg cattgcctgg 180
acactgctca aagagatttg tacagatgtg taatgttgga gaactacagc aacctggtct 240
tccttggtat tactgtttct aaaccagatg tgatttcctc attggagcaa ggaagaaaac 300
ctttgaccat gaagagaaat gagatgatag ccaaaccctc agtgagcttc cttcaagttc 360

acagtgagag ccaaagteet etteatgaca tataagagae tgeacagtgt ggetgetttt 420

<213> Homo sapiens

<220>

```
PCT/US01/06059
   WO 01/62927
ccataatttt tgggacgcac aaatgtetge atgattttga gaaactaaaa Etactetcaa 480
agttctcttt ttgcatcaga tctgaaatgt ctgagagtaa tagtttctgt tgaattttt 540
titgttcatt ttictgcaca gtccattcig tttttattac tatctaggct tgaaata
<210> 67
<211> 523 ·
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:794389.1:2000FEB01
<220>
<221> unsure
<222> 74
<223> a, t, c, g, or other
<400> 67
tgtaaggact gcaaaagacc ttttgtcgtg tgatgcagtt cactctgcac aggagaattc 60
atactggtga aaanccctat gaatgcaagg aatgtggaaa gtccttcagc gcccattctt 120
ctcttgttac tcataagaga acacacagtg gagaaaaacc gtataaatgc aaggaatgtg 180 gaaaagcctt cagtgcgcac tcttcccttg ttactcataa gagaacacac agtggagaga 240 aaccctatac atgccatgcc tgtgggaagg cctttaatac ttcctccaca ctttgtcaac 300 ataatagaat tcatactggt gaaaaaccct ttcagtgcag tcaatgcggg aagtccttta 360 gctgcagctc tcaccttact cgacactgta gaatgtgtaa tggaaaattt agcaaataac 420
caaaactcaa aatgttaatt ctgattatte tgtatcatca ccagtacttt gtactttgag 480
tctttttaaa tatgctctgt tagtttgtat ggaatgatat ttc
<210> 68
<211> 561
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:796010.1:2000FEB01
<220>
<221> unsure
<222> 92, 176, 216, 233
<223> a, t, c, g, or other
ctcattagaa atcaaagaat tcacacgggg agagacctta cagatgtcat gaatggagaa 60
atcettcagt gaaaagtcat ccettactca anatcagaga acacacgtgg ggagaaatca 120 tgaatgtcat gaatgtggga aaacctcgtt taagtcagtt ctaactgtgc atcagnaaac 180 acacagggga gaagcectat gaatgctatg catgtngcaa cacctttctc agnaaatccg 240
acctcattaa acatcagaga attcacacag gagaaaaacc ttatgaatgt aatgaatgtg 300
ggaagtcatt ctccgagaag tcaaccctta ctaaacatct aagaacacac agatgggaaa 360
tettatgeat gtatteaatg tggaaaattt ttetgetget actacagttt cacagaacat 420
ctgagaagac acacagggga gaaacctttt ggatgtaatg aatgtgggaa aaccttccat 480 cagaagttgg ccctaattgt tcaccagaga actcatataa gacagaaacc ctatggatgt 540
aatgaatgtg gaaaatcatt c
<210> 69
<211> 543
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:796324.1:2000FEB01
<220>
```

33/228

<221> unsure <222> 51, 54, 458

WO 01/62927

<223> a, t, c, or other

```
tctataagaa ttcagccctc attagaaatc aaagattcac acaggggaga nacnttacag 60
atgtcatgaa tggagaaatc cttcagtgaa aagtcatccc ttactcaaaa tcagagaaca 120
cacgtgggga gaaatcatga atgtcatgaa tgtgggaaaa cctcgtttaa gtcagttcta 180
actgtgcatc agaaaacaca caggggagaa gccctatgaa tgctatgcat gtggcaacac 240
ctttctcaga aaatccgacc tcattaaaca tcagagaatt cacacaggag aaaaacctta 300
tgaatgtaat gaatgtggga agtcattctc cgagaagtca acccttacta aacatctaag 360
aacacacaga tgggaaatct tatgcatgta ticaatgtgg aaaatttttc tgctgctact 420
acagtttcac agaacatctg agaagacaca cagggganaa accttttgga tgtaatgaat 480
gtgggaaaac cttccatcag aagttggccc taattgttca ccagagaact catataagac 540
<210> 70
<211> 567
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:796373.1:2000FEB01
cactggagag aaaccctatg tatgcaatga atgtgggaaa gcttcagcca gaagacatgt 60
ttaatatccc atcagagatt tcacacagga aagacaccct ttgtatgtac tgagtgtgga 120
aaatcetget cacacaagte aggteteatt aaccaceaga gaatteacae aggagagaaa 180 ceetatacat geagtgaetg tgggaaaget tteagagata aateatgtet caacagacat 240
cggagaactc atacagggga gagaccgtat ggatgctctg attgtgggaa agctttctcc 300
cacttgtcat gccttgttta tcataaggga atgctgcatg caagagagaa atgtgtaggt 360
tcagtcaaat tggaaaatcc ttgctcagag agtcatagct tatcacatac acgtgatctc 420 atacaggata aagactctgt taacatggtg actctgcaga tgccttctgt ggcagctcag 480
accteattaa ctaacagtgc gttccaagca gagagcaaag tagccattgt gagccagcct 540
gttgccagaa gttcagtctc agcagat
<210> 71
<211> 633
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:796415.1:2000FEB01
<400> 71
ctctgctctg ccaacactag tggaatatga tcacatccca gggatcagtg tcatttaggg 60
atgtgactat gggcttcact caagaggagt ggcatcatct ggaccctgct cagaggaccc 120 tgtagaggaa tgtgatgctg gagaactaca gccaccttgt ctcagtaggg tattgcattc 180
ctaaaccaga agtgatcctc aaattggaga caggcaagga gccatggata ttagaggaaa 240
aatttcgaag ccagagtcat ctgggtgagt tagtgccaga tggaatttaa agaattaatt 300
aataccagta gaaactattc aagaatgaag ttcaatgagt ttaacaaagg tggaaaatgt 360 ttctgtgatg aaagcatgaa ataattcatt ttgaagagga accttctgaa tataataaca 420
atgggaacag cttctggctg aatgaagacc tcatttggca tcagaagatt aaaaattggg 480
agcaaccttt tgaatacaat gaatgtggga aagctttccc tgagaattca ctcttccttg 540
tacataagag agcttacaca ggacagaaaa catgcaaata tactgaacat gggaaaacct 600
gttatatgtc atttttatt actcatcagc aaa
<210> 72
<211> 652
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:798636.1:2000FEB01
```

34/228

<220>

```
<221> unsure
 <222> 76
 <223> a, t, c, g, or other
 taatgaatgt ggtaaagcet taageteeca eteaacaett attatteatg agegaattea 60°
 tactggagaa aaaccntgta aatgtaaagt atgtggaaaa gccttcagac agagttccgc 120
 tctcattcaa catcagagaa tgcatactgg agaaagaccc tataagtgta acgaatgtga 180
caaaacattc aggtgtaact catcgcttag taatcaccag agaattcata ctggagagaa 240 accatatcga tgtttagaat gtgggatgtc ttttggccaa agtgcagctc ttatacaaca 300 tcagaggatt catacaggag aaaaaccctt taaatgtaat acatgtggaa aaacttttag 360 acaaaggtca
 taatgcatgt gggaaactct ttagccagag gtcatccctt actaatcatt ataaaattca 480
 cattgaagag gactcettaa aageegattt geatgtgtga aageettaaa eeaaaactea 540 teagagaata catgettgag agtgatttat taaatataat gaatattgag aaaactetta 600 gtteteatea gatactaagt tttaagaata aaetttaget atgtaataac tt 652
 <211> 860
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <223> Incyte ID No: LI:800045.1:2000FEB01
 <220>
 <221> unsure
 <222> 311, 500, 509, 541-543
 <223> a, t, c, g, or other
 <400> 73
 aaaattatgc acactgggga aaagcgctat gaatgtgatg actgtggagg gactttccgg 60
agcagetega geettegggt ceacaaaegg atceaeaetg gggagaagee gtacaagtgt 120 gaggaatgtg ggaaageeta catgteetae teeageetta taaaceaeaa aageaeecat 180 tetggggaga agaaetgtaa atgtgatgaa tgtggaaaat cetteaatta tagetetgtt 240
 ctggaccagc ataaaaggat ccacactggg gagaagccct atgaatgtgg tgagtgtggg 300
 aaggeettea ngaacagete tgggeteaga gtecacaaaa ggatecacae gggggagaag 360 ceetatgaat gegacatetg tgggaaaace tteagtaaca getetggeet cacagtgeat 420 aaaaggatee acacagttte agatgaacte ecataatgaa tgatgaattt gtgatgaggg 480
 ataccetgga agtggtattn acacattang ctacaataaa aggttetace gtggagagga 540
 nnntgacaca ttcagtaact aatggaacac accgtcaaca tgaattcgca ccttacatga 600
cagaagtgat tcagggattc ctatgaatag aaatgctgag aaggaacgca ttttattgca 660 gaagctaaaa agctaaagta ccagtcatct agagagaagg aaattaatgt ttcttaataa 720 tcctgttaaa tgtttgattg tttttggaat gtgttattgt aaagatgtca tgcaggacat 780
 gtatatgttg tetgttgtaa aatgttaacg aatactttgt teagggetea etetetett 840
 gtcatgaaag ccagctcctt
 <210> 74
 <211> 501
 <212> DNA
 <213> Homo sapiens
 <221> misc_feature
 <223> Incyte ID No: LI:800680.1:2000FEB01
 <400> 74
 gegetetegg cecacacaat atgacetegg ggaggatgeg aggaagatga actgtgatga 60
 tecaettett ettaatgaat gaetgaetta eetgagaaag aaaeteagag gaagaggaaa 120 gaaagaagag gagggaatgg etetttetea gggaetgttt acatteaagg atgtggeeat 180
 agaattetet caagaggagt gggagtgeet ggaecetgee cagagggeet tgtacaggga 240
 cgtgatgttg gagaactaca ggaacctgct ttctctcgat gaggataaca tccctccaga 300
 agatggttet cacettgcag cetgtggaca gageacactg cetetteett agaateetae 360 aaaateegae cettttattt tacteegta cettttattt eteteeett tetagettte 420
 tactctatcc gggaacttag ggagacctta gtcttcctga ttccatattc ttctaagatt 480
 tgcctctgaa agttgctttt g
```

a Tarenda Certical Made Paper

```
<210> 75
<211> 703
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:800894.1:2000FEB01
gtetegteet tactgetgtg tgteetetge teetagagte eeageetetg tggeectatg 60
acctgcaggt attgggagat ccacaactaa gtcgccagga ccccctggaa gcctagaaat 120
gggatcattg acatttaggg atgtggccat agaattctct ctggaggagt ggcaatgcct 180 ggacactgca cagcagaatt tatatagaaa tgtgatgtta gagaactaca gaaacctggt 240
cttcctgggt attgctgcct ttaagccaga cctgatcatt tttctggagg aaggaaaga 300
gtcctggaat atgaagagac atgagatggt ggaagaatcc ccagttatat gttctcattt 360
tgctcaagat ctttggccag agcagggcat agaagattct ttccaaaaag tgatattgag 420 aagatacaag attcatcatc atgcctgtga gctgggtcca ataatgaatc actatcctac 480
ctgtggccaa atgcatatat gacagttaca actetaactg cagactgcat cggcatgtaa 540
aatttaggtc accagtgggc tctctccatg tttgaatgtg gtgattctaa tggtcagega 600
ggtgtgcata ggagagtcac aatctcacct tcaggtgggc cttgtatcag cactctctct 660
actaccttaa gactgtatga cacatgggtg agctaaaaat gtt
<210> 76
<211> 256
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:801015.1:2000FEB01
<400> 76
ggaagcegga aaatggacte agtggcettt gaggatgtgg cagtgaactt cacccaggag 60
gagtgggctt tgctggatcc ttggcagaaa aaactctaca gagatgtgat gctggaaacc 120
tataggaacc tggcttcagt aggtgatgac gacaacattc cttcacttag agaacaagtt 180
gcccatcaac gatatttcaa gacctggcat gtggaaaggg aatacttcag taaataaacc 240
aagcatggtg acagct
<210> 77
<211> 458
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:801236.1:2000FEB01
<220>
<221> unsure
<222> 11, 25, 58, 61, 91, 428
<223> a, t, c, g, or other
<400> 77
aaagtttttt ngcccacagt acatnattaa tccgacatca gagaacccac acaggagngg 60
naaccatatg aatgtaatga atgtgggaaa ntttcagcca taccccagcc ttcattcaac 120
atcaaagaat tcatactgga gaaaaaccct atgagtgtaa tgcatgtgga aaggccttca 180
ateggagtge acatettaet gaacaccaga gaactcatae tggagagaag cectatgttt 240 gtaaagaatg tggaaaaace tteagtegaa gtacaccaet taetgaacat ctaaaaatte 300 attettgtgt gaaaccetat caatgtaatg aatgteagaa actgttttge tatagaacat 360
cactaatteg acateagagg acgeatacag gagagaaacc ctaccagtgt aatgaatgtg 420
ggaaatcntt cagcttaagc tcagctctaa ctaaacat
<210> 78
<211> 604
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> misc_feature
<223> Incyte ID No: LI:803335.1:2000FEB01
gggccagcet ggggettggt tetatgteee tgegggtegg tgegagggeg aagaggaace 60
cgtgggcccg ggggatcccg gggggccgga ccagtgttcc ccagttgtgg gagcagacgc 120
gtgggcgcat cgcgggcggg cagggcctga agtgcagcta tgtttccagt gttctctggc 180
tgtttccaag agctacaaga aaagaataaa tctctggagt tggtgtcctt tgaggaggta 240
gctgtgcact tcacctggga ggagtggcag gacctggatg acgctcagag gaccctgtac 300 agggacgtga tgctggagac ctacagcagc ctggtatcat tggggcattg cattaccaaa 360
cctgagatga tetteaaget agageaagga geagageeat ggatagtaga agaaaceeta 420
aacctgagac tttcaggcta agcctccctc cttttggtag aggctttttt ataccatttg 480
ggaactggtt tggataaget acettaatga aggacgacac atccetccag agatgataaa 540
agactttttg tetttetga tttaagaaaa etttateteg taagetaeet atagtttaca 600
aaaa
                                                                              604
<210> 79
<211> 641
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:803998.1:2000FEB01
aggetteaac cagteeteaa acettatgga acataagaga atteataetg gtgagaagee 60
ctacaaatgt gaagaatgtg ataaagactt caactggtcc tcacacctta ctactcataa 120
aagaatteat aetggaggaa aaaceetaca aatatgaaaa atgtggeaaa aetattaatt 180
aatteteaac gettaetgaa cataagggaa tttgtaeagg agggaaacce tacaaatetg 240
aagaatgtgg caagcetttt agetatteet caateettae taaacattea tgtaatteat 300
actggaggga attectacaa ttgtgtggaa tgttgcaatg cccttaacca gtccttaagg 360
cttactacat ataagacaac tcatactgga gagaaaccat gcatgtgtga agaatgtggg 420
aaagceteta atagateete aattettaag agacataage taatteatae acaagagaga 480 etetacaaac etgaaagatg tgacaatget tttggcaaca eeteagaett ttetgaatat 540
aaaagaaatc gtacagatga gaaatcctag aaaagtgaag aatatgacaa agcccttaag 600
tggctgtcac acttgattgt aggtaagata actcatactg g
<210> 80
<211> 991
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:478757.1:2000FEB01
gtgagaaggg aaaggagggg tgagggtgca ggggccctcc taggaggaca tcggacctgt 60
tgggccgaga cctcattaga gatctagagc accggatggg aggagcagag gctcgatttg 120
tgtgctgtcc agactcccac aggctgggtg atggtgggag atttgtgccc attcagatgt 180
ggcggcagag gagggcaagg cccgaaggag cagacagcac cgcttcttgg ggacttgtga 240 aggcatcatg cggagggccg agcttagcag ccaagtggag gacagcaccc tccatgcctg 300 gattcgttac tcgctcgttc tcgatgttga ctgctggcat attgcagcac aactagagat 360
gtacggatgc ccccatcttg atcttacaga atccagaggt gcagccgcaa gaaagctaca 420
cetteteggt ttetetgete tgecaacaet agtggatatg atcacatece agggateagt 480
gtcatttagg gatgtgacta tgggcttcac tcaagaggag tggcatcatc tggaccctgc 540
tcagaggacc ctgtagagga atgtgatgct ggagaactac agccaccttg tctcagtagg 600 gtattgcatc attcacaggg tattgcattc ctaaaccaga agtgatcctc aaattggaga 660 caggcaagga gccatggata ttagaggaaa aatttcgaag ccagagtcat ctggaattaa 720
ttaataccag tagaaactat tcaagaatga agttcaatga gtttaacaaa ggtggaaaat 780
gtttctgtga tgaaagcatg aaataattca ttttgaagag gaaccttctg aatataataa 840
caatgggaac agcttctggc tgaatgaaga cctcatttgg catcagaaga ttaaaaattg 900
ggagcaacct tttgaataca gtgaatgtgg gaaagctttc cctgagaatt cactcttcct 960
tgtacataag agagcttaca caggacaaaa a
```

Circ Strap Bud

```
<210> 81
<211> 680
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature .
<223> Incyte ID No: LI:808532.1:2000FEB01
<400> 81
gcacaattte cagetteaga aacateacag aatteataet ggggagaage catteaaatg 60 tgaaatatgt ggtaagaget tetgtettag gteaagtett aataggeatt geatggteea 120
cacagcagag aaactgtaca aatctgaaaa gtatggaaga ggtttcattg ataggctaga 180
tttgcataag catcagatga ttcatatggg acagaaacca tataattgta aagaatgtgg 240
gaagagette aaatggteet catatetttt ggteeateaa egagteeaca etggagaaaa 300
gccatacaaa tgtgaggagt gtgggaaggg ctacattagt aagtcaggtc ttgacttcca 360
ccatagaacc cacacgggag agagatetta taactgtgat aactgeggga agagetttag 420
acatgettet agtattttga ateataagaa aeteeaetge caaagaaage cattgaaatg 480
tgaagactgt ggaaagaggc ttgtatgccg gtcatactgt aaagaccaac aaagagacca 540
cagtggagaa aacccatcca aatgtgagga ctgtgggaag cgctacaaga ggcgcttgaa 600
totggatata attttatcat tattttaaa tgacatataa gttatacata tttatggagt 660
gtgaaatttg atacatgtat
<210> 82
<211> 420
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:443073.1:2000FEB01
aaaaccctat atgtgtaagg aatgtaggaa aacatttagc cagaatgcag gccttgctca 60
acatcagaga attcatactg gagagaaacc ttatgaatgt aatgtttgtg ggaaagcatt 120
tagetatagt ggatetetta etetacatea gagaatteat aetggagaaa gaceetatga 180
atgtaaagat tgcaggaaat ctttcaggca gcgtgcacat cttgctcatc atgagagaat 240
teatactatg gagteattet tgaetettte eteteeetea eceteeaeat caaateagtt 300
gecaagacet gtaggtttea teteetgaat atttetggaa teeacetett gaateeattt 360
ccatcccatc atccttgtcc aatgcacatt aatatatttg acatgggata ctcgagtagc 420
<210> 83
<211> 659
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:479671.1:2000FEB01
<400> 83
cytycccyca cytycytyte tegyteayta gecetycyet tetectteae tetegycygt 60
teaggagget etgeegeage eggggeeete etgtgaeetg catgtaetgg gggattegea 120
gggaggatgt egggacacce eggaagetgg gaaatgaact eggttgeett tgaggatgtg 180
getgtgaaet teaeceagga ggagtggget ttgttggate etteeeagaa gaatetetat 240
agagacgtga tgcaggaaac cttcaggaat ctggcttcca taggaaacaa aggggaagac 300
cagagcatty aagatcagta caaaaattct tcaagaaatc taagatgagg tttatataac 360
tttccaagac aaggaagttg tgcaaagcct cacagctact aagaggctgg gctgggactc 420
aggattaact tegtgactee aaageeeatg cacetetgea ageeacaega ateaageage 480
ttetetaaac etitgaagte etggaaagta actettetge aatagaagca agaateetgt 540
gagattggga tecatetagt actetteace atttggaaca actgeeteca gagaatgett 600
ctgacgcatc ttggaagaac ttggaataac ctgaggaaat ggtcgatttg ctaatttag 659
<210> 84
<211> 772
<212> DNA
```

38/228

<213> Homo sapiens

```
<220>
<221> misc_feature
<223> Incyte ID No: LI:810078.1:2000FEB01
ccctatgtat gtaaggaatg tgggaaagcc ttcactcagt actcgggcct tagtatgcat 60
gtacgatctc acagtggaga caagccctat gaatgtaagg aatgtgggaa atccttcctt 120
acatecteae geettattea acatataaga acteaeaetg gagagaagee ttttgtatgt 180
gttgaatgtg ggaaagcett tgcagtttce tcaaatctta gtggacattt gagaactcae 240 actgaagaga aggectgtga gtgtaagata tgtgggaaag tatttgggta tccctcatgt 300 cttaataatc acatgcgaac gcacagtgce cagaaaccat acactgtaa ggaatgtggg 360 aaggetttaa actattcaac ccaccttaaa attcaatg gaatccaca tggagaaaaa 420
cectatgagt gtaaacaatg tggaaaggee tteagteatt ceagtteatt teaaatacat 480
gaaaggactc acactggaga gaaaccctat gaatgcaagg agtgtgggaa agccttcacg 540
tgaagagat tcctttagaa ttcatgaaaa aactcacaca gaagagaaac cctataaatg 600 tcagcaatgc gggaaagctt acagtcatcc ccgttcactt cgaagacatg aacaaattca 660 ctagtgagaa actgtccatg taataaatgt gggaaagctc tcatttgttc cagttcactt 720
taaagacatg aatgaactca ctctggagag aagaagctgc atgaaaatta ct
<210> 85
<211> 441
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:810224.1:2000FEB01
<400> 85
ggggagaaat catgaatgtc atgaatgtgg gaaaccctcg tttaagtcag ttctaactgt 60 gcatcagcaa acacccaggg gagaagccct atgaatgcta tgcatgtggc aacacctttc 120 tcagaaaatc cgacctcatt aaacatcaga gaattcacac aggagaaaaa ccttatgaat 180
gtaatgaatg tgggaagtca ttctccgaga agtcaaccct tactaaacat ctaagaacac 240
acagatggga aatcttatgc atgtattcaa tgtggaaaat ttttctgctg ctactacagt 300 ttcacagaac atctgagaag ccacacaggg gagaaacctt ttggatgtaa tgaatgtggg 360 aaaaccttcc atcagaagtt gccctaattg ttcaccaaga gaactcaata taatgacaga 420
cacqcactat agatgtactg a
<210> 86
<211> 1072
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:817052.2:2000FEB01
<400> 86
aattccccgg gtcgacccac gcgtccgggt ggaagagcac ggcttccagg actcagagct 60 gggtgacccc tgtggggaac agccagacct ggacatgcag gagccagaga acacgctgga 120
ggagtccacg gaaggctcca gcgagttcag cgaactgaag cagatgctgg tgcagcagag 180
gaactgcacg gaggggatcg tgatcaagac agaggaacaa gacgaccact tacaccacga 240
ggaggaggat gagetgeege ageaettgea atceettggg cagetgteeg ggagatatga 300 ggeeagtatg taceagacee egetgeeegg ggagatgtee eeegagggeg aggagagee 360 eeegeeeetg cagetaggaa acceegeagt gaaaaggetg gegeeeteeg tgeaeggtga 420
geggeacetg agagecagea geageggaac eggegeggeg ageggeeett cacatgeatg 480
gagtgcggca agagcttccg cctgaagatc aacctcatca tccaccagcg caaccacatc 540
aaggaggggc cctacgagtg cgccgaatgc gagatcagct tccggcacaa gcaacagctc 600
acgctgcacc agcgcatcca ccgcgtgcgc ggaggctgcg tctcacccga acgcgggccc 660 acgttcaacc ccaagcacgc gctcaagccg cgtcccaagt cacccagctc tggtagcggc 720
ggcggtggcc ctaagcccta caagtgcccc gagtgcgaca gcagcttcag ccacaagtcc 780
agectgacea aacaccagat cacgcacacg ggtgagegge cetacacgtg eeeegagtge 840
aagaagaget teegeetgea cateagettg gtgateeate agegegtgea egegggeaag 900
catgaggtet cetteatetg cageetgtge ggcaagaget teageegeee etegeacetg 960 etgegeeace ageggaetea cacaggegag eggeeettea agtgeeeega gtgegagaag 1020
agetteageg agaagteeaa geteaceaac cactgeegeg tgeactegeg eg
                                                                                                    1072
```

```
<210> 87
<211> 759
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:892274.1:2000MAY19
<400> 87
ctgtcgggaa atgagatggg ggcctggact tgggtcccac aaacagtgag ggcattccca 60 gtccagacct taaccctgtt ttaggcatgg gttcctggag gcacattgat tccatcaccc 120 caggaacacc aggaagtgca ggattagatc tacctgccag agaaagaatc acattagttg 180
ggggagacaa acccatcaaa gttcccactg gtatttgggg aacttcacca gcaggataca 240
tgggactaat tttaggcaaa agccgcctta acttgcaagg catgactgta gtcccaggag 300 ctgttgactc tgattatgaa ggagaaactc aagtagtttt aatgtcacaa gatctttggg 360
tttttgaact gggagaatat attgctcaat tattgcttat tccctgcaaa ttacaccett 420
ctccatgaaa ggagaaacga ggaaataaag ggtttgggag cacaactaca tgggaaatct 480
atetateceg acceatagee tetaatagae ceaectgtgt agtacaaatt aaaggaaaga 540
aattttatgg gcttatggat acgggaactg atgtatcagt aatatctaaa gacaattggc 600 ccacatcctg gctcttgcaa ttaacttcta catccctagt ggaagtagga acagctcaaa 660
gtgttcaaca gagtgctgag attttacctt gtcttggtcc ggatgggcag tcatgtactt 720
ttcagcctta tgttgcaaat atagctatca gtttatggg
<210> 88
<211> 570
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1080959.1:2000MAY19
aaaaaaacaa gttgctttat ggaagaaagt aagtatagac agagagaaag ggatctgatg 60 accaaagcag ggaataaatg tttggagtcc acggcatcct gagaacttct tgggaataga 120 gtctaggccc ccaatgctgt cactctcacc catcctcctc tacacatgtg agatgtttca 180
ggacceagtg gettitaagg atgtggetgt gaactteace caggaggagt gggetttget 240
ggatatttec cagaagaate tetacaggga agtgatgetg gaaactttet ggaacetgae 300 etetatagga aaaaagtgga aagaccagaa cattgaatat gagtaccaaa accecaggag 360 aaacttcagg agtgtcacag aagagaaagt caatgaaatt aaagaagaca gtcattgtgg 420
agaaactttt accccagttc cagatgacag gctgaacttc cagaagaaga aagcttctcc 480
tgaagtaaaa tcatgtgaca gctttgtgtg tgaagttggc ctaggtaact catcttctaa 540
tatgaacatc agaggtgaca ctggacacaa
<210> 89
<211> 408
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1054900.1:2000MAY19
cggacgcgtg ggctaggccc ccagtgctgt cacteteacc catceteete tacacatgtg 60
agatgittca ggacccagtg gcctttgatg atgitgctgt gaacttcacc caggaggagt 120 gggctttgct ggatatttcc cagaggaaac tctacaagga agtgatgctg gaaactttca 180
ggaacctgac ctctgtagga aaaagttgga aagaccagaa cattgaatat gagtaccaaa 240
accccaggag aaacttcagg agtctcatag aaaagaaagt caatgaaatt aaagatgaca 300
gtcattgtgg agaaactttt acccaggttc cagatgacag gctgaacttc caggagaaga 360 aagcttctcc tgaaataaaa tcatgtgaca gctttgtgtg tggaaaac 408
<210> 90
<211> 532
<212> DNA
<213> Homo sapiens
```

40/228

```
<220×
<221> misc_feature
<223> Incyte ID No: LG:1077357.1:2000MAY19
cattcatgga ttgacttata aacagtcatg ctatgtgatg aagaagccca gaagaggaaa 60
gcaaaggagt cagggatggc tetteeteag ggacgettga catteatgga cgtggccate 120
gaattetete aggaggagtg gaaateeetg gaccetggae agagggettt atacagggae 180 gtgatgttgg agaactacag gaacetggte tttetgggaa tetgtettee tgacctaagt 240
attatttcca tgttgaagca aaggagagag cccttgattc tgcaaagtca agttaaaata 300 gtaaaaaata cagatggaag ggaatgtgtc agaagcgtga acacagggag gagctgtgta 360 ttgggaagca atgcagaaaa caagcctatt aaaaatcaac ttggattaac ccttgagtca 420
catctgtctg aattgcagct gtttcaagcc ggaaggaaaa tttacagaag taatccagtt 480
gaaaagttta caaaccatcg ttcctcagtt tcaccacttc aaaaaatttc tt
<210> 91
<211> 546
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1084051.1:2000MAY19
<400> 91
caacaagtta cataagaaca aaaacctatg aatgtaatat atgtgaaaaa atcttcaaac 60
aacctattca ccttactgaa catatgagaa ttcatactgg tgagaaacct ttcagatgta 120
aggaatgtgg aagggccttt agtcaaagtg catccctcag tacacaccag agaatccata 180
ctggtgagaa accetttgaa tgtgaggaat gtgggaaage etteagaeat egeteateae 240
ttaatcagca tcatagaact cacactgggg agaaacccta tgtatgtgat aaatgtcaga 300 aagctttcag ccagaacatt agcttggttc aacatttgag gactcattct ggagagaaac 360 cttttacttg caatgaatgt gggaaaacct ttagacagat tagacacctt agtgaacata 420
taagaattea taceggggag aageeetatg catgeactge atgttgtaaa acetttagte 480
atagagegta tetaacacat caccagagat ccatactggg gagagaceta caatgtaaag 540
aatgtg
<210> 92
<211> 1386
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1076853.1:2000MAY19
gcctttagtc gatgttcttc ccttgtccaa catgagagga ctcatactgg agagaaacct 60
tttgaatgta gcatatgtgg gagggctttt ggtcagagcc catcccttta taaacatatg 120 aggattcata agagaggcaa accttaccaa agcagtaact acagcataga tttcaagcac 180
agcacatete teacteagga tgaaagcact ettacegaag tgaaateeta ceattgtaat 240
gactgtgggg aagactttag teacattaca gactttactg accateagag gatecatact 300
gcagagaacc cctatgattg tgagcaggct tttagtcagc aagctatttc tcatcctgga 360
gagaaaccct atcaatgtaa tgtatgtggg aaagctttca aaaggagtac aagtttcata 420
gagcatcaca gaattcatac tggagagaaa ccctatgaat gtaatgagtg tggagaagcc 480 tttagtcgac gctcatcgct tactcaacat gagagaaccc acactggaga gaaaccctat 540
gaatgtattg actgtgggaa agcctttagt caaagttcat ctctcattca gcatgagaga 600
actcatactg gagagaagcc ctatgaatgt aatgaatgtg ggagagcctt ccgaaaaaaa 660
accaacetge atgateatea gagaatteat actggagaaa aaccetatte ttgtaaggaa 720 tgtgggaaaa actteageeg aagtteaget ettaetaaac accagagaat teataetega 780 aataaactet aggaacegtg aaattaagga atttgeagaa tgetttaget aaaatgttet 840
gattcaggat cagaggattc ttagagagct tgggaatgta atgaattacg tgtgtgttta 900
tacgttgtgt gtggagaaaa ctgccagtag acagattttt tttttttaa cataaagaca 960
cacattetea gatetgatta cagactagtg taaaaacage tacatgtatg tagetggttg 1020 gggatgatat geetgtatgt tggaettgge tttggaatat atgtatgeag gatateatea 1080 agttteaaca tettgaettg tgaececeaa tgteaacage ttttttaaaa ageaaattee 1140
tgcagtaatg accaaaaccc attttaaaaa ttgcttgaca actgcactca actggcagct 1200
ettacattaa etteaceatg gaaaceagtt eeaacteeag gaagteacea tteaaagaat 1260
```

WO 01/62927 PCT/US01/06059 tagatcaatt agcc cca cttcattggt ccagtatgaa gack aaag ccaaagatgt 1320 gacgtggttc ccacagtatg atacagecta taagggtaaa getgggttaa aaatgeggtt 1380 <210> 93 <211> 1039 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:481631.10:2000MAY19 acaggattga cttctaaaga ctcttggtac ctgaggaaga aacccagaag aggaagagga 60 aagcaaagga gteggggatg getetttete agggtetatt gaeatteagg gaegtggeea 120 tagaattete teaggaggag tggaaatgee tggaceetge teagaggaet etatacagag 180 acgtgatgct ggagaattat aggaacctgg tetecetgga tatetettee aaatgcacga 240 tgaaggagtt ettgteaaca gegeaaggea acagagaagt gtteeatgea gggacattge 300 aaatacatga aagtcatcac aatggagatt tttgctacca ggatgttgat aaagatattc 360 atgactatga atttcaatgg caagaagatg aaagaaatgg ccatgaagca cccatgacaa 420 aaatcaaaaa gttgacaggt attacagaac gatatgatca aagtcatgct agaaacaagc 480 ctattaaaga tcagcttgga tcaagctttc attcgcatct gcctgaaatg cacatatttc 540 agaccgaaga gaaaattgat aatcaagttg tgaagtctat ccacgatgct tccttggttt 600 caacageeca aagaatttet tgtaggeeca aaaceeatat atetaataac catgggaata 660 atttctggaa ttcttcatta ctcacacaaa aacaggaagt acacatgaga gaaaaatctt 720 tccaatgtaa tgagagtggc aaagcettta attacagete actettaagg aaacatcaga 780 taatccattt agcagacaaa tataaatgtg atgtatgtgg caagctettt aatcagaage 840 gaaacctage atgecategt agatgteaca etggtgagaa teettacaag tgtaatgagt 900 gtggcaagac cttcagtcag acgtcatece ttacatgcca tcgtagactt catactggag 960 agaaacctta caaatgtgaa gaatgtgaca aagctttcca tttcaaatca atacttgaaa 1020 gacataggat aattcatac 1039 <210> 94 <211> 521 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:1088431.2:2000MAY19 <400> 94 cggatctcgc ggggctactg gcgctctcgg cccacacaat atgacctcgg ggaggatgcg 60 aggaagatga actgtgatga tccacttctt cttaatgaat gactgactta cctgagaaag 120 aaactcagag gaagaggaaa gaaagaagag gagggaatgg ctctttctca gggactgttt 180 acattcaagg atgtggccat agaattctct caagaggagt gggagtgcct ggaccctgcc 240 cagagggcct tgtacaggga cgtgatgttg gagaactaca ggaacctgct ttctctcgat 300 gaggataaca tecetecaga agatggttet cacettgeag cetgtggaca gageacactg 360 · cctcttcctt agaatcctac aaaatccgac ccttttattt tactcccgta ccttttattt 420 ctctcccttt tctagctttc tactctatcc gggaacttag ggagacctta gtcttcctga 480 ttccatattc ttctaagatt tgcctctgaa agttgctttt g 521 <210> 95 <211> 1243 <212> DNA <213> Homo sapiens

<400> 95
gctcttcatc ctttaccaaa gagacaagca cttgaaaaaa gcaatggtac cagcgcggtc 60
tttaacccca gcgtcttgca ctaccagcag gctctcacca gcgcacagtt gcagcaacac 120
gccgcgttca ttccaacagg tatgtgccct tactgcccta cgtcctgtgc ccttctggtc 180
atgtgctttc ttctcatttc tctaagctgt ttggtggcat ctagtttgct tttgaaggta 240

<220>

<221> misc_feature

<223> Incyte ID No: LI:401619.10:2000MAY01

```
taatacagtt tgaaattcat egitgtccta gctatctaaa tgtatttacc etactttgaa 300
tgatagetaa agactgttag gattetaaag ecaaatattt gatagattga agagacagat 360
ttaacccatg agaaacagca gttagggctt ttggtttctt gtatttgcac aagccctgta 420
aaattgttta tgtaaataag accttttatg tgtgacaatt gaaatttgtc cttaactctg 480 aatgacctaa aaatagcaat tccagtaaat actaaccatt tttttctatt tctattcaga 540
gcactaaaac aatgaggcta ttcaaattaa agcaattete tactcatatt tttatattca 600
ttctatctct ttctccatcc ttctcaactt tcaccaagtt cacaagtata tagagctctt 660
atcctcagtg tctaagccaa tgcctgatac tattacgtac gatgtgcatt aactatgatt 720 ccactaaaag atccattgta atagtcatag aatcttagag tttaaaggac tcttagtgat 780
ctcctcatcc agctgattgt tttacagatg agaaaactga ggccccctaa atgagaagtg 840
actttccaag gtgccacaac taatgagaaa aagaactgag tttccctgtg accaaaccca 900
tttacatcac attctaccac ctgggcccgc ctatatatac acattccaca gagttctcct 960
gaaaaaagaa aaaagcagat aaaagtgaat ttttaaataa ctgaccccaa aaagtcagat 1020
aaaagtaaaa aaacaaaagt ataaatcatg tcatccctcc cccatttgca ccgacatctc 1080 taaccacaga cacacacag cacaccatac gcaaagatag tcaccataat tgaccatgtt 1140 tttcaccttt tagtcaatgt tagaagcaag gggtaactta agtgctgagt tgggagagcc 1200
tocattgagt totttgagag toaacatttt cagcgccggt agt
<210> 96
<211> 4338
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:1144007.1:2000MAY01
<220>
<221> unsure
<222> 2673, 3345, 4031
<223> a, t, c, g, or other
<400> 96
egtgtteega eeegetagge eeegegegge teggaateeg geggegetgt tteggteggg 60
agtgggtggg agagaagccg gggcagggga ggagccgccg gagctgtcgg agccggccct 120 tggaagaaaa tectcgctgt gtccaggctg aggcgggggg ctaatgacag tgtgagctct 180
agatggtgtg agaccaccc aaagccaaga aatggctaca gccgtggaac cagaggacca 240
ggatetttgg gaagaagagg gaattetgat ggtgaaactg gaagatgatt teacetgteg 300 gecagagtet gtettacaga gggatgacee ggtgetggaa aceteecace agaactteeg 360 aegetteege taccaggagg cageaageee tagagaaget eteateagae teegagaact 420
ttgtcaccag tggctgagac cagagaggeg gacaaaggag cagatectag agetgcttgt 480
getggaacaa titettaceg teetacetgg agaactacag agetgggtge ggggecaacg 540
gccagaaagt ggcgaggagg cagtgacgct ggtggagggt ttgcagaaac aacccaggag 600 accaaggcgg tgggtgactg tccatgttca cggccaggaa gtcctgtcag aggagacggt 660
gcatttagga gcggagcctg agtcacctaa tgagctgcag gatcctgtgc aaagctcgac 720
ccccgagcag tetectgagg aaaccacaca gagcccagat etgggggcac eggcagagca 780
gegtecacac caggaagagg agetecagae cetgeaggag agegaggtec cagtgeega 840 ggaeceagae etteetgeag agaggagete tggagaetea gagatggttg etettettae 900 tgetetgtea cagggaetgg taaegtteaa ggatgtggee gtatgetttt eccaggaeca 960
gtggagtgat ctggacccaa cacagaaaga gttctatgga gaatatgtct tggaagaaag 1020
actgtggaat tgttgtctct ctgtccattc ccaatccccc agacctgatg agattctccc 1080 agggttagac gaggaagagc ctggggtccc agatatccaa gagcctcagg agactcaaga 1140
gccagaaatc ctgagtttta cctacacagg agataggagt aaagatgagg aagagtgtct 1200 ggagcaggaa gatctgagtt tggaggatat acacaggcct gttttgggag aaccagaaat 1260
tcaccagact ccagattggg aaatagtctt tgaggacaat ccaggtagac ttaatgaaag 1320
aagatttggt tactgaatat ttcttcaagt gaatagtttt gtggaacctt cggggaaact 1380
acacccagte cacccctgt tagggaggca tcatgactgt tctgtgtgtg gaaagagctt 1440 cacttgtaac tcccaccttg ttagacacct gaggactcac acaggaggag gaaaccctat 1500 aaatgtatgg gaatgtggga aaaagttaca cacggaggct cacatcttgc cagggcacca 1560 aaaggttcac aaggatgaac gcgccttaca aatatcccct aaaccggaag aattttggaa 1620
gagacetece etgtgacaca ggetgagaga actecateag tggagaaace etatagatgt 1680 gatgattgeg ggaaageact teegetggae tteagacett gteagacate agaggacaca 1740
tactggagaa aaaccettet titgtactat tigtggcaaa agetteagee agaaatetgt 1800 gttaacagae acaccacaag aatecacetg ggaggeaaac cetactigtg tggagagtgt 1860 ggtgaggaet teagtgaaca caggeggtae etggegeaec ggaagaegea egetgetgta 1920
ggaactctac ctctgcagcg agtgcgggcg ctgcttcacc cacagcgcac ggatcgccaa 1980
```

gcacttgaga cgcaacgcct cagtgaggcc ctgccgatgc aacgaatgtg gggaagagct 2040

```
ctc gtcaggcatc agagaacaca cac
                                                                    ggag aaaaccaatt 2100
tcagtcgcag gga
ttttcccaac gtgccctacc tgtggaaaaa gcttcagcag aggatatcac ttaattaggc 2160
atcagaggac cccactcaga aaagacctcc tagctaggtc cccatgtgag gagatctgct 2220
ttcagcctc acctaaggga ggtgaggaag aggaaaagcc ctcttgtcag cctgggaaga 2280
ccttttcgag ggagtctccc tgacctgctc agatctgaca ttacctcttc ctgcaactaa 2340
acacgagect gggeagaace teteageett cetetaegee ttgaggggea tgttteatee 2400
aaagtacaac ctgaattgag gcttctctt cactcggagt gcacctgcct ctaccatcat 2460 gggtataaac gtaggagaac taagagactt aagagcgtcg tggttcctat atcgtccaaa 2520 aaataggctg ttacatatcc taaagactgc tcaacaagct tcaagttgaa aagtggccaa 2580
aggacagece etttaaggtt tgggaagggg acgaageetg aagggattet gtetttaetg 2640 ggggteaaat ettaaageae acagttetgg gantteaaga caggacggtt tgegteetga 2700 tgggetttge cacacattea cagggataae ttgcatagat tecetegetg tettgattea 2760
cttcttacca tgcactttcc tttgatgctg aggagaaatg gaagtgggcg aaaaatctca 2820
aggetgette atgtggaeet tggteaaget ggeteeetee eecagegtea aattgttate 2880
aggtgccaaa cactgctaga aagggggggc ctaggtcaga agcctctttc catacgagtt 2940
ttggttttgt ttttaatatt tttttcctat taaaatactt catgcattta accttcccgt 3000
tattcaacca gtctcttggg ttgcatccct agcacttctc actacaagtg agatggtagt 3060
gtttgagtgc ttattgagta aagcataatt cggtcataat gaaatcgttc acattccctc 3120
atatgcacaa gcccaccaac cccttcacac ccccttcac aggggtcgta tgagtaaggg 3180 gatttggaaa ctgtcaacct tacaaaggca ctataacaat tacagaatca tgattgccat 3240 gggccacttt atttacatga agacaactgg gagaacgact aagaccaaat tatggaaaat 3300 aagaaaaagc tgttgctggg caagaccatc aagactgttc tgacncaccc tgtccccatc 3360
atcccgtgac tgagtactgt gacatcacgg aaagtgttga acctggggaac ctgtagagga 3420
ttctcccaca ggattaattg cgcttcaatg tatttgtttt gtttgctttt tcttacgtga 3480
ttttatgttc atagagctag aaagtagcat ctcatgatgg cccaacaatc tctgttgcca 3540 gttaaaggtt ccttggagat gaggctgaat aattatgaac ctcaccettc tctgattgtg 3600
ggagtggcaa gaactgggga gaccgtcctc tccatagtgg agcacagggt atggggttaa 3660
agcatggaac aggggagagt cttetgtgec tggtttette teetetatet ccataatgea 3720
ttatgggccc gaggaatagg ggagggttaa taagactcca accctaatgg cccaacaggg 3780 aaattctcat tttggtcgat gatattctga tggactggtt tggtcttaat accagtcaac 3840
cgttgtcctt ctggaaatat acatatatga aataacataa cggtaacact tggcagccaa 3900
gttecetggt ttetgggaet teccatetta eccatteett ttecaggget tecagtgtee 3960
tgatacttet ggagggtggt tcatactcca aattagatte tggggagtta cagagtaatt 4020 tttteettgg nagggaaagg gaagggttgg gggatggatt taggcagagt teeggtggaa 4080 acattatttg cactetgaga taagatecaa geetggagtt tgeagaagat aetgteetaa 4140
taagcaggca tttctaaacc aagtatctaa gcctaagcac agcttgtcct gggtgaaatg 4200
tetgecacaa aagatagttt eteetagete agaettaace atttataaag gttggtaaaa 4260 taetggeagt gacaacaaat tgaetttta attttettat ttgeattatt ecaataaatg 4320
aaaatctgtc agagttcg
<210> 97
<211> 1827
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:331074.1:2000MAY01
<220>
<221> unsure
<222> 32, 57
<223> a, t, c, g, or other
<400> 97
cetacaccat ggaggtgetg etgeagaate aneggetgeg ggaccacaat atceggnegg 60
gegaggatag atgtgeteae geaagaagge tgagtttate aagggeagte aeaagtgeaa 120
cgtttgttca cggactttct tctcggagaa cgggctacgg gagcacctgc agacgcaccg 180 gggccctgcc aagcactaca tgtgtcccat ctgtggtgag cgcttccctt cgctgctgac 240
gctcaccgaa cacaaggtga cccacagcaa gagcctggac acgggcacct gtcgcatctg 300
caagatgccc ctgcagagcg aggaggagtt tattgagcac tgccagatgc accctgacct 360
gegeaactea eteaeggget teegetgtgt ggtetgeatg eagacagtea etteeaeget 420
tgagctcaag atccatggca cettecacat geagaagetg gegggeaget cageggegte 480 etcececaat ggecagggge tgeagaaget etacaagtge geeetgtgee teaaggagtt 540
ccgcagcaag caggacctgg tgaagcttga cgtcaatggg ctgccctacg gcctctgcgc 600
eggetgeatg geeegeagag ceaaeggaca ggtgggtgge etggeeeege eegageeege 660
cgaccggccc tgtgccggcc tccgttgccc cgagtgcagt gtcaagtttg agagtgccga 720
```

```
agacctggag agccacatgc aggtggacca ccgtgacctc acgccggaga ccagtgggcc 780
ccggaaaggc acccagacat cgccagtgcc ccggaaaaaag acataccagt gcatcaagtg 840
ccagatgacc ttcgagaacg agagagat ccaaatccac gatgccaacc acatgattga 900
ggaaggcatc aaccacgagt gtaagctgtg caaccagatg ttcgactccc cggccaagct 960
cctctgtcac ctcattgage acagettega gggcatggge ggcacettea aatgccccgt 1020 gtgtttcaca gtcttcgtcc aggccaacaa gttgcagcag cacatetttg ccgtgcacgg 1080
gcaggaggac aagatetacg actgeteaca gtgeeeteag aagttettet tecagacega 1140
gctgcagaac cacacgatga gccagcacgc acagtgaggg atcgctcaac aggacacctc 1200 tccgcagaag gcttgccgga gacgccgtgg ggagggccat ttgaacatta catccaatca 1260 aagtgtcatt tgcaacccag atgtaaaact ctaatgattt ggccatgagg cgctgctatt 1320 ataagcagct ggaaatgaat attaatggca gagattaaaa gtattccatg ctcagtattt 1380 tttattgcc tgctacagct agtgtgcttt taagactttcc gccgcagact acattctag 1440
agttagagaa acctgctitt taaggctatt gtcctttgtt ccttcatgta ttatattgat 1500
agtttttaaa aaagaattag tgtgattttt tttctttgct tcttttttt ctttcttgtt 1560
tttcttcccc cccacccct accccttcg gttaactact ttttaattgc aattctaggt 1620 aattgtgcat cgtgatgtga ttgcttggct attgtctgaa tatttccttt taattttta 1680
attaaagact aatgetitga tiggatitge cagitcaccg gacagigati aaaactaigt 1740
aatgaatata atcggtttca gtgcaactgg atggtctgct tttaaatgtg acttaatctg 1800
                                                                                       1827
actgcagtaa ctagtacagt tcaataa
<210> 98
<211> 825
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:1170349.1:2000MAY01
<400> 98
geogetgett caggteggeg ggetecaggg agacetgggt gggeagegte geogtttete 60
ctttettggg cagtattttt cccagegeca egeggagget gggecattat gagetetgea 120
tttccaggac ctggtcacta ttcaggacac ggttccagcg cagtgcgcgt tagccatgtc 180
tcagggatga gtgacattcc aagatgtggc cattgacttc tccaaggaag agtggggatt 240
cctgaaccct gctcagagag atttgtacac aactgtgatg ctggagaatt atcagaacct 300 ggtctggctg ggactttcca tttctaaatc tgtgatttca ctgttggaga aaaggaaact 360
gccttggata atggcaaaag aagagataag aggcccattg ccagatgtgc caggtgcaga 420
gattaaggag ttatctgcaa agagggctat taatgaagta ttatcgcagt ttgacacagt 480
gataaaatgt acaagaaacg tatgtaagga atgtggaaat ctatactgcc acaatatgca 540 gcttactctc cataagagaa atcatacaca aaagaaatgc aatcagtgtt tagattgtgg 600
gaaatacttc actcgtcaat cacctctcat tcagcatcaa agaatccaca cgggagagag 660
accetataaa tgtaacgaat gtattaaaac etteaaceag agggeacace ttacetagca 720
tgagagaatt cacactggtg agaaacctta caaatgtaag gaatgcagga aaaccttcag 780
ccagatgact catctcacac agcatcagac tacacatatg agaga
<210> 99
<211> 1100
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:335097.1:2000FEB18
tcatctgtgc tgtgaattat gtgctgtatt gactctcaag catgatgacc attggtggtt 60
totgtaccat ttootgttac tttactgaaa cacacctact ccattaactt cttgggttaa 120
gtcłagaaag taacagttta cttgtaaacc acatttctta tccccaataa gtatttttt 180
aagattatta aagttcatta ttactaccct atgatgtgaa agtgtcattt gcttaatctt 240 tttaatttt tattctcaac ctcatcttac tgaagagaat aaaactcttt taccatattc 300
ttaaaatgtg gaattetegg ceaggtgeag tgeteacgee tgtaatteea teactttggg 360
aggecaaggt gggtggatea tetgaggtea ggagtteaag accageetgg ccaacatggt 420
gaaaccccgt ctctactaaa aatacaaaaa ttatctgggt gtggtggcgc gtgcctgtag 480
geccagetae teaggagget gaggeaggag aattgettga acceaagagg tggaggttge 540 agtgageeta gattgetgee actgeactee ageetgggtg acageagaae tetgteteaa 600 aaaaaagatg tggaattett ttetgeaaat gttetetaat agtataeett etteagtetg 660
togatatatg tatgctatta ttttacaagt aatacatgtt gattgtattg gaaattatag 720
```

WO 01/62927 PCT/US01/06059 aaaagattat atto tgt ttagaaaata tttttaaatg tga aaaa tataaaaatt 780 actcocttgt tocactttcc ccactctcaa gtcagactat gitgttttca tagttagtag 840 ctagcagtet accecactag attatatget teacagaggg aagggaceet caagacttea 900 etggattgag tagcacecaa tacettgett getgeetggt ttgtgatggg catactgtaa 960 gaaaaaaaaa tetgaatgae aaaatgtttt tecataatae cagactteet ettgaagaga 1020 tgggtcgtaa tgttgtagtc ttacatgctt acgtagacga tcaaagcaag aatactcaat 1080 aaatggctat ttaccacttg <210> 100 <211> 584 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:1076451.1:2000FEB18 <400> 100 gtgtacttac tttctgccat tatatcctct ttcttaataa agggaaccac atcatattcc 60 taatcttatt actattaatg acagcacagg catcagattt caaggtgact tgtatgggca 120 cccattttt cttctgtttt ggctaacact ttactcgtat tgtttatgag ccccatcag 180 tcctcagttc ttaatcttat ttcaaaaact gtggtcatgg gaggctcaga tgggtcataa 240 cacacattag gttggtcatt tcctgggcta tgtaccttgt atagaataac attatacaag 300 caagttcttt ttagagttct agtacactta taataaccat aaaataatag gaccatagca 360 accitttgtc ctacctcagt gacttgatgt atacactagg aacagtcctc agtccaagga 420 aggtcagttg aagtccttac tgtacaagtc caaatgttaa ggaacatgag tcccgcgatg 480 agttttetea tgetteagee gigegtggae eagteagett eegggtgiga etggageagg 540 gettgtcgac ttettcagag ttaetttgca ggagttggcg aage <210> 101 <211> 392 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:805478.1:2000FEB01 <220> <221> unsure <222> 21 <223> a, t, c, g, or other <400> 101 gccaacccct gcaaagtgac nctgaagaag acgacaagct ctgctccagt cacacccaga 60 agetgactgg tecaegeaeg geegaageat gagaaaaete attgeggaae teatttteet 120 taaaatttgg acttttacag taaggacttc aactgacctt cctcagactg aggactgttc 180 cagtgtatac atcaagtcac tgaggtagga caaaaggttg ctacagtcct attatttat 240 ggttattata agtgtactgg aactctaaaa ataacttgtt tgtataatgt tattctgtac 300 aaggtatgta gcccaggaag tgaccaacct gatgtgtgtt atgacccatc tgagcttccc 360 atgaccacgg tttttaaaat aagattaagg ac <210> 102 <211> 856 <212> DNA <213> Homo sapiens <221> misc_feature <223> Incyte ID No: LG:101269.1:2000MAY19 ctctccttta ttattaacta aagagcattc tctaccattg cccagctgaa.agcacctage 60 tcatagattc tctgtgggga gagtgaataa agaatggggg attgaggcac agagtgttaa 120 aatagtgaga cacaggattc taactggcag actggcactt tatctcaatt cttaactgct 180 gtgttgcctc tcactttaaa gacatccaca ttccaccctg gccttgcccg tctggtgagc 240

ccaatctctg ctggtcagtc acgcagttga ggtcagggaa ggagtaactc aagatgattt 300

WO 01/62927 PCT/US01/06059 tgatgttgca gttttaaatt tcactttgac ttgagctggg aaatcctttg gcctattata 360 ccatggatgc taaaaatggt tctaactgaa aacccaaacc aagaaatagc aacaagtcta 420 gaattettae taetacaaaa eteaeetgga teeetaaggg cacageaaag aatgagetat 480 tacggcagca gctatcatat tatcaatgcg gacgcaaaat acccaggcta cccgccagag 540 cacattatag ctgagaagag aagagcaaga agacgattac ttcacaaaga tggcagctgt 600 aatgtctact tcaagcacat ttttggagaa tggggaagct atgtggttga catcttcacc 660 actettgtgg acaccaagtg gegecatatg titgtgatat titettate ttatattete 720 tegtggttga tatttggete tgtettttgg eteatageet tteateatgg egatetatta 780 aatgatccag acatcacacc ttgtgttgac aacgtccatt ctttcacagg ggcctttttg 840 ttctccctag agaccc 856 <210> 103 <211> 856 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:331087.1:2000MAY01 <400> 103 ccctctctct ttctgccctg tagccgcggg cgtccaaatg aagctggaat tcctccagcg 60 caaattetgg geggeaacge ggeaggatet ggaetgette gteategaca acaaegggtt 120 cattetgate tecaagaggt cecgagagag tgaetatgta tgaetateag gecatgtgea 180 aaccetegag teaceaceae agtgeageee ageecetggt cageecaatt tetgeettet 240 tgaeggegae caggtggetg etgeaggage tggtgetgtt cetgetggag tggagtgtet 300 ggggctcctg gtacgacaga ggggccgagg ccaaaagtgt cttccatcac tcccacaaac 360 acaagaagca ggacccgctg cagccctgcg accacggagt accccgtgtt tcgtgtacca 420 gccggccatc cgggaggcca acggaatcgt ggagtgcggg ccctgccaga aggtatttgt 480 ggtgcagcag attoccaaca gtaacctect ceteetggtg acagacceca cetgtgactg 540 cagcatette ceaecagtge tgcaggagge gacagaagte aaatataatg cetetgtcaa 600 atgtgacegg atgegetece agaageteeg eeggegacea gaeteetgee aegeetteea 660 tecagaggtg egggttgagg eggategagg gtgggetgga tttteatece caaaccetet 720 gtgcctgggt ctgtgcccct gcagacagga gcatataggg atgccaatga acacacctgt 780 gcctgtgctt ctcgggggaa acattcgcgt ttatgccctg tgacactgtg atataataag 840 aaacagatct ttattt <210> 104 <211> 8530 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:410188.1:2000MAY01 <220> <221> unsure <222> 6797, 7046, 7252, 7311, 7325-7326, 7502-7503, 7563
<223> a, t, c, g, or other <400> 104 geogetgage etgegeecag tgeecegage ecegegeega geegagteeg egecaageag 60 cagcegeeca ecceggggee eggeeggggg accageaget tecceaeagg caaegtgagg 120 agageetgtg eccagaagea ggatgagaag atggeaaact tectattace teggggeaec 180 agcagettee geaggtteae acgggagtee etggeageea tegagaageg catggeggag 240 aagcaagcce geggeteaac cacettgeag gagageegag aggggetgee egaggaggag 300 geteecegge eccagetgga cetgeaggee tecaaaaage tgeeagatet etatggeaat 360 ccaccccaag agctcatcgg agagccctg gaggacctgg accccttcta tagcacccaa 420 aagacttca tcgtactgaa taaaggcaag accatcttcc ggttcagtgc caccaacgcc 480 ttgtatgtcc tcagtcctt ccacccagtt cggagagcgg ctgtgaagat tctggttcac 540 tegetettea acatgeteat catgtgeace atceteacea actgegtgtt catggeceag 600 caegacecte caecetggae caagtatgte gagtacaect teaecgecat ttacaecttt 660 gagtetetgg teaagattet ggetegaget ttetgeetge acgegtteae ttteettegg 720 gaeceatgga actggetgga etttagtgtg attateatgg catacaeaac tgaatttgtg 780 gaectgggea atgetetage ettaegacec tteegagtee teegggeet gaaaactata 840

tcagtcattt cagggctgaa gaccatcgtg ggggccctga tccagtctgt gaagaagctg 900

gctgatgtga tggta cac agtettetge etcagegtet ttge Cat cggcctgcag 960 ctcttcatgg gcaacctaag gcacaagtgt gtgcgcaact tcacagcgct caacggcacc 1020 aacggeteeg tggaggeega eggettggte tgggaateee tggacettta eeteagtgat 1080 ccagaaaatt acctgctcaa gaacggcacc tctgatgtgt tactgtgtgg gaacagctct 1140 gacgctggga catgtccgga gggctaccgg tgcctaaagg caggcgagaa ccccgaccac 1200 ggctacacca gettegatte etttgeetgg geetttettg caetetteeg eetgatgaeg 1260 caggactgct gggagcgcct ctatcagcag accetcaggt ccgcagggaa gatctacatg 1320 atettettea tgettgteat etteetgggg teettetace tggtgaacet gateetggee 1380 gtggtegeaa tggeetatga ggageaaaac caageeacea tegetgagac egaggagaag 1440 gaaaagcgct tccaggaggc catggaaatg ctcaagaaag aacacgaggc cctcaccatc 1500 aggggtgtgg ataccgtgtc ccgtagctcc ttggagatgt cccctttggc cccagtaaac 1560 agccatgaga gaagaagcaa gaggagaaaa cggatgtctt caggaactga ggagtgtggg 1620 gaggacaggc tccccaagtc tgactcagaa gatggtccca gagcaatgaa tcatctcagc 1680 ctcacccgtg gcctcagcag gacttctatg aagccacgtt ccagccgcgg gagcattttc 1740 acctttcgca ggcgagacct gggttctgaa gcagattttg cagatgatga aaacagcaca 1800 gegegggaga gegagageea eeacaetea etgetggtge eetggeeeet gegeeggaee 1860 agtgcccagg gacagcccag tcccggaacc tcggctcctg gccacgccct ccatggcaaa 1920 aagaacagca ctgtggactg caatggggtg gtctcattac tgggggcagg cgacccagag 1980 gecacatece caggaageca ecteeteege cetgtgatge tagageacee gecagacaeg 2040 accacgccat cggaggagcc aggcggcccc cagatgctga cctcccaggc tccgtgtgta 2100 gatggcttcg aggagccagg agcacggcag cgggccctca gcgcagtcag cgtcctcaca 2160 agcgcactgg aagagttaga ggagtctcgc cacaagtgtc caccatgctg gaaccgtctc 2220 geceageget acctgatetg ggagtgetge cegetgtgga tgtecateaa geagggagtg 2280 aagttggtgg tcatggaccc gtttactgac ctcaccatca ctatgtgcat cgtactcaac 2340 acactettea tggegetgga geactacaac atgacaagtg aattegagga gatgetgeag 2400 gtcggaaacc tggtcttcac agggattttc acagcagaga tgaccttcaa gatcattgcc 2460 ctogaccoct actactactt coaacaggge tggaacatet tegacagcat categtcate 2520 cttagcetea tggagetggg cetgteeege atgageaact tgteggtget gegeteette 2580 egeetgetge gggtetteaa getggeeaaa teatggeeea eeetgaacae acteateaag 2640 atcatcggga actcagtggg ggcactgggg aacctgacac tggtgctagc catcatcgtg 2700 ttcatctttg ctctggttgg caagcagctc ctaggggaaa actaccgtaa caaccgaaaa 2760 aatateteeg egeeceatga agaetggeee egetggeaca tgeacgaett ettecaetet 2820 tteeteattg tetteegtat eetetgtgga gagtggattg agaacatgtg ggeetgeatg 2880 gaagttggcc aaaaatccat atgcctcatc cttttcttga cggtgatggt gctagggaac 2940 ctggtggtgc ttaacctgtt categecetg ctattgaact ctttcagtgc tgacaacctc 3000 acageceegg aggacgatgg ggaggtgaac aacetgeagg tggeeetgge eegeateeag 3060 aggggcctgc gctttgtcaa gcggaccacc tgggatttct gctgtggtct cctgcggcac 3120 eggeeteaga agecegeage cettgeegee cagggeeage tgeecagetg cattgeeace ccctactccc cgccaccccc agagacggag aaggtgcctc ccacccgcaa ggaaacacag 3240 tttgaggaag gcgagcaacc aggccagggc acccccgggg atccagagcc cgtgtgtgtg 3300 cccatcgctg tggccgagtc agacacagat gaccaagaag aggatgagga gaacagcctg 3360 ggcacggagg aggagtccag caagcagcag gaatcccagc ctgtgtccgg ctggcccaga 3420 ggccctccgg attccaggac ctggagccag gtgtcagcga ctgcctcctc tgaggccgag 3480 gccagtgcat ctcaggccga ctggcggcag cagtggaaag cggaacccca ggccccaggg 3540 tgcggtgaga ccccagagga cagttgctcc gagggcagca cagcagacat gaccaacacc 3600 getgagetee tggageagat ceetgacete ggeeaggatg teaaggacee agaggaetge 3660 tteaetgaag getgtgteeg gegetgteee tgetgtgegg tggacaceae acaggeecea 3720 gggaaggtet ggtggeggtt gegeaagaee tgetaceaea tegtggagea cagetggtte 3780 gagacattca teatetteat gateetaete ageagtggag egetggeett egaggacate 3840 tacctagagg ageggaagac catcaaggtt etgettgagt atgeegacaa gatgtteaca 3900 tatgtetteg tgetggagat getgeteaag tgggtggeet aeggetteaa gaagtaette 3960 accaatgeet ggtgetgget egaetteete ategtagaeg tetetetggt cageetggtg 4020 gccaacaccc tgggctttgc cgagatgggc cccatcaagt cactgcggac gctgcgtgca 4080 ctccgtcctc tgagagetet gtcacgattt gagggcatga gggtggtggt caatgccctg 4140 gtgggegcca tecegtecat catgaacgte etcetegtet geeteatett etggeteate 4200 ttcagcatca tgggcgtgaa cctctttgcg gggaagtttg ggaggtgcat caactatacc 4260 gatggagagt tttcccttgt acctttgtcg attgtgaata acaagtctga ctgcaagatt 4320 caaaactcca ctggcagctt cttctgggtc aatgtgaaag tcaactttga taatgttgca 4380 atgggttacc ttgcacttct gcaggtggca acctttaaag gctggatgga cattatgtat 4440 gcagctgttg attcccggga ggtcaacatg caacccaagt gggaggacaa cgtgtacatg 4500 tatttgtact ttgtcatctt catcattttt ggaggettet teacactgaa tetetttgtt 4560 ggggtcataa ttgacaactt caatcaacag aaaaaaaagt tagggggcca ggacatcttc 4620 atgacagagg agcagaagaa atactacaat gccatgaaga agttgggctc caagaagccc 4680 cagaagccca tcccacggcc cctgaacaag ttccagggtt ttgtctttga catcgtgacc 4740 agacaagctt ttgacatcac catcatggtc ctcatctgcc taaacatggt tcaccatgat 4800 ggtggagact gatgaccaaa gtgaagaaaa gacgaaaatt ctgggcaaaa tcaaccagtt 4860 ctttgtggcc gtcttcacag gcgaatgtgt catgaagatg ttcgctttga ggcagtacta 4920

PCT/US01/06059 WO 01/62927

				•		•	
						ecgcgagcct	
	gattttttct	gcaattctta	agtcacttca	aagttacttc	tccccaacgc	tcttcagagt	5040
	catccgcctg	gcccgaattg	gccgcatcct	cagactgatc	cgagcggcca	aggggatccg	5100 .
	cacactgete	tttgccctca	tgatgtccct	gcctgccctc	ttcaacatcg	ggctgttgct	5160
	attectiote	atottcatct	actccatctt	cogtatotcc	agettteece	atgtgaggtg.	5220
•						tgctgtgcct	
						tcaacacagg	
						actgtgggag	
	gccccccac	cgcgacccca	tottorocae	ctacatcatc	atctccttcc	tcatcgtggt	5460
	caacatgtac	accycaycya	ttetggagaa	ctttaatgtg	gccacggagg	agagcactga	5520
						ttgacccaga	
						tetetggtee	
						ctttggtccc	
						tcctaggaga	
						cagccaaccc	
	atccaagatc	tcctacgagc	ccatcaccac	cacactccgg	cgcaagcacg	aagaggtgtc	5880
	ggccatggtt	atccagagag	ccttccgcag	gcacctgctg	caacgctctt	tgaagcatgc	5940
	ctccttcctc	ttccgtcage	aggcgggcag	cggcctctcc	gaagaggatg	cccctgagcg	6000
	agagggcctc	atcgcctacg	tgatgagtga	gaacttctcc	cgaccccttg	gcccaccctc	6060
						ctagagccac	
	cagcgataac	ctccaggtgc	gggggtctga	ctacagecae	agtgaagate	tcgccgactt	6180
	eccepttet	ccaascsaaa	accotoacto	catcototoa	acctcaacct	ggctggccag	6240
	dacacactda	aaagcagcct	ttttcaccat	agcaaaccta	aatgcagtca	gtcacaaacc	6300
						ggatcaacca	
	agcergggge	tataacacca	cataascaa	caaaacaatt	aggetteet	tggaggcctc	6420
	agatagageee	atazaataat	charterage	aatacccata	caactotaa	aaagcaactt	6480
						atgggctttc	
						ttttccatgg	
						tatggagcag	
						ggtcttcact	
						gggctgaacc	
	cccactcaca	caagcanaca	cacacagtcc	tcacacacgg	aggccagaca	caggccgtgg	6840
	gacccaggct	cccagcctaa	gggagacagg	cctttccctg	ccddccccc	aaggatgggg	6900
	ttcttgtcca	cggggctcac	tetggeeece	tattgtctcc	caaggtccca	ttttccccct	6960
	tgtgttttca	cgcaggtcat	attgtcagtc	ctacaaaaat	aaaaggcttc	cagaggagag	7020
	tggcctgggg	teceaggget	gggccntagg	cactgatagt	tgccttttct	teceetectg	7080
						gcctggcatg	
	cagcttgtcc	ttgctcctgg	aacctggcag	gccctgccag	ccagccaatg	gaagagaggg	7200
	gctgagccat	gggggtttgg	ggctaagaag	ttcaccagcc	ctgagccatg	gnccctcagc	7260
	ctgcctgaag	agaggaaact	ggcgatctcc	cagggctctc	tggaccatac	neggaggagt	7320
	tttcnngtgt	ggtctccagc	tectetecag	acacagagac	atgggagtgg	ggagcggacg	7380
	ttggccctgg	ccctgtgcag	ggaaagggat	ggtcaggccc	agttctcgtg	ccccttagag	7440
	gggaatgaac	catggcacct	ttgagagagg	gggcactgtg	gtcaggccca	gcctctctgg	7500
						agatccaggt	
	ggntcccata	ggtcttgtga	aaaggctttt	tcagggaaaa	atattttact	agtccaatca	7620
	ccccaggac	ctcttcagct	gctgacaatc	ctatttagca	tatgcaaatc	ttttaacata	7680
	gagaactgtc	accetgaggt	aacagggtca	actggcgaag	ctgaggcagg	ccagggggct	7740
	taactaccc	attccagete	teceacggag	cccctccaac	cadacacata	ctcccaggcc	7800
	acctcactct	cacctaccaa	ctctaggeta	actactecta	acctaceted	ccgagctgtc	7860
	agagggggg	acatttataa	cantuctuaa	aaaaacatta	ccaacaaata	aagtattatg	7920
	tttcttctta	teacceast	tecetteete	dcaaccccad	acccasaccc	atgeceetga	7980
	cadatotadt	tetettetee	tatattacaa	tttgagtcca	actodadacc	aaggttttaa	8040
	ctatacasaca	agagatttat	coasetees	atccatattt	ttatasasta	tccatgcttt	8100
	ccycccaage	attacasas	tatataaaa	atacatacat	taataaaaa	ctgctacaca	21.50
	geteteaagg	cccyyayayg	acqueedac	actacasass	angeteacege	anagarant	8330
	ggcaggtaat	geggattgga	ggcaggcegg	gatgadagee	cayouggeeg	gaaggagact	0220
	geggeeete	rgrgrgrgga	cagcccggga	getttgagae	aggracerag	gggctggctg	0240
	cagacggtgt	agrraaaaar	gggaggtgag	ctagacccaa	cccttagctt	ttagcctggc	0.400
	tgtcaccttt	ttaatttcca	gaactgcaca	atgaccagca	ggaggggaga	agagagtagg	8400
	aaaaaggagg	gaaggaaaga	catcaagtgc	cagatgttgt	ctgaactaat	cgagcacttc	8460
		tcatgtataa	ataaaataca	tatttttaaa	acaaaccaat	aaatggctta	
	catgacctgg						8530

<210> 105 <211> 2965 <212> DNA <213> Homo sapiens

```
<220>
<221> misc_feature
<223> Incyte ID No: LI:1188288.1:2000MAY01
<400> 105
ctgaggtggc gtgggcgccc tgcgggccgg gcctccgcgg cgcgtccagt cccagtctcc 60
gegetggtet ggeeggtee eteageteea eccetgeet ecceteegg eccgetegeg 120
cctcctgaaa agccagctcg cccggggcgg cggcgcagag ccgggccggc gcacgaggca 180
gecagegegg ceatgaegge ggagaaggeg etgeceetgg geaatgggaa ggetgetgag 240 gaggegeggg agteegagge geegggtgge ggetgeagea gegggggege ggegeeegeg 300 egecaceege gegteaageg egacaaggeg gteeaegage geggeeaetg gaacaacaag 360
gtggagttcg tgctgagcgt ggccggggag atcattgggc ctgggcaacg tgtggcgctt 420
cccctacctt gtgctacaag aacggaggag gggcattcct gattccctac gtggtgtttt 480 ttatttgctg tggaattcct gttttttcc tggagacagc tctggggcag ttcacaagtg 540 aaggtggcat tacgtgttgg aggaaagttt gccctttatt tgaaggcatt ggctatgcaa 600
cacaggigat tgaggcccat cigaatgigt actacatcat catcciggca tgggccattt 660
tttacctgag caactgette actactgage taccetggge tacctgtggg catgagtgga 720
acacagagaa ttgtgtggag ttccagaaac tgaatgtgag caactacage catgtgtctc 780 tgcagaaatg ccacctccc tgtcatggag ttttgggage accgggtcct gggcatctct 840
gacgggatcg agcacatcgg gaaccttcgc tgggagctgg cettgtgtet ettggcagec 900
tggaccatct gttacttctg tatctggaag gggaccaagt ctacaggaaa ggttgtatac 960
gtgactgcga cattccccta catcatgctg ctgatcctcc tgatacgagg ggtcacgttg 1020 cccggggcct cagagggcat caagttctac ttgtaccctg acctctcccg gctctccgac 1080 ccccaggtct gggtagatgc tggaacgcag atcttttct cctatgccat ttgcctgggc 1140
tgtctgaccg ctctgggaag ttataacaat tataacaaca actgctacag ggactgcate 1200 atgctctgtt gcctgaacag cggcaccage tttcgtggct gggtttgcca tcttctcagt 1260 cctgggtttt atggcgtacg agcaggggt acccattgct gaggtggcag agtcaggcce 1320
eggtetggee tttattgegt acceeaagge ggteaceatg atgeceetet eccegetgtg 1380
ggccaccttg ttcttcatga tgctcatctt cctgggcctg gacagccagt ttgtgtgtgt 1440 ggaaagcctg gtgaccgccg tggtggacat gtaccccaat ggttttcccg gaggggttac 1500 cggcgggagc tgttcatcct agccttgtct gttatctcct atttctggg cctcgtgatg 1560
ttaacagagg gtggcatgta catcttccag ctctttgact cctatgccgc cagtgggatg 1620 tgccttctct tcagcggcca tctttgagtg catctgcatc ggctgggtgt atgggaagca 1680 accggttcta tgataacatt gaagacatga ttggctaccg gccaccgtcg ctcattaagt 1740 ggtgctggat gatcatgacc cctgggatct gacgacgggg atcttcatgc ttgcttcttg 1800
atcaaggtac aagaccactg caaggtacaa caacatctac acctacccag cctggggcta 1860
atggcattgg ctggctcatg ggccctgtcc tccatgctct gcatcccgct ctggatctgc 1920 atcacagtgt ggaagtacgg aggggacgct gcccgagaaa ctccagaagt tgacgacccc 1980
cagcacagat ctgaaaatgt cggggcaaga cttggggtga gcccacggat ggtgacagtt 2040
aatgactgtg atgccaaact caagagtgac gggaccatcg cagccatcac agagacagga 2100
gaacgccact tetgageggg ccaaaccaaa gccatettgg eggeteette tteetttett 2160 ecceegtgt atgtaaatga atteetgaac eccatactte acetaatggt aggggettge 2220
ttgttttgca caggattaat taacaagtta attttaaggt ggccactgta cactgctcta 2280
aagtcatatc cecteceege eecceagtte atcatggaag taaccactae aaagagataa 2340 cactgtaegg ggactgeeag atcttetgte etagggeagt tttaatcaat gttttetagg 2400
gattaggaag aagtgtataa tattgtaaaa ctttgtatta ctggggggttg tgggccaggt 2460
ggggtgggga gtgatggetg teeteetegt gteggeettt gtaatgaeeg ttetgtgtee 2520
cagtgtatgt ctctgaccat ccacagccgc ccctcctcca tacccccggg ataaattttc 2580
cetcaaaccc teceetteea caagggacae tggggttgge agacageaag getattgtgg 2640 cagagaagaa aaagteeage agacteagga eteetgget geaggeeece etetggeetg 2700
atcocatgaa ggtgaccttg ggaactccct ttccctccct gggcctcagt ttccccctct 2760
ccccaatgag aggaggagcc cgattggggt atttcttagg gatatctctt tgtgtgccta 2820 tgattgcttc cagacctgc gtggaccttg gcttccttct gaagacttgc aggccattat 2880 ctccgccctc cccagttgta cctcctccc acctgcttat ttaaaatcca gtttcttgtc 2940
gaaacacaca caaaacacac acaaa
                                                                                                           2965
<210> 106
<211> 2376
<212> DNA
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: LI:427997.4:2000MAY01
<400> 106
cgcgtacagg aggcggcggc ggctcccagt caccggcccc cgacggcgag cgcacgatgc 60
```

```
actgcctggg cgccgagtac ctggtttctg ccgacggcgc ccctaggcaa agggagtggc 120
gaccccagat ttataggaaa tgcacagata cggcatggtt attcctgttc tttctcttt 180
ggactggttt ggtgtttatc atgggctact cggtggtggc tggagccgcg ggaagactcc 240
tetttggeta tgacagettt ggeaacatgt gtggcaagaa gaacteece gtggaagggg 300
cccctctttc agggcaggac atgaccctaa aaaaacacgt gttctttatg aattcctgca 360
acctggaagt caaaggtacg cagctcaacc gcatggccct ctgtgtatcc aactgccctg 420 aagagcagct tgactccctg gaagaggtcc agttctttgc aaacaccagt gggtccttcc 480 tgtgtggtta tagtttgaat tccttcaact atacccacag tccaaaagca gactcactgt 540
gtcccaggct accagttect ccaagcaagt cattteeett atttaaccga tgtgteeete 600
aaacacctga gtgctactcc ctatttgcat ctgttttgat aaatgatgtt gacaccctcc 660 accgaattct aagtggaatc atgtcgggaa gagatacaat ccttggcctg tgtatcctcg 720 cattagcctt gtctttggcc atgatgttga ccgttcagat tcatacacca cccttctggt 780
tcacattttc atttcattgg ttattttggg attgttgttt agtctgcggt gttttatggt 840
ggctgtatta tgactatacc aacgacctca gcatagaatt ggacacagaa cagggaaaat 900
atgaagtgcg tgctggggta tgctatcgta atccacaggg catcacggca gatgctgctc 960
gtcttgatat tttgttctca gaaagagaat aaaattgaca agttgagctt ttccaaatca 1020 ccaaataaag ccaatcagca gttggctccc ttcctgggct ggttccaagc caactgggtg 1080 ggacgatttg gccatcctca ttgttcttcg tgggtcctct gggtggctgt gctgctgagc 1140
cttgggaact gcagggagct gccaggtta tgggaaggcg gccaagtgga atataagccc 1200
ctttcgggca ttccggtaac atgtgggtcg taccatttaa ttggcctcat ctggactagt 1260
gaattcatcc ttgcgtgcca gcaaatgact atatgctggg gcagtggtta cttgttattt 1320
caacagaagt aaaaaatgat ceteegtgat cateecagee gtttegtete gteeceatte 1380 tettetteta ceateeaagg aaccattgtg aaagggteat ttttaatete tgtggtgagg 1440
attccgagaa tcattgtcat gtacatggca acaacgcagc tgacaagata cagcatcggt 1500
geattegtae caggtacetg tteeggatga etgettaegg etgtteetgg tgtetggaea 1560
aaataceteg etecatetea ageeagaatg catatactae aateggeeta ttacatggga 1620 cagatttegt gtacateage aaaagatgea tteaaaatet tgteeaagaa eteaagteae 1680 tttacateta ttaatetget ttggagaett cataattttt etaggaaagg tgttagtget 1740
gtgtttcact gttttttgga ggactcatgg cttttaacta caatcgggca tttccaggtg 1800 tggggcagtc cctctgttat tggtagcttt ttttggccta cttagttagc ccatagtttt 1860
tttatctgtg tttgaaactg tgctggatgc acttttcctg tgttttgctg ttgatctgga 1920 aacaaatgat ggatcgtcag aaaagcccta ctttatggat caagaatttc tgagtttcgt 1980
aaaaaggagc aacaaattaa acaatgcaag ggccacagca gggacaagca ctccattaag 2040
gaatgaggag gggaacagaa ctcccaggcc attgtgcaga tagataccca tttaggtatc 2100 tgtacctggg aaaacatttc cttgctaaga ggccatttac agaatagaag atgagtatcc 2160 actagagata agtttgtgaa ttttttttc tcaaaagacc taataaaacc ctattcatca 2220
ctcattgtac titgtcatta ttgttcgaac caggataaca atactggaac tatattagtt 2280
tacctttttt tgtacaaatt aggacagaaa aactcttcta aaaccatgtt tatatgcatc 2340
aacttacaaa gtacactatg taagaactga ggtaag
<210> 107
<211> 821
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:451682.1:2000FEB18
cccatctcgc cgccgccgcg atgtctcgcc gctatgacag tcgcacgacg atcttctcgc 60
cggaggggcg tctctaccag gtggagtacg cgatggaggc gatcggcaac gccgggtcag 120
cectegggat cetggeggee gaeggegtag teetggtegg egagaagaag gtgaceteea 180 ageteeteea gaeeteegge teeggeggaa agatgtacaa gategaetee cacetggegt 240
gegetgtgge agggateatg teegaegeea acateeteat caacacegee egeetecaeg 300 cecagegeta egegetetee taccaggage ceateceegt egageagete gtecagteec 360
tetgegacae caageagggt tacacccagt ttggtggcet cegeceettt gggggteteet 420
tectattege eggttgggae aageaceaeg gttteeaget etacatgage gacceatetg 480
gcaactacgg cgggtggaag gccgccgctg ttggggccaa cagccaggcc gcgcagtcca 540
tgctcaagca ggactacaag gacgccttga cccgcgagga ggccgtcggt ctcgcgctca 600 aggtcctcag caagaccatg gactccacca gcttgactgc cgagaagctg gagctggccg 660 aggtatttet gcagcccgac accggggagg tacagtacca ggtgtgctct cctgaggcgc 720
tggggaaget gettgeaaac teeggeetga eacageeaae accegaggea taatgtactg 780
                                                                                                 821
gtttgcagtg gcatgtgatg ccttctactg ctcttagaca t
<210> 108
```

51/228

<211> 435

```
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1077283.1:2000FEB18
<400> 108
cgctgtctct tttcgccgct tgctgcagac atggtcaacc ccaccgtgtt cttcgacatc 60
acggctgatg gcgagccttt gggtcgcggt ctggcttcgg aagtggttgg cagacaaagt 120 tccaaagaca gcagaaaact ttcgtgctct gagcactggg gagaaaggat ttggctataa 180
egggtteetg ettteacaga attatteeag gatteatgtg eeagggtggt gaetteacae 240
gccataatgg cactggtggc aagtccatct acggagcaga aatttgcagg atgagaactt 300
catcetgaag catacaggte etggcatett gtecatggca aatgetggae caaacacaaa 360
tggttcccag ttttttatct gcactgccaa gactgagtgg ctggatggca agcatgtggt 420
ctttgggaag gtgaa
<210> 109
<211> 1430
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:481436.5:2000FEB18
ggcagatttt ctaaacatag aaagggagtt cacatgctac atggtcaaaa ataaaactga 60
tacatgtcca tttcagtatt caataaatat ttgtcagatg agtgaatgag agaatcagag 120
teatgattte etgtetetag acetttaagt caccaaacat tgaagtgata atggtgttgc 180
taatgtaatt gaaaataaaa tegaaggage aagetatgga ggggaacagg gatgaagetg 240 agaaatgtgt cgacategte caggaggete tgaatgetgg caacegegag aaggeccage 300
gtttcctgca gaaggccgag aagctctacc cactgccctt ggcctgcgca taaacaaata 360
tcaaaattac tatgaaagta cttggagtta cgaaagatag tggtgatgaa gatttgaaaa 420
aagettatag aaagettget ttgaagttte atecagacaa aaaceatgea eetggageaa 480 cagatgettt taaaaagatt ggaaatgett atgetgtttt aagtaateea gaaaagegaa 540
aacaqtatqa cctcacqqqc aatqaaqaac aaqcatqtaa ccaccaaaac aatqqcaqat 600
ttaatttcca tagaggttgt gaagctgata taactccaga agacttgttt aatatattt 660
ttgggggtgg atttccttca ggtagtgtac attcttttc aaatggaaga gctggttata 720 gccaacaaca tcagcatcga catagtggac atgaaagaga agaggaaaga ggagatggag 780
gtttttctgt gtttatccag ctgatgccca taattgtatt gatcctcgtg tcattattaa 840
gccagttgat ggtctctaat cctccttatt ccttatatcc cagatctgga actgggcaaa 900
ctattaaaat gcaaacagaa aacttgggtg ttgtttatta tgtcaacaag gacttcaaaa 960 atgaatataa aggaatgtta ttacaaaagg tagaaaagag tgtggaggaa gattatgtga 1020
ctaatattcg aaataactgc tggaaagaaa gacaacaaaa aacagatatg cagtatgcag 1080
caaaagtata ccgtgatgat cgactccgaa ggaaggcaga tgccttgagc atggacaact 1140
gtaaagaatt agageggett accagtettt ataaaggagg atgaactgga atttttattt 1200 atacetttta gegtaetett tatttttet gtaagtaagt ttggttteat eatgagggat 1260
gaaggaaaag atttgatact gaaaactaaa ctgaatagtt ggttcctgaa atcttggact 1320
gtttatgacc tactggctcc tttaaatagt aactgaaaac taaaatggaa tattttagtt 1380
aacgcttcta caagtatttt cattttaaaa gcttacatga ttcctaacta
<210> 110
<211> 889
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:793701.1:2000FEB01
<220>
<221> unsure
<222> 730, 733-735, 797-798
<223> a, t, c, g, or other
```

<400> 110

```
ccgacagcat aatgtgaggc aaggtctagc tgttccccc cggcatacaa gcttatagag 60 cagcctcctt tgaagatctc caggtggact tcacagagat gccaaagtgt ggaggtgttc 120
gagtgtggat caaggactgg aacgtagcct ctttgtgccc atggtggaaa ggaccccaga 180
etgtegteet gateacteec actgetgtga acgtagagag aatectagee tggatecate 240
acaaccgtgt aaaacctgca gegectgaat cetgggagge aagaccaagt etggacaacc 300 cetgcagagt gaccetgaag aagatgacaa geeetgetee agteacacce agaagetgae 360 tggtecacge acageegaag catgaggaag etcattgtga gatteatttt tettaaattt 420
tggacttata cagtaagggc ttcaactgat cttactcaaa ctggggactg ttcccagtgt 480
attcatcagg tcaccgaagt aggacagcaa attaaaacaa tctttctgtt ctatagttat 540
tatgaatgtg tggaaacaat aaaaaaactt gtttgtataa tgccactcag tacaaggtat 600 gtagcccgag aaatgaccga cctgatgcgt gttataaccc atctgagccc tccgcaacca 660 ccgtttttga aataagaata agaactggcc ttttcctagg tgatacaagt aaaataataa 720 ctagaacagn cannnaagaa attcccaagc aaataacttt aagatttgat gcttgtgcag 780
ccattaatag taaaaannta gaaataggat gtggttctct taactgagaa aggagctaaa 840
gagtagaaaa taaatatgtt tgtcatgagt caggggtttg taaaaattg
                                                                                               889
<210> 111
<211> 1106
<212> DNA
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: LI:373637.1:2000FEB01
<220>
<221> unsure
<222> 974
<223> a, t, c, g, or other
gccatccage atggtggact actacgaggt gctggacgtg ccccggcagg cctcatccga 60
ggccatcaag aaggcgtacc gcaagctggc gctcaagtgg caccccgaca aaaaccctga 120
gaacaaggag gaagcggaga ggagattcaa gcaggtggcc gaggcctacg aggtgttgtc 180
ggacgccaag aaacgcgata tetatgaccg ctatggcgag gcgggggcgg agggcggctg 240 cacaggcggc aggcccttcg aggaccctt cgagtacgtc ttcagcttcc gcgacccagc 300 cgacgtcttc agggagttct tcggcggcca ggacccattc tcctttgacc tcttgggaaa 360
cccgctggag aatattttgg gggggtcaga ggaactgctg gggaagcaga agcagagcgt 420
etgeacecet titetetgee tieagtgaat tieeagetti tigggggtgit tittettett 480
ttgatacagg atttcgttcc tttggctccc tgggaagtgg gggcctttct tccttctgca 540 tgtcctacgg tagtgatggg acaggcagct tcaagtccat gtcgacttcc actgaaatag 600
ttgatggtaa aaaaatcacc accaagagaa tcattgagaa tggccaagaa agggtggaag 660 tggaggaaga tggagagttg agttaaagtc cttcataata aatagcaaag agcagttact 720 ccgcattgac accaagtaat tccagtccac atttgacttt aagcacatct ggaggaatag 780 cggacttttt ttaggattga aagtgaactt tactttcaga acagctgtac ccaagaattt 840
ataaacactt catgccaaca cctgttctta tcgttgggac tacacggata ggacctctgt 900
ttgtctttca atcgttgtaa aatatctgta tgcaatttgc tatttattaa acttaagcct 960
gaggcagaca atgnttattt gctagtggta ggacagaatg ttcagttcag cactttgagc 1020
attacctttt tccgttggga aagtgtgagc caggtggttt gctctaaatc atttgacttt 1080
attgtttgtg tgtagtggtg aaatct
<210> 112
<211> 461
<212> DNA
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: LG:239368.2:2000MAY19
tegacteega cetegtgate tgececeteg geeteecaat getggataeg geatgageac 60
acgeceagee ectgeaagea gtttetttaa etetgttggg atgecatteg tgggcaaage 120
tagatttggg acaagttgcc cagctctgct aggaagagtc agtcctcagg gggaagtttc 180
ttttcacctc cgggatcccc agggettcct gggttgactc aggacttcat acgcagcctg 240 gatctccagg aagtgcctct gtgcctcctc tgtctggtcc aggttgtggt ctgggtgcca 300
gacetteact ageteetggt aacteegatg tatttettea titgtigeee ettetgagag 360
```

```
WO 01/62927
                                                                           PCT/US01/06059
gcccaaaacc tggtaagcca gctgacgctt ctcatcctga aaactgtgaa caaactcata 420
gagettegee cacteetgaa ageagetget gttgaageea g
<210> 113
<211> 1450
<212> DNA
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: LI:053826.1:2000MAY01
<400> 113
gaattccccc cccccccc tcacttggtg tgtctatatg tctggcagac attatcagca 60
cattetetgt tgttacetgt gatteatttt ttetteacte teeaggtgaa tttcaattge 120
tgaaaatttc ccactgaaaa tatgcagtaa tatattttgt ggttcagaca tttggggcaa 180
atggttcaca ttcattttag ggttagtggt catgctgttt atttttctct gctatacaaa 240 gttcctctta ggggtctgcc tcatgacact aaaaaatgaa tagagattct actgtaggtt 300
atctcctagg cttgagttca acatttgttt ggatttttga agaaagtcaa atcaagcaat 360
geteceaaat gatgtettig taaatteata eeetetggee etattititt teatagaeee 420
taactctacc tttctgcttt aaagcaaagt aaactcggtg gcctcttctt ctccacccct 480 caaaatgata gcaatctctg ccgtcagcag tgcactcctg ttctcccttc tctgtgaagc 540 aagtaccgtc gtcctactca attccactga ctcatcccg ccaaccaata atttcactga 600
tattgaagca gctctgaaag cacaattaga ttcagcggat atccccaaag ccaggcggaa 660
gegetacatt tegeagaatg acatgatege cattettgat tateataate cagtteeggg 720 ccaaggggte ecceeeggag geaatattge atattttggt tggggttgaa ateetgtgee 780
aatctcggca aaggcttggg cggctacttg catttgggac catggacctt cttacttact 840 gagatttttg ggccaaaatc tatctgtacg cactggaagg taggaaatat cgctctattc 900 tccagttggt caagccatgg tatgatgaag tgaaagatta tgcttttcca tatccccagg 960 attgcaaccc cagatgtcct atgagatgtt ttggtcccat gtgcacacat tatacgcaga 1020
tggtttgggc cacttccaat cggataggat gcgcaattca tacttgccaa aacatgaatg 1080
tttggggatc tgtgtggcga cgtgcagttt acttggtatg caactatgcc ccaaagggca 1140
attggattgg agaagcacca tataaagtag gggtaccatg ttcatcttgt cctccaagtt 1200 atgggggatc ttgtactgac aatctgtgtt ttccaggagt tacgtcaaac tacctgtact 1260
ggtttaaata agtttacctt ttcctccagg aaatataatg atttctggga acatgggcat 1320
gtatatatat atatggagag agaattttgc acatattata catattttgt gctaatcttg 1380
ttttcctctt agtattcctt tgtataaatt agtgtttgtc tagcatgttt gtttaatcct 1440
ttgggaattc
<210> 114
<211> 793
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:449393.1:2000MAY01
cagecatgte geteegegtg etgaaceeta acgeegaggt geteaacaag teggeagege 60
tgcacatgaa catcaacgcc gccaagggcc tccaggacgt gctcaagacc aacctcggcc 120
ccaagggcac catcaagatg cttgtgggtg gagctggtga cctgaagctg acgaaggatg 180
ggaacaccct cttgaaggaa atgcaaattc agaacccaac tgcaatcatg attgcgagga 240
cggctgtggc acaggatgac acaagtggtg atggcacaac ctccactgtg ctatttatcg 300
gggagetaat gaageagtet gageggtgea tegatgaagg aacteateea agattettgg 360
ttgatggttt tgatgttgct aagagagcgt gtcttgattt tctcgataag ttcaagacgc 420
cagtcgttac tggtgaagaa cctgacagag ataccttaaa aatggtagca agaacaacac 480
ttaggacaaa gttgtatgaa gggttggctg atcagttgac tgatattgtt gtgaatgcag 540
ttctgtgcat tcgcaaacca gatgaaccaa ttgatctatt tatggtggaa ataatgcaca 600
tgcgccacaa atttgatgtt gacaccegte tggttgaggg tetggteetg gaccaeggtt 660
ctcgtcaccc tgacatgaag cgcagggcag agaattgtta catcttgacc tgcaatgtct 720 cattagaata tgagaaaagt gaaatcaatg caggattttt ttactcaaac gcagaacaaa 780
aaaaaaaaa agg
<210> 115
<211> 2494
<212> DNA
```

```
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:1071427.96:2000MAY01
<400> 115
atgaaagtca ggcttttatt gagatgagac aagagaagat gcaatggcaa tggttgacca 60
ttgtttgaaa aaagcccttt ggtttcaggg gagatgtgtg aaggttgacc tgtctgagaa 120
atataaaaaa ctggttctga ggattccaaa cagaggcatt gatttactga aaaaagataa 180
atcccgaaaa agatcttact ctccagatgg caaagaatct ccaagtgata agaaatccaa 240
aactgatggt teccagaaga etgagagtte aaccgaaggt aaagaacaag aagagaagte 300
cggtgaagat ggtgagaaag acacaaagga tgaccagaca gagcaggaac ctaatatgct 360
tcttgaatct gaagatgagc tacttgtaga tgaagaagaa gcagcagcac tgctagaaag 420
tggcagttca gtgggagacg agaccgatct tgctaattta ggtgatgtgg cttctgatgg 480
gaaaaaggaa ccatcagata aagctgtgaa aaaagatgga agtgcttcag cagcagcaaa 540
gaaaaagctt aaaaagcgtc gttttccagg gagtatggaa ggttttgtca ctctagatga 600 ggttggtgat gaggaagatt cggaacttca gaaacttcgt aaatcgggca tggcatttaa 660
atctggtgac aaaaatgatg atggtttggt tgaaattaag gtggacaaga tcgaggaact 720
tgatcaagaa aacgaagcag cgttggaaaa tggaattaaa aatgaggaaa acacagaacc 780
aggtgctgaa tcttctgaga acgctgatga tcccaacaaa gatacaagtg aaaacgcaga 840
tggtcaaagt gatgagaaca aggacgacta tacaatccca gatgagtata gaattggacc 900 atatcagccc aatgttcctg ttggtataga ctatgtgata cctaaaacag ggttttactg 960
taagetgtgt teactetttt atacaaatga agaagttgca aagaatacte attgcageag 1020
cetteeteat tateagaaat taaagaaatt tetgaataaa ttggeagaag aacgeagaca 1080 gaagaaggaa acttaagatg tgeaaggaga tttaatgatt teaaagaaaa tgatggttet 1140 ttgttttaa tgttaacett ttttaaatae aataetgata gaagaaaact attgtaetet 1200 tttgttttag tggagaaata atagatgtet gtteatgtgt taagtgttat ageaaaaaaa 1200
atacacatat ggttaagtta atgaatagtt tttgttttat cagaatggca acagacagaa 1320
gtactttgta gagattgact tectaageta ettaagacaa ettgeaceae taagaaaaaa 1380
atgtagaacc atttggaaaa atgaaattta gtagttccaa gtttcaaaga aatgtcaaca 1440 ttttattcca ttcaataaag aacaaaacca atagtgttt tattactttc atctgaaaca 1500 ttccatgttt taatctgagc cttgcagact ttcatttgga gtttgaaccc gttttggttg 1560
catttcattt ttggagaact taattaacgt gagattggca attgaaatgc aggtgcagtt 1620
ttctgttaat gtcatgctgt tgtttaggta ataagaaata ttaagtaatt ggctttagat 1680 tttgtaattt ttttccctga gttcctgcta gatttcgtat tctagtagtc aatgtattt 1740 cagtgaaatg caaaaatatt cccattatct ttgaccagta ttaatttttg agatcttact 1800 gcttgtcact tgaatcccgt gattgtcata catctctggt ataagcaaca tttgatttt 1860
gaagtgtgta gaccatctct tcatattttc aagatgtaat tttacatttc tgcattttta 1920
aaacagtttg gccataatcc tagatgcacg cttctaattc atgtacctgc acatgtgacc 1980 tttgtgaaca gaaatttgca tgtataattt gtgtttactt gtaactttct ggttatatac 2040
tgcttatate tgtggattea agttactgaa gtgaatacca ataaaaagaa aaccctagge 2100
catgttaatt ggttatacat gtttggaatg ttaaccaacg tatttgtcag ttgtggtttt 2160
taticgetet taaaetttgt geatgettta acaatttatt aettttaaat etagagtgaa 2220
ttctaaagac tgccgctaaa gatctgagtt ttaaaaatgt tgttgctggt ggatttcttg 2280 ttcctgttac ataactaaaa gtgaggccat ttgtggtttt taaaaacctt atgaattaaa 2340
aatgctacag gtgaacaaac agaagcttat gtttagagag attgatgact taacagtaca 2400
attggaagta atacggatga gcaagaatta gttctgcagc ttttcaaaat aattacgtag 2460
agactcttgg tatattggat tatctgttgt aaac
<210> 116
<211> 957
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:336338.8:2000MAY01
<220>
<221> unsure
<222> 684, 708, 743
<223> a, t, c, g, or other
<400> 116
gcatcttata atatgtggca gtttacaact gctttgacca gaaaactgat gtgatatcag 60
tgttactgcc cagatatgag agttggatgc agagacatct gttcaaccga gttaggcaca 120
```

WO 01/62927 PCT/US01/06059 tgactacttc ttcttgtgtt gaatttaatt cttcttcttg tgttgaattt aattgecgtt 180 ctaaagaggt ttgaaaatta aactattgtt caatattcga aggaaagatt cttgcataag 240 catggaaaca aacaaaacag aatgttacat aagtataaca aatactttta ataagtctaa 300 aattaaaatt ctaattgata agacaatatt gtgtcacagt ttaatatgaa gcatcttttc 360 ctttgtgtta cttaaaatga tggtgcatct taaatcttgt gtcttagatt caatgaaata 420 tggtataaat gactgtatac tctctgctct aggtatctca aagaagacaa atttcttgct 480 ggataccaat tacatttacc atgggactgc aatgtctctc ctctccttga aaaacaatgc 600 ggttgactga aatcacttgg ggtggaccaa atttcctcct gttgactact cctgaatgat 660 ctcttccaat tccccaatc tgcntctctg gccaatcaca accttctncc atgtgtgtac 720 atcatgctgc tctcgtcttc aantcccctt ctctcttgct gacttctgga aaagcaacgg 780 aagagteetg ggeggaagga ggettetgta tgettgtgaa aaagaacaat etgtgeeaac 840 ggaaggttet teaacaactt tgetgeaaaa catgtacatt teaaggetga geageeatet 900 tagatttett tgtteetgta gaettataga ttatteeata ttattaaaaa gaaaaaa 957 <210> 117 <211> 1269 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:345527.1:2000FEB18 <400> 117 cagggagtta aaacgattca atgctgataa caaacttett ttgactggta etecettgca 60 aaacaattta tcagaacttt ggtcattgct aaactttttg ttgccagatg tatttgatga 120 cttgaaaagc tttgagtctt ggtttgacat cactagtctt tctgaaactg ctgaagatat 180 tattgctaaa gaaagagaac agaatgtatt gcatatgctg caccagattt taacaccttt 240 cttattgaga agactgaagt ctgatgttgc tcttgaagtt cctcctaaac gagaagtagt 300 cgtttatgct ccactttcaa agaagcagga gatcttttat acagccattg tgaaccgtac 360 aattgcaaac atgtttggat ccagtgagaa agaaacaatt gagttaagtc ctactggtcg 420 accaaaacga cgaactagaa aatcaataaa ttacagcaaa atagatgatt tccctaatga 480 attggaaaaa ctgatcagtc aaatacagcc agaggtggac cgagaaagag ctgttgtgga 540 agtgaatate cetgtagaat etgaagttaa tetgaagetg cagaatataa tgatgetaet 600 tegtaaatgt tgtaateate catatttgat tgaatateet atagaceetg ttacacaaga 660 atttaagate gatgaagaat tggtaacaaa ttetgggaag ttettgattt tggategaat 720 getgeeagaa etaaaaaaa gaggteacaa ggtgetgett tttteacaaa tgacaagcat 780 gttggacatt ttgatggatt actgccatct cagagatttc aacttcagca ggctgatggg 840 tccatgtctt actcagagag agaaaaaaac atgcacagct tcaacacgga tccagaggtg 900 tttatcttct tagtgagtac acgagetggt ggcctgggca ttaatctgac tgcagcagat 960 acagttatca tttatgatag tgattggaac ccccagtcgg atcttcaggc ccaggataga 1020 tgtcatagaa ttggtcagac aaagccagtt gttgtttatc gccttgttac agcaaatact 1080 atcgatcaga aaattgtgga aagagcagct gctaaaagga aactggaaaa gttgatcatc 1140 cataaaaatc atttcaaagg tggtcagtct ggattaaatc tgtctaagaa tttcttagat 1200 cctaaggaat taatggatta ttaaaatcta gagattatga aagggaaata aaaggatcag 1260 agagaggtc 1269 <210> 118 <211> 512 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:1089383.1:2000FEB18 <400> 118 cctgtagcca ctgaggttca caggctctgt ttgaggtgtt gtgttagatt gtgctgggtt 60 ggttttgctg cttattgagt gatgaagagc aacatattag ctactgagat attttgcaga 120 aaaaggaaga gatgtettea geteaaatge tateaaactg gtgaaataaa eagegttgtt 180 geteacacaa ageetgtttg gtagtetett cacatggaeg egtgtgaeat ttggtgetga 240 agacccggga caggaggact ccttcaggag acgggtcccc tgtccttgcc ctcactccgt 300 gaggagatee acetacgace teaggteete agaccaacca geceaaggaa cateteatga 360 atticaaatc ggattcccaa ctatatgaag acaccctagc tggacgatca gticttatta 420 agaacctgac ccctcaaact ctacaacctc gatggactgg accctactta gtcatctata 480

gtaccccaac tgccgtccgc ctgcaggatc ct

```
<210> 119
<211> 530
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1092522.1:2000FEB18
<400> 119
ggctaatgac ttattacttg ctgtttatat ttattttgga ctatggaaat gatgctagac 60
aaaaagcaaa gttgagtgat tttcttattt aagttcaaag tgggtcgtaa aacagcagag 120
acaacttgca atatcaacaa tgcatttggc ccaggaactg ctaatgaacg tacagtgcag 180 tggtggttca agacactttt caaaggagat gagaaccttg aagatgagga gcatagtggc 240 caaaccactg gaagttgaca atgaccaact gagagcaatc agcaaagctg atcctcttaa 300
ggctacttga gatgttgccg aagaactcaa tgtggaccat tctacagtca tttggcattt 360
gaagcaaatt ggaagagtga aaaagctcga taagtgggtg cctcatgagc tgagtgaaaa 420
tttaaaaaat agtcattttg aagtgtcctt atcccttatt ttttgcaaca acaaaccatt 480
tcttggtcag attgtgatgt gcgagaaaaa gtggatttta tacaacaact
                                                                                   530
<210> 120
<211> 671
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1093216.1:2000FEB18
<220>
<221> unsure
<222> 436, 454, 499, 554
<223> a, t, c, g, or other
aactgttttc ctttgaggaa tattgatgat cccactgctt gagtaatgga aaccagcttg 60
cagetgatag ttatititig tettititee tgttetatee actgtectag gtttggaatt 120
teagetggge agettegate ceaceacetg tagecactga ggtteacagg etetgtttga 180 ggtgttgtgt tagattgtge tgggttggtt ttgetgetta ttgagtgatg aagageaaca 240
tattagetae tgagatattt tgeagaaaaa ggaagagatg tetteagete aaatgetate 300
aaacttgtga aataaacagc gttgttgctc acacaaagcc tgtttggtag tctcttcaca 360 tggacgcgtg tgacatttgg tgctgaagac ccgggacagg aggactcctt caggagacgg 420 gtccctgtc cttgcnctca ctccgtgagg aganccacct acgacctcgg gtcctcagac 480 caaccagccc aaggaacanc tcatgaattt caaatcggat tcccaactat atgaagacac 540
cctagctgga cgancagttc ttattaagaa cctgacccct caaactctac aacctcgatg 600
gactggaccc tacttagtca tctatagtac cccaactgcc gtccgcctgc aggatcctcc 660
ccactgggtt c
<210> 121
<211> 257
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:270318.3:2000FEB01
ttctttgaga ctatttaaaa actggtacaa caggtctcta caacgccaag atctaactaa 60
gctttaaaag ggatagctgg gagtatggcc accctgctcc acgatgcggt aatgaatcca 120
gcagaagtgg tgaagcagcg cttgcagatg tacaactcgc agcaccggtc agcaatcagc 180
tgcatccgga cggtgtggag gaccgagggg ttggggggcct tctacggagc tacaccacgc 240
agctgaccat gaacatc
<210> 122
<211> 1353
```

<212> DNA

```
WO 01/62927
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:335671.2:2000FEB01
<400> 122
gggaagtgaa tatccctgta gaatctgaag ttaatctgaa gctgcagaat ataatgatgc 60 tacttcgtaa atgttgtaat catccatatt tgattgaata tcctatagac cctgttacac 120
aagaatttaa gatcgatgaa gaattggtaa caaattctgg gaagttcttg attttggatc 180
gaatgetgee agaactaaaa aaaagaggte acaaggtget gettttttea caaatgacaa 240
geatgttgga cattttgatg gattactgce ateteagaga ttteaaette ageaggettg 300
atgggtccat gtcttactca gagagagaaa aaaacatgca cagcttcaac acggatccag 360
aggigtitat cicttagiga giacacgage tggtggcctg ggcattaatc tgactgcage 420
agatacagtt atcatttatg atagtgattg gaacccccag teggatette aggeccagga 480 tagatgteat agaattggte agacaaagee agttgttgtt tategeettg ttacageaaa 540
tactatcgat cagaaaattg tggaaagagc agctgctaaa aggaaactgg aaaagttgat 600
catccataaa aatcatttca aaggtggtca gtctggatta aatctgtcta agaatttctt 660
agateetaag gaattaatgg aattattaaa atetagagat tatgaaaggg aaataaaagg 720
atcaagagag aaggtcatta gtgataaaga tctagagttg ttgttagatc gaagtgatct 780
tattgatcaa atgaatgett caggaccaat taaagagaag atggggatat tcaagatatt 840
agaaaattet gaagatteea gteetgaatg titgtittaa agtggagete aagaataget 900
titaaaagtt ettatttaca tetagigatt teeetgtatt gggtitgaaa tactgatigt 960
ccacttcacc ttttttatca tatcagttga catgtaacta gtaccatgcg tacttaaata 1020 gatggtaatt ttctgagcct taccaagaac aaagaagtat ccatattaag tttagatttt 1080
cagttaattt ttgagactga gtagtattct tggatacagg ctgatgtgta cttaaccact 1140
tecagattta tacagtette etgtggaagt ttagtaaatg tettttteec teetttette 1200
tagtaatgca gttcatgggc tttaggtact tcagttatga agtaggcttt tcatggggag 1260
agattgggat tatgetetet gttgtttaag aaactgtttg attttagagt etatttetat 1320
gagatagttt accaaataaa tgttccttat aag
                                                                          1353
<210> 123
<211> 671
<212> DNA
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: LI:793758.1:2000FEB01
<220>
<221> unsure
<222> 554
<223> a, t, c, g, or other
<400> 123
aactgttttc ctttgaggaa tattgatgat cccactgctt gagtaatgga aaccagcttg 60
cagetgatag ttattttttg tetttttee tgttetatee aetgteetag gtttggaatt 120
teagetggge agettegate ceaceactg tagecactga ggtteacagg etetgtttga 180
ggtgttgtgt tagattgtgc tgggttggtt ttgctgctta ttgagtgatg aagagcaaca 240
tattagctac tgagatattt tgcagaaaaa ggaagagatg tcttcagctc aaatgctatc 300
aaacttgtga aataaacagc gttgttgctc acacaaagcc tgtttggtag tctcttcaca 360 tggacgcgtg tgacatttgg tgctgaagac ccgggacagg aggactcctt caggagacgg 420
gteceetgte ettgeeetea eteegtgagg agateeacet aegaeetegg gteeteagae 480
caaccagece aaggaacate teatgaattt taaateggat teecaactat atgaagacae 540
cctagctgga cgancagttc ttattaagaa cctgacccct caaactctac aacctcgatg 600
gactggaccc tacttagtca tctatagtac cccaactgcc gtccgcctgc aggatcctcc 660
ccactgggtt c
<210> 124
<211> 512
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
```

<223> Incyte ID No: LI:803718.1:2000FEB01

PCT/US01/06059

```
WO 01/62927
```

```
<220>
<221> unsure
<222> 290
<223> a, t, c, g, or other
<400> 124
cctgtagcca ctgaggttca caggctctgt ttgaggtgtt gtgttagatt gtgctgggtt 60
ggttttgctg cttattgagt gatgaagagc aacatattag ctactgagat attttgcaga 120
aaaaggaaga gatgtettea geteaaatge tateaaactg gtgaaataaa cagegttgtt 180
geteacaeaa ageetgtttg gtagtetett caeatggaeg egtgtgaeat ttggtgetga 240
agacccggga caggaggact cettcaggag acgggtcccc tgtccttgcn ctcactccgt 300
gaggagatec acctacgace teaggteete agaceaacea geceaaggaa cateteatga 360 attteaaate ggatteecaa etatatgaag acaceetage tggacgatea gttettatta 420
agaacctgac ccctcaaact ctacaacctc gatggactgg accctactta gtcatctata 480
gtaccccaac tgccgtccgc ctgcaggatc ct
                                                                                  512
<210> 125
<211> 782
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:412179.1:2000FEB01
<400> 125
aggcagcatg acaacatgat ggacagagca cggattttct gagggataca gccaggtccc 60
accectaatt agettettga geteagetaa gttettaaaa ettetetgag eeettgattt 120 teteeatetg catgatggat tattttatag gttgaccaet egteetggtt tgeetgagae 180
tgaagggcat cctgggacac agaacttcca gtgctaaaac ccagaaaatc ccaggcatat 240
caagatgagt tggtcactta gaggacagat gaattgaaat gacatataga aatggactca 300
cactgtgccc tgcatctaat agctgctcta taaatgtagt cacacaaaaa cgtgctcctc 360
acatggtaaa agaaaaataa aatgaaacaa ataggtgagt gcaaaataat tgcagttttt 420
gaattgttgg aatttgctgt ataatactgg aatacattct taaataaatg tggttatgtt 480
atacatcatt ttaatggaca tttctcgctt tatgtttgct aatgacttat cacttgctgt 540
ttattttatg tgtatttaaa ctatagaaat gatgttagac ataaagcaaa ttcaagtgat 600
tttcttattc gagttcaaaa tgggtcgtaa aatagcagag acaactcgta acatcgacaa 660 tgcatttggc ccaggactgc taacgaatgt acagtgcagt ggcagttcaa ggagacaagg 720
agcgtagtgg tgggccattg gaagttgaca atgacaaact aagagcaatc attgaagctg 780
at
<210> 126
<211> 1937
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte ID No: LI:815679.1:2000FEB01
<220>
<221> unsure
<222> 635
<223> a, t, c, g, or other
<400> 126
ccaggtctac atgtataaaa ttttttaaca gtaacaaaat actttgcttt ctttttatat 60
taagtettea caatetaatg tgtatttgae aettetegea cattteagaa tgatggeage 120
agcccatatg gggggcccgc ccatgatgcc aaagatgggc cctcctcctc ctgggatgat 180
gccagtggga cctgctcttg gaatgaggcc gcccatggga ggccacatgc ctgtgatgcc 240 tgggtgccca atgataagac ctcctgcccg tctcatgatg gtgcccagtc agcccagaat 300 gacttgacca gacagataag gatagagggg aggcctcatt gcatcagtgt tgttttgttg 360 ttgttattgt tgtgtttttt ttgtttgtaa tgttttgtt tgttttttgag acagagtct 420
cctctgtcgc ctaggctgga gggcagtggc gtgatctcgg ctcactggaa cctccgcctc 480
cogggttcaa gogattcccc tgcctcggcc tcctgagtag tgtgggactg caggcgtatt 540
caccatgece eggetaattt titttattta giggagaegg ggitteaceg igitggeeag 600 atggietega teteetgaee tegigaeteg etegnicage etetgaaggit geigggatig 660
```

cacctgcagg ccatggttcg ttcagccggc aaactggttc ttattgacaa gttgcttcca 300 aagcttaaag ctggtggcca taaagttctg atcttctctc agatggtacg ctgcctagac 360 atcctagagg attatttaat ccagaggagg tacttatatg aacgtattga tgggcgagtt 420 agaggcaacc ttcgacaggc tgccattgac cgcttcagca agcctgactc agaccgcttt 480 gtcttcttac tgtgtacccg ggctggtgga cttggtatta atcttacagc tgctgatacc 540

```
tgcatcatct ttgattcaga ctggaatcca caaaatgacc tgcaggccca ggcacgatgt 600
categaattg ggeagageaa agetgtgaag gtgtacegee teateacteg taatteetae 660 gagagagaga tgtttgataa ggeeageete aagttggggt tggataagge tgtgetteaa 720
tccatgagtg gtcgggatgg caacattact ggaatccaac agttctctaa gaaggagatt 780
gaagatettt taagaaaagg ageatatgea geeateatgg aggaagatga tgaaggetee 840
aagttttgtg aagaggacat tgaccagatc ttgttaagac gaactacaac catcaccatt 900
gaatetgaag gaaaaggtte cacetttget aaggeaaget ttgttgette tgaaaacagg 960 acagatattt c
<210> 129
<211> 192
<212> DNA
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: LG:255789.10:2000MAY19
aactaaaaga attgacaatt ttattttcac atttcccaat acaaatgaaa actgcatctt 60
ttttggtccc acttctcccc tccaaaacta ttctctttga tagggcaagg gggcaagtct 120
tecttatget gttaagaaaa eecageatea eageecatga teteetggtg aagggageag 180
gtaaatataa ag
                                                                                             192
<210> 130
<211> 2002
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:787618.1:2000MAY01
<220>
<221> unsure
<222> 635
<223> a, t, c, g, or other
ccaggtctac atgtataaaa ttttttaaca gtaacaaaat actttgcttt ctttttatat 60
taagtettea caatetaatg tgtatttgae aettetegea cattteagaa tgatggeage 120
agcccatatg ggtggcccgc ccatgatgcc aaagatgggc cctcctcctc ctgggatgat 180
gccagtggga cctgctcttg gaatgaggcc gcccatggga ggccacatgc ctgtgatgcc 240
tgggtgccca atgataagac ctcctgcccg tctcatgatg gtgcccagtc agcccagaat 300
gacttgacca gacagataag gatagagggg aggcctcatt gcatcagtgt tgttttgttg 360 ttgttattgt tgtgttttt ttgtttgtaa tgttttgttt tgtttttgag acagagtctt 420
cetetgtege etaggetgga gggeagtgge gtgatetegg eteaetggaa ceteegeete 480 cegggtteaa gegatteece tgeeteggee teetgagtag tgtgggaetg eaggegtatt 540
caccatgece eggetaattt titttattta gtggagaegg ggttteaceg tgttggecag 600 atggtetega teteetgace tegtgaeteg etegnteage etetgaaggt getgggattg 660 caggtgtgaa gecaetgegg eetggeetat aatgaattta taatttaace tgeteeette 720 acccaggaga teatgetget gtgatgtega gttttetaa eageataagg aagaettgee 780
ctcttgccct atcaaagaga atagttttgg aggggagaag tgggaccaaa aaagatgcag 840
ttttcatttg tattgggaaa tgtgaaaata aaattgacaa ctcttttagt taaaaacaaa 900
aaaaaagaaa aggaaacaag atgtggggct gccatatgca ataccgtgga ttctacagat 960
cttctactct ggaggcaaat attatcttcg ctgaagccac gaccaacctg acacacaagg 1020 ccttttggtt ttttaaatgt gactgtgttt tattttagaa tgtgtaattc actttaggaa 1080
gggcagaagt acctggtctg ggggaagact atgttaattt cctgcatgtt atttagaatg 1140
ctggctgatg gttatctatg aagggaaaca gctctaacaa ctgagtgtcc cccacataga 1200
cacageteat gagtteaagg ggeaaaggaa ttgaacagca geeteetaat ageeggeett 1260 etttgtgatg tggaaataat tateageatg taaaagteta tatatatatt caacaattet 1320 gaeeecetge aaaatteaaa tetacaactg atttgettee tggggeteet gaaaacaact 1380 ttgteaaaat tegtteagaa atataateag ceaategttg eeecttggga eegeaggata 1440
aagcaagtca gccatgacca atgaggagtc ggccgtgcac aattacatgc agacctgcag 1500
gacatacgag tecetgetat ggteeeteec cagteaggee eccaetgeet gggetgeage 1560 tagaageatt caggeacaag tgeatteaac aaatacttat ttaattgeat tggtggetag 1620 agggetgttg ttgattaagg tacattaatg gatecattte etceetgtat ecaagactet 1680
```

```
gccatttgtc tetgcagttc etccecactg aagaateggg agtatatttc tecageceet 1740
aatgttgcat ttagtcacat gtctagcttt ggccactgga atattaatct acatgaccaa 1800
aaacttggaa agtgtgcatt catttgtgct cactcactcc tgctatcacc aaaagaacaa 1860
gcccaggcca gactgctgct tccagcagaa gataagagac accaagagca aagtcaagct 1920
teccagacae geteatgeca gattaaceaa tecteageta gacecatage tecatgaaaa 1980
taaatgactg ttgtattaag cc
<210> 131
<211> 8277
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:331610.2:2000MAY01
<220>
<221> unsure
<222> 4213, 4217, 4222
<223> a, t, c, g, or other
<400> 131
agcaatgcaa gattagatct ctaaatgcag caaaacactg cctgaaaaca gaccggcccg 60
cgcagcaagc agacatttca cggtgcgctg gggaagcttc aaaatatatc tgtgactctg 120 tettegttgc tetteatecc catcaatttc atcaegggag gegagcagca agtaagaatt 180 teaetttegg atetgeetag agacacact ceetgeteec teeeccactc gatgtgaaga 240
gtattccgga gtctccgggc gggagtagat ttgcagcacc cctaagcggg agcgagggaa 300
aacetactga ttetttaget eattateate teteceagae gagattteet tettategee 360
tgcctcatcg ctcaagtttg agcctcccga agtccgggcg ggagagacga aacccctggc 420 tcacccccag ccgcaggaag ccaccgcctt gctccaagcc cctgcagctc tgctgcaccg 480
'cagettetea cecagtgegg atgetgtaga teaacaggtt cagggaactt gagcagaata 540
aggagagace accgggtgee geageteggg tgeagaggga aaaaaggace catagacttg 600
tggetegegt egegegea egetgegeea ggggeeeagg etggggegea etecetetet 660
gggtcctcca gtccgattgc cctgcccca ccttacaggt ctgggatgta cctttccatc 720
tgttgctgct ttcttctatg ggcccctgcc ctcactctca agaacctcaa ctactccgtg 780
ccggaggage aaggggccgg cacggtgate gggaacateg gcagggatge tegactgcag 840
ectgggette egeetgeaga gegeggegge ggagggegea geaagteggg tagetaeegg 900
gtgctggaga actccgcacc gcacctgctg gacgtggacg cagacagegg gctcctttac 960
accaagcage geategaceg egagteeetg tgeegeeaca atgeeaagtg ecagetgtee 1020
ctcgaggtgt tcgccaacga caaggagatc tgcatgatca aggtagagat ccaggacatc 1080 aacgacaacg cgccctcctt ctcctcggac cagatcgaaa tggacatctc ggagaacgct 1140
getcegggea eccgettece ecteaceage geacatgace ecgaegeegg egagaatggg 1200
ctccgcacct acctgctcac gcgcgacgat cacggcctct ttggactgga cgttaagtca 1260 cgcggcgacg gcaccagagt tcccagaact ggtcatccag aaggctctgg accgcgagca 1320
acagaatcac catacgeteg tgctgactge cetggacggt ggcgagecte cacgttecge 1380
caccytacay atcaacytya agytyattya ctccaacyac aacaycccyy tettcyagyc 1440
gecatectae tiggiggaae igecegagaa cacteegetg ggiaeagigg icategatet 1500
gaacgccacc gacgccgatg aaggtcccaa tggtgaagtg ctctactett tcagcagcta 1560
cgtgcctgac cgcgtgcggg agctcttctc catcgacccc aagaccggcc taatccgtgt 1620
gaagggcaat ctggactatg aggaaaacgg gatgctggag attgacgtgc aggcccgaga 1680
cttggggcct aaccttatcc cagcccactg caaagtcacg gtcaagctca tcgaccgcaa 1740
cgacaatgcg ccgtccatcg gtttcgtctc cgtgcgccag gggggcgctga gcgaggccgc 1800 ccctcccggc accgtcatcg ccctggtgcg ggtcactgac cgggactctg gcaagaacgg 1860 acagctgcag tgtcgggtcc taggcggagg agggacggc ggcgggggg gcctgggcgg 1920
geeegggggt teegteeet teaagettga ggagaactae gacaacttet acaeggtggt 1980
gactgaccgc ccgatggacc gcgagacaca agacgagtac aacgtgacca tcgtggcgcg 2040
ggacgggggc teteetcece teaactecac caagtegtte gcgatcaaga ttetagacga 2100 gaacgacaac cegeeteggt teaccaaagg getetacgtg etteaggtge acgagaacaa 2160 cateceggga gagtacetgg getetgtget egeecaggat eeegacetgg gecaagaacg 2220
gcaccgtatc ctactctatc ctgccctcgc acatcggcga cgtgtctatc tacacctatg 2280
tgtetgtgaa teceaegaae ggggeeatet aegeeetgeg eteetttaae ttegageaga 2340
ccaaggettt tgagttcaag gtgettgeta aggaeteggg ggegeeegeg eacttggaga 2400 geaaegeeae ggtgagggtg acagtgetag acgtgaatga caaegegeea gtgategtge 2460
tecceaeget geagaaegae acegeggage tgeaggtgee gegeaaeget ggeetggget 2520
atctggtgag ccactgtgcg cgccctagac agcgacttcg gcgtagagcg ggcgtctcac 2580
ctacgaagat cgtggacggc aacgacgacc acctgtttga gatcgacccg tccagcggcg 2640 agatccgcac gctgcaccct ttctgggagg acgtgacgcc cgtggtggag ctggtggtga 2700
```

aggtgacega ceaeggeaag cetaceetgt eegeagtgge caageteate ateegetegg 2760 tgagcggate cettecegag ggggtaceae gggtgaatgg cgagcageae caetgggaea 2820 tgtegetgee geteategtg actetgagea etatetecat cateeteeta geggeeatga 2880 tcaccatcgc cgtcaagtgc aagcgcgaga acaaggagat ccgcacttac aactgccgca 2940 tegecgagta cagecacceg cagetgggtg ggggcaaggg caagaagaag aagatcaaca 3000 aaaatgatat catgctggtg cagagcgaag tggaggagag gaacgccatg aacgtcatga 3060 acgtggtgag cagcccctcc ctggccacct ccccatgta cttcgactac cagacccgcc 3120 tgcccctcag ctcgccccgg tcggaggtga tgtatctcaa accggcctcc aacaacctga 3180 ctgtccctca ggggcacgcg ggctgccaca ccagcttcac cggacaaggg actaatgcaa 3240 gegagaeeee tgeeactegg atgteeataa tteagaeaga caatttteee geagageeea 3300 attacatggg cagcaggcag cagtttgttc aaagtatttc agtagctcca cgtttaagga 3360 cccagaaaga gccagcctga gagacagtgg gcacggggac agtgatcagg ctgacagtga 3420 ccaagacact aacaaaggct cctgctgtga catgtctgtt agggaggcac tcaagatgaa 3480 aactacttca actaaaagcc aaccacttga acaagaacca gaagagtgtg ttaattgcac 3540 agatgaatge egagtgettg gteattetga eaggtgetgg atgeeaeagt teeetgeage 3600 caatcagget gaaaatgeag attacegeac aaatetettt gtacetacag ttgaagetaa 3660 tgttgagaet gagaettacg aaactgtgaa teccaetggg aaaaagaett tttgtacatt 3720 tggaaaagae aagegagage acaetattet cattgecaac gttaaacett atttaaaage 3780 caaacgtgcc ctgagccctc tcctccaaga ggtcccctca gcatcaagca gcccaaccaa 3840 ggcgtgcatc gagccttgca cctcaacaaa aggcctcccc tggatggcct gtgaaggcaa 3900 aacccaggag cccctggctg aagcaagcag tcagtacttg ccccactgac agtcaatatc 3960 tgtcacctag taagcaacca agagaccctc ccttcatggc ttccgatcag atggcaaggg 4020 tetttgeaga tgtgcattee agageeagee gggatteeag tgagatgggt getgttettg 4080 agcagettga ccaccccaac agggatctgg gcagagagtc tgtggatgca gaggaagttg 4140 tgagagaaat tgataagett ttgcaagaet geeggggaaa egaeeetgtg getgtgagaa 4200 agtgaaaaaa ganaaanaaa anggeattgg cattttettg tetettetgt tgatttaaaa 4260 atgatecete etggtgataa eacattttae agggatgaag aaagaceaat getgetttaa 4320 ggettttagt gaacatetga agtgeecaca agtatgttet ttecaetget gatttettt 4380 tcagagataa caatggtttc gttttgacca aacttgtatt aggacagaat taatgatgct 4440 taaagagaaa agaaaaaaag agagaagaaa aaggagagat gaaaaaggag gatgaggaga 4500 agaattacct tttgacaatc tgttaggaag gtatgcagtg tgagaactga agtatttctg 4560 atcactctca gactgtcctc cgtgatttat gctgacttaa ctgtttacct ataaaccccc 4620 atacaaagcc aggggcataa titgtgatct gtggtggatt tctagcagtc atcacaggct 4680 tetactgaaa gteetgaaaa gacettgeag tagteeaage tacaccaaac attaacacat 4740 atttgtgggt aaacatttct gtataaagtt acctgacaca catataaaca caaggaacat 4800 tecatateca tagteegaaa aecaaaaeca aaaaaaaaee tttggteeat ttgtaagaee 4860 atctccatgt catattaaaa gttaaatgta aaaagataca gtccattttg tcctgcacac 4920 acgtagacta attcacgtca ttaaagaaga agaaaactta aagatttaaa atgcctattt 4980 agcattttag tgtccaacaa agatttaaac aatgatgaat atgttttaaa tttgacatag 5040 aaaagttcta aaaaatagtt accattgagt ggtaagattc agagaaaatt aacttgatta 5100 atatgtttta ttcatttgtg gactactaat tatagctcta ggaaagtgaa aatgtcttag 5160 acatacgcta gtcacatgac catttaaatg tgctaatgta agaagattca atgtgtttac 5220 atctattgac atattttatt gatttattgc agattcagtg catatgagcc aaattgttga 5280 gtgtgtaaga gctatattgt gtattttatt aaattaatat atagttgtgt tgcaaaaata 5340 tttgggctta tattgtaaat ggacaagtgt tgccttggta gcctgtccga acctcctatg 5400 agatttatgt tttttcctgc tttccttttc cccatgggag tgtggggaag cagtgcctca 5460 gagcaaagte tettgtttaa tgtatagtet accaagtact acagtacata atetgttcaa 5520 aatgtgtttg agtgagetga tggagetaac tgaaaggtca aaaattacat ccatcagtca 5580 tggttatgtg caagtcettg tagaagettt tattaaagte atgetaaate acaagaattg 5640 acatttgtae caatatetga aacttettea tgttttttea ataacataca gettetgeet 5700 gtgtagatat tatgecatea gttggttete aaaagtattt taagtgette agatgtgtgt 5760 teceattata ttttgaaaae atgaaaaatg etttaatgea tgtatgtaee ageagtggtt 5820 acttgcattg tgtagtgttt ttcaagaggt ctgggtctta acaaaatgtt ttcctttatc 5880 teagtgetet tetgeetett tttgttgggg teetttgaga acaatacace ttetatteet 5940 teatttggtt acaeetttee tttgtgacat ttagegagtt teaaaettae tteeatatga 6000 ggctaagaga cctcagattt caggatttgg gaaaaataaa attagcactt gcagaagtag 6060 cagcagatgg gaaaatgcct tgattgacat tttctttcag catttaaaat ttttggcatt 6120 ttacagette atgacaaaca gttttgtgee catacettag aaaatgtggt getgagttaa 6180 ataaaggetg tttgageact ggageagaaa aatgeattat ttgeaaactg gtggataatt 6240 ttgtgeette tettetggee accaageeag tgtagaaaca geaaaaatgt cataaaaatt 6300 ettatattta aaacaaaac aaaageaaaa acaaacattg aattacatta agttttgtea 6360 ttttaaactt taaaaacttc tactgaaaat atttccgcca aatgccatca atattttaga 6420 ctgtaceteg tttgegaaac tgetttgaga gggaagagtg gacaacteec atcageetta 6480 ttetettgag aactatattt tggtteetag taacageett tecaaagete taetettggt 6540 ttttattact cataaatgtt taaattagaa aagaagggac cttgtacatg tgaaacctaa 6600 ttgactctct atattttgga caatttatgt atctgaaatg tgttgtgctc tgttatatga 6660 tgttattttt gccaggagac tacaggttga tttagcttga tagctgaaat ttgatggaaa 6720

```
actgatttcc atttagtctt accaagtgtt gcttctctct tactagacag atatccactt 6780
agtaaaatet aaageagtat gtaaatgaaa eeageaaaga gagtagggtt tattttaata 6840
aacattetta attgetaagt aaaccagttg ttcaatttat tatatgtgte tgaggacatt 6900
aaaacaccat taagattgta ataattggtt gtgcccaatg tgtgagggat ttacctttta 6960 ggctctctgt caccagtgat ttactagtgt tagctgttta acacattatc tgtatttagt 7020
agtgattatt tatttacaag ttggtggtaa ttcagcaggt caggagtcta agcttttata 7080
gttgaattga ggaaatctcg cttttattca tttagctggc aactgccttt attgcagacc 7140
tetggtgett ggettteaag gaageetatg agatgeeaaa ateacacett tagagageae 7200 ettgetetaa tagggtgatg catgageaaa cagtgagatt tgaaggggtt ttaacataac 7260
tttagaatgt gaaaacaata tcaattcata tctttcaagt actaacccct caaacaagcc 7320
cacacataca aaactatgtg atgtgatacc actttgtctt ttaggtcttt aagtaactga 7380
agttaagcac agaaaaaaa atcacttcat ggaaatttca gtaagaaacc caaactttct 7440
ttttcatcag agttaaaagt agtgagaatc tggttagtta tacgtaatac caaaggtaaa 7560
cattaaagaa gacattatca ggcaatttca aagaattctt tcatgctatt tcttaaccct 7620
gacatttcta actttattgc aggcaatata caaagattgg ctcactactc cataggttaa 7680
ttgaatteet ggttgagaaa etaaettgtt ttgtttteea aaattagetg aaatettgta 7740
aaacatgact tccctttaaa ggatctagat attgttcaat ttaaaatatg gcaccataaa 7800
aaagtcatgt agtaatagag catatgcttt tttagaacca ggttaaaagc tgtttgttat 7860
ctaatagagt aaaagttact gaggtcaaca gatagacagg tctggcataa tatatgcccc 7920
agteataata gtetaattat attetttga caacagacag catteatcag agcactaatt 7980 cgaatgagag ttttggetat caagatgtgt tgattetaaa tattattgaa tgagacetga 8040
ttaaagtetg actttteetg geeceagtgt tttgeaggtt ggetatttee attateagee 8100
catcactcca taaagttctt agctgccacc aagtgattgg tgaacaagga caacaacaaa 8160 agcagcatac attgtatgga tttatctcaa cggctattgt ttaatggctg tgtttaaatg 8220
tgatctatct ggaaaatgag gactccggaa taaaaagcta ttactaataa aaaaaaa
<210> 132
<211> 1417
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:982697.1:2000FEB18
<220>
<221> unsure
<222> 788, 802, 1173, 1187, 1207
<223> a, t, c, g, or other
<400> 132
gtggtgtggc tgcttctagc cacttatatt cagatgtggg agcaaagaca aaaggtagaa 60
cttatattta aaagggaagc agagcaaaaa aagtttggaa aatttgcagc ctggccatgt 120
ggcagagaaa gaaaaaagct ttttcagtag aggaattcaa gcagactgtg gaacaattac 180
ttgctagaga tgtttgcagg attaaagggg agccaagtgc tactatccaa gacaataggg 240
aaaaagcett gaaagcattt caaagaactt cagagtggct teteccatca caggeecaga 300
agettaggag gagagaatag atteatggae tgggeecagg gecatggtae ettgeacage 360 ettgggaeae tgeteaceae atectagetg etcetgtee caetettgee atggeteaaa 420
ggggcctaca tacagcttgg actgccactt tggagaatgc aaacagtaaa ccttggtagc 480
tttcatgtgg tgttaagcct gcaggcacac aaagtgcaag aatcgtggat tcttggcagc 540
ctctgcctag atttcagagg acatatggaa aagtctgttt gtccaggcag aagcctgtta 600 caggggtgga gcccttacaa agaacctcta ctagggcagt atagagggga aatgtggggt 660
tggaggetec aacagggtea cegetgggge actgeetaat ggaactatac gaagtgggec 720
actgccctcc agacctaagg atgatagatc taccagcagc ttgtattctg cacctggaaa 780
agccacange acteaactge ancecatgag egeageettg gattetttae eetgcaaage 840 cataggggea ggactgetea aggeetgggg agcceacce ttgtaccagt gtggeetgga 900
tgtggaacat gatgtcgaag attattttgg aactttaaga tttagtgact tccctactgg 960
gttttggagc tgtgtggatc ctgtagaccc tttcttttgg ccaatttccc cctttttggg 1020
atggaaacat ttacccaatc cctatacccc cattgtatct tggaagtaaa taatttgttt 1080
ttgattttac aggctcataa gtggaaggga cttgccttgt ctcatatgag actttggact 1140
tggacttttg aattaatgct ggaatgagtt aanactttga gggactnttg ggaagatata 1200
actgtanttt gcagtatgag aaggacatga gatttgggag acaccagagg tggaataata 1260 tgatttggat ctgcatcccc accaaaatct catgttcaat tgtaatccta aattttggag 1320
gttgagcctg gtggaagagg ttggataatg ggggtggttt ctcatggttt aacaccatcc 1380
ccctgggtgc tgttctcatg acagtgagtg agttatt
```

```
<210> 133
<211> 1143
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1080896.1:2000FEB18
geegacagea taatgtgagg caagtetage tgtteecece eggeatacaa gettatagag 60
caggeteett tgaagatett caggtggaet teacagaaat tgecaagttg tggaggtgte 120
gaagtgtgga tcaaggactg gaacgtagcc tcttgtgccc atggtgaagg acccagatgt 180
cgtcctgatc actcccactg ctgtgaacgt agagagaatc ctagcctgga tccatcacaa 240
ccgtgtaaaa cctgcagcgc ctgaatcctg ggaggcaaga ccaagtctgg acaaccctg 300 cagagtgacc ctgaagaaga tgacaagccc tgctccagtc acacccagaa gctgactggt 360
ccacgcacag ccgaagcatg aggaagctca ttgtgggctt catttttctt aaattttgga 420
cttacagtaa gggcttcaac tgaccttcct cagactgaga actgtttcca gtatatacat 480
caagtcactg aggtaggaca aaagattgct acattcctat tattttatgg ttattataag 540
tgtaccagga ctctaaaaga aacttgtttg tataatgcta ttctatccaa ggtatgtagc 600 ccaggaaata accaacttga tgcgtgttat gacccatttt aagcctccca tgatcacagt 660
ttttaaaata caattaagga ctggtccttt tctaggtgac acaagaaagg aaatagctag 720 aacagaagaa aaaggggtcc ccaaaaatgt aaccttaaaa tttgacgctt gtgccactat 780
tgatagtaag cagcatggaa taggatgcgg ttctctaaat tggaaaaaaa agttacacag 840 cagaaaataa gtacatctgt caaaaatcat atttatgcga gatgtgtcaa tactggtctt 900
gtgtcatttg agctacttaa aaagaaaata aaaaaagatc ctgtttggct ccaaaaatga 960
aaagtcagcc cctcctgcac aagtgggagc tgcatccttt taaaattgat aatcacaaac 1020
ccctcagacc caagtaaaat aaaaaaaaat gtaacattag gcattgatgg aaaagggctg 1080
gatcttagtg taagcatcct aataaaagga gaggttcaaa aacgctctcc agaaccagta 1140
<210> 134
<211> 899
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:811341.1:2000FEB01
<220>
<221> unsure
<222> 500
<223> a, t, c, g, or other
acctgacctg acaaaactct ttacactcta tgtgtcagaa agagaaaaaa tggcagttgg 60
agttttaacc catactgtga ggccctggcc aaggccagtg gcctatctct caaaacaact 120 agacaggatt tccaaaggct ggccccagg tctaagggcc ctagcagcaa cagccctgtt 180 agacagaa gcagataaac taacccttag gaaaacctga atataaaggc cccccatgct 240
gtggtaactt taatgactac caaaggacct cattggttac aaatgctaga ttaaccaagt 300
accaaagett getatgtgaa aatceccaca taaccactga agtttgcaac accetaacce 360
caccaccttg ctcctggtat cagagagect agttgaacat actgtgtaga ggtgttggac 420 tcagtttatt ctagcaggec caacctccga gactatectt aaacatcagt agactgtgag 480
gggtacgtgg acgggagtan ttcgccaacc cctgcaaagt gactctgaag aagacgacaa 540
gctctgctcc agtcacaccc agaagctgac tggtccacgc acggccgaag catgagaaaa 600
ctcattgegg aactcatttt ccttaaaatt tggactttta cagtaaggac ttcaactgac 660
cttcctcaga ctgaggactg ttccagtgta tacatcaagt cactgaggta ggacaaaagg 720 ttgctacagt cctattattt tatggttatt ataagtgtac tggaactcta aaaataactt 780
gtitgtataa tgttattetg tacaaggtat gtageecagg aagtgaecaa cetgatgtgt 840
gttatgaccc atctgagcct cccatgacca cggtttttaa aataagatta aggactgag
<210> 135
<211> 923
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> misc_feature
<223> Incyte ID No: LI:903225.1:2000FEB01
<220>
<221> unsure
<222> 239 ,
<223> a, t, c, g, or other
<400> 135
ggaggaaggt aatgaaggag attatettat cetaettatt attttaette ettattetgt 60
gggacagaag aatctcttga gtcctctaaa aaactatatg ctgatagcag gagttacaga 120
acaattcagt agtgtctgga atagaacagt ggtttgaaaa gtagagggct tgttaaagca 180
cgggatgctg attcagtagg ccttgagtgg ggataattta catatccaac aggccaggng 240
atgecetgge ttggggatea cattttgtga etgatgeaga gtaetgatgg teatceagte 300
cccttccttc ggtgtttgag accacttcat ctggaccgag ctaaagtcta ggaagaaata 360 aagtttcaaa cccagtagag ttacctcaaa gatacacttg agaccctttt cagaagatgg 420
caccgaaagt gaagaaggaa gctcctggcc cgcctaaagc tgaagccaaa gcaaaggctt 480
taaaggccaa gaaggtagtg ttgaaaggtg tccacggcca caaaaaaaaag aagatccgca 540
tgtcacccac cttccagcgg cccaagacac tgagactctg gaggccgccc agatatcctc 600 ggaagaccac ccccaggaga aacaagcttg accactatgc tatcatcaag tttcctctga 660
ccactgagtt tgctatgaag aagataaaag acaacaacac ccttgtgttc actgtggatg 720
ttaaagccaa caagcaccag atcaaacagg ctgtgaagaa gctctgtgac attgatgggg 780
ccaaggtcaa caccctgatg gagagatgaa ggcatatgtt ccactggctc ctgattatga 840.
tgctttggat gttgccaaca aaattgggat catccaaact gagtccatct ggctaattct 900
aaatatacat atctcttttc acc
<210> 136
<211> 343
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte ID No: LI:242079.2:2000FEB01
gctcagggtc ctgctgccct gcacaacctc aggaaactgc tccctgaatc ccagctacta 60
cagetecage tgtggeteaa aggaceecag gtatagetea ggetgeetgt ecagaggatg 120
caagccataa gccttagtgg ctcccgtgtg gtgttaaatt aagcctgtgg gcacatagag 180 tgcaagaatt gaggcttggg agcctccaac tagatttcag agtatgtgtg ggaaagcctg 240
gatgtccagg cagaagccag ctgcagggac agagccctca tggagaacct ctactagggt 300
agtgtggagg ggaaatttgg ggttggagtt cccacacagc ttc
<210> 137
<211> 1227
<212> DNA
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: LG:979580.1:2000MAY19
<400> 137
cttggatatc tgctcatttg gcccgatgag aagagaaaaa cagaaaacaa aagctctgag 60
tgggtagage gtggggggag cttgaagetg ttattaaagg aaggtatgat taactectaa 120
ctcacagccg cttcagctca tctccatggc tcagccacca ggccagcctt tgctgtcacc 180
taacagataa ttattgtctt ttctacaata tgattaagtg gaaggagaat cagaacactg 240
tagaactgga totgatattt ottgttagca tatatatata tatttaatot atgtgottgt 300
ccttgaaaac agcacttcct gtacccagca atcacagagc tgctcttgga atttaacacc 360
etggfggtte teaaatgeea tetgaaaaae attattagtg ttacceatea tgacetetgg 420
gtagtggaag gtgaatggga gaaatctctc cccatttgaa gaaataggga accagtctca 480
ettigitgee caggetggag igeagtggea caatettget caetgeaace accaecteee 540
gggttcaage gateeteeca eeteaaeete eeaggtaget gggtetgeag gegtgegeea 600
ccacaccegg ctaatttttg tgtttttagt acagaaagag tttcaccatg ttgaccagge 660 tggtctcaaa ctcctaacct caagtgattg gcccacctgg gcctcccaaa gtgctgggat 720 tacaggtgtg agccactgca gcccagccta cgaagttgtt tttgcggtta agcagcaatt 780
```

PCT/US01/06059

```
tggaaacgaa gcatttctga ggagctcagt ttaagaaaca ctgtgatgtt gtgttttaaa 840
cctatgaact cccctccgta gctcatccct ctacttttcc atctaacccc agtactggca 900 ccttctctat gattagtaaa tttcttcagc tagaaatgtt acagtctgtt ttttaacaat 960
gaagtcagga cccagtggat tatagcattg ttacacttca tgctcatgtt atataaaatt 1020
gcataaaatg tattaaaatt tatgtctgct cttatctctg ccttgcaaag aatgaatttg 1080 tatagctttt aactaagcat gtaacgggg cagcaccaca tctggaattc aagctgactt 1140 tctcacgtac cgtaatcttt gtgcttgggt ctaataagta caacccccat ggtgtggttt 1200 atcattttt tattgtatgc acaatct
<210> 138
<211> 1259
<212> DNA
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: LI:1169865.1:2000MAY01
ccggttgtag atgtatetet ccaggaageg ctgtgtecea ttaaacgegt agatteetge 60
cgtccctgga aaatgtgaat cccagccatg ctgattcctg tccagccatt tccagtgcta 120
gaggeceaca gttteagtet catgtgeete cagteggeet cagtteetea teactgttee 180
tgigctcaca gtcatcaatt atagacccca caacatgcgc cctgaagaca gaatgttcca 240
tatcagaget gtgatettga gagecetete ettggettte etgetgagte tecgaggage 300
tggggccatc aaggcggacc atgtgtcaac ttatgccgcg tttgtacaga cgcatagacc 360
ccacactcag gccaccaacg atcccctga ggtgaccgtg tttcccaagg agcctgtgga 600
gctgggccag cccaacaccc tcatctgcca cattgacaag ttcttcccac cagtgctcaa 660
cgtcacgtgg ctgtgcaacg gggagctggt cactgagggt gtcgctgaga gcctcttcct 720 gcccagaaca gattacagct tccacaagtt ccattacctg acctttgtgc cctcagcaga 780 ggagcttctat gactgcaggg tggagcactg gggcttggac cagccgctcc tcaagcactg 840 ggaggcccaa gagccaatcc agatgcctga gacaacggag actgtgctc gtgccctggg 900
cctggtgctg ggcctagtcg gcatcatcgt gggctccgtc ctcatcataa agtctctgcg 960 ttctggccat gacccccggg cccaggggac cctgtgaaat actgtaaagg tgacaaaata 1020 tctgaacaga agaggactta ggagagatct gaactccagc tgccctacaa actccatctc 1080 agctttctt ctcacttcat gtgaaaacta ctccagtggc tgactgaatt gctgaccctt 1140
caagetetgt cettatecat taceteaaag cagteattee ttagtaaagt ttecaacaaa 1200
tagaaattaa tgacactttg gtagcactaa tatggagatt atcctttcat tgagccttt 1259
<210> 139
<211> 2604
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte ID No: LG:337818.2:2000FEB18
cgcggagcct gggagaggag aaggagccga cctgccgaga tggaggcgac cggcacctgg 60
gegetgetge tggegetgge getgeteetg etgetgaege tggegetgte egggaecagg 120
georgaggee acetgeceee egggeeeaeg eggetaceae tgetgggaaa ceteetgeag 180 ctaeggeeeg gggegetgta tteagggete atgeggetga gtaagaagta eggaeeggtg 240 tteaceatet acetgggaee etggeggeet gtggtggtee tggttgggea ggaggetgtg 300 egggaggeee tgggaggtea ggetgaggag tteageggee ggggaaeeggt agegatgtg 360 gaagggaett ttgatggea tgggggttte tteteeaeeg gggagaeeggt gaggageggt 420
aggaagttta ccatgcttge tetgegggae etgggcatgg ggaagegaga aggegaggag 480 ctgatecagg eggaggeeg gtgtetggtg gagacattee aggggaeaga aggaegeea 540 ttegatecet ecetgetget ggeeaggee acetecaaeg tagtetgete eceteettt 600 ggeeteeget teteetatga ggataaggag tteeaggeeg tggteeggge agetggtggt 660 aceetgetgg gagteagete ecaggggggt cagaectaeg agatgteete etggteete 720
cggcccctgc caggccccca caagcagctc ctccaccacg tcagcacctt ggctgccttc 780
acagtcoggc aggtgcagca gcaccagggg aacctggatg cttcgggccc cgcacgtgac 840 cttgtcgatg ccttcctgct gaagatggca caggaggaac aaaacccagg cacagaattc 900 accaacaaga acatgctgat gacagtcatt tatttgctgt ttgctgggac gatgacggtc 960
```

WO 01/62927 PCT/US01/06059 agcaccaegg teggetatae cetectgete etgatgaaat acceteatgt ceaaaagtgg 1020 gtacgtgagg agctgaatcg ggagctgggg gctggccagg caccaagcct aggggaccgt 1080 accegectee ettacacega egeggttetg catgaggege ageggetget ggegetggtg 1140 cccatgggaa taccccgcac cctcatgcgg accacccgct tccgagggta caccctgccc 1200 cagggcacgg aggtcttccc cctccttggc tccatcctgc atgaccccaa catcttcaag 1260 cacccagaag agttcaaccc agaccgtttc ctggatgcag atggacggtt caggaagcat 1320 gaggcgttcc tgcccttctc cttagggaag cgtgtctgcc ttggagaggg cctggcaaaa 1380 geggagtget teetettett caccaccate etacaageet tetecetgga gageeegtge 1440 ccgccggaca ccctgagcct caagcccacc gtcagtggcc ttttcaacat tcccccagcc 1500 ttccagctgc aagtccgtcc cactgacctt cactccacca cgcagaccag atgaaggaag 1560 gcaacttgga agtggtgggt gcccaggacg gtgcctccag cctcaacagt gggcatggac 1620 agggttaatg tetecagagt gtacactgca ggcagecaca tttacacgcc tgcagttgtt 1680 ttccggagtc tgtcccacgg cccacacgct cacttgactc atgctgctaa gatgcacaac 1740 cgcacaccca tacacaacta caagggccac aaagcaactg ctgggttagc tttccacaga 1800 cataaatata gtccatctgc aatcacaagc acatagccag gtaacccacc aactcccctg 1860 gatetgeage ceaeacgtgg gagtetgget gteaecttea caagecacag aaaeggeeac 1920 acatgttcac ageteacaeg cectetecat teategaaet teteagtgte cetgtecetg 1980 gtgcetggca cagggaacag catgceccet ccggggtcat gccacccaga gactgtcgct 2040 gtctatggcc ccaactcatg ctccctctt tggctacacc actcteccag cctgtgacca 2100 ccgatgtcca cacacccca accacttgtc cacacagcta cccacgtacg acatcgtcct 2160 ggetecceag agtatettee caetgagaea egeegeeece acagaggeae agteceeage 2220 cacctctgca actgcagccc tcagtcaccc ctttttaagc accctgattc taccaaatgc 2280 aaacacatet gggtetgega ttatgeacag agaetttgga catacgagga ceetcagace 2340 ggaggaacac ctgcccaacc ccaacacgtg cttatgtaac cacgtggaaa gcggccctg 2400 etgecectee acacacacat acacacteae tgatetacag eccetgiteg gegicagagit 2460 ecceactaga eccagtggaa ggggttagag accaagtagg ggecagttte caatteacce 2520 tgtcagggag tgagccggat ctgacgttcc ttgtgactta agggtccggc ttgggaatta 2580 aagtttgttt ctggccttta gcct 2604 <210> 140 <211> 2114 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:337818.1:2000FEB01 cgcggagcct gggagaggag aaggagccga cctgccgaga tggaggcgac cggcacctgg 60 gegetgetge tggegetgge getgeteetg etgetgaege tggegetgte egggaecagg 120 gcccgaggcc acctgccccc cgggcccacg ccgctaccac tgctgggaaa cctcctgcag 180 ctacggcccg gggcgctgta ttcagggctc atgcggctga gtaagaagta cggaccggtg 240 ttcaccatct acctgggacc ctggcggcct gtggtggtcc tggttgggca ggaggctgtg 300 cgggaggccc tgggaggtca ggctgaggag ttcagcggcc ggggaaccgt agcgatgctg 360 gaagggactt ttgatggcca tggaggaaca aaacccaggc acagaattca ccaacaagaa 420 catgctgatg acagtcattt atttgctgtt tgctgggacg atgacggtca gcaccacggt 480 eggetatace etectgetee tgatgaaata eeeteatgte caaaagtggg taegtgagga 540 getgaategg gagetggggg etggeeagge accaageeta ggggaeegta ceegeeteec 600 ttacaccgac gcggttctgc atgaggcgca cgggctgctg gcgctggtgc ccatgggaat 660 acceegcace etcatggegg accaeceget teegagggta caccetgeee cagggeaegg 720 aggtetteee ecteettgge teeateetge atgaceecaa catetteaag cacceagaag 780 agttcaaccc agaccgtttc ctggatgcag atggacggtt caggaagcat gaggcgttcc 840 tgcccttctc cttagggaag cgtgtctgcc ttggagaggg cctggcaaaa gcggagtgct 900 tectettett caccaccate etacaageet tetecetgga gageeegtge eegeeggaca 960 eeetgageet caageecace gteagtggee ttttcaacat tececeagee ttecagetge 1020 aagteegtee cactgacett cactecacea egeagaceag atgaaggaag geaacttgga 1080 agtggtgggt gcccgggacg gtgcctccag cctcaacagt gggcatggac agggttaatg 1140 tetecagagt gtacaetgea ggeageeaca tttacaegee tgeagttgtt tteeggagte 1200 tgtcccacgg cccacacgct cacttgactc atgctgctaa gatgcacaac cgcacaccca 1260 tacacaacta caagggccac aaagcaactg ctgggttagc tttccacaga cataaatata 1320 gtccatctgc aatcacaagc acatagccag gtaacccacc aactcccctg gatctgcagc 1380 ccacacgtgg gagtetgget gteacettea caagecacag aaacggecae acatgtteae 1440 ageteacaeg ecetetecat teategaaet teteagtgte cetgtecetg gtgeetggea 1500 cagggaaeag catgeeceet eeggggteat geeaceeaga gaetgteget gtetatggee 1560

ccaactcatg etcectetet tggetacace acteteccag cetgtgacea eegatgteca 1620 cacacececa accaettgte cacacageta eccaegtacg acategteet ggeteeccag 1680

```
agtatettee caetgagaea egeegeeeee acagaggeae agteeceage caectetgea 1740
actgeagece teagteacee etttttaage accetgatte taccaaatge aaacacatet 1800
gggtctgcga ttatgcacag agactttgga catacgagga ccctcagacc ggaggaacac 1860
ctgcccaacc ccaacacgtg cttatgtaac cacgtggaaa gcggcccctg ctgcccctcc 1920
acacacacat acacactcac tgatctacag cccctgttcg gcgtcagagt ccccactaga 1980 cccagtggaa ggggttagag accaagtagg ggccagtttc caattcaccc tgtcagggag 2040 tgagccggat ctgacgttcc ttgtgactta agggtccggc ttgggaatta aagtttgttt 2104
ctggccttta gcct
<210> 141
<211> 773
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:241577.4:2000MAY19
ccaggtcgcg ctcccactgc cgagcccgcg agatgctccc cagagctgcc tggagcttgg 60
tgctgaggaa aggtggaggt ggaagacgag ggatgcacag ctcagaaggc accagtgaga 120
cctggactec ttectecetg ectaacteca gagatagggg caggggtece etetgeagge 180 tgeceettt geettecat gecaecetgg geetgtteet accaectte ccatgttece 240 atgateceae teettggtee aaggteaagt ttetecagga aatggagtge gegggeeegt 300
ggtgggggga agatgtcccc ctacaccaac tgctatgccc agcgctacta ccccatgcca 360
gaagagccct tctgcacaga actcaacgct gaggagcagg ccctgaagga gaaggagaag 420 ggaagctgga cccagctgac ccacgccgaa aaggtggcct tgtaccggct ccagttcaat 480
gagacetttg eggagatgaa eegtegetee aatgagtgga agacagtgat gggttgtgtc 540
ttettettea ttggattege agetetggtg atttggtgge agegggteta egtatteet 600
ccaaagccga tcaccttgac ggacgagcgg aaagcccagc agctgcagcg catgctggac 660 atgaaggtga atcctgtgca gggcctggcc tcccgctggg actatgagaa gaagcagtgg 720 aagaagtgac ttgcatccc agctgtctcc ctggagtccg ccctggctgg gac 773
<210> 142
<211> 296
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:344786.4:2000MAY19
<400> 142
cccatcttgt ggagcgtact ttcattttca atagagcttt gcttttgttg cttcattctt 60 tccttgcttt gtgtgttttg tccaattctt tgttcaagac accaagaacc tagacaccct 120 ccaccagtaa catattctag tgagccagcc aggagtttat tcaggatgat aacatggaga 180
agettgagga aattattgaa aaataccete gtgeetteee tttetggatt gggeeettte 240
aggcattttt ctgtatctat gacccagact atgcaaagac acttctgagc agaaca
<210> 143
<211> 1171
<212> DNA
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: LI:414307.1:2000FEB01
<220>
<221> unsure
<222> 574, 583
<223> a, t, c, g, or other
<400> 143
cgggatggga aaactatgcc tggggccgac gctctgcccg gctgctgccg ctgaggaaag 60 ccgggacgcg gagccccgcc gagagettct ttgctccgga cgcccctgga cgtggegggc 120 agccgcgagg gtaaccacca tgatccctg ggtgctcctg gcctgtgccc tcccctgtgc 180
```

```
WO 01/62927
                                                                        PCT/US01/06059
tgctgaccca ctgcttggcg cctttgctcg cagggacttc cggaaaggct cccctcaact 240
ggtctgcagc ctgcctggcc cccagggccc acccggcccc ccaggagccc cagggccctc 300
aggaatgatg ggacgaatgg gettteetgg caaagaegge caagatggae acgaeggega 360 eeggggggae ageggagagg aaggteeace tggeeggaea ggtaaeeggg gaaageeagg 420
accaaagggc aaagcegggg ccattgggeg ggetggeece egtggeecea agggggteaa 480
cggtaccccc gggaagcatg gcacaccagg caagaagggg cccaagggca agaaggggga 540
gccaggcctc ccaggcccct gcagctgtgg cagnggccat acnaagtcag ctttctcggt 600 ggcagtgacc aagagctacc cacgggagcg gctgcccatc aagtttgaca agattctgat 660
gaacgagggt ggccactaca atgettecag eggcaagtte gtetgeggeg tgeetgggat 720
ctactacttc acctacgaca tcacgctggc caacaagcac ctggccatcg gcctggtgca 780
caacggccag taccgcatcc ggacctttga tgccaacacc ggcaaccacg atgtggcctc 840 aggctccacc atcctggctc tcaagcaggg tgacgaagtt tggctgcaga tcttctactc 900
agagcagaac gggctcttct atgaccctta ctggacagac agcctcttta cgggcttcct 960
aatctatgcc gaccaggatg accccaacga ggtatagaca tgccacggcg gtcctccagg 1020
cagggaacaa gettetggac ttgggettac agagcaagac cecacaactg taggetgggg 1080 gtggggggte gagtgagegg ttetageete aggeteacet cetetgeete ttttttece 1140 etteattaaa tecaaagett tttatteate e 1171
<210> 144
<211> 372
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:202943.2:2000FEB01
<400> 144
gtgtgaaagc cacttattat tccaccaaaa ctgtctgttt ctagaaccta taaaatgtaa 60
ggctccagga aatccggaaa atggactcct caggtgagat ttatacagta ggtgccgaag 120
tcacattttc gtgtcaggaa ggataccagt tgatgggagt aaccaaaatc acatgtttgg 180
agtctggaga atggaatcat ctaataccat attgtaaagg tatgtttagt aaatttacca 240
cgtttcttat gtttggcaat cctagaaagg taaggcgtag acatatgaag tgttatgttg 300
tatcaatgtt ctttgtattt gaactgaggt attaggctca tgtttgaaca tgaccccaca 360
cacacacaca cc
<210> 145
<211> 337
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:246194.2:2000FEB01
<220>
<221> unsure
<222> 73, 82, 105, 126, 154, 334
<223> a, t, c, g, or other
<400> 145
tecteaacce accacegeeg cagcactggt gececeacce caggeeteec tecaceacct 60 ccageeacca ggngeteetg enetgetgee tecgeegeac caggneetgg ggeageecca 120
gttggngccc ccactcctgc atccaccacc tgcncagtcc tggcccgcac aacttccccc 180
tegggeteca etgecaggte agatgetget gagegggggt ecceggggee eggteececa 240
geegggeetg cageccageg teatggagga egacateete atggatetea tetgaateee 300
caacacccaa taaagttcct ttttaacaca aaanaaa
                                                                                337
<210> 146
<211> 866
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
```

<223> Incyte ID No: LI:815961.1:2000FEB01

```
<220>
<221> unsure
<222> 741, 759-760, 763, 788, 837
<223> a, t, c, g, or other
<400> 146
gaaaggatgt tgcagtcata ggacctgtgg aagagatggg actgctgcct gtagttgggg 60 aatgtgtggt gaagggtatg gttagcctgc tgctggtggc cgaggtggtg tgggccacag 120
gggttctggt gcctgtactg gtgtggttgg gggtgatggt ggtggtagaa gttggggtga 180
cttcaggata gtgtgtggag gaagtgtgtg aatgtaagga tgtagaggtt ttgcctgtgc 240
taaatgaget tgeggatggg etggteecac tggtggteac tgtgattggt ggggetgtgt 300
gggtggaccc tgtgaccttg agcgttgtta gtggaggaat ggtgcctgtt ggcgttgagt 360 ggatggaggc agaagtggac atctgtgcat gggtaggggt gatgaccttg tgagtacttg 420
gagtcaccaa ggaggtggag aaaggtggaa tgtgagtggg aagtgtgggtc tgagggtgtg 480
atggggttgg ataggtagtg gtggtctgaa aggatggtgc agtcatagga cctgtggaag 540
agatgggact geteeetgta ggtggggaat gtgtggtgaa gggtatgggt ageetgetge 600
tggtggccga ggtggtgtgg gccacagggg ttctggtgcc tgtactggtg tggttggggg 660 tgatgttggt ggtagaagtt ggggtgactt caggatagtg tgtggaggaa gtgtgtgaat 720 gtaaggatgt agaggttttg nctgtgctaa atgagcttnn ggnttggctg gtcccactgg 780
tggtcagnat cattggtggg gctgtgtggg tggaccctgt ggccttcagc gttgtcngtg 840
gaggaatggt gcctgttggc attgag
<210> 147
<211> 1115
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:120744.1:2000MAY19
<221> unsure
<222> 776
<223> a, t, c, g, or other
<400> 147
cgctgcaggg agaacggact ccgggcggag ggcagccaat ccgtttcagc gcaggtcttg 60
ctegggttgg gettgecact geetggaaca tacetgteee cetggegeaa cacteagetg 120
gctgcgacgg caaccccgag cctggacact gcgccaggaa tcctaaaacc aaaatattag 180 aacgaaaaca gaaacatggc tcactatatt acatttctct gcatggtttt ggtgctgctt 240 cttcagaatt ctgtgttagc tgaagatggg gaagtaagat caagttgtcg tactgctccg 300 acagatttag ttttcatctt agatggctct tatagtgttg gcccagaaaa ctttgaaata 360
gtgaaaaagt ggcttgtcaa tatcacaaaa aactttgaca tagggccgaa gtttattcaa 420
gttggagtgg ttcaatatag tgactaccet gtgctggaga ttcctctcgg aagctatgat 480 tcaggagaac atttgacggc agcagtggaa tccatactct acttaggagg aaacacaaag 540 acagggaagg ccatccagtt tgcgctcgat tacctttttg ccaagtcctc acgatttctg 600
actaagatag cagtggtact tacggatggc aaatcccaag atgacgtcaa ggatgcagct 660
caagcagcaa gagatagtaa gataacatta tttgctattg gtgttggttc agaaacagaa 720 gatgccgaac ttagagctat tgccaacaag ccttcgtcta cttatgtgtt ttatgnggaa 780 gactatattg caatatccaa aataagggaa gtgatgaagc agaaactttg tgaagaatct 840
gtctgtccaa cacgaattcc agtggcagct cgtgatgaaa ggggatttga tattctttag 900
gtttagatgt aaataaaaag gttaagaaaa gaatacagct ttcaccaaaa aagataaaag 960
gatatgaagt aacatcaaaa gttgatttat cagaactcac aagcaatgtt ttcccagaag 1020
gtcttcctcc atcatatgta tttgtgtcta ctcaaagatt taaagtcaag aaaatttggg 1080
atttatggag aatattaact attgatggaa ggcca
                                                                                              1115
<210> 148
<211> 2448
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:757520.1:2000MAY01
<400> 148
```

and the second second

cegeteceet gegeettte atgetagga gatgateet agttgteete etggeagetg 1800 tttteagagg catteecage eetteactta acteetaett ageteeaaa tacetgtate 1860 caatttgtat tatteecea geteteaggg acaagaceag teeceageg tggtggteag 1920 caeggaaget eeacettetg ggtggaggeg ceateetaac eateeagea ggeeaceae 1980 aaceegagaa teagggagaa agteetee eageageee eteeteetgg etgggaagaa 2040 tggteeceea geaageaett geetgtteat teeegtteat gttttgette teteteagae 2100 tgeetteetg ettetggget aacetgttee aageeagget eeteaatgtg acetegeagt 2160 tgagaageee attategtgg ggeateettt tgeetaeage eeetggttag ggeacetttgg 2220 acaggtettg etatteagtg aacetttgta catteaaag aagaeteeat ggetgeteea 2280 gatgeeceet tgetgggtge aggtgggae tggteeaatge agagetggg ggaacagagag 2340

ttaagccact tcctgggtct ccttcttatg actgtctatg gggtgaattg ccttctgggg 2400 ttgtctcgat ctgtgtttca ataaatgccg ctgcaatgca aaaaaaaaa 2448

<210> 149 <211> 650 <212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: LG:160570.1:2000FEB18

<220>

<221> unsure

<222> 609

<223> a, t, c, g, or other

<400> 149

getteecegg eggeteeegg gegetgaete teeegggett tteegeettt etegeteeeg 60 eeeegeeggg eggteegg geeggteeee ggaceegge gggagetget egteteaeee 120 tegeeaegge geggaeaata aattaatgea tegegettga gtggaggggg eggetgggeg 180 eeteggtggt agetteete eetggetgga gaegaeeaea aeegaeatgg getgtteetg 240 egetgtteeg gaagaattt aetgegaagt tttgeteetg gatgaateea agttaaeeet 300 taceaeceag eageagggea teaagaagte aaegaaaggt teegttgtee ttgaceaegt atteeateae gtaaaeettg tggagataga ttattttggg etaegtaete gtgacagaag 420 eeateagaeg tattggetgg ateetgeaaa aaeeettget gaacaeaaag aaetgateaa 480 eaetggaeet eeatataett tgtattttgg tattaaatte tatgetgaag ateeatgtaa 540 aettaaagaa gaaataaeea ggtatagtat tgaetttgtt tttgaacaga tacatgeatt 600

```
gcgtatacna aaagctttat ttaaaacaaa ttaaaattgg gctaaacgtt
                                                                                     650
<210> 150
<211> 257
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:350398.3:2000FEB01
<220>
<221> unsure
<222> 22, 117, 120, 220, 246
<223> a, t, c, g, or other
<400> 150
cagetgetee tgacacteec anaactgteg ecagegggga ggggaggeag tagggactge 60
egaageetgg ggeeetggtg ggtgaeaggg eageaceage etgggteeag eeacetnten 120
cacaggtgaa ccgcttccac aagatccgga accgggccct cctgctcaca gaccagcacc 180
tctacaagct ggaccctgac cggcagtacc gggtgatgen ggccgtgccc cttgaggcgg 240
tgactngctg agcgtga
<210> 151
<211> 1554
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:221285.1:2000FEB01
gcctggctgc caggggcgtg ttatcgcggg ggcagcctgg gagcgctgct gcgccgcggc 60
aggagaaaca gccgaggaca ccctggaaga gcaggagcac gtgggcctgc gagaatggcg 120 ccaacaccag ccctgcaaag ccacattcca aagccgggcc aaggacagcc accgttgccc 180
cgcaggcetc aaggatgacg gtcaagccag ccaaggcege etcectagec aggaaceteg 240
caaagcgcag gcgcacctac ctgggtggcg cggctgggcg gagtcaagag ccggaagtcc 300
cttgtgccgc agtccttccc gggaaacctg gggaccggaa ctgcccggag ttcccgcccc 360 cagacagaac cctgggttgc tgggcaaccg atgcggcccc cgcagctggt ctctgtggtg 420 ctgggagcga gcccagtata gctcccacct cctgcgctgg taacctcccg tcccgcccgc 480
ctecettgtt gtegeetete etegegtege ggaateettg ceettggeae tacttacate 540
teteegggte ceacaacace ttagegeeca cetgetteaa agecaagete cacegaaage 600
gaggcagtca gcccccggac atggcctcag cgctgactga tcgcacctct cgggccccga 660 gcacctacac ctacaccage cggccccgag cactgccctg ccagcgcagc cgttaccggg 720 acagcctgac gcagccagat gaagaaccta tgcattatgg aaacataatg tatgacagaa 780
gggtaatteg aggtaacact tatgcactec agacagggec actgctegga eggeetgatt 840
ctctagaget ecagagacaa egggaggeta ggaagagge tettgecaga aaacaageee 900
aagagcaget cagaccacaa acacctgaac ctgtggaagg cagaaagcat gtcgatgtgc 960 aaacagaatt ataccttgaa gaaattgctg atcgcataat agaagttgat atggaatgcc 1020
aaacagatgc atttttggac agaccaccaa caccactett tatteetgec aaaactggca 1080
aagatgtggc cacccaaata ctagaaggag agetetttga etttgatett gaagttaaac 1140
cagtgttaga agttttggtg gggaagacaa ttgagcagtc tcttctggaa gtaatggaag 1200 aagaagaget ggctaacctg cgggccagtc agcgtgagta tgaagaacta cggaatagtg. 1260 aacgtgctga agttcaacga cttgaagagc aagagaggcg acaccgagaa gaaaaagaac 1320
ggcgtaagaa acagcagtgg gaaataatgc acaagcacaa cgagacatca caaaaaatcg 1380
ccgcccgagc atttgcacag cgttacctgg ctgaccttct cccgtctgtt tttggcagcc 1440
tcagggatag tggctacttt tatgatccca ttgaaagaga tattgagata ggatttcttc 1500
catggctaat gaatgaagtt gaaaaaacca tggaatatag catggtggga agaa
<210> 152
<211> 623
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
```

WO 01/62927

<223> Incyte ID No: LI:401605.2:2000FEB01

```
<400> 152
ctggcagggc tggaacatga agaaagagaa gaattttatt tatctacgcc agaaaactac 60
taagagtaac agatttcatt ttcggtttca aaagattttt ttaaatagaa atagaagtaa 240
 ttccatttgg accagtgggt gagaacaggt atttccttct tgttccaagt catgaacttg 300
ttccaagttc taggctgaaa ggggtttgag gactcttctt tccttagaag atgagcgaat 360 gtgtcattca gggcagatgg gcagtttact tgggacagtg tgttcagaaa gtgtaccttc 420
cacccccaaa aaacccccca aatcatgggc ttcactctgg aaccagcaga tcctccattt 480
tggggcttac aagtaagatt tctttgaaaa acaaattcta tagctaaaaa caaatctgcc 540
agccattggc ccaggtgact gttgttgcag aattttggct ctttgttcag ctaaaacctg 600
ggggtcttgt cacacgatca gga
                                                                                623
<210> 153
<211> 1038
 <212> DNA
<213> Homo sapiens
<220>
 <221> misc_feature
 <223> Incyte ID No: LI:329017.1:2000FEB01
<400> 153
ctgggctgga ggctctagca gttgttgccc acctggctgt ccatggcaaa agtgggtggg 60
gtcatgtgca gcctcctgcc acctgagtgt ttcccgggac atcaggaggc tgtatcctgc 120
agetgaattt acacagaagt ggaacaactg ggetggaage tetatggega caaattgget 180
acttcaagtg gtgacactac agttaaatta tgggatctat gtacaggcga ttgcattttg 240 acctttgaag gacacagccg cgcagtgtgg tcctgcacat ggcactcctg cggcaatttt 300 gtggcttcct cctcactgga taaaactagc aaaatttggg atgttaatag tgaaagatgc 360
 agatgtactt tgtatggaca tacagattct gtgaacagca ttgagttttt tcctttctcc 420
 aatactette teacaagete tgeagacaag accetgteta tatgggatge aagaacaggt 480
atatgtgagc agtcacttta tggtcacatg cattctatca atgatgccat ttttgatccc 540 aggggtcaca tgatagcatc ctgtgatgcc tgtggggtta caaagctgtg ggactttcgg 600
aagetgttac caattgtgtc categatata ggtccaagtc ctggcaatga ggtgaatttt 660
 gattcatcag gtcgagtttt agctcaggca agtggcaatg gtgttatcca tttgctagat 720
cttaaatctg gggagattca caaattgatg ggccacgaaa acgaggcaca cacggttgtg 780 ttttctcacg acggggagat tctcttttct ggaggctctg acggcacagt tcgaacgtgg 840
 tettgacegt cagcacatec cgctgcagag ggcattecet ttaaggettg aaaatgcctc 900
ctgtagtccc aaaccagcaa agaactggtt aaatgtgcca gcaggtaaca tttacagtct 960
getttaaaae atgettigga catatatitt agtgeteata etgitaetaa taaaaaaata 1020
actttatgct caaaaaaa
                                                                                1038
<210> 154
 <211> 737
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <223> Incyte ID No: LI:401322.1:2000FEB01
. <220>
<221> unsure
 <222> 601, 625, 633, 698, 700, 711
 <223> a, t, c, g, or other
<400> 154
gcgacccaat gggagtcccc gccaggagac acaaccggcg gctctccggg gatttataag 60
gtcccgccag caaccgcgcg ttgggattcg tggtgttgct ggagacccgt atggtgtctg 120
cagtcagega cectecaact teaactactg gatcaaceat gtgtgagtge atetecatee 180 atgtgggeea ggeeggagtg cagatgggea atgeetgetg ggagetgtae tgeetggage 240 acgaeateca geecagtgge accatgeeca geeacaagge eetggggage agtgataact 300
 cettcaacac ettetteagg gagacecage etggeaggea tgtgteetgg getgtetgtg 360
 gacctggage ctgctgteat aggttggeat caactaceag tececeacag tggtgeeegg 420
 gggtgctgta gccaaggtgc agcgggcagt ctgcgtgcta aacaatacca cagccatcac 480
```

```
tgaggcctgg ggcccgcctc aaccaaaagt ttgacctgat gtatgccaag cgggcattta 540 tgcactgtta tgtggacagg ggcatggagg aaggtgagct ctctgggcct gagaggacct 600 ngctgccctg gagaaggatt atgangtagg canagaatct ttggacagcg aggatgagca 660
tgaggagttc taggggtcct ggcacctgta acacctgntn tctcgcacca nagttgtgtg 720
tgtatctcat tccactg
<210>.155
<211> 2275
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:403409'.1:2000MAY19
<400> 155
gtggccgcgg cagacggaag ccgaacgagt teeteggegg etgcaggatg ggggaeteca 60
aagtgaaagt ggeggtgegg ataegaeeea tgaaceggeg agagaetgae ttgeataeea 120
aatgtgtggt ggatgtggat gcaaacaagg ttattcttaa tcctgtaaat acgaatcttt 180
ccaaaggaga tgcccggggc cagccgaagg tgtttgctta tgatcattgt ttctggtcta 240
tggatgaatc tgtcaaagaa aagtatgcag gtcaagatat tgttttcaag tgccttggag 300 agaatatcct gcagaatgct tttgatggct acaatgcatg tatctttgcc tatggacaga 360
ctggctctgg aaaatcttat accatgatgg gcacagctga ccaacctgga ttaatcccaa 420
gactttgcag tggactcttt gaacgaactc agaaagagga aaatgaagaa cagagtttta 480
aagtagaagt gtcctacatg gaaatttata atgaaaaagt tcgagacctt cttgatccca 540 aaggaagccg tcagacgttg aaagtcagag agcatagtgt gttgggacct tatgtcgacg 600 gactttctaa actggctgtc acaagctaca aggatattga gtcgttgatg tctgagggta 660
acaaateteg cacagttget geaaceaaca tgaacgagga gagtageega teccatgeag 720
ttttcaaaat cacctcaca catactctct acgatgtgaa gtctgggaca tctggagaga 780°
aagtgggcaa actcagcctg gtggatttag ctggcagtga acgagcaacg aagacaggcg 840 ctgcagggga caggctgaag gaagggagca acattaacaa gtccctcaca accctcggtc 900
tggttatctc agetettgca gateagagtg etggcaaaaa caagaataaa tttgttccat 960
atogtgacto agtictcact tggctgctca aagacagcct cgggggtaac agcaagaccg 1020
ccatggtggc tactgtgagt cctgcagctg ataactatga tgaaaccctc tcaactctgc 1080
ggtatgcaga tcgagccaag cacattgtaa accacgctgt ggtgaatgag gaccctaatg 1140 cccgaattat ccgggatctc cgggaagaag ttgagaaact ccgggagcag ctgaccaaag 1200 cagaggcaat gaaatctcca gagctaaagg accggctgga agaatctgag aagctaatcc 1260
aggaaatgac tgtgacctgg gaggagaaat taaggaaaac ggaggagatt gcacaggaac 1320 gacagaaaca gcttgagagt cttggaatat ctcttcagtc ttcgggaatc aaagttgggg 1380 atgataaatg cttccttgtg aatctgaatg ctgacccagc tctgaatgag cttctggtgt 1440 actatttaaa ggaacataca ttgatagggt cagcaaattc ccaagatatc caactgtgcg 1500
gcatgggaat tetteetgaa caetgtatta tagacateae gteagaagge caggttatge 1560
tgactectea gaagaacace agaacatttg taaatgggte atetgtetee agteeaatac 1620
agctacacca tggggacagg atattatggg gaaacaatca tttcttcaga ctcaatttgc 1680 ctaaaaagaa aaagaaagca gaacgagagg atgaggacca ggatccctcc atgaagaacg 1740 agaatagttc tgagcagctg gatgtagacg gagactcctc cagcgaggtg tccagtgaag 1800
ttaactttaa ttacgaatac gcacagatgg aggtcaccat gaaggccctg ggcagcaatg 1860 atccgatgca gtccatatta aacagcttag aacaacagca tgaagaagaa aaacgatctg 1920 cactggagcg ccagaggctt atgtatgagc acgaattgga gcagctccgg agaaggctgt 1980 ctcctgagaa gcagaactgc cggagcatgg acaggtttc tttccactcg cccaaggctt 2040
agcaacgctt aagacagtgg gctgaggaga gagaagcaac gttgaataac agcctgatga 2100 ggctgaggga acaaattgtt aaggccaatc tattggtgag agaagctaat tacattgctg 2160
aggagetgga taaaagaaca gaatacaaag ttaccetaca gattecagec tecageetgg 2220
atgccaacag gaagegagge tetettetta gtgageetge aatecaggtg agaag
<210> 156
<211> 488
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte ID No: LG:233933.5:2000MAY19
<400> 156
ctccacgcca gcacttttgc atgcagtact cccttcaggt cgtcacagcc acctgcaagt 60
ttgggatgaa tgcgcttctc ctgtctgcct ggttcggcca cttacgaatc ctccagatct 120
```

WO 01/62927 PCT/US01/06059 tggtaaactc aggggecaag atccactgtg agagcaagga ggggaacact gcccttcatc 180 tggctgctgg tcggggccat atggctgtgc tgcagcgact tgtggacatc gggctggacc 240 tggaggagca gaatgcggaa ggtctgactg ccctgcattc ggctgctgga ggatcccacc 300 etgaetgtgt geageteete eteagggetg ggageacegt gaatgeeete acccagaaaa 360 acctaagctg cetteactat geagecetea gtggetegga ggatgtgtet egggteetea 420 tecaegeagg aggetgegee aaegtggttg ateateaggg tgeeteteet etgeaeeteg 480 ctgtgagg <210> 157 <211> 5106 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:290344.1:2000MAY01 <400> 157 gggaagtggg agagacagag ggagagtgtg catacagcag ctgtcgggca tccctgtctc 60 agggacttet tegetgatte acagaggeag eccageeceg geeteecage ttacagetge 120 cgcctgcttc tcagaacctg acggaatcag aagctacatg atattcgccg tgtgagtggc 180 tatcgtaata gataacattt gaatatctac taaatgccag aaactatgaa ttaactcctc 240 tcaacaaagc taagaggtgc ttgatgatca atagttggtg cactgcctat cctcatcccc 300 cccatgagcc ttggttttta tgcaacctat ggtcatgcag ggatgccctt acaccctccc 360 acgatgtcat gactggcagg cagctgacca gttccatcat agcagcagcc tccgaagcac 420 ctgcccccac cctcaggtta gagctgctgt caccagccct gcacctcctc aagatggtgc 480 tggggttecc tgcctaagcc taaagctgtt gaacgggtet gttggtgcct ctggacccct 540 ggaaccacca gccatgaatc tgtgttggaa tgaaataaaa aagaagtctc acaacctccg 600 cgctcgccta gaggccttct cagaccacag tggaaagctt cagctccctc ttcaagagat 660 tattgactgg ctcagccaaa aggatgagga gttgtcagct cagctgcccc tacaggggga 720 tegggeecce tacatetatt etgtgetgga gteageteag geetteetgt eccageacce 840 atttgaggag ttagaggagc ctcattctga gagcaaagat acctccccga aacagcggat 900 ccagaatctc agccgctttg tatggaagca ggcgacggtg gccagtgaac tgtgggagaa 960 gttgacagec egetgtgtgg accageaceg teacattgag eggactetgg ageagetett 1020 ggagattcaa ggggcaatgg aggaactaag cactactcta agccaagctg agggagtccg 1080 agccacttgg gagcccattg gggatctctt cattgattca ctcccagagc acatccaggc 1140 tattaagctg ttcaaagaag aattctccc catgaaagat ggagtaaagt tggtgaatga 1200 tetggeceae caacttgeca tttetgatgt geaettgtea atggagaatt eccaggeeet 1260 ggaacagatc aacgtccgat ggaaacaact acaggcgtca gttgatgaga ggcttaagca 1320 gctccaggat gcccaccggg actttgggcc tgggtcacag cactttctct cctcctctgt 1380 ccaggttccc tgggaaagag caatttcacc caataaagtt ccctactaca tcaaccacca 1440 ggeteagace acatgetggg accateceaa gatgacagag ttataceaaa ecetagetga 1500 totgaacaac attaagttot cagottatog cactgocatg aaactcogca gagtocagaa 1560 agecetgege ttggacetgg taactttaac cacagecetg gaaatettea atgageatga 1620 tetgeaggee agtgageacg tgatggatgt ggtagaggte atteactgee tgactgeett 1680 atatgaacgt ttggaggagg aaagaggcat cctggtcaat gtgccactct gtgtggacat 1740 gagcetcaat tggeteetca atgtttttga tagtggtege ageggaaaga tgegggcatt 1800 gtettttaag actggeattg catgettgtg tggeaeggaa gtgaaggaaa aaetteagta 1860 cetetteage caagtggeea acteaggeag ceagtgtgae cagegeeace ttggtgteet 1920 getteatgag gecatteagg tgeecegtea getgggtgaa gtggeageet ttggggggeag 1980 caatgtggag cccagtgtcc gtagttgctt ccgttttagc accgggaagc cagtcattga 2040 agcateccag tteetggagt gggteaacet ggageeccag teeatggtgt ggetgeetgt 2100 totgcatogg gtaaccattg otgagcaagt gaagcatcag accaagtgot otatotgtag 2160 ogcagtgooc catcaagggg ttoaggtaco ggagtotgaa gcaattcaac gttgacatot 2220 gccagacetg ettettgaca ggcagggeca gcaaaggeaa ttaagetgea etaceccate 2280 atggcagtat tacacaccga ccacatccag tgagaacatg agggactttg ccacaacctt 2340 aaagaacaaa ttccgctcca agcattattt cagcaaacac cctcagcgag gttatctgcc 2400 tgtgcaatca gtgctggagg ctgactacag tgagacgccg gcttcttccc cgatgtggcc 2460 acacgeegae acacacteee gaattgagea ttttgeeage aggettgetg ageatggaaa 2520 gtcaaaattg ctccttcttt aatgaaaggt tgttccccaa ttgaaagctt aaacgaggac 2580

cagtacetge tgcggcacte cagececate acagacegg agecageett tggacageag 2640 getecatgea gtgtgggcac agaaageaaa ggggagetac agaagateet ggeceaettg 2700 gaagatgaga aceggattet ceagggagag etgaggegee tgaagtggca geatgaggag 2760 geagetgagg cacecagtet ggetgaegge tecaetgagg cageaacaga ceaeegcaat 2820 gaggagette tggeegagge eegtateett eggeaacata agageegeet ggagaegege 2880 atgeagatee tegaagatea caacaageag etagagteee eagetgeage gtettgaggg 2940

```
agettettee tgeagecace caecgaatea gatggeagtg getetgeagg etegteeeta 3000
getteetete cacageagte agaaggeeag teaceeegg gagaagggae agactaetee 3060
agataccgag gctgcatgat gatgtggggt caaagagcca ggatgtcagc ctgtgcttgg 3120 cggacatcat ggagaaactc cgtcatgcct tcccccagtg tgcgaagttc tgatgtgact 3180
gegeaacace etgetggeet ettgatggag ceagateece atcetatagt teatagteet 3240
ctcctggttc cgggtcaaag cctttcctca aggcttcacc caacctttcc cagtttccac 3300
ctggcccac attcctcaac tagtattatt tgggcatctg ggcagcagca gggatctggt 3360
ggtatgtgag gtgcatgcgg gcagtgatgg gagaagggga gcgcatgatt ctttcttgac 3420 cctagaaagt gttcccttta atcttcaagt tcgagatcag ccctttaagt acctttctgt 3480 tgcagcccag ggcaaatatc acttggccat ttcagatggg gagcagagaa gcctgccttg 3540
cagaagctaa gcggtacatg ttggcccctc ttccttctcc gtgggaatta tggaaagaga 3600
gaageetaat tacegeeaag gtteeateea geattatgaa teeaacaggg ttttaceeet 3660
actetetgge geaacteagg gaggeaaaag ggtateece gagacacett ceecacece 3720 aagtggeece tgaaaaagte tgggeagtgt gtgtactatt aactteaget ceagggacag 3780 gattgetage cateetaatg etacetaggt ataggttet ceteaaatat etteattte 3840
tttagcctca gtccctgaca gaccttcctt aagggggaga acagttcatt ctgggttctt 3900
ctaccettat atttggaage attaaateca tacttatggg tttagaatgt ttgtttttge 3960 cggcacatgt gtcctattte gttaaagtee teagcatttt gagaggagee cactgagttg 4020 cgagttgete tggaaacetg getgaageea ecettgtget eetetgagte tgtgeeteag 4080 cagacetgag gacacagtgg ecagettgeg ttgageaagg gagtgtgget tteetgtggg 4140
taaggaagag gaagcccacc tcaagtcttg gaagtagtta tgacctgcca tgcccacaac 4200
cgcttcccaa ggctgtgacc cctttctagc ttctcaggct gaatcaggtg aaggtggctg 4260
attigtocco agotaatoat aaggoattig caactiggota cogtigtigtag tiggococtoc 4320 ataggagoca caggocacaa atcaggaago giggocacti tocagocaga caacaacago 4380 aaggoottoc tigtigoctaaa attigtiatti ctaactotig aaggigaato caatootcaa 4440
actgaactag ctcttcctag gcgacatata ccatgatctc tttatccaga aactgttcag 4500
aatagatagt aggggtgggg gagtgggctt gggaatgttg aatagattca gagcccactt 4560 aggcagettt eteccaagag gagetttata acetagagee etgcagttga etteatttge 4620 etaagtttat atacatacat atetatteta catatetaet gtacateagt geteteetgg 4680
cctcactcac acattaaatt ctaatacctc ttgaagtatt aatgttctgc cttgctcttt 4740
gttagcccca gcctctggtt ggaaagatag atgtatcctg gctgctcccc taggatatct 4800
ctctccattg atgtttggcg gtgggctgtc ctcaagacca aagcaacagg aaacctgtgg 4860 tcacagagaa tctaacagga agagtcactg ttctcttcac tcattccaaa tcttgttccc 4920 ttgagacctg ggccttgggt gaattttcct gggctcccca taaatggttc aggtgccaac 4980 aatagagcaa acccaagctc tgcccaccc atgcagcaaa aggacaaaca ggccttcatt 5040
agectttgee agetaagaea cagagaaeat cetetggete cettecagae tettatggte 5100
tcactc
<210> 158
<211> 3800
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:410742.1:2000MAY01
<220>
<221> unsure
<222> 3787
<223> a, t, c, g, or other
agaccatctg tagactcctt cggaaagcag cagagatgct gcagagggtt tttcttagac 60
attaactgca gacggctgtc aggatagaag cagcggctca cttggacttt ttcaccaggg 120
aaatcagaga caatgatggg gctcttcccc agaactacag gggctctggc catcttcgtg 180
gtggtcatat cggttcatgg agaattgcga atagagacta aaggtcaata tgatgaagaa 240
gagatgacta tgcaacaagc taaaagaagg caaaaacgtg aatgggtgaa atttgccaaa 300 ccctgcagag aaggagaaga taactcaaaa agaaacccaa ttgccaagat tacttcagga 360
tacccaacca acccagaaaa tcacctaccg aatctctgga gtgggaatcg atcagccgcc 420
ttttggaate tttgttgttg acaaaacae tggagatatt aacataacag ctatagtega 480 cegggaggaa acteeaaget teetgateae atgteggget etaaatgeee aaggaetaga 540
tgtagagaaa ccacttatac taacggttaa aattttggat attaatgata atcctccagt 600 attttcacaa caaattttca tgggtgaaat tgaagaaaat agtgcctcaa actcactggt 660
gatgatacta aatgccacag atgcagatga accaaaccac ttgaattcta aaattgcctt 720
caaaattgte teteaggaae cageaggeae acceatgtte eteetaagea gaaacaetgg 780
ggaagteegt aetttgaeea attetettga eegagageaa getageaget ategtetggt 840
```

```
tgtgagtggt gcagacaaag atggagaagg actatcaact caatgtgaat gtaatattaa 900
agtgaaagat gtcaacgata acttcccaat gtttagagac tetcagtatt cagcacgtat 960 tgaagaaaat attttaagtt etgaattact tegattcaa gtaacagatt tggatgaaga 1020
gtacacagat aattggcttg cagtatattt ctttacctct gggaatgaag gaaattggtt 1080
tgaaatacaa acgtgatcct agaactaatg aaggcatcct gaaagtggtg aaggctctag 1140
attatgaaca actacaaagc gtgaaactta gtattgctgt caaaaacaaa gctgaatttc 1200
accaatcagt tatctctega taccgagttc agtcaacccc agtcacaatt caggtaataa 1260
atgtaagaga aggaattgca ttccgtcctg cttccaagac atttactgtg caaaaaggca 1320
taagtagcaa aaaattggtg gattatatcc tgggaacata tcaagccatc gatgaggaca 1380
ctaacaaagc tgcctcaaat gtcaaatatg tcatgggacg taacgatggt ggatacctaa 1440
tgattgattc aaaaactgct gaaatcaaat ttgtcaaaaa tatgaaccga gattctactt 1500 tcatagttaa caaaacaatc acagctgagg ttctggccat agatgaatac acgggtaaaa 1560
cttctacagg cacggtatat gttagagtac ccgatttcaa tgacaattgt ccaacagctg 1620
teetegaaaa agatgeagtt tgeagttett cacetteegt ggttgtetee getagaacac 1680
tgaataatag atacactggc ccctatacat ttgcactgga agatcaacct gtaaagttgc 1740
ctgccgtatg gagtatcaca accetcaatg ctacetegge cetecteaga geccaggaac 1800
agatacetee tggagtatae cacateteee tggtaettae agacagteag aacaateggt 1860
gtgagatgcc acgcagcttg acactggaag tctgtcagtg tgacaacagg ggcatctgtg 1920 gaacttctta cccaaccaca agccctggga ccaggtatgg caggccgcac tcagggaggc 1980
tggggeetge egecategge etgetgetee ttggteteet getgetgetg ttggeecece 2040
ttetgetgtt gacetgtgae tgtggggeag gttetaetgg gggagtgaea ggtggtttta 2100
teccagttee tgatggetea gaaggaacaa tteateagtg gggaattgaa ggageecate 2160 etgaagacaa ggaaateaca aatatttgtg tgeeteetgt aacageeaat ggageegatt 2220
tcatggaaag ttctgaagtt tgtacaaata cgtatgccag aggcacagcg gtggaaggca 2280
cttcagggaa tggaaatgac cactaagett ggagcagcca ctgaatctgg aggtgctgca 2340
ggetttgeaa cagggacagt gtcaggaget gtttcaggat teggageage caetggagtt 2400
ggcatttggt ccctcaggcc agtctggaac catgagaaca aggcattcca ctggaggaac 2460
caataaggac tacgctgatg gggcgataag catgaatttt ctggactcct acttttctca 2520 gaaagcattt gcctgtgcgg aggaagacga tggccaggaa gcaaatgact gcttgtggat 2580
ctatgataat gaaggcgcag atgccactgg tgggtgctgt gggctccgtg ggttgttgca 2640 gttttattgc tgatgacctg gatgacagct tcttgggact cacttggacc caaatttaaa 2700 aaacttgccc agagataaag ccccttttgg ttgtttttga aattgggttg aaggcaaaga 2760 agttcagccc ccaccccct tgctaaagac cagcggttat gggattgaga tcctgtgggg 2820
cateccatat aaaagtecag cagacaggat ttggtaagtt gccaaacttt gtcaggaagt 2880
ctaagggage ttegtgtttg gteegeetet gggteetgte cagecaaget ggttteecaa 2940
ttcccttaac cttctggagc atggtaacta ctttagttaa cgggagattt atctccggct 3000
tettggttee eteggegeaa cegtteeage tgeaggettt tgateceaet gteteeaca 3060
gagaatgtga aaagtgecag aaaaagggtg actetgtege cagttteeca gtgteteegt 3120
ggccaaccta agctgggccc aacgcagcta cgaggcgtca cattactatg ctccggtaca 3180
gaggateett geteeegtet aatatgaace cagaatgage gtggagatat ceaeactgga 3240
gccaaattet ggggatettg tgggagetaa agtatteaaa catatgcata gcaaacgete 3300
acgtgtattt gggctaataa tttggccact tattagcttc tctcataaaa tggattcacg 3360
attataaatt aaatgttetg ggtteatace egeaaaagee eeataatgtt gteaeteeet 3420 aatteteaca ggtaettatt caaacttgtt agtaaateet taaaggtttt teaeaaacee 3480
ctcaaatcta tattccgcca cgcgaaattg ttccgtaaac agttcttaag cccttctcat 3540
ttttcccccc tgccccaacg gaaggtgttt taatcacttt taaaaaatgca aatagtgaat 3600
tttagtggga gttaaggcag gtagcgctgg gttcattgtc gtccaattgc ctgtttctgt 3660 atatgcagtt gatacatgat ggtaaggaat caacaaaggg gcccgggcgc cggtggctca 3720
cagccatgta atcgccagca cttgtgggag gccagaggca aggtggatct atgaggtcta 3780
ggagatncga gaccatcctg
                                                                                  3800
<210> 159
<211> 2281
<212> DNA
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: LG:406568.1:2000MAY19
<220>
<221> unsure
<222> 446, 875, 1361
<223> a, t, c, g, or other
cagoctgoca cttgcctccc tgcctgcttc tggctgcctt gaatgcctgg tccttcaagc 60
```

```
teettetggg tetgacaaag cagggaccat gtetacettt ggetacegaa gaggacteag 120
taaatacgaa tecategaeg gaggatgaac tectegeete eetgteagee gaggagetga 180 aggagetaga gagagagttg gaagacattg aacetgaeeg caacetteee gtggggetaa 240
ggcaaaagag cctgacagag aaaaccccca cagggacatt cagcagagag gcactgatgg 300
cctattggga aaaggagtcc caaaaactct tggagaagga gaggctgggg gaatgtggaa 360
aggttgcaga agacaaagag gaaagtgagg aagagcttat ctttactgaa agtaacagtg 420 aggtttctga ggaagtgtat acagangagg aggaggagga gtcccaggag gaagaggagg 480 aagaagacag tgacgaagag gaaagaacaa ttgaaactgc aaaagggatt aatggaactg 540 taaatatga tagtgtcaat tctgacaact ctaagccaaa gatatttaaa agtcaaatag 600
agaacataaa tttgaccaat ggcagcaatg ggaggaacac agagtcccca gctgccattc 660
accettgtgg aaatcetaca gtgattgagg acgetttgga caagattaaa agcaatgace 720 ctgacaccac agaagtcaat ttgaacaaca ttgagaacat cacaacacag accettacce 780
getttgetga ageceteaag gacaacaetg tggtgaagae gtteagtetg gecaacaege 840 atgeegaega eagtgeagee atggeeattg caganatget caaagteaat gageacatea 900
ccaacgtaaa cgtcgagtcc aacttcataa cgggaaaggg gatcctggcc atcatgagag 960
ctetecagea caacaeggtg etcaeggage tgegttteca taaccagagg cacateatgg 1020 geagecaggt ggaaatggag attgteaage tgetgaagga gaacaegaeg etgetgagge 1080 tgggatacea ttttgaacte ecaggaceaa gaatgageat gaegageatt ttgacaagaa 1140
atatggataa acagaggcaa aaacgtttgc aggagcaaaa acagcaggag ggatacgatg 1200
gaggacccaa tettaggace aaagtetgge aaagaggaac acetagetet teacettatg 1260
tateteccag geacteacce tggteatece caaaacteee caaaaagte cagactgtga 1320 ggageegtee tetgteteet gtggeeacae etecteetee negggaetee teeacteeca 1380
gagaaaaagc tcattaccag aaacattgca gaagtcatca aacaacagga gagtgcccaa 1440
cgggcattac aaaatggaca aaaaaagaaa aaagggaaaa aggtcaagaa acagccaaac 1500
agtattctaa aggaaataaa aaattctctg aggtcagtgc aagagaagaa aatggaagac 1560
agttcccgac cttctacccc acagagatca gctcatgaga atctcatgga agcaattcgg 1620 ggaagcagca taaaacagct aaagcgggtg gaagttccag aagccctgcg ataaaaacaat 1680 gatctttaga agaggatgca gaactgttca gtggtattac atgaaatgca ttgtgagatg 1740 tttctaaaat accttctca attcaaaatg atccctgact ttaaaaataa tctcaccat 1800
taattecaaa gagaatetta agaaacaate ageatgttte ttetgtaaat atgaaaataa 1860
atttetttt tatgtegtga gatttgtatt ggeaagaage agttaattta aagatgetet 1920 teetatetgt ggatgtgttg gtaacteega gttgtaatga gtteatgaaa tgtgetgtta 1980 tttttgtaat eteaataaat gtggattgaa gttttteee ttttttaaa geeaaactaa 2040
tatttttctg tgacttgata catctgtcag atttttgtaa tctcgataaa tgtgtattga 2100
agttttttcc cttttttaa aaagccaaac taatatttt ctgtgagtta atacatctgt 2160
caggtgtgta tgtaacatta ctggacatta aaaaaaatta ttacattctc acccaaaaag 2220 ggtttgggtc ctaagcattt gcctttcttt gtttcctctt gttcaagaaa atctgattag 2280
<210> 160
<211> 5408
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:283762.1:2000MAY01
<220>
<221> unsure
<222> 4004
<223> a, t, c, g, or other
<400> 160
gegagegegg tegagatege catgeetace egagtatget getgetgtte egetttgegt 60
cetegetaca aacgeetggt ggacaacata tteeetgaag atecaaaagt aatttgatet 120 acatetactg atecttetet ttgetgacee attetgeece eegetgacet eettaaggat 180
ggccttgtga aaactgatat ggagaaattg acattttatg cagtatctgc tccagagaaa 240
ctggatcgaa ttggttctta cctggcagaa aggttgagca gggatgttgt cagacatcgt 300
tetggatetgat tetggteteta tetggatgat aggregatgat gggatetetg tetggatat tettggatat tettggatgat tettggatat tettggatat tettggatat tettatatgg tetgatatet 360 caaagcatta agccatttgt agaaagctt ettetatatgg tegatatgg tettggatateg 420 ggggaaccaa agcttcaagt tettggatat aattetttgg teaaatttge aaatattgaa 480
qaaqacacac catcctactc acagacgtta tgactttttt gtgtctcgat tcagtgccat 540
gtgccattcc tgtcatagtg atccagaaat acgaacagag atacgaattg ctggaattag 600
aggtattcaa ggtgtggtte gcaaaacagt caacgatgaa cttcgggcca ccatttggga 660
acctcagcat atggataaga ttgttccate ceteetgtt aacatgcaaa agatagaaga 720 agttgacagt egcataggee eteettette teettetgea aetgacaaag aagagaatee 780
```

Land the sale that the best

tgctgtgctg gctgaaact gtttcagaga actgctgggt cgageaactt ttgggaatat 840 gaataatgct gttagaccag tttttgcgca tttagatcat cacaaactgt gggatcccaa 900 tgaatttgca gttcactgct ttaaaattat aatgtattcc attcaggctc agtattctca 960 ccatgtgatc caggagattc taggacacct tgatgctcgt aaaaaagatg ctccccgggt 1020 tcgagcaggt attattcagg ttctgttaga ggctgttgcc attgctgcta aaggttccat 1080 aggtccgaca gtgctggaag tcttcaatac ccttttgaaa catctgcgtc tcagcgttga 1140 attegaaage aaatgattac agggggggat etgtagecag tgtcaattta aattacaagt 1200 tccaaagaca atgatgagaa gattgtggca gaatgctatc atccaaacaa taggattttt 1260 tggaagtaac ctaccagatt atcagaggtc agaaatcatg atgttcatta tggggaaagt 1320 acctgtettt ggaacateta eccataettt ggatateagt eaactagggg atttgggaac 1380 caggagaatt cagataatgt tgctgagatc tttgcttatg gtgacctctg gatataaagc 1440 gaagacgatt gttactgcac tgccagggtc tttcctggat cctttggtta tcaccatctc 1500 tcatggagga ctacgaactg agacagttgg tcttggaagt aatgacataa tatcatggat 1560 cgtcatgaca atagggaaaa gcttcgaggg ataagaataa taacggatgt agctgaccta 1620 aagataaaaa gagaaaaaat ttgcagacaa gacacaagtt tcatgaaaaa gaatgggcaa 1680 cagetgtate gggcacatat atttgggttg taaagaggaa gacaacgtte agaaaaacta 1740 tgaactactt tatacttete ttgetettat aactattgaa etgggetaat gaagaagtag 1800 ttattgatet cattegacet ggccattget tttacaggae agtgcaatta tcaatgagga 1860 taattigeea atgiteeate gitgiggaat catggeactg gitgeageat accteaactt 1920 tgtaagtcag atgatagetg teeetgeatt ttgccagcat gttagcaagg ttattgaaat 1980 tcgaactatg gaagccctt attitctacc agagcatatc ttcagagata agtgcatgct 2040 tccaaaatct ttagaggaag catgaaaaag attigtactt tctgaccaac aagattgcag 2100 agtcgctagg tggaagtgga tatagtgttg agagattgtc agttccgtat gtaccacaag 2160 taacagatga agatcgactt tctagaagaa aaagcattgt ggacaccgta tccattcagg 2220 tggatatttt atccaacaat gttccttctg atgatgtggt tagtaacact gaagaaatca 2280 cttttgaagc attggagaaa gccattggat accagtggaa tggaagaaca ggaaaaggaa 2340 aagaggegte ttgtgataga gaaattteag aaagcacett ttgaagaaat agcagcacag 2400 tgtgaatcca aagcaaattt getteatgat agaettgeee caaatattgg aacteaccat 2460 acgtcctcct cccagtccat caggaacact gaccattact tctgggcatg cccaatacca 2520 atctgtccca gtctatgaga tgaagtttcc agatctgtgt gtgtactgat cggcgcatga 2580 agacctcagg atatgatttg taaagcctaa aaattaaggc caagctgagc tttcagggtt 2640 tacttaatgt gtattaacat acttcttgaa aataatgatg gaacatatct ttaaccaaat 2700 gtttggcata ccatattaga agttttggag ctatatataa tttcgagtac tttcaaagat 2760 agatttatgc catgttaatt tgctttgagg ttcctgttgc ctttttaagt tgaacatgtt 2820 ttggtttcac tttattccac tgttaagtag tatgttttaa acttttcaca aaatgtaatg 2880 ttttttaaaa agtaagcctt cagaggattg aaactggatt aattggttat ttcttaaaca 2940 tttaaacagg cggtttagat gtagaatttt tgttgttgtt ttctgcaaag gcagatacat 3000 ttaaatatat tcctagtcct gggggctgca aaactgttcg gtgggctttt tgtccccagt 3060 gcgttagata agctggcgat aggcaccttg ctattcagtt actataataa tatgtgatag 3120 gcattectca tettetteae aataatagga catetgttga atagcattee tegaatataa 3180 ccctaaaaac gccatacttt aaattgtctg gttcttgtaa tattgtgttt cctgccacag 3240 agtttggacc attctgcttg agaagtgtag cagcttactc ttggagtacc aaactgtgca 3300 atatttttta catcataaga tgtatacagt ttacaggctg tgcttcgaaa ttcatagtag 3360 tattttgctg tggctccatt aattaaatga gatatcatat ttagtgcaga aaacagacat 3420 ttacaacagc tattcaagtt cacctgtgaa ggagtctgta cattttgatt tctattaaga 3480 gcacatttat ttacatttgt atattatttg aaatcctcat actcaaaaaa ttctccagat 3540 gggactttta atttgtaagg atttgaactg tgacttgtat acatctgttt aggaatcaat 3600 tatatttgaa aagetgeetg tgttttaaca gtcaagtgtg ctaaagtttg tcaatttaag 3660 gctggctttt gatttcagct accaagatca caggtgcact ctacacataa cactggacag 3720 gacccataac attacataca tcttaggtgg aattctatca catgggtaaa atggaacggc 3780 tttctttgta actcataaaa ttctcttagg acatttttat aaagtcacct gtttatagtt 3840 ctatcttttc agattccatt tctttttaca taaaacagca tacatatgca aaaactgtaa 3900 ccttagaatc cagtttaatt tttgggcttt gtttttggtt taaaaaaatt gcagtgaaga 3960 atggggatgt ttgtgtttat gggctatttg gggcaccttt tagntaggaa acagacaaaa 4020 gtaaggacaa cgataatagg acaaggcata cttgaaaatt tctggaatac ttaaacaaaa 4080 gegeaacate ttggaaaace agtetagtea ttgaaaceta tgaaatgaca etgaaagate 4140 ctggggctgc ttcttaaata agtagatcca gcaagacttg tttccagagt gaacagtggg 4200 agtegttace getggaggae taaagggeee tgtgggeage tgteaetgga actttgeete 4260 ttgatcagga aaaatgcttc accagtccgt aaagccaagt tgtattttt ttattgccct 4320 ttttttcctt ctgtattttt aaagaaggat gttaattttt gacctatata ttttaaaaaa 4380 atctaagcag ggggacatgc aaaaacaatc atccacccac ttgggatgtc atttttatag 4440 attaacactg tgtgcttttg tatggaaaaa atatatataa tttaatagta taaaacataa 4500 catatatatt catttgcact tacgtgaaac acaaactttg ctctacaaaa tttcgtgttt 4560 cttaggtgat tttaaaaaatg catgtattgc atgtaaagga aaacccatta ccaattaatg 4620 tttaatccac acctttatcc ttggtctttg ttggatttgg ggttttgttg ggggtttttg 4680 ttactgtttt taaattacag taggetteet atataceeet ggatttetga actggtettg 4740 ttgacaagga ttcccaagaa atggatetta tcaactggct gactetecca tatetgcaag 4800

```
acceattetg caggaactgg gtcgtgcaca cggtgttgta gccagttcag gtactgaata 4860
tttaggattt ggtgaagtte actgtattge tatatttttg taagataaat aaaactcaat 4920 taaattgtta atccattete ttttttgetg tatagaattg ettatateae tetttette 4980 atgacattgg ttaacattta aatgtteete etgaacttgt gttgteetgt gaecegeett 5040 atagagttt attgttattg gtgtttaeee tgaatacet atgeegtaea cacacacata 5100 ttteettaat acttetgaae teattatett ttagaataat aatacetaee tacactttae 5160
 ccagcaatta acttoctocc ctaccccaaa atgtttttcc ttccctgtct gaaaatggaa 5220 ctaatttgtc ttattcgtgc ttatactgt attaaaatgc aataaaggtt agttttttga 5280
 aatgtaaaat ttccactgtg caatttcata tgtcagcaaa taaaccatag attatttgta 5340 tataagttca tttttatagc tattgttaca tttaattaaa tttattcaat atttgcttaa 5400
 attaaaaa
 <210> 161
<211> 2895
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <223> Incyte ID No: LI:347687.113:2000MAY01
agccaacett acttacagca taagggageg tagaatetgt gtagaegaag ggggcatetg 60 geettacace tegttaggga agagaaacag ggtgttgtca geatettete actecettet 120 cettgataac agctaceatg acaacectgt ggtttecaag gagetgagaa tagaaggaaa 180 ctagttaca tgagaacaga etggeetgag gageageagt tgetggtgge actgttetgt 240
 ggctgtggac atgaagccct cactggcaca gaaaagctaa ttgagaccta tttctccaaa 300
 aactaccaag actatgagta teteateaat gtgatecatg cettecagta tgteatetat 360 ggaactgeet ettetett eetttatggg geeeteetge tggetgaggg ettetacace 420 aceggegeag teaggeagat etttggegae tacaagacca ceatetgegg caagggeetg 480
 agegeaacgt ttgtgggeat cacctatgee etgacegttg tgtggeteet ggtgtttgee 540
 tgetetgetg tgeetgtgta catttactte aacacetgga ceacetgeea gtetattgee 600
ttcccagca agactctgc cagtataggc agtctctgtg ctgacgccag aatgtatggt 660 gttctccat ggaatgcttt ccctggcaag gtttgtggct ccaaccttct gtccatctgc 720 aaaacagctg agttccaaat gaccttccac ctgtttattg ctgcatttgt ggggggctgca 780 gctacactgg tttccctgct caccttcatg attgctgca cttacaactt tgccgtcctt 840 aaactcatgg gccgaggcac caagttctga tccccgtag aaatccccct ttctctaata 900
 gegaggetet aaccacacag cetacaatge tgegteteee atettaacte tttgeettge 960 caccaactgg cectettett acttgatgag tgtaacaaga aaggagagte ttgeagtgat 1020
 taaggtetet etttggaete teeeetetta tgtaeetett ttagteattt getteatage 1080
 tggttcctgc tagaaatggg aaatgcctaa gaagatgact tcccaactgc aagtcacaaa 1140
 ggaatggagg ctctaattga attttcaagc atctcctgag gatcagaaag taatttcttc 1200 tcaaagggta cttccactga tggaaacaaa gtggaaggaa agatgctcag gtacagagaa 1260 ggaatgtctt tggtcctctt gccatctata ggggccaaat atattctctt tggtgtacaa 1320
 aatggaattc attctggtct ctctattacc actgaagata gaagaaaaaa gaatgtcaga 1380
 aaaacaataa gagcgtttgc ccaaatctgc ctattgcagc tgggagaagg gggtcaaagc 1440 aaggatcttt cacccacaga aagagagcac tgaccccgat gggcgatgga ctactgaagc 1500 cctaactcag ccaaccttac ttacagcata agggagcgta gaatctgtgt agacgaaggg 1560
 ggcatctggc cttacacctc gttagggaag agaaacaggg tgttgtcagc atcttctcac 1620
 tecettetee ttgataacag etaecatgae aaceetgtgg ttteeaagga getgagaata 1680
 gaaggaaact agcttacatg agaacagact ggcctgagga gcagcagttg ctggtggcta 1740 atggtgtaac ctgagatggc cctctggtag acacaggata gataactctt tggatagcat 1800 gtctttttc tgttaattag ttgtgtactc tggcctctgt catatcttca caatggtgct 1860 catttcatgg ggtattatcc attcagtcat cgtaggtgat ttgaaggtct tgatttgttt 1920
 tagaatgatg cacatttcat gtattccagt ttgtttatta cttatttggg gttgcatcag 1980 aaatgtctgg agaataattc tttgattatg actgttttt aaactaggaa aattggacat 2040 taagcatcac aaatgatatt aaaaattggc tagttgaatc tattgggatt ttctacaagt 2100 attctgcctt tgcagaaaca gatttggtga atttgaatct caatttgagt aatctgatcg 2160
 ttettetag etaatggaaa atgattitae ttagcaatgt tatettggtg tgttaagagt 2220
 taggtttaac ataaaggtta ttttctcctg atatagatca cataacagaa tgcaccagtc 2280
 tacaaaaaga cacttgatac ttgttttcaa accagtatac aagataagct tctatgcagc 2580
 ctggaaggag gagagggaaa atgttttgta agaaaccaat caagataaag gacagtgaag 2640 taatccgtac cttgtgtttt gttttgattt aataacataa caaataacca acccttccct 2700
```

```
gaaaacetca catgoataca tacacatata tacacacaca aagagagtta atcaactgaa 2760
agtgtttcct tcatttctga tatagaattg caattttaac acacataaag gataaacttt 2820
2895
ctcaatcaaa aaaaa
<210> 162
<211> 561
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:1146510.1:2000MAY01
<400> 162
tgcataaaaa gcagagcgta gcaagtaagc tgcaaatctg aagaaaatcc atgtgtccac 60
cagctgccat ctccagaact cttactccag gaaatccgaa agagtgaaca ttcttttagt 120
ctcctactcc tcaattaagt aaatgagaat gagtcagcca acaaagttca tgacaacaag 180
gtgcaggatg gtgctggcaa agagaaaatc agcaaaggct cgctctgggg agatgccttg 240
gaaatccgct ttgttctctg ggttgactct gtaattacat cacggccata ccgctaggat 300 gaactcccca cacaagagat gaagcccgag agaaaagtag ttgaacgagc ggaatggtcc 360
ccagcgacgg agacagtgaa ccgaactgca gcgccccagg tcagccagta tatacagcag 420
qtacqcqtcc aqcaacttca gacqctqcqq aqtqqaqctc aaqtactctt ctaagaaccg 480
cgaaatgaca gacactaccg acgccgtaca taactgcaac gcaaggtact ccagtccgcg 540
ccccaaactc ttggaggacc c
<210> 163
<211> 630
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:451710.1:2000FEB18
<400> 163
gttegteege tagggtttta geeeggtaee eegaateeeg eteeteegee geetegegte 60
caccettect cttggegege tecgateeaa gagatggegg tgeegetget gacaaagaag 120
atcgtgaaga agcgggtcaa gcagttcaag aggccccatc tcgaccgcta taagtgcctt 180
aagccaaget ggegeaggee aaagggtatt gaeteeegtg teaggaggaa gtteaaggga 240
tgcaccttga tgcccaacat tggttacggc tctgacaaat caaccaggca ctacctcccc 300 aataagttca agaagtttgt ggtgcacaat gtctctgagc tggagttgct catgatgcac 360
aacagaacct actgtgccga gatcgcccac aacgtttcaa ccaagaagcg caaggagatt 420
gttgaacgtg ccgccagct cgacattgtg gtcaccaaca agctcgccag gctccgcagc 480 caggaggatg agtagtctgg tttcttgtca taacggccaa ctagatcctg ccattcccgg 540 ctgtaggaaa ctactctgct ttgtgccttg ttggtactta gaataccagt cattttctac 600
atttttggta ccagtagcga cttctatgtg
<210> 164 <211> 570
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:455771.1:2000FEB18
<400> 164
ccgcttcttg cagccgtcgc cgcgaagcgc tccagagaac ttccgtcaac atggggaaga 60
cacgtggtat gggagccggg cgcaagctca agacccaccg caggaaccag cggtgggctg 120
acaaggcata caagaagagc catttgggca atgagtggaa gaaacccttc gctgggtcat 180
cccatgccaa gggcattgtc ctggagaaga ttggtattga ggccaagcag cccaactccg 240 ctatccgtaa gtgtgctcgt gttcagcttg ttaagaatgg caagaagatt gctgccttcg 300 tgccaaatga cggttgtttg aactacattg aggaaaatga tgaggtcttg attgctggat 360
ttggtcgtaa ggggcacgct gtgggagata ttcctggtgt ccggttcaag gtcgtcaagg 420
tttccggtgt gtctctgctt gcccttttca aggagaagaa agagaagcca aggtcttaga 480
ttgctcttgc taccaaaatc agcaagcgtg gagttgaaac gggagggcgt tagatgatta 540
```

The second second

```
agaagaatgg ttgcattgct atgtttgcag
                                                                                                      570
<210> 165
<211> 821
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:452089.1:2000FEB18
<400> 165
ttacacgtcg tgactgggaa aacaccgtcg tccgccgccg ccgaaggacg gaaggagaag 60
agggtacggc cgtctcctcg cccccatggc ccacgagaag aagctgtcca acccgatgcg 120
ggagatcaag gtgcagaagc tcgtcctcaa tatctccgtc gggggagagcg gcgaccgtct 180 cacccgcgcc gcaaaggtgc tcgagcagct cagcggccag acccccgtct tctccaaggc 240 gaggtacacg gtgcggtcgt tcggcatccg gcgtaacgag aagatcgcct gctacgtcac 300 ggtgaggggc gagaaggcca tgcagctgct tgagagcggc ctcaaggtca aggagtacga 360
getgeteagg aggaacttea gegaeaeegg gtgetttggt tteggeatee aggageaeat 420
cgaccttggt atcaagtacg atcettcaac aggeatetac ggaatggact tetacgtcgt 480
getggagegt gegggetace gtgtggcaeg cegcaggagg tgcaagteec gegtegggat 540 teageacagg gtgaceaagg aggaeteeat gaagtggtte caggteaagt acgaaggegt 600 cateeteaaa caaggeteag geetacaegt ecceecete acetgtggge aaaacagete 660 tetggtetet teteeteete egtgteaacg caagaecaec acceaceteg ceaggetttt 720
ttgggtttaa tttgtgttct cagacctgat gatttagtct gctagcactc tgtgggatgc 780 tgttgtcgca agatcaccac catgtcaaat tagttccgtg c 821
<210> 166
<211> 503
<212> DNA
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: LG:246415.1:2000FEB18
tgcttcctcc agtccgtgcc tccaatatga tgaaaaaaag aaggaacaac ggtcgtacca 60
aaaagggeeg eggeeaegtg eageetattt gegaeaegaa etgtgeecaa tgtgtgeeca 120
aggacaagge tattaacaaa tteateattg gaaacacagt ggaggetgea geagteaggg 180 acatttetga agegagegte tttgatgeet atgtgettee caagetgtat ttgaagetac 240
attactgtct gagttgtgca attcacagca gagtagtcag gaatcgatct tgtgaagccc 300
acaaggactg aacaccccta ctccaattta gacctgcgga tgctgcccca caacccccac 360
caaagcccac gtaaggagtt gagtccttaa agtctgaaga cggactattc tcattgagaa 420 aaataaaatg gaaattgtac cttaattaaa aaatacaaaa agtagccatg agtggtgaca 480 tgcaccatgt ggtcccagct aca
<210> 167
<211> 753
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:414144.10:2000FEB18
ctgcaccact agaaagatgg cggagcaaga gcaaagaaaa atccctttgg ttccagaaaa 60
tetectgaaa aagaggaagg ettateaage eetcaaagee acceaggeaa ageaggeact 120 tttggcaaag aaggageaga agaaaggaaa agggeteagg tttaagegae tggaateatt 180 cetacatgat teetggegge agaaaegtga caaggtgegt etcagaegae tagaagtgaa 240
acctcatgcc ttggaattgc cagataaaca ttccttgggc ctttgttgta cgcatcgaaa 300
ggattgacgg cgtgagttta ctggtgcaga gaactcattt tgaaacgtgg acaagccaag 360
gtcaagaata agaccatccc tetgacagac aatacagtga ttgaggagca cetggggaag 420 tttggcgtca tttgcttgga agacctcatt catgaaattg cetteccagg gaagcattte 480 caggagatet catggttett gtgccettte cacctetcag tggcccgtca tgctaccaaa 540
aatagagtgg getteeteaa ggagatggge acacetgget ateggggtga acgeateaat 600
```

WO 01/62927 PCT/US01/06059 cageteatee gteagetgaa etagaceeag gtgeeaaaet geggtaaatt ttttateagt 660 gaagtggaag catgtgttt gttttggaaa tttttateaa gtatetteag agaagattat 720 ttcctgcttt atcttcagaa actggaaagg gtc <210> 168 <211> 885 <212> DNA <213> Homo sapiens <221> misc_feature <223> Incyte ID No: LG:1101445.1:2000FEB18 <220> <221> unsure <222> 754, 809, 855, 866 <223> a, t, c, g, or other <400> 168 ctggaaccat ggaggctgta ccagagaaga aaaagaaggt tgccgctgcg ccaggaaccc 60 ttaagaagaa aaaggttcct gcggtgccag aaacccttaa gaaaaagcga aggaatttcg 120 cagagttgaa ggtcaagcgc ctgaggaaga agtttgccct gaagacactg cgaaaggcaa 180 ggaggaaget catetatgag aaggeaaage aetateacaa ggagtacaga cagatgtace 240 ggactgagat tegeatgget aggatggega ggaaagetgg caacttetat gtgeeegeag 300 aaccaaaatt ggcctttgtc atcagaatcc gaggtatcaa tggagtgagc ccaaaggtgc 360 gcaaggtgct gcagctgctc cgtctccggc agatcttcaa tggcaccttt gtgaagctca 420 acaaggette agtgaacatg etgaggateg tggageceta cattgeatgg ggggtacece 480 aacetgaagt cagtaaacga geteatetae aaacgagget atggcaaaat caataaaaag 540 cgcattgcct tgacagataa ctccttggtt gctcgatctc ttggtaaatt tggcatcatc 600 tgcatggagg atctaattca tgagatctat acagttggaa aacgctttaa ggaagcaaat 660 aacttcctgt ggcccttcaa actgtcttcc ccacgaggtg gaatgaagaa aaagacaact 720 cactttgtag aaggtggaga tgctggcaac aggngaggac cagatcaaac aggcttatta 780 ggaaggaatg aacttaaggt ggtctaccna tggattattt ttctaagctg ggttgggtta 840 ataaacagta cctgnctctc aaaatngaaa aaaaaaagaa taaaa <210> 169 <211> 586 <212> DNA <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:452134.1:2000FEB18 <400> 169 tacaccegce gagatattga tgcctaagaa gaactgggat teccatttat gaacteettt 60 ttaaggagag agtcatggtg gccaagaagg atgtccacat gcctaagcac ctggagctgg 120 cagacaagaa tgtgcccaac catcatgtca tgaaggccat gcagcctctc aagtcccgag 180 gctaagtgaa ggtacagttt gcctggagac atctctactg ctaccttacc aatgagggca 240 tecagtatet cegtgattae etteatatge eeeggagatt gtgeetgeea eeetaegeeg 300 cagccattct gagactggca ggcctcagcc taaaggtctg aagggtgagc gacctgcaag 360 actcacaaga ggggaagccg acagagatac ctacaggcag attgctgtgc cccctgatgc 420 cgacaggaag gctgaggctg aggctggggc tgggtcagag acggaattcc agtttagagg 480 cagatttggt tgtggaggtg gtcagccacc tcagtaaagt tggagaggat tattttgcat 540 taaataaact tacagccaaa aaaaatttaa aaaaaaatct cattaa <210> 170 <211> 659 <212> DNA <213> Homo sapiens <221> misc_feature <223> Incyte ID No: LI:903021.1:2000FEB01 <400> 170 ctcagttgtg agggggaagg tagactcttt ccagaccttt gataaagggg ctgctcaaaa 60

84/228

```
aagccacgac cttgggcctc tgctaaaacc atggctttaa gtaaggaggg agcagatata 120
taaaaaaact tatccctctt tctaatctct tatgtcctgt gagtgtcacc cattgagtaa 180
acccaagtgg aagtcagcag gaaagtagct gggatgatgc agtctttaca gggtgttgaa 240 gagaagaaga aggttcctgc tgtgccagaa acccttaaga aaaagtgaag gaatttcaca 300 gagctgaaga tcaagcgcct gagaaataag tttgcccaaa agatgcttct aaaggcaagg 360
aggaagetta tetatgaaaa agcaaageae tateacaagg aatatatgea gatgtacaga 420
actgaaattc aaatatcgag gatagcaaga aaagctggca acttctatgt atctgcagaa 480 cccaaattgg cgtttgtcat caggatcgga ggttatcaat tgggtgagcc caaaggtctg 540
aaaggtgttg caacttcttt gccttcatca aatcttcaat agaaactttg tgaagctcag 600
cagggettea ataatgtget gaggtttgta gaaccatata ttgcatggge atacccaaa 659
<210> 171
<211> 443
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:246422.1:2000FEB01
<400> 171
tqttqccttc tttctqcctc cqctaccqcc atggcgccca tgaaaaagct tgtggtaaag 60
gagggctaaa aaaaaaggaa gcaggttcca aagttcactc ttgatcgcac ccaccccgta 120 gaagatggaa tcatggatgc tgccaacttt gagcagtttt tccaagaaag gatcaaaatg 180 aacggaaaag ctgggaactt tggtggaggg gtagtgaccc atcgaaggga gcaagagcaa 240 gaccagcgtg acatccaagc tgcccttttc caacaggtat ttgaaatatc tcaccaaaaa 300
atatctgaag aagaataatc tacatgattg gttgcgcgta gttgctaaca gcaaacagag 360
ttacgaatta cgttacttcc aaattaacca ggacgaagag gaggaaaacg aggattaaat 420
ttcatttatc ggccgggcgc ggt
                                                                                        443
<210> 172
<211> 586
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:449404.1:2000MAY19
atcogtogoc ccacggaagt ctcggcggcg ccggcgtgct tgtgatctca acccaagtcg 60
tgcctccgct ccggtcaccc gtcgctccac gcaaccatgt cgaggaggaa gaccagggag 120 cccaaggagg agaacgtcac ccttggaccc actgtccgtg aaggagagta tgtctttggt 180
gttgctcaca tctttgcatc cttcaatgac accttcattc atatcactga tttgtctggg 240
agggaaactc tggttcggat caccggtggc atgaaggtga aggctgaccg tgacgagtcg 300
teacettacg etgetatget tgetgeteaa gatgtegeae agegetgeaa ggagettgge 360
attactgcac tgcacattaa gcttcgtgcc accggaggca acaagaccaa gacccctgga 420
cetggtgece agtetgecet cagggegett getegtteeg ggatgaaaat eggaegeatt 480 gaggaegtta eeeeggteee caeggaeage aetegeagaa agggeggtag gaggggaaag 540
gaggactgta ggcgtcatca ttactgcgtg ccatttgctg gctctt
<210> 173
<211> 551
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:449413.1:2000MAY19
<400> 173
ccgccggcct ccaactctaa ccccgttgct tccggctccc gcagcgtcgc cgaccttcac 60
agccggttcc ttcctccgcc accatgggga agacacgtgg tatgggagct gggcgcaagc 120 tcaagaccca ccgcaggaac cagaggtggg ctgacaaagc atacaagaag agccacttgg 180
gcaatgagtg gaaaaaacct tttgctggat catctcacgc caagggcatc gttctggaga 240
agattggtat tgaggccaag cagccaaatt cggccatccg taagtgtgcc cgtgttcagc 300
tggtgaagaa tggaaagaag attgctgcct ttgtgccgaa tgatggttgc ctaaactaca 360
```

```
WO 01/62927
                                                                    PCT/US01/06059
tegaggagaa tgtatgatga ggtgttgatt getggatttg gtegtaaggg teatgetgtg 420
ggagacatte etggtgteag gtteaaggtt gttaaggtgt etggtgtgte getgettgea 480
ctcttcaagg agaagaagga gaagccaagg tcttagatca ctttcggtag tccagaatgg 540
tgtaaactgc c
<210> 174
<211> 565
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:450105.1:2000MAY19
<400> 174
geogteggea geteggeege egtacteeeg etacegaget aggaggeate acettegeeg 60
atccaacatg ggtaagacac gtggtatggg agctgggcgc aagctcaaga cccacagaag 120
gaaccagagg tgggctgaca aagcctacaa gaagagccat ctcggcaacg agtggaagaa 180
accetttget gggteatete acgeaaaggg aategteett gagaagateg geattgagge 240
taagcagcet aactetgeta teegtaagtg egetegtgte eagetggtga agaacgggaa 300 gaagattget geetttgtge caaacgatgg ttgettgaac tacategagg agaacgatga 360
ggtgctgatt gctggattcg gtcgtaaggg ccatgctgtg ggagatattc ccggcgtccg 420
tttcaaggtc gtgaaggtct ctggcgtttc cctcctcgct ctcttcaagg agaagaaaga 480
gaageegaga tettaaaaeg etgeaagggt ttgggeetgg tggegeaeee cacacetgta 540
gcgctcacac aagccatagc agacc
<210> 175
<211> 336
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:460809.1:2000MAY19
gcgcatgggt ggagtgggct tcaagaagtg cccctcgggc acacagagag atccagaaat 60
tegecatgaa ggagatgggg actecaaatt tgeacattga tgtgaggete aacaaagete 120
tctgggccaa aggaataagg aatgtcccat accatatcca tatgaagttg cccagaaaac 180
ttaatgagga tgaagattca ccagacaagc tctatgcttt ggttcctaca tatacctgtt 240
accactttca caaatctata gacaggcaat gtggaagaga gctaaccact gatggttcaa 300
tacattaagt aaaattattt ttaaaaaaga aattta
<210> 176
<211> 932
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:481781.1:2000MAY19
<400> 176
ggeggagegt aaggegaagg agtageagea geaggeggeg eegagtageg geteeceate 60
tcgagcttgc caccatggct agaggattga agaagcattt gaagaggctc aatgccccca 120 agcattggat gctggacaag cttggcggag cttttgctcc caagccatct tctggacctc 180
acaagtctag ggagtgcctg ccactgatcc tcatcatcag gaacaggctc aagtatgctc 240
ttacataccg tgaggtcatt tccatcctga tgcaacgcca tgtacttgtt gatggcaagg 300
tcaggacaga caagacctac cctgctgggt tcatggatgt catttccatc cccaagacca 360 atgagaacta caggctgctg tacgatacca agggccgctt ccgccttcac ccaatcaggg 420
atgaggatgc taagttcaag ctttgcaagg ttaggtctgt ccagtttggg cagaagggca 480
tecettatet gaacaegtat gaeggeegea ceateegeta eeetgaeeee eteateaagg 540
ccaacgacac catcaagatc gatctggaga ccaacaagat tgtggacttc atcaagtttg 600
atgttggcaa cgtcgtcatg gtgactggcg gaaggaacac tggccgcgtg ggtgttatca 660 agaacaggga gaagcacaag ggcagctttg agaccattca cgtggaggac tcctgggcca 720
ceggttegee accegtatgg geaacgtgtt caccategge aagggtaata ageegtgggt 780
```

gagcetgeee aagggeaagg gaatcaaget gagcateata gaagageaaa ggaageggga 840

```
tgccgctgcc caggctgctg ccaacgcata aatcctctga atgtgctgtg ttgagagttt
                                                                                     932
tttctagttg ctctgcaaga atatagaaca at
<210> 177
<211> 733
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1101153.1:2000MAY19
gegaaggega ccatteette ttegeteett egeegeeget atggttaagt actegeagga 60
geegggeaac cetaceaaat eggeeaagge catgggaagg gacetgaggg tecaetteaa 120
gaacacaagg gagacagett ttgegetteg caagetgeet ttgaccaagg ctaagegata 180 cettgaggat gttattgete acaageagge aatteeette eggagataet gtggaggtgt 240
tggtcgcacc gcacaagcaa agtctcgcca ctccaatggg cagggtcgct ggcctgttaa 300
gicagccagg ticatatigg attigctgaa gaatgctgag agtaacgctg atgtgaaagg 360
cttggacgtg gacaacctct atgtttcaca catccaggtg aaccaagccc agaagcagag 420
gegeegeace tacegtgete aeggaegeat taaceettae atgteeteee ettgeeacat 480
tgagctgatt ctgtcagaga aggaagagcc tgtgaagaaa gaggctgaca acattgtcgc 540
ggcaaggaag cagtgaagta tgttagcctg ctgataatgg catcctttcg aagcattata 600
geogragete tittatgtae ettiteagge tggtacegat accgtggate tggatitget 660
atgttttgta ctgtgctcga gtgtaaggtc agttcgtaat acaatcaatc tgcgtggaac 720
aatttgatat cct
<210> 178
<211> 699
<212> DNA
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: LI:257695.20:2000MAY01
ggcgccgcgc ggtgaaggtt gtctagtcca cgcttcggag ccatgccgtc caagggcccg 60
ctgcagtctg tgcaggtctt cggacgcaag aagacagcga cagctgtggg cgcactgcaa 120
acgcggcaat ggtctcatca aggtgaacgg gcggcccctg gagatgattg agccgcgcac 180 gctacagtac aagctgctgg agccagttct gcttctcggc aaggagcgat ttgctggtgt 240
agacatecgt gteegtgtaa agggtggtgg teaegtgeee cagatttatg gtgagteeca 300
ggaactgggc gcatggagga ggtggctctg ggagggaggc cttcacagcg ctcctgtacc 360 ctttaattgt gtgtctttct cacagctatc cgtcagtcca tctccaaagc cctggtggcc 420 tattaccaga aatgtgagtg agcatgggtc cttcccatga ggtaggtggg tgtgtgggga 480 tcaagtcaag gactctgtg gattatctaa atcctcgtcc ctgctcttct tgccagatgt 540 ggatgaggct tccaagaagg agatcaaaga catcctcatc cagtatgacc ggaccctgct 660
ggtagctgac cctcgtcgct gcgagtccaa aaagtttgga ggccctggtg cccgcgctcg 660
ctaccagaaa tcctaccgat aagcccatcg tgactcaaa
<210> 179
<211> 568
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<223> Incyte ID No: LI:455771.1:2000MAY01
ccgcttcttg cagccgtcgc cgcgaagcgc tccagagaac ttccgtcaac atggggaaga 60
cacgtggtat gggagccggg cgcaagctca agacccaccg caggaaccag cggtgggctg 120
acaaggcata caagaagagc catttgggca atgagtggaa gaaacccttc gctgggtcat 180
cccatgccaa gggcattgtc ctggagaaga ttggtattga ggccaagcag cccaactccg 240 ctatccgtaa gtgtgctcgt gttcagcttg ttaagaatgg caagaagatt gctgccttcg 300 tgccaaatga cggttgtttg aactacattg aggaaaatga tgaggtcttg attgctggat 360
tiggtegtaa ggggcacget gtgggagata ticctggtgt ceggtteaag gtegteaagg 420
```

```
WO 01/62927
                                                                    PCT/US01/06059
tttccggtgt gtctctgctt gcccttttca aggagaagaa agagaagcca aggtcttaga 480
ttgetettge taccaaaate agcaagegtg gagttgaaae gggagggegt tagatgatta 540
agaagaatgg ttgcttgcta tgtttgca
<210> 180
<211> 444
<212> DNA .
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:274551.1:2000MAY01
<400> 180
gtcacatect tggcctgaaa ttetttgctg tagecettea etgtgacaca actgcaacca 60
accaetttae aaagttttee ttgtetatea gtittacaaa ggettageea tgtetetggt 120
ttettaaggt cateaacett aattgggttg atttggtgtt eggeacaaag ggccaceet 180
agettgacat acataggete tteacatttg gatgeaagea egeaaagatg ggettggeee 240 ttgtetaagg etttggeage tttgeaggtt ceacetgeta ggeeateatg getgagggeg 300
gtetteagte tettgtagag cagtattaat atceattaca cetecageag egtgtettee 360
ttggcatggt ggtgggtaca ggtgaaggtg aatcttgagc cactcaactt ctgctctgag 420
catgttgcca tgcagagaaa gaga
<210> 181
<211> 779
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:035973.1:2000MAY01
<400> 181
tatagggtaa acatccaatt aaaaggcaga tattggctat ccttggggag gccagcaaat 60
ttccggataa gggaagctgg tgggcaggaa aaaggcatgc aatggccctc atgagccaga 120
agaatagetg etgaetgatg cetgggggac caageceata attgtggage tggageegea 180
ctgtgtccct tgcttcagtc tgatctttgg ggagcctgca cagttctgac ctcagttaag 240
agctaaggga agagatttgg gaatgtttgg ccctgtgtaa cagcaaaagg attcattggt 300 gagggtgtct ggcaggtatc cgtaaagata ataagatgaa gggaacatcg ccgtttggaa 360 agtgtcgtga tatgatacac aagttgtgct gcctctgtgg ctctaaggca taccaccttc 420
agaagtcaac ctgtggcaaa tgtggctccc ctgccaagcg caagagaaag tgtaactgga 480
ctgccacggc taaaagaaaa taccacggcg actggttgaa tgaagcacct aaacattgta 540
tactgcagat ttaggcatgg attetttgca ggaacaacac ctacacccaa gagggcagca 600 gttgtgtcat ccagttcatc ttaagaattt caatgattag tcacacaata aatattccgg 660
tttttaaaaa tgtatatatt ttaaacatat atatgtttat atgtatatgt tatatctgta 720
ttacatatat gtgaaaagag gcagagattg tcagattgga ttaaaaaagct gtctgtaag 779
<210> 182
<211> 524
<212> DNA
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: LG:978427.5:2000FEB18
<221> unsure
<222> 453
<223> a, t, c, g, or other
<400> 182
gtggtgggta tgtgacggat gcctctgttt taggactacg ccggctgtgc tgttctggca 60
gtggattaac cagteettea atgeegtegt caattacace aacagaagtg gagaegeace 120
cctcactgtc aatgagttgg gaacagetta cgtttctgca acaactggtg ccgtagcaac 180
agetetagga eteaatgeat tqaecaagea tgteteacea etgataggae gttttgttee 240
ctttgctgcc gtagctgctg ctaattgcat taatattcca ttaatgaggc aaagggaact 300
```

```
caaagttggc attcccgtca cggatgagaa tgggaaccgc ttgggggagt cggcgaacgc 360
tgcgaaacaa gccatcacgc aagttgtcgt gtccaggatt ctcatggcag cccctggcat 420 gggcatccct ccattcatta tgaacacttt ggnaaagaaa gcctttttga agaggttccc 480 catggatgag tgcacccatt caagttgggt tagttggatt ctgt 524
<210> 183 ·
<211> 2340
<212> DNA
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: LG:247781.2:2000FEB18
ggeaggggee cegtgtetta etagegatge egtatetece caacagtget gggtateate 60
acctatgegg geategacet ggeegtetae gagactetga agaactggtg getteageag 120
tacagcacg acteggeaga cecaggeate etegtgetee tggeetgegg taceatatee 180 ageacetgeg gecagatage cagttaceeg etggeeetgg teeggaceeg catgeaggea 240 caageeteea tegagggtgg ecceagetg teeatgetgg gtetgetaeg teaateetg 300
teccaggagg geatgegggg cetetacegg gggategece ceaactteat gaaggttatt 360
ccagctgtga gcatctccta tgtggtctac gagaacatga agcaggcctt gggggtcacg 420 tccaggtgag ggaccggag cccgtcccc caatcctca cccccacac ctcagccact 480 ggagactgat gatccaacaa caggatccct actctttggc cacgagatcc cagtacccag 540
atectggate ctagaetect atgeceeaac cattgggtea tgggateeca geatecagat 600
cetggateet agaeteetat geeceaacea etgggteatg egateeceae eetteagea 660 etagateeca gateeceetg taaccataac tgtggateec ttaetteage aacteaagte 720 tgetaceeta accacaagat teaagattat ceacaceeca geeettaate eccateecee 780 aaateactgg ateetgeage eccacateet aaggtggate ecaegettee etgtgeecee 840
tactggatcc tggacctcta cgtcttaacc actggatccc acacaaatca gtgaatggat 900
cecaacace caaccacagg agcacggatt cectgtacet caacacecag accetgete 960 cetcaggac cagatecagt gtectagtga aacgetggat cetagatece caaccecaga 1020 tececatgee tegagecetg gatetecaag etcagetget ggattetgga tgteaacaaa 1080 cetcacact ggatectgac aaccacaatg cetggatect ggggeececa teaetggate 1140
ccagatcccc teactccacc cactggattc ctgcattggt ttttggtttc ctgctccttt 1200
ttaacctcga cactgggtct cagatccttc tgctgactgc cagatccctg catttcaage 1260 actacgcctt ccaccccag gcactggatc ccagattccc aagccttcac ccaccagatt 1320 ctggctccta aaacaagtgc gggggcccca gtggcacagc aagtggatcc tggcaactgc 1380 agctgctgga ttccagattc tgggtcccca atccctctgc ccagttcctc aatgtgaaa 1440
cctcatctct tgaaggcaga tcctgatatt ccaaggcact gaatcccaag ccctgaatcc 1500
coggttetg atotgaatet tocaggogoc gggteccaaa tgttcaggoc ccaagtetag 1560 atoctggcag cccagtcaca gagtatecca cacacactgg tgcccagago cggettetca 1620 tgacatgaaa ttgcatggte gagggagtet gtggggaagg aagcccaggt cctggetgca 1680
acctgcacgg atgctggatt cccctcacc ccacctctgc atggccaccc cctcccagcc 1740
ctgtggggaa actgttcct ggaaccactc cactcctgc atcccacac ttcacagcat 1800 cttccatccc cctccacct tctaggcgaa tagtccccag agctgtgttc ctccaagggg 1860 tccgaggaat cactcactcc tggaggctgg caaggagaca gtctgaggcc agggacacat 1920 gaagggatgt ccccaccca gcactatcag ggcctcccaa ggcttccaga gttgaaagac 1980 aggagaaaat cggcaaaagac cacccttccc taaacccaag cacccaatga tgcaaaaaac 2040
ctgcctgtgt gtgttatttc aaaggaaaag aacaaaagga ataaattttc taagctcttt 2340
<210> 184
<211> 1199
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:034583.1:2000FEB01
<400> 184
gtgcagcatg ccaccgtgat tcccgagacc atggcaggca cccagcagct ggcggactgg 60
agaaatacgc atgctcacgg aagccattat aatcccatca tgcagcagcc tgcactattg 120
```

THE STATE WITH THAT

WO 01/62927 PCT/US01/06059

accggtcatg tgaccettcc agcagcacag cccttaaatg tgggtgtggc ccacgtgatg 180
cggcagcagc caaccagcac cacctcctcc cggaagagta agcagcacca gtcatctgtg 240

```
cggcagcage caaccagcae cacetectee cggaagagta agcagcacca gtcatetgtg 240
agaaatgtet ecacetgtga ggtgteetee teteaggeea teageteeee acagegatee 300 aagegtgtea aggagaacae aceteeege tgtgeeatgg tgeacagtag eeeggeetge 360
ageacetegg teacetgtgg gtggggegae gtggeeteea geaceaceeg ggaacggeag 420
eggeagacaa tigicatice egacacicee ageeecaegg teagegicat caccateage 480
agtgacacgg acgaggagga ggaacagaaa cacgccccca ccagcactgt ctccaagcaa 540
agaaaaaacg tcatcagctg tgtcacagtc cacgactccc cctactccga ctcctccagc 600
aacaccagec cetacteegt geageagegt getgggeaca acaatgecaa tgeetttgae 660
accaagggga geetggagaa teaetgeaeg gggaaceeee gaaccateat egtgeeaeee 720
ctgaaaaccc aggccagcga agtattggtg gagtgtgata gcctggtgcc agtcaacacc 780 agtcaccact cgtcctccta caagtccaag tcctccagca acgtgacctc caccagcggt 840 cactcttcag ggagctcatc tggagccatc acctaccggc agcagcggcc gggccccac 900
ttccagcagc agcagccact caatctcagc caggctcagc agcacatcac cacggaccgc 960
actgggagec acegaaggea geaggeetae ateaeteeca ceatggeeca ggeteegtae 1020
teetteeege acaacageee cagecaegge actgtgcaee egeatetgge tgeageeget 1080
geogetgece acetececae ceagececae etetacaeet acaetgegee ggeggecetg 1140
ggetecaceg geacegtgge ceacetggtg geetegeaag getetgegeg ceacacegt 1199
<210> 185
<211> 1012
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:333307.2:2000FEB01
<220>
<221> unsure
<222> 965
<223> a, t, c, g, or other
<400> 185
aacaqatqtg aaaaaaqaat tatqacaaqq acaacctaat ataagtttta taaattttaq 60
gaaatgtcat ctttttactg gtttcagaga ctttttcaaa tgttttaaac acaattttca 120
gataacaata atgaaaagct gagccccaaa ccagggacag gtgaaccagt tttaagtttg 180 cactacagca cagaaggaac aactacaagc acaataaaac tgaactttac agatgaatgg 240
ageagtatag catcaagttc tagaggaatt gggagccatt gcaaatctga gggtcaggag 300
gaatettteg teecacagag eteagtgeaa eeaccagaag gagacagtga aacaaaaget 360
cctgaagaat catcagagga tgtgacaaaa tatcaggaag gagtatctgc agaaaaccca 420
gttgagaacc atatcaatat aacacaatca gataagttca cagccaagcc attggattcc 480
aactcaggag aaagaaatga cctcaatctt gatcgctctt gtggggttcc agaagaatct 540
getteatetg aaaaageeaa ggaaceagaa aetteagate agaetageae tgagagtget 600
accaatgaaa ataacaccaa teetgageet cagtteeaaa cagaageeac tgggeettea 660
geteatgaag aaacatecae cagggaetet getetteagg acacagatga cagtgatgat 720
gacccagtee tgateecagg tgeaaggtat egageaggae etggtgatag atttaatate 780
agaggaacaa caataggtga tagaataatg agacgctctg ctgttgcccg tattcaggag 840
ttetteagae ggagaaaaga aaggaaagaa atggaagaat tggataettt gaacattaga 900 aggeegetag taaaaatggt ttataaagge categeaact ceaggacaat gataaaagaa 960
gccantttet ggggtgctaa ctttgtaatg agtggttetg actgtggcca ca
                                                                             1012
<210> 186
<211> 318
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:814710.2:2000FEB01
<400> 186
```

cgaaggacct gaaggaaagt ggaaaagtcc aaagtttaag atgccagaga tgcatttaa 60 gactccaaag atatccatgc cagatattga cctgaatctc acaggtccaa aaataaaagg 120 agatgtggat gttacaggcc ctaaggtaga gggagatctg aaaggtcctg aagttgacct 180 caaaggcccc aaagtggaca ttgatgtccc agatgttaat gttcagggtc cagactggca 240 cctgaagatg cccaagatga aaatgcctaa gttcagtatg cctggcttca aaggagaggg 300

90/228

```
318
cccaggttct agatcgcg
<210> 187
<211> 677
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:414732.1:2000MAY19
<220>
<221> unsure
<222> 45, 618
<223> a, t, c, g, or other
<400> 187
agaggagega aaageatggt ceggggggeg geggaegeet ggtangeget egggeegttg 60
ttgtggggct gegegetgge getgeaggge gggatgetgt acceaagaga gaggeegteg 120 egggagegga agaagetgga eegeetetgg agetteegeg eegaettett egacaaaetg 180
tgccttggct tctaggagta gtggtatcgg cgtctgctgc gagagtcggg ctccaccatg 240 gacataccgg ttccctccag cttcaacgac gttggccagg actggcggct gcggcatttt 300
gtagaccaga tgtggtacga acgggaggtg accttcctgg agcaatggac ccaggacctg 360 cacacagag tggtactgag gattgtcagt gcccactcct atgccatcgt gtgggtgaat 420 ggggtcgacg cgctagagca tgagggatct acctccctt tgacaccgac atcagtagcc 480
tgttccaggt ggggcccctg ccctcccgcc tccgcatcac tatcaccatc ggcaacatgc 540 tcatctcctc caccctgcca ccagggagca tcctcgacat ggccgacacc tccacgtggg 600 taccatcctg cttccacngc agacacccac cttcctgtcc caccccgtgg ggcattacat 660
tagggtaatt acattag
<210> 188
<211> 1295
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:413910.6:2000MAY19
<220>
<221> unsure
<222> 1275
<223> a, t, c, g, or other
<400> 188
gatttggctc ccagctttgt agttcggaag aagttgggtc tatagatttc cccctaactc 60 tccattgatg tgttgagctt cagagggaat aataactcta cgtaaagcat gctggcgtct 120 caaggagttc tcctgcatcc ttatggcgtg cctatgattg taccggcagc tccttacctt 180
cetggactga ttcagggtaa tcaggaagca gecgetgeee etgacacaat ggetcageet 240 tacgettegg eccagtttge teeccegeag aacggtatee eegeggaata caeggeeeet 300
catececace eegecaga gtacacagge cagaceacgg tteeegagea cacattaaac 360 etgtacecte eegecagae gcacteegag cagageeegg eggtetttt atttgteatt 420 acaegtgetg tggeattatt tacetegatt ttacggeeet etaceaeggt geegtgtaat 480
ttoteceteg ecetgteege ateggeacta ttttegaaag ttacgaaace aaatecettt 540 gageeteget cattaaaaat aattteaaca tetaagattt taccaaattg accaaacatt 600
tgtctgaggt ccggatcccg gaacctgaag gggatattgg agacatgcag ccgcttgggc 660 tgagacttgt tttccgtgt ttcagaaggt tgtgtctggg gctggccatc cgtcggtgct 720 gcgtcatctg tctgtgtgc ggtgccagag acggtctgag cgctcgtgtc cgccggggtc 780
tgctcggagt gcgtctgggc gggagggtac aggtttaatg tgtgctcggg aaccgtggtc 840
tggcctgtgt actctggcgc ggggtgggga tgaggggccg tgtattccgc ggggataccg 900 ttctgcgggg gagcaaactg ggccgaagcg taaggctgag ccattgtgtc aggggcagcg 960 gctgctcct gattacccct tagctgctct ctttcacaat tcatctgttg tcttgaaacc 1020
tttctgtctt ctatttccac gcaggtattg cagtctgctt tgatatcctg aagggcatct 1080
cccacqactg caattagctg ccaagatttc attgtcggct gcaaagtgcc tcctgtttcc 1140
tcaccgggaa aacacagcac gggagaagtc cgaggcaaca gcaaacggca cccacgtgct 1200
agcaatgtaa atgactccag tcatctgtcg ttgcgcgccg cgcgccttcg ctcgcccggg 1260
                                                                                                                   1295
ctgcctggca cgacngccag caggtgcaga acgcc
```

```
WO 01/62927
                                                                               PCT/US01/06059
<210> 189
<211> 751
<212> DNA
<213> Homo sapiens .
<220>
<221> misc_feature
<223> Incyte ID No: LI:414732.2:2000MAY01
gagagaggag cgaaaagcat ggtccggggg gcggcggacg cctggtaggc gctcgggccg 60
ttgttgtggg getgegeget ggegetgeag ggegggatge tgtacceaag agagaggeeg 120
tegegggage ggaagaaget ggacegeete tggagettee gegeegaett ettegacaaa 180
ctgtgccttg gcttctagga gtagtggtat cggcgtctgc tgcgagagtc gggctccacc 240 atggacatac cggttccctc cagcttcaac gacgttggcc aggactggcg gctgcggcat 300
tttgtagacc agatgtggta cgaacgggag gtgaccttcc tggagcaatg gacccaggac 360
ctgcacacaa gagtggtact gaggattgtc agtgcccact cctatgccat cgtgtgggtg 420
aatggggteg acgegetaga geatgaggga tetacetece etttgacace gacateagta 480 geetgtteea ggtggggeee etgeeeteee geeteegeat eactateace ateggeaaca 540
tgctcatctc ctccaccctg ccaccaggga gcatcctcga catggccgac acctccacgt 600
gggtaccatc ctgcttccac cgcagacacc caccttcctg tcccaccccg tggggcatta 660
cattagggta attacattag gagaacttgt tgtttaaaag agtgtggcac cttcatccac 720 ctttttcctt tcttgccatg tgacacacca g 751
<210> 190
<211> 4466
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:900264.2:2000MAY01
<400> 190
tgaaagtact ttgactccca agggtatctg atctgatgga gagaatgtat cacttgtacc 60
gatgeggata gaaegeteat taattacage acagttttea taaattecaa etteectagg 120
aattttgtct tttgaaggca tgttggaagt tggggcatta ggatataatc tcagtccatg 180
tactaageet etgeataaet gaaagataga gteaataaaa tteaetetet eattittigt 240
ttttaatete aagaattttt geettgaagg acgaatgtag tggcgaattt gatgtttgaa 300 cgaateecag teagaagtte eageetgeea etgttetetg atgeeatget atgaceaaca 360
tcaagetgta ttgteetete ateegtaaet gtgaaetgag caggatetat ggeaetgeat 420
gttactgtca ccagaaacat ctctgtttgt tcctcatcgt acattcctca gagtcgactg 480
agatacacac ctcatccage atatgetace ttttgeagge caaaggagaa ctggtggcag 540 tacacccaag gaaggagata tgettecaca ccacagaaat tttacctcac acctecacaa 600
gtcaatagca tccttaaagc taatgaatac agtttcaaag tgccagaatt tgacggcaaa 660
tagtgtcagt tctatcctgt cgatttgaca gcaatcagct gcctgcaaat gcacccattg 720 aggaccggag aagtgcagca acctgcttgc agaccagagg gctccttttg ggggtttttg 780 atggccatgc aggttgtgct tgttcccagg cagtcagtga aagactcttt tattatattg 840 ctgtctcttt gttaccccat gagactttgc tagagattga aaatgcagtg gagagcggcc 900
gggeactgct acceattete cagtggeaca ageaccecaa tgattacttt agtaaggagg 960
catecaaatt gtaetttaac agettgagga ettaetggea aggagettat agaeeteaac 1020 actgggtgag tegaetgata ttgatgttaa ggaggeteta attaatgeet teaagagget 1080
tgataatgac atctccttgg aggcgcaagt tgggtgatcc taattctttt ctcaactacc 1140
tggtgcttcg agtggcattt tctggagcca ctggcttgtg tggcccatgt ggatggtgtt 1200
gacetteatg tgggccaata etggcgatat cagagecatg etgggtgtge aggaagagga 1260
eggeteatgg teageagtea egetgtetaa tgaccacaat geteagaatg aaagagaact 1320
agaacggctg aaattggaac aatccaaaga gtgaggccaa gagtgtcgtg aaacaggatc 1380
ggctgcttgg ctttgctgat gccatttagg gcatttggag atgtcacgtt ccaatgggag 1440
cattgagett teaagaagag agtgatagaa tetggeecag aaccagttga atggacatga 1500
attiticeaag titaticete ciaattatea cacaceteet tiateteaet getgageeag 1560
aggtaactta ccagcgagtt aaggccacag ggataagttt ctggtgttgg ctactgatgg 1620 gttgtgggag actatgcagt aggcaggatg tggttaggat tgtgggtgag ttcccttaac 1680
tggcatgcat caccaacage caatagetgt tggtggctae aaggtgacte tgggacagat 1740
geatggeett ttaacagaaa ggagaaccaa aatgteeteg gtatttgagg atcagaacge 1800 atgcaaccge gategteatt eggecaccge tgtgggcaac aacgagtttg ggactgttga 1860 tcattgagee gettetetaa aatgettagt etteetgaag agettgeteg aatgtacaga 1920
```

gatgacatta caatcattgt agticagttc aattetecat gitgtagggg cgtttcaaaa 1980

```
cccagaatag tgagtggctc tttcactggc aattctcaaa tgatacacat ttaaagggca 2040
gattttctta aaaagatact actataataa acatttccag ttggtcattc taagcattta 2100
cccctttgga tactctagct agtcaggtac tccaaattga cctttgcagc agggtggcag 2160
ggtcaggaga gtctggtcct gcctagctca gatttcagtg gcagcctgca cttgaagcaa 2220
cgtcacttct ttatcacagg tcgtcttgag acattcagct tcttttacca aacctgagaa 2280
aattaggatg cacctggcca aataagatct tgaataggcc aaaagcaagt atcttgctgt 2340
gtgtagtete ttggtteaag tgaageaaca gtaetgttea cacetttett caetgagatt 2400 cecagtgtae atgagaacat atatttattg catgattte ctagatacae agteetatge 2460
attattcata tacatttatt ttagcctaaa agtgggtttc aaatcccagt tccttcaagc 2520
cataaatgac caaggtccaa ggcaatctgg aatttgtttt tgtgattatt tgactggaat 2580
gettettaag tggaataace tatacteegt tatecaceeg atttectaat gtaattgaaa 2640 gatttteeta ttttgecaca caettggaga acaataatgg gtttttagtt ttatetaete 2700 ttetattgaa gttaaagaaa gaaaaaaaga tttttttatt tggtattaat gaaaagettt 2760 agtttaaaat aaggagatee agaataaaaa gaagagaetg atetetteaa ttattgteat 2820
ctgtagccac cagcacatca ctcttatgta atccccaaag gcttggcatg ccgtaagtgt 2880 gtggtgggta gactgctgcc ggggaatcgt acttcttatt tagtaatgat aagacttttc 2940
attaattttg ccattttaa agatgacata aataagttta aatatcaatt tggggagtaa 3000 ggtttaatat tgccatcggg tattgagaca ggaggaagtt tctgtttttc tccatttaga 3060 ccataggtca attaaaatat ttgggtttaa aaattgacct aaatgcttta aacatattgt 3120
agettaagat atatgtgtta agatatatae atgagaaact ttaaaaggta actactgtgc 3180
atgcctgatg cttaatagaa tacttagtgg catcaaatgt ttgcagcagt ctccatgagt 3240
talgtteggt ecettetaat aetgtaleaa tgtaaatgaa ataaagtata tteaaattgg 3300
ctttttgata tgcatcaagt ggcattttgt ctcctgtgtt taatagtgat ctgtatacag 3360 gctgtgcaca tattgtcatc acttattcta gcatcactgt taaaggctgt gattatgttt 3420
gatattcacc tgcgatttta atacaagcca atatcagctt cccattgtgt aataacttgg 3480
gtgtttagga gtcttttcac attttttggc gatatgaact agatgttcca agaaactcct 3540
tectggactg tggatactga atcagtgtac tattggetge agaatttgtt teaattgaaa 3600 atagacteag gaagattget geteagaata teatatagat gtetattttt tgaggtgttt 3660 ttgttttat ttgtgtgttt ttetttttt taagteaget tggaactttt tteetggta 3720
gtatttggga gagggaaagg ctgtcactat atatttattt ctctaatgtt ttggctcggg 3780
cetttttete tttaatgaga atatagtgtg getggtetea tgacaaaace catattacag 3840
tctactatga gaatattett gaacaccacc actgaagagt ttcatataca ccaaataatg 3900 tctcatctct atagtacagg gaatataaaa ttggttteet gtggtcatga tccagatagt 3960
aggtattatt accacaagaa cttgggtctg ccagtcctgg aaagcttgtc tgctctatag 4020
aaatgaaaat gcagcatgaa gttgacattg tggaaatgaa aagtaattgg gtattagaaa 4080 tctgaaagta ctgtccatct aaaagcaatt gtggatttta ttgtaattgg ttgtcccctt 4140 ttgttccggt ttcttagaat taaaagaata catgtaaacc tttccatggt atttaagccc 4200
tttccttaaa ttttttaaa atttaaactt tcctaaccct atgtattcaa cttctgtatt 4260
tatatttaat ccagtggttc atgttatata atacaccett aactagttaa atggaatgtt 4320
ggtatggtac agagtaccat attgctaaga aaactgtctt ataaaagatg tatatggtgt 4380
gaagacatga aagtttaatg taacagaatg gttggagaaa tgcctatggt gaattaaagc 4440
ttcatatctg ctttctgaaa aaaaaa
                                                                                             4466
<210> 191
<211> 1798
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:335593.1:2000MAY01
<220>
<221> unsure
<222> 111, 145, 147
<223> a, t, c, g, or other
<400> 191
aaccagcage gggaggageg caacgctage geggegeggg gaccgcegeg ettecttece 60
ggeteetgee etectetgee getegeteet eteteggeat ceaceteett neceteetee 120
tgetcattca etettteet cactninece teeteetegg etteteeeeg egeecegeea 180 geectegege teteceacte ectetgeetg teeteeeegg teeceteete eegetcatte 240 actegeect eteettee eacteteee ecetgtetee titetteete tietteace 300
etecgtetet cacaceceet ceatteceet gteteettte tgacactgea etgeagetge 360
tcctcagccc tgcccctcc ccagtgagaa caaaccagca acattgcttt ttttcctaaa 420
gagatttata ttgatccgat taaaaaaaaa aaaccttaag aaaccccga cgcccgaaag 480
aaaaagaaaa aaaaaaagaa aaaagaaaag aaaaagccaa aacaaaaggg agaaccttct 540
```

```
cccggtagca gcggcaggaa ctgcaaacat gatggcggca gctcccatcc agcagaacgg 600
gacccacact ggggttccct atagacctgg acccgccgga ctcgcggaaa aggccgctgg 660
aageeecee tgaageegge ageaceaaga ggaceaatae gggegaagae ggeeagtatt 720 ttetaaaggg tteteataee tagttatget getggateta taattgggga agggaggaca 780
gacaattgtt cagttgcaaa aagaaactgg agccaccatc aagctgtcta agtccaaaga 840
tttttaccca ggtactagct gcagcgagtg tgctgtgagt ccagggaact gttgaagtgc 900
tgaatgcatg gttcatggca cttcattgca tcagacacat agttcgagaa tatgccctat 960
aaatatggee aagacagaac cagteageat tetacaacee cagaceaceg ttaatecaga 1020
tegeateaaa caaacatttg ceatetteee caatetacea ceaagteete teeatetgat 1080
cccatgagcc ccctccagag ctaatcaggt acagtatcat cctgtcatct acaccatact 1140
tttcaccggg tgattgcctg caaaactgga gcaacacaag atcatggtgg gttccaggat 1200 ttcattcgtt cattcacata tatgtcacca tagtcagatt tccaataacc tatagaaaga 1260
aatateteat tattitetea acattiteta tgeetiteta attitagata acaaataeta 1320
tattcagata ttataactac tctaattttt taattaattt ttccctaaaa atttgactac 1380
ctaatggggc acctgaagcc tatttattga aattggtaat ttttaatctc cccttattgt 1440
atcttcctag gaatttttca aaagtaaatt aaggatatct atatatgtaa aaaaaaaaat 1500
gtataaattg agcaaaggta tatctttaaa agtgaatgca attttattt cttttattt 1560
gagacatgcc ttatgatgta aacaactttc aactattgat gaaaagcatt tctagcaatc 1620
taaaagaaac tgaaaattgg tatttgtggt aattttaatg tttaacaact caggagatgg 1680
tgttttctta gtattttaaa aaattctaag cattttcatt gctctgctga caaactttgc 1740 caagtagaat atattttatt agtttggatt tatggattgg tttgggtact atttgtag 1798
<210> 192
<211> 3690
<212> DNA
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: LI:1189543.1:2000MAY01
<221> unsure
<222> 2889
<223> a, t, c, g, or other
<400> 192
gaatteegae aaaacaaaag ggagaacett eteeeggtag cageggeagg aactgeaaac 60
atgatggcgg cageteceat ceageagaac gggacecaca etggggttee catagacetg 120
gaccegcegg actegeggaa aaggeegetg gaageeeee etgaageegg cagcaccaag 180 aggaccaata eggeegaaga eggeeagtat tttctaaagg ttctcatace tagttatget 240
getggateta taattgggaa gggaggacag acaattgtte agttgcaaaa agaaactgga 300
gecaccatea agetgtetaa getgtetaag tecaaagatt tttacecagg tactactgag 360
cgagtgtgct tgatccaggg aacggttgaa gcactgaatg cagttcatgg attcattgca 420 gaaaaaaattc gagaaatgcc ccaaaatgtg gccaagacag aaccagtcag cattctacaa 480
ecceagacea cegttaatee agategeate aaacaaacat tgecatette eccaactace 540
accaagteet etecatetga teecatgace acetecagag etaateaggt aaagattata 600
gttcccaaca gcacagcagg tctgataata gggaagggag gtgctactgt gaaggctgta 660 atggagcagt caggggcttg ggtgcagctt tcccagaaac ctgatgggat caacttgcaa 720
gagagggttg teactgtgag tggagaaeet gaacaaaaee gaaaagetgt tgaaettate 780
atccagaaga tacaagagga tccacaaagt ggcagctgtc tcaatatcag ttatgccaat 840
gtgacaggic cagtgggcaa attecaatec aaceggatet cettatgeaa acaetgetga 900
agtgttacca actgctgcag cagctgcagg gctattagga catgctaacc ttgctggcgt 960
tgcagcettt ccagcagttt tatctggett cacaggcaat gacctggtgg ccatcacete 1020
tgcacttaat acattagcca gctatggata taatctcaac actttaggtt taggtctcag 1080
tcaagcagca gcaacagggg ctttggctgc agcagctgcc agtgccaacc cagcagcagc 1140 agcagccaat ttattggcca cctatgccag tgaagcctca gccagtggca gcacagctgg 1200
tggtacggcg gggacatttg cattaggtag cctggctgct gctactgctg caaccaatgg 1260
atattttgga getgettete eeetagetge eagtgeeatt etaggaacag aaaagteeac 1320
agatggatcc aaggatgtag ttgaaatagc agtgccagaa aacttagttg gtgcaatact 1380 tggcaaagga gggaaaacat tagtggaata ccaggagttg actggtgcaa ggatacagat 1440
ctccaaaaaa ggagaatteg tacetggeae aaggaategg aaggtaacea ttactggaac 1500
accagetgea acacaggetg etcaatattt aattacacaa aggateacat atgageaagg 1560
agttcgggct gccaatcctc agaaagtggg ttgagtgccc cagttacaca tcagattgtt 1620
ttaacccctc ctttacccca ttttcaagaa ggatgtactg tactttgcag aagtgaagtt 1680 tttctgttat taatatataa ttatgcaaat gaatgcgact atgttgacaa tgtgtatatg 1740
taaataatat gtgttttacc agatgtttca tagaaagaat tttttcttga tctgttttgt 1800
```

```
tetetatact ttgettgtgt atatttgtea gaggtgttte tagtgtaaga tttaageetg 1860
ccattttace agcattatig tagtttaatg attgaatgta gacagggata tgcgtatagt 1920
tttcagtatt agttctagat aacactaaat taactactgt taggttgagt atggtggggt 1980
cagtgaceta aaatggagtg aggccaaagc actgtcetgt aagtettact teetgettag 2040 ggcacagtga cagteggaaa catatttega aactaaegte teaaatttaa aatgateaaa 2100
accyccatat acyttyccct acaacyccct ytcaactatt ctacacyytt aaactytyya 2160
ccattatatg ggtaagttta cagatcaata aaagcacctg ttctccatct gaactagaca 2220
atggaaataa tgctgcatgc tggccatggc ccattcttca tcatttgtaa gttcaacaaa 2280
agttctcaca tggagtccca cctcttcaga ggtttgtaca tttgttttta agcactgaat 2340 tcactactga tcccatcgcc tggccagtag aacagtcatt actccattaa catcctcact 2400 gtttagacac ataactgtgg tacagtgtat tggaaatttt ataaacaaaa gtgaaagtgc 2460
caacaaatta ttgatagctg ataatgtttc attatctgca actgcttgat aagtatgttg 2520
cattttaaga gettataatt gtgtataatt tgttaacact agaaacetat tagtattgtg 2580 aatgtagatt ttaetgtgaa getatetgtg atttagetgt ttgeteecat gatggagtet 2640 ttgeageatg gegetageag ceaatgeagt ttetaatact eggtaatttg catgttttgt 2700 ggageatttt tatgteacea accagaeagt attteetgea tgettattta gaagaggeag 2760
cttatettga gaggtagtgt tatetacett tgteaggett titgaeaggt eatiteagag 2820
taagcettg tteccaagae ccaacaactg teaccetett etgtacetet ectgagtgee 2880 aactgtgena ggecatttga cacaccatet gttaacetet gagtttgeee acteaaggee 2940 acteatagg geatectage ectgtgeaet cageacteat aggateatee agacteteat 3000 geggeatgea gtetaateat gteacataat getgetaate tgatactetgg etgageaact 3060 gagtatacaa gagaattaa gteacaactaa getgetaatee staatetgg etgageaact 3060
gaattacaaa agagaattac ttccatctca acttcaaccc attgattacg tccatcctag 3120
caagetaaat ggcatccag etgeteett etgtgeaace aattaaagaa caatgagtgt 3180 gatgeteeat gtetgaatt egteeageet etetetgaae tgtgatett gteeteatga 3240 aettteett ttgtteattg aactatatgg actetgteat tteatattga tttaetgtge 3300 aatttaettt tggacattga gaacttgaaa ttatteetg ateeeteet 3360
taataattca tttctgtcaa actgtaagag tagactcatt ttttttttt tagttttaa 3420
cattggactg ttatttcatt tagagttctc tatctctaaa tatttattta gagaatgatt 3480
ttaaaaggga atgatatgcc ttgtttaaat gaaagagaaa agctgtagta aactgtgtta 3540 attggtaatg actatttatc gtcgatactc tgtagctgtg taagttttga caaatagtgt 3600 atctcgtgga atcagtggtt agcattgccg ctattatatt tactcatttt atcattataa 3660
atgtgcttag ttcatcatgt aaaaaaaaa
<210> 193
<211> 588
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:455450.1:2000FEB18
<400> 193
ggeggeggea teettegeeg eteeggeage ageteeaget ceageagete gteatetgaa 60
gacgacggca tgggtgggcg ccggaagaag ggcctgaagg agaagatcaa ggagaaaatg 120
ccaggaggcc acagggaagg ccagggccag gcgacggcca ccggtgcgta cggcgggaca 180 gggtacgtgg ctgggccgac gaccggaggc ccccacgaga agaagggtgt ggtggagaag 240 atcaaggaga agatcccagg cggccacaag gactacgacc agcatcagca caccaccgcg 300 gcaaccggtg gcggcggtgg ctatggcgga accaccgaca ccacgtatgg gacgacgacc 360
actgaaggca ctcacgagaa gaagggcttc atggacaaaa tcaaggagaa actccccggt 420
cagcactaag cactaagcag ctgcctcttt cctcttccgg ctagctgcct ctttcctctt 480
ccggttggcg actgcctgta agtacatgta tacagaataa ataaagcaat aaagaataag 540
eggeagetae gtatgtgtgt gtattegtgt gtatgeattg taaggeag
                                                                                                           588
<210> 194
<211> 640
<212> DNA
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: LG:1040978.1:2000FEB18
ctectaceta egeageagag gecagecace teccegtege teteacgete ttegtgeeeg 60
cegeetetee teegtetetg cetetetee teteceetee egtetgaege acatggeete 120
```

categorgga tetteggere teteettege caggeregte aaggeaatea acacaaatte 180

```
tetagettte teeceggega ggaagggeaa cacatteete egeetgeaae caatgeetat 240
gagatetgtt teetgegetg eeaagaagga tacaacagae aaggtttgtg agattgtgaa 300
gaagcagctt getetteetg accatactga agtttgeggt gaatcgaaat tetetgaact 360 eggtgeagat teactggaca eggttgagat tgtgatgagt etegaggage acttegatat 420
tagegtggag gagteeageg cacaaacaat egecacagtt gaagaegeeg eggaceteat 480
egacaagett gttgetggea aagegtagtt etgtacetee tetategttg teetaceact 540
ctaggtetat eccttgatet aggtttetat ggtetgaaga tttgtgattt teteegeact 600
gttgttgcta tccccgtgtc gtaataatac gagatgtttt
<210> 195
<211> 380
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:446649.1:2000FEB18
<400> 195
gctgaaagcg cgggagcaag ctcagaagag ggaagcaatc caggtcacct cgccagtatg 60
teteaggetg attttgagaa aggegggtga ggaggtgaag egeeteaaga eteageeaac 120
tgatgaagag atgctgttca tctacagcca cttcaaacaa gctactgtgg gcgatgtaaa 180
cacagategg eeggggetgt tggaeeteaa gggeaaagee aagtgggaet egtggaacaa 240
gctgaaagga acttccaagg aaaatgccat gaagacctat gtggaaaagg tagaagagct 300 aaagaagaaa tatggaatat taacgaccag atttggtggg cagccacatg tgtgacataa 360
                                                                                            380
tacctgtgag gacataatgc
<210> 196 <211> 3854
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:132147.3:2000FEB18
cegegteete egeggeteag gaegaetaeg eteggeaegt eegggaeeet eeggeegtgg 60
cggttgcagc gccaaaagct cgggcctcag cccctgacgc tgtggtgact ccgccgcgcc 120
tegeogtege coetgteece gteetgeecg ecgecteege egetggggae atgteeaace 180 eeggaageeg gaggaaeggg ecegteaage tgeacetgae agtactetgt geaaaaaace 240 tggtgaaaaa ggattttte egactteetg ateeatttge taaggtggtg gttgatggat 300
ctgggcaatg ccattctaca gatactgtga agaatacgct tgatccaaag tggaatcagc 360
attatgacct gtatattgga aagtetgatt cagttacgat cagtgtatgg aatcacaaga 420
agatccataa gaaacaaggt getggattte teggttgtgt tegtettett tecaatgeea 480 teaacegeet caaagacaet ggttatcaga ggttggattt atgeaaacte gggeeaaatg 540
acaatgatac agttagagga cagatagtag taagtcttca gtccagagac cgaataggca 600 caggaggaca agttgtggac tgcagtcgtt tatttgataa cgatttacca gacggctggg 660
aagaaaggag aaccgcctct ggaagaatcc agtatctaaa ccatataaca agaactacgc 720 aatgggagcg cccaacacga ccggcatccg aatattctag ccctggcaga cctcttagct 780
gctttgttga tgagaacact ccaattagtg gaacaaatgg tgcaacatgt ggacagtctt 840
cagateccag getggeagag aggagagtea ggteacaaeg acatagaaat tacatgagea 900 gaacacattt acatactect ecagacetae cagaaggeta tgaacagagg acaaegeaac 960 aaggeeaggt gtatttetta catacacaga etggtgtgag cacatggeat gatecaagag 1020
tgcccaggga tcttagcaac atcaattgtg aagagcttgg tccattgcct cctggatggg 1080
agateegtaa taeggeaaca ggeagagttt atttegttga ecataacaac agaacaacac 1140
aatttacaga tootoggotg totgotaact tgoatttagt tttaaatogg cagaaccaat 1200 tgaaagacca acagcaacag caagtggtat cgttatgtoc tgatgacaca gaatgcotga 1260
cagtcccaag gtacaagcga gacctggttc agaaactaaa aattttgcgg caagaacttt 1320
cccaacaaca gcctcaggca ggtcattgcc gcattgaggt ttccagggaa gagatttttg 1380
aggaatcata tegacaggte atgaaaatga gaccaaaaga tetetggaag egattaatga 1440
taaaatttcg tggagaagaa ggccttgact atggaggcgt tgccagggaa tggttgtatc 1500 tcttgtcaca tgaaatgttg aatccatact atggcctctt ccagtattca agagatgata 1560
tttatacatt gcagatcaat cctgattctg cagttaatcc ggaacattta tcctatttcc 1620
actttgttgg acgaataatg ggaatggctg tgtttcatgg acattatatt gatggtggtt 1680 tcacattgcc tttttataag caattgcttg ggaagtcaat taccttggat gacatggagt 1740 tagtagatcc ggatcttcac aacagtttag tgtggatact tgagaatgat attacaggtg 1800
```

```
ttttggacca taccttctgt gttgaacata atgcatatgg tgaaattatt cagcatgaac 1860
ttaaaccaaa tggcaaaagt atccctgtta atgaagaaaa taaaaaagaa tatgtcaggc 1920
tctatgtgaa ctggagattt ttacgaggca ttgaggctca attcttggct ctgcagaaag 1980
gatttaatga agtaattcca caacatctgc tgaagacatt tgatgagaag gagttagagc 2040 tcattatttg tggacttgga aagatagatg ttaatgactg gaaggtaaac acceggttaa 2100 aacactgtac accagacage aacattgtca aatggttctg gaaagctgtg gagttttttg 2160 atgaagagg acgagcaaga ttgcttcagt ttgtgacagg atcctctcga gtgcctctgc 2220
agggetteaa ageattgeaa ggtgetgeag geeegagaet etttaccata caccagattg 2280
atgcctgcac taacaacctg ccgaaagccc acacttgctt caatcgaata gacattccac 2340
cctatgaaag ctatgaaaag ctatatgaaa agctgctaac agccattgaa gaaacatgtg 2400 gatttgctgt ggaatgacaa gcttcaagga tttacccagg actctattta tacaacccca 2460 actgacagcc tcctttcagc agagtttcaa agaatatgct gaaatacagg aaaacactcc 2520
cccccccc ctttttttt ttttttaca ttttaggaca ctgtgagggg aaaggacaat 2580
tttgaaattc cttttcaagg aaaaaaagg tctttatgct ttgccatgag gccacattca 2640 gctgctattt aaacttaata tcttgaacct aaagaatgct gacttttcct acatttccag 2700 agttaggcag tattctacac ttaaagacta ctactattt tataaaaggt aatctattca 2760
aatttettea cagattteaa gteteteaaa cateaagaea aetteageag teggtacaag 2820
tcacatttca ttttgattga atacatgatc ttgaacagct cctgtacttg ctctttgtaa 2880
aaaaaaataa aattattttg aattattcta cctttgtaaa caattggcta aaagaatcat 2940 ctttaagaaa ttaagccatt tacatgtttg tgtttttcta tagcagagca ttatattttg 3000 cattatatgt ttcaacctag tctaagtggg tcttttttac atttttcaag aacggatttc 3060 ctggaataca gcgatataat tttggttgtc aaattcctaa tgcaaccatt tagtctaaac 3120
ttagtcattt atttgtgaca ataagatgtg ttcaggggct ccctgttttt aagagactct 3180
ttaaaaaaaa aaaaacctaa tgtttttatc ttgagtcaat atgattaggt attttggatt 3240
acaaaaccat cctaaagcgt taactgctca taattttaat cagctacagt tatgaaaaag 3480
gaagaatttt getetaaaga ttattaataa gettagaaaa teetgetttt acetaacaga 3540
atgaagtggg gttgagggge ggtagtatga acagtgatte taactetatg gegtaaatta 3600 etttgaagag tteattttgg aagtaaggga atceegette eettggtgtt gaagatetge 3660 atctgatttt gaaacgteea gatttagett teaaggtgeg tgeatgttga atgateeaga 3720
agcaacgaaa actctggggt gagggattga aaaaatctga aatcacagtt ggatttttaa 3780
attcaaccat caaaaatatg tactatcagt ttttttctac attgatgtga aataagcaat 3840
tttcatgata atta
<210> 197
<211> 905
<212> DNA
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: LI:036034.1:2000FEB01
gggaggatga cetettaceg ggageggagt geegacetgg eeegttteta caetgteace 60
gagececage gacacecgag gggetacaca gtatataagg teacegeceg ggttgtttca 120
cgaagaaatc cagaggatgt ccaggaggga gaatcctgaa ccaacctatc catgaacata 180 ctctctgcca ttttcttagt cctttttcg ggaaaactct tttataataa caactgttgg 240 tgaaccattc atctgaaaac tcttataatt gtatggaaga gatacagtga ttttaagaaa 300
ctacacaaag aactatggca aattcacaaa aacttattcc gacattcaga gttgtttcct 360
ccatttgcta aaggaatagt gtttgggcga tttgatgaaa ctgttatcga agagagaaga 420
caatatgctg aagacctgct acagttctct gccaatattc ctgctcttta caatagtaaa 480
cagettgaag actttttcaa gggtggaata attaatgata gttctgaatt aattggtcct 540
gctgaagctc actcagattc cctcattgat acctttcctg agtgtagtac ggaaggcttc 600
tecagtgaea gtgatetggt atetettaet gttgatgtgg attetettge tgagttagat 660
gatggaatgg cttccaatca aaattctccc attagaactt ttggtctcaa tctttcttcg 720
gattetteag cactagggge tgttgettet gacagtgaac agageaaaac agaagaagaa 780 egggaaagte gtageetett teetggeagt ttaaageega agettggeaa gagagattat 840
ttggagaaag caggagaatt aataaagctg gctttaaaaa aggaagaaga agacgactat 900
                                                                                              905
gaagc
<210> 198
<211> 585
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> misc_feature
<223> Incyte ID No: LG:162161.1:2000MAY19
gagtettegg egagacetae egggeeetgt etgtgeegge egtgagetge ggeaggaegg 60
ctggagatta cttctctaac aggatcacca gtttgctcca caaagcacaa tgtctcgatc 120
acgacaaccc ccccttgtga ccggcatctc tccaaatgaa gggataccat ggacgaaggt 180 cacaatcagg ggagaaaatc tggggactgg ccccaccgac ctcataggct tgaccatttg 240
tggacataat tgcctcctga cggcagaatg gatgtctgca agtaaaatag tatgtcgagt 300
gggacaagcc aaaaatgaca aaggagacat tattgtcacc actaagtcag gtggcagagg 360 aacctcaaca gtctctttca agctactcaa acctgagaaa ataggcattt tggatcagtc 420 tgctgtgtgg gttgatgaaa tgaattatta tgatatgcgc actgacagga acaaaggaat 480
teegeettg teettaegte etgetaacee gettggeatg gagattgaae caagtacatt 540
ttcgcagaag gacttagaaa tgctattcca tggaatgagt gctga
<210> 199
<211> 518
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature .
<223> Incyte ID No: LG:407214.10:2000MAY19
<400> 199
gaaaagagtg ctccaccttc actgaagcca gcaatttggc cggctgttag cacttcattc 60
atatteeeta gtatgagtta attetttgte attttattte tigtgattee agaateteat 120
tttcagcttc tgccagagcc agtagcagtt gggaaagaag gctgtgctct ttgaagagag 180 tcagccagcc tgaaagagca ggatggatct tgatgtggtt aacatgtttg tgattgeggg 240
eggeaegetg gecateceaa teetggeatt tgtggettea tttettetgt ggeetteage 300
actgataaga atctattatt ggtactggcg gaggacattg ggcatgcaag teegetatgt 360 teaccatgaa gactateagt tetgttatte etteegggge aggeetggge acaaaceete 420
catectcatg etccaeggat tetetggeca caaggatatg tggetcagtg tggtcaaagt 480
tecttecaaa gaacetgeae ttggtetgeg tggacatg
<210> 200
<211> 1233
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:204626.1:2000MAY19
gcagaaccag attctccagg tgtgaagtaa gcaatctatt ttcacttgct attaacagca 60 aacgtacaac tttatctctt atttgacttc attatttggc tttcaaatta acaacatgaa 120
aactatacag aaattagtet gtgeeetata agacagagat ttagataatt tgtteaaaac 180
atgagatgat attcagatat tetetcaaag geaggaetee aacacegeag gtggaaaace 240
aacaaaagga agaaaacaga aaggtggggg agataaggag tagccaggaa aaagaaaata 300
gtgataaagg aagagccaaa aaggaggaaa gggaagatga aagaccgact tcaagaacta 360 aagcagagaa caaaggaaat tgaactctct agagacagtc atgtatcaac tacagaaaca 420
gaggaacaag gggtgtttct acagcaaget gttatttatg aaagagagec tgtagetgag 480
agacacctac atgaaatcca aaaactacag gaaagtatta acaatttggc agataatgtt 540
caaaaatttg ggcagcaaca gaaaagtctg gtggcttcaa tgagaaggtt tagtctactt 600 aagagagagt ctaccattac aaaggagata aaaattcagg cagaatacat caacagaagt 660
ttgaatgatt tagttaaaga agttaaaaag tcagaggttg aaaatggtcc atcttcagtg 720
gtcacaagga tacttaaatc tcagcatgct gcaatgttcc gccattttca gcaaatcatg 780
tttatataca atgacacaat agcagcaaag caagagaagt gcaagacatt tattttacgt 840 cagcttgaag ttgctggaaa agagatgtct gaagaagatg taaatgatat gcttcatcaa 900
ggaaaatggg aagtttttaa tgaaagctta cttacagaaa tcaatatcac taaagcacaa 960
ctttcagaga ttgaacagag acacaaggaa cttgttaatt tggagaacca aataaaggat 1020
ttaagggatc ttttcattca gatatctctt ttagtagagg aacaaggaga gagcatcaac 1080 aatattgaaa tgacagtgaa tagtacaaaa gagtatgtta acaatactaa agagaaattt 1140
ggactagetg taaaatacaa aaaaagaaat cettgeagag taetgtgttg ttggtgetgt 1200
ccatgctgta gctcaaaata aagaagctat ttt
                                                                                       1233
```

```
<210> 201
<211> 1002
<212> DNA
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: LI:007401.1:2000MAY01
<400> 201
geggeegett tgeeggteat teecgaagee eggeaactga gggeggeece ettteettaa 60 cagteteete getacagate gtetgeteec teageetege eggaaceea etteeceagt 120
ctcgcccggg tggaggtcga cgaggaggag acaagagtca cccttcctcc aggcggcgcc 180
ggcccccctc acccgcgggt gtgtcctata aatggcgtcg gaaagcgaca ccgaggaatt 240
ctatgatgee cetgaagatg tgeacetagg gggeggetae eeegtggggt etecaggaaa 300
agttgggctt tcaacattca aggaaacaga gaacactgca tacaaagttg gaaatgagtc 360 ccctgtacaa gaattgaaac aagatgtgtc taacaagatt atcgaaagta ttatcgagga 420
gagtcagaaa gtactacagc ttgaagatga ctctttggat tccacaggaa aagaactctc 480
tgatcaagct actgccagtc ctattgtggc tagaacagat ctgagcaata tacccggact 540
gttagccata gatcaagtac taccggaaga atcccaaaag gcagagagtc agaatacatt 600 tgaagagact gaattagaat ttaaaaaaat gctttccttc tgatgaaacc tgtgagaaac 660 cagtagatga aaccacgaag ttaactcaaa caagttcaac tgagcagctt aatgtgcttg 720 aaactgaaac agaagtattg aacaaggaag cagtggaagt caaaggaggt ggtgatgttt 780
tagageetgt gteeteagae teettateta etaaagattt tgeegetgtg gaagaagtgg 840 ceeetgeeaa acceeeaaga cacettaete cagageetga tatagtgget agtacaaaga 900
agectgttee ageacgeeca ectectecaa etaattteee acetectaga eccecacete 960
                                                                                                1002**
cttctcgacc tgctccacca ccaagaaaaa ggaaaagcga at
<210> 202
<211> 444
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:476342.1:2000MAY01
<400> 202
ggacggacgc gcgtctccgg tcccgtccgt aataacactg atccgatcca cgccggccgg 60
egatggaget catcaagtec agggegaceg tgtgegeget ceteetggeg etgeteetge 120
teteacacta egaeggeggg acgaegaega egatggtgge ggaggeeegg gtgtgeatgg 180 geaagageea geaceaeteg tteeeetgea teteegaeeg eetetgeage aacgagtgeg 240
tcaaggagga cggcgggtgg accgccggct actgccacct ccgctactgc aggtgccaga 300 aggcgtgcta agcaaagctc ttcaaacacc cttggcttgc cagaactgaa ctctagtagt 360
actaagtaac accettgget agetgtgeac aacetaegta eegtgeatge atgtaatgtg 420
gtgtcatgta acgtgacagc aata
<210> 203
<211> 1956
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:1072759.1:2000MAY01
tctagatcgc gagcgggccg cttttttttt cgcaacgggt ttgccgccag caacacaggt 60
gtctgtgaac actacccct aaaagtccaa taactgggaa caggaaactg actcatatta 120 acacttggtc cgtcacttgt gacacggttg aatccgggca aggtcccacc aattatgggc 180 catctgattc taataaatgc ggtggcatcg aacaaaagaa ccattgaaaa atttgacgac 240
aggaggetge tgageatggg aaagggetee tteaagtatg cettgggtet etggataaac 300
tgaaaggcta gagcgtgaac gtggtatcac cattgatatc tccttgtggg aaccttctga 360
gaaccagcaa gtactatgtg actatcattg actgccccag cgacacagca gacctttact 420 caacacaaca tgcattacag ggtacatctc aggctgactt gtgctgtcct gattgttgct 480 gctggtgttg gtgaatttga cagctggtat ctccaagcaa tggggcggaa cccggagagc 540
atgcccttct ggccgtaccc actggggtgt gaaaccaact aatagctcgg tgttaacaaa 600
```

567 (1) 179 (2004) 0094

```
agtggattcc actgagccaa cctaaaggcc cgaagaagat atgaggcaac ttgttcacgg 660
aagtcagega ggtacattaa gaaaaatggg cttacaaccc cgacacagta gectttggtg 720
ccaatttctg gttggaatgg tgacaacatt ctggaagcaa ggtgctatca ttgccttggt 780
ttcaaggaga tggaaagtca cccgtaaggg atggcaatgc caggtgagaa ccacgcttgc 840
ttgcaggcta ctagactgca tcctaccacc aaactcgtac aactgacaag gcccttgtgc 900 ccgtgcactc tccaggatgt ctacaaaaatt ggtggtagtt ggtactgtgt cctgttgtgc 960
gegatgtgga gactggtgtt ctcataaccc gcgtatcggt aggtcacctg ttgctccgag 1020
tcagacgtta acatctcgaa gtaaacatct gtcgaaatgg gccctgaaag gcttggagtg 1080 aagctcttcc tgggggacaa tgtgggcttc aatgtcaacg aatgtgtctg tcaagggact 1140 gttcgtcgtg gcaacgttgc tggtgacagc aaaaattgac ccaccaatgg gagcagacgt 1200 gtggcttcac atgctcaggt gattattcct tgaaaccatc caggccaaat aatgcgccgg 1260
ctatgctctc tgtattggat tgcctactct ggctcactat tgcatgcagg ttttgctgag 1320
tetgaaggaa aagattgate geegttetgg tataaaagte tggaagtatg geectaggat 1380
aacgtgaaga tetggtgatg etgegeatgt gttgatatgg gtteetggea aggeeeatgt 1440 getgttgaga gettetetag actateeace tttggggteg etttgetgtt egtgatatgt 1500
agactagaca gttgcggtgg gtgtctatct aatagtctag tggactaaga taggctgctg 1560
gtagetggte ataggtetae ccaagtetge ccagaaaget cagaagggtt aattggaata 1620
ttatccccta atacctgcct acccctactc ttaatcagtg ggtgaaagaa cggttctcag 1680 aacctgtttg ttttcaattg gccaatttaa agttaagtag taaaagactg gtttaatgaa 1740
taacaatgca tcgtaaaccc cttcagaagg aacaggagaa tgttttgtgg accactttgg 1800
ttttctattt ttttgcgtgt ggcagtttca agttattagt ttttaaaaatc agtactttt 1860
aatggaaaca acttgaccaa aaattgtgtc acagaaattt tgagacccat taaaaaaagt 1920
taaatgcaga aaaaaaaca aaaaggtggc gggccg
<210> 204
<211> 1726
<212> DNA
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: LG:998857.1:2000FEB18
<400> 204
ctccatgcca ctctgacacc ctggcagtgc actgtgggta cacctcgacc ccgcctcacg 60
gatgagggt gctgagcggt cattggtgat ggtgggacga agcttgacag tggcaaaagg 120
atttgtgccc ctcgggaaga gctcctgtgg tgggtactgc tctgaggaca tcagtttctt 180
gacgtcagtg gcaactgctg tgctgcccat gctgctgcgg cggctgctgg gcaagggtgg 240 aggtgcaggg ctgggggcac ggcttggcac ccggcttggg gtggagttgc ccggccggtc 300
caggaggtca tcgaggctgt ggctgccccg gagtgggtag gacctggaag gcagctcgtt 360
cccggggttc atgggtgtca tgggtgtcat gggggacatg gaggtcatgg aggtcatggg 420
ggtcatgggg gtcatgggat tcacgggccc ctcctccaga gccttcacgt acgcctcggg 480
gaaccaaccg ctcgcggacg agccctccag cttgccgtag agccagccgt tctgggcctc 540
gggcaccaac acctecacca cgtececage ggagaagege ageagegtgt ggttggegee 600
cteggagtgg gagaccaggg cgcggactct cctggcgccc ccgccgccgc ccgggcgctc 660
gccaaaggag ttggagcgcg agctttgggc gctgccgctg tagagcgagg aggccgacgg 720 cgtgcggggc agggagcgac ggtctggctc tagctgggac gcgggcctcg cgtcgggctc 780
ggtgccgtag gagccggagc cgtgccggct gcggggggag ctgaactctc ccaggggcct 840
cgggggcatg tccaggcagg tgggcgtcag gcggcccgag gggtagggcg gccccagcgc 900
ggggcccagc aggccggggg agtgggcgcg cgacgggctg cggctggcct cagactgctc 960 cttccacagc agcacgcggt tctggagcat cccccgggcc cggccgaaga actgcaggaa 1020
ggtgttggaa agtagcaggt gcttctctgc taggaagcga tagcgccgct tctcttccaa 1080
ttcagccgcc cgctgactct cagacacgaa ggcctgcatc tgtgcgtgca gccggttcac 1140
acteteette ateteegga egitettgte tetettgege tecatgegee acageteaga 1200
catgcacttc tccaggttgg ccgctcggtg gcggtactcg agctcatagt gctggcggct 1260 gtctttgatg aactgcatgt ccagcttggt gttcttctcc atgtgctgca gcaggcctcc 1320
atggaatgte tgeaceacea cetecaggte agagtteaag tgeegetggg tgteagacat 1380
ctgcaccaag atctccccca gaatctgtga ggtggggctc tgcagggcac gctccccaat 1440
cttctggatg gcactgaagt agacctcggc cgcctcggac agagcgtgga aggcacgcag 1500
gtagttgttg cccaggtaca ccaggttete cagggegggg ttaaactget ccatgatget 1560
cttgtagatg gccatggtgg acctgtagaa ctggtccatc tcggggggcca tggaggggct 1620
gtcccgggtc tgagcaggag gctgggagct ggtggcgatg gcacagccgg gagcagtggt 1680
aggtagtece teaggtgeec acgaeteage tggeagegag gaagee
                                                                                   1726
```

<210> 205 <211> 1595 <212> DNA

```
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:482261.1:2000FEB18
ctccacgttg cgatggatcc ttggacccac ttttgttaac tcttaaactt tgtgtctttg 60
tetttattte titteteatt ecclegtete cacegggaag gggagageet gegggtggtg 120
tatcaggeag gttecectae atetttggea eccaacaegg teteetegaa eccaggtgaa 180
gttacacctg agcgtggtcg ttgtgaagaa cggtctgtcc aggaactccc gagaacgtgt 240 ggtcggcctt gcggtaagct tgtgcactcg gagcattcca gggacaccat gggacaatcc 300 aaaagtaaac attctgcata tttacatttt attaagctcc tcttaaagag ggcaggaatt 360
aaggetagea cagaaaattt gattactetg tttecaacag tagageaata ttgteettgg 420
tttcctgaac atggtaccat ggacttcaaa gattgggaac aggtgggaat tgccttaaaa 480
caagtttgta aggaaggaaa atttatcccc ctaacagcct ggtcaaactg ggctatagtt 540 aaagcagcct cggaaccgtt tcaatcggaa aatgaggctt atcctccagc agaaagaatt 600 tctgcagagg aaggtggtga tgctgctgaa ggaggagagg atagtgaaga agattttgag 660
gaaaatacag acaaacctgg agatgagtta atttetttg aggagcacgt gggaccttca 720
getgeteeta aaatagagaa gecatatatg ceaagatgtt taaaacaaag aagggeettg 780 aggageagte ggeteeteat tgggateate eggagtggee geeteeaata aageaatgta 840 gettggagee ttggaggeet ttgagggeet ttgaggageet ttgagageet ttgagageet ttgagageet tgaateteaaa tttgeeetgt tteaegaatg aatgaattgt 900
ggcctcagga accacaagcg catggtgtag caccagtaca acataaggct gcactgccat 960
ctaatgttaa tgaatcgcca ttacagttta ttattcggca ggctagatta gccggagatc 1020
ttgatgcctg gcagtttgca gtagttttgc aacccccacg acagcaaggt ggagcccatc 1080
aagcggtatg ggaaccattt tettttaage tgeteaaaga tettaaagea getgttggte 1140 agtatggtee caattegeet ttegteegat egetattgea atetgtgget cagaataage 1200
tattgactcc gtgtgattgg gagattttaa cgaaagttac actttcgccc tcccaatttc 1260 ttcagtttaa gacttggtgg accgacgagg ctcaaaatca gatcgaaaaa accgtgctgc 1320
taateetget attgecatta catttgaaca aettetagga atagggggte aatggggaac 1380
tgtaaacaac catcaggact tcgagatgat gccattgaac aaattcgcaa ttgctgtttg 1440 agggcatggg agaaaattca ggatctggga actacttatc agtcttttaa ttctattaga 1500
caaggeteaa aggaaceata teetgattte attgetegee tteaagaege ageacagaag 1560
geteteactg atgaaagtge caggaaggee gggtg
<210> 206
<211> 2006
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:480328.1:2000FEB18
<400> 206
gccacaagcc tcatatatca tgaccgaact catgctggtg aaaagtccta tgaatgtaaa 60
gaatgtgggg aaacttttag tcatgcttca catcttatta ttcatgagag aattcatacc 120
agtgataaac cctatgaatg taaaagatgt gggaaggcat ttcactgtgc ctcatatctt 180
gttagacatg aaagcgttca tgctgatgga aatccctata tgtgtgaaga gtgtgggaaa 240 gctttaata gtagccatga acttagtata catcatagag ttcatactgg tgagaaaccc 300 tttaaatgta acaaatgcag aaggtccttt aggcttagat ccatccttga agtacatcag 360
agaattcata tttgatagag aaattgtggc atatacaggt agtaaagaaa gcacattgtg 420
tcaatggatt tatcccactg aacaatttga atgaagacaa tgtggaatgg ctttgagata 480
cagttcagtt tttattaggc atcaatttgt attggtgtga acttttcaaa atgtaaatca 540
tatatgcagt ttctttggta tgacctgtgt taactccaga ttcagagaat ttataatgta 600 tttttttaat aacataagaa aacttttctg atattcctct agttttggat tgccaaaata 660
ttcatagtag aggaaaactg agaaaacgta ggaaaccatt ctttatactt gcatgtaaac 720
atcttccage aacaatcatt tattgttaaa cetggaaaaa gecattacac aggaaacete 780
tgttgatata agcgatgatg ggaaaggcta tttagccact ctgcatattt aatgctcatg 840
atcaacatct getteetata getgggatga tatgggggaa gatatttate cettetgggg 900 atcatatata aatgatgata gtagtaceta cagtatagtg etgttagaat tacatgagtt 960 agatgtggag gteagagtgg aageaggtgt gagagggtee egeagaagaa aacatggetg 1020
gtgaactctg ccttatgtaa tgtggatgct gggcacagag ctgccatctt tgaccaattc 1140 cgtggagtac agaacattgt ggtaggggaa gggactcact ttctcatccc atgtgtacaa 1200
aaaccaatta tetttgaetg etgtteteaa ceaegtagtg egecagteat caetggtage 1260 aaagatttae agaatgteaa catcacactg tgeateetet teeggeeeat caetageeag 1320
```

```
WO 01/62927
                                                                        PCT/US01/06059
cttcctcgca tcttcaccag cattggagag gactacgatg agtgtgtgct gccgttcatt 1380
accacggaga tecteaagte actggtgget egetttgatg etggagaact aatcacccag 1440
agggagctgg tetecageca ggtgagcaac aacettatgg agtgagcage cacetttggg 1500
ctcattctgg acgacgtgtc tttgacacat ctgaccttct tgaaggagtt aacagacagg 1560
tggccccca ggaagcagag agcgccagat ttgtggtgga aaaggcggcc atcatctctg 1620
ctgagggtga ctccaaggca gctgagctga tcgccaactc actggccact gcaggggacg 1680 gccagagcga gctgtgcaag ctggaagctg cagaagacat tgcataccag ctctcatgct 1740
cteggaacat cacetgeetg ceggeaggge agteegtget ceteeagetg ceetagtgag 1800
geoceageet acctgeacet cogtgaggea actgggecae ageocegatg attegtaaca 1860
ccacctttcg ccctcacccc agaaatcact gaaatttcat gattggctta aagtgaagga 1920
agtaaaggta aaatcacttc agatctctaa aaaacaaaga attacatgag ttagtacatg 1980
aaaaaattat gggaaactac atgaaa
                                                                                2006
<210> 207
<211> 984
<212> DNA
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: LG:311197.1:2000MAY19
<400> 207
getetecaeg tgegegaetg egaggetgga egetaeggge teetggaaag gagttaagat 60
gccaaatttg atatctggag cacctggaac cttgcagagt gttttgaaga ggaggttaca 120
atgaaaaaca aaacaaaaaa gaaattttgc tctgcaagtc tactgacaag tcccgtttcc 180
ttcccacatt ccaatctatg tctgcctttg tgttcagcag acaccagcat ttgccacaat 240 gctgtcatcc actgacttta catttgcttc ctgggagctt gtggtccgcg ttgaccatcc 300
caatgaagag cagcagaaag acgtcacact gagagtatet ggagacette acgttggagg 360
agtgatgete aagttagtag aacagateaa tatateeeaa gaetggteag aetttgetet 420
ttggtgggaa cagaagcatt gctggcttct gaaaacccac tggaccctgg acaaatatgg 480 ggtccaggca gatgcaaagc ttctcttcac ccctcagcat aaaatgctgc gccttcgtct 540
gccgaatttg aagatggtga ggttgcgagt cagcttctca gctgtggttt ttaaagctgt 600
cagtgatatc tgcaaaatcc tgaatattag aagatcagaa gagctttcct tgttaaagcc 660
gtctggtgac tattttaaga agaagaagaa aaaagacaaa aataataagg aacccataat 720 tgaagatatt ctaaacctgg agagttctcc aacagcttca ggttcatcag taagtcctgg 780
tttatacagt aaaaccatga cccctatata tgaccccatc aatggaacac cagcatcatc 840
caccatgact tggttcagtg acagcccttt gacggaacaa aactgcagca tcctcgcatt 900 cagccaaccc ccccagtccc cagaagcact tgcggatatg taccagcctc ggtctctggt 960
tgatacagcc aagctcaatg cagg
                                                                                984
<210> 208
<211> 565
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1054883.1:2000MAY19
<220>
<221> unsure
<222> 19
<223> a, t, c, g, or other
<400> 208
gcagagtgcc cctgaagang ccgacagccc ctgctccagt cacacccgga agctgactgg 60
tecaegeatg geogaageat gaggaagete ategttagat teatttttet taaattttgg 120
acttatacag taagggette aactaacett actcaaaatg gggactgtte ccagtgtatt 180 tatcaggtea ccgaagtagg acagcaaatt aaaacaatet ttetgtteta tagttattat 240 gaatgtatgg aaacattaaa agaaacttgt ttgtataatg ccactcagta caaggtatgt 300
agecegagaa atgaeegaee tgatgegtgt talaaceeat etgageeege tgeaaceaee 360
gtttttgaaa taagaactgg ccttttgcta ggtgatacaa gtaaaataat aactagaaca 420
gaagaaaaag aaatecccaa gcaaataact ttaagatttg atgettgtge agecattaat 480
agtaaaaagc tagaaatagg atgtggttct cttaactgag aaaggagcta aagagtagaa 540
```

aataaatatg tttgtcatga gtcag

```
<210> 209
<211> 567
<212> DNA
<213> Homo sapiens
<220> '
<221> misc_feature
<223> Incyte ID No: LG:399395.1:2000MAY19
<400> 209
acagttcaca cttactactg ttgtagttat aaattattca cttgttttaa ataagcacat 60
atatgatggc tgagtgagaa tgatctagaa ctatgccagg gattagataa aaacacagag 120
taaaagttgg ccatatagta acatttttga tgtccaaatt ggagaggaat ccctcaaatg 180
ttcaaaaata taggaatggg tegggtgtgg tggctcatgc ctgtaatccc agcactttgg 240 gaggccaagg caggaagatc acttgagccc aggagttcaa gaccagcctg ggcaacacag 300 tgagacctg actcaaaaa taaaaagaaa agacaaaaat acaagaatgg ctaagcaaac 360 tagtgtacat caacctggag gaatattata tagtctttta aaataacaaa tatgtagatt 420 gttaatacat gggaaaaggt atatgaaata ggtggaacca agcagaactg agtcccaagg 480
tgggtgggaa agaggctgcc atgctggctg aggtacctga gaacaatgaa aacaagtcat 540
attaagacca atatcaatat cccactg
<210> 210
<211> 971
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:380497.2:2000MAY19
tegeceegte egetgeagte egeeggegag ggagttaege aegteetgat teteetggag 60
telecageee geceagtgge egeagteace caggtecaga ggeggeggta teacaggete 120
tecgacatgt ctatgetgge tgaacgtegg eggaageaga agtgggetgt ggatecteag 180 aacactgeet ggagtaatga egattecaag tttggeeage ggatgetaga gaagatgggg 240 tggtetaaag gaaagggttt aggggeteag gageaaggag ecacagatea tattaaagtt 300 caagtgaaaa ataaccact gggaetegga getaccatea ataatgaaga caactggatt 360
gcccatcagg atgatttaa ccagcttetg gccgaactga acactgcca tgggcaggaa 420 accacagatt cctcggacaa gaaggaaaag aaatcttta gccttgagga aaagtccaaa 480 atctccaaaa accgtgttca ctatatgaaa ttcacaaaag ggcgatgcca gtccctccac 540 tccagaggag aacgaaacca cgacaaccag cgccttcacc atccaggagt actttgccaa 600
geggatggea geactgaaga acaageeeca ggtteeagtt ceagggtetg acatttetga 660
gacgcaggtg gaacgtaaaa gggggaagaa aagaaataaa gaggccacag gtaaagatgt 720 ggaaagttac ctccagccta aggccaagag gcacacggag ggaaagcccg agagggccga 780 ggcccaggag cgagtggcca agaagaagag cgcgccagca gaagagcagc tcagaggccc 840 ctgctgggac cagagttcca aggcctctgc tcaggatgca ggggaccatg tgcagccgcc 900
tgagggccgg gacttcaccc tgaaagccaa aaagaggaga ggcgagaaaa agctgcaaaa 960
accagtagag a
<210> 211
<211> 486
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:272913.22:2000MAY01
agegegacag eggeageace aagggaacgg aaaatggege etcaeggece gggtagtett 60
acgaecetgg tgeeetggge tgeegeeetg etectegete tgggegtgga aagggetetg 120
gcgctacccg agatatgcac ccaatgtcca gggagcgtgc aaaatttgtc aaaagtggcc 180
ttttattgta aaacgacacg agagctaatg ctgcatgccc gttgctgcct gaatcagaag 240 gaccctggtc caaactttca tcaggcacat accactgtca tcatagacct gcaagcaaac 300
cccctcaaag gtgacttggc caacaccttc cgtggcttta ctcagctcca gactctgata 360 ctgccacaac atgtcaactg ttctggagga attaatgcct ggaatactat cacctcttat 420
atagacaacc aaatctgtca agggcaaaag aacctttgca ataacactgg ggacccagaa 480
```

486

WO 01/62927 atgtgt <210> 212 <211> 115 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:1040582.1.orf3:2000FEB18 Ile Leu Ala Thr Leu Ser Ser Pro Gln Pro Val Leu Ile Ala Lys 10 Gly Thr Met Thr Ala Ser Ser Val Leu Leu His Thr Gly Gln Lys 20 25 30 Met Pro Leu Ile Gly Leu Gly Thr Trp Lys Ser Glu Pro Gly Gln 35 40 45 Val Lys Ala Ala Ile Lys Tyr Ala Leu Ser Val Gly Tyr Arg His 55 Ile Asp Cys Ala Ser Val Tyr Gly Asn Glu Thr Glu Ile Gly Glu 70 65 Ala Leu Lys Glu Ser Val Gly Ser Gly Lys Ala Val Pro Arg Glu 80 85 90 Glu Leu Phe Val Thr Ser Lys Leu Trp Asn Thr Lys His His Pro 95 100 Glu Asp Val Glu Pro Ala Leu Arg Lys Thr 110 <210> 213 <211> 161 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:453570.1.orf3:2000FEB18 <400> 213 Cys Thr Leu Leu Arg Leu Ile Pro Ser Ala Ser His Phe Lys Arg 10 Phe Asp Arg Val Arg Arg Phe Ala Pro Ala Ala Met Ala Thr Ser 20 25 Ser Gly Pro Lys Glu Ala Pro Ala Asn Asn Pro Gly Leu Gln Thr Glu Val Asp Pro Ala Thr Lys Gly Tyr Phe Leu Gln Gln Thr Met 50 55 Leu Arg Val Lys Asp Pro Lys Val Ser Leu Asp Phe Tyr Ser Arg 65 70 Val Met Gly Met Ser Leu Leu Lys Arg Leu Asp Phe Glu Glu Met 80 85 90 Lys Phe Ser Leu Tyr Phe Leu Gly Tyr Glu Asp Val Thr Leu Ala

<210> 214 <211> 332 <212> PRT

<213> Homo sapiens

95

110

125

140

155

Gly His Ile Gly Val Thr Val Asp Asp Val His

100

115

130

145

Pro Asp Asp His Ile Lys Arg Thr Glu Trp Thr Phe Arg Gln Lys

Ala Thr Leu Glu Leu Thr His Asn Trp Gly Thr Glu Asn Asp Pro

Glu Phe Lys Gly Tyr His Asn Gly Asn Ser Asp Pro Arg Gly Phe

105

120

<220> <221> misc_feature <223> Incyte ID No: LG:408751.3.orf2:2000FEB18 <400> 214 Arg Asp Pro Gly Trp Gln Ile Arg Asp Arg Ala Gly Leu Ala Trp 10 15 Asn Met Leu Ala Asn Ser Ala Ser Val Arg Ile Leu Ile Lys Gly 30 20 Gly Lys Val Val Asn Asp Asp Cys Thr His Glu Ala Asp Val Tyr 35 40 Ile Glu Asn Gly Ile Ile Gln Gln Val Gly Arg Glu Leu Met Ile 60 Pro Gly Gly Ala Lys Val Ile Asp Ala Thr Gly Lys Leu Val Ile 65 70 75 Pro Gly Gly Ile Asp Thr Ser Thr His Phe His Gln Thr Phe Met 80 85 90 Asn Ala Thr Cys Val Asp Asp Phe Tyr His Gly Thr Lys Ala Ala 95 100. Leu Val Gly Gly Thr Thr Met Ile Ile Gly His Val Leu Pro Asp 115 110 Lys Glu Thr Ser Leu Val Asp Ala Tyr Glu Lys Cys Arg Gly Leu 135 125 130 Ala Asp Pro Lys Val Cys Cys Asp Tyr Ala Leu His Val Gly Ile 140 145 Thr Trp Trp Ala Pro Lys Val Lys Ala Glu Met Glu Thr Leu Val 155 160 165 Arg Glu Lys Gly Val Asn Ser Phe Gln Met Phe Met Thr Tyr Lys 170 175 180 Asp Leu Tyr Met Leu Arg Asp Ser Glu Leu Tyr Gln Val Leu His 190 185 Ala Cys Lys Asp Ile Gly Ala Ile Ala Arg Val His Ala Glu Asn 200 205 Gly Glu Leu Val Ala Glu Gly Ala Lys Glu Ala Leu Asp Leu Gly 215 220 225 Ile Thr Gly Pro Glu Gly Ile Glu Ile Ser Arg Pro Glu Glu Leu 230 235 240 Glu Ala Glu Ala Thr His Arg Val Ile Thr Ile Ala Asn Arg Thr 250 255 245 His Cys Pro Ile Tyr Leu Val Asn Val Ser Ser Ile Ser Ala Gly 270 260 265 Asp Val Ile Ala Ala Ala Lys Met Gln Gly Lys Val Val Leu Ala 280 285 Glu Thr Thr Ala His Ala Thr Leu Thr Gly Leu His Tyr Tyr 290 295 300 His Gln Asp Trp Ser His Ala Ala Ala Tyr Val Thr Val Pro Pro 305 310 Leu Arg Leu Asp Thr Asn Thr Ser Thr Tyr Leu Met Ser Leu Leu 320 Ala Lys <210> 215 <211> 274 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:090574.1.orf3:2000FEB01 <400> 215 Ala Arg Asn Ser Ala Arg Val Pro Pro Arg Gly Thr Met Ser Arg 15 Tyr Arg Glu His Asn Gly Pro Ile His 20 25

Glu Phe Phe Pro Ile Ala Asp Gly Asp Gln Gln Ser Pro Ile Glu

```
Ile Lys Thr Lys Glu Val Lys Tyr Asp Ser Ser Leu Arg Pro Leu
                 50
                                      55
Ser Ile Lys Tyr Asp Pro Ser Ser Ala Lys Ile Ile Ser Asn Ser
                                      70
Gly His Ser Phe Asn Val Asp Phe Asp Asp Thr Glu Asn Lys Ser
Val Leu Arg Gly Gly Pro Leu Thr Gly Ser Tyr Arg Leu Arg Gln
                 95
                                     100
                                                         105
Val His Leu His Trp Gly Ser Ala Asp Asp His Gly Ser Glu His
                110
                                     115
                                                         120
Ile Val Asp Gly Val Ser Tyr Ala Ala Glu Leu His Val Val His
                125
                                     130
                                                         135
Trp Asn Ser Asp Lys Tyr Pro Ser Phe Val Glu Ala Ala His Glu
Pro Asp Gly Leu Ala Val Leu Gly Val Phe Leu Gln Ile Gly Glu
                155
                                     160
                                                         165
Pro Asn Ser Gln Leu Gln Lys Ile Thr Asp Thr Leu Asp Ser Ile
                170
                                     175
                                                         180
Lys Glu Lys Gly Lys Gln Thr Arg Phe Thr Asn Phe Asp Leu Leu
                185
                                     190
                                                         195
Ser Leu Leu Pro Pro Ser Trp Asp Tyr Trp Thr Tyr Pro Gly Ser
                                     205
                200
                                                         210
Leu Thr Val Pro Pro Leu Leu Glu Ser Val Thr Trp Ile Val Leu
                                     220
                                                         225
                215
Lys Gln Pro Ile Asn Ile Ser Ser Gln Gln Leu Ala Lys Phe Arg
                230
                                     235
                                                         240
Ser Leu Leu Cys Thr Ala Glu Gly Glu Ala Ala Ala Phe Leu Val
                                     250
                                                         255
                245
His His Leu Ala Thr Ile Pro Cys Gly Ser Ser Ala Thr Cys
                                                         270
                                     265
                260
Ser Gly His Cys
```

<210> 216 <211> 182 <212> PRT

<213> Homo sapiens

<220>
<221> misc_feature

<223> Incyte ID No: LI:229932.2.orf1:2000FEB01

<400> 216 Lys Leu Pro Leu Pro Pro Gly Ala Phe Ser Gly Leu Trp Lys Asn Gln Glu Ala Phe Lys His Leu Tyr Phe Glu Lys Phe Pro Gly Tyr 25 Tyr Asp Thr Met Asp Ala Gly Tyr Met Asp Glu Glu Gly Tyr Leu 40 Tyr Val Met Ser Arg Val Asp Asp Val Ile Asn Val Ala Gly His 50 55 60 Arg Ile Ser Ala Gly Ala Ile Glu Glu Ser Ile Leu Ser His Gly Thr Val Ala Asp Cys Ala Val Val Gly Lys Glu Asp Pro Leu Lys 85 Gly His Val Pro Leu Ala Leu Cys Val Leu Arg Lys Asp Ile Asn 95 100 Ala Thr Glu Glu Gln Val Leu Glu Glu Ile Val Lys His Val Arg 110 115 120 Gln Asn Ile Gly Pro Val Ala Ala Phe Arg Asn Ala Val Phe Val 125 130 135 Lys Gln Leu Pro Lys Thr Arg Ser Gly Lys Ile Pro Arg Ser Ala 140 145 Leu Ser Ala Ile Val Asn Gly Lys Pro Tyr Lys Ile Thr Ser Thr 155 160

Ile Glu Asp Pro Ser Ile Phe Gly His Val Glu Glu Met Leu Lys

15

170 175 180

40

Gln Ala

```
<210> 217
<211> 359
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:332176.1.orf2:2000FEB01
<400> 217
Leu Ile Lys Arg Ser Lys Gly Lys Glu Arg Pro Phe Val Leu Thr
                                      10
Arg Ser Phe Phe Ala Gly Ser Gln Lys Tyr Gly Ala Val Trp Thr
                                      25
Gly Asp Asn Thr Ala Glu Trp Ser Asn Leu Lys Ile Ser Ile Pro
```

35

50 55 Asp Ile Gly Gly Phe Ile Gly Asn Pro Glu Thr Glu Leu Leu Val 70 65 Arg Trp Tyr Gln Ala Gly Ala Tyr Gln Pro Phe Phe Arg Gly His

Met Leu Leu Thr Leu Ser Ile Thr Gly Ile Ser Phe Cys Gly Ala

80 85 Ala Thr Met Asn Thr Lys Arg Arg Glu Pro Trp Leu Phe Gly Glu 95 100 Glu His Thr Arg Leu Ile Arg Glu Ala Ile Arg Glu Arg Tyr Gly

110 115 120 Leu Leu Pro Tyr Trp Tyr Ser Leu Phe Tyr His Ala His Val Ala 125 130 135 Ser Gln Pro Val Met Arg Pro Leu Trp Val Glu Phe Pro Asp Glu 140 145

Leu Lys Thr Phe Asp Met Glu Asp Glu Tyr Met Leu Gly Ser Ala 155 160 Leu Trp Val His Pro Val Thr Glu Pro Lys Ala Thr Thr Val Asp 170 175

Val Phe Leu Pro Gly Ser Asn Glu Val Trp Tyr Asp Tyr Lys Thr 185 190 195 Phe Ala His Gly Glu Gly Cys Thr Val Lys Ile Pro Val Ala 205 200 210 Leu Asp Thr Ile Pro Val Phe Gln Arg Gly Gly Ser Val Ile Pro

215 220 225 Ile Lys Thr Thr Val Gly Lys Ser Thr Gly Trp Met Thr Glu Ser 230 235 240 Ser Tyr Gly Leu Arg Val Ala Leu Ser Thr Lys Gly Ser Ser Val 245 250

Gly Glu Leu Tyr Leu Asp Asp Gly His Ser Phe Gln Tyr Leu His 260 265 270 Gln Lys Gln Phe Leu His Arg Lys Phe Ser Phe Cys Ser Ser Val

280 285 275 Leu Ile Asn Ser Phe Ala Asp Gln Arg Gly His Tyr Pro Ser Lys

295 300 290 Cys Val Val Glu Lys Ile Leu Val Leu Gly Phe Arg Lys Glu Pro 305 310 315

Ser Ser Val Thr Thr His Ser Ser Asp Gly Lys Asp Gln Pro Val 325 320

Ala Phe Thr Tyr Cys Ala Lys Thr Ser Ile Leu Ser Leu Glu Lys 335 340 Leu Ser Leu Asn Ile Ala Thr Asp Trp Glu Val Arg Ile Ile 350 355

<210> 218

<211> 110

<212> PRT

<213> Homo sapiens

```
<220>
<221> misc_feature
<223> Incyte ID No: LI:403248.2.orf2:2000FEB01
Ser Pro Phe Ile Ser Leu Pro Cys Ser Ala Leu Leu Lys Pro Ser
Thr Glu Gln Pro Leu Tyr Ser Ser Leu Trp Gly Pro Ala Val
                 20
                                      25
Asp Gly Cys Asp Cys Val Ala Glu Gly Leu Trp Leu Pro Gln Leu
                 35
                                      40
His Val Gly Asp Trp Leu Val Phe Asp Asn Met Gly Ala Tyr Thr
                                      55
                                                          60
Val Gly Met Gly Ser Pro Phe Trp Gly Thr Gln Ala Cys His Ile
                                      70
                                                          75
Thr Tyr Ala Met Ser Arg Val Ala Trp Glu Ala Leu Arg Arg Gln
                 80
                                      85
                                                          90
Leu Met Ala Ala Glu Gln Glu Asp Asp Val Glu Gly Val Cys
                                                         Lvs
                 95
                                     100
                                                         105
Pro Leu Ser Cys Gly
<210> 219
<211> 549
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:220992.1.orf3:2000MAY19
<400> 219
Arg Pro Val Thr Ser Phe Ser Pro Leu Pro Gly Ser Cys Gly Gly
                                      10
Arg Leu Gly Thr Arg Thr Met Leu Gly Arg Ser Leu Arg Glu Val
                 20
                                                          30
Ser Ala Ala Leu Lys Gln Gly Gln Ile Thr Pro Thr Glu Leu Cys
                                      40
                                                          45
Gln Lys Cys Leu Ser Leu Ile Lys Lys Thr Lys Phe Leu Asn Ala
Tyr Ile Thr Val Ser Glu Glu Val Ala Leu Lys Gln Ala Glu Glu
                 65
                                      70
                                                          75
Ser Glu Lys Arg Tyr Lys Asn Gly Gln Ser Leu Gly Asp Leu Asp
                 80
                                      85
                                                          90
Gly Ile Pro Ile Ala Val Lys Asp Asn Phe Ser Thr Ser Gly Ile
                 95
                                     100
                                                         105
Glu Thr Thr Cys Ala Ser Asn Met Leu Lys Gly Tyr Ile Pro Pro
                                     115
                                                          120
Tyr Asn Ala Thr Val Val Gln Lys Leu Leu Asp Gln Gly Ala Leu
                125
                                     130
                                                         135
Leu Met Gly Lys Thr Asn Leu Asp Glu Phe Ala Met Gly Ser Gly
                140
                                     145
                                                          150
Ser Thr Asp Gly Val Phe Gly Pro Val Lys Asn Pro Trp Ser Tyr
                155
                                     160
                                                          165
Ser Lys Gln Tyr Arg Glu Lys Arg Lys Gln Asn Pro His Ser Glu
                170
                                     175
Asn Glu Asp Ser Asp Trp Leu Ile Thr Gly Gly Ser Ser Gly Gly
                                     190
                185
                                                          195
Ser Ala Ala Ala Val Ser Ala Phe Thr Cys Tyr Ala Ala Leu Gly
                200
                                     205
                                                          210
Ser Asp Thr Gly Gly Ser Thr Arg Asn Pro Ala Ala His Cys Gly
                215
                                                         225
                                     220
Leu Val Gly Phe Lys Pro Ser Tyr Gly Leu Val Ser Arg His Gly
                                                          240
                230
                                     235
Leu Ile Pro Leu Val Asn Ser Met Asp Val Pro Gly Ile Leu Thr
                245
                                     250
Arg Cys Val Asp Asp Ala Ala Ile Val Leu Gly Ala Leu Ala Gly
```

```
2.60
                                     265
                                                          270
Pro Asp Pro Arg Asp Ser Thr Thr Val His Glu Pro Ile Asn Lys
                275
                                     280
Pro Phe Met Leu Pro Ser Leu Ala Asp Val Ser Lys Leu Cys Ile
                                                          300
                290
                                     295
Gly Ile Pro Lys Glu Tyr Leu Val Pro Glu Leu Ser Ser Glu Val
                305
                                     310
Gln Ser Leu Trp Ser Lys Ala Ala Asp Leu Phe Glu Ser Glu Gly
                320
                                     325
                                                         330
Ala Lys Val Ile Glu Val Ser Leu Pro His Thr Ser Tyr Ser Ile
                335
                                     340
                                                          345
Val Cys Tyr His Val Leu Cys Thr Ser Glu Val Ala Ser Asn Met
                                     355
                350
                                                          360
Ala Arg Phe Asp Gly Leu Gln Tyr Gly His Arg Cys Asp Ile Asp
                                                          375
                365
                                     370
Val Ser Thr Glu Ala Met Tyr Ala Ala Thr Arg Arg Glu Gly Phe
                380
                                     385
Asn Asp Val Val Arg Gly Arg Ile Leu Ser Gly Asn Phe Phe Leu
                395
                                     400
                                                          405
Leu Lys Glu Asn Tyr Glu Asn Tyr Phe Val Lys Ala Gln Lys Val
                                     415
                                                          420
                410.
Arg Arg Leu Ile Ala Asn Asp Phe Val Asn Ala Phe Asn Ser Gly
                                                          435
                425
                                     430
Val Asp Val Leu Leu Thr Pro Thr Thr Leu Ser Glu Ala Val Pro
                                                          450
                440
                                     445
Tyr Leu Glu Phe Ile Lys Glu Asp Asn Arg Thr Arg Ser Ala Gln
                                     460
                455
Asp Asp Ile Phe Thr Gln Ala Val Asn Met Ala Gly Leu Pro Ala
                470
                                     475
                                                          480
Val Ser Ile Pro Val Ala Leu Ser Asn Gln Gly Leu Pro Ile Gly
                485
                                     490
                                                          495
Leu Gln Phe Ile Gly Arg Ala Phe Cys Asp Gln Gln Leu Leu Thr
                500
                                     505
Val Ala Lys Trp Phe Glu Lys Gln Val Gln Phe Pro Val Ile Gln
                                                          525
                515
                                     520
Leu Gln Glu Leu Met Asp Asp Cys Ser Ala Val Leu Glu Asn Glu
                530
Lys Leu Ala Ser Val Ser Leu Lys Gln
                545
<210> 220
<211> 264
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature ·
<223> Incyte ID No: LG:1094571.1.orf1:2000MAY19
Arg Thr Pro Ala Ala Arg Arg Pro Ala Leu Arg Phe Gly Pro Pro
                                      10
            Thr Pro Leu Thr Leu Gly Thr Tyr Phe Gly Cys Leu
                 20
                                      25
Arg Cys Pro Pro Ala Glu Thr Gln Leu Leu Arg Arg Pro Ala Val
                 35
                                      40
Phe Val Gly Ser'Ala Ala Ser Gly Ile Arg Ser Gly Leu Trp Ser
                 50
                                      55
Ala Ser Ser Gly His Trp Cys Ala Pro Ala Ala Gly Arg Ala His
                 65
                                      70
Ala Pro Val Pro Arg Leu Val Arg Gly Leu Gly Ala Ala Ser Thr
                 80
                                      85
Ala Ala Pro Gln Asp Ala Gln Thr Gly Pro Gln Pro Met Pro Arg
                 95
                                     100
                                                          105
Ala Asp Cys Ile Met Arg His Leu Pro Tyr Phe Cys Arg Gly Gln
                 110
                                     115
Val Val Arg Gly Phe Gly Arg Gly Ser Lys Gln Leu Gly Ile Pro
```

```
130
Thr Ala Asn Phe Pro Glu Gln Val Val Asp Asn Leu Pro Ala Asp
                140
                                     145
                                                          150
Ile Ser Thr Gly Ile Tyr Tyr Gly Trp Ala Ser Val Gly Ser Gly
                155
                                     160
                                                          165
Asp Val His Lys Met Val Val Ser Ile Gly Trp Asn Pro Tyr Tyr
                 170
                                     175
Lys Asn Thr Lys Lys Ser Met Glu Thr His Ile Met His Thr Phe
                185
                                     190
                                                          195
Lys Glu Asp Phe Tyr Gly Glu Ile Leu Asn Val Ala Ile Val Gly
                200
                                     205
Tyr Leu Arg Pro Glu Lys Asn Phe Asp Ser Leu Glu Ser Leu Ile
                215
                                     220
Ser Ala Ile Gln Gly Asp Ile Glu Glu Ala Lys Lys Arg Leu Glu
                 230
Leu Pro Glu His Leu Lys Ile Lys Glu Asp Asn Phe Phe Gln Val
                245
Ser Lys Ser Lys Ile Met Asn Gly His
                260
<210> 221
<211> 701
```

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: LI:350754.4.orf3:2000MAY01

<400> 221 Glu Glu Ala Glu Glu Gly Arg Asn Met Ala Ala Leu Gly Val Gln Ser Ile Asn Trp Gln Lys Ala Phe Asn Arg Gln Ala His His Thr 20 Asp Lys Phe Ser Ser Gln Glu Leu Ile Leu Arg Arg Gly Gln Asn 40 35 Phe Gln Val Leu Met Ile Met Asn Lys Gly Leu Gly Ser Asn Glu Arg Leu Glu Phe Ile Asp Thr Thr Gly Pro Tyr Pro Ser Glu Ser 70 75 65 Ala Met Thr Lys Ala Val Phe Pro Leu Ser Asn Gly Ser Ser Gly 85 80 Gly Trp Ser Ala Val Leu Gln Ala Ser Asn Gly Asn Thr Leu Thr 100 105 95 Ile Ser Ile Ser Ser Pro Ala Ser Ala Pro Ile Gly Arg Tyr Thr 110 115 120 Met Ala Leu Gln Ile Phe Ser Gln Gly Gly Ile Ser Ser Val Lys 125 130 135 Leu Gly Thr Phe Ile Leu Leu Phe Asn Pro Trp Leu Asn Val Asp 140 145 150 Ser Val Phe Met Gly Asn His Ala Glu Arg Glu Glu Tyr Val Gln 155 160 165 Glu Asp Ala Gly Ile Ile Phe Val Gly Ser Thr Asn Arg Ile Gly 170 175 Met Ile Gly Trp Asn Phe Gly Gln Phe Glu Glu Asp Ile Leu Ser 185 190 Ile Cys Leu Ser Ile Leu Asp Arg Ser Leu Asn Phe Arg Arg Asp 200 205 210 Ala Ala Thr Asp Val Ala Ser Arg Asn Asp Pro Lys Tyr Val Gly 215 225 220 Arg Val Leu Ser Ala Met Ile Asn Ser Asn Asp Asp Asn Gly Val 230 235 240 Leu Ala Gly Asn Trp Ser Gly Thr Tyr Thr Gly Gly Arg Asp Pro 245 250 255 Arg Ser Trp Asp Gly Ser Val Glu Ile Leu Lys Asn Trp Lys Lys 260 265 Ser Gly Phe Ser Pro Val Arg Tyr Gly Gln Cys Trp Val Phe Ala

```
285
                275
                                     280
Gly Thr Leu Asn Thr Ala Leu Arg Ser Leu Gly Ile Pro Ser Arg
                290
                                     295
Val Ile Thr Asn Phe Asn Ser Ala His Asp Thr Asp Arg Asn Leu
                305
                                     310
Ser Val Asp Val Tyr Tyr Asp Pro Met Gly Asn Pro Leu Asp Lys
                320
                                     325
                                                          330
Gly Ser Asp Ser Val Trp Asn Phe His Val Trp Asn Glu Gly Trp
                335
                                     340
                                                         345
Phe Val Arg Ser Asp Leu Gly Pro Pro Tyr Gly Gly Trp Gln Val
                350
                                     355
                                                          360
Leu Asp Ala Thr Pro Gln Glu Arg Ser Glr
                                         Gly Val Phe Gln
                                                          CVS
                365
                                     370
                                                          375
Gly Pro Ala Ser Val Ile Gly Val Arg Glu Gly Asp
                                                 Val Gln Leu
                                     385
                                                          390
                380
Asn Phe Asp Met Pro Phe Ile Phe Ala Glu Val Asn Ala Asp Arg
                395
                                                          405
                                     400
Ile Thr Trp Leu Tyr Asp Asn Thr Thr Gly Lys Gln Trp Lys Asn
                410
                                     415
                                                          420
Ser Val Asn Ser His Thr Ile Gly Arg Tyr Ile Ser Thr Lys Ala
                425
                                     430
                                                          435
Val Gly Ser Asn Ala Arg Met Asp Val Thr Asp Lys Tyr Lys Tyr
                440
                                     445
                                                          450
Pro Glu Gly Ser Asp Gln Glu Arg Gln Val Phe Gln Lys Ala Leu
                                                          465
                455
                                     460
Gly Lys Leu Lys Pro Asn Thr Pro Phe Ala Ala Thr Ser Ser Met
                470
                                     475
Gly Leu Glu Thr Glu Glu Glu Pro Ser Ile Ile Gly Lys Leu
                                     490
                                                          495
                485
Lys Val Ala Gly Met Leu Ala Val Gly Lys Glu Val Asn Leu Val
                                     505
                500
                                                          510
Leu Leu Leu Lys Asn Leu Ser Arg Asp Thr Lys Thr Val Thr Val
                                     520
                                                          525
                515
Asn Met Thr Ala Trp Thr Ile Ile Tyr Asn Gly Thr Leu Val His
                530
                                     535
                                                          540
Glu Val Trp Lys Asp Ser Ala Thr Met Ser Leu Asp Pro Glu Glu
                                     550
                                                          555
                545
Glu Ala Glu His Pro Ile Lys Ile Ser Tyr Ala Gln Tyr Glu Arg
                560
                                     565
                                                          570
Tyr Leu Lys Ser Asp Asn Met Ile Arg Ile Thr Ala Val Cys Lys
                575
                                     580
Val Pro Asp Glu Ser Glu Val Val Val Glu Arg Asp Ile Ile Leu
                590
                                     595
                                                          600
Asp Asn Pro Thr Leu Thr Leu Glu Val Leu Asn Glu Ala Arg Val
                                                          615
                605
                                     610
Arg Lys Pro Val Asn Val Gln Met Leu Phe Ser Asn Pro Leu Asp
                                     625
                620
Glu Pro Val Arg Asp Cys Val Leu Met Val Glu Gly Ser Gly Leu
                635
                                     640
                                                          645
Leu Leu Gly Asn Leu Lys Ile Asp Val Pro Thr Leu Gly Pro Lys
                650
                                     655
                                                          660
Glu Arg Ser Arg Val Arg Phe Asp Ile Leu Pro Ser Arg Ser Gly
                                                          675
                665
                                     670
Thr Lys Gln Leu Leu Ala Asp Phe Ser Cys Asn Lys Phe Pro Ala
                                     685
                680
Ile Lys Ala Met Leu Ser Ile Asp Val Ala Glu
                695
                                     700
<210> 222
```

<211> 150

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: LI:255828.29.orf2:2000MAY01

```
<400> 222
Cys Thr Ile Gly Pro Ala Ser Arg Ser Val Glu Thr Leu Lys Glu
Met Ile Lys Ser Gly Met Asn Val Ala Arg Leu Asn Phe Ser His
Gly Thr His Glu Tyr His Ala Glu Thr Ile Lys Asn Val Arg Thr
                                      40
Ala Thr Glu Ser Phe Ala Ser Asp Pro Ile Leu Tyr Arg Pro Val
                 50
                                      55
Ala Val Ala Leu Asp Thr Lys Gly Pro Glu Ile Arg Thr Gly Leu
                                      70
Ile Lys Gly Ser Gly Thr Ala Glu Val Glu Leu Lys Lys Ala Ala
Thr Leu Lys Ile Thr Leu Asp Asn Ala Tyr Met Glu Lys Cys Asp
                                     100
                 95
Glu Asn Ile Leu Trp Leu Asp Tyr Lys Asn Ile Cys Lys Val Val
                110
                                     115
                                                         120
Glu Val Ser Arg Leu His His Ala Val Trp Arg Asn Ser Gln Arg
                125
                                     130
                                                         135
Gly Leu Ser Ser Gly Gly Cys Ala His Ala Ala Pro Asp Ser Ser
                                     145
<210> 223
<211> 234
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:1190263.1.orf2:2000MAY01
<400> 223
Ala Ala Gly Ser Leu Phe Pro Gly Leu Leu Ile Phe Ser Met Ile
Leu Phe Ile Phe Leu Leu Gly Tyr Ala Trp Phe Ser Ser His Thr
Ser Pro Leu Tyr Trp Asp Cys Leu Leu Met Arg Gly His Glu Ile
                                      40
                                                          45
Thr Glu Gln Pro Met Lys Ala Glu Arg Ala Gly Ser Ile Met Val
                 50
Lys Glu Ala Ile Ser Phe Leu Glu Arg His Ser Lys Glu Thr Phe
                 65
Leu Leu Phe Phe Ser Phe Leu His Val His Thr Pro Leu Pro Thr
Thr Asp Asp Phe Thr Gly Thr Ser Lys His Gly Leu Tyr Gly Asp
                 95
                                     100
                                                         105
Asn Val Asp Glu Met Asp Ser Met Val Gly Lys Ile Leu Asp Ala
                110
                                     115
                                                         120
Ile Asp Asp Phe Gly Leu Arg Asn Asn Thr Leu Val Tyr Phe Thr
                125
                                     130
                                                         135
Ser Asp His Gly Gly His Leu Glu Ala Arg Arg Gly His Ala Gln
                140
                                     145
                                                         150
Leu Gly Gly Trp Asn Gly Ile Tyr Lys Gly Gly Lys Gly Met Gly
                155
                                     160
                                                         165
Gly Trp Glu Gly Gly Ile Arg Val Pro Gly Ile Val Arg Trp Pro
                170
                                     175
                                                         180
Gly Lys Val Pro Ala Gly Arg Leu Ile Lys Glu Pro Thr Ser Leu
                185
                                     190
                                                         195
Met Asp Ile Leu Pro Thr Val Ala Ser Val Ser Gly Gly Ser Leu
                200
                                     205
                                                         210
Pro Gln Asp Arg Val Ile Asp Gly Arg Asp Leu Met Pro Leu Leu
                215
                                     220
Ala Gly Gln Arg Gln Ala Leu Gly Ala
                230
```

<210> 224

```
<211> 86
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:270916.2.orf2:2000FEB18
<400> 224
Lys Phe Ser Ser Asn Gly Leu Trp Pro Ser Thr Trp Leu Leu Thr
                                      10
Thr Arg Thr Leu Pro Met Ile Ser Arg Cys Ser Pro Met His Leu
                 20
                                      25
                                                           30
Leu Thr Ile Ser Ser Ala Phe Cys Leu Leu Cys Pro Pro Pro Arg
                                                           45
                 35
                                      40
Met Pro Phe Gln Lys Cys Leu Leu Ser Arg Tyr Arg Ser Arg
                  50
                                      55
                                                           60
Gly Val Leu Val Ala Val Ile Trp Gly Thr Thr Glu Ala Ser Gly
                 65
                                      70
Ile Ser Gly Leu Ile Thr Ala Leu Trp Glu Phe
                 80
<210> 225
<211> 173
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:999414.3.orf2:2000FEB18
<400> 225
Ile Leu Thr Ser Val Ser Ser Ser Phe Trp Cys Pro Phe Phe Leu
                                                           15
                                      10
Ser Leu Leu Asp Ser Gln Leu His Ser Trp Ile Val Leu Gln Leu
                                      25
                  20
Thr Ile Ile Lys Asn Val Glu Ile Ser Asn Leu Val Cys Asp Pro
                                                           45
                 35
                                      40
Ser Gln Leu Leu Asn Leu Ala Cys Ser Asp Ser Val Ile Asp Ser
                 50
                                      55
                                                           60
Ile Phe Ile Tyr Leu Asp Ser Thr Ile Phe Gly Phe Leu Pro Ile
                  65
                                      70
Ser Gly Ile Leu Leu Ser Tyr Tyr Lys Ile Val Pro Ser Ile Leu
                                      85
                                                           90
Arg Ile Ser Ser Ser Asp Gly Lys Tyr Lys Ala Phe Ser Thr Cys
                 95
                                     100
Arg Ser His Leu Ala Val Val Cys Leu Phe Tyr Gly Thr Gly Ile
                110
                                     115
                                                          120
Gly Val Tyr Leu Thr Ser Ala Val Ala Pro Ala Pro Arg Ser Gly
                                                          135
                125
                                     130
Val Val Val Ser Val Met Tyr Thr Val Val Thr Pro Met Leu Asn
                                     145
                                                          150
                140
Pro Phe Ile Tyr Cys Leu Arg Lys Gln Gly His Ser Lys Arg Leu
                155
                                     160
                                                          165
Trp Arg Cys Ala Ala Glu Gln Ser
                170
<210> 226
<211> 68
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:429446.1.orf2:2000FEB18
```

113/228

<400> 226

```
His Leu Val Ala Thr Val Arg Gly Phe Ser Lys Val Phe Val Ser
                                     10
Ser Arg Ile Lys Thr Val Lys Leu Gln Ile Val Leu Gln Met Glu
                 20
                                                          30
Pro Gln Met Gln Ser Met Thr Lys Ile Tyr His Arg Pro Leu Asp
                 35
                                     40
                                                          45
Arg Pro Ala Ser Pro Cys Ser Asp Val Asp Asp Ile Glu Gly Ala
                - 50
                                     55
Pro Pro Lys Glu Ile Ser Thr Ala
<210> 227
<211> 70
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:057229.1.orf1:2000FEB01
<400> 227
Gln Pro Ser Leu Pro Glu Phe Ser His Phe Gln Lys Thr Val Leu
                                      10
Leu Glu Ser Lys Ile Ala Arg Gln Phe Ile Leu Phe Tyr Phe Ile
                 20
                                     25
Leu His Ile Phe Leu Arg Gln Ser Leu Ala Leu Phe Pro Arg Leu
                 35
                                      40
                                                          45
Glu Cys Gly Gly Ala Val Leu Ala His Cys Asn Leu Cys Leu Leu
                                      55
                 50
Gly Ser Ser Asp Ser Pro Ala Ser Ala Ser
                 65.
<210> 228
<211> 117
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:351965.1.orf2:2000FEB01
<400> 228
Pro Thr Thr Ser Asn Arg Ala Ile Thr Leu Thr Ala Arg Pro Lys
                                      10
Ile Pro Phe Leu Arg Ile Arg Glu Ala Lys Asn Pro Arg Ser Glu
                 20
                                      25
                                                          30
Asn Met Arg Leu Ala Thr Ile Leu Glu Val Ala Cys Arg His Phe
Gly Ser Gly Leu Pro Pro Ser Trp Glu Leu Trp Glu Gln Gly Pro
                 50
                                      55
Pro Gly Asn Ser Ser Arg Tyr Ile Glu Phe Leu Asn Lys His Thr
                 65
                                      70
Tyr Ile Lys Gly Thr Leu Arg Val Tyr Thr Lys Lys Phe Cys Met
                 80
                                      85
                                                           90
Leu Val Ile Lys Ser Phe Glu Ser Lys Ser Cys Val Cys Val Tyr
                 95
                                     100
Asp Phe Asp Ser Lys Ser Ser Val Asn Val Thr Val
                ,110
<210> 229
<211> 294
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
```

114/228

<223> Incyte ID No: LG:068682.1.orf2:2000FEB18

```
<400> 229
Gln Arg Pro Met Ser Gly Ser Gly His Met Gly Val Arg Gly Cys
                                      10
Arg Cys Gln Ala Pro Trp Leu Arg Pro Glu Ile Gly Val Arg Pro
Pro Pro Arg Ser Gln Ala Ala Ser Cys Pro Pro Cys Ala Leu Gly
                 35
                                      40
Ala Thr Met Ser Gly Asp Lys Leu Leu Ser Glu Leu Gly Tyr Lys
                                      55
                 50
Leu Gly Arg Thr Ile Gly Glu Gly Ser Tyr Ser Lys Val Lys Val
                                      70
                                                           75
                 65
Ala Thr Ser Lys Lys Tyr Lys Gly Thr Val Ala Ile Lys Val Val
                 80
                                      85
                                                           90
Asp Arg Arg Ala Pro Pro Asp Phe Val Asn Lys Phe Leu Pro
                                                          105
                                     100
Arg Glu Leu Ser Ile Leu Arg Gly Val Arg His Pro His Ile Val
                110
                                     115
His Val Phe Glu Phe Ile Glu Val Cys Asn Gly Lys Leu Tyr Ile
                                     130.
                                                          135
                125
Val Met Glu Ala Ala Ala Thr Asp Leu Leu Gln Ala Val Gln Arg
                                                          150
                140
                                     145
Asn Gly Arg Ile Pro Gly Val Gln Ala Arg Asp Leu Phe Ala Gln
                155
                                     160
                                                          165
Ile Ala Gly Ala Val Arg Tyr Leu His Asp His His Leu Val His
                170
                                     175
                                                          180
Arg Asp Leu Lys Cys Glu Asn Val Leu Leu Ser Pro Asp Glu Arg
                                     190
                185
Arg Val Lys Leu Thr Asp Phe Gly Phe Gly Arg Gln Ala His Gly
                200
                                     205
Tyr Pro Asp Leu Ser Thr Thr Tyr Cys Gly Ser Ala Ala Tyr Ala
                                                          225
                                     220
                215
Ser Pro Glu Val Leu Leu Gly Ile Pro Tyr Asp Pro Lys Lys Tyr
                                                          240
                                     235
                230
Asp Val Trp Ser Met Gly Val Val Leu Tyr Val Met Val Thr Gly
                                     250
                245
Cys Met Pro Phe Asp Asp Ser Asp Ile Ala Gly Leu Pro Arg Arg
                260
                                     265
                                                          270
Gln Lys Arg Gly Val Leu Tyr Pro Glu Gly Leu Glu Leu Ser Glu
                 275
                                     280
                                                          285
Arg Cys Lys Ala Leu Ile Ala Glu Leu
                290
<210> 230
<211> 326
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:242665.1.orf1:2000FEB18
<400> 230
His His Leu Ile Ser Leu Tyr Phe Thr Asp Phe Pro Ile Ser Phe
                                      10
                                                           15
Phe Met Phe Tyr Ala Asn Phe Ser Arg Arg Thr Gly Pro Ala Pro
                  20
                                      25
Pro Leu Arg Thr Thr Pro Arg Ala Trp Leu Arg Arg Glu Cys Gly
                                                           45
                 35
                                      40
Ala Ser Thr Met Ser Ala Pro Gly Ser Pro
                                         Asp Gln Ala Tyr Asp
                 50
                                      55
                                                           60
Phe Leu Leu Lys Phe Leu Leu Val Gly Asp
                                         Arg Asp Val Gly Lys
                                      70
                 65
Ser Glu Ile Leu Glu Ser Leu Gln Asp Gly Ala Ala Glu Ser Pro
                  80
                                      85
                                         Thr Thr Thr Ile Leu
Tyr Ser His Leu Gly Gly Ile Asp Tyr Lys
```

100

Leu Asp Gly Gln Arg Val Lys Leu Lys Leu Trp Asp Thr Ser Gly

WO 01/62927 PCT/US01/06059 Gln Gly Arg Phe Cys Thr Ile Phe Arg Ser Tyr Ser Arg Gly Ala Gln Gly Val Ile Leu Val Tyr Asp Ile Ala Asn Arg Trp Ser Phe Glu Gly Met Asp Arg Trp Ile Lys Lys Ile Glu Glu His Ala Pro Gly Val Pro Lys Ile Leu Val Gly Asn Arg Leu His Leu Ala Phe Lys Arg Gln Val Pro Arg Glu Gln Ala Gln Ala Tyr Ala Glu Arg Leu Gly Val Thr Phe Phe Glu Val Ser Pro Leu Cys Asn Phe Asn Ile Ile Glu Ser Phe Thr Glu Leu Ala Arg Ile Val Leu Leu Arg His Arg Met Asn Trp Leu Gly Arg Pro Ser Lys Val Leu Ser Leu Gln Asp Leu Cys Cys Arg Thr Ile Val Ser Cys Thr Pro Val His Leu Val Asp Lys Leu Pro Leu Pro Ser Thr Leu Arg Ser His Leu Lys Ser Phe Ser Met Ala Lys Gly Leu Asn Ala Arg Met Met Arg Gly Leu Ser Tyr Ser Leu Thr Thr Ser Ser Thr His Lys Arg Ser Ser Leu Cys Lys Val Lys Ile Val Cys Pro Pro Gln Ser Pro Pro Lys Asn Cys Thr Arg Asn Ser Cys Lys Ile Ser **'<210> 231** <211> 182 <212> PRT <213> Homo sapiens <220> <221> misc feature <223> Incyte ID No: LG:241743.1.orf1:2000FEB18 <400> 231 Lys Ser Gly Thr Pro Arg Arg Ala Leu Leu Leu Phe Leu Val Phe Lys Ile Arg Gly Ser Pro Val Ser His Leu Met Pro Arg Leu Lys Glu Ser Arg Ser His Glu Ser Leu Leu Ser Pro Ser Ser Ala Val Glu Ala Leu Asp Leu Ser Met Glu Glu Glu Val Val Ile Lys Pro Val His Ser Ser Ile Leu Gly Gln Asp Tyr Cys Phe Glu Val Thr Thr Ser Ser Gly Ser Lys Cys Phe Ser Cys Arg Ser Ala Ala Glu Arg Asp Lys Trp Met Glu Asn Leu Arg Arg Ala Val His Pro Asn

Lys Asp Asn Ser Arg Arg Val Glu His Ile Leu Lys Leu Trp Val

Ile Glu Ala Lys Asp Leu Pro Ala Lys Lys Lys Tyr Leu Cys Glu

Leu Cys Leu Asp Asp Val Leu Tyr Ala Arg Thr Thr Gly Lys Leu

Lys Thr Asp Asn Val Phe Trp Gly Glu His Phe Glu Phe His Asn

Leu Pro Pro Leu Arg Thr Val Thr Val His Leu Tyr Arg Glu Thr

116/228

Asp Lys

```
<210> 232
<211> 358
<212> PRT
<213> Homo sapiens
<220> '
<221> misc_feature
<223> Incyte ID No: LI:034212.1.orf1:2000FEB01
<220>
<221> unsure
<222> 25
<223> unknown or other
<400> 232
Asn Ser Ser Leu Thr Gln Leu Arg Arg Leu Glu Glu Leu Asp Leu
                                      10
Gly Asn Asn Glu Ile Tyr Asn Leu Pro Xaa Ser Ile Gly Ala Leu
                 20
                                      25
Leu His Leu Lys Asp Leu Trp Leu Asp Gly Asn Gln Leu Ser Glu
                                      40
                 35
Leu Pro Gln Glu Ile Gly Asn Leu Lys Asn Leu Leu Cys Leu Asp
                                      55
                                                           60
                 50
Val Ser Glu Asn Arg Leu Glu Arg Leu Pro Glu Glu Ile Ser Gly
                                                           75
                 65
                                      70
Leu Thr Ser Leu Thr Asp Leu Val Ile Ser Gln Asn Leu Leu Glu
                 80
                                      85
Thr Ile Pro Asp Gly Ile Gly Lys Leu Lys Lys Leu Ser Ile Leu
                 95
                                     100
Lys Val Asp Gln Asn Arg Leu Thr Gln Leu Pro Glu Ala Val Gly
                110
                                     115
                                                          120
Glu Cys Glu Ser Leu Thr Glu Leu Val Leu Thr Glu Asn Gln Leu
                125
                                     130
Leu Thr Leu Pro Lys Ser Ile Gly Lys Leu Lys Lys Leu Ser Asn
                                     145
                                                          150
                140
Leu Asn Ala Asp Arg Asn Lys Leu Val Ser Leu Pro Lys Glu Ile
                                     160
                155
Gly Gly Cys Cys Ser Leu Thr Val Phe Cys Val Arg Asp Asn Arg
                                     175
                                                          180
                170
Leu Thr Arg Ile Pro Ala Glu Val Ser Gln Ala Thr Glu Leu His
                                     190
                185
                                                          195
Val Leu Asp Val Ala Gly Asn Arg Leu Leu His Leu Pro Leu Ser
                200
                                     205
                                                          210
Leu Thr Ala Leu Lys Leu Lys Ala Leu Trp Leu Ser Asp Asn Gln
                                     220
                215
Ser Gln Pro Leu Leu Thr Phe Gln Thr Asp Thr Asp Tyr Thr Thr
                230
                                     235
Gly Glu Lys Ile Leu Thr Cys Val Leu Leu Pro Gln Leu Pro Ser
                245
                                     250
                                                          255
Glu Pro Thr Cys Gln Glu Asn Leu Pro Arg Cys Gly Ala Leu Glu
                                                          270
                260
                                     265
Asn Leu Val Asn Asp Val Ser Asp Glu Ala Trp Asn Glu Arg Ala
                275
                                     280
                                                          285
Val Asn Arg Val Ser Ala Ile Arg Phe Val Glu Asp Glu Lys Asp
                                     295
                                                          300
                290
Glu Glu Asp Asn Glu Thr Arg Thr Leu Leu Arg Arg Ala Thr Pro
                305
                                     310
His Pro Gly Glu Leu Lys His Met Lys Lys Thr Val Glu Asn Leu
                                     325
                320
                                                          330
Arg Asn Asp Met Asn Ala Ala Lys Gly Leu Asp Ser Asn Lys Asn
                335
                                     340
                                                          345
Glu Val Asn His Ala Ile Asp Arg Val Thr Thr Ser Val
                350
                                     355
<210> 233
<211> 194
<212> PRT
```

117/228

```
WO 01/62927

<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No:

<400> 233
Glu Lys Met Gly Lys
1 5
Ser Val Gly Lys Thr
```

<223> Incyte ID No: LG:344886.1.orf1:2000MAY19 <400> 233 Glu Lys Met Gly Lys Gly Cys Lys Val Val Cys Gly Leu Leu Ser Val Gly Lys Thr Ala Ile Leu Glu Gln Leu Leu Tyr Gly Asn 20 His Thr Ile Gly Met Glu Asp Cys Glu Thr Met Glu Asp Val Tyr 45 35 40 Met Ala Ser Val Glu Thr Asp Arg Gly Val Lys Glu Gln Leu His 55 60 Leu Tyr Asp Thr Arg Gly Leu Gln Glu Gly Val Glu Leu Pro Lys 70 His Tyr Phe Ser Phe Ala Asp Gly Phe Val Leu Val Tyr Ser Val 80 85 90

Asn Asn Leu Glu Ser Phe Gln Arg Val Glu Leu Leu Lys Lys Glu 95 100 105 Ile Asp Lys Phe Lys Asp Lys Lys Glu Val Ala Ile Val Val Leu 110 115 120 Gly Asn Lys Ile Asp Leu Ser Glu Gln Arg Gln Val Asp Ala Glu 125 130 135 Val Ala Gln Gln Trp Ala Lys Ser Glu Lys Val Arg Leu Trp Glu 140 145 150 Val Thr Val Thr Asp Arg Lys Thr Leu Ile Glu Pro Phe Thr Leu

155 160 165

Leu Ala Ser Lys Leu Ser Gln Pro Gln Ser Lys Ser Ser Phe Pro
170 175 180

Leu Pro Gly Arg Lys Asn Lys Gly Asn Ser Asn Ser Glu Asn
185 190

<210> 234 <211> 222

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: LG:228930.1.orf2:2000MAY19

<400> 234

Ala Gln Met Ala Gly Ala Gln Pro Gly Val His Ala Leu Gln Leu Lys Pro Val Cys Val Ser Asp Ser Leu Lys Lys Gly Thr Lys Phe Val Lys Trp Asp Asp Ser Thr Ile Val Thr Pro Ile Ile Leu 35 40 Arg Thr Asp Pro Gln Gly Phe Phe Tyr Trp Thr Asp Gln Asn 50 55 60 Lys Glu Thr Glu Leu Leu Asp Leu Ser Leu Val Lys Asp Ala Arg 70 Cys Gly Arg His Ala Lys Ala Pro Lys Asp Pro Lys Leu Arg Glu Leu Leu Asp Val Gly Asn Ile Gly Arg Leu Glu Gln Arg Met Ile 100 Thr Val Val Tyr Gly Pro Asp Leu Val Asn Ile Ser His Leu Asn 110 115 120 Leu Val Ala Phe Gln Glu Glu Val Ala Lys Glu Trp Thr Asn Glu 130 125 135 Val Phe Ser Leu Ala Thr Asn Leu Leu Ala Gln Asn Met Ser Arg 145 150 140 Asp Ala Phe Leu Glu Lys Ala Tyr Thr Lys Leu Lys Leu Gln Val 155 160 Thr Pro Glu Gly Arg Ile Pro Leu Lys Asn Ile Tyr Arg Leu Phe

```
170
                                     175
                                                          180
Ser Ala Asp Arg Lys Arg Val Glu Thr Ala Leu Glu Ala Cys Ser
                                    190
                                                          195
                185
Leu Pro Ser Ser Arg Val Glu Lys Ala Asn Glu Ala Ala Lys Ser
                200
                                     205
                                                          210
Glu Gln Ser Cys Gly Lys Ala Pro Pro Lys His Phe
                215
                                     220
<210> 235
<211> 185
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:338927.1.orf3:2000MAY19
<400> 235
Leu Arg Ser Thr Pro Glu Thr Gly Arg Met Lys Gly Ala Ser Glu
                                      10
Glu Lys Leu Ala Ser Val Ser Asn Leu Val Thr Val Phe Glu Asn
                                      25
                                                           30
                 20
Ser Arg Thr Pro Glu Ala Ala Pro Arg Gly Gln Arg Leu Glu Asp
                 35
                                      40
Val His His Arg Pro Glu Cys Arg Pro Pro Glu Ser Pro Gly Pro
                                                           60
                 50
                                      55
Arg Glu Lys Thr Asn Val Gly Glu Ala Val Gly Ser Glu Pro Arg
                                                           75
                                      70
                 65
Thr Val Ser Arg Arg Tyr Leu Asn Ser Leu Lys Asn Lys Leu Ser
                                                           90
                 80
                                      85
Ser Glu Ala Trp Arg Lys Ser Cys Gln Pro Val Thr Leu Ser Gly
                 95
                                     100
                                                          105
Ser Gly Thr Gln Glu Pro Glu Lys Lys Ile Val Gln Glu Leu Leu
                110
                                     115
                                                          120
Glu Thr Glu Gln Ala Tyr Val Ala Arg Leu His Leu Leu Asp Gln
                                     130
                125
Val Phe Phe Gln Glu Leu Leu Lys Thr Ala Arg Ser Ser Lys Ala
                140
                                     145
Phe Pro Glu Asp Val Val Arg Val Ile Phe Ser Asn Ile Ser Ser
                155
                                     160
                                                          165
Ile Tyr Gln Phe His Ser Gln Phe Phe Leu Pro Glu Leu Gln Arg
                170
                                                          180
                                     175
Arg Leu Asp Asp Trp
                185
<210> 236
<211> 192
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:898771.1.orf2:2000MAY19
<400> 236
Arg Pro Leu Glu His Gly Thr His Arg His Ile Ala Ser Leu Lys
Thr Glu Glu Thr Arg Arg Ala Arg Pro Ala Ala Ala Gln Ala Val
                 20
                                      25
Tyr Leu Pro Val Ser Gln His Gly His Gln Asp Pro Val His Phe
                  35
                                       40
                                                            45
Ala Leu Ser Gln Arg Arg Gly Pro Ser Leu Pro Ala Ala Ala Thr
                  50
                                      55
                                                           60
Val Pro Pro Asp Leu Pro Ser Glu Asp Pro His Pro Gly Ala Gly
                  65
                                      70
Pro Pro Glu His Gly Gln Pro Arg Pro Leu Pro Asp Gly His His
                                      85
```

WO 01/62927 PCT/US01/06059 Gln Cys Pro Gln Leu Leu Pro Ser Gln Ser Thr Arg Cys Arg Leu 95 100 Leu Gln Leu Pro Leu Cys Ala Glu Arg Asp Leu Gly Pro Ala Ala 110 115 Gly Ser Arg Val Cys Ser Lys Gly Arg Val Gly Ala Ala Gly Arg 125 130 135 His Val Trp Arg Arg Gln Pro Gln Gly Leu Ser Pro Pro Gly Ala 140 145 150 Val Val His Leu Val Thr Gln Asp Arg Ala Ile Val Thr Arg Arg 155 160 165 Gly Arg His Arg Gln Pro Arg Ala Cys Gly Arg Val Leu Glu Val 170 175 180 Val Ser Ala His Arg Glu Trp Ser Arg Ser Trp Arg 185 190 <210> 237 <211> 61 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:257664.67.orf3:2000MAY01 Ala His Ser Lys Pro Glu Lys Ile Val Asn Lys Pro Asn Lys His 10 Glu Asp His Thr Gly Lys Leu Arg Pro Glu Thr Arg Glu Glu Asn 25 Lys Asn His Leu Lys Asp His Gln Pro Tyr Trp His Thr Phe Val 35 40 45 Asn Asn Thr Gln Phe Pro Asp Ile Trp Glu Gln Val Lys Cys Val Thr <210> 238 <211> 335 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:001496.2.orf2:2000MAY01 <400> 238 Arg Cys Gly Ala Ala Ala Ser Ala Gly Arg Glu Ser Ala Ala Gly Ser Glu Glu Gln Ala Gly Leu Arg Pro Ser Gln Leu Arg Gly Pro 20 Pro Asp Pro Pro Thr Glu Thr Ala Ala Val Ser Gly Gln Ala Val 35 40 Gly Ala Ala Trp Pro Ala Ala Gly Lys Met Phe Ser Val Glu Ser 55 60 50 Leu Glu Arg Ala Glu Leu Cys Glu Ser Leu Leu Thr Trp Ile Gln 65 Thr Phe Asn Val Gly Cys Thr Met Pro Glu Pro Val Glu Asp Leu 80 85 Thr Asn Gly Val Val Met Ala Gln Val Leu Gln Lys Ile Asp Pro

95

110

125

140

120/228

100

115

130

145

Ala Tyr Phe Asp Glu Asn Trp Leu Asn Arg Ile Lys Thr Glu Val

Gly Asp Asn Trp Arg Leu Lys Ile Ser Asn Leu Lys Lys Ile Leu

Lys Gly Ile Leu Asp Tyr Asn His Glu Ile Leu Gly Gln Gln Ile

Asn Asp Phe Thr Leu Pro Asp Val Asn Leu Ile Gly Glu His Ser

105

120

```
160
Asp Ala Ala Glu Leu Gly Arg Met Leu Gln Leu Ile Leu Gly Cys
                170
                                     175
Ala Val Asn Cys Glu Gln Lys Gln Glu Tyr Ile Gln Ala Ile Met
                                                         195
                                     190
                185
Met Met Glu Glu Ser Val Gln His Val Val Met Thr Ala Ile Gln
                                    . 205
                200
                                                          210
Glu Leu Met Ser Lys Glu Ser Pro Val Ser Ala Gly Asn Asp Ala
                                     220
                215
Tyr Val Asp Leu Asp Arg Gln Leu Lys Lys Thr Thr Glu Glu Leu
                                     235
                230
Asn Glu Ala Leu Ser Ala Lys Glu Glu Ile Ala Gln Arg Cys His
                                     250
                                                          255
                245
Glu Leu Asp Met Gln Val Ala Ala Leu Gln Glu Lys Ser Ser
                                     265
                                                          270
                260
Leu Leu Ala Glu Asn Gln Val Leu Met Glu Arg Leu Asn Gln Ser
                275
                                     280
                                                          285
Asp Ser Ile Glu Asp Pro Asn Ser Pro Ala Gly Arg Arg His Leu
                                     295
                290
Gln Leu Gln Thr Gln Leu Glu Gln Leu Gln' Glu Glu Thr Phe Arg
                                     310
                305
Leu Glu Ala Ala Lys Asp Asp Tyr Arg Ile Arg Cys Glu Glu Leu
                                     325
                320
Glu Lys Gly Asp Leu
                335
<210> 239
<211> 346
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:1085273.2.orf1:2000MAY01
<400> 239
Ala Arg Ala Gly Ser Pro Pro Arg Pro Pro Arg Pro Arg Pro
                                         Thr Ser Pro Arg
Ala His Cys Ser Arg Ala Cys Ala Ala Cys
                                      25
                                                           30
Ala Cys Arg Thr Leu Thr Ala Ser Ser Ala Pro Ser Pro Trp Thr
                                                           45
                 35
                                      40
Ser Ser Leu Pro Thr Pro Leu Ala Gly Gly
                                         Pro Thr Ala Pro
                                                         Glv
                                                           60
                 50
                                      55
Pro Pro Thr Pro Ala Arg Pro Arg Ser Ser
                                         Ala Ser Trp Thr Ala
                 65
                                      70
Arg Arg Gly Pro Arg Trp Ala Cys Pro Arg
                                         Pro Ala Arg Thr Ala
                                      85
                 80
Arg Thr Pro Arg Leu Arg Arg Gly Pro Arg Pro Arg Arg Arg Pro
                                                          105
                 95
                                     100
Arg Pro Pro Ala Gly Ser Pro Ala Arg Ser Pro Ala His Ser Leu
                                     115
                                                          120
                110
Gly Leu Asn Phe Gly Asp Ala Ala Arg Gln Thr Pro Arg His Gly
                                                          135
                1.25
                                     130
Leu Ser Ala Leu Ser Ala Pro Gly Leu Pro Gly Pro Gly Gln Pro
                                     145
                140
Ala Gly Pro Gly Ala Trp Ala Pro Pro Leu Asp Ser Pro Gly Thr
                155
                                     160
Pro Ser Pro Asp Gly Pro Trp Cys Phe Ser Pro Glu Gly Ala Gln
                170
                                     175
                                                          180
Gly Ala Gly Gly Val Leu Phe Ala Pro Phe Gly Arg Ala Gly Ala
                185
                                     190
                                                          195
Pro Gly Pro Gly Gly Gly Ser Asp Leu Arg Arg Glu Ala Ala
                                     205
                200
Arg Ala Glu Pro Arg Asp Ala Arg Thr Gly Trp Pro Glu Glu Pro
                                     220
                215
Ala Pro Glu Thr Gln Phe Lys Arg Arg Ser Cys Gln Met Glu Phe
```

WO 01/62927 PCT/US01/06059 Glu Glu Gly Met Val Glu Gly Arg Ala Arg Gly Glu Glu Leu Ala 245 250 Ala Leu Gly Lys Gln Ala Ser Phe Ser Gly Asn Val Glu Val Ile 260 Gln Val Val Ser Asp Pro Ser Ala Ala Phe Gly Pro Ala Ala Arg 275 280 285 Ser Gln Ala Arg Asn Lys Cys Ile Leu Tyr Ile Met Gln Arg Lys 290 295 300 Val Asn Gly Leu Thr Gly Asn Phe Asn Pro Arg Ser Lys Ile Ile 305 310 315 Ser Ile Phe Tyr Leu Phe Lys Leu Phe Ile Leu Ala Met Asp Leu 320 325 330 Ala Thr Val Arg Val Val Leu Glu Leu Pro Phe Leu Leu Ser Gly 340 335 Ile <210> 240 <211> 298 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:333138.2.orf3:2000MAY01 <400> 240 Ala Thr Trp Ala Phe Ile Ser Ala Pro Val Pro Val Phe Pro Asp Ser Phe Gly Ile Lys Ala Ser Ser Glu Ala Ser Thr Leu Glu Ala 20 Met Gly Arg Lys Glu Glu Asp Asp Cys Ser Ser Trp Lys Lys Gln 35 40 Thr Thr Asn Ile Arg Lys Thr Phe Ile Phe Met Glu Val Leu Gly 55 Ser Gly Ala Phe Ser Glu Val Phe Leu Val Lys Gln Arg Leu Thr Gly Lys Leu Phe Ala Leu Lys Cys Ile Lys Lys Ser Pro Ala Phe 80 85 90 Arg Asp Ser Ser Leu Glu Asn Glu Ile Ala Val Leu Lys Lys Ile 95 100 105 Lys His Glu Asn Ile Val Thr Leu Glu Asp Ile Tyr Glu Ser Thr 110 115 Thr His Tyr Tyr Leu Val Met Gln Leu Val Ser Gly Gly Glu Leu 125 130 Phe Asp Arg Ile Leu Glu Arg Gly Val Tyr Thr Glu Lys Asp Ala 140 145 150 Ser Leu Val Ile Gln Gln Val Leu Ser Ala Val Lys Tyr Leu His 155 160 Glu Asn Gly Ile Val His Arg Asp Leu Lys Pro Glu Asn Leu Leu 170 175 180 Tyr Leu Thr Pro Glu Glu Asn Ser Lys Ile Met Ile Thr Asp Phe 185 190 Gly Leu Ser Lys Met Glu Gln Asn Gly Ile Met Ser Thr Ala Cys 200 205 210 Gly Thr Pro Gly Tyr Val Ala Pro Glu Val Leu Ala Gln Lys Pro 215 220 225 Tyr Ser Lys Ala Val Asp Cys Trp Ser Ile Gly Val Ile Thr Tyr 230 235 Ile Leu Leu Cys Gly Tyr Pro Pro Phe Tyr Glu Glu Thr Glu Ser 245 Lys Leu Phe Glu Lys Ile Lys Glu Gly Tyr Tyr Glu Phe Glu Ser 260 265 270 Pro Phe Trp Asp Asp Ile Ser Glu Ser Ala Lys Asp Phe Ile Cys

122/228

280

275

His Leu Leu Glu Lys Asp Pro Asn Glu Gly Val Thr Leu

```
<210> 241
<211> 133
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:338927.1.orf1:2000MAY01
<400> 241
Asp Pro Pro Arg Glu Thr Gly Arg Met Lys Gly Ala Ser Glu Glu
Lys Leu Ala Ser Val Ser Asn Leu Val Thr Val Phe Glu Asn Ser
                                      25
                 20
Arg Thr Pro Glu Ala Ala Pro Arg Gly Gln Arg Leu Glu Asp Val
                                     40
                                                           45
                 35
His His Arg Pro Glu Cys Arg Pro Pro Glu Ser Pro Gly Pro Arg
                 50
                                      55
                                                           60
Glu Lys Thr Asn Val Gly Glu Ala Val Gly Ser Glu Pro Arg Thr
                 65
                                      70
Val Ser Arg Arg Tyr Leu Asn Ser Leu Lys Asn Lys Leu Ser Ser
                 80
                                      85
Glu Ala Trp Arg Lys
                    Ser Leu Pro Ala Cys Asp Pro Leu Arg Ile
                 95
                                     100
                                                          105
Gly Asp Ala Gly Ala Arg Glu Glu Asp Arg Pro Gly Ala Ala Trp
                                     115
                110
Arg His Asp Ala Gly His Met Trp Arg Ala Ser Thr Cys
                                     130
                125
<210> 242
<211> 354
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:335558.1.orf2:2000FEB18
<220>
<221> unsure
<222> 341
<223> unknown or other
<400> 242
Leu Ile Gly Val Leu Gln Val Leu Gln Val Glu Leu Gly Ile Asn
                                      10
                                                           15
Ser Val Thr Gly Thr
                    Ser Thr Val Asn Asn Val Asn Ile Thr Ala
                  20
                                      25
Val Gly Ser Phe Asn Pro Asn Val Thr Ser Ser Met Leu Gly Asn
                 35
                                      40
Val Asn Ile Ser Thr Ser Asn Ile Pro Ser Ala Ala Gly Val Ser
                 50
                                      55
Val Gly Pro Gly Val Thr Ser Gly Val Asn Val Asn Ile Leu Ser
                  65
                                      70
Gly Met Gly Asn Gly Thr Ile Ser Ser Ser Ala Ala Val Ser Ser
                 80
                                      85
Val Pro Asn Ala Ala Ala Gly Met Thr Gly Gly Ser Val Ser Ser
                 95
                                     100
                                                          105
Gln Gln Gln Pro Thr Val Asn Thr Ser Arg Phe Arg Val Val
                110
                                     115
                                                          120
Lys Leu Asp Ser Ser Ser Glu Pro Phe Lys Lys Gly Arg Trp Thr
                125
                                                          135
                                     130
Cys Thr Glu Phe Tyr Glu Lys Glu Asn Ala Val Pro Ala Thr Glu
                140
                                     145
Gly Val Leu Ile Asn Lys Val Val Glu Thr Val Lys Gln Asn Pro
```

```
Ile Glu Val Thr Ser Glu Arg Glu Ser Thr Ser Gly Ser Ser Val
                                     175
                170
                                                          180
Ser Ser Ser Val Ser Thr Leu Ser His Tyr Thr Glu Ser Val Gly
                185
                                     190
                                                          195
Ser Gly Glu Met Gly Ala Pro Thr Val Val Val Gln Gln Gln Gln
                200
                                     205
                                                          210
Gln Gln Gln Arg Leu Leu Gln Gln Gln Pro Ala Leu Gln Gly Val
                215
                                     220
                                                          225
Thr Leu Gln Gln Met Asp Phe Gly Ser Thr Gly Pro Gln Ser Ile
                230
                                     235
                                                          240
Pro Ala Val Ser Ile Pro Gln Ser Ile Ser Gln Ser Gln Ile Ser
                245
                                     250
                                                          255
Gln Val Gln Leu Gln Ser Gln Glu Leu Ser Tyr Gln Gln Lys Gln
                260
                                     265
                                                          270
Gly Leu Gln Pro Val Pro Leu Gln Ala Thr Met Ser Ala Ala Thr
                275
                                     280
Gly Ile Gln Pro Ser Pro Val Asn Val Val Gly Val Thr Ser Ala
                290
                                     295
                                                          300
Leu Gly Gln Gln Pro Ser Ile Ser Ser Leu Ala Gln Pro Gln Leu
                305
                                     310
                                                          315
Pro Tyr Ser Gln Ala Ala Pro Pro Val Gln Thr Pro Leu Pro Gly
                320
                                     325
                                                          330
Ala Pro Pro Pro Gln Gln Leu Gln Tyr Gly Xaa Gln Gln Pro Met
                335
                                     340
Val Ser Thr Gln Met Ala Pro Gly Met
                350
```

<210> 243

<211> 237

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: LG:998283.7.orf1:2000FEB18

<400> 243 Leu Tyr Cys Ile Cys Lys Thr Pro Tyr Asp Glu Ser Lys Phe Tyr Ile Gly Cys Asp Leu Cys Thr Asn Trp Tyr His Gly Glu Cys Val Gly Ile Thr Glu Lys Glu Ala Lys Lys Met Asp Val Tyr Ile Cys Asn Asp Cys Lys Arg Ala Gln Glu Gly Ser Ser Glu Glu Leu Tyr Cys Ile Cys Arg Thr Pro Tyr Asp Glu Ser Gln Phe Tyr Ile Gly Cys Asp Arg Cys Gln Asn Trp Tyr His Gly Arg Cys Val Gly Ile Leu Gln Ser Glu Ala Glu Leu Ile Asp Glu Tyr Val Cys Pro Gln Cys Gln Ser Thr Glu Asp Ala Met Thr Val Leu Thr Pro Leu Thr Glu Lys Asp Tyr Glu Gly Leu Lys Arg Val Leu Arg Ser Leu Gln Ala His Lys Met Ala Trp Pro Phe Leu Glu Pro Val Asp Pro Asn Asp Ala Pro Asp Tyr Tyr Gly Val Ile Lys Glu Pro Met Asp Leu Ala Thr Met Glu Glu Arg Val Gln Arg Arg Tyr Tyr Glu Lys Leu Thr Glu Phe Val Ala Asp Met Thr Lys Ile Phe Asp Asn Cys Arg Tyr Tyr Asn Pro Ser Asp Ser Pro Phe Tyr Gln Cys Ala Glu Val Leu Glu Ser Phe Phe Val Gln Lys Leu Lys Gly Phe Lys Ala Ser

```
215
                                     220
                                                         225
Arg Ser His Asn Asn Lys Leu Gln Ser Thr Ala Ser
                230
                                     235
<210> 244
<211> 161
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:402739.1.orf1:2000FEB01
<400> 244
Pro Pro Trp Gly Gln Arg Ser Pro Thr Pro Pro Ser Asp Thr Gly
                                                          15
Gly Thr Ser Arg Pro Arg Thr Met Ile Pro Pro Gly Glu Cys Thr
                 20
                                      25
                                                           30
Tyr Ala Gly Arg Lys Arg Arg Pro Leu Gln Lys Gln Arg Pro
                                      40
                 35
                                                           45
Ala Val Gly Ala Glu Lys Ser Asn Pro Ser Lys Arg His Arg Asp
                                      55
                 50
Arg Leu Asn Ala Glu Leu Asp His Leu Ala Ser Leu Leu Pro Phe
                                      70
                 65
Pro Pro Asp Ile Ile Ser Lys Leu Asp Lys Leu Ser Val Leu Arg
                                      85
                 80
Leu Ser Val Ser Tyr Leu Arg Val Lys Ser Phe Phe Gln Gly Gln
                 95
                                     100
                                                          105
Gly Leu Ala Val Ala Asp Ala Glu Asp Val Asp Asp His Thr Gly
                110
                                     115
                                                          120
Glu Arg Arg Pro Met Ser Phe Arg Arg Pro Arg Ala Leu Asp Thr
                125
                                     130
Gln Ala Leu Arg Arg Thr Gln Phe Gly Leu His Leu Leu Met Val
                140
                                     145
Asn Ile Ala Gly Leu Ile Ala Thr Asp Arg Leu
              , 155
                                     160
<210> 245
<211> 151
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:175223.1.orf3:2000FEB01
<400> 245
Ile Asp Ala Glu Asp His Ser Val Pro Lys Gly Lys Phe Ser Ser
                                                           15
                                      10
His Glu Phe Gly Ala Glu Gly Pro Trp Gly Asn Met Ala Glu Gly
                 20
                                                           3 በ
Gly Ala Ser Lys Gly Gly Glu Glu Pro Gly Lys Leu Pro Glu
Pro Ala Glu Glu Ser Gln Val Leu Arg Gly Thr Gly His Cys
                 50
                                      55
Lys Trp Phe Asn Val Arg Met Gly Phe Gly Phe Ile Ser Met Ile
                                      70
                                                           75
                 65
Asn Arg Glu Gly Ser Pro Leu Asp Ile Pro Val Asp Val Phe Val
                 80
                                      85
                                                           90
His Gln Ser Lys Leu Phe Met Glu Gly Phe Arg Ser Leu Lys Glu
                 95
                                     100
Gly Glu Pro Val Glu Phe Thr Phe Lys Lys Ser Ser Lys Gly Leu
                                                          120
                                     115
                110
Glu Ser Ile Arg Val Thr Gly Pro Gly Gly Ser Pro Cys Leu Gly
                                     130
                                                          135
                125
Ser Glu Arg Arg Pro Lys Gly Lys Thr Leu Gln Lys Arg Lys Pro
                140
                                     145
                                                          150
```

```
Lys
<210> 246
<211> 160
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:981076.2.orf2:2000MAY19
<220>
<221> unsure
<222> 157
<223> unknown or other
<400> 246
Met Ala Ser Lys Val Thr Asp Ala Ile Val Trp Tyr Gln Lys Lys
                                     10
Ile Gly Ala Tyr Asp Gln Gln Ile Trp Glu Lys Ser Val Glu Gln
                 20
                                      25
Arg Glu Ile Lys Gly Leu Arg Asn Lys Pro Lys Lys Thr Ala His
                 35
Val Lys Pro Asp Leu Ile Asp Val Asp Leu Val Arg Gly Ser Ala
                 50
                                      55
                                                          60
Phe Ala Lys Ala Lys Pro Glu Ser Pro Trp Thr Ser Leu Thr Arg
                 65
                                     70
Lys Gly Ile Val Arg Val Val Phe Phe Pro Phe Phe Arg
                                                         Trp
                 80
                                      85
                                                          90
Trp Leu Gln Val Thr Ser Lys Val Ile Phe Phe Trp Leu Leu Val
                 95
                                     100
Leu Tyr Leu Leu Gln Val Ala Val Ile Val Leu Phe Cys Ser Thr
                110
                                     115
                                                         120
Ser Ser Pro His Ser Ile Pro Leu Thr Glu Val Ile Gly Pro Ile
                125
                                     130
                                                          135
Trp Leu Met Leu Leu Gly Thr Val His Cys Gln Ile Val Ser
                140
                                     145
                                                         150
Thr Arg Thr Pro Lys Pro Xaa Leu Ser Thr
                155
<210> 247
<211> 160
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:1008973.1.orf3:2000MAY01
<400> 247
Leu His Ile Pro Arg Ser Pro Pro Gly Asp Arg Ala Ala Arg Thr
Gly His Pro Arg Leu Pro Val Pro Pro Pro Arg Ala Arg Thr Glu
Pro Arg Pro Arg Gly Gln Arg Arg Leu His Ser Ser Gly Glu Met
                                      40
Ala Ala Gly Ser Thr Thr Leu Arg Ala Val Gly Lys Leu Gln Val
                 50
                                      55
                                                           60
Arg Leu Ala Thr Lys Thr Glu Pro Lys Lys Leu Glu Lys Tyr Leu
                 65
                                      70
                                                          75
Gln Lys Leu Ser Ala Leu Pro Met Thr Ala Asp Ile Leu Ala Glu
                 80
                                      85
                                                          90
```

126/228

100

115

105

120

Thr Gly Leu Arg Lys Thr Val Lys Arg Leu Arg Lys His Gln His

Val Gly Asp Phe Ala Arg Asp Leu Ala Ala Arg Trp Lys Lys Leu

95

```
Val Leu Val Asp Arg Asn Thr Gly Pro Asp Pro Gln Asp Pro Glu
                                     130
                125,
Glu Ser Ala Ser Arg Gln Arg Tyr Gly Glu Ala Leu Gln Glu Arg
                140
                                     145
                                                          150
Glu Lys Gly Trp Gly Leu Pro Arg Lys Arg
                155
                                    160
<210> 248
<211> 171
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:1190250.1.orf1:2000MAY01
<400> 248
Arg Ala His Ser Gly Val Leu Met Ser Ala Met Leu Ser His Gly
                                                           15
                                      10
Val Leu Lys Arg Ala Ser Glu Arg Gly Ala Glu Arg His Ser Leu
                                                           3.0
                 20
                                      25
Pro Pro Ser Arg Leu Val Leu Val Pro Gly Arg Arg Ala Leu Arg
                 35
                                      40
                                                           45
Ser Ala Pro Gln Val Pro Gly Ser Gly Trp Arg Val Gly Thr Glu
                 50
                                      55
                                                           60
Pro Pro Val Leu His Asp Pro Ala Gly Arg Gly Arg Phe Pro Gln
                 65
Ser Gly Glu Val Ser Ala Ala Pro Glu Met Ser Lys Leu Ser Phe
                 80
                                      85
Arg Ala Arg Ala Leu Asp Ala Ser Lys Pro Leu Pro Val Phe Arg
                 95
                                     100
                                                          105
Cys Glu Asp Leu Pro Asp Leu His Glu Tyr Ala Ser Ile Asn Arg
                110
                                     115
                                                          120
Ala Val Pro Gln Met Pro Thr Gly Ile Glu Lys Glu Glu Glu Ser
                125
                                     130
                                                          135
Glu His His Leu Pro Ala Gly Leu Phe Gln His Ser Arg Cys Met
                140
                                     145
                                                          150
Ala Arg Arg Gly Ile Tyr Met Val Ile Pro Val Pro Glu Ala Glu
                155
                                     160
Ser Asn Tyr Cys Leu Leu
                170
<210> 249
<211> 449
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:021371.3.orf2:2000FEB18
<400> 249
Pro Gly Met Ser Val Ala Gly Val Glu Gly Glu Pro Leu Val Ser
                                                           15
                                      10
Ser Gln Ser Gly Gln Ser Pro Pro Glu Pro Gln Asp Pro Glu Ala
Pro Ser Ser 'Gly Pro Gly His Leu Val Ala Met Gly Lys Val
                                      40
Ser Arg Thr Pro Val Glu Ala Gly Val Ser Gln Ser Asp Ala Glu
                                      55
                 50
                                                          60
Asn Ala Ala Pro Ser Cys Pro Asp Glu His Asp Thr Leu Pro Arg
                                      70
                 65
                                                           75
Arg Arg Gly Arg Pro Ser Arg Arg Phe Leu Gly Lys Lys Tyr Arg
                 80
                                      85
                                                           90
            Tyr Lys Ser Pro Lys Pro Leu Leu Arg Pro Phe Leu
                 95
                                     100
Cys Arg Ile Cys Gly Ser Arg Phe Leu Ser His Glu Asp Leu Arg
```

```
Phe His Val Asn Ser His Glu Ala Gly Asp Pro Gln Leu Phe Lys
                125
                                     130
                                                          135
Cys Leu Gln Cys Ser Tyr Arg Ser Arg Arg Trp Ser Ser Leu Lys
                140
                                     145
                                                          150
Glu His Met Phe Asn His Val Gly Ser Lys Pro Tyr Lys Cys Asp
                155
                                     160
                                                          165
Glu Cys Ser Tyr Thr Ser Val Tyr Arg Lys Asp Val Ile Arg His
                 170
                                     175
Ala Ala Val His Ser Arg Asp Arg Lys Lys Arg Pro Asp Pro Thr
                185
                                     190
                                                          195
Pro Lys Leu Ser Ser Phe Pro Cys Pro Val Cys Gly Arg Val Tyr
                 200
                                     205
                                                          210
Pro Met Gln Lys Arg Leu Thr Gln His Met Lys Thr His Ser Thr
                215
                                     220
                                                          225
Glu Lys Pro His Met Cys Asp Lys Cys Gly Lys Ser Phe Lys Lys
                 230
                                     235
Arg Tyr Thr Phe Lys Met His Leu Leu Thr His Ile Gln Ala Val
                 245
                                     250
Ala Asn Arg Arg Phe Lys Cys Glu Phe Cys Glu Phe Val Cys Glu
                 260
                                     265
                                                          270
Asp Lys Lys Ala Leu Leu Asn His Gln Leu Ser His Val Ser Asp
                275
                                     280
                                                          285
Lys Pro Phe Lys Cys Ser Phe Cys Pro Tyr Arg Thr Phe Arg Glu
                 290
                                     295
Asp Phe Leu Leu Ser His Val Ala Val Lys His Thr Gly Ala Lys
                 305
                                     310
Pro Phe Ala Cys Glu Tyr Cys His Phe Ser Thr Arg His Lys Lys
                 320
                                     325
Asn Leu Arg Leu His Val Arg Cys Arg His Ala Ser Ser Phe Glu
                335
                                     340
                                                          345
Glu Trp Gly Arg Arg His Pro Glu Glu Pro Pro Ser Arg Arg Arg
                 350
                                     355
Pro Phe Phe Ser Leu Gln Gln Ile Glu Glu Leu Lys Gln Gln His
                 365
                                     370
                                                          375
Ser Ala Ala Pro Gly Pro Pro Pro Ser Ser Pro Gly Pro Pro Glu
                 380
                                     385
                                                          390
Ile Pro Pro Glu Ala Thr Thr Phe Gln Ser Ser Glu Ala Pro Ser
                 395
                                     400
                                                          405
Leu Leu Cys Ser Asp Thr Leu Gly Gly Ala Thr Ile Ile Tyr Gln
                 410
                                      415
Gln Gly Ala Glu Glu Ser Thr Ala Met Ala Thr Gln Thr Ala Leu
                                     430
                 425
Asp Leu Leu Asn Met Ser Ala Gln Arg Glu Leu Gly Gly
                                     445
                 440
```

```
<210> 250
```

<400> 250

 Leu Thr Pro Gly His Pro Gly Ser Arg Gly Met Asp Ser Val Ala

 1
 5
 10
 15

 Phe Glu Asp Val Ala Val Asn Phe Thr Gln Glu Glu Trp Ala Leu
 20
 25
 30

 Leu Asp Ser Ser Gln Lys Asn Leu Tyr Arg Glu Val Met Gln Glu
 45

 Thr Cys Arg Asn Leu Ala Ser Val Gly Ser Gln Trp Lys Asp Gln
 55
 60

 Asn Ile Glu Asp His Phe Glu Lys Pro Gly Lys Asp Ile Arg Asn
 65
 70
 75

 His Ile Val Gln Arg Leu Cys Glu Ser Lys Glu Asp Gly Gln Tyr

<211> 127 <212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: LG:475404.1.orf2:2000FEB18

```
80
                                      85
                                                          ัจก
Gly Glu Val Val Ser Gln Ile Pro Asn Leu Asp Leu Asn Glu Asn
                 95
                                     100
Ile Ser Thr Gly Leu Lys Pro Cys Glu Cys Ser Ile Cys Gly Lys
                                     115
                110
Val Phe Val Arg His Ser Leu
                125
<210> 251
<211> 157
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:979406.2.orf1:2000FEB18
<220>
<221> unsure
<222> 136
<223'> unknown or other
<400> 251
Asn Ser Leu Ser Val Ala Ser Ala Pro Pro Gln Arg Asp Pro Gly
                                                           15
                                      10
 .₁
Met Ala Met Ala Leu Pro Met Pro Gly Pro Gln Glu Ala Val Val
                                                           30
                 20
                                      25
Phe Glu Asp Val Ala Val Tyr Phe Thr Arg Ile Glu Trp Ser Cys
                                                           45
                 35
                                      40
Leu Ala Pro Asp Gln Gln Ala Leu Tyr Arg Asp Val Met Leu Glu
                 50
                                      55
                                                           60
Asn Tyr Gly Asn Leu Ala Ser Leu Gly Phe Leu Val Ala Lys Pro
                 65
Ala Leu Ile Ser Leu Leu Glu Gln Gly Glu Pro Gly Ala Leu
                                      85
                                                           90
                 80
Ile Leu Gln Val Ala Glu Gln Ser Val Ala Lys Ala Ser Leu Cys
                 95
                                     100
Thr Glu Asp Pro Asn Thr Leu Pro Ser Arg Ser Gln Glu Gly Ser
                                     115
                                                          120
                110
Pro Ala Ser Ser Glu Gly Gly Pro Gly Glu Lys Gly Val Ala Gly
                                                          135
                                     130
                125
Xaa Val Ala Gly Gly Gly Ala Ala Ser Ser Trp Pro His Gly Glu
                                     145
                140
His Pro Val Thr Pro Asn Arg
                155
<210> 252
<211> 305
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:410726.1.orf1:2000FEB18
<400> 252
Asp Thr Met Gln Ala Val Val Pro Leu Asn Lys Met Thr Ala Ile
                                      10
Ser Pro Glu Pro Gln Thr Leu Ala Ser Thr Glu Gln Asn Glu Val
                                                           30
                 20
                                      25
Pro Arg Val Val Thr Ser Gly Glu Glu Ala Ile Leu Arg Gly
                 35
Asn Ala Ala Asp Ala Glu Ser Phe Arg Gln Arg Phe Arg Trp Phe
                                      55
                 50
Cys Tyr Ser Glu Val Ala Gly Pro Arg Lys Ala Leu Ser Gln Leu
                 65
Trp Glu Leu Cys Asn Gln Trp Leu Arg Pro Asp Ile His Thr Lys
```

```
Glu Gln Ile Leu Glu Leu Leu Val Phe Glu Gln Phe Leu Thr Ile
                 95
                                    100
                                                         105
Leu Pro Gly Glu Ile Arg Ile Trp Val Lys Ser Gln His Pro Glu
                110
                                                         120
Ser Ser Glu Glu Val Val Thr Leu Ile Glu Asp Leu Thr Gln Met
                125
                                    130
Leu Glu Glu Lys Asp Pro Val Ser Gln Asp Ser Thr Val Ser Gln
                140
Glu Glu Asn Ser Lys Glu Asp Lys Met Val Thr Val Cys Pro Asn
                                    160
                155
Thr Glu Ser Cys Glu Ser Ile Thr Leu Lys Asp Val Ala Val Asn
                                     175
                170
Phe Ser Arg Gly Glu Trp Lys Lys Leu Glu Pro Phe Gln Lys Glu
                                                         195
                185
                                    190
Leu Tyr Lys Glu Val Leu Leu Glu Asn Leu Arg Asn Leu Glu Phe
                                     205
                200
Leu Asp Phe Pro Val Ser Lys Leu Glu Leu Ile Ser Gln Leu Lys
                                    220
                215
Trp Val Glu Leu Pro Trp Leu Leu Glu Glu Val Ser Lys Ser Ser
                230
                                     235
                                                         240
Arg Leu Asp Glu Ser Ala Leu Asp Lys Ile Ile Glu Arg Cys Leu
                                                         255
                245
                                    250
Arg Asp Asp His Gly Leu Met Glu Glu Ser Gln Gln Tyr
                                                         Cys
                                                         270
                                     265
                260
Gly Ser Ser Glu Glu Asp His Gly Asn Gln Gly Asn Ser Lys Gly
                                                         285
                                     280
                275
Arg Val Ala Gln Tyr Lys Thr Leu Gly Ser Gly Ser Arg Gly Lys
                290
                                     295
                                                         300
Lys Phe Asp Pro Asp
<210> 253
<211> 717
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:200005.1.orf2:2000FEB18
<400> 253
Glu Cys Ser Arg Val Thr Val Thr Glu His Trp Ser Lys Val Phe
Pro Lys Gly Gln Gly Ser Gln Glu His Leu Leu Lys Leu Met Thr
                 20
                                      25
Met Gly Asp Met Lys Thr Pro Asp Phe Asp Asp Leu Leu Ala Ala
Phe Asp Ile Pro Asp Met Val Asp Pro Lys Ala Ala Ile Glu Ser
Gly His Asp Asp His Glu Ser His Met Lys Gln Asn Ala His Gly
                 65
Glu Asp Asp Ser His Ala Pro Ser Ser Ser Asp Val Gly Val Ser
                 80
                                      85
Val Ile Val Lys Asn Val Arg Asn Ile Asp Ser Ser Glu Gly Gly
                                                          105
Glu Lys Asp Gly His Asn Pro Thr Gly Asn Gly Leu His Asn Gly
                                     115
                                                          120
                110
Phe Leu Thr Ala Ser Ser Leu Asp Ser Tyr Ser Lys Asp Gly Ala
                                     130
                125
                                                          135
Lys Ser Leu Lys Gly Asp Val Pro Ala Ser Glu Val Thr Leu Lys
                                                          150
                140
                                     145
Asp Ser Thr Phe Ser Gln Phe Ser Pro Ile Ser Ser Ala Glu Glu
                                                          165
                 155
                                     160
Phe Asp Asp Glu Lys Ile Glu Val Asp Asp Pro Pro Asp Lys
```

175

Glu Asp Met Arg Ser Ser Phe Arg Ser Asn Val Leu Thr Gly Ser

	•									ı		•		100	
Ala	Pro	Gln	Gln		Tyr	Asp	Lys	Leu	190 Lys 205	Ala	Leu	Gly	Gly	195 Glu 210	
Asn	Ser	Ser	Lys	200 Thr 215	GjÀ	Leu	Ser	Thr		Gly	Asn	Val	Glu		
Asn	Lys	Ala	Val		Arg	Glu	Thr	Glu		Ser	Ser	Ile	Asn		
Ser	Val	Tyr	Glu		Phe	Lys	Val	Arg		Ala	Glu·	Asp	Lys		
				260					265				Asp	270	
				275					280				Val	285	,
		_	•	290				_	295		•		Ile	300	
			٠.	305					310				Ser	315	
_			•	320			_		325	•			Pro	330	ı
			_	335		_		٠.	340				Glu	345	
				350			_		355		1		Gln Gly	360	
				365					370				Val	375	,
			Ile	380					385					390 Val	
			*	395					400		_		Lys	405	
	_			410			_		415		_		Leu	420	
				425					430				Arg	435	
				440					445				Ala	450	
Leu	Thr	Pro	Lys		Val	Thr	Ile	Lys		Val	Ala	Thr	Ala		
Leu	Pro	Val	Ser		Val	Lys	Thr	Ala		Ser	Gln	Val	Ile		
Leu	Lys	Leu	Ala		Asn	Thr	Thr	Val		Ala	Thr	Val	Ile		
Ala	Ala	Ser	Val		Ser	Ala	Ser	Ser	505 Ala 520	Ile	Ile	Lys	Ala	510 Ala 525	
Asn	Ala	Ile	Gln	515 Gln 530	Gln	Thr	Val	Val		Pro	Ala	Ser	Ser	Leu 540	
Ala	Asn	Ala	Lys		Val	Pro	Lys	Thr		His	Leu	Ala	Asn		
Asn	Leu	Leu	Pro		Gly	Ala	Gln	Ala		Ser	Glu	Leu	Arg		
Val	Leu	Thr	Lys		Gln	Gln	Gln	Ile		Gln	Ala	Ile	Ile	Asn 585	
Ala	Ala	Ala	Ser	Gln 590	Pro	Pro	Lys	ГÄЗ	Val 595	Ser	Arg	Val	Gln	Val 600	
Val	Ser	Ser	Leu	Gln 605	Ser	Ser	Val	Val	Glu 610	Ala	Phe	Asn	Lys	Val 615	
Leu	Ser	Ser	Val	Asn 620	Pro	Val	Pro	Val	Tyr 625	Ile	Pro	Asn	Leu	Ser 630	
				635	-	•			640				Tyr	645	
				650					655				Leu	660	
				665	_				670				Cys -	675	
His	Суз	Thr	Lys	Asn 680	Leu	Val	Phe	Tyr	Asn 685	ГÀè	Суѕ	Ser	Leu	Leu 690	

```
WO 01/62927
```

```
Ser His Ala Arg Gly His Lys Glu Lys Gly Val Val Met Gln Cys 695 700 705

Ser His Leu Ile Leu Ser Gln Ser Gln Gln Ile Lys 715

<210> 254
<211> 211
<212> PRT
<213> Homo sapiens
```

<220>
<221> misc_feature
<223> Incyte ID No: LG:1076828.1.orf1:2000FEB18

<220>
<221> unsure
<222> 25, 54, 93, 113, 116, 121
<223> unknown or other

<400> 254 Thr Pro Lys Pro Gln Val Ile Ser Leu Leu Glu Gln Gly Lys Glu Pro Trp Met Val Gly Arg Glu Leu Thr Xaa Gly Leu Cys Ser Asp 25 30 Leu Glu Ser Met Cys Glu Thr Lys Leu Leu Ser Leu Lys Lys Glu Val Tyr Glu Ile Glu Leu Cys Gln Xaa Glu Ile Met Gly Leu Thr 50 55 60 Lys His Gly Leu Glu Tyr Ser Ser Phe Gly Asp Val Leu Glu Tyr 65 70 Arg Ser His Leu Ala Lys Gln Leu Gly Tyr Pro Asn Gly His Phe 80 85 90 Ser Gln Xaa Ile Phe Thr Pro Glu Tyr Met Pro Thr Phe Ile Gln 100 Gln Thr Phe Leu Thr Leu His Xaa Ile Ile Xaa Asn Glu Asp Arg 110 115 120 Xaa Tyr Glu Cys Lys Glu Cys Gly Lys Met Phe Ser His Gly Ser 125 130 135 Gln Leu Thr Gln His Gln Arg Ile His Thr Gly Glu Lys Pro Tyr 150 140 145 Gln Cys Lys Glu Cys Gly Lys Ala Phe Asn Arg Gly Ser Leu Leu 155 160 165 Thr Arg His Gln Arg Ile His Thr Gly Glu Lys Pro Tyr Glu Cys 175 180 170 Lys Glu Cys Gly Lys Thr Phe Ser Arg Gly Ser Glu Leu Thr Gln 190 195 185 His Glu Arg Ile His Thr Ala Gly Ala Pro Leu Leu Ser Trp Gly 200 205 210 Leu

<210> 255
<211> 103
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1076931.1.orf2:2000FEB18
<400> 255
Gly Gly Glu Gly Gln Ser Ala Asp Leu Arg Pro Leu L

Gly Gly Glu Gly Gln Ser Ala Asp Leu Arg Pro Leu Leu Thr Asp
1 5 10 15

Phe Arg Leu Gln Phe Ile Cys Ala Pro Ala Ser Ser Leu Ser Leu
20 25 30

Arg Arg Leu Arg Leu Arg Pro Gln Lys Glu Ile Ser Ile Leu Cys
35 40 45

132/228

BNSDOCID: <WO__0162927A2_I_>

```
Pro Glu Gln Asn Arg Met Ala Met Ser Gln Glu Ser Leu Thr Phe
Lys Asp Val Phe Val Gly Phe Thr Leu Glu Glu Trp Gln Gln Leu
                                     · 70
                 65
Asp Pro Ser Gln Arg Ala Leu Tyr Arg Asp Val Met Leu Glu Asn
                                      85
                 80
Tyr Ser Asn Leu Val Ser Val Gly Tyr Cys Ala His Lys
                                     100
                 95
<210> 256
<211> 84
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1078121.1.orf3:2000FEB18
<400> 256
Glu Gly Ile Pro Glu Lys Lys Glu Glu Glu Glu Glu Met Ala Gly
                                      10
Ser Gln Gly Leu Leu Ile Phe Arg Asp Val Ala Ile Glu Phe Ser
                                      25
Pro Glu Glu Trp Ser Tyr Leu Asp Pro Ala Gln Asn Leu Tyr
Arg Asp Val Met Leu Glu Asn Tyr Arg Asn Leu Val Ser Leu Gly
                                      55
                 50
Ile Ala Val Ser Lys Pro Glu Leu Ile Thr Cys Leu Glu Gln Arg
                 65
Asn Glu Pro Trp Asn Val Lys Lys His
                 80
<210> 257
<211> 194
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1079203.1.orf1:2000FEB18
<400> 257
Asp Ala Arg Thr Thr Trp Lys Pro Arg Asn Val Ile Tyr Ser His
Phe Thr Glu Asp Leu Trp Pro Glu His Ser Ile Lys Asp Ser Phe
                 20
                                      25
Gln Lys Val Ile Leu Arg Gly Tyr Gly Lys Cys Gly His Glu Asn
                                      40
                 35
Leu Gln Leu Arg Ile Ser Cys Lys Ser Val Asp Glu Ser Lys Val
                                      55
                                                           60
                 50
Phe Lys Glu Gly Tyr Asn Glu Leu Asn Gln Cys Leu Arg Thr Thr
                                                           75
                 65
                                      70
Gln Ser Lys Ile Phe Gln Cys Asp Lys Tyr
                                         Val Lys Val Phe His
                                      85
Lys Phe Ser Asn Ser Asn Ser His Lys Lys Arg Asn Thr Gly Lys
                 95
                                     100
Lys Val Phe Lys Cys Lys Glu Cys Gly Lys Ser Phe Cys Met Leu
                110
                                     115
                                                          120
Ser His Leu Thr Gln His Ile Arg Ile His Thr Arg Glu Asn Ser
                                                          135
                125
                                     130
Tyr Lys Cys Lys Glu Cys Gly Lys Val Leu Asn Gln Ser Ser Glu
                140
                                     145
                                                          150
Leu Ile Lys His Lys Lys Ile His Thr Gly Glu Lys Pro Tyr Thr
```

155

170

160

175

Cys Glu Lys Cys Gly Lys Thr Phe Asn Gln Ser Ala Asn Leu Tyr

Ala His Lys Lys Ile His Thr Gly Asp Lys Thr Ile Gln Val

```
185
                                     190
<210> 258
<211> 129
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1082586.1.orf1:2000FEB18
<220>
<221> unsure
<222> 5
<223> unknown or other
<400> 258
Ala Gln Pro Arg Xaa Pro Met Gly Gln Tyr Gln Ala Asp Gln Tyr
  1
                                      10
Ile His Arg Arg Ser Ser Ser Arg Arg Glu Lys Gly Ala Glu Arg
                 20
                                      25
                                                          30
Ile Leu Glu Glu Ile Met Ala Glu Asn Phe Ser Ser Leu Ile Lys
                 35
                                      40
Asp Met Asn Ile Asn Ile Gln Glu Ala Gln Gln Thr Pro Ser Met
Met Asn Ser Lys Ile Ala Thr Leu Arg His Ile Ile Lys Leu
                 65
                                      70
                                                          75
Ser Lys Asp Lys His Arg Pro Leu Ser Leu Thr Ala Ala Arg Ala
                 80
                                      85
                                                          90
Pro Ser Leu Val Phe Thr Ser Leu Phe Leu Leu Leu Glu Ala
                 95
                                     100
Gln Pro Leu Trp Pro Cys Asp Leu Gln Val Leu Gly Asp Pro Leu
                110
Leu Arg Cys Gln Asp Pro Leu Glu Ala
                125
<210> 259
<211> 93
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1082774.1.orf3:2000FEB18
<400> 259
Pro Ala Gly Ile Arg Arg Val Thr Ala Arg Thr Pro Gly Pro Pro
Gly Ser Leu Glu Met Gly Pro Leu Gln Phe Arg Asp Val Ala Ile
                 20
                                      25
Glu Phe Ser Leu Glu Glu Trp His Cys Leu Asp Ala Ala Gln Arg
                 35
                                      40
Asn Leu Tyr Arg Asp Val Met Leu Glu Asn Tyr Arg Asn Leu Ile
                 50
                                      55
                                                          60
Phe Leu Gly Ile Val Val Ser Lys Pro Asn Leu Ile Thr Cys Leu
                                      70
                                                          75
                 65
Glu Gln Gly Lys Lys Pro Leu Thr Met Lys Arg His Glu Met Ile
                                      85
                , 80
Ala Lys Pro
<210> 260
<211> 193
<212> PRT
```

<213> Homo sapiens

<220>

```
<221> misc_feature
<223> Incyte ID No: LG:1082775.1.orf3:2000FEB18
<400> 260
Lys His Glu Ile Ile His Phe Glu Glu Glu Pro Ser Glu Tyr Asn
                                                           15
                                      .10
Asn Asn Gly Asn Ser Phe Trp Leu Asn Glu Asp Leu Ile Trp His
                 20
                                      25
Gln Lys Ile Lys Asn Trp Glu Gln Pro Phe Glu Tyr Asn Glu Cys
                 35
                                      40
Gly Lys Ala Phe Pro Glu Asn Ser Leu Phe Leu Val His Lys Arg
                 50
                                      55
                                                           60
Ala Tyr Thr Gly Gln Lys Thr Cys Lys Tyr
                                         Thr Glu His Gly Lys
                                      70
                 65
Thr Cys Tyr Met Ser Phe Phe Ile Thr His Gln Gln Thr His Pro
                 80
                                      85
Arg Glu Asn His Tyr Glu Cys Asn Glu Cys Gly Glu Ser Ile Phe
                 95
                                     100
Glu Glu Ser Ile Leu Phe Glu His Gln Asn Val Tyr Pro Phe Ser
                                     115
                110
Gln Asn Leu Asn Pro Thr Leu Ile Gln Arg Thr His Ser Ile Ser
                125
                                     130
                                                          135
Asn Ile Ile Glu Tyr Asn Glu Cys Gly Thr Phe Phe Ser Glu Lys
                140
                                                          150
                                     145
Leu Ala Leu His Leu Gln Gln Arg Thr His Pro Gly Glu Lys Pro
                                                          165
                155
                                     160
Tyr Glu Cys His Glu Cys Gly Lys Thr Phe Thr Gln Lys Ser Ala
                170
                                     175
His Thr Arg His Gln Arg Thr His Thr Gly Lys Thr Leu
                 185
                                     190
<210> 261
<211> 111
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1083120.1.orf3:2000FEB18
Pro Gly Leu Arg Asp Leu Thr Cys Lys Glu Leu Leu Ile Leu Thr
                                      10
Glu Arg Glu Ala Gln Lys Arg Lys Arg Lys Glu Lys Glu Ser
                                      25
Gly Met Ala Leu Thr Gln Gly Pro Leu Thr Phe Arg Asp Val Ala
                                      40
                  35
Ile Glu Phe Ser Gln Glu Glu Trp Lys Ser Leu Asp Pro Val Gln
                                      55
                  50
Lys Ala Leu Tyr Trp Asp Val Met Leu Glu Asn Tyr Arg Asn Leu
                  65
                                      70
                                                           75
Val Phe Leu Gly Lys Asp Asn Phe Ala Leu Glu Val Lys Ile Cys
                  80
                                      85
                                                           90
Pro Arg Val Phe Leu Tyr Phe Leu Cys Cys Leu Ser Val Gly Ala
                  95
                                      100
Arg Ser Ile His Leu His
                 110
<210> 262
<211> 137
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1087707.1.orf3:2000FEB18
```

```
Leu His His Ser Pro Cys Tyr Pro Val Thr Cys Arg Tyr Trp Asp
                                      10
Ile His Arg Glu Glu Gly Gly Thr Ser Gly Gly Trp Glu Met Arg
                 20
Val Leu Thr Phe Arg Asp Val Ala Val Glu Phe Ser Pro Glu Glu
                                      40
Trp Glu Cys Leu Asp Ser Ala Gln Gln Arg Leu Tyr Arg Asp Val
                 50
Met Leu Glu Asn Tyr Gly Asn Leu Phe Ser Leu Gly Leu Ala Ile
                 65
                                      70
Phe Lys Pro Asp Leu Ile Thr Tyr Leu Glu Gln Arg Lys Glu Pro
                 80
                                      85
Trp Asn Ala Arg Arg Gln Lys Thr Val Ala Lys His Pro Asp
                                                         Tyr
                 95
                                     100
                                                         105
Tyr Asp Val Cys Asn Glu Asp Tyr Glu Tyr Asn Trp Ser Tyr Met
                110
                                     115
                                                         120
Phe Leu Asn Ser Glu Gln Leu Phe Ile Lys Phe Tyr Pro Thr Phe
                125
                                     130
                                                         135
Phe Cys
<210> 263
<211> 68
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1090915.1.orf3:2000FEB18
<400> 263
Met Phe Pro Val Leu Glu Pro His Gln Val Gly Leu Ile Arg Ser
Tyr Asn Ser Lys Thr Met Thr Cys Phe Gln Glu Leu Val Thr Phe
                 20
                                      25
                                                          30
Arg Asp Val Ala Ile Asp Phe Ser Arg Gln Glu Trp Glu Cys Leu
                 3.5
                                      40
                                                          45
Asp Pro Asn Gln Arg Asp Leu Tyr Arg Asp Val Met Leu Glu Asn
                 50
                                      55
Tyr Arg Asn Leu Val Ser Leu Gly
                 65
<210> 264
<211> 101
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1094230.1.orf3:2000FEB18
<400> 264
Asp Thr Gly Thr Ser Trp Lys Pro Lys Met Gly Pro Leu Gln Phe
Arg Asp Val Ala Ile Glu Phe Ser Leu Glu Glu Trp His Cys Leu
Asp Thr Ala Gln Arg Asn Leu Tyr Arg Asn Val Met Leu Glu Asn
                                      40
Tyr Ser Asn Leu Val Phe Leu Gly Ile Thr Val Ser Lys Pro Asp
                 50
                                      55
Leu Ile Thr Cys Leu Glu Gln Gly Arg Lys Pro Leu Thr Met Lys
                 65
                                      70
Arg Asn Glu Met Ile Ala Lys Pro Ser Val Ser Phe Leu Gln Val
                 80
                                      85
His Ser Glu Ser Gln Ser Pro Leu His Asp Ile
```

<400> 262

```
<210> 265
<211> 96
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:474848.3.orf1:2000FEB18
<400> 265
Ser Ala Ala Met Phe Pro Val Phe Ser Gly Cys Phe Gln Glu Leu
                                      10
Gln Glu Lys Asn Lys Ser Leu Glu Leu Val Ser Phe Glu Glu Val
                 20
                                      25
Ala Val His Phe Thr Trp Glu Glu Trp Gln Asp Leu Asp Asp Ala
Gln Arg Thr Leu Tyr Arg Asp Val Met Leu Glu Thr Tyr Ser Ser
                 50
                                      55
Leu Val Ser Leu Gly His Cys Ile Thr Lys Pro Glu Met Ile Phe
                                      70
                 65
Lys Leu Glu Gln Gly Ala Glu Pro Trp Ile Val Glu Glu Thr Leu
                                      85
                 80
Asn Leu Arg Leu Ser Gly
<210> 266
<211> 251
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:251656.1.orf2:2000FEB01
<220>
<221> unsure
<222> 234
<223> unknown or other
<400> 266
Glu Asn Gly Glu Asn Cys Asn Gln Asp Met Phe Glu Asn Glu Ser
Arg Lys Ile Phe Ser Glu Met Pro Glu Gly Glu Ser Ala Gln His
                 20
Ser Asp Gly Glu Ser Asp Phe Glu Arg Asp Ala Gly Ile Gln Arg
                                      40
                 35
Leu Gln Gly His Thr Pro Gly Glu Asp His Gly Glu Val Val Ser
                                                           60
                 50
                                      55
Gln Asp Arg Glu Val Gly Gln Leu Ile Gly Leu Gln Gly Thr Tyr
                                      70
                 65
Leu Gly Glu Lys Pro Tyr Glu Cys Pro Gln Cys Gly Lys Thr Phe
                 80
                                      85
Ser Arg Lys Ser His Leu Ile Thr His Glu Arg Thr His Thr Gly
                                     100
                                                          105
Glu Lys Tyr Tyr Lys Cys Asp Glu Cys Gly Lys Ser Phe Ser Asp
                110
                                     115
Gly Ser Asn Phe Ser Arg His Gln Thr Thr His Thr Gly Glu Lys
                                                          135
                125
                                     130
Pro Tyr Lys Cys Arg Asp Cys Gly Lys Ser Phe Ser Arg Ser Ala
                140
                                     145
                                                          150
Asn Leu Ile Thr His Gln Arg Ile His Thr Gly Glu Lys Pro Phe
                155
                                     160
Gln Cys Ala Glu Cys Gly Lys Ser Phe Ser Arg Ser Pro Asn Leu
                170
                                                          180
Ile Ala His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Ser Cys
                185
                                     190
Pro Glu Cys Gly Lys Ser Phe Gly Asn Arg Ser Ser Leu Asn Thr
```

<210> 267 <211> 522

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: LI:021371.1.orf3:2000FEB01

Pro Gly Met Ser Val Ala Gly Val Glu Gly Glu Pro Leu Val Ser Ser Gln Ser Gly Gln Ser Pro Pro Glu Pro Gln Asp Pro Glu Ala 20 25 30 Pro Ser Ser Ser Gly Pro Gly His Leu Val Ala Met Gly Lys Val Ser Arg Thr Pro Val Glu Ala Gly Val Ser Gln Ser Asp Ala Glu 50 55 Asn Ala Ala Pro Ser Cys Pro Asp Glu His Asp Thr Leu Pro Arg 65 70 Arg Arg Gly Arg Pro Ser Arg Arg Phe Leu Gly Lys Lys Tyr Arg 80 85 Lys Tyr Tyr Tyr Lys Ser Pro Lys Pro Leu Leu Arg Pro Phe Leu 100 105 Cys Arg Ile Cys Gly Ser Arg Phe Leu Ser His Glu Asp Leu Arg 110 115 120 Phe His Val Asn Ser His Glu Ala Gly Asp Pro Gln Leu Phe Lys 125 130 135 Cys Leu Gln Cys Ser Tyr Arg Ser Arg Arg Trp Ser Ser Leu Lys 140 145 Glu His Met Phe Asn His Val Gly Ser Lys Pro Tyr Lys Cys Asp Glu Cys Ser Tyr Thr Ser Val Tyr Arg Lys Asp Val Ile Arg His 170 175 Ala Ala Val His Ser Arg Asp Arg Lys Lys Arg Pro Asp Pro Thr 185 190 195 Pro Lys Leu Ser Ser Phe Pro Cys Pro Val Cys Gly Arg Val Tyr 200 205 Pro Met Gln Lys Arg Leu Thr Gln His Met Lys Thr His Ser Thr Glu Lys Pro His Met Cys Asp Lys Cys Gly Lys Ser Phe Lys Lys 230 235 Arg Tyr Thr Phe Lys Met His Leu Leu Thr His Ile Gln Ala Val 245 250 255 Ala Asn Arg Arg Phe Lys Cys Glu Phe Cys Glu Phe Val Cýs Glu 260 265 270 Asp Lys Lys Ala Leu Leu Asn His Gln Leu Ser His Val Ser Asp Lys Pro Phe Lys Cys Ser Phe Cys Pro Tyr Arg Thr Phe Arg Glu 290 295 Asp Phe Leu Leu Ser His Val Ala Val Lys His Thr Gly Ala Lys 305 310 315 Pro Phe Ala Cys Glu Tyr Cys His Phe Ser Thr Arg His Lys Lys 325 320 330 Asn Leu Arg Leu His Val Arg Cys Arg His Ala Ser Ser Phe Glu 335 345 340 Glu Trp Gly Arg Arg His Pro Glu Glu Pro Pro Ser Arg Arg Arg 355 Pro Phe Phe Ser Leu Gln Gln Ile Glu Glu Leu Lys Gln Gln His

```
WO 01/62927
                365
Ser Ala Ala Pro Gly Pro Pro Pro Ser Ser Pro Gly Pro Pro Glu
                380
                                     385
                                                          390
Ile Pro Pro Glu Ala Thr Thr Phe Gln Ser Ser Glu Ala Pro Ser
                                                          405
                395
                                     400
Leu Leu Cys Ser Asp Thr Leu Gly Gly Ala Thr Ile Ile Tyr Gln
                410
                                     415
Gln Gly Ala Glu Glu Ser Thr Ala Met Ala Thr Gln Thr Ala Leu
                                     430
                425
Asp Leu Leu Asn Met Ser Ala Gln Arg Gly Pro Gly Gly Thr
                440
                                     445
                                                          450
Ala Leu Gln Val Cys Cys Leu Gly Thr Cys Ser Pro Ser Gln Leu
                455
                                     460
                                                          465
Pro Gln Tyr Pro Ala Leu His Trp Thr Leu Gly Leu Glu Glu Asn
                470
                                     475
                                                          480
Ser Val Ser Glu Leu Leu Arg Pro Trp Gly Leu Pro Gly Ser Gly
                                     490
                                                          495
                485
Gly Asp Arg Ser Ala Glu Val Trp Trp Ala Asn Arg Glu Glu Gln
                500
                                     505
Ala Leu Pro Arg Arg Pro Gln Gly Ile Pro Ser Ile
                515
                                     520
<210> 268
<211> 267
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:133095.1.orf2:2000FEB01
<220>
<221> unsure
<222> 36
<223> unknown or other
<400> 268
Gly Leu Gly Glu Glu Val Pro Cys Ala Met Met Glu Gly Val Ala
                                       10
Ala Tyr Thr Gln Thr Glu Pro Glu Gly Ser Gln Pro Ser Thr Met
                                       25
                  20
Asp Ala Thr Ala Val Xaa Gly Ile Glu Thr Lys Lys Glu Lys Glu
                  35
                                                           45
                                       40
Asp Leu Cys Leu Leu Lys Lys Glu Glu Lys Glu Glu Pro Val Ala
                  50
Pro Glu Leu Ala Thr Thr Val Pro Glu Ser Ala Glu Pro Glu Ala
                                      70
                  65
Glu Ala Asp Gly Glu Glu Leu Asp Gly Ser Asp Met Ser Ala Ile
                                      85
                 80
Ile Tyr Glu Ile Pro Lys Glu Pro Glu Lys Arg Arg Arg Ser Lys
                                                          105
                  95
                                     100
```

Arg Ser Arg Val Met Asp Ala Asp Gly Leu Leu Glu Met Phe His

Cys Pro Tyr Glu Gly Cys Ser Gln Val Tyr Val Ala Leu Ser Ser

Phe Gln Asn His Val Asn Leu Val His Arg Lys Gly Lys Thr Lys

Val Cys Pro His Pro Gly Cys Gly Lys Lys Phe Tyr Leu Ser Asn

His Leu Arg Arg His Met Ile Ile His Ser Gly Val Arg Glu Phe

Thr Cys Glu Thr Cys Gly Lys Ser Phe Lys Arg Lys Asn His Leu

Glu Val His Arg Arg Thr His Thr Gly Glu Thr Pro Leu Gln Cys

Glu Ile Cys Gly Tyr Gln Cys Arg Gln Arg Ala Ser Leu Asn Trp

```
His Met Lys Lys His Thr Ala Glu Val Gln Tyr Asn Phe Thr Cys
                230
                                     235
Asp Arg Cys Gly Lys Arg Phe Glu Lys Leu Asp Ser Val Lys Phe
                245
                                     250
His Thr Leu Lys Ser His Pro Asp His Lys Pro Thr
                260
                                     265
<210> 269
<211> 286
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:236654.2.orf2:2000FEB01
<400> 269
Arg Pro Leu Pro Ala Asp Leu Pro Val Gly Gly His His Cys Leu
His Gly Pro Gln Glu Ala Gly Leu Ser Ala Leu Gln Arg Pro Gln
                 20
Pro Arg Pro Gly Leu Arg Thr Arg Gly Ala Glu Gly Leu Glu Leu
                                      40
Pro Ala Leu Trp Gln Thr Val His Ser Gly Leu Glu Ala Ala Ala
Ser Arg Pro Val Gly Pro Arg Thr Val His Leu Pro Asp Arg Ile
                                      70
Arg Gly Pro Gly Gly Pro Val Leu Gly Leu Ala Glu Val Ala Ala
                 80
                                      85
Ala Val Ser Ala Val Val Gly Pro Ala Ala Glu Ala Lys Ser Pro
                 95
                                     100
                                                         105
Arg Ala Ser Gly Ser Gly Leu Thr Arg Arg Ser Pro Pro Val Leu
                                     115
                110
Cys Ala Arg Arg Pro Ser Ala Pro Ser Ala Thr Ser Lys Cys Thr
                125
                                     130
Cys Ala His Thr Gln Ala Ser Gly Pro Met Leu Ala Thr Ser Val
                                     145
                140
                                                          150
Pro Thr Pro Ala Pro Arg Ala Ala Ser Ser Thr Ala Thr Arg Arg
                155
                                     160
Pro Thr Gly Arg Cys Arg Pro Arg Ala Pro Ser Trp Pro Thr Pro
                170
                                     175
Ala Arg Ser Arg Pro Leu Gln Pro Leu Arg Ser Arg Leu Ser Met
                185
                                     190
                                                          195
Leu Leu Pro Pro Pro Ala Pro Phe His Ala Ala Val Val Arg Gly
                200
                                     205
                                                          210
Leu Glu Pro Pro Pro Gln Gln Val Ser Arg Asn Pro Gly Leu Leu
                215
                                     220
Ala Val Gly Leu Lys Pro Ala Leu Val Glu Thr Leu Gly Glu Pro
                230
Ser Pro Arg Asn Lys Glu Leu Thr Leu Gln Thr Ala Arg Arg His
                245
                                     250
His Pro Lys Arg Cys Pro Ser Gln Gly Ala Arg Ala Ala Gly Pro
                260
                                     265
                                                          270
Gly Ala Ala Val Ser Ser Ala Gly Ser Ile Leu Pro Thr Ala Ala
                275
                                     280
Thr
<210> 270
<211> 194
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:200009.1.orf3:2000FEB01
```

```
<400> 270
Gly Leu Ser Pro Lys. Ala Ala Asn Leu Ala Pro Thr Thr Gln Gln
                                      10
Arg Ser Val Val Phe Pro Gln Thr Pro Cys Ser Arg Asn Phe Ser
                                                           30
                 20
Leu Leu Asp Lys Ser Gly Pro Ile Glu Ser Gly Phe Asn Gln Ile
                                      40
Asn Val Lys Asn Gln Arg Val Leu Ala Ser Pro Thr Ser Thr Ser
                                      55
                                                           60
                 50
Gln Leu His Ser Glu Phe Ser Asp Trp His Leu Trp
                                                 Lys Cys Gly
                                      70
                 65
Gln Cys Phe Lys Thr Phe Thr Gln Arg Ile Leu Leu Gln Met His
                                                           90
                                      85
                 80
Val Cys Thr Gln Asn Pro Asp Arg Pro Tyr Gln Cys Gly His Cys
                 95
                                     100
                                                          105
Ser Gln Ser Phe Ser Gln Pro Ser Glu Leu Arg Asn His Val Val
                110
Thr His Ser Ser Asp Arg Pro Phe Lys Cys Gly Tyr Cys Gly Arg
                125
                                     130
Ala Phe Ala Gly Ala Thr Thr Leu Asn Asn His Ile Arg Thr His
                                    . 145
                                                          150
                140
Thr Gly Glu Lys Pro Phe Lys Cys Glu Arg Cys Glu Arg Ser
                                                          Phe
                155
                                     160
                                                          165
Thr Gln Ala Thr Gln Leu Ser Arg His Gln Arg Met Pro Asn Glu
                170
                                     175
                                                          180
Cys Lys Pro Ile Thr Glu Ser Pro Glu Ser Ile Glu Val Asp
                185
                                     190
<210> 271
<211> 263
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:758502.1.orf3:2000FEB01
<400> 271
Thr Leu Ile Lys His Gln Arg Thr His Thr Gly Glu Arg Pro Tyr
                                                           15
                                      10
                    Gly Lys Thr Phe Gly Arg Lys Pro His
                                                         Leu
Glu Cys Pro Glu Cys
                                                           30
                  20
                                      25
                    Thr His Thr Gly Glu Lys Pro Tyr Ala Cys
Ile Met His Gln Arg
                                                           45
                 35
                                      40
Leu Glu Cys His Lys Ser Phe Ser Arg Ser
                                         Ser Asn Phe Ile Thr
                  50
                                      55
                                                           60
His Gln Arg Thr His Thr Gly Val Lys Pro
                                         Tyr Arg Cys Asn Asp
                  65
                                      70
                                                           75
Cys Gly Glu Ser Phe Ser Gln Ser Ser Asp Leu Ile Lys His Gln
                 80
                                      85
                                                           90
Arg Thr His Thr Gly
                     Glu Arg Pro Phe Lys Cys Pro Glu Cys Gly
                 95
                                     100
                                                          105
Lys Gly Phe Arg Asp Ser Ser His Phe Val Ala His Met Ser Thr
                                                          120
                110
                                     115
His Ser Gly Glu Arg Pro Phe Ser Cys Pro Asp Cys His Lys Ser
                                     130
Phe Ser Gln Ser Ser His Leu Val Thr His Gln Arg Thr His Thr
```

145

160

175

190

205

Ile His Thr Gly Glu

195

Gly Glu Arg Pro Phe Lys Cys Glu Asn Cys Gly Lys Gly Phe Ala

Arg Pro Tyr Lys Cys Gly Glu Cys Gly Lys Ser Phe Asn Gln Ser

Ser His Phe Ile Thr His Gln Arg Ile His Leu Gly Asp Arg Pro

Tyr Arg Cys Pro Glu Cys Gly Lys Thr Phe Asn Gln Arg Ser His

140

155

170

185

200

Asp Ser Ser Ala Leu Thr Lys His Gln Arg

WO 01/62927 PCT/US01/06059 220 225 Phe Leu Thr His Gln Arg Thr His Thr Gly Glu Lys Pro Phe His 230 235 240 Cys Ser Lys Cys Asn Lys Ser Phe Arg Gln Lys Ala His Leu Leu 245 250 Cys His Gln Asp Thr His Leu Ile 260 <210> 272 <211> 142 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:344772.1.orf2:2000FEB01 <221> unsure <222> 142 <223> unknown or other <400> 272 Ala Lys Asn Leu Phe Lys Met Asp Ile Glu Asp Cys Asn Gly Arg 10 Ser Tyr Val Ser Gly Ser Gly Asp Ser Ser Leu Glu Lys Glu Phe 20 25 Leu Gly Ala Pro Val Gly Pro Ser Val Ser Thr Pro Asn Ser Gln 35 40 45 His Ser Ser Pro Ser Arg Ser Leu Ser Ala Asn Ser Ile Lys Val 50 55 60 Glu Met Tyr Ser Asp Glu Glu Ser Ser Arg Leu Leu Gly Pro Asp 75 65 70 Glu Arg Leu Leu Glu Lys Asp Asp Ser Val Ile Val Glu Asp Ser 85 80 Leu Ser Glu Pro Leu Gly Tyr Cys Asp Gly Ser Gly Pro Glu Pro 95 100 105 His Ser Pro Gly Gly Ile Arg Leu Pro Asn Gly Lys Leu Lys Cys 110 115 120 Asp Val Cys Gly Met Val Cys Ile Gly Pro Asn Val Leu Met Val 125 130 His Lys Arg Ser His Thr Xaa 140 <210> 273 <211> 164 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:789445.1.orf2:2000FEB01 <400> 273 Glu His Arg Glu Ala Lys Ala Ser Gly Trp Val Thr Asp Gly Leu 10 15 Leu Met Asp Ser Ser Gln His Leu Val Thr Phe Glu Asp Val Ala Val Asp Phe Thr Gln Glu Glu Trp Thr Leu Leu Asp Gln Ala Gln 35 40 45 Arg Asp Leu Tyr Arg Asp Val Met Leu Glu Asn Tyr Lys Asn Leu 50 55 60 Ile Ile Leu Ala Gly Ser Glu Leu Phe Lys Arg Ser Leu Met Ser 65 70 75 Gly Leu Glu Gln Met Glu Glu Leu Arg Thr Gly Val Thr Gly Val

142/228

Leu Gln Glu Leu Asp Leu Gln Leu Lys Thr Lys Gly Ser Pro Leu

```
95
                                     100
                                                          105
Leu Gln Asp Ile Ser Ala Glu Arg Ser Pro Asn Gly Val Gln Leu
                110
                                     115
Glu Arg Ser Asn Thr Ala Glu Lys Leu Tyr Asp Ser Asn His Ser
                125
                                     130
                                                          135
Gly Lys Val Phe Asn Glu His Pro Phe Leu Met Thr His Met Ile
                140
                                     145
Thr His Ile Gly Glu Lys Thr Ser Glu Asp Asn Gln Ser Gly
                155
                                     160
<210> 274
<211> 107
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:789657.1.orf2:2000FEB01
<220>
<221> unsure
<222> 5
<223> unknown or other
<400> 274
Met Trp Gln Val Xaa Ser Lys Ser Ser His Leu Ala Val His Gln
                                      10
                                                           15
Arg Ile His Thr Gly Glu Lys Pro Tyr Lys Cys Asn Arg Cys Gly
                                                           30
                 20
                                      25
Lys Cys Phe Ser Gln Ser Ser Leu Ala Arg His Gln Thr Val
                 35
                                      40
                                                           45
His Thr Gly Glu Lys Pro Tyr Ile Cys Ala Glu Cys Gly Lys Ala
                 50
                                      55
                                                           60
Phe Ser Gln Lys Ser Asp Leu Val Val His Gln Ile Ile His Thr
                 65
Gly Glu Lys Pro Asp Arg Cys Thr Val Cys Gly Lys Ala Phe
                                                         Ile
                                      85
                                                           90
                 80
Gln Lys Ser Gln Leu Thr Val His Gln Arg Ile His Thr Leu Met
                 95
                                     100
Lys Ser
<210> 275
<211> 105
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:789808.1.orf3:2000FEB01
<400> 275
Glu His Thr Asp Gly Lys Ser Tyr Ala Cys Ile Gln Cys Gly Lys
                                      10
                                                           15
                    Tyr Ser Phe Thr Glu His Leu Arg Arg His
Phe Phe Cys Cys Tyr
                                      25
Thr Gly Glu Lys Pro Phe Gly Cys Asn Glu Cys Gly Lys Thr Phe
                 35
                                      40
                                                           45
His Gln Lys Leu Ala Leu Ile Val His Gln Arg Thr His Ile Arg
                 50
                                      55
                                                           60
Gln Lys Pro Tyr Gly Cys Asn Glu Cys Gly Lys Ser Phe Cys Val
                 65
                                      70
                                                           75
Lys Ser Lys Leu Ile Ala His His Arg Thr Tyr Thr Gly Glu Lys
                 80
                                      85
Pro Tyr Glu Cys Asn Val Cys Gly Lys Leu Leu Ser Gln Asn
                                     100
```

WO 01/62927 <210> 276 <211> 149 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:792919.1.orf1:2000FEB01 <400> 276 His Gln Met Ile His Met Gly Gln Asn Pro Tyr Asn Cys Lys Glu 10 Cys Gly Lys Ser Phe Lys Trp Ser Ser Tyr Leu Leu Val His Gln 30 Arg Val His Thr Gly Glu Lys Pro Tyr Lys Cys Glu Glu Cys Gly 35 40 45 Lys Gly Tyr Ile Ser Lys Ser Gly Leu Asp Phe His His Arg Thr 50 55 His Thr Gly Glu Arg Ser Tyr Asn Cys Asp Asn Cys Gly Lys Ser 65 70 75 Phe Arg His Ala Ser Ser Ile Leu Asn His Lys Lys Leu His Cys 90 85 Gln Arg Lys Pro Leu Lys Cys Glu Asp Cys Gly Lys Arg Leu Val 95 100 Cys Arg Ser Tyr Cys Lys Asp Gln Gln Arg Asp His Ser Gly Glu 110 115 120 Asn Pro Ser Lys Cys Glu Asp Cys Gly Lys Arg Tyr Lys Arg 125 130 Leu Asn Leu Asp Ile Ile Leu Ser Leu Phe Leu Asn Asp Ile <210> 277 <211> 101 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:793949.1.orf3:2000FEB01 <400> 277 Asp Thr Gly Thr Ser Trp Lys Pro Lys Met Gly Pro Leu Gln Phe 10 Arg Asp Val Ala Ile Asp Phe Ser Gln Glu Glu Trp His Cys Leu 20 25 Asp Thr Ala Gln Arg Asp Leu Tyr Arg Cys Val Met Leu Glu Asn Tyr Ser Asn Leu Val Phe Leu Gly Ile Thr Val Ser Lys Pro Asp 55 50 60 Val Ile Ser Ser Leu Glu Gln Gly Arg Lys Pro Leu Thr Met Lys 65 70 Arg Asn Glu Met Ile Ala Lys Pro Ser Val Ser Phe Leu Gln Val 80 85 His Ser Glu Ser Gln Ser Pro Leu His Asp Ile 95 100 <210> 278 <211> 137 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:794389.1.orf3:2000FEB01 <220>

PCT/US01/06059

144/228

<221> unsure

<222> 23 <223> unknown or other <400> 278 Gly Leu Gln Lys Thr Phe Cys Arg Val Met Gln Phe Thr Leu His 10 Arg Arg Ile His Thr Gly Glu Xaa Pro Tyr Glu Cys Lys Glu Cys 30 20 Gly Lys Ser Phe Ser Ala His Ser Ser Leu Val Thr His Lys Arg 35 40 45 Thr His Ser Gly Glu Lys Pro Tyr Lys Cys Lys Glu Cys Gly Lys 55 60 50 Ala Phe Ser Ala His Ser Ser Leu Val Thr His Lys Arg Thr His 70 Ser Gly Glu Lys Pro Tyr Thr Cys His Ala Cys Gly Lys Ala Phe 85 90 80 Asn Thr Ser Ser Thr Leu Cys Gln His Asn Arg Ile His Thr Gly 95 100 105 Glu Lys Pro Phe Gln Cys Ser Gln Cys Gly Lys Ser Phe Ser Cys 115 120 110 Ser Ser His Leu Thr Arg His Cys Arg Met Cys Asn Gly Lys 135 125 130 Ser Lys <210> 279 <211> 97 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:796010.1.orf3:2000FEB01 <220> <221> unsure <222> 4, 18, 23 <223> unknown or other <400> 279 Leu Cys Ile Xaa Lys His Thr Gly Glu Lys Pro Tyr Glu Cys Tyr Ala Cys Xaa Asn Thr Phe Leu Xaa Lys Ser Asp Leu Ile Lys His 25 20 Gln Arg Ile His Thr Gly Glu Lys Pro Tyr Glu Cys Asn Glu Cys 40 35 Gly Lys Ser Phe Ser Glu Lys Ser Thr Leu Thr Lys His Leu Arg 55 60 50 Thr His Arg Trp Glu Ile Leu Cys Met Tyr
65 70 Ser Met Trp Lys Ile 75 65 Phe Leu Leu Leu Gln Phe His Arg Thr Ser Glu Lys Thr His 80 85 Arg Gly Glu Thr Phe Trp Met <210> 280 <211> 97 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:796324.1.orf2:2000FEB01 <220> <221> unsure

<222> 93

<223> unknown or other

<400> 280 Leu Cys Ile Arg Lys' His Thr Gly Glu Lys Pro Tyr Glu Cys Tyr Ala Cys Gly Asn Thr Phe Leu Arg Lys Ser Asp Leu Ile Lys His 20 Gln Arg Ile His Thr Gly Glu Lys Pro Tyr Glu Cys Asn Glu Cys 35 40 Gly Lys Ser Phe Ser Glu Lys Ser Thr Leu Thr Lys His Leu Arg 55 60 50 Thr His Arg Trp Glu Ile Leu Cys Met Tyr Ser Met Trp Lys Ile 70 75 65 Phe Leu Leu Leu Gln Phe His Arg Thr Ser Glu Lys Thr His , 85 90 80 Arg Gly Xaa Thr Phe Trp Met 95

<210> 281 <211> 179 <212> PRT

<213> Homo sapiens

<220> <221> misc_feature

<223> Incyte ID No: LI:796373.1.orf1:2000FEB01

<400> 281 Met Trp Glu Ser Phe Ser Gln Lys Thr Cys Leu Ile Ser His Gln 15 10 Arg Phe His Thr Gly Lys Thr Pro Phe Val Cys Thr Glu Cys Gly 30 20 25 Lys Ser Cys Ser His Lys Ser Gly Leu Ile Asn His Gln Arg Ile 45 35 His Thr Gly Glu Lys Pro Tyr Thr Cys Ser Asp Cys Gly Lys Ala 60 50 55 Phe Arg Asp Lys Ser Cys Leu Asn Arg His Arg Arg Thr His Thr 75 70 65 Gly Glu Arg Pro Tyr Gly Cys Ser Asp Cys Gly Lys Ala Phe Ser 90 85 80 His Leu Ser Cys Leu Val Tyr His Lys Cly Met Leu His Ala Arg 95 100 Glu Lys Cys Val Gly Ser Val Lys Leu Glu Asn Pro Cys Ser Glu 110 120 115 Ser His Ser Leu Ser His Thr Arg Asp Leu Ile Gln Asp Lys Asp 135 125 130 Ser Val Asn Met Val Thr Leu Gln Met Pro Ser Val Ala Ala Gln 150 140 145 Thr Ser Leu Thr Asn Ser Ala Phe Gin Ala Glu Ser Lys Val Ala 155 160 Ile Val Ser Gln Pro Val Ala Arg Ser Ser Val Ser Ala Asp

<210> 282

<211> 87

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: LI:796415.1.orf3:2000FEB01

170

<400> 282

Lys His Glu Ile Ile His Phe Glu Glu Glu Pro Ser Glu Tyr Asn 1 5 10 15 Asn Asn Gly Asn Ser Phe Trp Leu Asn Glu Asp Leu Ile Trp His 20 25 30

146/228

```
Gln Lys Ile Lys Asn Trp Glu Gln Pro Phe Glu Tyr Asn Glu Cys
                 35,
                                      40
Gly Lys Ala Phe Pro Glu Asn Ser Leu Phe Leu Val His Lys Arg
                 50
                                      55
                                                           60
Ala Tyr Thr Gly Gln Lys Thr Cys Lys Tyr
                                         Thr Glu His Gly Lys
                                      70
                                                           75
                 65
Thr Cys Tyr Met Ser Phe Phe Ile Thr His Gln Gln
               80
<210> 283
<211> 172
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:798636.1.orf2:2000FEB01
<400> 283
Asn Glu Cys Gly Lys Ala Leu Ser Ser His Ser Thr Leu Ile Ile
                                      10
His Glu Arg Ile His Thr Gly Glu Lys Pro Cys Lys Cys Lys Val
                                      25
                 20
Cys Gly Lys Ala Phe Arg Gln Ser Ser Ala Leu Ile Gln His Gln
                                      40
                 35
                                                           45
Arg Met His Thr Gly Glu Arg Pro Tyr Lys
                                         Cys Asn Glu Cys Asp
                 50
                                      55
                                                           60
Lys Thr Phe Arg Cys Asn Ser Ser Leu Ser Asn His Gln Arg Ile
                 65
                                      70
                                                           75
His Thr Gly Glu Lys Pro Tyr Arg Cys Leu Glu Cys Gly Met Ser
                 80
                                      85
                                                           90
Phe Gly Gln Ser Ala Ala Leu Ile Gln His Gln Arg Ile His Thr
                 95
                                     100
                                                          105
Gly Glu Lys Pro Phe Lys Cys Asn Thr Cys Gly Lys Thr Phe Arg
                                     115
                                                          120
                110
Gln Ser Ser Leu Ile Ala His Gln Arg Ile His Thr Gly Glu
                125
                                     130
Lys Pro Tyr Glu Cys Asn Ala Cys Gly Lys Leu Phe Ser Gln Arg
                                     145
                                                          150
                140
Ser Ser Leu Thr Asn His Tyr Lys Ile His Ile Glu Glu Asp Ser
                                                          165
                155
                                     160
Leu Lys Ala Asp Leu His Val
                170
<210> 284
<211> 151
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:800045.1.orf1:2000FEB01
<220>
<221> unsure
<222> 104
<223> unknown or other
<400> 284
Lys Ile Met His Thr Gly Glu Lys Arg Tyr Glu Cys Asp Asp Cys
                                                           15
                                      10
Gly Gly Thr Phe Arg Ser Ser Ser Leu Arg Val His Lys Arg
                                                           30
                 20
                                      25
Ile His Thr Gly Glu Lys Pro Tyr Lys Cys Glu Glu Cys Gly Lys
                 35
                                                           45
Ala Tyr Met Ser Tyr Ser Ser Leu Ile Asn His Lys Ser Thr His
                 50
```

```
WO 01/62927
Ser Gly Glu Lys Asn Cys Lys Cys Asp Glu Cys Gly Lys Ser Phe
                 65
                                      70
Asn Tyr Ser Ser Val Leu Asp Gln His Lys Arg Ile His Thr Gly
                 80
                                      85
                                                          90
Glu Lys Pro Tyr Glu Cys Gly Glu Cys Gly Lys Ala Phe Xaa Asn
                 95
                                     100
Ser Ser Gly Leu Arg Val His Lys Arg Ile His Thr Gly Glu Lys
                110
                                     115
Pro Tyr Glu Cys Asp Ile Cys Gly Lys Thr Phe Ser Asn Ser Ser
                125
                                     130
                                                          135
Gly Leu Thr Val His Lys Arg Ile His Thr Val Ser Asp Glu Leu
                140
                                     145
                                                         150
Pro
<210> 285
<211> 89
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:800680.1.orf2:2000FEB01
<400> 285
Leu Thr Tyr Leu Arg Lys Lys Leu Arg Gly Arg Gly Lys Lys Glu
Glu Glu Gly Met Ala Leu Ser Gln Gly Leu Phe Thr Phe Lys Asp
                 20
Val Ala Ile Glu Phe Ser Gln Glu Glu Trp Glu Cys Leu Asp Pro
Ala Gln Arg Ala Leu Tyr Arg Asp Val Met Leu Glu Asn Tyr Arg
                                      55
                 50
Asn Leu Leu Ser Leu Asp Glu Asp Asn Ile Pro Pro Glu Asp Gly
                 65
                                      70
Ser His Leu Ala Ala Cys Gly Gln Ser Thr Leu Pro Leu Pro
                 80
<210> 286
<211> 146
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:800894.1.orf2:2000FEB01
<400> 286
Pro Ala Gly Ile Gly Arg Ser Thr Thr Lys Ser Pro Gly Pro Pro
Gly Ser Leu Glu Met Gly Ser Leu Thr Phe Arg Asp Val Ala Ile
                 20
                                      25
Glu Phe Ser Leu Glu Glu Trp Gln Cys Leu Asp Thr Ala Gln Gln
                                      40
Asn Leu Tyr Arg Asn Val Met Leu Glu Asn Tyr Arg Asn Leu Val
                 50
                                      55
Phe Leu Gly Ile Ala Ala Phe Lys Pro Asp Leu Ile Ile Phe Leu
                 65
                                      70
                                                          75
```

Glu Glu Gly Lys Glu Ser Trp Asn Met Lys Arg His Glu Met Val

Glu Glu Ser Pro Val Ile Cys Ser His Phe Ala Gln Asp Leu Trp

Pro Glu Gln Gly Ile Glu Asp Ser Phe Gln Lys Val Ile Leu Arg

Arg Tyr Lys Ile His His His Ala Cys Glu Leu Gly Pro Ile Met

80

95

110

125

Asn His Tyr Pro Thr Cys Gly Gln Met His Ile

148/228

85

100

90

```
<210> 287
<211> 78
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:801015.1.orf1:2000FEB01
<400> 287
Gly Ser Arg Lys Met Asp Ser Val Ala Phe Glu Asp Val Ala Val
                                      10
Asn Phe Thr Gln Glu Glu Trp Ala Leu Leu Asp Pro Trp Gln Lys
                                                           30
                 20
                                      25
Lys Leu Tyr Arg Asp Val Met Leu Glu Thr Tyr Arg Asn Leu Ala
                  35
                                       40
                    Asp Asn Ile Pro Ser Leu Arg Glu Gln Val
Ser Val Gly Asp Asp
                 50
                                      55
Ala His Gln Arg Tyr Phe Lys Thr Trp His Val Glu Arg Glu Tyr
Phe Ser Lys
<210> 288
<211> 126
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:801236.1.orf3:2000FEB01
<220>
<221> unsure
<222> 4
<223> unknown or other
<400> 288
Met Trp Glu Xaa Phe Ser His Thr Pro Ala Phe Ile Gln His Gln
                                                           15
                                       10
Arg Ile His Thr Gly Glu Lys Pro Tyr Glu Cys Asn Ala Cys
                                                          Gly
                  20
                                       25
                                                           30
Lys Ala Phe Asn Arg Ser Ala His Leu Thr Glu His Gln Arg Thr
His Thr Gly Glu Lys Pro Tyr Val Cys Lys Glu Cys Gly Lys Thr
                  50
                                       55
Phe Ser Arg Ser Thr His Leu Thr Glu His Leu Lys Ile His Ser
                                                           75
                  65
                                       70
Cys Val Lys Pro Tyr Gln Cys Asn Glu Cys Gln Lys Leu Phe Cys
                                                           90
                                       85
                  80
Tyr Arg Thr Ser Leu Ile Arg His Gln Arg Thr His Thr Gly Glu
                                                           105
                  95
                                      100
Lys Pro Tyr Gln Cys Asn Glu Cys Gly Lys Ser Phe Ser Leu Ser
                 110
                                      115
                                                           120
Ser Ala Leu Thr Lys His
                125
<210> 289
<211> 96
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:803335.1.orf1:2000FEB01
```

```
<400> 289
Ser Ala Ala Met Phe Pro Val Phe Ser Gly Cys Phe Gln Glu Leu
Gln Glu Lys Asn Lys Ser Leu Glu Leu Val Ser Phe Glu Glu Val
                                      25
Ala Val His Phe Thr Trp Glu Glu Trp Gln Asp Leu Asp Asp Ala
                                      40
Gln Arg Thr Leu Tyr Arg Asp Val Met Leu Glu Thr Tyr Ser Ser
                 50
                                      55
Leu Val Ser Leu Gly His Cys Ile Thr Lys Pro Glu Met Ile Phe
                                      70
                 65
Lys Leu Glu Gln Gly Ala Glu Pro Trp Ile Val Glu Glu Thr Leu
                 80
                                      85
                                                          90
Asn Leu Arg Leu Ser Gly
                 95
<210> 290
<211> 149
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature -
<223> Incyte ID No: LI:803998.1.orf1:2000FEB01
<400> 290
Lys Asn Ser Tyr Trp Arg Lys Asn Pro Thr Asn Met Lys Asn Val
                                      10
                                                          15
Ala Lys Leu Leu Ile Asn Ser Gln Arg Leu Leu Asn Ile Arg Glu
                 20
                                      25
                                                          30
Phe Val Gln Glu Gly Asn Pro Thr Asn Leu Lys Asn Val Ala Ser
                                      40
Leu Leu Ala Ile Pro Gln Ser Leu Leu Asn Ile His Val Ile His
                 50
                                      55
Thr Gly Gly Asn Ser Tyr Asn Cys Val Glu Cys Cys Asn Ala Leu
                 65
                                      70
Asn Gln Ser Leu Arg Leu Thr Thr Tyr Lys Thr Thr His Thr Gly
                80
                                                          90
                                      85
Glu Lys Pro Cys Met Cys Glu Glu Cys Gly Lys Ala Ser Asn Arg
                 95
                                     100
Ser Ser Ile Leu Lys Arg His Lys Leu Ile His Thr Gln Glu Arg
                110
                                     115
                                                          120
Leu Tyr Lys Pro Glu Arg Cys Asp Asn Ala Phe Gly Asn Thr Ser
                125
                                     130
Asp Phe Ser Glu Tyr Lys Arg Asn Arg Thr Asp Glu Lys Ser
                140
                                     145
<210> 291
<211> 134
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:478757.1.orf2:2000FEB01
<400> 291
Trp Trp Glu Ile Cys Ala His Ser Asp Val Ala Ala Glu Glu Gly
Lys Ala Arg Arg Ser Arg Gln His Arg Phe Leu Gly Thr Cys Glu
                 20
                                      25
Gly Ile Met Arg Arg Ala Glu Leu Ser Ser Gln Val Glu Asp Ser
                                                           45
                                      40
Thr Leu His Ala Trp Ile Arg Tyr Ser Leu Val Leu Asp Val Asp
                 50
                                                           60
                                      55
Cys Trp His Ile Ala Ala Gln Leu Glu Met Tyr Gly Cys Pro His
                                      70
```

150/228

```
Leu Asp Leu Thr Glu Ser Arg Gly Ala Ala Ala Arg Lys Leu His
Leu Leu Gly Phe Ser Ala Leu Pro Thr Leu Val Asp Met Ile Thr
                 95
                                     100
Ser Gln Gly Ser Val Ser Phe Arg Asp Val Thr Met Gly Phe Thr
                110
                                     115
Gln Glu Glu Trp His His Leu Asp Pro Ala Gln Arg Thr Leu
                125
                                     130
<210> 292
<211> 212
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:808532.1.orf2:2000FEB01
<400> 292
His Asn Phe Gln Leu Gln Lys His His Arg Ile His Thr Gly Glu
                                      10
                    Glu Ile Cys Gly Lys Ser Phe Cys Leu Arg
Lys Pro Phe Lys Cys
                 20
                                      25
                                                           30
                    His Cys Met Val His Thr Ala Glu Lys Leu
Ser Ser Leu Asn Arg
                 35
                                      40
                                                           45
Tyr Lys Ser Glu Lys Tyr Gly Arg Gly Phe Ile Asp Arg Leu Asp
                                                           60
Leu His Lys His Gln Met Ile His Met Gly Gln Lys Pro Tyr Asn
                 65
                                      70
                                                           75
Cys Lys Glu Cys Gly Lys Ser Phe Lys Trp Ser Ser Tyr Leu Leu
                 80
                                      85
Val His Gln Arg Val His Thr Gly Glu Lys Pro Tyr Lys Cys
                                                         Glu
                 95
                                     100
Glu Cys Gly Lys Gly Tyr Ile Ser Lys Ser Gly Leu Asp Phe His
                                                          120
                110
                                     .115
His Arg Thr His Thr Gly Glu Arg Ser Tyr Asn Cys Asp Asn Cys
                125
                                     130
                                                          135
Gly Lys Ser Phe Arg His Ala Ser Ser Ile Leu Asn His Lys
                140
                                     145
                                                          150
Leu His Cys Gln Arg Lys Pro Leu Lys Cys Glu Asp Cys Gly Lys
                155
                                     160
Arg Leu Val Cys Arg Ser Tyr Cys Lys Asp Gln Gln Arg Asp His
                170
                                     175
                                                          180
Ser Gly Glu Asn Pro Ser Lys Cys Glu Asp Cys Gly Lys Arg
                                                         Tvr
                                                          195
                                     190
                185
Lys Arg Arg Leu Asn Leu Asp Ile Ile Leu Ser Leu Phe Leu Asn
                200
Asp Ile
<210> 293
<211> 108
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:443073.1.orf2:2000FEB01
<400> 293
Lys Pro Tyr Met Cys Lys Glu Cys Arg Lys Thr Phe Ser Gln Asn
                                      10
Ala Gly Leu Ala Gln His Gln Arg Ile His Thr Gly Glu Lys Pro
                                                           30
                 20
                                      25
Tyr Glu Cys Asn Val Cys Gly Lys Ala Phe Ser Tyr Ser Gly Ser
                 35
```

Leu Thr Leu His Gln Arg Ile His Thr Gly Glu Arg Pro Tyr Glu

```
Cys Lys Asp Cys Arg Lys Ser Phe Arg Gln Arg Ala His Leu Ala
                 65
                                      70
His His Glu Arg Ile His Thr Met Glu Ser Phe Leu Thr Leu Ser
                 80
                                                          90
                                      85
Ser Pro Ser Pro Ser Thr Ser Asn Gln Leu Pro Arg Pro Val Gly
                 95
                                    100
                                                         105
Phe Ile Ser
<210> 294
<211> 83
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:479671.1.orf1:2000FEB01
<400> 294
Pro Ala Cys Thr Gly Gly Phe Ala Gly Arg Met Ser Gly His Pro
Gly Ser Trp Glu Met Asn Ser Val Ala Phe Glu Asp Val Ala Val
Asn Phe Thr Gln Glu Glu Trp Ala Leu Leu Asp Pro Ser Gln Lys
                                      40
                                                           45
Asn Leu Tyr Arg Asp Val Met Gln Glu Thr Phe Arg Asn Leu Ala
                 50
                                      55
                                                          60
Ser Ile Gly Asn Lys Gly Glu Asp Gln Ser Ile Glu Asp Gln Tyr
                 65
                                      70
Lys Asn Ser Ser Arg Asn Leu Arg
                 80
<210> 295
<211> 180
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:810078.1.orf1:2000FEB01
<400> 295
Pro Tyr Val Cys Lys Glu Cys Gly Lys Ala Phe Thr Gln Tyr Ser
Gly Leu Ser Met His Val Arg Ser His Ser Gly Asp Lys Pro Tyr
                                      25
                                                          30
                 20
Glu Cys Lys Glu Cys Gly Lys Ser Phe Leu Thr Ser Ser Arg Leu
Ile Gln His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Val Cys
                 50
                                      55
                                                           60
Val Glu Cys Gly Lys Ala Phe Ala Val Ser Ser Asn Leu Ser Gly
                 65
                                      70
                                                           75
His Leu Arg Thr His Thr Glu Glu Lys Ala Cys Glu Cys Lys Ile
                 80
                                      85
Cys Gly Lys Val Phe Gly Tyr Pro Ser Cys Leu Asn Asn His Met
                                                          105
Arg Thr His Ser Ala Gln Lys Pro Tyr Thr Cys Lys Glu Cys Gly
                110
                                     115
                                                          120
Lys Ala Phe Asn Tyr Ser Thr His Leu Lys Ile His Met Arg Ile
                125
                                     130
                                                          135
His Thr Gly Glu Lys Pro Tyr Glu Cys Lys Gln Cys Gly Lys Ala
                140
                                     145
                                                         150
Phe Ser His Ser Ser Ser Phe Gln Ile His Glu Arg Thr His Thr
                155
                                     160
                                                          165
Gly Glu Lys Pro Tyr Glu Cys Lys Glu Cys Gly Lys Ala Phe Thr
                                     175
```

```
<210> 296
<211> 97
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:810224.1.orf3:2000FEB01
<400> 296
Leu Cys Ile Ser Lys His Pro Gly Glu Lys Pro Tyr Glu Cys
                                      10
                                                           15
Ala Cys Gly Asn Thr Phe Leu Arg Lys Ser Asp Leu Ile Lys
                 20
                                      25
                                                           30
Gln Arg Ile His Thr Gly Glu Lys Pro Tyr Glu Cys Asn Glu Cys
                 35
                                      40
                                                           45
Gly Lys Ser Phe Ser Glu Lys Ser Thr Leu Thr Lys His Leu Arg
                 50
                                      55,
                                                           60
Thr His Arg Trp Glu Ile Leu Cys Met Tyr Ser Met Trp Lys Ile
                                      70
                                                           75
                 65
Phe Leu Leu Leu Gln Phe His Arg Thr Ser Glu Lys Pro
                                                         His
                 80
                                      85
Arg Gly Glu Thr Phe Trp Met
                 95
<210> 297
<211> 217
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:817052.2.orf1:2000FEB01
<400> 297
Ala Ala Pro Glu Ser Gln Gln Gln Arg Asn Arg Arg Gly Glu Arg
  1
                                      10
                                                           15
Pro Phe Thr Cys Met Glu Cys Gly Lys Ser Phe Arg Leu Lys Ile
                 20
                                      25
                                                           30
Asn Leu Ile Ile His Gln Arg Asn His Ile Lys Glu Gly Pro
                                                         Tyr
                 35
                                                           45
                                      40
Glu Cys Ala Glu Cys Glu Ile Ser Phe Arg His Lys Gln Gln Leu
Thr Leu His Gln Arg Ile His Arg Val Arg Gly Gly Cys Val Ser
                 65
                                      70
                                                           75
Pro Glu Arg Gly Pro Thr Phe Asn Pro Lys His Ala Leu Lys Pro
                                                           90
                 80
                                      85
Arg Pro Lys Ser Pro Ser Ser Gly Ser Gly Gly Gly Pro Lys
                                     100
                                                          105
                 95
Pro Tyr Lys Cys Pro Glu Cys Asp Ser Ser Phe Ser His Lys Ser
                110
                                     115
                                                          120
Ser Leu Thr Lys His Gln Ile Thr His Thr Gly Glu Arg Pro Tyr
                125
                                     130
                                                          135
Thr Cys Pro Glu Cys Lys Lys Ser Phe Arg Leu His Ile Ser Leu
                140
                                     145
Val Ile His Gln'Arg Val His Ala Gly Lys His Glu Val Ser Phe
                155
                                     160
                                                          165
Ile Cys Ser Leu Cys Gly Lys Ser Phe Ser Arg Pro Ser His Leu
                170
                                     175
                                                          180
Leu Arg His Gln Arg Thr His Thr Gly Glu Arg Pro Phe Lys
                                                         Cvs
                185
                                     190
                                                          195
Pro Glu Cys Glu Lys Ser Phe Ser Glu Lys Ser Lys Leu Thr Asn
                200
                                     205
His Cys Arg Val His Ser Arg
                215
```

WO 01/62927 <210> 298 <211> 137 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:892274.1.orf3:2000MAY19 <400> 298 Asp Gly Gly Leu Asp Leu Gly Pro Thr Asn Ser Glu Gly Ile Pro Ser Pro Asp Leu Asn Pro Val Leu Gly Met Gly Ser Trp Arg His 30 Ile Asp Ser Ile Thr Pro Gly Thr Pro Gly Ser Ala Gly Leu Asp 35 40 45 Leu Pro Ala Arg Glu Arg Ile Thr Leu Val Gly Gly Asp Lys Pro 50 55 60 Ile Lys Val Pro Thr Gly Ile Trp Gly Thr Ser Pro Ala Gly Tyr 70 65 Met Gly Leu Ile Leu Gly Lys Ser Arg Leu Asn Leu Gln Gly Met 80 85 90 Thr Val Val Pro Gly Ala Val Asp Ser Asp Tyr Glu Gly Glu Thr 95 100 Gln Val Val Leu Met Ser Gln Asp Leu Trp Val Phe Glu Leu Gly 110 115 120 Glu Tyr Ile Ala Gln Leu Leu Ile Pro Cys Lys Leu His Pro 125 130 135 Ser Pro <210> 299 <211> 169 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:1080959.1.orf2:2000MAY19 <400> 299 Pro Lys Gln Gly Ile Asn Val Trp Ser Pro Arg His Pro Glu Asn Phe Leu Gly Ile Glu Ser Arg Pro Pro Met Leu Ser Leu Ser Pro Ile Leu Leu Tyr Thr Cys Glu Met Phe Gln Asp Pro Val Ala Phe Lys Asp Val Ala Val Asn Phe Thr Gln Glu Glu Trp Ala Leu Leu 50 55 Asp Ile Ser Gln Lys Asn Leu Tyr Arg Glu Val Met Leu Glu Thr 65 70 Phe Trp Asn Leu Thr Ser Ile Gly Lys Lys Trp Lys Asp Gln Asn 80 85 Ile Glu Tyr Glu Tyr Gln Asn Pro Arg Arg Asn Phe Arg Ser Val 100 105 Thr Glu Glu Lys Val Asn Glu Ile Lys Glu Asp Ser His Cys Gly 110 115 120 Glu Thr Phe Thr Pro Val Pro Asp Asp Arg Leu Asn Phe Gln Lys 125 130 135 Lys Lys Ala Ser Pro Glu Val Lys Ser Cys Asp Ser Phe Val Cys 140 145 150 Glu Val Gly Leu Gly Asn Ser Ser Ser Asn Met Asn Ile Arg Gly 155 160 165 Asp Thr Gly His

PCT/US01/06059

<210> 300

```
<211> 135
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1054900.1.orf3:2000MAY19
Asp Ala Trp Ala Arg Pro Pro Val Leu Ser Leu Ser Pro Ile Leu
Leu Tyr Thr Cys Glu Met Phe Gln Asp Pro Val Ala Phe Asp Asp
                                                           30
                 20
                                      25
Val Ala Val Asn Phe Thr Gln Glu Glu Trp Ala Leu Leu Asp Ile
                 35
                                      40
                                                           45
Ser Gln Arg Lys Leu Tyr Lys Glu Val Met Leu Glu Thr Phe Arg
                 50
                                      55
Asn Leu Thr Ser Val Gly Lys Ser Trp Lys Asp Gln Asn Ile Glu
                 65
                                      70
Tyr Glu Tyr Gln Asn Pro Arg Arg Asn Phe Arg Ser Leu Ile Glu
                 80
                                      85
Lys Lys Val Asn Glu Ile Lys Asp Asp Ser His Cys Gly Glu Thr
                                     100
                 95
Phe Thr Gln Val Pro Asp Asp Arg Leu Asn Phe Gln Glu Lys Lys
                                                          120
                110
                                     115
Ala Ser Pro Glu Ile Lys Ser Cys Asp Ser Phe Val Cys Gly Lys
                                                          135
                125
<210> 301
<211> 170
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1077357.1.orf1:2000MAY19
<400> 301
Thr Val Met Leu Cys Asp Glu Glu Ala Gln Lys Arg Lys Ala Lys
                                      10
Glu Ser Gly Met Ala Leu Pro Gln Gly Arg Leu Thr Phe Met Asp
                                                           30
Val Ala Ile Glu Phe Ser Gln Glu Glu Trp Lys Ser Leu Asp Pro
                 35
                                      40
                                                           45
Gly Gln Arg Ala Leu Tyr Arg Asp Val Met Leu Glu Asn Tyr Arg
                 50
                                      55
                                                           60
Asn Leu Val Phe Leu Gly Ile Cys Leu Pro Asp Leu Ser Ile Ile
                 65
                                      70
Ser Met Leu Lys Gln Arg Arg Glu Pro Leu Ile Leu Gln Ser Gln
                                                           90
                                      85
                 80
Val Lys Ile Val Lys Asn Thr Asp Gly Arg Glu Cys Val Arg Ser
                                     100
                 95
Val Asn Thr Gly Arg Ser Cys Val Leu Gly Ser Asn Ala Glu Asn
                110
                                     115
                                                          120
Lys Pro Ile Lys Asn Gln Leu Gly Leu Thr Leu Glu Ser His Leu
                125
                                     130
Ser Glu Leu Gln Leu Phe Gln Ala Gly Arg Lys Ile Tyr Arg Ser
                                     145
                140
Asn Pro Val Glu Lys Phe Thr Asn His Arg Ser Ser Val Ser Pro
                155
                                     160
Leu Gln Lys Ile Ser
                170
<210> 302
<211> 181
```

155/228

<212> PRT

ď,

```
WO 01/62927

<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: LG:1084051.1.orf3:2000MAY19

<400> 302

Thr Ser Tyr Ile Arg Thr Lys Thr Tyr Glu Cys Asn
1
1
10

Lys Ile Pho Lys Cla Pro Ile His Ley Thr Clu His
```

Phe Ser Gln Ser Ala Ser Leu Ser Thr His Gln Arg Ile His Thr 50 55 60

Gly Glu Lys Pro Phe Glu Cys Glu Glu Cys Gly Lys Ala Phe Arg 65 70 75

His Arg Ser Ser Leu Asn Gln His His Arg Thr His Thr Gly Glu 80 85

Lys Pro Tyr Val Cys Asp Lys Cys Gln Lys Ala Phe Ser Gln Asn 95 100 105

Ile Ser Leu Val Gln His Leu Arg Thr His Ser Gly Glu Lys Pro 110 115

Phe Thr Cys Asn Glu Cys Gly Lys Thr Phe Arg Gln Ile Arg His
125
130
135
Leu Ser Glu His Ile Arg Ile His Thr Gly Glu Lys Pro Tyr Ala

Cys Thr Ala Cys Cys Lys Thr Phe Ser His Arg Ala Tyr Leu Thr
155 160 165
His His Gln Arg Ser Ile Leu Gly Arg Asp Leu Gln Cys Lys Glu

Cys

```
<210> 303
```

<211> 263 <212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: LG:1076853.1.orf1:2000MAY19

170

<400> 303

Ala Phe Ser Arg Cys Ser Ser Leu Val Gln His Glu Arg Thr His Thr Gly Glu Lys Pro Phe Glu Cys Ser Ile Cys Gly Arg Ala Phe 20 25 Gly Gln Ser Pro Ser Leu Tyr Lys His Met Arg Ile His Lys Arg 35 40 Gly Lys Pro Tyr Gln Ser Ser Asn Tyr Ser Ile Asp Phe Lys His 50 55 60 Ser Thr Ser Leu Thr Gln Asp Glu Ser Thr Leu Thr Glu Val Lys Ser Tyr His Cys Asn Asp Cys Gly Glu Asp Phe Ser His Ile Thr 80 85 90 Asp Phe Thr Asp His Gln Arg Ile His Thr Ala Glu Asn Pro Tyr 95 100 105 Asp Cys Glu Gln Ala Phe Ser Gln Gln Ala Ile Ser His Pro Gly 110 115 120 Glu Lys Pro Tyr Gln Cys Asn Val Cys Gly Lys Ala Phe Lys Arg 130 Ser Thr Ser Phe Ile Glu His His Arg Ile His Thr Gly Glu Lys 140 145 150 Pro Tyr. Glu Cys Asn Glu Cys Gly Glu Ala Phe Ser Arg Arg Ser 155 160 Ser Leu Thr Gln His Glu Arg Thr His Thr Gly Glu Lys Pro Tyr

```
170
                                     175
Glu Cys Ile Asp Cys Gly Lys Ala Phe Ser Gln Ser Ser Leu
                185
                                     190
Ile Gln His Glu Arg Thr His Thr Gly Glu Lys Pro Tyr Glu Cys
                200
                                                          210
                                     205
Asn Glu Cys Gly Arg Ala Phe Arg Lys Lys Thr Asn Leu His Asp
                 215
                                      220
His Gln Arg Ile His Thr Gly Glu Lys Pro Tyr Ser Cys Lys Glu
                230
                                      235
Cys Gly Lys Asn Phe Ser Arg Ser Ser Ala Leu Thr Lys His Gln
                245
                                     250
Arg Ile His Thr Arg Asn Lys Leu
                260
<210> 304
<211> 340
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:481631.10.orf3:2000MAY19
<400> 304
Arg Leu Leu Val Pro Glu Glu Glu Thr Gln Lys Arg Lys Arg Lys
                                      10
Ala Lys Glu Ser Gly Met Ala Leu Ser Gln Gly Leu Leu Thr
                                                           30
                  20
                                       25
Arg Asp Val Ala Ile Glu Phe Ser Gln Glu Glu Trp Lys Cys Leu
                 35
                                       40
                                                           45
Asp Pro Ala Gln Arg
                    Thr Leu Tyr Arg Asp
                                         Val Met Leu Glu Asn
                  50
                                       55
Tyr Arg Asn Leu Val Ser Leu Asp Ile Ser Ser Lys Cys Thr Met
                                      70
                                                           75
                  65
Lys Glu Phe Leu Ser Thr Ala Gln Gly Asn Arg Glu Val Phe His
                 '80
Ala Gly Thr Leu Gln Ile His Glu Ser His His Asn Gly Asp Phe
                  95
                                      100
Cys Tyr Gln Asp Val Asp Lys Asp Ile His Asp Tyr Glu Phe Gln
                                      115
                                                          120
                110
Trp Gln Glu Asp Glu Arg Asn Gly His Glu Ala Pro Met Thr Lys
                                                          135
                                      130
                125
Ile Lys Lys Leu Thr Gly Ile Thr Glu Arg Tyr Asp Gln Ser His
                 140
                                      145
                                                          150
Ala Arg Asn Lys Pro Ile Lys Asp Gln Leu Gly Ser Ser Phe His
                 155
                                      160
Ser His Leu Pro Glu Met His Ile Phe Gln Thr Glu Glu Lys Ile
                 170
                                      175
                                                          180
Asp Asn Gln Val Val Lys Ser Ile His Asp Ala Ser Leu Val Ser
                                      190
                 185
Thr Ala Gln Arg Ile Ser Cys Arg Pro Lys Thr His Ile Ser Asn
                 200
                                      205
                                                          210
Asn His Gly Asn Asn Phe Trp Asn Ser Ser Leu Leu Thr Gln Lys
                                                          225
                 215
                                      220
Gln Glu Val His Met Arg Glu Lys Ser Phe Gln Cys Asn Glu Ser
                 230
                                      235
Gly Lys Ala Phe Asn Tyr Ser Ser Leu Leu Arg Lys His Gln Ile
                 245
                                      250
                                                          255
Ile His Leu Ala Asp Lys Tyr Lys Cys Asp Val Cys Gly Lys Leu
                 260
                                      265
Phe Asn Gln Lys Arg Asn Leu Ala Cys His Arg Arg Cys His Thr
                 275
                                                          285
                                      280
Gly Glu Asn Pro Tyr Lys Cys Asn Glu Cys Gly Lys Thr Phe Ser
                 290
                                                          300
                                      295
Gln Thr Ser Ser Leu Thr Cys His Arg Arg Leu His Thr Gly Glu
                 305
                                      310
```

Lys Pro Tyr Lys Cys Glu Glu Cys Asp Lys Ala Phe His Phe Lys

```
WO 01/62927
                                                         330
Ser Ile Leu Glu Arg His Arg Ile Ile His
                335
                                     340
<210> 305
<211> 89
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1088431.2.orf1:2000MAY19
<400> 305
Leu Thr Tyr Leu Arg Lys Lys Leu Arg Gly Arg Gly Lys Lys Glu
 1
                                      10
                                                          15
Glu Glu Gly Met Ala Leu Ser Gln Gly Leu Phe Thr Phe Lys Asp
                 20
                                      25
                                                          30
Val Ala Ile Glu Phe Ser Gln Glu Glu Trp Glu Cys Leu Asp Pro
                 35
                                      40
                                                          45
Ala Gln Arg Ala Leu Tyr Arg Asp Val Met Leu Glu Asn Tyr Arg
                 50
                                      55
                                                          60
Asn Leu Leu Ser Leu Asp Glu Asp Asn Ile Pro Pro Glu Asp Gly
                 65
                                      70
Ser His Leu Ala Ala Cys Gly Gln Ser Thr Leu Pro Leu Pro
                 80
                                      85
<210> 306
<211> 80
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:401619.10.orf1:2000MAY01
<400> 306
Ala Leu His Pro Leu Pro Lys Arg Gln Ala Leu Glu Lys Ser Asn
Gly Thr Ser Ala Val Phe Asn Pro Ser Val Leu His Tyr Gln Gln
Ala Leu Thr Ser Ala Gln Leu Gln Gln His Ala Ala Phe Ile Pro
                 35
                                      40
Thr Gly Met Cys Pro Tyr Cys Pro Thr Ser Cys Ala Leu Leu Val
                 50
                                      55
                                                           60
Met Cys Phe Leu Leu Ile Ser Leu Ser Cys Leu Val Ala Ser Ser
                 65
                                      70
Leu Leu Lys Val
<210> 307
<211> 386
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:1144007.1.orf2:2000MAY01
<400> 307
Ala Leu Asp Gly Val Arg Pro Pro Gln Ser Gln Glu Met Ala Thr
                                      10
Ala Val Glu Pro Glu Asp Gln Asp Leu Trp Glu Glu Glu Gly Ile
                                                          30
                 20
Leu Met Val Lys Leu Glu Asp Asp Phe Thr Cys Arg Pro Glu Ser
                 35
                                      40
```

PCT/US01/06059

158/228

Val Leu Gln Arg Asp Asp Pro Val Leu Glu Thr Ser His Gln Asn

BNSDOCID: <WO___0162927A2_I_>

```
50
                                      55
                                                           60
Phe Arg Arg Phe Arg Tyr Gln Glu Ala Ala Ser Pro Arg Glu Ala
                                      70
                 65
Leu Ile Arg Leu Arg Glu Leu Cys His Gln Trp Leu Arg Pro Glu
                                                           90
                 80
                                      85
Arg Arg Thr Lys Glu Gln Ile Leu Glu Leu Leu Val Leu Glu Gln
                 95
                                     100
Phe Leu Thr Val Leu Pro Gly Glu Leu Gln Ser Trp Val Arg Gly
                110
                                     115
                                                          120
Gln Arg Pro Glu Ser Gly Glu Glu Ala Val Thr Leu Val Glu Gly
                                                          135
                125
                                     130
Leu Gln Lys Gln Pro Arg Arg Pro Arg Arg Trp Val Thr Val His
                                                          150
                                     145
                140
Val His Gly Gln Glu Val Leu Ser Glu Glu Thr Val His Leu Gly
                155
                                     160
                                                          165
Ala Glu Pro Glu Ser Pro Asn Glu Leu Gln Asp Pro Val Gln Ser
                170
                                                          180
Ser Thr Pro Glu Gln Ser Pro Glu Glu Thr Thr Gln Ser Pro Asp
                185
                                     190
Leu Gly Ala Pro Ala Glu Gln Arg Pro His Gln Glu Glu Leu
                200.
                                     205
                                                          210
Gln Thr Leu Gln Glu Ser Glu Val Pro Val Pro Glu Asp Pro Asp
                                                          225
                215
                                     220
Leu Pro Ala Glu Arg Ser Ser Gly Asp Ser Glu Met Val Ala Leu
                                                          240
                230
                                     235
Leu Thr Ala Leu Ser Gln Gly Leu Val Thr Phe Lys Asp Val Ala
                245
                                     250
Val Cys Phe Ser Gln Asp Gln Trp Ser Asp Leu Asp Pro Thr Gln
                260
                                     265
Lys Glu Phe Tyr Gly Glu Tyr Val Leu Glu Glu Arg Leu Trp Asn
                275
                                     280
Cys Cys Leu Ser Val His Ser Gln Ser Pro Arg Pro Asp Glu Ile
                290
                                     295
Leu Pro Gly Leu Asp Glu Glu Glu Pro Gly Val Pro Asp Ile Gln
                                                          315
                305
                                     310
Glu Pro Gln Glu Thr Gln Glu Pro Glu Ile Leu Ser Phe Thr
                                                          330
                320
                                     325
Thr Gly Asp Arg Ser Lys Asp Glu Glu Glu Cys Leu Glu Glu Glu
                                                          345
                335
                                     340
Asp Leu Ser Leu Glu Asp Ile His Arg Pro Val Leu Gly Glu Pro
                350
                                     355
                                                          360
Glu Ile His Gln Thr Pro Asp Trp Glu Ile Val Phe Glu Asp Asn
                                     370
                                                          375
                365
Pro Gly Arg Leu Asn Glu Arg Arg Phe Gly Tyr
                380
<210> 308
<211> 368
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:331074.1.orf2:2000MAY01
<400> 308
Met Cys Ser Arg Lys Lys Ala Glu Phe Ile Lys Gly Ser His Lys
                                      10
Cys Asn Val Cys Ser Arg Thr Phe Phe Ser Glu Asn Gly Leu Arg
                 20
                                      25
                                                           30
Glu His Leu Gln Thr His Arg Gly Pro Ala Lys His Tyr Met Cys
                 35
                                      40
                                                           45
Pro Ile Cys Gly Glu Arg Phe Pro Ser Leu Leu Thr Leu Thr Glu
                                                           60
                 50
                                      55
His Lys Val Thr His Ser Lys Ser Leu Asp Thr Gly Thr Cys Arg
                 65
```

Ile Cys Lys Met Pro Leu Gln Ser Glu Glu Phe Ile Glu His

PCT/US01/06059

160/228

100

115

Lys Glu Cys Gly Asn Leu Tyr Cys His Asn Met Gln Leu Thr Leu

His Lys Arg Asn His Thr Gln Lys Lys Cys Asn Gln Cys Leu Asp

105

95

```
130
                125
Cys Gly Lys Tyr Phe Thr Arg Gln Ser Pro Leu Ile Gln His Gln
                140
                                     145
Arg Ile His Thr Gly Glu Arg Pro Tyr Lys Cys Asn Glu Cys Ile
                155
                                     160
                                                          165
Lys Thr Phe Asn Gln Arg Ala His Leu Thr
                170
                                     175
<210> 310
<211> 78
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:335097.1.orf2:2000FEB18
<400> 310
Thr Gln Glu Val Glu Val Ala Val Ser Leu Asp Cys Cys His Cys
                                                           15
  1
                                      10
Thr Pro Ala Trp Val Thr Ala Glu Leu Cys Leu Lys Lys Lys Met
                 20
                                      25
                                                           30
Trp Asn Ser Phe Leu Gln Met Phe Ser Asn Ser Ile Pro Ser Ser
                 35
                                      40
Val Cys Arg Tyr Met Tyr Ala Ile Ile Leu Gln Val Ile His Val
                 50
                                      55
Asp Cys Ile Gly Asn Tyr Arg Lys Asp Tyr Ile Gly Leu Phe Arg
                 65
Lys Tyr Phe
<210> 311
<211> 61
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1076451.1.orf1:2000FEB18
<400> 311
Glu Gln Ser Ser Val Gln Gly Arg Ser Val Glu Val Leu Thr Val
                                      10
                                                           15
Gln Val Gln Met Leu Arg Asn Met Ser Pro Ala Met Ser Phe Leu
Met Leu Gln Pro Cys Val Asp Gln Ser Ala Ser Gly Cys Asp
                 35
                                      40
                                                           45
Ser Arg Ala Cys Arg Leu Leu Gln Ser Tyr Phe Ala Gly Val Gly
Glu
<210> 312
<211> 73
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:805478.1.orf1:2000FEB01
<400> 312
Gly Leu Phe Gln Cys Ile His Gln Val Thr Glu Val Gly Gln Lys
                                      10
Val Ala Thr Val Leu Leu Phe Tyr Gly Tyr Tyr Lys Cys Thr Gly
```

161/228

Thr Leu Lys Ile Thr Cys Leu Tyr Asn Val Ile Leu Tyr Lys Val

20

WO 01/62927 PCT/US01/06059 45 Cys Ser Pro Gly Ser Asp Gln Pro Asp Val Cys Tyr Asp Pro 55 50 60 Glu Leu Pro Met Thr Thr Val Phe Lys Ile Arg Leu Arg <210> 313 <211> 184 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:101269.1.orf1:2000MAY19 <400> 313 Cys Cys Ser Phe Lys Phe His Phe Asp Leu Ser Trp Glu Ile Leu 10 Trp Pro Ile Ile Pro Trp Met Leu Lys Met Val Leu Thr Glu Asn 30 20 25 Pro Asn Glu Glu Ile Ala Thr Ser Leu Glu'Phe Leu Leu Gln 35 Asn Ser Pro Gly Ser Leu Arg Ala Gln Gln Arg Met Ser Tyr Tyr Gly Ser Ser Tyr His Ile Ile Asn Ala Asp Ala Lys Tyr Pro Gly 65 70 Tyr Pro Pro Glu His Ile Ile Ala Glu Lys Arg Arg Ala Arg Arg 90 80 85 Arg Leu Leu His Lys Asp Gly Ser Cys Asn Val Tyr Phe Lys 95 100 105 Ile Phe Gly Glu Trp Gly Ser Tyr Val Val Asp Ile Phe Thr Thr 110 115 Leu Val Asp Thr Lys Trp Arg His Met Phe Val Ile Phe Ser Leu 125 130 135 Ser Tyr Ile Leu Ser Trp Leu Ile Phe Gly Ser Val Phe Trp Leu 145 150 140 Ile Ala Phe His His Gly Asp Leu Leu Asn Asp Pro Asp Ile Thr 155 160 165 Pro Cys Val Asp Asn Val His Ser Phe Thr Gly Ala Phe Leu Phe 175 170 Ser Leu Glu Thr <210> 314 <211> 219 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:331087.1.orf2:2000MAY01 <400> 314 Leu Ser Gly His Val Gln Thr Leu Glu Ser Pro Pro Gln Cys Ser Pro Ala Pro Gly Gln Pro Asn Phe Cys Leu Leu Asp Gly Asp Gln 20 Val Ala Ala Gly Ala Gly Ala Val Pro Ala Gly Val Glu Cys 40 Leu Gly Leu Leu Val Arg Gln Arg Gly Arg Gly Gln Lys Cys Leu 50 Pro Ser Leu Pro Gln Thr Gln Glu Ala Gly Pro Ala Ala Ala Leu 65 Arg Pro Arg Ser Thr Pro Cys Phe Val Tyr Gln Pro Ala Ile Arg

162/228

85

Glu Ala Asn Gly Ile Val Glu Cys Gly Pro Cys Gln Lys Val Phe

90

```
Val Val Gln Gln Ile Pro Asn Ser Asn Leu Leu Leu Val Thr
                110
                                    115
Asp Pro Thr Cys Asp Cys Ser Ile Phe Pro Pro Val Leu Gln Glu
                125
                                    130
                                                         135
Ala Thr Glu Val Lys Tyr Asn Ala Ser Val Lys Cys Asp Arg Met
                140
Arg Ser Gln Lys Leu Arg Arg Pro Asp Ser Cys His Ala Phe
                155
                                    160
His Pro Glu Val Arg Val Glu Ala Asp Arg Gly Trp Ala Gly Phe
                170
                                    175
Ser Ser Pro Asn Pro Leu Cys Leu Gly Leu Cys Pro Cys Arg Gln
                                    190
                185
Glu His Ile Gly Met Pro Met Asn Thr Pro Val Pro Val Leu Leu
                200
                                   - 205
                                                         210
Gly Gly Asn Ile Arg Val Tyr Ala Leu
                215
```

<210> 315

<211> 1603

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: LI:410188.1.orf1:2000MAY01

<400> 315 Ala Ala Glu Pro Ala Pro Ser Ala Pro Ser Pro Ala Pro Ser Arg 15 10 Val Arg Ala Lys Gln Gln Pro Pro Thr Pro Gly Pro Gly Arg Gly 30 20 25 Thr Ser Ser Phe Pro Thr Gly Asn Val Arg Arg Ala Cys Ala Gln 35 40 Lys Gln Asp Glu Lys Met Ala Asn Phe Leu Leu Pro Arg Gly Thr Ser Ser Phe Arg Arg Phe Thr Arg Glu Ser Leu Ala Ala Ile Glu 65 70 Lys Arg Met Ala Glu Lys Gln Ala Arg Gly Ser Thr Thr Leu Gln 85 80 Glu Ser Arg Glu Gly Leu Pro Glu Glu Glu Ala Pro Arg Pro Gln 100 95 Leu Asp Leu Gln Ala Ser Lys Lys Leu Pro Asp Leu Tyr Gly Asn 110 115 120 Pro Pro Gln Glu Leu Ile Gly Glu Pro Leu Glu Asp Leu Asp Pro 130 Phe Tyr Ser Thr Gln Lys Thr Phe Ile Val Leu Asn Lys Gly Lys 140 145 Thr Ile Phe Arg Phe Ser Ala Thr Asn Ala Leu Tyr Val Leu Ser 155 160 165 Pro Phe His Pro Val Arg Arg Ala Ala Val Lys Ile Leu Val His 170 175 Ser Leu Phe Asn Met Leu Ile Met Cys Thr Ile Leu Thr Asn Cys 190 195 185 Val Phe Met Ala Gln His Asp Pro Pro Pro Trp Thr Lys Tyr Val 205 210 200 Glu Tyr Thr Phe Thr Ala Ile Tyr Thr Phe Glu Ser Leu Val Lys 225 215 220 Ile Leu Ala Arg Ala Phe Cys Leu His Ala Phe Thr Phe Leu Arg 230 235 240 Asp Pro Trp Asn Trp Leu Asp Phe Ser Val Ile Ile Met Ala Tyr 245 250 255 Thr Thr Glu Phe Val Asp Leu Gly Asn Val Ser Ala Leu Arg Thr 270 260 265 Phe Arg Val Leu Arg Ala Leu Lys Thr Ile Ser Val Ile Ser Gly 275 280 285 Leu Lys Thr Ile Val Gly Ala Leu Ile Gln Ser Val Lys Lys Leu 290 295 300

Ala Asp Val Met Val Leu Thr Val Phe Cys Leu Ser Väl Phe Ala Leu Ile Gly Leu Gln Leu Phe Met Gly Asn Leu Arg His Lys Cys Val Arg Asn Phe Thr Ala Leu Asn Gly Thr Asn Gly Ser Val Glu Ala Asp Gly Leu Val Trp Glu Ser Leu Asp Leu Tyr Leu Ser Asp Pro Glu Asn Tyr Leu Leu Lys Asn Gly Thr Ser Asp Val Leu Leu Cys Gly Asn Ser Ser Asp Ala Gly Thr Cys Pro Glu Gly Tyr Arg Cys Leu Lys Ala Gly Glu Asn Pro Asp His Gly Tyr Thr Ser Phe Asp Ser Phe Ala Trp Ala Phe Leu Ala Leu Phe Arg Leu Met Thr Gln Asp Cys Trp Glu Arg Leu Tyr Gln Gln Thr Leu Arg Ser Ala Gly Lys Ile Tyr Met Ile Phe Phe Met Leu Val Ile Phe Leu Gly Ser Phe Tyr Leu Val Asn Leu Ile Leu Ala Val Val Ala Met Ala Tyr Glu Glu Gln Asn Gln Ala Thr Ile Ala Glu Thr Glu Glu Lys Glu Lys Arg Phe Gln Glu Ala Met Glu Met Leu Lys Lys Glu His Glu Ala Leu Thr Ile Arg Gly Val Asp Thr Val Ser Arg Ser Ser Leu Glu Met Ser Pro Leu Ala Pro Val Asn Ser His Glu Arg Arg 'Ser Lys Arg Arg Lys Arg Met Ser Ser Gly Thr Glu Glu Cys Gly Glu Asp Arg Leu Pro Lys Ser Asp Ser Glu Asp Gly Pro Arg Ala Met Asn His Leu Ser Leu Thr Arg Gly Leu Ser Arg Thr Ser Met Lys Pro Arg Ser Ser Arg Gly Ser Ile Phe Thr Phe Arg Arg Arg Asp Leu Gly Ser Glu Ala Asp Phe Ala Asp Asp Glu Asn Ser Thr Ala Arq Glu Ser Glu Ser His His Thr Ser Leu Leu Val Pro Trp Pro Leu Arg Arg Thr Ser Ala Gln Gly Gln Pro Ser Pro Gly Thr Ser Ala Pro Gly His Ala Leu His Gly Lys Lys Asn Ser Thr Val Asp Cys Asn Gly Val Val Ser Leu Leu Gly Ala Gly Asp Pro Glu Ala Thr Ser Pro Gly Ser His Leu Leu Arg Pro Val Met Leu Glu His Pro Pro Asp Thr Thr Pro Ser Glu Glu Pro Gly Gly Pro Gln Met Leu Thr Ser Gln Ala Pro Cys Val Asp Gly Phe Glu Glu Pro Gly Ala Arg Gln Arg Ala Leu Ser Ala Val Ser Val Leu Thr Ser Ala Leu Glu Glu Leu Glu Glu Ser Arg His Lys Cys Pro Pro Cys Trp Asn Arg Leu Ala Gln Arg Tyr Leu Ile Trp Glu Cys Cys Pro Leu Trp Met Ser Ile Lys Gln Gly Val Lys Leu Val Val Met Asp Pro Phe Thr Asp Leu Thr Ile Thr Met Cys Ile Val Leu Asn Thr Leu Phe Met Ala Leu Glu His Tyr Asn Met Thr Ser Glu Phe Glu Glu Met Leu Gln Val Gly Asn Leu Val Phe Thr Gly Ile Phe

				900	12				805				. 810
Thr	Ala	Glu	Met	800 Thr 815		Lys	Ile	Ile		Leu	Asp	Pro	Tyr Tyr
Tyr	Phe	Gln	Gln		Trp	Asn	Ile	Phe		Ser	Ile	Ile	Val Ile 840
Leu	Ser	Leu	Met		Leu	Gly	Leu	Ser		Met	Ser	Asn	Leu Ser 855
Val	Leu	Arg	Ser		Arg	Ļeu	Leu	Arg		Phe	Lys	Leu	Ala Lys 870
Ser	Trp	Pro	Thr		Asn	Thr	Leu	Ile		Ile	Ile	Gly	Asn Ser 885
Val	Gly	Ala	Leu		Asn	Leu	Thr	Leu		Leu	Ala	Ile	Ile Val
Phe	Ile	Phe	Ala	_	Val	Gly	Lys	Gln		Leu	Gly	Glu	Asn Tyr 915
Arg	Asn	Asn	Arg		Asn	Ile	Ser	Ala		His	Glu	Asp,	Trp Pro 930
Arg	Trp	His	Met		Asp	Phe	Phe	His		Phe	Leu	Ile	Val Phe 945
Arg	Ile	Leu	Cys	Gly 950	Glu	Trp	Ile	Glu	Asn 955	Met	Trp	Ala	Cys Met 960
Glu	Val	Gly	Gln	Lys 965	Ser	Ile	Cys	Leu	Ile 970	Leu	Phe	Leu	Thr Val 975
Met	Val	Leu	Gly	Asn 980	Leu	Val	Val	Leu	Asn 985	Leu	Phe	Ile	Ala Leu 990
Leu	Leu	Asn	Ser	Phe	Ser	Ala	Asp		Leu 1000	Thr	Ala	Pro	Glu Asp 1005
Asp	Gly	Glu		Asn 1010	Asn	Leu	Gln		Ala 1015	Leu	Ala	Arg	Ile Gln 1020
Arg	Gly	Leu		Phe 1025	Val	Lys	Arg		Thr 1030	Trp	Asp	Phe	Cys Cys 1035
Gly	Leu	Leu		His 1040	Arg	Pro	Gln		Pro 1045	Ala	Ala	Leu	Ala Ala 1050
Gln	Gly	Gln		Pro 1055	Ser	Суз	Ile		Thr 1060	Pro	Tyr	Ser	Pro Pro 1065
Pro	Pro	Glu		Glu 1070	Lys	Val	Pro		Thr 1075	Arg	Lys	Glu	Thr Gln 1080
Phe	Glu	Glu		Glu 1085	Gln	Pro	Gly		Gly 1090	Thr	Pro	Gly	Asp Pro 1095
Glu	Pro	Val		Val 1100	Pro	Ile	Ala		Ala 1105	Glu	Ser	Asp	Thr Asp 1110
Asp	Gln	Glu		Asp 1115	Glu	Glu	Asn		Leu 1120	Gly	Thr	Glu	Glu Glu 1125
		_		1130				,	1135		_		Pro Arg 1140
Gly	Pro	Pro		Ser 1145		Thr	Trp		Gln 1150		Ser	Ala	Thr Ala 1155
Ser	Ser	Glu		Glu 1160	Ala	Ser	Ala		Gln 1165	Ala	Asp	Trp	Arg Gln 1170
Gln	Trp	Lys		Glu 1175	Pro	Gln	Ala		Gly 1180	Cys	Gly	Glu	Thr Pro 1185
Glu	Asp	Ser		Ser 1190	Glu	Gly	Ser		Ala 1195	Asp	Met	Thr	Asn Thr 1200
Ala	Glu	Leu		Glu 1205	Gln	Ile	Pro		Leu 1210	Gly	Gln	Asp	Val Lys 1215
Asp	Pro	Glu		Cys 1220	Phe	Thr	Glu		Cys 1225	Val	Arg	Arg	Cys Pro 1230
Cys	Cys	Ala		Asp 1235	Thr	Thr	Gln		Pro 1240	Gly	Lys	Val	Trp Trp 1245
Arg	Leu	Arg		Thr 1250	Cys	Tyr	His	Ile		Glu	His	Ser	Trp Phe 1260
Glu	Thr	Phe	Ile		Phe	Met	Ile	Leu		Ser	Ser	Gly	Ala Leu 1275
Ala	Phe	Glu	Asp		Tyr	Leu	Glu	Glu		Lys	Thr	Ile	Lys Val 1290
Leu	Leu	Glu	Tyr		Asp	Lys	Met	Phe		Tyr	Val	Phe	Val Leu 1305

```
Glu Met Leu Leu Lys Trp Val Ala Tyr Gly Phe Lys Lys Tyr Phe
               1310
                                    1315
Thr Asn Ala Trp Cys Trp Leu Asp Phe Leu Ile Val Asp Val Ser
               1325
                                    1330
                                                         1335
Leu Val Ser Leu Val Ala Asn Thr Leu Gly Phe Ala Glu Met Gly
                             7,
               1340
                                . 1345
                                                       . 1350
Pro Ile Lys Ser Leu Arg Thr Leu Arg Ala Leu Arg Pro Leu Arg
               1,355
                                    1360
                                                         1365
Ala Leu Ser Arg Phe Glu Gly Met Arg Val Val Val Asn Ala Leu
               1370
                                    1375
                                                         1380
Val Gly Ala Ile Pro Ser Ile Met Asn Val Leu Leu Val Cys Leu
               1385
                                    1390
Ile Phe Trp Leu Ile Phe Ser Ile Met Gly Val Asn' Leu Phe Ala
               1400
                                    1405
                                                         1410
Gly Lys Phe Gly Arg Cys Ile Asn Tyr Thr Asp Gly Glu Phe Ser
                                    1420
               1415
Leu Val Pro Leu Ser Ile Val Asn Asn Lys Ser Asp Cys Lys Ile
               1430
                                    1435
Gln Asn Ser Thr Gly Ser Phe Phe Trp Val Asn Val Lys Val Asn
                                    1450
               1445
                                                         1455
Phe Asp Asn Val Ala Met Gly Tyr Leu Ala Leu Leu Gln Val Ala
               1460
                                    1465
                                                         1470
Thr Phe Lys Gly Trp Met Asp Ile Met Tyr Ala Ala Val Asp Ser
               1475
                                    1480
                                                         1485
Arg Glu Val Asn Met Gln Pro Lys Trp Glu Asp Asn Val Tyr Met
                                    1495
               1490
                                                        1500
Tyr Leu Tyr Phe Val Ile Phe Ile Ile Phe Gly Gly Phe Phe Thr
               1505
                                    1510
                                                         1515
Leu Asn Leu Phe Val Gly Val Ile Ile Asp Asn Phe Asn Gln Gln
               1520
                                    1525
                                                         1530
Lys Lys Lys Leu Gly Gly Gln Asp Ile Phe Met Thr Glu Glu Gln
               1535
                                    1540
                                                         1545
Lys Lys Tyr Tyr Asn Ala Met Lys Lys Leu Gly Ser Lys Lys Pro
               1550
                                    1555
                                                         1560
Gln Lys Pro Ile Pro Arg Pro Leu Asn Lys Phe Gln Gly Phe Val
               1565
                                    1570
                                                         1575
Phe Asp Ile Val Thr Arg Gln Ala Phe Asp Ile Thr Ile Met Val
               1580
                                    1585
                                                         1590
Leu Ile Cys Leu Asn Met Val His His Asp Gly Gly Asp
               1595
                                    1600
<210> 316
<211> 200
```

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: LI:1188288.1.orf3:2000MAY01

<400> 316

Gly Gly Ala Gly Val Arg Gly Ala Gly Trp Arg Leu Gln Gln Arg Gly Arg Gly Ala Arg Ala Pro Pro Ala Arg Gln Ala Arg Gln Gly Gly Pro Arg Ala Arg Pro Leu Glu Gln Gly Gly Val Arg Ala 40 Glu Arg Gly Arg Gly Asp His Trp Ala Trp Ala Thr Cys Gly Ala 50 55 Ser Pro Thr Leu Cys Tyr Lys Asn Gly Gly Gly Ala Phe Leu Ile 70 65 Pro Tyr Val Val Phe Phe Ile Cys Cys Gly Ile Pro Val Phe Phe 85 Leu Glu Thr Ala Leu Gly Gln Phe Thr Ser Glu Gly Gly Ile Thr 95 100 105 Cys Trp Arg Lys Val Cys Pro Leu Phe Glu Gly Ile Gly Tyr Ala 110 115 120

```
Thr Gln Val Ile Glu Ala His Leu Asn Val Tyr Tyr Ile Ile Ile
                                     130
Leu Ala Trp Ala Ile Phe Tyr Leu Ser Asn Cys Phe Thr Thr Glu
                140
                                     145
                                                          150
Leu Pro Trp Ala Thr Cys Gly His Glu Trp Asn Thr Glu Asn Cys
                                                          165
                155
                                     160
Val Glu Phe Gln Lys Leu Asn Val Ser Asn Tyr Ser His Val
                                                          Ser
                170
                                     175
Leu Gln Lys Cys His Leu Pro Cys His Gly
                                         Val Leu Gly Ala Pro
                185
                                     190
Gly Pro Gly His Leu
<210> 317
<211> 329
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:427997.4.orf3:2000MAY01
<400> 317
Arg Thr Gly Gly Gly Gly Ser Gln Ser Pro Ala Pro Asp Gly
                                                           15
Glu Arg Thr Met His Cys Leu Gly Ala Glu Tyr Leu Val Ser Ala
Asp Gly Ala Pro Arg Gln Arg Glu Trp Arg Pro Gln Ile Tyr Arg
                                                           45
Lys Cys Thr Asp Thr Ala Trp Leu Phe Leu Phe Phe Leu Phe Trp
                 50
                                      55
Thr Gly Leu Val Phe Ile Met Gly Tyr Ser Val Val Ala Gly Ala
                                      70
                 65
Ala Gly Arg Leu Leu Phe Gly Tyr Asp Ser Phe Gly Asn Met Cys
                                                           90
                 80
                                      85
Gly Lys Lys Asn Ser Pro Val Glu Gly Ala Pro Leu Ser Gly Gln
                 95
                                     100
Asp Met Thr Leu Lys Lys His Val Phe Phe Met Asn Ser Cys Asn
                110
                                     115
                                                          120
Leu Glu Val Lys Gly Thr Gln Leu Asn Arg Met Ala Leu Cys Val
                125
                                     130
                                                          135
Ser Asn Cys Pro Glu Glu Gln Leu Asp Ser Leu Glu Glu Val Gln
                140
                                     145
Phe Phe Ala Asn Thr Ser Gly Ser Phe Leu Cys Gly Tyr Ser Leu
                                     160
                155
Asn Ser Phe Asn Tyr
                    Thr His Ser Pro Lys
                                         Ala Asp Ser Leu Cys
                170
                                     175
Pro Arg Leu Pro Val Pro Pro Ser Lys Ser Phe Pro Leu Phe Asn
                                     190
                                                          195
                185
Arg Cys Val Pro Gln Thr Pro Glu Cys Tyr Ser Leu Phe Ala Ser
                                     205
                200
                                                          210
Val Leu Ile Asn Asp Val Asp Thr Leu His Arg Ile Leu Ser Gly
                215
                                     220
                                                          225
Ile Met Ser Gly Arg Asp Thr Ile Leu Gly Leu Cys Ile Leu Ala
                230
Leu Ala Leu Ser Leu Ala Met Met Leu Thr Val Gln Ile His Thr
                245
                                     250
Pro Pro Phe Trp Phe Thr Phe Ser Phe His Trp Leu Phe Trp Asp
                                                          270
                260
                                     265
Cys Cys Leu Val Cys Gly Val Leu Trp Trp Leu Tyr Tyr Asp
                                                          Tyr
                                                          285
                275
                                     280
Thr Asn Asp Leu Ser Ile Glu Leu Asp Thr Glu Gln Gly Lys
                                                          Tvr
                290
                                     295
                                                          300
Glu Val Arg Ala Gly Val Cys Tyr Arg Asn Pro Gln Gly Ile Thr
                305
                                     310
Ala Asp Ala Ala Arg Leu Asp Ile Leu Phe Ser Glu Arg Glu
```

325

<210> 318 <211> 256 <212> PRT <213> Homo sapiens · <220> <221> misc_feature <223> Incyte ID No: LG:451682.1.orf3:2000FEB18 <400> 318 His Leu Ala Ala Ala Ala Met Ser Arg Arg Tyr Asp Ser Arg Thr 10 Thr Ile Phe Ser Pro Glu Gly Arg Leu Tyr Gln Val Glu Tyr Ala 20 30 Met Glu Ala Ile Gly Asn Ala Gly Ser Ala Leu Gly Ile Leu Ala 45 Ala Asp Gly Val Val Leu Val Gly Glu Lys Lys Val Thr Ser Lys Leu Leu Gln Thr Ser Arg Ser Ala Glu Lys Met Tyr Lys Ile Asp 65 70 75 Ser His Leu Ala Cys Ala Val Ala Gly Ile Met Ser Asp Ala Asn 80 85 90 Ile Leu Ile Asn Thr Ala Arg Leu His Ala Gln Arg Tyr Ala Leu 100 Ser Tyr Gln Glu Pro Ile Pro Val Glu Gln Leu Val Gln Ser Leu 110 115 120 Cys Asp Thr Lys Gln Gly Tyr Thr Gln Phe Gly Gly Leu Arg Pro 125 130 135 Phe Gly Val Ser Phe Leu Phe Ala Gly Trp Asp Lys His His Gly 140 150 145 Phe Gln Leu Tyr Met Ser Asp Pro Ser Gly Asn Tyr Gly Gly Trp 165 155 160 Lys Ala Ala Ala Val Gly Ala Asn Ser Gln Ala Ala Gln Ser Met 170 175 Leu Lys Gln Asp Tyr Lys Asp Ala Leu Thr Arg Glu Glu Ala Val 185 190 195 Gly Leu Ala Leu Lys Val Leu Ser Lys Thr Met Asp Ser Thr Ser 200 205 210 Leu Thr Ala Glu Lys Leu Glu Leu Ala Glu Val Phe Leu Gln Pro 215 220 225 Asp Thr Gly Glu Val Gln Tyr Gln Val Cys Ser Pro Glu Ala Leu 230 235 Gly Lys Leu Leu Ala Asn Ser Gly Leu Thr Gln Pro Thr Pro Glu 245 250 255 Ala <210> 319 <211> 76 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:1077283.1.orf2:2000FEB18 <400> 319 Ala Val Ser Phe Arg Arg Leu Leu Gln Thr Trp Ser Thr Pro Pro Cys Ser Ser Thr Ser Arg Leu Met Ala Ser Leu Trp Val Ala Val 20 25 Trp Leu Arg Lys Trp Leu Ala Asp Lys Val Pro Lys Thr Ala Glu 35 40 45 Asn Phe Arg Ala Leu Ser Thr Gly Glu Lys Gly Phe Gly Tyr Asn 50 55 60

PCT/US01/06059

WO 01/62927

168/228

Gly Phe Leu Leu Ser Gln Asn Tyr Ser Arg Ile His Val Pro Gly

PCT/US01/06059

WO 01/62927 Trp <210> 320 <211> 276 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:481436.5.orf3:2000FEB18 <400> 320 Thr Asn Ile Lys Ile Thr Met Lys Val Leu Gly Val Thr Lys Asp 10 15 Ser Gly Asp Glu Asp Leu Lys Lys Ala Tyr Arg Lys Leu Ala Leu 25 Lys Phe His Pro Asp Lys Asn His Ala Pro Gly Ala Thr Asp Ala 40 Phe Lys Lys Ile Gly Asn Ala Tyr Ala Val Leu Ser Asn Pro Glu 50 60 55 Lys Arg Lys Gln Tyr Asp Leu Thr Gly Asn Glu Glu Gln Ala Cys 75 65 70 Asn His Gln Asn Asn Gly Arg Phe Asn Phe His Arg Gly Cys Glu 80 85 90 Ala Asp Ile Thr Pro Glu Asp Leu Phe Asn Ile Phe Phe Gly Gly 95 100 Gly Phe Pro Ser Gly Ser Val His Ser Phe Ser Asn Gly Arg Ala 110 115 Gly Tyr Ser Gln Gln His Gln His Arg His Ser Gly His Glu Arg 125 130 Glu Glu Glu Arg Gly Asp Gly Gly Phe Ser Val Phe Ile Gln Leu 140 145 Met Pro Ile Ile Val Leu Ile Leu Val Ser Leu Leu Ser Gln Leu 155 160 165 Met Val Ser Asn Pro Pro Tyr Ser Leu Tyr Pro Arg Ser Gly Thr 175 170 Gly Gln Thr Ile Lys Met Gln Thr Glu Asn Leu Gly Val Val 195 185 190 Tyr Val Asn Lys Asp Phe Lys Asn Glu Tyr Lys Gly Met Leu Leu 200 205 210 Gln Lys Val Glu Lys Ser Val Glu Glu Asp Tyr Val Thr Asn Ile 215 220 Arg Asn Asn Cys Trp Lys Glu Arg Gln Gln Lys Thr Asp Met Gln 230 235 Tyr Ala Ala Lys Val Tyr Arg Asp Asp Arg Leu Arg Arg Lys 245 250 Asp Ala Leu Ser Met Asp Asn Cys Lys Glu Leu Glu Arg Leu Thr 260 265 Ser Leu Tyr Lys Gly Gly 275 <210> 321 <211> 115 <212> PRT <213> Homo sapiens <220> <221> misc_feature

<223> Incyte ID No: LI:793701.1.orf1:2000FEB01

<400> 321

Gln Ala Leu Leu Gln Ser His Pro Glu Ala Asp Trp Ser Thr His 15 10 Ser Arg Ser Met Arg Lys Leu Ile Val Arg Phe Ile Phe Leu Lys Phe Trp Thr Tyr Thr Val Arg Ala Ser Thr Asp Leu Thr Gln Thr

```
WO 01/62927
                                                             PCT/US01/06059
Gly Asp Cys Ser Gln Cys Ile His Gln Val Thr Glu Val Gly Gln
                 50
                                      55
Gln Ile Lys Thr Ile Phe Leu Phe Tyr Ser Tyr Tyr Glu Cys Val
                                      70
                 65
                                                          75
Glu Thr Ile Lys Lys Leu Val Cys Ile Met Pro Leu Ser Thr Arg
                 80
                                      85
                                                          90
Tyr Val Ala Arg Glu Met Thr Asp Leu Met Arg Val Ile Thr His
                 95
                                     100
                                                          105
Leu Ser Pro Pro Gln Pro Pro Phe Leu Lys
                110
<210> 322
<211> 227
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:373637.1.orf3:2000FEB01
<400> 322
His Pro Ala Trp Trp Thr Thr Thr Arg Cys Trp Thr Cys Pro Gly
                                      10
                                                          15
Arg Pro His Pro Arg Pro Ser Arg Arg Arg Thr Ala Ser Trp Arg
                                      25
                 20
Ser Ser Gly Thr Pro Thr Lys Thr Leu Arg Thr Arg Arg Lys Arg
                 35
                                      40
                                                           45
Arg Gly Asp Ser Ser Arg Trp Pro Arg Pro Thr Arg Cys Cys Arg
                 50
                                      55
                                                           60
Thr Pro Arg Asn Ala Ile Ser Met Thr Ala Met Ala Arg Arg Gly
                 65
Arg Arg Ala Ala Gln Ala Gly Pro Ser Arg Thr Pro Ser
                 80
                                      85
Ser Thr Ser Ser Ala Ser Ala Thr Gln Pro Thr Ser Ser Gly Ser
                 95
                                     100
                                                          105
Ser Ser Ala Ala Arg Thr His Ser Pro Leu Thr Ser Trp Glu Thr
                110
                                     115
                                                          120
Arg Trp Arg Ile Phe Trp Gly Gly Gln Arg Asn Cys Trp Gly Ser
                125
                                     130
Arg Ser Arg Ala Ser Ala Pro Leu Phe Ser Ala Phe Ser Glu Phe
                140
                                     145
Pro Ala Phe Gly Gly Val Phe Ser Ser Phe Asp Thr Gly Phe Arg
                155
                                     160
Ser Phe Gly Ser Leu Gly Ser Gly Gly Leu Ser Ser Phe Cys Met
                170
                                     175
Ser Tyr Gly Ser Asp Gly Thr Gly Ser Phe Lys Ser Met Ser Thr
                185
                                     190
Ser Thr Glu Ile Val Asp Gly Lys Lys Ile Thr Thr Lys Arg Ile
                200
                                     205
                                                          210
Ile Glu Asn Gly Gln Glu Arg Val Glu Val Glu Glu Asp Gly Glu
                215
                                     220
Leu Ser
<210> 323
<211> 100
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:239368.2.orf3:2000MAY19
<400> 323
Glu Glu Ser Val Leu Arg Gly Lys Phe Leu Phe Thr Ser Gly Ile
```

170/228

BNSDOCID: <WO___0162927A2_I_>

```
Pro Arg Ala Ser Trp Val Asp Ser Gly Leu His Thr Gln Pro Gly
                 20
Ser Pro Gly Ser Ala Ser Val Pro Pro Leu Ser Gly Pro Gly Cys
                                     40
                                                           45
                 35
Gly Leu Gly Ala Arg Pro Ser Leu Ala Pro Gly Asn Ser Asp Val
                 50
                                      55
Phe Leu His Leu Leu Pro Leu Leu Arg Gly Pro Lys Pro Gly
                 65
                                      70
Pro Ala Asp Ala Ser His Pro Glu Asn Cys Glu Gln Thr His Arg
                                      85
                 80
Ala Ser Pro Thr Pro Glu Ser Ser Cys Cys
                 95
                                     100
<210> 324
<211> 142
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:053826.1.orf3:2000MAY01
<400> 324
Asp Phe Trp Ala Lys Ile Tyr Leu Tyr Ala Leu Glu Gly Arg Lys
                                                           15
Tyr Arg Ser Ile Leu Gln Leu Val Lys Pro Trp Tyr Asp Glu Val
                 20
                                      25
                                                           30
Lys Asp Tyr Ala Phe Pro Tyr Pro Gln Asp Cys Asn Pro Arg
                                                         Cys
                 35
                                      40
Pro Met Arg Cys Phe Gly Pro Met Cys Thr His Tyr Thr Gln Met
                 50
                                      55
                                                           60
Val Trp Ala Thr Ser Asn Arg Ile Gly Cys Ala Ile His Thr Cys
                                                           75
                 65
                                      70
Gln Asn Met Asn Val Trp Gly Ser Val Trp Arg Arg Ala Val Tyr
                 80
                                      85
                                                           90
Leu Val Cys Asn Tyr Ala Pro Lys Gly Asn Trp Ile Gly Glu Ala
                 95
                                     100
                                                          105
Pro Tyr Lys Val Gly Val Pro Cys Ser Ser Cys Pro Pro Ser Tyr
                110
                                     115
Gly Gly Ser Cys Thr Asp Asn Leu Cys Phe Pro Gly Val Thr Ser
                125
Asn Tyr Leu Tyr Trp Phe Lys
                140
<210> 325
<211> 263
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:449393.1.orf3:2000MAY01
<400> 325
Ala Met Ser Leu Arg Val Leu Asn Pro Asn Ala Glu Val Leu Asn
Lys Ser Ala Ala Leu His Met Asn Ile Asn Ala Ala Lys Gly Leu
                  20
                                      25
Gln Asp Val Leu Lys Thr Asn Leu Gly Pro Lys Gly Thr Ile Lys
                                                           45
                  35
                                      40
Met Leu Val Gly Gly Ala Gly Asp Leu Lys Leu Thr Lys Asp Gly
                                       55
Asn Thr Leu Leu Lys Glu Met Gln Ile Gln Asn Pro Thr Ala Ile
                                      70
                  65
```

Met Ile Ala Arg Thr Ala Val Ala Gln Asp Asp Thr Ser Gly

Gly Thr Thr Ser Thr Val Leu Phe Ile Gly Glu Leu Met Lys Gln

80

Asp

Ser Glu Lys Tyr Lys Lys Leu Val Leu Arg Ile Pro Asn Arg Gly Ile Asp Leu Leu Lys Lys Asp Lys Ser Arg Lys Arg Ser Tyr Ser Pro Asp Gly Lys Glu Ser Pro Ser Asp Lys Lys Ser Lys Thr Asp Gly Ser Gln Lys Thr Glu Ser Ser Thr Glu Gly Lys Glu Gln Glu Glu Lys Ser Gly Glu Asp Gly Glu Lys Asp Thr Lys Asp Asp Gln Thr Glu Gln Glu Pro Asn Met Leu Leu Glu Ser Glu Asp Glu Leu Leu Val Asp Glu Glu Glu Ala Ala Leu Leu Glu Ser Gly Ser Ser Val Gly Asp Glu Thr Asp Leu Ala Asn Leu Gly Asp Val Ala Ser Asp Gly Lys Lys Glu Pro Ser Asp Lys Ala Val Lys Lys Asp Gly Ser Ala Ser Ala Ala Ala Lys Lys Lys Leu Lys Lys Arg Arg Phe Pro Gly Ser Met Glu Gly Phe Val Thr Leu Asp Glu Val Gly Asp Glu Glu Asp Ser Glu Leu Gln Lys Leu Arg Lys Ser Gly Met Ala Phe Lys Ser Gly Asp Lys Asn Asp Asp Gly Leu Val Glu Ile Lys Val Asp Lys Ile Glu Glu Leu Asp Gln Glu Asn Glu Ala Ala

Leu Glu Asn Gly Ile Lys Asn Glu Glu Asn Thr Glu Pro Gly Ala

```
245
                                     250
Glu Ser Ser Glu Asn Ala Asp Asp Pro Asn Lys Asp Thr Ser Glu
                260
                                     265
                                                          270
Asn Ala Asp Gly Gln Ser Asp Glu Asn Lys Asp Asp Tyr Thr Ile
                275
                                     280
Pro Asp Glu Tyr Arg Ile Gly Pro Tyr Gln Pro Asn Val Pro Val
                290
                                     295
Gly Ile Asp Tyr Val Ile Pro Lys Thr Gly Phe Tyr Cys Lys Leu
                305
                                     310
                                                          315
Cys Ser Leu Phe Tyr Thr Asn Glu Glu Val Ala Lys Asn Thr His
                320
                                     325
Cys Ser Ser Leu Pro His Tyr Gln Lys Leu Lys Lys Phe Leu Asn
                335
                                     340
                                         Glu Thr
Lys Leu Ala Glu Glu Arg Arg Gln Lys Lys
                350
                                     355
<210> 327
<211> 100
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:336338.8.orf2:2000MAY01
<220>
<221> unsure
<222> 10, 18, 30 <223> unknown or other
<400> 327
Met Ile Ser Ser Asn Ser Pro Asn Leu Xaa Leu Trp Pro Ile Thr
Thr Phe Xaa His Val Cys Thr Ser Cys Cys Ser Arg Leu Gln Xaa
                  20
                                       25
Pro Phe Ser Leu Ala Asp Phe Trp Lys Ser Asn Gly Arg Val Leu
                                       40
Gly Gly Arg Arg Leu Leu Tyr Ala Cys Glu Lys Glu Gln Ser Val
                  50
                                       55
Pro Thr Glu Gly Ser Ser Thr Thr Leu Leu Gln Asn Met Tyr Ile
                  65
                                       70
Ser Arg Leu Ser Ser His Leu Arg Phe Leu Cys Ser Cys Arg Leu
                                       85
                  80
Ile Asp Tyr Ser Ile Leu Leu Lys Arg Lys
                  95
<210> 328
<211> 303
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:345527.1.orf2:2000FEB18
<400> 328
Arg Glu Leu Lys Arg Phe Asn Ala Asp Asn Lys Leu Leu Leu Thr
                                                            15
                                       10
Gly Thr Pro Leu Gln Asn Asn Leu Ser Glu Leu Trp Ser Leu Leu
                                                            30
                  20
                                       25
Asn Phe Leu Leu Pro Asp Val Phe Asp Asp Leu Lys Ser Phe Glu
Ser Trp Phe Asp Ile Thr Ser Leu Ser Glu Thr Ala Glu Asp Ile
                  50
                                       55
Ile Ala Lys Glu Arg Glu Gln Asn Val Leu His Met Leu His Gln
                  65
                                       70
```

Ile Leu Thr Pro Phe Leu Leu Arg Arg Leu Lys Ser Asp Val Ala

```
80
Leu Glu Val Pro Pro Lys Arg Glu Val Val Val Tyr Ala Pro Leu
                 95
                                     100
                                                         105
Ser Lys Lys Gln Glu Ile Phe Tyr Thr Ala Ile Val Asn Arg Thr
                110
                                    115
Ile Ala Asn Met Phe Gly Ser Ser Glu Lys Glu Thr Ile Glu Leu
                125
                                     130
                                                         135
Ser Pro Thr Gly Arg Pro Lys Arg Arg Thr Arg Lys Ser Ile Asn
                140
                                    145
Tyr Ser Lys Ile Asp Asp Phe Pro Asn Glu Leu Glu Lys Leu Ile
                                     160
                155
Ser Gln Ile Gln Pro Glu Val Asp Arg Glu Arg Ala Val Val Glu
                170
                                     175
Val Asn Ile Pro Val Glu Ser Glu Val Asn Leu Lys Leu Gln Asn
                185
                                     190
                                                         195
Ile Met Met Leu Leu Arg Lys Cys Cys Asn His Pro Tyr Leu Ile
                200
                                     205
                                                         210
Glu Tyr Pro Ile Asp Pro Val Thr Glu Phe Lys Ile Asp Glu
                                                         225
                215
                                     220
Glu Leu Val Thr Asn Ser Gly Lys Phe Leu Ile Leu Asp Arg Met
                230
                                     235
                                                         240
Leu Pro Glu Leu Lys Lys Arg Gly His Lys Val Leu Phe Ser
                245
                                     250
                                                         255
Gln Met Thr Ser Met Leu Asp Ile Leu Met Asp Tyr Cys His Leu
                260
                                     265
                                                         270
Arg Asp Phe Asn Phe Ser Arg Leu Met Gly Pro Cys Leu Thr Gln
                275
                                     280
                                                         285
Arg Glu Lys Lys Thr Cys Thr Ala Ser Thr Arg Ile Gln Arg Cys
                                     295
                                                         300
Leu Ser Ser
<210> 329
<211> 72
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1089383.1.orf2:2000FEB18
<400> 329
Thr Ala Leu Leu Thr Gln Ser Leu Phe Gly Ser Leu Phe Thr
                                      10
                                                          15
Trp Thr Arg Val Thr Phe Gly Ala Glu Asp Pro Gly Gln Glu Asp
                 20
                                      25
                                                          30
Ser Phe Arg Arg Val Pro Cys Pro Cys Pro His Ser Val Arg
                 35
                                      40
                                                           45
Arg Ser Thr Tyr Asp Leu Arg Ser Ser Asp Gln Pro Ala Gln Gly
                 50
                                      55
                                                           60
Thr Ser His Glu Phe Gln Ile Gly Phe Pro Thr Ile
                 65
<210> 330
<211> 76
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1092522.1.orf2:2000FEB18
<400> 330
Phe Ser Tyr Leu Ser Ser Lys Trp Val Val Lys Gln Gln Arg Gln
                                      10
Leu Ala Ile Ser Thr Met His Leu Ala Gln Glu Leu Leu Met Asn
                 20
```

```
WO 01/62927
Val Gln Cys Ser Gly Gly Ser Arg His Phe Ser Lys Glu Met Arg
                 35
                                      40
Thr Leu Lys Met Arg Ser Ile Val Ala Lys Pro Leu Glu Val Asp
                                      55
                                                           60
                 50
Asn Asp Gln Leu Arg Ala Ile Ser Lys Ala Asp Pro Leu Lys Ala
                                                           75
                 65
                                      70
Thr
<210> 331
<211> 74
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1093216.1.orf2:2000FEB18
<220>
<221> unsure
<222> 2, 17, 36
<223> unknown or other
<400> 331
Gly Xaa Pro Pro Thr Thr Ser Gly Pro Gln Thr Asn Gln Pro Lys
                                      10
Glu Xaa Leu Met Asn Phe Lys Ser Asp Ser Gln Leu Tyr Glu Asp
                 20
                                      25
                                                           30
Thr Leu Ala Gly Arg Xaa Val Leu Ile Lys Asn Leu Thr Pro Gln
                                      40
Thr Leu Gln Pro Arg Trp Thr Gly Pro Tyr Leu Val Ile Tyr Ser
                                      55
                 50
Thr Pro Thr Ala Val Arg Leu Gln Asp Pro Pro His Trp Val
                 65
<210> 332
<211> 67
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:270318.3.orf3:2000FEB01
<400> 332
Leu Ser Phe Lys Arg Asp Ser Trp Glu Tyr Gly His Pro Ala Pro
                                      10
Arg Cys Gly Asn Glu Ser Ser Arg Ser Gly Glu Ala Ala Leu Ala
                                      25
                                                           30
Asp Val Gln Leu Ala Ala Pro Val Ser Asn Gln Leu His Pro Asp
                 35
Gly Val Glu Asp Arg Gly Val Gly Gly Leu Leu Arg Ser Tyr Thr
                 50
Thr Gln Leu Thr Met Asn Ile
                 65
<210> 333
<211> 192
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
```

Trp Val His Val Leu Leu Arg Glu Arg Lys Lys His Ala Gln Leu

<223> Incyte ID No: LI:335671.2.orf2:2000FEB01

```
Gln His Gly Ser Arg Gly Val Tyr Leu Leu Val Ser Thr Arg Ala
                 20
Gly Gly Leu Gly Ile Asn Leu Thr Ala Ala Asp Thr Val Ile Ile
                                      40
                                                          45
Tyr Asp Ser Asp Trp Asn Pro Gln Ser Asp Leu Gln Ala Gln Asp
                 50
Arg Cys His Arg Ile Gly Gln Thr Lys Pro Val Val Tyr Arg
                 65
                                      70
Leu Val Thr Ala Asn Thr Ile Asp Gln Lys Ile Val Glu Arg Ala
                 80
                                      85
                                                          90
Ala Ala Lys Arg Lys Leu Glu Lys Leu Ile Ile His Lys Asn His
                 95
                                     100
Phe Lys Gly Gln Ser Gly Leu Asn Leu Ser Lys Asn Phe Leu
                110
Asp Pro Lys Glu Leu Met Glu Leu Leu Lys Ser Arg Asp Tyr Glu
                125
                                     130
Arg Glu Ile Lys Gly Ser Arg Glu Lys Val Ile Ser Asp Lys Asp
                140
                                     145
Leu Glu Leu Leu Asp Arg Ser Asp Leu Ile Asp Gln Met Asn
                155
                                     160
Ala Ser Gly Pro Ile Lys Glu Lys Met Gly Ile Phe Lys Ile Leu
                170
                                     175
Glu Asn Ser Glu Asp Ser Ser Pro Glu Cys Leu Phe
                185
                                     190
<210> 334
<211> 74
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:793758.1.orf2:2000FEB01
<220>
<221> unsure
<222> 36
<223> unknown or other
<400> 334
Gly Asp Pro Pro Thr Thr Ser Gly Pro Gln Thr Asn Gln Pro Lys
                                      10
Glu His Leu Met Asn Phe Lys Ser Asp Ser Gln Leu Tyr Glu Asp
                                                          30
                 20
Thr Leu Ala Gly Arg Xaa Val Leu Ile Lys Asn Leu Thr Pro Gln
                 35
                                      40
                                                           45
Thr Leu Gln Pro Arg Trp Thr Gly Pro Tyr Leu Val Ile Tyr Ser
                 50
                                      55
Thr Pro Thr Ala Val Arg Leu Gln Asp Pro Pro His Trp Val
                                      70
                 65
<210> 335
<211> 72
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:803718.1.orf2:2000FEB01
<220>
<221> unsure
<222> 41
<223> unknown or other
<400> 335
```

```
Thr Ala Leu Leu Teu Thr Gln Ser Leu Phe Gly Ser Leu Phe Thr
                                                           15
                                      10
Trp Thr Arg Val Thr Phe Gly Ala Glu Asp Pro Gly Gln Glu Asp
                                                           30
                 20
                                     - 25
Ser Phe Arg Arg Arg Val Pro Cys Pro Cys Xaa His Ser Val Arg
                 35
                                      40
                                                           45
Arg Ser Thr Tyr Asp Leu Arg Ser Ser Asp Gln Pro Ala Gln Gly
                 50
                                      55
Thr Ser His Glu Phe Gln Ile Gly Phe Pro Thr Ile
                 65
<210> 336
<211> 55
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:412179.1.orf2:2000FEB01
<400> 336
Thr Ile Glu Met Met Leu Asp Ile Lys Gln Ile Gln Val Ile Phe
Leu Phe Glu Phe Lys Met Gly Arg Lys Ile Ala Glu Thr Thr Arg
                 20
                                      25
Asn Ile Asp Asn Ala Phe Gly Pro Gly Leu Leu Thr Asn Val Gln
                                      40
                 35
Cys Ser Gly Ser Ser Arg Arg Gln Gly Ala
                 50
<210> 337
<211> 107
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:815679.1.orf3:2000FEB01
<400> 337
Leu Arg Tyr Ile Asn Gly Ser Met Ser Ser Leu Tyr Pro Arg Leu
Cys His Leu Ser Leu Gln Phe Leu Pro Leu Lys Asn Arg Ser Ile
                 20
                                      25
Phe Leu Gln Ser Leu Met Leu Gly Phe Glu Leu Cys Leu Ala Leu
                                      40
                 35
Ala Thr Gly Ile Leu Ile Cys Met Thr Lys Asn Leu Glu Ser Val
                 50
                                       55
                                                           60
Asn Ser Phe Val Leu Ala His Ser Cys Tyr His His Glu Asn Lys
65 70 75
                 65
Pro Arg Pro Gly Cys Cys Phe Gln Gln Lys Ile Arg Asp Thr Lys
                 80
                                       85
                                                           90
Asn Lys Val Glu Leu Pro Arg His Ala His Ala Arg Leu Thr Asn
Pro Gln
<210> 338
<211> 147
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:481361.3.orf3:2000FEB01
<400> 338
```

```
Yu Met Lys Pro Gln Arg Asn Thr
                                                   a Asp Leu
Cys Pro Leu Gln
Leu Pro Lys Leu Lys Ser Met Ala Leu Ala Asp Arg Ala Val Phe
Glu Lys Gly Met Lys Ala Phe Val Ser Tyr Val Gln Ala Tyr Ala
                                                          45
Lys His Glu Cys Asn Leu Ile Phe Arg Leu Lys Asp Leu Asp Phe
                 50
                                      55
Ala Ser Leu Ala Arg Gly Phe Ala Leu Leu Arg Met Pro Lys Met
                                      70
                                                          75
                 65
Pro Glu Leu Arg Gly Lys Gln Phe Pro Asp Phe Val Pro Val Asp
                 ឧ೧
                                      85
Val Asn Thr Asp Thr Ile Pro Phe Lys Asp Lys Ile Arg Glu Lys
                 95
                                     100
Gln Arg Gln Lys Leu Leu Glu Gln Gln Arg Arg Glu Lys Thr Glu
                110
                                     115
                                                         120
Asn Glu Gly Arg Arg Lys Phe Ile Lys Asn Lys Ala Trp Ser Lys
                                                         135
                125
                                     130
Gln Lys Ala Lys Lys Glu Lys Lys Lys Lys Met Asn
                140
                                     145
```

```
<210> 339
<211> 257
<212> PRT
<213> Homo sapiens
```

<220>

<221> misc_feature
<223> Incyte ID No: LG:247388.1.orf1:2000MAY19

<400> 339 Gln Asn Ser Val Lys Leu Ala Ile Leu Tyr Leu Met Thr Phe His Leu Gln Ala Met Val Arg Ser Ala Gly Lys Leu Val Leu Ile Asp 20 Lys Leu Leu Pro Lys Leu Lys Ala Gly Gly His Lys Val Leu Ile Phe Ser Gln Met Val Arg Cys Leu Asp Ile Leu Glu Asp Tyr Leu 50 Ile Gln Arg Arg Tyr Leu Tyr Glu Arg Ile Asp Gly Arg Val Arg Gly Asn Leu Arg Gln Ala Ala Ile Asp Arg Phe Ser Lys Pro Asp 80 85 Ser Asp Arg Phe Val Phe Leu Leu Cys Thr Arg Ala Gly Gly Leu 100 Gly Ile Asn Leu Thr Ala Ala Asp Thr Cys Ile Ile Phe Asp Ser 110 115 120 Asp Trp Asn Pro Gln Asn Asp Leu Gln Ala Gln Ala Arg Cys His 125 130 135 Arg Ile Gly Gln Ser Lys Ala Val Lys Val Tyr Arg Leu Ile Thr 140 145 150 Arg Asn Ser Tyr Glu Arg Glu Met Phe Asp Lys Ala Ser Leu Lys 155 160 Leu Gly Leu Asp Lys Ala Val Leu Gln Ser Met Ser Gly Arg Asp 170 175 180 Gly Asn Ile Thr Gly Ile Gln Gln Phe Ser Lys Lys Glu Ile Glu 185 190 195 Asp Leu Leu Arg Lys Gly Ala Tyr Ala Ala Ile Met Glu Glu Asp 200 205 210 Asp Glu Gly Ser Lys Phe Cys Glu Glu Asp Ile Asp Gln Ile Leu 225 215 220 Leu Arg Arg Thr Thr Ile Thr Ile Glu Ser Glu Gly Lys Gly 230 235 240 Ser Thr Phe Ala Lys Ala Ser Phe Val Ala Ser Glu Asn Arg Thr 255 245 250 Asp Ile

```
<210> 340
<211> 63
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:255789.10.orf3:2000MAY19
<400> 340
Leu Lys Glu Leu Thr Ile Leu Phe Ser His Phe Pro Ile Gln Met
                                      10
Lys Thr Ala Ser Phe Leu Val Pro Leu Leu Pro Ser Lys Thr Ile
                                                          30
                 20
                                      25
Leu Phe Asp Arg Ala Arg Gly Gln Val Phe Leu Met Leu Leu Arg
                 35
                                      40
                                                          45
Lys Pro Ser Ile Thr Ala His Asp Leu Leu Val Lys Gly Ala Gly
                                                          60
                                      55
Lys Tyr Lys
<210> 341
<211> 112
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:787618.1.orf1:2000MAY01
<400> 341
Gly Thr Leu Met Asp Pro Phe Pro Pro Cys Ile Gln Asp Ser Ala
Ile Cys Leu Cys Ser Ser Ser Pro Leu Lys Asn Arg Glu Tyr Ile
                 20
                                      25
Ser Pro Ala Pro Asn Val Ala Phe Ser His Met Ser Ser Phe Gly
                 35
                                      40
His Trp Asn Ile Asn Leu His Asp Gln Lys Leu Gly Lys Cys Ala
                 50
                                      55
Phe Ile Cys Ala His Ser Leu Leu Leu Ser Pro Lys Glu Gln Ala
                                      70
                 65
Gln Ala Arg Leu Leu Pro Ala Glu Asp Lys Arg His Gln Glu
                                      85
                 80
Gln Ser Gln Ala Ser Gln Thr Arg Ser Cys Gln Ile Asn Gln Ser
                 95
                                     100
Ser Ala Arg Pro Ile Ala Pro
                110
<210> 342
<211> 427
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:331610.2.orf3:2000MAY01
<400> 342
Thr Arg Thr Thr Arg Leu Gly Ser Pro Lys Gly Ser Thr Cys
                                      10
           Thr Arg Thr Thr Ser Arg Glu Ser Thr Trp Ala Leu
                                                           30
Cys Ser Pro Arg Ile Pro Thr Trp Ala Lys Asn Gly Thr Val Ser
                 35
                                      40
Tyr Ser Ile Leu Pro Ser His Ile Gly Asp Val Ser Ile Tyr Thr
                 50
                                      55
```

Tyr Val Ser Val Asn Pro Thr Asn Gly Ala Ile Tyr Ala Leu Arg

```
WO 01/62927
```

```
Ser Phe Asn Phe Glu Gln Thr Lys Ala Phe Glu Phe Lys Val Leu
                 80
                                      85
Ala Lys Asp Ser Gly Ala Pro Ala His Leu Glu Ser Asn Ala Thr
                                     100
Val Arg Val Thr Val Leu Asp Val Asn Asp Asn Ala Pro Val Ile
                110
                                                          120
Val Leu Pro Thr Leu Gln Asn Asp Thr Ala Glu Leu Gln Val Pro
                                     130
                125
Arg Asn Ala Gly Leu Gly Tyr Leu Val Ser His Cys Ala Arg Pro
                                     145
                140
                                                          150
Arg Gln Arg Leu Arg Arg Arg Ala Gly Val Ser Pro Thr Lys Ile
                155
                                     160
Val Asp Gly Asn Asp Asp His Leu Phe Glu Ile Asp Pro Ser Ser
                170
                                     175
                                                          180
Gly Glu Ile Arg Thr Leu His Pro Phe Trp Glu Asp Val Thr Pro
                                     190
                185
Val Val Glu Leu Val Val Lys Val Thr Asp His Gly Lys Pro Thr
                200
                                     205
                                                          210
Leu Ser Ala Val Ala Lys Leu Ile Ile Arg Ser Val Ser Gly Ser
                215
                                     220
                                                          225
Leu Pro Glu Gly Val Pro Arg Val Asn Gly Glu Gln His His Trp
                230
                                     235
                                                          240
Asp Met Ser Leu Pro Leu Ile Val Thr Leu Ser Thr Ile Ser Ile
                245
                                     250
                                                          255
Ile Leu Leu Ala Ala Met Ile Thr Ile Ala Val Lys Cys Lys Arg
                260
                                     265
                                                          270
Glu Asn Lys Glu Ile Arg Thr Tyr Asn Cys Arg Ile Ala Glu Tyr
                275
                                     280
                                                          285
Ser His Pro Gln Leu Gly Gly Gly Lys Gly Lys Lys Lys Ile
                290
                                     295
                                                          300
Asn Lys Asn Asp Ile Met Leu Val Gln Ser Glu Val Glu Glu Arg
                305
                                     310
Asn Ala Met Asn Val Met Asn Val Val Ser Ser Pro Ser Leu Ala
                320
                                     325
                                                          330
Thr Ser Pro Met Tyr Phe Asp Tyr Gln Thr Arg Leu Pro Leu Ser
                335
                                     340
                                                          345
Ser Pro Arg Ser Glu Val Met Tyr Leu Lys Pro Ala Ser Asn Asn
                350
                                     355
                                                          360
Leu Thr Val Pro Gln Gly His Ala Gly Cys His Thr Ser Phe Thr
                                     370
                365
Gly Gln Gly Thr Asn Ala Ser Glu Thr Pro Ala Thr Arg Met Ser
                                     385
                                                          390
                380
Ile Ile Gln Thr Asp Asn Phe Pro Ala Glu Pro Asn Tyr Met Gly
                                                          405
                395
                                     400
Ser Arg Gln Gln Phe Val Gln Ser Ile Ser Val Ala Pro Arg Leu
                410
                                     415
Arg Thr Gln Lys Glu Pro Ala
                425
<210> 343
<211> 144
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:982697.1.orf2:2000FEB18
<220>
<221> unsure
<222> 52, 56
<223> unknown or other
<400> 343
```

180/228

Gly Ser Ile Glu Gly Lys Cys Gly Val Gly Gly Ser Asn Arg Val

```
Thr Ala Gly Ala Leu Pro Asn Gly Thr Ile Arg Ser Gly Pro Leu
                                                           30
                 20
Pro Ser Arg Pro Lys Asp Asp Arg Ser Thr Ser Ser Leu Tyr Ser
                 35
                                     40
Ala Pro Gly Lys Ala Thr Kaa Thr Gln Leu Kaa Pro Met Ser Ala
                 50
                                                           60
                                      55
Ala Leu Asp Ser Leu Pro Cys Lys Ala Ile Gly Ala Gly Leu Leu
                                                           75
                 65
                                      70
Lys Ala Trp Gly Ala His Pro Leu Tyr Gln Cys Gly Leu Asp Val
                 80
                                      85
Glu His Asp Val Glu Asp Tyr Phe Gly Thr Leu Arg Phe Ser Asp
                 95
                                     100
Phe Pro Thr Gly Phe Trp Ser Cys Val Asp Pro Val Asp Pro Phe
                                     115
                                                          120
                110
Phe Trp Pro Ile Ser Pro Phe Leu Gly Trp Lys His Leu Pro Asn
                125
                                     130
Pro Tyr Thr Pro Ile Val Ser Trp Lys
                140
<210> 344
```

<211> 97 <212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: LG:1080896.1.orf2:2000FEB18

<400> 344

<210> 345

<211> 75

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: LI:811341.1.orf3:2000FEB01

<400> 345

Gly Leu Phe Gln Cys Ile His Gln Val Thr Glu Val Gly Gln Lys 10 Tyr Lys Cys Thr Gly Val Ala Thr Val Leu Leu Phe Tyr Gly Tyr 25 30 20 Thr Leu Lys Ile Thr Cys Leu Tyr Asn Val Ile Leu Tyr Lys Val 45 35 40 Cys Ser Pro Gly Ser Asp Gln Pro Asp Val Cys Tyr Asp Pro Ser 50 55 Glu Pro Pro Met Thr Thr Val Phe Lys Ile Arg Leu Arg Thr Glu

<210> 346

```
WO 01/62927

<211> 135
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:903225.1.orf3:2000FEB01
<400> 346
Asp Pro Phe Gln Lys Met Ala Pro Lys Val Lys Ly
1 5 10
Gly Pro Pro Lys Ala Glu Ala Lys Ala Lys Ala Le
20 25
```

Asp Pro Phe Gln Lys Met Ala Pro Lys Val Lys Lys Glu Ala Pro 10 Gly Pro Pro Lys Ala Glu Ala Lys Ala Lys Ala Leu Lys Ala Lys 30 25 Lys Val Val Leu Lys Gly Val His Gly His Lys Lys Lys Ile 35 40 45 Arg Met Ser Pro Thr Phe Gln Arg Pro Lys Thr Leu Arg Leu Trp 50 55 Arg Pro Pro Arg Tyr Pro Arg Lys Thr Thr Pro Arg Arg Asn Lys 75 65 70 Leu Asp His Tyr Ala Ile Ile Lys Phe Pro Leu Thr Thr Glu Phe 80 85 90 Ala Met Lys Lys Ile Lys Asp Asn Asn Thr Leu Val Phe Thr Val 95 100

95 100 105
Asp Val Lys Ala Asn Lys His Gln Ile Lys Gln Ala Val Lys Lys
110 115 120
Leu Cys Asp Ile Asp Gly Ala Lys Val Asn Thr Leu Met Glu Arg
125 130 135

<210> 347 <211> 55 <212> PRT <213> Homo sapiens <220> <221> misc_feature

<210> 348 <211> 129 <212> PRT <213> Homo sapiens <220>

50

<221> misc_feature
<223> Incyte ID No: LG:979580.1.orf2:2000MAY19

<223> Incyte ID No: LI:242079.2.orf2:2000FEB01

```
65
                                      70
Val Asp Gln Ala Gly Leu Lys Leu Leu Thr Ser Ser Asp Trp Pro
                                      85
                 80
Thr Trp Ala Ser Gln Ser Ala Gly Ile Thr Gly Val Ser His Cys
                                                          105
                                     100
                 95
Ser Pro Ala Tyr Glu Val Val Phe Ala Val Lys Gln Gln Phe Gly
                110
Asn Glu Ala Phe Leu Arg Ser Ser Val
                125
<210> 349
<211> 291
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:1169865.1.orf2:2000MAY01
Arg Pro Thr Val Ser Val Ser Cys Ala Ser Ser Arg Pro Gln Phe
Leu Ile Thr Val Pro Val Leu Thr Val Ile Asn Tyr Arg Pro His
Asn Met Arg Pro Glu Asp Arg Met Phe His Ile Arg Ala Val Ile
                                      40
                                                           45
                 35
Leu Arg Ala Leu Ser Leu Ala Phe Leu Leu Ser Leu Arg Gly Ala
                                      55
                 50
Gly Ala Ile Lys Ala Asp His Val Ser Thr Tyr Ala Ala Phe Val
                                                           75
                 65
                                      70
Gln Thr His Arg Pro Thr Gly Glu Phe Met Phe Glu Phe Asp Glu
                 80
                                      85
Asp Glu Met Phe Tyr Val Asp Leu Asp Lys Lys Glu Thr Val Trp
                 95
                                     100
                                                          105
His Leu Glu Glu Phe Gly Gln Ala Phe Ser Phe Glu Ala Gln Gly
                110
                                     115
                                                          120
Gly Leu Ala Asn Ile Ala Ile Leu Asn Asn Asn Leu Asn Thr Leu
                                     130
                125
Ile Gln Arg Ser Asn His Thr Gln Ala Thr Asn Asp Pro Pro Glu
                140
                                     145
Val Thr Val Phe Pro Lys Glu Pro Val Glu Leu Gly Gln Pro Asn
                155
                                     160
Thr Leu Ile Cys His Ile Asp Lys Phe Phe Pro Pro Val Leu Asn
                                     175
                170
Val Thr Trp Leu Cys Asn Gly Glu Leu Val Thr Glu Gly Val Ala
                                     190
                                                          195
                185
Glu Ser Leu Phe Leu Pro Arg Thr Asp Tyr Ser Phe His Lys Phe
                200
                                     205
                                                          210
His Tyr Leu Thr Phe Val Pro Ser Ala Glu Asp Phe Tyr Asp Cys
                                     220
                                                          225
                215
Arg Val Glu His Trp Gly Leu Asp Gln Pro Leu Leu Lys His Trp
                230
Glu Ala Gln Glu Pro Ile Gln Met Pro Glu Thr Thr Glu Thr Val
                                     250
                245
Leu Cys Ala Leu Gly Leu Val Leu Gly Leu Val Gly Ile Ile Val
                                                          270
                260
                                     265
Gly Ser Val Leu Ile Ile Lys Ser Leu Arg Ser Gly His Asp Pro
                275
                                     280
                                                          285
Arg Ala Gln Gly Thr Leu
                290
<210> 350
<211> 517
<212> PRT
<213> Homo sapiens
<220>
```

WO 01/62927

<400> 350 Arg Gly Ala Trp Glu Arg Arg Ser Arg Pro Ala Glu Met Glu Ala Thr Gly Thr Trp Ala Leu Leu Leu Ala Leu Ala Leu Leu Leu Leu Leu Thr Leu Ala Leu Ser Gly Thr Arg Ala Arg Gly His Leu Pro Pro Gly Pro Thr Pro Leu Pro Leu Gly Asn Leu Leu Gln Leu Arg Pro Gly Ala Leu Tyr Ser Gly Leu Met Arg'Leu Ser Lys Lys Tyr Gly Pro Val Phe Thr Ile Tyr Leu Gly Pro Trp Arg Pro Val Val Leu Val Gly Gln Glu Ala Val Arg Glu Ala Leu Gly Gly Gln Ala Glu Glu Phe Ser Gly Arg Gly Thr Val Ala Met Leu Glu Gly Thr Phe Asp Gly His Gly Val Phe Phe Ser Asn Gly Glu Arg Trp Arg Gln Leu Arg Lys Phe Thr Met Leu Ala Leu Arg Asp Leu Gly Met Gly Lys Arg Glu Gly Glu Leu Ile Gln Ala Glu Ala Arg Cys Leu Val Glu Thr Phe Gln Gly Thr Glu Gly Arg Pro Phe Asp Pro Ser Leu Leu Leu Ala Gln Ala Thr Ser Asn Val Val Cys Ser Leu Leu Phe Gly Leu Arg Phe Ser Tyr Glu Asp Lys Glu Phe Gln Ala Val Val Arg Ala Ala Gly Gly Thr Leu Leu Gly Val Ser Ser Gln Gly Gly Gln Thr Tyr Glu Met Phe Ser Trp Phe Leu Arg Pro Leu Pro Gly Pro His Lys Gln Leu Leu His His Val Ser Thr Leu Ala Ala Phe Thr Val Arg Gln Val Gln Gln His Gln Gly Asn Leu Asp Ala Ser Gly Pro Ala Arg Asp Leu Val Asp Ala Phe Leu Leu Lys Met Ala Gln Glu Gln Asn Pro Gly Thr Glu Phe Thr Asn Lys Asn Met Leu Met Thr Val Ile Tyr Leu Leu Phe Ala Gly Thr Met Thr Val Ser Thr Thr Val Gly Tyr Thr Leu Leu Leu Leu Met Lys Tyr Pro His Val Gln Lys Trp Val Arg Glu Glu Leu Asn Arg Glu Leu Gly Ala Gly Gln Ala Pro Ser Leu Gly Asp Arg Thr Arg Leu Pro Tyr Thr Asp Ala Val Leu His Glu Ala Gln Arg Leu Leu Ala Leu Val Pro Met Gly Ile Pro Arg Thr Leu Met Arg Thr Thr Arg Phe Arg Gly Tyr Thr Leu Pro Gln Gly Thr Glu Val Phe Pro Leu Gly Ser Ile Leu His Asp Pro Asn Ile Phe Lys His Pro Glu Glu Phe Asn Pro Asp Arg Phe Leu Asp Ala Asp Gly Arg Phe Arg Lys His Glu Ala Phe Leu Pro Phe Ser Leu Gly Lys Arg Val Cys Leu Gly Glu Gly Leu Ala Lys Ala Glu Cys Phe Leu Phe Phe Thr Thr Ile Leu Gln Ala Phe Ser Leu Glu Ser Pro Cys

```
470
                                     475
Pro Pro Asp Thr Leu Ser Leu Lys Pro Thr Val Ser Gly Leu Phe
                485
                                     490
Asn Ile Pro Pro Ala Phe Gln Leu Gln Val Arg Pro Thr Asp Leu
                500
                                     505
                                                          510
His Ser Thr Thr Gln Thr Arg
                515
<210> 351
<211> 232
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:337818.1.orf1:2000FEB01
<400> 351
Leu Ser Thr Asp Ile Asn Ile Val His Leu Gln Ser Gln Ala His
                                                           15
                                      10
Ser Gln Val Thr His Gln Leu Pro Trp Ile Cys Ser Pro His Val
                                                           30
                 20
                                      25
Gly Val Trp Leu Ser Pro Ser Gln Ala Thr Glu Thr Ala Thr His
                 35
                                       40
                                                           45
Val His Ser Ser His Ala Leu Ser Ile His Arg Thr Ser Gln Cys
                  50
                                                           60
Pro Cys Pro Trp Cys Leu Ala Gln Gly Thr Ala Cys Pro Leu Arg
                                      70
                                                           75
                  65
Gly His Ala Thr Gln Arg Leu Ser Leu Ser Met Ala Pro Thr His
                                      85
                                                           90
                 80
Ala Pro Ser Leu Gly Tyr Thr Thr Leu Pro Ala Cys Asp His
                                                          Arg
                 95
                                                          105
                                     100
Cys Pro His Thr Pro Asn His Leu Ser Thr Gln Leu Pro Thr
                                                          120
                110
                                      115
Asp Ile Val Leu Ala Pro Gln Ser Ile Phe Pro Leu Arg His Ala
                125
                                      130
Ala Pro Thr Glu Ala Gln Ser Pro Ala Thr Ser Ala Thr Ala Ala
                 140
                                     145
                                                          150
Leu Ser His Pro Phe Leu Ser Thr Leu Ile Leu Pro Asn Ala Asn
                 155
                                      160
                                                          165
Thr Ser Gly Ser Ala Ile Met His Arg Asp Phe Gly His Thr Arg
                 170
                                      175
                                                          180
Thr Leu Arg Pro Glu Glu His Leu Pro Asn Pro Asn Thr Cys Leu
                                      190
                 185
Cys Asn His Val Glu Ser Gly Pro Cys Cys Pro Ser Thr His Thr
                                      205
                                                          210
                 200
Tyr Thr Leu Thr Asp Leu Gln Pro Leu Phe Gly Val Arg Val Pro
                                     220
                215
Thr Arg Pro Ser Gly Arg Gly
                230
<210> 352
<211> 220
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:241577.4.orf1:2000MAY19
<400> 352
Gly Lys Val Glu Val Glu Asp Glu Gly Cys Thr Ala Gln Lys Ala
                                                           15
                                       10
Pro Val Arg Pro Gly Leu Leu Pro Pro Cys Leu Thr Pro Glu Ile
                  20
                                       25
Gly Ala Gly Val Pro Ser Ala Gly Cys Pro Leu Cys Pro Ser Met
```

WO 01/62927 PCT/US01/06059 Pro Pro Trp Ala ys Ser Tyr His Thr Ser His Val o Met Ile 50 55 Pro Leu Leu Gly Pro Arg Ser Ser Phe Ser Arg Lys Trp Ser Ala 70 Arg Ala Arg Gly Gly Lys Met Ser Pro Tyr Thr Asn Cys Tyr 80 ['] 85 Ala Gln Arg Tyr Tyr Pro Met Pro Glu Glu Pro Phe Cys Thr Glu 95 100 105 Leu Asn Ala Glu Glu Gln Ala Leu Lys Glu Lys Glu Lys Gly Ser 110 115 120 Trp Thr Gln Leu Thr His Ala Glu Lys Val Ala Leu Tyr Arg Leu 125 130 135 Gln Phe Asn Glu Thr Phe Ala Glu Met Asn Arg Arg Ser Asn Glu 140 145 150 Trp Lys Thr Val Met Cly Cys Val Phe Phe Phe Ile Cly Phe Ala 155 160 165 Ala Leu Val Ile Trp Trp Gln Arg Val Tyr Val Phe Pro Pro Lys 170 175 180 Pro Ile Thr Leu Thr Asp Glu Arg Lys Ala Gln Gln Leu Gln Arg 190 195 185 Met Leu Asp Met Lys Val Asn Pro Val Gln Gly Leu Ala Ser Arg 200 205 210 Trp Asp Tyr Glu Lys Lys Gln Trp Lys Lys 215 220 <210> 353 <211> 95 <212> PRT <213> Homo sapiens ,<220> <221> misc_feature <223> Incyte ID No: LG:344786.4.orf1:2000MAY19 <400> 353 Pro Ile Leu Trp Ser Val Leu Ser Phe Ser Ile Glu Leu Cys Phe Cys Cys Phe Ile Leu Ser Leu Leu Cys Val Phe Cys Pro Ile Leu 20 25 30 Cys Ser Arg His Gln Glu Pro Arg His Pro Pro Pro Val Thr Tyr 35 40 45 Ser Ser Glu Pro Ala Arg Ser Leu Phe Arg Met Ile Thr Trp Arg 50 55 60 Ser Leu Arg Lys Leu Leu Lys Asn Thr Leu Val Pro Ser Leu Ser 65 70 Gly Leu Gly Pro Phe Arg His Phe Ser Val Ser Met Thr Gln Thr 80 85 Met Gln Arg His Phe <210> 354 <211> 331 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:414307.1.orf2:2000FEB01 <220> <221> unsure <222> 191 <223> unknown or other <400> 354 Gly Met Gly Lys Leu Cys Leu Gly Pro Thr Leu Cys Pro Ala Ala

```
Ala Ala Glu Glu Ser Arg Asp Ala Glu Pro Arg Arg Glu Leu Leu
                 20
Cys Ser Gly Arg Pro Trp Thr Trp Arg Ala Ala Ala Arg Val Thr
                 35
Thr Met Ile Pro Trp Val Leu Leu Ala Cys Ala Leu Pro Cys Ala
                                      55
                 50
Ala Asp Pro Leu Leu Gly Ala Phe Ala Arg Arg Asp Phe Arg Lys
                                      70
                 65
Gly Ser Pro Gln Leu Val Cys Ser Leu Pro Gly Pro Gln Gly Pro
                 80
                                      85
Pro Gly Pro Pro Gly Ala Pro Gly Pro Ser Gly Met Met Gly Arg
                                     100
Met Gly Phe Pro Gly Lys Asp Gly Gln Asp Gly His Asp Gly Asp
                110
                                     115
Arg Gly Asp Ser Gly Glu Glu Gly Pro Pro Gly Arg Thr Gly Asn
                                     130
                125
Arg Gly Lys Pro Gly Pro Lys Gly Lys Ala Gly Ala Ile Gly Arg
                                                          150
                140
                                     145
Ala Gly Pro Arg Gly Pro Lys Gly Val Asn Gly Thr Pro Gly Lys
                155
                                     160
                                                          165
His Gly Thr Pro Gly Lys Lys Gly Pro Lys Gly Lys Lys Gly Glu
                170
                                     175
Pro Gly Leu Pro Gly Pro Cys Ser Cys Gly Xaa Gly His Thr Lys
                                     190
                185
Ser Ala Phe Ser Val Ala Val Thr Lys Ser Tyr Pro Arg Glu Arg
                200
                                     205
Leu Pro Ile Lys Phe Asp Lys Ile Leu Met Asn Glu Gly Gly His
                215
                                     220
                                                          225
Tyr Asn Ala Ser Ser Gly Lys Phe Val Cys Gly Val Pro Gly Ile
                230
                                     235
                                                          240
Tyr Tyr Phe Thr Tyr Asp Ile Thr Leu Ala Asn Lys His Leu Ala
                245
                                     250
                                                          255
Ile Gly Leu Val His Asn Gly Gln Tyr Arg Ile Arg Thr Phe Asp
                260
                                     265
Ala Asn Thr Gly Asn His Asp Val Ala Ser
                                         Gly Ser Thr Ile Leu
                275
                                     280
Ala Leu Lys Gln Gly Asp Glu Val Trp Leu Gln Ile Phe Tyr Ser
                290
                                     295
Glu Gln Asn Gly Leu Phe Tyr Asp Pro Tyr Trp Thr Asp Ser Leu
                305
                                     310
                                                          315
Phe Thr Gly Phe Leu Ile Tyr Ala Asp Gln Asp Asp Pro Asn Glu
                                     325
                                                          330
                320
Val
```

```
<210> 355
<211> 93
<212> PRT
<213> Homo sapiens
```

<220>
<221> misc_feature

<223> Incyte ID No: LI:202943.2.orf3:2000FEB01

Asn Val Arg Leu Gln Glu Ile Arg Lys Met Asp Ser Ser Gly Glu 10 Ala Glu Val Thr Phe Ser Cys Gln Glu Gly Ile Tyr Thr Val Gly 30 20 25 Tyr Gln Leu Met Gly Val Thr Lys Ile Thr Cys Leu Glu Ser Gly 35 40 45 Glu Trp Asn His Leu Ile Pro Tyr Cys Lys Gly Met Phe Ser Lys 60 Phe Thr Thr Phe Leu Met Phe Gly Asn Pro Arg Lys Val Arg Arg 70 65 Arg His Met Lys Cys Tyr Val Val Ser Met Phe Phe Val Phe Glu 80 85

Leu Arg Tyr <210> 356 <211> 112 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:246194.2.orf1:2000FEB01 <220> <221> unsure <222> 25, 28, 52, 112 <223> unknown or other <400> 356 Ser Ser Thr His His Arg Arg Ser Thr Gly Ala Pro Thr Pro Gly 10 15 Leu Pro Pro Pro Pro Ala Thr Arg Xaa Ser Cys Xaa Ala Ala Ser Ala Ala Pro Gly Pro Gly Ala Ala Pro Val Gly Ala Pro Thr 35 40 Pro Ala Ser Thr Thr Cys Xaa Val Leu Ala Arg Thr Thr Ser Pro 50 55 Ser Gly Ser Thr Ala Arg Ser Asp Ala Ala Glu Arg Gly Ser Pro 70 75 65 Gly Pro Gly Pro Pro Ala Gly Pro Ala Ala Gln Arg His Gly Gly 90 80 Arg His Pro His Gly Ser His Leu Asn Pro Gln His Pro Ile Lys 95 Phe Leu Phe Asn Thr Lys Xaa 110 <210> 357 <211> 73 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:815961.1.orf3:2000FEB01 <400> 357 Cys Val Glu Glu Val Cys Glu Cys Lys Asp Val Glu Val Leu Pro 15 10 Val Leu Asn Glu Leu Ala Asp Gly Leu Val Pro Leu Val Val Thr 25 20 Val Ile Gly Gly Ala Val Trp Val Asp Pro Val Thr Leu Ser Val 45 35 40 Val Ser Gly Gly Met Val Pro Val Gly Val Glu Trp Met Glu Ala 50 55 Glu Val Asp Ile Cys Ala Trp Val Gly Val Met Thr Leu 65 <210> 358 <211> 239 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:120744.1.orf1:2000MAY19 <220>

188/228

<221> unsure

<222> 199 <223> unknown or other <400> 358 Asn Glu Asn Arg Asn Met Ala His Tyr Ile Thr Phe Leu Cys Met 10 Val Leu Val Leu Leu Gln Asn Ser Val Leu Ala Glu Asp Gly 20 25 Glu Val Arg Ser Ser Cys Arg Thr Ala Pro Thr Asp Leu Val Phe 35 Ile Leu Asp Gly Ser Tyr Ser Val Gly Pro Glu Asn Phe Glu Ile 55 50 Val Lys Lys Trp Leu Val Asn Ile Thr Lys Asn Phe Asp Ile Gly 70 65 Pro Lys Phe Ile Gln Val Gly Val Val Gln Tyr Ser Asp Tyr Pro 80 85 90 Val Leu Glu Ile Pro Leu Gly Ser Tyr Asp Ser Gly Glu His Leu 95 100 105 Thr Ala Ala Val Glu Ser Ile Leu Tyr Leu Gly Gly Asn Thr Lys 110 115 120 Thr Gly Lys Ala Ile Gln Phe Ala Leu Asp Tyr Leu Phe Ala Lys 135 130 125 Ser Ser Arg Phe Leu Thr Lys Ile Ala Val Val Leu Thr Asp Gly 140 145 Lys Ser Gln Asp Asp Val Lys Asp Ala Ala Gln Ala Ala Arg Asp 155 160 165 Ser Lys Ile Thr Leu Phe Ala Ile Gly Val Gly Ser Glu Thr Glu 170 175 180 Asp Ala Glu Leu Arg Ala Ile Ala Asn Lys Pro Ser Ser Thr Tvr 185 190 195 Val Phe Tyr Xaa Glu Asp Tyr Ile Ala Ile Ser Lys Ile Arg Glu 200 205 Val Met Lys Gln Lys Leu Cys Glu Glu Ser Val Cys Pro Thr Arg 215 220 Ile Pro Val Ala Ala Arg Asp Glu Arg Gly Phe Asp Ile Leu , 230 235 <210> 359 <211> 528 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:757520.1.orf1:2000MAY01 <400> 359 Ala Ser His Ser Ala Ala Arg Thr Thr Phe Arg Cys Leu Ser Asp Ser Ala Gln Pro His Thr Met Ser Cys Arg Ser Tyr Arg Ile Ser Ser Gly Cys Gly Val Thr Arg Asn Phe Ser Ser Cys Ser Ala Val 40 35 Ala Pro Lys Thr Gly Asn Arg Cys Cys Ile Ser Ala Ala Pro Tyr 50 55 Tyr Arg Gly Leu Thr Gly Phe Gly Ser Arg Arg Gly Val Ser Cys 75 65 70 Ser Leu Cys Asn Leu Gly Ser Cys Gly Pro Arg Ile Ala Val Gly 80 85 90 Gly Phe Arg Ala Gly Ser Cys Gly Arg Ser Phe Gly Tyr Arg Ser 100 Gly Gly Val Cys Gly Pro Ser Pro Pro Cys Ile Thr Thr Val Ser

115

130

135

150

Val Asn Glu Ser Leu Leu Thr Pro Leu Asn Leu Glu Ile Asp Pro

Asn Ala Gln Cys Val Lys Gln Glu Glu Lys Glu Gln Ile Lys Ser

110

125

140

WO 01/62927 PCT/US01/06059 Leu Asn Ser Arg he Ala Ala Phe Ile Asp Lys Val 🚾 Phe Leu Glu Gln Gln Asn Lys Leu Leu Glu Thr Lys Trp Gln Phe Tyr Gln Asn Gln Arg Cys Cys Glu Ser Asn Leu Glu Pro Leu Phe Ser Gly Tyr Ile Glu Thr Leu Arg Arg Glu Ala Glu Cys Val Glu Ala Asp Ser Gly Arg Leu Ala Ser Glu Leu Asn His Val Gln Glu Val Leu Glu Gly Tyr Lys Lys Lys Tyr Glu Glu Val Ala Leu Arg Ala Thr Ala Glu Asn Glu Phe Val Val Leu Lys Lys Asp Val Asp Cys Ala Tyr Leu Arg Lys Ser Asp Leu Glu Ala Asn Val Glu Ala Leu Val Glu Glu Ser Ser Phe Leu Arg Arg Leu Tyr Glu Glu Glu Ile Arg Val Leu Gln Ala His Ile Ser Asp Thr Ser Val Ile Val Lys Met Asp Asn Ser Arg Asp Leu Asn Met Asp Cys Ile Ile Ala Glu Ile Lys Ala Gln Tyr Asp Asp Val Ala Ser Arg Ser Arg Ala Glu Ala Glu Ser Trp Tyr Arg Ser Lys Cys Glu Glu Met Lys Ala Thr Val Ile Arg His Gly Glu Thr Leu Arg Arg Thr Lys Glu Glu Ile Asn Glu Leu Asn Arg Met Ile Gln Arg Leu Thr Ala Glu Ile Glu Asn Ala Lys Cys Gln Arg Ala Lys Leu Glu Ala Ala Val Ala Glu Ala Glu Gln Gln Gly Glu Ala Ala Leu Ser Asp Ala Arg Cys Lys Leu Ala Glu Leu Glu Gly Ala Leu Gln Lys Ala Lys Gln Asp Met Ala Cys Leu Leu Lys Glu Tyr Gln Glu Val Met Asn Ser Lys Leu Gly Leu Asp Ile Glu Ile Ala Thr Tyr Arg Arg Leu Leu Glu Gly Glu Glu His Arg Leu Cys Glu Gly Val Gly Ser Val Asn Val Cys Val Ser Ser Ser Arg Gly Gly Val Ser Cys Gly Gly Leu Ser Tyr Ser Thr Thr Pro Gly Arg Gln Ile Thr Ser Gly Pro Ser Ala Ile Gly Gly Ser Ile Thr Val Val Ala Pro Asp Ser Cys Ala Pro Cys Gln Pro Arg Ser Ser Ser Phe Ser Cys Gly Ser Ser Arg Ser Val Arg Phe Ala <210> 360 <211> 157 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:160570.1.orf2:2000FEB18

<223> Incyte ID No: LG
<220>
<221> unsure
<222> 150
<223> unknown or other

```
<400> 360
Val Glu Gly Ala Ala Gly Arg Leu Gly Gly Ser Phe Leu Ser Trp
                                                           15
Leu Glu Thr Thr Thr Asp Met Gly Cys Phe Cys Ala Val Pro
                 20
Glu Glu Phe Tyr Cys Glu Val Leu Leu Leu Asp Glu Ser Lys Leu
                                      40
                                                           45
                 35
Thr Leu Thr Thr Gln Gln Gln Gly Ile Lys Lys Ser Thr Lys Gly 50 55 60
                 50
Ser Val Val Leu Asp His Val Phe His His Val Asn Leu Val Glu
                 65
                                      70
                                                           75
Ile Asp Tyr Phe Gly Leu Arg Tyr Cys Asp Arg Ser His Gln Thr
                 80
                                      85
Tyr Trp Leu Asp Pro Ala Lys Thr Leu Ala Glu His Lys Glu Leu
                                     100
                 95
Ile Asn Thr Gly Pro Pro Tyr Thr Leu Tyr Phe Gly Ile Lys Phe
                110
                                     115
                                                          120
Tyr Ala Glu Asp Pro Cys Lys Leu Lys Glu Glu Ile Thr Arg
                                                          135
                125
                                     130
Ser Ile Asp Phe Val Phe Glu Gln Ile His Ala Leu Arg Ile Xaa
                140
                                     145
Lys Ala Leu Phe Lys Thr Asn
                155
<210> 361
<211> 65
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:350398.3.orf3:2000FEB01
<220>
<221> unsure
<222> 22-23, 56, 65
<223> unknown or other
<400> 361
Gly Leu Pro Lys Pro Gly Ala Leu Val Gly Asp Arg Ala Ala Pro
                                      10
Ala Trp Val Gln Pro Pro Xaa Xaa Gln Val Asn Arg Phe His Lys
                                                           30
                                      25
                  20
Ile Arg Asn Arg Ala Leu Leu Leu Thr Asp Gln His Leu Tyr
                                                           45
                 35
                                      40
Leu Asp Pro Asp Arg Gln Tyr Arg Val Met Xaa Ala Val Pro Leu
                 50
                                      55
                                                           60
Glu Ala Val Thr Xaa
<210> 362
<211> 517
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:221285.1.orf3:2000FEB01
<400> 362
Leu Ala Ala Arg Gly Val Leu Ser Arg Gly Gln Pro Gly Ser Ala
Ala Ala Pro Arg Gln Glu Lys Gln Pro Arg Thr Pro Trp Lys
                                                           30
                  20
Arg Ser Thr Trp Ala Cys Glu Asn Gly Ala Asn Thr Ser Pro
                                                          Ala
                 35
                                      40
Lys Pro His Ser Lys Ala Gly Pro Arg Thr Ala Thr Val Ala Pro
```

				50					55					60
Gln	Ala	Ser	Arg	Met 65	Thr	Val [']	Ļys	Pro		Lys	Ala	Ala	Ser	
Ala	Arg	Asn	Leu	Ala 80	Lys	Arg	Arg	Arg	Thr 85	Tyr	Leu	Gly	Gly	Ala 90
Ala	Gly	Arg	Ser	Gln 95	Gļu	Pro	Glu	Val		Суз	Ala	Ala	Val	
Pro	Gly	Lys	Pro	Gly 110	Asp	Arg	Asn	Сув	Pro 115	Glu	Phe	Pro	Pro	Pro 120
Asp	Arg	Thr	Leu	Gly 125	Cys	Trp	Ala	Thr		Ala	Ala	Pro	Ala	
Gly	Leu	Cys	Gly	Ala 140	Gly	Ser	Glu	Pro		Ile	Ala	Pro	Thr	
CÀR	Ala	Gly	Asn	Leu 155	Pro	Ser	Arg	Pro		Pro	Leu	Leu	Ser	
Leu	Leu	Ala	Ser	Arg 170	Asn	Pro	Cys	Pro		His	Tyr	Leu	His	
Ser	Gly	Ser	His	Asn 185	Thr	Leu	Ala	Pro		Cys	Phe	Lys	Ala	
Leu	His	Arg	Lys	Arg 200	Gly	Ser	Gln	Pro			Met	Ala	Ser	
Leu	Thr	Asp	Arg	Thr 215	Ser	Arg	Ala	Pro			Tyr	Thr	Tyr	
Ser	Arg	Pro	Arg	Ala 230	Leu	Pro	СЛа	Gln		Ser	Arg	Tyr	Arg	
Ser	Leu	Thr	Gln	Pro 245	Asp	Glu	Glu	Pro		His	Tyr	Gly	Asn	
Met	Tyr	Asp	Arg	Arg 260	Val	Ile	Arg	Gly		Thr	Tyr	Ala	Leu	
Thr	Gly	Pro	Leu	Leu 275	Gly	Arg	Pro	Asp		Leu	Glu	Leu	Gln	
Gln	Arg	Glu	Ala	Arg 290	Lys	Arg	Ala	Leu		Arg	Lys	Gln	Ala	
Glu	Gln	Leu	Arg	Pro	Gln	Thr	Pro	Glu		Val	Glu	Gly	Arg	Lys 315
His	Val	Asp	Val	Gln 320	Thr	Glu	Leu	Tyr		Glu	Glu	Ile	Ala	Asp 330
Arg	Ile	Ile	Glu	Val 335	Asp	Met	Glu	Cys		Thr	Asp	Ala	Phe	
Asp	Arg	Pro	Pro	Thr 350	Pro	Leu	Phe	Ile	Pro 355	Ala	ГÀЗ	Thr	Gly	Lys 360
Asp	Val	Ala	Thr	Gln 365	Ile	Leu	Glu	Gly		Leu	Phe	Asp	Phe	Asp 375
Leu	Glu	Val	Lys	Pro 380	Val	Leu	Glu	Val	Leu 385	Val	Gly	Lys	Thr	Ile 390
Glu	Gln	Ser	Leu	Leu 395	Glu	Val	Met	Glu	Glu 400	Glu	Glu	Leu	Ala	Asn 405
Leu	Arg	Ala	Ser	Gln 410	Arg	Glu	Tyr	Glu	Glu 415	Leu	Arg	Asn	Ser	Glu 420
Arg	Ala	Glu	Val	Gln 425	Arg	Leu	Glu	Glu	Gln 430	Glu	Arg	Arg	His	Arg 435
Glu	Glu	Lys	Glu	Arg 440	Arg	Lys	Lys	Gln		Trp	Glu	Ile	Met	His 450
Lys	His	Asn	Glu		Ser	Gln	Lys	Ile		Ala	Arg	Ala	Phe	Ala 465
Gln	Arg	Tyr	Leu	Ala 470	Asp	Leu	Leu	Pro		Val	Phe	Gly	Ser	
Arg	Asp	Ser	GJÀ		Phe	Tyr	Asp	Pro		Glu	Arg	Asp	Ile	Glu 495
Ile	Gly	Phe	Leu		Trp	Leu	Met	Asn		Val	Glu	Lys	Thr	Met 510
Glu	Tyr	Ser	Met	Val 515	Gly	Arg			203					310

<210> 363 <211> 60 <212> PRT

```
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:401605.2.orf2:2000FEB01
<400> 363
Ala Glu Arg Gly Leu Arg Thr Leu Leu Ser Leu Glu Asp Glu Arg
                                                           15
                                      10
           Ser Gly Gln Met Gly Ser Leu Leu Gly Thr Val Cys
Met Cys His
                                                           3.0
                 20
                                      25
Ser Glu Ser Val Pro Ser Thr Pro Lys Lys Pro Pro Lys Ser Trp
                                      40
                                                           45
                 35
Ala Ser Leu Trp Asn Gln Gln Ile Leu His Phe Gly Ala Tyr Lys
<210> 364
<211> 239
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:329017.1.orf1:2000FEB01
<400> 364
Ile Tyr Thr Glu Val Glu Gln Leu Gly Trp Lys Leu Tyr Gly Asp
                                                           15
                                      10
Lys Leu Ala Thr Ser Ser Gly Asp Thr Thr Val Lys Leu Trp Asp
                 20
                                      25
                                                           30
Leu Cys Thr Gly Asp Cys Ile Leu Thr Phe Glu Gly His Ser Arg
                                      40
Ala Val Trp Ser Cys
                    Thr Trp His Ser Cys
                                         Gly Asn Phe Val Ala
                 50
                                      55
Ser Ser Ser Leu Asp Lys Thr Ser Lys Ile
                                         Trp Asp Val Asn Ser
                 65
                                      70
Glu Arg Cys Arg Cys Thr Leu Tyr Gly His
                                         Thr Asp Ser Val Asn
                 80
                                      85
Ser Ile Glu Phe Phe Pro Phe Ser Asn Thr Leu Leu Thr Ser Ser
                 95
                                     100
                                                          105
Ala Asp Lys Thr Leu Ser Ile Trp Asp Ala Arg Thr Gly Ile Cys
                110
                                     115
                                                          120
Glu Gln Ser Leu Tyr Gly His Met His Ser Ile Asn Asp Ala Ile
                125
                                     130
                                                          135
Phe Asp Pro Arg Gly His Met Ile Ala Ser Cys Asp Ala Cys Gly
                                                          150
                140
                                     145
Val Thr Lys Leu Trp Asp Phe Arg Lys Leu Leu Pro Ile Val Ser
                155
                                     160
                                                          165
Ile Asp Ile Gly Pro Ser Pro Gly Asn Glu Val Asn Phe Asp Ser
                                     175
                170
Ser Gly Arg Val Leu Ala Gln Ala Ser Gly Asn Gly Val Ile His
                                     190
                185
Leu Leu Asp Leu Lys Ser Gly Glu Ile His Lys Leu Met Gly His
                200
                                     205
                                                          210
Glu Asn Glu Ala His Thr Val Val Phe Ser His Asp Gly Glu
                                                          Ile
                                     220
                215
                                                          225
Leu Phe Ser Gly Gly Ser Asp Gly Thr Val Arg Thr Trp Ser
                230
                                     235
<210> 365
<211> 160
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
```

WO 01/62927

<223> Incyte ID : LI:401322.1.orf1:2000FEB01

```
<400> 365
Ala Thr Gln Trp Glu Ser Pro Pro Gly Asp Thr Thr Gly Gly Ser
                                      10
Pro Gly Ile Tyr Lys Val Pro Pro Ala Thr Ala Arg Trp Asp Ser
                 20
                                      25
Trp Cys Cys Trp Arg Pro Val Trp Cys Leu Gln Ser Ala Thr Leu
                 35
Gln Leu Gln Leu Leu Asp Gln Pro Cys Val Ser Ala Ser Pro Ser
                 50
                                                           60
Met Trp Ala Arg Pro
                    Glu Cys Arg Trp Ala Met Pro Ala Gly Ser
                 65
                                      70
Cys Thr Ala Trp Ser Thr Thr Ser Ser Pro Val Ala Pro Cys Pro
                 80
                                      85
                                                           90
Ala Thr Arg Pro Trp Gly Ala Val Ile Thr Pro Ser Thr Pro Ser
                 95
                                     100
                                                          105
Ser Gly Arg Pro Ser Leu Ala Gly Met Cys Pro Gly Leu Ser Val
                110
                                     115
                                                          120
Asp Leu Glu Pro Ala Val Ile Gly Trp His Gln Leu Pro Val Pro
                125
                                     130
                                                          135
His Ser Gly Ala Arg Gly Cys Cys Ser Gln Gly Ala Ala Gly Ser
                                     145
                140
                                                          150
Leu Arg Ala Lys Gln Tyr His Ser His His
                155
                                     160
```

<210> 366

<211> 757

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: LG:403409.1.orf3:2000MAY19

<400> 366

Gly Arg Gly Arg Arg Lys Pro Asn Glu Phe Leu Gly Gly Cys Arg 10 Met Gly Asp Ser Lys Val Lys Val Ala Val Arg Ile Arg Pro Met 20 25 30 Asn Arg Arg Glu Thr Asp Leu His Thr Lys Cys Val Val Asp Val 40 45 Asp Ala Asn Lys Val Ile Leu Asn Pro Val Asn Thr Asn Leu Ser 50 55 Lys Gly Asp Ala Arg Gly Gln Pro Lys Val Phe Ala Tyr Asp His 65 70 75 Cys Phe Trp Ser Met Asp Glu Ser Val Lys Glu Lys Tyr Ala Gly 80 85 90 Gln Asp Ile Val Phe Lys Cys Leu Gly Glu Asn Ile Leu Gln Asn 95 100 Ala Phe Asp Gly Tyr Asn Ala Cys Ile Phe Ala Tyr Gly Gln Thr 110 Gly Ser Gly Lys Ser Tyr Thr Met Met Gly Thr Ala Asp Gln Pro 125 130 135 Gly Leu Ile Pro Arg Leu Cys Ser Gly Leu Phe Glu Arg Thr Gln 140 145 150 Lys Glu Glu Asn Glu Glu Gln Ser Phe Lys Val Glu Val Ser Tyr 160 155 165 Met Glu Ile Tyr Asn Glu Lys Val Arg Asp Leu Leu Asp Pro Lys 170 Gly Ser Arg Gln Thr Leu Lys Val Arg Glu His Ser Val Leu Gly 195 185 190 Pro Tyr Val Asp Gly Leu Ser Lys Leu Ala Val Thr Ser Tyr Lys 200 205 210 Asp Ile Glu Ser Leu Met Ser Glu Gly Asn Lys Ser Arg Thr Val 220 225 215 Ala Ala Thr Asn Met Asn Glu Glu Ser Ser Arg Ser His Ala Val

PCT/US01/06059

				230					235					240
Phe	Lys	Ile		Leu 245	Thr	His	Thr	Leu	Tyr 250	Asp	Val "	Lys	Ser	Gly . 255
Thr	Ser	Gly	Glu	Lys 260	Val	Gly	Lys	Leu	Ser 265	Leu	Val	Asp	Leu	Ala 270
Gly	Ser	Glu	Arg	Ala 275	Thr	Lys	Thr	Gly	Ala 280	Ala	Gly	Asp	Arg	Leu 285
_		_		Asn 290		•			295					300
				Leu 305		_			310					315
				Tyr 320					325					330
				Gly 335					340					Val 345
				Asp 350		_	_		355					360
_				Ala 365					370					375
				A1a 380				. –	385					390
	-	:	_	Glu 395				_	400				_	405
			_	Asp 410	-				415					420
				Thr 425					430			,		435
				Arg 440					445					450
				Gly 455					460				_	465
				Ala 470	_				475					480
		-		His 485				_	490					495
				Gly 500					505					510
_				Glu 515	_				520				_	525
	_			Val 530		_			53,5				Ile	540
			-	Asp 545					550					555
_				Pro 560					565					570
	_		_	Pro 575					580		1			585
				Gly 590					595					600
			_	Glu 605	_				610					615
	_			Asp 620					625		4			630
				Glu 635					640					645
		_		His 650					655					660
•		_		Asn 665	_	_			670					675
				Gln 680		_		-	685	_				690
				Asn 695					700		_			705
				Leu 710					715					720
Glu	Leu	Asp	Lys	Arg 725	Thr	Glu	Tyr	Lys	Val 730	Thr	Leu	Gln	Ile	Pro 735

PCT/US01/06059

```
Ala Ser Ser Leu Asp Ala Asn Arg Lys Arg Gly Ser Leu Leu Ser
                740
                                     745
                                                         750
Glu Pro Ala Ile Gln Val Arg
                755
<210> 367
<211> 162
<212> PRT '
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:233933.5.orf3:2000MAY19
<400> 367
Pro Arg Gln His Phe Cys Met Gln Tyr Ser Leu Gln Val Val Thr
                                      10
Ala Thr Cys Lys Phe Gly Met Asn Ala Leu Leu Leu Ser Ala Trp
                 20
                                                          30
Phe Gly His Leu Arg Ile Leu Gln Ile Leu Val Asn Ser Gly Ala
                                                          45
                                      40
Lys Ile His Cys Glu Ser Lys Glu Gly Asn Thr Ala Leu His Leu
Ala Ala Gly Arg Gly His Met Ala Val Leu Gln Arg Leu Val Asp
                                      70
                                                          75
Ile Gly Leu Asp Leu Glu Glu Gln Asn Ala Glu Gly Leu Thr Ala
                                                          90
                 80
Leu His Ser Ala Ala Gly Gly Ser His Pro Asp Cys Val Gln Leu
                                     100
                 95
Leu Leu Arg Ala Gly Ser Thr Val Asn Ala Leu Thr Gln Lys Asn
Leu Ser Cys Leu His Tyr Ala Ala Leu Ser Gly Ser Glu Asp Val
                 125
                                     130
Ser Arg Val Leu Ile His Ala Gly Gly Cys Ala Asn Val Val Asp
                 140
                                     145
                                                         150
His Gln Gly Ala Ser Pro Leu His Leu Ala Val Arg
                155
                                     160
<210> 368
<211> 635
<212> PRT
<213> Homo sapiens
<221> misc_feature
<223> Incyte ID No: LI:290344.1.orf2:2000MAY01
Ala Leu Val Phe Met Gln Pro Met Val Met Gln Gly Cys Pro Tyr
Thr Leu Pro Arg Cys His Asp Trp Gln Ala Ala Asp Gln Phe His
                  20
                                      25
His Ser Ser Ser Leu Arg Ser Thr Cys Pro His Pro Gln Val Arg
Ala Ala Val Thr Ser Pro Ala Pro Pro Gln Asp Gly Ala Gly Val
                 50
                                      55
Pro Cys Leu Ser Leu Lys Leu Leu Asn Cly Ser Val Gly Ala Ser
                  65
                                      70
                                                           75
Gly Pro Leu Glu'Pro Pro Ala Met Asn Leu Cys Trp Asn Glu Ile
                                                          90
                  80
                                      85
Lys Lys Lys Ser His Asn Leu Arg Ala Arg Leu Glu Ala Phe Ser
                 95
                                     100
                                                          105
Asp His Ser Gly Lys Leu Gln Leu Pro Leu Gln Glu Ile Ile Asp
```

WO 01/62927

196/228

115

130

Trp Leu Ser Gln Lys Asp Glu Glu Leu Ser Ala Gln Leu Pro Leu

Gln Gly Asp Val Ala Leu Val Gln Gln Glu Lys Glu Thr His Ala

120

- 135

110

125

BNSDOCID: <WO___0162927A2_I_>

				140	٠.	,			145				•	150
Ala	Phe	Met	Glu	140 Glu 155	Val	Lys	Ser	Arg	Ala 160	Pro	Tyr	Ile	Tyr	Ser 165
Val	Leu	Glu	Ser		Gln	Ala	Phe	Leu	Ser 175	Gln	His	Pro	Phe	
Glu	Leu	Glu	Glu		His	ser	Glu		Lys 190	Asp	Thr	Ser	Pro	
Gln	Arg	Ile	Gln		Leu	Ser	Arg		Val 205	Trp	Lys	Gln	Ala	
Val	Ala	Ser	Glu	Leu 215	Trp	Glu	Lys	Leu	Thr 220	Ala	Arg	Cys	Val	Asp 225
Gln	His	Arg	His	Ile 230	Glu	Arg	Thr	Leu	Glu 235	Gln	L'eu	Leu	Glu	Ile 240
	_			245					Thr 250					255
				260					Gly 265					270
				275					Lys 280,					285
				290					Leu 295			•		300
				3,05					Leu 310					315
				320				_	Trp 325	_	,	•		330
				335					Gln 340 Ser					345
	_			350					355 Lys					360 Ile
	_		_	365					370 Asp			_	_	375
				380			-		385 Asn					390
		_		395			_		400 Arg	_			_	405
Arg	Leu	Asp	Leu	410 Val	Thr	Leu	Thr	Thr	415 Ala	Leu	Glu	Ile	Phe	
Glu	His	Asp	Leu		Ala	Ser	Glu	His	430 Val	Met	Asp	Val	Val	
Val	Ile	His	Cys		Thr	Ala	Leu	Tyr	445 Glu	Arg	Leu	Glu	Glu	
Arg	Gly	Ile	Leu	455 Val 470	Asn	val	Pro	Leu	460 Cys 475	Val	Asp	Met	Ser	
Asn	Trp	Leu	Leu		Val	Phe	Asp	Ser	Gly 490	Arg	Ser	Gly	Lys	480 Met 495
Arg	Ala	Leu	Ser		Lys	Thr	Gly	Ile	Ala 505	Суѕ	Leu	Суз	Gly	
Glu	Val	Lys	Glu		Leu	Gln	Tyr	Leu	Phe 520	Ser	Gln	Val	Ala	
Ser	Gly	Ser	Gln		Asp	Gln	Arg	His	Leu 535	Gly	Val	Leu	Leu	
Glu	Ala	Ile	Gln	Val 545	Pro	Arg	Gln	Leu	Gly 550	Glu	Val	Ala	Ala	Phe 555
_				560					Arg 565					570
				575					Ser 580					585
				590					Trp 595					600
_				605				_	His 610			_		615
	_			620	Pro	His	Gln	Gly	Val 625	Gln	Val	Pro	Glu	Ser 630
Glu	Ala	Ile	Gln	Arg 635										

```
<210> 369
<211> 433
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:410742.1.orf3:2000MAY01
<400> 369
Gln Ile Trp Met Lys Ser Thr Gln Ile Ile Gly Leu Gln Tyr Ile
Ser Leu Pro Leu Gly Met Lys Glu Ile Gly Leu Lys Tyr Lys Arg
                                      25
                                                           30
                 20
Asp Pro Arg Thr Asn Glu Gly Ile Leu Lys Val Val Lys Ala Leu
Asp Tyr Glu Gln Leu Gln Ser Val Lys Leu Ser Ile Ala Val Lys
                 50
                                      55
                                                           60
Asn Lys Ala Glu Phe His Gln Ser Val Ile Ser Arg Tyr Arg Val
                                      70
                  65
Gln Ser Thr Pro Val Thr Ile Gln Val Ile Asn Val Arg Glu Gly
                                      85
                 80
Ile Ala Phe Arg Pro Ala Ser Lys Thr Phe Thr Val Gln Lys Gly
                                     100
Ile Ser Ser Lys Lys Leu Val Asp Tyr Ile Leu Gly Thr Tyr Gln
                110
                                     115
                                                          120
Ala Ile Asp Glu Asp Thr Asn Lys Ala Ala Ser Asn Val Lys Tyr
                 125
                                     130
                                                          135
Val Met Gly Arg Asn Asp Gly Gly Tyr Leu Met Ile Asp Ser Lys
                140
                                     145
                                                          150
Thr Ala Glu Ile Lys Phe Val Lys Asn Met Asn Arg Asp Ser Thr
                 155
                                     160
Phe Ile Val Asn Lys Thr Ile Thr Ala Glu Val Leu Ala Ile Asp
                170
                                     175
                                                          180
Glu Tyr Thr Gly Lys Thr Ser Thr Gly Thr Val Tyr Val Arg Val
                185
                                     190
                                                          195
Pro Asp Phe Asn Asp Asn Cys Pro Thr Ala Val Leu Glu Lys Asp
                200
                                     205
                                                          210
Ala Val Cys Ser Ser Ser Pro Ser Val Val Val Ser Ala Arg Thr
                 215
                                     220
                                                          225
Leu Asn Asn Arg Tyr Thr Gly Pro Tyr Thr Phe Ala Leu Glu Asp
                 230
                                     235
                                                          240
Gln Pro Val Lys Leu Pro Ala Val Trp Ser Ile Thr Thr Leu Asn
                                     250
                                                          255
                245
Ala Thr Ser Ala Leu Leu Arg Ala Gln Glu Gln Ile Pro Pro Gly
                                                          270
                260
                                     265
Val Tyr His Ile Ser Leu Val Leu Thr Asp Ser Gln Asn Asn Arg
                275
                                     280
                                                          285
Cys Glu Met Pro Arg Ser Leu Thr Leu Glu Val Cys' Gln Cys Asp
                290
                                     295
                                                          300
Asn Arg Gly Ile Cys Gly Thr Ser Tyr Pro Thr Thr Ser Pro Gly
                305
                                     310
                                                          315
Thr Arg Tyr Gly Arg Pro His Ser Gly Arg Leu Gly Pro Ala Ala
                 320
                                     325
                                                          330
Ile Gly Leu Leu Leu Gly Leu Leu Leu Leu Leu Ala Pro
                 335
                                     340
                                                          345
Leu Leu Leu Thr Cys Asp Cys Gly Ala Gly Ser Thr Gly Gly
                 350
                                     355
                                                          360
Val Thr Gly Gly Phe Ile Pro Val Pro Asp Gly Ser Glu Gly Thr
                                     370
                                                          375
                365
Ile His Gln Trp Gly Ile Glu Gly Ala His Pro Glu Asp Lys Glu
                 380
                                     385
                                                          390
Ile Thr Asn Ile Cys Val Pro Pro Val Thr Ala Asn Gly Ala Asp
                 395
                                      400
                                                          405
Phe Met Glu Ser Ser Glu Val Cys Thr Asn Thr Tyr Ala Arg Gly
                 410
                                     415
                                                          420
Thr Ala Val Glu Gly Thr Ser Gly Asn Gly Asn Asp His
```

, 430

425

```
<210> 370
<211> 531
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:406568.1.orf3:2000MAY19
<220>
<221> unsure
<222> 148, 291
<223> unknown or other
<400> 370
Ala Cys His Leu Pro Pro Cys Leu Leu Leu Ala Ala Leu Asn Ala
                                                          . 15
                                      10
Trp Ser Phe Lys Leu Leu Leu Gly Leu Thr Lys Gln Gly Pro Cys
                                                           30
                 20
Leu Pro Leu Ala Thr Glu Glu Asp Ser Val Asn Thr Asn Pro Ser
Thr Glu Asp Glu Leu Leu Ala Ser Leu Ser Ala Glu Glu Leu Lys
                                      55
                 50
Glu Leu Glu Arg Glu Leu Glu Asp Ile Glu Pro Asp Arg Asn Leu
                 65
                                      70
Pro Val Gly Leu Arg Gln Lys Ser Leu Thr Glu Lys Thr Pro Thr
                 80
                                      85
Gly Thr Phe Ser Arg Glu Ala Leu Met Ala Tyr Trp Glu Lys Glu
                 95
                                     100
                                                          105
Ser Gln Lys Leu Leu Glu Lys Glu Arg Leu Gly Glu Cys Gly Lys
                110
                                     115
Val Ala Glu Asp Lys Glu Glu Ser Glu Glu Glu Leu Ile Phe Thr
                125
                                     130
                                                          135
Glu Ser Asn Ser Glu Val Ser Glu Glu Val Tyr Thr Xaa Glu Glu
                140
                                     145
                                                          150
Glu Glu Glu Ser Gln Glu Glu Glu Glu Glu Asp Ser Asp Glu
                155
                                     160
Glu Glu Arg Thr Ile Glu Thr Ala Lys Gly Ile Asn Gly Thr Val
                170
                                     175
Asn Tyr Asp Ser Val Asn Ser Asp Asn Ser Lys Pro Lys Ile Phe
                185
                                     190
Lys Ser Gln Ile Glu Asn Ile Asn Leu Thr Asn Gly Ser Asn Gly
                200
                                     205
                                                          210
Arg Asn Thr Glu Ser Pro Ala Ala Ile His Pro Cys Gly Asn Pro
                                     220
                                                          225
                215
Thr Val Ile Glu Asp Ala Leu Asp Lys Ile Lys Ser Asn Asp Pro
                230
                                     235
                                                          240
Asp Thr Thr Glu Val Asn Leu Asn Asn Ile Glu Asn Ile Thr Thr
                245
Gln Thr Leu Thr Arg Phe Ala Glu Ala Leu Lys Asp Asn Thr Val
                                     265
                                                          270
                260
Val Lys Thr Phe Ser Leu Ala Asn Thr His Ala Asp Asp Ser Ala
                275
                                     280
                                                          285
Ala Met Ala Ile Ala Xaa Met Leu Lys Val Asn Glu His Ile Thr
                                                          300
                                     295
                290
Asn Val Asn Val Glu Ser Asn Phe Ile Thr Gly Lys Gly Ile Leu
                305
                                     310
                                                          315
Ala Ile Met Arg Ala Leu Gln His Asn Thr Val Leu Thr Glu Leu
                                     325
                320
Arg Phe His Asn Gln Arg His Ile Met Gly Ser Gln Val Glu Met
                335
                                     340
Glu Ile Val Lys Leu Leu Lys Glu Asn Thr Thr Leu Leu Arg Leu
                                     355
                                                          360
                350
Gly Tyr His Phe Glu Leu Pro Gly Pro Arg Met Ser Met Thr Ser
                365
                                     370
                                                          375
```

```
📆 g Leu Gln
Ile Leu Thr Arg
                  šn Met Asp Lys Gln Arg Gln Lys
                380
                                     385
Glu Gln Lys Gln Gln Glu Gly Tyr Asp Gly Gly Pro Asn Leu Arg
                395
                                     400
Thr Lys Val Trp Gln Arg Gly Thr Pro Ser Ser Ser Pro Tyr Val
                410
                                     415
                                                          420
Ser Pro Arg His Ser Pro Trp Ser Ser Pro Lys Leu Pro Lys Lys
                425
                                     430
                                                          435
Val Gln Thr Val Arg Ser Arg Pro Leu Ser Pro Val Ala Thr Pro
                440
                                     445
Pro Pro Pro Arg Asp Ser Ser Thr Pro Arg Glu Lys Ala His Tyr
                455
                                     460
Gln Lys His Cys Arg Ser His Gln Thr Thr Gly Glu Cys Pro Thr
                470
                                     475
Gly Ile Thr Lys Trp Thr Lys Lys Glu Lys Arg Glu Lys Gly Gln
                485
                                     490
                                                          495
Glu Thr Ala Lys Gln Tyr Ser Lys Gly Asn Lys Lys Phe Ser Glu
                500
                                     505
                                                          510
Val Ser Ala Arg Glu Glu Asn Gly Arg Gln Phe Pro Thr Phe Tyr
                                     520
                515
Pro Thr Glu Ile Ser Ser
                530
<210> 371
<211> 257
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
```

<223> Incyte ID No: LI:283762.1.orf2:2000MAY01

<400> 371

Lys Ala Phe Phe Ile Trp Trp Gln Ser Cys Trp Asn Arg Gly Asn Gln Ser Phe Lys Phe Leu Glu Gln Ile Leu Trp Ser Asn Leu Gln Ile Leu Lys Lys Thr His His Pro Thr His Arg Arg Tyr Asp Phe Phe Val Ser Arg Phe Ser Ala Met Cys His Ser Cys His Ser Asp Pro Glu Ile Arg Thr Glu Ile Arg Ile Ala Gly Ile Arg Gly Ile Gln Gly Val Val Arg Lys Thr Val Asn Asp Glu Leu Arg Ala Thr Ile Trp Glu Pro Gln His Met Asp Lys Ile Val Pro Ser Leu Leu Phe Asn Met Gln Lys Ile Glu Glu Val Asp Ser Arg Ile Gly Pro Pro Ser Ser Pro Ser Ala Thr Asp Lys Glu Glu Asn Pro Ala Val Leu Ala Glu Asn Cys Phe Arg Glu Leu Leu Gly Arg Ala Thr Phe Gly Asn Met Asn Asn Ala Val Arg Pro Val Phe Ala His Leu Asp His His Lys Leu Trp Asp Pro Asn Glu Phe Ala Val His Cys Phe Lys Ile Ile Met Tyr Ser Ile Gln Ala Gln Tyr Ser His His Val Ile Gln Glu Ile Leu Gly His Leu Asp Ala Arg Lys Lys Asp Ala Pro Arg Val Arg Ala Gly Ile Ile Gln Val Leu Leu Glu Ala Val Ala Ile Ala Ala Lys Gly Ser Ile Gly Pro Thr Val Leu Glu Val Phe Asn Thr Leu Leu Lys His Leu Arg Leu Ser Val Glu Phe Glu

200/228

Ser Lys

```
<210> 372
<211> 242
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:347687.113.orf1:2000MAY01
<400> 372
Gln Pro Cys Gly Phe Gln Gly Ala Glu Asn Arg Arg Lys Leu Ala
 1
                    Trp Pro Glu Glu Gln Gln Leu Leu Val Ala
Tyr Met Arg Thr Asp
                 20
                                      25
Leu Phe Cys Gly Cys Gly His Glu Ala Leu Thr Gly Thr Glu Lys
                                                           45
                 35
                                      40
Leu Ile Glu Thr Tyr Phe Ser Lys Asn Tyr Gln Asp Tyr Glu Tyr
                                      55
                 50
                                                           60
Leu Ile Asn Val Ile His Ala Phe Gln Tyr
                                         Val Ile Tyr Gly Thr
                 65
Ala Ser Phe Phe Phe Leu Tyr Gly Ala Leu Leu Leu Ala Glu Gly
                 80
                                      85
Phe Tyr Thr Thr Gly Ala Val Arg Gln Ile Phe Gly Asp Tyr Lys
                 95
                                     100
                                                          105
Thr Thr Ile Cys Gly Lys Gly Leu Ser Ala Thr Phe Val Gly Ile
                110
                                     115
                                                          120
Thr Tyr Ala Leu Thr Val Val Trp Leu Leu Val Phe Ala Cys Ser
                125
                                     130
                                                          135
Ala Val Pro Val Tyr Ile Tyr Phe Asn Thr Trp Thr Thr Cys Gln
                140
Ser Ile Ala Phe Pro Ser Lys Thr Ser Ala Ser Ile Gly Ser Leu
                155
                                     160
Cys Ala Asp Ala Arg Met Tyr Gly Val Leu Pro Trp Asn Ala Phe
                170
                                     175
                                                          180
Pro Gly Lys Val Cys Gly Ser Asn Leu Leu Ser' Ile Cys Lys
                                                         Thr
                185
                                     190
Ala Glu Phe Gln Met Thr Phe His Leu Phe Ile Ala Ala Phe Val
                                     205
                                                          210
                200
Gly Ala Ala Ala Thr Leu Val Ser Leu Leu Thr Phe Met Ile Ala
                215
                                     220
Ala Thr Tyr Asn Phe Ala Val Leu Lys Leu Met Gly Arg Gly Thr
                230
                                     235
                                                          240
Lys Phe
<210> 373
<211> 60
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:1146510.1.orf2:2000MAY01
<400> 373
Thr Glu Leu Gln Arg Pro Arg Ser Ala Ser Ile Tyr Ser Arg Tyr
Ala Ser Ser Asn Phe Arg Arg Cys Gly Val Glu Leu Lys Tyr Ser
                 20
Ser Lys Asn Arg Glu Met Thr Asp Thr Thr Asp Ala Val His Asn
                 35
                                      40
Cys Asn Ala Arg Tyr Ser Ser Pro Arg Pro Lys Leu Leu Glu Asp
```

<210> 374 <211>. 157 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:451710.1.orf1:2000FEB18 <400> 374 Pro Gly Thr Pro Asn Pro Ala Pro Pro Pro Pro Arg Val His Pro Ser Ser Trp Arg Ala Pro Ile Gln Glu Met Ala Val Pro Leu Leu Thr Lys Lys Ile Val Lys Lys Arg Val Lys Gln Phe Lys Arg Pro 35 40 His Leu Asp Arg Tyr Lys Cys Leu Lys Pro Ser Trp Arg Arg Pro 50 55 Lys Gly Ile Asp Ser Arg Val Arg Arg Lys Phe Lys Gly Cys Thr 65 Leu Met Pro Asn Ile Gly Tyr Gly Ser Asp Lys Ser Thr Arg His Tyr Leu Pro Asn Lys Phe Lys Lys Phe Val Val His Asn Val Ser 95 100 Glu Leu Glu Leu Leu Met Met His Asn Arg Thr Tyr Cys Ala Glu 110 115 120 Ile Ala His Asn Val Ser Thr Lys Lys Arg Lys Glu Ile Val Glu 125 130 135 Arg Ala Ala Gln Leu Asp Ile Val Val Thr Asn Lys Leu Ala Arg 145 140 Leu Arg Ser Gln Glu Asp Glu 155 <210> 375 <211> 158 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:455771.1.orf3:2000FEB18 <400> 375 Ala Ser Cys Ser Arg Arg Glu Ala Leu Gln Arg Thr Ser Val Asn Met Gly Lys Thr Arg Gly Met Gly Ala Gly Arg Lys Leu Lys Thr His Arg Arg Asn Gln Arg Trp Ala Asp Lys Ala Tyr Lys Lys 35 40 45 Ser His Leu Gly Asn Glu Trp Lys Lys Pro Phe Ala Gly Ser Ser 50 55 60 His Ala Lys Gly Ile Val Leu Glu Lys Ile Gly Ile Glu Ala Lys 65 70 Gln Pro Asn Ser Ala Ile Arg Lys Cys Ala Arg Val Gln Leu Val 80 85 Lys Asn Gly Lys Lys Ile Ala Ala Phe Val Pro Asn Asp Gly Cys 95 100 105 Leu Asn Tyr Ile Glu Glu Asn Asp Glu Val Leu Ile Ala Gly Phe 110 115 Gly Arg Lys Gly His Ala Val Gly Asp Ile Pro Gly Val Arg Phe 125 130 Lys Val Val Lys Val Ser Gly Val Ser Leu Leu Ala Leu Phe Lys 140 145 Glu Lys Lys Glu Lys Pro Arg Ser 155 <210> 376

PCT/US01/06059

WO 01/62927

```
<211> 238
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:452089.1.orf2:2000FEB18
Leu Gly Lys His Arg Arg Pro Pro Pro Pro Lys Asp Gly Arg Arg
                                                           15
            Gly Arg Leu Leu Ala Pro Met Ala His Glu Lys Lys
                                                           30
                 20
Leu Ser Asn Pro Met Arg Glu Ile Lys Val Gln Lys Leu Val Leu
                                                           45
                                      40
Asn Ile Ser Val Gly Glu Ser Gly Asp Arg Leu Thr Arg Ala Ala
                 50
                                      55
                                                           60
Lys Val Leu Glu Gln Leu Ser Gly Gln Thr Pro Val Phe Ser Lys
                 65
                                      70
                                                           75
Ala Arg Tyr Thr Val Arg Ser Phe Gly Ile Arg Arg Asn Glu Lys
                 80
                                      85
                                                           90
                    Thr Val Arg Gly Glu Lys Ala Met Gln Leu
Ile Ala Cys Tyr Val
                 95
                                                          105
                                     100
Leu Glu Ser Gly Leu Lys Val Lys Glu Tyr
                                         Glu Leu Leu Arg Arg
                                     115
                                                          120
                110
Asn Phe Ser Asp Thr Gly Cys Phe Gly Phe Gly Ile Gln Glu His
                                                          135
                125
                                     130
Ile Asp Leu Gly Ile Lys Tyr Asp Pro Ser Thr Gly Ile Tyr
                                                         Gly
                                                          1.50
                140
                                     145
Met Asp Phe Tyr Val Val Leu Glu Arg Ala Gly Tyr Arg Val Ala
                155
                                     160
                                                          165
Arg Arg Arg Cys Lys Ser Arg Val Gly Ile Gln His Arg Val
                170
                                     175
Thr Lys Glu Asp Ser Met Lys Trp Phe Gln Val Lys Tyr Glu Gly
                                     190
                185
Val Ile Leu Lys Gln Gly Ser Gly Leu His Val Pro Pro Leu Thr
                200
                                     205
                                                          210
Cys Gly Gln Asn Ser Ser Leu Val Ser Ser Pro Pro Cys
                                                         Gln
                                                          225
                                     220
                215
Arg Lys Thr Thr His Leu Ala Arg Leu Phe Trp Val
                                     235
                230
<210> 377
<211> 102
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:246415.1.orf3:2000FEB18
<400> 377
Leu Pro Pro Val Arg Ala Ser Asn Met Met Lys Lys Arg Arg Asn
                                                           15
  1
Asn Gly Arg Thr Lys Lys Gly Arg Gly His Val Gln Pro Ile Cys
                                                           30
                  20
                                      25
Asp Thr Asn Cys Ala Gln Cys Val Pro Lys Asp Lys Ala Ile Asn
                                                           45
                 35
                                      40
Lys Phe Ile Ile Gly Asn Thr Val Glu Ala Ala Ala Val Arg Asp
                 50
                                      55
                                                           60
Ile Ser Glu Ala Ser Val Phe Asp Ala Tyr Val Leu Pro Lys Leu
                                      70
                                                           75
                  65
Tyr Leu Lys Leu His Tyr Cys Leu Ser Cys Ala Ile His Ser Arg
                 80
                                      85
Val Val Arg Asn Arg Ser Cys Glu Ala His Lys Asp
                 95
                                     100
```

```
<210> 378
<211> 102
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:414144.10.orf1:2000FEB18
<400> 378
Val Tyr Trp Cys Arg Glu Leu Ile Leu Lys Arg Gly Gln Ala Lys
Val Lys Asn Lys Thr Ile Pro Leu Thr Asp Asn Thr Val Ile Glu
                 20
                                      25
                                                          30
Glu His Leu Gly Lys Phe Gly Val Ile Cys Leu Glu Asp Leu Ile
                                      40
                                                          45
His Glu Ile Ala Phe Pro Gly Lys His Phe Gln Glu Ile Ser Trp
                                      55
                 50
Phe Leu Cys Pro Phe His Leu Ser Val Ala Arg His Ala Thr Lys
                 65
                                      70
Asn Arg Val Gly Phe Leu Lys Glu Met Gly Thr Pro Gly Tyr Arg
                                      85
                 80
Gly Glu Arg Ile Asn Gln Leu Ile Arg Gln Leu Asn.
<210> 379
<211> 177
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1101445.1.orf3:2000FEB18
<400> 379
Gly Thr Met Glu Ala Val Pro Glu Lys Lys Lys Val Ala Ala
                                      10
                                                          15
Ala Pro Gly Thr Leu Lys Lys Lys Val Pro Ala Val Pro Glu
                                                          30
                 20
Thr Leu Lys Lys Lys Arg Arg Asn Phe Ala Glu Leu Lys Val Lys
                 35
                                      40
                                                          45
Arg Leu Arg Lys Lys Phe Ala Leu Lys Thr Leu Arg Lys Ala Arg
                 50
                                      55
                                                          60
Arg Lys Leu Ile Tyr Glu Lys Ala Lys His Tyr His Lys Glu Tyr
                                      70
                 65
Arg Gln Met Tyr Arg Thr Glu Ile Arg Met Ala Arg Met Ala Arg
                 80
                                      85
Lys Ala Gly Asn Phe Tyr Val Pro Ala Glu Pro Lys Leu Ala Phe
                 95
                                     100
                                                         105
Val Ile Arg Ile Arg Gly Ile Asn Gly Val Ser Pro Lys Val Arg
                110
                                     115
                                                         120
Lys Val Leu Gln Leu Leu Arg Leu Arg Gln Ile Phe Asn Gly Thr
                125
                                     130
                                                         135
Phe Val Lys Leu Asn Lys Ala Ser Val Asn Met Leu Arg Ile Val
                140
                                     145
                                                          150
Glu Pro Tyr Ile Ala Trp Gly Val Pro Gln Pro Glu Val Ser Lys
                155
                                     160
Arg Ala His Leu Gln Thr Arg Leu Trp Gln Asn Gln
                170
<210> 380
<211> 86
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
```

PCT/US01/06059

WO 01/62927

<223> Incyte ID No: LG:452134.1.orf2:2000FEB18

```
<400> 380
Leu Pro Ser Tyr Ala Pro Glu Ile Val Pro Ala Thr Leu Arg Arg
                                      10
                                                          15
Ser His Ser Glu Thr Gly Arg Pro Gln Pro Lys Gly Leu Lys Gly
                 20
                                      25
                                                          30
Glu Arg Pro Ala Arg Leu Thr Arg Gly Glu Ala Asp Arg Asp Thr
                                      40
Tyr Arg Gln Ile Ala Val Pro Pro Asp Ala Asp Arg Lys Ala Glu
                                                          60
                 50
                                      55
Ala Glu Ala Gly Ala Gly Ser Glu Thr Glu Phe Gln Phe Arg Gly
                                      70
                 65
Arg Phe Gly Cys Gly Gly Gln Pro Pro Gln
                 80
```

```
<210> 381

<211> 97

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: LI:903021.1.orf1:2000FEB01
```

<400> 381 Arg Asn Phe Thr Glu Leu Lys Ile Lys Arg Leu Arg Asn Lys Phe 10 Ala Gln Lys Met Leu Leu Lys Ala Arg Arg Lys Leu Ile Tyr Glu 30 20 25 Lys Ala Lys His Tyr His Lys Glu Tyr Met Gln Met Tyr Arg Thr Glu Ile Gln Ile Ser Arg Ile Ala Arg Lys Ala Gly Asn Phe Tyr 50 55 Val Ser Ala Glu Pro Lys Leu Ala Phe Val Ile Arg Ile Gly Gly 70 65 Tyr Gln Leu Gly Glu Pro Lys Gly Leu Lys Gly Val Ala Thr Ser 80 Leu Pro Ser Ser Asn Leu Gln

```
<210> 382
<211> 82
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:246422.1.orf1:2000FEB01
```

<400> 382 Lys Lys Arg Lys Gln Val Pro Lys Phe Thr Leu Asp Arg Thr His 10 Pro Val Glu Asp Gly Ile Met Asp Ala Ala Asn Phe Glu Gln Phe 25 20 Phe Gln Glu Arg Ile Lys Met Asn Gly Lys Ala Gly Asn Phe Gly 45 40 35 Gly Gly Val Val Thr His Arg Glu Gln Glu Gln Asp Gln Arg 50 55 60 Asp Ile Gln Ala Ala Leu Phe Gln Gln Val Phe Glu Ile Ser His 65 Gln Lys Ile Ser Glu Glu Glu 80

```
<210> 383
<211> 180
<212> PRT
```

150

165

```
WO 01/62927
<213> Homo sapiens
<220>
<221> misc_feature
```

<223> Incyte ID No: LG:449404.1.orf1:2000MAY19 Ser Gln Pro Lys Ser Cys Leu Arg Ser Gly His Pro Ser Leu His Ala Thr Met Ser Arg Arg Lys Thr Arg Glu Pro Lys Glu Glu Asn Val Thr Leu Gly Pro Thr Val Arg Glu Gly Glu Tyr Val Phe Gly 40 35 Val Ala His Ile Phe Ala Ser Phe Asn Asp Thr Phe Ile His Ile Thr Asp Leu Ser Gly Arg Glu Thr Leu Val Arg Ile Thr Gly Gly 65 70 Met Lys Val Lys Ala Asp Arg Asp Glu Ser Ser Pro Tyr Ala Ala 80 85 90 Met Leu Ala Ala Gln Asp Val Ala Gln Arg Cys Lys Glu Leu Gly 95 100 105 Ile Thr Ala Leu His Ile Lys Leu Arg Ala Thr Gly Gly Asn Lys 110 115 120 Thr Lys Thr Pro Gly Pro Gly Ala Gln Ser Ala Leu Arg Ala Leu 125 130 135 Ala Arg Ser Gly Met Lys Ile Gly Arg Ile Glu Asp Val Thr Pro

Val Pro Thr Asp Ser Thr Arg Arg Lys Gly Gly Arg Arg Gly Lys

Glu Asp Cys Arg Arg His His Tyr Cys Val Pro Phe Ala Gly Ser

145

160

175

```
<210> 384

<211> 118

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: LG:449413.1.orf3:2000MAY19

<400> 384
```

140

155

170

 Pro Arg Cys
 Phe Arg Leu
 Pro Gin Arg Arg Arg Arg Pro Ser Gin Pro 15

 Val Pro Ser Ser Ala Thr Met Gly Lys
 Thr Arg Gly Met Gly Ala 25

 Gly Arg Lys
 Leu Lys Thr His Arg Arg Arg Asn Gln Arg Trp Ala Asp 40

 Lys Ala Tyr Lys
 Ser His Leu Gly Asn Glu Trp Lys Lys Pro 50

 Phe Ala Gly Ser Ser His Ala Lys Gly Ile Val Leu Glu Lys Ile 65

 Gly Ile Glu Ala Lys Gln Pro Asn Ser Ala Ile Arg Lys Cys Ala 85

 Arg Val Gln Leu Val Lys Asn Gly Lys Lys Ile Ala Ala Phe Val 95

 Pro Asn Asp Gly Cys Leu Asn Tyr Ile Glu Glu Asn Val 110

```
<210> 385
<211> 164
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
```

<223> Incyte ID No: LG:450105.1.orf2:2000MAY19 <400> 385 Pro Ser Ala Ala Arg Pro Pro Tyr Ser Arg Tyr Arg Ala Arg Arg 10 Ser Asn Met Gly Lys Thr Arg Gly Met Gly His His Leu Arg Arg 30 25 20 Ala Gly Arg Lys Leu Lys Thr His Arg Arg Asn Gln Arg Trp Ala 45 35 40 Asp Lys Ala Tyr Lys Lys Ser His Leu Gly Asn Glu Trp Lys Lys 50 55 60 Pro Phe Ala Gly Ser Ser His Ala Lys Gly Ile Val Leu Glu Lys 65 Ile Cly Ile Clu Ala Lys Gln Pro Asn Ser Ala Ile Arg Lys Cys 90 85 80 Ala Arg Val Gln Leu Val Lys Asn Gly Lys Lys Ile Ala Ala Phe 100 105 95 Val Pro Asn Asp Gly Cys Leu Asn Tyr Ile Glu Glu Asn Asp Glu 110 115 120 Val Leu Ile Ala Gly Phe Gly Arg Lys Gly His Ala Val Gly Asp 125 130 Ile Pro Gly Val Arg Phe Lys Val Val Lys Val Ser Gly Val Ser 140 145 Leu Leu Ala Leu Phe Lys Glu Lys Glu Lys Pro Arg Ser 155 160 <210> 386 <211> 101 <212> PRT <213> Homo sapiens <220> <221> misc_feature

<223> Incyte ID No: LG:460809.1.orf3:2000MAY19

<400> 386 Ala Trp Val Glu Trp Ala Ser Arg Ser Ala Pro Arg Ala His Arg 10 Glu Ile Gln Lys Phe Ala Met Lys Glu Met Gly Thr Pro Asn Leu 25 30 His Ile Asp Val Arg Leu Asn Lys Ala Leu Trp Ala Lys Gly Ile Arg Asn Val Pro Tyr His Ile His Met Lys Leu Pro Arg Lys Leu 55 50 Asn Glu Asp Glu Asp Ser Pro Asp Lys Leu Tyr Ala Leu Val Pro 70 65 Thr Tyr Thr Cys Tyr His Phe His Lys Ser Ile Asp Arg Gln Cys 80 85 Gly Arg Glu Leu Thr Thr Asp Gly Ser Ile His 95

<210> 387 <211> 259 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:481781.1.orf3:2000MAY19

<400> 387 Arg Ser Val Arg Arg Arg Ser Ser Ser Ser Arg Arg Arg Val 15 10 Ala Ala Pro His Leu Glu Leu Ala Thr Met Ala Arg Gly Leu Lys 30 20 25 Lys His Leu Lys Arg Leu Asn Ala Pro Lys His Trp Met Leu Asp

```
Ta Phe Ala Pro Lys Pro Ser Ser Gry Pro His
Lys Leu Gly Gly
                                      55
Lys Ser Arg Glu Cys Leu Pro Leu Ile Leu Ile Ile Arg Asn Arg
                                      70
Leu Lys Tyr Ala Leu Thr Tyr Arg Glu Val Ile Ser Ile Leu Met
                                      85
                 80
Gln Arg His Val Leu Val Asp Gly Lys Val Arg Thr Asp Lys Thr
                 95
                                     100
                                                         105
Tyr Pro Ala Gly Phe Met Asp Val Ile Ser Ile Pro Lys Thr Asn
                110
                                     115
Glu Asn Tyr Arg Leu Leu Tyr Asp Thr Lys Gly Arg Phe Arg Leu
                                     130
His Pro Ile Arg Asp Glu Asp Ala Lys Phe Lys Leu'Cys Lys Val
                140
                                     145
                                                         150
Arg Ser Val Gln Phe Gly Gln Lys Gly Ile Pro Tyr Leu Asn Thr
                155
                                     160
Tyr Asp Gly Arg Thr Ile Arg Tyr Pro Asp Pro Leu Ile Lys Ala
                170
                                     175
Asn Asp Thr Ile Lys Ile Asp Leu Glu Thr Asn Lys Ile Val Asp
                                                         195
                185
                                     190
Phe Ile Lys Phe Asp Val Gly Asn Val Val Met Val Thr Gly Gly
                200
                                     205
Arg Asn Thr Gly Arg Val Gly Val Ile Lys Asn Arg Glu Lys His
                215
                                     220
                                                         225
Lys Gly Ser Phe Glu Thr Ile His Val Glu Asp Ser Trp Ala Thr
                                     235
                230
                                                         240
Gly Ser Pro Pro Val Trp Ala Thr Cys Ser Pro Ser Ala Arg Val
                                     250
                245
Ile Ser Arg Gly
```

<210> 388 <211> 184 <212> PRT <213> Homo sapiens

<220>

<221> misc_feature
<223> Incyte ID No: LG:1101153.1.orf2:2000MAY19

<400> 388 Arg Arg Arg Pro Phe Leu Leu Arg Ser Phe Ala Ala Met Val Lys Tyr Ser Gln Glu Pro Gly Asn Pro Thr Lys Ser Ala Lys Ala Met Gly Arg Asp Leu Arg Val His Phe Lys Asn Thr Arg Glu Thr 35 40 45 Ala Phe Ala Leu Arg Lys Leu Pro Leu Thr Lys Ala Lys Arg Tyr 55 Leu Glu Asp Val Ile Ala His Lys Gln Ala Ile Pro Phe Arg Arg Tyr Cys Gly Gly Val Gly Arg Thr Ala Gln Ala Lys Ser Arg His Ser Asn Gly Gln Gly Arg Trp Pro Val Lys Ser Ala Arg Phe Ile 95 100 Leu Asp Leu Leu Lys Asn Ala Glu Ser Asn Ala Asp Val Lys Gly 110 115 Leu Asp Val Asp Asn Leu Tyr Val Ser His Ile Gln Val Asn Gln 125 130 Ala Gln Lys Gln Arg Arg Arg Thr Tyr Arg Ala His Gly Arg Ile 150 140 145 Asn Pro Tyr Met Ser Ser Pro Cys His Ile Glu Leu Ile Leu Ser 160 165 155 Glu Lys Glu Glu Pro Val Lys Lys Glu Ala Asp Asn Ile Val Ala 170 175 Ala Arg Lys Gln

```
<210> 389
<211> 152
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:257695.20.orf2:2000MAY01
<400> 389
Ala Pro Arg Gly Glu Gly Cys Leu Val His Ala Ser Glu Pro Cys
Arg Pro Arg Ala Arg Cys Ser Leu Cys Arg Ser Ser Asp Ala Arg
                                                           30
                                      25
Arg Gln Arg Gln Leu Trp Ala His Cys Lys Arg Gly Asn Gly Leu
                 35
                                      40
                                                           45
Ile Lys Val Asn Gly Arg Pro Leu Glu Met Ile Glu Pro Arg Thr
                                      55
                 50
Leu Gln Tyr Lys Leu Leu Glu Pro Val Leu Leu Gly Lys Glu
                 65
                                      70
Arg Phe Ala Gly Val Asp Ile Arg Val Arg Val Lys Gly Gly Gly
                 80
                                      85
His Val Pro Gln Ile Tyr Gly Glu Ser Gln Glu Leu Gly Ala Trp
                 95
                                     100
                                                          105
Arg Arg Trp Leu Trp Glu Gly Gly Leu His Ser Ala Pro Val Pro
                110
                                     115
                                                          120
Phe Asn Cys Val Ser Phe Ser Gln Leu Ser Val Ser Pro Ser
                                                         Pro
                125
                                     130
                                                          135
Lys Pro Trp Trp Pro Ile Thr Arg Asn Val Ser Glu His Gly Ser
                                     145
                140
Phe Pro
<210> 390
<211> 158
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:455771.1.orf3:2000MAY01
<400> 390
Ala Ser Cys Ser Arg Arg Glu Ala Leu Gln Arg Thr Ser Val
                                                           15
 1
                                      10
Asn Met Gly Lys Thr Arg Gly Met Gly Ala Gly Arg Lys Leu Lys
                                                           30
                 20
                                      25
Thr His Arg Arg Asn Gln Arg Trp Ala Asp Lys Ala Tyr Lys Lys
                 35
                                      40
                                                           45
Ser His Leu Gly Asn Glu Trp Lys Lys Pro Phe Ala Gly Ser Ser
                                                           60
His Ala Lys Gly Ile Val Leu Glu Lys Ile Gly Ile Glu Ala Lys
                                                           75
                  65
                                      70
Gln Pro Asn Ser Ala Ile Arg Lys Cys Ala Arg Val Gln Leu Val
                                      85
                                                           90
                 80
Lys Asn Gly Lys Lys Ile Ala Ala Phe Val Pro Asn Asp Gly
                                                          Cys
                                                          105
                 95
                                     100
Leu Asn Tyr Ile Glu Glu Asn Asp Glu Val Leu Ile Ala Gly Phe
                110
                                     115
Gly Arg Lys Gly His Ala Val Gly Asp Ile Pro Gly Val Arg Phe
                                                          135
                125
                                     130
Lys Val Val Lys Val Ser Gly Val Ser Leu Leu Ala Leu Phe Lys
                140
                                                          150
                                     145
Glu Lys Lys Glu Lys Pro Arg Ser
                155
```

<210> 391

<211> 94 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:274551.1.orf1:2000MAY01 <400> 391 Pro Phe Thr Val Thr Gln Leu Gln Pro Thr Thr Leu Gln Ser Phe 10 15 Pro Cys Leu Ser Val Leu Gln Arg Leu Ser His Val Ser Gly Phe 20 25 Leu Arg Ser Ser Thr Leu Ile Cly Leu Ile Trp Cys Ser Ala Gln 35 40 45 Arg Ala Thr Pro Ser Leu Thr Tyr Ile Gly Ser Ser His Leu Asp 50 55 60 Ala Ser Thr Gln Arg Trp Ala Trp Pro Leu Ser Lys Ala Leu Ala 65 70 75 Ala Leu Gln Val Pro Pro Ala Arg Pro Ser Trp Leu Arg Ala Val 85 90 Phe Ser Leu Leu <210> 392 <211> 83 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:035973.1.orf3:2000MAY01 <400> 392 Gly Cys Leu Ala Gly Ile Arg Lys Asp Asn Lys Met Lys Gly Thr Ser Pro Phe Gly Lys Cys Arg Asp Met Ile His Lys Leu Cys Cys 25 Leu Cys Gly Ser Lys Ala Tyr His Leu Gln Lys Ser Thr Cys Gly 40 Lys Cys Gly Ser Pro Ala Lys Arg Lys Arg Lys Cys Asn Trp Thr 50 55 Ala Thr Ala Lys Arg Lys Tyr His Gly Asp Trp Leu Asn Glu Ala 65 Pro Lys His Cys Ile Leu Gln Ile 80 <210> 393 <211> 174 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:978427.5.orf2:2000FEB18 <220> <221> unsure <222> 151 <223> unknown or other

<400> 393 Trp Trp Val Cys Asp Gly Cys Leu Cys Phe Arg Thr Thr Pro Ala 15 10 Val Leu Phe Trp Gln Trp Ile Asn Gln Ser Phe Asn Ala Val Val

20 25 Asn Tyr Thr Asn Arg Ser Gly Asp Ala Pro Leu Thr Val Asn Glu

```
45
Leu Gly Thr Ala Tyr Val Ser Ala Thr Thr Gly Ala Val Ala Thr
                 50
Ala Leu Gly Leu Asn Ala Leu Thr Lys His Val Ser Pro Leu Ile
                 65
                                      70
Gly Arg Phe Val Pro Phe Ala Ala Val Ala Ala Ala Asn Cys Ile
                 80
                                      ·85
Asn Ile Pro Leu Met Arg Gln Arg Glu Leu Lys Val Gly Ile Pro
                                     100
                 95
                                                          105
Val Thr Asp Glu Asn Gly Asn Arg Leu Gly Glu Ser Ala Asn Ala
                110
                                     115
Ala Lys Gln Ala Ile Thr Gln Val Val Val Ser Arg Ile Leu Met
                125
                                     130
Ala Ala Pro Gly Met Gly Ile Pro Pro Phe Ile Met Asn Thr Leu
                                     145
                140
                                                          150
Xaa Lys Lys Ala Phe Leu Lys Arg Phe Pro Met Asp Glu Cys Thr
                155
                                     160
His Ser Ser Trp Val Ser Trp Ile Leu
                170
<210> 394
<211> 183
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:247781.2.orf3:2000FEB18
<400> 394
Gln Gly Pro Arg Val Leu Leu Ala Met Pro Tyr Leu Pro Asn Ser
                                                           15
                                      10
Ala Gly Tyr His His Leu Cys Gly His Arg Pro Gly Arg Leu Arg
                                                           30
                 20
Asp Ser Glu Glu Leu Val Ala Ser Ala Val Gln Pro Arg Leu Gly
                                                           45
                 35
                                      40
Arg Pro Arg His Pro Arg Ala Pro Gly Leu Arg Tyr His Ile Gln
                 50
                                      55
                                                           60
His Leu Arg Pro Asp
                    Ser Gln Leu Pro Ala Gly Pro Gly Pro Asp
                 65
                                      70
                                                           75
Pro His Ala Gly Thr Ser Leu His Arg Gly Trp Pro Pro Ala Val
                                      85
His Ala Gly Ser Ala Thr Ser His Pro Val Pro Gly Gly His Ala
                 95
                                     100
Gly Pro Leu Pro Gly Asp Arg Pro Gln Leu His Glu Gly Tyr Ser
                                     115
                                                          120
                110
Ser Cys Glu His Leu Leu Cys Gly Leu Arg Glu His Glu Ala Gly
                                                          135
                125
                                     130
Leu Gly Gly His Val Gln Val Arg Asp Pro Glu Pro Val Pro Pro
                140
                                     145
                                                          150
Ile Pro His Pro Pro His Leu Ser His Trp Arg Leu Met Ile Gln
                155
                                     160
Pro Gln Asp Pro Tyr Ser Leu Ala Thr Arg Ser Gln Tyr Pro Asp
                170
Pro Gly Ser
<210> 395
<211> 399
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:034583.1.orf1:2000FEB01
<400> 395
```

```
Val Gln His Ala Thr Val Ile Pro Glu Thr Met Ala Gly Thr Gln
Gln Leu Ala Asp Trp Arg Asn Thr His Ala His Gly Ser His Tyr
Asn Pro Ile Met Gln Gln Pro Ala Leu Leu Thr Gly His Val Thr
                 35
                                      40
Leu Pro Ala Ala Gln Pro Leu Asn Val Gly Val Ala His Val Met
                                      55
                 50
Arg Gln Gln Pro Thr Ser Thr Thr Ser Ser Arg Lys Ser Lys Gln
                                     70
                65
His Gln Ser Ser Val Arg Asn Val Ser Thr Cys Glu Val Ser Ser
                 80
Ser Gln Ala Ile Ser Ser Pro Gln Arg Ser Lys Arg' Val Lys Glu
                 95
                                    100
Asn Thr Pro Pro Arg Cys Ala Met Val His Ser Ser Pro Ala Cys
                110
                                    115
                                                         120
Ser Thr Ser Val Thr Cys Gly Trp Gly Asp Val Ala Ser Ser Thr
                125
                                    130
                                                         135
Thr Arg Glu Arg Gln Arg Gln Thr Ile Val Ile Pro Asp Thr Pro
                140
                                    145
                                                         150
Ser Pro Thr Val Ser Val Ile Thr Ile Ser Ser Asp Thr Asp Glu
                155
                                    160
Glu Glu Glu Gln Lys His Ala Pro Thr Ser Thr Val Ser Lys Gln
                                    175
                170
                                                         180
Arg Lys Asn Val Ile Ser Cys Val Thr Val His Asp Ser Pro Tyr
                185
                                    190
                                                         195
Ser Asp Ser Ser Ser Asn Thr Ser Pro Tyr Ser Val Gln Gln Arg
                200
                                    205
                                                         210
Ala Gly His Asn Asn Ala Asn Ala Phe Asp Thr Lys Gly Ser Leu
                215
                                     220
Glu Asn His Cys Thr Gly Asn Pro Arg Thr Ile Ile Val Pro Pro
                230
                                     235
Leu Lys Thr Gln Ala Ser Glu Val Leu Val Glu Cys Asp Ser Leu
                245
                                     250
                                                         255
Val Pro Val Asn Thr Ser His His Ser Ser Ser Tyr Lys Ser Lys
                260
                                     265
                                                         270
Ser Ser Ser Asn Val Thr Ser Thr Ser Gly His Ser Ser Gly Ser
                275
                                     280
Ser Ser Gly Ala Ile Thr Tyr Arg Gln Gln Arg Pro Gly Pro His
                290
                                     295
                                                         300
Phe Gln Gln Gln Pro Leu Asn Leu Ser Gln Ala Gln His
                305
                                     310
                                                         315
Ile Thr Thr Asp Arg Thr Gly Ser His Arg Arg Gln Gln Ala Tyr
                320
                                    325
                                                         330
Ile Thr Pro Thr Met Ala Gln Ala Pro Tyr Ser Phe Pro His Asn
                335
                                     340
Ser Pro Ser His Gly Thr Val His Pro His Leu Ala Ala Ala Ala
                350
                                     355
                                                         360
Ala Ala Ala His Leu Pro Thr Gln Pro His Leu Tyr Thr Tyr
                                                         Thr
                365
                                     370
                                                         375
Ala Pro Ala Ala Leu Gly Ser Thr Gly Thr Val Ala His Leu Val
                380
                                     385
Ala Ser Gln Gly Ser Ala Arg His Thr
                395
<210> 396
<211> 301
<212> PRT
```

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: LI:333307.2.orf1:2000FEB01

<220>

<221> unsure

<222> 286

212/228

PCT/US01/06059

<223> unknown or other

```
<400> 396
Thr Gln Phe Ser Asp Asn Asn Asn Glu Lys Leu Ser Pro Lys Pro
Gly Thr Gly Glu Pro Val Leu Ser Leu His Tyr Ser Thr Glu Gly
                                      25
                 20
Thr Thr Thr Ser Thr Ile Lys Leu Asn Phe Thr Asp Glu Trp Ser
                                                           45
                 35
                                      40
Ser Ile Ala Ser Ser Ser Arg Gly Ile Gly Ser His Cys Lys Ser
                                      55
                                                           60
                 50
Glu Gly Gln Glu Glu Ser Phe Val Pro Gln Ser Ser Val Gln Pro
                 65
Pro Glu Gly Asp Ser Glu Thr Lys Ala Pro Glu Glu Ser Ser Glu
                                      85
                 80
Asp Val Thr Lys Tyr Gln Glu Gly Val Ser Ala Glu Asn Pro Val
                                                          105
                 95
                                     100
Glu Asn His Ile Asn Ile Thr Gln Ser Asp Lys Phe Thr Ala Lys
                110
                                     115
                                                          120
Pro Leu Asp Ser Asn Ser Gly Glu Arg Asn Asp Leu Asn Leu Asp
                125
                                     130
                                                          135
Arg Ser Cys Gly Val Pro Glu Glu Ser Ala Ser Ser Glu Lys Ala
                                     145
                140
Lys Glu Pro Glu Thr Ser Asp Gln Thr Ser
                                         Thr Glu Ser Ala Thr
                                     160
                                                          165
                155
Asn Glu Asn Asn Thr Asn Pro Glu Pro Gln Phe Gln Thr Glu Ala
                                     175
                                                          180
                170
Thr Gly Pro Ser Ala His Glu Glu Thr Ser Thr Arg Asp Ser
                                     190
                                                          195
                185
Leu Gln Asp Thr Asp Asp Ser Asp Asp Asp Pro Val Leu Ile Pro
                200
                                     205
                                                          210
Gly Ala Arg Tyr Arg Ala Gly Pro Gly Asp Arg Phe Asn Ile Arg
                                     220
                215
Gly Thr Thr Ile Gly Asp Arg Ile Met Arg Arg Ser Ala Val Ala
                                     235
                230
Arg Ile Gln Glu Phe Phe Arg Arg Lys Glu Arg Lys Glu Met
                                     250
                245
Glu Glu Leu Asp Thr Leu Asn Ile Arg Arg Pro Leu Val Lys Met
                                     265
                                                          270
                260
Val Tyr Lys Gly His Arg Asn Ser Arg Thr Met Ile Lys Glu Ala
                                                          285
                                     280
                275
Xaa Phe Trp Gly Ala Asn Phe Val Met Ser Gly Ser Asp Cys Gly
                290
                                     295
His
```

```
<210> 397
<211> 105
```

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: LI:814710.2.orf2:2000FEB01

<400> 397 Glu Gly Pro Glu Gly Lys Trp Lys Ser Pro Lys Phe Lys Met Pro 15 10 Thr Pro Lys Ile Ser Met Pro Asp Ile Asp Glu Met His Phe Lys 25 30 Leu Asn Leu Thr Gly Pro Lys Ile Lys Gly Asp Val Asp Val Thr Gly Pro Lys Val Glu Gly Asp Leu Lys Gly Pro Glu Val Asp Leu 55 50 Lys Gly Pro Lys Val Asp Ile Asp Val Pro Asp Val Asn Val Gln 70 65 Gly Pro Asp Trp His Leu Lys Met Pro Lys Met Lys Met Pro Lys

90 85 Phe Ser Met Pro Gly Phe Lys Gly Glu Gly Pro Gly Ser Arg Ser 100 105 <210> 398 <211> 153 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:414732.1.orf1:2000MAY19 <400> 398 Trp Tyr Arg Arg Leu Leu Arg Glu Ser Gly Ser Thr Met Asp Ile 10 15 Pro Val Pro Ser Ser Phe Asn Asp Val Gly Gln Asp Trp Arg Leu 20 25 30 Arg His Phe Val Asp Gln Met Trp Tyr Glu Arg Glu Val Thr Phe 40 Leu Glu Gln Trp Thr Gln Asp Leu His Thr Arg Val Val Leu Arg 50 55 60 Ile Val Ser Ala His Ser Tyr Ala Ile Val Trp Val Asn Gly Val 65 70 Asp Ala Leu Glu His Glu Gly Ser Thr Ser Pro Leu Thr Pro Thr 80 85 90 Ser Val Ala Cys Ser Arg Trp Gly Pro Cys Pro Pro Ala Ser Ala 95 100 105 Ser Leu Ser Pro Ser Ala Thr Cys Ser Ser Pro Pro Pro Cys His 110 115 120 Gln Gly Ala Ser Ser Thr Trp Pro Thr Pro Pro Arg Gly Tyr His 125 130 135 Pro Ala Ser Thr Ala Asp Thr His Leu Pro Val Pro Pro Arg Gly 140 145 150 Ala Leu His <210> 399 <211> 161 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:413910.6.orf1:2000MAY19 <400> 399 Ser Met Leu Ala Ser Gln Gly Val Leu Leu His Pro Tyr Gly Val Pro Met Ile Val Pro Ala Ala Pro Tyr Leu Pro Gly Leu Ile Gln 20 25 Gly Asn Gln Glu Ala Ala Ala Pro Asp Thr Met Ala Gln Pro 40 Tyr Ala Ser Ala Gln Phe Ala Pro Pro Gln Asn Gly Ile Pro Ala 50 55 60 Glu Tyr Thr Ala Pro His Pro His Pro Ala Pro Glu Tyr Thr Gly 65 70 Gln Thr Thr Val Pro Glu His Thr Leu Asn Leu Tyr Pro Pro Ala 80 85 90 Gln Thr His Ser Glu Gln Ser Pro Ala Val Phe Leu Phe Val Ile 100 Thr Arg Ala Val Ala Leu Phe Thr Ser Ile Leu Arg Pro Ser Thr

214/228

115

130

Thr Val Pro Cys Asn Phe Ser Leu Ala Leu Ser Ala Ser Ala Leu

Phe Ser Lys Val Thr Lys Pro Asn Pro Phe Glu Pro Arg Ser Leu

120

110

PCT/US01/06059

```
150
                140
                                     145
Lys Ile Ile Ser Thr Ser Lys Ile Leu Pro Asn
                155
                                     160
<210> 400
<211> 153
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:414732.2.orf1:2000MAY01
<400> 400
Trp Tyr Arg Arg Leu Leu Arg Glu Ser Gly Ser Thr Met Asp Ile
Pro Val Pro Ser Ser Phe Asn Asp Val Gly Gln Asp Trp Arg Leu
                 20
                                                           30
Arg His Phe Val Asp Gln Met Trp Tyr Glu Arg Glu Val Thr Phe
                                                           45
                                      40
                 35
Leu Glu Gln Trp Thr Gln Asp Leu His Thr Arg Val Val Leu Arg
                                                           60
                 50
                                      55
Ile Val Ser Ala His Ser Tyr Ala Ile Val Trp Val Asn Gly Val
                                                           75
                 65
                                      70
Asp Ala Leu Glu His Glu Gly Ser Thr Ser Pro Leu Thr Pro Thr
                 80
Ser Val Ala Cys Ser Arg Trp Gly Pro Cys Pro Pro Ala Ser Ala
                                     100
                                                          105
                 95
Ser Leu Ser Pro Ser Ala Thr Cys Ser Ser Pro Pro Pro Cys His
                                     115
                110
Gln Gly Ala Ser Ser Thr Trp Pro Thr Pro Pro Arg Gly Tyr His
                                                          135
                                     130
                125
Pro Ala Ser Thr Ala Asp Thr His Leu Pro Val Pro Pro Arg Gly
                140
                                     145
Ala Leu His
<210> 401
<211> 135
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:900264.2.orf3:2000MAY01
<400> 401
Arg Gln Ile Val Ser Val Leu Ser Cys Arg Phe Asp Ser Asn Gln
Leu Pro Ala Asn Ala Pro Ile Glu Asp Arg Arg Ser Ala Ala Thr
                 20
Cys Leu Gln Thr Arg Gly Leu Leu Gly Val Phe Asp Gly His
                                      40
                 35
Ala Gly Cys Ala Cys Ser Gln Ala Val Ser Glu Arg Leu Phe Tyr
                 50
                                      55
Tyr Ile Ala Val Ser Leu Leu Pro His Glu Thr Leu Leu Glu Ile
                                                           75
                 65
                                      70
Glu Asn Ala Val Glu Ser Gly Arg Ala Leu Leu Pro Ile Leu Gln
                                                           90
                 80
                                      85
Trp His Lys His Pro Asn Asp Tyr Phe Ser Lys Glu Ala Ser Lys
                                     100
                 95
Leu Tyr Phe Asn Ser Leu Arg Thr Tyr Trp Gln Gly Ala Tyr Arg
                                     115
                                                          120
                110
Pro Gln His Trp Val Ser Arg Leu Ile Leu Met Leu Arg Arg Leu
                 125
                                     130
                                                          135
```

WO 01/62927 <210> 402 <211> 129 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:335593.1.orf3:2000MAY01 <221> unsure <222> 28, 39-40 <223> unknown or other <400> 402 Arg Gly Ala Gly Thr Ala Ala Leu Pro Ser Arg Leu Leu Pro Ser 10 Ser Ala Ala Arg Ser Ser Leu Gly Ile His Leu Leu Xaa Leu Leu 20 25 30 Leu Leu Ile His Ser Phe Pro His Xaa Xaa Leu Leu Leu Gly Phe 35 40 Ser Pro Arg Pro Ala Ser Pro Arg Ala Leu Pro Leu Pro Leu Pro 55 50 60 Val Leu Pro Gly Pro Leu Leu Pro Leu Ile His Ser Pro Leu Ser 65 70 75 Leu Leu His Ser Leu Pro Leu Ser Pro Phe Phe Phe Phe His 80 85 Pro Pro Ser Leu Thr Pro Pro Pro Phe Pro Cys Leu Leu Ser Asp 100 95 105 Thr Ala Leu Gln Leu Leu Ser Pro Ala Pro Ser Pro Val Arg 110 115 120 Thr Asn Gln Gln His Cys Phe Phe Ser 125 <210> 403 <211> 299 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:1189543.1.orf1:2000MAY01 <400> 403 Glu Phe Arg Gln Asn Lys Arg Glu Asn Leu Leu Pro Val Ala Ala 10 Ala Gly Thr Ala Asn Met Met Ala Ala Pro Ile Gln Gln Asn 20 25 30 Gly Thr His Thr Gly Val Pro Ile Asp Leu Asp Pro Pro Asp Ser 45 40 Arg Lys Arg Pro Leu Glu Ala Pro Pro Glu Ala Gly Ser Thr Lys 50 55 60 Arg Thr Asn Thr Gly Glu Asp Gly Gln Tyr Phe Leu Lys Val Leu 70 65 75 Ile Pro Ser Tyr Ala Ala Gly Ser Ile Ile Gly Lys Gly Gly Gln 80 85 90 Thr Ile Val Gln Leu Gln Lys Glu Thr Gly Ala Thr Ile Lys Leu 95 100 105 Ser Lys Leu Ser Lys Ser Lys Asp Phe Tyr Pro Gly Thr Thr Glu 110 115 Arg Val Cys Leu Ile Gln Gly Thr Val Glu Ala Leu Asn Ala Val 125 130 His Gly Phe Ile Ala Glu Lys Ile Arg Glu Met Pro Gln Asn Val 140 145 150 Ala Lys Thr Glu Pro Val Ser Ile Leu Gln Pro Gln Thr Thr Val 155 160

PCT/US01/06059

Asn Pro Asp Arg Ile Lys Gln Thr Leu Pro Ser Ser Pro Thr Thr

```
175
                                                          180
                170
Thr Lys Ser Ser Pro Ser Asp Pro Met Thr Thr Ser Arg Ala Asn.
                                     190
                185
Gln Val Lys Ile Ile Val Pro Asn Ser Thr Ala Gly Leu Ile Ile
                                     205
                                                          210
                200
Gly Lys Gly Gly Ala Thr Val Lys Ala Val Met Glu Gln Ser Gly
                                     220
                215
                                                         225
Ala Trp Val Gln Leu Ser Gln Lys Pro Asp Gly Ile Asn Leu Gln
                230
                                     235
                                                          240
Glu Arg Val Val Thr Val Ser Gly Glu Pro Glu Gln Asn Arg Lys
                                     250
                                                          255
                245
Ala Val Glu Leu Ile Ile Gln Lys Ile Gln Glu Asp Pro Gln Ser
                                                          270
                260
                                     265
Gly Ser Cys Leu Asn Ile Ser Tyr Ala Asn Val Thr Gly Pro Val
                275
                                     280
Gly Lys Phe Gln Ser Asn Arg Ile Ser Leu Cys Lys His Cys
                290
                                     295
<210> 404
<211> 142
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:455450.1.orf1:2000FEB18
<400> 404
Gly Gly Gly Ile Leu Arg Arg Ser Gly Ser Ser Ser Ser Ser
                                      10
Ser Ser Ser Glu Asp Asp Gly Met Gly Gly Arg Arg Lys Lys
                                                           30
                 20
                                      25
Gly Leu Lys Glu Lys Ile Lys Glu Lys Met Pro Gly Gly His Arg
Glu Gly Gln Gly Gln Ala Thr Ala Thr Gly Ala Tyr Gly Gly Thr
                 50
                                      55
                                                           60
Gly Tyr Val Ala Gly Pro Thr Thr Gly Gly Pro His Glu Lys Lys
                                      70
                 65
Gly Val Val Glu Lys Ile Lys Glu Lys Ile Pro Gly Gly His Lys
                                                           90
                 80
                                      85
Asp Tyr Asp Gln His Gln His Thr Thr Ala Ala Thr Gly Gly Gly
                 95
                                     100
Gly Gly Tyr Gly Gly Thr Thr Asp Thr Thr Tyr Gly Thr Thr Thr
                                     115
                                                          120
                110
Thr Glu Gly Thr His Glu Lys Lys Gly Phe Met Asp Lys Ile Lys
                                     130
                125
Glu Lys Leu Pro Gly Gln. His
                140
<210> 405
<211> 168
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1040978.1.orf2:2000FEB18
<400> 405
Ser Tyr Leu Arg Ser Arg Gly Gln Pro Pro Pro Arg Arg Ser His
                                                           15
                                      10
Ala Leu Arg Ala Arg Arg Leu Ser Ser Val Ser Ala Ser Leu Pro
                                      25
Leu Pro Ser Arg Leu Thr His Met Ala Ser Ile Ala Gly Ser
                                      40
                                                           45
                 35
Ala Leu Ser Phe Ala Arg Pro Val Lys Ala Ile Asn Thr Asn Ser
```

217/228

WO 01/62927 PCT/US01/06059 fo Ala Arg Lys Gly Asn Thr Phe beu Arg Leu Leu Ala Phe Ser 65 70 Gln Pro Met Pro Met Arg Ser Val Ser Cys Ala Ala Lys Lys Asp 80 85 Thr Thr Asp Lys Val Cys Glu Ile Val Lys Lys Gln Leu Ala Leu 95 100 105 Pro Asp His Thr Glu Val Cys Gly Glu Ser Lys Phe Ser Glu Leu 110 115 120 Gly Ala Asp Ser Leu Asp Thr Val Glu Ile Val Met Ser Leu Glu 130 135 Glu His Phe Asp Ile Ser Val Glu Glu Ser Ser Ala Gln Thr Ile 140 145 150 Ala Thr Val Glu Asp Ala Ala Asp Leu Ile Asp Lys' Leu Val Ala 155 160 165 Gly Lys Ala <210> 406 <211> 117 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:446649.1.orf2:2000FEB18 <400> 406 Leu Lys Ala Arg Glu Gln Ala Gln Lys Arg Glu Ala Ile Gln Val 10 Thr Ser Pro Val Cys Leu Arg Leu Ile Leu Arg Lys Ala Gly Glu 20 25 Glu Val Lys Arg Leu Lys Thr Gln Pro Thr Asp Glu Glu Met Leu 35 45 40

Phe Ile Tyr Ser His Phe Lys Gln Ala Thr Val Gly Asp Val Asn 60 55 Thr Asp Arg Pro Gly Leu Leu Asp Leu Lys Gly Lys Ala Lys Trp 70 75 65 Asp Ser Trp Asn Lys Leu Lys Gly Thr Ser Lys Glu Asn Ala Met 80 85 90 Lys Thr Tyr Val Glu Lys Val Glu Glu Leu Lys Lys Lys Tyr Gly 95 100 105 Ile Leu Thr Thr Arg Phe Gly Gly Gln Pro His Val 110

<210> 407 <211> 804 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:132147.3.orf3:2000FEB18

<400> 407 Ala Ser Ser Ala Ala Gln Asp Asp Tyr Ala Arg His Val Arg Asp 10 15 Pro Pro Ala Val Ala Val Ala Pro Lys Ala Arg Ala Ser Ala 20 25 30 Pro Asp Ala Val 'Val Thr Pro Pro Arg Leu Ala Val Ala Pro Val 35 40 45 Pro Val Leu Pro Ala Ala Ser Ala Ala Gly Asp Met Ser Asn Pro 50 55 Gly Ser Arg Arg Asn Gly Pro Val Lys Leu His Leu Thr Val Leu 65 70 75 Cys Ala Lys Asn Leu Val Lys Lys Asp Phe Phe Arg Leu Pro Asp 80 85 Pro Phe Ala Lys Val Val Val Asp Gly Ser Gly Gln Cys His Ser

Thr	Asp	Thr	Val	95 Lys	Asn	Thr	Leu	Asp		Lys	Trp	Asn		
Tyr	Asp	Leu	Tyr	110 Ile	Gly	Lys	Ser	Asp		Val	Thr	Ile	Ser	120 Val
Trp	Asn	His	Lys	125 Lys	īle	His	Lys	Lys		дlу	Ala	Gly	Phe	135 Leu 150
Gly	Cys	Val	Arg	140 Leu 155	Leu	Ser	Asn	Ala	145 Ile 160	Asn	Arg	Leu	Lys	_
Thr	Gly	Tyr	Gln	Arg 170	Leu	Asp	Leu	Суз		Leu	Gly	Pro	Asn	
Asn	Asp	Thr	Val	Arg 185	Gly	Gln	Ile	Val		Ser	Leu	Gln	Ser	Arg 195
Asp	Arg	Ile	Gly	Thr 200	Gly	Gly	Gln	Val,		Asp	Cys	Ser	Arg	
Phe	Asp	Asn	Asp	Leu 215	Pro	Asp	Gly	Trp		Gĺu	Arg	Arg	Thr	Ala 225
Ser	Gly	Arg	Ile	Gln 230	Tyr	Leu	Asn	His			Arg	Thr	Thr	Gln 240
Trp	Glu	Arg	Pro	Thr 245	Arg	Pro	Ala	Ser	Glu 250	Tyr	Ser	Ser	Pro	Gly 255
_				Cys 260					265					270
Thr	Asn	Gly	Ala	Thr 275	Сув	Gly	Gln	Ser	Ser 280	Asp	Pro	Arg	Leu	Ala 285
	_	_		Arg 290			_		295		_			300
				Thr 305					310					315
				Gln 320					325					330
_				Trp 335		_			340		_	Asp		345
				Glu 350					355	_		_	•	360
	_		,	Ala 365		. –	. –		370			Asp		375
				Gln 380					385					390
				Asn 395					400					405
				Ser 410		_			415					420
				Lys 425					430					435
				Ser					445					450
				Arg 455					460					465
		_		Arg		_	_		475					480
-		_	_	Glu 485		_			490					495
	_		_	Leu 500					505					510
				Tyr 515					520					525
				Ala 530					535					540
				Ile 545		_			550					555
	_	_	_	Phe 560					565	_				570
_				Leu 575	_	_			580					585
HIS	ASN	ser	ьeu	Val 590	тrр	тте	ьeu	GIU	Asn 595	Asp	TTE	THE	чπĀ	600

WO 01/62927 Leu Asp His Thr Phe Cys Val Glu His Asn Ala Tyr Gly Glu Ile Ile Gln His Glu Leu Lys Pro Asn Gly Lys Ser Ile Pro Val Asn Glu Glu Asn Lys Lys Glu Tyr Val Arg Leu Tyr Val Asn Trp Arg Phe Leu Arg Gly Ile Glu Ala Gln Phe Leu Ala Leu Gln Lys Gly Phe Asn Glu Val Ile Pro Gln His Leu Leu Lys Thr Phe Asp Glu Lys Glu Leu Glu Leu Ile Ile Cys Gly Leu Gly Lys Ile Asp Val Asn Asp Trp Lys Val Asn Thr Arg Leu Lys His Cys Thr Pro Asp Ser Asn Ile Val Lys Trp Phe Trp Lys Ala Val Glu Phe Phe Asp Glu Glu Arg Arg Ala Arg Leu Leu Gln Phe Val Thr Gly Ser Ser Arg Val Pro Leu Gln Gly Phe Lys Ala Leu Gln Gly Ala Ala Gly Pro Arg Leu Phe Thr Ile His Gln Ile Asp Ala Cys Thr Asn Asn Leu Pro Lys Ala His Thr Cys Phe Asn Arg Ile Asp Ile Pro Pro Tyr Glu Ser Tyr Glu Lys Leu Tyr Glu Lys Leu Leu Thr Ala Ile Glu Glu Thr Cys Gly Phe Ala Val Glu <210> 408 <211> 220 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LI:036034.1.orf1:2000FEB01 Thr Ile His Leu Lys Thr Leu Ile Ile Val Trp Lys Arg Tyr Ser Asp Phe Lys Lys Leu His Lys Glu Leu Trp Gln Ile His Lys Asn Leu Phe Arg His Ser Glu Leu Phe Pro Pro Phe Ala Lys Gly Ile Val Phe Gly Arg Phe Asp Glu Thr Val Ile Glu Glu Arg Arg Gln Tyr Ala Glu Asp Leu Leu Gln Phe Ser Ala Asn Ile Pro Ala Leu Tyr Asn Ser Lys Gln Leu Glu Asp Phe Phe Lys Gly Gly Ile Ile Asn Asp Ser Ser Glu Leu Ile Gly Pro Ala Glu Ala His Ser Asp Ser Leu Ile Asp Thr Phe Pro Glu Cys Ser Thr Glu Gly Phe Ser Ser Asp Ser Asp Leu Val Ser Leu Thr Val Asp Val Asp Ser Leu Ala Glu Leu Asp Asp Gly Met Ala Ser Asn Gln Asn Ser Pro Ile Arg Thr Phe Gly Leu Asn Leu Ser Ser Asp Ser Ser Ala Leu Gly Ala Val Ala Ser Asp Ser Glu Gln Ser Lys Thr Glu Glu Glu Arg

PCT/US01/06059

220/228

Glu Ser Arg Ser Leu Phe Pro Gly Ser Leu Lys Pro Lys Leu Gly

Lys Arg Asp Tyr Leu Glu Lys Ala Gly Glu Leu Ile Lys Leu Ala

```
Leu Lys Lys Glu Glu Glu Asp Asp Tyr Glu
                                                        . .
                215
                                     220
<210> 409
<211> 168
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:162161.1.orf2:2000MAY19
<400> 409
Gln Asp His Gln Phe Ala Pro Gln Ser Thr Met Ser Arg Ser Arg
                                                           15
Gln Pro Pro Leu Val Thr Gly Ile Ser Pro Asn Glu Gly Ile Pro
                 20
                                      25
Trp Thr Lys Val Thr Ile Arg Gly Glu Asn Leu Gly Thr Gly Pro
                 35
                                      40
Thr Asp Leu Ile Gly Leu Thr Ile Cys Gly His Asn Cys Leu Leu
                 50
Thr Ala Glu Trp Met Ser Ala Ser Lys Ile Val Cys Arg Val Gly
                                      70
                 65
Gln Ala Lys Asn Asp Lys Gly Asp Ile Ile Val Thr Thr Lys Ser
                                                           90
                 80
                                      85
Gly Gly Arg Gly Thr Ser Thr Val Ser Phe Lys Leu Leu Lys Pro
                 95
                                     100
                                                          105
Glu Lys Ile Gly Ile Leu Asp Gln Ser Ala Val Trp Val Asp Glu
                110
                                     115
                                                          120
Met Asn Tyr Tyr Asp Met Arg Thr Asp Arg Asn Lys Gly Ile Pro
                                     130
                125
Pro Leu Ser Leu Arg Pro Ala Asn Pro Leu Gly Met Glu Ile Glu
                                     145
                                                          150
                140
Pro Ser Thr Phe Ser Gln Lys Asp Leu Glu Met Leu Phe His Gly
                155
                                     160
Met Ser Ala
<210> 410
<211> 108
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:407214.10.orf2:2000MAY19
<400> 410
Lys Ser Arg Met Asp Leu Asp Val Val Asn Met Phe Val Ile Ala
Gly Gly Thr Leu Ala Ile Pro Ile Leu Ala Phe Val Ala Ser Phe
Leu Leu Trp Pro Ser Ala Leu Ile Arg Ile Tyr Tyr Trp Tyr Trp
                                                           45
                 35
                                      40
Arg Arg Thr Leu Gly Met Gln Val Arg Tyr Val His His Glu Asp
                                      55
                 50
Tyr Gln Phe Cys Tyr Ser Phe Arg Gly Arg Pro Gly His Lys Pro
                 65
                                      70
                                                           75
Ser Ile Leu Met Leu His Gly Phe Ser Gly His Lys Asp Met
                                                          Trp
                 80
                                      85
Leu Ser Val Val Lys Val Pro Ser Lys Glu Pro Ala Leu Gly Leu
                                                          105
                                     100
                 95
Arg Gly His
<210> 411
<211> 314
```

```
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:204626.1.orf1:2000MAY19
<400> 411
Gly Val Ala Arg Lys Lys Lys Ile Val Ile Lys Glu Glu Pro Lys
Arg Arg Lys Gly Lys Met Lys Asp Arg Leu Gln Glu Leu Lys Gln
                 20
                                      25
Arg Thr Lys Glu Ile Glu Leu Ser Arg Asp Ser His Val Ser Thr
Thr Glu Thr Glu Glu Gln Gly Val Phe Leu Gln Gln Ala Val Ile
                                    55
                 50
Tyr Glu Arg Glu Pro Val Ala Glu Arg His Leu His Glu Ile Gln
                 65
                                      70
Lys Leu Gln Glu Ser Ile Asn Asn Leu Ala Asp Asn Val Gln Lys
                                      85
                 80
Phe Gly Gln Gln Lys Ser Leu Val Ala Ser Met Arg Arg Phe
                 95
                                    100
                                                         105
Ser Leu Leu Lys Arg Glu Ser Thr Ile Thr Lys Glu Ile Lys Ile
                110
                                     115
                                                         120
Gln Ala Glu Tyr Ile Asn Arg Ser Leu Asn Asp Leu Val Lys Glu
                125
                                     130
                                                         135
Val Lys Lys Ser Glu Val Glu Asn Gly Pro Ser Ser Val Val Thr
                140
                                     145
                                                         150
Arg Ile Leu Lys Ser Gln His Ala Ala Met Phe Arg His Phe Gln
                155
                                     160
                                                         165
Gln Ile Met Phe Ile Tyr Asn Asp Thr Ile Ala Ala Lys Gln Glu
                170
                                     175
                                                         180
Lys Cys Lys Thr Phe Ile Leu Arg Gln Leu Glu Val Ala Gly Lys
                185
                                     190
                                                         195
Glu Met Ser Glu Glu Asp Val Asn Asp Met Leu His Gln Gly Lys
                200
Trp Glu Val Phe Asn Glu Ser Leu Leu Thr Glu Ile Asn Ile Thr
                215
                                     220
Lys Ala Gln Leu Ser Glu Ile Glu Gln Arg His Lys Glu Leu Val
                230
                                     235
Asn Leu Glu Asn Gln Ile Lys Asp Leu Arg Asp Leu Phe Ile Gln
                                     250
                245
                                                         255
Ile Ser Leu Leu Val Glu Glu Gln Gly Glu Ser Ile Asn Asn Ile
                260
                                     265
Glu Met Thr Val Asn Ser Thr Lys Glu Tyr Val Asn Asn Thr Lys
                275
                                     280
Glu Lys Phe Gly Leu Ala Val Lys Tyr Lys Lys Arg Asn Pro Cys
                290
                                     295
Arg Val Leu Cys Cys Trp Cys Cys Pro Cys Cys Ser Ser Lys
                305
                                     310
<210> 412
<211> 143
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:007401.1.orf2:2000MAY01
<400> 412
Met Ala Ser Glu Ser Asp Thr Glu Glu Phe Tyr Asp Ala Pro Glu
Asp Val His Leu Gly Gly Gly Tyr Pro Val Gly Ser Pro Gly Lys
                 20
                                      25
Val Gly Leu Ser Thr Phe Lys Glu Thr Glu Asn Thr Ala Tyr Lys
```

222/228

```
Val Gly Asn Glu Ser Pro Val Gln Glu Leu Lys Gln Asp Val Ser
                                                           60 .
                                      55
                 50
Asn Lys Ile Ile Glu Ser Ile Ile Glu Glu Ser Gln Lys Val Leu
                                                          75
                 65
                                     . 70
Gln Leu Glu Asp Asp Ser Leu Asp Ser Thr Gly Lys Glu Leu Ser
                 80
                                      85
Asp Gln Ala Thr Ala Ser Pro Ile Val Ala Arg Thr Asp Leu Ser
                                     100
                 95
Asn Ile Pro Gly Leu Leu Ala Ile Asp Gln Val Leu Pro Glu Glu
                110
                                     115
                                                         120
Ser Gln Lys Ala Glu Ser Gln Asn Thr Phe Glu Glu Thr Glu Leu
                                     130
                                                         135
                125
Glu Phe Lys Lys Met Leu Ser Phe
                140
<210> 413
<211> 122
<212> PRT
<213> Homo sapiens
<220×
<221> misc_feature
<223> Incyte ID No: LI:476342.1.orf1:2000MAY01
<400> 413
Gly Arg Thr Arg Val Ser Gly Pro Val Arg Asn Asn Thr Asp Pro
                                      10
Ile His Ala Gly Arg
                    Arg Trp Ser Ser Ser Pro Gly Arg Pro
                                                           30
                 20
                                      25
                    Trp Arg Cys Ser Cys Ser His Thr Thr
                                                         Thr
Cys Ala Arg Ser Ser
                 35
                                      40
                                                           45
Ala Gly Arg Arg Arg Trp Trp Arg Arg Pro Gly Cys Ala Trp
                                                           60
Ala Arg Ala Ser Thr Thr Arg Ser Pro Ala Ser Pro Thr Ala Ser
                                      70
                                                           75
                 65
Ala Ala Thr Ser Ala Ser Arg Arg Thr Ala Gly Gly Pro Pro Ala
                                      85
                 80
Thr Ala Thr Ser Ala Thr Ala Gly Ala Arg Arg Arg Ala Lys Gln
                 95
                                     100
Ser Ser Ser Asn Thr Leu Gly Leu Pro Glu Leu Asn Ser Ser Ser
                                     115
                110
Thr Lys
<210> 414
<211> 86
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LI:1072759.1.orf2:2000MAY01
<400> 414
Arg Pro Glu Glu Asp Met Arg Gln Leu Val His Gly Ser Gln Arg
                                                           15
                                      10
Gly Thr Leu Arg Lys Met Gly Leu Gln Pro Arg His Ser Ser Leu
                                                           30
                 20
                                      25
Trp Cys Gln Phe Leu Val Gly Met Val Thr Thr Phe Trp Lys Gln
                 35
                                      40
                                                           45
Gly Ala Ile Ile Ala Leu Val Ser Arg Arg Trp Lys Val Thr Arg
                 50
Lys Gly Trp Gln Cys Gln Val Arg Thr Thr Leu Ala Cys Arg Leu
                                      70
                 65
Leu Asp Cys Ile Leu Pro Pro Asn Ser Tyr Asn
```

```
<210> 415
<211> 213
<212> PRT
<213> Homo sapiens .
<220>
<221> misc_feature
<223> Incyte ID No: LG:998857.1.orf3:2000FEB18
<400> 415
Arg Gln Trp Gln Leu Leu Cys Cys Pro Cys Cys Cys Gly Gly Cys
                                      10
Trp Ala Arg Val Glu Val Gln Gly Trp Gly His Gly Leu Ala Pro
                 20
                                      25
                                                           30
Gly Leu Gly Trp Ser Cys Pro Ala Gly Pro Gly Gly His Arg Gly
                                                           45
                                      40
Cys Gly Cys Pro Gly Val Gly Arg Thr Trp Lys Ala Ala Arg Ser
Arg Gly Ser Trp Val Ser Trp Val Ser Trp Gly Thr Trp Arg Ser
                 65
                                      70
                                                          75
Trp Arg Ser Trp Gly Ser Trp Gly Ser Trp Asp Ser Arg Ala Pro
                 80
                                      85
Pro Pro Glu Pro Ser Arg Thr Pro Arg Gly Thr Asn Arg Ser Arg
                 95
                                     100
                                                         105
Thr Ser Pro Pro Ala Cys Arg Arg Ala Ser Arg Ser Gly Pro Arg
                                                         120
                110
                                     115
Ala Pro Thr Pro Pro Pro Arg Pro Gln Arg Arg Ser Ala Ala Ala
                125
                                     130
                                                          135
Cys Gly Trp Arg Pro Arg Ser Gly Arg Pro Gly Arg Gly Leu Ser
                140
                                     145
                                                          150
Trp Arg Pro Arg Arg Pro Gly Ala Arg Gln Arg Ser Trp Ser
                155
                                     160
                                                          165
Ala Ser Phe Gly Arg Cys Arg Cys Arg Ala Arg Arg Pro Thr Ala
                170
                                     175
                                                          180
Cys Gly Ala Gly Ser Asp Gly Leu Ala Leu Ala Gly Thr Arg Ala
                185
                                     190
                                                          195
Ser Arg Arg Ala Arg Cys Arg Arg Ser Arg Ser Arg Ala Gly Cys
               1 200
                                     205
                                                          210
Gly Gly Ser
<210> 416
<211> 263
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:482261.1.orf1:2000FEB18
<400> 416
Leu Leu Asn Phe Val Ser Leu Ser Leu Phe Leu Phe Ser Phe Pro
Arg Leu His Arg Glu Gly Glu Ser Leu Arg Val Val Tyr Gln Ala
                 20
                                                           30
Gly Ser Pro Thr Ser Leu Ala Pro Asn Thr Val Ser Ser Asn Pro
                 35
                                      40
Gly Glu Val Thr Pro Glu Arg Gly Arg Cys Glu Glu Arg Ser Val
                 50
                                      55
Gln Glu Leu Pro Arg Thr Cys Gly Arg Pro Cys Gly Lys Leu Val
                 65
                                      70
His Ser Glu His Ser Arg Asp Thr Met Gly Gln Ser Lys Ser Lys
                                                           90
                                      85
His Ser Ala Tyr Leu His Phe Ile Lys Leu Leu Leu Lys Arg Ala
                 95
                                     100
                                                          105
Gly Ile Lys Ala Ser Thr Glu Asn Leu Ile Thr Leu Phe Pro
                                                         Thr
                110
                                     115
                                                          120
```

```
Val Glu Gln Tyr Cys Pro Trp Phe Pro Glu His Gly Thr Met Asp
                125
                                     130
Phe Lys Asp Trp Glu Gln Val Gly Ile Ala Leu Lys Gln Val Cys
                                                         150
                140
                                     145
Lys Glu Gly Lys Phe Ile Pro Leu Thr Ala Trp Ser Asn Trp Ala
                                     160
Ile Val Lys Ala Ala Ser Glu Pro Phe Gln Ser Glu Asn Glu Ala
                170
                                     175
                                                          180
Tyr Pro Pro Ala Glu Arg Ile Ser Ala Glu Glu Gly Gly Asp Ala
                                     190
                185
Ala Glu Gly Gly Glu Asp Ser Glu Glu Asp Phe Glu Glu Asn Thr
                                                          210
                200
                                     205
Asp Lys Pro Gly Asp Glu Leu Ile Ser Phe Glu Glu His Val Gly
                                                          225
                215
                                    220
Pro Ser Ala Ala Pro Lys Ile Glu Lys Pro Tyr Met Pro Arg Cys
                230
                                     235
                                                          240
Leu Lys Gln Arg Arg Ala Leu Arg Ser Ser Arg Leu Leu Ile Gly
                245
                                     250
Ile Ile Arg Ser Gly Arg Leu Gln
                260
<210> 417
<211> 175
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:480328.1.orf1:2000FEB18
Val Arg Cys Gly Gly Gln Ser Gly Ser Arg Cys Glu Arg Val Pro
Gln Lys Lys Thr Trp Leu Pro Lys Cys Leu Ser Pro Ser Ala Ser
Leu Gly Leu Ala Leu Ala Val Ala Gly Gly Met Val Asn Ser Ala
                 35
                                      40
Leu Cys Asn Val Asp Ala Gly His Arg Ala Ala Ile Phe Asp Gln
                 50
                                      55
Phe Arg Gly Val Gln Asn Ile Val Val Gly Glu Gly Thr His Phe
                                      70
                 65
Leu Ile Pro Cys Val Gln Lys Pro Ile Ile Phe Asp Cys Cys Ser
                 80
                                      85
Gln Pro Arg Ser Ala Pro Val Ile Thr Gly Ser Lys Asp Leu Gln
                                     100
Asn Val Asn Ile Thr Leu Cys Ile Leu Phe Arg Pro Ile Thr Ser
                110
                                     115
                                                          120
Gln Leu Pro Arg Ile Phe Thr Ser Ile Gly Glu Asp Tyr Asp Glu
                125
                                     130
Cys Val Leu Pro Phe Ile Thr Thr Glu Ile Leu Lys Ser Leu Val
                                     145
                                                          150
                140
Ala Arg Phe Asp Ala Gly Glu Leu Ile Thr Gln Arg Glu Leu Val
                                                          165
                155
                                     160
Ser Ser Gln Val Ser Asn Asn Leu Met Glu
                170
<210> 418
<211> 272
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:311197.1.orf2:2000MAY19
Gln Val Pro Phe Pro Ser His Ile Pro Ile Tyr Val Cys Leu Cys
```

```
10
Val Gln Gln Thr Pro Ala Phe Ala Thr Met Leu Ser Ser Thr Asp
Phe Thr Phe Ala Ser Trp Glu Leu Val Val Arg Val Asp His Pro
                 35
                                      40
                                                          45
Asn Glu Glu Gln Gln Lys Asp Val Thr Leu Arg Val Ser Gly Asp
                                      55
                 50
Leu His Val Gly Gly Val Met Leu Lys Leu Val Glu Gln Ile Asn
                                                          75
                                      70
                 65
Ile Ser Gln Asp Trp Ser Asp Phe Ala Leu Trp Trp Glu Gln Lys
                 80
                                      85
His Cys Trp Leu Leu Lys Thr His Trp Thr Leu Asp Lys Tyr Gly
                 95
                                     100
Val Gln Ala Asp Ala Lys Leu Leu Phe Thr Pro Gln His Lys Met
                110
                                     115
                                                         120
Leu Arg Leu Arg Leu Pro Asn Leu Lys Met Val Arg Leu Arg Val
                125
                                     130
                                                         135
Ser Phe Ser Ala Val Val Phe Lys Ala Val Ser Asp Ile Cys Lys
                140
                                     145
                                                          150
Ile Leu Asn Ile Arg Arg Ser Glu Glu Leu Ser Leu Leu Lys Pro
                155
                                     160
Ser Gly Asp Tyr Phe Lys Lys Lys Lys Lys Asp Lys Asn Asn
                170
                                     175
                                                          180
Lys Glu Pro Ile Ile Glu Asp Ile Leu Asn Leu Glu Ser Ser Pro
                185
                                     190
                                                          195
Thr Ala Ser Gly Ser Ser Val Ser Pro Gly Leu Tyr Ser Lys Thr
                200
                                     205
Met Thr Pro Ile Tyr Asp Pro Ile Asn Gly Thr Pro Ala Ser Ser
                215
Thr Met Thr Trp Phe Ser Asp Ser Pro Leu Thr Glu Gln Asn Cys
                230
                                     235
Ser Ile Leu Ala Phe Ser Gln Pro Pro Gln Ser Pro Glu Ala Leu
                                     250
                                                          255
                245
Ala Asp Met Tyr Gln Pro Arg Ser Leu Val Asp Thr Ala Lys Leu
                260
                                     265
Asn Ala
<210> 419
<211> 167
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> Incyte ID No: LG:1054883.1.orf1:2000MAY19
<220>
<221> unsure
<222> 2
<223> unknown or other
<400> 419
Arg Xaa Arg Gln Pro Leu Leu Gln Ser His Pro Glu Ala Asp Trp
                                      10
Ser Thr His Gly Arg Ser Met Arg Lys Leu Ile Val Arg Phe Ile
                 20
                                      25
Phe Leu Lys Phe Trp Thr Tyr Thr Val Arg Ala Ser Thr Asn Leu
                                                           45
                  35
                                      40
Thr Gln Asn Gly Asp Cys Ser Gln Cys Ile Tyr Gln Val Thr Glu
                  50
                                      55
                                                           60
Val Gly Gln Gln Ile Lys Thr Ile Phe Leu Phe Tyr Ser Tyr Tyr
Glu Cys Met Glu Thr Leu Lys Glu Thr Cys Leu Tyr Asn Ala Thr
                                      85
                                                           90
                  80
Gln Tyr Lys Val Cys Ser Pro Arg Asn Asp Arg Pro Asp Ala Cys
```

226/228

WO 01/62927 PCT/US01/06059 Tyr Asn Pro Ser Glu Pro Ala Ala Thr Thr Val Phe Glu Ile 115 110 Thr Gly Leu Leu Gly Asp Thr Ser Lys Ile Ile Thr Arg Thr 125 130 135 Glu Glu Lys Glu Ile Pro Lys Gln Ile Thr Leu Arg Phe Asp Ala 140 145 Cys Ala Ala Ile Asn Ser Lys Lys Leu Glu Ile Gly Cys Gly Ser 155 160 Leu Asn <210> 420 <211> 59 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:399395.1.orf2:2000MAY19 Ser Gln His Phe Gly Arg Pro Arg Gln Glu Asp His Leu Ser Pro 10 Gly Val Gln Asp Gln Pro Gly Gln His Ser Glu Thr Leu Thr Gln 25 20 Lys Ile Lys Arg Lys Asp Lys Asn Thr Arg Met Ala Lys Gln Thr 40 35 Ser Val His Gln Pro Gly Gly Ile Leu Tyr Ser Leu Leu Lys <210> 421 <211> 216 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Incyte ID No: LG:380497.2.orf1:2000MAY19 Ser Pro Arg Pro Leu Gln Ser Ala Gly Glu Gly Val Thr His Val 10 Leu Ile Leu Leu Glu Ser Pro Ala Arg Pro Val Ala Ala Val Thr 20 Gln Val Gln Arg Arg Tyr His Arg Leu Ser Asp Met Ser Met 35 40 45 Leu Ala Glu Arg Arg Lys Gln Lys Trp Ala Val Asp Pro Gln 55 50 Asn Thr Ala Trp Ser Asn Asp Asp Ser Lys Phe Gly Gln Arg Met 70 65 Leu Glu Lys Met Gly Trp Ser Lys Gly Lys Gly Leu Gly Ala Gln 80 85 Glu Gln Gly Ala Thr Asp His Ile Lys Val Gln Val Lys Asn Asn 95 100 105 His Leu Gly Leu Gly Ala Thr Ile Asn Asn Glu Asp Asn Trp Ile 115 120 110 Ala His Gln Asp Asp Phe Asn Gln Leu Leu Ala Glu Leu Asn Thr 130 135 125 Cys His Gly Gln Glu Thr Thr Asp Ser Ser Asp Lys Lys Glu Lys 150 145 Lys Ser Phe Ser Leu Glu Glu Lys Ser Lys Ile Ser Lys Asn Arg 155 160 165 Val His Tyr Met Lys Phe Thr Lys Gly Arg Cys Gln Ser Leu His 175 170 180 Ser Arg Gly Glu Arg Asn His Asp Asn Gln Arg Leu His His Pro

227/228

190

Gly Val Leu Cys Gln Ala Asp Gly Ser Thr Glu Glu Gln Ala Pro

185

210

150

. 205

Gly Ser Ser Ser Arg Val 215

<210> 422

<211> 162 <212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: LI:272913.22.orf1:2000MAY01

<400> 422 Ser Ala Thr Ala Ala Ala Pro Arg Glu Arg Lys Met Ala Pro His 10 Gly Pro Gly Ser Leu Thr Thr Leu Val Pro Trp Ala Ala Ala Leu 20 25 Leu Leu Ala Leu Gly Val Glu Arg Ala Leu Ala Leu Pro Glu Ile 40 45 35 Cys Thr Gln Cys Pro Gly Ser Val Gln Asn Leu Ser Lys Val Ala 50 55 60 Phe Tyr Cys Lys Thr Thr Arg Glu Leu Met Leu His Ala Arg Cys 65 70 Cys Leu Asn Gln Lys Asp Pro Gly Pro Asn Phe His Gln Ala His 90 80 85 Thr Thr Val Ile Ile Asp Leu Gln Ala Asn Pro Leu Lys Gly Asp 95 100 105 Leu Ala Asn Thr Phe Arg Gly Phe Thr Gln Leu Gln Thr Leu Ile 110 115 120 Leu Pro Gln His Val Asn Cys Ser Gly Gly Ile Asn Ala Trp Asn 125 130 135

Thr Ile Thr Ser Tyr Ile Asp Asn Gln Ile Cys Gln Gly Gln Lys

145

160

140

155

Asn Leu Cys Asn Asn Thr Gly Asp Pro Glu Met Cys